Torsade NNP B-Disease
de FW I-Disease
pointes VBZ I-Disease
ventricular JJ B-Disease
tachycardia NN I-Disease
during IN O
low JJ O
dose NN O
intermittent JJ O
dobutamine NN O
treatment NN O
in IN O
a DT O
patient NN O
with IN O
dilated JJ B-Disease
cardiomyopathy NN I-Disease
and CC O
congestive JJ B-Disease
heart NN I-Disease
failure NN I-Disease
. . O
null null null-Disease
The DT O
authors NNS O
describe VBP O
the DT O
case NN O
of IN O
a DT O
56 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
chronic JJ O
, , O
severe JJ O
heart NN B-Disease
failure NN I-Disease
secondary JJ O
to IN O
dilated VBN B-Disease
cardiomyopathy NN I-Disease
and CC O
absence NN O
of IN O
significant JJ O
ventricular JJ B-Disease
arrhythmias NNS I-Disease
who WP O
developed VBD O
QT NNP B-Disease
prolongation NN I-Disease
and CC O
torsade NN B-Disease
de FW I-Disease
pointes FW I-Disease
ventricular JJ B-Disease
tachycardia NN I-Disease
during IN O
one CD O
cycle NN O
of IN O
intermittent JJ O
low JJ O
dose NN O
( , O
2 CD O
. . O
5 CD O
mcg NN O
/ SYM O
kg NN O
per IN O
min NN O
) -RRB- O
dobutamine NN O
. . O
null null null-Disease
This DT O
report NN O
of IN O
torsade NN B-Disease
de FW I-Disease
pointes VBZ I-Disease
ventricular JJ B-Disease
tachycardia NN I-Disease
during IN O
intermittent JJ O
dobutamine NN O
supports VBZ O
the DT O
hypothesis NN O
that IN O
unpredictable JJ O
fatal JJ O
arrhythmias NNS B-Disease
may MD O
occur VB O
even RB O
with IN O
low JJ O
doses NNS O
and CC O
in IN O
patients NNS O
with IN O
no DT O
history NN O
of IN O
significant JJ O
rhythm NN O
disturbances NNS O
. . O
null null null-Disease
The DT O
mechanisms NNS O
of IN O
proarrhythmic JJ O
effects NNS O
of IN O
Dubutamine NNP O
are VBP O
discussed VBN O
. . O
null null null-Disease
Positive JJ O
skin NN O
tests NNS O
in IN O
late JJ O
reactions NNS O
to IN O
radiographic JJ O
contrast NN O
media NN O
. . O
null null null-Disease
In IN O
the DT O
last JJ O
few JJ O
years NNS O
delayed VBN O
reactions NNS O
several JJ O
hours NNS O
after IN O
the DT O
injection NN O
of IN O
radiographic JJ O
and CC O
contrast NN O
materials NNS O
( -LRB- O
PRC NNP O
) -RRB- O
have VBP O
been VBN O
described VBN O
with IN O
increasing VBG O
frequency NN O
. . O
null null null-Disease
The DT O
authors NNS O
report VBP O
two CD O
observations NNS O
on IN O
patients NNS O
with IN O
delayed VBN O
reactions NNS O
in IN O
whom WP O
intradermoreactions NNS O
( , O
IDR NNP O
) -RRB- O
and CC O
patch NN O
tests NNS O
to IN O
a DT O
series NN O
of IN O
ionic JJ O
and CC O
non JJ O
ionic JJ O
PRC NNP O
were VBD O
studied VBN O
. . O
null null null-Disease
After IN O
angiography NN O
by IN O
the DT O
venous JJ O
route NN O
in IN O
patient JJ O
n NN O
degree NN O
1 CD O
a DT O
biphasic JJ O
reaction NN O
with IN O
an DT O
immediate JJ O
reaction NN O
( , O
dyspnea NN B-Disease
, , O
loss NN B-Disease
of IN I-Disease
consciousness NN I-Disease
) , O
and CC O
delayed VBN O
macro JJ B-Disease
- HYPH I-Disease
papular JJ I-Disease
rash NN I-Disease
appeared VBD O
, , O
whilst IN O
patient JJ O
n NN O
degree NN O
2 CD O
developed VBD O
a DT O
generalised VBN O
sensation NN O
of IN O
heat NN O
, , O
persistent JJ O
pain NN B-Disease
at IN O
the DT O
site NN O
of IN O
injection NN O
immediately RB O
and CC O
a DT O
generalised JJ O
macro JJ O
- HYPH O
papular JJ O
reaction NN O
after IN O
24 CD O
hours NNS O
. . O
null null null-Disease
The DT O
skin NN O
tests NNS O
revealed VBD O
positive JJ O
delayed JJ O
reactions NNS O
of IN O
24 CD O
hours NNS O
and CC O
48 CD O
hours NNS O
by IN O
IDR NNP O
and CC O
patch NN O
tests NNS O
to IN O
only RB O
some DT O
PRC NNP O
with IN O
common JJ O
chains NNS O
in IN O
their PRP$ O
structures NNS O
. . O
null null null-Disease
The DT O
positive JJ O
skin NN O
tests NNS O
are VBP O
in IN O
favour NN O
of IN O
immunological JJ O
reactions NNS O
and CC O
may MD O
help VB O
in IN O
diagnosis NN O
of IN O
allergy NN B-Disease
in IN O
the DT O
patients NNS O
. . O
null null null-Disease
Risk NN O
of IN O
transient JJ O
hyperammonemic JJ B-Disease
encephalopathy NN I-Disease
in IN O
cancer NN B-Disease
patients NNS O
who WP O
received VBD O
continuous JJ O
infusion NN O
of IN O
5 CD O
- HYPH O
fluorouracil NN O
with IN O
the DT O
complication NN O
of IN O
dehydration NN B-Disease
and CC O
infection NN B-Disease
. . O
null null null-Disease
From IN O
1986 CD O
to IN O
1998 CD O
, , O
29 CD O
cancer NN B-Disease
patients NNS O
who WP O
had VBD O
32 CD O
episodes NNS O
of IN O
transient JJ O
hyperammonemic JJ B-Disease
encephalopathy NN I-Disease
related VBN O
to IN O
continuous JJ O
infusion NN O
of IN O
5 CD O
- HYPH O
fluorouracil NN O
( HYPH O
5 CD O
- HYPH O
FU NN O
) -RRB- O
were VBD O
identified VBN O
. . O
null null null-Disease
null NN O
of IN O
the DT O
patients NNS O
had VBD O
decompensated VBN O
liver NN B-Disease
disease NN I-Disease
. . O
null null null-Disease
Onset NN O
of IN O
hyperammonemic JJ B-Disease
encephalopathy NN I-Disease
varied VBD O
from IN O
0 CD O
. . O
5 CD O
to IN O
5 CD O
days NNS O
( : O
mean JJ O
: : O
2 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
3 CD O
days NNS O
) -RRB- O
after IN O
the DT O
initiation NN O
of IN O
chemotherapy NN O
. . O
null null null-Disease
Plasma NN O
ammonium NN O
level NN O
ranged VBD O
from IN O
248 CD O
to IN O
2387 CD O
microg NN O
% NN O
( , O
mean JJ O
: : O
626 CD O
+ SYM O
/ SYM O
- HYPH O
431 CD O
microg NN O
% NN O
) -RRB- O
. . O
null null null-Disease
Among IN O
the DT O
32 CD O
episodes NNS O
, , O
26 CD O
( SYM O
81 CD O
% NN O
) , O
had VBD O
various JJ O
degrees NNS O
of IN O
azotemia NN B-Disease
, , O
18 CD O
( SYM O
56 CD O
% NN O
) -RRB- O
occurred VBD O
during IN O
bacterial JJ B-Disease
infections NNS I-Disease
and CC O
14 CD O
( SYM O
44 CD O
% NN O
) , O
without IN O
infection NN B-Disease
occurred VBD O
during IN O
periods NNS O
of IN O
dehydration NN B-Disease
. . O
null null null-Disease
Higher JJR O
plasma NN O
ammonium NN O
levels NNS O
and CC O
more JJR O
rapid JJ O
onset NN O
of IN O
hyperammonemia NN B-Disease
were VBD O
seen VBN O
in IN O
18 CD O
patients NNS O
with IN O
bacterial JJ B-Disease
infections NNS I-Disease
( , O
p NN O
= SYM O
0 CD O
. , O
003 CD O
and CC O
0 CD O
. , O
0006 CD O
, , O
respectively RB O
) , O
and CC O
in IN O
nine CD O
patients NNS O
receiving VBG O
high JJ O
daily JJ O
doses NNS O
( : O
2600 CD O
or CC O
1800 CD O
mg NNS O
/ SYM O
m2 CD O
) -RRB- O
of IN O
5 CD O
- HYPH O
FU NN O
( : O
p NN O
= SYM O
0 CD O
. . O
0001 CD O
and CC O
< NN O
0 CD O
. . O
0001 CD O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
In IN O
25 CD O
out IN O
of IN O
32 CD O
episodes NNS O
( : O
78 CD O
% NN O
) -RRB- O
, , O
plasma NN O
ammonium NN O
levels NNS O
and CC O
mental JJ O
status NN O
returned VBD O
to IN O
normal JJ O
within IN O
2 CD O
days NNS O
after IN O
adequate JJ O
management NN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
hyperammonemic JJ B-Disease
encephalopathy NN I-Disease
can MD O
occur VB O
in IN O
patients NNS O
receiving VBG O
continuous JJ O
infusion NN O
of IN O
5 CD O
- HYPH O
FU NN O
. . O
null null null-Disease
Azotemia NNP B-Disease
, , O
body NN O
fluid JJ O
insufficiency NN O
and CC O
bacterial JJ B-Disease
infections NNS I-Disease
were VBD O
frequently RB O
found VBN O
in IN O
these DT O
patients NNS O
. . O
null null null-Disease
It PRP O
is VBZ O
therefore RB O
important JJ O
to TO O
recognize VB O
this DT O
condition NN O
in IN O
patients NNS O
receiving VBG O
continuous JJ O
infusion NN O
of IN O
5 CD O
- HYPH O
FU NN O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
quinine NN O
and CC O
4 CD O
- HYPH O
aminopyridine NN O
on IN O
conditioned VBN O
place NN O
preference NN O
and CC O
changes NNS O
in IN O
motor NN O
activity NN O
induced VBN O
by IN O
morphine NN O
in IN O
rats NNS O
. . O
null null null-Disease
1 LS O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
two CD O
unselective JJ O
potassium NN O
( HYPH O
K NN O
( , O
+ CC O
) -RRB- O
- : O
) -RRB- O
channel NN O
blockers NNS O
, , O
quinine NN O
( , O
12 CD O
. , O
5 CD O
, , O
25 CD O
and CC O
50 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
and CC O
4 CD O
- HYPH O
aminopyridine NN O
( , O
1 CD O
and CC O
2 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
, , O
on IN O
conditioned VBN O
place NN O
preference NN O
and CC O
biphasic JJ O
changes NNS O
in IN O
motor NN O
activity NN O
induced VBN O
by IN O
morphine NN O
( , O
10 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
were VBD O
tested VBN O
in IN O
Wistar NNP O
rats NNS O
. . O
null null null-Disease
Quinine NNP O
is VBZ O
known VBN O
to TO O
block VB O
voltage NN O
- HYPH O
, , O
calcium NN O
- HYPH O
and CC O
ATP NN O
- HYPH O
sensitive JJ O
K NNP O
( , O
+ CC O
) -RRB- O
- HYPH O
channels NNS O
while IN O
4 CD O
- HYPH O
aminopyridine NN O
is VBZ O
known VBN O
to TO O
block VB O
voltage NN O
- HYPH O
sensitive JJ O
K NN O
( , O
+ CC O
) -RRB- O
- HYPH O
channels NNS O
. . O
null null null-Disease
2 LS O
. . O
null null null-Disease
In IN O
the DT O
counterbalanced VBN O
method NN O
, , O
quinine NN O
attenuated VBD O
morphine NN O
- HYPH O
induced VBN O
place NN O
preference NN O
, , O
whereas IN O
4 CD O
- HYPH O
aminopyridine NN O
was VBD O
ineffective JJ O
. . O
null null null-Disease
In IN O
the DT O
motor NN O
activity NN O
test NN O
measured VBN O
with IN O
an DT O
Animex NNP O
- HYPH O
activity NN O
meter NN O
neither DT O
of IN O
the DT O
K NNP O
( , O
+ SYM O
) CD O
- HYPH O
channel NN O
blockers NNS O
affected VBD O
morphine NN O
- HYPH O
induced VBN O
hypoactivity NN B-Disease
, , O
but CC O
both DT O
K NNP O
( , O
+ CC O
) -RRB- O
- HYPH O
channel NN O
blockers NNS O
prevented VBD O
morphine NN O
- HYPH O
induced VBN O
secondary JJ O
hyperactivity NN B-Disease
. . O
null null null-Disease
3 LS O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
the DT O
involvement NN O
of IN O
quinine NN O
- HYPH O
sensitive JJ O
but CC O
not RB O
4 CD O
- HYPH O
aminopyridine NN O
- HYPH O
sensitive JJ O
K NN O
( , O
+ CC O
) -RRB- O
- HYPH O
channels NNS O
in IN O
morphine NN O
reward NN O
. . O
null null null-Disease
It PRP O
is VBZ O
also RB O
suggested VBN O
that IN O
the DT O
blockade NN O
of IN O
K NNP O
( : O
+ SYM O
) CD O
- HYPH O
channels NNS O
sensitive JJ O
to IN O
these DT O
blockers NNS O
is VBZ O
not RB O
sufficient JJ O
to TO O
prevent VB O
morphine NN O
- HYPH O
induced VBN O
hypoactivity NN B-Disease
whereas IN O
morphine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
seems VBZ O
to TO O
be VB O
connected VBN O
to IN O
both CC O
quinine NN O
- HYPH O
and CC O
4 CD O
- HYPH O
aminopyridine NN O
- HYPH O
sensitive JJ O
K NN O
( : O
+ CC O
) -RRB- O
- HYPH O
channels NNS O
. . O
null null null-Disease
Nociceptin NN O
/ SYM O
orphanin NN O
FQ NN O
and CC O
nocistatin NN O
on IN O
learning NN B-Disease
and CC I-Disease
memory NN I-Disease
impairment NN I-Disease
induced VBN O
by IN O
scopolamine NN O
in IN O
mice NNS O
. . O
null null null-Disease
1 LS O
. . O
null null null-Disease
Nociceptin NNP O
, , O
also RB O
known VBN O
as IN O
orphanin NN O
FQ NN O
, , O
is VBZ O
an DT O
endogenous JJ O
ligand NN O
for IN O
the DT O
orphan NN O
opioid NN O
receptor NN O
- HYPH O
like JJ O
receptor NN O
1 CD O
( , O
ORL1 NN O
) -RRB- O
and CC O
involves VBZ O
in IN O
various JJ O
functions NNS O
in IN O
the DT O
central JJ O
nervous JJ O
system NN O
( : O
CNS NNP O
) -RRB- O
. . O
null null null-Disease
On IN O
the DT O
other JJ O
hand NN O
, , O
nocistatin NN O
is VBZ O
recently RB O
isolated VBN O
from IN O
the DT O
same JJ O
precursor NN O
as IN O
nociceptin NN O
and CC O
blocks VBZ O
nociceptin NN O
- HYPH O
induced VBN O
allodynia NN B-Disease
and CC O
hyperalgesia NN B-Disease
. . O
null null null-Disease
2 LS O
. . O
null null null-Disease
Although IN O
ORL1 NNP O
receptors NNS O
which WDT O
display VBP O
a DT O
high JJ O
degree NN O
of IN O
sequence NN O
homology NN O
with IN O
classical JJ O
opioid NN O
receptors NNS O
are VBP O
abundant JJ O
in IN O
the DT O
hippocampus NN O
, , O
little JJ O
is VBZ O
known VBN O
regarding VBG O
their PRP$ O
role NN O
in IN O
learning NN O
and CC O
memory NN O
. . O
null null null-Disease
3 LS O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
was VBD O
designed VBN O
to TO O
investigate VB O
whether IN O
nociceptin NN O
/ SYM O
orphanin NN O
FQ NN O
and CC O
nocistatin NN O
could MD O
modulate VB O
impairment NN B-Disease
of IN I-Disease
learning NN I-Disease
and CC I-Disease
memory NN I-Disease
induced VBN O
by IN O
scopolamine NN O
, , O
a DT O
muscarinic JJ O
cholinergic JJ O
receptor NN O
antagonist NN O
, , O
using VBG O
spontaneous JJ O
alternation NN O
of IN O
Y NN O
- HYPH O
maze NN O
and CC O
step VB O
- HYPH O
down RP O
type NN O
passive JJ O
avoidance NN O
tasks NNS O
in IN O
mice NNS O
. . O
null null null-Disease
4 LS O
. . O
null null null-Disease
While IN O
nocistatin NN O
( : O
0 CD O
. . O
5 CD O
- SYM O
5 CD O
. . O
0 CD O
nmol NN O
mouse NN O
- HYPH O
1 CD O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
. . O
) -RRB- O
administered VBN O
30 CD O
min NN O
before IN O
spontaneous JJ O
alternation NN O
performance NN O
or CC O
the DT O
training NN O
session NN O
of IN O
the DT O
passive JJ O
avoidance NN O
task NN O
, , O
had VBD O
no DT O
effect NN O
on IN O
spontaneous JJ O
alternation NN O
or CC O
passive JJ O
avoidance NN O
behaviours NNS O
, , O
a DT O
lower JJR O
per IN O
cent NN O
alternation NN O
and CC O
shorter JJR O
median JJ O
step NN O
- HYPH O
down RP O
latency NN O
in IN O
the DT O
retention NN O
test NN O
were VBD O
obtained VBN O
in IN O
nociceptin NN O
( : O
1 CD O
. . O
5 CD O
and CC O
/ SYM O
or CC O
5 CD O
. . O
0 CD O
nmol NN O
mouse NN O
- HYPH O
1 CD O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
. . O
) -RRB- O
- HYPH O
treated VBN O
normal JJ O
mice NNS O
. . O
null null null-Disease
5 LS O
. . O
null null null-Disease
Administration NN O
of IN O
nocistatin NN O
( : O
1 CD O
. . O
5 CD O
and CC O
/ SYM O
or CC O
5 CD O
. . O
0 NFP O
nmol NN O
mouse NN O
- HYPH O
1 CD O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
. . O
) SYM O
30 CD O
min NN O
before IN O
spontaneous JJ O
alternation NN O
performance NN O
or CC O
the DT O
training NN O
session NN O
of IN O
the DT O
passive JJ O
avoidance NN O
task NN O
, , O
attenuated VBD O
the DT O
scopolamine NN O
- HYPH O
induced VBN O
impairment NN O
of IN O
spontaneous JJ O
alternation NN O
and CC O
passive JJ O
avoidance NN O
behaviours NNS O
. . O
null null null-Disease
6 LS O
. . O
null null null-Disease
These DT O
results NNS O
indicated VBD O
that IN O
nocistatin NN O
, , O
a DT O
new JJ O
biologically RB O
active JJ O
peptide NN O
, , O
ameliorates VBZ O
impairments NNS O
of IN O
spontaneous JJ O
alternation NN O
and CC O
passive JJ O
avoidance NN O
induced VBN O
by IN O
scopolamine NN O
, , O
and CC O
suggested VBD O
that IN O
these DT O
peptides NNS O
play VBP O
opposite JJ O
roles NNS O
in IN O
learning NN O
and CC O
memory NN O
. . O
null null null-Disease
Meloxicam NNP O
- HYPH O
induced VBN O
liver NN B-Disease
toxicity NN I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
the DT O
case NN O
of IN O
a DT O
female JJ O
patient NN O
with IN O
rheumatoid NN B-Disease
arthritis NN I-Disease
who WP O
developed VBD O
acute JJ O
cytolytic JJ O
hepatitis NN B-Disease
due JJ O
to IN O
meloxicam NN O
. . O
null null null-Disease
Recently RB O
introduced VBN O
in IN O
Belgium NNP O
, , O
meloxicam NNP O
is VBZ O
the DT O
first JJ O
nonsteroidal JJ O
antiinflammatory JJ O
drug NN O
with IN O
selective JJ O
action NN O
on IN O
the DT O
inducible JJ O
form NN O
of IN O
cyclooxygenase NN O
2 CD O
. . O
null null null-Disease
The DT O
acute JJ O
cytolytic JJ O
hepatitis NN B-Disease
occurred VBD O
rapidly RB O
after IN O
meloxicam JJ O
administration NN O
and CC O
was VBD O
associated VBN O
with IN O
the DT O
development NN O
of IN O
antinuclear JJ O
antibodies NNS O
suggesting VBG O
a DT O
hypersensitivity NN B-Disease
mechanism NN O
. . O
null null null-Disease
This DT O
first JJ O
case NN O
of IN O
meloxicam JJ O
related JJ O
liver NN B-Disease
toxicity NN I-Disease
demonstrates VBZ O
the DT O
potential NN O
of IN O
this DT O
drug NN O
to TO O
induce VB O
hepatic JJ B-Disease
damage NN I-Disease
. . O
null null null-Disease
Induction NN O
of IN O
apoptosis NN O
by IN O
remoxipride NN O
metabolites NNS O
in IN O
HL60 NN O
and CC O
CD34 NN O
+ SYM O
/ SYM O
CD19 CD O
- HYPH O
human JJ O
bone NN O
marrow NN O
progenitor NN O
cells NNS O
: : O
potential JJ O
relevance NN O
to IN O
remoxipride NN O
- HYPH O
induced VBN O
aplastic JJ B-Disease
anemia NN I-Disease
. . O
null null null-Disease
The DT O
antipsychotic JJ O
agent NN O
, , O
remoxipride NN O
[ -LRB- O
( , O
S NNP O
) NFP O
- HYPH O
( NFP O
- HYPH O
) NFP O
- HYPH O
3 CD O
- HYPH O
bromo NN O
- HYPH O
N NNP O
- HYPH O
[ -LRB- O
( -LRB- O
1 CD O
- HYPH O
ethyl NN O
- HYPH O
2 CD O
- HYPH O
pyrrolidinyl NN O
) -RRB- O
methyl NN O
] -RRB- O
- HYPH O
2 CD O
, , O
6 CD O
- HYPH O
dimethoxybenz NN O
amide NN O
] -RRB- O
has VBZ O
been VBN O
associated VBN O
with IN O
acquired VBN O
aplastic JJ B-Disease
anemia NN I-Disease
. . O
null null null-Disease
We PRP O
have VBP O
examined VBN O
the DT O
ability NN O
of IN O
remoxipride NN O
, , O
three CD O
pyrrolidine NN O
ring NN O
metabolites NNS O
and CC O
five CD O
aromatic JJ O
ring NN O
metabolites NNS O
of IN O
the DT O
parent NN O
compound NN O
to TO O
induce VB O
apoptosis NN O
in IN O
HL60 NN O
cells NNS O
and CC O
human JJ O
bone NN O
marrow NN O
progenitor NN O
( , O
HBMP NNP O
) -RRB- O
cells NNS O
. . O
null null null-Disease
Cells NNS O
were VBD O
treated VBN O
for IN O
0 CD O
- SYM O
24 CD O
h NN O
with IN O
each DT O
compound NN O
( , O
0 CD O
- HYPH O
200 CD O
microM NN O
) -RRB- O
. . O
null null null-Disease
Apoptosis NN O
was VBD O
assessed VBN O
by IN O
fluorescence NN O
microscopy NN O
in IN O
Hoechst NNP O
33342 CD O
- HYPH O
and CC O
propidium NN O
iodide NN O
stained VBD O
cell NN O
samples NNS O
. . O
null null null-Disease
Results NNS O
were VBD O
confirmed VBN O
by IN O
determination NN O
of IN O
internucleosomal JJ O
DNA NN O
fragmentation NN O
using VBG O
gel NN O
electrophoresis NN O
for IN O
HL60 NN O
cell NN O
samples NNS O
and CC O
terminal JJ O
deoxynucleotidyl NN O
transferase NN O
assay NN O
in IN O
HBMP NNP O
cells NNS O
. . O
null null null-Disease
The DT O
catechol NN O
and CC O
hydroquinone NN O
metabolites NNS O
, , O
NCQ436 NNP O
and CC O
NCQ344 NNP O
, , O
induced VBD O
apoptosis NN O
in IN O
HL60 NN O
and CC O
HBMP NNP O
cells NNS O
in IN O
a DT O
time NN O
- HYPH O
and CC O
concentration NN O
dependent JJ O
manner NN O
, , O
while IN O
the DT O
phenols NNS O
, , O
NCR181 NNP O
, , O
FLA873 NNP O
, , O
and CC O
FLA797 NNP O
, , O
and CC O
the DT O
derivatives NNS O
formed VBN O
by IN O
oxidation NN O
of IN O
the DT O
pyrrolidine NN O
ring NN O
, , O
FLA838 NNP O
, , O
NCM001 NNP O
, , O
and CC O
NCL118 NNP O
, , O
had VBD O
no DT O
effect NN O
. . O
null null null-Disease
No DT O
necrosis NN B-Disease
was VBD O
observed VBN O
in IN O
cells NNS O
treated VBN O
with IN O
NCQ436 NNP O
but CC O
NCQ344 NNP O
had VBD O
a DT O
biphasic JJ O
effect NN O
in IN O
both DT O
cell NN O
types NNS O
, , O
inducing VBG O
apoptosis NN O
at IN O
lower JJR O
concentrations NNS O
and CC O
necrosis NN B-Disease
at IN O
higher JJR O
concentrations NNS O
. . O
null null null-Disease
These DT O
data NNS O
show VBP O
that IN O
the DT O
catechol NN O
and CC O
hydroquinone NN O
metabolites NNS O
of IN O
remoxipride NN O
have VBP O
direct JJ O
toxic JJ O
effects NNS O
in IN O
HL60 NNP O
and CC O
HBMP NNP O
cells NNS O
, , O
leading VBG O
to IN O
apoptosis NN O
, , O
while IN O
the DT O
phenol NN O
metabolites NNS O
were VBD O
inactive JJ O
. . O
null null null-Disease
Similarly RB O
, , O
benzene NN O
- HYPH O
derived VBN O
catechol NN O
and CC O
hydroquinone NN O
, , O
but CC O
not RB O
phenol NN O
, , O
induce VBP O
apoptosis NN O
in IN O
HBMP NNP O
cells NNS O
[ -LRB- O
Moran NNP O
et FW O
al NNP O
. . O
, , O
Mol NNP O
. . O
Pharmacol NNP O
. . O
, , O
50 CD O
( SYM O
1996 CD O
) SYM O
610 CD O
- HYPH O
615 CD O
] -RRB- O
. . O
null null null-Disease
We PRP O
propose VBP O
that IN O
remoxipride NN O
and CC O
benzene NN O
may MD O
induce VB O
aplastic JJ B-Disease
anemia NN I-Disease
via IN O
production NN O
of IN O
similar JJ O
reactive JJ O
metabolites NNS O
and CC O
that IN O
the DT O
ability NN O
of IN O
NCQ436 NNP O
and CC O
NCQ344 NNP O
to TO O
induce VB O
apoptosis NN O
in IN O
HBMP NNP O
cells NNS O
may MD O
contribute VB O
to IN O
the DT O
mechanism NN O
underlying VBG O
acquired VBN O
aplastic JJ B-Disease
anemia NN I-Disease
that WDT O
has VBZ O
been VBN O
associated VBN O
with IN O
remoxipride NN O
. . O
null null null-Disease
Synthesis NN O
and CC O
preliminary JJ O
pharmacological JJ O
investigations NNS O
of IN O
1 CD O
- HYPH O
( SYM O
1 CD O
, , O
2 CD O
- HYPH O
dihydro NN O
- HYPH O
2 CD O
- HYPH O
acenaphthylenyl NN O
) -RRB- O
piperazine NN O
derivatives NNS O
as IN O
potential JJ O
atypical JJ O
antipsychotic JJ O
agents NNS O
in IN O
mice NNS O
. . O
null null null-Disease
In IN O
research NN O
towards IN O
the DT O
development NN O
of IN O
new JJ O
atypical JJ O
antipsychotic JJ O
agents NNS O
, , O
one CD O
strategy NN O
is VBZ O
that IN O
the DT O
dopaminergic JJ O
system NN O
can MD O
be VB O
modulated VBN O
through IN O
manipulation NN O
of IN O
the DT O
serotonergic JJ O
system NN O
. . O
null null null-Disease
The DT O
synthesis NN O
and CC O
preliminary JJ O
pharmacological JJ O
evaluation NN O
of IN O
a DT O
series NN O
of IN O
potential JJ O
atypical JJ O
antipsychotic JJ O
agents NNS O
based VBN O
on IN O
the DT O
structure NN O
of IN O
1 CD O
- HYPH O
( SYM O
1 CD O
, , O
2 CD O
- HYPH O
dihydro NN O
- HYPH O
2 CD O
- HYPH O
acenaphthylenyl NN O
) -RRB- O
piperazine NN O
( SYM O
7 CD O
) -RRB- O
is VBZ O
described VBN O
. . O
null null null-Disease
Compound VB O
7e CD O
, , O
5 CD O
- HYPH O
{ NN O
2 CD O
- HYPH O
[ -LRB- O
4 CD O
- HYPH O
( SYM O
1 CD O
, , O
2 CD O
- HYPH O
dihydro NN O
- HYPH O
2 CD O
- HYPH O
acenaphthylenyl NN O
) , O
piperazinyl NN O
] -RRB- O
ethyl NN O
} NFP O
- HYPH O
2 CD O
, , O
3 CD O
- HYPH O
dihy NN O
dro NN O
- HYPH O
1H NN O
- HYPH O
indol NN O
- HYPH O
2 CD O
- HYPH O
one CD O
, , O
from IN O
this DT O
series NN O
showed VBD O
significant JJ O
affinities NNS O
at IN O
the DT O
5 CD O
- HYPH O
HT1A NNP O
and CC O
5 CD O
- HYPH O
HT2A NN O
receptors NNS O
and CC O
moderate JJ O
affinity NN O
at IN O
the DT O
D2 NNP O
receptor NN O
. . O
null null null-Disease
7e CD O
exhibits VBZ O
a DT O
high JJ O
reversal NN O
of IN O
catalepsy NN B-Disease
induced VBN O
by IN O
haloperidol NN O
indicating VBG O
its PRP$ O
atypical JJ O
antipsychotic JJ O
nature NN O
. . O
null null null-Disease
Sub NN O
- HYPH O
chronic JJ O
inhibition NN O
of IN O
nitric JJ O
- HYPH O
oxide NN O
synthesis NN O
modifies VBZ O
haloperidol NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
and CC O
the DT O
number NN O
of IN O
NADPH NNP O
- HYPH O
diaphorase NN O
neurons NNS O
in IN O
mice NNS O
. . O
null null null-Disease
RATIONALE NN O
: : O
NG NNP O
- HYPH O
nitro NNP O
- HYPH O
L NNP O
- HYPH O
arginine NNP O
( -LRB- O
L NNP O
- HYPH O
NOARG NNP O
) -RRB- O
, , O
an DT O
inhibitor NN O
of IN O
nitric NN O
- HYPH O
oxide NN O
synthase NN O
( , O
NOS NNP O
) -RRB- O
, , O
induces VBZ O
catalepsy NN B-Disease
in IN O
mice NNS O
. . O
null null null-Disease
This DT O
effect NN O
undergoes VBZ O
rapid JJ O
tolerance NN O
, , O
showing VBG O
a DT O
significant JJ O
decrease NN O
after IN O
2 CD O
days NNS O
of IN O
sub NN O
- HYPH O
chronic JJ O
L NN O
- HYPH O
NOARG NNP O
treatment NN O
. . O
null null null-Disease
Nitric JJ O
oxide NN O
( -LRB- O
NO NNP O
) -RRB- O
has VBZ O
been VBN O
shown VBN O
to TO O
influence VB O
dopaminergic JJ O
neurotransmission NN O
in IN O
the DT O
striatum NN O
. . O
null null null-Disease
Neuroleptic JJ O
drugs NNS O
such JJ O
as IN O
haloperidol NN O
, , O
which WDT O
block VBP O
dopamine NN O
receptors NNS O
, , O
also RB O
cause VBP O
catalepsy NN B-Disease
in IN O
rodents NNS O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
To TO O
investigate VB O
the DT O
effects NNS O
of IN O
subchronic JJ O
L NNP O
- HYPH O
NOARG NNP O
treatment NN O
in IN O
haloperidol NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
and CC O
the DT O
number NN O
of IN O
NOS NNP O
neurons NNS O
in IN O
areas NNS O
related VBN O
to IN O
motor NN O
control NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Male JJ O
albino JJ O
Swiss JJ O
mice NNS O
were VBD O
treated VBN O
sub NN O
- HYPH O
chronically RB O
( : O
twice PDT O
a DT O
day NN O
for IN O
4 CD O
days NNS O
) : O
with IN O
L NNP O
- HYPH O
NOARG NNP O
( : O
40 CD O
mg NNS O
/ SYM O
kg CD O
i NN O
. . O
p NN O
. . O
) -RRB- O
or CC O
haloperidol NN O
( : O
1 CD O
mg CD O
/ SYM O
kg CD O
i NN O
. . O
p NN O
. . O
) -RRB- O
. . O
null null null-Disease
Catalepsy NN B-Disease
was VBD O
evaluated VBN O
at IN O
the DT O
beginning NN O
and CC O
the DT O
end NN O
of IN O
the DT O
treatments NNS O
. . O
null null null-Disease
Reduced VBN O
nicotinamide NN O
adenine NN O
dinucleotide NN O
phosphate NN O
- HYPH O
diaphorase NN O
( -LRB- O
NADPH NN O
- HYPH O
d NN O
) -RRB- O
histochemistry NN O
was VBD O
also RB O
employed VBN O
to TO O
visualize VB O
NOS NNP O
as IN O
an DT O
index NN O
of IN O
enzyme NN O
expression NN O
in IN O
mice NNS O
brain NN O
regions NNS O
related VBN O
to IN O
motor NN O
control NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
L NNP O
- HYPH O
NOARG NNP O
sub NN O
- HYPH O
chronic JJ O
administration NN O
produced VBN O
tolerance NN O
of IN O
L NNP O
- HYPH O
NOARG NNP O
and CC O
of IN O
haloperidol NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
. . O
null null null-Disease
It PRP O
also RB O
induced VBD O
an DT O
increase NN O
in IN O
the DT O
number NN O
of IN O
NADPH NNP O
- HYPH O
d NN O
- HYPH O
positive JJ O
cells NNS O
in IN O
the DT O
dorsal JJ O
part NN O
of IN O
the DT O
caudate NN O
and CC O
accumbens NNS O
nuclei NNS O
compared VBN O
with IN O
haloperidol NN O
and CC O
in IN O
the DT O
pedunculopontine NN O
tegmental JJ O
nucleus NN O
compared VBN O
with IN O
saline NN O
. . O
null null null-Disease
In IN O
contrast NN O
, , O
there EX O
was VBD O
a DT O
decrease NN O
in IN O
NADPH NNP O
- HYPH O
d NNP O
neuron NN O
number NN O
in IN O
the DT O
substantia JJ O
nigra NN O
, , O
pars NNS O
compacta NN O
in IN O
both CC O
haloperidol NN O
- HYPH O
treated VBN O
and CC O
L NNP O
- HYPH O
NOARG NNP O
- HYPH O
treated VBN O
animals NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
results NNS O
give VBP O
further JJ O
support NN O
to IN O
the DT O
hypothesis NN O
that IN O
NO NNP O
plays VBZ O
a DT O
role NN O
in IN O
motor NN O
behavior NN O
control NN O
and CC O
suggest VB O
that IN O
it PRP O
may MD O
take VB O
part NN O
in IN O
the DT O
synaptic JJ O
changes NNS O
produced VBN O
by IN O
antipsychotic JJ O
treatment NN O
. . O
null null null-Disease
Prolonged VBN O
left JJ B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
occurs VBZ O
in IN O
patients NNS O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
after IN O
both CC O
dobutamine NN O
and CC O
exercise NN O
induced VBN O
myocardial JJ B-Disease
ischaemia NN I-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
determine VB O
whether IN O
pharmacological JJ O
stress NN O
leads VBZ O
to IN O
prolonged JJ O
but CC O
reversible JJ O
left VBN B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
in IN O
patients NNS O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
, , O
similar JJ O
to IN O
that DT O
seen VBN O
after IN O
exercise NN O
. . O
null null null-Disease
DESIGN NN O
: : O
A DT O
randomised JJ O
crossover NN O
study NN O
of IN O
recovery NN O
time NN O
of IN O
systolic JJ O
and CC O
diastolic JJ O
left VBD O
ventricular JJ O
function NN O
after IN O
exercise NN O
and CC O
dobutamine NN O
induced VBD O
ischaemia NN B-Disease
. . O
null null null-Disease
SUBJECTS NNS O
: : O
10 CD O
patients NNS O
with IN O
stable JJ B-Disease
angina NN I-Disease
, , O
angiographically RB O
proven VBN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
, , O
and CC O
normal JJ O
left VBD O
ventricular JJ O
function NN O
. . O
null null null-Disease
INTERVENTIONS NNS O
: : O
Treadmill NN O
exercise NN O
and CC O
dobutamine NN O
stress NN O
were VBD O
performed VBN O
on IN O
different JJ O
days NNS O
. . O
null null null-Disease
Quantitative JJ O
assessment NN O
of IN O
systolic JJ O
and CC O
diastolic JJ O
left JJ O
ventricular JJ O
function NN O
was VBD O
performed VBN O
using VBG O
transthoracic JJ O
echocardiography NN O
at IN O
baseline NN O
and CC O
at IN O
regular JJ O
intervals NNS O
after IN O
each DT O
test NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Both DT O
forms NNS O
of IN O
stress NN O
led VBD O
to IN O
prolonged JJ O
but CC O
reversible JJ O
systolic JJ O
and CC O
diastolic JJ O
dysfunction NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
difference NN O
in IN O
the DT O
maximum JJ O
double JJ O
product NN O
( : O
p NN O
= SYM O
0 CD O
. . O
53 CD O
) -RRB- O
or CC O
ST NNP O
depression NN B-Disease
( : O
p NN O
= SYM O
0 CD O
. . O
63 CD O
) -RRB- O
with IN O
either DT O
form NN O
of IN O
stress NN O
. . O
null null null-Disease
After IN O
exercise NN O
, , O
ejection NN O
fraction NN O
was VBD O
reduced VBN O
at IN O
15 CD O
and CC O
30 CD O
minutes NNS O
compared VBN O
with IN O
baseline NN O
( : O
mean JJ O
( : O
SEM NNP O
) -RRB- O
, , O
- HYPH O
5 CD O
. . O
6 CD O
( SYM O
1 CD O
. . O
5 CD O
) NFP O
% NN O
, , O
p NN O
< NN O
0 CD O
. . O
05 CD O
; : O
and CC O
- HYPH O
6 CD O
. . O
1 CD O
( SYM O
2 CD O
. . O
2 CD O
) NFP O
% NN O
, , O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
and CC O
at IN O
30 CD O
and CC O
45 CD O
minutes NNS O
after IN O
dobutamine NN O
( : O
- : O
10 CD O
. . O
8 CD O
( SYM O
1 CD O
. . O
8 CD O
) CD O
% NN O
and CC O
- HYPH O
5 CD O
. . O
5 CD O
( SYM O
1 CD O
. . O
8 CD O
) NFP O
% NN O
, , O
both DT O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Regional JJ O
analysis NN O
showed VBD O
a DT O
reduction NN O
in IN O
the DT O
worst JJS O
affected VBN O
segment NN O
15 CD O
and CC O
30 CD O
minutes NNS O
after IN O
exercise NN O
( : O
- : O
27 CD O
. . O
9 CD O
( SYM O
7 CD O
. . O
2 CD O
) CD O
% NN O
and CC O
- HYPH O
28 CD O
. . O
6 CD O
( SYM O
5 CD O
. . O
7 CD O
) CD O
% NN O
, , O
both DT O
p NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
and CC O
at IN O
30 CD O
minutes NNS O
after IN O
dobutamine NN O
( : O
- HYPH O
32 CD O
( SYM O
5 CD O
. . O
3 CD O
) SYM O
% NN O
, , O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
isovolumic JJ O
relaxation NN O
period NN O
was VBD O
prolonged VBN O
45 CD O
minutes NNS O
after IN O
each DT O
form NN O
of IN O
stress NN O
( , O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
In IN O
patients NNS O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
, , O
dobutamine NN O
induced VBN O
ischaemia NN B-Disease
results VBZ O
in IN O
prolonged VBN O
reversible JJ O
left VBN B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
, , O
presumed VBN O
to TO O
be VB O
myocardial JJ B-Disease
stunning JJ I-Disease
, , O
similar JJ O
to IN O
that DT O
seen VBN O
after IN O
exercise NN O
. . O
null null null-Disease
Dobutamine NN O
induced VBN O
ischaemia NN B-Disease
could MD O
therefore RB O
be VB O
used VBN O
to TO O
study VB O
the DT O
pathophysiology NN O
of IN O
this DT O
phenomenon NN O
further RB O
in IN O
patients NNS O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
Anorexigens NNS O
and CC O
pulmonary JJ B-Disease
hypertension NN I-Disease
in IN O
the DT O
United NNP O
States NNP O
: : O
results NNS O
from IN O
the DT O
surveillance NN O
of IN O
North JJ O
American JJ O
pulmonary JJ B-Disease
hypertension NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
The DT O
use NN O
of IN O
appetite NN O
suppressants NNS O
in IN O
Europe NNP O
has VBZ O
been VBN O
associated VBN O
with IN O
the DT O
development NN O
of IN O
primary JJ B-Disease
pulmonary JJ I-Disease
hypertension NN I-Disease
( , O
PPH NNP B-Disease
) -RRB- O
. . O
null null null-Disease
Recently RB O
, , O
fenfluramine NN O
appetite NN O
suppressants NNS O
became VBD O
widely RB O
used VBN O
in IN O
the DT O
United NNP O
States NNP O
but CC O
were VBD O
withdrawn VBN O
in IN O
September NNP O
1997 CD O
because IN O
of IN O
concerns NNS O
over IN O
adverse JJ O
effects NNS O
. . O
null null null-Disease
MATERIALS NNS O
AND CC O
METHODS NNS O
: : O
We PRP O
conducted VBD O
a DT O
prospective JJ O
surveillance NN O
study NN O
on IN O
patients NNS O
diagnosed VBN O
with IN O
pulmonary JJ B-Disease
hypertension NN I-Disease
at IN O
12 CD O
large JJ O
referral NN O
centers NNS O
in IN O
North NNP O
America NNP O
. . O
null null null-Disease
Data NNS O
collected VBN O
on IN O
patients NNS O
seen VBN O
from IN O
September NNP O
1 CD O
, , O
1996 CD O
, , O
to IN O
December NNP O
31 CD O
, , O
1997 CD O
, , O
included VBD O
the DT O
cause NN O
of IN O
the DT O
pulmonary JJ B-Disease
hypertension NN I-Disease
and CC O
its PRP$ O
severity NN O
. . O
null null null-Disease
Patients NNS O
with IN O
no DT O
identifiable JJ O
cause NN O
of IN O
pulmonary JJ B-Disease
hypertension NN I-Disease
were VBD O
classed VBN O
as IN O
PPH NNP B-Disease
. . O
null null null-Disease
A DT O
history NN O
of IN O
drug NN O
exposure NN O
also RB O
was VBD O
taken VBN O
with IN O
special JJ O
attention NN O
on IN O
the DT O
use NN O
of IN O
antidepressants NNS O
, , O
anorexigens NNS O
, , O
and CC O
amphetamines NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Five CD O
hundred CD O
seventy CD O
- HYPH O
nine CD O
patients NNS O
were VBD O
studied VBN O
, , O
205 CD O
with IN O
PPH NNP B-Disease
and CC O
374 CD O
with IN O
pulmonary JJ B-Disease
hypertension NN I-Disease
from IN O
other JJ O
causes NNS O
( , O
secondary JJ O
pulmonary JJ B-Disease
hypertension NN I-Disease
[ -LRB- O
SPH NNP O
] -RRB- O
) -RRB- O
. . O
null null null-Disease
The DT O
use NN O
of IN O
anorexigens NNS O
was VBD O
common JJ O
in IN O
both DT O
groups NNS O
. . O
null null null-Disease
However RB O
, , O
of IN O
the DT O
medications NNS O
surveyed VBN O
, , O
only RB O
the DT O
fenfluramines NNS O
had VBD O
a DT O
significant JJ O
preferential JJ O
association NN O
with IN O
PPH NNP B-Disease
as IN O
compared VBN O
with IN O
SPH NNP O
( HYPH O
adjusted VBN O
odds NNS O
ratio NN O
for IN O
use NN O
> SYM O
6 CD O
months NNS O
, , O
7 CD O
. . O
5 CD O
; : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
1 CD O
. . O
7 CD O
to TO O
32 CD O
. . O
4 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
association NN O
was VBD O
stronger JJR O
with IN O
longer JJR O
duration NN O
of IN O
use NN O
when WRB O
compared VBN O
to IN O
shorter JJR O
duration NN O
of IN O
use NN O
and CC O
was VBD O
more RBR O
pronounced VBN O
in IN O
recent JJ O
users NNS O
than IN O
in IN O
remote JJ O
users NNS O
. . O
null null null-Disease
An DT O
unexpectedly RB O
high JJ O
( : O
11 CD O
. . O
4 CD O
% NN O
) SYM O
number NN O
of IN O
patients NNS O
with IN O
SPH NNP O
had VBD O
used VBN O
anorexigens NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
magnitude NN O
of IN O
the DT O
association NN O
with IN O
PPH NNP B-Disease
, , O
the DT O
increase NN O
of IN O
association NN O
with IN O
increasing VBG O
duration NN O
of IN O
use NN O
, , O
and CC O
the DT O
specificity NN O
for IN O
fenfluramines NNS O
are VBP O
consistent JJ O
with IN O
previous JJ O
studies NNS O
indicating VBG O
that IN O
fenfluramines NNS O
are VBP O
causally RB O
related VBN O
to IN O
PPH NNP B-Disease
. . O
null null null-Disease
The DT O
high JJ O
prevalence NN O
of IN O
anorexigen NN O
use NN O
in IN O
patients NNS O
with IN O
SPH NNP O
also RB O
raises VBZ O
the DT O
possibility NN O
that IN O
these DT O
drugs NNS O
precipitate VBP O
pulmonary JJ B-Disease
hypertension NN I-Disease
in IN O
patients NNS O
with IN O
underlying VBG O
conditions NNS O
associated VBN O
with IN O
SPH NNP O
. . O
null null null-Disease
Clinical JJ O
aspects NNS O
of IN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
and CC O
thrombosis NN B-Disease
and CC O
other JJ O
side NN O
effects NNS O
of IN O
heparin NN O
therapy NN O
. . O
null null null-Disease
Heparin NNP O
, , O
first RB O
used VBN O
to TO O
prevent VB O
the DT O
clotting NN O
of IN O
blood NN O
in IN O
vitro NN O
, , O
has VBZ O
been VBN O
clinically RB O
used VBN O
to TO O
treat VB O
thrombosis NN B-Disease
for IN O
more JJR O
than IN O
50 CD O
years NNS O
. . O
null null null-Disease
Although IN O
several JJ O
new JJ O
anticoagulant JJ O
drugs NNS O
are VBP O
in IN O
development NN O
, , O
heparin NN O
remains VBZ O
the DT O
anticoagulant NN O
of IN O
choice NN O
to TO O
treat VB O
acute JJ O
thrombotic JJ B-Disease
episodes NNS O
. . O
null null null-Disease
The DT O
clinical JJ O
effects NNS O
of IN O
heparin NN O
are VBP O
meritorious JJ O
, , O
but CC O
side NN O
effects NNS O
do VBP O
exist VB O
. . O
null null null-Disease
Bleeding VBG B-Disease
is VBZ O
the DT O
primary JJ O
untoward JJ O
effect NN O
of IN O
heparin NN O
. . O
null null null-Disease
Major JJ O
bleeding NN B-Disease
is VBZ O
of IN O
primary JJ O
concern NN O
in IN O
patients NNS O
receiving VBG O
heparin NN O
therapy NN O
. . O
null null null-Disease
However RB O
, , O
additional JJ O
important JJ O
untoward JJ O
effects NNS O
of IN O
heparin NN O
therapy NN O
include VBP O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
, , O
heparin NN O
- HYPH O
associated VBN O
osteoporosis NN B-Disease
, , O
eosinophilia NN B-Disease
, , O
skin NN B-Disease
reactions NNS I-Disease
, , O
allergic JJ B-Disease
reactions NNS I-Disease
other JJ O
than IN O
thrombocytopenia NN B-Disease
, , O
alopecia NN B-Disease
, , O
transaminasemia NN O
, , O
hyperkalemia NN B-Disease
, , O
hypoaldosteronism NN B-Disease
, , O
and CC O
priapism NN B-Disease
. . O
null null null-Disease
These DT O
side NN O
effects NNS O
are VBP O
relatively RB O
rare JJ O
in IN O
a DT O
given VBN O
individual NN O
, , O
but CC O
given VBN O
the DT O
extremely RB O
widespread JJ O
use NN O
of IN O
heparin NN O
, , O
some DT O
are VBP O
quite RB O
common JJ O
, , O
particularly RB O
HITT NNP B-Disease
and CC O
osteoporosis NN B-Disease
. . O
null null null-Disease
Although IN O
reasonable JJ O
incidences NNS O
of IN O
many JJ O
of IN O
these DT O
side NN O
effects NNS O
can MD O
be VB O
"""" `` O
softly RB O
"""" '' O
deduced VBN O
from IN O
current JJ O
reports NNS O
dealing VBG O
with IN O
unfractionated JJ O
heparin NN O
, , O
at IN O
present NN O
the DT O
incidences NNS O
of IN O
these DT O
side JJ O
effects NNS O
with IN O
newer JJR O
low JJ O
molecular JJ O
weight NN O
heparins NNS O
appear VBP O
to TO O
be VB O
much RB O
less RBR O
common JJ O
. . O
null null null-Disease
However RB O
, , O
only RB O
longer JJR O
experience NN O
will MD O
more RBR O
clearly RB O
define VB O
the DT O
incidence NN O
of IN O
each DT O
side NN O
effect NN O
with IN O
low JJ O
molecular JJ O
weight NN O
preparations NNS O
. . O
null null null-Disease
A DT O
case NN O
of IN O
bilateral JJ O
optic JJ B-Disease
neuropathy NN I-Disease
in IN O
a DT O
patient NN O
on IN O
tacrolimus NN O
( , O
FK506 CD O
) -RRB- O
therapy NN O
after IN O
liver NN O
transplantation NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
report VB O
a DT O
case NN O
of IN O
bilateral JJ O
optic JJ B-Disease
neuropathy NN I-Disease
in IN O
a DT O
patient NN O
receiving VBG O
tacrolimus NN O
( , O
FK NNP O
506 CD O
, , O
Prograf NNP O
; : O
Fujisawa NNP O
USA NNP O
, , O
Inc NNP O
, , O
Deerfield NNP O
, , O
Illinois NNP O
) , O
for IN O
immunosuppression NN O
after IN O
orthotropic JJ O
liver NN O
transplantation NN O
. . O
null null null-Disease
METHOD NN O
: : O
Case NN O
report NN O
. . O
null null null-Disease
In IN O
a DT O
58 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
receiving VBG O
tacrolimus NN O
after IN O
orthotropic JJ O
liver NN O
transplantation NN O
, , O
serial JJ O
neuro NN O
- HYPH O
ophthalmologic JJ O
examinations NNS O
and CC O
laboratory NN O
studies NNS O
were VBD O
performed VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
patient NN O
had VBD O
episodic JJ O
deterioration NN O
of IN O
vision NN O
in IN O
both DT O
eyes NNS O
, , O
with IN O
clinical JJ O
features NNS O
resembling VBG O
ischemic JJ B-Disease
optic JJ I-Disease
neuropathies NNS I-Disease
. . O
null null null-Disease
Deterioration NN B-Disease
of IN I-Disease
vision NN I-Disease
occurred VBD O
despite IN O
discontinuation NN O
of IN O
the DT O
tacrolimus NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Tacrolimus NNP O
and CC O
other JJ O
immunosuppressive JJ O
agents NNS O
may MD O
be VB O
associated VBN O
with IN O
optic JJ B-Disease
nerve NN I-Disease
toxicity NN I-Disease
. . O
null null null-Disease
Hypercalcemia NN B-Disease
, , O
arrhythmia NN B-Disease
, , O
and CC O
mood NN O
stabilizers NNS O
. . O
null null null-Disease
Recent JJ O
findings NNS O
in IN O
a DT O
bipolar JJ B-Disease
patient NN O
receiving VBG O
maintenance NN O
lithium NN O
therapy NN O
who WP O
developed VBD O
hypercalcemia NN B-Disease
and CC O
severe JJ O
bradyarrhythmia NN B-Disease
prompted VBD O
the DT O
authors NNS O
to TO O
conduct VB O
a DT O
retrospective JJ O
study NN O
of IN O
bipolar JJ B-Disease
patients NNS O
with IN O
lithium NN O
- HYPH O
associated VBN O
hypercalcemia NN B-Disease
. . O
null null null-Disease
A DT O
printout NN O
of IN O
all DT O
cases NNS O
of IN O
hypercalcemia NN B-Disease
that WDT O
presented VBD O
during IN O
a DT O
1 CD O
- HYPH O
year NN O
period NN O
was VBD O
generated VBN O
. . O
null null null-Disease
After IN O
eliminating VBG O
spurious JJ O
hypercalcemias NNS B-Disease
or CC O
those DT O
associated VBN O
with IN O
intravenous JJ O
fluids NNS O
, , O
the DT O
authors NNS O
identified VBD O
18 CD O
non AFX O
- HYPH O
lithium NN O
- HYPH O
treated VBN O
patients NNS O
with IN O
hypercalcemias NNS B-Disease
related VBN O
to IN O
malignancies NNS B-Disease
and CC O
other JJ O
medical JJ O
conditions NNS O
( , O
group NN O
A NN O
) -RRB- O
and CC O
12 CD O
patients NNS O
with IN O
lithium NN O
- HYPH O
associated VBN O
hypercalcemia NN B-Disease
( , O
group NN O
B NNP O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
in IN O
group NN O
B NN O
were VBD O
not RB O
comparable JJ O
to IN O
those DT O
in IN O
group NN O
A NNP O
, , O
as IN O
the DT O
latter JJ O
were VBD O
medically RB O
compromised VBN O
and CC O
were VBD O
receiving VBG O
multiple JJ O
pharmacotherapies NNS O
. . O
null null null-Disease
Thus RB O
, , O
two CD O
control NN O
groups NNS O
were VBD O
generated VBN O
: : O
group NN O
C1 NNP O
, , O
which WDT O
included VBD O
age NN O
- HYPH O
and CC O
sex NN O
- HYPH O
comparable JJ O
lithium NN O
- HYPH O
treated VBN O
bipolar JJ B-Disease
normocalcemic JJ O
patients NNS O
, , O
and CC O
group NN O
C2 NNP O
, , O
which WDT O
included VBD O
bipolar JJ B-Disease
normocalcemic JJ O
patients NNS O
treated VBN O
with IN O
anticonvulsant JJ O
mood NN O
stabilizers NNS O
. . O
null null null-Disease
The DT O
electrocardiographic JJ O
( -LRB- O
ECG NNP O
) -RRB- O
findings NNS O
for IN O
patients NNS O
in IN O
group NN O
B NN O
were VBD O
compared VBN O
with IN O
those DT O
of IN O
patients NNS O
in IN O
groups NNS O
C1 NN O
and CC O
C2 NNP O
. . O
null null null-Disease
It PRP O
was VBD O
found VBN O
that IN O
these DT O
groups NNS O
did VBD O
not RB O
differ VB O
in IN O
their PRP$ O
overall JJ O
frequency NN O
of IN O
ECG NNP O
abnormalities NNS O
; : O
however RB O
, , O
there EX O
were VBD O
significant JJ O
differences NNS O
in IN O
the DT O
frequency NN O
of IN O
conduction NN O
defects NNS O
. . O
null null null-Disease
Patients NNS O
with IN O
hypercalcemia NN B-Disease
resulting VBG O
from IN O
medical JJ O
diseases NNS O
and CC O
bipolar JJ B-Disease
patients NNS O
with IN O
lithium NN O
- HYPH O
associated VBN O
hypercalcemia NN B-Disease
had VBD O
significantly RB O
higher JJR O
frequencies NNS O
of IN O
conduction NN O
defects NNS O
. . O
null null null-Disease
Patients NNS O
in IN O
group NN O
A NN O
had VBD O
significant JJ O
mortality NN O
at IN O
2 CD O
- HYPH O
year NN O
follow NN O
- HYPH O
up NN O
( : O
28 CD O
% NN O
) -RRB- O
, , O
in IN O
contrast NN O
to IN O
zero CD O
mortality NN O
in IN O
the DT O
other JJ O
three CD O
groups NNS O
. . O
null null null-Disease
The DT O
clinical JJ O
implications NNS O
of IN O
these DT O
findings NNS O
are VBP O
discussed VBN O
. . O
null null null-Disease
Attenuation NN O
of IN O
nephrotoxicity NN B-Disease
by IN O
a DT O
novel JJ O
lipid JJ O
nanosphere NN O
( , O
NS NNP O
- HYPH O
718 CD O
) -RRB- O
incorporating VBG O
amphotericin NN O
B NN O
. . O
null null null-Disease
NS NNP O
- HYPH O
718 CD O
, , O
a DT O
lipid JJ O
nanosphere NN O
incorporating VBG O
amphotericin NN O
B NN O
, , O
is VBZ O
effective JJ O
against IN O
pathogenic JJ O
fungi NN O
and CC O
has VBZ O
low JJ O
toxicity NN B-Disease
. . O
null null null-Disease
We PRP O
compared VBD O
the DT O
toxicity NN B-Disease
of IN O
NS NNP O
- HYPH O
718 CD O
with IN O
that DT O
of IN O
Fungizone NNP O
( , O
amphotericin NN O
B NN O
- HYPH O
sodium NN O
deoxycholate NN O
; : O
D NN O
- HYPH O
AmB NNP O
) -RRB- O
in IN O
vitro FW O
using VBG O
renal JJ O
cell NN O
cultures NNS O
and CC O
in IN O
vivo NN O
by IN O
biochemical JJ O
analysis NN O
, , O
histopathological JJ O
study NN O
of IN O
the DT O
kidney NN O
and CC O
pharmacokinetic JJ O
study NN O
of IN O
amphotericin NN O
B NN O
following VBG O
intravenous JJ O
infusion NN O
of IN O
the DT O
formulation NN O
in IN O
rats NNS O
. . O
null null null-Disease
Incubation NN O
with IN O
NS NNP O
- HYPH O
718 CD O
resulted VBD O
in IN O
significantly RB O
less JJR O
damage NN O
of IN O
cultured JJ O
human JJ O
renal JJ O
proximal JJ O
tubular JJ O
epithelial JJ O
cells NNS O
compared VBN O
with IN O
D NNP O
- HYPH O
AmB NNP O
. . O
null null null-Disease
Serum NN O
blood NN O
urea NN O
and CC O
creatinine NN O
concentrations NNS O
increased VBD O
significantly RB O
in IN O
rats NNS O
given VBN O
an DT O
iv NN O
infusion NN O
of IN O
D NN O
- HYPH O
AmB NN O
3 CD O
mg NN O
/ SYM O
kg NN O
but CC O
not RB O
in IN O
those DT O
given VBN O
the DT O
same JJ O
dose NN O
of IN O
NS NNP O
- HYPH O
718 CD O
. . O
null null null-Disease
Histopathological JJ O
examination NN O
of IN O
the DT O
kidney NN O
showed VBD O
tubular JJ B-Disease
necrosis NN I-Disease
in IN O
D NNP O
- HYPH O
AmB NN O
- HYPH O
treated VBN O
rats NNS O
but CC O
no DT O
change NN O
in IN O
NS NNP O
- HYPH O
718 CD O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Amphotericin NN O
B NN O
concentrations NNS O
in IN O
the DT O
kidney NN O
in IN O
NS NNP O
- HYPH O
718 CD O
- HYPH O
treated VBN O
rats NNS O
were VBD O
higher JJR O
than IN O
those DT O
in IN O
D NNP O
- HYPH O
AmB NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Our PRP$ O
in IN O
vitro NN O
and CC O
in IN O
vivo NN O
results NNS O
suggest VBP O
that IN O
incorporation NN O
of IN O
amphotericin NN O
B NN O
into IN O
lipid JJ O
nanospheres NNS O
of IN O
NS NNP O
- HYPH O
718 CD O
attenuates VBZ O
the DT O
nephrotoxicity NN B-Disease
of IN O
amphotericin NN O
B NN O
. . O
null null null-Disease
Patterns NNS O
of IN O
sulfadiazine NN O
acute JJ B-Disease
nephrotoxicity NN I-Disease
. . O
null null null-Disease
Sulfadiazine NN O
acute JJ B-Disease
nephrotoxicity NN I-Disease
is VBZ O
reviving VBG O
specially RB O
because IN O
of IN O
its PRP$ O
use NN O
in IN O
toxoplasmosis NN B-Disease
in IN O
HIV NNP O
- HYPH O
positive JJ O
patients NNS O
. . O
null null null-Disease
We PRP O
report VBP O
4 CD O
cases NNS O
, , O
one CD O
of IN O
them PRP O
in IN O
a DT O
previously RB O
healthy JJ O
person NN O
. . O
null null null-Disease
Under IN O
treatment NN O
with IN O
sulfadiazine NN O
they PRP O
developed VBD O
oliguria NN B-Disease
, , O
abdominal JJ B-Disease
pain NN I-Disease
, , O
renal JJ B-Disease
failure NN I-Disease
and CC O
showed VBD O
multiple JJ O
radiolucent JJ O
renal JJ B-Disease
calculi NN I-Disease
in IN O
echography NN O
. . O
null null null-Disease
All DT O
patients NNS O
recovered VBD O
their PRP$ O
previous JJ O
normal JJ O
renal JJ O
function NN O
after IN O
adequate JJ O
hydration NN O
and CC O
alcalinization NN O
. . O
null null null-Disease
A DT O
nephrostomy NN O
tube NN O
had VBD O
to TO O
be VB O
placed VBN O
in IN O
one CD O
of IN O
the DT O
patients NNS O
for IN O
ureteral JJ B-Disease
lithiasis NN I-Disease
in IN O
a DT O
single JJ O
functional JJ O
kidney NN O
. . O
null null null-Disease
null NN O
of IN O
them PRP O
needed VBD O
dialysis NN O
or CC O
a DT O
renal JJ O
biopsy NN O
because IN O
of IN O
a DT O
typical JJ O
benign JJ O
course NN O
. . O
null null null-Disease
Treatment NN O
with IN O
sulfadiazine NN O
requires VBZ O
exquisite JJ O
control NN O
of IN O
renal JJ O
function NN O
, , O
an DT O
increase NN O
in IN O
water NN O
ingestion NN O
and CC O
possibly RB O
the DT O
alcalinization NN O
of IN O
the DT O
urine NN O
. . O
null null null-Disease
We PRP O
communicate VBP O
a DT O
case NN O
in IN O
a DT O
previously RB O
healthy JJ O
person NN O
, , O
a DT O
fact NN O
not RB O
found VBN O
in IN O
the DT O
recent JJ O
literature NN O
. . O
null null null-Disease
Probably RB O
many JJ O
more JJR O
cases NNS O
are VBP O
not RB O
detected VBN O
. . O
null null null-Disease
We PRP O
think VBP O
that IN O
a DT O
prospective JJ O
study NN O
would MD O
be VB O
useful JJ O
. . O
null null null-Disease
Downbeat JJ B-Disease
nystagmus NN I-Disease
associated VBN O
with IN O
intravenous JJ O
patient NN O
- HYPH O
controlled VBN O
administration NN O
of IN O
morphine NN O
. . O
null null null-Disease
IMPLICATIONS NNS O
: : O
This DT O
case NN O
documents VBZ O
a DT O
patient NN O
who WP O
developed VBD O
dizziness NN B-Disease
with IN O
downbeating JJ B-Disease
nystagmus NN I-Disease
while IN O
receiving VBG O
a DT O
relatively RB O
large JJ O
dose NN O
of IN O
IV NN O
patient NN O
- HYPH O
controlled VBN O
analgesia NN O
morphine NN O
. . O
null null null-Disease
Although IN O
there EX O
have VBP O
been VBN O
case NN O
reports NNS O
of IN O
epidural JJ O
morphine NN O
with IN O
these DT O
symptoms NNS O
and CC O
signs NNS O
, , O
this DT O
has VBZ O
not RB O
been VBN O
previously RB O
documented VBN O
with IN O
IV NN O
or CC O
patient NN O
- HYPH O
controlled VBN O
analgesia NN O
morphine NN O
. . O
null null null-Disease
Hemodynamic JJ O
and CC O
antiadrenergic JJ O
effects NNS O
of IN O
dronedarone NN O
and CC O
amiodarone NN O
in IN O
animals NNS O
with IN O
a DT O
healed VBN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
The DT O
hemodynamic JJ O
and CC O
antiadrenergic JJ O
effects NNS O
of IN O
dronedarone NN O
, , O
a DT O
noniodinated JJ O
compound NN O
structurally RB O
related VBN O
to IN O
amiodarone NN O
, , O
were VBD O
compared VBN O
with IN O
those DT O
of IN O
amiodarone NN O
after IN O
prolonged VBN O
oral JJ O
administration NN O
, , O
both CC O
at IN O
rest NN O
and CC O
during IN O
sympathetic JJ O
stimulation NN O
in IN O
conscious JJ O
dogs NNS O
with IN O
a DT O
healed VBN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
All DT O
dogs NNS O
( , O
n CD O
= SYM O
6 CD O
) -RRB- O
randomly RB O
received VBD O
orally RB O
dronedarone NN O
( : O
10 CD O
and CC O
30 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
, , O
amiodarone NN O
( : O
10 CD O
and CC O
30 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
, , O
and CC O
placebo NN O
twice RB O
daily RB O
for IN O
7 CD O
days NNS O
, , O
with IN O
a DT O
3 CD O
- HYPH O
week NN O
washout NN O
between IN O
consecutive JJ O
treatments NNS O
. . O
null null null-Disease
Heart NN O
rate NN O
( , O
HR NN O
) -RRB- O
, , O
mean JJ O
arterial JJ O
pressure NN O
( , O
MBP NN O
) -RRB- O
, , O
positive JJ O
rate NN O
of IN O
increase NN O
of IN O
left JJ O
ventricular JJ O
pressure NN O
( , O
+ CC O
LVdP NN O
/ SYM O
dt NN O
) -RRB- O
, , O
echocardiographically RB O
assessed VBN O
left VBN O
ventricular JJ O
ejection NN O
fraction NN O
( , O
LVEF NNP O
) -RRB- O
, , O
and CC O
fractional JJ O
shortening NN O
( , O
FS NNP O
) -RRB- O
, , O
as RB O
well RB O
as IN O
chronotropic JJ O
response NN O
to IN O
isoproterenol NN O
and CC O
exercise NN O
- HYPH O
induced VBN O
sympathetic JJ O
stimulation NN O
were VBD O
evaluated VBN O
under IN O
baseline NN O
and CC O
posttreatment NN O
conditions NNS O
. . O
null null null-Disease
Resting VBG O
values NNS O
of IN O
LVEF NNP O
, , O
FS NNP O
, , O
+ SYM O
LVdP NNP O
/ SYM O
dt NNP O
, , O
and CC O
MBP NNP O
remained VBD O
unchanged JJ O
whatever WDT O
the DT O
drug NN O
and CC O
the DT O
dosing NN O
regimen NN O
, , O
whereas IN O
resting VBG O
HR NN O
was VBD O
significantly RB O
and CC O
dose NN O
- HYPH O
dependently RB O
lowered VBN O
after IN O
dronedarone NN O
and CC O
to IN O
a DT O
lesser JJR O
extent NN O
after IN O
amiodarone NN O
. . O
null null null-Disease
Both CC O
dronedarone NN O
and CC O
amiodarone NN O
significantly RB O
reduced VBD O
the DT O
exercise NN O
- HYPH O
induced VBN O
tachycardia NN B-Disease
and CC O
, , O
at IN O
the DT O
highest JJS O
dose NN O
, , O
decreased VBD O
the DT O
isoproterenol NN O
- HYPH O
induced VBN O
tachycardia NN B-Disease
. . O
null null null-Disease
Thus RB O
, , O
dronedarone NN O
and CC O
amiodarone NN O
displayed VBD O
a DT O
similar JJ O
level NN O
of IN O
antiadrenergic JJ O
effect NN O
and CC O
did VBD O
not RB O
impair VB O
the DT O
resting NN O
left VBD O
ventricular JJ O
function NN O
. . O
null null null-Disease
Consequently RB O
, , O
dronedarone NN O
might MD O
be VB O
particularly RB O
suitable JJ O
for IN O
the DT O
treatment NN O
and CC O
prevention NN O
of IN O
various JJ O
clinical JJ O
arrhythmias NNS B-Disease
, , O
without IN O
compromising VBG O
the DT O
left JJ O
ventricular JJ O
function NN O
. . O
null null null-Disease
Phase NN O
2 CD O
trial NN O
of IN O
liposomal JJ O
doxorubicin NN O
( : O
40 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) NN O
) -RRB- O
in IN O
platinum NN O
/ SYM O
paclitaxel NN O
- HYPH O
refractory JJ O
ovarian JJ B-Disease
and CC I-Disease
fallopian JJ I-Disease
tube NN I-Disease
cancers NNS I-Disease
and CC O
primary JJ O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
peritoneum NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Several JJ O
studies NNS O
have VBP O
demonstrated VBN O
liposomal JJ O
doxorubicin NN O
( -LRB- O
Doxil NNP O
) -RRB- O
to TO O
be VB O
an DT O
active JJ O
antineoplastic JJ O
agent NN O
in IN O
platinum NN O
- HYPH O
resistant JJ O
ovarian JJ B-Disease
cancer NN I-Disease
, , O
with IN O
dose NN O
limiting VBG O
toxicity NN B-Disease
of IN O
the DT O
standard JJ O
dosing NN O
regimen NN O
( , O
50 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) SYM O
q CD O
4 CD O
weeks NNS O
) , O
being VBG O
severe JJ O
erythrodysesthesia NN B-Disease
( , O
"""" `` O
hand NN B-Disease
- HYPH I-Disease
foot NN I-Disease
syndrome NN I-Disease
"""" '' O
) -RRB- O
and CC O
stomatitis NN B-Disease
. . O
null null null-Disease
We PRP O
wished VBD O
to TO O
develop VB O
a DT O
more RBR O
tolerable JJ O
liposomal JJ O
doxorubicin NN O
treatment NN O
regimen NN O
and CC O
document VB O
its PRP$ O
level NN O
of IN O
activity NN O
in IN O
a DT O
well RB O
- HYPH O
defined VBN O
patient JJ O
population NN O
with IN O
platinum NN O
/ SYM O
paclitaxel NN O
- HYPH O
refractory JJ O
disease NN O
. . O
null null null-Disease
METHODS NNS O
AND CC O
MATERIALS NNS O
: : O
Patients NNS O
with IN O
ovarian JJ B-Disease
or CC I-Disease
fallopian NN I-Disease
tube NN I-Disease
cancers NNS I-Disease
or CC O
primary JJ O
peritoneal JJ B-Disease
carcinoma NN I-Disease
with IN O
platinum NN O
/ SYM O
paclitaxel NN O
- HYPH O
refractory JJ O
disease NN O
( , O
stable JJ O
or CC O
progressive JJ O
disease NN O
following VBG O
treatment NN O
with IN O
these DT O
agents NNS O
or CC O
previous JJ O
objective JJ O
response NN O
< : O
3 CD O
months NNS O
in IN O
duration NN O
) -RRB- O
were VBD O
treated VBN O
with IN O
liposomal JJ O
doxorubicin NN O
at IN O
a DT O
dose NN O
of IN O
40 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) SYM O
q CD O
4 CD O
weeks NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
A DT O
total NN O
of IN O
49 CD O
patients NNS O
( , O
median JJ O
age NN O
: : O
60 CD O
; : O
range NN O
41 CD O
- HYPH O
81 CD O
) -RRB- O
entered VBD O
this DT O
phase NN O
2 CD O
trial NN O
. . O
null null null-Disease
The DT O
median JJ O
number NN O
of IN O
prior JJ O
regimens NNS O
was VBD O
2 CD O
( SYM O
range NN O
: : O
1 CD O
- SYM O
6 CD O
) -RRB- O
. . O
null null null-Disease
Six CD O
( SYM O
12 CD O
% NN O
) SYM O
and CC O
4 CD O
( SYM O
8 CD O
% NN O
) , O
patients NNS O
experienced VBD O
grade NN O
2 CD O
hand NN B-Disease
- HYPH I-Disease
foot NN I-Disease
syndrome NN I-Disease
and CC O
stomatitis NN B-Disease
, , O
respectively RB O
( , O
no DT O
episodes NNS O
of IN O
grade NN O
3 CD O
) -RRB- O
. . O
null null null-Disease
One CD O
patient NN O
developed VBD O
grade NN O
3 CD O
diarrhea NN B-Disease
requiring VBG O
hospitalization NN O
for IN O
hydration NN O
. . O
null null null-Disease
Six CD O
( SYM O
12 CD O
% NN O
) SYM O
individuals NNS O
required VBD O
dose NN O
reductions NNS O
. . O
null null null-Disease
The DT O
median JJ O
number NN O
of IN O
courses NNS O
of IN O
liposomal JJ O
doxorubicin NN O
administered VBN O
on IN O
this DT O
protocol NN O
was VBD O
2 CD O
( SYM O
range NN O
: : O
1 CD O
- HYPH O
12 CD O
) -RRB- O
. . O
null null null-Disease
Four CD O
of IN O
44 CD O
patients NNS O
( : O
9 CD O
% NN O
) , O
evaluable JJ O
for IN O
response NN O
exhibited VBD O
objective JJ O
and CC O
subjective JJ O
evidence NN O
of IN O
an DT O
antineoplastic JJ O
effect NN O
of IN O
therapy NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
This DT O
modified VBN O
liposomal JJ O
doxorubicin NN O
regimen NN O
results VBZ O
in IN O
less JJR O
toxicity NN B-Disease
( , O
stomatitis NN B-Disease
, , O
hand NN B-Disease
- HYPH I-Disease
foot NN I-Disease
syndrome NN I-Disease
) -RRB- O
than IN O
the DT O
standard JJ O
FDA NNP O
- HYPH O
approved VBN O
dose NN O
schedule NN O
. . O
null null null-Disease
Definite JJ O
, , O
although IN O
limited JJ O
, , O
antineoplastic JJ O
activity NN O
is VBZ O
observed VBN O
in IN O
patients NNS O
with IN O
well RB O
- HYPH O
defined VBN O
platinum NN O
- HYPH O
and CC O
paclitaxel NN O
- HYPH O
refractory JJ O
ovarian JJ B-Disease
cancer NN I-Disease
. . O
null null null-Disease
Efficacy NN O
of IN O
olanzapine NN O
in IN O
acute JJ O
bipolar JJ B-Disease
mania NN I-Disease
: : O
a DT O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
- HYPH O
controlled VBN O
study NN O
. . O
null null null-Disease
The DT O
Olanzipine NNP O
HGGW NNP O
Study NNP O
Group NNP O
. . O
null null null-Disease
BACKGROUND NN O
: : O
We PRP O
compared VBD O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
olanzapine NN O
vs IN O
placebo NN O
for IN O
the DT O
treatment NN O
of IN O
acute JJ O
bipolar JJ B-Disease
mania NN I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Four CD O
- HYPH O
week NN O
, , O
randomized JJ O
, , O
double JJ O
- HYPH O
blind JJ O
, , O
parallel JJ O
study NN O
. . O
null null null-Disease
A DT O
total NN O
of IN O
115 CD O
patients NNS O
with IN O
a DT O
DSM NN O
- HYPH O
IV NN O
diagnosis NN O
of IN O
bipolar JJ B-Disease
disorder NN I-Disease
, , O
manic JJ B-Disease
or CC O
mixed JJ O
, , O
were VBD O
randomized VBN O
to IN O
olanzapine NN O
, , O
5 CD O
to TO O
20 CD O
mg NN O
/ SYM O
d CD O
( SYM O
n CD O
= SYM O
55 CD O
) -RRB- O
, , O
or CC O
placebo NN O
( SYM O
n CD O
= SYM O
60 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
primary JJ O
efficacy NN O
measure NN O
was VBD O
the DT O
Young NNP O
- HYPH O
Mania NNP B-Disease
Rating NNP O
Scale NNP O
( -LRB- O
Y NNP O
- HYPH O
MRS NNP O
) -RRB- O
total JJ O
score NN O
. . O
null null null-Disease
Response NN O
and CC O
euthymia NN O
were VBD O
defined VBN O
, , O
a DT O
priori NN O
, , O
as IN O
at IN O
least JJS O
a DT O
50 CD O
% NN O
improvement NN O
from IN O
baseline NN O
to IN O
end NN O
point NN O
and CC O
as IN O
a DT O
score NN O
of IN O
no DT O
less JJR O
than IN O
12 CD O
at IN O
end NN O
point NN O
in IN O
the DT O
Y NNP O
- HYPH O
MRS NNP O
total JJ O
score NN O
, , O
respectively RB O
. . O
null null null-Disease
Safety NN O
was VBD O
assessed VBN O
using VBG O
adverse JJ O
events NNS O
, , O
Extrapyramidal NNP B-Disease
Symptom NNP I-Disease
( , O
EPS NNP B-Disease
) -RRB- O
rating NN O
scales NNS O
, , O
laboratory NN O
values NNS O
, , O
electrocardiograms NNS O
, , O
vital JJ O
signs NNS O
, , O
and CC O
weight NN O
change NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Olanzapine NN O
- HYPH O
treated VBN O
patients NNS O
demonstrated VBD O
a DT O
statistically RB O
significant JJ O
greater JJR O
mean NN O
( , O
+ SYM O
/ SYM O
- HYPH O
SD NN O
) -RRB- O
improvement NN O
in IN O
Y NN O
- HYPH O
MRS NNP O
total JJ O
score NN O
than IN O
placebo NN O
- HYPH O
treated VBN O
patients NNS O
( : O
- HYPH O
14 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
12 CD O
. . O
5 CD O
and CC O
- HYPH O
8 CD O
. . O
1 CD O
+ SYM O
/ SYM O
- HYPH O
12 CD O
. . O
7 CD O
, , O
respectively RB O
; : O
P NN O
< NN O
. . O
001 CD O
) -RRB- O
, , O
which WDT O
was VBD O
evident JJ O
at IN O
the DT O
first JJ O
postbaseline JJ O
observation NN O
1 CD O
week NN O
after IN O
randomization NN O
and CC O
was VBD O
maintained VBN O
throughout IN O
the DT O
study NN O
( , O
last JJ O
observation NN O
carried VBN O
forward RB O
) -RRB- O
. . O
null null null-Disease
Olanzapine NN O
- HYPH O
treated VBN O
patients NNS O
demonstrated VBD O
a DT O
higher JJR O
rate NN O
of IN O
response NN O
( : O
65 CD O
% NN O
vs IN O
43 CD O
% NN O
, , O
respectively RB O
; : O
P NN O
= SYM O
. . O
02 CD O
) -RRB- O
and CC O
euthymia NN O
( : O
61 CD O
% NN O
vs IN O
36 CD O
% NN O
, , O
respectively RB O
; : O
P NN O
= SYM O
. . O
01 CD O
) -RRB- O
than IN O
placebo NN O
- HYPH O
treated VBN O
patients NNS O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
statistically RB O
significant JJ O
differences NNS O
in IN O
EPSs NNS B-Disease
between IN O
groups NNS O
. . O
null null null-Disease
However RB O
, , O
olanzapine NN O
- HYPH O
treated VBN O
patients NNS O
had VBD O
a DT O
statistically RB O
significant JJ O
greater JJR O
mean NN O
( , O
+ SYM O
/ SYM O
- HYPH O
SD NN O
) -RRB- O
weight NN B-Disease
gain NN I-Disease
than IN O
placebo NN O
- HYPH O
treated VBN O
patients NNS O
( , O
2 CD O
. . O
1 CD O
+ SYM O
/ SYM O
- HYPH O
2 CD O
. . O
8 CD O
vs IN O
0 CD O
. . O
45 CD O
+ NN O
/ SYM O
- HYPH O
2 CD O
. . O
3 CD O
kg NN O
, , O
respectively RB O
) -RRB- O
and CC O
also RB O
experienced VBD O
more JJR O
treatment NN O
- HYPH O
emergent JJ O
somnolence NN B-Disease
( : O
21 CD O
patients NNS O
[ -LRB- O
38 CD O
. . O
2 CD O
% NN O
] -RRB- O
vs IN O
5 CD O
[ -LRB- O
8 CD O
. . O
3 CD O
% NN O
] -RRB- O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Olanzapine NNP O
demonstrated VBD O
greater JJR O
efficacy NN O
than IN O
placebo NN O
in IN O
the DT O
treatment NN O
of IN O
acute JJ O
bipolar JJ B-Disease
mania NN I-Disease
and CC O
was VBD O
generally RB O
well RB O
tolerated VBN O
. . O
null null null-Disease
The DT O
effect NN O
of IN O
pupil NN B-Disease
dilation NN I-Disease
with IN O
tropicamide NN O
on IN O
vision NN O
and CC O
driving NN O
simulator NN O
performance NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
assess VB O
the DT O
effect NN O
of IN O
pupil NN B-Disease
dilation NN I-Disease
on IN O
vision NN O
and CC O
driving NN O
ability NN O
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
series NN O
of IN O
tests NNS O
on IN O
various JJ O
parameters NNS O
of IN O
visual JJ O
function NN O
and CC O
driving NN O
simulator NN O
performance NN O
were VBD O
performed VBN O
on IN O
12 CD O
healthy JJ O
drivers NNS O
, , O
before IN O
and CC O
after IN O
pupil NN B-Disease
dilation NN I-Disease
using VBG O
guttae NN O
tropicamide NN O
1 CD O
% NN O
. . O
null null null-Disease
A DT O
driving VBG O
simulator NN O
( , O
Transport NNP O
Research NNP O
Laboratory NNP O
) -RRB- O
was VBD O
used VBN O
to TO O
measure VB O
reaction NN O
time NN O
( , O
RT NNP O
) -RRB- O
, , O
speed NN O
maintenance NN O
and CC O
steering NN O
accuracy NN O
. . O
null null null-Disease
Tests NNS O
of IN O
basic JJ O
visual JJ O
function NN O
included VBD O
high JJ O
- HYPH O
and CC O
low JJ O
- HYPH O
contrast NN O
visual JJ O
acuity NN O
( , O
HCVA NNP O
and CC O
LCVA NNP O
) -RRB- O
, , O
Pelli NNP O
- HYPH O
Robson NNP O
contrast NN O
threshold NN O
( , O
CT NNP O
) -RRB- O
and CC O
Goldmann NNP O
perimetry NN O
( -LRB- O
FIELDS NNP O
) -RRB- O
. . O
null null null-Disease
Useful JJ O
Field NNP O
of IN O
View NNP O
( : O
UFOV NNP O
- : O
- : O
a DT O
test NN O
of IN O
visual JJ O
attention NN O
) -RRB- O
was VBD O
also RB O
undertaken VBN O
. . O
null null null-Disease
The DT O
mean JJ O
differences NNS O
in IN O
the DT O
pre NN O
- HYPH O
and CC O
post NN O
- HYPH O
dilatation NN O
measurements NNS O
were VBD O
tested VBN O
for IN O
statistical JJ O
significance NN O
at IN O
the DT O
95 CD O
% NN O
level NN O
using VBG O
one CD O
- HYPH O
tail NN O
paired VBN O
t NN O
- HYPH O
tests NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Pupillary NN B-Disease
dilation NN I-Disease
resulted VBD O
in IN O
a DT O
statistically RB O
significant JJ O
deterioration NN O
in IN O
CT NNP O
and CC O
HCVA NNP O
only RB O
. . O
null null null-Disease
Five CD O
of IN O
12 CD O
drivers NNS O
also RB O
exhibited VBD O
deterioration NN O
in IN O
LCVA NNP O
, , O
CT NNP O
and CC O
RT NNP O
. . O
null null null-Disease
Little JJ O
evidence NN O
emerged VBD O
for IN O
deterioration NN O
in IN O
FIELDS NNP O
and CC O
UFOV NNP O
. . O
null null null-Disease
Also RB O
, , O
7 CD O
of IN O
12 CD O
drivers NNS O
appeared VBD O
to TO O
adjust VB O
their PRP$ O
driving VBG O
behaviour NN O
by IN O
reducing VBG O
their PRP$ O
speed NN O
on IN O
the DT O
driving NN O
simulator NN O
, , O
leading VBG O
to IN O
improved JJ O
steering NN O
accuracy NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Pupillary JJ B-Disease
dilation NN I-Disease
may MD O
lead VB O
to IN O
a DT O
decrease NN O
in IN O
vision NN O
and CC O
daylight NN O
driving NN O
performance NN O
in IN O
young JJ O
people NNS O
. . O
null null null-Disease
A DT O
larger JJR O
study NN O
, , O
including VBG O
a DT O
broader JJR O
spectrum NN O
of IN O
subjects NNS O
, , O
is VBZ O
warranted VBN O
before IN O
guidelines NNS O
can MD O
be VB O
recommended VBN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
isotretinoin JJ B-Disease
embryopathy NN I-Disease
with IN O
bilateral JJ O
anotia NN B-Disease
and CC O
Taussig NNP B-Disease
- HYPH I-Disease
Bing NNP I-Disease
malformation NN I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
newborn JJ O
infant NN O
with IN O
multiple JJ O
congenital JJ O
anomalies NNS O
( , O
anotia NN B-Disease
and CC O
Taussig NNP B-Disease
- HYPH I-Disease
Bing NNP I-Disease
malformation NN I-Disease
) -RRB- O
due IN O
to IN O
exposure NN O
to IN O
isotretinoin NN O
within IN O
the DT O
first JJ O
trimester NN O
. . O
null null null-Disease
In IN O
this DT O
paper NN O
we PRP O
aim VBP O
to TO O
draw VB O
to IN O
the DT O
fact NN O
that IN O
caution NN O
is VBZ O
needed VBN O
when WRB O
prescribing VBG O
vitamin NN O
A NN O
- HYPH O
containing VBG O
drugs NNS O
to IN O
women NNS O
of IN O
childbearing JJ O
years NNS O
. . O
null null null-Disease
Effect NN O
of IN O
methoxamine NN O
on IN O
maximum JJ O
urethral JJ O
pressure NN O
in IN O
women NNS O
with IN O
genuine JJ O
stress NN B-Disease
incontinence NN I-Disease
: : O
a DT O
placebo NN O
- HYPH O
controlled VBN O
, , O
double JJ O
- HYPH O
blind JJ O
crossover NN O
study NN O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
study NN O
was VBD O
to TO O
evaluate VB O
the DT O
potential JJ O
role NN O
for IN O
a DT O
selective JJ O
alpha1 NN O
- HYPH O
adrenoceptor NN O
agonist NN O
in IN O
the DT O
treatment NN O
of IN O
urinary JJ B-Disease
stress NN I-Disease
incontinence NN I-Disease
. . O
null null null-Disease
A DT O
randomised JJ O
, , O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
- HYPH O
controlled VBN O
, , O
crossover NN O
study NN O
design NN O
was VBD O
employed VBN O
. . O
null null null-Disease
Half NN O
log VBP O
incremental JJ O
doses NNS O
of IN O
intravenous JJ O
methoxamine NN O
or CC O
placebo NN O
( , O
saline NN O
) -RRB- O
were VBD O
administered VBN O
to IN O
a DT O
group NN O
of IN O
women NNS O
with IN O
genuine JJ O
stress NN B-Disease
incontinence NN I-Disease
while IN O
measuring VBG O
maximum JJ O
urethral JJ O
pressure NN O
( , O
MUP NNP O
) -RRB- O
, , O
blood NN O
pressure NN O
, , O
heart NN O
rate NN O
, , O
and CC O
symptomatic JJ O
side NN O
effects NNS O
. . O
null null null-Disease
Methoxamine NN O
evoked VBD O
non NN O
- HYPH O
significant JJ O
increases NNS O
in IN O
MUP NNP O
and CC O
diastolic JJ O
blood NN O
pressure NN O
but CC O
caused VBD O
a DT B-Disease
significant JJ I-Disease
rise NN I-Disease
in IN I-Disease
systolic JJ I-Disease
blood NN I-Disease
pressure NN I-Disease
and CC O
significant JJ O
fall NN O
in IN O
heart NN O
rate NN O
at IN O
maximum JJ O
dosage NN O
. . O
null null null-Disease
Systemic JJ O
side NN O
effects NNS O
including VBG O
piloerection NN O
, , O
headache NN B-Disease
, , O
and CC O
cold JJ O
extremities NNS O
were VBD O
experienced VBN O
in IN O
all DT O
subjects NNS O
. . O
null null null-Disease
The DT O
results NNS O
indicate VBP O
that IN O
the DT O
clinical JJ O
usefulness NN O
of IN O
direct JJ O
, , O
peripherally RB O
acting VBG O
sub NN O
- HYPH O
type NN O
- HYPH O
selective JJ O
alpha1 NN O
- HYPH O
adrenoceptor NN O
agonists NNS O
in IN O
the DT O
medical JJ O
treatment NN O
of IN O
stress NN B-Disease
incontinence NN I-Disease
may MD O
be VB O
limited VBN O
by IN O
associated VBN O
piloerection NN O
and CC O
cardiovascular JJ O
side NN O
effects NNS O
. . O
null null null-Disease
Hyperglycemic JJ B-Disease
effect NN O
of IN O
amino NN O
compounds NNS O
structurally RB O
related VBN O
to IN O
caproate NN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
chronic JJ O
feeding NN O
of IN O
small JJ O
amounts NNS O
( , O
0 CD O
. . O
3 CD O
- SYM O
3 CD O
% NN O
of IN O
diet NN O
weight NN O
) -RRB- O
of IN O
certain JJ O
amino NN O
derivatives NNS O
of IN O
caproate NN O
resulted VBD O
in IN O
hyperglycemia NN B-Disease
, , O
an DT O
elevated JJ O
glucose NN O
tolerance NN O
curve NN O
and CC O
, , O
occasionally RB O
, , O
glucosuria NN B-Disease
. . O
null null null-Disease
Effective JJ O
compounds NNS O
included VBD O
norleucine NN O
, , O
norvaline NN O
, , O
glutamate NN O
, , O
epsilon NN O
- HYPH O
aminocaproate NN O
, , O
methionine NN O
, , O
and CC O
leucine NN O
. . O
null null null-Disease
Toleration NN O
of IN O
high JJ O
doses NNS O
of IN O
angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
inhibitors NNS O
in IN O
patients NNS O
with IN O
chronic JJ O
heart NN B-Disease
failure NN I-Disease
: : O
results NNS O
from IN O
the DT O
ATLAS NNP O
trial NN O
. . O
null null null-Disease
The DT O
Assessment NN O
of IN O
Treatment NN O
with IN O
Lisinopril NNP O
and CC O
Survival NNP O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Treatment NN O
with IN O
angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
( -LRB- O
ACE NN O
) -RRB- O
inhibitors NNS O
reduces VBZ O
mortality NN O
and CC O
morbidity NN O
in IN O
patients NNS O
with IN O
chronic JJ O
heart NN B-Disease
failure NN I-Disease
( , O
CHF NNP B-Disease
) -RRB- O
, , O
but CC O
most RBS O
affected VBN O
patients NNS O
are VBP O
not RB O
receiving VBG O
these DT O
agents NNS O
or CC O
are VBP O
being VBG O
treated VBN O
with IN O
doses NNS O
lower JJR O
than IN O
those DT O
found VBN O
to TO O
be VB O
efficacious JJ O
in IN O
trials NNS O
, , O
primarily RB O
because IN O
of IN O
concerns NNS O
about IN O
the DT O
safety NN O
and CC O
tolerability NN O
of IN O
these DT O
agents NNS O
, , O
especially RB O
at IN O
the DT O
recommended VBN O
doses NNS O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
examines VBZ O
the DT O
safety NN O
and CC O
tolerability NN O
of IN O
high JJ O
- HYPH O
compared VBN O
with IN O
low JJ O
- HYPH O
dose NN O
lisinopril NN O
in IN O
CHF NNP B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
The DT O
Assessment NN O
of IN O
Lisinopril NNP O
and CC O
Survival NNP O
study NN O
was VBD O
a DT O
multicenter JJ O
, , O
randomized JJ O
, , O
double JJ O
- HYPH O
blind JJ O
trial NN O
in IN O
which WDT O
patients NNS O
with IN O
or CC O
without IN O
previous JJ O
ACE NN O
inhibitor NN O
treatment NN O
were VBD O
stabilized VBN O
receiving VBG O
medium NN O
- HYPH O
dose NN O
lisinopril NN O
( : O
12 CD O
. . O
5 CD O
or CC O
15 CD O
. . O
0 CD O
mg NN O
once RB O
daily RB O
[ -LRB- O
OD NN O
] -RRB- O
) -RRB- O
for IN O
2 CD O
to TO O
4 CD O
weeks NNS O
and CC O
then RB O
randomized VBN O
to IN O
high JJ O
- HYPH O
( : O
35 CD O
. . O
0 CD O
or CC O
32 CD O
. . O
5 CD O
mg NN O
OD NN O
) -RRB- O
or CC O
low JJ O
- HYPH O
dose NN O
( : O
5 CD O
. . O
0 CD O
or CC O
2 CD O
. . O
5 CD O
mg NN O
OD NN O
) -RRB- O
groups NNS O
. . O
null null null-Disease
Patients NNS O
with IN O
New NNP O
York NNP O
Heart NNP O
Association NNP O
classes NNS O
II CD O
to IN O
IV NN O
CHF NN B-Disease
and CC O
left VBD O
ventricular JJ O
ejection NN O
fractions NNS O
of IN O
no DT O
greater JJR O
than IN O
0 CD O
. . O
30 CD O
( SYM O
n CD O
= SYM O
3164 CD O
) -RRB- O
were VBD O
randomized VBN O
and CC O
followed VBN O
up RP O
for IN O
a DT O
median NN O
of IN O
46 CD O
months NNS O
. . O
null null null-Disease
We PRP O
examined VBD O
the DT O
occurrence NN O
of IN O
adverse JJ O
events NNS O
and CC O
the DT O
need NN O
for IN O
discontinuation NN O
and CC O
dose NN O
reduction NN O
during IN O
treatment NN O
, , O
with IN O
a DT O
focus NN O
on IN O
hypotension NN B-Disease
and CC O
renal JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
Of IN O
405 CD O
patients NNS O
not RB O
previously RB O
receiving VBG O
an DT O
ACE NNP O
inhibitor NN O
, , O
doses NNS O
in IN O
only RB O
4 CD O
. . O
2 CD O
% NN O
could MD O
not RB O
be VB O
titrated VBN O
to IN O
the DT O
medium JJ O
doses NNS O
required VBN O
for IN O
randomization NN O
because IN O
of IN O
symptoms NNS O
possibly RB O
related VBN O
to IN O
hypotension NN B-Disease
( : O
2 CD O
. . O
0 CD O
% NN O
) -RRB- O
or CC O
because IN O
of IN O
renal JJ B-Disease
dysfunction NN I-Disease
or CC O
hyperkalemia NN B-Disease
( : O
2 CD O
. . O
3 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Doses NNS O
in IN O
more JJR O
than IN O
90 CD O
% NN O
of IN O
randomized VBN O
patients NNS O
in IN O
the DT O
high JJ O
- HYPH O
and CC O
low JJ O
- HYPH O
dose NN O
groups NNS O
were VBD O
titrated VBN O
to IN O
their PRP$ O
assigned VBN O
target NN O
, , O
and CC O
the DT O
mean JJ O
doses NNS O
of IN O
blinded VBN O
medication NN O
in IN O
both DT O
groups NNS O
remained VBD O
similar JJ O
throughout IN O
the DT O
study NN O
. . O
null null null-Disease
Withdrawals NNS O
occurred VBD O
in IN O
27 CD O
. . O
1 CD O
% NN O
of IN O
the DT O
high JJ O
- HYPH O
and CC O
30 CD O
. . O
7 CD O
% NN O
of IN O
the DT O
low JJ O
- HYPH O
dose NN O
groups NNS O
. . O
null null null-Disease
Subgroups NNS O
presumed VBN O
to TO O
be VB O
at IN O
higher JJR O
risk NN O
for IN O
ACE NN O
inhibitor NN O
intolerance NN O
( , O
blood NN O
pressure NN O
, , O
< SYM O
120 CD O
mm NN O
Hg NN O
; : O
creatinine NN O
, , O
> NFP O
or CC O
= SYM O
132 CD O
. . O
6 CD O
micromol NN O
/ SYM O
L NNP O
[ -LRB- O
> SYM O
or CC O
= SYM O
1 CD O
. . O
5 CD O
mg NN O
/ SYM O
dL NN O
] -RRB- O
; : O
age NN O
, , O
> SYM O
or CC O
= SYM O
70 CD O
years NNS O
; : O
and CC O
patients NNS O
with IN O
diabetes NN B-Disease
) -RRB- O
generally RB O
tolerated VBD O
the DT O
high JJ O
- HYPH O
dose NN O
strategy NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
These DT O
findings NNS O
demonstrate VBP O
that IN O
ACE NN O
inhibitor NN O
therapy NN O
in IN O
most JJS O
patients NNS O
with IN O
CHF NNP B-Disease
can MD O
be VB O
successfully RB O
titrated VBN O
to IN O
and CC O
maintained VBN O
at IN O
high JJ O
doses NNS O
, , O
and CC O
that IN O
more RBR O
aggressive JJ O
use NN O
of IN O
these DT O
agents NNS O
is VBZ O
warranted VBN O
. . O
null null null-Disease
Cocaine NN O
, , O
ethanol NN O
, , O
and CC O
cocaethylene NN O
cardiotoxity NN B-Disease
in IN O
an DT O
animal NN O
model NN O
of IN O
cocaine NN B-Disease
and CC I-Disease
ethanol NN I-Disease
abuse NN I-Disease
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
Simultaneous JJ O
abuse NN B-Disease
of IN I-Disease
cocaine NN I-Disease
and CC I-Disease
ethanol NN I-Disease
affects VBZ O
12 CD O
million CD O
Americans NNPS O
annually RB O
. . O
null null null-Disease
In IN O
combination NN O
, , O
these DT O
substances NNS O
are VBP O
substantially RB O
more RBR O
toxic JJ O
than IN O
either DT O
drug NN O
alone RB O
. . O
null null null-Disease
Their PRP$ O
combined VBN O
cardiac JJ B-Disease
toxicity NN I-Disease
may MD O
be VB O
due IN O
to IN O
independent JJ O
effects NNS O
of IN O
each DT O
drug NN O
; : O
however RB O
, , O
they PRP O
may MD O
also RB O
be VB O
due IN O
to IN O
cocaethylene NN O
( , O
CE NN O
) -RRB- O
, , O
a DT O
cocaine NN O
metabolite NN O
formed VBN O
only RB O
in IN O
the DT O
presence NN O
of IN O
ethanol NN O
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
delineate VB O
the DT O
role NN O
of IN O
CE NN O
in IN O
the DT O
combined VBN O
cardiotoxicity NN B-Disease
of IN O
cocaine NN O
and CC O
ethanol NN O
in IN O
a DT O
model NN O
simulating VBG O
their PRP$ O
abuse NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Twenty CD O
- HYPH O
three CD O
dogs NNS O
were VBD O
randomized VBN O
to TO O
receive VB O
either CC O
1 CD O
) SYM O
three CD O
intravenous JJ O
( -LRB- O
IV NN O
) -RRB- O
boluses NNS O
of IN O
cocaine NN O
7 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NN O
with IN O
ethanol NN O
( : O
1 CD O
g NNS O
/ SYM O
kg NN O
) -RRB- O
as IN O
an DT O
IV NN O
infusion NN O
( , O
C NN O
+ SYM O
E NNP O
, , O
n CD O
= SYM O
8 CD O
) -RRB- O
, , O
2 CD O
) SYM O
three CD O
cocaine NN O
boluses NNS O
only RB O
( : O
C NNP O
, , O
n CD O
= SYM O
6 CD O
) -RRB- O
, , O
3 CD O
) SYM O
ethanol NN O
infusion NN O
only RB O
( : O
E NN O
, , O
n CD O
= SYM O
5 CD O
) -RRB- O
, , O
or CC O
4 CD O
) SYM O
placebo NN O
boluses NNS O
and CC O
infusion NN O
( : O
n NN O
= SYM O
4 CD O
) -RRB- O
. . O
null null null-Disease
Hemodynamic JJ O
measurements NNS O
, , O
electrocardiograms NNS O
, , O
and CC O
serum NN O
drug NN O
concentrations NNS O
were VBD O
obtained VBN O
at IN O
baseline NN O
, , O
and CC O
then RB O
at IN O
fixed VBN O
time NN O
intervals NNS O
after IN O
each DT O
drug NN O
was VBD O
administered VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Two CD O
of IN O
eight CD O
dogs NNS O
in IN O
the DT O
C NNP O
+ SYM O
E NNP O
group NN O
experienced VBD O
cardiovascular JJ B-Disease
collapse NN I-Disease
. . O
null null null-Disease
The DT O
most RBS O
dramatic JJ O
hemodynamic JJ O
changes NNS O
occurred VBD O
after IN O
each DT O
cocaine NN O
bolus NN O
in IN O
the DT O
C NN O
+ CC O
E NN O
and CC O
C NN O
only RB O
groups NNS O
; : O
however RB O
, , O
persistent JJ O
hemodynamic JJ O
changes NNS O
occurred VBD O
in IN O
the DT O
C NNP O
+ SYM O
E NNP O
group NN O
. . O
null null null-Disease
Peak NN O
CE NN O
levels NNS O
were VBD O
associated VBN O
with IN O
a DT O
45 CD O
% NN O
( , O
SD NN O
+ SYM O
/ SYM O
- SYM O
22 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
22 CD O
% NN O
to TO O
69 CD O
% NN O
) , O
decrease NN B-Disease
in IN I-Disease
cardiac JJ I-Disease
output NN I-Disease
( : O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
, , O
a DT O
56 CD O
% NN O
( , O
SD NN O
+ SYM O
/ SYM O
- SYM O
23 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
32 CD O
% NN O
to TO O
80 CD O
% NN O
) , O
decrease NN O
in IN O
dP NN O
/ : O
dt VBN O
( HYPH O
max NN O
) -RRB- O
( , O
p NN O
< NN O
. . O
006 CD O
) -RRB- O
, , O
and CC O
a DT O
23 CD O
% NN O
( , O
SD NN O
+ SYM O
/ SYM O
- SYM O
15 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
7 CD O
% NN O
to TO O
49 CD O
% NN O
) , O
decrease NN O
in IN O
SVO NNP O
( SYM O
2 CD O
) -RRB- O
( : O
p NN O
< SYM O
0 CD O
. . O
025 CD O
) -RRB- O
. . O
null null null-Disease
Ventricular JJ B-Disease
arrhythmias NNS I-Disease
were VBD O
primarily RB O
observed VBN O
in IN O
the DT O
C NNP O
+ SYM O
E NNP O
group NN O
, , O
in IN O
which WDT O
four CD O
of IN O
eight CD O
dogs NNS O
experienced VBD O
ventricular JJ B-Disease
tachycardia NN I-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Cocaine NN O
and CC O
ethanol NN O
in IN O
combination NN O
were VBD O
more RBR O
toxic JJ O
than IN O
either DT O
substance NN O
alone RB O
. . O
null null null-Disease
Co NN O
- HYPH O
administration NN O
resulted VBD O
in IN O
prolonged VBN O
cardiac JJ B-Disease
toxicity NN I-Disease
and CC O
was VBD O
dysrhythmogenic JJ O
. . O
null null null-Disease
Peak NN O
serum NN O
cocaethylene NN O
concentrations NNS O
were VBD O
associated VBN O
with IN O
prolonged VBN O
myocardial JJ B-Disease
depression NN I-Disease
. . O
null null null-Disease
Worsening VBG O
of IN O
Parkinsonism NNP B-Disease
after IN O
the DT O
use NN O
of IN O
veralipride NN O
for IN O
treatment NN O
of IN O
menopause NN O
: : O
case NN O
report NN O
. . O
null null null-Disease
We PRP O
describe VBP O
a DT O
female JJ O
patient NN O
with IN O
stable JJ O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
who WP O
has VBZ O
shown VBN O
a DT O
marked JJ O
worsening NN O
of IN O
her PRP$ O
motor NN O
functions NNS O
following VBG O
therapy NN O
of IN O
menopause NN O
related VBN O
symptoms NNS O
with IN O
veralipride NN O
, , O
as RB O
well RB O
as IN O
the DT O
improvement NN O
of IN O
her PRP$ O
symptoms NNS O
back RB O
to IN O
baseline NN O
after IN O
discontinuation NN O
of IN O
the DT O
drug NN O
. . O
null null null-Disease
We PRP O
emphasize VBP O
the DT O
anti AFX O
- HYPH O
dopaminergic JJ O
effect NN O
of IN O
veralipride NN O
. . O
null null null-Disease
Viracept NN O
and CC O
irregular JJ B-Disease
heartbeat NN I-Disease
warning NN O
. . O
null null null-Disease
A DT O
group NN O
of IN O
doctors NNS O
in IN O
Boston NNP O
warn VBP O
that IN O
the DT O
protease NN O
inhibitor NN O
Viracept NNP O
may MD O
cause VB O
an DT O
irregular JJ B-Disease
heart NN I-Disease
beat NN I-Disease
, , O
known VBN O
as IN O
bradycardia NN B-Disease
, , O
in IN O
people NNS O
with IN O
HIV NNP O
. . O
null null null-Disease
Bradycardia NNP B-Disease
occurred VBD O
in IN O
a DT O
45 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male JJ O
patient NN O
who WP O
was VBD O
Viracept NNP O
in IN O
combination NN O
with IN O
other JJ O
anti JJ O
- HYPH O
HIV NNP O
drugs NNS O
. . O
null null null-Disease
The DT O
symptoms NNS O
ceased VBD O
after IN O
switching VBG O
to IN O
another DT O
drug NN O
combination NN O
. . O
null null null-Disease
Frequency NN O
of IN O
appearance NN O
of IN O
myeloperoxidase NN O
- HYPH O
antineutrophil NN O
cytoplasmic JJ O
antibody NN O
( , O
MPO NNP O
- HYPH O
ANCA NNP O
) -RRB- O
in IN O
Graves NNPS B-Disease
' POS I-Disease
disease NN I-Disease
patients NNS O
treated VBN O
with IN O
propylthiouracil NN O
and CC O
the DT O
relationship NN O
between IN O
MPO NNP O
- HYPH O
ANCA NNP O
and CC O
clinical JJ O
manifestations NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
Myeloperoxidase NN O
antineutrophil JJ O
cytoplasmic JJ O
antibody NN O
( -LRB- O
MPO NNP O
- HYPH O
ANCA NNP O
) -RRB- O
- HYPH O
positive JJ O
vasculitis NN B-Disease
has VBZ O
been VBN O
reported VBN O
in IN O
patients NNS O
with IN O
Graves NNP B-Disease
' POS I-Disease
disease NN I-Disease
who WP O
were VBD O
treated VBN O
with IN O
propylthiouracil NN O
( , O
PTU NNP O
) -RRB- O
. . O
null null null-Disease
The DT O
appearance NN O
of IN O
MPO NNP O
- HYPH O
ANCA NNP O
in IN O
these DT O
cases NNS O
was VBD O
suspected VBN O
of IN O
being VBG O
related VBN O
to IN O
PTU NNP O
because IN O
the DT O
titres NNS O
of IN O
MPO NNP O
- HYPH O
ANCA NNP O
decreased VBD O
when WRB O
PTU NNP O
was VBD O
stopped VBN O
. . O
null null null-Disease
Nevertheless RB O
, , O
there EX O
have VBP O
been VBN O
no DT O
studies NNS O
on IN O
the DT O
temporal JJ O
relationship NN O
between IN O
the DT O
appearance NN O
of IN O
MPO NNP O
- HYPH O
ANCA NNP O
and CC O
vasculitis NN B-Disease
during IN O
PTU NNP O
therapy NN O
, , O
or CC O
on IN O
the DT O
incidence NN O
of IN O
MPO NNP O
- HYPH O
ANCA NNP O
in IN O
untreated JJ O
Graves NNPS B-Disease
' POS I-Disease
disease NN I-Disease
patients NNS O
. . O
null null null-Disease
Therefore RB O
, , O
we PRP O
sought VBD O
to TO O
address VB O
these DT O
parameters NNS O
in IN O
patients NNS O
with IN O
Graves NNPS B-Disease
' POS I-Disease
disease NN I-Disease
. . O
null null null-Disease
PATIENTS NNS O
: : O
We PRP O
investigated VBD O
102 CD O
untreated JJ O
patients NNS O
with IN O
hyperthyroidism NN B-Disease
due IN O
to IN O
Graves NNP B-Disease
' POS I-Disease
disease NN I-Disease
for IN O
the DT O
presence NN O
of IN O
MPO NNP O
- HYPH O
ANCA NNP O
, , O
and CC O
for IN O
the DT O
development NN O
vasculitis NN B-Disease
after IN O
starting VBG O
PTU NNP O
therapy NN O
. . O
null null null-Disease
Twenty CD O
- HYPH O
nine CD O
of IN O
them PRP O
were VBD O
later RB O
excluded VBN O
because IN O
of IN O
adverse JJ O
effects NNS O
of IN O
PTU NNP O
or CC O
because IN O
the DT O
observation NN O
period NN O
was VBD O
less JJR O
than IN O
3 CD O
months NNS O
. . O
null null null-Disease
The DT O
remaining VBG O
73 CD O
patients NNS O
( , O
55 CD O
women NNS O
and CC O
18 CD O
men NNS O
) -RRB- O
, , O
all DT O
of IN O
whom WP O
were VBD O
examined VBN O
for IN O
more JJR O
than IN O
3 CD O
months NNS O
, , O
were VBD O
adopted VBN O
as IN O
the DT O
subjects NNS O
of IN O
the DT O
investigation NN O
. . O
null null null-Disease
The DT O
median JJ O
observation NN O
period NN O
was VBD O
23 CD O
. . O
6 CD O
months NNS O
( : O
range NN O
: : O
3 CD O
- SYM O
37 CD O
months NNS O
) -RRB- O
. . O
null null null-Disease
MEASUREMENTS NNS O
: : O
MPO NNP O
- HYPH O
ANCA NNP O
was VBD O
measured VBN O
at IN O
intervals NNS O
of IN O
2 CD O
- SYM O
6 CD O
months NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Before IN O
treatment NN O
, , O
the DT O
MPO NNP O
- HYPH O
ANCA NNP O
titres NNS O
of IN O
all DT O
102 CD O
untreated JJ O
Graves NNPS B-Disease
' POS I-Disease
disease NN I-Disease
patients NNS O
were VBD O
within IN O
the DT O
reference NN O
range NN O
( : O
below IN O
10 CD O
U NN O
/ SYM O
ml NN O
) -RRB- O
. . O
null null null-Disease
Three CD O
( SYM O
4 CD O
. . O
1 CD O
% NN O
) -RRB- O
of IN O
the DT O
73 CD O
patients NNS O
were VBD O
positive JJ O
for IN O
MPO NNP O
- HYPH O
ANCA NNP O
at IN O
13 CD O
, , O
16 CD O
and CC O
17 CD O
months NNS O
, , O
respectively RB O
, , O
after IN O
the DT O
start NN O
of IN O
PTU NNP O
therapy NN O
. . O
null null null-Disease
In IN O
two CD O
of IN O
them PRP O
, , O
the DT O
MPO NNP O
- HYPH O
ANCA NNP O
titres NNS O
transiently RB O
increased VBD O
to IN O
12 CD O
. . O
8 CD O
and CC O
15 CD O
. . O
0 CD O
U NN O
/ SYM O
ml CD O
, , O
respectively RB O
, , O
despite IN O
continued JJ O
PTU NN O
therapy NN O
, , O
but CC O
no DT O
vasculitic JJ B-Disease
disorders NNS I-Disease
developed VBN O
. . O
null null null-Disease
In IN O
the DT O
third JJ O
patient NN O
, , O
the DT O
MPO NNP O
- HYPH O
ANCA NNP O
titre NN O
increased VBD O
to IN O
204 CD O
U NN O
/ SYM O
ml NNS O
and CC O
she PRP O
developed VBD O
a DT O
higher JJR O
fever NN B-Disease
, , O
oral JJ B-Disease
ulcers NNS I-Disease
and CC O
polyarthralgia NN B-Disease
, , O
but CC O
the DT O
symptoms NNS O
resolved VBN O
2 CD O
weeks NNS O
after IN O
stopping VBG O
PTU NNP O
therapy NN O
, , O
and CC O
the DT O
MPO NNP O
- HYPH O
ANCA NNP O
titre NN O
decreased VBD O
to IN O
20 CD O
. . O
7 CD O
U NN O
/ SYM O
ml NN O
by IN O
4 CD O
months NNS O
after IN O
discontinuing VBG O
PTU NNP O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
PTU NN O
therapy NN O
may MD O
be VB O
related VBN O
to IN O
the DT O
appearance NN O
of IN O
MPO NNP O
- HYPH O
ANCA NNP O
, , O
but CC O
MPO NNP O
- HYPH O
ANCA NNP O
does VBZ O
not RB O
appear VB O
to TO O
be VB O
closely RB O
related VBN O
to IN O
vasculitis NN B-Disease
. . O
null null null-Disease
Prevalence NN O
of IN O
heart NN B-Disease
disease NN I-Disease
in IN O
asymptomatic JJ O
chronic JJ O
cocaine NN O
users NNS O
. . O
null null null-Disease
To TO O
determine VB O
the DT O
prevalence NN O
of IN O
heart NN B-Disease
disease NN I-Disease
in IN O
outpatient JJ O
young JJ O
asymptomatic JJ O
chronic JJ O
cocaine NN O
users NNS O
, , O
35 CD O
cocaine NN O
users NNS O
and CC O
32 CD O
age NN O
- HYPH O
matched VBN O
controls NNS O
underwent VBD O
resting NN O
and CC O
exercise NN O
electrocardiography NN O
( , O
ECG NNP O
) -RRB- O
and CC O
Doppler NNP O
echocardiography NN O
. . O
null null null-Disease
Findings NNS O
consistent JJ O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
were VBD O
detected VBN O
in IN O
12 CD O
( SYM O
34 CD O
% NN O
) SYM O
patients NNS O
and CC O
3 CD O
( SYM O
9 CD O
% NN O
) -RRB- O
controls NNS O
( : O
p NN O
= SYM O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Decreased VBN O
left JJ O
ventricular JJ O
systolic JJ O
function NN O
was VBD O
demonstrated VBN O
in IN O
5 CD O
( SYM O
14 CD O
% NN O
) SYM O
patients NNS O
, , O
but CC O
in IN O
none NN O
of IN O
the DT O
controls NNS O
( : O
p NN O
= SYM O
0 CD O
. . O
055 CD O
) -RRB- O
. . O
null null null-Disease
Finally RB O
, , O
resting NN O
and CC O
peak NN O
exercise NN O
abnormal JJ B-Disease
left JJ I-Disease
ventricular JJ I-Disease
filling NN I-Disease
was VBD O
detected VBN O
in IN O
38 CD O
and CC O
35 CD O
% NN O
of IN O
patients NNS O
as IN O
compared VBN O
to IN O
19 CD O
and CC O
9 CD O
% NN O
of IN O
controls NNS O
, , O
respectively RB O
( : O
p NN O
= SYM O
0 CD O
. . O
11 CD O
and CC O
0 CD O
. . O
02 CD O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
coronary JJ B-Disease
artery NN I-Disease
or CC I-Disease
myocardial JJ I-Disease
disease NN I-Disease
is VBZ O
common JJ O
( : O
38 CD O
% NN O
) -RRB- O
in IN O
young JJ O
asymptomatic JJ O
chronic JJ O
cocaine NN O
users NNS O
. . O
null null null-Disease
Therefore RB O
, , O
screening VBG O
ECG NNP O
and CC O
echocardiography NN O
may MD O
be VB O
warranted VBN O
in IN O
these DT O
patients NNS O
. . O
null null null-Disease
Cardioprotective JJ O
effects NNS O
of IN O
Picrorrhiza NNP O
kurroa NN O
against IN O
isoproterenol NN O
- HYPH O
induced VBN O
myocardial JJ O
stress NN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
cardioprotective JJ O
effect NN O
of IN O
the DT O
ethanol NN O
extract NN O
of IN O
Picrorrhiza NNP O
kurroa NN O
rhizomes NNS O
and CC O
roots NNS O
( , O
PK NNP O
) -RRB- O
on IN O
isoproterenol NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
infarction NN I-Disease
in IN O
rats NNS O
with IN O
respect NN O
to IN O
lipid JJ O
metabolism NN O
in IN O
serum NN O
and CC O
heart NN O
tissue NN O
has VBZ O
been VBN O
investigated VBN O
. . O
null null null-Disease
Oral JJ O
pre NN O
- HYPH O
treatment NN O
with IN O
PK NNP O
( : O
80 CD O
mg CD O
kg NNS O
( SYM O
- HYPH O
1 CD O
) SYM O
day NN O
( HYPH O
- HYPH O
1 CD O
) -RRB- O
for IN O
15 CD O
days NNS O
) -RRB- O
significantly RB O
prevented VBD O
the DT O
isoproterenol NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
infarction NN I-Disease
and CC O
maintained VBD O
the DT O
rats NNS O
at IN O
near IN O
normal JJ O
status NN O
. . O
null null null-Disease
Phase NN O
2 CD O
early JJ O
afterdepolarization NN O
as IN O
a DT O
trigger NN O
of IN O
polymorphic JJ O
ventricular JJ B-Disease
tachycardia NN I-Disease
in IN O
acquired VBN O
long JJ B-Disease
- HYPH I-Disease
QT NNP I-Disease
syndrome NN I-Disease
: : O
direct JJ O
evidence NN O
from IN O
intracellular JJ O
recordings NNS O
in IN O
the DT O
intact JJ O
left JJ O
ventricular JJ O
wall NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
This DT O
study NN O
examined VBD O
the DT O
role NN O
of IN O
phase NN O
2 CD O
early JJ O
afterdepolarization NN O
( , O
EAD NNP O
) -RRB- O
in IN O
producing VBG O
a DT O
trigger NN O
to TO O
initiate VB O
torsade NN B-Disease
de FW I-Disease
pointes FW I-Disease
( -LRB- O
TdP NNP B-Disease
) -RRB- O
with IN O
QT NNP B-Disease
prolongation NN I-Disease
induced VBN O
by IN O
dl NN O
- HYPH O
sotalol NN O
and CC O
azimilide NN O
. . O
null null null-Disease
The DT O
contribution NN O
of IN O
transmural JJ O
dispersion NN O
of IN O
repolarization NN O
( , O
TDR NNP O
) -RRB- O
to IN O
transmural JJ O
propagation NN O
of IN O
EAD NNP O
and CC O
the DT O
maintenance NN O
of IN O
TdP NNP B-Disease
was VBD O
also RB O
evaluated VBN O
. . O
null null null-Disease
METHODS NNS O
AND CC O
RESULTS NNS O
: : O
Transmembrane NN O
action NN O
potentials NNS O
from IN O
epicardium NN O
, , O
midmyocardium NN O
, , O
and CC O
endocardium NN O
were VBD O
recorded VBN O
simultaneously RB O
, , O
together RB O
with IN O
a DT O
transmural JJ O
ECG NNP O
, , O
in IN O
arterially RB O
perfused VBN O
canine NN O
and CC O
rabbit NN O
left VBN O
ventricular JJ O
preparations NNS O
. . O
null null null-Disease
dl NNP O
- HYPH O
Sotalol NNP O
preferentially RB O
prolonged VBN O
action NN O
potential JJ O
duration NN O
( , O
APD NNP O
) -RRB- O
in IN O
M NN O
cells NNS O
dose NN O
- HYPH O
dependently RB O
( : O
1 CD O
to TO O
100 CD O
micromol NN O
/ SYM O
L NNP O
) -RRB- O
, , O
leading VBG O
to IN O
QT NNP B-Disease
prolongation NN I-Disease
and CC O
an DT O
increase NN O
in IN O
TDR NNP O
. . O
null null null-Disease
Azimilide NNP O
, , O
however RB O
, , O
significantly RB O
prolonged VBD O
APD NNP O
and CC O
QT NNP O
interval NN O
at IN O
concentrations NNS O
from IN O
0 CD O
. . O
1 CD O
to IN O
10 CD O
micromol NN O
/ SYM O
L NNP O
but CC O
shortened VBD O
them PRP O
at IN O
30 CD O
micromol NN O
/ SYM O
L NN O
. . O
null null null-Disease
Unlike IN O
dl NNP O
- HYPH O
sotalol NN O
, , O
azimilide NN O
( , O
> SYM O
3 CD O
micromol NN O
/ SYM O
L NNP O
) -RRB- O
increased VBN O
epicardial JJ O
APD NN O
markedly RB O
, , O
causing VBG O
a DT O
diminished VBN O
TDR NN O
. . O
null null null-Disease
Although IN O
both DT O
dl NN O
- HYPH O
sotalol NN O
and CC O
azimilide NN O
rarely RB O
induced VBD O
EADs NNS O
in IN O
canine NN O
left JJ O
ventricles NNS O
, , O
they PRP O
produced VBD O
frequent JJ O
EADs NNS O
in IN O
rabbits NNS O
, , O
in IN O
which WDT O
more RBR O
pronounced JJ O
QT NNP B-Disease
prolongation NN I-Disease
was VBD O
seen VBN O
. . O
null null null-Disease
An DT O
increase NN O
in IN O
TDR NNP O
by IN O
dl NN O
- HYPH O
sotalol NN O
facilitated VBD O
transmural JJ O
propagation NN O
of IN O
EADs NNS O
that WDT O
initiated VBD O
multiple JJ O
episodes NNS O
of IN O
spontaneous JJ O
TdP NNP B-Disease
in IN O
3 CD O
of IN O
6 CD O
rabbit NN O
left JJ O
ventricles NNS O
. . O
null null null-Disease
Of IN O
note NN O
, , O
although IN O
azimilide NN O
( , O
3 CD O
to TO O
10 CD O
micromol NN O
/ SYM O
L NNP O
) -RRB- O
increased VBD O
APD NNP O
more JJR O
than IN O
dl NN O
- HYPH O
sotalol NN O
, , O
its PRP$ O
EADs NNS O
often RB O
failed VBD O
to TO O
propagate VB O
transmurally RB O
, , O
probably RB O
because IN O
of IN O
a DT O
diminished JJ O
TDR NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
This DT O
study NN O
provides VBZ O
the DT O
first JJ O
direct JJ O
evidence NN O
from IN O
intracellular JJ O
action NN O
potential JJ O
recordings NNS O
that WDT O
phase NN O
2 CD O
EAD NN O
can MD O
be VB O
generated VBN O
from IN O
intact JJ O
ventricular JJ O
wall NN O
and CC O
produce VB O
a DT O
trigger NN O
to TO O
initiate VB O
the DT O
onset NN O
of IN O
TdP NNP B-Disease
under IN O
QT NNP B-Disease
prolongation NN I-Disease
. . O
null null null-Disease
A DT O
pilot NN O
study NN O
to TO O
assess VB O
the DT O
safety NN O
of IN O
dobutamine NN O
stress NN O
echocardiography NN O
in IN O
the DT O
emergency NN O
department NN O
evaluation NN O
of IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
STUDY NN O
OBJECTIVE NN O
: : O
Chest NN B-Disease
pain NN I-Disease
in IN O
the DT O
setting NN O
of IN O
cocaine NN O
use NN O
poses VBZ O
a DT O
diagnostic JJ O
dilemma NN O
. . O
null null null-Disease
Dobutamine NN O
stress NN O
echocardiography NN O
( -LRB- O
DSE NNP O
) -RRB- O
is VBZ O
a DT O
widely RB O
available JJ O
and CC O
sensitive JJ O
test NN O
for IN O
evaluating VBG O
cardiac JJ O
ischemia NN B-Disease
. . O
null null null-Disease
Because IN O
of IN O
the DT O
theoretical JJ O
concern NN O
regarding VBG O
administration NN O
of IN O
dobutamine NN O
in IN O
the DT O
setting NN O
of IN O
cocaine NN O
use NN O
, , O
we PRP O
conducted VBD O
a DT O
pilot NN O
study NN O
to TO O
assess VB O
the DT O
safety NN O
of IN O
DSE NNP O
in IN O
emergency NN O
department NN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
prospective JJ O
case NN O
series NN O
was VBD O
conducted VBN O
in IN O
the DT O
intensive JJ O
diagnostic JJ O
and CC O
treatment NN O
unit NN O
in IN O
the DT O
ED NNP O
of IN O
an DT O
urban JJ O
tertiary JJ O
- HYPH O
care NN O
teaching NN O
hospital NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
eligible JJ O
for IN O
DSE NNP O
if IN O
they PRP O
had VBD O
used VBN O
cocaine NN O
within IN O
24 CD O
hours NNS O
preceding VBG O
the DT O
onset NN O
of IN O
chest NN B-Disease
pain NN I-Disease
and CC O
had VBD O
a DT O
normal JJ O
ECG NN O
and CC O
tropinin NN O
I NN O
level NN O
. . O
null null null-Disease
Patients NNS O
exhibiting VBG O
signs NNS O
of IN O
continuing VBG O
cocaine NN O
toxicity NN B-Disease
were VBD O
excluded VBN O
from IN O
the DT O
study NN O
. . O
null null null-Disease
All DT O
patients NNS O
were VBD O
admitted VBN O
to IN O
the DT O
hospital NN O
for IN O
serial JJ O
testing NN O
after IN O
the DT O
DSE NNP O
testing NN O
in IN O
the DT O
intensive JJ O
diagnostic JJ O
and CC O
treatment NN O
unit NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Twenty CD O
- HYPH O
four CD O
patients NNS O
were VBD O
enrolled VBN O
. . O
null null null-Disease
Two CD O
patients NNS O
had VBD O
inadequate JJ O
resting NN O
images NNS O
, , O
one CD O
DSE NN O
was VBD O
terminated VBN O
because IN O
of IN O
inferior JJ O
hypokinesis NN B-Disease
, , O
another DT O
DSE NNP O
was VBD O
terminated VBN O
because IN O
of IN O
a DT O
rate NN O
- HYPH O
related VBN O
atrial JJ O
conduction NN O
deficit NN O
, , O
and CC O
1 CD O
patient NN O
did VBD O
not RB O
reach VB O
the DT O
target NN O
heart NN O
rate NN O
. . O
null null null-Disease
Thus RB O
, , O
19 CD O
patients NNS O
completed VBD O
a DT O
DSE NN O
and CC O
reached VBD O
their PRP$ O
target NN O
heart NN O
rates NNS O
. . O
null null null-Disease
null NN O
of IN O
the DT O
patients NNS O
experienced VBD O
signs NNS O
of IN O
exaggerated VBN O
adrenergic JJ O
response NN O
, , O
which WDT O
was VBD O
defined VBN O
as IN O
a DT O
systolic JJ O
blood NN O
pressure NN O
of IN O
greater JJR O
than IN O
200 CD O
mm NN O
Hg NNS O
or CC O
the DT O
occurrence NN O
of IN O
tachydysrhythmias NN B-Disease
( , O
excluding VBG O
sinus NN B-Disease
tachycardia NN I-Disease
) -RRB- O
. . O
null null null-Disease
Further RB O
suggesting VBG O
lack NN O
of IN O
exaggerated JJ O
adrenergic JJ O
response NN O
, , O
13 CD O
( SYM O
65 CD O
% NN O
) CD O
of IN O
20 CD O
patients NNS O
required VBD O
supplemental JJ O
atropine NN O
to TO O
reach VB O
their PRP$ O
target NN O
heart NN O
rates NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
No DT O
exaggerated JJ O
adrenergic JJ O
response NN O
was VBD O
detected VBN O
when WRB O
dobutamine NN O
was VBD O
administered VBN O
to IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
related VBN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
Prenatal JJ O
cocaine NN O
exposure NN O
and CC O
cranial JJ O
sonographic JJ O
findings NNS O
in IN O
preterm JJ B-Disease
infants NNS I-Disease
. . O
null null null-Disease
PURPOSE NN O
: : O
Prenatal JJ O
cocaine NN O
exposure NN O
has VBZ O
been VBN O
linked VBN O
with IN O
subependymal JJ O
hemorrhage NN B-Disease
and CC O
the DT O
formation NN O
of IN O
cysts NNS B-Disease
that WDT O
are VBP O
detectable JJ O
on IN O
cranial JJ O
sonography NN O
in IN O
neonates NNS O
born VBN O
at IN O
term NN O
. . O
null null null-Disease
We PRP O
sought VBD O
to TO O
determine VB O
if IN O
prenatal JJ O
cocaine NN O
exposure NN O
increases VBZ O
the DT O
incidence NN O
of IN O
subependymal JJ B-Disease
cysts NNS I-Disease
in IN O
preterm JJ B-Disease
infants NNS I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
retrospectively RB O
reviewed VBD O
the DT O
medical JJ O
records NNS O
and CC O
cranial JJ O
sonograms NNS O
obtained VBN O
during IN O
a DT O
1 CD O
- HYPH O
year NN O
period NN O
on IN O
122 CD O
premature JJ B-Disease
( : I-Disease
< SYM I-Disease
36 CD I-Disease
weeks NNS I-Disease
of IN I-Disease
gestation NN I-Disease
) , I-Disease
infants NNS I-Disease
. . O
null null null-Disease
Infants NNS O
were VBD O
categorized VBN O
into IN O
1 CD O
of IN O
2 CD O
groups NNS O
: : O
those DT O
exposed VBN O
to IN O
cocaine NN O
and CC O
those DT O
not RB O
exposed VBN O
to IN O
cocaine NN O
. . O
null null null-Disease
Infants NNS O
were VBD O
assigned VBN O
to IN O
the DT O
cocaine NN O
- HYPH O
exposed VBN O
group NN O
if IN O
there EX O
was VBD O
a DT O
maternal JJ O
history NN O
of IN O
cocaine NN B-Disease
abuse NN I-Disease
during IN O
pregnancy NN O
or CC O
if IN O
maternal JJ O
or CC O
neonatal JJ O
urine NN O
toxicology NN O
results NNS O
were VBD O
positive JJ O
at IN O
the DT O
time NN O
of IN O
delivery NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Five CD O
of IN O
the DT O
122 CD O
infants NNS O
were VBD O
excluded VBN O
from IN O
the DT O
study NN O
because IN O
of IN O
insufficient JJ O
medical JJ O
and CC O
drug NN O
histories NNS O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
subependymal JJ B-Disease
cysts NNS I-Disease
in IN O
the DT O
117 CD O
remaining VBG O
infants NNS O
was VBD O
14 CD O
% NN O
( , O
16 CD O
of IN O
117 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
subependymal JJ B-Disease
cysts NNS I-Disease
in IN O
infants NNS O
exposed VBN O
to IN O
cocaine NN O
prenatally RB O
was VBD O
44 CD O
% NN O
( , O
8 CD O
of IN O
18 CD O
) CD O
compared VBN O
with IN O
8 CD O
% NN O
( , O
8 CD O
of IN O
99 CD O
) -RRB- O
in IN O
the DT O
unexposed JJ O
group NN O
( , O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
We PRP O
found VBD O
an DT O
increased JJ O
incidence NN O
of IN O
subependymal JJ B-Disease
cyst NN I-Disease
formation NN O
in IN O
preterm JJ B-Disease
infants NNS I-Disease
who WP O
were VBD O
exposed VBN O
to IN O
cocaine NN O
prenatally RB O
. . O
null null null-Disease
This DT O
result NN O
is VBZ O
consistent JJ O
with IN O
results NNS O
of IN O
similar JJ O
studies NNS O
in IN O
term NN O
infants NNS O
. . O
null null null-Disease
Thalidomide NN O
neuropathy NN B-Disease
in IN O
patients NNS O
treated VBN O
for IN O
metastatic JJ O
prostate NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
We PRP O
prospectively RB O
evaluated VBD O
thalidomide NN O
- HYPH O
induced VBN O
neuropathy NN B-Disease
using VBG O
electrodiagnostic JJ O
studies NNS O
. . O
null null null-Disease
Sixty CD O
- HYPH O
seven CD O
men NNS O
with IN O
metastatic JJ O
androgen NN O
- HYPH O
independent JJ O
prostate NN B-Disease
cancer NN I-Disease
in IN O
an DT O
open JJ O
- HYPH O
label NN O
trial NN O
of IN O
oral JJ O
thalidomide NN O
underwent VBD O
neurologic JJ O
examinations NNS O
and CC O
nerve NN O
conduction NN O
studies NNS O
( -LRB- O
NCS NNP O
) -RRB- O
prior RB O
to IN O
and CC O
at IN O
3 CD O
- HYPH O
month NN O
intervals NNS O
during IN O
treatment NN O
. . O
null null null-Disease
NCS NNP O
included VBD O
recording NN O
of IN O
sensory JJ O
nerve NN O
action NN O
potentials NNS O
( , O
SNAPs NNS O
) -RRB- O
from IN O
median JJ O
, , O
radial NN O
, , O
ulnar NN O
, , O
and CC O
sural JJ O
nerves NNS O
. . O
null null null-Disease
SNAP NNP O
amplitudes NNS O
for IN O
each DT O
nerve NN O
were VBD O
expressed VBN O
as IN O
the DT O
percentage NN O
of IN O
its PRP$ O
baseline NN O
, , O
and CC O
the DT O
mean NN O
of IN O
the DT O
four CD O
was VBD O
termed VBN O
the DT O
SNAP NNP O
index NN O
. . O
null null null-Disease
A DT O
40 CD O
% NN O
decline NN O
in IN O
the DT O
SNAP NNP O
index NN O
was VBD O
considered VBN O
clinically RB O
significant JJ O
. . O
null null null-Disease
Thalidomide NN O
was VBD O
discontinued VBN O
in IN O
55 CD O
patients NNS O
for IN O
lack NN O
of IN O
therapeutic JJ O
response NN O
. . O
null null null-Disease
Of IN O
67 CD O
patients NNS O
initially RB O
enrolled VBN O
, , O
24 CD O
remained VBD O
on IN O
thalidomide NN O
for IN O
3 CD O
months NNS O
, , O
8 CD O
remained VBD O
at IN O
6 CD O
months NNS O
, , O
and CC O
3 CD O
remained VBD O
at IN O
9 CD O
months NNS O
. . O
null null null-Disease
Six CD O
patients NNS O
developed VBD O
neuropathy NN B-Disease
. . O
null null null-Disease
Clinical JJ O
symptoms NNS O
and CC O
a DT O
decline NN O
in IN O
the DT O
SNAP NNP O
index NN O
occurred VBD O
concurrently RB O
. . O
null null null-Disease
Older JJR O
age NN O
and CC O
cumulative JJ O
dose NN O
were VBD O
possible JJ O
contributing VBG O
factors NNS O
. . O
null null null-Disease
Neuropathy NN B-Disease
may MD O
thus RB O
be VB O
a DT O
common JJ O
complication NN O
of IN O
thalidomide NN O
in IN O
older JJR O
patients NNS O
. . O
null null null-Disease
The DT O
SNAP NNP O
index NN O
can MD O
be VB O
used VBN O
to TO O
monitor VB O
peripheral JJ B-Disease
neuropathy NN I-Disease
, , O
but CC O
not RB O
for IN O
early JJ O
detection NN O
. . O
null null null-Disease
Overexpression NN O
of IN O
copper NN O
/ SYM O
zinc NN O
- HYPH O
superoxide NN O
dismutase NN O
protects VBZ O
from IN O
kanamycin NN O
- HYPH O
induced VBN O
hearing NN B-Disease
loss NN I-Disease
. . O
null null null-Disease
The DT O
participation NN O
of IN O
reactive JJ O
oxygen NN O
species NNS O
in IN O
aminoglycoside NN O
- HYPH O
induced VBN O
ototoxicity NN B-Disease
has VBZ O
been VBN O
deduced VBN O
from IN O
observations NNS O
that IN O
aminoglycoside JJ O
- HYPH O
iron NN O
complexes NNS O
catalyze VBP O
the DT O
formation NN O
of IN O
superoxide NN O
radicals NNS O
in IN O
vitro NN O
and CC O
that IN O
antioxidants NNS O
attenuate VBP O
ototoxicity NN B-Disease
in IN O
vivo NN O
. . O
null null null-Disease
We PRP O
therefore RB O
hypothesized VBD O
that IN O
overexpression NN O
of IN O
Cu NNP O
/ SYM O
Zn NNP O
- HYPH O
superoxide NN O
dismutase NN O
( , O
h NN O
- HYPH O
SOD1 NN O
) -RRB- O
should MD O
protect VB O
transgenic JJ O
mice NNS O
from IN O
ototoxicity NN B-Disease
. . O
null null null-Disease
Immunocytochemistry NNP O
confirmed VBD O
expression NN O
of IN O
h NN O
- HYPH O
SOD1 NN O
in IN O
inner JJ O
ear NN O
tissues NNS O
of IN O
transgenic JJ O
C57BL NN O
/ SYM O
6 CD O
- HYPH O
TgN NN O
[ -LRB- O
SOD1 NN O
] -RRB- O
3Cje NN O
mice NN O
. . O
null null null-Disease
Transgenic JJ O
and CC O
nontransgenic JJ O
littermates NNS O
received VBD O
kanamycin NN O
( , O
400 CD O
mg NN O
/ SYM O
kg NN O
body NN O
weight NN O
/ SYM O
day NN O
) -RRB- O
for IN O
10 CD O
days NNS O
beginning VBG O
on IN O
day NN O
10 CD O
after IN O
birth NN O
. . O
null null null-Disease
Auditory JJ O
thresholds NNS O
were VBD O
tested VBN O
by IN O
evoked VBN O
auditory JJ O
brain NN O
stem NN O
responses NNS O
at IN O
1 CD O
month NN O
after IN O
birth NN O
. . O
null null null-Disease
In IN O
nontransgenic JJ O
animals NNS O
, , O
the DT O
threshold NN O
in IN O
the DT O
kanamycin NN O
- HYPH O
treated VBN O
group NN O
was VBD O
45 CD O
- SYM O
50 CD O
dB NN O
higher JJR O
than IN O
in IN O
saline NN O
- HYPH O
injected VBN O
controls NNS O
. . O
null null null-Disease
In IN O
the DT O
transgenic JJ O
group NN O
, , O
kanamycin NN O
increased VBD O
the DT O
threshold NN O
by IN O
only RB O
15 CD O
dB NNS O
over IN O
the DT O
respective JJ O
controls NNS O
. . O
null null null-Disease
The DT O
effects NNS O
were VBD O
similar JJ O
at IN O
12 CD O
and CC O
24 CD O
kHz NN O
. . O
null null null-Disease
The DT O
protection NN O
by IN O
overexpression NN O
of IN O
superoxide NN O
dismutase NN O
supports VBZ O
the DT O
hypothesis NN O
that IN O
oxidant NN O
stress NN O
plays VBZ O
a DT O
significant JJ O
role NN O
in IN O
aminoglycoside NN O
- HYPH O
induced VBN O
ototoxicity NN B-Disease
. . O
null null null-Disease
The DT O
results NNS O
also RB O
suggest VBP O
transgenic JJ O
animals NNS O
as IN O
suitable JJ O
models NNS O
to TO O
investigate VB O
the DT O
underlying VBG O
mechanisms NNS O
and CC O
possible JJ O
strategies NNS O
for IN O
prevention NN O
. . O
null null null-Disease
Fatty JJ B-Disease
liver NN I-Disease
induced VBN O
by IN O
tetracycline NN O
in IN O
the DT O
rat NN O
. . O
null null null-Disease
Dose NN O
- HYPH O
response NN O
relationships NNS O
and CC O
effect NN O
of IN O
sex NN O
. . O
null null null-Disease
Dose NN O
- HYPH O
response NN O
relationships NNS O
, , O
biochemical JJ O
mechanisms NNS O
, , O
and CC O
sex NN O
differences NNS O
in IN O
the DT O
experimental JJ O
fatty JJ B-Disease
liver NN I-Disease
induced VBN O
by IN O
tetracycline NN O
were VBD O
studied VBN O
in IN O
the DT O
intact JJ O
rat NN O
and CC O
with IN O
the DT O
isolated VBN O
perfused VBN O
rat NN O
liver NN O
in IN O
vitro NN O
. . O
null null null-Disease
In IN O
the DT O
intact JJ O
male JJ O
and CC O
female JJ O
rat NN O
, , O
no DT O
direct JJ O
relationship NN O
was VBD O
observed VBN O
between IN O
dose NN O
of IN O
tetracycline NN O
and CC O
hepatic JJ O
accumulation NN O
of IN O
triglyceride NN O
. . O
null null null-Disease
With IN O
provision NN O
of IN O
adequate JJ O
oleic NN O
acid NN O
as IN O
a DT O
substrate NN O
for IN O
the DT O
isolated VBN O
perfused VBN O
liver NN O
, , O
a DT O
direct JJ O
relationship NN O
was VBD O
observed VBN O
between IN O
dose NN O
of IN O
tetracycline NN O
and CC O
both DT O
accumulation NN O
of IN O
triglyceride NN O
in IN O
the DT O
liver NN O
and CC O
depression NN B-Disease
of IN O
output NN O
of IN O
triglyceride NN O
by IN O
livers NNS O
from IN O
male JJ O
and CC O
female JJ O
rats NNS O
. . O
null null null-Disease
Marked JJ O
differences NNS O
were VBD O
observed VBN O
between IN O
female JJ O
and CC O
male JJ O
rats NNS O
with IN O
regard NN O
to IN O
base NN O
line NN O
( HYPH O
control NN O
) , O
hepatic JJ O
concentration NN O
of IN O
triglyceride NN O
and CC O
output NN O
of IN O
triglyceride NN O
. . O
null null null-Disease
Accumulation NN O
of IN O
hepatic JJ O
triglyceride NN O
, , O
as IN O
a DT O
per NN O
cent NN O
of IN O
control NN O
values NNS O
, , O
in IN O
response NN O
to IN O
graded VBN O
doses NNS O
of IN O
tetracycline NN O
, , O
did VBD O
not RB O
differ VB O
significantly RB O
between IN O
male JJ O
, , O
female JJ O
and CC O
pregnant JJ O
rat NN O
livers NNS O
. . O
null null null-Disease
However RB O
, , O
livers NNS O
from IN O
female JJ O
, , O
and CC O
especially RB O
pregnant JJ O
female JJ O
rats NNS O
, , O
were VBD O
strikingly RB O
resistant JJ O
to IN O
the DT O
effects NNS O
of IN O
tetracycline NN O
on IN O
depression NN B-Disease
of IN O
output NN O
of IN O
triglyceride NN O
under IN O
these DT O
experimental JJ O
conditions NNS O
. . O
null null null-Disease
These DT O
differences NNS O
between IN O
the DT O
sexes NNS O
could MD O
not RB O
be VB O
related VBN O
to IN O
altered JJ O
disposition NN O
of IN O
tetracycline NN O
or CC O
altered VBN O
uptake NN O
of IN O
oleic NN O
acid NN O
. . O
null null null-Disease
Depressed JJ O
hepatic JJ O
secretion NN O
of IN O
triglyceride NN O
accounted VBD O
only RB O
for IN O
30 CD O
to TO O
50 CD O
% NN O
of IN O
accumulated VBN O
hepatic JJ O
triglyceride NN O
, , O
indicating VBG O
that IN O
additional JJ O
mechanisms NNS O
must MD O
be VB O
involved VBN O
in IN O
the DT O
production NN O
of IN O
the DT O
triglyceride NN O
- HYPH O
rich JJ O
fatty JJ B-Disease
liver NN I-Disease
in IN O
response NN O
to IN O
tetracycline NN O
. . O
null null null-Disease
Prednisone NNP O
induces VBZ O
anxiety NN B-Disease
and CC O
glial NN O
cerebral JJ O
changes NNS O
in IN O
rats NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
assess VB O
whether IN O
prednisone NN O
( , O
PDN NNP O
) -RRB- O
produces VBZ O
anxiety NN B-Disease
and CC O
/ SYM O
or CC O
cerebral JJ O
glial NN O
changes NNS O
in IN O
rats NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
Male JJ O
Wistar NNP O
rats NNS O
were VBD O
studied VBN O
and CC O
3 CD O
groups NNS O
were VBD O
formed VBN O
( , O
8 CD O
rats NNS O
per IN O
group NN O
) -RRB- O
. . O
null null null-Disease
The DT O
moderate JJ O
- HYPH O
dose NN O
group NN O
received VBD O
5 CD O
mg CD O
/ SYM O
kg NN O
/ SYM O
day NN O
PDN NN O
released VBN O
from IN O
a DT O
subcutaneous JJ O
implant NN O
. . O
null null null-Disease
In IN O
the DT O
high JJ O
- HYPH O
dose NN O
group NN O
, , O
implants NNS O
containing VBG O
PDN NNP O
equivalent JJ O
to IN O
60 CD O
mg NNS O
/ SYM O
kg NNS O
/ SYM O
day NN O
were VBD O
applied VBN O
. . O
null null null-Disease
In IN O
the DT O
control NN O
group NN O
implants NNS O
contained VBD O
no DT O
PDN NN O
. . O
null null null-Disease
Anxiety NN B-Disease
was VBD O
assessed VBN O
using VBG O
an DT O
open JJ O
field NN O
and CC O
elevated VBN O
plus JJ O
- HYPH O
maze NN O
devices NNS O
. . O
null null null-Disease
The DT O
number NN O
of IN O
cells NNS O
and CC O
cytoplasmic JJ O
transformation NN O
of IN O
astrocytes NNS O
and CC O
microglia NN O
cells NNS O
were VBD O
assessed VBN O
by IN O
immunohistochemical JJ O
analyses NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Anxiety NN B-Disease
was VBD O
documented VBN O
in IN O
both DT O
groups NNS O
of IN O
PDN NNP O
treated VBN O
rats NNS O
compared VBN O
with IN O
controls NNS O
. . O
null null null-Disease
The DT O
magnitude NN O
of IN O
transformation NN O
of IN O
the DT O
microglia NN O
assessed VBN O
by IN O
the DT O
number NN O
of IN O
intersections NNS O
was VBD O
significantly RB O
higher JJR O
in IN O
the DT O
PDN NNP O
groups NNS O
than IN O
in IN O
controls NNS O
in IN O
the DT O
prefrontal JJ O
cortex NN O
( , O
moderate JJ O
- HYPH O
dose NN O
, , O
24 CD O
. . O
1 CD O
; : O
high JJ O
- HYPH O
dose NN O
, , O
23 CD O
. . O
6 CD O
; : O
controls VBZ O
18 CD O
. . O
7 CD O
; : O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
and CC O
striatum NN O
( , O
moderate JJ O
- HYPH O
dose NN O
25 CD O
. . O
6 CD O
; : O
high JJ O
- HYPH O
dose NN O
26 CD O
. . O
3 CD O
; : O
controls VBZ O
18 CD O
. . O
9 CD O
; : O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
but CC O
not RB O
in IN O
hippocampus NN O
. . O
null null null-Disease
The DT O
number NN O
of IN O
stained VBN O
microglia NN O
cells NNS O
was VBD O
significantly RB O
higher JJR O
in IN O
the DT O
PDN NNP O
treated VBN O
groups NNS O
in IN O
the DT O
prefrontal JJ O
cortex NN O
than IN O
in IN O
controls NNS O
( , O
moderate JJ O
- HYPH O
dose NN O
, , O
29 CD O
. . O
1 CD O
; : O
high JJ O
- HYPH O
dose NN O
, , O
28 CD O
. . O
4 CD O
; : O
control NN O
, , O
17 CD O
. . O
7 CD O
cells NNS O
per IN O
field NN O
; : O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Stained VBN O
microglia NN O
cells NNS O
were VBD O
significantly RB O
more RBR O
numerous JJ O
striatum NN O
and CC O
hippocampus NN O
in IN O
the DT O
high JJ O
- HYPH O
dose NN O
group NN O
compared VBN O
to IN O
controls NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Subacute JJ O
exposure NN O
to IN O
PDN NNP O
induced VBD O
anxiety NN B-Disease
and CC O
reactivity NN O
of IN O
microglia NN O
. . O
null null null-Disease
The DT O
relevance NN O
of IN O
these DT O
features NNS O
for IN O
patients NNS O
using VBG O
PDN NNP O
remains VBZ O
to TO O
be VB O
elucidated VBN O
. . O
null null null-Disease
Phase NNP O
II NNP O
study NN O
of IN O
carboplatin NN O
and CC O
liposomal JJ O
doxorubicin NN O
in IN O
patients NNS O
with IN O
recurrent JJ O
squamous JJ B-Disease
cell NN I-Disease
carcinoma NN I-Disease
of IN I-Disease
the DT I-Disease
cervix NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
The DT O
activity NN O
of IN O
the DT O
combination NN O
of IN O
carboplatin NN O
and CC O
liposomal JJ O
doxorubicin NN O
was VBD O
tested VBN O
in IN O
a DT O
Phase NNP O
II NNP O
study NN O
of IN O
patients NNS O
with IN O
recurrent JJ O
cervical JJ B-Disease
carcinoma NN I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
The DT O
combination NN O
of IN O
carboplatin NN O
( , O
area NN O
under IN O
the DT O
concentration NN O
curve NN O
[ -LRB- O
AUC NNP O
] -RRB- O
, , O
5 CD O
) -RRB- O
and CC O
liposomal JJ O
doxorubicin NN O
( , O
Doxil NNP O
; : O
starting VBG O
dose NN O
, , O
40 CD O
mg NN O
/ SYM O
m NN O
( , O
2 CD O
) NN O
) , O
was VBD O
administered VBN O
intravenously RB O
every DT O
28 CD O
days NNS O
to IN O
37 CD O
patients NNS O
with IN O
recurrent JJ O
squamous JJ B-Disease
cell NN I-Disease
cervical JJ I-Disease
carcinoma NN I-Disease
to TO O
determine VB O
antitumor JJ O
activity NN O
and CC O
toxicity NN B-Disease
profile NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Twenty CD O
- HYPH O
nine CD O
patients NNS O
were VBD O
assessable JJ O
for IN O
response NN O
, , O
and CC O
35 CD O
patients NNS O
were VBD O
assessable JJ O
for IN O
toxicity NN B-Disease
. . O
null null null-Disease
The DT O
overall JJ O
response NN O
rate NN O
was VBD O
38 CD O
% NN O
, , O
the DT O
median JJ O
time NN O
to IN O
response NN O
was VBD O
10 CD O
weeks NNS O
, , O
the DT O
median JJ O
duration NN O
of IN O
response NN O
was VBD O
26 CD O
weeks NNS O
, , O
and CC O
the DT O
median JJ O
survival NN O
was VBD O
37 CD O
weeks NNS O
. . O
null null null-Disease
The DT O
main JJ O
toxic JJ O
effect NN O
was VBD O
myelosuppression NN B-Disease
, , O
with IN O
Grade NNP O
3 CD O
and CC O
4 CD O
neutropenia NN B-Disease
in IN O
16 CD O
patients NNS O
, , O
anemia NN B-Disease
in IN O
12 CD O
patients NNS O
, , O
thrombocytopenia NN B-Disease
in IN O
11 CD O
patients NNS O
, , O
and CC O
neutropenic JJ B-Disease
fever NN I-Disease
in IN O
3 CD O
patients NNS O
. . O
null null null-Disease
Four CD O
patients NNS O
had VBD O
five CD O
infusion NN O
- HYPH O
related VBN O
reactions NNS O
during IN O
the DT O
infusion NN O
of IN O
liposomal JJ O
doxorubicin NN O
, , O
leading VBG O
to IN O
treatment NN O
discontinuation NN O
in IN O
three CD O
patients NNS O
. . O
null null null-Disease
Grade NN O
> : O
or CC O
= SYM O
2 CD O
nonhematologic JJ O
toxicity NN B-Disease
included VBD O
nausea NN B-Disease
in IN O
17 CD O
patients NNS O
, , O
emesis NN B-Disease
in IN O
14 CD O
patients NNS O
, , O
fatigue NN B-Disease
in IN O
9 CD O
patients NNS O
, , O
mucositis NN B-Disease
and CC O
/ SYM O
or CC O
stomatitis NN B-Disease
in IN O
8 CD O
patients NNS O
, , O
constipation NN B-Disease
in IN O
6 CD O
patients NNS O
, , O
weight NN B-Disease
loss NN I-Disease
in IN O
5 CD O
patients NNS O
, , O
hand NN B-Disease
- HYPH I-Disease
foot NN I-Disease
syndrome NN I-Disease
in IN O
2 CD O
patients NNS O
, , O
and CC O
skin NN B-Disease
reactions NNS I-Disease
in IN O
3 CD O
patients NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
combination NN O
of IN O
carboplatin NN O
and CC O
liposomal JJ O
doxorubicin NN O
has VBZ O
modest JJ O
activity NN O
in IN O
patients NNS O
with IN O
recurrent JJ O
cervical JJ B-Disease
carcinoma NN I-Disease
. . O
null null null-Disease
Antimicrobial NN O
- HYPH O
induced VBN O
mania NN B-Disease
( , O
antibiomania NN B-Disease
) -RRB- O
: : O
a DT O
review NN O
of IN O
spontaneous JJ O
reports NNS O
. . O
null null null-Disease
The DT O
authors NNS O
reviewed VBD O
reported JJ O
cases NNS O
of IN O
antibiotic JJ O
- HYPH O
induced VBN O
manic JJ B-Disease
episodes NNS O
by IN O
means NNS O
of IN O
a DT O
MEDLINE NNP O
and CC O
PsychLit NNP O
search NN O
for IN O
reports NNS O
of IN O
antibiotic JJ O
- HYPH O
induced VBN O
mania NN B-Disease
. . O
null null null-Disease
Unpublished JJ O
reports NNS O
were VBD O
requested VBN O
from IN O
the DT O
World NNP O
Health NNP O
Organization NNP O
( , O
WHO NNP O
) -RRB- O
and CC O
the DT O
Food NNP O
and CC O
Drug NNP O
Administration NNP O
( -LRB- O
FDA NNP O
) -RRB- O
. . O
null null null-Disease
Twenty CD O
- HYPH O
one CD O
reports NNS O
of IN O
antimicrobial JJ O
- HYPH O
induced VBN O
mania NN B-Disease
were VBD O
found VBN O
in IN O
the DT O
literature NN O
. . O
null null null-Disease
There EX O
were VBD O
6 CD O
cases NNS O
implicating VBG O
clarithromycin NN O
, , O
13 CD O
implicating VBG O
isoniazid NN O
, , O
and CC O
1 CD O
case NN O
each DT O
implicating VBG O
erythromycin NN O
and CC O
amoxicillin NN O
. . O
null null null-Disease
The DT O
WHO NNP O
reported VBD O
82 CD O
cases NNS O
. . O
null null null-Disease
Of IN O
these DT O
, , O
clarithromycin NN O
was VBD O
implicated VBN O
in IN O
23 CD O
( SYM O
27 CD O
. . O
6 CD O
% NN O
) , O
cases NNS O
, , O
ciprofloxacin NN O
in IN O
12 CD O
( SYM O
14 CD O
. . O
4 CD O
% NN O
) -RRB- O
cases NNS O
, , O
and CC O
ofloxacin NN O
in IN O
10 CD O
( SYM O
12 CD O
% NN O
) -RRB- O
cases NNS O
. . O
null null null-Disease
Cotrimoxazole NNP O
, , O
metronidazole NN O
, , O
and CC O
erythromycin NN O
were VBD O
involved VBN O
in IN O
15 CD O
reported VBN O
manic JJ B-Disease
episodes NNS O
. . O
null null null-Disease
Cases NNS O
reported VBN O
by IN O
the DT O
FDA NNP O
showed VBD O
clarithromycin NN O
and CC O
ciprofloxacin NN O
to TO O
be VB O
the DT O
most RBS O
frequently RB O
associated VBN O
with IN O
the DT O
development NN O
of IN O
mania NN B-Disease
. . O
null null null-Disease
Statistical JJ O
analysis NN O
of IN O
the DT O
data NNS O
would MD O
not RB O
have VB O
demonstrated VBN O
a DT O
significant JJ O
statistical JJ O
correlative JJ O
risk NN O
and CC O
was VBD O
therefore RB O
not RB O
undertaken VBN O
. . O
null null null-Disease
Patients NNS O
have VBP O
an DT O
increased VBN O
risk NN O
of IN O
developing VBG O
mania NN B-Disease
while IN O
being VBG O
treated VBN O
with IN O
antimicrobials NNS O
. . O
null null null-Disease
Although IN O
this DT O
is VBZ O
not RB O
a DT O
statistically RB O
significant JJ O
risk NN O
, , O
physicians NNS O
must MD O
be VB O
aware JJ O
of IN O
the DT O
effect NN O
and CC O
reversibility NN O
. . O
null null null-Disease
Further JJ O
research NN O
clearly RB O
is VBZ O
required VBN O
to TO O
determine VB O
the DT O
incidence NN O
of IN O
antimicrobial NN O
- HYPH O
induced VBN O
mania NN B-Disease
, , O
the DT O
relative JJ O
risk NN O
factors NNS O
of IN O
developing VBG O
an DT O
antimicrobial JJ O
- HYPH O
induced VBN O
manic JJ B-Disease
episode NN O
among IN O
various JJ O
demographic JJ O
populations NNS O
, , O
and CC O
the DT O
incidence NN O
of IN O
patients NNS O
who WP O
continue VBP O
to TO O
have VB O
persistent JJ O
affective JJ O
disorders NNS O
once IN O
the DT O
initial JJ O
episode NN O
, , O
which WDT O
occurs VBZ O
while IN O
the DT O
patient NN O
is VBZ O
taking VBG O
antibiotics NNS O
, , O
subsides VBZ O
. . O
null null null-Disease
The DT O
authors NNS O
elected VBD O
to TO O
name VB O
this DT O
syndrome NN O
"""" `` O
antibiomania NN B-Disease
. . O
"""" '' O
null null null-Disease
Levodopa NNP O
- HYPH O
induced VBN O
ocular JJ B-Disease
dyskinesias NNS I-Disease
in IN O
Parkinson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
Levodopa NNP O
- HYPH O
induced VBN O
ocular JJ B-Disease
dyskinesias NNS I-Disease
are VBP O
very RB O
uncommon JJ O
. . O
null null null-Disease
Usually RB O
they PRP O
occur VBP O
simultaneously RB O
with IN O
limb JJ O
peak NN O
- HYPH O
dose NN O
choreatic JJ B-Disease
dyskinesias NNS I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
on IN O
a DT O
patient NN O
with IN O
leftward JJ O
and CC O
upward JJ O
deviations NNS O
of IN O
gaze NN O
during IN O
the DT O
peak NN O
effect NN O
of IN O
levodopa NN O
, , O
and CC O
hypothesize VBP O
that IN O
a DT O
severe JJ O
dopaminergic JJ O
denervation NN O
in IN O
the DT O
caudate NN O
nucleus NN O
is VBZ O
needed VBN O
for IN O
the DT O
appearance NN O
of IN O
these DT O
levodopa NN O
- HYPH O
induce VB O
ocular JJ B-Disease
dyskinesias NNS I-Disease
. . O
null null null-Disease
A DT O
comparison NN O
of IN O
glyceryl NN O
trinitrate NN O
with IN O
diclofenac NN O
for IN O
the DT O
treatment NN O
of IN O
primary JJ O
dysmenorrhea NN B-Disease
: : O
an DT O
open JJ O
, , O
randomized JJ O
, , O
cross JJ O
- HYPH O
over JJ O
trial NN O
. . O
null null null-Disease
Primary JJ O
dysmenorrhea NN B-Disease
is VBZ O
a DT O
syndrome NN O
characterized VBN O
by IN O
painful JJ O
uterine NN O
contractility NN O
caused VBN O
by IN O
a DT O
hypersecretion NN O
of IN O
endometrial JJ O
prostaglandins NNS O
; : O
non JJ O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
are VBP O
the DT O
first JJ O
choice NN O
for IN O
its PRP$ O
treatment NN O
. . O
null null null-Disease
However RB O
, , O
in IN O
vivo NN O
and CC O
in FW O
vitro FW O
studies NNS O
have VBP O
demonstrated VBN O
that IN O
myometrial JJ O
cells NNS O
are VBP O
also RB O
targets NNS O
of IN O
the DT O
relaxant JJ O
effects NNS O
of IN O
nitric JJ O
oxide NN O
( , O
NO NNP O
) -RRB- O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
determine VB O
the DT O
efficacy NN O
of IN O
glyceryl NN O
trinitrate NN O
( , O
GTN NNP O
) -RRB- O
, , O
an DT O
NO NNP O
donor NN O
, , O
in IN O
the DT O
resolution NN O
of IN O
primary JJ O
dysmenorrhea NN B-Disease
in IN O
comparison NN O
with IN O
diclofenac NN O
( -LRB- O
DCF NNP O
) -RRB- O
. . O
null null null-Disease
A DT O
total NN O
of IN O
24 CD O
patients NNS O
with IN O
the DT O
diagnosis NN O
of IN O
severe JJ O
primary JJ O
dysmenorrhea NN B-Disease
were VBD O
studied VBN O
during IN O
two CD O
consecutive JJ O
menstrual JJ O
cycles NNS O
. . O
null null null-Disease
In IN O
an DT O
open JJ O
, , O
cross NN O
- HYPH O
over RB O
, , O
controlled VBN O
design NN O
, , O
patients NNS O
were VBD O
randomized VBN O
to TO O
receive VB O
either CC O
DCF NNP O
per IN O
os NN O
or CC O
GTN NNP O
patches NNS O
the DT O
first JJ O
days NNS O
of IN O
menses NNS O
, , O
when WRB O
menstrual JJ O
cramps NNS O
became VBD O
unendurable JJ O
. . O
null null null-Disease
In IN O
the DT O
subsequent JJ O
cycle NN O
the DT O
other JJ O
treatment NN O
was VBD O
used VBN O
. . O
null null null-Disease
Patients NNS O
received VBD O
up IN O
to TO O
3 CD O
doses NNS O
/ SYM O
day NN O
of IN O
50 CD O
mg NN O
DCF NNP O
or CC O
2 CD O
. . O
5 CD O
mg NN O
/ SYM O
24 CD O
h NN O
transdermal JJ O
GTN NN O
for IN O
the DT O
first JJ O
3 CD O
days NNS O
of IN O
the DT O
cycle NN O
, , O
according VBG O
to IN O
their PRP$ O
needs NNS O
. . O
null null null-Disease
The DT O
participants NNS O
recorded VBD O
menstrual JJ O
symptoms NNS O
and CC O
possible JJ O
side NN O
- HYPH O
effects NNS O
at IN O
different JJ O
times NNS O
( , O
0 CD O
, , O
30 CD O
, , O
60 CD O
, , O
120 CD O
minutes NNS O
) , O
after IN O
the DT O
first JJ O
dose NN O
of IN O
medication NN O
on IN O
the DT O
first JJ O
day NN O
of IN O
the DT O
cycle NN O
, , O
with IN O
both DT O
drugs NNS O
. . O
null null null-Disease
The DT O
difference NN O
in IN O
pain NN B-Disease
intensity NN O
score NN O
( : O
DPI NNP O
) -RRB- O
was VBD O
the DT O
main JJ O
outcome NN O
variable JJ O
. . O
null null null-Disease
Both DT O
treatments NNS O
significantly RB O
reduced VBD O
DPI NNP O
by IN O
the DT O
30th JJ O
minute NN O
( , O
GTN NNP O
, , O
- HYPH O
12 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
17 CD O
. . O
9 CD O
; : O
DCF NNP O
, , O
- HYPH O
18 CD O
. . O
9 CD O
+ SYM O
/ SYM O
- HYPH O
16 CD O
. . O
6 CD O
) -RRB- O
. . O
null null null-Disease
However RB O
, , O
DCF NNP O
continued VBD O
to TO O
be VB O
effective JJ O
in IN O
reducing VBG O
pelvic JJ B-Disease
pain NN I-Disease
for IN O
two CD O
hours NNS O
, , O
whereas IN O
GTN NNP O
scores NNS O
remained VBD O
more RBR O
or CC O
less RBR O
stable JJ O
after IN O
30 CD O
min NN O
and CC O
significantly RB O
higher JJR O
than IN O
those DT O
for IN O
DFC NNP O
( : O
after IN O
one CD O
hour NN O
: : O
GTN NNP O
, , O
- HYPH O
12 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
17 CD O
. . O
9 CD O
; : O
DFC NNP O
, , O
- HYPH O
18 CD O
. . O
9 CD O
+ CD O
/ SYM O
- HYPH O
16 CD O
. . O
6 CD O
and CC O
after IN O
two CD O
hours NNS O
: : O
GTN NNP O
, , O
- HYPH O
23 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- HYPH O
20 CD O
. . O
5 CD O
; : O
DFC NNP O
, , O
- HYPH O
59 CD O
. . O
7 CD O
+ CD O
/ SYM O
- HYPH O
17 CD O
. . O
9 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
0001 CD O
) -RRB- O
. . O
null null null-Disease
Low JJ B-Disease
back JJ I-Disease
pain NN I-Disease
was VBD O
also RB O
relieved VBN O
by IN O
both DT O
drugs NNS O
. . O
null null null-Disease
Headache NN B-Disease
was VBD O
significantly RB O
increased VBN O
by IN O
GTN NNP O
but CC O
not RB O
by IN O
DCF NNP O
. . O
null null null-Disease
Eight CD O
patients NNS O
stopped VBD O
using VBG O
GTN NNP O
because IN O
headache NN B-Disease
- HYPH O
- HYPH O
attributed VBN O
to IN O
its PRP$ O
use NN O
- , O
- , O
became VBD O
intolerable JJ O
. . O
null null null-Disease
These DT O
findings NNS O
indicate VBP O
that IN O
GTN NNP O
has VBZ O
a DT O
reduced VBN O
efficacy NN O
and CC O
tolerability NN O
by IN O
comparison NN O
with IN O
DCF NNP O
in IN O
the DT O
treatment NN O
of IN O
primary JJ O
dysmenorrhea NN B-Disease
. . O
null null null-Disease
Temocapril NNP O
, , O
a DT O
long RB O
- HYPH O
acting VBG O
non JJ O
- HYPH O
SH NN O
group NN O
angiotensin NN O
converting VBG O
enzyme NN O
inhibitor NN O
, , O
modulates VBZ O
glomerular JJ B-Disease
injury NN I-Disease
in IN O
chronic JJ O
puromycin NN O
aminonucleoside NN O
nephrosis NN B-Disease
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
chronic JJ O
administration NN O
of IN O
temocapril NN O
, , O
a DT O
long RB O
- HYPH O
acting VBG O
non JJ O
- HYPH O
SH NN O
group NN O
angiotensin NN O
converting VBG O
enzyme NN O
( -LRB- O
ACE NN O
) -RRB- O
inhibitor NN O
, , O
reduced VBN O
proteinuria NN B-Disease
, , O
inhibited VBN O
glomerular JJ O
hypertrophy NN B-Disease
and CC O
prevented VBN O
glomerulosclerosis NN B-Disease
in IN O
chronic JJ O
puromycin NN O
aminonucleoside NN O
( , O
PAN NNP O
) -RRB- O
- HYPH O
induced VBN O
nephrotic JJ B-Disease
rats NNS O
. . O
null null null-Disease
Nephrosis NNP B-Disease
was VBD O
induced VBN O
by IN O
injection NN O
of IN O
PAN NNP O
( , O
15mg CD O
/ SYM O
100g CD O
body NN O
weight NN O
) -RRB- O
in IN O
male JJ O
Sprague NNP O
- HYPH O
Dawley NNP O
( -LRB- O
SD NNP O
) -RRB- O
rats NNS O
. . O
null null null-Disease
Four CD O
groups NNS O
were VBD O
used VBN O
, , O
i PRP O
) , O
the DT O
PAN NNP O
group NN O
( : O
14 CD O
) -RRB- O
, , O
ii IN O
) SYM O
PAN NNP O
/ SYM O
temocapril NN O
( : O
13 CD O
) -RRB- O
, , O
iii FW O
) -RRB- O
temocapril NN O
( , O
14 CD O
) -RRB- O
and CC O
iv NN O
) -RRB- O
untreated JJ O
controls NNS O
( SYM O
15 CD O
) -RRB- O
. . O
null null null-Disease
Temocapril NNP O
( : O
8 CD O
mg CD O
/ SYM O
kg NNS O
/ SYM O
day NN O
) -RRB- O
was VBD O
administered VBN O
to IN O
the DT O
rats NNS O
which WDT O
were VBD O
killed VBN O
at IN O
weeks NNS O
4 CD O
, , O
14 CD O
or CC O
20 CD O
. . O
null null null-Disease
At IN O
each DT O
time NN O
point NN O
, , O
systolic JJ O
blood NN O
pressure NN O
( , O
BP NNP O
) -RRB- O
, , O
urinary JJ O
protein NN O
excretion NN O
and CC O
renal JJ O
histopathological JJ O
findings NNS O
were VBD O
evaluated VBN O
, , O
and CC O
morphometric JJ O
image NN O
analysis NN O
was VBD O
done VBN O
. . O
null null null-Disease
Systolic JJ O
BP NNP O
in IN O
the DT O
PAN NNP O
group NN O
was VBD O
significantly RB O
high JJ O
at IN O
4 CD O
, , O
14 CD O
and CC O
20 CD O
weeks NNS O
, , O
but CC O
was VBD O
normal JJ O
in IN O
the DT O
PAN NNP O
/ SYM O
temocapril NN O
group NN O
. . O
null null null-Disease
Urinary JJ O
protein NN O
excretion NN O
in IN O
the DT O
PAN NNP O
group NN O
increased VBD O
significantly RB O
, , O
peaking VBG O
at IN O
8 CD O
days NNS O
, , O
then RB O
decreased VBD O
at IN O
4 CD O
weeks NNS O
, , O
but CC O
rose VBD O
again RB O
significantly RB O
at IN O
14 CD O
and CC O
20 CD O
weeks NNS O
. . O
null null null-Disease
Temocapril NNP O
did VBD O
not RB O
attenuate VB O
proteinuria NN B-Disease
at IN O
8 CD O
days NNS O
, , O
but CC O
it PRP O
did VBD O
markedly RB O
lower VB O
it PRP O
from IN O
weeks NNS O
4 CD O
to IN O
20 CD O
. . O
null null null-Disease
The DT O
glomerulosclerosis NN B-Disease
index NN O
( -LRB- O
GSI NNP O
) -RRB- O
was VBD O
6 CD O
. . O
21 CD O
% NN O
at IN O
4 CD O
weeks NNS O
and CC O
respectively RB O
25 CD O
. . O
35 CD O
% NN O
and CC O
30 CD O
. . O
49 CD O
% NN O
at IN O
14 CD O
and CC O
20 CD O
weeks NNS O
in IN O
the DT O
PAN NNP O
group NN O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
significant JJ O
correlation NN O
between IN O
urinary JJ O
protein NN O
excretion NN O
and CC O
GSI NNP O
( : O
r NN O
= SYM O
0 CD O
. . O
808 CD O
, , O
p NN O
< NN O
0 CD O
. . O
0001 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
ratio NN O
of IN O
glomerular JJ O
tuft NN O
area NN O
to IN O
the DT O
area NN O
of IN O
Bowman NNP O
' POS O
s NN O
capsules NNS O
( -LRB- O
GT NNP O
/ SYM O
BC NNP O
) -RRB- O
in IN O
the DT O
PAN NNP O
group NN O
was VBD O
significantly RB O
increased VBN O
, , O
but CC O
it PRP O
was VBD O
significantly RB O
lower JJR O
in IN O
the DT O
PAN NNP O
/ SYM O
temocapril NN O
group NN O
. . O
null null null-Disease
It PRP O
appears VBZ O
that IN O
temocapril NN O
was VBD O
effective JJ O
in IN O
retarding VBG O
renal JJ O
progression NN O
and CC O
protected VBN O
renal JJ O
function NN O
in IN O
PAN NNP O
neprotic JJ B-Disease
rats NNS O
. . O
null null null-Disease
Pulmonary JJ B-Disease
hypertension NN I-Disease
after IN O
ibuprofen JJ O
prophylaxis NN O
in IN O
very RB O
preterm JJ O
infants NNS O
. . O
null null null-Disease
We PRP O
report VBP O
three CD O
cases NNS O
of IN O
severe JJ O
hypoxaemia NN B-Disease
after IN O
ibuprofen NN O
administration NN O
during IN O
a DT O
randomised VBN O
controlled VBN O
trial NN O
of IN O
prophylactic JJ O
treatment NN O
of IN O
patent NN B-Disease
ductus NN I-Disease
arteriosus NN I-Disease
with IN O
ibuprofen NN O
in IN O
premature JJ O
infants NNS O
born VBN O
at IN O
less JJR O
than IN O
28 CD O
weeks NNS O
of IN O
gestation NN O
. . O
null null null-Disease
Echocardiography NN O
showed VBD O
severely RB O
decreased VBN O
pulmonary JJ O
blood NN O
flow NN O
. . O
null null null-Disease
Hypoxaemia NNP B-Disease
resolved VBD O
quickly RB O
on IN O
inhaled VBN O
nitric JJ O
oxide NN O
therapy NN O
. . O
null null null-Disease
We PRP O
suggest VBP O
that IN O
investigators NNS O
involved VBN O
in IN O
similar JJ O
trials NNS O
pay VBP O
close JJ O
attention NN O
to IN O
pulmonary JJ O
pressure NN O
if IN O
hypoxaemia NN B-Disease
occurs VBZ O
after IN O
prophylactic JJ O
administration NN O
of IN O
ibuprofen NN O
. . O
null null null-Disease
Hyponatremia NN B-Disease
and CC O
syndrome NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
anti JJ I-Disease
- HYPH I-Disease
diuretic JJ I-Disease
hormone NN I-Disease
reported VBN O
with IN O
the DT O
use NN O
of IN O
Vincristine NNP O
: : O
an DT O
over IN O
- HYPH O
representation NN O
of IN O
Asians NNPS O
? . O
null null null-Disease
PURPOSE NN O
: : O
This DT O
retrospective JJ O
study NN O
used VBD O
a DT O
pharmaceutical JJ O
company NN O
' POS O
s POS O
global JJ O
safety NN O
database NN O
to TO O
determine VB O
the DT O
reporting NN O
rate NN O
of IN O
hyponatremia NN B-Disease
and CC O
/ SYM O
or CC O
syndrome NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
secretion NN I-Disease
of IN I-Disease
anti JJ I-Disease
- HYPH I-Disease
diuretic JJ I-Disease
hormone NN I-Disease
( , O
SIADH NNP B-Disease
) -RRB- O
among IN O
vincristine NN O
- HYPH O
treated VBN O
patients NNS O
and CC O
to TO O
explore VB O
the DT O
possibility NN O
of IN O
at IN O
- HYPH O
risk NN O
population NN O
subgroups NNS O
. . O
null null null-Disease
METHOD NN O
: : O
We PRP O
searched VBD O
the DT O
Eli NNP O
Lilly NNP O
and CC O
Company NNP O
' POS O
s POS O
computerized JJ O
adverse JJ O
event NN O
database NN O
for IN O
all DT O
reported VBN O
cases NNS O
of IN O
hyponatremia NN B-Disease
and CC O
/ SYM O
or CC O
SIADH NNP B-Disease
as IN O
of IN O
1 CD O
November NNP O
1999 CD O
that WDT O
had VBD O
been VBN O
reported VBN O
during IN O
the DT O
use NN O
of IN O
vincristine NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
A DT O
total NN O
of IN O
76 CD O
cases NNS O
of IN O
hyponatremia NN B-Disease
and CC O
/ SYM O
or CC O
SIADH NNP B-Disease
associated VBN O
with IN O
vincristine NN O
use NN O
were VBD O
identified VBN O
. . O
null null null-Disease
The DT O
overall JJ O
reporting NN O
rate NN O
was VBD O
estimated VBN O
to TO O
be VB O
1 CD O
. . O
3 CD O
/ SYM O
100 CD O
, , O
000 CD O
treated VBN O
patients NNS O
. . O
null null null-Disease
The DT O
average JJ O
age NN O
of IN O
patients NNS O
was VBD O
35 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- SYM O
28 CD O
. . O
3 CD O
years NNS O
, , O
and CC O
62 CD O
% NN O
were VBD O
males NNS O
. . O
null null null-Disease
Approximately RB O
75 CD O
% NN O
of IN O
the DT O
patients NNS O
were VBD O
receiving VBG O
treatment NN O
for IN O
leukemia NN B-Disease
or CC O
lymphoma NN B-Disease
. . O
null null null-Disease
Among IN O
the DT O
39 CD O
reports NNS O
that WDT O
included VBD O
information NN O
on IN O
race NN O
, , O
the DT O
racial JJ O
distribution NN O
was VBD O
: : O
1 CD O
Black JJ O
, , O
3 CD O
Caucasian JJ O
, , O
and CC O
35 CD O
Asian JJ O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Our PRP$ O
data NNS O
suggest VBP O
that IN O
Asian JJ O
patients NNS O
may MD O
be VB O
at IN O
increased VBN O
risk NN O
of IN O
hyponatremia NN B-Disease
and CC O
/ SYM O
or CC O
SIADH NNP B-Disease
associated VBN O
with IN O
vincristine NN O
use NN O
. . O
null null null-Disease
Although IN O
the DT O
overall JJ O
reported JJ O
rate NN O
of IN O
SIADH NNP B-Disease
associated VBN O
with IN O
vincristine NN O
is VBZ O
very RB O
low JJ O
, , O
physicians NNS O
caring VBG O
for IN O
Asian JJ O
oncology NN O
patients NNS O
should MD O
be VB O
aware JJ O
of IN O
this DT O
potential JJ O
serious JJ O
but CC O
reversible JJ O
adverse JJ O
event NN O
. . O
null null null-Disease
Delayed VBN O
toxicity NN B-Disease
of IN O
cyclophosphamide NN O
on IN O
the DT O
bladder NN O
of IN O
DBA NNP O
/ SYM O
2 CD O
and CC O
C57BL NN O
/ SYM O
6 CD O
female JJ O
mouse NN O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
describes VBZ O
the DT O
delayed VBN O
development NN O
of IN O
a DT O
severe JJ O
bladder NN O
pathology NN O
in IN O
a DT O
susceptible JJ O
strain NN O
of IN O
mice NNS O
( -LRB- O
DBA NNP O
/ SYM O
2 CD O
) -RRB- O
but CC O
not RB O
in IN O
a DT O
resistant JJ O
strain NN O
( -LRB- O
C57BL NNP O
/ SYM O
6 CD O
) , O
when WRB O
both DT O
were VBD O
treated VBN O
with IN O
a DT O
single JJ O
300 CD O
mg NN O
/ SYM O
kg NN O
dose NN O
of IN O
cyclophosphamide NN O
( -LRB- O
CY NN O
) -RRB- O
. . O
null null null-Disease
Inbred NNP O
DBA NNP O
/ SYM O
2 CD O
and CC O
C57BL NNP O
/ SYM O
6 CD O
female JJ O
mice NNS O
were VBD O
injected VBN O
with IN O
CY NNP O
, , O
and CC O
the DT O
effect NN O
of IN O
the DT O
drug NN O
on IN O
the DT O
bladder NN O
was VBD O
assessed VBN O
during IN O
100 CD O
days NNS O
by IN O
light JJ O
microscopy NN O
using VBG O
different JJ O
staining NN O
procedures NNS O
, , O
and CC O
after IN O
30 CD O
days NNS O
by IN O
conventional JJ O
electron NN O
microscopy NN O
. . O
null null null-Disease
Early JJ O
CY NN O
toxicity NN B-Disease
caused VBD O
a DT O
typical JJ O
haemorrhagic JJ B-Disease
cystitis NN B-Disease
in IN O
both DT O
strains NNS O
that WDT O
was VBD O
completely RB O
repaired VBN O
in IN O
about RB O
7 CD O
- SYM O
10 CD O
days NNS O
. . O
null null null-Disease
After IN O
30 CD O
days NNS O
of IN O
CY NN O
injection NN O
ulcerous JJ O
and CC O
non JJ O
- HYPH O
ulcerous JJ O
forms NNS O
of IN O
chronic JJ O
cystitis NN B-Disease
appeared VBD O
in IN O
86 CD O
% NN O
of IN O
DBA NNP O
/ SYM O
2 CD O
mice NNS O
but CC O
only RB O
in IN O
4 CD O
% NN O
of IN O
C57BL NN O
/ SYM O
6 CD O
mice NNS O
. . O
null null null-Disease
Delayed VBN O
cystitis NN B-Disease
was VBD O
characterized VBN O
by IN O
infiltration NN O
and CC O
transepithelial JJ O
passage NN O
into IN O
the DT O
lumen NN O
of IN O
inflammatory JJ O
cells NNS O
and CC O
by IN O
frequent JJ O
exfoliation NN O
of IN O
the DT O
urothelium NN O
. . O
null null null-Disease
Mast JJ O
cells NNS O
appeared VBD O
in IN O
the DT O
connective JJ O
and CC O
muscular JJ O
layers NNS O
of IN O
the DT O
bladder NN O
at IN O
a DT O
much RB O
higher JJR O
number NN O
in IN O
DBA NNP O
/ SYM O
2 CD O
mice NNS O
than IN O
in IN O
C57BL NNP O
/ SYM O
6 CD O
mice NNS O
or CC O
untreated JJ O
controls NNS O
. . O
null null null-Disease
Electron NN O
microscopy NN O
disclosed VBD O
the DT O
absence NN O
of IN O
the DT O
typical JJ O
discoidal JJ O
vesicles NNS O
normally RB O
present JJ O
in IN O
the DT O
cytoplasm NN O
of IN O
surface NN O
cells NNS O
. . O
null null null-Disease
Instead RB O
, , O
numerous JJ O
abnormal JJ O
vesicles NNS O
containing VBG O
one CD O
or CC O
several JJ O
dark JJ O
granules NNS O
were VBD O
observed VBN O
in IN O
the DT O
cytoplasm NN O
of IN O
cells NNS O
from IN O
all PDT O
the DT O
epithelial JJ O
layers NNS O
. . O
null null null-Disease
Delayed VBN O
cystitis NN B-Disease
still RB O
persisted VBD O
in IN O
DBA NNP O
/ SYM O
2 CD O
mice NNS O
100 CD O
days NNS O
after IN O
treatment NN O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
delayed VBN O
toxicity NN B-Disease
of IN O
CY NN O
in IN O
female JJ O
DBA NNP O
/ SYM O
2 CD O
mice NNS O
causes VBZ O
a DT O
bladder NN O
pathology NN O
that WDT O
is VBZ O
not RB O
observed VBN O
in IN O
C57BL NNP O
/ SYM O
6 CD O
mice NNS O
. . O
null null null-Disease
This DT O
pathology NN O
resembles VBZ O
interstitial JJ B-Disease
cystitis NN I-Disease
in IN O
humans NNS O
and CC O
could MD O
perhaps RB O
be VB O
used VBN O
as IN O
an DT O
animal NN O
model NN O
for IN O
studies NNS O
on IN O
the DT O
disease NN O
. . O
null null null-Disease
High JJ O
- HYPH O
dose NN O
5 CD O
- HYPH O
fluorouracil NN O
/ SYM O
folinic JJ O
acid NN O
in IN O
combination NN O
with IN O
three CD O
- HYPH O
weekly JJ O
mitomycin NN O
C NN O
in IN O
the DT O
treatment NN O
of IN O
advanced JJ O
gastric JJ B-Disease
cancer NN I-Disease
. . O
null null null-Disease
A DT O
phase NN O
II NNP O
study NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
The DT O
24 CD O
- HYPH O
hour NN O
continuous JJ O
infusion NN O
of IN O
5 CD O
- HYPH O
fluorouracil NN O
( , O
5 CD O
- HYPH O
FU NN O
) -RRB- O
and CC O
folinic JJ O
acid NN O
( -LRB- O
FA NN O
) -RRB- O
as IN O
part NN O
of IN O
several JJ O
new JJ O
multidrug NN O
chemotherapy NN O
regimens NNS O
in IN O
advanced JJ O
gastric JJ B-Disease
cancer NN I-Disease
( -LRB- O
AGC NNP B-Disease
) -RRB- O
has VBZ O
shown VBN O
to TO O
be VB O
effective JJ O
, , O
with IN O
low JJ O
toxicity NN B-Disease
. . O
null null null-Disease
In IN O
a DT O
previous JJ O
phase NN O
II NN O
study NN O
with IN O
3 CD O
- HYPH O
weekly JJ O
bolus NN O
5 CD O
- HYPH O
FU NNP O
, , O
FA NNP O
and CC O
mitomycin NN O
C NNP O
( , O
MMC NNP O
) -RRB- O
we PRP O
found VBD O
a DT O
low JJ O
toxicity NN B-Disease
rate NN O
and CC O
response NN O
rates NNS O
comparable JJ O
to IN O
those DT O
of IN O
regimens NNS O
such JJ O
as IN O
ELF NNP O
, , O
FAM NNP O
or CC O
FAMTX NNP O
, , O
and CC O
a DT O
promising JJ O
median JJ O
overall JJ O
survival NN O
. . O
null null null-Disease
In IN O
order NN O
to TO O
improve VB O
this DT O
MMC NNP O
- HYPH O
dependent JJ O
schedule NN O
we PRP O
initiated VBD O
a DT O
phase NN O
II NN O
study NN O
with IN O
high JJ O
- HYPH O
dose NN O
5 CD O
- HYPH O
FU NNP O
/ SYM O
FA NNP O
and CC O
3 CD O
- HYPH O
weekly JJ O
bolus NN O
MMC NNP O
. . O
null null null-Disease
PATIENTS NNS O
AND CC O
METHODS NNS O
: : O
From IN O
February NNP O
, , O
1998 CD O
to IN O
September NNP O
, , O
2000 CD O
we PRP O
recruited VBD O
33 CD O
patients NNS O
with IN O
AGC NNP B-Disease
to TO O
receive VB O
weekly JJ O
24 CD O
- HYPH O
hour NN O
5 CD O
- HYPH O
FU NN O
2 CD O
, , O
600 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) -RRB- O
preceded VBN O
by IN O
2 CD O
- HYPH O
hour NN O
FA NNP O
500 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) -RRB- O
for IN O
6 CD O
weeks NNS O
, , O
followed VBN O
by IN O
a DT O
2 CD O
- HYPH O
week NN O
rest NN O
period NN O
. . O
null null null-Disease
Bolus NNP O
MMC NNP O
10 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) -RRB- O
was VBD O
added VBN O
in IN O
3 CD O
- HYPH O
weekly JJ O
intervals NNS O
. . O
null null null-Disease
Treatment NN O
given VBN O
on IN O
an DT O
outpatient JJ O
basis NN O
, , O
using VBG O
portable JJ O
pump NN O
systems NNS O
, , O
was VBD O
repeated VBN O
on IN O
day NN O
57 CD O
. . O
null null null-Disease
Patients NNS O
' POS O
characteristics NNS O
were VBD O
: : O
male JJ O
/ SYM O
female JJ O
ratio NN O
20 CD O
/ SYM O
13 CD O
; : O
median JJ O
age NN O
57 CD O
( SYM O
27 CD O
- SYM O
75 CD O
) -RRB- O
years NNS O
; : O
median JJ O
WHO NNP O
status NN O
1 CD O
( SYM O
0 CD O
- SYM O
2 CD O
) -RRB- O
. . O
null null null-Disease
18 CD O
patients NNS O
had VBD O
a DT O
primary JJ O
AGC NNP B-Disease
, , O
and CC O
15 CD O
showed VBD O
a DT O
relapsed VBN O
AGC NNP B-Disease
. . O
null null null-Disease
Median NNP O
follow NN O
- HYPH O
up NN O
was VBD O
11 CD O
. . O
8 CD O
months NNS O
( : O
range NN O
of IN O
those DT O
surviving VBG O
: : O
2 CD O
. . O
7 CD O
- SYM O
11 CD O
. . O
8 CD O
months NNS O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
32 CD O
patients NNS O
were VBD O
evaluable JJ O
for IN O
response NN O
- HYPH O
complete JJ O
remission NN O
9 CD O
. . O
1 CD O
% NN O
( , O
n CD O
= SYM O
3 CD O
) -RRB- O
, , O
partial JJ O
remission NN O
45 CD O
. . O
5 CD O
% NN O
( , O
n CD O
= SYM O
15 CD O
) -RRB- O
, , O
no DT O
change NN O
27 CD O
. . O
3 CD O
% NN O
( : O
n NN O
= SYM O
9 CD O
) -RRB- O
, , O
progressive JJ O
disease NN O
15 CD O
. . O
1 CD O
% NN O
( : O
n CD O
= SYM O
5 CD O
) -RRB- O
. . O
null null null-Disease
Median JJ O
overall JJ O
survival NN O
time NN O
was VBD O
10 CD O
. . O
2 CD O
months NNS O
[ -LRB- O
95 CD O
% NN O
confidence NN O
interval NN O
( , O
CI NN O
) NFP O
: : O
8 CD O
. . O
7 CD O
- SYM O
11 CD O
. . O
6 CD O
] -RRB- O
, , O
and CC O
median JJ O
progression NN O
- HYPH O
free JJ O
survival NN O
time NN O
was VBD O
7 CD O
. . O
6 CD O
months NNS O
( : O
95 CD O
% NN O
CI NN O
: : O
4 CD O
. . O
4 CD O
- SYM O
10 CD O
. . O
9 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
worst JJS O
toxicities NNS B-Disease
( : O
% NN O
) -RRB- O
observed VBN O
were VBD O
( , O
CTC NNP O
- HYPH O
NCI NNP O
1 CD O
/ SYM O
2 CD O
/ SYM O
3 CD O
) -RRB- O
: : O
leukopenia NN B-Disease
45 CD O
. . O
5 CD O
/ SYM O
18 CD O
. . O
2 CD O
/ SYM O
6 CD O
. . O
1 CD O
, , O
thrombocytopenia NN B-Disease
33 CD O
. . O
3 CD O
/ SYM O
9 CD O
. . O
1 CD O
/ SYM O
6 CD O
. . O
1 CD O
, , O
vomitus NN B-Disease
24 CD O
. . O
2 CD O
/ SYM O
9 CD O
. . O
1 CD O
/ SYM O
0 CD O
, , O
diarrhea NN B-Disease
36 CD O
. . O
4 CD O
/ SYM O
6 CD O
. . O
1 CD O
/ SYM O
3 CD O
. . O
0 CD O
, , O
stomatitis NN B-Disease
18 CD O
. . O
2 CD O
/ SYM O
9 CD O
. . O
1 CD O
/ SYM O
0 CD O
, , O
hand NN B-Disease
- HYPH I-Disease
foot NN I-Disease
syndrome NN I-Disease
12 CD O
. . O
1 CD O
/ SYM O
0 CD O
/ SYM O
0 CD O
. . O
null null null-Disease
Two CD O
patients NNS O
developed VBD O
hemolytic JJ B-Disease
- HYPH I-Disease
uremic NN I-Disease
syndrome NN I-Disease
( -LRB- O
HUS NNP B-Disease
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
High JJ O
- HYPH O
dose NN O
5 CD O
- HYPH O
FU NNP O
/ SYM O
FA NNP O
/ SYM O
MMC NNP O
is VBZ O
an DT O
effective JJ O
and CC O
well RB O
- HYPH O
tolerated VBN O
outpatient JJ O
regimen NN O
for IN O
AGC NNP B-Disease
( HYPH O
objective JJ O
response NN O
rate NN O
54 CD O
. . O
6 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
It PRP O
may MD O
serve VB O
as IN O
an DT O
alternative NN O
to IN O
cisplatin NN O
- HYPH O
containing VBG O
regimens NNS O
; : O
however RB O
, , O
it PRP O
has VBZ O
to TO O
be VB O
considered VBN O
that IN O
possibly RB O
HUS NNP B-Disease
may MD O
occur VB O
. . O
null null null-Disease
Persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
is VBZ O
associated VBN O
with IN O
impaired VBN B-Disease
renal JJ I-Disease
function NN I-Disease
in IN O
human JJ B-Disease
immunodeficiency NN I-Disease
virus NN I-Disease
type NN I-Disease
1 CD I-Disease
- HYPH I-Disease
infected VBN I-Disease
children NNS O
treated VBN O
with IN O
indinavir NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Prolonged VBN O
administration NN O
of IN O
indinavir NN O
is VBZ O
associated VBN O
with IN O
the DT O
occurrence NN O
of IN O
a DT O
variety NN O
of IN O
renal JJ O
complications NNS O
in IN O
adults NNS O
. . O
null null null-Disease
These DT O
well RB O
- HYPH O
documented VBN O
side NN O
effects NNS O
have VBP O
restricted VBN O
the DT O
use NN O
of IN O
this DT O
potent JJ O
protease NN O
inhibitor NN O
in IN O
children NNS O
. . O
null null null-Disease
DESIGN NN O
: : O
A DT O
prospective JJ O
study NN O
to TO O
monitor VB O
indinavir NN O
- HYPH O
related VBN O
nephrotoxicity NN B-Disease
in IN O
a DT O
cohort NN O
of IN O
30 CD O
human JJ B-Disease
immunodeficiency NN I-Disease
virus NN I-Disease
type NN I-Disease
1 CD I-Disease
- HYPH I-Disease
infected VBN I-Disease
children NNS O
treated VBN O
with IN O
indinavir NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Urinary JJ O
pH NN O
, , O
albumin NN O
, , O
creatinine NN O
, , O
the DT O
presence NN O
of IN O
erythrocytes NNS O
, , O
leukocytes NNS O
, , O
bacteria NNS O
and CC O
crystals NNS O
, , O
and CC O
culture NN O
were VBD O
analyzed VBN O
every DT O
3 CD O
months NNS O
for IN O
96 CD O
weeks NNS O
. . O
null null null-Disease
Serum NN O
creatinine NN O
levels NNS O
were VBD O
routinely RB O
determined VBN O
at IN O
the DT O
same JJ O
time NN O
points NNS O
. . O
null null null-Disease
Steady JJ O
- HYPH O
state NN O
pharmacokinetics NNS O
of IN O
indinavir NN O
were VBD O
done VBN O
at IN O
week NN O
4 CD O
after IN O
the DT O
initiation NN O
of IN O
indinavir NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
cumulative JJ O
incidence NN O
of IN O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
( : O
> NFP O
or CC O
= SYM O
75 CD O
cells NNS O
/ SYM O
micro NN O
L NN O
in IN O
at RB O
least RBS O
2 CD O
consecutive JJ O
visits NNS O
) -RRB- O
after IN O
96 CD O
weeks NNS O
was VBD O
53 CD O
% NN O
. . O
null null null-Disease
Persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
was VBD O
frequently RB O
associated VBN O
with IN O
a DT O
mild JJ O
increase NN O
in IN O
the DT O
urine NN O
albumin NN O
/ SYM O
creatinine NN O
ratio NN O
and CC O
by IN O
microscopic JJ O
hematuria NN B-Disease
. . O
null null null-Disease
The DT O
cumulative JJ O
incidence NN O
of IN O
serum NN O
creatinine NN O
levels NNS O
> : O
50 CD O
% NN O
above IN O
normal JJ O
was VBD O
33 CD O
% NN O
after IN O
96 CD O
weeks NNS O
. . O
null null null-Disease
Children NNS O
with IN O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
more RBR O
frequently RB O
had VBD O
serum JJ O
creatinine NN O
levels NNS O
of IN O
50 CD O
% NN O
above IN O
normal JJ O
than IN O
those DT O
children NNS O
without IN O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
. . O
null null null-Disease
In IN O
children NNS O
younger JJR O
than IN O
5 CD O
. . O
6 CD O
years NNS O
, , O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
was VBD O
significantly RB O
more RBR O
frequent JJ O
than IN O
in IN O
older JJR O
children NNS O
. . O
null null null-Disease
A DT O
higher JJR O
cumulative JJ O
incidence NN O
of IN O
persistent JJ O
leukocyturia NN B-Disease
was VBD O
found VBN O
in IN O
children NNS O
with IN O
an DT O
area NN O
under IN O
the DT O
curve NN O
> SYM O
19 CD O
mg NN O
/ SYM O
L NN O
x NN O
h NN O
or CC O
a DT O
peak NN O
serum NN O
level NN O
of IN O
indinavir NN O
> SYM O
12 CD O
mg NNS O
/ SYM O
L NN O
. . O
null null null-Disease
In IN O
4 CD O
children NNS O
, , O
indinavir NN O
was VBD O
discontinued VBN O
because IN O
of IN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
Subsequently RB O
, , O
the DT O
serum NN O
creatinine NN O
levels NNS O
decreased VBD O
, , O
the DT O
urine NN O
albumin NN O
/ SYM O
creatinine NN O
ratios NNS O
returned VBD O
to IN O
zero CD O
, , O
and CC O
the DT O
leukocyturia NN B-Disease
disappeared VBD O
within IN O
3 CD O
months NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Children NNS O
treated VBN O
with IN O
indinavir NN O
have VBP O
a DT O
high JJ O
cumulative JJ O
incidence NN O
of IN O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
. . O
null null null-Disease
Children NNS O
with IN O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
more RBR O
frequently RB O
had VBD O
an DT O
increase NN O
in IN O
serum JJ O
creatinine NN O
levels NNS O
of IN O
> $ O
50 CD O
% NN O
above IN O
normal JJ O
. . O
null null null-Disease
Younger JJR O
children NNS O
have VBP O
an DT O
additional JJ O
risk NN O
for IN O
renal JJ O
complications NNS O
. . O
null null null-Disease
The DT O
impairment NN B-Disease
of IN I-Disease
the DT I-Disease
renal JJ I-Disease
function NN I-Disease
in IN O
these DT O
children NNS O
occurred VBD O
in IN O
the DT O
absence NN O
of IN O
clinical JJ O
symptoms NNS O
of IN O
nephrolithiasis NN B-Disease
. . O
null null null-Disease
Indinavir NNP O
- HYPH O
associated VBN O
nephrotoxicity NN B-Disease
must MD O
be VB O
monitored VBN O
closely RB O
, , O
especially RB O
in IN O
children NNS O
with IN O
risk NN O
factors NNS O
such JJ O
as IN O
persistent JJ O
sterile JJ O
leukocyturia NN B-Disease
, , O
age NN O
< : O
5 CD O
. . O
6 CD O
years NNS O
, , O
an DT O
area NN O
under IN O
the DT O
curve NN O
of IN O
indinavir NN O
> SYM O
19 CD O
mg NN O
/ SYM O
L NN O
x NN O
h NN O
, , O
and CC O
a DT O
C NN O
( , O
max NN O
) NFP O
> SYM O
12 CD O
mg NN O
/ SYM O
L NN O
. . O
null null null-Disease
Utility NN O
of IN O
troponin NN O
I NN O
in IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
Baseline NN O
electrocardiogram NN O
abnormalities NNS O
and CC O
market NN O
elevations NNS O
not RB O
associated VBN O
with IN O
myocardial JJ B-Disease
necrosis NN I-Disease
make VBP O
accurate JJ O
diagnosis NN O
of IN O
myocardial JJ B-Disease
infarction NN I-Disease
( -LRB- O
MI NNP B-Disease
) -RRB- O
difficult JJ O
in IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
Troponin NN O
sampling NN O
may MD O
offer VB O
greater JJR O
diagnostic JJ O
utility NN O
in IN O
these DT O
patients NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
assess VB O
outcomes NNS O
based VBN O
on IN O
troponin NN O
positivity NN O
in IN O
patients NNS O
with IN O
cocaine NN O
chest NN B-Disease
pain NN I-Disease
admitted VBN O
for IN O
exclusion NN O
of IN O
MI NNP B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Outcomes NNS O
were VBD O
examined VBN O
in IN O
patients NNS O
admitted VBN O
for IN O
possible JJ O
MI NNP B-Disease
after IN O
cocaine NN O
use NN O
. . O
null null null-Disease
All DT O
patients NNS O
underwent VBD O
a DT O
rapid JJ O
rule NN O
- HYPH O
in IN O
protocol NN O
that WDT O
included VBD O
serial JJ O
sampling NN O
of IN O
creatine JJ O
kinase NN O
( , O
CK NNP O
) -RRB- O
, , O
CK NNP O
- HYPH O
MB NNP O
, , O
and CC O
cardiac JJ O
troponin NN O
I NNP O
( , O
cTnI NNP O
) -RRB- O
over IN O
eight CD O
hours NNS O
. . O
null null null-Disease
Outcomes NNS O
included VBD O
CK NNP O
- HYPH O
MB NNP O
MI NNP B-Disease
( -LRB- O
CK NNP O
- HYPH O
MB NNP O
> SYM O
or CC O
= SYM O
8 CD O
ng CD O
/ SYM O
mL NN O
with IN O
a DT O
relative JJ O
index NN O
[ -LRB- O
( -LRB- O
CK NN O
- HYPH O
MB NN O
x SYM O
100 CD O
) -RRB- O
/ SYM O
total JJ O
CK NN O
] -RRB- O
> NFP O
or CC O
= SYM O
4 CD O
, , O
cardiac JJ B-Disease
death NN I-Disease
, , O
and CC O
significant JJ O
coronary JJ B-Disease
disease NN I-Disease
( : O
> NFP O
or CC O
= SYM O
50 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
Of IN O
the DT O
246 CD O
admitted VBN O
patients NNS O
, , O
34 CD O
( SYM O
14 CD O
% NN O
) , O
met VBD O
CK NNP O
- HYPH O
MB NN O
criteria NNS O
for IN O
MI NNP B-Disease
and CC O
38 CD O
( SYM O
16 CD O
% NN O
) -RRB- O
had VBD O
cTnI NN O
elevations NNS O
. . O
null null null-Disease
Angiography NN O
was VBD O
performed VBN O
in IN O
29 CD O
of IN O
38 CD O
patients NNS O
who WP O
were VBD O
cTnI NN O
- HYPH O
positive JJ O
, , O
with IN O
significant JJ O
disease NN O
present JJ O
in IN O
25 CD O
( SYM O
86 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Three CD O
of IN O
the DT O
four CD O
patients NNS O
without IN O
significant JJ O
disease NN O
who WP O
had VBD O
cTnI NN O
elevations NNS O
met VBD O
CK NNP O
- HYPH O
MB NN O
criteria NNS O
for IN O
MI NNP B-Disease
, , O
and CC O
the DT O
other JJ O
had VBD O
a DT O
peak NN O
CK NN O
- HYPH O
MB NN O
level NN O
of IN O
13 CD O
ng CD O
/ SYM O
mL NN O
. . O
null null null-Disease
Sensitivities NNS O
, , O
specificities NNS O
, , O
and CC O
positive JJ O
and CC O
negative JJ O
likelihood NN O
ratios NNS O
for IN O
predicting VBG O
cardiac JJ B-Disease
death NN I-Disease
or CC O
significant JJ O
disease NN O
were VBD O
high JJ O
for IN O
both CC O
CK NNP O
- HYPH O
MB NNP O
MI NNP B-Disease
and CC O
cTnI NNP O
and CC O
were VBD O
not RB O
significantly RB O
different JJ O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Most JJS O
patients NNS O
with IN O
cTnI NN O
elevations NNS O
meet VBP O
CK NNP O
- HYPH O
MB NNP O
criteria NNS O
for IN O
MI NNP B-Disease
, , O
as RB O
well RB O
as IN O
have VBP O
a DT O
high JJ O
incidence NN O
of IN O
underlying VBG O
significant JJ O
disease NN O
. . O
null null null-Disease
Troponin NN O
appears VBZ O
to TO O
have VB O
an DT O
equivalent JJ O
diagnostic JJ O
accuracy NN O
compared VBN O
with IN O
CK NNP O
- HYPH O
MB NN O
for IN O
diagnosing VBG O
necrosis NN B-Disease
in IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
and CC O
suspected VBN O
MI NNP B-Disease
. . O
null null null-Disease
Acute JJ O
interstitial JJ B-Disease
nephritis NN I-Disease
due JJ O
to IN O
nicergoline NN O
( , O
Sermion NNP O
) -RRB- O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
acute JJ O
interstitial JJ B-Disease
nephritis NN I-Disease
( : O
AIN NNP B-Disease
) -RRB- O
due IN O
to IN O
nicergoline NN O
( , O
Sermion NNP O
) -RRB- O
. . O
null null null-Disease
A DT O
50 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
patient NN O
admitted VBN O
to IN O
our PRP$ O
hospital NN O
for IN O
fever NN B-Disease
and CC O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
. . O
null null null-Disease
Before IN O
admission NN O
, , O
he PRP O
had VBD O
been VBN O
taking VBG O
nicergoline NN O
and CC O
bendazac NN O
lysine NN O
due IN O
to IN O
retinal JJ B-Disease
vein NN I-Disease
occlusion NN I-Disease
at IN O
ophthalmologic JJ O
department NN O
. . O
null null null-Disease
Thereafter RB O
, , O
he PRP O
experienced VBD O
intermittent JJ O
fever NN B-Disease
and CC O
skin NN B-Disease
rash NN I-Disease
. . O
null null null-Disease
On IN O
admission NN O
, , O
clinical JJ O
symptoms NNS O
( : O
i LS O
. . O
e LS O
. . O
arthralgia NN B-Disease
and CC O
fever NN B-Disease
) -RRB- O
and CC O
laboratory NN O
findings NNS O
( : O
i LS O
. . O
e -RRB- O
. . O
eosinophilia NN B-Disease
and CC O
renal JJ B-Disease
failure NN I-Disease
) -RRB- O
suggested VBD O
AIN NNP B-Disease
, , O
and CC O
which WDT O
was VBD O
confirmed VBN O
by IN O
pathologic JJ O
findings NNS O
on IN O
renal JJ O
biopsy NN O
. . O
null null null-Disease
A DT O
lymphocyte NN O
transformation NN O
test NN O
demonstrated VBD O
a DT O
positive JJ O
result NN O
against IN O
nicergoline NN O
. . O
null null null-Disease
Treatment NN O
was VBD O
consisted VBN O
of IN O
withdrawal NN O
of IN O
nicergoline NN O
and CC O
intravenous JJ O
methylprednisolone NN O
, , O
and CC O
his PRP$ O
renal JJ O
function NN O
was VBD O
completely RB O
recovered VBN O
. . O
null null null-Disease
To IN O
our PRP$ O
knowledge NN O
, , O
this DT O
is VBZ O
the DT O
first JJ O
report NN O
of IN O
nicergoline NN O
- HYPH O
associated VBN O
AIN NNP B-Disease
. . O
null null null-Disease
Neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
complicated VBN O
by IN O
massive JJ O
intestinal JJ O
bleeding NN B-Disease
in IN O
a DT O
patient NN O
with IN O
chronic JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
. . O
null null null-Disease
A DT O
patient NN O
with IN O
chronic JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
( , O
CRF NNP B-Disease
) -RRB- O
developed VBD O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
( , O
NMS NNP B-Disease
) -RRB- O
after IN O
administration NN O
of IN O
risperidone NN O
and CC O
levomepromazine NN O
. . O
null null null-Disease
In IN O
addition NN O
to IN O
the DT O
typical JJ O
symptoms NNS O
of IN O
NMS NNP B-Disease
, , O
massive JJ O
intestinal JJ O
bleeding NN B-Disease
was VBD O
observed VBN O
during IN O
the DT O
episode NN O
. . O
null null null-Disease
This DT O
report NN O
suggests VBZ O
that IN O
NMS NNP B-Disease
in IN O
a DT O
patient NN O
with IN O
CRF NNP B-Disease
may MD O
be VB O
complicated VBN O
by IN O
intestinal JJ O
bleeding NN B-Disease
and CC O
needs VBZ O
special JJ O
caution NN O
for IN O
this DT O
complication NN O
. . O
null null null-Disease
Blood NN O
brain NN O
barrier NN O
in IN O
right RB O
- HYPH O
and CC O
left RB O
- HYPH O
pawed VBD O
female JJ O
rats NNS O
assessed VBN O
by IN O
a DT O
new JJ O
staining NN O
method NN O
. . O
null null null-Disease
The DT O
asymmetrical JJ O
breakdown NN O
of IN O
the DT O
blood NN O
- HYPH O
brain NN O
barrier NN O
( , O
BBB NNP O
) -RRB- O
was VBD O
studied VBN O
in IN O
female JJ O
rats NNS O
. . O
null null null-Disease
Paw NN O
preference NN O
was VBD O
assessed VBN O
by IN O
a DT O
food NN O
reaching VBG O
test NN O
. . O
null null null-Disease
Adrenaline NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
was VBD O
used VBN O
to TO O
destroy VB O
the DT O
BBB NNP O
, , O
which WDT O
was VBD O
evaluated VBN O
using VBG O
triphenyltetrazolium NN O
( -LRB- O
TTC NNP O
) -RRB- O
staining NN O
of IN O
the DT O
brain NN O
slices NNS O
just RB O
after IN O
giving VBG O
adrenaline NN O
for IN O
30 CD O
s NNS O
. . O
null null null-Disease
In IN O
normal JJ O
rats NNS O
, , O
the DT O
whole JJ O
brain NN O
sections NNS O
exhibited VBD O
complete JJ O
staining VBG O
with IN O
TTC NNP O
. . O
null null null-Disease
After IN O
adrenaline NN O
infusion NN O
for IN O
30 CD O
s NNS O
, , O
there EX O
were VBD O
large JJ O
unstained JJ O
areas NNS O
in IN O
the DT O
left JJ O
brain NN O
in IN O
right RB O
- HYPH O
pawed JJ O
animals NNS O
, , O
and CC O
vice RB O
versa RB O
in IN O
left RB O
- HYPH O
pawed JJ O
animals NNS O
. . O
null null null-Disease
Similar JJ O
results NNS O
were VBD O
obtained VBN O
in IN O
seizure NN B-Disease
- HYPH O
induced VBN O
breakdown NN O
of IN O
BBB NNP O
. . O
null null null-Disease
These DT O
results NNS O
were VBD O
explained VBN O
by IN O
an DT O
asymmetric JJ O
cerebral JJ O
blood NN O
flow NN O
depending VBG O
upon IN O
the DT O
paw NN O
preference NN O
in IN O
rats NNS O
. . O
null null null-Disease
It PRP O
was VBD O
suggested VBN O
that IN O
this DT O
new JJ O
method NN O
and CC O
the DT O
results NNS O
are VBP O
consistent JJ O
with IN O
contralateral JJ O
motor NN O
control NN O
that WDT O
may MD O
be VB O
important JJ O
in IN O
determining VBG O
the DT O
dominant JJ O
cerebral JJ O
hemisphere NN O
in IN O
animals NNS O
. . O
null null null-Disease
Carvedilol NNP O
protects VBZ O
against IN O
doxorubicin NN O
- HYPH O
induced VBN O
mitochondrial JJ O
cardiomyopathy NN B-Disease
. . O
null null null-Disease
Several JJ O
cytopathic JJ O
mechanisms NNS O
have VBP O
been VBN O
suggested VBN O
to TO O
mediate VB O
the DT O
dose NN O
- HYPH O
limiting VBG O
cumulative JJ O
and CC O
irreversible JJ O
cardiomyopathy NN B-Disease
caused VBN O
by IN O
doxorubicin NN O
. . O
null null null-Disease
Recent JJ O
evidence NN O
indicates VBZ O
that IN O
oxidative JJ O
stress NN O
and CC O
mitochondrial JJ B-Disease
dysfunction NN I-Disease
are VBP O
key JJ O
factors NNS O
in IN O
the DT O
pathogenic JJ O
process NN O
. . O
null null null-Disease
The DT O
objective NN O
of IN O
this DT O
investigation NN O
was VBD O
to TO O
test VB O
the DT O
hypothesis NN O
that IN O
carvedilol NN O
, , O
a DT O
nonselective JJ O
beta NN O
- HYPH O
adrenergic JJ O
receptor NN O
antagonist NN O
with IN O
potent JJ O
antioxidant JJ O
properties NNS O
, , O
protects VBZ O
against IN O
the DT O
cardiac JJ O
and CC O
hepatic JJ O
mitochondrial JJ O
bioenergetic JJ O
dysfunction NN O
associated VBN O
with IN O
subchronic JJ O
doxorubicin NN O
toxicity NN B-Disease
. . O
null null null-Disease
Heart NN O
and CC O
liver NN O
mitochondria NN O
were VBD O
isolated VBN O
from IN O
rats NNS O
treated VBN O
for IN O
7 CD O
weeks NNS O
with IN O
doxorubicin NN O
( , O
2 CD O
mg NN O
/ SYM O
kg NN O
sc NN O
/ SYM O
week NN O
) -RRB- O
, , O
carvedilol NN O
( , O
1 CD O
mg NN O
/ SYM O
kg NN O
ip NN O
/ SYM O
week NN O
) -RRB- O
, , O
or CC O
the DT O
combination NN O
of IN O
the DT O
two CD O
drugs NNS O
. . O
null null null-Disease
Heart NN O
mitochondria NN O
isolated VBN O
from IN O
doxorubicin NN O
- HYPH O
treated VBN O
rats NNS O
exhibited VBD O
depressed VBN O
rates NNS O
for IN O
state NN O
3 CD O
respiration NN O
( SYM O
336 CD O
+ SYM O
/ SYM O
- HYPH O
26 CD O
versus IN O
425 CD O
+ CC O
/ SYM O
- HYPH O
53 CD O
natom NN O
O NN O
/ SYM O
min NN O
/ SYM O
mg NN O
protein NN O
) -RRB- O
and CC O
a DT O
lower JJR O
respiratory JJ O
control NN O
ratio NN O
( -LRB- O
RCR NN O
) -RRB- O
( , O
4 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
6 CD O
versus IN O
5 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
4 CD O
) , O
compared VBN O
with IN O
cardiac JJ O
mitochondria NN O
isolated VBN O
from IN O
saline NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Mitochondrial JJ O
calcium NN O
- HYPH O
loading VBG O
capacity NN O
and CC O
the DT O
activity NN O
of IN O
NADH NNP O
- HYPH O
dehydrogenase NN O
were VBD O
also RB O
suppressed VBN O
in IN O
cardiac JJ O
mitochondria NN O
from IN O
doxorubicin NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Doxorubicin NNP O
treatment NN O
also RB O
caused VBD O
a DT O
decrease NN O
in IN O
RCR NN O
for IN O
liver NN O
mitochondria NN O
( : O
3 CD O
. . O
9 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
9 CD O
versus IN O
5 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
for IN O
control NN O
rats NNS O
) , O
and CC O
inhibition NN O
of IN O
hepatic JJ O
cytochrome NN O
oxidase NN O
activity NN O
. . O
null null null-Disease
Coadministration NN O
of IN O
carvedilol NN O
decreased VBD O
the DT O
extent NN O
of IN O
cellular JJ O
vacuolization NN O
in IN O
cardiac JJ O
myocytes NNS O
and CC O
prevented VBD O
the DT O
inhibitory JJ O
effect NN O
of IN O
doxorubicin NN O
on IN O
mitochondrial JJ O
respiration NN O
in IN O
both DT O
heart NN O
and CC O
liver NN O
. . O
null null null-Disease
Carvedilol NNP O
also RB O
prevented VBD O
the DT O
decrease NN O
in IN O
mitochondrial JJ O
Ca NN O
( , O
2 CD O
+ CC O
) -RRB- O
loading NN O
capacity NN O
and CC O
the DT O
inhibition NN O
of IN O
the DT O
respiratory JJ O
complexes NNS O
of IN O
heart NN O
mitochondria NN O
caused VBN O
by IN O
doxorubicin NN O
. . O
null null null-Disease
Carvedilol NNP O
by IN O
itself PRP O
did VBD O
not RB O
affect VB O
any DT O
of IN O
the DT O
parameters NNS O
measured VBN O
for IN O
heart NN O
or CC O
liver NN O
mitochondria NNS O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
this DT O
protection NN O
by IN O
carvedilol NN O
against IN O
both CC O
the DT O
structural JJ O
and CC O
functional JJ O
cardiac JJ O
tissue NN O
damage NN O
may MD O
afford VB O
significant JJ O
clinical JJ O
advantage NN O
in IN O
minimizing VBG O
the DT O
dose NN O
- HYPH O
limiting VBG O
mitochondrial JJ B-Disease
dysfunction NN I-Disease
and CC O
cardiomyopathy NN B-Disease
that WDT O
accompanies VBZ O
long JJ O
- HYPH O
term NN O
doxorubicin NN O
therapy NN O
in IN O
cancer NN B-Disease
patients NNS O
. . O
null null null-Disease
Cocaine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
is VBZ O
more RBR O
influenced VBN O
by IN O
adenosine JJ O
receptor NN O
agonists NNS O
than IN O
amphetamine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
. . O
null null null-Disease
The DT O
influence NN O
of IN O
adenosine NN O
receptor NN O
agonists NNS O
and CC O
antagonists NNS O
on IN O
cocaine NN O
- , O
and CC O
amphetamine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
was VBD O
examined VBN O
in IN O
mice NNS O
. . O
null null null-Disease
All DT O
adenosine NN O
receptor NN O
agonists NNS O
significantly RB O
decreased VBD B-Disease
the DT I-Disease
locomotor NN I-Disease
activity NN I-Disease
in IN O
mice NNS O
, , O
and CC O
the DT O
effects NNS O
were VBD O
dose NN O
- HYPH O
dependent JJ O
. . O
null null null-Disease
It PRP O
seems VBZ O
that IN O
adenosine JJ O
A1 NN O
and CC O
A2 NN O
receptors NNS O
might MD O
be VB O
involved VBN O
in IN O
this DT O
reaction NN O
. . O
null null null-Disease
Moreover RB O
, , O
all DT O
adenosine NN O
receptor NN O
agonists NNS O
: : O
2 CD O
- HYPH O
p NN O
- HYPH O
( : O
2 CD O
- HYPH O
carboxyethyl NN O
) : O
phenethylamino NN O
- HYPH O
5 CD O
' NN O
- HYPH O
N NN O
- HYPH O
ethylcarboxamidoadenosine NN O
( -LRB- O
CGS NNP O
21680 CD O
) -RRB- O
, , O
A2A NNP O
receptor NN O
agonist NN O
, , O
N6 NNP O
- HYPH O
cyclopentyladenosine NN O
( , O
CPA NN O
) -RRB- O
, , O
A1 NN O
receptor NN O
agonist NN O
, , O
and CC O
5 CD O
' NN O
- HYPH O
N NN O
- HYPH O
ethylcarboxamidoadenosine NN O
( : O
NECA NNP O
) -RRB- O
, , O
A2 NNP O
/ SYM O
A1 CD O
receptor NN O
agonist NN O
significantly RB O
and CC O
dose NN O
- HYPH O
dependently RB O
decreased VBN O
cocaine NN O
- HYPH O
induced VBN O
locomotor NN O
activity NN O
. . O
null null null-Disease
CPA NN O
reduced VBD O
cocaine NN O
action NN O
at IN O
the DT O
doses NNS O
which WDT O
, , O
given VBN O
alone RB O
, , O
did VBD O
not RB O
influence VB O
motility NN O
, , O
while IN O
CGS NNP O
21680 CD O
and CC O
NECA NNP O
decreased VBD O
the DT O
action NN O
of IN O
cocaine NN O
at IN O
the DT O
doses NNS O
which WDT O
, , O
given VBN O
alone RB O
, , O
decreased VBD O
locomotor NN O
activity NN O
in IN O
animals NNS O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
the DT O
involvement NN O
of IN O
both CC O
adenosine JJ O
receptors NNS O
in IN O
the DT O
action NN O
of IN O
cocaine NN O
although IN O
agonists NNS O
of IN O
A1 NNP O
receptors NNS O
seem VBP O
to TO O
have VB O
stronger JJR O
influence NN O
on IN O
it PRP O
. . O
null null null-Disease
The DT O
selective JJ O
blockade NN O
of IN O
A2 NN O
adenosine NN O
receptor NN O
by IN O
DMPX NNP O
( : O
3 CD O
, , O
7 CD O
- HYPH O
dimethyl NN O
- HYPH O
1 CD O
- HYPH O
propargylxanthine NN O
) -RRB- O
significantly RB O
enhanced VBD O
cocaine NN O
- HYPH O
induced VBN O
locomotor NN O
activity NN O
of IN O
animals NNS O
. . O
null null null-Disease
Caffeine NNP O
had VBD O
similar JJ O
action NN O
but CC O
the DT O
effect NN O
was VBD O
not RB O
significant JJ O
. . O
null null null-Disease
CPT NNP O
( : O
8 CD O
- HYPH O
cyclopentyltheophylline NN O
) : O
- HYPH O
- HYPH O
A1 NN O
receptor NN O
antagonist NN O
, , O
did VBD O
not RB O
show VB O
any DT O
influence NN O
in IN O
this DT O
test NN O
. . O
null null null-Disease
Similarly RB O
, , O
all DT O
adenosine NN O
receptor NN O
agonists NNS O
decreased VBD O
amphetamine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
, , O
but CC O
at IN O
the DT O
higher JJR O
doses NNS O
than IN O
those DT O
which WDT O
were VBD O
active JJ O
in IN O
cocaine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
. . O
null null null-Disease
The DT O
selective JJ O
blockade NN O
of IN O
A2 NN O
adenosine NN O
receptors NNS O
( -LRB- O
DMPX NNP O
) -RRB- O
and CC O
non JJ O
- HYPH O
selective JJ O
blockade NN O
of IN O
adenosine NN O
receptors NNS O
( , O
caffeine NN O
) -RRB- O
significantly RB O
increased VBD O
the DT O
action NN O
of IN O
amphetamine NN O
in IN O
the DT O
locomotor NN O
activity NN O
test NN O
. . O
null null null-Disease
Our PRP$ O
results NNS O
have VBP O
shown VBN O
that IN O
all DT O
adenosine NN O
receptor NN O
agonists NNS O
( -LRB- O
A1 NNP O
and CC O
A2 NNP O
) -RRB- O
reduce VBP O
cocaine NN O
- HYPH O
and CC O
amphetamine NN O
- HYPH O
induced VBN O
locomotor NN O
activity NN O
and CC O
indicate VBP O
that IN O
cocaine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
is VBZ O
more RBR O
influenced VBN O
by IN O
adenosine NN O
receptor NN O
agonists NNS O
( , O
particularly RB O
A1 NN O
receptors NNS O
) -RRB- O
than IN O
amphetamine NN O
- HYPH O
induced VBN O
hyperactivity NN B-Disease
. . O
null null null-Disease
Amiodarone NN O
and CC O
the DT O
risk NN O
of IN O
bradyarrhythmia NN B-Disease
requiring VBG O
permanent JJ O
pacemaker NN O
in IN O
elderly JJ O
patients NNS O
with IN O
atrial JJ B-Disease
fibrillation NN I-Disease
and CC O
prior JJ O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
whether IN O
the DT O
use NN O
of IN O
amiodarone NN O
in IN O
patients NNS O
with IN O
atrial JJ B-Disease
fibrillation NN I-Disease
( , O
AF NNP B-Disease
) -RRB- O
increases VBZ O
the DT O
risk NN O
of IN O
bradyarrhythmia NN B-Disease
requiring VBG O
a DT O
permanent JJ O
pacemaker NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Reports NNS O
of IN O
severe JJ O
bradyarrhythmia NN B-Disease
during IN O
amiodarone NN O
therapy NN O
are VBP O
infrequent JJ O
and CC O
limited VBN O
to IN O
studies NNS O
assessing VBG O
the DT O
therapy NN O
' POS O
s NN O
use NN O
in IN O
the DT O
management NN O
of IN O
patients NNS O
with IN O
ventricular JJ B-Disease
arrhythmias NNS I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
study NN O
cohort NN O
of IN O
8 CD O
, , O
770 CD O
patients NNS O
age NN O
> : O
or CC O
= SYM O
65 CD O
years NNS O
with IN O
a DT O
new JJ O
diagnosis NN O
of IN O
AF NNP B-Disease
was VBD O
identified VBN O
from IN O
a DT O
provincewide JJ O
database NN O
of IN O
Quebec NNP O
residents NNS O
with IN O
a DT O
myocardial JJ B-Disease
infarction NN I-Disease
( -LRB- O
MI NNP B-Disease
) -RRB- O
between IN O
1991 CD O
and CC O
1999 CD O
. . O
null null null-Disease
Using VBG O
a DT O
nested VBN O
case NN O
- HYPH O
control NN O
design NN O
, , O
477 CD O
cases NNS O
of IN O
bradyarrhythmia NN B-Disease
requiring VBG O
a DT O
permanent JJ O
pacemaker NN O
were VBD O
matched VBN O
( : O
1 CD O
: SYM O
4 CD O
) -RRB- O
to IN O
1 CD O
, , O
908 CD O
controls NNS O
. . O
null null null-Disease
Multivariable JJ O
logistic JJ O
regression NN O
was VBD O
used VBN O
to TO O
estimate VB O
the DT O
odds NNS O
ratio NN O
( -LRB- O
OR NN O
) -RRB- O
of IN O
pacemaker NN O
insertion NN O
associated VBN O
with IN O
amiodarone NN O
use NN O
, , O
controlling VBG O
for IN O
baseline NN O
risk NN O
factors NNS O
and CC O
exposure NN O
to IN O
sotalol NN O
, , O
Class NNP O
I NNP O
antiarrhythmic JJ O
agents NNS O
, , O
beta NN O
- HYPH O
blockers NNS O
, , O
calcium NN O
channel NN O
blockers NNS O
, , O
and CC O
digoxin NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
amiodarone NN O
use NN O
was VBD O
associated VBN O
with IN O
an DT O
increased VBN O
risk NN O
of IN O
pacemaker NN O
insertion NN O
( , O
OR CC O
: : O
2 CD O
. . O
14 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
[ -LRB- O
CI NN O
] -RRB- O
: : O
1 CD O
. . O
30 CD O
to TO O
3 CD O
. . O
54 CD O
) -RRB- O
. . O
null null null-Disease
This DT O
effect NN O
was VBD O
modified VBN O
by IN O
gender NN O
, , O
with IN O
a DT O
greater JJR O
risk NN O
in IN O
women NNS O
versus IN O
men NNS O
( , O
OR CC O
: : O
3 CD O
. . O
86 CD O
, , O
95 CD O
% NN O
CI NN O
: : O
1 CD O
. . O
70 CD O
to TO O
8 CD O
. . O
75 CD O
vs NNS O
. . O
OR CC O
: : O
1 CD O
. . O
52 CD O
, , O
95 CD O
% NN O
CI NN O
: : O
0 CD O
. . O
80 CD O
to TO O
2 CD O
. . O
89 CD O
) -RRB- O
. . O
null null null-Disease
Digoxin NNP O
was VBD O
the DT O
only JJ O
other JJ O
medication NN O
associated VBN O
with IN O
an DT O
increased VBN O
risk NN O
of IN O
pacemaker NN O
insertion NN O
( : O
OR CC O
: : O
1 CD O
. . O
78 CD O
, , O
95 CD O
% NN O
CI NN O
: : O
1 CD O
. . O
37 CD O
to TO O
2 CD O
. . O
31 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
This DT O
study NN O
suggests VBZ O
that IN O
the DT O
use NN O
of IN O
amiodarone NN O
in IN O
elderly JJ O
patients NNS O
with IN O
AF NNP B-Disease
and CC O
a DT O
previous JJ O
MI NNP B-Disease
increases VBZ O
the DT O
risk NN O
of IN O
bradyarrhythmia NN B-Disease
requiring VBG O
a DT O
permanent JJ O
pacemaker NN O
. . O
null null null-Disease
The DT O
finding NN O
of IN O
an DT O
augmented VBN O
risk NN O
of IN O
pacemaker NN O
insertion NN O
in IN O
elderly JJ O
women NNS O
receiving VBG O
amiodarone NN O
requires VBZ O
further JJ O
investigation NN O
. . O
null null null-Disease
Indomethacin NN O
- HYPH O
induced VBN O
morphologic JJ O
changes NNS O
in IN O
the DT O
rat JJ O
urinary JJ O
bladder NN O
epithelium NN O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
To TO O
evaluate VB O
the DT O
morphologic JJ O
changes NNS O
in IN O
rat NN O
urothelium NN O
induced VBN O
by IN O
indomethacin NN O
. . O
null null null-Disease
Nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drug NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
is VBZ O
a DT O
poorly RB O
recognized VBN O
and CC O
under IN O
- HYPH O
reported VBN O
condition NN O
. . O
null null null-Disease
In IN O
addition NN O
to IN O
tiaprofenic JJ O
acid NN O
, , O
indomethacin NN O
has VBZ O
been VBN O
reported VBN O
to TO O
be VB O
associated VBN O
with IN O
this DT O
condition NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Three CD O
groups NNS O
were VBD O
established VBN O
: : O
a DT O
control NN O
group NN O
( , O
n NN O
= SYM O
10 CD O
) -RRB- O
, , O
a DT O
high JJ O
- HYPH O
dose NN O
group NN O
( , O
n NN O
= SYM O
10 CD O
) -RRB- O
, , O
treated VBN O
with IN O
one CD O
intraperitoneal JJ O
injection NN O
of IN O
indomethacin NN O
20 CD O
mg NN O
/ SYM O
kg NN O
, , O
and CC O
a DT O
therapeutic JJ O
dose NN O
group NN O
( , O
n NN O
= SYM O
10 CD O
) -RRB- O
in IN O
which WDT O
oral JJ O
indomethacin NN O
was VBD O
administered VBN O
3 CD O
. . O
25 CD O
mg NN O
/ SYM O
kg NN O
body NN O
weight NN O
daily RB O
for IN O
3 CD O
weeks NNS O
. . O
null null null-Disease
The DT O
animals NNS O
were VBD O
then RB O
killed VBN O
and CC O
the DT O
bladders NNS O
removed VBN O
for IN O
light JJ O
and CC O
electron NN O
microscopic JJ O
studies NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
light JJ O
microscopic JJ O
findings NNS O
showed VBD O
some DT O
focal JJ O
epithelial JJ O
degeneration NN O
that WDT O
was VBD O
more RBR O
prominent JJ O
in IN O
the DT O
high JJ O
- HYPH O
dose NN O
group NN O
. . O
null null null-Disease
When WRB O
compared VBN O
with IN O
the DT O
control NN O
group NN O
, , O
both CC O
indomethacin NN O
groups NNS O
revealed VBD O
statistically RB O
increased VBN O
numbers NNS O
of IN O
mast NN O
cells NNS O
in IN O
the DT O
mucosa NN O
( , O
P NN O
< SYM O
0 CD O
. . O
0001 CD O
) -RRB- O
and CC O
penetration NN O
of IN O
lanthanum NN O
nitrate NN O
through IN O
intercellular JJ O
areas NNS O
of IN O
the DT O
epithelium NN O
. . O
null null null-Disease
Furthermore RB O
, , O
the DT O
difference NN O
in IN O
mast JJ O
cell NN O
counts NNS O
between IN O
the DT O
high JJ O
and CC O
therapeutic JJ O
dose NN O
groups NNS O
was VBD O
also RB O
statistically RB O
significant JJ O
( : O
P NN O
< NN O
0 CD O
. . O
0001 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Indomethacin NN O
resulted VBD O
in IN O
histopathologic JJ O
findings NNS O
typical JJ O
of IN O
interstitial JJ B-Disease
cystitis NN I-Disease
, , O
such JJ O
as IN O
leaky JJ O
bladder NN O
epithelium NN O
and CC O
mucosal JJ O
mastocytosis NN B-Disease
. . O
null null null-Disease
The DT O
true JJ O
incidence NN O
of IN O
nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drug NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
in IN O
humans NNS O
must MD O
be VB O
clarified VBN O
by IN O
prospective JJ O
clinical JJ O
trials NNS O
. . O
null null null-Disease
An DT O
open JJ O
- HYPH O
label NN O
phase NN O
II NN O
study NN O
of IN O
low JJ O
- HYPH O
dose NN O
thalidomide NN O
in IN O
androgen NN O
- HYPH O
independent JJ O
prostate NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
The DT O
antiangiogenic JJ O
effects NNS O
of IN O
thalidomide NN O
have VBP O
been VBN O
assessed VBN O
in IN O
clinical JJ O
trials NNS O
in IN O
patients NNS O
with IN O
various JJ O
solid JJ O
and CC O
haematological JJ B-Disease
malignancies NNS I-Disease
. . O
null null null-Disease
Thalidomide NN O
blocks VBZ O
the DT O
activity NN O
of IN O
angiogenic JJ O
agents NNS O
including VBG O
bFGF NNP O
, , O
VEGF NNP O
and CC O
IL NN O
- HYPH O
6 CD O
. . O
null null null-Disease
We PRP O
undertook VBD O
an DT O
open JJ O
- HYPH O
label NN O
study NN O
using VBG O
thalidomide NN O
100 CD O
mg NN O
once RB O
daily RB O
for IN O
up IN O
to TO O
6 CD O
months NNS O
in IN O
20 CD O
men NNS O
with IN O
androgen NN O
- HYPH O
independent JJ O
prostate NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
The DT O
mean JJ O
time NN O
of IN O
study NN O
was VBD O
109 CD O
days NNS O
( : O
median JJ O
107 CD O
, , O
range NN O
4 CD O
- SYM O
184 CD O
days NNS O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
underwent VBD O
regular JJ O
measurement NN O
of IN O
prostate NN O
- HYPH O
specific JJ O
antigen NN O
( , O
PSA NNP O
) -RRB- O
, , O
urea NN O
and CC O
electrolytes NNS O
, , O
serum NN O
bFGF NNP O
and CC O
VEGF NNP O
. . O
null null null-Disease
Three CD O
men NNS O
( : O
15 CD O
% NN O
) , O
showed VBD O
a DT O
decline NN O
in IN O
serum NN O
PSA NN O
of IN O
at RB O
least RBS O
50 CD O
% NN O
, , O
sustained VBN O
throughout IN O
treatment NN O
. . O
null null null-Disease
Of IN O
16 CD O
men NNS O
treated VBN O
for IN O
at RB O
least RBS O
2 CD O
months NNS O
, , O
six CD O
( SYM O
37 CD O
. . O
5 CD O
% NN O
) -RRB- O
showed VBD O
a DT O
fall NN O
in IN O
absolute JJ O
PSA NN O
by IN O
a DT O
median NN O
of IN O
48 CD O
% NN O
. . O
null null null-Disease
Increasing VBG O
levels NNS O
of IN O
serum NN O
bFGF NNP O
and CC O
VEGF NNP O
were VBD O
associated VBN O
with IN O
progressive JJ O
disease NN O
; : O
five CD O
of IN O
six CD O
men NNS O
who WP O
demonstrated VBD O
a DT O
fall NN O
in IN O
PSA NNP O
also RB O
showed VBD O
a DT O
decline NN O
in IN O
bFGF NNP O
and CC O
VEGF NNP O
levels NNS O
, , O
and CC O
three CD O
of IN O
four CD O
men NNS O
with IN O
a DT O
rising VBG O
PSA NNP O
showed VBD O
an DT O
increase NN O
in IN O
both DT O
growth NN O
factors NNS O
. . O
null null null-Disease
Adverse JJ O
effects NNS O
included VBD O
constipation NN B-Disease
, , O
morning NN O
drowsiness NN B-Disease
, , O
dizziness NN B-Disease
and CC O
rash NN B-Disease
, , O
and CC O
resulted VBD O
in IN O
withdrawal NN O
from IN O
the DT O
study NN O
by IN O
three CD O
men NNS O
. . O
null null null-Disease
Evidence NN O
of IN O
peripheral JJ B-Disease
sensory JJ I-Disease
neuropathy NN I-Disease
was VBD O
found VBN O
in IN O
nine CD O
of IN O
13 CD O
men NNS O
before IN O
treatment NN O
. . O
null null null-Disease
In IN O
the DT O
seven CD O
men NNS O
who WP O
completed VBD O
six CD O
months NNS O
on IN O
thalidomide NN O
, , O
subclinical JJ O
evidence NN O
of IN O
peripheral JJ B-Disease
neuropathy NN I-Disease
was VBD O
found VBN O
in IN O
four CD O
before IN O
treatment NN O
, , O
but CC O
in IN O
all DT O
seven CD O
at IN O
repeat NN O
testing NN O
. . O
null null null-Disease
The DT O
findings NNS O
indicate VBP O
that IN O
thalidomide NN O
may MD O
be VB O
an DT O
option NN O
for IN O
patients NNS O
who WP O
have VBP O
failed VBN O
other JJ O
forms NNS O
of IN O
therapy NN O
, , O
provided VBN O
close JJ O
follow NN O
- HYPH O
up NN O
is VBZ O
maintained VBN O
for IN O
development NN O
of IN O
peripheral JJ B-Disease
neuropathy NN I-Disease
. . O
null null null-Disease
Central JJ B-Disease
nervous JJ I-Disease
system NN I-Disease
toxicity NN I-Disease
following VBG O
the DT O
administration NN O
of IN O
levobupivacaine NN O
for IN O
lumbar JJ O
plexus NN O
block NN O
: : O
A DT O
report NN O
of IN O
two CD O
cases NNS O
. . O
null null null-Disease
BACKGROUND NN O
AND CC O
OBJECTIVES NNS O
: : O
Central JJ B-Disease
nervous JJ I-Disease
system NN I-Disease
and CC I-Disease
cardiac JJ I-Disease
toxicity NN I-Disease
following VBG O
the DT O
administration NN O
of IN O
local JJ O
anesthetics NNS O
is VBZ O
a DT O
recognized VBN O
complication NN O
of IN O
regional JJ O
anesthesia NN O
. . O
null null null-Disease
Levobupivacaine NNP O
, , O
the DT O
pure JJ O
S NNP O
( , O
- HYPH O
) -RRB- O
enantiomer NN O
of IN O
bupivacaine NN O
, , O
was VBD O
developed VBN O
to TO O
improve VB O
the DT O
cardiac JJ O
safety NN O
profile NN O
of IN O
bupivacaine NN O
. . O
null null null-Disease
We PRP O
describe VBP O
2 CD O
cases NNS O
of IN O
grand JJ B-Disease
mal NN I-Disease
seizures NNS I-Disease
following VBG O
accidental JJ O
intravascular JJ O
injection NN O
of IN O
levobupivacaine NN O
. . O
null null null-Disease
CASE NNP O
REPORT NN O
: : O
Two CD O
patients NNS O
presenting VBG O
for IN O
elective JJ O
orthopedic JJ O
surgery NN O
of IN O
the DT O
lower JJR O
limb NN O
underwent VBD O
blockade NN O
of IN O
the DT O
lumbar JJ O
plexus NN O
via IN O
the DT O
posterior JJ O
approach NN O
. . O
null null null-Disease
Immediately RB O
after IN O
the DT O
administration NN O
of IN O
levobupivacaine NN O
0 CD O
. . O
5 CD O
% NN O
with IN O
epinephrine NN O
2 CD O
. . O
5 CD O
microgram NN O
/ SYM O
mL NN O
, , O
the DT O
patients NNS O
developed VBD O
grand JJ B-Disease
mal NN I-Disease
seizures NNS I-Disease
, , O
despite IN O
negative JJ O
aspiration NN O
for IN O
blood NN O
and CC O
no DT O
clinical JJ O
signs NNS O
of IN O
intravenous JJ O
epinephrine NN O
administration NN O
. . O
null null null-Disease
The DT O
seizures NNS B-Disease
were VBD O
successfully RB O
treated VBN O
with IN O
sodium NN O
thiopental NN O
in IN O
addition NN O
to IN O
succinylcholine NN O
in IN O
1 CD O
patient NN O
. . O
null null null-Disease
Neither DT O
patient NN O
developed VBD O
signs NNS O
of IN O
cardiovascular JJ B-Disease
toxicity NN I-Disease
. . O
null null null-Disease
Both DT O
patients NNS O
were VBD O
treated VBN O
preoperatively RB O
with IN O
beta NN O
- HYPH O
adrenergic JJ O
antagonist NN O
medications NNS O
, , O
which WDT O
may MD O
have VB O
masked VBN O
the DT O
cardiovascular JJ O
signs NNS O
of IN O
the DT O
unintentional JJ O
intravascular JJ O
administration NN O
of IN O
levobupivacaine NN O
with IN O
epinephrine NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Although IN O
levobupivacaine NN O
may MD O
have VB O
a DT O
safer JJR O
cardiac JJ B-Disease
toxicity NN I-Disease
profile NN O
than IN O
racemic JJ O
bupivacaine NN O
, , O
if IN O
adequate JJ O
amounts NNS O
of IN O
levobupivacaine NN O
reach VBP O
the DT O
circulation NN O
, , O
it PRP O
will MD O
result VB O
in IN O
convulsions NNS B-Disease
. . O
null null null-Disease
Plasma NN O
concentrations NNS O
sufficient JJ O
to TO O
result VB O
in IN O
central JJ B-Disease
nervous JJ I-Disease
system NN I-Disease
toxicity NN I-Disease
did VBD O
not RB O
produce VB O
manifestations NNS O
of IN O
cardiac JJ B-Disease
toxicity NN I-Disease
in IN O
these DT O
2 CD O
patients NNS O
. . O
null null null-Disease
Amiodarone NN O
- HYPH O
induced VBN O
torsade NN B-Disease
de FW I-Disease
pointes NNS I-Disease
during IN O
bladder NN O
irrigation NN O
: : O
an DT O
unusual JJ O
presentation NN O
- : O
- : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
The DT O
authors NNS O
present VBP O
a DT O
case NN O
of IN O
early JJ O
( , O
within IN O
4 CD O
days NNS O
) , O
development NN O
of IN O
torsade NN B-Disease
de FW I-Disease
pointes FW I-Disease
( , O
TdP NNP B-Disease
) -RRB- O
associated VBN O
with IN O
oral JJ O
amiodarone NN O
therapy NN O
. . O
null null null-Disease
Consistent JJ O
with IN O
other JJ O
reports NNS O
this DT O
case NN O
of IN O
TdP NNP B-Disease
occurred VBD O
in IN O
the DT O
context NN O
of IN O
multiple JJ O
exacerbating VBG O
factors NNS O
including VBG O
hypokalemia NN B-Disease
and CC O
digoxin NN O
excess NN O
. . O
null null null-Disease
Transient JJ O
prolongation NN O
of IN O
the DT O
QT NNP O
during IN O
bladder NN O
irrigation NN O
prompted VBD O
the DT O
episode NN O
of IN O
TdP NNP B-Disease
. . O
null null null-Disease
It PRP O
is VBZ O
well RB O
known VBN O
that IN O
bradycardia NN B-Disease
exacerbates VBZ O
acquired VBN O
TdP NNP B-Disease
. . O
null null null-Disease
The DT O
authors NNS O
speculate VBP O
that IN O
the DT O
increased VBN O
vagal JJ O
tone NN O
during IN O
bladder NN O
irrigation NN O
, , O
a DT O
vagal JJ O
maneuver NN O
, , O
in IN O
the DT O
context NN O
of IN O
amiodarone NN O
therapy NN O
resulted VBD O
in IN O
amiodarone NN O
- HYPH O
induced VBN O
proarrhythmia NN B-Disease
. . O
null null null-Disease
In IN O
the DT O
absence NN O
of IN O
amiodarone NN O
therapy NN O
, , O
a DT O
second JJ O
bladder NN O
irrigation NN O
did VBD O
not RB O
induce VB O
TdP NNP B-Disease
despite IN O
hypokalemia NN B-Disease
and CC O
hypomagnesemia NN B-Disease
. . O
null null null-Disease
Anaesthetic JJ O
complications NNS O
associated VBN O
with IN O
myotonia NN B-Disease
congenita NN I-Disease
: : O
case NN O
study NN O
and CC O
comparison NN O
with IN O
other JJ O
myotonic JJ B-Disease
disorders NNS I-Disease
. . O
null null null-Disease
Myotonia NNP B-Disease
congenita NN I-Disease
( -LRB- O
MC NNP B-Disease
) -RRB- O
is VBZ O
caused VBN O
by IN O
a DT O
defect NN O
in IN O
the DT O
skeletal JJ O
muscle NN O
chloride NN O
channel NN O
function NN O
, , O
which WDT O
may MD O
cause VB O
sustained JJ B-Disease
membrane NN I-Disease
depolarisation NN I-Disease
. . O
null null null-Disease
We PRP O
describe VBP O
a DT O
previously RB O
healthy JJ O
32 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
who WP O
developed VBD O
a DT O
life NN O
- HYPH O
threatening VBG O
muscle NN B-Disease
spasm NN I-Disease
and CC O
secondary JJ O
ventilation NN O
difficulties NNS O
following VBG O
a DT O
preoperative JJ O
injection NN O
of IN O
suxamethonium NN O
. . O
null null null-Disease
The DT O
muscle NN B-Disease
spasms NNS I-Disease
disappeared VBD O
spontaneously RB O
and CC O
the DT O
surgery NN O
proceeded VBD O
without IN O
further JJ O
problems NNS O
. . O
null null null-Disease
When WRB O
subsequently RB O
questioned VBN O
, , O
she PRP O
reported VBD O
minor JJ O
symptoms NNS O
suggesting VBG O
a DT O
myotonic JJ B-Disease
condition NN I-Disease
. . O
null null null-Disease
Myotonia NNP B-Disease
was VBD O
found VBN O
on IN O
clinical JJ O
examination NN O
and CC O
EMG NNP O
. . O
null null null-Disease
The DT O
diagnosis NN O
MC NNP B-Disease
was VBD O
confirmed VBN O
genetically RB O
. . O
null null null-Disease
Neither CC O
the DT O
patient NN O
nor CC O
the DT O
anaesthetist NN O
were VBD O
aware JJ O
of IN O
the DT O
diagnosis NN O
before IN O
this DT O
potentially RB O
lethal JJ O
complication NN O
occurred VBD O
. . O
null null null-Disease
We PRP O
give VBP O
a DT O
brief JJ O
overview NN O
of IN O
ion NN B-Disease
channel NN I-Disease
disorders NNS I-Disease
including VBG O
malignant JJ B-Disease
hyperthermia NN I-Disease
and CC O
their PRP$ O
anaesthetic JJ O
considerations NNS O
. . O
null null null-Disease
Respiratory JJ O
pattern NN O
in IN O
a DT O
rat NN O
model NN O
of IN O
epilepsy NN B-Disease
. . O
null null null-Disease
PURPOSE NN O
: : O
Apnea NNP B-Disease
is VBZ O
known VBN O
to TO O
occur VB O
during IN O
seizures NNS B-Disease
, , O
but CC O
systematic JJ O
studies NNS O
of IN O
ictal JJ O
respiratory JJ O
changes NNS O
in IN O
adults NNS O
are VBP O
few JJ O
. . O
null null null-Disease
Data NNS O
regarding VBG O
respiratory JJ O
pattern NN O
defects NNS O
during IN O
interictal JJ O
periods NNS O
also RB O
are VBP O
scarce JJ O
. . O
null null null-Disease
Here RB O
we PRP O
sought VBD O
to TO O
generate VB O
information NN O
with IN O
regard NN O
to IN O
the DT O
interictal JJ O
period NN O
in IN O
animals NNS O
with IN O
pilocarpine NN O
- HYPH O
induced VBN O
epilepsy NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Twelve CD O
rats NNS O
( , O
six CD O
chronically RB O
epileptic JJ B-Disease
animals NNS O
and CC O
six CD O
controls NNS O
) , O
were VBD O
anesthetized VBN O
, , O
given VBN O
tracheotomies NNS O
, , O
and CC O
subjected VBN O
to IN O
hyperventilation NN B-Disease
or CC O
hypoventilation NN O
conditions NNS O
. . O
null null null-Disease
Breathing NN O
movements NNS O
caused VBD O
changes NNS O
in IN O
thoracic JJ O
volume NN O
and CC O
forced VBN O
air NN O
to TO O
flow VB O
tidally RB O
through IN O
a DT O
pneumotachograph NN O
. . O
null null null-Disease
This DT O
flow NN O
was VBD O
measured VBN O
by IN O
using VBG O
a DT O
differential JJ O
pressure NN O
transducer NN O
, , O
passed VBN O
through IN O
a DT O
polygraph NN O
, , O
and CC O
from IN O
this DT O
to IN O
a DT O
computer NN O
with IN O
custom NN O
software NN O
that WDT O
derived VBD O
ventilation NN O
( , O
VE NNP O
) -RRB- O
, , O
tidal JJ O
volume NN O
( , O
VT NNP O
) -RRB- O
, , O
inspiratory JJ O
time NN O
( , O
TI NNP O
) -RRB- O
, , O
expiratory JJ O
time NN O
( , O
TE NNP O
) -RRB- O
, , O
breathing VBG O
frequency NN O
( , O
f LS O
) -RRB- O
, , O
and CC O
mean JJ O
inspiratory JJ O
flow NN O
( , O
VT NNP O
/ SYM O
TI NNP O
) -RRB- O
on IN O
a DT O
breath NN O
- HYPH O
by IN O
- HYPH O
breath NN O
basis NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
hyperventilation NN B-Disease
maneuver NN O
caused VBD O
a DT O
decrease NN O
in IN O
spontaneous JJ O
ventilation NN O
in IN O
pilocarpine NN O
- HYPH O
treated VBN O
and CC O
control NN O
rats NNS O
. . O
null null null-Disease
Although IN O
VE NNP O
had VBD O
a DT O
similar JJ O
decrease NN O
in IN O
both DT O
groups NNS O
, , O
in IN O
the DT O
epileptic JJ B-Disease
group NN O
, , O
the DT O
decrease NN O
in IN O
VE NNP O
was VBD O
due JJ O
to IN O
a DT O
significant JJ O
( , O
p NN O
< SYM O
0 CD O
. SYM O
05 CD O
) , O
increase NN O
in IN O
TE NNP O
peak NN O
in IN O
relation NN O
to IN O
that DT O
of IN O
the DT O
control NN O
animals NNS O
. . O
null null null-Disease
The DT O
hypoventilation NN O
maneuver NN O
led VBD O
to IN O
an DT O
increase NN O
in IN O
the DT O
arterial JJ O
Paco2 NNP O
, , O
followed VBN O
by IN O
an DT O
increase NN O
in IN O
VE NNP O
. . O
null null null-Disease
In IN O
the DT O
epileptic JJ B-Disease
group NN O
, , O
the DT O
increase NN O
in IN O
VE NNP O
was VBD O
mediated VBN O
by IN O
a DT O
significant JJ O
( , O
p NN O
< SYM O
0 CD O
. SYM O
05 CD O
) -RRB- O
decrease NN O
in IN O
TE NNP O
peak NN O
compared VBN O
with IN O
the DT O
control NN O
group NN O
. . O
null null null-Disease
Systemic JJ O
application NN O
of IN O
KCN NNP O
, , O
to TO O
evaluate VB O
the DT O
effects NNS O
of IN O
peripheral JJ O
chemoreception NN O
activation NN O
on IN O
ventilation NN O
, , O
led VBD O
to IN O
a DT O
similar JJ O
increase NN O
in IN O
VE NNP O
for IN O
both DT O
groups NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
data NNS O
indicate VBP O
that IN O
pilocarpine NN O
- HYPH O
treated VBN O
animals NNS O
have VBP O
an DT O
altered VBN O
ability NN O
to TO O
react VB O
to IN O
( : O
or CC O
compensate VB O
for IN O
) , O
blood NN O
gas NN O
changes NNS O
with IN O
changes NNS O
in IN O
ventilation NN O
and CC O
suggest VBP O
that IN O
it PRP O
is VBZ O
centrally RB O
determined VBN O
. . O
null null null-Disease
We PRP O
speculate VBP O
on IN O
the DT O
possible JJ O
relation NN O
of IN O
the DT O
current JJ O
findings NNS O
on IN O
treating VBG O
different JJ O
epilepsy NN B-Disease
- HYPH O
associated VBN O
conditions NNS O
. . O
null null null-Disease
Fatal JJ O
myeloencephalopathy NN B-Disease
due JJ O
to IN O
intrathecal JJ O
vincristine NN O
administration NN O
. . O
null null null-Disease
Vincristine NNP O
was VBD O
accidentally RB O
given VBN O
intrathecally RB O
to IN O
a DT O
child NN O
with IN O
leukaemia NN B-Disease
, , O
producing VBG O
sensory NN B-Disease
and CC I-Disease
motor NN I-Disease
dysfunction NN I-Disease
followed VBN O
by IN O
encephalopathy NN B-Disease
and CC O
death NN O
. . O
null null null-Disease
Separate JJ O
times NNS O
for IN O
administering VBG O
vincristine NN O
and CC O
intrathecal JJ O
therapy NN O
is VBZ O
recommended VBN O
. . O
null null null-Disease
Progesterone NN O
potentiation NN O
of IN O
bupivacaine NN O
arrhythmogenicity NN O
in IN O
pentobarbital NN O
- HYPH O
anesthetized VBN O
rats NNS O
and CC O
beating VBG O
rat NN O
heart NN O
cell NN O
cultures NNS O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
progesterone NN O
treatment NN O
on IN O
bupivacaine NN O
arrhythmogenicity NN O
in IN O
beating VBG O
rat NN O
heart NN O
myocyte NN O
cultures NNS O
and CC O
on IN O
anesthetized JJ O
rats NNS O
were VBD O
determined VBN O
. . O
null null null-Disease
After IN O
determining VBG O
the DT O
bupivacaine NN O
AD50 NNP O
( , O
the DT O
concentration NN O
of IN O
bupivacaine NN O
that WDT O
caused VBD O
50 CD O
% NN O
of IN O
all DT O
beating VBG O
rat JJ O
heart NN O
myocyte NN O
cultures NNS O
to TO O
become VB O
arrhythmic JJ B-Disease
) -RRB- O
, , O
we PRP O
determined VBD O
the DT O
effect NN O
of IN O
1 CD O
- HYPH O
hour NN O
progesterone NN O
HCl NN O
exposure NN O
on IN O
myocyte NN O
contractile JJ O
rhythm NN O
. . O
null null null-Disease
Each DT O
concentration NN O
of IN O
progesterone NN O
( : O
6 CD O
. . O
25 CD O
, , O
12 CD O
. . O
5 CD O
, , O
25 CD O
, , O
and CC O
50 CD O
micrograms NNS O
/ SYM O
ml NNS O
) -RRB- O
caused VBD O
a DT O
significant JJ O
and CC O
concentration NN O
- HYPH O
dependent JJ O
reduction NN O
in IN O
the DT O
AD50 NNP O
for IN O
bupivacaine NN O
. . O
null null null-Disease
Estradiol NNP O
treatment NN O
also RB O
increased VBD O
the DT O
arrhythmogenicity NN O
of IN O
bupivacaine NN O
in IN O
myocyte NN O
cultures NNS O
, , O
but CC O
was VBD O
only RB O
one CD O
fourth NN O
as RB O
potent JJ O
as IN O
progesterone NN O
. . O
null null null-Disease
Neither CC O
progesterone NN O
nor CC O
estradiol NN O
effects NNS O
on IN O
bupivacaine NN O
arrhythmogenicity NN O
were VBD O
potentiated VBN O
by IN O
epinephrine NN O
. . O
null null null-Disease
Chronic JJ O
progesterone NN O
pretreatment NN O
( : O
5 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
day NN O
for IN O
21 CD O
days NNS O
) -RRB- O
caused VBD O
a DT O
significant JJ O
increase NN O
in IN O
bupivacaine NN O
arrhythmogenicity NN O
in IN O
intact JJ O
pentobarbital NN O
- HYPH O
anesthetized VBN O
rats NNS O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
significant JJ O
decrease NN O
in IN O
the DT O
time NN O
to IN O
onset NN O
of IN O
arrhythmia NN B-Disease
as IN O
compared VBN O
with IN O
control NN O
nonprogesterone NN O
- HYPH O
treated VBN O
rats NNS O
( , O
6 CD O
. . O
2 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
3 CD O
vs NN O
. . O
30 CD O
. . O
8 CD O
+ NN O
/ SYM O
- HYPH O
2 CD O
. . O
5 CD O
min NN O
, , O
mean VB O
+ NFP O
/ SYM O
- HYPH O
SE NN O
) -RRB- O
. . O
null null null-Disease
The DT O
results NNS O
of IN O
this DT O
study NN O
indicate VBP O
that IN O
progesterone NN O
can MD O
potentiate VB O
bupivacaine NN O
arrhythmogenicity NN O
both CC O
in IN O
vivo NN O
and CC O
in IN O
vitro NN O
. . O
null null null-Disease
Potentiation NN O
of IN O
bupivacaine NN O
arrhythmia NN B-Disease
in IN O
myocyte NN O
cultures NNS O
suggests VBZ O
that IN O
this DT O
effect NN O
is VBZ O
at IN O
least JJS O
partly RB O
mediated VBN O
at IN O
the DT O
myocyte NN O
level NN O
. . O
null null null-Disease
Increased VBN O
serum JJ O
soluble JJ O
Fas NNP O
in IN O
patients NNS O
with IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
due JJ O
to IN O
paracetamol NN O
overdose NN B-Disease
. . O
null null null-Disease
BACKGROUND NN O
/ SYM O
AIMS NNS O
: : O
Experimental JJ O
studies NNS O
have VBP O
suggested VBN O
that IN O
apoptosis NN O
via IN O
the DT O
Fas NNP O
/ SYM O
Fas NNP O
Ligand NNP O
signaling NN O
system NN O
may MD O
play VB O
an DT O
important JJ O
role NN O
in IN O
the DT O
development NN O
of IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
study NN O
was VBD O
to TO O
investigate VB O
the DT O
soluble JJ O
form NN O
of IN O
Fas NNP O
in IN O
patients NNS O
with IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
. . O
null null null-Disease
METHODOLOGY NN O
: : O
Serum NN O
levels NNS O
of IN O
sFas NNP O
( -LRB- O
soluble JJ O
Fas NNP O
) -RRB- O
were VBD O
measured VBN O
by IN O
ELISA NNP O
in IN O
24 CD O
patients NNS O
with IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
and CC O
10 CD O
normal JJ O
control NN O
subjects NNS O
. . O
null null null-Disease
Serum NN O
levels NNS O
of IN O
tumor NN B-Disease
necrosis NN B-Disease
factor NN O
- HYPH O
alpha NN O
and CC O
interferon NN O
- HYPH O
gamma NN O
were VBD O
also RB O
determined VBN O
by IN O
ELISA NNP O
. . O
null null null-Disease
RESULTS NNS O
: : O
Serum NNP O
sFas NNP O
was VBD O
significantly RB O
increased VBN O
in IN O
patients NNS O
with IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
( : O
median NN O
, , O
26 CD O
. . O
8 CD O
U NN O
/ SYM O
mL NN O
; : O
range NN O
, , O
6 CD O
. . O
9 CD O
- SYM O
52 CD O
. . O
7 CD O
U NN O
/ SYM O
mL NN O
) , O
compared VBN O
to IN O
the DT O
normal JJ O
controls NNS O
( : O
median JJ O
, , O
8 CD O
. . O
6 CD O
U NN O
/ SYM O
mL NN O
; : O
range NN O
, , O
6 CD O
. . O
5 CD O
- SYM O
12 CD O
. . O
0 CD O
U NN O
/ SYM O
mL NN O
, , O
P NN O
< NN O
0 CD O
. . O
0001 CD O
) -RRB- O
. . O
null null null-Disease
Levels NNS O
were VBD O
significantly RB O
greater JJR O
in IN O
patients NNS O
with IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
due JJ O
to IN O
paracetamol NN O
overdose NN B-Disease
( : O
median JJ O
, , O
28 CD O
. . O
7 CD O
U NN O
/ SYM O
mL NN O
; : O
range NN O
, , O
12 CD O
. . O
8 CD O
- SYM O
52 CD O
. . O
7 CD O
U NN O
/ SYM O
mL NN O
, , O
n CD O
= SYM O
17 CD O
) -RRB- O
than IN O
those DT O
due JJ O
to IN O
non JJ O
- HYPH O
A NN O
to IN O
E NN O
hepatitis NN B-Disease
( , O
median JJ O
, , O
12 CD O
. . O
5 CD O
U NN O
/ SYM O
mL NN O
; : O
range NN O
, , O
6 CD O
. . O
9 CD O
- SYM O
46 CD O
. . O
0 CD O
U NN O
/ SYM O
mL NN O
, , O
n CD O
= SYM O
7 CD O
, , O
P NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
relationship NN O
of IN O
sFas NNP O
to IN O
eventual JJ O
outcome NN O
in IN O
the DT O
patients NNS O
. . O
null null null-Disease
A DT O
significant JJ O
correlation NN O
was VBD O
observed VBN O
between IN O
serum NN O
sFas NNP O
levels NNS O
and CC O
aspartate NN O
aminotransferase NN O
( , O
r NN O
= SYM O
0 CD O
. . O
613 CD O
, , O
P NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
increased JJ O
concentration NN O
of IN O
sFas NNP O
in IN O
serum NN O
of IN O
patients NNS O
with IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
may MD O
reflect VB O
activation NN O
of IN O
Fas NNP O
- HYPH O
mediated VBN O
apoptosis NN O
in IN O
the DT O
liver NN O
and CC O
this DT O
together RB O
with IN O
increased VBN O
tumor NN B-Disease
necrosis NN B-Disease
factor NN O
- HYPH O
alpha NN O
may MD O
be VB O
an DT O
important JJ O
factor NN O
in IN O
liver NN O
cell NN O
loss NN O
. . O
null null null-Disease
Bilateral JJ O
subthalamic JJ O
nucleus NN O
stimulation NN O
for IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
. . O
null null null-Disease
High JJ O
frequency NN O
stimulation NN O
of IN O
the DT O
subthalamic JJ O
nucleus NN O
( -LRB- O
STN NNP O
) -RRB- O
is VBZ O
known VBN O
to TO O
ameliorate VB O
the DT O
signs NNS O
and CC O
symptoms NNS O
of IN O
advanced JJ O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
. . O
null null null-Disease
AIM NN O
: : O
We PRP O
studied VBD O
the DT O
effect NN O
of IN O
high JJ O
frequency NN O
STN NNP O
stimulation NN O
in IN O
23 CD O
patients NNS O
. . O
null null null-Disease
METHOD NN O
: : O
Twenty CD O
- HYPH O
three CD O
patients NNS O
suffering VBG O
from IN O
severe JJ O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
( , O
Stages NNPS O
III NNP O
- HYPH O
V NNP O
on IN O
Hoehn NNP O
and CC O
Yahr NNP O
scale NN O
) -RRB- O
and CC O
, , O
particularly RB O
bradykinesia NN B-Disease
, , O
rigidity NN B-Disease
, , O
and CC O
levodopa NN O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
underwent VBD O
bilateral JJ O
implantation NN O
of IN O
electrodes NNS O
in IN O
the DT O
STN NNP O
. . O
null null null-Disease
Preoperative JJ O
and CC O
postoperative JJ O
assessments NNS O
of IN O
these DT O
patients NNS O
at IN O
1 CD O
, , O
3 CD O
, , O
6 CD O
and CC O
12 CD O
months NNS O
follow VBP O
- HYPH O
up NN O
, , O
in IN O
"""" `` O
on IN O
"""" '' O
and CC O
"""" `` O
off RB O
"""" '' O
drug NN O
conditions NNS O
, , O
was VBD O
carried VBN O
out RP O
using VBG O
Unified NNP O
Parkinson NNP B-Disease
' POS I-Disease
s NNP I-Disease
Disease NNP I-Disease
Rating NNP O
Scale NNP O
, , O
Hoehn NNP O
and CC O
Yahr NNP O
staging NN O
, , O
England NNP O
activities NNS O
of IN O
daily JJ O
living NN O
score NN O
and CC O
video NN O
recordings NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
After IN O
one CD O
year NN O
of IN O
electrical JJ O
stimulation NN O
of IN O
the DT O
STN NNP O
, , O
the DT O
patients NNS O
' POS O
scores NNS O
for IN O
activities NNS O
of IN O
daily JJ O
living NN O
and CC O
motor NN O
examination NN O
scores NNS O
( , O
Unified NNP O
Parkinson NNP B-Disease
' POS I-Disease
s NNP I-Disease
Disease NNP I-Disease
Rating NNP O
Scale NNP O
parts NNS O
II NNP O
and CC O
III NNP O
) -RRB- O
off IN O
medication NN O
improved VBD O
by IN O
62 CD O
% NN O
and CC O
61 CD O
% NN O
respectively RB O
( : O
p NN O
< NN O
0 CD O
. . O
0005 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
subscores NNS O
for IN O
the DT O
akinesia NN B-Disease
, , O
rigidity NN B-Disease
, , O
tremor NN B-Disease
and CC O
gait NN O
also RB O
improved VBD O
. . O
null null null-Disease
( : O
p NN O
< NN O
0 CD O
. . O
0005 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
average JJ O
levodopa NN O
dose NN O
decreased VBD O
from IN O
813 CD O
mg CD O
to IN O
359 CD O
mg NN O
. . O
null null null-Disease
The DT O
cognitive JJ O
functions NNS O
remained VBD O
unchanged JJ O
. . O
null null null-Disease
Two CD O
patients NNS O
developed VBD O
device NN O
- HYPH O
related VBN O
complications NNS O
and CC O
two CD O
patients NNS O
experienced VBD O
abnormal JJ O
weight NN O
gain NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Bilateral JJ O
subthalamic JJ O
nucleus NN O
stimulation NN O
is VBZ O
an DT O
effective JJ O
treatment NN O
for IN O
advanced JJ O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
. . O
null null null-Disease
It PRP O
reduces VBZ O
the DT O
severity NN O
of IN O
"""" `` O
off RB O
"""" '' O
phase NN O
symptoms NNS O
, , O
improves VBZ O
the DT O
axial JJ O
symptoms NNS O
and CC O
reduces VBZ O
levodopa NN O
requirements NNS O
. . O
null null null-Disease
The DT O
reduction NN O
in IN O
the DT O
levodopa NN O
dose NN O
is VBZ O
useful JJ O
in IN O
controlling VBG O
drug NN B-Disease
- HYPH I-Disease
induced VBN I-Disease
dyskinesias NNS I-Disease
. . O
null null null-Disease
Acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
occurring VBG O
during IN O
intravenous JJ O
desferrioxamine NN O
therapy NN O
: : O
recovery NN O
after IN O
haemodialysis NN O
. . O
null null null-Disease
A DT O
patient NN O
with IN O
transfusion NN O
- HYPH O
dependent JJ O
thalassemia NN B-Disease
was VBD O
undergoing VBG O
home NN O
intravenous JJ O
desferrioxamine NN O
( HYPH O
DFX NNP O
) -RRB- O
treatment NN O
by IN O
means NNS O
of IN O
a DT O
totally RB O
implanted VBN O
system NN O
because IN O
of IN O
his PRP$ O
poor JJ O
compliance NN O
with IN O
the DT O
nightly RB O
subcutaneous JJ O
therapy NN O
. . O
null null null-Disease
Due IN O
to IN O
an DT O
accidental JJ O
malfunctioning NN O
of IN O
the DT O
infusion NN O
pump NN O
, , O
the DT O
patient NN O
was VBD O
inadvertently RB O
administered VBN O
a DT O
toxic JJ O
dosage NN O
of IN O
the DT O
drug NN O
which WDT O
caused VBD O
renal JJ B-Disease
insufficiency NN I-Disease
. . O
null null null-Disease
Given VBN O
the DT O
progressive JJ O
deterioration NN O
of IN O
the DT O
symptoms NNS O
and CC O
of IN O
the DT O
laboratory NN O
values NNS O
, , O
despite IN O
adequate JJ O
medical JJ O
treatment NN O
, , O
a DT O
decision NN O
was VBD O
made VBN O
to TO O
introduce VB O
haemodialytical JJ O
therapy NN O
in IN O
order NN O
to TO O
remove VB O
the DT O
drug NN O
and CC O
therapy NN O
reduce VB O
the DT O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
From IN O
the DT O
results NNS O
obtained VBN O
, , O
haemodialysis NN O
can MD O
therefore RB O
be VB O
suggested VBN O
as IN O
a DT O
useful JJ O
therapy NN O
in IN O
rare JJ O
cases NNS O
of IN O
progressive JJ O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
caused VBN O
by IN O
desferrioxamine NN O
. . O
null null null-Disease
Ocular JJ O
motility NN O
changes VBZ O
after IN O
subtenon NN O
carboplatin NN O
chemotherapy NN O
for IN O
retinoblastoma NN B-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Focal JJ O
subtenon NN O
carboplatin NN O
injections NNS O
have VBP O
recently RB O
been VBN O
used VBN O
as IN O
a DT O
presumably RB O
toxicity NN B-Disease
- HYPH O
free JJ O
adjunct NN O
to IN O
systemic JJ O
chemotherapy NN O
for IN O
intraocular JJ O
retinoblastoma NN B-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
report VB O
our PRP$ O
clinical JJ O
experience NN O
with IN O
abnormal JJ B-Disease
ocular JJ I-Disease
motility NN I-Disease
in IN O
patients NNS O
treated VBN O
with IN O
subtenon NN O
carboplatin NN O
chemotherapy NN O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
noted VBD O
abnormal JJ B-Disease
ocular JJ I-Disease
motility NN I-Disease
in IN O
10 CD O
consecutive JJ O
patients NNS O
with IN O
retinoblastoma NN B-Disease
who WP O
had VBD O
received VBN O
subtenon NN O
carboplatin NN O
. . O
null null null-Disease
During IN O
ocular JJ O
manipulation NN O
under IN O
general JJ O
anesthesia NN O
, , O
we PRP O
assessed VBD O
their PRP$ O
eyes NNS O
by IN O
forced JJ O
duction NN O
testing NN O
, , O
comparing VBG O
ocular JJ O
motility NN O
after IN O
tumor NN B-Disease
control NN O
with IN O
ocular JJ O
motility NN O
at IN O
diagnosis NN O
. . O
null null null-Disease
Eyes NNS O
subsequently RB O
enucleated VBD O
because IN O
of IN O
treatment NN O
failure NN O
( : O
n -LRB- O
= SYM O
4 CD O
) -RRB- O
were VBD O
examined VBN O
histologically RB O
. . O
null null null-Disease
RESULTS NNS O
: : O
Limitation NN O
of IN O
ocular JJ O
motility NN O
was VBD O
detected VBN O
in IN O
all DT O
12 CD O
eyes NNS O
of IN O
10 CD O
patients NNS O
treated VBN O
for IN O
intraocular JJ O
retinoblastoma NN B-Disease
with IN O
1 CD O
to TO O
6 CD O
injections NNS O
of IN O
subtenon NN O
carboplatin NN O
as IN O
part NN O
of IN O
multimodality NN O
therapy NN O
. . O
null null null-Disease
Histopathological JJ O
examination NN O
revealed VBD O
many JJ O
lipophages NNS O
in IN O
the DT O
periorbital JJ O
fat NN O
surrounding VBG O
the DT O
optic JJ O
nerve NN O
in IN O
1 CD O
eye NN O
, , O
indicative JJ O
of IN O
phagocytosis NN O
of IN O
previously RB O
existing VBG O
fat JJ O
cells NNS O
and CC O
suggesting VBG O
prior JJ O
fat JJ O
necrosis NN B-Disease
. . O
null null null-Disease
The DT O
enucleations NNS O
were VBD O
technically RB O
difficult JJ O
and CC O
hazardous JJ O
for IN O
globe NN O
rupture NN B-Disease
because IN O
of IN O
extensive JJ O
orbital JJ O
soft JJ O
tissue NN O
adhesions NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Subtenon JJ O
carboplatin NN O
chemotherapy NN O
is VBZ O
associated VBN O
with IN O
significant JJ O
fibrosis NN B-Disease
of IN O
orbital JJ O
soft JJ O
tissues NNS O
, , O
leading VBG O
to IN O
mechanical JJ O
restriction NN O
of IN O
eye NN O
movements NNS O
and CC O
making VBG O
subsequent JJ O
enucleation NN O
difficult JJ O
. . O
null null null-Disease
Subtenon NN O
carboplatin NN O
is VBZ O
not RB O
free JJ O
of IN O
toxicity NN B-Disease
, , O
and CC O
its PRP$ O
use NN O
is VBZ O
best RBS O
restricted VBN O
to IN O
specific JJ O
indications NNS O
. . O
null null null-Disease
Ethambutol NNP O
and CC O
optic JJ B-Disease
neuropathy NN I-Disease
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
demonstrate VB O
the DT O
association NN O
between IN O
ethambutol NN O
and CC O
optic JJ B-Disease
neuropathy NN I-Disease
. . O
null null null-Disease
METHOD NN O
: : O
Thirteen CD O
patients NNS O
who WP O
developed VBD O
optic JJ B-Disease
neuropathy NN I-Disease
after IN O
being VBG O
treated VBN O
with IN O
ethambutol NN O
for IN O
tuberculosis NNS B-Disease
of IN I-Disease
the DT I-Disease
lung NN I-Disease
or CC I-Disease
lymph NN I-Disease
node NN I-Disease
at IN O
Siriraj NNP O
Hospital NNP O
between IN O
1997 CD O
and CC O
2001 CD O
were VBD O
retrospectively RB O
reviewed VBN O
. . O
null null null-Disease
The DT O
clinical JJ O
characteristics NNS O
and CC O
initial JJ O
and CC O
final JJ O
visual JJ O
acuity NN O
were VBD O
analyzed VBN O
to TO O
determine VB O
visual JJ O
outcome NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
All DT O
patients NNS O
had VBD O
optic JJ B-Disease
neuropathy NN I-Disease
between IN O
1 CD O
to TO O
6 CD O
months NNS O
( , O
mean NN O
= SYM O
2 CD O
. . O
9 CD O
months NNS O
) -RRB- O
after IN O
starting VBG O
ethambutol NN O
therapy NN O
at IN O
a DT O
dosage NN O
ranging VBG O
from IN O
13 CD O
to IN O
20 CD O
mg NNS O
/ SYM O
kg NNS O
/ SYM O
day NN O
( , O
mean NN O
= SYM O
17 CD O
mg NNS O
/ SYM O
kg NN O
/ SYM O
day NN O
) -RRB- O
. . O
null null null-Disease
Seven CD O
( SYM O
54 CD O
% NN O
) NN O
of IN O
the DT O
13 CD O
patients NNS O
experienced VBD O
visual JJ O
recovery NN O
after IN O
stopping VBG O
the DT O
drug NN O
. . O
null null null-Disease
Of IN O
6 CD O
patients NNS O
with IN O
irreversible JJ O
visual JJ B-Disease
impairment NN I-Disease
, , O
4 CD O
patients NNS O
had VBD O
diabetes NN B-Disease
mellitus NN I-Disease
, , O
glaucoma NN B-Disease
and CC O
a DT O
history NN O
of IN O
heavy JJ O
smoking NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Early JJ O
recognition NN O
of IN O
optic JJ B-Disease
neuropathy NN I-Disease
should MD O
be VB O
considered VBN O
in IN O
patients NNS O
with IN O
ethambutol NN O
therapy NN O
. . O
null null null-Disease
A DT O
low JJ O
dose NN O
and CC O
prompt JJ O
discontinuation NN O
of IN O
the DT O
drug NN O
is VBZ O
recommended VBN O
particularly RB O
in IN O
individuals NNS O
with IN O
diabetes NN B-Disease
mellitus NN I-Disease
, , O
glaucoma NN B-Disease
or CC O
who WP O
are VBP O
heavy JJ O
smokers NNS O
. . O
null null null-Disease
Treatment NN O
of IN O
compensatory JJ O
gustatory JJ B-Disease
hyperhidrosis NN I-Disease
with IN O
topical JJ O
glycopyrrolate NN O
. . O
null null null-Disease
Gustatory JJ B-Disease
hyperhidrosis NN I-Disease
is VBZ O
facial JJ O
sweating NN B-Disease
usually RB O
associated VBN O
with IN O
the DT O
eating NN O
of IN O
hot JJ O
spicy JJ O
food NN O
or CC O
even RB O
smelling VBG O
this DT O
food NN O
. . O
null null null-Disease
Current JJ O
options NNS O
of IN O
treatment NN O
include VBP O
oral JJ O
anticholinergic JJ O
drugs NNS O
, , O
the DT O
topical JJ O
application NN O
of IN O
anticholinergics NNS O
or CC O
aluminum NN O
chloride NN O
, , O
and CC O
the DT O
injection NN O
of IN O
botulinum NN O
toxin NN O
. . O
null null null-Disease
Thirteen CD O
patients NNS O
have VBP O
been VBN O
treated VBN O
to IN O
date NN O
with IN O
1 CD O
. . O
5 CD O
% NN O
or CC O
2 CD O
% NN O
topical JJ O
glycopyrrolate NN O
. . O
null null null-Disease
All DT O
patients NNS O
had VBD O
gustatory JJ B-Disease
hyperhidrosis NN I-Disease
, , O
which WDT O
interfered VBD O
with IN O
their PRP$ O
social JJ O
activities NNS O
, , O
after IN O
transthroacic JJ O
endoscopic JJ O
sympathectomy NN O
, , O
and CC O
which WDT O
was VBD O
associated VBN O
with IN O
compensatory JJ O
focal JJ O
hyperhidrosis NN B-Disease
. . O
null null null-Disease
After IN O
applying VBG O
topical JJ O
glycopyrrolate NN O
, , O
the DT O
subjective JJ O
effect NN O
was VBD O
excellent JJ O
( , O
no DT O
sweating NN B-Disease
after IN O
eating VBG O
hot JJ O
spicy JJ O
food NN O
) , O
in IN O
10 CD O
patients NNS O
( : O
77 CD O
% NN O
) -RRB- O
, , O
and CC O
fair JJ O
( , O
clearly RB O
reduced VBN O
sweating NN B-Disease
) -RRB- O
in IN O
3 CD O
patients NNS O
( : O
23 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
All DT O
had VBD O
reported VBN O
incidents NNS O
of IN O
being VBG O
very RB O
embarrassed JJ O
whilst IN O
eating VBG O
hot JJ O
spicy JJ O
foods NNS O
. . O
null null null-Disease
Adverse JJ O
effects NNS O
included VBD O
a DT O
mildly RB O
dry JJ B-Disease
mouth NN I-Disease
and CC O
a DT O
sore JJ B-Disease
throat NN I-Disease
in IN O
2 CD O
patients NNS O
( , O
2 CD O
% NN O
glycopyrrolate NN O
) -RRB- O
, , O
a DT O
light JJ O
headache NN B-Disease
in IN O
1 CD O
patient NN O
( , O
1 CD O
. . O
5 CD O
% NN O
glycopyrrolate NN O
) -RRB- O
. . O
null null null-Disease
The DT O
topical JJ O
application NN O
of IN O
a DT O
glycopyrrolate JJ O
pad NN O
appeared VBD O
to TO O
be VB O
safe JJ O
, , O
efficacious JJ O
, , O
well RB O
tolerated VBN O
, , O
and CC O
a DT O
convenient JJ O
method NN O
of IN O
treatment NN O
for IN O
moderate JJ O
to IN O
severe JJ O
symptoms NNS O
of IN O
gustatory JJ B-Disease
hyperhidrosis NN I-Disease
in IN O
post NN O
transthoracic JJ O
endoscopic JJ O
sympathectomy NN O
or CC O
sympathicotomy NN O
patients NNS O
, , O
with IN O
few JJ O
side NN O
effects NNS O
. . O
null null null-Disease
Neuroleptic NN O
- HYPH O
associated VBN O
hyperprolactinemia NN B-Disease
. . O
null null null-Disease
Can MD O
it PRP O
be VB O
treated VBN O
with IN O
bromocriptine NN O
? . O
null null null-Disease
Six CD O
stable JJ O
psychiatric JJ O
outpatients NNS O
with IN O
hyperprolactinemia NN B-Disease
and CC O
amenorrhea NN B-Disease
/ SYM O
oligomenorrhea NN B-Disease
associated VBN O
with IN O
their PRP$ O
neuroleptic JJ O
medications NNS O
were VBD O
treated VBN O
with IN O
bromocriptine NN O
. . O
null null null-Disease
Daily JJ O
dosages NNS O
of IN O
5 CD O
- SYM O
10 CD O
mg NN O
corrected VBD O
the DT O
hyperprolactinemia NN B-Disease
and CC O
restored VBD O
menstruation NN O
in IN O
four CD O
of IN O
the DT O
six CD O
patients NNS O
. . O
null null null-Disease
One CD O
woman NN O
, , O
however RB O
, , O
developed VBD O
worsened VBN O
psychiatric JJ B-Disease
symptoms NNS I-Disease
while IN O
taking VBG O
bromocriptine NN O
, , O
and CC O
it PRP O
was VBD O
discontinued VBN O
. . O
null null null-Disease
Thus RB O
, , O
three CD O
of IN O
six CD O
patients NNS O
had VBD O
their PRP$ O
menstrual JJ O
irregularity NN O
successfully RB O
corrected VBN O
with IN O
bromocriptine NN O
. . O
null null null-Disease
This DT O
suggests VBZ O
that IN O
bromocriptine NN O
should MD O
be VB O
further RB O
evaluated VBN O
as IN O
potential JJ O
therapy NN O
for IN O
neuroleptic NN O
- HYPH O
associated VBN O
hyperprolactinemia NN B-Disease
and CC O
amenorrhea NN B-Disease
/ SYM O
galactorrhea NN B-Disease
. . O
null null null-Disease
Ethacrynic NN O
acid NN O
- HYPH O
induced VBN O
convulsions NNS B-Disease
and CC O
brain NN O
neurotransmitters NNS O
in IN O
mice NNS O
. . O
null null null-Disease
Intracerebroventricular JJ O
injection NN O
of IN O
ethacrynic NN O
acid NN O
( : O
50 CD O
% NN O
convulsive JJ B-Disease
dose NN O
; : O
50 CD O
micrograms NNS O
/ SYM O
mouse NN O
) -RRB- O
accelerated VBD O
the DT O
synthesis NN O
/ SYM O
turnover NN O
of IN O
5 CD O
- HYPH O
hydroxytryptamine NN O
( : O
5 CD O
- HYPH O
HT NN O
) -RRB- O
but CC O
suppressed VBD O
the DT O
synthesis NN O
of IN O
gamma NN O
- HYPH O
aminobutyric NN O
acid NN O
and CC O
acetylcholine NN O
in IN O
mouse NN O
brain NN O
. . O
null null null-Disease
These DT O
effects NNS O
were VBD O
completely RB O
antagonized VBN O
by IN O
pretreatment NN O
with IN O
a DT O
glutamate NN O
/ SYM O
N NN O
- HYPH O
methyl NN O
- HYPH O
D NN O
- HYPH O
aspartate NN O
antagonist NN O
, , O
aminophosphonovaleric JJ O
acid NN O
. . O
null null null-Disease
In IN O
ethacrynic JJ O
acid NN O
- HYPH O
induced VBN O
convulsions NNS B-Disease
, , O
these DT O
neurotransmitter NN O
systems NNS O
may MD O
be VB O
differentially RB O
modulated VBN O
, , O
probably RB O
through IN O
activation NN O
of IN O
glutaminergic JJ O
neurons NNS O
in IN O
the DT O
brain NN O
. . O
null null null-Disease
Pharmacology NN O
of IN O
gamma NN O
- HYPH O
aminobutyric JJ O
acidA NN O
receptor NN O
complex NN O
after IN O
the DT O
in IN O
vivo NN O
administration NN O
of IN O
the DT O
anxioselective JJ O
and CC O
anticonvulsant JJ O
beta NN O
- HYPH O
carboline NN O
derivative JJ O
abecarnil NN O
. . O
null null null-Disease
In IN O
rodents NNS O
, , O
the DT O
effect NN O
of IN O
the DT O
beta NN O
- HYPH O
carboline NN O
derivative JJ O
isopropyl NN O
- HYPH O
6 CD O
- HYPH O
benzyloxy NN O
- HYPH O
4 CD O
- HYPH O
methoxymethyl NN O
- HYPH O
beta NN O
- HYPH O
carboline NN O
- HYPH O
3 CD O
- HYPH O
carboxylate NN O
( HYPH O
abecarrnil NN O
) -RRB- O
, , O
a DT O
new JJ O
ligand NN O
for IN O
benzodiazepine NN O
receptors NNS O
possessing VBG O
anxiolytic JJ O
and CC O
anticonvulsant JJ O
properties NNS O
, , O
was VBD O
evaluated VBN O
on IN O
the DT O
function NN O
of IN O
central JJ O
gamma NN O
- HYPH O
aminobutyric JJ O
acid NN O
( -LRB- O
GABA NNP O
) -RRB- O
A NN O
receptor NN O
complex NN O
, , O
both CC O
in IN O
vitro NN O
and CC O
in IN O
vivo NN O
. . O
null null null-Disease
Added VBN O
in IN O
vitro NN O
to IN O
rat NN O
cortical JJ O
membrane NN O
preparation NN O
, , O
abecarnil NN O
increased VBD O
[ -LRB- O
3H CD O
] -RRB- O
GABA NNP O
binding NN O
, , O
enhanced VBN O
muscimol NN O
- HYPH O
stimulated VBN O
36Cl NN O
- HYPH O
uptake NN O
and CC O
reduced VBN O
the DT O
binding NN O
of IN O
t NN O
- HYPH O
[ -LRB- O
35S NN O
] -RRB- O
butylbicyclophosphorothionate NN O
( -LRB- O
[ -LRB- O
35S CD O
] -RRB- O
TBPS NNP O
) -RRB- O
. . O
null null null-Disease
These DT O
effects NNS O
were VBD O
similar JJ O
to IN O
those DT O
induced VBN O
by IN O
diazepam NN O
, , O
whereas IN O
the DT O
partial JJ O
agonist NN O
Ro NNP O
16 CD O
- HYPH O
6028 CD O
( HYPH O
tert NN O
- HYPH O
butyl NN O
- HYPH O
( -LRB- O
S NNP O
) SYM O
- HYPH O
8 CD O
- HYPH O
bromo NN O
- HYPH O
11 CD O
, , O
12 CD O
, , O
13 CD O
, , O
13a CD O
- HYPH O
tetrahydro NN O
- HYPH O
9 CD O
- HYPH O
oxo NN O
- HYPH O
9H NN O
- HYPH O
imidazo NN O
[ -LRB- O
1 CD O
, , O
5 CD O
- HYPH O
a NN O
] -RRB- O
- HYPH O
pyrrolo NN O
- HYPH O
[ -LRB- O
2 CD O
, , O
1 CD O
- HYPH O
c NN O
] -RRB- O
[ -LRB- O
1 CD O
, , O
4 CD O
] -RRB- O
benzodiazepine NN O
- HYPH O
1 CD O
- HYPH O
carboxylate NN O
) -RRB- O
showed VBD O
very RB O
weak JJ O
efficacy NN O
in IN O
these DT O
biochemical JJ O
tests NNS O
. . O
null null null-Disease
After IN O
i PRP O
. . O
p LS O
. . O
injection NN O
to IN O
rats NNS O
, , O
abecarnil NN O
and CC O
diazepam NN O
decreased VBD O
in IN O
a DT O
time NN O
- HYPH O
dependent JJ O
and CC O
dose NN O
- HYPH O
related VBN O
( : O
0 CD O
. . O
25 CD O
- SYM O
20 CD O
mg NN O
/ SYM O
kg CD O
i NN O
. . O
p NN O
. . O
) -RRB- O
manner NN O
[ -LRB- O
35S NN O
] -RRB- O
TBPS NN O
binding NN O
measured VBN O
ex IN O
vivo NN O
in IN O
the DT O
cerebral JJ O
cortex NN O
. . O
null null null-Disease
Moreover RB O
, , O
both DT O
drugs NNS O
at IN O
the DT O
dose NN O
of IN O
0 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NN O
antagonized VBD O
completely RB O
the DT O
convulsant JJ O
activity NN O
and CC O
the DT O
increase NN O
of IN O
[ -LRB- O
35S NNP O
] -RRB- O
TBPS NNP O
binding NN O
induced VBN O
by IN O
isoniazide NN O
( , O
350 CD O
mg NNS O
/ SYM O
kg NNS O
s NNS O
. . O
c NN O
. . O
) -RRB- O
as RB O
well RB O
as IN O
the DT O
increase NN O
of IN O
[ -LRB- O
35S CD O
] -RRB- O
TBPS NN O
binding NN O
induced VBN O
by IN O
foot NN O
- HYPH O
shock NN O
stress NN O
. . O
null null null-Disease
To TO O
better RBR O
correlate VB O
the DT O
biochemical JJ O
and CC O
the DT O
pharmacological JJ O
effects NNS O
, , O
we PRP O
studied VBD O
the DT O
action NN O
of IN O
abecarnil NN O
on IN O
[ -LRB- O
35S NNP O
] -RRB- O
TBPS NNP O
binding NN O
, , O
exploratory JJ O
motility NN O
and CC O
on IN O
isoniazid NN O
- HYPH O
induced VBN O
biochemical JJ O
and CC O
pharmacological JJ O
effects NNS O
in IN O
mice NNS O
. . O
null null null-Disease
In IN O
these DT O
animals NNS O
, , O
abecarnil NNP O
produced VBD O
a DT O
paralleled JJ O
dose NN O
- HYPH O
dependent JJ O
( : O
0 CD O
. . O
05 CD O
- HYPH O
1 CD O
mg NN O
/ SYM O
kg CD O
i NN O
. . O
p NN O
. . O
) -RRB- O
reduction NN O
of IN O
both CC O
motor NN O
behavior NN O
and CC O
cortical JJ O
[ -LRB- O
35S NN O
] -RRB- O
TBPS NN O
binding NN O
. . O
null null null-Disease
Moreover RB O
, , O
0 CD O
. . O
05 CD O
mg NN O
/ SYM O
kg NN O
of IN O
this DT O
beta NN O
- HYPH O
carboline NN O
reduced VBD O
markedly RB O
the DT O
increase NN O
of IN O
[ -LRB- O
35S CD O
] -RRB- O
TBPS NN O
binding NN O
and CC O
the DT O
convulsions NNS B-Disease
induced VBN O
by IN O
isoniazid NN O
( : O
200 CD O
mg NNS O
/ SYM O
kg NNS O
s NNS O
. . O
c NN O
. . O
) -RRB- O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) -RRB- O
null null null-Disease
Recurrent JJ O
myocardial JJ B-Disease
infarction NN I-Disease
in IN O
a DT O
postpartum JJ O
patient NN O
receiving VBG O
bromocriptine NN O
. . O
null null null-Disease
Myocardial JJ B-Disease
infarction NN I-Disease
in IN O
puerperium NN O
is VBZ O
infrequently RB O
reported VBN O
. . O
null null null-Disease
Spasm NN B-Disease
, , O
coronary JJ O
dissection NN O
, , O
or CC O
atheromatous JJ O
etiology NN O
has VBZ O
been VBN O
described VBN O
. . O
null null null-Disease
Bromocriptine NNP O
has VBZ O
been VBN O
implicated VBN O
in IN O
several JJ O
previous JJ O
case NN O
reports NNS O
of IN O
myocardial JJ B-Disease
infarction NN I-Disease
in IN O
the DT O
puerperium NN O
. . O
null null null-Disease
Our PRP$ O
case NN O
( , O
including VBG O
an DT O
inadvertent JJ O
rechallenge NN O
) -RRB- O
suggests VBZ O
such PDT O
a DT O
relationship NN O
. . O
null null null-Disease
Although IN O
generally RB O
regarded VBN O
as IN O
"""" `` O
safe JJ O
, , O
"""" '' O
possible JJ O
serious JJ O
cardiac JJ O
effects NNS O
of IN O
bromocriptine NN O
should MD O
be VB O
acknowledged VBN O
. . O
null null null-Disease
Asterixis NNP B-Disease
induced VBN O
by IN O
carbamazepine NN O
therapy NN O
. . O
null null null-Disease
There EX O
are VBP O
very RB O
few JJ O
reports NNS O
about IN O
asterixis NN B-Disease
as IN O
a DT O
side NN O
effect NN O
of IN O
treatment NN O
with IN O
psychopharmacologic JJ O
agents NNS O
. . O
null null null-Disease
In IN O
this DT O
report NN O
we PRP O
present VBP O
four CD O
patients NNS O
treated VBN O
with IN O
a DT O
combination NN O
of IN O
different JJ O
psychotropic JJ O
drugs NNS O
, , O
in IN O
whom WP O
asterixis NN B-Disease
was VBD O
triggered VBN O
either CC O
by IN O
adding VBG O
carbamazepine NN O
( , O
CBZ NNP O
) -RRB- O
to IN O
a DT O
treatment NN O
regimen NN O
, , O
or CC O
by IN O
increasing VBG O
its PRP$ O
dosage NN O
. . O
null null null-Disease
Neither DT O
dosage NN O
nor CC O
serum JJ O
levels NNS O
of IN O
CBZ NNP O
were VBD O
in IN O
a DT O
higher JJR O
range NN O
. . O
null null null-Disease
We PRP O
consider VBP O
asterixis NN B-Disease
to TO O
be VB O
an DT O
easily RB O
overlooked VBN O
sign NN O
of IN O
neurotoxicity NN B-Disease
, , O
which WDT O
may MD O
occur VB O
even RB O
at IN O
low JJ O
or CC O
moderate JJ O
dosage NN O
levels NNS O
, , O
if IN O
certain JJ O
drugs NNS O
as IN O
lithium NN O
or CC O
clozapine NN O
are VBP O
used VBN O
in IN O
combination NN O
with IN O
CBZ NNP O
. . O
null null null-Disease
Pharmacodynamics NNS O
of IN O
the DT O
hypotensive JJ B-Disease
effect NN O
of IN O
levodopa NN O
in IN O
parkinsonian NN B-Disease
patients NNS O
. . O
null null null-Disease
Blood NN O
pressure NN O
effects NNS O
of IN O
i DT O
. . O
v NN O
. . O
levodopa NN O
were VBD O
examined VBN O
in IN O
parkinsonian JJ B-Disease
patients NNS O
with IN O
stable JJ O
and CC O
fluctuating JJ O
responses NNS O
to IN O
levodopa NN O
. . O
null null null-Disease
The DT O
magnitude NN O
of IN O
the DT O
hypotensive JJ B-Disease
effect NN O
of IN O
levodopa NN O
was VBD O
concentration NN O
dependent JJ O
and CC O
was VBD O
fit JJ O
to IN O
an DT O
Emax NNP O
model NN O
in IN O
fluctuating VBG O
responders NNS O
. . O
null null null-Disease
Stable JJ O
responders NNS O
demonstrated VBD O
a DT O
small JJ O
hypotensive JJ B-Disease
response NN O
. . O
null null null-Disease
Baseline NN O
blood NN O
pressures NNS O
were VBD O
higher JJR O
in IN O
fluctuating VBG O
patients NNS O
; : O
a DT O
higher JJR O
baseline NN O
blood NN O
pressure NN O
correlated VBD O
with IN O
greater JJR O
hypotensive JJ B-Disease
effects NNS O
. . O
null null null-Disease
Antiparkinsonian JJ O
effects NNS O
of IN O
levodopa NN O
temporally RB O
correlated VBD O
with IN O
blood NN O
pressure NN O
changes NNS O
. . O
null null null-Disease
Phenylalanine NNP O
, , O
a DT O
large JJ O
neutral JJ O
amino NN O
acid NN O
( , O
LNAA NNP O
) -RRB- O
competing VBG O
with IN O
levodopa NN O
for IN O
transport NN O
across IN O
the DT O
blood NN O
- HYPH O
brain NN O
barrier NN O
, , O
reduced VBD O
the DT O
hypotensive JJ B-Disease
and CC O
antiparkinsonian JJ O
effects NNS O
of IN O
levodopa NN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
levodopa NN O
has VBZ O
a DT O
central JJ O
hypotensive JJ B-Disease
action NN O
that WDT O
parallels VBZ O
the DT O
motor NN O
effects NNS O
in IN O
fluctuating VBG O
patients NNS O
. . O
null null null-Disease
The DT O
hypotensive JJ B-Disease
effect NN O
appears VBZ O
to TO O
be VB O
related JJ O
to IN O
the DT O
higher JJR O
baseline NN O
blood NN O
pressure NN O
we PRP O
observed VBD O
in IN O
fluctuating VBG O
patients NNS O
relative JJ O
to IN O
stable JJ O
patients NNS O
. . O
null null null-Disease
Syndrome NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
secretion NN I-Disease
of IN I-Disease
antidiuretic JJ I-Disease
hormone NN I-Disease
after IN O
infusional JJ O
vincristine NN O
. . O
null null null-Disease
A DT O
77 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
refractory JJ O
multiple JJ B-Disease
myeloma NN I-Disease
was VBD O
treated VBN O
with IN O
a DT O
4 CD O
- HYPH O
day NN O
continuous JJ O
intravenous JJ O
infusion NN O
of IN O
vincristine NN O
and CC O
doxorubicin NN O
and CC O
4 CD O
days NNS O
of IN O
oral JJ O
dexamethasone NN O
. . O
null null null-Disease
Nine CD O
days NNS O
after IN O
her PRP$ O
second JJ O
cycle NN O
she PRP O
presented VBD O
with IN O
lethargy NN B-Disease
and CC O
weakness NN B-Disease
associated VBN O
with IN O
hyponatremia NN B-Disease
. . O
null null null-Disease
Evaluation NN O
revealed VBD O
the DT O
syndrome NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
secretion NN I-Disease
of IN I-Disease
antidiuretic JJ I-Disease
hormone NN I-Disease
, , O
which WDT O
was VBD O
attributed VBN O
to IN O
the DT O
vincristine NN O
infusion NN O
. . O
null null null-Disease
After IN O
normal JJ O
serum NN O
sodium NN O
levels NNS O
returned VBD O
, , O
further JJ O
doxorubicin NN O
and CC O
dexamethasone NN O
chemotherapy NN O
without IN O
vincristine NN O
did VBD O
not RB O
produce VB O
this DT O
complication NN O
. . O
null null null-Disease
Heart NN B-Disease
failure NN I-Disease
: : O
to TO O
digitalise VB O
or CC O
not RB O
? . O
null null null-Disease
The DT O
view NN O
against IN O
. . O
null null null-Disease
Despite IN O
extensive JJ O
clinical JJ O
experience NN O
the DT O
role NN O
of IN O
digoxin NN O
is VBZ O
still RB O
not RB O
well RB O
defined VBN O
. . O
null null null-Disease
In IN O
patients NNS O
with IN O
atrial JJ B-Disease
fibrillation NN I-Disease
digoxin NN O
is VBZ O
beneficial JJ O
for IN O
ventricular JJ O
rate NN O
control NN O
. . O
null null null-Disease
For IN O
patients NNS O
in IN O
sinus JJ O
rhythm NN O
and CC O
heart NN B-Disease
failure NN I-Disease
the DT O
situation NN O
is VBZ O
less RBR O
clear JJ O
. . O
null null null-Disease
Digoxin NNP O
has VBZ O
a DT O
narrow JJ O
therapeutic JJ O
: : O
toxic JJ O
ratio NN O
and CC O
concentrations NNS O
are VBP O
affected VBN O
by IN O
a DT O
number NN O
of IN O
drugs NNS O
. . O
null null null-Disease
Also RB O
, , O
digoxin NN O
has VBZ O
undesirable JJ O
effects NNS O
such JJ O
as IN O
increasing VBG O
peripheral JJ O
resistance NN O
and CC O
myocardial JJ O
demands NNS O
, , O
and CC O
causing VBG O
arrhythmias NNS B-Disease
. . O
null null null-Disease
There EX O
is VBZ O
a DT O
paucity NN O
of IN O
data NNS O
from IN O
well RB O
- HYPH O
designed VBN O
trials NNS O
. . O
null null null-Disease
The DT O
trials NNS O
that WDT O
are VBP O
available JJ O
are VBP O
generally RB O
small JJ O
with IN O
limitations NNS O
in IN O
design NN O
and CC O
these DT O
show VBP O
variation NN O
in IN O
patient JJ O
benefit NN O
. . O
null null null-Disease
More RBR O
convincing JJ O
evidence NN O
is VBZ O
required VBN O
showing VBG O
that IN O
digoxin NN O
improves VBZ O
symptoms NNS O
or CC O
exercise NN O
capacity NN O
. . O
null null null-Disease
Furthermore RB O
, , O
no DT O
trial NN O
has VBZ O
had VBN O
sufficient JJ O
power NN O
to TO O
evaluate VB O
mortality NN O
. . O
null null null-Disease
Pooled JJ O
analysis NN O
of IN O
the DT O
effects NNS O
of IN O
other JJ O
inotropic JJ O
drugs NNS O
shows VBZ O
an DT O
excess JJ O
mortality NN O
and CC O
there EX O
is VBZ O
a DT O
possibility NN O
that IN O
digoxin NN O
may MD O
increase VB O
mortality NN O
after IN O
myocardial JJ B-Disease
infarction NN I-Disease
( , O
MI NNP B-Disease
) -RRB- O
. . O
null null null-Disease
Angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
( -LRB- O
ACE NN O
) -RRB- O
inhibitors NNS O
should MD O
be VB O
used VBN O
first RB O
as IN O
they PRP O
are VBP O
safer JJR O
, , O
do VBP O
not RB O
require VB O
blood NN O
level NN O
monitoring NN O
, , O
modify VB O
progression NN O
of IN O
disease NN O
, , O
relieve VB O
symptoms NNS O
, , O
improve VB O
exercise NN O
tolerance NN O
and CC O
reduce VB O
mortality NN O
. . O
null null null-Disease
Caution NN O
should MD O
be VB O
exercised VBN O
in IN O
using VBG O
digoxin NN O
until IN O
large JJ O
mortality NN O
trials NNS O
are VBP O
completed VBN O
showing VBG O
either CC O
benefit NN O
or CC O
harm NN O
. . O
null null null-Disease
Until IN O
then RB O
digoxin NN O
should MD O
be VB O
considered VBN O
a DT O
third JJ O
- HYPH O
line NN O
therapy NN O
. . O
null null null-Disease
Isradipine NNP O
treatment NN O
for IN O
hypertension NN B-Disease
in IN O
general JJ O
practice NN O
in IN O
Hong NNP O
Kong NNP O
. . O
null null null-Disease
A DT O
6 CD O
- HYPH O
week NN O
open JJ O
study NN O
of IN O
the DT O
introduction NN O
of IN O
isradipine NN O
treatment NN O
was VBD O
conducted VBN O
in IN O
general JJ O
practice NN O
in IN O
Hong NNP O
Kong NNP O
. . O
null null null-Disease
303 CD O
Chinese JJ O
patients NNS O
with IN O
mild NN O
to IN O
moderate JJ O
hypertension NN B-Disease
entered VBD O
the DT O
study NN O
. . O
null null null-Disease
Side JJ O
effects NNS O
were VBD O
reported VBN O
in IN O
21 CD O
% NN O
of IN O
patients NNS O
and CC O
caused VBD O
withdrawal NN O
from IN O
the DT O
study NN O
in IN O
3 CD O
patients NNS O
. . O
null null null-Disease
The DT O
main JJ O
side NN O
- HYPH O
effects NNS O
were VBD O
headache NN B-Disease
, , O
dizziness NN B-Disease
, , O
palpitation NN B-Disease
and CC O
flushing NN B-Disease
and CC O
these DT O
were VBD O
not RB O
more RBR O
frequent JJ O
than IN O
reported VBN O
in IN O
other JJ O
studies NNS O
with IN O
isradipine NN O
or CC O
with IN O
placebo NN O
. . O
null null null-Disease
Supine JJ O
blood NN O
pressure NN O
was VBD O
reduced VBN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
from IN O
170 CD O
+ CD O
/ SYM O
- SYM O
20 CD O
/ SYM O
102 CD O
+ CC O
/ SYM O
- SYM O
6 CD O
mmHg NN O
to IN O
153 CD O
+ SYM O
/ SYM O
- HYPH O
19 CD O
/ SYM O
92 CD O
+ SYM O
/ SYM O
- HYPH O
8 CD O
, , O
147 CD O
+ SYM O
/ SYM O
- HYPH O
18 CD O
/ SYM O
88 CD O
+ SYM O
/ SYM O
- HYPH O
7 CD O
and CC O
144 CD O
+ SYM O
/ SYM O
- HYPH O
14 CD O
/ SYM O
87 CD O
+ SYM O
/ SYM O
- HYPH O
6 CD O
mmHg NN O
at IN O
2 CD O
, , O
4 CD O
and CC O
6 CD O
weeks NNS O
respectively RB O
in IN O
evaluable JJ O
patients NNS O
. . O
null null null-Disease
Similar JJ O
reductions NNS O
occurred VBD O
in IN O
standing VBG O
blood NN O
pressure NN O
and CC O
there EX O
was VBD O
no DT O
evidence NN O
of IN O
postural JJ B-Disease
hypotension NN I-Disease
. . O
null null null-Disease
Normalization NN O
and CC O
responder NN O
rates NNS O
at IN O
6 CD O
weeks NNS O
were VBD O
86 CD O
% NN O
and CC O
69 CD O
% NN O
respectively RB O
. . O
null null null-Disease
Dosage NN O
was VBD O
increased VBN O
from IN O
2 CD O
. . O
5 CD O
mg CD O
b NN O
. . O
d LS O
. . O
to IN O
5 CD O
mg NN O
b NN O
. . O
d LS O
. . O
at IN O
4 CD O
weeks NNS O
in IN O
patients NNS O
with IN O
diastolic JJ O
blood NN O
pressure NN O
greater JJR O
than IN O
90 CD O
mmHg NN O
and CC O
their PRP$ O
further JJ O
response NN O
was VBD O
greater JJR O
than IN O
those DT O
remaining VBG O
on IN O
2 CD O
. . O
5 CD O
mg CD O
b NN O
. . O
d LS O
. . O
null null null-Disease
Pharmacological JJ O
characteristics NNS O
and CC O
side NN O
effects NNS O
of IN O
a DT O
new JJ O
galenic JJ O
formulation NN O
of IN O
propofol NN O
without IN O
soyabean NN O
oil NN O
. . O
null null null-Disease
We PRP O
compared VBD O
the DT O
pharmacokinetics NNS O
, , O
pharmacodynamics NNS O
and CC O
safety NN O
profile NN O
of IN O
a DT O
new JJ O
galenic JJ O
formulation NN O
of IN O
propofol NN O
( : O
AM149 NN O
1 CD O
% NN O
) -RRB- O
, , O
which WDT O
does VBZ O
not RB O
contain VB O
soyabean NN O
oil NN O
, , O
with IN O
a DT O
standard JJ O
formulation NN O
of IN O
propofol NN O
( : O
Disoprivan NN O
1 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
In IN O
a DT O
randomised VBN O
, , O
double JJ O
- HYPH O
blind JJ O
, , O
cross NN O
- HYPH O
over IN O
study NN O
, , O
30 CD O
healthy JJ O
volunteers NNS O
received VBD O
a DT O
single JJ O
intravenous JJ O
bolus NN O
injection NN O
of IN O
2 CD O
. . O
5 CD O
mg NN O
. . O
kg NN O
- HYPH O
1 CD O
propofol NN O
. . O
null null null-Disease
Plasma NN O
propofol NN O
levels NNS O
were VBD O
measured VBN O
for IN O
48 CD O
h NNS O
following VBG O
drug NN O
administration NN O
and CC O
evaluated VBN O
according VBG O
to IN O
a DT O
three CD O
- HYPH O
compartment NN O
model NN O
. . O
null null null-Disease
The DT O
pharmacodynamic JJ O
parameters NNS O
assessed VBN O
included VBD O
induction NN O
and CC O
emergence NN O
times NNS O
, , O
respiratory JJ O
and CC O
cardiovascular JJ O
effects NNS O
, , O
and CC O
pain NN B-Disease
on IN O
injection NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
monitored VBN O
for IN O
side NN O
effects NNS O
over IN O
48 CD O
h NN O
. . O
null null null-Disease
Owing VBG O
to IN O
a DT O
high JJ O
incidence NN O
of IN O
thrombophlebitis NN B-Disease
, , O
the DT O
study NN O
was VBD O
terminated VBN O
prematurely RB O
and CC O
only RB O
the DT O
data NNS O
of IN O
the DT O
two CD O
parallel JJ O
treatment NN O
groups NNS O
( , O
15 CD O
patients NNS O
in IN O
each DT O
group NN O
) -RRB- O
were VBD O
analysed VBN O
. . O
null null null-Disease
Plasma NN O
concentrations NNS O
did VBD O
not RB O
differ VB O
significantly RB O
between IN O
the DT O
two CD O
formulations NNS O
. . O
null null null-Disease
Anaesthesia NN O
induction NN O
and CC O
emergence NN O
times NNS O
, , O
respiratory JJ O
and CC O
cardiovascular JJ O
variables NNS O
showed VBD O
no DT O
significant JJ O
differences NNS O
between IN O
the DT O
two CD O
treatment NN O
groups NNS O
. . O
null null null-Disease
Pain NN B-Disease
on IN O
injection NN O
( , O
80 CD O
vs NN O
. . O
20 CD O
% NN O
, , O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
and CC O
thrombophlebitis NN B-Disease
( : O
93 CD O
. . O
3 CD O
vs NN O
. . O
6 CD O
. . O
6 CD O
% NN O
, , O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
occurred VBD O
more RBR O
frequently RB O
with IN O
AM149 NNP O
than IN O
with IN O
Disoprivan NNP O
. . O
null null null-Disease
Although IN O
both DT O
formulations NNS O
had VBD O
similar JJ O
pharmacokinetic JJ O
and CC O
pharmacodynamic JJ O
profiles NNS O
the DT O
new JJ O
formulation NN O
is VBZ O
not RB O
suitable JJ O
for IN O
clinical JJ O
use NN O
due IN O
to IN O
the DT O
high JJ O
incidence NN O
of IN O
thrombophlebitis NN B-Disease
produced VBN O
. . O
null null null-Disease
Pure JJ B-Disease
red JJ I-Disease
cell NN I-Disease
aplasia NN I-Disease
, , O
toxic JJ B-Disease
dermatitis NN I-Disease
and CC O
lymphadenopathy NN B-Disease
in IN O
a DT O
patient NN O
taking VBG O
diphenylhydantoin NN O
. . O
null null null-Disease
A DT O
patient NN O
taking VBG O
diphenylhydantoin NN O
for IN O
3 CD O
weeks NNS O
developed VBD O
a DT O
generalized VBN O
skin NN B-Disease
rash NN I-Disease
, , O
lymphadenopathy NN B-Disease
and CC O
pure JJ B-Disease
red JJ I-Disease
cell NN I-Disease
aplasia NN I-Disease
. . O
null null null-Disease
After IN O
withdrawal NN O
of IN O
the DT O
pharmacon NN O
all DT O
symptoms NNS O
disappeared VBD O
spontaneously RB O
. . O
null null null-Disease
Skin NN B-Disease
rash NN I-Disease
is VBZ O
a DT O
well RB O
- HYPH O
known VBN O
complication NN O
of IN O
diphenylhydantoin NN O
treatment NN O
as IN O
is VBZ O
benign JJ O
and CC O
malignant JJ O
lymphadenopathy NN B-Disease
. . O
null null null-Disease
Pure JJ B-Disease
red JJ I-Disease
cell NN I-Disease
aplasia NN I-Disease
associated VBN O
with IN O
diphenylhydantoin NN O
medication NN O
has VBZ O
been VBN O
reported VBN O
in IN O
3 CD O
patients NNS O
. . O
null null null-Disease
The DT O
exact JJ O
mechanism NN O
by IN O
which WDT O
diphenylhydantoin NN O
exerts VBZ O
its PRP$ O
toxic JJ O
effects NNS O
is VBZ O
not RB O
known VBN O
. . O
null null null-Disease
In IN O
this DT O
patient NN O
the DT O
time NN O
relation NN O
between IN O
the DT O
ingestion NN O
of IN O
diphenylhydantoin NN O
and CC O
the DT O
occurrence NN O
of IN O
the DT O
skin NN B-Disease
rash NN I-Disease
, , O
lymphadenopathy NN B-Disease
and CC O
pure JJ B-Disease
red JJ I-Disease
cell NN I-Disease
aplasia NN I-Disease
is VBZ O
very RB O
suggestive JJ O
of IN O
a DT O
direct JJ O
connection NN O
. . O
null null null-Disease
Vinorelbine NN O
- HYPH O
related VBN O
cardiac JJ O
events NNS O
: : O
a DT O
meta JJ O
- HYPH O
analysis NN O
of IN O
randomized VBN O
clinical JJ O
trials NNS O
. . O
null null null-Disease
Several JJ O
cases NNS O
of IN O
cardiac JJ O
adverse JJ O
reactions NNS O
related VBN O
to IN O
vinorelbine NN O
( , O
VNR NNP O
) -RRB- O
have VBP O
been VBN O
reported VBN O
in IN O
the DT O
literature NN O
. . O
null null null-Disease
In IN O
order NN O
to TO O
quantify VB O
the DT O
incidence NN O
of IN O
these DT O
cardiac JJ O
events NNS O
, , O
we PRP O
performed VBD O
a DT O
meta JJ O
- HYPH O
analysis NN O
of IN O
clinical JJ O
trials NNS O
comparing VBG O
VNR NN O
with IN O
other JJ O
chemotherapeutic JJ O
agents NNS O
in IN O
the DT O
treatment NN O
of IN O
various JJ O
malignancies NNS B-Disease
. . O
null null null-Disease
Randomized JJ O
clinical JJ O
trials NNS O
comparing VBG O
VNR NN O
with IN O
other JJ O
drugs NNS O
in IN O
the DT O
treatment NN O
of IN O
cancer NN B-Disease
were VBD O
searched VBN O
in IN O
Medline NNP O
, , O
Embase NNP O
, , O
Evidence NNP O
- HYPH O
based VBN O
Medicine NNP O
Reviews NNPS O
databases NNS O
and CC O
the DT O
Cochrane NNP O
library NN O
from IN O
1987 CD O
to IN O
2002 CD O
. . O
null null null-Disease
Outcomes NNS O
of IN O
interest NN O
were VBD O
severe JJ O
cardiac JJ O
events NNS O
, , O
toxic JJ O
deaths NNS O
and CC O
cardiac JJ O
event NN O
- HYPH O
related VBN O
deaths NNS O
reported VBN O
in IN O
each DT O
publication NN O
. . O
null null null-Disease
We PRP O
found VBD O
19 CD O
trials NNS O
, , O
involving VBG O
2441 CD O
patients NNS O
treated VBN O
by IN O
VNR NNP O
and CC O
2050 CD O
control NN O
patients NNS O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
cardiac JJ O
events NNS O
with IN O
VNR NNP O
was VBD O
1 CD O
. . O
19 CD O
% NN O
[ -LRB- O
95 CD O
% NN O
confidence NN O
interval NN O
( , O
CI NNP O
) -RRB- O
( , O
0 CD O
. . O
75 CD O
; : O
1 CD O
. . O
67 CD O
) -RRB- O
] -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
difference NN O
in IN O
the DT O
risk NN O
of IN O
cardiac JJ O
events NNS O
between IN O
VNR NNP O
and CC O
other JJ O
drugs NNS O
[ -LRB- O
odds NNS O
ratio NN O
: : O
0 CD O
. . O
92 CD O
, , O
95 CD O
% NN O
CI NN O
( : O
0 CD O
. . O
54 CD O
; : O
1 CD O
. . O
55 CD O
) -RRB- O
] -RRB- O
. . O
null null null-Disease
The DT O
risk NN O
of IN O
VNR NNP O
cardiac JJ O
events NNS O
was VBD O
similar JJ O
to IN O
vindesine NN O
( , O
VDS NN O
) -RRB- O
and CC O
other JJ O
cardiotoxic JJ B-Disease
drugs NNS O
[ -LRB- O
fluorouracil NN O
, , O
anthracyclines NNS O
, , O
gemcitabine NN O
( , O
GEM NNP O
) -RRB- O
em NN O
leader NN O
] -RRB- O
. . O
null null null-Disease
Even RB O
if IN O
it PRP O
did VBD O
not RB O
reach VB O
statistical JJ O
significance NN O
because IN O
of IN O
a DT O
few JJ O
number NN O
of IN O
cases NNS O
, , O
the DT O
risk NN O
was VBD O
lower JJR O
in IN O
trials NNS O
excluding VBG O
patients NNS O
with IN O
cardiac JJ O
history NN O
, , O
and CC O
seemed VBD O
to TO O
be VB O
higher JJR O
in IN O
trials NNS O
including VBG O
patients NNS O
with IN O
pre NN O
- HYPH O
existing VBG O
cardiac JJ B-Disease
diseases NNS I-Disease
. . O
null null null-Disease
Vinorelbine NN O
- HYPH O
related VBN O
cardiac JJ O
events NNS O
concern VBP O
about RB O
1 CD O
% NN O
of IN O
treated VBN O
patients NNS O
in IN O
clinical JJ O
trials NNS O
. . O
null null null-Disease
However RB O
, , O
the DT O
risk NN O
associated VBN O
with IN O
VNR NNP O
seems VBZ O
to TO O
be VB O
similar JJ O
to IN O
that DT O
of IN O
other JJ O
chemotherapeutic JJ O
agents NNS O
in IN O
the DT O
same JJ O
indications NNS O
. . O
null null null-Disease
MRI NNP O
findings NNS O
of IN O
hypoxic JJ O
cortical JJ O
laminar NN O
necrosis NN B-Disease
in IN O
a DT O
child NN O
with IN O
hemolytic JJ B-Disease
anemia NN I-Disease
crisis NN O
. . O
null null null-Disease
We PRP O
present VBP O
magnetic JJ O
resonance NN O
imaging NN O
findings NNS O
of IN O
a DT O
5 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
girl NN O
who WP O
had VBD O
a DT O
rapidly RB O
installing VBG O
hemolytic JJ B-Disease
anemia NN I-Disease
crisis NN O
induced VBN O
by IN O
trimethoprim NN O
- HYPH O
sulfomethoxazole NN O
, , O
resulting VBG O
in IN O
cerebral JJ B-Disease
anoxia NN I-Disease
leading VBG O
to IN O
permanent JJ O
damage NN O
. . O
null null null-Disease
Magnetic JJ O
Resonance NN O
imaging NN O
revealed VBD O
cortical JJ O
laminar NN O
necrosis NN B-Disease
in IN O
arterial JJ O
border NN O
zones NNS O
in IN O
both DT O
cerebral JJ O
hemispheres NNS O
, , O
ischemic JJ O
changes NNS O
in IN O
subcortical JJ O
white JJ O
matter NN O
of IN O
left JJ O
cerebral JJ O
hemisphere NN O
, , O
and CC O
in IN O
the DT O
left JJ O
putamen NN O
. . O
null null null-Disease
Although IN O
cortical JJ O
laminar NN O
necrosis NN B-Disease
is VBZ O
a DT O
classic JJ O
entity NN O
in IN O
adulthood NN O
related VBN O
to IN O
conditions NNS O
of IN O
energy NN O
depletions NNS O
, , O
there EX O
are VBP O
few JJ O
reports NNS O
available JJ O
in IN O
children NNS O
. . O
null null null-Disease
A DT O
wide JJ O
review NN O
of IN O
the DT O
literature NN O
is VBZ O
also RB O
presented VBN O
. . O
null null null-Disease
The DT O
natural JJ O
history NN O
of IN O
Vigabatrin NNP O
associated VBN O
visual JJ B-Disease
field NN I-Disease
defects NNS I-Disease
in IN O
patients NNS O
electing VBG O
to TO O
continue VB O
their PRP$ O
medication NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
determine VB O
the DT O
natural JJ O
history NN O
of IN O
visual JJ B-Disease
field NN I-Disease
defects NNS I-Disease
in IN O
a DT O
group NN O
of IN O
patients NNS O
known VBN O
to TO O
have VB O
Vigabatrin NNP O
- HYPH O
associated VBN O
changes NNS O
who WP O
elected VBD O
to TO O
continue VB O
the DT O
medication NN O
because IN O
of IN O
good JJ O
seizure NN B-Disease
control NN O
. . O
null null null-Disease
METHODS NNS O
: : O
All DT O
patients NNS O
taking VBG O
Vigabatrin NNP O
alone RB O
or CC O
in IN O
combination NN O
with IN O
other JJ O
antiepileptic JJ O
drugs NNS O
for IN O
at RB O
least RBS O
5 CD O
years NNS O
( -LRB- O
range NN O
5 CD O
- SYM O
12 CD O
years NNS O
) -RRB- O
were VBD O
entered VBN O
into IN O
a DT O
visual JJ O
surveillance NN O
programme NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
followed VBN O
up RP O
at IN O
6 CD O
- HYPH O
monthly JJ O
intervals NNS O
for IN O
not RB O
less JJR O
than IN O
18 CD O
months NNS O
( : O
range NN O
18 CD O
- SYM O
43 CD O
months NNS O
) -RRB- O
. . O
null null null-Disease
In IN O
all DT O
, , O
16 CD O
patients NNS O
with IN O
unequivocal JJ O
defects NNS O
continued VBD O
the DT O
medication NN O
. . O
null null null-Disease
Following VBG O
already RB O
published VBN O
methodology NN O
( -LRB- O
Eye NNP O
2002 CD O
; : O
16 CD O
; : O
567 CD O
- HYPH O
571 CD O
) -RRB- O
monocular JJ O
mean JJ O
radial JJ O
degrees NNS O
( , O
MRDs NNP O
) -RRB- O
to IN O
the DT O
I NNP O
/ SYM O
4e CD O
isopter NN O
on IN O
Goldmann NNP O
perimetry NN O
was VBD O
calculated VBN O
for IN O
the DT O
right JJ O
eye NN O
at IN O
the DT O
time NN O
of IN O
discovery NN O
of IN O
a DT O
visual JJ B-Disease
field NN I-Disease
defect NN I-Disease
and CC O
again RB O
after IN O
not RB O
less JJR O
than IN O
18 CD O
months NNS O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Mean JJ O
right JJ O
eye NN O
MRD NN O
at IN O
presentation NN O
was VBD O
36 CD O
. . O
98 CD O
degrees NNS O
( : O
range NN O
22 CD O
. . O
25 CD O
- SYM O
51 CD O
. . O
0 CD O
) -RRB- O
, , O
compared VBN O
to IN O
38 CD O
. . O
40 CD O
degrees NNS O
( : O
range NN O
22 CD O
. . O
5 CD O
- SYM O
49 CD O
. . O
75 CD O
) -RRB- O
after IN O
follow NN O
- HYPH O
up NN O
; : O
P NN O
= SYM O
0 CD O
. . O
338 CD O
unpaired JJ O
t NN O
- HYPH O
test NN O
. . O
null null null-Disease
Only RB O
one CD O
patient NN O
demonstrated VBD O
a DT O
deterioration NN B-Disease
in IN I-Disease
visual JJ I-Disease
field NN I-Disease
during IN O
the DT O
study NN O
period NN O
and CC O
discontinued VBD O
treatment NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Established VBN O
visual JJ B-Disease
field NN I-Disease
defects NNS I-Disease
presumed VBN O
to TO O
be VB O
due IN O
to IN O
Vigabatrin NNP O
therapy NN O
did VBD O
not RB O
usually RB O
progress VB O
in IN O
spite NN O
of IN O
continuing VBG O
use NN O
of IN O
the DT O
medication NN O
. . O
null null null-Disease
These DT O
data NNS O
give VBP O
support NN O
to IN O
the DT O
hypothesis NN O
that IN O
the DT O
pathogenesis NN O
of IN O
Vigabatrin NNP O
- HYPH O
associated VBN O
visual JJ B-Disease
field NN I-Disease
defects NNS I-Disease
may MD O
be VB O
an DT O
idiosyncratic JJ O
adverse JJ O
drug NN O
reaction NN O
rather RB O
than IN O
dose NN O
- HYPH O
dependent JJ O
toxicity NN B-Disease
. . O
null null null-Disease
Induction NN O
of IN O
rosaceiform NN O
dermatitis NN B-Disease
during IN O
treatment NN O
of IN O
facial JJ B-Disease
inflammatory JJ I-Disease
dermatoses NNS I-Disease
with IN O
tacrolimus NN O
ointment NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Tacrolimus NNP O
ointment NN O
is VBZ O
increasingly RB O
used VBN O
for IN O
anti JJ O
- HYPH O
inflammatory JJ O
treatment NN O
of IN O
sensitive JJ O
areas NNS O
such JJ O
as IN O
the DT O
face NN O
, , O
and CC O
recent JJ O
observations NNS O
indicate VBP O
that IN O
the DT O
treatment NN O
is VBZ O
effective JJ O
in IN O
steroid NN O
- HYPH O
aggravated VBN O
rosacea NN B-Disease
and CC O
perioral JJ B-Disease
dermatitis NN I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
on IN O
rosaceiform NN O
dermatitis NN B-Disease
as IN O
a DT O
complication NN O
of IN O
treatment NN O
with IN O
tacrolimus NN O
ointment NN O
. . O
null null null-Disease
OBSERVATIONS NNS O
: : O
Six CD O
adult NN O
patients NNS O
with IN O
inflammatory JJ B-Disease
facial JJ I-Disease
dermatoses NNS I-Disease
were VBD O
treated VBN O
with IN O
tacrolimus NN O
ointment NN O
because IN O
of IN O
the DT O
ineffectiveness NN O
of IN O
standard JJ O
treatments NNS O
. . O
null null null-Disease
Within IN O
2 CD O
to TO O
3 CD O
weeks NNS O
of IN O
initially RB O
effective JJ O
and CC O
well RB O
- HYPH O
tolerated VBN O
treatment NN O
, , O
3 CD O
patients NNS O
with IN O
a DT O
history NN O
of IN O
rosacea NN B-Disease
and CC O
1 CD O
with IN O
a DT O
history NN O
of IN O
acne NN B-Disease
experienced VBD O
sudden JJ O
worsening NN O
with IN O
pustular JJ O
rosaceiform NN O
lesions NNS O
. . O
null null null-Disease
Biopsy NN O
revealed VBD O
an DT O
abundance NN O
of IN O
Demodex NNP O
mites NNS O
in IN O
2 CD O
of IN O
these DT O
patients NNS O
. . O
null null null-Disease
In IN O
1 CD O
patient NN O
with IN O
eyelid NN O
eczema NN B-Disease
, , O
rosaceiform NN O
periocular JJ B-Disease
dermatitis NN I-Disease
gradually RB O
appeared VBD O
after IN O
3 CD O
weeks NNS O
of IN O
treatment NN O
. . O
null null null-Disease
In IN O
1 CD O
patient NN O
with IN O
atopic JJ B-Disease
dermatitis NN I-Disease
, , O
telangiectatic JJ O
and CC O
papular JJ B-Disease
rosacea NN I-Disease
insidiously RB O
appeared VBD O
after IN O
5 CD O
months NNS O
of IN O
treatment NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Our PRP$ O
observations NNS O
suggest VBP O
that IN O
the DT O
spectrum NN O
of IN O
rosaceiform NN O
dermatitis NN B-Disease
as IN O
a DT O
complication NN O
of IN O
treatment NN O
with IN O
tacrolimus NN O
ointment NN O
is VBZ O
heterogeneous JJ O
. . O
null null null-Disease
A DT O
variety NN O
of IN O
factors NNS O
, , O
such JJ O
as IN O
vasoactive JJ O
properties NNS O
of IN O
tacrolimus NN O
, , O
proliferation NN O
of IN O
Demodex NNP O
due IN O
to IN O
local JJ O
immunosuppression NN O
, , O
and CC O
the DT O
occlusive JJ O
properties NNS O
of IN O
the DT O
ointment NN O
, , O
may MD O
be VB O
involved VBN O
in IN O
the DT O
observed VBN O
phenomena NNS O
. . O
null null null-Disease
Future JJ O
studies NNS O
are VBP O
needed VBN O
to TO O
identify VB O
individual JJ O
risk NN O
factors NNS O
. . O
null null null-Disease
Intravascular JJ O
hemolysis NN B-Disease
and CC O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
following VBG O
intermittent JJ O
rifampin NN O
therapy NN O
. . O
null null null-Disease
Renal JJ B-Disease
failure NN I-Disease
is VBZ O
a DT O
rare JJ O
complication NN O
associated VBN O
with IN O
the DT O
use NN O
of IN O
rifampin NN O
. . O
null null null-Disease
Intravascular JJ O
hemolysis NN B-Disease
leading VBG O
to IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
following VBG O
rifampin NN O
therapy NN O
is VBZ O
extremely RB O
rare JJ O
. . O
null null null-Disease
Two CD O
patients NNS O
with IN O
leprosy NN B-Disease
who WP O
developed VBD O
hemolysis NN B-Disease
and CC O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
following VBG O
rifampin NN O
are VBP O
reported VBN O
. . O
null null null-Disease
Structural JJ O
abnormalities NNS O
in IN O
the DT O
brains NNS O
of IN O
human JJ O
subjects NNS O
who WP O
use VBP O
methamphetamine NN O
. . O
null null null-Disease
We PRP O
visualize VBP O
, , O
for IN O
the DT O
first JJ O
time NN O
, , O
the DT O
profile NN O
of IN O
structural JJ B-Disease
deficits NNS I-Disease
in IN I-Disease
the DT I-Disease
human JJ I-Disease
brain NN I-Disease
associated VBN O
with IN O
chronic JJ O
methamphetamine NN O
( , O
MA NN O
) -RRB- O
abuse NN O
. . O
null null null-Disease
Studies NNS O
of IN O
human JJ O
subjects NNS O
who WP O
have VBP O
used VBN O
MA NNP O
chronically RB O
have VBP O
revealed VBN O
deficits NNS O
in IN O
dopaminergic JJ O
and CC O
serotonergic JJ O
systems NNS O
and CC O
cerebral JJ O
metabolic JJ B-Disease
abnormalities NNS I-Disease
. . O
null null null-Disease
Using VBG O
magnetic JJ O
resonance NN O
imaging NN O
( , O
MRI NNP O
) -RRB- O
and CC O
new JJ O
computational JJ O
brain NN O
- HYPH O
mapping NN O
techniques NNS O
, , O
we PRP O
determined VBD O
the DT O
pattern NN O
of IN O
structural JJ O
brain NN O
alterations NNS O
associated VBN O
with IN O
chronic JJ O
MA NN O
abuse NN O
in IN O
human JJ O
subjects NNS O
and CC O
related VBN O
these DT O
deficits NNS O
to IN O
cognitive JJ B-Disease
impairment NN I-Disease
. . O
null null null-Disease
We PRP O
used VBD O
high JJ O
- HYPH O
resolution NN O
MRI NN O
and CC O
surface NN O
- HYPH O
based VBN O
computational JJ O
image NN O
analyses NNS O
to TO O
map VB O
regional JJ O
abnormalities NNS B-Disease
in IN I-Disease
the DT I-Disease
cortex NN I-Disease
, , I-Disease
hippocampus NN I-Disease
, , I-Disease
white JJ I-Disease
matter NN I-Disease
, , I-Disease
and CC I-Disease
ventricles NNS I-Disease
in IN O
22 CD O
human JJ O
subjects NNS O
who WP O
used VBD O
MA NN O
and CC O
21 CD O
age NN O
- HYPH O
matched VBN O
, , O
healthy JJ O
controls NNS O
. . O
null null null-Disease
Cortical JJ O
maps NNS O
revealed VBD O
severe JJ O
gray JJ O
- HYPH O
matter NN O
deficits NNS O
in IN O
the DT O
cingulate NN O
, , O
limbic NN O
, , O
and CC O
paralimbic JJ O
cortices NNS O
of IN O
MA NNP O
abusers NNS O
( , O
averaging VBG O
11 CD O
. . O
3 CD O
% NN O
below IN O
control NN O
; : O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
On IN O
average JJ O
, , O
MA NNP O
abusers NNS O
had VBD O
7 CD O
. . O
8 CD O
% NN O
smaller JJR O
hippocampal JJ O
volumes NNS O
than IN O
control NN O
subjects NNS O
( : O
p NN O
< NN O
0 CD O
. . O
01 CD O
; : O
left JJ O
, , O
p NN O
= SYM O
0 CD O
. . O
01 CD O
; : O
right UH O
, , O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
and CC O
significant JJ O
white JJ O
- HYPH O
matter NN O
hypertrophy NN B-Disease
( : O
7 CD O
. . O
0 CD O
% NN O
; : O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Hippocampal JJ O
deficits NNS O
were VBD O
mapped VBN O
and CC O
correlated VBN O
with IN O
memory NN O
performance NN O
on IN O
a DT O
word NN O
- HYPH O
recall NN O
test NN O
( , O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
MRI NN O
- HYPH O
based VBN O
maps NNS O
suggest VBP O
that IN O
chronic JJ O
methamphetamine NN O
abuse NN O
causes VBZ O
a DT O
selective JJ O
pattern NN O
of IN O
cerebral JJ O
deterioration NN O
that WDT O
contributes VBZ O
to IN O
impaired JJ B-Disease
memory NN I-Disease
performance NN I-Disease
. . O
null null null-Disease
MA NNP O
may MD O
selectively RB O
damage VB O
the DT O
medial JJ O
temporal JJ O
lobe NN O
and CC O
, , O
consistent JJ O
with IN O
metabolic JJ O
studies NNS O
, , O
the DT O
cingulate NN O
- HYPH O
limbic NN O
cortex NN O
, , O
inducing VBG O
neuroadaptation NN O
, , O
neuropil NN O
reduction NN O
, , O
or CC O
cell NN O
death NN O
. . O
null null null-Disease
Prominent JJ O
white JJ O
- HYPH O
matter NN O
hypertrophy NN B-Disease
may MD O
result VB O
from IN O
altered JJ O
myelination NN O
and CC O
adaptive JJ O
glial NN O
changes NNS O
, , O
including VBG O
gliosis NN B-Disease
secondary JJ O
to IN O
neuronal JJ B-Disease
damage NN I-Disease
. . O
null null null-Disease
These DT O
brain NN O
substrates NNS O
may MD O
help VB O
account VB O
for IN O
the DT O
symptoms NNS O
of IN O
MA NNP O
abuse NN O
, , O
providing VBG O
therapeutic JJ O
targets NNS O
for IN O
drug NN O
- HYPH O
induced VBN O
brain NN B-Disease
injury NN I-Disease
. . O
null null null-Disease
Disruption NN O
of IN O
hepatic JJ O
lipid NN O
homeostasis NN O
in IN O
mice NNS O
after IN O
amiodarone NN O
treatment NN O
is VBZ O
associated VBN O
with IN O
peroxisome NN O
proliferator NN O
- HYPH O
activated VBN O
receptor NN O
- HYPH O
alpha NN O
target NN O
gene NN O
activation NN O
. . O
null null null-Disease
Amiodarone NNP O
, , O
an DT O
efficacious JJ O
and CC O
widely RB O
used VBN O
antiarrhythmic JJ O
agent NN O
, , O
has VBZ O
been VBN O
reported VBN O
to TO O
cause VB O
hepatotoxicity NN B-Disease
in IN O
some DT O
patients NNS O
. . O
null null null-Disease
To TO O
gain VB O
insight NN O
into IN O
the DT O
mechanism NN O
of IN O
this DT O
unwanted JJ O
effect NN O
, , O
mice NNS O
were VBD O
administered VBN O
various JJ O
doses NNS O
of IN O
amiodarone NN O
and CC O
examined VBN O
for IN O
changes NNS O
in IN O
hepatic JJ O
histology NN O
and CC O
gene NN O
regulation NN O
. . O
null null null-Disease
Amiodarone NN O
induced VBD O
hepatomegaly NN B-Disease
, , O
hepatocyte NN O
microvesicular JJ O
lipid NN O
accumulation NN O
, , O
and CC O
a DT O
significant JJ O
decrease NN O
in IN O
serum NN O
triglycerides NNS O
and CC O
glucose NN O
. . O
null null null-Disease
Northern JJ O
blot NN O
analysis NN O
of IN O
hepatic JJ O
RNA NNP O
revealed VBD O
a DT O
dose NN O
- HYPH O
dependent JJ O
increase NN O
in IN O
the DT O
expression NN O
of IN O
a DT O
number NN O
of IN O
genes NNS O
critical JJ O
for IN O
fatty NN O
acid NN O
oxidation NN O
, , O
lipoprotein NN O
assembly NN O
, , O
and CC O
lipid NN O
transport NN O
. . O
null null null-Disease
Many JJ O
of IN O
these DT O
genes NNS O
are VBP O
regulated VBN O
by IN O
the DT O
peroxisome NN O
proliferator NN O
- HYPH O
activated VBN O
receptor NN O
- HYPH O
alpha NN O
( , O
PPARalpha NNP O
) -RRB- O
, , O
a DT O
ligand NN O
- HYPH O
activated VBN O
nuclear JJ O
hormone NN O
receptor NN O
transcription NN O
factor NN O
. . O
null null null-Disease
The DT O
absence NN O
of IN O
induction NN O
of IN O
these DT O
genes NNS O
as RB O
well RB O
as IN O
hepatomegaly NN B-Disease
in IN O
PPARalpha NNP O
knockout NN O
[ -LRB- O
PPARalpha NNP O
- HYPH O
/ SYM O
- : O
] -RRB- O
mice NNS O
indicated VBD O
that IN O
the DT O
effects NNS O
of IN O
amiodarone NN O
were VBD O
dependent JJ O
upon IN O
the DT O
presence NN O
of IN O
a DT O
functional JJ O
PPARalpha NNP O
gene NN O
. . O
null null null-Disease
Compared VBN O
to IN O
wild JJ O
- HYPH O
type NN O
mice NNS O
, , O
treatment NN O
of IN O
PPARalpha NN O
- HYPH O
/ SYM O
- HYPH O
mice NNS O
with IN O
amiodarone NN O
resulted VBD O
in IN O
an DT O
increased JJ O
rate NN O
and CC O
extent NN O
of IN O
total JJ O
body NN O
weight NN B-Disease
loss NN I-Disease
. . O
null null null-Disease
The DT O
inability NN O
of IN O
amiodarone NN O
to TO O
directly RB O
activate VB O
either CC O
human JJ O
or CC O
mouse NN O
PPARalpha NNP O
transiently RB O
expressed VBN O
in IN O
human JJ O
HepG2 NNP O
hepatoma NN B-Disease
cells NNS O
indicates VBZ O
that IN O
the DT O
effects NNS O
of IN O
amiodarone NN O
on IN O
the DT O
function NN O
of IN O
this DT O
receptor NN O
were VBD O
indirect JJ O
. . O
null null null-Disease
Based VBN O
upon IN O
these DT O
results NNS O
, , O
we PRP O
conclude VBP O
that IN O
amiodarone NN O
disrupts VBZ O
hepatic JJ O
lipid NN O
homeostasis NN O
and CC O
that IN O
the DT O
increased VBN O
expression NN O
of IN O
PPARalpha NNP O
target NN O
genes NNS O
is VBZ O
secondary JJ O
to IN O
this DT O
toxic JJ O
effect NN O
. . O
null null null-Disease
These DT O
results NNS O
provide VBP O
important JJ O
new JJ O
mechanistic JJ O
information NN O
regarding VBG O
the DT O
hepatotoxic JJ B-Disease
effects NNS O
of IN O
amiodarone NN O
and CC O
indicate VBP O
that IN O
PPARalpha NNP O
protects VBZ O
against IN O
amiodarone NN O
- HYPH O
induced VBN O
hepatotoxicity NN B-Disease
. . O
null null null-Disease
Safety NN O
and CC O
compliance NN O
with IN O
once RB O
- HYPH O
daily JJ O
niacin NN O
extended VBN O
- HYPH O
release NN O
/ SYM O
lovastatin NN O
as IN O
initial JJ O
therapy NN O
in IN O
the DT O
Impact NNP O
of IN O
Medical NNP O
Subspecialty NNP O
on IN O
Patient NNP O
Compliance NNP O
to IN O
Treatment NNP O
( -LRB- O
IMPACT NNP O
) -RRB- O
study NN O
. . O
null null null-Disease
Niacin NNP O
extended VBN O
- HYPH O
release NN O
/ SYM O
lovastatin NN O
is VBZ O
a DT O
new JJ O
combination NN O
product NN O
approved VBN O
for IN O
treatment NN O
of IN O
primary JJ O
hypercholesterolemia NN B-Disease
and CC O
mixed JJ O
dyslipidemia NN B-Disease
. . O
null null null-Disease
This DT O
open RB O
- HYPH O
labeled VBN O
, , O
multicenter JJ O
study NN O
evaluated VBD O
the DT O
safety NN O
of IN O
bedtime JJ O
niacin NN O
extended VBN O
- HYPH O
release NN O
/ SYM O
lovastatin NN O
when WRB O
dosed VBN O
as IN O
initial JJ O
therapy NN O
and CC O
patient NN O
compliance NN O
to IN O
treatment NN O
in IN O
various JJ O
clinical JJ O
practice NN O
settings NNS O
. . O
null null null-Disease
A DT O
total NN O
of IN O
4 CD O
, , O
499 CD O
patients NNS O
with IN O
dyslipidemia NN B-Disease
requiring VBG O
drug NN O
intervention NN O
was VBD O
enrolled VBN O
at IN O
1 CD O
, , O
081 CD O
sites NNS O
. . O
null null null-Disease
Patients NNS O
were VBD O
treated VBN O
with IN O
1 CD O
tablet NN O
( : O
500 CD O
mg NNS O
of IN O
niacin NN O
extended VBN O
- HYPH O
release NN O
/ SYM O
20 CD O
mg NN O
of IN O
lovastatin NN O
) , O
once RB O
nightly RB O
for IN O
4 CD O
weeks NNS O
and CC O
then RB O
2 CD O
tablets NNS O
for IN O
8 CD O
weeks NNS O
. . O
null null null-Disease
Patients NNS O
also RB O
received VBD O
dietary JJ O
counseling NN O
, , O
educational JJ O
materials NNS O
, , O
and CC O
reminders NNS O
to TO O
call VB O
a DT O
toll NN O
- HYPH O
free JJ O
number NN O
that WDT O
provided VBD O
further JJ O
education NN O
about IN O
dyslipidemia NN B-Disease
and CC O
niacin NN O
extended VBN O
- HYPH O
release NN O
/ SYM O
lovastatin NN O
. . O
null null null-Disease
Primary JJ O
end NN O
points NNS O
were VBD O
study NN O
compliance NN O
, , O
increases NNS O
in IN O
liver NN O
transaminases NNS O
to IN O
> SYM O
3 CD O
times NNS O
the DT O
upper JJ O
limit NN O
of IN O
normal JJ O
, , O
and CC O
clinical JJ O
myopathy NN B-Disease
. . O
null null null-Disease
Final JJ O
study NN O
status NN O
was VBD O
available JJ O
for IN O
4 CD O
, , O
217 CD O
patients NNS O
( : O
94 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Compliance NN O
to IN O
niacin NN O
extended VBN O
- HYPH O
release NN O
/ SYM O
lovastatin NN O
was VBD O
77 CD O
% NN O
, , O
with IN O
3 CD O
, , O
245 CD O
patients NNS O
completing VBG O
the DT O
study NN O
. . O
null null null-Disease
Patients NNS O
in IN O
the DT O
southeast NN O
and CC O
those DT O
enrolled VBN O
by IN O
endocrinologists NNS O
had VBD O
the DT O
lowest JJS O
compliance NN O
and CC O
highest JJS O
adverse JJ O
event NN O
rates NNS O
. . O
null null null-Disease
Flushing NN B-Disease
was VBD O
the DT O
most RBS O
common JJ O
adverse JJ O
event NN O
, , O
reported VBN O
by IN O
18 CD O
% NN O
of IN O
patients NNS O
and CC O
leading VBG O
to IN O
discontinuation NN O
by IN O
6 CD O
% NN O
. . O
null null null-Disease
Incidence NN O
of IN O
increased VBN O
aspartate NN O
aminotransferase NN O
and CC O
/ SYM O
or CC O
alanine NN O
aminotransferase NN O
> SYM O
3 CD O
times NNS O
the DT O
upper JJ O
limit NN O
of IN O
normal JJ O
was VBD O
< $ O
0 CD O
. . O
3 CD O
% NN O
. . O
null null null-Disease
An DT O
increase NN O
of IN O
creatine JJ O
phosphokinase NN O
to IN O
> SYM O
5 CD O
times NNS O
the DT O
upper JJ O
limit NN O
of IN O
normal JJ O
occurred VBD O
in IN O
0 CD O
. . O
24 CD O
% NN O
of IN O
patients NNS O
, , O
and CC O
no DT O
cases NNS O
of IN O
drug NN O
- HYPH O
induced VBN O
myopathy NN B-Disease
were VBD O
observed VBN O
. . O
null null null-Disease
Niacin NNP O
extended VBN O
- HYPH O
release NN O
/ SYM O
lovastatin NN O
1 CD O
, , O
000 CD O
/ SYM O
40 CD O
mg NN O
, , O
dosed VBN O
as IN O
initial JJ O
therapy NN O
, , O
was VBD O
associated VBN O
with IN O
good JJ O
compliance NN O
and CC O
safety NN O
and CC O
had VBD O
very RB O
low JJ O
incidences NNS O
of IN O
increased VBN O
liver NN O
and CC O
muscle NN O
enzymes NNS O
. . O
null null null-Disease
Protective JJ O
effect NN O
of IN O
Terminalia NNP O
chebula NN O
against IN O
experimental JJ O
myocardial JJ B-Disease
injury NN I-Disease
induced VBN O
by IN O
isoproterenol NN O
. . O
null null null-Disease
Cardioprotective JJ O
effect NN O
of IN O
ethanolic JJ O
extract NN O
of IN O
Terminalia NNP O
chebula NN O
fruits NNS O
( , O
500 CD O
mg NNS O
/ SYM O
kg NN O
body NN O
wt NN O
) , O
was VBD O
examined VBN O
in IN O
isoproterenol NN O
( , O
200 CD O
mg NN O
/ SYM O
kg NN O
body NN O
wt NN O
) , O
induced VBN O
myocardial JJ B-Disease
damage NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
In IN O
isoproterenol NN O
administered VBN O
rats NNS O
, , O
the DT O
level NN O
of IN O
lipid NN O
peroxides NNS O
increased VBD O
significantly RB O
in IN O
the DT O
serum NN O
and CC O
heart NN O
. . O
null null null-Disease
A DT O
significant JJ O
decrease NN O
was VBD O
observed VBN O
in IN O
the DT O
activity NN O
of IN O
the DT O
myocardial JJ O
marker NN O
enzymes NNS O
with IN O
a DT O
concomitant JJ O
increase NN O
in IN O
their PRP$ O
activity NN O
in IN O
serum NN O
. . O
null null null-Disease
Histopathological JJ O
examination NN O
was VBD O
carried VBN O
out RP O
to TO O
confirm VB O
the DT O
myocardial JJ O
necrosis NN B-Disease
. . O
null null null-Disease
T NNP O
. . O
chebula NN O
extract NN O
pretreatment NN O
was VBD O
found VBN O
to TO O
ameliorate VB O
the DT O
effect NN O
of IN O
isoproterenol NN O
on IN O
lipid NN O
peroxide NN O
formation NN O
and CC O
retained VBN O
the DT O
activities NNS O
of IN O
the DT O
diagnostic JJ O
marker NN O
enzymes NNS O
. . O
null null null-Disease
A DT O
case NN O
of IN O
postoperative JJ O
anxiety NN B-Disease
due IN O
to IN O
low JJ O
dose NN O
droperidol NN O
used VBN O
with IN O
patient NN O
- HYPH O
controlled VBN O
analgesia NN O
. . O
null null null-Disease
A DT O
multiparous JJ O
woman NN O
in IN O
good JJ O
psychological JJ O
health NN O
underwent VBD O
urgent JJ O
caesarean NN O
section NN O
in IN O
labour NN O
. . O
null null null-Disease
Postoperatively RB O
, , O
she PRP O
was VBD O
given VBN O
a DT O
patient NN O
- HYPH O
controlled VBN O
analgesia NN O
device NN O
delivering VBG O
boluses NNS O
of IN O
diamorphine NN O
0 CD O
. . O
5 CD O
mg NN O
and CC O
droperidol NN O
0 CD O
. . O
025 CD O
mg NN O
. . O
null null null-Disease
Whilst IN O
using VBG O
the DT O
device NN O
she PRP O
gradually RB O
became VBD O
anxious JJ O
, , O
the DT O
feeling NN O
worsening VBG O
after IN O
each DT O
bolus NN O
. . O
null null null-Disease
The DT O
diagnosis NN O
of IN O
droperidol NN O
- HYPH O
induced VBN O
psychological JJ B-Disease
disturbance NN I-Disease
was VBD O
not RB O
made VBN O
straight RB O
away RB O
although IN O
on IN O
subsequent JJ O
close JJ O
questioning VBG O
the DT O
patient NN O
gave VBD O
a DT O
very RB O
clear JJ O
history NN O
. . O
null null null-Disease
After IN O
she PRP O
had VBD O
received VBN O
a DT O
total NN O
of IN O
only RB O
0 CD O
. . O
9 CD O
mg NN O
droperidol NN O
, , O
a DT O
syringe NN O
containing VBG O
diamorphine NN O
only RB O
was VBD O
substituted VBN O
and CC O
her PRP$ O
unease NN O
resolved VBN O
completely RB O
. . O
null null null-Disease
We PRP O
feel VBP O
that IN O
, , O
although IN O
the DT O
dramatic JJ O
extrapyramidal JJ O
side NN O
effects NNS O
of IN O
dopaminergic JJ O
antiemetics NNS O
are VBP O
well RB O
known VBN O
, , O
more RBR O
subtle JJ O
manifestations NNS O
may MD O
easily RB O
be VB O
overlooked VBN O
. . O
null null null-Disease
Accurate JJ O
patient JJ O
history NN O
contributes VBZ O
to IN O
differentiating VBG O
diabetes NN B-Disease
insipidus NN I-Disease
: : O
a DT O
case NN O
study NN O
. . O
null null null-Disease
This DT O
case NN O
study NN O
highlights VBZ O
the DT O
important JJ O
contribution NN O
of IN O
nursing NN O
in IN O
obtaining VBG O
an DT O
accurate JJ O
health NN O
history NN O
. . O
null null null-Disease
The DT O
case NN O
discussed VBN O
herein RB O
initially RB O
appeared VBD O
to TO O
be VB O
neurogenic JJ B-Disease
diabetes NN I-Disease
insipidus NN I-Disease
( -LRB- O
DI NNP B-Disease
) -RRB- O
secondary JJ O
to IN O
a DT O
traumatic JJ B-Disease
brain NN I-Disease
injury NN I-Disease
. . O
null null null-Disease
The DT O
nursing NN O
staff NN O
, , O
by IN O
reviewing VBG O
the DT O
patient NN O
' POS O
s POS O
health NN O
history NN O
with IN O
his PRP$ O
family NN O
, , O
discovered VBD O
a DT O
history NN O
of IN O
polydipsia NN B-Disease
and CC O
long RB O
- HYPH O
standing VBG O
lithium NN O
use NN O
. . O
null null null-Disease
Lithium NN O
is VBZ O
implicated VBN O
in IN O
drug NN O
- HYPH O
induced VBN O
nephrogenic JJ B-Disease
DI NNP I-Disease
, , O
and CC O
because IN O
the DT O
patient NN O
had VBD O
not RB O
received VBN O
lithium NN O
since IN O
being VBG O
admitted VBN O
to IN O
the DT O
hospital NN O
, , O
his PRP$ O
treatment NN O
changed VBD O
to TO O
focus VB O
on IN O
nephrogenic JJ B-Disease
DI NNP I-Disease
. . O
null null null-Disease
By IN O
combining VBG O
information NN O
from IN O
the DT O
patient JJ O
history NN O
, , O
the DT O
physical JJ O
examination NN O
, , O
and CC O
radiologic JJ O
and CC O
laboratory NN O
studies NNS O
, , O
the DT O
critical JJ O
care NN O
team NN O
demonstrated VBD O
that IN O
the DT O
patient NN O
had VBD O
been VBN O
self NN O
- HYPH O
treating VBG O
his PRP$ O
lithium NN O
- HYPH O
induced VBN O
nephrogenic JJ B-Disease
DI NN I-Disease
and CC O
developed VBD O
neurogenic JJ B-Disease
DI NNP I-Disease
secondary JJ O
to IN O
brain NN B-Disease
trauma NN I-Disease
. . O
null null null-Disease
Thus RB O
successful JJ O
treatment NN O
required VBD O
that IN O
nephrogenic JJ O
and CC O
neurogenic JJ B-Disease
DI NN I-Disease
be VB O
treated VBN O
concomitantly RB O
. . O
null null null-Disease
Factors NNS O
contributing VBG O
to IN O
ribavirin NN O
- HYPH O
induced VBN O
anemia NN B-Disease
. . O
null null null-Disease
BACKGROUND NN O
AND CC O
AIM NN O
: : O
Interferon NN O
and CC O
ribavirin NN O
combination NN O
therapy NN O
for IN O
chronic JJ B-Disease
hepatitis NN I-Disease
C NNP I-Disease
produces VBZ O
hemolytic JJ B-Disease
anemia NN I-Disease
. . O
null null null-Disease
This DT O
study NN O
was VBD O
conducted VBN O
to TO O
identify VB O
the DT O
factors NNS O
contributing VBG O
to IN O
ribavirin NN O
- HYPH O
induced VBN O
anemia NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Eighty CD O
- HYPH O
eight CD O
patients NNS O
with IN O
chronic JJ B-Disease
hepatitis NN I-Disease
C NN I-Disease
who WP O
received VBD O
interferon NN O
- HYPH O
alpha NN O
- HYPH O
2b NN O
at IN O
a DT O
dose NN O
of IN O
6 CD O
MU NN O
administered VBN O
intramuscularly RB O
for IN O
24 CD O
weeks NNS O
in IN O
combination NN O
with IN O
ribavirin NN O
administered VBN O
orally RB O
at IN O
a DT O
dose NN O
of IN O
600 CD O
mg CD O
or CC O
800 CD O
mg NNS O
participated VBD O
in IN O
the DT O
study NN O
. . O
null null null-Disease
A DT O
hemoglobin NN O
concentration NN O
of IN O
< $ O
10 CD O
g NNS O
/ SYM O
dL NN O
was VBD O
defined VBN O
as IN O
ribavirin NN O
- HYPH O
induced VBN O
anemia NN B-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
Ribavirin NN O
- HYPH O
induced VBN O
anemia NN B-Disease
occurred VBD O
in IN O
18 CD O
( SYM O
20 CD O
. . O
5 CD O
% NN O
) SYM O
patients NNS O
during IN O
treatment NN O
. . O
null null null-Disease
A DT O
2 CD O
g NN O
/ SYM O
dL NN O
decrease NN O
in IN O
hemoglobin NN O
concentrations NNS O
in IN O
patients NNS O
with IN O
anemia NN B-Disease
was VBD O
observed VBN O
at IN O
week NN O
2 CD O
after IN O
the DT O
start NN O
of IN O
treatment NN O
. . O
null null null-Disease
The DT O
hemoglobin NN O
concentration NN O
in IN O
patients NNS O
with IN O
> SYM O
or CC O
= SYM O
2 CD O
g NN O
/ SYM O
dL NN O
decrease NN O
at IN O
week NN O
2 CD O
was VBD O
observed VBN O
to TO O
be VB O
significantly RB O
lower JJR O
even RB O
after IN O
week NN O
2 CD O
than IN O
in IN O
patients NNS O
with IN O
< SYM O
2 CD O
g NN O
/ SYM O
dL NN O
decrease NN O
( : O
P NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
A DT O
significant JJ O
relationship NN O
was VBD O
observed VBN O
between IN O
the DT O
rate NN O
of IN O
reduction NN O
of IN O
hemoglobin NN O
concentrations NNS O
at IN O
week NN O
2 CD O
and CC O
the DT O
severity NN O
of IN O
anemia NN B-Disease
( , O
P NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Such JJ O
factors NNS O
as IN O
sex NN O
( , O
female JJ O
) -RRB- O
, , O
age NN O
( : O
> SYM O
or CC O
= SYM O
60 CD O
years NNS O
old JJ O
) -RRB- O
, , O
and CC O
the DT O
ribavirin NN O
dose NN O
by IN O
body NN O
weight NN O
( : O
12 CD O
mg NN O
/ SYM O
kg NN O
or CC O
more JJR O
) -RRB- O
were VBD O
significant JJ O
by IN O
univariate JJ O
analysis NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Careful JJ O
administration NN O
is VBZ O
necessary JJ O
in IN O
patients NNS O
> : O
or CC O
= SYM O
60 CD O
years NNS O
old JJ O
, , O
in IN O
female JJ O
patients NNS O
, , O
and CC O
in IN O
patients NNS O
receiving VBG O
a DT O
ribavirin NN O
dose NN O
of IN O
12 CD O
mg NNS O
/ SYM O
kg NNS O
or CC O
more JJR O
. . O
null null null-Disease
Patients NNS O
who WP O
experience VBP O
a DT O
fall NN O
in IN O
hemoglobin NN O
concentrations NNS O
of IN O
2 CD O
g NN O
/ SYM O
dL NN O
or CC O
more JJR O
at IN O
week NN O
2 CD O
after IN O
the DT O
start NN O
of IN O
treatment NN O
should MD O
be VB O
monitored VBN O
with IN O
particular JJ O
care NN O
. . O
null null null-Disease
Zidovudine NNP O
- HYPH O
induced VBN O
hepatitis NN B-Disease
. . O
null null null-Disease
A DT O
case NN O
of IN O
acute JJ O
hepatitis NN B-Disease
induced VBN O
by IN O
zidovudine NN O
in IN O
a DT O
38 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
patient NN O
with IN O
AIDS NNP B-Disease
is VBZ O
presented VBN O
. . O
null null null-Disease
The DT O
mechanism NN O
whereby WRB O
the DT O
hepatitis NN B-Disease
was VBD O
induced VBN O
is VBZ O
not RB O
known VBN O
. . O
null null null-Disease
However RB O
, , O
the DT O
patient NN O
tolerated VBD O
well RB O
an DT O
alternative JJ O
reverse JJ O
transcriptase NN O
inhibitor NN O
, , O
2 CD O
' NN O
3 CD O
' '' O
dideoxyinosine NN O
. . O
null null null-Disease
Physicians NNS O
caring VBG O
for IN O
patients NNS O
with IN O
AIDS NNP B-Disease
should MD O
be VB O
aware JJ O
of IN O
this DT O
hitherto RB O
rarely RB O
reported VBN O
complication NN O
. . O
null null null-Disease
Oxidative JJ O
damage NN O
precedes VBZ O
nitrative JJ O
damage NN O
in IN O
adriamycin NN O
- HYPH O
induced VBN O
cardiac JJ O
mitochondrial JJ B-Disease
injury NN I-Disease
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
determine VB O
if IN O
elevated VBN O
reactive JJ O
oxygen NN O
( , O
ROS NNP O
) , O
/ SYM O
nitrogen NN O
species NNS O
( , O
RNS NNP O
) -RRB- O
reported VBN O
to TO O
be VB O
present JJ O
in IN O
adriamycin NN O
( , O
ADR NNP O
) -RRB- O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
actually RB O
resulted VBD O
in IN O
cardiomyocyte NN O
oxidative NN O
/ SYM O
nitrative JJ O
damage NN O
, , O
and CC O
to TO O
quantitatively RB O
determine VB O
the DT O
time NN O
course NN O
and CC O
subcellular JJ O
localization NN O
of IN O
these DT O
postulated VBN O
damage NN O
products NNS O
using VBG O
an DT O
in IN O
vivo NN O
approach NN O
. . O
null null null-Disease
B6C3 NN O
mice NNS O
were VBD O
treated VBN O
with IN O
a DT O
single JJ O
dose NN O
of IN O
20 CD O
mg NN O
/ SYM O
kg NN O
ADR NNP O
. . O
null null null-Disease
Ultrastructural JJ O
damage NN O
and CC O
levels NNS O
of IN O
4 CD O
- HYPH O
hydroxy NN O
- HYPH O
2 CD O
- HYPH O
nonenal JJ O
( HYPH O
4HNE NNP O
) -RRB- O
- HYPH O
protein NN O
adducts NNS O
and CC O
3 CD O
- HYPH O
nitrotyrosine NN O
( -LRB- O
3NT NNP O
) -RRB- O
were VBD O
analyzed VBN O
. . O
null null null-Disease
Quantitative JJ O
ultrastructural JJ O
damage NN O
using VBG O
computerized VBN O
image NN O
techniques NNS O
showed VBD O
cardiomyocyte NN O
injury NN O
as RB O
early RB O
as IN O
3 CD O
hours NNS O
, , O
with IN O
mitochondria NN O
being VBG O
the DT O
most RBS O
extensively RB O
and CC O
progressively RB O
injured VBN O
subcellular JJ O
organelle NN O
. . O
null null null-Disease
Analysis NN O
of IN O
4HNE NNP O
protein NN O
adducts NNS O
by IN O
immunogold NN O
electron NN O
microscopy NN O
showed VBD O
appearance NN O
of IN O
4HNE NNP O
protein NN O
adducts NNS O
in IN O
mitochondria NN O
as RB O
early RB O
as IN O
3 CD O
hours NNS O
, , O
with IN O
a DT O
peak NN O
at IN O
6 CD O
hours NNS O
and CC O
subsequent JJ O
decline NN O
at IN O
24 CD O
hours NNS O
. . O
null null null-Disease
3NT NN O
levels NNS O
were VBD O
significantly RB O
increased VBN O
in IN O
all DT O
subcellular JJ O
compartments NNS O
at IN O
6 CD O
hours NNS O
and CC O
subsequently RB O
declined VBD O
at IN O
24 CD O
hours NNS O
. . O
null null null-Disease
Our PRP$ O
data NNS O
showed VBD O
ADR NNP O
induced VBD O
4HNE NNP O
- HYPH O
protein NN O
adducts NNS O
in IN O
mitochondria NN O
at IN O
the DT O
same JJ O
time NN O
point NN O
as IN O
when WRB O
mitochondrial JJ B-Disease
injury NN I-Disease
initially RB O
appeared VBD O
. . O
null null null-Disease
These DT O
results NNS O
document VBP O
for IN O
the DT O
first JJ O
time NN O
in IN O
vivo NN O
that IN O
mitochondrial JJ B-Disease
oxidative JJ I-Disease
damage NN I-Disease
precedes VBZ O
nitrative JJ O
damage NN O
. . O
null null null-Disease
The DT O
progressive JJ O
nature NN O
of IN O
mitochondrial JJ B-Disease
injury NN I-Disease
suggests VBZ O
that IN O
mitochondria NN O
, , O
not RB O
other JJ O
subcellular JJ O
organelles NNS O
, , O
are VBP O
the DT O
major JJ O
site NN O
of IN O
intracellular JJ O
injury NN O
. . O
null null null-Disease
Sotalol NNP O
- HYPH O
induced VBN O
coronary JJ B-Disease
spasm NN I-Disease
in IN O
a DT O
patient NN O
with IN O
dilated VBN B-Disease
cardiomyopathy NN I-Disease
associated VBN O
with IN O
sustained JJ O
ventricular JJ B-Disease
tachycardia NN I-Disease
. . O
null null null-Disease
A DT O
54 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
with IN O
severe JJ O
left JJ O
ventricular JJ B-Disease
dysfunction NN I-Disease
due JJ O
to IN O
dilated VBN B-Disease
cardiomyopathy NN I-Disease
was VBD O
referred VBN O
to IN O
our PRP$ O
hospital NN O
for IN O
symptomatic JJ O
incessant JJ O
sustained VBN O
ventricular JJ B-Disease
tachycardia NN I-Disease
( , O
VT NNP B-Disease
) -RRB- O
. . O
null null null-Disease
After IN O
the DT O
administration NN O
of IN O
nifekalant NN O
hydrochloride NN O
, , O
sustained VBN O
VT NNP B-Disease
was VBD O
terminated VBN O
. . O
null null null-Disease
An DT O
alternate JJ O
class NN O
III NNP O
agent NN O
, , O
sotalol NN O
, , O
was VBD O
also RB O
effective JJ O
for IN O
the DT O
prevention NN O
of IN O
VT NNP B-Disease
. . O
null null null-Disease
However RB O
, , O
one CD O
month NN O
after IN O
switching VBG O
over IN O
nifekalant NN O
to IN O
sotalol NN O
, , O
a DT O
short JJ O
duration NN O
of IN O
ST NNP O
elevation NN O
was VBD O
documented VBN O
in IN O
ECG NNP O
monitoring NN O
at IN O
almost RB O
the DT O
same JJ O
time NN O
for IN O
three CD O
consecutive JJ O
days NNS O
. . O
null null null-Disease
ST NNP O
elevation NN O
with IN O
chest NN O
discomfort NN O
disappeared VBD O
since IN O
he PRP O
began VBD O
taking VBG O
long RB O
- HYPH O
acting VBG O
diltiazem NN O
. . O
null null null-Disease
Coronary JJ B-Disease
vasospasm NN I-Disease
may MD O
be VB O
induced VBN O
by IN O
the DT O
non AFX O
- HYPH O
selective JJ O
beta NN O
- HYPH O
blocking VBG O
properties NNS O
of IN O
sotalol NN O
. . O
null null null-Disease
Effects NNS O
of IN O
the DT O
antidepressant JJ O
trazodone NN O
, , O
a DT O
5 CD O
- HYPH O
HT NN O
2A NN O
/ SYM O
2C NN O
receptor NN O
antagonist NN O
, , O
on IN O
dopamine NN O
- HYPH O
dependent JJ O
behaviors NNS O
in IN O
rats NNS O
. . O
null null null-Disease
RATIONALE NN O
: : O
5 CD O
- HYPH O
Hydroxytryptamine NN O
, , O
via IN O
stimulation NN O
of IN O
5 CD O
- HYPH O
HT NN O
2C NN O
receptors NNS O
, , O
exerts VBZ O
a DT O
tonic JJ O
inhibitory NN O
influence NN O
on IN O
dopaminergic JJ O
neurotransmission NN O
, , O
whereas IN O
activation NN O
of IN O
5 CD O
- HYPH O
HT NNP O
2A NN O
receptors NNS O
enhances VBZ O
stimulated VBN O
DAergic JJ O
neurotransmission NN O
. . O
null null null-Disease
The DT O
antidepressant JJ O
trazodone NN O
is VBZ O
a DT O
5 CD O
- HYPH O
HT NN O
2A NN O
/ SYM O
2C NN O
receptor NN O
antagonist NN O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
To TO O
evaluate VB O
the DT O
effect NN O
of IN O
trazodone NN O
treatment NN O
on IN O
behaviors NNS O
dependent JJ O
on IN O
the DT O
functional JJ O
status NN O
of IN O
the DT O
nigrostriatal JJ O
DAergic NNP O
system NN O
. . O
null null null-Disease
METHODS NNS O
: : O
The DT O
effect NN O
of IN O
pretreatment NN O
with IN O
trazodone NN O
on IN O
dexamphetamine NN O
- : O
and CC O
apomorphine NN O
- HYPH O
induced VBN O
oral JJ B-Disease
stereotypies NNS I-Disease
, , O
on IN O
catalepsy NN B-Disease
induced VBN O
by IN O
haloperidol NN O
and CC O
apomorphine NN O
( , O
0 CD O
. . O
05 CD O
mg NN O
/ SYM O
kg NN O
, , O
i CD O
. . O
p NN O
. . O
) -RRB- O
, , O
on IN O
ergometrine NN O
- HYPH O
induced VBN O
wet JJ O
dog NN O
shake NN O
( , O
WDS NN O
) , O
behavior NN O
and CC O
fluoxetine NN O
- HYPH O
induced VBN O
penile NN O
erections NNS O
was VBD O
studied VBN O
in IN O
rats NNS O
. . O
null null null-Disease
We PRP O
also RB O
investigated VBD O
whether IN O
trazodone NN O
induces VBZ O
catalepsy NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Trazodone NN O
at IN O
2 CD O
. . O
5 CD O
- SYM O
20 CD O
mg NN O
/ SYM O
kg NN O
i CD O
. . O
p NN O
. . O
did VBD O
not RB O
induce VB O
catalepsy NN B-Disease
, , O
and CC O
did VBD O
not RB O
antagonize VB O
apomorphine NN O
( : O
1 CD O
. . O
5 CD O
and CC O
3 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
stereotypy NN O
and CC O
apomorphine NN O
( : O
0 CD O
. . O
05 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
- HYPH O
induced VBN O
catalepsy NN B-Disease
. . O
null null null-Disease
However RB O
, , O
pretreatment NN O
with IN O
5 CD O
, , O
10 CD O
and CC O
20 CD O
mg NNS O
/ SYM O
kg NN O
i PRP O
. . O
p NN O
. . O
trazodone NN O
enhanced VBN O
dexamphetamine NN O
stereotypy NN O
, , O
and CC O
antagonized VBN O
haloperidol NN O
catalepsy NN B-Disease
, , O
ergometrine NN O
- HYPH O
induced VBN O
WDS NNP O
behavior NN O
and CC O
fluoxetine NN O
- HYPH O
induced VBN O
penile JJ O
erections NNS O
. . O
null null null-Disease
Trazodone NNP O
at IN O
30 CD O
, , O
40 CD O
and CC O
50 CD O
mg NNS O
/ SYM O
kg NN O
i NN O
. . O
p NN O
. . O
induced VBN O
catalepsy NN B-Disease
and CC O
antagonized VBN O
apomorphine NN O
and CC O
dexamphetamine NN O
stereotypies NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Our PRP$ O
results NNS O
indicate VBP O
that IN O
trazodone NN O
at IN O
2 CD O
. . O
5 CD O
- SYM O
20 CD O
mg NN O
/ SYM O
kg NN O
does VBZ O
not RB O
block VB O
pre NN O
- HYPH O
and CC O
postsynaptic JJ O
striatal JJ O
D2 NN O
DA NN O
receptors NNS O
, , O
while IN O
at IN O
30 CD O
, , O
40 CD O
and CC O
50 CD O
mg NNS O
/ SYM O
kg NN O
it PRP O
blocks VBZ O
postsynaptic JJ O
striatal JJ O
D2 NNP O
DA NN O
receptors NNS O
. . O
null null null-Disease
Furthermore RB O
, , O
at IN O
5 CD O
, , O
10 CD O
and CC O
20 CD O
mg NNS O
/ SYM O
kg NN O
, , O
trazodone NN O
blocks NNS O
5 CD O
- HYPH O
HT NN O
2A NN O
and CC O
5 CD O
- HYPH O
HT NN O
2C NN O
receptors NNS O
. . O
null null null-Disease
We PRP O
suggest VBP O
that IN O
trazodone NN O
( , O
5 CD O
, , O
10 CD O
and CC O
20 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
, , O
by IN O
blocking VBG O
the DT O
5 CD O
- HYPH O
HT NN O
2C NN O
receptors NNS O
, , O
releases VBZ O
the DT O
nigrostriatal JJ O
DAergic JJ O
neurons NNS O
from IN O
tonic NN O
inhibition NN O
caused VBN O
by IN O
5 CD O
- HYPH O
HT NN O
, , O
and CC O
thereby RB O
potentiates VBZ O
dexamphetamine NN O
stereotypy NN O
and CC O
antagonizes VBZ O
haloperidol NN O
catalepsy NN B-Disease
. . O
null null null-Disease
Swallowing VBG B-Disease
abnormalities NNS I-Disease
and CC O
dyskinesia NN B-Disease
in IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
. . O
null null null-Disease
Gastrointestinal JJ B-Disease
abnormalities NNS I-Disease
in IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
( -LRB- O
PD NNP B-Disease
) -RRB- O
have VBP O
been VBN O
known VBN O
for IN O
almost RB O
two CD O
centuries NNS O
, , O
but CC O
many JJ O
aspects NNS O
concerning VBG O
their PRP$ O
pathophysiology NN O
have VBP O
not RB O
been VBN O
completely RB O
clarified VBN O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
characterize VB O
the DT O
oropharyngeal JJ O
dynamics NNS O
in IN O
PD NN B-Disease
patients NNS O
with IN O
and CC O
without IN O
levodopa NN O
- HYPH O
induced VBN O
dyskinesia NN B-Disease
. . O
null null null-Disease
Fifteen CD O
dyskinetic JJ B-Disease
, , O
12 CD O
nondyskinetic JJ O
patients NNS O
, , O
and CC O
a DT O
control NN O
group NN O
were VBD O
included VBN O
. . O
null null null-Disease
Patients NNS O
were VBD O
asked VBN O
about IN O
dysphagia NN B-Disease
and CC O
evaluated VBN O
with IN O
the DT O
Unified NNP O
Parkinson NNP B-Disease
' POS I-Disease
s NNP I-Disease
Disease NNP I-Disease
Rating NNP O
Scale NNP O
Parts NNP O
II NNP O
and CC O
III NNP O
and CC O
the DT O
Hoehn NNP O
and CC O
Yahr NNP O
scale NN O
. . O
null null null-Disease
Deglutition NN O
was VBD O
assessed VBN O
using VBG O
modified VBN O
barium NN O
swallow NN O
with IN O
videofluoroscopy NN O
. . O
null null null-Disease
Nondyskinetic JJ O
patients NNS O
, , O
but CC O
not RB O
the DT O
dyskinetic JJ B-Disease
ones NNS O
, , O
showed VBD O
less JJR O
oropharyngeal JJ O
swallowing NN O
efficiency NN O
( , O
OPSE NNP O
) -RRB- O
for IN O
liquid JJ O
food NN O
than IN O
controls NNS O
( : O
Dunnett NNP O
, , O
P NN O
= SYM O
0 CD O
. . O
02 CD O
) -RRB- O
. . O
null null null-Disease
Dyskinetic JJ B-Disease
patients NNS O
tended VBD O
to TO O
have VB O
a DT O
greater JJR O
OPSE NN O
than IN O
nondyskinetic JJ O
( , O
Dunnett NNP O
, , O
P NN O
= SYM O
0 CD O
. . O
06 CD O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
who WP O
were VBD O
using VBG O
a DT O
higher JJR O
dose NN O
of IN O
levodopa NN O
had VBD O
a DT O
greater JJR O
OPSE NN O
and CC O
a DT O
trend NN O
toward IN O
a DT O
smaller JJR O
oral JJ O
transit NN O
time NN O
( : O
Pearson NNP O
' POS O
s POS O
correlation NN O
, , O
P NN O
= SYM O
0 CD O
. . O
01 CD O
and CC O
0 CD O
. . O
08 CD O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
Neither CC O
the DT O
report NN O
of IN O
dysphagia NN B-Disease
nor CC O
any DT O
of IN O
the DT O
PD NN B-Disease
severity NN O
parameters NNS O
correlated VBD O
to IN O
the DT O
videofluoroscopic JJ O
variables NNS O
. . O
null null null-Disease
In IN O
the DT O
current JJ O
study NN O
, , O
dyskinetic JJ B-Disease
patients NNS O
performed VBD O
better RBR O
in IN O
swallowing NN O
function NN O
, , O
which WDT O
could MD O
be VB O
explained VBN O
on IN O
the DT O
basis NN O
of IN O
a DT O
greater JJR O
levodopa NN O
dose NN O
. . O
null null null-Disease
Our PRP$ O
results NNS O
suggest VBP O
a DT O
role NN O
for IN O
levodopa NN O
in IN O
the DT O
oral JJ O
phase NN O
of IN O
deglutition NN O
and CC O
confirm VB O
that IN O
dysphagia NN B-Disease
is VBZ O
not RB O
a DT O
good JJ O
predictor NN O
of IN O
deglutition NN O
alterations NNS O
in IN O
PD NN B-Disease
. . O
null null null-Disease
Inhibition NN O
of IN O
nuclear JJ O
factor NN O
- HYPH O
kappaB NN O
activation NN O
attenuates VBZ O
tubulointerstitial JJ B-Disease
nephritis NN I-Disease
induced VBN O
by IN O
gentamicin NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Animals NNS O
treated VBN O
with IN O
gentamicin NN O
can MD O
show VB O
residual JJ O
areas NNS O
of IN O
interstitial JJ O
fibrosis NN B-Disease
in IN O
the DT O
renal JJ O
cortex NN O
. . O
null null null-Disease
This DT O
study NN O
investigated VBD O
the DT O
expression NN O
of IN O
nuclear JJ O
factor NN O
- HYPH O
kappaB NN O
( , O
NF NNP O
- HYPH O
kappaB NNP O
) -RRB- O
, , O
mitogen NN O
- HYPH O
activated VBN O
protein NN O
( , O
MAP NNP O
) -RRB- O
kinases NNS O
and CC O
macrophages NNS O
in IN O
the DT O
renal JJ O
cortex NN O
and CC O
structural JJ O
and CC O
functional JJ O
renal JJ O
changes NNS O
of IN O
rats NNS O
treated VBN O
with IN O
gentamicin NN O
or CC O
gentamicin NN O
+ CC O
pyrrolidine NN O
dithiocarbamate NN O
( , O
PDTC NNP O
) -RRB- O
, , O
an DT O
NF NNP O
- HYPH O
kappaB NN O
inhibitor NN O
. . O
null null null-Disease
METHODS NNS O
: : O
38 CD O
female JJ O
Wistar NNP O
rats NNS O
were VBD O
injected VBN O
with IN O
gentamicin NN O
, , O
40 CD O
mg NNS O
/ SYM O
kg NN O
, , O
twice PDT O
a DT O
day NN O
for IN O
9 CD O
days NNS O
, , O
38 CD O
with IN O
gentamicin NN O
+ CC O
PDTC NNP O
, , O
and CC O
28 CD O
with IN O
0 CD O
. . O
15 CD O
M NN O
NaCl NNP O
solution NN O
. . O
null null null-Disease
The DT O
animals NNS O
were VBD O
killed VBN O
5 CD O
and CC O
30 CD O
days NNS O
after IN O
these DT O
injections NNS O
and CC O
the DT O
kidneys NNS O
were VBD O
removed VBN O
for IN O
histological JJ O
and CC O
immunohistochemical JJ O
studies NNS O
. . O
null null null-Disease
The DT O
results NNS O
of IN O
the DT O
immunohistochemical JJ O
studies NNS O
were VBD O
scored VBN O
according VBG O
to IN O
the DT O
extent NN O
of IN O
staining NN O
. . O
null null null-Disease
The DT O
fractional JJ O
interstitial JJ O
area NN O
was VBD O
determined VBN O
by IN O
morphometry NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Gentamicin NN O
- HYPH O
treated VBN O
rats NNS O
presented VBD O
a DT O
transitory JJ O
increase NN O
in IN O
plasma NN O
creatinine NN O
levels NNS O
. . O
null null null-Disease
Increased JJ O
ED NN O
- HYPH O
1 CD O
, , O
MAP NNP O
kinases NNS O
and CC O
NF NNP O
- HYPH O
kappaB NN O
staining NN O
were VBD O
also RB O
observed VBN O
in IN O
the DT O
renal JJ O
cortex NN O
from IN O
all DT O
gentamicin NN O
- HYPH O
treated VBN O
rats NNS O
compared VBN O
to IN O
control NN O
( : O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
animals NNS O
killed VBN O
on IN O
day NN O
30 CD O
also RB O
presented VBD O
fibrosis NN B-Disease
in IN O
the DT O
renal JJ O
cortex NN O
despite IN O
the DT O
recovery NN O
of IN O
renal JJ O
function NN O
. . O
null null null-Disease
Treatment NN O
with IN O
PDTC NNP O
reduced VBD O
the DT O
functional JJ O
and CC O
structural JJ O
changes NNS O
induced VBN O
by IN O
gentamicin NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
These DT O
data NNS O
show VBP O
that IN O
inhibition NN O
of IN O
NF NNP O
- HYPH O
kappaB NN O
activation NN O
attenuates VBZ O
tubulointerstitial JJ B-Disease
nephritis NN I-Disease
induced VBN O
by IN O
gentamicin NN O
. . O
null null null-Disease
Glucose NN O
metabolism NN O
in IN O
patients NNS O
with IN O
schizophrenia NN B-Disease
treated VBN O
with IN O
atypical JJ O
antipsychotic JJ O
agents NNS O
: : O
a DT O
frequently RB O
sampled VBN O
intravenous JJ O
glucose NN O
tolerance NN O
test NN O
and CC O
minimal JJ O
model NN O
analysis NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
While IN O
the DT O
incidence NN O
of IN O
new JJ O
- HYPH O
onset NN O
diabetes NN B-Disease
mellitus NN I-Disease
may MD O
be VB O
increasing VBG O
in IN O
patients NNS O
with IN O
schizophrenia NN B-Disease
treated VBN O
with IN O
certain JJ O
atypical JJ O
antipsychotic JJ O
agents NNS O
, , O
it PRP O
remains VBZ O
unclear JJ O
whether IN O
atypical JJ O
agents NNS O
are VBP O
directly RB O
affecting VBG O
glucose NN O
metabolism NN O
or CC O
simply RB O
increasing VBG O
known VBN O
risk NN O
factors NNS O
for IN O
diabetes NNS B-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
study VB O
the DT O
2 CD O
drugs NNS O
most RBS O
clearly RB O
implicated VBN O
( , O
clozapine NN O
and CC O
olanzapine NN O
) -RRB- O
and CC O
risperidone NN O
using VBG O
a DT O
frequently RB O
sampled VBN O
intravenous JJ O
glucose NN O
tolerance NN O
test NN O
. . O
null null null-Disease
DESIGN NN O
: : O
A DT O
cross JJ O
- HYPH O
sectional JJ O
design NN O
in IN O
stable JJ O
, , O
treated VBN O
patients NNS O
with IN O
schizophrenia NN B-Disease
evaluated VBN O
using VBG O
a DT O
frequently RB O
sampled VBN O
intravenous JJ O
glucose NN O
tolerance NN O
test NN O
and CC O
the DT O
Bergman NNP O
minimal JJ O
model NN O
analysis NN O
. . O
null null null-Disease
SETTING NN O
: : O
Subjects NNS O
were VBD O
recruited VBN O
from IN O
an DT O
urban JJ O
community NN O
mental JJ O
health NN O
clinic NN O
and CC O
were VBD O
studied VBN O
at IN O
a DT O
general JJ O
clinical JJ O
research NN O
center NN O
. . O
null null null-Disease
Patients NNS O
Fifty CD O
subjects NNS O
signed VBD O
informed JJ O
consent NN O
and CC O
41 CD O
underwent VBD O
the DT O
frequently RB O
sampled VBN O
intravenous JJ O
glucose NN O
tolerance NN O
test NN O
. . O
null null null-Disease
Thirty CD O
- HYPH O
six CD O
nonobese JJ O
subjects NNS O
with IN O
schizophrenia NN B-Disease
or CC O
schizoaffective JJ B-Disease
disorder NN I-Disease
, , O
matched VBN O
by IN O
body NN O
mass NN O
index NN O
and CC O
treated VBN O
with IN O
either CC O
clozapine NN O
, , O
olanzapine NN O
, , O
or CC O
risperidone NN O
, , O
were VBD O
included VBN O
in IN O
the DT O
analysis NN O
. . O
null null null-Disease
MAIN JJ O
OUTCOME NN O
MEASURES NNS O
: : O
Fasting VBG O
plasma NN O
glucose NN O
and CC O
fasting VBG O
serum NN O
insulin NN O
levels NNS O
, , O
insulin NN B-Disease
sensitivity NN I-Disease
index NN O
, , O
homeostasis NN O
model NN O
assessment NN O
of IN O
insulin NN B-Disease
resistance NN I-Disease
, , O
and CC O
glucose NN O
effectiveness NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
mean JJ O
+ CC O
/ SYM O
- HYPH O
SD NN O
duration NN O
of IN O
treatment NN O
with IN O
the DT O
identified VBN O
atypical JJ O
antipsychotic JJ O
agent NN O
was VBD O
68 CD O
. . O
3 CD O
+ CD O
/ SYM O
- SYM O
28 CD O
. . O
9 CD O
months NNS O
( : O
clozapine NN O
) -RRB- O
, , O
29 CD O
. . O
5 CD O
+ SYM O
/ SYM O
- HYPH O
17 CD O
. . O
5 CD O
months NNS O
( : O
olanzapine NN O
) -RRB- O
, , O
and CC O
40 CD O
. . O
9 CD O
+ SYM O
/ SYM O
- HYPH O
33 CD O
. . O
7 CD O
( : O
risperidone NN O
) -RRB- O
. . O
null null null-Disease
Fasting VBG O
serum NN O
insulin NN O
concentrations NNS O
differed VBD O
among IN O
groups NNS O
( , O
F NNP O
( , O
33 CD O
) SYM O
= SYM O
3 CD O
. . O
35 CD O
; : O
P NN O
= : O
. . O
047 CD O
) -RRB- O
( : O
clozapine NN O
> : O
olanzapine NN O
> SYM O
risperidone NN O
) -RRB- O
with IN O
significant JJ O
differences NNS O
between IN O
clozapine NN O
and CC O
risperidone NN O
( : O
t NN O
( SYM O
33 CD O
) NN O
= SYM O
2 CD O
. . O
32 CD O
; : O
P NN O
= SYM O
. . O
03 CD O
) -RRB- O
and CC O
olanzapine NN O
and CC O
risperidone NN O
( : O
t NN O
( SYM O
33 CD O
) CD O
= SYM O
2 CD O
. . O
15 CD O
; : O
P NN O
= : O
. . O
04 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
significant JJ O
difference NN O
in IN O
insulin NN B-Disease
sensitivity NN I-Disease
index NN O
among IN O
groups NNS O
( , O
F NNP O
( , O
33 CD O
) SYM O
= SYM O
10 CD O
. . O
66 CD O
; : O
P NN O
< NN O
. . O
001 CD O
) -RRB- O
( , O
clozapine NN O
< -LRB- O
olanzapine NN O
< -LRB- O
risperidone NN O
) -RRB- O
, , O
with IN O
subjects NNS O
who WP O
received VBD O
clozapine NN O
and CC O
olanzapine NN O
exhibiting VBG O
significant JJ O
insulin NN B-Disease
resistance NN I-Disease
compared VBN O
with IN O
subjects NNS O
who WP O
were VBD O
treated VBN O
with IN O
risperidone NN O
( , O
clozapine NN O
vs IN O
risperidone NN O
, , O
t CD O
( SYM O
33 CD O
) SYM O
= SYM O
- HYPH O
4 CD O
. . O
29 CD O
; : O
P NN O
< NN O
. . O
001 CD O
; : O
olanzapine NN O
vs IN O
risperidone NN O
, , O
t CD O
( HYPH O
33 CD O
) NFP O
= SYM O
- HYPH O
3 CD O
. . O
62 CD O
; : O
P NN O
= SYM O
. . O
001 CD O
[ -LRB- O
P NN O
< NN O
. . O
001 CD O
] -RRB- O
) -RRB- O
. . O
null null null-Disease
The DT O
homeostasis NN O
model NN O
assessment NN O
of IN O
insulin NN B-Disease
resistance NN I-Disease
also RB O
differed VBD O
significantly RB O
among IN O
groups NNS O
( , O
F NNP O
( , O
33 CD O
) SYM O
= SYM O
4 CD O
. . O
92 CD O
; : O
P NN O
= : O
. . O
01 CD O
) -RRB- O
( , O
clozapine NN O
> : O
olanzapine NN O
> SYM O
risperidone NN O
) -RRB- O
( , O
clozapine NN O
vs IN O
risperidone NN O
, , O
t CD O
( SYM O
33 CD O
) SYM O
= SYM O
2 CD O
. . O
94 CD O
; : O
P NN O
= : O
. . O
006 CD O
; : O
olanzapine NN O
vs IN O
risperidone NN O
, , O
t CD O
( SYM O
33 CD O
) NFP O
= SYM O
2 CD O
. . O
42 CD O
; : O
P NN O
= : O
. . O
02 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
significant JJ O
difference NN O
among IN O
groups NNS O
in IN O
glucose NN O
effectiveness NN O
( , O
F NN O
( : O
30 CD O
) SYM O
= SYM O
4 CD O
. . O
18 CD O
; : O
P NN O
= : O
. . O
02 CD O
) -RRB- O
( , O
clozapine NN O
< NN O
olanzapine NN O
< NN O
risperidone NN O
) -RRB- O
with IN O
significant JJ O
differences NNS O
between IN O
clozapine NN O
and CC O
risperidone NN O
( : O
t NN O
( SYM O
30 CD O
) NFP O
= SYM O
- HYPH O
2 CD O
. . O
59 CD O
; : O
P NN O
= SYM O
. . O
02 CD O
) -RRB- O
and CC O
olanzapine NN O
and CC O
risperidone NN O
( : O
t NN O
( SYM O
30 CD O
) NFP O
= SYM O
- HYPH O
2 CD O
. . O
34 CD O
, , O
P NN O
= SYM O
. . O
03 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Both CC O
nonobese JJ O
clozapine NN O
- HYPH O
and CC O
olanzapine NN O
- HYPH O
treated VBN O
groups NNS O
displayed VBD O
significant JJ O
insulin NN B-Disease
resistance NN I-Disease
and CC O
impairment NN O
of IN O
glucose NN O
effectiveness NN O
compared VBN O
with IN O
risperidone NN O
- HYPH O
treated VBN O
subjects NNS O
. . O
null null null-Disease
Patients NNS O
taking VBG O
clozapine NN O
and CC O
olanzapine NN O
must MD O
be VB O
examined VBN O
for IN O
insulin NN B-Disease
resistance NN I-Disease
and CC O
its PRP$ O
consequences NNS O
. . O
null null null-Disease
Thoracic JJ B-Disease
hematomyelia NN I-Disease
secondary JJ O
to IN O
coumadin JJ O
anticoagulant JJ O
therapy NN O
: : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
thoracic JJ B-Disease
hematomyelia NN I-Disease
secondary JJ O
to IN O
anticoagulant JJ O
therapy NN O
is VBZ O
presented VBN O
. . O
null null null-Disease
Clinical JJ O
features NNS O
, , O
similar JJ O
to IN O
2 CD O
other JJ O
previously RB O
reported VBN O
cases NNS O
, , O
are VBP O
discussed VBN O
. . O
null null null-Disease
A DT O
high JJ O
index NN O
of IN O
suspicion NN O
may MD O
lead VB O
to IN O
a DT O
quick JJ O
diagnostic JJ O
procedure NN O
and CC O
successful JJ O
decompressive JJ O
surgery NN O
. . O
null null null-Disease
Mania NNP B-Disease
associated VBN O
with IN O
fluoxetine NN O
treatment NN O
in IN O
adolescents NNS O
. . O
null null null-Disease
Fluoxetine NNP O
, , O
a DT O
selective JJ O
serotonin NN O
reuptake NN O
inhibitor NN O
, , O
is VBZ O
gaining VBG O
increased VBN O
acceptance NN O
in IN O
the DT O
treatment NN O
of IN O
adolescent JJ O
depression NN B-Disease
. . O
null null null-Disease
Generally RB O
safe JJ O
and CC O
well RB O
tolerated VBN O
by IN O
adults NNS O
, , O
fluoxetine NN O
has VBZ O
been VBN O
reported VBN O
to TO O
induce VB O
mania NN B-Disease
. . O
null null null-Disease
The DT O
cases NNS O
of IN O
five CD O
depressed VBN B-Disease
adolescents NNS O
, , O
14 CD O
- SYM O
16 CD O
years NNS O
of IN O
age NN O
, , O
who WP O
developed VBD O
mania NN B-Disease
during IN O
pharmacotherapy NN O
with IN O
fluoxetine NN O
, , O
are VBP O
reported VBN O
here RB O
. . O
null null null-Disease
Apparent JJ O
risk NN O
factors NNS O
for IN O
the DT O
development NN O
of IN O
mania NN B-Disease
or CC O
hypomania NN B-Disease
during IN O
fluoxetine NN O
pharmacotherapy NN O
in IN O
this DT O
population NN O
were VBD O
the DT O
combination NN O
of IN O
attention NN B-Disease
- HYPH I-Disease
deficit NN I-Disease
hyperactivity NN I-Disease
disorder NN I-Disease
and CC O
affective JJ O
instability NN O
; , O
major JJ O
depression NN B-Disease
with IN O
psychotic JJ B-Disease
features NNS O
; : O
a DT O
family NN O
history NN O
of IN O
affective JJ B-Disease
disorder NN I-Disease
, , O
especially RB O
bipolar JJ B-Disease
disorder NN I-Disease
; : O
and CC O
a DT O
diagnosis NN O
of IN O
bipolar JJ B-Disease
disorder NN I-Disease
. . O
null null null-Disease
Further JJ O
study NN O
is VBZ O
needed VBN O
to TO O
determine VB O
the DT O
optimal JJ O
dosage NN O
and CC O
to TO O
identify VB O
risk NN O
factors NNS O
that WDT O
increase VBP O
individual JJ O
vulnerability NN O
to IN O
fluoxetine NN O
induced VBN O
mania NN B-Disease
in IN O
adolescents NNS O
. . O
null null null-Disease
Acute JJ B-Disease
renal JJ I-Disease
insufficiency NN I-Disease
after IN O
high JJ O
- HYPH O
dose NN O
melphalan NN O
in IN O
patients NNS O
with IN O
primary JJ B-Disease
systemic JJ I-Disease
amyloidosis NN I-Disease
during IN O
stem NN O
cell NN O
transplantation NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Patients NNS O
with IN O
primary JJ B-Disease
systemic JJ I-Disease
amyloidosis NN I-Disease
( -LRB- O
AL NNP B-Disease
) -RRB- O
have VBP O
a DT O
poor JJ O
prognosis NN O
. . O
null null null-Disease
Median JJ O
survival NN O
time NN O
from IN O
standard JJ O
treatments NNS O
is VBZ O
only RB O
17 CD O
months NNS O
. . O
null null null-Disease
High JJ O
- HYPH O
dose NN O
intravenous JJ O
melphalan NN O
followed VBN O
by IN O
peripheral JJ O
blood NN O
stem NN O
cell NN O
transplant NN O
( -LRB- O
PBSCT NNP O
) -RRB- O
appears VBZ O
to TO O
be VB O
the DT O
most RBS O
promising JJ O
therapy NN O
, , O
but CC O
treatment NN O
mortality NN O
can MD O
be VB O
high JJ O
. . O
null null null-Disease
The DT O
authors NNS O
have VBP O
noted VBN O
the DT O
development NN O
of IN O
acute JJ B-Disease
renal JJ I-Disease
insufficiency NN I-Disease
immediately RB O
after IN O
melphalan NN O
conditioning NN O
. . O
null null null-Disease
This DT O
study NN O
was VBD O
undertaken VBN O
to TO O
further RB O
examine VB O
its PRP$ O
risk NN O
factors NNS O
and CC O
impact NN O
on IN O
posttransplant NN O
mortality NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Consecutive JJ O
AL NNP B-Disease
patients NNS O
who WP O
underwent VBD O
PBSCT NNP O
were VBD O
studied VBN O
retrospectively RB O
. . O
null null null-Disease
Acute JJ B-Disease
renal JJ I-Disease
insufficiency NN I-Disease
( -LRB- O
ARI NN B-Disease
) -RRB- O
after IN O
high JJ O
- HYPH O
dose NN O
melphalan NN O
was VBD O
defined VBN O
by IN O
a DT O
minimum JJ O
increase NN O
of IN O
0 CD O
. . O
5 CD O
mg NN O
/ SYM O
dL NN O
( SYM O
44 CD O
micromol NN O
/ SYM O
L NN O
) -RRB- O
in IN O
the DT O
serum NN O
creatinine NN O
level NN O
that WDT O
is VBZ O
greater JJR O
than IN O
50 CD O
% NN O
of IN O
baseline NN O
immediately RB O
after IN O
conditioning NN O
. . O
null null null-Disease
Urine NN O
sediment NN O
score NN O
was VBD O
the DT O
sum NN O
of IN O
the DT O
individual JJ O
types NNS O
of IN O
sediment NN O
identified VBN O
on IN O
urine NN O
microscopy NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Of IN O
the DT O
80 CD O
patients NNS O
studied VBN O
, , O
ARI NNP B-Disease
developed VBD O
in IN O
18 CD O
. . O
8 CD O
% NN O
of IN O
the DT O
patients NNS O
after IN O
high JJ O
- HYPH O
dose NN O
melphalan NN O
. . O
null null null-Disease
Univariate NN O
analysis NN O
identified VBD O
age NN O
, , O
hypoalbuminemia NN B-Disease
, , O
heavy JJ O
proteinuria NN B-Disease
, , O
diuretic JJ O
use NN O
, , O
and CC O
urine NN O
sediment NN O
score NN O
( , O
> SYM O
3 CD O
) -RRB- O
as IN O
risk NN O
factors NNS O
. . O
null null null-Disease
Age NN O
and CC O
urine NN O
sediment NN O
score NN O
remained VBD O
independently RB O
significant JJ O
risk NN O
factors NNS O
in IN O
the DT O
multivariate NN O
analysis NN O
. . O
null null null-Disease
Patients NNS O
who WP O
had VBD O
ARI NN B-Disease
after IN O
high JJ O
- HYPH O
dose NN O
melphalan NN O
underwent VBD O
dialysis NN O
more RBR O
often RB O
( : O
P NN O
= SYM O
0 CD O
. . O
007 CD O
) -RRB- O
, , O
and CC O
had VBD O
a DT O
worse JJR O
1 CD O
- HYPH O
year NN O
survival NN O
( : O
P NN O
= SYM O
0 CD O
. . O
03 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
timing NN O
of IN O
renal JJ B-Disease
injury NN I-Disease
strongly RB O
suggests VBZ O
melphalan NN O
as IN O
the DT O
causative JJ O
agent NN O
. . O
null null null-Disease
Ongoing JJ O
tubular JJ B-Disease
injury NN I-Disease
may MD O
be VB O
a DT O
prerequisite NN O
for IN O
renal JJ B-Disease
injury NN I-Disease
by IN O
melphalan NN O
as IN O
evidenced VBN O
by IN O
the DT O
active JJ O
urinary JJ O
sediment NN O
. . O
null null null-Disease
Development NN O
of IN O
ARI NNP B-Disease
adversely RB O
affected VBD O
the DT O
outcome NN O
after IN O
PBSCT NNP O
. . O
null null null-Disease
Effective JJ O
preventive JJ O
measures NNS O
may MD O
help VB O
decrease VB O
the DT O
treatment NN O
mortality NN O
of IN O
PBSCT NNP O
in IN O
AL NNP B-Disease
patients NNS O
. . O
null null null-Disease
Focal JJ O
cerebral JJ B-Disease
ischemia NN I-Disease
in IN O
rats NNS O
: : O
effect NN O
of IN O
phenylephrine NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
during IN O
reperfusion NN O
. . O
null null null-Disease
After IN O
180 CD O
min NN O
of IN O
temporary JJ O
middle JJ B-Disease
cerebral JJ I-Disease
artery NN I-Disease
occlusion NN I-Disease
in IN O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
, , O
the DT O
effect NN O
of IN O
phenylephrine NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
on IN O
ischemic JJ B-Disease
brain NN I-Disease
injury NN I-Disease
and CC O
blood NN O
- HYPH O
brain NN O
barrier NN O
permeability NN O
was VBD O
determined VBN O
. . O
null null null-Disease
Blood NN O
pressure NN O
was VBD O
manipulated VBN O
by IN O
one CD O
of IN O
the DT O
following VBG O
schedules NNS O
during IN O
120 CD O
min NN O
of IN O
reperfusion NN O
: : O
Control NN O
, , O
normotensive JJ O
reperfusion NN O
; : O
90 CD O
/ SYM O
hypertension NN B-Disease
( : O
90 CD O
/ SYM O
HTN NNP B-Disease
) -RRB- O
, , O
blood NN O
pressure NN O
was VBD O
increased VBN O
by IN O
35 CD O
mm NN O
Hg NNS O
during IN O
the DT O
initial JJ O
90 CD O
min NN O
of IN O
reperfusion NN O
only RB O
; : O
15 CD O
/ SYM O
hypertension NN B-Disease
( SYM O
15 CD O
/ SYM O
HTN NN B-Disease
) -RRB- O
, , O
normotensive JJ O
reperfusion NN O
for IN O
30 CD O
min NN O
followed VBN O
by IN O
15 CD O
min NN O
of IN O
hypertension NN B-Disease
and CC O
75 CD O
min NN O
of IN O
normotension NN O
. . O
null null null-Disease
Part NNP O
A NNP O
, , O
for IN O
eight CD O
rats NNS O
in IN O
each DT O
group NN O
brain NN B-Disease
injury NN I-Disease
was VBD O
evaluated VBN O
by IN O
staining VBG O
tissue NN O
using VBG O
2 CD O
, , O
3 CD O
, , O
5 CD O
- HYPH O
triphenyltetrazolium NN O
chloride NN O
and CC O
edema NN B-Disease
was VBD O
evaluated VBN O
by IN O
microgravimetry NN O
. . O
null null null-Disease
Part NN O
B NN O
, , O
for IN O
eight CD O
different JJ O
rats NNS O
in IN O
each DT O
group NN O
blood NN O
- HYPH O
brain NN O
barrier NN O
permeability NN O
was VBD O
evaluated VBN O
by IN O
measuring VBG O
the DT O
amount NN O
and CC O
extent NN O
of IN O
extravasation NN O
of IN O
Evans NNP O
Blue NNP O
dye NN O
. . O
null null null-Disease
Brain NN B-Disease
injury NN I-Disease
( , O
percentage NN O
of IN O
the DT O
ischemic JJ B-Disease
hemisphere NN I-Disease
) -RRB- O
was VBD O
less JJR O
in IN O
the DT O
15 CD O
/ SYM O
HTN NNP B-Disease
group NN O
( : O
16 CD O
+ SYM O
/ SYM O
- HYPH O
6 CD O
, , O
mean VB O
+ CC O
/ SYM O
- HYPH O
SD NN O
) -RRB- O
versus IN O
the DT O
90 CD O
/ SYM O
HTN NNP B-Disease
group NN O
( : O
30 CD O
+ SYM O
/ SYM O
- HYPH O
6 CD O
) -RRB- O
, , O
which WDT O
was VBD O
in IN O
turn NN O
less JJR O
than IN O
the DT O
control NN O
group NN O
( , O
42 CD O
+ SYM O
/ SYM O
- HYPH O
5 CD O
) -RRB- O
. . O
null null null-Disease
Specific JJ O
gravity NN O
was VBD O
greater JJR O
in IN O
the DT O
15 CD O
/ SYM O
HTN NNP B-Disease
group NN O
( : O
1 CD O
. . O
043 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
002 CD O
) -RRB- O
versus IN O
the DT O
90 CD O
/ SYM O
HTN NNP B-Disease
( , O
1 CD O
. . O
036 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
003 CD O
) -RRB- O
and CC O
control NN O
( : O
1 CD O
. . O
037 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
003 CD O
) -RRB- O
groups NNS O
. . O
null null null-Disease
Evans NNP O
Blue NNP O
( HYPH O
mug NN O
g NN O
- HYPH O
1 CD O
of IN O
brain NN O
tissue NN O
) -RRB- O
was VBD O
greater JJR O
in IN O
the DT O
90 CD O
/ SYM O
HTN NNP B-Disease
group NN O
( : O
24 CD O
. . O
4 CD O
+ NN O
/ SYM O
- HYPH O
6 CD O
. . O
0 CD O
) -RRB- O
versus IN O
the DT O
control NN O
group NN O
( : O
12 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- HYPH O
4 CD O
. . O
1 CD O
) -RRB- O
, , O
which WDT O
was VBD O
in IN O
turn NN O
greater JJR O
than IN O
the DT O
15 CD O
/ SYM O
HTN NNP B-Disease
group NN O
( : O
7 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- HYPH O
3 CD O
. . O
2 CD O
) -RRB- O
. . O
null null null-Disease
This DT O
study NN O
supports VBZ O
a DT O
hypothesis NN O
that IN O
during IN O
reperfusion NN O
, , O
a DT O
short JJ O
interval NN O
of IN O
hypertension NN B-Disease
decreases VBZ O
brain NN B-Disease
injury NN I-Disease
and CC O
edema NN B-Disease
; , O
and CC O
that IN O
sustained VBN O
hypertension NN B-Disease
increases VBZ O
the DT O
risk NN O
of IN O
vasogenic JJ B-Disease
edema NN I-Disease
. . O
null null null-Disease
People NNS O
aged VBN O
over IN O
75 CD O
in IN O
atrial JJ B-Disease
fibrillation NN I-Disease
on IN O
warfarin NN O
: : O
the DT O
rate NN O
of IN O
major JJ O
hemorrhage NN B-Disease
and CC O
stroke NN B-Disease
in IN O
more JJR O
than IN O
500 CD O
patient JJ O
- HYPH O
years NNS O
of IN O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
To TO O
determine VB O
the DT O
incidence NN O
of IN O
major JJ O
hemorrhage NN B-Disease
and CC O
stroke NN B-Disease
in IN O
people NNS O
aged VBN O
76 CD O
and CC O
older JJR O
with IN O
atrial JJ B-Disease
fibrillation NN I-Disease
on IN O
adjusted VBN O
- HYPH O
dose NN O
warfarin NN O
who WP O
had VBD O
been VBN O
recently RB O
been VBN O
admitted VBN O
to IN O
hospital NN O
. . O
null null null-Disease
DESIGN NN O
: : O
A DT O
retrospective JJ O
observational JJ O
cohort NN O
study NN O
. . O
null null null-Disease
SETTING VBG O
: : O
A DT O
major JJ O
healthcare NN O
network NN O
involving VBG O
four CD O
tertiary JJ O
hospitals NNS O
. . O
null null null-Disease
PARTICIPANTS NNS O
: : O
Two CD O
hundred CD O
thirty CD O
- HYPH O
five CD O
patients NNS O
aged VBN O
76 CD O
and CC O
older JJR O
admitted VBN O
to IN O
a DT O
major JJ O
healthcare NN O
network NN O
between IN O
July NNP O
1 CD O
, , O
2001 CD O
, , O
and CC O
June NNP O
30 CD O
, , O
2002 CD O
, , O
with IN O
atrial JJ B-Disease
fibrillation NN I-Disease
on IN O
warfarin NN O
were VBD O
enrolled VBN O
. . O
null null null-Disease
MEASUREMENTS NNS O
: : O
Information NN O
regarding VBG O
major JJ O
bleeding NN B-Disease
episodes NNS O
, , O
strokes NNS B-Disease
, , O
and CC O
warfarin JJ O
use NN O
was VBD O
obtained VBN O
from IN O
patients NNS O
, , O
relatives NNS O
, , O
primary JJ O
physicians NNS O
, , O
and CC O
medical JJ O
records NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Two CD O
hundred CD O
twenty CD O
- HYPH O
eight CD O
patients NNS O
( : O
42 CD O
% NN O
men NNS O
) -RRB- O
with IN O
a DT O
mean JJ O
age NN O
of IN O
81 CD O
. . O
1 CD O
( SYM O
range NN O
76 CD O
- HYPH O
94 CD O
) -RRB- O
were VBD O
included VBN O
in IN O
the DT O
analysis NN O
. . O
null null null-Disease
Total JJ O
follow NN O
- HYPH O
up NN O
on IN O
warfarin NN O
was VBD O
530 CD O
years NNS O
( , O
mean JJ O
28 CD O
months NNS O
) -RRB- O
. . O
null null null-Disease
There EX O
were VBD O
53 CD O
major JJ O
hemorrhages NNS B-Disease
, , O
for IN O
an DT O
annual JJ O
rate NN O
of IN O
10 CD O
. . O
0 CD O
% NN O
, , O
including VBG O
24 CD O
( SYM O
45 CD O
. . O
3 CD O
% NN O
) SYM O
life NN O
- HYPH O
threatening VBG O
and CC O
five CD O
( SYM O
9 CD O
. . O
4 CD O
% NN O
) -RRB- O
fatal JJ O
bleeds NNS O
. . O
null null null-Disease
The DT O
annual JJ O
stroke NN B-Disease
rate NN O
after IN O
initiation NN O
of IN O
warfarin NN O
was VBD O
2 CD O
. . O
6 CD O
% NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
rate NN O
of IN O
major JJ O
hemorrhage NN B-Disease
was VBD O
high JJ O
in IN O
this DT O
old JJ O
, , O
frail JJ O
group NN O
, , O
but CC O
excluding VBG O
fatalities NNS O
, , O
resulted VBD O
in IN O
no DT O
long JJ O
- HYPH O
term NN O
sequelae NN O
, , O
and CC O
the DT O
stroke NN B-Disease
rate NN O
on IN O
warfarin NN O
was VBD O
low JJ O
, , O
demonstrating VBG O
how WRB O
effective JJ O
warfarin JJ O
treatment NN O
is VBZ O
. . O
null null null-Disease
Safety NN O
of IN O
celecoxib NN O
in IN O
patients NNS O
with IN O
adverse JJ O
skin NN B-Disease
reactions NNS I-Disease
to IN O
acetaminophen NN O
( , O
paracetamol NN O
) -RRB- O
and CC O
nimesulide NN O
associated VBN O
or CC O
not RB O
with IN O
common JJ O
non JJ O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Acetaminophen NNP O
( : O
paracetamol NN O
- HYPH O
- HYPH O
P NN O
) -RRB- O
and CC O
Nimesulide NNP O
( -LRB- O
N NNP O
) -RRB- O
are VBP O
widely RB O
used VBN O
analgesic JJ O
- HYPH O
antipyretic JJ O
/ SYM O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
. . O
null null null-Disease
The DT O
rate NN O
of IN O
adverse JJ O
hypersensitivity NN B-Disease
reactions NNS O
to IN O
these DT O
agents NNS O
is VBZ O
generally RB O
low JJ O
. . O
null null null-Disease
On IN O
the DT O
contrary JJ O
non AFX O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
( -LRB- O
NSAIDs NNP O
) -RRB- O
are VBP O
commonly RB O
involved VBN O
in IN O
such JJ O
reactions NNS O
. . O
null null null-Disease
Celecoxib NNP O
( , O
CE NNP O
) -RRB- O
is VBZ O
a DT O
novel JJ O
drug NN O
, , O
with IN O
high JJ O
selectivity NN O
and CC O
affinity NN O
for IN O
COX NNP O
- HYPH O
2 CD O
enzyme NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
We PRP O
evaluated VBD O
the DT O
tolerability NN O
of IN O
CE NN O
in IN O
a DT O
group NN O
of IN O
patients NNS O
with IN O
documented VBN O
history NN O
of IN O
adverse JJ O
cutaneous JJ B-Disease
reactions NNS I-Disease
to IN O
P NN O
and CC O
N NNP O
associated VBN O
or CC O
not RB O
to IN O
classic JJ O
NSAIDs NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
studied VBD O
9 CD O
patients NNS O
with IN O
hypersensitivity NN B-Disease
to IN O
P NN O
and CC O
N NNP O
with IN O
or CC O
without IN O
associated JJ O
reactions NNS O
to IN O
classic JJ O
NSAIDs NNS O
. . O
null null null-Disease
The DT O
diagnosis NN O
of IN O
P NN O
and CC O
N NN O
- HYPH O
induced VBN O
skin NN B-Disease
reactions NNS I-Disease
was VBD O
based VBN O
in IN O
vivo NN O
challenge NN O
. . O
null null null-Disease
The DT O
placebo NN O
was VBD O
blindly RB O
administered VBN O
at IN O
the DT O
beginning NN O
of IN O
each DT O
challenge NN O
. . O
null null null-Disease
After IN O
three CD O
days NNS O
, , O
a DT O
cumulative JJ O
dosage NN O
of IN O
200 CD O
mg NNS O
of IN O
CE NN O
in IN O
refracted JJ O
doses NNS O
were VBD O
given VBN O
. . O
null null null-Disease
After IN O
2 CD O
- SYM O
3 CD O
days NNS O
, , O
a DT O
single JJ O
dose NN O
of IN O
200 CD O
mg NN O
was VBD O
administered VBN O
. . O
null null null-Disease
All DT O
patients NNS O
were VBD O
observed VBN O
for IN O
6 CD O
hours NNS O
after IN O
each DT O
challenge NN O
, , O
and CC O
controlled VBN O
again RB O
after IN O
24 CD O
hours NNS O
to TO O
exclude VB O
delayed VBN O
reactions NNS O
. . O
null null null-Disease
The DT O
challenge NN O
was VBD O
considered VBN O
positive JJ O
if IN O
one CD O
or CC O
more JJR O
of IN O
the DT O
following VBG O
appeared VBD O
: : O
erythema NN B-Disease
, , O
rush NN O
or CC O
urticaria NN B-Disease
- HYPH O
angioedema NN B-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
No DT O
reaction NN O
was VBD O
observed VBN O
with IN O
placebo NN O
and CC O
eight CD O
patients NNS O
( : O
88 CD O
. . O
8 CD O
% NN O
) -RRB- O
tolerated VBN O
CE NNP O
. . O
null null null-Disease
Only RB O
one CD O
patient NN O
developed VBD O
a DT O
moderate JJ O
angioedema NN B-Disease
of IN O
the DT O
lips NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Only RB O
one CD O
hypersensitivity NN B-Disease
reaction NN O
to IN O
CE NNP O
was VBD O
documented VBN O
among IN O
9 CD O
P NN O
and CC O
N NNP O
- HYPH O
highly RB O
NSAIDs NNPS O
intolerant JJ O
patients NNS O
. . O
null null null-Disease
Thus RB O
, , O
we PRP O
conclude VBP O
that IN O
CE NNP O
is VBZ O
a DT O
reasonably RB O
safe JJ O
alternative NN O
to TO O
be VB O
used VBN O
in IN O
subjects NNS O
who WP O
do VBP O
not RB O
tolerate VB O
P NN O
and CC O
N NNP O
. . O
null null null-Disease
Case NN O
- HYPH O
control NN O
study NN O
of IN O
regular JJ O
analgesic JJ O
and CC O
nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
use NN O
and CC O
end NN B-Disease
- HYPH I-Disease
stage NN I-Disease
renal JJ I-Disease
disease NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Studies NNS O
on IN O
the DT O
association NN O
between IN O
the DT O
long JJ O
- HYPH O
term NN O
use NN O
of IN O
aspirin NN O
and CC O
other JJ O
analgesic JJ O
and CC O
nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
( -LRB- O
NSAIDs NNP O
) -RRB- O
and CC O
end NN B-Disease
- HYPH I-Disease
stage NN I-Disease
renal JJ I-Disease
disease NN I-Disease
( , O
ESRD NNP B-Disease
) -RRB- O
have VBP O
given VBN O
conflicting JJ O
results NNS O
. . O
null null null-Disease
In IN O
order NN O
to TO O
examine VB O
this DT O
association NN O
, , O
a DT O
case NN O
- HYPH O
control NN O
study NN O
with IN O
incident NN O
cases NNS O
of IN O
ESRD NNP B-Disease
was VBD O
carried VBN O
out RP O
. . O
null null null-Disease
METHODS NNS O
: : O
The DT O
cases NNS O
were VBD O
all DT O
patients NNS O
entering VBG O
the DT O
local JJ O
dialysis NN O
program NN O
because IN O
of IN O
ESRD NNP B-Disease
in IN O
the DT O
study NN O
area NN O
between IN O
June NNP O
1 CD O
, , O
1995 CD O
and CC O
November NNP O
30 CD O
, , O
1997 CD O
. . O
null null null-Disease
They PRP O
were VBD O
classified VBN O
according VBG O
to IN O
the DT O
underlying VBG O
disease NN O
, , O
which WDT O
had VBD O
presumably RB O
led VBN O
them PRP O
to IN O
ESRD NNP B-Disease
. . O
null null null-Disease
Controls NNS O
were VBD O
patients NNS O
admitted VBN O
to IN O
the DT O
same JJ O
hospitals NNS O
from IN O
where WRB O
the DT O
cases NNS O
arose VBP O
, , O
also RB O
matched VBN O
by IN O
age NN O
and CC O
sex NN O
. . O
null null null-Disease
Odds NNS O
ratios NNS O
were VBD O
calculated VBN O
using VBG O
a DT O
conditional JJ O
logistic JJ O
model NN O
, , O
including VBG O
potential JJ O
confounding VBG O
factors NNS O
, , O
both CC O
for IN O
the DT O
whole JJ O
study NN O
population NN O
and CC O
for IN O
the DT O
various JJ O
underlying VBG O
diseases NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Five CD O
hundred CD O
and CC O
eighty CD O
- HYPH O
three CD O
cases NNS O
and CC O
1190 CD O
controls NNS O
were VBD O
included VBN O
in IN O
the DT O
analysis NN O
. . O
null null null-Disease
Long JJ O
- HYPH O
term NN O
use NN O
of IN O
any DT O
analgesic NN O
was VBD O
associated VBN O
with IN O
an DT O
overall JJ O
odds NNS O
ratio NN O
of IN O
1 CD O
. . O
22 CD O
( SYM O
95 CD O
% NN O
CI NN O
, , O
0 CD O
. . O
89 CD O
- HYPH O
1 CD O
. . O
66 CD O
) -RRB- O
. . O
null null null-Disease
For IN O
specific JJ O
groups NNS O
of IN O
drugs NNS O
, , O
the DT O
risks NNS O
were VBD O
1 CD O
. . O
56 CD O
( SYM O
1 CD O
. . O
05 CD O
- HYPH O
2 CD O
. . O
30 CD O
) -RRB- O
for IN O
aspirin NN O
, , O
1 CD O
. . O
03 CD O
( SYM O
0 CD O
. . O
60 CD O
- HYPH O
1 CD O
. . O
76 CD O
) -RRB- O
for IN O
pyrazolones NNS O
, , O
0 CD O
. . O
80 CD O
( SYM O
0 CD O
. . O
39 CD O
- HYPH O
1 CD O
. . O
63 CD O
) -RRB- O
for IN O
paracetamol NN O
, , O
and CC O
0 CD O
. . O
94 CD O
( SYM O
0 CD O
. . O
57 CD O
- HYPH O
1 CD O
. . O
56 CD O
) -RRB- O
for IN O
nonaspirin JJ O
NSAIDs NNS O
. . O
null null null-Disease
The DT O
risk NN O
of IN O
ESRD NNP B-Disease
associated VBN O
with IN O
aspirin NN O
was VBD O
related VBN O
to IN O
the DT O
cumulated VBN O
dose NN O
and CC O
duration NN O
of IN O
use NN O
, , O
and CC O
it PRP O
was VBD O
particularly RB O
high JJ O
among IN O
the DT O
subset NN O
of IN O
patients NNS O
with IN O
vascular JJ O
nephropathy NN B-Disease
as IN O
underlying VBG O
disease NN O
[ -LRB- O
2 CD O
. . O
35 CD O
( SYM O
1 CD O
. . O
17 CD O
- SYM O
4 CD O
. . O
72 CD O
) -RRB- O
] -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Our PRP$ O
data NNS O
indicate VBP O
that IN O
long JJ O
- HYPH O
term NN O
use NN O
of IN O
nonaspirin JJ O
analgesic JJ O
drugs NNS O
and CC O
NSAIDs NNPS O
is VBZ O
not RB O
associated VBN O
with IN O
an DT O
increased VBN O
risk NN O
of IN O
ESRD NNP B-Disease
. . O
null null null-Disease
However RB O
, , O
the DT O
chronic JJ O
use NN O
of IN O
aspirin NN O
may MD O
increase VB O
the DT O
risk NN O
of IN O
ESRD NNP B-Disease
. . O
null null null-Disease
Two CD O
cases NNS O
of IN O
amisulpride NN O
overdose NN B-Disease
: : O
a DT O
cause NN O
for IN O
prolonged VBN B-Disease
QT NNP I-Disease
syndrome NN I-Disease
. . O
null null null-Disease
Two CD O
cases NNS O
of IN O
deliberate JJ O
self NN O
- HYPH O
poisoning NN B-Disease
with IN O
5 CD O
g NN O
and CC O
3 CD O
. . O
6 CD O
g NN O
of IN O
amisulpride NN O
, , O
respectively RB O
, , O
are VBP O
reported VBN O
. . O
null null null-Disease
In IN O
both DT O
cases NNS O
, , O
QT NNP B-Disease
prolongation NN I-Disease
and CC O
hypocalcaemia NN B-Disease
were VBD O
noted VBN O
. . O
null null null-Disease
The DT O
QT NNP B-Disease
prolongation NN I-Disease
appeared VBD O
to TO O
respond VB O
to IN O
administration NN O
of IN O
i ADD O
. . O
v NN O
. . O
calcium NN O
gluconate NN O
. . O
null null null-Disease
Growth NN O
- HYPH O
associated VBN O
protein NN O
43 CD O
expression NN O
in IN O
hippocampal JJ O
molecular JJ O
layer NN O
of IN O
chronic JJ O
epileptic JJ B-Disease
rats NNS O
treated VBN O
with IN O
cycloheximide NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
GAP43 NNP O
has VBZ O
been VBN O
thought VBN O
to TO O
be VB O
linked VBN O
with IN O
mossy JJ O
fiber NN O
sprouting NN O
( , O
MFS NNP O
) -RRB- O
in IN O
various JJ O
experimental JJ O
models NNS O
of IN O
epilepsy NN B-Disease
. . O
null null null-Disease
To TO O
investigate VB O
how WRB O
GAP43 NNP O
expression NN O
( -LRB- O
GAP43 NNP O
- HYPH O
ir NN O
) -RRB- O
correlates VBZ O
with IN O
MFS NNP O
, , O
we PRP O
assessed VBD O
the DT O
intensity NN O
( , O
densitometry NN O
) -RRB- O
and CC O
extension NN O
( , O
width NN O
) -RRB- O
of IN O
GAP43 NN O
- HYPH O
ir NN O
in IN O
the DT O
inner JJ O
molecular JJ O
layer NN O
of IN O
the DT O
dentate NN O
gyrus NN O
( , O
IML NN O
) -RRB- O
of IN O
rats NNS O
subject JJ O
to IN O
status NN B-Disease
epilepticus NN I-Disease
induced VBN O
by IN O
pilocarpine NN O
( , O
Pilo NNP O
) -RRB- O
, , O
previously RB O
injected VBN O
or CC O
not RB O
with IN O
cycloheximide NN O
( , O
CHX NNP O
) -RRB- O
, , O
which WDT O
has VBZ O
been VBN O
shown VBN O
to TO O
inhibit VB O
MFS NNP O
. . O
null null null-Disease
METHODS NNS O
: : O
CHX NNP O
was VBD O
injected VBN O
before IN O
the DT O
Pilo NNP O
injection NN O
in IN O
adult NN O
Wistar NNP O
rats NNS O
. . O
null null null-Disease
The DT O
Pilo NNP O
group NN O
was VBD O
injected VBN O
with IN O
the DT O
same JJ O
drugs NNS O
, , O
except IN O
for IN O
CHX NNP O
. . O
null null null-Disease
Animals NNS O
were VBD O
killed VBN O
between IN O
30 CD O
and CC O
60 CD O
days NNS O
later RB O
, , O
and CC O
brain NN O
sections NNS O
were VBD O
processed VBN O
for IN O
GAP43 NNP O
immunohistochemistry NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Densitometry NNP O
showed VBD O
no DT O
significant JJ O
difference NN O
regarding VBG O
GAP43 NNP O
- HYPH O
ir NN O
in IN O
the DT O
IML NNP O
between IN O
Pilo NNP O
, , O
CHX NNP O
+ CC O
Pilo NNP O
, , O
and CC O
control NN O
groups NNS O
. . O
null null null-Disease
However RB O
, , O
the DT O
results NNS O
of IN O
the DT O
width NN O
of IN O
the DT O
GAP43 NNP O
- HYPH O
ir NN O
band NN O
in IN O
the DT O
IML NNP O
showed VBD O
that IN O
CHX NNP O
+ CC O
Pilo NNP O
and CC O
control NN O
animals NNS O
had VBD O
a DT O
significantly RB O
larger JJR O
band NN O
( : O
p NN O
= SYM O
0 CD O
. . O
03 CD O
) -RRB- O
as IN O
compared VBN O
with IN O
that DT O
in IN O
the DT O
Pilo NNP O
group NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Our PRP$ O
current JJ O
finding NN O
that IN O
animals NNS O
in IN O
the DT O
CHX NNP O
+ SYM O
Pilo NNP O
group NN O
have VBP O
a DT O
GAP43 NNP O
- HYPH O
ir NN O
band NN O
in IN O
the DT O
IML NNP O
, , O
similar JJ O
to IN O
that DT O
of IN O
controls NNS O
, , O
reinforces VBZ O
prior JJ O
data NNS O
on IN O
the DT O
blockade NN O
of IN O
MFS NNP O
in IN O
these DT O
animals NNS O
. . O
null null null-Disease
The DT O
change NN O
in IN O
GAP43 NNP O
- HYPH O
ir `` O
present JJ O
in IN O
Pilo NNP O
- HYPH O
treated VBN O
animals NNS O
was VBD O
a DT O
thinning NN O
of IN O
the DT O
band NN O
to IN O
a DT O
very RB O
narrow JJ O
layer NN O
just RB O
above IN O
the DT O
granule NN O
cell NN O
layer NN O
that WDT O
is VBZ O
likely JJ O
to TO O
be VB O
associated VBN O
with IN O
the DT O
loss NN O
of IN O
hilar JJ O
cell NN O
projections NNS O
that WDT O
express VBP O
GAP NNP O
- HYPH O
43 CD O
. . O
null null null-Disease
Nicotine NN O
antagonizes VBZ O
caffeine NN O
- : O
but CC O
not RB O
pentylenetetrazole NN O
- HYPH O
induced VBN O
anxiogenic JJ O
effect NN O
in IN O
mice NNS O
. . O
null null null-Disease
RATIONALE NN O
: : O
Nicotine NN O
and CC O
caffeine NN O
are VBP O
widely RB O
consumed VBN O
licit JJ O
psychoactive JJ O
drugs NNS O
worldwide RB O
. . O
null null null-Disease
Epidemiological JJ O
studies NNS O
showed VBD O
that IN O
they PRP O
were VBD O
generally RB O
used VBN O
concurrently RB O
. . O
null null null-Disease
Although IN O
some DT O
studies NNS O
in IN O
experimental JJ O
animals NNS O
indicate VBP O
clear JJ O
pharmacological JJ O
interactions NNS O
between IN O
them PRP O
, , O
no DT O
studies NNS O
have VBP O
shown VBN O
a DT O
specific JJ O
interaction NN O
on IN O
anxiety NN B-Disease
responses NNS O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
The DT O
present JJ O
study NN O
investigates VBZ O
the DT O
effects NNS O
of IN O
nicotine NN O
on IN O
anxiety NN B-Disease
induced VBN O
by IN O
caffeine NN O
and CC O
another DT O
anxiogenic JJ O
drug NN O
, , O
pentylenetetrazole NN O
, , O
in IN O
mice NNS O
. . O
null null null-Disease
The DT O
elevated JJ O
plus JJ O
- HYPH O
maze NN O
( , O
EPM NNP O
) -RRB- O
test NN O
was VBD O
used VBN O
to TO O
evaluate VB O
the DT O
effects NNS O
of IN O
drugs NNS O
on IN O
anxiety NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Adult NN O
male JJ O
Swiss NNP O
Webster NNP O
mice NNS O
( : O
25 CD O
- SYM O
32 CD O
g CD O
) -RRB- O
were VBD O
given VBN O
nicotine NN O
( : O
0 CD O
. . O
05 CD O
- HYPH O
0 CD O
. . O
25 CD O
mg NN O
/ SYM O
kg NN O
s NNS O
. . O
c NN O
. . O
) -RRB- O
or CC O
saline NN O
10 CD O
min NN O
before IN O
caffeine NN O
( : O
70 CD O
mg NN O
/ SYM O
kg NN O
i CD O
. . O
p NN O
. . O
) -RRB- O
or CC O
pentylenetetrazole NN O
( SYM O
15 CD O
and CC O
30 CD O
mg CD O
/ SYM O
kg CD O
i NN O
. . O
p NN O
. . O
) -RRB- O
injections NNS O
. . O
null null null-Disease
After IN O
15 CD O
min NN O
, , O
mice NNS O
were VBD O
evaluated VBN O
for IN O
their PRP$ O
open JJ O
- HYPH O
and CC O
closed JJ O
- HYPH O
arm NN O
time NN O
and CC O
entries NNS O
on IN O
the DT O
EPM NNP O
for IN O
a DT O
10 CD O
- HYPH O
min NN O
session NN O
. . O
null null null-Disease
Locomotor NN O
activity NN O
was VBD O
recorded VBN O
for IN O
individual JJ O
groups NNS O
by IN O
using VBG O
the DT O
same JJ O
treatment NN O
protocol NN O
with IN O
the DT O
EPM NNP O
test NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Nicotine NN O
( : O
0 CD O
. . O
05 CD O
- HYPH O
0 CD O
. . O
25 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
itself PRP O
did VBD O
not RB O
produce VB O
any DT O
significant JJ O
effect NN O
in IN O
the DT O
EPM NNP O
test NN O
, , O
whereas IN O
caffeine NN O
( , O
70 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
and CC O
pentylenetetrazole NN O
( SYM O
30 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
produced VBD O
an DT O
anxiogenic JJ O
effect NN O
, , O
apparent JJ O
with IN O
decreases NNS O
in IN O
open JJ O
- HYPH O
arm NN O
time NN O
and CC O
entry NN O
. . O
null null null-Disease
Nicotine NN O
( : O
0 CD O
. . O
25 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
pretreatment NN O
blocked VBD O
the DT O
caffeine NN O
- : O
but CC O
not RB O
pentylenetetrazole NN O
- HYPH O
induced VBN O
anxiety NN B-Disease
. . O
null null null-Disease
Administration NN O
of IN O
each DT O
drug NN O
and CC O
their PRP$ O
combinations NNS O
did VBD O
not RB O
produce VB O
any DT O
effect NN O
on IN O
locomotor NN O
activity NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Our PRP$ O
results NNS O
suggest VBP O
that IN O
the DT O
antagonistic JJ O
effect NN O
of IN O
nicotine NN O
on IN O
caffeine NN O
- HYPH O
induced VBN O
anxiety NN B-Disease
is VBZ O
specific JJ O
to IN O
caffeine NN O
, , O
instead RB O
of IN O
a DT O
non AFX O
- HYPH O
specific JJ O
anxiolytic JJ O
effect NN O
. . O
null null null-Disease
Thus RB O
, , O
it PRP O
may MD O
extend VB O
the DT O
current JJ O
findings NNS O
on IN O
the DT O
interaction NN O
between IN O
nicotine NN O
and CC O
caffeine NN O
. . O
null null null-Disease
Long JJ O
term NN O
hormone NN O
therapy NN O
for IN O
perimenopausal JJ O
and CC O
postmenopausal JJ O
women NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Hormone NN O
therapy NN O
( : O
HT NN O
) -RRB- O
is VBZ O
widely RB O
used VBN O
for IN O
controlling VBG O
menopausal JJ B-Disease
symptoms NNS I-Disease
. . O
null null null-Disease
It PRP O
has VBZ O
also RB O
been VBN O
used VBN O
for IN O
the DT O
management NN O
and CC O
prevention NN O
of IN O
cardiovascular JJ B-Disease
disease NN I-Disease
, , O
osteoporosis NN B-Disease
and CC O
dementia NN B-Disease
in IN O
older JJR O
women NNS O
but CC O
the DT O
evidence NN O
supporting VBG O
its PRP$ O
use NN O
for IN O
these DT O
indications NNS O
is VBZ O
largely RB O
observational JJ O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
To TO O
assess VB O
the DT O
effect NN O
of IN O
long JJ O
- HYPH O
term NN O
HT NN O
on IN O
mortality NN O
, , O
heart NN B-Disease
disease NN I-Disease
, , O
venous JJ B-Disease
thromboembolism NN I-Disease
, , O
stroke NN B-Disease
, , O
transient JJ B-Disease
ischaemic JJ I-Disease
attacks NNS I-Disease
, , O
breast NN B-Disease
cancer NN I-Disease
, , O
colorectal JJ B-Disease
cancer NN I-Disease
, , O
ovarian JJ B-Disease
cancer NN I-Disease
, , O
endometrial JJ B-Disease
cancer NN I-Disease
, , O
gallbladder NN B-Disease
disease NN I-Disease
, , O
cognitive JJ O
function NN O
, , O
dementia NN B-Disease
, , O
fractures NNS B-Disease
and CC O
quality NN O
of IN O
life NN O
. . O
null null null-Disease
SEARCH NN O
STRATEGY NN O
: : O
We PRP O
searched VBD O
the DT O
following VBG O
databases NNS O
up IN O
to IN O
November NNP O
2004 CD O
: : O
the DT O
Cochrane NNP O
Menstrual NNP O
Disorders NNPS O
and CC O
Subfertility NNP O
Group NNP O
Trials NNPS O
Register NNP O
, , O
Cochrane NNP O
Central NNP O
Register NNP O
of IN O
Controlled NNP O
Trials NNPS O
( -LRB- O
CENTRAL NNP O
) -RRB- O
, , O
MEDLINE NNP O
, , O
EMBASE NNP O
, , O
Biological NNP O
Abstracts NNPS O
. . O
null null null-Disease
Relevant JJ O
non AFX O
- HYPH O
indexed VBN O
journals NNS O
and CC O
conference NN O
abstracts NNS O
were VBD O
also RB O
searched VBN O
. . O
null null null-Disease
SELECTION NN O
CRITERIA NNS O
: : O
Randomised JJ O
double JJ O
- HYPH O
blind JJ O
trials NNS O
of IN O
HT NNP O
( , O
oestrogens NNS O
with IN O
or CC O
without IN O
progestogens NNS O
) , O
versus IN O
placebo NN O
, , O
taken VBN O
for IN O
at RB O
least RBS O
one CD O
year NN O
by IN O
perimenopausal JJ O
or CC O
postmenopausal JJ O
women NNS O
. . O
null null null-Disease
DATA NN O
COLLECTION NN O
AND CC O
ANALYSIS NN O
: : O
Fifteen JJ O
RCTs NNS O
were VBD O
included VBN O
. . O
null null null-Disease
Trials NNS O
were VBD O
assessed VBN O
for IN O
quality NN O
and CC O
two CD O
review NN O
authors NNS O
extracted VBN O
data NNS O
independently RB O
. . O
null null null-Disease
They PRP O
calculated VBD O
risk NN O
ratios NNS O
for IN O
dichotomous JJ O
outcomes NNS O
and CC O
weighted VBN O
mean JJ O
differences NNS O
for IN O
continuous JJ O
outcomes NNS O
. . O
null null null-Disease
Clinical JJ O
heterogeneity NN O
precluded VBD O
meta JJ O
- HYPH O
analysis NN O
for IN O
most JJS O
outcomes NNS O
. . O
null null null-Disease
MAIN JJ O
RESULTS NNS O
: : O
All PDT O
the DT O
statistically RB O
significant JJ O
results NNS O
were VBD O
derived VBN O
from IN O
the DT O
two CD O
biggest JJS O
trials NNS O
. . O
null null null-Disease
In IN O
relatively RB O
healthy JJ O
women NNS O
, , O
combined VBN O
continuous JJ O
HT NNP O
significantly RB O
increased VBD O
the DT O
risk NN O
of IN O
venous JJ B-Disease
thromboembolism NN I-Disease
or CC O
coronary JJ O
event NN O
( , O
after IN O
one CD O
year NN O
' POS O
s VBZ O
use NN O
) -RRB- O
, , O
stroke NN B-Disease
( , O
after IN O
3 CD O
years NNS O
) -RRB- O
, , O
breast NN B-Disease
cancer NN I-Disease
( , O
after IN O
5 CD O
years NNS O
) , O
and CC O
gallbladder NN B-Disease
disease NN I-Disease
. . O
null null null-Disease
Long JJ O
- HYPH O
term NN O
oestrogen NN O
- HYPH O
only RB O
HT NNP O
also RB O
significantly RB O
increased VBD O
the DT O
risk NN O
of IN O
stroke NN B-Disease
and CC O
gallbladder NN B-Disease
disease NN I-Disease
. . O
null null null-Disease
Overall RB O
, , O
the DT O
only JJ O
statistically RB O
significant JJ O
benefits NNS O
of IN O
HT NNP O
were VBD O
a DT O
decreased VBN O
incidence NN O
of IN O
fractures NNS B-Disease
and CC O
colon NN B-Disease
cancer NN I-Disease
with IN O
long JJ O
- HYPH O
term NN O
use NN O
. . O
null null null-Disease
Among IN O
relatively RB O
healthy JJ O
women NNS O
over IN O
65 CD O
years NNS O
taking VBG O
continuous JJ O
combined VBN O
HT NNP O
, , O
there EX O
was VBD O
a DT O
statistically RB O
significant JJ O
increase NN O
in IN O
the DT O
incidence NN O
of IN O
dementia NN B-Disease
. . O
null null null-Disease
Among IN O
women NNS O
with IN O
cardiovascular JJ B-Disease
disease NN I-Disease
, , O
long JJ O
- HYPH O
term NN O
use NN O
of IN O
combined VBN O
continuous JJ O
HT NNP O
significantly RB O
increased VBD O
the DT O
risk NN O
of IN O
venous JJ B-Disease
thromboembolism NN I-Disease
. . O
null null null-Disease
No DT O
trials NNS O
focussed VBN O
specifically RB O
on IN O
younger JJR O
women NNS O
. . O
null null null-Disease
However RB O
, , O
one CD O
trial NN O
analysed VBD O
subgroups NNS O
of IN O
2839 CD O
relatively RB O
healthy JJ O
50 CD O
to TO O
59 CD O
year NN O
- HYPH O
old JJ O
women NNS O
taking VBG O
combined VBN O
continuous JJ O
HT NNP O
and CC O
1637 CD O
taking VBG O
oestrogen NN O
- HYPH O
only RB O
HT NNP O
, , O
versus IN O
similar JJ O
- HYPH O
sized JJ O
placebo NN O
groups NNS O
. . O
null null null-Disease
The DT O
only JJ O
significantly RB O
increased VBN O
risk NN O
reported VBN O
was VBD O
for IN O
venous JJ B-Disease
thromboembolism NN I-Disease
in IN O
women NNS O
taking VBG O
combined VBN O
continuous JJ O
HT NNP O
; : O
their PRP$ O
absolute JJ O
risk NN O
remained VBD O
very RB O
low JJ O
. . O
null null null-Disease
AUTHORS NNS O
' POS O
CONCLUSIONS NNS O
: : O
HT NNP O
is VBZ O
not RB O
indicated VBN O
for IN O
the DT O
routine JJ O
management NN O
of IN O
chronic JJ B-Disease
disease NN I-Disease
. . O
null null null-Disease
We PRP O
need VBP O
more JJR O
evidence NN O
on IN O
the DT O
safety NN O
of IN O
HT NNP O
for IN O
menopausal JJ O
symptom NN O
control NN O
, , O
though IN O
short JJ O
- HYPH O
term NN O
use NN O
appears VBZ O
to TO O
be VB O
relatively RB O
safe JJ O
for IN O
healthy JJ O
younger JJR O
women NNS O
. . O
null null null-Disease
Drug NN B-Disease
- HYPH I-Disease
induced VBN I-Disease
liver NN I-Disease
injury NN I-Disease
: : O
an DT O
analysis NN O
of IN O
461 CD O
incidences NNS O
submitted VBN O
to IN O
the DT O
Spanish JJ O
registry NN O
over IN O
a DT O
10 CD O
- HYPH O
year NN O
period NN O
. . O
null null null-Disease
BACKGROUND NN O
& CC O
AIMS NNS O
: : O
Progress NN O
in IN O
the DT O
understanding NN O
of IN O
susceptibility NN O
factors NNS O
to IN O
drug NN B-Disease
- HYPH I-Disease
induced VBN I-Disease
liver NN I-Disease
injury NN I-Disease
( , O
DILI NNP B-Disease
) -RRB- O
and CC O
outcome NN O
predictability NN O
are VBP O
hampered VBN O
by IN O
the DT O
lack NN O
of IN O
systematic JJ O
programs NNS O
to TO O
detect VB O
bona FW O
fide FW O
cases NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
cooperative JJ O
network NN O
was VBD O
created VBN O
in IN O
1994 CD O
in IN O
Spain NNP O
to TO O
identify VB O
all DT O
suspicions NNS O
of IN O
DILI NNP B-Disease
following VBG O
a DT O
prospective JJ O
structured VBN O
report NN O
form NN O
. . O
null null null-Disease
The DT O
liver NN B-Disease
damage NN I-Disease
was VBD O
characterized VBN O
according VBG O
to IN O
hepatocellular JJ O
, , O
cholestatic JJ B-Disease
, , O
and CC O
mixed JJ O
laboratory NN O
criteria NNS O
and CC O
to IN O
histologic JJ O
criteria NNS O
when WRB O
available JJ O
. . O
null null null-Disease
Further JJ O
evaluation NN O
of IN O
causality NN O
assessment NN O
was VBD O
centrally RB O
performed VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Since IN O
April NNP O
1994 CD O
to IN O
August NNP O
2004 CD O
, , O
461 CD O
out IN O
of IN O
570 CD O
submitted VBN O
cases NNS O
, , O
involving VBG O
505 CD O
drugs NNS O
, , O
were VBD O
deemed VBN O
to TO O
be VB O
related VBN O
to IN O
DILI NNP B-Disease
. . O
null null null-Disease
The DT O
antiinfective JJ O
group NN O
of IN O
drugs NNS O
was VBD O
the DT O
more RBR O
frequently RB O
incriminated VBN O
, , O
amoxicillin NN O
- HYPH O
clavulanate NN O
accounting VBG O
for IN O
the DT O
12 CD O
. . O
8 CD O
% NN O
of IN O
the DT O
whole JJ O
series NN O
. . O
null null null-Disease
The DT O
hepatocellular JJ O
pattern NN O
of IN O
damage NN O
was VBD O
the DT O
most RBS O
common JJ O
( : O
58 CD O
% NN O
) -RRB- O
, , O
was VBD O
inversely RB O
correlated VBN O
with IN O
age NN O
( : O
P NN O
< NN O
. . O
0001 CD O
) -RRB- O
, , O
and CC O
had VBD O
the DT O
worst JJS O
outcome NN O
( , O
Cox NNP O
regression NN O
, , O
P NN O
< NN O
. . O
034 CD O
) -RRB- O
. . O
null null null-Disease
Indeed RB O
, , O
the DT O
incidence NN O
of IN O
liver NN O
transplantation NN O
and CC O
death NN O
in IN O
this DT O
group NN O
was VBD O
11 CD O
. . O
7 CD O
% NN O
if IN O
patients NNS O
had VBD O
jaundice NN B-Disease
at IN O
presentation NN O
, , O
whereas IN O
the DT O
corresponding JJ O
figure NN O
was VBD O
3 CD O
. . O
8 CD O
% NN O
in IN O
nonjaundiced JJ O
patients NNS O
( , O
P NN O
< NN O
. . O
04 CD O
) -RRB- O
. . O
null null null-Disease
Factors NNS O
associated VBN O
with IN O
the DT O
development NN O
of IN O
fulminant JJ B-Disease
hepatic JJ I-Disease
failure NN I-Disease
were VBD O
female JJ O
sex NN O
( , O
OR CC O
= SYM O
25 CD O
; : O
95 CD O
% NN O
CI NN O
: : O
4 CD O
. . O
1 CD O
- SYM O
151 CD O
; : O
P NN O
< NN O
. . O
0001 CD O
) -RRB- O
, , O
hepatocellular JJ O
damage NN O
( : O
OR CC O
= SYM O
7 CD O
. . O
9 CD O
; : O
95 CD O
% NN O
CI NN O
: : O
1 CD O
. . O
6 CD O
- SYM O
37 CD O
; : O
P NN O
< NN O
. . O
009 CD O
) -RRB- O
, , O
and CC O
higher JJR O
baseline NN O
plasma NN O
bilirubin NN O
value NN O
( : O
OR CC O
= SYM O
1 CD O
. . O
15 CD O
; : O
95 CD O
% NN O
CI NN O
: : O
1 CD O
. . O
09 CD O
- HYPH O
1 CD O
. . O
22 CD O
; : O
P NN O
< NN O
. . O
0001 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Patients NNS O
with IN O
drug NN O
- HYPH O
induced VBN O
hepatocellular JJ O
jaundice NN B-Disease
have VBP O
11 CD O
. . O
7 CD O
% NN O
chance NN O
of IN O
progressing VBG O
to IN O
death NN O
or CC O
transplantation NN O
. . O
null null null-Disease
Amoxicillin NNP O
- HYPH O
clavulanate NNP O
stands VBZ O
out RP O
as IN O
the DT O
most RBS O
common JJ O
drug NN O
related VBN O
to IN O
DILI NNP B-Disease
. . O
null null null-Disease
Morphological JJ O
evaluation NN O
of IN O
the DT O
effect NN O
of IN O
d NN O
- HYPH O
ribose NN O
on IN O
adriamycin NN O
- HYPH O
evoked VBD O
cardiotoxicity NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
influence NN O
of IN O
d NN O
- HYPH O
ribose NN O
on IN O
adriamycin NN O
- HYPH O
induced VBN O
myocardiopathy NN B-Disease
in IN O
rats NNS O
was VBD O
studied VBN O
. . O
null null null-Disease
Adriamycin NNP O
in IN O
the DT O
cumulative JJ O
dose NN O
of IN O
25 CD O
mg NN O
/ SYM O
kg NN O
evoked VBD O
fully RB O
developed VBN O
cardiac JJ B-Disease
toxicity NN I-Disease
. . O
null null null-Disease
D NN O
- HYPH O
ribose NN O
in IN O
the DT O
multiple JJ O
doses NNS O
of IN O
200 CD O
mg NNS O
/ SYM O
kg NN O
did VBD O
not RB O
influence VB O
ADR NNP O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
In IN O
vivo NN O
evidences NNS O
suggesting VBG O
the DT O
role NN O
of IN O
oxidative JJ O
stress NN O
in IN O
pathogenesis NN O
of IN O
vancomycin NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
: : O
protection NN O
by IN O
erdosteine NN O
. . O
null null null-Disease
The DT O
aims NNS O
of IN O
this DT O
study NN O
were VBD O
to TO O
examine VB O
vancomycin NN O
( , O
VCM NNP O
) -RRB- O
- HYPH O
induced VBN O
oxidative JJ O
stress NN O
that WDT O
promotes VBZ O
production NN O
of IN O
reactive JJ O
oxygen NN O
species NNS O
( , O
ROS NNP O
) -RRB- O
and CC O
to TO O
investigate VB O
the DT O
role NN O
of IN O
erdosteine NN O
, , O
an DT O
expectorant JJ O
agent NN O
, , O
which WDT O
has VBZ O
also RB O
antioxidant JJ O
properties NNS O
, , O
on IN O
kidney NN O
tissue NN O
against IN O
the DT O
possible JJ O
VCM NN O
- HYPH O
induced VBN O
renal JJ B-Disease
impairment NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
Rats NNS O
were VBD O
divided VBN O
into IN O
three CD O
groups NNS O
: : O
sham NN O
, , O
VCM NN O
and CC O
VCM NN O
plus CC O
erdosteine NN O
. . O
null null null-Disease
VCM NNP O
was VBD O
administrated VBN O
intraperitoneally RB O
( : O
i ADD O
. . O
p NN O
. . O
) -RRB- O
with IN O
200mgkg CD O
( SYM O
- HYPH O
1 CD O
) SYM O
twice RB O
daily RB O
for IN O
7 CD O
days NNS O
. . O
null null null-Disease
Erdosteine NNP O
was VBD O
administered VBN O
orally RB O
. . O
null null null-Disease
VCM NNP O
administration NN O
to TO O
control VB O
rats NNS O
significantly RB O
increased VBD O
renal JJ O
malondialdehyde NN O
( , O
MDA NNP O
) -RRB- O
and CC O
urinary JJ O
N NN O
- HYPH O
acetyl NN O
- HYPH O
beta NN O
- HYPH O
d NN O
- HYPH O
glucosaminidase NN O
( -LRB- O
NAG NNP O
, , O
a DT O
marker NN O
of IN O
renal JJ B-Disease
tubular JJ I-Disease
injury NN I-Disease
) , O
excretion NN O
but CC O
decreased VBN O
superoxide NN O
dismutase NN O
( -LRB- O
SOD NN O
) -RRB- O
and CC O
catalase NN O
( -LRB- O
CAT NN O
) -RRB- O
activities NNS O
. . O
null null null-Disease
Erdosteine NNP O
administration NN O
with IN O
VCM NNP O
injections NNS O
caused VBD O
significantly RB O
decreased VBN O
renal JJ O
MDA NN O
and CC O
urinary JJ O
NAG NNP O
excretion NN O
, , O
and CC O
increased VBN O
SOD NNP O
activity NN O
, , O
but CC O
not RB O
CAT NN O
activity NN O
in IN O
renal JJ O
tissue NN O
when WRB O
compared VBN O
with IN O
VCM NNP O
alone RB O
. . O
null null null-Disease
Erdosteine NNP O
showed VBD O
histopathological JJ O
protection NN O
against IN O
VCM NNP O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
There EX O
were VBD O
a DT O
significant JJ O
dilatation NN O
of IN O
tubular JJ O
lumens NNS O
, , O
extensive JJ O
epithelial JJ O
cell NN O
vacuolization NN O
, , O
atrophy NN B-Disease
, , O
desquamation NN B-Disease
, , O
and CC O
necrosis NN B-Disease
in IN O
VCM NN O
- HYPH O
treated VBN O
rats NNS O
more RBR O
than IN O
those DT O
of IN O
the DT O
control NN O
and CC O
the DT O
erdosteine NN O
groups NNS O
. . O
null null null-Disease
Erdosteine NNP O
caused VBD O
a DT O
marked JJ O
reduction NN O
in IN O
the DT O
extent NN O
of IN O
tubular JJ O
damage NN O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
oxidative JJ O
tubular JJ O
damage NN O
plays VBZ O
an DT O
important JJ O
role NN O
in IN O
the DT O
VCM NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
and CC O
the DT O
modulation NN O
of IN O
oxidative JJ O
stress NN O
with IN O
erdosteine NN O
reduces VBZ O
the DT O
VCM NNP O
- HYPH O
induced VBN O
kidney NN B-Disease
damage NN I-Disease
both CC O
at IN O
the DT O
biochemical JJ O
and CC O
histological JJ O
levels NNS O
. . O
null null null-Disease
Gemfibrozil NNP O
- HYPH O
lovastatin NN O
therapy NN O
for IN O
primary JJ O
hyperlipoproteinemias NNS B-Disease
. . O
null null null-Disease
The DT O
specific JJ O
aim NN O
of IN O
this DT O
retrospective JJ O
, , O
observational JJ O
study NN O
was VBD O
to TO O
assess VB O
safety NN O
and CC O
efficacy NN O
of IN O
long JJ O
- HYPH O
term NN O
( : O
21 CD O
months NNS O
/ SYM O
patient NN O
) -RRB- O
, , O
open JJ O
- HYPH O
label NN O
, , O
gemfibrozil NN O
- HYPH O
lovastatin NN O
treatment NN O
in IN O
80 CD O
patients NNS O
with IN O
primary JJ O
mixed VBN O
hyperlipidemia NN B-Disease
( : O
68 CD O
% NN O
of IN O
whom WP O
had VBD O
atherosclerotic JJ B-Disease
vascular JJ I-Disease
disease NN I-Disease
) -RRB- O
. . O
null null null-Disease
Because IN O
ideal JJ O
lipid NN O
targets NNS O
were VBD O
not RB O
reached VBN O
( , O
low JJ O
- HYPH O
density NN O
lipoprotein NN O
( , O
LDL NNP O
) -RRB- O
cholesterol NN O
less JJR O
than IN O
130 CD O
mg NN O
/ SYM O
dl NN O
, , O
high JJ O
- HYPH O
density NN O
lipoprotein NN O
( , O
HDL NNP O
) , O
cholesterol NN O
greater JJR O
than IN O
35 CD O
mg NN O
/ SYM O
dl NN O
, , O
or CC O
total JJ O
cholesterol NN O
/ SYM O
HDL NNP O
cholesterol NN O
less JJR O
than IN O
4 CD O
. . O
5 CD O
mg NN O
/ SYM O
dl NN O
) -RRB- O
with IN O
diet NN O
plus CC O
a DT O
single JJ O
drug NN O
, , O
gemfibrozil NN O
( : O
1 CD O
. . O
2 CD O
g NN O
/ SYM O
day NN O
) -RRB- O
- HYPH O
lovastatin NN O
( : O
primarily RB O
20 CD O
or CC O
40 CD O
mg NN O
) -RRB- O
treatment NN O
was VBD O
given VBN O
. . O
null null null-Disease
Follow VB O
- HYPH O
up NN O
visits NNS O
were VBD O
scheduled VBN O
with IN O
2 CD O
- HYPH O
drug NN O
therapy NN O
every DT O
6 CD O
to TO O
8 CD O
weeks NNS O
, , O
an DT O
average NN O
of IN O
10 CD O
. . O
3 CD O
visits NNS O
per IN O
patient NN O
, , O
with IN O
741 CD O
batteries NNS O
of IN O
6 CD O
liver NN O
function NN O
tests NNS O
and CC O
714 CD O
creatine JJ O
phosphokinase NN O
levels NNS O
measured VBN O
. . O
null null null-Disease
Only RB O
1 CD O
of IN O
the DT O
4 CD O
, , O
446 CD O
liver NN O
function NN O
tests NNS O
( , O
0 CD O
. . O
02 CD O
% NN O
) -RRB- O
, , O
a DT O
gamma NN O
glutamyl NN O
transferase NN O
, , O
was VBD O
greater JJR O
than IN O
or CC O
equal JJ O
to IN O
3 CD O
times NNS O
the DT O
upper JJ O
normal JJ O
limit NN O
. . O
null null null-Disease
Of IN O
the DT O
714 CD O
creatine JJ O
phosphokinase NN O
levels NNS O
, , O
9 CD O
% NN O
were VBD O
high JJ O
; : O
only RB O
1 CD O
( SYM O
0 CD O
. . O
1 CD O
% NN O
) -RRB- O
was VBD O
greater JJR O
than IN O
or CC O
equal JJ O
to IN O
3 CD O
times NNS O
the DT O
upper JJ O
normal JJ O
limit NN O
. . O
null null null-Disease
With IN O
2 CD O
- HYPH O
drug NN O
therapy NN O
, , O
mean JJ O
total JJ O
cholesterol NN O
decreased VBD O
22 CD O
% NN O
from IN O
255 CD O
to IN O
200 CD O
mg NNS O
/ SYM O
dl NN O
, , O
triglyceride NN O
levels NNS O
decreased VBD O
35 CD O
% NN O
from IN O
236 CD O
to IN O
154 CD O
mg NNS O
/ SYM O
dl NN O
, , O
LDL NNP O
cholesterol NN O
decreased VBD O
26 CD O
% NN O
from IN O
176 CD O
to IN O
131 CD O
mg NNS O
/ SYM O
dl NN O
, , O
and CC O
the DT O
total JJ O
cholesterol NN O
/ SYM O
HDL NNP O
cholesterol NN O
ratio NN O
decreased VBD O
24 CD O
% NN O
from IN O
7 CD O
. . O
1 CD O
to IN O
5 CD O
. . O
4 CD O
, , O
all DT O
p NN O
less JJR O
than IN O
or CC O
equal JJ O
to IN O
0 CD O
. . O
0001 CD O
. . O
null null null-Disease
Myositis NN B-Disease
, , O
attributable JJ O
to IN O
the DT O
drug NN O
combination NN O
and CC O
symptomatic JJ O
enough RB O
to TO O
discontinue VB O
it PRP O
, , O
occurred VBD O
in IN O
3 CD O
% NN O
of IN O
patients NNS O
, , O
and CC O
in IN O
1 CD O
% NN O
with IN O
concurrent JJ O
high JJ O
creatine NN O
phosphokinase NN O
( SYM O
769 CD O
U NN O
/ SYM O
liter NN O
) -RRB- O
; : O
no DT O
patients NNS O
had VBD O
rhabdomyolysis NN B-Disease
or CC O
myoglobinuria NN B-Disease
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) -RRB- O
null null null-Disease
Does VBZ O
domperidone NN O
potentiate VB O
mirtazapine NN O
- HYPH O
associated VBN O
restless JJ B-Disease
legs NNS I-Disease
syndrome NN I-Disease
? . O
null null null-Disease
There EX O
is VBZ O
now RB O
evidence NN O
to TO O
suggest VB O
a DT O
central JJ O
role NN O
for IN O
the DT O
dopaminergic JJ O
system NN O
in IN O
restless JJ B-Disease
legs NNS I-Disease
syndrome NN I-Disease
( , O
RLS NNP B-Disease
) -RRB- O
. . O
null null null-Disease
For IN O
example NN O
, , O
the DT O
symptoms NNS O
of IN O
RLS NNP B-Disease
can MD O
be VB O
dramatically RB O
improved VBN O
by IN O
levodopa NN O
and CC O
dopamine NN O
agonists NNS O
, , O
whereas IN O
central JJ O
dopamine NN O
D2 NN O
receptor NN O
antagonists NNS O
can MD O
induce VB O
or CC O
aggravate VB O
RLS NNP B-Disease
symptoms NNS O
. . O
null null null-Disease
To IN O
our PRP$ O
knowledge NN O
, , O
there EX O
is VBZ O
no DT O
previous JJ O
report NN O
regarding VBG O
whether IN O
domperidone NN O
, , O
a DT O
peripheral JJ O
dopamine NN O
D2 NN O
receptor NN O
antagonist NN O
, , O
can MD O
also RB O
induce VB O
or CC O
aggravate VB O
symptoms NNS O
of IN O
RLS NNP B-Disease
. . O
null null null-Disease
Mirtazapine NNP O
, , O
the DT O
first JJ O
noradrenergic JJ O
and CC O
specific JJ O
serotonergic JJ O
antidepressant NN O
( , O
NaSSA NNP O
) -RRB- O
, , O
has VBZ O
been VBN O
associated VBN O
with IN O
RLS NNP B-Disease
in IN O
several JJ O
recent JJ O
publications NNS O
. . O
null null null-Disease
The DT O
authors NNS O
report VBP O
here RB O
a DT O
depressed JJ O
patient NN O
comorbid NN O
with IN O
postprandial JJ B-Disease
dyspepsia NN I-Disease
who WP O
developed VBD O
RLS NNP B-Disease
after IN O
mirtazapine NN O
had VBD O
been VBN O
added VBN O
to IN O
his PRP$ O
domperidone NN O
therapy NN O
. . O
null null null-Disease
Our PRP$ O
patient NN O
started VBD O
to TO O
have VB O
symptoms NNS O
of IN O
RLS NNP B-Disease
only RB O
after IN O
he PRP O
had VBD O
been VBN O
treated VBN O
with IN O
mirtazapine NN O
, , O
and CC O
his PRP$ O
RLS NNP B-Disease
symptoms NNS O
resolved VBN O
completely RB O
upon IN O
discontinuation NN O
of IN O
his PRP$ O
mirtazapine NN O
. . O
null null null-Disease
Such PDT O
a DT O
temporal JJ O
relationship NN O
between IN O
the DT O
use NN O
of IN O
mirtazapine NN O
and CC O
the DT O
symptoms NNS O
of IN O
RLS NNP B-Disease
in IN O
our PRP$ O
patient NN O
did VBD O
not RB O
support VB O
a DT O
potentiating VBG O
effect NN O
of IN O
domperione NN O
on IN O
mirtazapine NN O
- HYPH O
associated VBN O
RLS NNP B-Disease
. . O
null null null-Disease
However RB O
, , O
physicians NNS O
should MD O
be VB O
aware JJ O
of IN O
the DT O
possibility NN O
that IN O
mirtazapine NN O
can MD O
be VB O
associated VBN O
with IN O
RLS NNP B-Disease
in IN O
some DT O
individuals NNS O
, , O
especially RB O
those DT O
receiving VBG O
concomitant JJ O
dopamine NN O
D2 NNP O
receptor NN O
antagonists NNS O
. . O
null null null-Disease
Antiandrogenic JJ O
therapy NN O
can MD O
cause VB O
coronary JJ B-Disease
arterial JJ I-Disease
disease NN I-Disease
. . O
null null null-Disease
AIM NN O
: : O
To TO O
study VB O
the DT O
change NN O
of IN O
lipid NN O
metabolism NN O
by IN O
antiandrogen NN O
therapy NN O
in IN O
patients NNS O
with IN O
prostate NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
MATERIALS NNS O
AND CC O
METHODS NNS O
: : O
We PRP O
studied VBD O
with IN O
a DT O
2 CD O
. . O
5 CD O
years NNS O
follow NN O
- HYPH O
up NN O
the DT O
changes NNS O
in IN O
plasma NN O
cholesterols NNS O
( -LRB- O
C NNP O
) -RRB- O
, , O
triglycerides NNS O
( , O
TG NNP O
) -RRB- O
, , O
lipoproteins NNS O
( , O
LP NNP O
) -RRB- O
, , O
and CC O
apolipoproteins NNS O
( , O
Apo NNP O
) -RRB- O
B NNP O
- HYPH O
100 CD O
, , O
A NN O
- HYPH O
I NN O
, , O
and CC O
A NN O
- HYPH O
II NN O
pro FW O
fi FW O
les FW O
in IN O
24 CD O
patients NNS O
of IN O
mean JJ O
age NN O
60 CD O
years NNS O
with IN O
low JJ O
risk NN O
prostate NN B-Disease
cancer NN I-Disease
( , O
stage NN O
: : O
T1cN0M0 NNP O
, , O
Gleason NNP O
score NN O
: : O
2 CD O
- HYPH O
5 CD O
) -RRB- O
during IN O
treatment NN O
with IN O
cyproterone NN O
acetate NN O
( -LRB- O
CPA NN O
) -RRB- O
without IN O
surgical JJ O
management NN O
or CC O
radiation NN O
therapy NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Significant JJ O
decreases NNS O
of IN O
HDL NNP O
- HYPH O
C NNP O
, , O
Apo NNP O
A NNP O
- HYPH O
I NNP O
and CC O
Apo NNP O
A NNP O
- HYPH O
II NN O
and CC O
an DT O
increase NN O
of IN O
triglyceride NN O
levels NNS O
in IN O
VLDL NNP O
were VBD O
induced VBN O
by IN O
CPA NNP O
. . O
null null null-Disease
After IN O
a DT O
period NN O
of IN O
2 CD O
. . O
5 CD O
years NNS O
on IN O
CPA NN O
treatment NN O
, , O
four CD O
patients NNS O
out IN O
of IN O
twenty CD O
- HYPH O
four CD O
were VBD O
found VBN O
to TO O
be VB O
affected VBN O
by IN O
coronary JJ B-Disease
heart NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Ischaemic JJ O
coronary JJ B-Disease
arteriosclerosis NN I-Disease
with IN O
an DT O
incidence NN O
rate NN O
of IN O
16 CD O
. . O
6 CD O
% NN O
as IN O
caused VBN O
by IN O
prolonged VBN O
CPA NN O
therapy NN O
is VBZ O
mediated VBN O
through IN O
changes NNS O
in IN O
HDL NNP O
cholesterol NN O
, , O
Apo NNP O
A NNP O
- HYPH O
I NNP O
and CC O
Apo NNP O
A NNP O
- HYPH O
II NNP O
pro FW O
fi FW O
les FW O
, , O
other JJ O
than IN O
the DT O
well RB O
- HYPH O
known VBN O
hyperglyceridemic JJ B-Disease
effect NN I-Disease
caused VBN O
by IN O
estrogen NN O
. . O
null null null-Disease
5 CD O
- HYPH O
Fluorouracil NN O
cardiotoxicity NN B-Disease
induced VBN O
by IN O
alpha NN O
- HYPH O
fluoro NN O
- HYPH O
beta NN O
- HYPH O
alanine NN O
. . O
null null null-Disease
Cardiotoxicity NN B-Disease
is VBZ O
a DT O
rare JJ O
complication NN O
occurring VBG O
during IN O
5 CD O
- HYPH O
fluorouracil NN O
( HYPH O
5 CD O
- HYPH O
FU NN O
) -RRB- O
treatment NN O
for IN O
malignancies NNS B-Disease
. . O
null null null-Disease
We PRP O
herein RB O
report VBP O
the DT O
case NN O
of IN O
a DT O
70 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
with IN O
5 CD O
- HYPH O
FU NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
, , O
in IN O
whom WP O
a DT O
high JJ O
serum JJ O
level NN O
of IN O
alpha NN O
- HYPH O
fluoro NN O
- HYPH O
beta NN O
- HYPH O
alanine NN O
( , O
FBAL NNP O
) -RRB- O
was VBD O
observed VBN O
. . O
null null null-Disease
The DT O
patient NN O
, , O
who WP O
had VBD O
unresectable JJ O
colon NN B-Disease
cancer NN I-Disease
metastases NNS O
to IN O
the DT O
liver NN O
and CC O
lung NN O
, , O
was VBD O
referred VBN O
to IN O
us PRP O
for IN O
chemotherapy NN O
from IN O
an DT O
affiliated JJ O
hospital NN O
; : O
he PRP O
had VBD O
no DT O
cardiac JJ O
history NN O
. . O
null null null-Disease
After IN O
admission NN O
, , O
the DT O
patient NN O
received VBD O
a DT O
continuous JJ O
intravenous JJ O
infusion NN O
of IN O
5 CD O
- HYPH O
FU NN O
( SYM O
1000 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
, , O
during IN O
which WDT O
precordial JJ B-Disease
pain NN I-Disease
with IN O
right JJ B-Disease
bundle NN I-Disease
branch NN I-Disease
block NN I-Disease
occurred VBD O
concomitantly RB O
with IN O
a DT O
high JJ O
serum NN O
FBAL NNP O
concentration NN O
of IN O
1955 CD O
ng NN O
/ SYM O
ml NN O
. . O
null null null-Disease
Both CC O
the DT O
precordial JJ B-Disease
pain NN I-Disease
and CC O
the DT O
electrocardiographic JJ O
changes NNS O
disappeared VBD O
spontaneously RB O
after IN O
the DT O
discontinuation NN O
of IN O
5 CD O
- HYPH O
FU NNP O
. . O
null null null-Disease
As IN O
the DT O
precordial JJ B-Disease
pain NN I-Disease
in IN O
this DT O
patient NN O
was VBD O
considered VBN O
to TO O
have VB O
been VBN O
due JJ O
to IN O
5 CD O
- HYPH O
FU NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
, , O
the DT O
administration NN O
of IN O
5 CD O
- HYPH O
FU NNP O
was VBD O
abandoned VBN O
. . O
null null null-Disease
Instead RB O
, , O
oral JJ O
administration NN O
of IN O
S NNP O
- HYPH O
1 CD O
( , O
a DT O
derivative NN O
of IN O
5 CD O
- HYPH O
FU NNP O
) -RRB- O
, , O
at IN O
200 CD O
mg NNS O
/ SYM O
day NN O
twice RB O
a DT O
week NN O
, , O
was VBD O
instituted VBN O
, , O
because IN O
S NNP O
- HYPH O
1 CD O
has VBZ O
a DT O
strong JJ O
inhibitory JJ O
effect NN O
on IN O
dihydropyrimidine NN O
dehydrogenase NN O
, , O
which WDT O
catalyzes VBZ O
the DT O
degradative NN O
of IN O
5 CD O
- HYPH O
FU NN O
into IN O
FBAL NNP O
. . O
null null null-Disease
The DT O
serum NN O
FBAL NNP O
concentration NN O
subsequently RB O
decreased VBD O
to IN O
352 CD O
ng CD O
/ SYM O
ml NNS O
, , O
the DT O
same JJ O
as IN O
the DT O
value NN O
measured VBN O
on IN O
the DT O
first JJ O
day NN O
of IN O
S NNP O
- HYPH O
1 CD O
administration NN O
. . O
null null null-Disease
Thereafter RB O
, , O
no DT O
cardiac JJ B-Disease
symptoms NNS I-Disease
were VBD O
observed VBN O
. . O
null null null-Disease
The DT O
patient NN O
achieved VBD O
a DT O
partial JJ O
response NN O
6 CD O
months NNS O
after IN O
the DT O
initiation NN O
of IN O
the DT O
S NNP O
- HYPH O
1 CD O
treatment NN O
. . O
null null null-Disease
The DT O
experience NN O
of IN O
this DT O
case NN O
, , O
together RB O
with IN O
a DT O
review NN O
of IN O
the DT O
literature NN O
, , O
suggests VBZ O
that IN O
FBAL NNP O
is VBZ O
related VBN O
to IN O
5 CD O
- HYPH O
FU NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
S NNP O
- HYPH O
1 CD O
may MD O
be VB O
administered VBN O
safely RB O
to IN O
patients NNS O
with IN O
5 CD O
- HYPH O
FU NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
Hepatocellular JJ B-Disease
carcinoma NN I-Disease
in IN O
Fanconi NNP B-Disease
' POS I-Disease
s POS I-Disease
anemia NN I-Disease
treated VBN O
with IN O
androgen NN O
and CC O
corticosteroid NN O
. . O
null null null-Disease
The DT O
case NN O
of IN O
an DT O
11 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
boy NN O
is VBZ O
reported VBN O
who WP O
was VBD O
known VBN O
to TO O
have VB O
Fanconi NNP B-Disease
' POS I-Disease
s POS I-Disease
anemia NN I-Disease
for IN O
3 CD O
years NNS O
and CC O
was VBD O
treated VBN O
with IN O
androgens NNS O
, , O
corticosteroids NNS O
and CC O
transfusions NNS O
. . O
null null null-Disease
Two CD O
weeks NNS O
before IN O
his PRP$ O
death NN O
he PRP O
was VBD O
readmitted VBN O
because IN O
of IN O
aplastic JJ O
crisis NN O
with IN O
septicemia NN B-Disease
and CC O
marked VBN O
abnormalities NNS O
in IN O
liver NN O
function NN O
and CC O
died VBD O
of IN O
hemorrhagic JJ B-Disease
bronchopneumonia NN I-Disease
. . O
null null null-Disease
At IN O
autopsy NN O
peliosis NN B-Disease
and CC O
multiple JJ O
hepatic JJ B-Disease
tumors NNS I-Disease
were VBD O
found VBN O
which WDT O
histologically RB O
proved VBD O
to TO O
be VB O
well RB O
- HYPH O
differentiated VBN O
hepatocellular JJ B-Disease
carcinoma NN I-Disease
. . O
null null null-Disease
This DT O
case NN O
contributes VBZ O
to IN O
the DT O
previous JJ O
observations NNS O
that IN O
non RB O
- HYPH O
metastasizing VBG O
hepatic JJ B-Disease
neoplasms NNS I-Disease
and CC O
peliosis NN B-Disease
can MD O
develop VB O
in IN O
patients NNS O
with IN O
androgen NN O
- HYPH O
and CC O
corticosteroid NN O
- HYPH O
treated VBN O
Fanconi NNP B-Disease
' POS I-Disease
s NN I-Disease
anemia NN I-Disease
. . O
null null null-Disease
The DT O
influence NN O
of IN O
the DT O
time NN O
interval NN O
between IN O
monoHER NNP O
and CC O
doxorubicin NN O
administration NN O
on IN O
the DT O
protection NN O
against IN O
doxorubicin NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
in IN O
mice NNS O
. . O
null null null-Disease
PURPOSE NN O
: : O
Despite IN O
its PRP$ O
well RB O
- HYPH O
known VBN O
cardiotoxicity NN B-Disease
, , O
the DT O
anthracyclin NN O
doxorubicin NN O
( -LRB- O
DOX NNP O
) -RRB- O
continues VBZ O
to TO O
be VB O
an DT O
effective JJ O
and CC O
widely RB O
used VBN O
chemotherapeutic JJ O
agent NN O
. . O
null null null-Disease
DOX NNP O
- HYPH O
induced VBN O
cardiac JJ B-Disease
damage NN I-Disease
presumably RB O
results VBZ O
from IN O
the DT O
formation NN O
of IN O
free JJ O
radicals NNS O
by IN O
DOX NNP O
. . O
null null null-Disease
Reactive JJ O
oxygen NN O
species NNS O
particularly RB O
affect VBP O
the DT O
cardiac JJ O
myocytes NNS O
because IN O
these DT O
cells NNS O
seem VBP O
to TO O
have VB O
a DT O
relatively RB O
poor JJ O
antioxidant JJ O
defense NN O
system NN O
. . O
null null null-Disease
The DT O
semisynthetic JJ O
flavonoid NN O
monohydroxyethylrutoside NN O
( -LRB- O
monoHER NN O
) -RRB- O
showed VBD O
cardioprotection NN O
against IN O
DOX NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
through IN O
its PRP$ O
radical JJ O
scavenging NN O
and CC O
iron NN O
chelating NN O
properties NNS O
. . O
null null null-Disease
Because IN O
of IN O
the DT O
relatively RB O
short JJ O
final JJ O
half JJ O
- HYPH O
life NN O
of IN O
monoHER NNP O
( : O
about RB O
30 CD O
min NN O
) -RRB- O
, , O
it PRP O
is VBZ O
expected VBN O
that IN O
the DT O
time NN O
interval NN O
between IN O
monoHER NNP O
and CC O
DOX NNP O
might MD O
be VB O
of IN O
influence NN O
on IN O
the DT O
cardioprotective JJ O
effect NN O
of IN O
monoHER NN O
. . O
null null null-Disease
Therefore RB O
, , O
the DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
investigate VB O
this DT O
possible JJ O
effect NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Six CD O
groups NNS O
of IN O
6 CD O
BALB NNP O
/ SYM O
c NN O
mice NNS O
were VBD O
treated VBN O
with IN O
saline NN O
, , O
DOX NNP O
alone RB O
or CC O
DOX NNP O
( , O
4 CD O
mg NNS O
/ SYM O
kg NN O
i CD O
. . O
v NN O
. . O
) -RRB- O
preceded VBN O
by IN O
monoHER NNP O
( : O
500 CD O
mg NN O
/ SYM O
kg NN O
i CD O
. . O
p NN O
. . O
) -RRB- O
with IN O
an DT O
interval NN O
of IN O
10 CD O
, , O
30 CD O
, , O
60 CD O
or CC O
120 CD O
min NN O
. . O
null null null-Disease
After IN O
a DT O
6 CD O
- HYPH O
week NN O
treatment NN O
period NN O
and CC O
additional JJ O
observation NN O
for IN O
2 CD O
weeks NNS O
, , O
the DT O
mice NNS O
were VBD O
sacrificed VBN O
. . O
null null null-Disease
Their PRP$ O
cardiac JJ O
tissues NNS O
were VBD O
processed VBN O
for IN O
light JJ O
microscopy NN O
, , O
after IN O
which WDT O
cardiomyocyte NN B-Disease
damage NN I-Disease
was VBD O
evaluated VBN O
according VBG O
to IN O
Billingham NNP O
( : O
in IN O
Cancer NNP B-Disease
Treat NNP O
Rep NNP O
62 CD O
( SYM O
6 CD O
) SYM O
: : O
865 CD O
- HYPH O
872 CD O
, , O
1978 CD O
) -RRB- O
. . O
null null null-Disease
Microscopic JJ O
evaluation NN O
revealed VBD O
that IN O
treatment NN O
with IN O
DOX NNP O
alone RB O
induced VBD O
significant JJ O
cardiac JJ B-Disease
damage NN I-Disease
in IN O
comparison NN O
to IN O
the DT O
saline NN O
control NN O
group NN O
( , O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
number NN O
of IN O
damaged VBN O
cardiomyocytes NNS O
was VBD O
9 CD O
. . O
6 CD O
- HYPH O
fold NN O
( : O
95 CD O
% NN O
CI NN O
4 CD O
. . O
4 CD O
- SYM O
21 CD O
. . O
0 CD O
) -RRB- O
higher JJR O
in IN O
mice NNS O
treated VBN O
with IN O
DOX NNP O
alone RB O
than IN O
that DT O
in IN O
animals NNS O
of IN O
the DT O
control NN O
group NN O
. . O
null null null-Disease
The DT O
ratio NN O
of IN O
aberrant JJ O
cardiomyocytes NNS O
in IN O
mice NNS O
treated VBN O
with IN O
DOX NNP O
preceded VBN O
by IN O
monoHER NNP O
and CC O
those DT O
in IN O
mice NNS O
treated VBN O
with IN O
saline NN O
ranged VBD O
from IN O
1 CD O
. . O
6 CD O
to IN O
2 CD O
. . O
8 CD O
( , O
mean JJ O
2 CD O
. . O
2 CD O
, , O
95 CD O
% NN O
CI NN O
1 CD O
. . O
2 CD O
- SYM O
4 CD O
. . O
1 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
019 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
mean JJ O
protective JJ O
effect NN O
by IN O
adding VBG O
monoHER NNP O
before IN O
DOX NNP O
led VBD O
to IN O
a DT O
significant JJ O
4 CD O
. . O
4 CD O
- HYPH O
fold NN O
reduction NN O
( : O
P NN O
< SYM O
0 CD O
. . O
001 CD O
, , O
95 CD O
% NN O
CI NN O
2 CD O
. . O
3 CD O
- SYM O
8 CD O
. . O
2 CD O
) -RRB- O
of IN O
abnormal JJ O
cardiomyocytes NNS O
. . O
null null null-Disease
This DT O
protective JJ O
effect NN O
did VBD O
not RB O
depend VB O
on IN O
the DT O
time NN O
interval NN O
between IN O
monoHER NNP O
and CC O
DOX NNP O
administration NN O
( : O
P NNP O
= SYM O
0 CD O
. . O
345 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
results NNS O
indicate VBP O
that IN O
in IN O
an DT O
outpatient JJ O
clinical JJ O
setting NN O
monoHER NNP O
may MD O
be VB O
administered VBN O
shortly RB O
before IN O
DOX NNP O
. . O
null null null-Disease
Clinical JJ O
evaluation NN O
of IN O
adverse JJ O
effects NNS O
during IN O
bepridil JJ O
administration NN O
for IN O
atrial JJ B-Disease
fibrillation NN I-Disease
and CC I-Disease
flutter NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Bepridil NNP O
hydrochloride NN O
( -LRB- O
Bpd NNP O
) -RRB- O
has VBZ O
attracted VBN O
attention NN O
as IN O
an DT O
effective JJ O
drug NN O
for IN O
atrial JJ B-Disease
fibrillation NN I-Disease
( , O
AF NNP B-Disease
) -RRB- O
and CC O
atrial JJ B-Disease
flutter NN I-Disease
( , O
AFL NNP B-Disease
) -RRB- O
. . O
null null null-Disease
However RB O
, , O
serious JJ O
adverse JJ O
effects NNS O
, , O
including VBG O
torsade NN B-Disease
de FW I-Disease
pointes FW I-Disease
( , O
Tdp NNP B-Disease
) -RRB- O
, , O
have VBP O
been VBN O
reported VBN O
. . O
null null null-Disease
METHODS NNS O
AND CC O
RESULTS NNS O
: : O
Adverse JJ O
effects NNS O
of IN O
Bpd NNP O
requiring VBG O
discontinuation NN O
of IN O
treatment NN O
were VBD O
evaluated VBN O
. . O
null null null-Disease
Bpd NNP O
was VBD O
administered VBN O
to IN O
459 CD O
patients NNS O
( , O
361 CD O
males NNS O
, , O
63 CD O
+ CD O
/ SYM O
- HYPH O
12 CD O
years NNS O
old JJ O
) , O
comprising VBG O
378 CD O
AF NNP B-Disease
and CC O
81 CD O
AFL NNP B-Disease
cases NNS O
. . O
null null null-Disease
Mean JJ O
left JJ O
ventricular JJ O
ejection NN O
fraction NN O
and CC O
atrial JJ O
dimension NN O
( -LRB- O
LAD NNP O
) -RRB- O
were VBD O
66 CD O
+ CD O
/ SYM O
- SYM O
11 CD O
% NN O
and CC O
40 CD O
+ NN O
/ SYM O
- SYM O
6 CD O
mm NN O
, , O
respectively RB O
. . O
null null null-Disease
Adverse JJ O
effects NNS O
were VBD O
observed VBN O
in IN O
19 CD O
patients NNS O
( : O
4 CD O
% NN O
) -RRB- O
during IN O
an DT O
average JJ O
follow NN O
- HYPH O
up NN O
of IN O
20 CD O
months NNS O
. . O
null null null-Disease
There EX O
was VBD O
marked VBN O
QT NNP B-Disease
prolongation NN I-Disease
greater JJR O
than IN O
0 CD O
. . O
55 CD O
s NNS O
in IN O
13 CD O
patients NNS O
, , O
bradycardia NN B-Disease
less JJR O
than IN O
40 CD O
beats NNS O
/ SYM O
min NN O
in IN O
6 CD O
patients NNS O
, , O
dizziness NN B-Disease
and CC O
general JJ O
fatigue NN B-Disease
in IN O
1 CD O
patient NN O
each DT O
. . O
null null null-Disease
In IN O
4 CD O
of IN O
13 CD O
patients NNS O
with IN O
QT NNP B-Disease
prolongation NN I-Disease
, , O
Tdp NNP B-Disease
occurred VBD O
. . O
null null null-Disease
The DT O
major JJ O
triggering VBG O
factors NNS O
of IN O
Tdp NNP B-Disease
were VBD O
hypokalemia NN B-Disease
and CC O
sudden JJ O
decrease NN O
in IN O
heart NN O
rate NN O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
differences NNS O
in IN O
the DT O
clinical JJ O
backgrounds NNS O
of IN O
the DT O
patients NNS O
with IN O
and CC O
without IN O
Tdp NNP B-Disease
other JJ O
than IN O
LAD NN O
and CC O
age NN O
, , O
which WDT O
were VBD O
larger JJR O
and CC O
older JJR O
in IN O
the DT O
patients NNS O
with IN O
Tdp NNP B-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
Careful JJ O
observation NN O
of IN O
serum NN O
potassium NN O
concentration NN O
and CC O
the DT O
ECG NNP O
should MD O
always RB O
be VB O
done VBN O
during IN O
Bpd NNP O
administration NN O
, , O
particularly RB O
in IN O
elderly JJ O
patients NNS O
. . O
null null null-Disease
Enhanced VBN O
isoproterenol NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
hypertrophy NN I-Disease
in IN O
transgenic JJ O
rats NNS O
with IN O
low JJ O
brain NN O
angiotensinogen NN O
. . O
null null null-Disease
We PRP O
have VBP O
previously RB O
shown VBN O
that IN O
a DT O
permanent JJ O
deficiency NN O
in IN O
the DT O
brain NN O
renin NN O
- HYPH O
angiotensin NN O
system NN O
( , O
RAS NNP O
) -RRB- O
may MD O
increase VB O
the DT O
sensitivity NN O
of IN O
the DT O
baroreflex NN O
control NN O
of IN O
heart NN O
rate NN O
. . O
null null null-Disease
In IN O
this DT O
study NN O
we PRP O
aimed VBN O
at IN O
studying VBG O
the DT O
involvement NN O
of IN O
the DT O
brain NN O
RAS NN O
in IN O
the DT O
cardiac JJ O
reactivity NN O
to IN O
the DT O
beta NN O
- HYPH O
adrenoceptor NN O
( , O
beta NN O
- HYPH O
AR NN O
) -RRB- O
agonist NN O
isoproterenol NN O
( , O
Iso NNP O
) -RRB- O
. . O
null null null-Disease
Transgenic JJ O
rats NNS O
with IN O
low JJ O
brain NN O
angiotensinogen NN O
( -LRB- O
TGR NNP O
) -RRB- O
were VBD O
used VBN O
. . O
null null null-Disease
In IN O
isolated JJ O
hearts NNS O
, , O
Iso NNP O
induced VBD O
a DT O
significantly RB O
greater JJR O
increase NN O
in IN O
left JJ O
ventricular JJ O
( , O
LV NN O
) , O
pressure NN O
and CC O
maximal JJ O
contraction NN O
( , O
+ SYM O
dP NN O
/ SYM O
dt FW O
( -LRB- O
max NN O
) -RRB- O
) -RRB- O
in IN O
the DT O
TGR NNP O
than IN O
in IN O
the DT O
Sprague NNP O
- HYPH O
Dawley NNP O
( -LRB- O
SD NNP O
) -RRB- O
rats NNS O
. . O
null null null-Disease
LV NN B-Disease
hypertrophy NN I-Disease
induced VBN O
by IN O
Iso NNP O
treatment NN O
was VBD O
significantly RB O
higher JJR O
in IN O
TGR NNP O
than IN O
in IN O
SD NN O
rats NNS O
( , O
in IN O
g VBG O
LV NN O
wt NN O
/ SYM O
100 CD O
g NN O
body NN O
wt NN O
, , O
0 CD O
. . O
28 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
004 CD O
vs NN O
. . O
0 CD O
. . O
24 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
004 CD O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
The DT O
greater JJR O
LV NN B-Disease
hypertrophy NN I-Disease
in IN O
TGR NNP O
rats NNS O
was VBD O
associated VBN O
with IN O
more RBR O
pronounced JJ O
downregulation NN O
of IN O
beta NN O
- HYPH O
AR NN O
and CC O
upregulation NN O
of IN O
LV NN O
beta NN O
- HYPH O
AR NN O
kinase NN O
- HYPH O
1 CD O
mRNA NN O
levels NNS O
compared VBN O
with IN O
those DT O
in IN O
SD NNP O
rats NNS O
. . O
null null null-Disease
The DT O
decrease NN O
in IN O
the DT O
heart NN O
rate NN O
( -LRB- O
HR NN O
) -RRB- O
induced VBN O
by IN O
the DT O
beta NN O
- HYPH O
AR NN O
antagonist NN O
metoprolol NN O
in IN O
conscious JJ O
rats NNS O
was VBD O
significantly RB O
attenuated VBN O
in IN O
TGR NNP O
compared VBN O
with IN O
SD NN O
rats NNS O
( -LRB- O
- SYM O
9 CD O
. . O
9 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
7 CD O
% NN O
vs IN O
. . O
- : O
18 CD O
. . O
1 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
5 CD O
% NN O
) -RRB- O
, , O
whereas IN O
the DT O
effect NN O
of IN O
parasympathetic JJ O
blockade NN O
by IN O
atropine NN O
on IN O
HR NN O
was VBD O
similar JJ O
in IN O
both DT O
strains NNS O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
TGR NNP O
are VBP O
more RBR O
sensitive JJ O
to IN O
beta NN O
- HYPH O
AR NN O
agonist NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
inotropic JJ I-Disease
response NN O
and CC O
hypertrophy NN B-Disease
, , O
possibly RB O
due IN O
to IN O
chronically RB O
low JJ O
sympathetic JJ O
outflow NN O
directed VBN O
to IN O
the DT O
heart NN O
. . O
null null null-Disease
Drug NN O
- HYPH O
induced VBN O
long JJ B-Disease
QT NNP I-Disease
syndrome NN I-Disease
in IN O
injection NN O
drug NN O
users NNS O
receiving VBG O
methadone NN O
: : O
high JJ O
frequency NN O
in IN O
hospitalized JJ O
patients NNS O
and CC O
risk NN O
factors NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Drug NN O
- HYPH O
induced VBN O
long JJ B-Disease
QT NNP I-Disease
syndrome NN I-Disease
is VBZ O
a DT O
serious JJ O
adverse JJ O
drug NN O
reaction NN O
. . O
null null null-Disease
Methadone NN O
prolongs VBZ O
the DT O
QT NNP O
interval NN O
in IN O
vitro FW O
in IN O
a DT O
dose NN O
- HYPH O
dependent JJ O
manner NN O
. . O
null null null-Disease
In IN O
the DT O
inpatient JJ O
setting NN O
, , O
the DT O
frequency NN O
of IN O
QT NNP B-Disease
interval JJ I-Disease
prolongation NN I-Disease
with IN O
methadone NN O
treatment NN O
, , O
its PRP$ O
dose NN O
dependence NN O
, , O
and CC O
the DT O
importance NN O
of IN O
cofactors NNS O
such JJ O
as IN O
drug NN O
- HYPH O
drug NN O
interactions NNS O
remain VBP O
unknown JJ O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
performed VBD O
a DT O
systematic JJ O
, , O
retrospective JJ O
study NN O
comparing VBG O
active JJ O
or CC O
former JJ O
intravenous JJ O
drug NN O
users NNS O
receiving VBG O
methadone NN O
and CC O
those DT O
not RB O
receiving VBG O
methadone NN O
among IN O
all DT O
patients NNS O
hospitalized VBN O
over IN O
a DT O
5 CD O
- HYPH O
year NN O
period NN O
in IN O
a DT O
tertiary JJ O
care NN O
hospital NN O
. . O
null null null-Disease
A DT O
total NN O
of IN O
167 CD O
patients NNS O
receiving VBG O
methadone NN O
fulfilled VBD O
the DT O
inclusion NN O
criteria NNS O
and CC O
were VBD O
compared VBN O
with IN O
a DT O
control NN O
group NN O
of IN O
80 CD O
injection NN O
drug NN O
users NNS O
not RB O
receiving VBG O
methadone NN O
. . O
null null null-Disease
In IN O
addition NN O
to IN O
methadone NN O
dose NN O
, , O
15 CD O
demographic JJ O
, , O
biological JJ O
, , O
and CC O
pharmacological JJ O
variables NNS O
were VBD O
considered VBN O
as IN O
potential JJ O
risk NN O
factors NNS O
for IN O
QT NNP B-Disease
prolongation NN I-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
Among IN O
167 CD O
methadone NN O
maintenance NN O
patients NNS O
, , O
the DT O
prevalence NN O
of IN O
QTc NNP O
prolongation NN O
to IN O
0 CD O
. . O
50 CD O
second NN O
( : O
( : O
1 CD O
/ SYM O
2 CD O
) NN O
) -RRB- O
or CC O
longer JJR O
was VBD O
16 CD O
. . O
2 CD O
% NN O
compared VBN O
with IN O
0 CD O
% NN O
in IN O
80 CD O
control NN O
subjects NNS O
. . O
null null null-Disease
Six CD O
patients NNS O
( , O
3 CD O
. . O
6 CD O
% NN O
) -RRB- O
in IN O
the DT O
methadone NN O
group NN O
presented VBD O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
. . O
null null null-Disease
QTc NNP O
length NN O
was VBD O
weakly RB O
but CC O
significantly RB O
associated VBN O
with IN O
methadone NN O
daily JJ O
dose NN O
( , O
Spearman NNP O
rank NN O
correlation NN O
coefficient JJ O
, , O
0 CD O
. . O
20 CD O
; : O
P NN O
< NN O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Multivariate NN O
regression NN O
analysis NN O
allowed VBD O
attribution NN O
of IN O
31 CD O
. . O
8 CD O
% NN O
of IN O
QTc NNP O
variability NN O
to IN O
methadone NN O
dose NN O
, , O
cytochrome NN O
P NN O
- HYPH O
450 CD O
3A4 CD O
drug NN O
- HYPH O
drug NN O
interactions NNS O
, , O
hypokalemia NN B-Disease
, , O
and CC O
altered VBN O
liver NN O
function NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
QT NNP B-Disease
interval JJ I-Disease
prolongation NN I-Disease
in IN O
methadone NN O
maintenance NN O
patients NNS O
hospitalized VBN O
in IN O
a DT O
tertiary JJ O
care NN O
center NN O
is VBZ O
a DT O
frequent JJ O
finding NN O
. . O
null null null-Disease
Methadone NN O
dose NN O
, , O
presence NN O
of IN O
cytochrome NN O
P NNP O
- HYPH O
450 CD O
3A4 CD O
inhibitors NNS O
, , O
potassium NN O
level NN O
, , O
and CC O
liver NN O
function NN O
contribute VBP O
to IN O
QT NNP B-Disease
prolongation NN I-Disease
. . O
null null null-Disease
Long JJ B-Disease
QT NNP I-Disease
syndrome NN I-Disease
can MD O
occur VB O
with IN O
low JJ O
doses NNS O
of IN O
methadone NN O
. . O
null null null-Disease
Mechanisms NNS O
of IN O
hypertension NN B-Disease
induced VBN O
by IN O
nitric JJ O
oxide NN O
( -LRB- O
NO NNP O
) -RRB- O
deficiency NN O
: : O
focus VBP O
on IN O
venous JJ O
function NN O
. . O
null null null-Disease
Loss NN O
of IN O
endothelial JJ O
cell NN O
- HYPH O
derived VBN O
nitric JJ O
oxide NN O
( -LRB- O
NO NNP O
) , O
in IN O
hypertension NN B-Disease
is VBZ O
a DT O
hallmark NN O
of IN O
arterial JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
Experimental JJ O
hypertension NN B-Disease
created VBN O
by IN O
the DT O
removal NN O
of IN O
NO NNP O
, , O
however RB O
, , O
involves VBZ O
mechanisms NNS O
in IN O
addition NN O
to IN O
decreased VBN O
arterial JJ O
vasodilator NN O
activity NN O
. . O
null null null-Disease
These DT O
include VBP O
augmented JJ O
endothelin NN O
- HYPH O
1 CD O
( HYPH O
ET NNP O
- HYPH O
1 CD O
) -RRB- O
release NN O
, , O
increased VBN O
sympathetic JJ O
nervous JJ O
system NN O
activity NN O
, , O
and CC O
elevated VBN O
tissue NN O
oxidative JJ O
stress NN O
. . O
null null null-Disease
We PRP O
hypothesized VBD O
that IN O
increased VBN O
venous JJ O
smooth JJ O
muscle NN O
( -LRB- O
venomotor NN O
) -RRB- O
tone NN O
plays VBZ O
a DT O
role NN O
in IN O
Nomega NNP O
- HYPH O
nitro NNP O
- HYPH O
L NN O
- HYPH O
arginine NN O
( , O
LNNA NNP O
) -RRB- O
hypertension NN B-Disease
through IN O
these DT O
mechanisms NNS O
. . O
null null null-Disease
Rats NNS O
were VBD O
treated VBN O
with IN O
the DT O
NO NNP O
synthase NN O
inhibitor NN O
LNNA NNP O
( : O
0 CD O
. . O
5 CD O
g NN O
/ SYM O
L NN O
in IN O
drinking NN O
water NN O
) -RRB- O
for IN O
2 CD O
weeks NNS O
. . O
null null null-Disease
Mean JJ O
arterial JJ O
pressure NN O
of IN O
conscious JJ O
rats NNS O
was VBD O
119 CD O
+ SYM O
/ SYM O
- SYM O
2 CD O
mm NN O
Hg NN O
in IN O
control NN O
and CC O
194 CD O
+ SYM O
/ SYM O
- SYM O
5 CD O
mm NN O
Hg NN O
in IN O
LNNA NNP O
rats NNS O
( , O
P NN O
< SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Carotid NN O
arteries NNS O
and CC O
vena NN O
cava NN O
were VBD O
removed VBN O
for IN O
measurement NN O
of IN O
isometric JJ O
contraction NN O
. . O
null null null-Disease
Maximal JJ O
contraction NN O
to IN O
norepinephrine NN O
was VBD O
modestly RB O
reduced VBN O
in IN O
arteries NNS O
from IN O
LNNA NNP O
compared VBN O
with IN O
control NN O
rats NNS O
whereas IN O
the DT O
maximum JJ O
contraction NN O
to IN O
ET NNP O
- HYPH O
1 CD O
was VBD O
significantly RB O
reduced VBN O
( : O
54 CD O
% NN O
control NN O
) -RRB- O
. . O
null null null-Disease
Maximum JJ O
contraction NN O
of IN O
vena NN O
cava NN O
to IN O
norepinephrine NN O
( : O
37 CD O
% NN O
control NN O
) -RRB- O
also RB O
was VBD O
reduced VBN O
but CC O
no DT O
change NN O
in IN O
response NN O
to IN O
ET NNP O
- HYPH O
1 CD O
was VBD O
observed VBN O
. . O
null null null-Disease
Mean JJ O
circulatory JJ O
filling NN O
pressure NN O
, , O
an DT O
in IN O
vivo NN O
measure NN O
of IN O
venomotor NN O
tone NN O
, , O
was VBD O
not RB O
elevated VBN O
in IN O
LNNA NNP O
hypertension NN B-Disease
at IN O
1 CD O
or CC O
2 CD O
weeks NNS O
after IN O
LNNA NNP O
. . O
null null null-Disease
The DT O
superoxide NN O
scavenger NN O
tempol NN O
( : O
30 CD O
, , O
100 CD O
, , O
and CC O
300 CD O
micromol NN O
kg NNS O
( SYM O
- HYPH O
1 CD O
) -RRB- O
, , O
IV NN O
) -RRB- O
did VBD O
not RB O
change VB O
arterial JJ O
pressure NN O
in IN O
control NN O
rats NNS O
but CC O
caused VBD O
a DT O
dose NN O
- HYPH O
dependent JJ O
decrease NN O
in IN O
LNNA NNP O
rats NNS O
( : O
- HYPH O
18 CD O
+ SYM O
/ SYM O
- HYPH O
8 CD O
, , O
- HYPH O
26 CD O
+ SYM O
/ SYM O
- HYPH O
15 CD O
, , O
and CC O
- HYPH O
54 CD O
+ NN O
/ SYM O
- HYPH O
11 CD O
mm NN O
Hg NN O
) -RRB- O
. . O
null null null-Disease
Similarly RB O
, , O
ganglionic JJ O
blockade NN O
with IN O
hexamethonium NN O
caused VBD O
a DT O
significantly RB O
greater JJR O
fall NN O
in IN O
LNNA NNP O
hypertensive JJ B-Disease
rats NNS O
( : O
76 CD O
+ SYM O
/ SYM O
- SYM O
9 CD O
mm NN O
Hg NNP O
) -RRB- O
compared VBN O
with IN O
control NN O
rats NNS O
( , O
35 CD O
+ CD O
/ SYM O
- SYM O
10 CD O
mm NN O
Hg NNP O
) -RRB- O
. . O
null null null-Disease
Carotid NN O
arteries NNS O
, , O
vena NN O
cava NN O
, , O
and CC O
sympathetic JJ O
ganglia NN O
from IN O
LNNA NNP O
rats NNS O
had VBD O
higher JJR O
basal JJ O
levels NNS O
of IN O
superoxide NN O
compared VBN O
with IN O
those DT O
from IN O
control NN O
rats NNS O
. . O
null null null-Disease
These DT O
data NNS O
suggest VBP O
that IN O
while IN O
NO NNP O
deficiency NN O
increases VBZ O
oxidative JJ O
stress NN O
and CC O
sympathetic JJ O
activity NN O
in IN O
both CC O
arterial JJ O
and CC O
venous JJ O
vessels NNS O
, , O
the DT O
impact NN O
on IN O
veins NNS O
does VBZ O
not RB O
make VB O
a DT O
major JJ O
contribution NN O
to IN O
this DT O
form NN O
of IN O
hypertension NN B-Disease
. . O
null null null-Disease
Association NNP O
of IN O
DRD2 NNP O
polymorphisms NNS O
and CC O
chlorpromazine NN O
- HYPH O
induced VBN O
extrapyramidal JJ B-Disease
syndrome NN I-Disease
in IN O
Chinese JJ O
schizophrenic JJ B-Disease
patients NNS O
. . O
null null null-Disease
AIM NN O
: : O
Extrapyramidal JJ B-Disease
syndrome NN I-Disease
( : O
EPS NNP B-Disease
) -RRB- O
is VBZ O
most RBS O
commonly RB O
affected VBN O
by IN O
typical JJ O
antipsychotic JJ O
drugs NNS O
that WDT O
have VBP O
a DT O
high JJ O
affinity NN O
with IN O
the DT O
D2 NNP O
receptor NN O
. . O
null null null-Disease
Recently RB O
, , O
many JJ O
research NN O
groups NNS O
have VBP O
reported VBN O
on IN O
the DT O
positive JJ O
relationship NN O
between IN O
the DT O
genetic JJ O
variations NNS O
in IN O
the DT O
DRD2 NNP O
gene NN O
and CC O
the DT O
therapeutic JJ O
response NN O
in IN O
schizophrenia NN B-Disease
patients NNS O
as IN O
a DT O
result NN O
of IN O
the DT O
role NN O
of IN O
variations NNS O
in IN O
the DT O
receptor NN O
in IN O
modulating VBG O
receptor NN O
expression NN O
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
we PRP O
evaluate VBP O
the DT O
role NN O
DRD2 NNP O
plays VBZ O
in IN O
chlorpromazine NN O
- HYPH O
induced VBN O
EPS NNP B-Disease
in IN O
schizophrenic JJ B-Disease
patients NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
identified VBD O
seven CD O
SNP NNP O
( HYPH O
single JJ O
nucleotide NN O
polymorphism NN O
) -RRB- O
( , O
- HYPH O
141Cins NNP O
> SYM O
del NN O
, , O
TaqIB NNP O
, , O
TaqID NNP O
, , O
Ser311Cys NNP O
, , O
rs6275 NNP O
, , O
rs6277 CD O
and CC O
TaqIA NNP O
) -RRB- O
in IN O
the DT O
DRD2 NNP O
gene NN O
in IN O
146 CD O
schizophrenic JJ B-Disease
inpatients NNS O
( : O
59 CD O
with IN O
EPS NNP B-Disease
and CC O
87 CD O
without IN O
EPS NNP B-Disease
according VBG O
to IN O
the DT O
Simpson NNP O
- HYPH O
Angus NNP O
Scale NNP O
) -RRB- O
treated VBN O
with IN O
chlorpromazine NN O
after IN O
8 CD O
weeks NNS O
. . O
null null null-Disease
The DT O
alleles NNS O
of IN O
all DT O
loci NN O
were VBD O
determined VBN O
by IN O
PCR NNP O
( , O
polymerase NN O
chain NN O
reaction NN O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
Polymorphisms NNS O
TaqID NNP O
, , O
Ser311Cys NNP O
and CC O
rs6277 CD O
were VBD O
not RB O
polymorphic JJ O
in IN O
the DT O
population NN O
recruited VBN O
in IN O
the DT O
present JJ O
study NN O
. . O
null null null-Disease
No DT O
statistical JJ O
significance NN O
was VBD O
found VBN O
in IN O
the DT O
allele JJ O
distribution NN O
of IN O
- HYPH O
141Cins NNS O
> SYM O
del NN O
, , O
TaqIB NNP O
, , O
rs6275 NNP O
and CC O
TaqIA NNP O
or CC O
in IN O
the DT O
estimated VBN O
haplotypes NNS O
( , O
constituted VBN O
by IN O
TaqIB NNP O
, , O
rs6275 CD O
and CC O
TaqIA NNP O
) -RRB- O
in IN O
linkage NN O
disequilibrium NN O
between IN O
the DT O
two CD O
groups NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Our PRP$ O
results NNS O
did VBD O
not RB O
lend VB O
strong JJ O
support NN O
to IN O
the DT O
view NN O
that IN O
the DT O
genetic JJ O
variation NN O
of IN O
the DT O
DRD2 NNP O
gene NN O
plays VBZ O
a DT O
major JJ O
role NN O
in IN O
the DT O
individually RB O
variable JJ O
adverse JJ O
effect NN O
induced VBN O
by IN O
chlorpromazine NN O
, , O
at IN O
least JJS O
in IN O
Chinese JJ O
patients NNS O
with IN O
schizophrenia NN B-Disease
. . O
null null null-Disease
Our PRP$ O
results NNS O
confirmed VBD O
a DT O
previous JJ O
study NN O
on IN O
the DT O
relationship NN O
between IN O
DRD2 NNP O
and CC O
EPS NNP B-Disease
in IN O
Caucasians NNPS O
. . O
null null null-Disease
Physical JJ O
training NN O
decreases VBZ O
susceptibility NN O
to IN O
subsequent JJ O
pilocarpine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
in IN O
the DT O
rat NN O
. . O
null null null-Disease
Regular JJ O
motor NN O
activity NN O
has VBZ O
many JJ O
benefits NNS O
for IN O
mental JJ O
and CC O
physical JJ O
condition NN O
but CC O
its PRP$ O
implications NNS O
for IN O
epilepsy NN B-Disease
are VBP O
still RB O
controversial JJ O
. . O
null null null-Disease
In IN O
order NN O
to TO O
elucidate VB O
this DT O
problem NN O
, , O
we PRP O
have VBP O
studied VBN O
the DT O
effect NN O
of IN O
long JJ O
- HYPH O
term NN O
physical JJ O
activity NN O
on IN O
susceptibility NN O
to IN O
subsequent JJ O
seizures NNS B-Disease
. . O
null null null-Disease
Male JJ O
Wistar NNP O
rats NNS O
were VBD O
subjected VBN O
to IN O
repeated VBN O
training NN O
sessions NNS O
in IN O
a DT O
treadmill NN O
and CC O
swimming NN O
pool NN O
. . O
null null null-Disease
Thereafter RB O
, , O
seizures NNS B-Disease
were VBD O
induced VBN O
by IN O
pilocarpine NN O
injections NNS O
in IN O
trained VBN O
and CC O
non RB O
- HYPH O
trained VBN O
control NN O
groups NNS O
. . O
null null null-Disease
During IN O
the DT O
acute JJ O
period NN O
of IN O
status NN B-Disease
epilepticus NN I-Disease
, , O
we PRP O
measured VBD O
: : O
( , O
1 CD O
) -RRB- O
the DT O
latency NN O
of IN O
the DT O
first JJ O
motor NN O
sign NN O
, , O
( , O
2 CD O
) -RRB- O
the DT O
intensity NN O
of IN O
seizures NNS B-Disease
, , O
( , O
3 CD O
) , O
the DT O
time NN O
when WRB O
it PRP O
occurred VBD O
within IN O
the DT O
6 CD O
- HYPH O
h NN O
observation NN O
period NN O
, , O
and CC O
( , O
4 CD O
) , O
the DT O
time NN O
when WRB O
the DT O
acute JJ O
period NN O
ended VBD O
. . O
null null null-Disease
All PDT O
these DT O
behavioral JJ O
parameters NNS O
showed VBD O
statistically RB O
significant JJ O
changes NNS O
suggesting VBG O
that IN O
regular JJ O
physical JJ O
exercises NNS O
decrease VBP O
susceptibility NN O
to IN O
subsequently RB O
induced VBN O
seizures NNS B-Disease
and CC O
ameliorate VBP O
the DT O
course NN O
of IN O
experimentally RB O
induced VBN O
status NN B-Disease
epilepticus NN I-Disease
. . O
null null null-Disease
Tonic NN O
dopaminergic JJ O
stimulation NN O
impairs VBZ B-Disease
associative JJ I-Disease
learning NN I-Disease
in IN O
healthy JJ O
subjects NNS O
. . O
null null null-Disease
Endogenous JJ O
dopamine NN O
plays VBZ O
a DT O
central JJ O
role NN O
in IN O
salience NN O
coding NN O
during IN O
associative JJ O
learning NN O
. . O
null null null-Disease
Administration NN O
of IN O
the DT O
dopamine NN O
precursor NN O
levodopa NN O
enhances VBZ O
learning NN O
in IN O
healthy JJ O
subjects NNS O
and CC O
stroke NN B-Disease
patients NNS O
. . O
null null null-Disease
Because IN O
levodopa NN O
increases VBZ O
both CC O
phasic JJ O
and CC O
tonic NN O
dopaminergic JJ O
neurotransmission NN O
, , O
the DT O
critical JJ O
mechanism NN O
mediating VBG O
the DT O
enhancement NN O
of IN O
learning NN O
is VBZ O
unresolved JJ O
. . O
null null null-Disease
We PRP O
here RB O
probed VBD O
how WRB O
selective JJ O
tonic JJ O
dopaminergic JJ O
stimulation NN O
affects VBZ O
associative JJ O
learning NN O
. . O
null null null-Disease
Forty CD O
healthy JJ O
subjects NNS O
were VBD O
trained VBN O
in IN O
a DT O
novel JJ O
vocabulary NN O
of IN O
45 CD O
concrete JJ O
nouns NNS O
over IN O
the DT O
course NN O
of IN O
5 CD O
consecutive JJ O
training NN O
days NNS O
in IN O
a DT O
prospective JJ O
, , O
randomized JJ O
, , O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
- HYPH O
controlled VBN O
design NN O
. . O
null null null-Disease
Subjects NNS O
received VBD O
the DT O
tonically RB O
stimulating VBG O
dopamine NN O
- HYPH O
receptor NN O
agonist NN O
pergolide NN O
( : O
0 CD O
. . O
1 CD O
mg NN O
) -RRB- O
vs IN O
placebo NN O
120 CD O
min NN O
before IN O
training NN O
on IN O
each DT O
training NN O
day NN O
. . O
null null null-Disease
The DT O
dopamine NN O
agonist NN O
significantly RB O
impaired VBD B-Disease
novel JJ I-Disease
word NN I-Disease
learning NN I-Disease
compared VBN O
to IN O
placebo NN O
. . O
null null null-Disease
This DT O
learning NN O
decrement NN O
persisted VBD O
up RP O
to IN O
the DT O
last JJ O
follow NN O
- HYPH O
up NN O
4 CD O
weeks NNS O
post NN O
- HYPH O
training NN O
. . O
null null null-Disease
Subjects NNS O
treated VBN O
with IN O
pergolide NN O
also RB O
showed VBD O
restricted VBN O
emotional JJ O
responses NNS O
compared VBN O
to IN O
the DT O
PLACEBO NNP O
group NN O
. . O
null null null-Disease
The DT O
extent NN O
of IN O
' `` O
flattened JJ O
' '' O
affect NN O
with IN O
pergolide NN O
was VBD O
related VBN O
to IN O
the DT O
degree NN O
of IN O
learning NN O
inhibition NN O
. . O
null null null-Disease
These DT O
findings NNS O
suggest VBP O
that IN O
tonic NN O
occupation NN O
of IN O
dopamine NN O
receptors NNS O
impairs VBZ O
learning VBG O
by IN O
competition NN O
with IN O
phasic JJ O
dopamine NN O
signals NNS O
. . O
null null null-Disease
Thus RB O
, , O
phasic JJ O
signaling NN O
seems VBZ O
to TO O
be VB O
the DT O
critical JJ O
mechanism NN O
by IN O
which WDT O
dopamine NN O
enhances VBZ O
associative JJ O
learning NN O
in IN O
healthy JJ O
subjects NNS O
and CC O
stroke NN B-Disease
patients NNS O
. . O
null null null-Disease
Minocycline NN O
- HYPH O
induced VBN O
vasculitis NN B-Disease
fulfilling VBG O
the DT O
criteria NNS O
of IN O
polyarteritis NN B-Disease
nodosa NN I-Disease
. . O
null null null-Disease
A DT O
47 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
who WP O
had VBD O
been VBN O
taking VBG O
minocycline NN O
for IN O
palmoplantar JJ B-Disease
pustulosis NN I-Disease
developed VBD O
fever NN B-Disease
, , O
myalgias NNS B-Disease
, , O
polyneuropathy NN B-Disease
, , O
and CC O
testicular JJ B-Disease
pain NN I-Disease
, , O
with IN O
elevated JJ O
C NN O
- HYPH O
reactive JJ O
protein NN O
( -LRB- O
CRP NNP O
) -RRB- O
. . O
null null null-Disease
Neither CC O
myeloperoxidase NN O
- HYPH O
nor CC O
proteinase NN O
- HYPH O
3 CD O
- HYPH O
antineutrophil NN O
cytoplasmic JJ O
antibody NN O
was VBD O
positive JJ O
. . O
null null null-Disease
These DT O
manifestations NNS O
met VBD O
the DT O
American NNP O
College NNP O
of IN O
Rheumatology NNP O
1990 CD O
criteria NNS O
for IN O
the DT O
classification NN O
of IN O
polyarteritis NN B-Disease
nodosa NN I-Disease
. . O
null null null-Disease
Stopping VBG O
minocycline NN O
led VBD O
to IN O
amelioration NN O
of IN O
symptoms NNS O
and CC O
normalization NN O
of IN O
CRP NNP O
level NN O
. . O
null null null-Disease
To IN O
our PRP$ O
knowledge NN O
, , O
this DT O
is VBZ O
the DT O
second JJ O
case NN O
of IN O
minocycline NN O
- HYPH O
induced VBN O
vasculitis NN B-Disease
satisfying VBG O
the DT O
criteria NNS O
. . O
null null null-Disease
Differential JJ O
diagnosis NN O
for IN O
drug NN O
- HYPH O
induced VBN O
disease NN O
is VBZ O
invaluable JJ O
even RB O
for IN O
patients NNS O
with IN O
classical JJ O
polyarteritis NN B-Disease
nodosa NN I-Disease
. . O
null null null-Disease
Intramuscular JJ O
hepatitis NN B-Disease
B NN I-Disease
immune JJ O
globulin NN O
combined VBN O
with IN O
lamivudine NN O
in IN O
prevention NN O
of IN O
hepatitis NN B-Disease
B NN I-Disease
recurrence NN O
after IN O
liver NN O
transplantation NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Combined VBN O
hepatitis NN B-Disease
B NNP I-Disease
immune JJ O
globulin NN O
( , O
HBIg NNP O
) -RRB- O
and CC O
lamivudine NN O
in IN O
prophylaxis NN O
of IN O
the DT O
recurrence NN O
of IN O
hepatitis NNP B-Disease
B NNP I-Disease
after IN O
liver NN O
transplantation NN O
has VBZ O
significantly RB O
improved VBN O
the DT O
survival NN O
of IN O
HBsAg NNP O
positive JJ O
patients NNS O
. . O
null null null-Disease
This DT O
study NN O
was VBD O
undertaken VBN O
to TO O
evaluate VB O
the DT O
outcomes NNS O
of IN O
liver NN O
transplantation NN O
for IN O
patients NNS O
with IN O
hepatitis NN B-Disease
B NNP I-Disease
virus NN O
( : O
HBV NNP O
) -RRB- O
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
retrospective JJ O
chart NN O
analysis NN O
and CC O
a DT O
review NN O
of IN O
the DT O
organ JJ O
transplant NN O
database NN O
identified VBD O
51 CD O
patients NNS O
( , O
43 CD O
men NNS O
and CC O
8 CD O
women NNS O
) -RRB- O
transplanted VBN O
for IN O
benign JJ O
HBV NN O
- HYPH O
related VBN O
cirrhotic JJ B-Disease
diseases NNS I-Disease
between IN O
June NNP O
2002 CD O
and CC O
December NNP O
2004 CD O
who WP O
had VBD O
survived VBN O
more JJR O
than IN O
3 CD O
months NNS O
. . O
null null null-Disease
HBIg NNP O
was VBD O
administered VBN O
intravenously RB O
during IN O
the DT O
first JJ O
week NN O
and CC O
intramuscularly RB O
thereafter RB O
. . O
null null null-Disease
RESULTS NNS O
: : O
At IN O
a DT O
median JJ O
follow NN O
- HYPH O
up NN O
of IN O
14 CD O
. . O
1 CD O
months NNS O
, , O
the DT O
overall JJ O
recurrence NN O
rate NN O
in IN O
the DT O
51 CD O
patients NNS O
was VBD O
3 CD O
. . O
9 CD O
% NN O
( SYM O
2 CD O
/ SYM O
51 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
overall JJ O
patient JJ O
survival NN O
was VBD O
88 CD O
. . O
3 CD O
% NN O
, , O
and CC O
82 CD O
. . O
4 CD O
% NN O
after IN O
1 CD O
and CC O
2 CD O
years NNS O
, , O
respectively RB O
. . O
null null null-Disease
A DT O
daily JJ O
oral JJ O
dose NN O
of IN O
100 CD O
mg NN O
lamivudine NN O
for IN O
2 CD O
weeks NNS O
before IN O
transplantation NN O
for IN O
10 CD O
patients NNS O
enabled VBD O
57 CD O
. . O
1 CD O
% NN O
( SYM O
4 CD O
/ SYM O
7 CD O
) SYM O
and CC O
62 CD O
. . O
5 CD O
% NN O
( SYM O
5 CD O
/ SYM O
8 CD O
) -RRB- O
of IN O
HBV NNP O
- HYPH O
DNA NN O
and CC O
HBeAg NNP O
positive JJ O
patients NNS O
respectively RB O
to TO O
convert VB O
to TO O
be VB O
negative JJ O
. . O
null null null-Disease
Intramuscular JJ O
HBIg NNP O
was VBD O
well RB O
tolerated VBN O
in IN O
all DT O
patients NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Lamivudine NNP O
combined VBN O
with IN O
intramuscular JJ O
HBIg NNP O
can MD O
effectively RB O
prevent VB O
allograft NN O
from IN O
the DT O
recurrence NN O
of IN O
HBV NN O
after IN O
liver NN O
transplantation NN O
. . O
null null null-Disease
Anticonvulsant JJ O
effect NN O
of IN O
eslicarbazepine NN O
acetate NN O
( , O
BIA NNP O
2 CD O
- HYPH O
093 CD O
) -RRB- O
on IN O
seizures NNS B-Disease
induced VBN O
by IN O
microperfusion NN O
of IN O
picrotoxin NN O
in IN O
the DT O
hippocampus NN O
of IN O
freely RB O
moving VBG O
rats NNS O
. . O
null null null-Disease
Eslicarbazepine NNP O
acetate NN O
( , O
BIA NNP O
2 CD O
- HYPH O
093 CD O
, , O
S NN O
- HYPH O
( NFP O
- HYPH O
) NFP O
- HYPH O
10 CD O
- HYPH O
acetoxy NN O
- HYPH O
10 CD O
, , O
11 CD O
- HYPH O
dihydro NN O
- HYPH O
5H CD O
- HYPH O
dibenzo NN O
/ : O
b NN O
, , O
f NN O
/ SYM O
azepine NN O
- HYPH O
5 CD O
- HYPH O
carboxamide NN O
) -RRB- O
is VBZ O
a DT O
novel JJ O
antiepileptic JJ O
drug NN O
, , O
now RB O
in IN O
Phase NNP O
III NNP O
clinical JJ O
trials NNS O
, , O
designed VBN O
with IN O
the DT O
aim NN O
of IN O
improving VBG O
efficacy NN O
and CC O
safety NN O
in IN O
comparison NN O
with IN O
the DT O
structurally RB O
related VBN O
drugs NNS O
carbamazepine NN O
( , O
CBZ NNP O
) -RRB- O
and CC O
oxcarbazepine NN O
( , O
OXC NNP O
) -RRB- O
. . O
null null null-Disease
We PRP O
have VBP O
studied VBN O
the DT O
effects NNS O
of IN O
oral JJ O
treatment NN O
with IN O
eslicarbazepine NN O
acetate NN O
on IN O
a DT O
whole JJ O
- HYPH O
animal NN O
model NN O
in IN O
which WDT O
partial JJ O
seizures NNS B-Disease
can MD O
be VB O
elicited VBN O
repeatedly RB O
on IN O
different JJ O
days NNS O
without IN O
changes NNS O
in IN O
threshold NN O
or CC O
seizure NN B-Disease
patterns NNS O
. . O
null null null-Disease
In IN O
the DT O
animals NNS O
treated VBN O
with IN O
threshold NN O
doses NNS O
of IN O
picrotoxin NN O
, , O
the DT O
average JJ O
number NN O
of IN O
seizures NNS B-Disease
was VBD O
2 CD O
. . O
3 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
2 CD O
, , O
and CC O
average JJ O
seizure NN B-Disease
duration NN O
was VBD O
39 CD O
. . O
5 CD O
+ SYM O
/ SYM O
- SYM O
8 CD O
. . O
4s NNS O
. . O
null null null-Disease
Pre VB O
- HYPH O
treatment NN O
with IN O
a DT O
dose NN O
of IN O
30 CD O
mg NN O
/ SYM O
kg NN O
2h CD O
before IN O
picrotoxin NN O
microperfusion NN O
prevented VBD O
seizures NNS B-Disease
in IN O
the DT O
75 CD O
% NN O
of IN O
the DT O
rats NNS O
. . O
null null null-Disease
Lower JJR O
doses NNS O
( : O
3 CD O
and CC O
10mg CD O
/ SYM O
kg NN O
) -RRB- O
did VBD O
not RB O
suppress VB O
seizures NNS B-Disease
, , O
however RB O
, , O
after IN O
administration NN O
of IN O
10mg CD O
/ SYM O
kg NN O
, , O
significant JJ O
reductions NNS O
in IN O
seizures NNS B-Disease
duration NN O
( SYM O
24 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- SYM O
6 CD O
. . O
8s NNS O
) -RRB- O
and CC O
seizure NN B-Disease
number NN O
( , O
1 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
34 CD O
) -RRB- O
were VBD O
found VBN O
. . O
null null null-Disease
No DT O
adverse JJ O
effects NNS O
of IN O
eslicarbazepine NN O
acetate NN O
were VBD O
observed VBN O
in IN O
the DT O
behavioral JJ O
/ SYM O
EEG NNP O
patterns NNS O
studied VBN O
, , O
including VBG O
sleep NN O
/ SYM O
wakefulness NN O
cycle NN O
, , O
at IN O
the DT O
doses NNS O
studied VBN O
. . O
null null null-Disease
Acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
associated VBN O
with IN O
prolonged VBN O
intake NN O
of IN O
slimming NN O
pills NNS O
containing VBG O
anthraquinones NNS O
. . O
null null null-Disease
Chinese JJ O
herbal JJ O
medicine NN O
preparations NNS O
are VBP O
widely RB O
available JJ O
and CC O
often RB O
regarded VBN O
by IN O
the DT O
public NN O
as IN O
natural JJ O
and CC O
safe JJ O
remedies NNS O
for IN O
a DT O
variety NN O
of IN O
medical JJ O
conditions NNS O
. . O
null null null-Disease
Nephropathy NN B-Disease
caused VBN O
by IN O
Chinese JJ O
herbs NNS O
has VBZ O
previously RB O
been VBN O
reported VBN O
, , O
usually RB O
involving VBG O
the DT O
use NN O
of IN O
aristolochic JJ O
acids NNS O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
23 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
who WP O
developed VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
following VBG O
prolonged VBN O
use NN O
of IN O
a DT O
proprietary JJ O
Chinese JJ O
herbal JJ O
slimming NN O
pill NN O
that WDT O
contained VBD O
anthraquinone NN O
derivatives NNS O
, , O
extracted VBN O
from IN O
Rhizoma NNP O
Rhei NNP O
( , O
rhubarb NNP O
) -RRB- O
. . O
null null null-Disease
The DT O
renal JJ B-Disease
injury NN I-Disease
was VBD O
probably RB O
aggravated VBN O
by IN O
the DT O
concomitant JJ O
intake NN O
of IN O
a DT O
non AFX O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drug NN O
, , O
diclofenac NN O
. . O
null null null-Disease
Renal JJ O
pathology NN O
was VBD O
that IN O
of IN O
hypocellular JJ O
interstitial JJ O
fibrosis NN B-Disease
. . O
null null null-Disease
Spontaneous JJ O
renal JJ O
recovery NN O
occurred VBD O
upon IN O
cessation NN O
of IN O
the DT O
slimming NN O
pills NNS O
, , O
but CC O
mild JJ O
interstitial JJ O
fibrosis NN B-Disease
and CC O
tubular JJ O
atrophy NN B-Disease
was VBD O
still RB O
evident JJ O
histologically RB O
4 CD O
months NNS O
later RB O
. . O
null null null-Disease
Although IN O
a DT O
causal JJ O
relationship NN O
between IN O
the DT O
use NN O
of IN O
an DT O
anthraquinone NN O
- HYPH O
containing VBG O
herbal JJ O
agent NN O
and CC O
renal JJ B-Disease
injury NN I-Disease
remains VBZ O
to TO O
be VB O
proven VBN O
, , O
phytotherapy NN O
- HYPH O
associated VBN O
interstitial JJ O
nephropathy NN B-Disease
should MD O
be VB O
considered VBN O
in IN O
patients NNS O
who WP O
present VBP O
with IN O
unexplained JJ O
renal JJ B-Disease
failure NN I-Disease
. . O
null null null-Disease
Chloroacetaldehyde NNP O
as IN O
a DT O
sulfhydryl NN O
reagent NN O
: : O
the DT O
role NN O
of IN O
critical JJ O
thiol NN O
groups NNS O
in IN O
ifosfamide NN O
nephropathy NN B-Disease
. . O
null null null-Disease
Chloroacetaldehyde NNP O
( , O
CAA NNP O
) -RRB- O
is VBZ O
a DT O
metabolite NN O
of IN O
the DT O
alkylating VBG O
agent NN O
ifosfamide NN O
( , O
IFO NNP O
) -RRB- O
and CC O
putatively RB O
responsible JJ O
for IN O
renal JJ B-Disease
damage NN I-Disease
following VBG O
anti JJ O
- HYPH O
tumor NN B-Disease
therapy NN O
with IN O
IFO NNP O
. . O
null null null-Disease
Depletion NN O
of IN O
sulfhydryl NN O
( -LRB- O
SH NN O
) , O
groups NNS O
has VBZ O
been VBN O
reported VBN O
from IN O
cell NN O
culture NN O
, , O
animal NN O
and CC O
clinical JJ O
studies NNS O
. . O
null null null-Disease
In IN O
this DT O
work NN O
the DT O
effect NN O
of IN O
CAA NNP O
on IN O
human JJ O
proximal JJ O
tubule NN O
cells NNS O
in IN O
primary JJ O
culture NN O
( , O
hRPTEC NNP O
) -RRB- O
was VBD O
investigated VBN O
. . O
null null null-Disease
Toxicity NN B-Disease
of IN O
CAA NNP O
was VBD O
determined VBN O
by IN O
protein NN O
content NN O
, , O
cell NN O
number NN O
, , O
LDH NNP O
release NN O
, , O
trypan NN O
blue JJ O
exclusion NN O
assay NN O
and CC O
caspase NN O
- HYPH O
3 CD O
activity NN O
. . O
null null null-Disease
Free JJ O
thiols NNS O
were VBD O
measured VBN O
by IN O
the DT O
method NN O
of IN O
Ellman NNP O
. . O
null null null-Disease
CAA NNP O
reduced VBD O
hRPTEC NNP O
cell NN O
number NN O
and CC O
protein NN O
, , O
induced VBD O
a DT O
loss NN O
in IN O
free JJ O
intracellular JJ O
thiols NNS O
and CC O
an DT O
increase NN O
in IN O
necrosis NN B-Disease
markers NNS O
. . O
null null null-Disease
CAA NN O
but CC O
not RB O
acrolein NN O
inhibited VBD O
the DT O
cysteine NN O
proteases NNS O
caspase NN O
- HYPH O
3 CD O
, , O
caspase NN O
- HYPH O
8 CD O
and CC O
cathepsin NN O
B NN O
. . O
null null null-Disease
Caspase NN O
activation NN O
by IN O
cisplatin NN O
was VBD O
inhibited VBN O
by IN O
CAA NNP O
. . O
null null null-Disease
In IN O
cells NNS O
stained VBN O
with IN O
fluorescent JJ O
dyes NNS O
targeting VBG O
lysosomes NNS O
, , O
CAA NNP O
induced VBD O
an DT O
increase NN O
in IN O
lysosomal JJ O
size NN O
and CC O
lysosomal JJ O
leakage NN O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
CAA NNP O
on IN O
cysteine NN O
protease NN O
activities NNS O
and CC O
thiols NNS O
could MD O
be VB O
reproduced VBN O
in IN O
cell NN O
lysate NN O
. . O
null null null-Disease
Acidification NN O
, , O
which WDT O
slowed VBD O
the DT O
reaction NN O
of IN O
CAA NNP O
with IN O
thiol NN O
donors NNS O
, , O
could MD O
also RB O
attenuate VB O
effects NNS O
of IN O
CAA NN O
on IN O
necrosis NN B-Disease
markers NNS O
, , O
thiol NN O
depletion NN O
and CC O
cysteine NN O
protease NN O
inhibition NN O
in IN O
living NN O
cells NNS O
. . O
null null null-Disease
Thus RB O
, , O
CAA NNP O
directly RB O
reacts VBZ O
with IN O
cellular JJ O
protein NN O
and CC O
non JJ O
- HYPH O
protein NN O
thiols NNS O
, , O
mediating VBG O
its PRP$ O
toxicity NN B-Disease
on IN O
hRPTEC NNP O
. . O
null null null-Disease
This DT O
effect NN O
can MD O
be VB O
reduced VBN O
by IN O
acidification NN O
. . O
null null null-Disease
Therefore RB O
, , O
urinary JJ O
acidification NN O
could MD O
be VB O
an DT O
option NN O
to TO O
prevent VB O
IFO NN O
nephropathy NN B-Disease
in IN O
patients NNS O
. . O
null null null-Disease
Stereological JJ O
methods NNS O
reveal VBP O
the DT O
robust JJ O
size NN O
and CC O
stability NN O
of IN O
ectopic JJ O
hilar NN O
granule NN O
cells NNS O
after IN O
pilocarpine NN O
- HYPH O
induced VBN O
status NN B-Disease
epilepticus NN I-Disease
in IN O
the DT O
adult NN O
rat NN O
. . O
null null null-Disease
Following VBG O
status NN B-Disease
epilepticus NN I-Disease
in IN O
the DT O
rat NN O
, , O
dentate JJ O
granule NN O
cell NN O
neurogenesis NN O
increases VBZ O
greatly RB O
, , O
and CC O
many JJ O
of IN O
the DT O
new JJ O
neurons NNS O
appear VBP O
to TO O
develop VB O
ectopically RB O
, , O
in IN O
the DT O
hilar JJ O
region NN O
of IN O
the DT O
hippocampal JJ O
formation NN O
. . O
null null null-Disease
It PRP O
has VBZ O
been VBN O
suggested VBN O
that IN O
the DT O
ectopic JJ O
hilar JJ O
granule NN O
cells NNS O
could MD O
contribute VB O
to IN O
the DT O
spontaneous JJ O
seizures NNS B-Disease
that WDT O
ultimately RB O
develop VBP O
after IN O
status NN B-Disease
epilepticus NN I-Disease
. . O
null null null-Disease
However RB O
, , O
the DT O
population NN O
has VBZ O
never RB O
been VBN O
quantified VBN O
, , O
so CC O
it PRP O
is VBZ O
unclear JJ O
whether IN O
it PRP O
is VBZ O
substantial JJ O
enough RB O
to TO O
have VB O
a DT O
strong JJ O
influence NN O
on IN O
epileptogenesis NN O
. . O
null null null-Disease
To TO O
quantify VB O
this DT O
population NN O
, , O
the DT O
total JJ O
number NN O
of IN O
ectopic JJ O
hilar NN O
granule NN O
cells NNS O
was VBD O
estimated VBN O
using VBG O
unbiased JJ O
stereology NN O
at IN O
different JJ O
times NNS O
after IN O
pilocarpine NN O
- HYPH O
induced VBN O
status NN B-Disease
epilepticus NN I-Disease
. . O
null null null-Disease
The DT O
number NN O
of IN O
hilar JJ O
neurons NNS O
immunoreactive JJ O
for IN O
Prox NNP O
- HYPH O
1 CD O
, , O
a DT O
granule NN O
- HYPH O
cell NN O
- HYPH O
specific JJ O
marker NN O
, , O
was VBD O
estimated VBN O
using VBG O
the DT O
optical JJ O
fractionator NN O
method NN O
. . O
null null null-Disease
The DT O
results NNS O
indicate VBP O
that IN O
the DT O
size NN O
of IN O
the DT O
hilar JJ O
ectopic JJ O
granule NN O
cell NN O
population NN O
after IN O
status NN B-Disease
epilepticus NN I-Disease
is VBZ O
substantial JJ O
, , O
and CC O
stable JJ O
over IN O
time NN O
. . O
null null null-Disease
Interestingly RB O
, , O
the DT O
size NN O
of IN O
the DT O
population NN O
appears VBZ O
to TO O
be VB O
correlated VBN O
with IN O
the DT O
frequency NN O
of IN O
behavioral JJ O
seizures NNS B-Disease
, , O
because IN O
animals NNS O
with IN O
more JJR O
ectopic JJ O
granule NN O
cells NNS O
in IN O
the DT O
hilus NN O
have VBP O
more JJR O
frequent JJ O
behavioral JJ O
seizures NNS B-Disease
. . O
null null null-Disease
The DT O
hilar JJ O
ectopic JJ O
granule NN O
cell NN O
population NN O
does VBZ O
not RB O
appear VB O
to TO O
vary VB O
systematically RB O
across IN O
the DT O
septotemporal JJ O
axis NN O
, , O
although IN O
it PRP O
is VBZ O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
volume NN O
of IN O
the DT O
hilus NN O
. . O
null null null-Disease
The DT O
results NNS O
provide VBP O
new JJ O
insight NN O
into IN O
the DT O
potential JJ O
role NN O
of IN O
ectopic JJ O
hilar NN O
granule NN O
cells NNS O
in IN O
the DT O
pilocarpine NN O
model NN O
of IN O
temporal JJ B-Disease
lobe NN I-Disease
epilepsy NN I-Disease
. . O
null null null-Disease
A DT O
prospective JJ O
, , O
open JJ O
- HYPH O
label NN O
trial NN O
of IN O
galantamine NN O
in IN O
autistic JJ B-Disease
disorder NN I-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
Post JJ O
- HYPH O
mortem NN O
studies NNS O
have VBP O
reported VBN O
abnormalities NNS O
of IN O
the DT O
cholinergic JJ O
system NN O
in IN O
autism NN B-Disease
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
assess VB O
the DT O
use NN O
of IN O
galantamine NN O
, , O
an DT O
acetylcholinesterase NN O
inhibitor NN O
and CC O
nicotinic JJ O
receptor NN O
modulator NN O
, , O
in IN O
the DT O
treatment NN O
of IN O
interfering VBG O
behaviors NNS O
in IN O
children NNS O
with IN O
autism NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Thirteen CD O
medication NN O
- HYPH O
free JJ O
children NNS O
with IN O
autism NN B-Disease
( , O
mean JJ O
age NN O
, , O
8 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
3 CD O
. . O
5 CD O
years NNS O
) -RRB- O
participated VBD O
in IN O
a DT O
12 CD O
- HYPH O
week NN O
, , O
open JJ O
- HYPH O
label NN O
trial NN O
of IN O
galantamine NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
rated VBN O
monthly RB O
by IN O
parents NNS O
on IN O
the DT O
Aberrant NNP O
Behavior NNP O
Checklist NNP O
( -LRB- O
ABC NNP O
) -RRB- O
and CC O
the DT O
Conners NNPS O
' POS O
Parent NNP O
Rating NNP O
Scale NNP O
- HYPH O
Revised VBN O
, , O
and CC O
by IN O
a DT O
physician NN O
using VBG O
the DT O
Children NNPS O
' POS O
s POS O
Psychiatric NNP O
Rating NNP O
Scale NNP O
and CC O
the DT O
Clinical NNP O
Global NNP O
Impressions NNPS O
scale NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Patients NNS O
showed VBD O
a DT O
significant JJ O
reduction NN O
in IN O
parent NN O
- HYPH O
rated VBN O
irritability NN B-Disease
and CC O
social JJ O
withdrawal NN O
on IN O
the DT O
ABC NNP O
as RB O
well RB O
as IN O
significant JJ O
improvements NNS O
in IN O
emotional JJ O
lability NN O
and CC O
inattention NN O
on IN O
the DT O
Conners NNPS O
' POS O
Parent NNP O
Rating NNP O
Scale NNP O
- : O
- : O
Revised VBN O
. . O
null null null-Disease
Similarly RB O
, , O
clinician NN O
ratings NNS O
showed VBD O
reductions NNS O
in IN O
the DT O
anger NN O
subscale NN O
of IN O
the DT O
Children NNPS O
' POS O
s NNP O
Psychiatric NNP O
Rating NNP O
Scale NNP O
. . O
null null null-Disease
Eight CD O
of IN O
13 CD O
participants NNS O
were VBD O
rated VBN O
as IN O
responders NNS O
on IN O
the DT O
basis NN O
of IN O
their PRP$ O
improvement NN O
scores NNS O
on IN O
the DT O
Clinical NNP O
Global NNP O
Impressions NNPS O
scale NN O
. . O
null null null-Disease
Overall RB O
, , O
galantamine NN O
was VBD O
well RB O
- HYPH O
tolerated VBN O
, , O
with IN O
no DT O
significant JJ O
adverse JJ O
effects NNS O
apart RB O
from IN O
headaches NNS B-Disease
in IN O
one CD O
patient NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
In IN O
this DT O
open JJ O
trial NN O
, , O
galantamine NN O
was VBD O
well RB O
- HYPH O
tolerated VBN O
and CC O
appeared VBN O
to TO O
be VB O
beneficial JJ O
for IN O
the DT O
treatment NN O
of IN O
interfering VBG O
behaviors NNS O
in IN O
children NNS O
with IN O
autism NN B-Disease
, , O
particularly RB O
aggression NN B-Disease
, , O
behavioral JJ B-Disease
dyscontrol NN I-Disease
, , O
and CC O
inattention NN B-Disease
. . O
null null null-Disease
Further RB O
controlled VBN O
trials NNS O
are VBP O
warranted VBN O
. . O
null null null-Disease
Randomized VBN O
comparison NN O
of IN O
olanzapine NN O
versus IN O
risperidone NN O
for IN O
the DT O
treatment NN O
of IN O
first JJ O
- HYPH O
episode NN O
schizophrenia NN B-Disease
: : O
4 CD O
- HYPH O
month NN O
outcomes NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
The DT O
authors NNS O
compared VBD O
4 CD O
- HYPH O
month NN O
treatment NN O
outcomes NNS O
for IN O
olanzapine NN O
versus IN O
risperidone NN O
in IN O
patients NNS O
with IN O
first JJ O
- HYPH O
episode NN O
schizophrenia NN B-Disease
spectrum NN O
disorders NNS O
. . O
null null null-Disease
METHOD NN O
: : O
One CD O
hundred CD O
twelve CD O
subjects NNS O
( : O
70 CD O
% NN O
male JJ O
; : O
mean JJ O
age NN O
= SYM O
23 CD O
. . O
3 CD O
years NNS O
[ -LRB- O
SD NN O
= SYM O
5 CD O
. . O
1 CD O
] -RRB- O
) -RRB- O
with IN O
first JJ O
- HYPH O
episode NN O
schizophrenia NN B-Disease
( , O
75 CD O
% NN O
) -RRB- O
, , O
schizophreniform NN B-Disease
disorder NN I-Disease
( , O
17 CD O
% NN O
) -RRB- O
, , O
or CC O
schizoaffective JJ B-Disease
disorder NN I-Disease
( : O
8 CD O
% NN O
) -RRB- O
were VBD O
randomly RB O
assigned VBN O
to IN O
treatment NN O
with IN O
olanzapine NN O
( : O
2 CD O
. . O
5 CD O
- SYM O
20 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
or CC O
risperidone NN O
( , O
1 CD O
- SYM O
6 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
Response NN O
rates NNS O
did VBD O
not RB O
significantly RB O
differ VB O
between IN O
olanzapine NN O
( : O
43 CD O
. . O
7 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
28 CD O
. . O
8 CD O
% NN O
- SYM O
58 CD O
. . O
6 CD O
% NN O
) -RRB- O
and CC O
risperidone NN O
( SYM O
54 CD O
. . O
3 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
39 CD O
. . O
9 CD O
% NN O
- SYM O
68 CD O
. . O
7 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Among IN O
those DT O
responding VBG O
to IN O
treatment NN O
, , O
more JJR O
subjects NNS O
in IN O
the DT O
olanzapine NN O
group NN O
( : O
40 CD O
. . O
9 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
16 CD O
. . O
8 CD O
% NN O
- SYM O
65 CD O
. . O
0 CD O
% NN O
) -RRB- O
than IN O
in IN O
the DT O
risperidone NN O
group NN O
( : O
18 CD O
. . O
9 CD O
% NN O
, , O
95 CD O
% NN O
CI NN O
= SYM O
0 CD O
% NN O
- HYPH O
39 CD O
. . O
2 CD O
% NN O
) -RRB- O
had VBD O
subsequent JJ O
ratings NNS O
not RB O
meeting VBG O
response NN O
criteria NNS O
. . O
null null null-Disease
Negative JJ O
symptom NN O
outcomes NNS O
and CC O
measures NNS O
of IN O
parkinsonism NN B-Disease
and CC O
akathisia NN B-Disease
did VBD O
not RB O
differ VB O
between IN O
medications NNS O
. . O
null null null-Disease
Extrapyramidal JJ B-Disease
symptom NN I-Disease
severity NN O
scores NNS O
were VBD O
1 CD O
. . O
4 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
1 CD O
. . O
2 CD O
- SYM O
1 CD O
. . O
6 CD O
) -RRB- O
with IN O
risperidone NN O
and CC O
1 CD O
. . O
2 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
1 CD O
. . O
0 CD O
- SYM O
1 CD O
. . O
4 CD O
) -RRB- O
with IN O
olanzapine NN O
. . O
null null null-Disease
Significantly RB O
more JJR O
weight NN B-Disease
gain NN I-Disease
occurred VBD O
with IN O
olanzapine NN O
than IN O
with IN O
risperidone NN O
: : O
the DT O
increase NN O
in IN O
weight NN O
at IN O
4 CD O
months NNS O
relative JJ O
to IN O
baseline NN O
weight NN O
was VBD O
17 CD O
. . O
3 CD O
% NN O
( : O
95 CD O
% NN O
CI NN O
= SYM O
14 CD O
. . O
2 CD O
% NN O
- SYM O
20 CD O
. . O
5 CD O
% NN O
) -RRB- O
with IN O
olanzapine NN O
and CC O
11 CD O
. . O
3 CD O
% NN O
( : O
95 CD O
% NN O
CI NN O
= SYM O
8 CD O
. . O
4 CD O
% NN O
- SYM O
14 CD O
. . O
3 CD O
% NN O
) -RRB- O
with IN O
risperidone NN O
. . O
null null null-Disease
Body NN O
mass NN O
index NN O
at IN O
baseline NN O
and CC O
at IN O
4 CD O
months NNS O
was VBD O
24 CD O
. . O
3 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
22 CD O
. . O
8 CD O
- SYM O
25 CD O
. . O
7 CD O
) -RRB- O
versus IN O
28 CD O
. . O
2 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
26 CD O
. . O
7 CD O
- SYM O
29 CD O
. . O
7 CD O
) -RRB- O
with IN O
olanzapine NN O
and CC O
23 CD O
. . O
9 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
22 CD O
. . O
5 CD O
- SYM O
25 CD O
. . O
3 CD O
) , O
versus IN O
26 CD O
. . O
7 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
25 CD O
. . O
2 CD O
- SYM O
28 CD O
. . O
2 CD O
) -RRB- O
with IN O
risperidone NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Clinical JJ O
outcomes NNS O
with IN O
risperidone NN O
were VBD O
equal JJ O
to IN O
those DT O
with IN O
olanzapine NN O
, , O
and CC O
response NN O
may MD O
be VB O
more RBR O
stable JJ O
. . O
null null null-Disease
Olanzapine NNP O
may MD O
have VB O
an DT O
advantage NN O
for IN O
motor NN O
side NN O
effects NNS O
. . O
null null null-Disease
Both DT O
medications NNS O
caused VBD O
substantial JJ O
rapid JJ O
weight NN B-Disease
gain NN I-Disease
, , O
but CC O
weight NN B-Disease
gain NN I-Disease
was VBD O
greater JJR O
with IN O
olanzapine NN O
. . O
null null null-Disease
Early JJ O
paracentral JJ O
visual JJ B-Disease
field NN I-Disease
loss NN I-Disease
in IN O
patients NNS O
taking VBG O
hydroxychloroquine NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
review VB O
the DT O
natural JJ O
history NN O
and CC O
ocular JJ O
and CC O
systemic JJ O
adverse JJ O
effects NNS O
of IN O
patients NNS O
taking VBG O
hydroxychloroquine NN O
sulfate NN O
who WP O
attended VBD O
an DT O
ophthalmic JJ O
screening NN O
program NN O
. . O
null null null-Disease
DESIGN NN O
: : O
Retrospective JJ O
study NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Records NNS O
of IN O
262 CD O
patients NNS O
who WP O
were VBD O
taking VBG O
hydroxychloroquine NN O
and CC O
screened VBN O
in IN O
the DT O
Department NNP O
of IN O
Ophthalmology NNP O
were VBD O
reviewed VBN O
. . O
null null null-Disease
Of IN O
the DT O
262 CD O
patients NNS O
, , O
14 CD O
( SYM O
18 CD O
% NN O
) CD O
of IN O
76 CD O
who WP O
had VBD O
stopped VBN O
treatment NN O
at IN O
the DT O
time NN O
of IN O
the DT O
study NN O
experienced VBD O
documented VBN O
adverse JJ O
effects NNS O
. . O
null null null-Disease
Systemic JJ O
adverse JJ O
effects NNS O
occurred VBD O
in IN O
8 CD O
patients NNS O
( , O
10 CD O
. . O
5 CD O
% NN O
) -RRB- O
and CC O
ocular JJ O
adverse JJ O
effects NNS O
, , O
in IN O
5 CD O
( SYM O
6 CD O
. . O
5 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Thirty CD O
- HYPH O
five CD O
patients NNS O
( SYM O
13 CD O
. . O
4 CD O
% NN O
) -RRB- O
had VBD O
visual JJ B-Disease
field NN I-Disease
abnormalities NNS I-Disease
, , O
which WDT O
were VBD O
attributed VBN O
to IN O
hydroxychloroquine NN O
treatment NN O
in IN O
4 CD O
patients NNS O
( , O
1 CD O
. . O
5 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Three CD O
of IN O
the DT O
4 CD O
patients NNS O
were VBD O
taking VBG O
less JJR O
than IN O
6 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NNS O
per IN O
day NN O
and CC O
all DT O
patients NNS O
had VBD O
normal JJ O
renal JJ O
and CC O
liver NN O
function NN O
test NN O
results NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
current JJ O
study NN O
used VBD O
a DT O
protocol NN O
of IN O
visual JJ O
acuity NN O
and CC O
color NN O
vision NN O
assessment NN O
, , O
funduscopy NN O
, , O
and CC O
Humphrey NNP O
10 CD O
- HYPH O
2 CD O
visual JJ O
field NN O
testing NN O
and CC O
shows VBZ O
that IN O
visual JJ B-Disease
field NN I-Disease
defects NNS I-Disease
appeared VBD O
before IN O
any DT O
corresponding VBG O
changes NNS O
in IN O
any DT O
other JJ O
tested VBN O
clinical JJ O
parameters NNS O
; : O
the DT O
defects NNS O
were VBD O
reproducible JJ O
and CC O
the DT O
test NN O
parameters NNS O
were VBD O
reliable JJ O
. . O
null null null-Disease
Patients NNS O
taking VBG O
hydroxychloroquine NN O
can MD O
demonstrate VB O
a DT O
toxic JJ O
reaction NN O
in IN O
the DT O
retina NN O
despite IN O
the DT O
absence NN O
of IN O
known JJ O
risk NN O
factors NNS O
. . O
null null null-Disease
Screening NN O
, , O
including VBG O
Humphrey NNP O
10 CD O
- HYPH O
2 CD O
visual JJ O
field NN O
assessment NN O
, , O
is VBZ O
recommended VBN O
2 CD O
years NNS O
after IN O
the DT O
initial JJ O
baseline NN O
and CC O
yearly RB O
thereafter RB O
. . O
null null null-Disease
Peri NNP O
- HYPH O
operative NN O
atrioventricular JJ B-Disease
block NN I-Disease
as IN O
a DT O
result NN O
of IN O
chemotherapy NN O
with IN O
epirubicin NN O
and CC O
paclitaxel NN O
. . O
null null null-Disease
A DT O
47 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
presented VBN O
for IN O
mastectomy NN O
and CC O
immediate JJ O
latissimus NN O
dorsi NN O
flap NN O
reconstruction NN O
having VBG O
been VBN O
diagnosed VBN O
with IN O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
breast NN I-Disease
6 CD O
months NNS O
previously RB O
. . O
null null null-Disease
In IN O
the DT O
preceding VBG O
months NNS O
she PRP O
had VBD O
received VBN O
neo JJ O
- HYPH O
adjuvant NN O
chemotherapy NN O
with IN O
epirubicin NN O
, , O
paclitaxel NN O
( , O
Taxol NNP O
) -RRB- O
and CC O
cyclophosphamide NN O
. . O
null null null-Disease
This DT O
had VBD O
been VBN O
apparently RB O
uncomplicated JJ O
and CC O
she PRP O
had VBD O
maintained VBN O
a DT O
remarkably RB O
high JJ O
level NN O
of IN O
physical JJ O
activity NN O
. . O
null null null-Disease
She PRP O
was VBD O
found VBN O
to TO O
be VB O
bradycardic JJ B-Disease
at IN O
pre JJ O
- HYPH O
operative NN O
assessment NN O
but CC O
had VBD O
no DT O
cardiac JJ O
symptoms NNS O
. . O
null null null-Disease
Second JJ O
degree NN O
Mobitz NN O
type NN O
II NN O
atrioventricular JJ B-Disease
block NN I-Disease
was VBD O
diagnosed VBN O
on IN O
electrocardiogram NN O
, , O
and CC O
temporary JJ O
transvenous JJ O
ventricular JJ O
pacing NN O
instituted VBN O
in IN O
the DT O
peri JJ O
- HYPH O
operative NN O
period NN O
. . O
null null null-Disease
We PRP O
discuss VBP O
how WRB O
evidence NN O
- HYPH O
based VBN O
guidelines NNS O
would MD O
not RB O
have VB O
been VBN O
helpful JJ O
in IN O
this DT O
case NN O
, , O
and CC O
how WRB O
chemotherapy NN O
can MD O
exhibit VB O
substantial JJ O
cardiotoxicity NN B-Disease
that WDT O
may MD O
develop VB O
over IN O
many JJ O
years NNS O
. . O
null null null-Disease
We PRP O
suggest VBP O
that IN O
patients NNS O
who WP O
have VBP O
received VBN O
chemotherapy NN O
at IN O
any DT O
time NN O
should MD O
have VB O
a DT O
pre JJ O
- HYPH O
operative NN O
electrocardiogram NN O
even RB O
if IN O
they PRP O
are VBP O
asymptomatic JJ O
. . O
null null null-Disease
Risks NNS O
and CC O
benefits NNS O
of IN O
COX NNP O
- HYPH O
2 CD O
inhibitors NNS O
vs IN O
non JJ O
- HYPH O
selective JJ O
NSAIDs NNS O
: : O
does VBZ O
their PRP$ O
cardiovascular JJ O
risk NN O
exceed VB O
their PRP$ O
gastrointestinal JJ O
benefit NN O
? . O
null null null-Disease
A DT O
retrospective JJ O
cohort NN O
study NN O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
The DT O
risk NN O
of IN O
acute JJ B-Disease
myocardial JJ I-Disease
infarction NN I-Disease
( , O
AMI NNP B-Disease
) -RRB- O
with IN O
COX NNP O
- HYPH O
2 CD O
inhibitors NNS O
may MD O
offset VB O
their PRP$ O
gastrointestinal JJ O
( , O
GI NN O
) -RRB- O
benefit NN O
compared VBN O
with IN O
non JJ O
- HYPH O
selective JJ O
( , O
NS NNP O
) -RRB- O
non JJ O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
( , O
NSAIDs NNP O
) -RRB- O
. . O
null null null-Disease
We PRP O
aimed VBD O
to TO O
compare VB O
the DT O
risks NNS O
of IN O
hospitalization NN O
for IN O
AMI NNP B-Disease
and CC O
GI NNP B-Disease
bleeding VBG I-Disease
among IN O
elderly JJ O
patients NNS O
using VBG O
COX NNP O
- HYPH O
2 CD O
inhibitors NNS O
, , O
NS NNP O
- HYPH O
NSAIDs NNP O
and CC O
acetaminophen NN O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
conducted VBD O
a DT O
retrospective JJ O
cohort NN O
study NN O
using VBG O
administrative JJ O
data NNS O
of IN O
patients NNS O
> : O
or CC O
= SYM O
65 CD O
years NNS O
of IN O
age NN O
who WP O
filled VBD O
a DT O
prescription NN O
for IN O
NSAID NNP O
or CC O
acetaminophen NN O
during IN O
1999 CD O
- SYM O
2002 CD O
. . O
null null null-Disease
Outcomes NNS O
were VBD O
compared VBN O
using VBG O
Cox NNP O
regression NN O
models NNS O
with IN O
time NN O
- HYPH O
dependent JJ O
exposures NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Person NN O
- HYPH O
years NNS O
of IN O
exposure NN O
among IN O
non NN O
- HYPH O
users NNS O
of IN O
aspirin NN O
were VBD O
: : O
75 CD O
, , O
761 CD O
to IN O
acetaminophen NN O
, , O
42 CD O
, , O
671 CD O
to IN O
rofecoxib NN O
65 CD O
, , O
860 CD O
to IN O
celecoxib NN O
, , O
and CC O
37 CD O
, , O
495 CD O
to IN O
NS NNP O
- HYPH O
NSAIDs NNS O
. . O
null null null-Disease
Among IN O
users NNS O
of IN O
aspirin NN O
, , O
they PRP O
were VBD O
: : O
14 CD O
, , O
671 CD O
to IN O
rofecoxib NN O
, , O
22 CD O
, , O
875 CD O
to IN O
celecoxib NN O
, , O
9 CD O
, , O
832 CD O
to IN O
NS NNP O
- HYPH O
NSAIDs NNS O
and CC O
38 CD O
, , O
048 CD O
to IN O
acetaminophen NN O
. . O
null null null-Disease
Among IN O
non JJ O
- HYPH O
users NNS O
of IN O
aspirin NN O
, , O
the DT O
adjusted VBN O
hazard NN O
ratios NNS O
( : O
95 CD O
% NN O
confidence NN O
interval NN O
) -RRB- O
of IN O
hospitalization NN O
for IN O
AMI NNP B-Disease
/ SYM O
GI NNP O
vs IN O
the DT O
acetaminophen NN O
( , O
with IN O
no DT O
aspirin NN O
) -RRB- O
group NN O
were VBD O
: : O
rofecoxib NN O
1 CD O
. . O
27 CD O
( SYM O
1 CD O
. . O
13 CD O
, , O
1 CD O
. . O
42 CD O
) -RRB- O
, , O
celecoxib NN O
0 CD O
. . O
93 CD O
( SYM O
0 CD O
. . O
83 CD O
, , O
1 CD O
. . O
03 CD O
) -RRB- O
, , O
naproxen NN O
1 CD O
. . O
59 CD O
( SYM O
1 CD O
. . O
31 CD O
, , O
1 CD O
. . O
93 CD O
) -RRB- O
, , O
diclofenac NN O
1 CD O
. . O
17 CD O
( SYM O
0 CD O
. . O
99 CD O
, , O
1 CD O
. . O
38 CD O
) -RRB- O
and CC O
ibuprofen NN O
1 CD O
. . O
05 CD O
( SYM O
0 CD O
. . O
74 CD O
, , O
1 CD O
. . O
51 CD O
) -RRB- O
. . O
null null null-Disease
Among IN O
users NNS O
of IN O
aspirin NN O
, , O
they PRP O
were VBD O
: : O
rofecoxib NN O
1 CD O
. . O
73 CD O
( SYM O
1 CD O
. . O
52 CD O
, , O
1 CD O
. . O
98 CD O
) -RRB- O
, , O
celecoxib NN O
1 CD O
. . O
34 CD O
( SYM O
1 CD O
. . O
19 CD O
, , O
1 CD O
. . O
52 CD O
) -RRB- O
, , O
ibuprofen NN O
1 CD O
. . O
51 CD O
( SYM O
0 CD O
. . O
95 CD O
, , O
2 CD O
. . O
41 CD O
) -RRB- O
, , O
diclofenac NN O
1 CD O
. . O
69 CD O
( SYM O
1 CD O
. . O
35 CD O
, , O
2 CD O
. . O
10 CD O
) -RRB- O
, , O
naproxen NN O
1 CD O
. . O
35 CD O
( SYM O
0 CD O
. . O
97 CD O
, , O
1 CD O
. . O
88 CD O
) -RRB- O
and CC O
acetaminophen NN O
1 CD O
. . O
29 CD O
( SYM O
1 CD O
. . O
17 CD O
, , O
1 CD O
. . O
42 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Among IN O
non JJ O
- HYPH O
users NNS O
of IN O
aspirin NN O
, , O
naproxen NN O
seemed VBD O
to TO O
carry VB O
the DT O
highest JJS O
risk NN O
for IN O
AMI NNP B-Disease
/ SYM O
GI NNP B-Disease
bleeding NN I-Disease
. . O
null null null-Disease
The DT O
AMI NNP B-Disease
/ SYM O
GI NNP O
toxicity NN B-Disease
of IN O
celecoxib NN O
was VBD O
similar JJ O
to IN O
that DT O
of IN O
acetaminophen NN O
and CC O
seemed VBD O
to TO O
be VB O
better JJR O
than IN O
those DT O
of IN O
rofecoxib NN O
and CC O
NS NNP O
- HYPH O
NSAIDs NNS O
. . O
null null null-Disease
Among IN O
users NNS O
of IN O
aspirin NN O
, , O
both CC O
celecoxib NN O
and CC O
naproxen NN O
seemed VBD O
to TO O
be VB O
the DT O
least RBS O
toxic JJ O
. . O
null null null-Disease
Quinine NN O
- HYPH O
induced VBN O
arrhythmia NN B-Disease
in IN O
a DT O
patient NN O
with IN O
severe JJ B-Disease
malaria NN I-Disease
. . O
null null null-Disease
It PRP O
was VBD O
reported VBN O
that IN O
there EX O
was VBD O
a DT O
case NN O
of IN O
severe JJ B-Disease
malaria NN I-Disease
patient NN O
with IN O
jaundice NN B-Disease
who WP O
presented VBD O
with IN O
arrhythmia NN B-Disease
( , O
premature JJ B-Disease
ventricular JJ I-Disease
contraction NN I-Disease
) , O
while IN O
getting VBG O
quinine NN O
infusion NN O
was VBD O
reported VBN O
. . O
null null null-Disease
A DT O
man NN O
, , O
25 CD O
years NNS O
old JJ O
, , O
was VBD O
admitted VBN O
to IN O
hospital NN O
with IN O
high JJ O
fever NN B-Disease
, , O
chill NN B-Disease
, , O
vomiting NN B-Disease
, , O
jaundice NN B-Disease
. . O
null null null-Disease
The DT O
patient NN O
was VBD O
fully RB O
conscious JJ O
, , O
blood NN O
pressure NN O
120 CD O
/ SYM O
80 CD O
mmHg NN O
, , O
pulse NN O
rate NN O
100 CD O
x NN O
/ SYM O
minute NN O
, , O
regular JJ O
. . O
null null null-Disease
On IN O
admission NN O
, , O
laboratory NN O
examination NN O
showed VBD O
Plasmodium NN O
falciparum NN O
( , O
+ SYM O
+ SYM O
+ SYM O
+ SYM O
) -RRB- O
, , O
total JJ O
bilirubin NN O
8 CD O
. . O
25 CD O
mg NN O
/ SYM O
dL NN O
, , O
conjugated VBN O
bilirubin NN O
4 CD O
. . O
36 CD O
mg NN O
/ SYM O
dL NN O
, , O
unconjugated JJ O
bilirubin NN O
3 CD O
. . O
89 CD O
mg NN O
/ SYM O
dL NN O
, , O
potassium NN O
3 CD O
. . O
52 CD O
meq NNS O
/ SYM O
L NNP O
Patient NN O
was VBD O
diagnosed VBN O
as IN O
severe JJ B-Disease
malaria NN I-Disease
with IN O
jaundice NN B-Disease
and CC O
got VBD O
quinine NN O
infusion NN O
in IN O
dextrose JJ O
5 CD O
% NN O
500 CD O
mg NN O
/ SYM O
8 CD O
hour NN O
. . O
null null null-Disease
On IN O
the DT O
second JJ O
day NN O
the DT O
patient NN O
had VBD O
vomitus NN B-Disease
, , O
diarrhea NN B-Disease
, , O
tinnitus NN B-Disease
, , O
loss NN B-Disease
of IN I-Disease
hearing NN I-Disease
. . O
null null null-Disease
After IN O
30 CD O
hours NNS O
of IN O
quinine NN O
infusion NN O
the DT O
patient NN O
felt VBD O
palpitation NN B-Disease
and CC O
electrocardiography NN O
( , O
ECG NNP O
) -RRB- O
recording NN O
showed VBD O
premature JJ B-Disease
ventricular JJ I-Disease
contraction NN I-Disease
( -LRB- O
PVC NN B-Disease
) SYM O
> SYM O
5 CD O
x SYM O
/ SYM O
minute NN O
, , O
trigemini NN O
, , O
constant JJ O
type NN O
- HYPH O
- HYPH O
sinoatrial NN B-Disease
block NN I-Disease
, , O
positive JJ O
U NN O
wave NN O
. . O
null null null-Disease
He PRP O
was VBD O
treated VBN O
with IN O
lidocaine NN O
50 CD O
mg NN O
intravenously RB O
followed VBN O
by IN O
infusion NN O
1500 CD O
mg NN O
in IN O
dextrose JJ O
5 CD O
% NN O
/ SYM O
24 CD O
hour NN O
and CC O
potassium NN O
aspartate NN O
tablet NN O
. . O
null null null-Disease
Quinine NNP O
infusion NN O
was VBD O
discontinued VBN O
and CC O
changed VBN O
with IN O
sulfate NN O
quinine NN O
tablets NNS O
. . O
null null null-Disease
Three CD O
hours NNS O
later RBR O
the DT O
patient NN O
felt VBD O
better JJR O
, , O
the DT O
frequency NN O
of IN O
PVC NNP B-Disease
reduced VBD O
to IN O
4 CD O
- SYM O
5 CD O
x SYM O
/ SYM O
minute NN O
and CC O
on IN O
the DT O
third JJ O
day NN O
ECG NNP O
was VBD O
normal JJ O
, , O
potassium NN O
level NN O
was VBD O
3 CD O
. . O
34 CD O
meq NNS O
/ SYM O
L NN O
. . O
null null null-Disease
He PRP O
was VBD O
discharged VBN O
on IN O
7th JJ O
day NN O
in IN O
good JJ O
condition NN O
. . O
null null null-Disease
Quinine NNP O
, , O
like IN O
quinidine NN O
, , O
is VBZ O
a DT O
chincona NN O
alkaloid NN O
that WDT O
has VBZ O
anti JJ O
- HYPH O
arrhythmic JJ B-Disease
property NN O
, , O
although IN O
it PRP O
also RB O
pro RB O
- HYPH O
arrhythmic NN B-Disease
that WDT O
can MD O
cause VB O
various JJ O
arrhythmias NNS B-Disease
, , O
including VBG O
severe JJ O
arrhythmia NN B-Disease
such JJ O
as IN O
multiple JJ O
PVC NN B-Disease
. . O
null null null-Disease
Administration NN O
of IN O
parenteral JJ O
quinine NN O
must MD O
be VB O
done VBN O
carefully RB O
and CC O
with IN O
good JJ O
observation NN O
because IN O
of IN O
its PRP$ O
pro JJ O
- HYPH O
arrhythmic JJ B-Disease
effect NN O
, , O
especially RB O
in IN O
older JJR O
patients NNS O
who WP O
have VBP O
heart NN B-Disease
diseases NNS I-Disease
or CC O
patients NNS O
with IN O
electrolyte NN B-Disease
disorder NN I-Disease
( : O
hypokalemia NN B-Disease
) , O
which WDT O
frequently RB O
occurs VBZ O
due IN O
to IN O
vomiting NN B-Disease
and CC O
or CC O
diarrhea NN B-Disease
in IN O
malaria NN B-Disease
cases NNS O
. . O
null null null-Disease
Penicillamine NN O
- HYPH O
related VBN O
lichenoid NN B-Disease
dermatitis NN I-Disease
and CC O
utility NN O
of IN O
zinc NN O
acetate NN O
in IN O
a DT O
Wilson NNP B-Disease
disease NN I-Disease
patient NN O
with IN O
hepatic JJ O
presentation NN O
, , O
anxiety NN B-Disease
and CC O
SPECT NN O
abnormalities NNS O
. . O
null null null-Disease
Wilson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
is VBZ O
an DT O
autosomal JJ O
recessive JJ O
disorder NN O
of IN O
hepatic JJ O
copper NN O
metabolism NN O
with IN O
consequent JJ O
copper NN O
accumulation NN O
and CC O
toxicity NN B-Disease
in IN O
many JJ O
tissues NNS O
and CC O
consequent JJ O
hepatic JJ B-Disease
, , I-Disease
neurologic JJ I-Disease
and CC I-Disease
psychiatric JJ I-Disease
disorders NNS I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
Wilson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
with IN O
chronic JJ B-Disease
liver NN I-Disease
disease NN I-Disease
; : O
moreover RB O
, , O
in IN O
our PRP$ O
patient NN O
, , O
presenting VBG O
also RB O
with IN O
high JJ O
levels NNS O
of IN O
state NN O
anxiety NN B-Disease
without IN O
depression NN B-Disease
, , O
99mTc NNP O
- HYPH O
ECD NN O
- HYPH O
SPECT NN O
showed VBD O
cortical JJ O
hypoperfusion NN O
in IN O
frontal JJ O
lobes NNS O
, , O
more RBR O
marked JJ O
on IN O
the DT O
left JJ O
frontal JJ O
lobe NN O
. . O
null null null-Disease
During IN O
the DT O
follow NN O
- HYPH O
up NN O
of IN O
our PRP$ O
patient NN O
, , O
penicillamine NN O
was VBD O
interrupted VBN O
after IN O
the DT O
appearance NN O
of IN O
a DT O
lichenoid NN B-Disease
dermatitis NN I-Disease
, , O
and CC O
zinc NN O
acetate NN O
permitted VBN O
to TO O
continue VB O
the DT O
successful JJ O
treatment NN O
of IN O
the DT O
patient NN O
without IN O
side NN O
- HYPH O
effects NNS O
. . O
null null null-Disease
In IN O
our PRP$ O
case NN O
the DT O
therapy NN O
with IN O
zinc NN O
acetate NN O
represented VBD O
an DT O
effective JJ O
treatment NN O
for IN O
a DT O
Wilson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
patient NN O
in IN O
which WDT O
penicillamine NN O
- HYPH O
related VBN O
side NN O
effects NNS O
appeared VBD O
. . O
null null null-Disease
The DT O
safety NN O
of IN O
the DT O
zinc NN O
acetate NN O
allowed VBD O
us PRP O
to TO O
avoid VB O
other JJ O
potentially RB O
toxic JJ O
chelating JJ O
drugs NNS O
; : O
this DT O
observation NN O
is VBZ O
in IN O
line NN O
with IN O
the DT O
growing VBG O
evidence NN O
on IN O
the DT O
efficacy NN O
of IN O
the DT O
drug NN O
in IN O
the DT O
treatment NN O
of IN O
Wilson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
Since IN O
most JJS O
of IN O
Wilson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
penicillamine NN O
- HYPH O
treated VBN O
patients NNS O
do VBP O
not RB O
seem VB O
to TO O
develop VB O
this DT O
skin NN B-Disease
lesion NN I-Disease
, , O
it PRP O
could MD O
be VB O
conceivable JJ O
that IN O
a DT O
specific JJ O
genetic JJ O
factor NN O
is VBZ O
involved VBN O
in IN O
drug NN O
response NN O
. . O
null null null-Disease
Further JJ O
studies NNS O
are VBP O
needed VBN O
for IN O
a DT O
better JJR O
clarification NN O
of IN O
Wilson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
therapy NN O
, , O
and CC O
in IN O
particular JJ O
to TO O
differentiate VB O
specific JJ O
therapies NNS O
for IN O
different JJ O
Wilson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
phenotypes NNS O
. . O
null null null-Disease
A DT O
dramatic JJ O
drop NN B-Disease
in IN I-Disease
blood NN I-Disease
pressure NN I-Disease
following VBG O
prehospital JJ O
GTN NNP O
administration NN O
. . O
null null null-Disease
A DT O
male NN O
in IN O
his PRP$ O
sixties NNS O
with IN O
no DT O
history NN O
of IN O
cardiac JJ O
chest NN B-Disease
pain NN I-Disease
awoke VBD O
with IN O
chest NN B-Disease
pain NN I-Disease
following VBG O
an DT O
afternoon NN O
sleep NN O
. . O
null null null-Disease
The DT O
patient NN O
did VBD O
not RB O
self NN O
medicate VB O
. . O
null null null-Disease
The DT O
patient NN O
' POS O
s POS O
observations NNS O
were VBD O
within IN O
normal JJ O
limits NNS O
, , O
he PRP O
was VBD O
administered VBN O
oxygen NN O
via IN O
a DT O
face NN O
mask NN O
and CC O
glyceryl NN O
trinitrate NN O
( , O
GTN NNP O
) -RRB- O
. . O
null null null-Disease
Several JJ O
minutes NNS O
after IN O
the DT O
GTN NNP O
the DT O
patient NN O
experienced VBD O
a DT O
sudden JJ O
drop NN B-Disease
in IN I-Disease
blood NN I-Disease
pressure NN I-Disease
and CC O
heart NN O
rate NN O
, , O
this DT O
was VBD O
rectified VBN O
by IN O
atropine NN O
sulphate NN O
and CC O
a DT O
fluid JJ O
challenge NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
further JJ O
deterioration NN O
in IN O
the DT O
patient NN O
' '' O
s NN O
condition NN O
during IN O
transport NN O
to IN O
hospital NN O
. . O
null null null-Disease
There EX O
are VBP O
very RB O
few JJ O
documented VBN O
case NN O
like IN O
this DT O
in IN O
the DT O
prehospital JJ O
scientific JJ O
literature NN O
. . O
null null null-Disease
The DT O
cause NN O
appears VBZ O
to TO O
be VB O
the DT O
Bezold NNP O
- HYPH O
Jarish NNP O
reflex NN O
, , O
stimulation NN O
of IN O
the DT O
ventricular JJ O
walls NNS O
which WDT O
in IN O
turn NN O
decreases VBZ O
sympathetic JJ O
outflow NN O
from IN O
the DT O
vasomotor NN O
centre NN O
. . O
null null null-Disease
Prehospital JJ O
care NN O
providers NNS O
who WP O
are VBP O
managing VBG O
any DT O
patient NN O
with IN O
a DT O
syncopal JJ B-Disease
episode NN I-Disease
that WDT O
fails VBZ O
to TO O
recover VB O
within IN O
a DT O
reasonable JJ O
time NN O
frame NN O
should MD O
consider VB O
the DT O
Bezold NNP O
- HYPH O
Jarisch NNP O
reflex NN O
as IN O
the DT O
cause NN O
and CC O
manage VB O
the DT O
patient NN O
accordingly RB O
. . O
null null null-Disease
Chronic JJ O
lesion NN O
of IN O
rostral JJ O
ventrolateral JJ O
medulla NN O
in IN O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
. . O
null null null-Disease
We PRP O
studied VBD O
the DT O
effects NNS O
of IN O
chronic JJ O
selective JJ O
neuronal JJ O
lesion NN O
of IN O
rostral JJ O
ventrolateral JJ O
medulla NN O
on IN O
mean JJ O
arterial JJ O
pressure NN O
, , O
heart NN O
rate NN O
, , O
and CC O
neurogenic JJ O
tone NN O
in IN O
conscious JJ O
, , O
unrestrained JJ O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
. . O
null null null-Disease
The DT O
lesions NNS O
were VBD O
placed VBN O
via IN O
bilateral JJ O
microinjections NNS O
of IN O
30 CD O
nmol NN O
/ SYM O
200 CD O
nl NN O
N NN O
- HYPH O
methyl NN O
- HYPH O
D NN O
- HYPH O
aspartic JJ O
acid NN O
. . O
null null null-Disease
The DT O
restimulation NN O
of IN O
this DT O
area NN O
with IN O
N NN O
- HYPH O
methyl NN O
- HYPH O
D NN O
- HYPH O
aspartic JJ O
acid NN O
15 CD O
days NNS O
postlesion NN O
failed VBD O
to TO O
produce VB O
a DT O
pressor NN O
response NN O
. . O
null null null-Disease
One CD O
day NN O
postlesion NN O
, , O
the DT O
resting VBG O
mean JJ O
arterial JJ O
pressure NN O
was VBD O
significantly RB O
decreased VBN O
in IN O
lesioned JJ O
rats NNS O
when WRB O
compared VBN O
with IN O
sham NN O
rats NNS O
( , O
100 CD O
+ CD O
/ SYM O
- HYPH O
7 CD O
versus IN O
173 CD O
+ SYM O
/ SYM O
- SYM O
4 CD O
mm NN O
Hg CD O
, , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Fifteen CD O
days NNS O
later RB O
, , O
the DT O
lesioned JJ O
group NN O
still RB O
showed VBD O
values NNS O
significantly RB O
lower JJR O
than IN O
the DT O
sham NN O
group NN O
( , O
150 CD O
+ SYM O
/ SYM O
- HYPH O
6 CD O
versus IN O
167 CD O
+ SYM O
/ SYM O
- SYM O
5 CD O
mm NN O
Hg CD O
, , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
No DT O
significant JJ O
heart NN O
rate NN O
differences NNS O
were VBD O
observed VBN O
between IN O
the DT O
sham NN O
and CC O
lesioned VBN O
groups NNS O
. . O
null null null-Disease
The DT O
ganglionic JJ O
blocker NN O
trimethaphan NN O
( : O
5 CD O
mg NN O
/ SYM O
kg CD O
i NN O
. . O
v NN O
. . O
) -RRB- O
caused VBD O
similar JJ O
reductions NNS O
in IN O
mean JJ O
arterial JJ O
pressure NN O
in IN O
both CC O
lesioned VBN O
and CC O
sham NN O
groups NNS O
. . O
null null null-Disease
The DT O
trimethaphan NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
was VBD O
accompanied VBN O
by IN O
a DT O
significant JJ O
bradycardia NN B-Disease
in IN O
lesioned JJ O
rats NNS O
( , O
- SYM O
32 CD O
+ NN O
/ SYM O
- HYPH O
13 CD O
beats NNS O
per IN O
minute NN O
) -RRB- O
but CC O
a DT O
tachycardia NN B-Disease
in IN O
sham NN O
rats NNS O
( : O
+ SYM O
33 CD O
+ NN O
/ SYM O
- HYPH O
12 CD O
beats NNS O
per IN O
minute NN O
) SYM O
1 CD O
day NN O
postlesion NN O
. . O
null null null-Disease
Therefore RB O
, , O
rostral JJ O
ventrolateral JJ O
medulla NN O
neurons NNS O
appear VBP O
to TO O
play VB O
a DT O
significant JJ O
role NN O
in IN O
maintaining VBG O
hypertension NN B-Disease
in IN O
conscious JJ O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
. . O
null null null-Disease
Spinal JJ O
or CC O
suprabulbar NN O
structures NNS O
could MD O
be VB O
responsible JJ O
for IN O
the DT O
gradual JJ O
recovery NN O
of IN O
the DT O
hypertension NN B-Disease
in IN O
the DT O
lesioned VBN O
rats NNS O
. . O
null null null-Disease
Acute JJ B-Disease
encephalopathy NN I-Disease
and CC O
cerebral JJ B-Disease
vasospasm NN I-Disease
after IN O
multiagent NN O
chemotherapy NN O
including VBG O
PEG NNP O
- HYPH O
asparaginase NN O
and CC O
intrathecal JJ O
cytarabine NN O
for IN O
the DT O
treatment NN O
of IN O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
. . O
null null null-Disease
A DT O
7 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
girl NN O
with IN O
an DT O
unusual JJ O
reaction NN O
to IN O
induction NN O
chemotherapy NN O
for IN O
precursor NN O
B NN O
- HYPH O
cell NN O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
( -LRB- O
ALL NNP B-Disease
) -RRB- O
is VBZ O
described VBN O
. . O
null null null-Disease
The DT O
patient NN O
developed VBD O
acute JJ B-Disease
encephalopathy NN I-Disease
evidenced VBN O
by IN O
behavioral JJ O
changes NNS O
, , O
aphasia NN B-Disease
, , O
incontinence NN B-Disease
, , O
visual JJ B-Disease
hallucinations NNS I-Disease
, , O
and CC O
right RB O
- HYPH O
sided JJ O
weakness NN B-Disease
with IN O
diffuse JJ O
cerebral JJ B-Disease
vasospasm NN I-Disease
on IN O
magnetic JJ O
resonance NN O
angiography NN O
after IN O
the DT O
administration NN O
of IN O
intrathecal JJ O
cytarabine NN O
. . O
null null null-Disease
Vincristine NNP O
, , O
dexamethasone NN O
, , O
and CC O
polyethylene NN O
glycol NN O
- HYPH O
asparaginase NN O
were VBD O
also RB O
administered VBN O
before IN O
the DT O
episode NN O
as IN O
part NN O
of IN O
induction NN O
therapy NN O
. . O
null null null-Disease
Neurologic JJ O
status NN O
returned VBD O
to IN O
baseline NN O
within IN O
10 CD O
days NNS O
of IN O
the DT O
acute JJ O
event NN O
, , O
and CC O
magnetic JJ O
resonance NN O
angiography NN O
findings NNS O
returned VBD O
to IN O
normal JJ O
4 CD O
months NNS O
later RB O
. . O
null null null-Disease
Comparison NN O
of IN O
valsartan NN O
/ SYM O
hydrochlorothiazide NN O
combination NN O
therapy NN O
at IN O
doses NNS O
up IN O
to IN O
320 CD O
/ SYM O
25 CD O
mg NN O
versus IN O
monotherapy NN O
: : O
a DT O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
- HYPH O
controlled VBN O
study NN O
followed VBN O
by IN O
long JJ O
- HYPH O
term NN O
combination NN O
therapy NN O
in IN O
hypertensive JJ B-Disease
adults NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
One CD O
third NN O
of IN O
patients NNS O
treated VBN O
for IN O
hypertension NN B-Disease
attain VBP O
adequate JJ O
blood NN O
pressure NN O
( -LRB- O
BP NN O
) -RRB- O
control NN O
, , O
and CC O
multidrug NN O
regimens NNS O
are VBP O
often RB O
required VBN O
. . O
null null null-Disease
Given VBN O
the DT O
lifelong JJ O
nature NN O
of IN O
hypertension NN B-Disease
, , O
there EX O
is VBZ O
a DT O
need NN O
to TO O
evaluate VB O
the DT O
long JJ O
- HYPH O
term NN O
efficacy NN O
and CC O
tolerability NN O
of IN O
higher JJR O
doses NNS O
of IN O
combination NN O
anti JJ O
- HYPH O
hypertensive JJ B-Disease
therapies NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
This DT O
study NN O
investigated VBD O
the DT O
efficacy NN O
and CC O
tolerability NN O
of IN O
valsartan NN O
( , O
VAL NNP O
) -RRB- O
or CC O
hydrochlorothiazide NN O
( -LRB- O
HCTZ NNP O
) -RRB- O
- HYPH O
monotherapy NN O
and CC O
higher JJR O
- HYPH O
dose NN O
combinations NNS O
in IN O
patients NNS O
with IN O
essential JJ B-Disease
hypertension NN I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
The DT O
first JJ O
part NN O
of IN O
this DT O
study NN O
was VBD O
an DT O
8 CD O
- HYPH O
week NN O
, , O
multicenter NN O
, , O
randomized JJ O
, , O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
controlled VBN O
, , O
parallel JJ O
- HYPH O
group NN O
trial NN O
. . O
null null null-Disease
Patients NNS O
with IN O
essential JJ B-Disease
hypertension NN I-Disease
( , O
mean JJ O
sitting VBG O
diastolic JJ O
BP NNP O
[ -LRB- O
MSDBP NNP O
] -RRB- O
, , O
> SYM O
or CC O
= SYM O
95 CD O
mm NN O
Hg NN O
and CC O
< $ O
110 CD O
mm NN O
Hg NN O
) -RRB- O
were VBD O
randomized VBN O
to IN O
1 CD O
of IN O
8 CD O
treatment NN O
groups NNS O
: : O
VAL NNP O
160 CD O
or CC O
320 CD O
mg NN O
; : O
HCTZ NNP O
12 CD O
. . O
5 CD O
or CC O
25 CD O
mg NN O
; : O
VAL NNP O
/ SYM O
HCTZ NNP O
160 CD O
/ SYM O
12 CD O
. . O
5 CD O
, , O
320 CD O
/ SYM O
12 CD O
. . O
5 CD O
, , O
or CC O
320 CD O
/ SYM O
25 CD O
mg NN O
; : O
or CC O
placebo NN O
. . O
null null null-Disease
Mean JJ O
changes NNS O
in IN O
MSDBP NNP O
and CC O
mean VBP O
sitting VBG O
systolic JJ O
BP NNP O
( , O
MSSBP NNP O
) -RRB- O
were VBD O
analyzed VBN O
at IN O
the DT O
8 CD O
- HYPH O
week NN O
core NN O
study NN O
end NN O
point NN O
. . O
null null null-Disease
VAL NNP O
/ SYM O
HCTZ NNP O
320 CD O
/ SYM O
12 CD O
. . O
5 CD O
and CC O
320 CD O
/ SYM O
25 CD O
mg NN O
were VBD O
further RB O
investigated VBN O
in IN O
a DT O
54 CD O
- HYPH O
week NN O
, , O
open JJ O
- HYPH O
label NN O
extension NN O
. . O
null null null-Disease
Response NN O
was VBD O
defined VBN O
as IN O
MSDBP NNP O
< SYM O
90 CD O
mm NN O
Hg CD O
or CC O
a DT O
> SYM O
or CC O
= SYM O
10 CD O
mm NN O
Hg NN O
decrease NN O
compared VBN O
to IN O
baseline NN O
. . O
null null null-Disease
Control NN O
was VBD O
defined VBN O
as IN O
MSDBP NNP O
< SYM O
90 CD O
mm NN O
Hg NNP O
compared VBN O
with IN O
baseline NN O
. . O
null null null-Disease
Tolerability NN O
was VBD O
assessed VBN O
by IN O
monitoring VBG O
adverse JJ O
events NNS O
at IN O
randomization NN O
and CC O
all DT O
subsequent JJ O
study NN O
visits NNS O
and CC O
regular JJ O
evaluation NN O
of IN O
hematology NN O
and CC O
blood NN O
chemistry NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
A DT O
total NN O
of IN O
1346 CD O
patients NNS O
were VBD O
randomized VBN O
into IN O
the DT O
8 CD O
- HYPH O
week NN O
core NN O
study NN O
( , O
734 CD O
men NNS O
, , O
612 CD O
women NNS O
; : O
924 CD O
white JJ O
, , O
291 CD O
black JJ O
, , O
23 CD O
Asian JJ O
, , O
108 CD O
other JJ O
; : O
mean JJ O
age NN O
, , O
52 CD O
. . O
7 CD O
years NNS O
; : O
mean JJ O
weight NN O
, , O
92 CD O
. . O
6 CD O
kg NNS O
) -RRB- O
. . O
null null null-Disease
All DT O
active JJ O
treatments NNS O
were VBD O
associated VBN O
with IN O
significantly RB O
reduced VBN O
MSSBP NNP O
and CC O
MSDBP NNP O
during IN O
the DT O
core NN O
8 CD O
- HYPH O
week NN O
study NN O
, , O
with IN O
each DT O
monotherapy NN O
significantly RB O
contributing VBG O
to IN O
the DT O
overall JJ O
effect NN O
of IN O
combination NN O
therapy NN O
( , O
VAL NNP O
and CC O
HCTZ NNP O
, , O
P NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Each DT O
combination NN O
was VBD O
associated VBN O
with IN O
significantly RB O
greater JJR O
reductions NNS O
in IN O
MSSBP NNP O
and CC O
MSDBP NNP O
compared VBN O
with IN O
the DT O
monotherapies NNS O
and CC O
placebo NN O
( , O
all DT O
, , O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
mean JJ O
reduction NN O
in IN O
MSSBP NNP O
/ SYM O
MSDBP NNP O
with IN O
VAL NNP O
/ SYM O
HCTZ NNP O
320 CD O
/ SYM O
25 CD O
mg NN O
was VBD O
24 CD O
. . O
7 CD O
/ SYM O
16 CD O
. . O
6 CD O
mm NN O
Hg NN O
, , O
compared VBN O
with IN O
5 CD O
. . O
9 CD O
/ SYM O
7 CD O
. . O
0 CD O
mm NN O
Hg NN O
with IN O
placebo NN O
. . O
null null null-Disease
The DT O
reduction NN O
in IN O
MSSBP NNP O
was VBD O
significantly RB O
greater JJR O
with IN O
VAL NNP O
/ SYM O
HCTZ NNP O
320 CD O
/ SYM O
25 CD O
mg NN O
compared VBN O
with IN O
VAL NNP O
/ SYM O
HCTZ NNP O
160 CD O
/ SYM O
12 CD O
. . O
5 CD O
mg NN O
( SYM O
P NN O
< NN O
0 CD O
. . O
002 CD O
) -RRB- O
. . O
null null null-Disease
Rates NNS O
of IN O
response NN O
and CC O
BP NNP O
control NN O
were VBD O
significantly RB O
higher JJR O
in IN O
the DT O
groups NNS O
that WDT O
received VBD O
combination NN O
treatment NN O
compared VBN O
with IN O
those DT O
that WDT O
received VBD O
monotherapy NN O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
hypokalemia NN B-Disease
was VBD O
lower JJR O
with IN O
VAL NNP O
/ SYM O
HCTZ NNP O
combinations NNS O
( : O
1 CD O
. . O
8 CD O
% NN O
- SYM O
6 CD O
. . O
1 CD O
% NN O
) -RRB- O
than IN O
with IN O
HCTZ NNP O
monotherapies NNS O
( : O
7 CD O
. . O
1 CD O
% NN O
- SYM O
13 CD O
. . O
3 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
The DT O
majority NN O
of IN O
adverse JJ O
events NNS O
in IN O
the DT O
core NN O
study NN O
were VBD O
of IN O
mild JJ O
to IN O
moderate JJ O
severity NN O
. . O
null null null-Disease
The DT O
efficacy NN O
and CC O
tolerability NN O
of IN O
VAL NNP O
/ SYM O
HCTZ NNP O
combinations NNS O
were VBD O
maintained VBN O
during IN O
the DT O
extension NN O
( : O
797 CD O
patients NNS O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
In IN O
this DT O
study NN O
population NN O
, , O
combination NN O
therapies NNS O
with IN O
VAL NNP O
/ SYM O
HCTZ NNP O
were VBD O
associated VBN O
with IN O
significantly RB O
greater JJR O
BP NN O
reductions NNS O
compared VBN O
with IN O
either CC O
monotherapy NN O
, , O
were VBD O
well RB O
tolerated VBN O
, , O
and CC O
were VBD O
associated VBN O
with IN O
less JJR O
hypokalemia NN B-Disease
than IN O
HCTZ NNP O
alone RB O
. . O
null null null-Disease
Succimer JJ O
chelation NN O
improves VBZ O
learning NN O
, , O
attention NN O
, , O
and CC O
arousal NN O
regulation NN O
in IN O
lead NN O
- HYPH O
exposed VBN O
rats NNS O
but CC O
produces VBZ O
lasting VBG O
cognitive JJ B-Disease
impairment NN I-Disease
in IN O
the DT O
absence NN O
of IN O
lead NN O
exposure NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
There EX O
is VBZ O
growing VBG O
pressure NN O
for IN O
clinicians NNS O
to TO O
prescribe VB O
chelation NN O
therapy NN O
at IN O
only RB O
slightly RB O
elevated VBN O
blood NN O
lead NN O
levels NNS O
. . O
null null null-Disease
However RB O
, , O
very RB O
few JJ O
studies NNS O
have VBP O
evaluated VBN O
whether IN O
chelation NN O
improves VBZ O
cognitive JJ O
outcomes NNS O
in IN O
Pb NNP O
- HYPH O
exposed VBN O
children NNS O
, , O
or CC O
whether IN O
these DT O
agents NNS O
have VBP O
adverse JJ O
effects NNS O
that WDT O
may MD O
affect VB O
brain NN O
development NN O
in IN O
the DT O
absence NN O
of IN O
Pb NN O
exposure NN O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
The DT O
present JJ O
study NN O
was VBD O
designed VBN O
to TO O
answer VB O
these DT O
questions NNS O
, , O
using VBG O
a DT O
rodent JJ O
model NN O
of IN O
early JJ O
childhood NN O
Pb NN O
exposure NN O
and CC O
treatment NN O
with IN O
succimer NN O
, , O
a DT O
widely RB O
used VBN O
chelating VBG O
agent NN O
for IN O
the DT O
treatment NN O
of IN O
Pb NN B-Disease
poisoning NN I-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
Pb NN O
exposure NN O
produced VBD O
lasting VBG O
impairments NNS B-Disease
in IN I-Disease
learning NN I-Disease
, , I-Disease
attention NN I-Disease
, , I-Disease
inhibitory JJ I-Disease
control NN I-Disease
, , I-Disease
and CC I-Disease
arousal NN I-Disease
regulation NN I-Disease
, , O
paralleling VBG O
the DT O
areas NNS O
of IN O
dysfunction NN O
seen VBN O
in IN O
Pb NNP O
- HYPH O
exposed VBN O
children NNS O
. . O
null null null-Disease
Succimer NNP O
treatment NN O
of IN O
the DT O
Pb NNP O
- HYPH O
exposed VBN O
rats NNS O
significantly RB O
improved VBD O
learning NN O
, , O
attention NN O
, , O
and CC O
arousal NN O
regulation NN O
, , O
although IN O
the DT O
efficacy NN O
of IN O
the DT O
treatment NN O
varied VBD O
as IN O
a DT O
function NN O
of IN O
the DT O
Pb NNP O
exposure NN O
level NN O
and CC O
the DT O
specific JJ O
functional JJ O
deficit NN O
. . O
null null null-Disease
In IN O
contrast NN O
, , O
succimer NN O
treatment NN O
of IN O
rats NNS O
not RB O
previously RB O
exposed VBN O
to IN O
Pb NNP O
produced VBD O
lasting VBG O
and CC O
pervasive JJ O
cognitive JJ B-Disease
and CC I-Disease
affective JJ I-Disease
dysfunction NN I-Disease
comparable JJ O
in IN O
magnitude NN O
to IN O
that DT O
produced VBN O
by IN O
the DT O
higher JJR O
Pb NN O
exposure NN O
regimen NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
These DT O
are VBP O
the DT O
first JJ O
data NNS O
, , O
to IN O
our PRP$ O
knowledge NN O
, , O
to TO O
show VB O
that IN O
treatment NN O
with IN O
any DT O
chelating JJ O
agent NN O
can MD O
alleviate VB O
cognitive JJ B-Disease
deficits NNS I-Disease
due IN O
to IN O
Pb NNP O
exposure NN O
. . O
null null null-Disease
These DT O
findings NNS O
suggest VBP O
that IN O
it PRP O
may MD O
be VB O
possible JJ O
to TO O
identify VB O
a DT O
succimer NN O
treatment NN O
protocol NN O
that WDT O
improves VBZ O
cognitive JJ O
outcomes NNS O
in IN O
Pb NNP O
- HYPH O
exposed VBN O
children NNS O
. . O
null null null-Disease
However RB O
, , O
they PRP O
also RB O
suggest VBP O
that IN O
succimer NN O
treatment NN O
should MD O
be VB O
strongly RB O
discouraged VBN O
for IN O
children NNS O
who WP O
do VBP O
not RB O
have VB O
elevated VBN O
tissue NN O
levels NNS O
of IN O
Pb NN O
or CC O
other JJ O
heavy JJ O
metals NNS O
. . O
null null null-Disease
Caffeine NN O
challenge NN O
test NN O
in IN O
panic NN B-Disease
disorder NN I-Disease
and CC O
depression NN B-Disease
with IN O
panic NN B-Disease
attacks NNS I-Disease
. . O
null null null-Disease
Our PRP$ O
aim NN O
was VBD O
to TO O
observe VB O
if IN O
patients NNS O
with IN O
panic NN B-Disease
disorder NN I-Disease
( , O
PD NN B-Disease
) -RRB- O
and CC O
patients NNS O
with IN O
major JJ B-Disease
depression NN I-Disease
with IN O
panic NN B-Disease
attacks NNS I-Disease
( -LRB- O
MDP NNP B-Disease
) -RRB- O
( , O
Diagnostic NNP O
and CC O
Statistical NNP O
Manual NNP O
of IN O
Mental NNP B-Disease
Disorders NNPS I-Disease
, , O
Fourth NNP O
Edition NNP O
criteria NNS O
) , O
respond VBP O
in IN O
a DT O
similar JJ O
way NN O
to IN O
the DT O
induction NN O
of IN O
panic NN B-Disease
attacks NNS I-Disease
by IN O
an DT O
oral JJ O
caffeine NN O
challenge NN O
test NN O
. . O
null null null-Disease
We PRP O
randomly RB O
selected VBD O
29 CD O
patients NNS O
with IN O
PD NNP B-Disease
, , O
27 CD O
with IN O
MDP NNP B-Disease
, , O
25 CD O
with IN O
major JJ B-Disease
depression NN I-Disease
without IN O
panic NN B-Disease
attacks NNS I-Disease
( , O
MD NNP B-Disease
) -RRB- O
, , O
and CC O
28 CD O
healthy JJ O
volunteers NNS O
. . O
null null null-Disease
The DT O
patients NNS O
had VBD O
no DT O
psychotropic JJ O
drug NN O
for IN O
at IN O
least JJS O
a DT O
4 CD O
- HYPH O
week NN O
period NN O
. . O
null null null-Disease
In IN O
a DT O
randomized VBN O
double JJ O
- HYPH O
blind JJ O
experiment NN O
performed VBN O
in IN O
2 CD O
occasions NNS O
7 CD O
days NNS O
apart RB O
, , O
480 CD O
mg NN O
caffeine NN O
and CC O
a DT O
caffeine NN O
- HYPH O
free JJ O
( , O
placebo NN O
) -RRB- O
solution NN O
were VBD O
administered VBN O
in IN O
a DT O
coffee NN O
form NN O
and CC O
anxiety NN B-Disease
scales NNS O
were VBD O
applied VBN O
before IN O
and CC O
after IN O
each DT O
test NN O
. . O
null null null-Disease
A DT O
total NN O
of IN O
58 CD O
. . O
6 CD O
% NN O
( SYM O
n CD O
= SYM O
17 CD O
) -RRB- O
of IN O
patients NNS O
with IN O
PD NN B-Disease
, , O
44 CD O
. . O
4 CD O
% NN O
( , O
n CD O
= SYM O
12 CD O
) -RRB- O
of IN O
patients NNS O
with IN O
MDP NNP B-Disease
, , O
12 CD O
. . O
0 CD O
% NN O
( , O
n CD O
= SYM O
3 CD O
) -RRB- O
of IN O
patients NNS O
with IN O
MD NNP B-Disease
, , O
and CC O
7 CD O
. . O
1 CD O
% NN O
( , O
n CD O
= SYM O
2 CD O
) -RRB- O
of IN O
control NN O
subjects NNS O
had VBD O
a DT O
panic NN B-Disease
attack NN I-Disease
after IN O
the DT O
480 CD O
- HYPH O
mg NN O
caffeine NN O
challenge NN O
test NN O
( , O
chi NN O
( , O
2 CD O
) SYM O
( SYM O
3 CD O
) SYM O
= SYM O
16 CD O
. . O
22 CD O
, , O
P NN O
= SYM O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
patients NNS O
with IN O
PD NNP B-Disease
and CC O
MDP NNP B-Disease
were VBD O
more RBR O
sensitive JJ O
to IN O
caffeine NN O
than IN O
were VBD O
patients NNS O
with IN O
MD NNP B-Disease
and CC O
healthy JJ O
volunteers NNS O
. . O
null null null-Disease
No DT O
panic NN B-Disease
attack NN I-Disease
was VBD O
observed VBN O
after IN O
the DT O
caffeine NN O
- HYPH O
free JJ O
solution NN O
intake NN O
. . O
null null null-Disease
The DT O
patients NNS O
with IN O
MD NNP B-Disease
had VBD O
a DT O
lower JJR O
heart NN O
rate NN O
response NN O
to IN O
the DT O
test NN O
than IN O
all PDT O
the DT O
other JJ O
groups NNS O
( , O
2 CD O
- HYPH O
way NN O
analysis NN O
of IN O
variance NN O
, , O
group NN O
by IN O
time NN O
interaction NN O
with IN O
Greenhouse NNP O
- HYPH O
Geisser NNP O
correction NN O
: : O
F NNP O
( : O
3 CD O
, , O
762 CD O
) -RRB- O
= SYM O
2 CD O
. . O
85 CD O
, , O
P NN O
= SYM O
. . O
026 CD O
) -RRB- O
. . O
null null null-Disease
Our PRP$ O
data NNS O
suggest VBP O
that IN O
there EX O
is VBZ O
an DT O
association NN O
between IN O
panic NN B-Disease
attacks NNS I-Disease
, , O
no DT O
matter NN O
if IN O
associated VBN O
with IN O
PD NN B-Disease
or CC O
MDP NNP B-Disease
, , O
and CC O
hyperreactivity NN O
to IN O
an DT O
oral JJ O
caffeine NN O
challenge NN O
test NN O
. . O
null null null-Disease
Mitral JJ O
annuloplasty NN O
as IN O
a DT O
ventricular JJ O
restoration NN O
method NN O
for IN O
the DT O
failing VBG B-Disease
left JJ I-Disease
ventricle NN I-Disease
: : O
a DT O
pilot NN O
study NN O
. . O
null null null-Disease
BACKGROUND NN O
AND CC O
AIM NN O
OF IN O
THE DT O
STUDY NN O
: : O
Undersized JJ O
mitral JJ O
annuloplasty NN O
( , O
MAP NNP O
) -RRB- O
is VBZ O
effective JJ O
in IN O
patients NNS O
with IN O
dilated VBN B-Disease
cardiomyopathy NN I-Disease
and CC O
functional JJ O
mitral NN B-Disease
regurgitation NN I-Disease
( -LRB- O
MR NN B-Disease
) -RRB- O
since IN O
, , O
as RB O
well RB O
as IN O
addressing VBG O
the DT O
MR NNP B-Disease
, , O
the DT O
MAP NNP O
may MD O
also RB O
reshape VB O
the DT O
dilated VBN O
left JJ O
ventricular JJ O
( -LRB- O
LV NN O
) -RRB- O
base NN O
. . O
null null null-Disease
However RB O
, , O
the DT O
direct JJ O
benefits NNS O
of IN O
this DT O
possible JJ O
reshaping NN O
on IN O
LV NN O
function NN O
in IN O
the DT O
absence NN O
of IN O
underlying VBG O
MR NN B-Disease
remain VBP O
incompletely RB O
understood VBN O
. . O
null null null-Disease
The DT O
study NN O
aim NN O
was VBD O
to TO O
identify VB O
these DT O
benefits NNS O
in IN O
a DT O
canine NN O
model NN O
of IN O
acute JJ O
heart NN B-Disease
failure NN I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Six CD O
dogs NNS O
underwent VBD O
MAP NNP O
with IN O
a DT O
prosthetic JJ O
band NN O
on IN O
the DT O
posterior JJ O
mitral NN O
annulus NN O
, , O
using VBG O
four CD O
mattress NN O
sutures NNS O
. . O
null null null-Disease
The DT O
sutures NNS O
were VBD O
passed VBN O
individually RB O
through IN O
four CD O
tourniquets NNS O
and CC O
exteriorized VBN O
untied VBN O
via IN O
the DT O
left JJ O
atriotomy NN O
. . O
null null null-Disease
Sonomicrometry NN O
crystals NNS O
were VBD O
implanted VBN O
around IN O
the DT O
mitral JJ O
annulus NN O
and CC O
left VBN O
ventricle NN O
to TO O
measure VB O
geometry NN O
and CC O
regional JJ O
function NN O
. . O
null null null-Disease
Acute JJ O
heart NN B-Disease
failure NN I-Disease
was VBD O
induced VBN O
by IN O
propranolol NN O
and CC O
volume NN O
loading NN O
after IN O
weaning VBG O
from IN O
cardiopulmonary JJ O
bypass NN O
; : O
an DT O
absence NN O
of IN O
MR NNP B-Disease
was VBD O
confirmed VBN O
by IN O
echocardiography NN O
. . O
null null null-Disease
MAP NNP O
was VBD O
accomplished VBN O
by IN O
cinching VBG O
the DT O
tourniquets NNS O
. . O
null null null-Disease
Data NNS O
were VBD O
acquired VBN O
at IN O
baseline NN O
, , O
after IN O
induction NN O
of IN O
acute JJ O
heart NN B-Disease
failure NN I-Disease
, , O
and CC O
after IN O
MAP NNP O
. . O
null null null-Disease
RESULTS NNS O
: : O
MAP NNP O
decreased VBD O
mitral JJ O
annular JJ O
dimensions NNS O
in IN O
both CC O
commissure JJ O
- HYPH O
commissure NN O
and CC O
septal JJ O
- HYPH O
lateral JJ O
directions NNS O
. . O
null null null-Disease
Concomitantly RB O
, , O
the DT O
diastolic JJ O
diameter NN O
of IN O
the DT O
LV NN O
base NN O
and CC O
LV NN O
sphericity NN O
decreased VBD O
( : O
i LS O
. . O
e -RRB- O
. . O
, , O
improved VBN O
) -RRB- O
from IN O
37 CD O
. . O
4 CD O
+ NN O
/ SYM O
- HYPH O
9 CD O
. . O
3 CD O
to TO O
35 CD O
. . O
9 CD O
+ NN O
/ SYM O
- SYM O
10 CD O
mm NN O
( : O
p NN O
= SYM O
0 CD O
. . O
063 CD O
) -RRB- O
, , O
and CC O
from IN O
67 CD O
. . O
9 CD O
+ CD O
/ SYM O
- HYPH O
18 CD O
. . O
6 CD O
% NN O
to TO O
65 CD O
. . O
3 CD O
+ NN O
/ SYM O
- HYPH O
18 CD O
. . O
9 CD O
% NN O
( , O
p NN O
= SYM O
0 CD O
. . O
016 CD O
) -RRB- O
, , O
respectively RB O
. . O
null null null-Disease
Decreases NNS O
were VBD O
evident JJ O
in IN O
both CC O
LV NN O
end NN O
- HYPH O
diastolic JJ O
pressure NN O
( , O
from IN O
17 CD O
+ CD O
/ SYM O
- HYPH O
7 CD O
to IN O
15 CD O
+ CD O
/ SYM O
- HYPH O
6 CD O
mmHg NN O
, , O
p NN O
= SYM O
0 CD O
. . O
0480 CD O
and CC O
Tau NNP O
( : O
from IN O
48 CD O
+ CD O
/ SYM O
- HYPH O
8 CD O
to TO O
45 CD O
+ NN O
/ SYM O
- HYPH O
8 CD O
ms NNS O
, , O
p NN O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
while IN O
fractional JJ O
shortening NN O
at IN O
the DT O
LV NN O
base NN O
increased VBD O
from IN O
7 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- SYM O
4 CD O
. . O
5 CD O
% NN O
to IN O
9 CD O
. . O
4 CD O
+ SYM O
/ SYM O
- SYM O
4 CD O
. . O
5 CD O
% NN O
( : O
p NN O
= SYM O
0 CD O
. . O
045 CD O
) -RRB- O
. . O
null null null-Disease
After IN O
MAP NNP O
, , O
increases NNS O
were VBD O
identified VBN O
in IN O
both DT O
cardiac JJ O
output NN O
( : O
from IN O
1 CD O
. . O
54 CD O
+ CD O
/ SYM O
- SYM O
0 CD O
. . O
57 CD O
to IN O
1 CD O
. . O
65 CD O
+ NN O
/ SYM O
- SYM O
0 CD O
. . O
57 CD O
1 CD O
/ SYM O
min NN O
) : O
and CC O
Emax NNP O
( : O
from IN O
1 CD O
. . O
86 CD O
+ NN O
/ : O
- SYM O
0 CD O
. . O
9 CD O
to TO O
2 CD O
. . O
41 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
31 CD O
mmHg NN O
/ SYM O
ml NN O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
data NNS O
acquired VBN O
suggest VBP O
that IN O
isolated VBN O
MAP NNP O
may MD O
have VB O
certain JJ O
benefits NNS O
on IN O
LV NN O
dimension NN O
/ SYM O
function NN O
in IN O
acute JJ O
heart NN B-Disease
failure NN I-Disease
, , O
even RB O
in IN O
the DT O
absence NN O
of IN O
MR NNP B-Disease
. . O
null null null-Disease
However RB O
, , O
further JJ O
investigations NNS O
are VBP O
warranted VBN O
in IN O
a DT O
model NN O
of IN O
chronic JJ O
heart NN B-Disease
failure NN I-Disease
. . O
null null null-Disease
Piperacillin NNP O
/ SYM O
tazobactam NN O
- HYPH O
induced VBN O
seizure NN B-Disease
rapidly RB O
reversed VBN O
by IN O
high JJ O
flux NN O
hemodialysis NN O
in IN O
a DT O
patient NN O
on IN O
peritoneal JJ O
dialysis NN O
. . O
null null null-Disease
Despite IN O
popular JJ O
use NN O
of IN O
piperacillin NN O
, , O
the DT O
dire JJ O
neurotoxicity NN B-Disease
associated VBN O
with IN O
piperacillin NN O
still RB O
goes VBZ O
unrecognized JJ O
, , O
leading VBG O
to IN O
a DT O
delay NN O
in IN O
appropriate JJ O
management NN O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
57 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
end JJ B-Disease
- HYPH I-Disease
stage NN I-Disease
renal JJ I-Disease
disease NN I-Disease
receiving VBG O
continuous JJ O
ambulatory JJ O
peritoneal JJ O
dialysis NN O
( , O
CAPD NNP O
) -RRB- O
, , O
who WP O
developed VBD O
slurred VBN O
speech NN O
, , O
tremor NN B-Disease
, , O
bizarre JJ O
behavior NN O
, , O
progressive JJ O
mental JJ O
confusion NN B-Disease
, , O
and CC O
2 CD O
episodes NNS O
of IN O
generalized VBN O
tonic NN B-Disease
- HYPH I-Disease
clonic JJ I-Disease
seizure NN I-Disease
( , O
GTCS NNP B-Disease
) -RRB- O
after IN O
5 CD O
doses NNS O
of IN O
piperacillin NN O
/ SYM O
tazobactam NN O
( SYM O
2 CD O
g CD O
/ SYM O
250 CD O
mg NN O
) -RRB- O
were VBD O
given VBN O
for IN O
bronchiectasis NN B-Disease
with IN O
secondary JJ B-Disease
infection NN I-Disease
. . O
null null null-Disease
The DT O
laboratory NN O
data NNS O
revealed VBD O
normal JJ O
plasma NN O
electrolyte NN O
and CC O
ammonia NN O
levels NNS O
but CC O
leukocytosis NN B-Disease
. . O
null null null-Disease
Neurologic JJ O
examinations NNS O
showed VBD O
dysarthria NN B-Disease
and CC O
bilateral JJ O
Babinski NNP O
sign NN O
. . O
null null null-Disease
Computed VBN O
tomography NN O
of IN O
brain NN O
and CC O
electroencephalogram NN O
were VBD O
unremarkable JJ O
. . O
null null null-Disease
Despite IN O
the DT O
use NN O
of IN O
antiepileptic JJ O
agents NNS O
, , O
another DT O
GTCS NNP B-Disease
episode NN O
recurred VBD O
after IN O
the DT O
sixth JJ O
dose NN O
of IN O
piperacillin NN O
/ SYM O
tazobactam NN O
. . O
null null null-Disease
Brain NN O
magnetic JJ O
resonance NN O
imaging NN O
did VBD O
not RB O
demonstrate VB O
acute JJ O
infarction NN B-Disease
and CC O
organic JJ B-Disease
brain NN I-Disease
lesions NNS I-Disease
. . O
null null null-Disease
Initiation NN O
of IN O
high JJ O
- HYPH O
flux NN O
hemodialysis NN O
rapidly RB O
reversed VBD O
the DT O
neurologic JJ O
symptoms NNS O
within IN O
4 CD O
hours NNS O
. . O
null null null-Disease
Piperacillin NNP O
- HYPH O
induced VBN O
encephalopathy NN B-Disease
should MD O
be VB O
considered VBN O
in IN O
any DT O
uremic JJ B-Disease
patients NNS O
with IN O
unexplained JJ O
neurological JJ O
manifestations NNS O
. . O
null null null-Disease
CAPD NNP O
is VBZ O
inefficient JJ O
in IN O
removing VBG O
piperacillin NN O
, , O
whereas IN O
hemodialysis NN O
can MD O
rapidly RB O
terminate VB O
the DT O
piperacillin NN O
- HYPH O
induced VBN O
encephalopathy NN B-Disease
. . O
null null null-Disease
Frequency NN O
of IN O
transient JJ O
ipsilateral JJ O
vocal JJ B-Disease
cord NN I-Disease
paralysis NN I-Disease
in IN O
patients NNS O
undergoing VBG O
carotid JJ O
endarterectomy NN O
under IN O
local JJ O
anesthesia NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Especially RB O
because IN O
of IN O
improvements NNS O
in IN O
clinical JJ O
neurologic JJ O
monitoring NN O
, , O
carotid JJ O
endarterectomy NN O
done VBN O
under IN O
local JJ O
anesthesia NN O
has VBZ O
become VBN O
the DT O
technique NN O
of IN O
choice NN O
in IN O
several JJ O
centers NNS O
. . O
null null null-Disease
Temporary JJ O
ipsilateral JJ O
vocal JJ B-Disease
nerve JJ I-Disease
palsies NNS I-Disease
due JJ O
to IN O
local JJ O
anesthetics NNS O
have VBP O
been VBN O
described VBN O
, , O
however RB O
. . O
null null null-Disease
Such JJ O
complications NNS O
are VBP O
most RBS O
important JJ O
in IN O
situations NNS O
where WRB O
there EX O
is VBZ O
a DT O
pre NN O
- HYPH O
existing VBG O
contralateral JJ O
paralysis NN B-Disease
. . O
null null null-Disease
We PRP O
therefore RB O
examined VBD O
the DT O
effect NN O
of IN O
local JJ O
anesthesia NN O
on IN O
vocal JJ O
cord NN O
function NN O
to TO O
better RBR O
understand VB O
its PRP$ O
possible JJ O
consequences NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
This DT O
prospective JJ O
study NN O
included VBD O
28 CD O
patients NNS O
undergoing VBG O
carotid JJ O
endarterectomy NN O
under IN O
local JJ O
anesthesia NN O
. . O
null null null-Disease
Vocal JJ O
cord NN O
function NN O
was VBD O
evaluated VBN O
before RB O
, , O
during IN O
, , O
and CC O
after IN O
surgery NN O
( , O
postoperative JJ O
day NN O
1 CD O
) , O
using VBG O
flexible JJ O
laryngoscopy NN O
. . O
null null null-Disease
Anesthesia NN O
was VBD O
performed VBN O
by IN O
injecting VBG O
20 CD O
to TO O
40 CD O
mL NNS O
of IN O
a DT O
mixture NN O
of IN O
long JJ O
- HYPH O
acting NN O
( : O
ropivacaine NN O
) -RRB- O
and CC O
short JJ O
- HYPH O
acting VBG O
( : O
prilocaine NN O
) NFP O
anesthetic NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
All DT O
patients NNS O
had VBD O
normal JJ O
vocal JJ O
cord NN O
function NN O
preoperatively RB O
. . O
null null null-Disease
Twelve CD O
patients NNS O
( : O
43 CD O
% NN O
) CD O
were VBD O
found VBN O
to TO O
have VB O
intraoperative JJ O
ipsilateral JJ O
vocal JJ B-Disease
cord NN I-Disease
paralysis NN I-Disease
. . O
null null null-Disease
It PRP O
resolved VBD O
in IN O
all DT O
cases NNS O
< : O
or CC O
= SYM O
24 CD O
hours NNS O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
operating VBG O
time NN O
or CC O
volume NN O
or CC O
frequency NN O
of IN O
anesthetic JJ O
administration NN O
in IN O
patients NNS O
with IN O
temporary JJ O
vocal JJ B-Disease
cord NN I-Disease
paralysis NN I-Disease
compared VBN O
with IN O
those DT O
without IN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Local JJ O
anesthesia NN O
led VBD O
to IN O
temporary JJ O
ipsilateral JJ O
vocal JJ B-Disease
cord NN I-Disease
paralysis NN I-Disease
in IN O
almost RB O
half NN O
of IN O
these DT O
patients NNS O
. . O
null null null-Disease
Because IN O
pre NN O
- HYPH O
existing VBG O
paralysis NN B-Disease
is VBZ O
of IN O
a DT O
relevant JJ O
frequency NN O
( , O
up IN O
to TO O
3 CD O
% NN O
) -RRB- O
, , O
a DT O
preoperative JJ O
evaluation NN O
of IN O
vocal JJ O
cord NN O
function NN O
before IN O
carotid NN O
endarterectomy NN O
under IN O
local JJ O
anesthesia NN O
is VBZ O
recommended VBN O
to TO O
avoid VB O
intraoperative JJ O
bilateral JJ O
paralysis NN B-Disease
. . O
null null null-Disease
In IN O
patients NNS O
with IN O
preoperative JJ O
contralateral JJ O
vocal JJ B-Disease
cord NN I-Disease
paralysis NN I-Disease
, , O
surgery NN O
under IN O
general JJ O
anesthesia NN O
should MD O
be VB O
considered VBN O
. . O
null null null-Disease
Impaired VBN B-Disease
fear NN I-Disease
recognition NN I-Disease
in IN O
regular JJ O
recreational JJ O
cocaine NN O
users NNS O
. . O
null null null-Disease
INTRODUCTION NN O
: : O
The DT O
ability NN O
to TO O
read VB O
facial JJ O
expressions NNS O
is VBZ O
essential JJ O
for IN O
normal JJ O
human JJ O
social JJ O
interaction NN O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
conduct VB O
the DT O
first JJ O
investigation NN O
of IN O
facial JJ O
expression NN O
recognition NN O
performance NN O
in IN O
recreational JJ O
cocaine NN O
users NNS O
. . O
null null null-Disease
MATERIALS NNS O
AND CC O
METHODS NNS O
: : O
Three CD O
groups NNS O
, , O
comprised VBN O
of IN O
21 CD O
cocaine NN O
naive JJ O
participants NNS O
( , O
CN NNP O
) -RRB- O
, , O
30 CD O
occasional JJ O
cocaine NN O
( -LRB- O
OC NNP O
) -RRB- O
, , O
and CC O
48 CD O
regular JJ O
recreational JJ O
cocaine NN O
( -LRB- O
RC NN O
) -RRB- O
users NNS O
, , O
were VBD O
compared VBN O
. . O
null null null-Disease
An DT O
emotional JJ O
facial JJ O
expression NN O
( , O
EFE NNP O
) -RRB- O
task NN O
consisting VBG O
of IN O
a DT O
male JJ O
and CC O
female JJ O
face NN O
expressing VBG O
six CD O
basic JJ O
emotions NNS O
( , O
happiness NN O
, , O
surprise NN O
, , O
sadness NN O
, , O
anger NN O
, , O
fear NN O
, , O
and CC O
disgust NN O
) , O
was VBD O
administered VBN O
. . O
null null null-Disease
Mean JJ O
percent NN O
accuracy NN O
and CC O
latencies NNS O
for IN O
correct JJ O
responses NNS O
across IN O
eight CD O
presentations NNS O
of IN O
each DT O
basic JJ O
emotion NN O
were VBD O
derived VBN O
. . O
null null null-Disease
Participants NNS O
were VBD O
also RB O
assessed VBN O
with IN O
the DT O
"""" `` O
Eyes NNP O
task NN O
"""" '' O
to TO O
investigate VB O
their PRP$ O
ability NN O
to TO O
recognize VB O
more RBR O
complex JJ O
emotional JJ O
states NNS O
and CC O
the DT O
Symptom NNP O
CheckList NNP O
- : O
90 CD O
- HYPH O
Revised VBN O
to TO O
measure VB O
psychopathology NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
There EX O
were VBD O
no DT O
group NN O
differences NNS O
in IN O
psychopathology NN O
or CC O
"""" `` O
eyes NNS O
task NN O
"""" '' O
performance NN O
, , O
but CC O
the DT O
RC NNP O
group NN O
, , O
who WP O
otherwise RB O
had VBD O
similar JJ O
illicit JJ O
substance NN O
use NN O
histories NNS O
to IN O
the DT O
OC NNP O
group NN O
, , O
exhibited VBD O
impaired JJ B-Disease
fear NN I-Disease
recognition NN I-Disease
accuracy NN O
compared VBN O
to IN O
the DT O
OC NNP O
and CC O
CN NNP O
groups NNS O
. . O
null null null-Disease
The DT O
RC NNP O
group NN O
also RB O
correctly RB O
identified VBD O
anger NN O
, , O
fear NN O
, , O
happiness NN O
, , O
and CC O
surprise NN O
, , O
more RBR O
slowly RB O
than IN O
CN NNP O
, , O
but CC O
not RB O
OC NNP O
participants NNS O
. . O
null null null-Disease
The DT O
OC NNP O
group NN O
was VBD O
slower JJR O
than IN O
CN NNP O
when WRB O
correctly RB O
identifying VBG O
disgust NN O
. . O
null null null-Disease
The DT O
selective JJ O
deficit NN B-Disease
in IN I-Disease
fear NN I-Disease
recognition NN I-Disease
accuracy NN O
manifested VBN O
by IN O
the DT O
RC NNP O
group NN O
cannot MD O
be VB O
explained VBN O
by IN O
the DT O
subacute JJ O
effects NNS O
of IN O
cocaine NN O
, , O
or CC O
ecstasy NN O
, , O
because IN O
recent JJ O
and CC O
less RBR O
recent JJ O
users NNS O
of IN O
these DT O
drugs NNS O
within IN O
this DT O
group NN O
were VBD O
similarly RB O
impaired JJ O
. . O
null null null-Disease
Possible JJ O
parallels NNS O
between IN O
RC NNP O
users NNS O
and CC O
psychopaths NNS B-Disease
with IN O
respect NN O
to IN O
impaired JJ B-Disease
fear NN I-Disease
recognition NN I-Disease
, , O
amygdala NN B-Disease
dysfunction NN I-Disease
, , O
and CC O
etiology NN O
are VBP O
discussed VBN O
. . O
null null null-Disease
Damage NN B-Disease
of IN I-Disease
substantia JJ I-Disease
nigra NN I-Disease
pars NNS I-Disease
reticulata NN I-Disease
during IN O
pilocarpine NN O
- HYPH O
induced VBN O
status NN B-Disease
epilepticus NN I-Disease
in IN O
the DT O
rat NN O
: : O
immunohistochemical JJ O
study NN O
of IN O
neurons NNS O
, , O
astrocytes NNS O
and CC O
serum NN O
- HYPH O
protein NN O
extravasation NN O
. . O
null null null-Disease
The DT O
substantia JJ O
nigra NN O
has VBZ O
a DT O
gating NN O
function NN O
controlling VBG O
the DT O
spread NN O
of IN O
epileptic JJ B-Disease
seizure NN I-Disease
activity NN O
. . O
null null null-Disease
Additionally RB O
, , O
in IN O
models NNS O
of IN O
prolonged VBN B-Disease
status NN I-Disease
epilepticus NN I-Disease
the DT O
pars NNS O
reticulata NN O
of IN O
substantia JJ O
nigra NN O
( , O
SNR NNP O
) -RRB- O
suffers VBZ O
from IN O
a DT O
massive JJ O
lesion NN O
which WDT O
may MD O
arise VB O
from IN O
a DT O
massive JJ O
metabolic JJ B-Disease
derangement NN I-Disease
and CC O
hyperexcitation NN O
developing VBG O
in IN O
the DT O
activated VBN O
SNR NNP O
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
status NN B-Disease
epilepticus NN I-Disease
was VBD O
induced VBN O
by IN O
systemic JJ O
injection NN O
of IN O
pilocarpine NN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
neuropathology NN O
of IN O
SNR NNP O
was VBD O
investigated VBN O
using VBG O
immunohistochemical JJ O
techniques NNS O
with IN O
the DT O
major JJ O
emphasis NN O
on IN O
the DT O
time NN O
- HYPH O
course NN O
of IN O
changes NNS O
in IN O
neurons NNS O
and CC O
astrocytes NNS O
. . O
null null null-Disease
Animals NNS O
surviving VBG O
20 CD O
, , O
30 CD O
, , O
40 CD O
, , O
60 CD O
min NN O
, , O
2 CD O
, , O
3 CD O
, , O
6 CD O
hours NNS O
, , O
1 CD O
, , O
2 CD O
, , O
and CC O
3 CD O
days NNS O
after IN O
induction NN O
of IN O
status NN B-Disease
epilepticus NN I-Disease
were VBD O
perfusion NN O
- HYPH O
fixed VBN O
, , O
and CC O
brains NNS O
processed VBN O
for IN O
immunohistochemical JJ O
staining NN O
of IN O
SNR NNP O
. . O
null null null-Disease
Nissl NN O
- HYPH O
staining NN O
and CC O
antibodies NNS O
against IN O
the DT O
neuron NN O
- HYPH O
specific JJ O
calcium NN O
- HYPH O
binding VBG O
protein NN O
, , O
parvalbumin NN O
, , O
served VBN O
to TO O
detect VB O
neuronal JJ B-Disease
damage NN I-Disease
in IN O
SNR NNP O
. . O
null null null-Disease
Antibodies NNS O
against IN O
the DT O
astroglia NN O
- HYPH O
specific JJ O
cytoskeletal NN O
protein NN O
, , O
glial NN O
fibrillary NN O
acidic JJ O
protein NN O
( , O
GFAP NNP O
) -RRB- O
, , O
and CC O
against IN O
the DT O
glial NN O
calcium NN O
- HYPH O
binding VBG O
protein NN O
, , O
S NNP O
- HYPH O
100 CD O
protein NN O
, , O
were VBD O
used VBN O
to TO O
assess VB O
the DT O
status NN O
of IN O
astrocytes NNS O
. . O
null null null-Disease
Immunohistochemical JJ O
staining NN O
for IN O
serum NN O
- HYPH O
albumin NN O
and CC O
immunoglobulins NNS O
in IN O
brain NN O
tissue NN O
was VBD O
taken VBN O
as IN O
indicator NN O
of IN O
blood NN O
- HYPH O
brain NN O
barrier NN O
disturbances NNS O
and CC O
vasogenic JJ B-Disease
edema NN I-Disease
formation NN O
. . O
null null null-Disease
Immunohistochemical JJ O
staining NN O
indicated VBD O
loss NN O
of IN O
GFAP NN O
- HYPH O
staining VBG O
already RB O
at IN O
30 CD O
min NN O
after IN O
induction NN O
of IN O
seizures NNS B-Disease
in IN O
an DT O
oval JJ O
focus NN O
situated VBN O
in IN O
the DT O
center NN O
of IN O
SNR NNP O
while IN O
sparing VBG O
medial JJ O
and CC O
lateral JJ O
aspects NNS O
. . O
null null null-Disease
At IN O
1 CD O
h NN O
there EX O
was VBD O
additional JJ O
vacuolation NN O
in IN O
S NNP O
- HYPH O
100 CD O
protein NN O
staining NN O
. . O
null null null-Disease
By IN O
2 CD O
hours NNS O
, , O
parvalbumin NN O
- HYPH O
staining NN O
changed VBN O
in IN O
the DT O
central JJ O
SNR NN O
indicating VBG O
neuronal JJ B-Disease
damage NN I-Disease
, , O
and CC O
Nissl NNP O
- HYPH O
staining NN O
visualized VBD O
some DT O
neuronal JJ O
distortion NN O
. . O
null null null-Disease
Staining VBG O
for IN O
serum NN O
- HYPH O
proteins NNS O
occurred VBD O
in IN O
a DT O
patchy JJ O
manner NN O
throughout IN O
the DT O
forebrain NN O
during IN O
the DT O
first JJ O
hours NNS O
. . O
null null null-Disease
By IN O
6 CD O
h CD O
, , O
vasogenic JJ B-Disease
edema NN I-Disease
covered VBD O
the DT O
lesioned VBN B-Disease
SNR NNP I-Disease
. . O
null null null-Disease
By IN O
24 CD O
h NNS O
, , O
glial NN O
and CC O
neuronal JJ O
markers NNS O
indicated VBD O
a DT O
massive JJ O
lesion NN O
in IN O
the DT O
center NN O
of IN O
SNR NNP O
. . O
null null null-Disease
By IN O
48 CD O
- SYM O
72 CD O
h NN O
, , O
astrocytes NNS O
surrounding VBG O
the DT O
lesion NN O
increased VBD O
in IN O
size NN O
, , O
and CC O
polymorphic JJ O
phagocytotic JJ O
cells NNS O
invaded VBD O
the DT O
damaged VBN O
area NN O
. . O
null null null-Disease
In IN O
a DT O
further JJ O
group NN O
of IN O
animals NNS O
surviving VBG O
1 CD O
to TO O
5 CD O
days NNS O
, , O
conventional JJ O
paraffin NN O
- HYPH O
sections NNS O
confirmed VBD O
the DT O
neuronal JJ O
and CC O
glial JJ O
damage NN B-Disease
of IN I-Disease
SNR NNP I-Disease
. . O
null null null-Disease
Additional JJ O
pathology NN O
of IN O
similar JJ O
quality NN O
was VBD O
found VBN O
in IN O
the DT O
globus NN O
pallidus NN O
. . O
null null null-Disease
Since IN O
astrocytes NNS O
were VBD O
always RB O
damaged VBN O
in IN O
parallel NN O
with IN O
neurons NNS O
in IN O
SNR NNP O
it PRP O
is VBZ O
proposed VBN O
that IN O
the DT O
anatomical JJ O
and CC O
functional JJ O
interrelationship NN O
between IN O
neurons NNS O
and CC O
astrocytes NNS O
is VBZ O
particularly RB O
tight JJ O
in IN O
SNR NNP O
. . O
null null null-Disease
Both DT O
cell NN O
elements NNS O
may MD O
suffer VB O
in IN O
common JJ O
from IN O
metabolic JJ O
disturbance NN O
and CC O
neurotransmitter NN B-Disease
dysfunction NN I-Disease
as IN O
occur NN O
during IN O
massive JJ O
status NN B-Disease
epilepticus NN I-Disease
. . O
null null null-Disease
Neuroprotective JJ O
effects NNS O
of IN O
melatonin NN O
upon IN O
the DT O
offspring NN O
cerebellar NN O
cortex NN O
in IN O
the DT O
rat NN O
model NN O
of IN O
BCNU NNP O
- HYPH O
induced VBN O
cortical JJ B-Disease
dysplasia NN I-Disease
. . O
null null null-Disease
Cortical JJ B-Disease
dysplasia NN I-Disease
is VBZ O
a DT O
malformation NN O
characterized VBN O
by IN O
defects NNS O
in IN O
proliferation NN O
, , O
migration NN O
and CC O
maturation NN O
. . O
null null null-Disease
This DT O
study NN O
was VBD O
designed VBN O
to TO O
evaluate VB O
the DT O
alterations NNS O
in IN O
offspring NN O
rat NN O
cerebellum NN O
induced VBN O
by IN O
maternal JJ O
exposure NN O
to IN O
carmustine NN O
- HYPH O
[ -LRB- O
1 CD O
, , O
3 CD O
- HYPH O
bis NN O
( , O
2 CD O
- HYPH O
chloroethyl NN O
) NFP O
- HYPH O
1 CD O
- HYPH O
nitrosoure NN O
] -RRB- O
( , O
BCNU NNP O
) -RRB- O
and CC O
to TO O
investigate VB O
the DT O
effects NNS O
of IN O
exogenous JJ O
melatonin NN O
upon IN O
cerebellar NN O
BCNU NNP O
- HYPH O
induced VBN O
cortical JJ B-Disease
dysplasia NN I-Disease
, , O
using VBG O
histological JJ O
and CC O
biochemical JJ O
analyses NNS O
. . O
null null null-Disease
Pregnant JJ O
Wistar NNP O
rats NNS O
were VBD O
assigned VBN O
to IN O
five CD O
groups NNS O
: : O
intact JJ O
- HYPH O
control NN O
, , O
saline NN O
- HYPH O
control NN O
, , O
melatonin NN O
- HYPH O
treated VBN O
, , O
BCNU NNP O
- HYPH O
exposed VBN O
and CC O
BCNU NNP O
- HYPH O
exposed VBN O
plus CC O
melatonin NN O
. . O
null null null-Disease
Rats NNS O
were VBD O
exposed VBN O
to IN O
BCNU NNP O
on IN O
embryonic JJ O
day NN O
15 CD O
and CC O
melatonin NN O
was VBD O
given VBN O
until IN O
delivery NN O
. . O
null null null-Disease
Immuno NN O
/ SYM O
histochemistry NN O
and CC O
electron NN O
microscopy NN O
were VBD O
carried VBN O
out RP O
on IN O
the DT O
offspring NN O
cerebellum NN O
, , O
and CC O
levels NNS O
of IN O
malondialdehyde NN O
and CC O
superoxide NN O
dismutase NN O
were VBD O
determined VBN O
. . O
null null null-Disease
Histopathologically RB O
, , O
typical JJ O
findings NNS O
were VBD O
observed VBN O
in IN O
the DT O
cerebella NN O
from IN O
the DT O
control NN O
groups NNS O
, , O
but CC O
the DT O
findings NNS O
consistent JJ O
with IN O
early JJ O
embryonic JJ O
development NN O
were VBD O
noted VBN O
in IN O
BCNU NNP O
- HYPH O
exposed VBN O
cortical JJ B-Disease
dysplasia NN I-Disease
group NN O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
marked JJ O
increase NN O
in IN O
the DT O
number NN O
of IN O
TUNEL NNP O
positive JJ O
cells NNS O
and CC O
nestin NN O
positive JJ O
cells NNS O
in IN O
BCNU NNP O
- HYPH O
exposed VBN O
group NN O
, , O
but CC O
a DT O
decreased VBN O
immunoreactivity NN O
to IN O
glial NN O
fibrillary NN O
acidic JJ O
protein NN O
, , O
synaptophysin NN O
and CC O
transforming VBG O
growth NN O
factor NN O
beta1 NN O
was VBD O
observed VBN O
, , O
indicating VBG O
a DT O
delayed VBN O
maturation NN O
, , O
and CC O
melatonin NN O
significantly RB O
reversed VBD O
these DT O
changes NNS O
. . O
null null null-Disease
Malondialdehyde NNP O
level NN O
in IN O
BCNU NNP O
- HYPH O
exposed VBN O
group NN O
was VBD O
higher JJR O
than IN O
those DT O
in IN O
control NN O
groups NNS O
and CC O
melatonin NN O
decreased VBD O
malondialdehyde NN O
levels NNS O
in IN O
BCNU NNP O
group NN O
( , O
P NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
while IN O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
the DT O
superoxide NN O
dismutase NN O
levels NNS O
between IN O
these DT O
groups NNS O
. . O
null null null-Disease
These DT O
data NNS O
suggest VBP O
that IN O
exposure NN O
of IN O
animals NNS O
to IN O
BCNU NNP O
during IN O
pregnancy NN O
leads VBZ O
to IN O
delayed VBN O
maturation NN O
of IN O
offspring NN O
cerebellum NN O
and CC O
melatonin NN O
protects VBZ O
the DT O
cerebellum NN O
against IN O
the DT O
effects NNS O
of IN O
BCNU NNP O
. . O
null null null-Disease
Reduced VBN O
cardiotoxicity NN B-Disease
of IN O
doxorubicin NN O
given VBN O
in IN O
the DT O
form NN O
of IN O
N NN O
- HYPH O
( : O
2 CD O
- HYPH O
hydroxypropyl NN O
) -RRB- O
methacrylamide NN O
conjugates NNS O
: : O
and CC O
experimental JJ O
study NN O
in IN O
the DT O
rat NN O
. . O
null null null-Disease
A DT O
rat NN O
model NN O
was VBD O
used VBN O
to TO O
evaluate VB O
the DT O
general JJ O
acute JJ O
toxicity NN B-Disease
and CC O
the DT O
late JJ O
cardiotoxicity NN B-Disease
of IN O
4 CD O
mg NN O
/ SYM O
kg NN O
doxorubicin NN O
( -LRB- O
DOX NNP O
) -RRB- O
given VBN O
either CC O
as IN O
free JJ O
drug NN O
or CC O
in IN O
the DT O
form NN O
of IN O
three CD O
N NNP O
- HYPH O
( HYPH O
2 CD O
- HYPH O
hydroxypropyl NN O
) -RRB- O
methacrylamide NN O
( -LRB- O
HPMA NNP O
) -RRB- O
copolymer NN O
conjugates NNS O
. . O
null null null-Disease
In IN O
these DT O
HPMA NNP O
copolymers NNS O
, , O
DOX NNP O
was VBD O
covalently RB O
bound VBN O
via IN O
peptide NN O
linkages NNS O
that WDT O
were VBD O
either CC O
non RB O
- HYPH O
biodegradable JJ O
( , O
Gly NNP O
- HYPH O
Gly JJ O
) -RRB- O
or CC O
degradable JJ O
by IN O
lysosomal JJ O
proteinases NNS O
( : O
Gly NNP O
- HYPH O
Phe NNP O
- HYPH O
Leu NNP O
- HYPH O
Gly NNP O
) -RRB- O
. . O
null null null-Disease
In IN O
addition NN O
, , O
one CD O
biodegradable JJ O
conjugate NN O
containing VBG O
galactosamine NN O
was VBD O
used VBN O
; : O
this DT O
residue NN O
was VBD O
targeted VBN O
to IN O
the DT O
liver NN O
. . O
null null null-Disease
Over IN O
the DT O
first JJ O
3 CD O
weeks NNS O
after IN O
the DT O
i NN O
. . O
v NN O
. . O
administration NN O
of IN O
free JJ O
and CC O
polymer NN O
- HYPH O
bound VBN O
DOX NNP O
, , O
all DT O
animals NNS O
showed VBD O
a DT O
transient JJ O
reduction NN O
in IN O
body NN O
weight NN O
. . O
null null null-Disease
However RB O
, , O
the DT O
maximal JJ O
reduction NN O
in IN O
body NN O
weight NN O
seen VBN O
in IN O
animals NNS O
that WDT O
received VBD O
polymer NN O
- HYPH O
bound VBN O
DOX NNP O
( SYM O
4 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
was VBD O
significantly RB O
lower JJR O
than IN O
that DT O
observed VBN O
in IN O
those DT O
that WDT O
received VBD O
free JJ O
DOX NNP O
( : O
4 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
or CC O
a DT O
mixture NN O
of IN O
the DT O
unmodified JJ O
parent NN O
HPMA NN O
copolymer NN O
and CC O
free JJ O
DOX NNP O
( SYM O
4 CD O
mg NN O
/ SYM O
kg NN O
; : O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Throughout IN O
the DT O
study NN O
( , O
20 CD O
weeks NNS O
) -RRB- O
, , O
deaths NNS O
related VBN O
to IN O
cardiotoxicity NN B-Disease
were VBD O
observed VBN O
only RB O
in IN O
animals NNS O
that WDT O
received VBD O
either CC O
free JJ O
DOX NNP O
or CC O
the DT O
mixture NN O
of IN O
HPMA NN O
copolymer NN O
and CC O
free JJ O
DOX NNP O
; : O
in IN O
these DT O
cases NNS O
, , O
histological JJ O
investigations NNS O
revealed VBD O
marked JJ O
changes NNS O
in IN O
the DT O
heart NN O
that WDT O
were VBD O
consistent JJ O
with IN O
DOX NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
Sequential JJ O
measurements NNS O
of IN O
cardiac JJ O
output NN O
in IN O
surviving VBG O
animals NNS O
that WDT O
received VBD O
either CC O
free JJ O
DOX NNP O
or CC O
the DT O
mixture NN O
of IN O
HPMA NN O
copolymer NN O
and CC O
free JJ O
DOX NNP O
showed VBD O
a DT O
reduction NN O
of IN O
approximately RB O
30 CD O
% NN O
in IN O
function NN O
beginning VBG O
at IN O
the DT O
4th JJ O
week NN O
after IN O
drug NN O
administration NN O
. . O
null null null-Disease
The DT O
heart NN O
rate NN O
in IN O
these DT O
animals NNS O
was VBD O
approximately RB O
12 CD O
% NN O
lower JJR O
than IN O
that DT O
measured VBN O
in IN O
age NN O
- HYPH O
matched VBN O
control NN O
rats NNS O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Animals NNS O
that WDT O
were VBD O
given VBN O
the DT O
HPMA NNP O
copolymer NN O
conjugates NNS O
containing VBG O
DOX NNP O
exhibited VBD O
no DT O
significant JJ O
change NN O
in IN O
cardiac JJ O
output NN O
throughout IN O
the DT O
study NN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
addition NN O
, , O
no DT O
significant JJ O
histological JJ O
change NN O
was VBD O
observed VBN O
in IN O
the DT O
heart NN O
of IN O
animals NNS O
that WDT O
received VBD O
DOX NNP O
in IN O
the DT O
form NN O
of IN O
HPMA NN O
copolymer NN O
conjugates NNS O
and CC O
were VBD O
killed VBN O
at IN O
the DT O
end NN O
of IN O
the DT O
study NN O
. . O
null null null-Disease
However RB O
, , O
these DT O
animals NNS O
had VBD O
shown VBN O
a DT O
significant JJ O
increase NN O
in IN O
heart NN O
rate NN O
beginning VBG O
at IN O
8 CD O
weeks NNS O
after IN O
drug NN O
administration NN O
( : O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
400 CD O
WORDS NNS O
) : O
null null null-Disease
Corneal JJ B-Disease
ulcers NNS I-Disease
associated VBN O
with IN O
aerosolized JJ O
crack NN O
cocaine NN O
use NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
We PRP O
report VBP O
4 CD O
cases NNS O
of IN O
corneal JJ B-Disease
ulcers NNS I-Disease
associated VBN O
with IN O
drug NN B-Disease
abuse NN I-Disease
. . O
null null null-Disease
The DT O
pathogenesis NN O
of IN O
these DT O
ulcers NNS B-Disease
and CC O
management NN O
of IN O
these DT O
patients NNS O
are VBP O
also RB O
reviewed VBN O
. . O
null null null-Disease
METHODS NNS O
: : O
Review NN O
of IN O
all DT O
cases NNS O
of IN O
corneal JJ B-Disease
ulcers NNS I-Disease
associated VBN O
with IN O
drug NN B-Disease
abuse NN I-Disease
seen VBN O
at IN O
our PRP$ O
institution NN O
from IN O
July NNP O
2006 CD O
to IN O
December NNP O
2006 CD O
. . O
null null null-Disease
RESULTS NNS O
: : O
Four CD O
patients NNS O
with IN O
corneal JJ B-Disease
ulcers NNS I-Disease
associated VBN O
with IN O
crack NN O
cocaine NN O
use NN O
were VBD O
reviewed VBN O
. . O
null null null-Disease
All DT O
corneal JJ B-Disease
ulcers NNS I-Disease
were VBD O
cultured VBN O
, , O
and CC O
the DT O
patients NNS O
were VBD O
admitted VBN O
to IN O
the DT O
hospital NN O
for IN O
intensive JJ O
topical JJ O
antibiotic JJ O
treatment NN O
. . O
null null null-Disease
Each DT O
patient NN O
received VBD O
comprehensive JJ O
health NN O
care NN O
, , O
including VBG O
medical JJ O
and CC O
substance NN B-Disease
abuse NN I-Disease
consultations NNS O
. . O
null null null-Disease
Streptococcal JJ O
organisms NNS O
were VBD O
found VBN O
in IN O
3 CD O
cases NNS O
and CC O
Capnocytophaga NNP O
and CC O
Brevibacterium NN O
casei NN O
in IN O
1 CD O
patient NN O
. . O
null null null-Disease
The DT O
infections NNS B-Disease
responded VBD O
to IN O
antibiotic JJ O
treatment NN O
. . O
null null null-Disease
Two CD O
patients NNS O
needed VBD O
a DT O
lateral JJ O
tarsorrhaphy NN O
for IN O
persistent JJ O
epithelial JJ B-Disease
defects NNS I-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Aerosolized JJ O
crack NN O
cocaine NN O
use NN O
can MD O
be VB O
associated VBN O
with IN O
the DT O
development NN O
of IN O
corneal JJ B-Disease
ulcers NNS I-Disease
. . O
null null null-Disease
Drug NN B-Disease
abuse NN I-Disease
provides VBZ O
additional JJ O
challenges NNS O
for IN O
management NN O
. . O
null null null-Disease
Not RB O
only RB O
treatment NN O
of IN O
their PRP$ O
infections NNS B-Disease
but CC O
also RB O
the DT O
overall JJ O
poor JJ O
health NN O
of IN O
the DT O
patients NNS O
and CC O
increased VBN O
risk NN O
of IN O
noncompliance NN O
need VBP O
to TO O
be VB O
addressed VBN O
. . O
null null null-Disease
Comprehensive JJ O
care NN O
may MD O
provide VB O
the DT O
patient NN O
the DT O
opportunity NN O
to TO O
discontinue VB O
their PRP$ O
substance NN B-Disease
abuse NN I-Disease
, , O
improve VB O
their PRP$ O
overall JJ O
health NN O
, , O
and CC O
prevent VB O
future JJ O
corneal JJ O
complications NNS O
. . O
null null null-Disease
Topical JJ O
0 CD O
. . O
025 CD O
% NN O
capsaicin NN O
in IN O
chronic JJ O
post NN B-Disease
- HYPH I-Disease
herpetic JJ I-Disease
neuralgia NN I-Disease
: : O
efficacy NN O
, , O
predictors NNS O
of IN O
response NN O
and CC O
long JJ O
- HYPH O
term NN O
course NN O
. . O
null null null-Disease
In IN O
order NN O
to TO O
evaluate VB O
the DT O
efficacy NN O
, , O
time NN O
- HYPH O
course NN O
of IN O
action NN O
and CC O
predictors NNS O
of IN O
response NN O
to IN O
topical JJ O
capsaicin NN O
, , O
39 CD O
patients NNS O
with IN O
chronic JJ O
post NN B-Disease
- HYPH I-Disease
herpetic JJ I-Disease
neuralgia NN I-Disease
( , O
PHN NNP B-Disease
) -RRB- O
, , O
median JJ O
duration NN O
24 CD O
months NNS O
, , O
were VBD O
treated VBN O
with IN O
0 CD O
. . O
025 CD O
% NN O
capsaicin NN O
cream NN O
for IN O
8 CD O
weeks NNS O
. . O
null null null-Disease
During IN O
therapy NN O
the DT O
patients NNS O
rated VBD O
their PRP$ O
pain NN B-Disease
on IN O
a DT O
visual JJ O
analogue NN O
scale NN O
( : O
VAS NN O
) -RRB- O
and CC O
a DT O
verbal JJ O
outcome NN O
scale NN O
. . O
null null null-Disease
A DT O
follow NN O
- HYPH O
up NN O
investigation NN O
was VBD O
performed VBN O
10 CD O
- SYM O
12 CD O
months NNS O
after IN O
study NN O
onset NN O
on IN O
the DT O
patients NNS O
who WP O
had VBD O
improved VBN O
. . O
null null null-Disease
Nineteen CD O
patients NNS O
( : O
48 CD O
. . O
7 CD O
% NN O
) -RRB- O
substantially RB O
improved VBD O
after IN O
the DT O
8 CD O
- HYPH O
week NN O
trial NN O
; : O
5 CD O
( SYM O
12 CD O
. . O
8 CD O
% NN O
) -RRB- O
discontinued VBN O
therapy NN O
due JJ O
to IN O
side NN O
- HYPH O
effects NNS O
such JJ O
as IN O
intolerable JJ O
capsaicin NN O
- HYPH O
induced VBN O
burning NN O
sensations NNS O
( , O
4 CD O
) , O
or CC O
mastitis NN B-Disease
( , O
1 CD O
) SYM O
; : O
15 CD O
( SYM O
38 CD O
. . O
5 CD O
% NN O
) -RRB- O
reported VBN O
no DT O
benefit NN O
. . O
null null null-Disease
The DT O
decrease NN O
in IN O
VAS NNP O
ratings NNS O
was VBD O
significant JJ O
after IN O
2 CD O
weeks NNS O
of IN O
continuous JJ O
application NN O
. . O
null null null-Disease
Of IN O
the DT O
responders NNS O
72 CD O
. . O
2 CD O
% NN O
were VBD O
still RB O
improved VBN O
at IN O
the DT O
follow NN O
- HYPH O
up NN O
; : O
only RB O
one CD O
- HYPH O
third NN O
of IN O
them PRP O
had VBD O
continued VBN O
application NN O
irregularly RB O
. . O
null null null-Disease
Treatment NN O
effect NN O
was VBD O
not RB O
dependent JJ O
on IN O
patient NN O
' '' O
s POS O
age NN O
, , O
duration NN O
or CC O
localization NN O
of IN O
PHN NNP B-Disease
( , O
trigeminal JJ O
involvement NN O
was VBD O
excluded VBN O
) -RRB- O
, , O
sensory JJ B-Disease
disturbance NN I-Disease
or CC O
pain NN B-Disease
character NN O
. . O
null null null-Disease
Treatment NN O
response NN O
was VBD O
not RB O
correlated VBN O
with IN O
the DT O
incidence NN O
, , O
time NN O
- HYPH O
course NN O
or CC O
severity NN O
of IN O
capsaicin NN O
- HYPH O
induced VBN O
burning NN O
. . O
null null null-Disease
If IN O
confirmed VBN O
in IN O
controlled VBN O
trials NNS O
, , O
the DT O
long JJ O
- HYPH O
term NN O
results NNS O
of IN O
this DT O
open JJ O
, , O
non RB O
- HYPH O
randomized VBN O
study NN O
might MD O
indicate VB O
that IN O
the DT O
analgesic JJ O
effect NN O
of IN O
capsaicin NN O
in IN O
PHN NNP B-Disease
is VBZ O
mediated VBN O
by IN O
both CC O
interference NN O
with IN O
neuropeptide NN O
metabolism NN O
and CC O
morphological JJ O
changes NNS O
( , O
perhaps RB O
degeneration NN O
) , O
of IN O
nociceptive JJ O
afferents NNS O
. . O
null null null-Disease
Myo NNP O
- HYPH O
inositol NNP O
- HYPH O
1 CD O
- HYPH O
phosphate NN O
( : O
MIP NN O
) -RRB- O
synthase NN O
inhibition NN O
: : O
in IN O
- HYPH O
vivo NN O
study NN O
in IN O
rats NNS O
. . O
null null null-Disease
Lithium NN O
and CC O
valproate NN O
are VBP O
the DT O
prototypic JJ O
mood NN O
stabilizers NNS O
and CC O
have VBP O
diverse JJ O
structures NNS O
and CC O
targets NNS O
. . O
null null null-Disease
Both DT O
drugs NNS O
influence VBP O
inositol JJ O
metabolism NN O
. . O
null null null-Disease
Lithium NN O
inhibits VBZ O
IMPase NN O
and CC O
valproate JJ O
inhibits VBZ O
MIP NNP O
synthase NN O
. . O
null null null-Disease
This DT O
study NN O
shows VBZ O
that IN O
MIP NNP O
synthase NN O
inhibition NN O
does VBZ O
not RB O
replicate VB O
or CC O
augment VB O
the DT O
effects NNS O
of IN O
lithium NN O
in IN O
the DT O
inositol NN O
sensitive JJ O
pilocarpine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
model NN O
. . O
null null null-Disease
This DT O
lack NN O
of IN O
effects NNS O
may MD O
stem VB O
from IN O
the DT O
low JJ O
contribution NN O
of IN O
de FW O
- HYPH O
novo NN O
synthesis NN O
to IN O
cellular JJ O
inositol NN O
supply NN O
or CC O
to IN O
the DT O
inhibition NN O
of IN O
the DT O
de NN O
- HYPH O
novo NN O
synthesis NN O
by IN O
lithium NN O
itself PRP O
. . O
null null null-Disease
Non JJ O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
- HYPH O
associated VBN O
acute JJ O
interstitial JJ B-Disease
nephritis NN I-Disease
with IN O
granular JJ O
tubular JJ O
basement NN O
membrane NN O
deposits NNS O
. . O
null null null-Disease
Acute JJ B-Disease
tubulo NN I-Disease
- HYPH I-Disease
interstitial JJ I-Disease
nephritis NN I-Disease
( , O
ATIN NNP B-Disease
) -RRB- O
is VBZ O
an DT O
important JJ O
cause NN O
of IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
resulting VBG O
from IN O
a DT O
variety NN O
of IN O
insults NNS O
, , O
including VBG O
immune JJ O
complex NN O
- HYPH O
mediated VBN O
tubulo NN B-Disease
- HYPH I-Disease
interstitial JJ I-Disease
injury NN I-Disease
, , O
but CC O
drugs NNS O
such JJ O
as IN O
non JJ O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
( -LRB- O
NSAIDs NNP O
) -RRB- O
are VBP O
a DT O
far RB O
more RBR O
frequent JJ O
cause NN O
. . O
null null null-Disease
Overall RB O
, , O
as IN O
an DT O
entity NN O
, , O
ATIN NNP B-Disease
remains VBZ O
under IN O
- HYPH O
diagnosed VBN O
, , O
as IN O
symptoms NNS O
resolve VBP O
spontaneously RB O
if IN O
the DT O
medication NN O
is VBZ O
stopped VBN O
. . O
null null null-Disease
We PRP O
report VBP O
on IN O
a DT O
14 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
boy NN O
who WP O
developed VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
2 CD O
weeks NNS O
after IN O
aortic JJ O
valve NN O
surgery NN O
. . O
null null null-Disease
He PRP O
was VBD O
put VBN O
on IN O
aspirin NN O
following VBG O
surgery NN O
and CC O
took VBD O
ibuprofen NN O
for IN O
fever NN B-Disease
for IN O
nearly RB O
a DT O
week NN O
prior RB O
to IN O
presentation NN O
. . O
null null null-Disease
He PRP O
then RB O
presented VBD O
to IN O
the DT O
emergency NN O
department NN O
feeling VBG O
quite RB O
ill JJ O
and CC O
was VBD O
found VBN O
to TO O
have VB O
a DT O
blood NN O
urea NN O
nitrogen NN O
( HYPH O
BUN NNP O
) -RRB- O
concentration NN O
of IN O
of IN O
147 CD O
mg NN O
/ SYM O
dl NN O
, , O
creatinine NN O
of IN O
15 CD O
. . O
3 CD O
mg NN O
/ SYM O
dl NN O
and CC O
serum NN O
potassium NN O
of IN O
8 CD O
. . O
7 CD O
mEq NNS O
/ SYM O
l NN O
. . O
null null null-Disease
Dialysis NNP O
was VBD O
immediately RB O
initiated VBN O
. . O
null null null-Disease
A DT O
kidney NN O
biopsy NN O
showed VBD O
inflammatory JJ O
infiltrate NN O
consistent JJ O
with IN O
ATIN NNP B-Disease
. . O
null null null-Disease
However RB O
, , O
in IN O
the DT O
tubular JJ O
basement NN O
membrane NN O
( -LRB- O
TBM NNP O
) -RRB- O
, , O
very RB O
intense JJ O
granular JJ O
deposits NNS O
of IN O
polyclonal JJ O
IgG NNP O
and CC O
C3 NNP O
were VBD O
noted VBN O
. . O
null null null-Disease
He PRP O
needed VBD O
dialysis NN O
for IN O
2 CD O
weeks NNS O
and CC O
was VBD O
treated VBN O
successfully RB O
with IN O
steroids NNS O
for IN O
6 CD O
months NNS O
. . O
null null null-Disease
His PRP$ O
renal JJ O
recovery NN O
and CC O
disappearance NN O
of IN O
proteinuria NN B-Disease
took VBD O
a DT O
year NN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
this DT O
is VBZ O
a DT O
first JJ O
report NN O
of IN O
NSAIDs NNP O
- HYPH O
associated VBN O
ATIN NNP B-Disease
, , O
showing VBG O
deposits NNS O
of IN O
granular JJ O
immune JJ O
complex NN O
present JJ O
only RB O
in IN O
the DT O
TBM NNP O
and CC O
not RB O
in IN O
the DT O
glomeruli NN O
. . O
null null null-Disease
Rifampicin NN O
- HYPH O
associated VBN O
segmental JJ O
necrotizing JJ O
glomerulonephritis NN B-Disease
in IN O
staphylococcal JJ B-Disease
endocarditis NN I-Disease
. . O
null null null-Disease
Segmental JJ O
necrotising NN O
glomerulonephritis NN B-Disease
has VBZ O
been VBN O
reported VBN O
as IN O
complication NN O
of IN O
rifampicin NN O
therapy NN O
in IN O
patients NNS O
receiving VBG O
treatment NN O
for IN O
tuberculosis NN B-Disease
. . O
null null null-Disease
Changing VBG O
epidemiology NN O
of IN O
infections NNS B-Disease
such JJ O
as IN O
infective JJ B-Disease
endocarditis NN I-Disease
( : O
IE NN B-Disease
) -RRB- O
has VBZ O
led VBN O
to IN O
an DT O
increase NN O
in IN O
the DT O
use NN O
of IN O
rifampicin NN O
for IN O
Staphylococcal JJ B-Disease
infections NNS I-Disease
. . O
null null null-Disease
We PRP O
describe VBP O
a DT O
case NN O
of IN O
a DT O
patient NN O
with IN O
Staphylococcal NNP B-Disease
IE NNP I-Disease
who WP O
developed VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
secondary JJ O
to IN O
a DT O
segmental JJ O
necrotising VBG O
glomerulonephritis NN B-Disease
while IN O
being VBG O
treated VBN O
with IN O
rifampicin NN O
, , O
and CC O
review VB O
the DT O
literature NN O
regarding VBG O
this DT O
complication NN O
of IN O
rifampicin NN O
therapy NN O
. . O
null null null-Disease
Rate NN O
of IN O
YMDD NN O
motif NN O
mutants NNS O
in IN O
lamivudine NN O
- HYPH O
untreated JJ O
Iranian JJ O
patients NNS O
with IN O
chronic JJ B-Disease
hepatitis NN I-Disease
B NN I-Disease
virus NN I-Disease
infection NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Lamivudine NNP O
is VBZ O
used VBN O
for IN O
the DT O
treatment NN O
of IN O
chronic JJ B-Disease
hepatitis NN I-Disease
B NNP I-Disease
patients NNS O
. . O
null null null-Disease
Recent JJ O
studies NNS O
show VBP O
that IN O
the DT O
YMDD NNP O
motif NN O
mutants NNS O
( -LRB- O
resistant JJ O
hepatitis NN B-Disease
B NNP I-Disease
virus NN O
) -RRB- O
occur VBP O
as IN O
natural JJ O
genome NN O
variability NN O
in IN O
lamivudine NN O
- HYPH O
untreated JJ O
chronic JJ B-Disease
hepatitis NNP I-Disease
B NNP I-Disease
patients NNS O
. . O
null null null-Disease
In IN O
this DT O
study NN O
we PRP O
aimed VBD O
to TO O
determine VB O
the DT O
rate NN O
of IN O
YMDD NNP O
motif NN O
mutants NNS O
in IN O
lamivudine NN O
- HYPH O
untreated JJ O
chronic JJ B-Disease
hepatitis NNP I-Disease
B NNP I-Disease
patients NNS O
in IN O
Iran NNP O
. . O
null null null-Disease
PATIENTS NNS O
AND CC O
METHODS NNS O
: : O
A DT O
total NN O
of IN O
77 CD O
chronic JJ B-Disease
hepatitis NN I-Disease
B NNP I-Disease
patients NNS O
who WP O
had VBD O
not RB O
been VBN O
treated VBN O
with IN O
lamivudine NN O
were VBD O
included VBN O
in IN O
the DT O
study NN O
. . O
null null null-Disease
Serum NN O
samples NNS O
from IN O
patients NNS O
were VBD O
tested VBN O
by IN O
polymerase NN O
chain NN O
reaction NN O
- HYPH O
restriction NN O
fragment NN O
length NN O
polymorphism NN O
( , O
PCR NNP O
- HYPH O
RFLP NNP O
) -RRB- O
for IN O
detection NN O
of IN O
YMDD NNP O
motif NN O
mutants NNS O
. . O
null null null-Disease
All DT O
patients NNS O
were VBD O
also RB O
tested VBN O
for IN O
liver NN O
enzymes NNS O
, , O
anti JJ O
- HYPH O
HCV NN O
, , O
HBeAg NNP O
, , O
and CC O
anti JJ O
- HYPH O
HBe NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Of IN O
the DT O
77 CD O
patients NNS O
enrolled VBN O
in IN O
the DT O
study NN O
, , O
73 CD O
% NN O
were VBD O
male JJ O
and CC O
27 CD O
% NN O
were VBD O
female JJ O
. . O
null null null-Disease
Mean NNP O
ALT NNP O
and CC O
AST NNP O
levels NNS O
were VBD O
124 CD O
. . O
4 CD O
+ CD O
/ SYM O
- HYPH O
73 CD O
. . O
4 CD O
and CC O
103 CD O
. . O
1 CD O
+ SYM O
/ SYM O
- HYPH O
81 CD O
IU NN O
/ SYM O
l NN O
, , O
respectively RB O
. . O
null null null-Disease
HBeAg NNP O
was VBD O
positive JJ O
in IN O
40 CD O
% NN O
and CC O
anti JJ O
- HYPH O
HBe NN O
in IN O
60 CD O
% NN O
of IN O
the DT O
patients NNS O
. . O
null null null-Disease
Anti NNP O
- HYPH O
HCV NNP O
was VBD O
negative JJ O
in IN O
all DT O
of IN O
them PRP O
. . O
null null null-Disease
YMDD NNP O
motif NN O
mutants NNS O
were VBD O
not RB O
detected VBN O
in IN O
any DT O
of IN O
the DT O
patients NNS O
despite IN O
the DT O
liver NN O
enzyme NN O
levels NNS O
and CC O
the DT O
presence NN O
of IN O
HBeAg NNP O
or CC O
anti JJ O
- HYPH O
HBe NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Although IN O
the DT O
natural JJ O
occurrence NN O
of IN O
YMDD NNP O
motif NN O
mutants NNS O
in IN O
lamivudine NN O
- HYPH O
untreated JJ O
patients NNS O
with IN O
chronic JJ B-Disease
hepatitis NN I-Disease
B NNP I-Disease
has VBZ O
been VBN O
reported VBN O
, , O
these DT O
mutants NNS O
were VBD O
not RB O
detected VBN O
in IN O
Iranian JJ O
lamivudine NN O
- HYPH O
untreated JJ O
chronic JJ B-Disease
hepatitis NN I-Disease
B NNP I-Disease
patients NNS O
. . O
null null null-Disease
Branch NN O
retinal JJ B-Disease
vein NN I-Disease
occlusion NN I-Disease
and CC O
fluoxetine NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
branch NN O
retinal JJ B-Disease
vein NN I-Disease
occlusion NN I-Disease
associated VBN O
with IN O
fluoxetine NN O
- HYPH O
induced VBN O
secondary JJ O
hypertension NN B-Disease
is VBZ O
described VBN O
. . O
null null null-Disease
Although IN O
an DT O
infrequent JJ O
complication NN O
of IN O
selective JJ O
serotonin NN O
reuptake NN O
inhibitor NN O
therapy NN O
, , O
it PRP O
is VBZ O
important JJ O
that IN O
ophthalmologists NNS O
are VBP O
aware JJ O
that IN O
these DT O
agents NNS O
can MD O
cause VB O
hypertension NN B-Disease
because IN O
this DT O
class NN O
of IN O
drugs NNS O
is VBZ O
widely RB O
prescribed VBN O
. . O
null null null-Disease
The DT O
differential JJ O
effects NNS O
of IN O
bupivacaine NN O
and CC O
lidocaine NN O
on IN O
prostaglandin NN O
E2 NN O
release NN O
, , O
cyclooxygenase NN O
gene NN O
expression NN O
and CC O
pain NN B-Disease
in IN O
a DT O
clinical JJ O
pain NN B-Disease
model NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
In IN O
addition NN O
to IN O
blocking VBG O
nociceptive JJ O
input NN O
from IN O
surgical JJ O
sites NNS O
, , O
long RB O
- HYPH O
acting VBG O
local JJ O
anesthetics NNS O
might MD O
directly RB O
modulate VB O
inflammation NN B-Disease
. . O
null null null-Disease
In IN O
the DT O
present JJ O
study NN O
, , O
we PRP O
describe VBP O
the DT O
proinflammatory JJ O
effects NNS O
of IN O
bupivacaine NN O
on IN O
local JJ O
prostaglandin NN O
E2 NNP O
( -LRB- O
PGE2 NNP O
) -RRB- O
production NN O
and CC O
cyclooxygenase NN O
( -LRB- O
COX NNP O
) -RRB- O
gene NN O
expression NN O
that WDT O
increases VBZ O
postoperative JJ B-Disease
pain NN I-Disease
in IN O
human JJ O
subjects NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
Subjects NNS O
( : O
n CD O
= SYM O
114 CD O
) -RRB- O
undergoing VBG O
extraction NN O
of IN O
impacted VBN O
third JJ O
molars NNS O
received VBD O
either CC O
2 CD O
% NN O
lidocaine NN O
or CC O
0 CD O
. . O
5 CD O
% NN O
bupivacaine NN O
before IN O
surgery NN O
and CC O
either CC O
rofecoxib NN O
50 CD O
mg NN O
or CC O
placebo NN O
orally RB O
90 CD O
min NN O
before IN O
surgery NN O
and CC O
for IN O
the DT O
following VBG O
48 CD O
h NN O
. . O
null null null-Disease
Oral JJ O
mucosal JJ O
biopsies NNS O
were VBD O
taken VBN O
before IN O
surgery NN O
and CC O
48 CD O
h NN O
after IN O
surgery NN O
. . O
null null null-Disease
After IN O
extraction NN O
, , O
a DT O
microdialysis NN O
probe NN O
was VBD O
placed VBN O
at IN O
the DT O
surgical JJ O
site NN O
for IN O
PGE2 NNP O
and CC O
thromboxane NN O
B2 NNP O
( -LRB- O
TXB2 NNP O
) -RRB- O
measurements NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
bupivacaine NN O
/ SYM O
rofecoxib NN O
group NN O
reported VBD O
significantly RB O
less JJR O
pain NN B-Disease
, , O
as IN O
assessed VBN O
by IN O
a DT O
visual JJ O
analog NN O
scale NN O
, , O
compared VBN O
with IN O
the DT O
other JJ O
three CD O
treatment NN O
groups NNS O
over IN O
the DT O
first JJ O
4 CD O
h NN O
. . O
null null null-Disease
However RB O
, , O
the DT O
bupivacaine NN O
/ SYM O
placebo NN O
group NN O
reported VBD O
significantly RB O
more JJR O
pain NN B-Disease
at IN O
24 CD O
h NN O
and CC O
PGE2 NNP O
levels NNS O
during IN O
the DT O
first JJ O
4 CD O
h NN O
were VBD O
significantly RB O
higher JJR O
than IN O
the DT O
other JJ O
three CD O
treatment NN O
groups NNS O
. . O
null null null-Disease
Moreover RB O
, , O
bupivacaine NN O
significantly RB O
increased VBD O
COX NNP O
- HYPH O
2 CD O
gene NN O
expression NN O
at IN O
48 CD O
h NN O
as IN O
compared VBN O
with IN O
the DT O
lidocaine NN O
/ SYM O
placebo NN O
group NN O
. . O
null null null-Disease
Thromboxane NN O
levels NNS O
were VBD O
not RB O
significantly RB O
affected VBN O
by IN O
any DT O
of IN O
the DT O
treatments NNS O
, , O
indicating VBG O
that IN O
the DT O
effects NNS O
seen VBN O
were VBD O
attributable JJ O
to IN O
inhibition NN O
of IN O
COX NNP O
- HYPH O
2 CD O
, , O
but CC O
not RB O
COX NNP O
- HYPH O
1 CD O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
These DT O
results NNS O
suggest VBP O
that IN O
bupivacaine NN O
stimulates VBZ O
COX NN O
- HYPH O
2 CD O
gene NN O
expression NN O
after IN O
tissue NN B-Disease
injury NN I-Disease
, , O
which WDT O
is VBZ O
associated VBN O
with IN O
higher JJR O
PGE2 NN O
production NN O
and CC O
pain NN B-Disease
after IN O
the DT O
local JJ O
anesthetic JJ O
effect NN O
dissipates VBZ O
. . O
null null null-Disease
p75NTR NN O
expression NN O
in IN O
rat JJ O
urinary JJ O
bladder NN O
sensory NN O
neurons NNS O
and CC O
spinal JJ O
cord NN O
with IN O
cyclophosphamide NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
. . O
null null null-Disease
A DT O
role NN O
for IN O
nerve JJ O
growth NN O
factor NN O
( , O
NGF NNP O
) -RRB- O
in IN O
contributing VBG O
to IN O
increased VBN O
voiding VBG O
frequency NN O
and CC O
altered VBN O
sensation NN O
from IN O
the DT O
urinary JJ O
bladder NN O
has VBZ O
been VBN O
suggested VBN O
. . O
null null null-Disease
Previous JJ O
studies NNS O
have VBP O
examined VBN O
the DT O
expression NN O
and CC O
regulation NN O
of IN O
tyrosine NN O
kinase NN O
receptors NNS O
( -LRB- O
Trks NNS O
) -RRB- O
in IN O
micturition NN O
reflexes NNS O
with IN O
urinary JJ B-Disease
bladder NN I-Disease
inflammation NN I-Disease
. . O
null null null-Disease
The DT O
present JJ O
studies NNS O
examine VBP O
the DT O
expression NN O
and CC O
regulation NN O
of IN O
another DT O
receptor NN O
known VBN O
to TO O
bind VB O
NGF NNP O
, , O
p75 NN O
( , O
NTR NNP O
) -RRB- O
, , O
after IN O
various JJ O
durations NNS O
of IN O
bladder NN B-Disease
inflammation NN I-Disease
induced VBN O
by IN O
cyclophosphamide NN O
( -LRB- O
CYP NNP O
) -RRB- O
. . O
null null null-Disease
CYP NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
increased VBN O
( : O
P NN O
< , O
or CC O
= SYM O
0 CD O
. . O
001 CD O
) -RRB- O
p75 NN O
( -LRB- O
NTR NN O
) -RRB- O
expression NN O
in IN O
the DT O
superficial JJ O
lateral JJ O
and CC O
medial JJ O
dorsal JJ O
horn NN O
in IN O
L1 NNP O
- HYPH O
L2 NNP O
and CC O
L6 NNP O
- HYPH O
S1 NN O
spinal JJ O
segments NNS O
. . O
null null null-Disease
The DT O
number NN O
of IN O
p75 NN O
( , O
NTR NN O
) -RRB- O
- HYPH O
immunoreactive JJ O
( , O
- HYPH O
IR NN O
) -RRB- O
cells NNS O
in IN O
the DT O
lumbosacral JJ O
dorsal JJ O
root NN O
ganglia NN O
( -LRB- O
DRG NN O
) -RRB- O
also RB O
increased VBD O
( : O
P NN O
< , O
or CC O
= SYM O
0 CD O
. . O
05 CD O
) -RRB- O
with IN O
CYP NNP O
- HYPH O
induced VBN O
cystitis NN B-Disease
( , O
acute JJ O
, , O
intermediate JJ O
, , O
and CC O
chronic JJ O
) -RRB- O
. . O
null null null-Disease
Quantitative JJ O
, , O
real JJ O
- HYPH O
time NN O
polymerase NN O
chain NN O
reaction NN O
also RB O
demonstrated VBD O
significant JJ O
increases NNS O
( : O
P NN O
< : O
or CC O
= SYM O
0 CD O
. . O
01 CD O
) -RRB- O
in IN O
p75 NN O
( -LRB- O
NTR NNP O
) -RRB- O
mRNA NN O
in IN O
DRG NNP O
with IN O
intermediate JJ O
and CC O
chronic JJ O
CYP NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
. . O
null null null-Disease
Retrograde JJ O
dye NN O
- HYPH O
tracing VBG O
techniques NNS O
with IN O
Fastblue NNP O
were VBD O
used VBN O
to TO O
identify VB O
presumptive JJ O
bladder NN O
afferent JJ O
cells NNS O
in IN O
the DT O
lumbosacral JJ O
DRG NN O
. . O
null null null-Disease
In IN O
bladder NN O
afferent JJ O
cells NNS O
in IN O
DRG NNP O
, , O
p75 NN O
( , O
NTR NNP O
) -RRB- O
- : O
IR NN O
was VBD O
also RB O
increased VBN O
( : O
P NN O
< : O
or CC O
= SYM O
0 CD O
. . O
01 CD O
) -RRB- O
with IN O
cystitis NN B-Disease
. . O
null null null-Disease
In IN O
addition NN O
to IN O
increases NNS O
in IN O
p75 NN O
( : O
NTR NNP O
) -RRB- O
- : O
IR NN O
in IN O
DRG NNP O
cell NN O
bodies NNS O
, , O
increases NNS O
( , O
P NN O
< SYM O
or CC O
= SYM O
0 CD O
. . O
001 CD O
) -RRB- O
in IN O
pericellular JJ O
( -LRB- O
encircling VBG O
DRG NNP O
cells NNS O
) -RRB- O
p75 CD O
( , O
NTR NNP O
) -RRB- O
- : O
IR NN O
in IN O
DRG NNP O
also RB O
increased VBD O
. . O
null null null-Disease
Confocal JJ O
analyses NNS O
demonstrated VBD O
that IN O
pericellular JJ O
p75 NN O
( , O
NTR NNP O
) -RRB- O
- : O
IR NN O
was VBD O
not RB O
colocalized VBN O
with IN O
the DT O
glial NN O
marker NN O
, , O
glial NN O
fibrillary NN O
acidic JJ O
protein NN O
( , O
GFAP NNP O
) -RRB- O
. . O
null null null-Disease
These DT O
studies NNS O
demonstrate VBP O
that IN O
p75 NN O
( -LRB- O
NTR NN O
) -RRB- O
expression NN O
in IN O
micturition NN O
reflexes VBZ O
is VBZ O
present JJ O
constitutively RB O
and CC O
modified VBN O
by IN O
bladder NN B-Disease
inflammation NN I-Disease
. . O
null null null-Disease
The DT O
functional JJ O
significance NN O
of IN O
p75 NN O
( , O
NTR NN O
) -RRB- O
expression NN O
in IN O
micturition NN O
reflexes VBZ O
remains VBZ O
to TO O
be VB O
determined VBN O
. . O
null null null-Disease
Azathioprine NNP O
- HYPH O
induced VBN O
suicidal JJ O
erythrocyte NN O
death NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Azathioprine NNP O
is VBZ O
widely RB O
used VBN O
as IN O
an DT O
immunosuppressive JJ O
drug NN O
. . O
null null null-Disease
The DT O
side NN O
effects NNS O
of IN O
azathioprine NN O
include VBP O
anemia NN B-Disease
, , O
which WDT O
has VBZ O
been VBN O
attributed VBN O
to IN O
bone NN O
marrow NN O
suppression NN O
. . O
null null null-Disease
Alternatively RB O
, , O
anemia NN B-Disease
could MD O
result VB O
from IN O
accelerated JJ O
suicidal JJ O
erythrocyte NN O
death NN O
or CC O
eryptosis NN O
, , O
which WDT O
is VBZ O
characterized VBN O
by IN O
exposure NN O
of IN O
phosphatidylserine NN O
( , O
PS NN O
) -RRB- O
at IN O
the DT O
erythrocyte NN O
surface NN O
and CC O
by IN O
cell NN O
shrinkage NN O
. . O
null null null-Disease
METHODS NNS O
: : O
The DT O
present JJ O
experiments NNS O
explored VBD O
whether IN O
azathioprine NN O
influences VBZ O
eryptosis NN O
. . O
null null null-Disease
According VBG O
to IN O
annexin NN O
V NN O
binding NN O
, , O
erythrocytes NNS O
from IN O
patients NNS O
indeed RB O
showed VBD O
a DT O
significant JJ O
increase NN O
of IN O
PS NNP O
exposure NN O
within IN O
1 CD O
week NN O
of IN O
treatment NN O
with IN O
azathioprine NN O
. . O
null null null-Disease
In IN O
a DT O
second JJ O
series NN O
, , O
cytosolic NN O
Ca2 NN O
+ CC O
activity NN O
( , O
Fluo3 NN O
fluorescence NN O
) -RRB- O
, , O
cell NN O
volume NN O
( , O
forward JJ O
scatter NN O
) -RRB- O
, , O
and CC O
PS NN O
- HYPH O
exposure NN O
( , O
annexin NN O
V NN O
binding NN O
) -RRB- O
were VBD O
determined VBN O
by IN O
FACS NNP O
analysis NN O
in IN O
erythrocytes NNS O
from IN O
healthy JJ O
volunteers NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Exposure NN O
to IN O
azathioprine NN O
( : O
> NFP O
or CC O
= SYM O
2 CD O
microg NN O
/ SYM O
mL NNP O
) -RRB- O
for IN O
48 CD O
hours NNS O
increased VBD O
cytosolic JJ O
Ca2 NN O
+ CC O
activity NN O
and CC O
annexin NN O
V NN O
binding NN O
and CC O
decreased VBN O
forward JJ O
scatter NN O
. . O
null null null-Disease
The DT O
effect NN O
of IN O
azathioprine NN O
on IN O
both DT O
annexin NN O
V NN O
binding NN O
and CC O
forward JJ O
scatter NN O
was VBD O
significantly RB O
blunted VBN O
in IN O
the DT O
nominal JJ O
absence NN O
of IN O
extracellular JJ O
Ca2 NN O
+ SYM O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Azathioprine NNP O
triggers VBZ O
suicidal JJ O
erythrocyte NN O
death NN O
, , O
an DT O
effect NN O
presumably RB O
contributing VBG O
to IN O
azathioprine NN O
- HYPH O
induced VBN O
anemia NN B-Disease
. . O
null null null-Disease
Levetiracetam NNP O
as IN O
an DT O
adjunct NN O
to IN O
phenobarbital JJ O
treatment NN O
in IN O
cats NNS O
with IN O
suspected VBN O
idiopathic JJ B-Disease
epilepsy NN I-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
assess VB O
pharmacokinetics NN O
, , O
efficacy NN O
, , O
and CC O
tolerability NN O
of IN O
oral JJ O
levetiracetam NN O
administered VBN O
as IN O
an DT O
adjunct NN O
to IN O
phenobarbital JJ O
treatment NN O
in IN O
cats NNS O
with IN O
poorly RB O
controlled VBN O
suspected VBN O
idiopathic JJ B-Disease
epilepsy NN I-Disease
. . O
null null null-Disease
DESIGN NN O
- HYPH O
Open JJ O
- HYPH O
label NN O
, , O
noncomparative JJ O
clinical JJ O
trial NN O
. . O
null null null-Disease
ANIMALS NNS O
: : O
12 CD O
cats NNS O
suspected VBN O
to TO O
have VB O
idiopathic JJ B-Disease
epilepsy NN I-Disease
that WDT O
was VBD O
poorly RB O
controlled VBN O
with IN O
phenobarbital NN O
or CC O
that WDT O
had VBD O
unacceptable JJ O
adverse JJ O
effects NNS O
when WRB O
treated VBN O
with IN O
phenobarbital NN O
. . O
null null null-Disease
PROCEDURES NNS O
: : O
Cats NNS O
were VBD O
treated VBN O
with IN O
levetiracetam NN O
( : O
20 CD O
mg NN O
/ SYM O
kg NNS O
[ -LRB- O
9 CD O
. . O
1 CD O
mg NN O
/ SYM O
lb NN O
] -RRB- O
, , O
PO NN O
, , O
q NN O
8 CD O
h NN O
) -RRB- O
. . O
null null null-Disease
After IN O
a DT O
minimum NN O
of IN O
1 CD O
week NN O
of IN O
treatment NN O
, , O
serum JJ O
levetiracetam NN O
concentrations NNS O
were VBD O
measured VBN O
before IN O
and CC O
2 CD O
, , O
4 CD O
, , O
and CC O
6 CD O
hours NNS O
after IN O
drug NN O
administration NN O
, , O
and CC O
maximum NN O
and CC O
minimum JJ O
serum NN O
concentrations NNS O
and CC O
elimination NN O
half JJ O
- HYPH O
life NN O
were VBD O
calculated VBN O
. . O
null null null-Disease
Seizure NN B-Disease
frequencies NNS O
before IN O
and CC O
after IN O
initiation NN O
of IN O
levetiracetam NN O
treatment NN O
were VBD O
compared VBN O
, , O
and CC O
adverse JJ O
effects NNS O
were VBD O
recorded VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Median JJ O
maximum JJ O
serum NN O
levetiracetam NN O
concentration NN O
was VBD O
25 CD O
. . O
5 CD O
microg NN O
/ SYM O
mL NN O
, , O
median JJ O
minimum NN O
serum NN O
levetiracetam NN O
concentration NN O
was VBD O
8 CD O
. . O
3 CD O
microg NN O
/ SYM O
mL NN O
, , O
and CC O
median NN O
elimination NN O
half JJ O
- HYPH O
life NN O
was VBD O
2 CD O
. . O
9 CD O
hours NNS O
. . O
null null null-Disease
Median JJ O
seizure NN B-Disease
frequency NN O
prior RB O
to IN O
treatment NN O
with IN O
levetiracetam NN O
( SYM O
2 CD O
. . O
1 CD O
seizures NNS B-Disease
/ SYM O
mo NN O
) -RRB- O
was VBD O
significantly RB O
higher JJR O
than IN O
median JJ O
seizure NN B-Disease
frequency NN O
after IN O
initiation NN O
of IN O
levetiracetam NN O
treatment NN O
( : O
0 CD O
. . O
42 CD O
seizures NNS B-Disease
/ SYM O
mo NN O
) -RRB- O
, , O
and CC O
7 CD O
of IN O
10 CD O
cats NNS O
were VBD O
classified VBN O
as IN O
having VBG O
responded VBN O
to IN O
levetiracetam NN O
treatment NN O
( : O
ie IN O
, , O
reduction NN O
in IN O
seizure NN B-Disease
frequency NN O
of IN O
> SYM O
or CC O
= SYM O
50 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Two CD O
cats NNS O
had VBD O
transient JJ O
lethargy NN B-Disease
and CC O
inappetence NN B-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
AND CC O
CLINICAL JJ O
RELEVANCE NN O
: : O
Results NNS O
suggested VBD O
that IN O
levetiracetam NN O
is VBZ O
well RB O
tolerated VBN O
in IN O
cats NNS O
and CC O
may MD O
be VB O
useful JJ O
as IN O
an DT O
adjunct NN O
to IN O
phenobarbital JJ O
treatment NN O
in IN O
cats NNS O
with IN O
idiopathic JJ B-Disease
epilepsy NN I-Disease
. . O
null null null-Disease
Serotonin NN O
reuptake NN O
inhibitors NNS O
, , O
paranoia NN B-Disease
, , O
and CC O
the DT O
ventral JJ O
basal JJ O
ganglia NN O
. . O
null null null-Disease
Antidepressants NNS O
have VBP O
previously RB O
been VBN O
associated VBN O
with IN O
paranoid JJ B-Disease
reactions NNS O
in IN O
psychiatric JJ O
patients NNS O
. . O
null null null-Disease
Five CD O
cases NNS O
of IN O
paranoid JJ B-Disease
exacerbation NN O
with IN O
the DT O
serotonin NN O
reuptake NN O
inhibitors NNS O
fluoxetine NN O
and CC O
amitriptyline NN O
are VBP O
reported VBN O
here RB O
. . O
null null null-Disease
Elements NNS O
common JJ O
to IN O
these DT O
cases NNS O
included VBD O
a DT O
history NN O
of IN O
paranoid JJ B-Disease
symptomatology NN O
and CC O
the DT O
concomitant JJ O
occurrence NN O
of IN O
depressive JJ B-Disease
and CC I-Disease
psychotic JJ I-Disease
symptoms NNS I-Disease
. . O
null null null-Disease
Complicated JJ O
depressive JJ B-Disease
disorders NNS I-Disease
( , O
including VBG O
atypicality NN O
of IN O
course NN O
and CC O
symptomatology NN O
, , O
chronicity NN O
, , O
psychosis NN B-Disease
, , O
bipolarity NN O
, , O
and CC O
secondary JJ O
onset NN O
in IN O
the DT O
course NN O
of IN O
a DT O
primary JJ O
psychosis NN B-Disease
) , O
may MD O
present VB O
particular JJ O
vulnerability NN O
to IN O
paranoid JJ B-Disease
exacerbations NNS O
associated VBN O
with IN O
serotonin NN O
reuptake NN O
inhibitors NNS O
. . O
null null null-Disease
Although IN O
the DT O
pharmacology NN O
and CC O
neurobiology NN O
of IN O
paranoia NN B-Disease
remain VBP O
cryptic JJ O
, , O
several JJ O
mechanisms NNS O
, , O
including VBG O
5HT3 NNP O
receptor NN O
- HYPH O
mediated VBN O
dopamine NN O
release NN O
, , O
beta JJ O
- HYPH O
noradrenergic JJ O
receptor NN O
downregulation NN O
, , O
or CC O
GABAB NNP O
receptor NN O
upregulation NN O
acting VBG O
in IN O
the DT O
vicinity NN O
of IN O
the DT O
ventral JJ O
basal JJ O
ganglia NN O
( , O
possibly RB O
in IN O
lateral JJ O
orbitofrontal JJ O
or CC O
anterior JJ O
cingulate JJ O
circuits NNS O
) -RRB- O
, , O
might MD O
apply VB O
to IN O
this DT O
phenomenon NN O
. . O
null null null-Disease
These DT O
cases NNS O
call VBP O
attention NN O
to IN O
possible JJ O
paranoid JJ B-Disease
exacerbations NNS O
with IN O
serotonin NN O
reuptake NN O
blockers NNS O
in IN O
select JJ O
patients NNS O
and CC O
raise VBP O
neurobiological JJ O
considerations NNS O
regarding VBG O
paranoia NN B-Disease
. . O
null null null-Disease
Clinical JJ O
comparison NN O
of IN O
cardiorespiratory JJ O
effects NNS O
during IN O
unilateral JJ O
and CC O
conventional JJ O
spinal JJ O
anaesthesia NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Spinal JJ O
anaesthesia NN O
is VBZ O
widely RB O
employed VBN O
in IN O
clinical JJ O
practice NN O
but CC O
has VBZ O
the DT O
main JJ O
drawback NN O
of IN O
post NN O
- HYPH O
spinal NN O
block NN O
hypotension NN B-Disease
. . O
null null null-Disease
Efforts NNS O
must MD O
therefore RB O
continue VB O
to TO O
be VB O
made VBN O
to TO O
obviate VB O
this DT O
setback NN O
OBJECTIVE NN O
: : O
To TO O
evaluate VB O
the DT O
cardiovascular JJ O
and CC O
respiratory JJ O
changes NNS O
during IN O
unilateral JJ O
and CC O
conventional JJ O
spinal JJ O
anaesthesia NN O
. . O
null null null-Disease
METHODS NNS O
: : O
With IN O
ethical JJ O
approval NN O
, , O
we PRP O
studied VBD O
74 CD O
American NNP O
Society NNP O
of IN O
Anesthesiologists NNPS O
( , O
ASA NNP O
) -RRB- O
, , O
physical JJ O
status NN O
class NN O
1 CD O
and CC O
2 CD O
patients NNS O
scheduled VBN O
for IN O
elective JJ O
unilateral JJ O
lower JJR O
limb NN O
surgery NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
randomly RB O
allocated VBN O
into IN O
one CD O
of IN O
two CD O
groups NNS O
: : O
lateral JJ O
and CC O
conventional JJ O
spinal JJ O
anaesthesia NN O
groups NNS O
. . O
null null null-Disease
In IN O
the DT O
lateral JJ O
position NN O
with IN O
operative JJ O
side NN O
down RB O
, , O
patients NNS O
recived VBD O
10 CD O
mg NN O
( HYPH O
2mls NNS O
) -RRB- O
of IN O
0 CD O
. . O
5 CD O
% NN O
hyperbaric JJ O
bupivacaine NN O
through IN O
a DT O
25 CD O
- HYPH O
gauge NN O
spinal JJ O
needle NN O
. . O
null null null-Disease
Patients NNS O
in IN O
the DT O
unilateral JJ O
group NN O
were VBD O
maintained VBN O
in IN O
the DT O
lateral JJ O
position NN O
for IN O
15 CD O
minutes NNS O
following VBG O
spinal JJ O
injection NN O
while IN O
those DT O
in IN O
the DT O
conventional JJ O
group NN O
were VBD O
turned VBN O
supine JJ O
immediately RB O
after IN O
injection NN O
. . O
null null null-Disease
Blood NN O
pressure NN O
, , O
heart NN O
rate NN O
, , O
respiratory JJ O
rate NN O
and CC O
oxygen NN O
saturation NN O
were VBD O
monitored VBN O
over IN O
1 CD O
hour NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Three CD O
patients NNS O
( : O
8 CD O
. . O
1 CD O
% NN O
) -RRB- O
in IN O
the DT O
unilateral JJ O
group NN O
and CC O
5 CD O
( SYM O
13 CD O
. . O
5 CD O
% NN O
) -RRB- O
in IN O
the DT O
conventional JJ O
group NN O
developed VBN O
hypotension NN B-Disease
, , O
P NN O
= SYM O
0 CD O
. . O
71 CD O
. . O
null null null-Disease
Four CD O
( SYM O
10 CD O
. . O
8 CD O
% NN O
) SYM O
patients NNS O
in IN O
the DT O
conventional JJ O
group NN O
and CC O
1 CD O
( SYM O
2 CD O
. . O
7 CD O
% NN O
) -RRB- O
in IN O
the DT O
unilateral JJ O
group NN O
, , O
P NN O
= SYM O
0 CD O
. . O
17 CD O
required VBN O
epinephrine NN O
infusion NN O
to TO O
treat VB O
hypotension NN B-Disease
. . O
null null null-Disease
Patients NNS O
in IN O
the DT O
conventional JJ O
group NN O
had VBD O
statistically RB O
significant JJ O
greater JJR O
fall NN O
in IN O
the DT O
systolic JJ O
blood NN O
pressures NNS O
at IN O
15 CD O
, , O
30 CD O
and CC O
45 CD O
minutes NNS O
when WRB O
compared VBN O
to IN O
the DT O
baseline NN O
( , O
P NN O
= SYM O
0 CD O
. . O
003 CD O
, , O
0 CD O
. . O
001 CD O
and CC O
0 CD O
. . O
004 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
mean JJ O
respiratory JJ O
rate NN O
and CC O
oxygen NN O
saturations NNS O
in IN O
the DT O
two CD O
groups NNS O
were VBD O
similar JJ O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Compared VBN O
to IN O
conventional JJ O
spinal JJ O
anaesthesia NN O
, , O
unilateral JJ O
spinal JJ O
anaesthesia NN O
was VBD O
associated VBN O
with IN O
fewer JJR O
cardiovascular JJ O
perturbations NNS O
. . O
null null null-Disease
Also RB O
, , O
the DT O
type NN O
of IN O
spinal JJ O
block NN O
instituted VBN O
affected VBD O
neither CC O
the DT O
respiratory JJ O
rate NN O
nor CC O
the DT O
arterial JJ O
oxygen NN O
saturation NN O
. . O
null null null-Disease
Spectrum NN O
of IN O
adverse JJ O
events NNS O
after IN O
generic JJ O
HAART NN O
in IN O
southern JJ O
Indian JJ O
HIV NNP B-Disease
- HYPH I-Disease
infected VBN I-Disease
patients NNS O
. . O
null null null-Disease
To TO O
determine VB O
the DT O
incidence NN O
of IN O
clinically RB O
significant JJ O
adverse JJ O
events NNS O
after IN O
long JJ O
- HYPH O
term NN O
, , O
fixed VBN O
- HYPH O
dose NN O
, , O
generic JJ O
highly RB O
active JJ O
antiretroviral JJ O
therapy NN O
( , O
HAART NNP O
) -RRB- O
use NN O
among IN O
HIV NNP B-Disease
- HYPH I-Disease
infected VBN I-Disease
individuals NNS O
in IN O
South NNP O
India NNP O
, , O
we PRP O
examined VBD O
the DT O
experiences NNS O
of IN O
3154 CD O
HIV NNP B-Disease
- HYPH I-Disease
infected VBN I-Disease
individuals NNS O
who WP O
received VBD O
a DT O
minimum NN O
of IN O
3 CD O
months NNS O
of IN O
generic JJ O
HAART NNP O
between IN O
February NNP O
1996 CD O
and CC O
December NNP O
2006 CD O
at IN O
a DT O
tertiary JJ O
HIV NNP O
care NN O
referral NN O
center NN O
in IN O
South NNP O
India NNP O
. . O
null null null-Disease
The DT O
most RBS O
common JJ O
regimens NNS O
were VBD O
3TC NNP O
+ CC O
d4T NN O
+ CC O
nevirapine NN O
( -LRB- O
NVP NNP O
) -RRB- O
( : O
54 CD O
. . O
8 CD O
% NN O
) -RRB- O
, , O
zidovudine NN O
( -LRB- O
AZT NNP O
) -RRB- O
+ CC O
3TC NN O
+ SYM O
NVP NN O
( SYM O
14 CD O
. . O
5 CD O
% NN O
) -RRB- O
, , O
3TC NN O
+ CC O
d4T NN O
+ CC O
efavirenz NN O
( -LRB- O
EFV NNP O
) -RRB- O
( : O
20 CD O
. . O
1 CD O
% NN O
) -RRB- O
, , O
and CC O
AZT NN O
+ CC O
3TC NN O
+ SYM O
EFV NN O
( SYM O
5 CD O
. . O
4 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
The DT O
most RBS O
common JJ O
adverse JJ O
events NNS O
and CC O
median JJ O
CD4 NN O
at IN O
time NN O
of IN O
event NN O
were VBD O
rash NN B-Disease
( , O
15 CD O
. . O
2 CD O
% NN O
; , O
CD4 NNP O
, , O
285 CD O
cells NNS O
/ SYM O
microL NN O
) -RRB- O
and CC O
peripheral JJ B-Disease
neuropathy NN I-Disease
( : O
9 CD O
. . O
0 CD O
% NN O
and CC O
348 CD O
cells NNS O
/ SYM O
microL NN O
) -RRB- O
. . O
null null null-Disease
Clinically RB O
significant JJ O
anemia NN B-Disease
( , O
hemoglobin NN O
< NN O
7 CD O
g NN O
/ SYM O
dL NN O
) -RRB- O
was VBD O
observed VBN O
in IN O
5 CD O
. . O
4 CD O
% NN O
of IN O
patients NNS O
( , O
CD4 NNP O
, , O
165 CD O
cells NNS O
/ SYM O
microL NN O
) -RRB- O
and CC O
hepatitis NN B-Disease
( : O
clinical JJ O
jaundice NN B-Disease
with IN O
alanine NN O
aminotransferase NN O
> SYM O
5 CD O
times NNS O
upper JJ O
limits NNS O
of IN O
normal JJ O
) -RRB- O
in IN O
3 CD O
. . O
5 CD O
% NN O
of IN O
patients NNS O
( , O
CD4 NNP O
, , O
260 CD O
cells NNS O
/ SYM O
microL NN O
) -RRB- O
. . O
null null null-Disease
Women NNS O
were VBD O
significantly RB O
more RBR O
likely JJ O
to TO O
experience VB O
lactic JJ B-Disease
acidosis NN I-Disease
, , O
while IN O
men NNS O
were VBD O
significantly RB O
more RBR O
likely JJ O
to TO O
experience VB O
immune JJ B-Disease
reconstitution NN I-Disease
syndrome NN I-Disease
( : O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Among IN O
the DT O
patients NNS O
with IN O
1 CD O
year NN O
of IN O
follow NN O
- HYPH O
up NN O
, , O
NVP NNP O
therapy NN O
was VBD O
significantly RB O
associated VBN O
with IN O
developing VBG O
rash NN B-Disease
and CC O
d4T NN O
therapy NN O
with IN O
developing VBG O
peripheral JJ B-Disease
neuropathy NN I-Disease
( : O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Anemia NN B-Disease
and CC O
hepatitis NN B-Disease
often RB O
occur VBP O
within IN O
12 CD O
weeks NNS O
of IN O
initiating VBG O
generic JJ O
HAART NNP O
. . O
null null null-Disease
Frequent JJ O
and CC O
early JJ O
monitoring NN O
for IN O
these DT O
toxicities NNS B-Disease
is VBZ O
warranted VBN O
in IN O
developing VBG O
countries NNS O
where WRB O
generic JJ O
HAART NN O
is VBZ O
increasingly RB O
available JJ O
. . O
null null null-Disease
Thalidomide NN O
and CC O
sensory JJ B-Disease
neurotoxicity NN I-Disease
: : O
a DT O
neurophysiological JJ O
study NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Recent JJ O
studies NNS O
confirmed VBD O
a DT O
high JJ O
incidence NN O
of IN O
sensory JJ B-Disease
axonal JJ I-Disease
neuropathy NN I-Disease
in IN O
patients NNS O
treated VBN O
with IN O
different JJ O
doses NNS O
of IN O
thalidomide NN O
. . O
null null null-Disease
The DT O
study NN O
' '' O
s POS O
aims NNS O
were VBD O
to TO O
measure VB O
variations NNS O
in IN O
sural JJ O
nerve NN O
sensory NN O
action NN O
potential NN O
( , O
SAP NNP O
) -RRB- O
amplitude NN O
in IN O
patients NNS O
with IN O
refractory JJ O
cutaneous JJ B-Disease
lupus NN I-Disease
erythematosus NN I-Disease
( , O
CLE NNP B-Disease
) -RRB- O
treated VBN O
with IN O
thalidomide NN O
and CC O
use VB O
these DT O
findings NNS O
to TO O
identify VB O
the DT O
neurotoxic JJ B-Disease
potential NN O
of IN O
thalidomide NN O
and CC O
the DT O
recovery NN O
capacity NN O
of IN O
sensory JJ O
fibres NNS O
after IN O
discontinuation NN O
of IN O
treatment NN O
. . O
null null null-Disease
PATIENTS NNS O
AND CC O
METHODS NNS O
: : O
Clinical JJ O
and CC O
electrophysiological JJ O
data NNS O
in IN O
12 CD O
female JJ O
patients NNS O
with IN O
CLE NNP B-Disease
during IN O
treatment NN O
with IN O
thalidomide NN O
and CC O
up IN O
to TO O
47 CD O
months NNS O
after IN O
discontinuation NN O
of IN O
treatment NN O
were VBD O
analysed VBN O
. . O
null null null-Disease
Sural JJ O
nerve NN O
SAP NN O
amplitude NN O
reduction NN O
> : O
or CC O
= SYM O
40 CD O
% NN O
was VBD O
the DT O
criteria NNS O
for IN O
discontinuing VBG O
therapy NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
During IN O
treatment NN O
, , O
11 CD O
patients NNS O
showed VBD O
a DT O
reduction NN O
in IN O
sural JJ O
nerve NN O
SAP NNP O
amplitude NN O
compared VBN O
to IN O
baseline NN O
values NNS O
( : O
9 CD O
with IN O
a DT O
reduction NN O
> : O
or CC O
= SYM O
50 CD O
% NN O
and CC O
2 CD O
< SYM O
50 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
One CD O
patient NN O
showed VBD O
no DT O
changes NNS O
in IN O
SAP NNP O
amplitude NN O
. . O
null null null-Disease
Five CD O
patients NNS O
complained VBD O
of IN O
paresthesias NNS B-Disease
and CC O
leg NN O
cramps NNS B-Disease
. . O
null null null-Disease
After IN O
thalidomide NN O
treatment NN O
, , O
sural JJ O
SAP NNP O
amplitude NN O
recovered VBD O
in IN O
3 CD O
patients NNS O
. . O
null null null-Disease
At IN O
detection NN O
of IN O
reduction NN O
in IN O
sural JJ O
nerve NN O
SAP NNP O
amplitude NN O
, , O
the DT O
median JJ O
thalidomide NN O
cumulative JJ O
dose NN O
was VBD O
21 CD O
. . O
4 CD O
g NN O
. . O
null null null-Disease
The DT O
threshold NN O
neurotoxic JJ B-Disease
dosage NN O
is VBZ O
lower JJR O
than IN O
previously RB O
reported VBN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Sural JJ O
nerve NN O
SAP NNP O
amplitude NN O
reduction NN O
is VBZ O
a DT O
reliable JJ O
and CC O
sensitive JJ O
marker NN O
of IN O
degeneration NN O
and CC O
recovery NN O
of IN O
sensory JJ O
fibres NNS O
. . O
null null null-Disease
This DT O
electrophysiological JJ O
parameter NN O
provides VBZ O
information NN O
about IN O
subclinical JJ O
neurotoxic JJ B-Disease
potential NN O
of IN O
thalidomide NN O
but CC O
is VBZ O
not RB O
helpful JJ O
in IN O
predicting VBG O
the DT O
appearance NN O
of IN O
sensory JJ O
symptoms NNS O
. . O
null null null-Disease
Five CD O
cases NNS O
of IN O
encephalitis NN B-Disease
during IN O
treatment NN O
of IN O
loiasis NNS B-Disease
with IN O
diethylcarbamazine NN O
. . O
null null null-Disease
Five CD O
cases NNS O
of IN O
encephalitis NN B-Disease
following VBG O
treatment NN O
with IN O
diethylcarbamazine NN O
( -LRB- O
DEC NNP O
) -RRB- O
were VBD O
observed VBN O
in IN O
Congolese JJ O
patients NNS O
with IN O
Loa NNP O
loa NN O
filariasis NN B-Disease
. . O
null null null-Disease
Two CD O
cases NNS O
had VBD O
a DT O
fatal JJ O
outcome NN O
and CC O
one CD O
resulted VBD O
in IN O
severe JJ O
sequelae NN O
. . O
null null null-Disease
The DT O
notable JJ O
fact NN O
was VBD O
that IN O
this DT O
complication NN O
occurred VBD O
in IN O
three CD O
patients NNS O
hospitalized VBN O
before IN O
treatment NN O
began VBD O
, , O
with IN O
whom WP O
particularly RB O
strict JJ O
therapeutic JJ O
precautions NNS O
were VBD O
taken VBN O
, , O
i PRP O
. . O
e LS O
. . O
, , O
initial JJ O
dose NN O
less JJR O
than IN O
10 CD O
mg NN O
of IN O
DEC NNP O
, , O
very RB O
gradual JJ O
dose NN O
increases VBZ O
, , O
and CC O
associated VBN O
anti JJ O
- HYPH O
allergic JJ O
treatment NN O
. . O
null null null-Disease
This DT O
type NN O
of IN O
drug NN O
- HYPH O
induced VBN O
complication NN O
may MD O
not RB O
be VB O
that RB O
uncommon JJ O
in IN O
highly RB O
endemic JJ O
regions NNS O
. . O
null null null-Disease
It PRP O
occurs VBZ O
primarily RB O
, , O
but CC O
not RB O
exclusively RB O
, , O
in IN O
subjects NNS O
presenting VBG O
with IN O
a DT O
high JJ O
microfilarial JJ O
load NN O
. . O
null null null-Disease
The DT O
relationship NN O
between IN O
the DT O
occurrence NN O
of IN O
encephalitis NN B-Disease
and CC O
the DT O
decrease NN O
in IN O
microfilaremia NN B-Disease
is VBZ O
evident JJ O
. . O
null null null-Disease
The DT O
pathophysiological JJ O
mechanisms NNS O
are VBP O
discussed VBN O
in IN O
the DT O
light NN O
of IN O
these DT O
observations NNS O
and CC O
the DT O
few JJ O
other JJ O
comments NNS O
on IN O
this DT O
subject NN O
published VBN O
in IN O
the DT O
literature NN O
. . O
null null null-Disease
Amiodarone NN O
- HYPH O
related VBN O
pulmonary JJ B-Disease
mass NN I-Disease
and CC O
unique JJ O
membranous JJ B-Disease
glomerulonephritis NN I-Disease
in IN O
a DT O
patient NN O
with IN O
valvular JJ B-Disease
heart NN I-Disease
disease NN I-Disease
: : O
Diagnostic JJ O
pitfall NN O
and CC O
new JJ O
findings NNS O
. . O
null null null-Disease
Amiodarone NNP O
is VBZ O
an DT O
anti AFX O
- HYPH O
arrhythmic JJ B-Disease
drug NN O
for IN O
life NN O
- HYPH O
threatening VBG O
tachycardia NN B-Disease
, , O
but CC O
various JJ O
adverse JJ O
effects NNS O
have VBP O
been VBN O
reported VBN O
. . O
null null null-Disease
Reported VBN O
herein RB O
is VBZ O
an DT O
autopsy NN O
case NN O
of IN O
valvular JJ B-Disease
heart NN I-Disease
disease NN I-Disease
, , O
in IN O
a DT O
patient NN O
who WP O
developed VBD O
a DT O
lung NN B-Disease
mass NN I-Disease
( , O
1 CD O
. . O
5 CD O
cm NN O
in IN O
diameter NN O
) , O
and CC O
proteinuria NN B-Disease
( , O
2 CD O
. . O
76 CD O
g NNS O
/ SYM O
day NN O
) -RRB- O
after IN O
treatment NN O
with IN O
amiodarone NN O
for IN O
a DT O
long JJ O
time NN O
. . O
null null null-Disease
The DT O
lung NN B-Disease
mass NN I-Disease
was VBD O
highly RB O
suspected VBN O
to TO O
be VB O
lung NN B-Disease
cancer NN I-Disease
on IN O
CT NN O
and CC O
positron NN O
emission NN O
tomography NN O
, , O
but CC O
histologically RB O
the DT O
lesion NN O
was VBD O
composed VBN O
of IN O
lymphoplasmacytic JJ O
infiltrates NNS O
in IN O
alveolar JJ O
walls NNS O
and CC O
intra JJ O
- HYPH O
alveolar JJ O
accumulation NN O
of IN O
foamy JJ O
macrophages NNS O
containing VBG O
characteristic JJ O
myelinoid NN O
bodies NNS O
, , O
indicating VBG O
that IN O
it PRP O
was VBD O
an DT O
amiodarone NN O
- HYPH O
related VBN O
lesion NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
the DT O
lung NN O
tissue NN O
had VBD O
unevenly RB O
distributed VBN O
hemosiderin NN B-Disease
deposition NN O
, , O
and CC O
abnormally RB O
tortuous JJ O
capillaries NNS O
were VBD O
seen VBN O
in IN O
the DT O
mass NN O
and CC O
in IN O
heavily RB O
hemosiderotic JJ B-Disease
lung NN O
portions NNS O
outside IN O
the DT O
mass NN O
. . O
null null null-Disease
In IN O
the DT O
kidneys NNS O
, , O
glomeruli NN O
had VBD O
membrane NN O
spikes NNS O
, , O
prominent JJ O
swelling NN O
of IN O
podocytes NNS O
and CC O
subepithelial JJ O
deposits NNS O
, , O
which WDT O
were VBD O
sometimes RB O
large JJ O
and CC O
hump NN O
- HYPH O
like JJ O
. . O
null null null-Disease
Autoimmune JJ B-Disease
diseases NNS I-Disease
, , O
viral JJ B-Disease
hepatitis NN I-Disease
, , O
malignant JJ O
neoplasms NNS B-Disease
or CC O
other JJ O
diseases NNS O
with IN O
a DT O
known VBN O
relationship NN O
to IN O
membranous JJ B-Disease
glomerulonephritis NNS I-Disease
were VBD O
not RB O
found VBN O
. . O
null null null-Disease
The DT O
present JJ O
case NN O
highlights VBZ O
the DT O
possibility NN O
that IN O
differential JJ O
diagnosis NN O
between IN O
an DT O
amiodarone NN O
- HYPH O
related VBN O
pulmonary JJ B-Disease
lesion NN I-Disease
and CC O
a DT O
neoplasm NN B-Disease
can MD O
be VB O
very RB O
difficult JJ O
radiologically RB O
, , O
and CC O
suggests VBZ O
that IN O
membranous JJ B-Disease
glomerulonephritis NN I-Disease
might MD O
be VB O
another DT O
possible JJ O
complication NN O
of IN O
amiodarone NN O
treatment NN O
. . O
null null null-Disease
Risk NN O
of IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
associated VBN O
with IN O
initial JJ O
sulphonylurea NN O
treatment NN O
of IN O
patients NNS O
with IN O
type NN B-Disease
2 CD I-Disease
diabetes NNS I-Disease
: : O
a DT O
matched VBN O
case NN O
- HYPH O
control NN O
study NN O
. . O
null null null-Disease
AIMS NNP O
: : O
This DT O
study NN O
sought VBD O
to TO O
assess VB O
the DT O
risk NN O
of IN O
developing VBG O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
( , O
CAD NN B-Disease
) -RRB- O
associated VBN O
with IN O
initial JJ O
treatment NN O
of IN O
type NN B-Disease
2 CD I-Disease
diabetes NNS I-Disease
with IN O
different JJ O
sulphonylureas NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
In IN O
type NN B-Disease
2 CD I-Disease
diabetic JJ I-Disease
patients NNS O
, , O
cases NNS O
who WP O
developed VBD O
CAD NNP B-Disease
were VBD O
compared VBN O
retrospectively RB O
with IN O
controls NNS O
that WDT O
did VBD O
not RB O
. . O
null null null-Disease
The DT O
20 CD O
- HYPH O
year NN O
risk NN O
of IN O
CAD NN B-Disease
at IN O
diagnosis NN O
of IN O
diabetes NNS B-Disease
, , O
using VBG O
the DT O
UKPDS NNP O
risk NN O
engine NN O
, , O
was VBD O
used VBN O
to TO O
match VB O
cases NNS O
with IN O
controls NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
76 CD O
cases NNS O
of IN O
CAD NNP B-Disease
were VBD O
compared VBN O
with IN O
152 CD O
controls NNS O
. . O
null null null-Disease
The DT O
hazard NN O
of IN O
developing VBG O
CAD NN B-Disease
( : O
95 CD O
% NN O
CI NN O
) , O
associated VBN O
with IN O
initial JJ O
treatment NN O
increased VBD O
by IN O
2 CD O
. . O
4 CD O
- HYPH O
fold NN O
( : O
1 CD O
. . O
3 CD O
- HYPH O
4 CD O
. . O
3 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
004 CD O
) -RRB- O
with IN O
glibenclamide NN O
; : O
2 CD O
- HYPH O
fold NN O
( : O
0 CD O
. . O
9 CD O
- HYPH O
4 CD O
. . O
6 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
099 CD O
) -RRB- O
with IN O
glipizide NN O
; : O
2 CD O
. . O
9 CD O
- HYPH O
fold NN O
( : O
1 CD O
. . O
6 CD O
- SYM O
5 CD O
. . O
1 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
000 CD O
) -RRB- O
with IN O
either CC O
, , O
and CC O
was VBD O
unchanged JJ O
with IN O
metformin NN O
. . O
null null null-Disease
The DT O
hazard NN O
decreased VBD O
0 CD O
. . O
3 CD O
- HYPH O
fold NN O
( : O
0 CD O
. . O
7 CD O
- HYPH O
1 CD O
. . O
7 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
385 CD O
) -RRB- O
with IN O
glimepiride NN O
, , O
0 CD O
. . O
4 CD O
- HYPH O
fold NN O
( : O
0 CD O
. . O
7 CD O
- HYPH O
1 CD O
. . O
3 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
192 CD O
) -RRB- O
with IN O
gliclazide NN O
, , O
and CC O
0 CD O
. . O
4 CD O
- HYPH O
fold NN O
( : O
0 CD O
. . O
7 CD O
- HYPH O
1 CD O
. . O
1 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
09 CD O
) NFP O
with IN O
either RB O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Initiating VBG O
treatment NN O
of IN O
type NN B-Disease
2 CD I-Disease
diabetes NNS I-Disease
with IN O
glibenclamide NN O
or CC O
glipizide NN O
is VBZ O
associated VBN O
with IN O
increased VBN O
risk NN O
of IN O
CAD NN B-Disease
in IN O
comparison NN O
to IN O
gliclazide NN O
or CC O
glimepiride NN O
. . O
null null null-Disease
If IN O
confirmed VBN O
, , O
this DT O
may MD O
be VB O
important JJ O
because IN O
most JJS O
Indian JJ O
patients NNS O
receive VBP O
the DT O
cheaper JJR O
older JJR O
sulphonylureas NNS O
, , O
and CC O
present JJ O
guidelines NNS O
do VBP O
not RB O
distinguish VB O
between IN O
individual JJ O
agents NNS O
. . O
null null null-Disease
Reduced VBN O
progression NN O
of IN O
adriamycin NN O
nephropathy NN B-Disease
in IN O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
treated VBN O
by IN O
losartan NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
The DT O
aim NN O
of IN O
the DT O
study NN O
was VBD O
to TO O
investigate VB O
the DT O
antihypertensive JJ O
effects NNS O
of IN O
angiotensin NN O
II NN O
type NN O
- HYPH O
1 CD O
receptor NN O
blocker NN O
, , O
losartan NN O
, , O
and CC O
its PRP$ O
potential NN O
in IN O
slowing VBG O
down RP O
renal JJ B-Disease
disease NN I-Disease
progression NN O
in IN O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
( -LRB- O
SHR NNP O
) -RRB- O
with IN O
adriamycin NN O
( , O
ADR NN O
) , O
nephropathy NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Six CD O
- HYPH O
month NN O
- HYPH O
old JJ O
female JJ O
SHR NNP O
were VBD O
randomly RB O
selected VBN O
in IN O
six CD O
groups NNS O
. . O
null null null-Disease
Two CD O
control NN O
groups NNS O
( , O
SH NNP O
( , O
6 CD O
) -RRB- O
, , O
SH NNP O
( , O
12 CD O
) -RRB- O
) -RRB- O
received VBD O
vehicle NN O
. . O
null null null-Disease
Groups NNS O
ADR NNP O
( , O
6 CD O
) -RRB- O
, , O
ADR NNP O
+ CC O
LOS NNP O
( , O
6 CD O
) -RRB- O
and CC O
ADR NNP O
( SYM O
12 CD O
) -RRB- O
, , O
and CC O
ADR NNP O
+ CC O
LOS NNP O
( SYM O
12 CD O
) -RRB- O
received VBD O
ADR NNP O
( : O
2 CD O
mg NNS O
/ SYM O
kg NNS O
/ SYM O
b NN O
. . O
w LS O
. . O
i LS O
. . O
v NN O
. . O
) -RRB- O
twice RB O
in IN O
a DT O
3 CD O
- HYPH O
week NN O
interval NN O
. . O
null null null-Disease
Group NNP O
ADR NNP O
+ CC O
LOS NNP O
( : O
6 CD O
) -RRB- O
received VBD O
losartan NN O
( SYM O
10 CD O
mg NNS O
/ SYM O
kg NNS O
/ SYM O
b NN O
. . O
w LS O
. . O
/ SYM O
day NN O
by IN O
gavages NNS O
) -RRB- O
for IN O
6 CD O
weeks NNS O
and CC O
group NN O
ADR NNP O
+ SYM O
LOS NNP O
( SYM O
12 CD O
) -RRB- O
for IN O
12 CD O
weeks NNS O
after IN O
second JJ O
injection NN O
of IN O
ADR NNP O
. . O
null null null-Disease
Animals NNS O
were VBD O
killed VBN O
after IN O
6 CD O
or CC O
12 CD O
weeks NNS O
, , O
respectively RB O
. . O
null null null-Disease
Haemodynamic JJ O
measurements NNS O
were VBD O
performed VBN O
on IN O
anaesthetized VBN O
animals NNS O
, , O
blood NN O
and CC O
urine NN O
samples NNS O
were VBD O
taken VBN O
for IN O
biochemical JJ O
analysis NN O
and CC O
the DT O
left JJ O
kidney NN O
was VBD O
processed VBN O
for IN O
morphological JJ O
studies NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Short JJ O
- HYPH O
term NN O
losartan JJ O
treatment NN O
, , O
besides IN O
antihypertensive JJ O
effect NN O
, , O
improved VBN O
glomerular JJ O
filtration NN O
rate NN O
and CC O
ameliorated JJ O
glomerulosclerosis NN B-Disease
resulting VBG O
in IN O
decreased VBN O
proteinuria NN B-Disease
. . O
null null null-Disease
Prolonged JJ O
treatment NN O
with IN O
losartan NN O
showed VBD O
further JJ O
reduction NN O
of IN O
glomerulosclerosis NN B-Disease
associated VBN O
with IN O
reduced VBN O
progression NN O
of IN O
tubular JJ O
atrophy NN B-Disease
and CC O
interstitial JJ B-Disease
fibrosis NN I-Disease
, , O
thus RB O
preventing VBG O
heavy JJ O
proteinuria NN B-Disease
and CC O
chronic JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
. . O
null null null-Disease
Losartan NNP O
reduced VBD O
uraemia NN B-Disease
and CC O
increased VBD O
urea NN O
clearance NN O
in IN O
advanced JJ O
ADR NN O
nephropathy NN B-Disease
in IN O
SHR NNP O
. . O
null null null-Disease
Histological JJ O
examination NN O
showed VBD O
that IN O
losartan NN O
could MD O
prevent VB O
tubular JJ O
atrophy NN B-Disease
, , O
interstitial JJ O
infiltration NN O
and CC O
fibrosis NN B-Disease
in IN O
ADR NNP O
nephropathy NN B-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
Losartan NNP O
reduces VBZ O
the DT O
rate NN O
of IN O
progression NN O
of IN O
ADR NN O
- HYPH O
induced VBN O
focal JJ B-Disease
segmental JJ I-Disease
glomerulosclerosis NN I-Disease
to IN O
end NN B-Disease
- HYPH I-Disease
stage NN I-Disease
renal JJ I-Disease
disease NN I-Disease
in IN O
SHR NNP O
. . O
null null null-Disease
The DT O
risks NNS O
of IN O
aprotinin NN O
and CC O
tranexamic JJ O
acid NN O
in IN O
cardiac JJ O
surgery NN O
: : O
a DT O
one CD O
- HYPH O
year NN O
follow NN O
- HYPH O
up NN O
of IN O
1188 CD O
consecutive JJ O
patients NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Our PRP$ O
aim NN O
was VBD O
to TO O
investigate VB O
postoperative JJ O
complications NNS O
and CC O
mortality NN O
after IN O
administration NN O
of IN O
aprotinin NN O
compared VBN O
to IN O
tranexamic JJ O
acid NN O
in IN O
an DT O
unselected JJ O
, , O
consecutive JJ O
cohort NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Perioperative JJ O
data NNS O
from IN O
consecutive JJ O
cardiac JJ O
surgery NN O
patients NNS O
were VBD O
prospectively RB O
collected VBN O
between IN O
September NNP O
2005 CD O
and CC O
June NNP O
2006 CD O
in IN O
a DT O
university NN O
- HYPH O
affiliated VBN O
clinic NN O
( , O
n CD O
= SYM O
1188 CD O
) -RRB- O
. . O
null null null-Disease
During IN O
the DT O
first JJ O
5 CD O
mo CD O
, , O
596 CD O
patients NNS O
received VBD O
aprotinin NN O
( HYPH O
Group NNP O
A NNP O
) -RRB- O
; : O
in IN O
the DT O
next JJ O
5 CD O
mo CD O
, , O
592 CD O
patients NNS O
were VBD O
treated VBN O
with IN O
tranexamic JJ O
acid NN O
( -LRB- O
Group NNP O
T NNP O
) -RRB- O
. . O
null null null-Disease
Except IN O
for IN O
antifibrinolytic JJ O
therapy NN O
, , O
the DT O
anesthetic JJ O
and CC O
surgical JJ O
protocols NNS O
remained VBD O
unchanged JJ O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
pre NN O
- HYPH O
and CC O
intraoperative JJ O
variables NNS O
were VBD O
comparable JJ O
between IN O
the DT O
treatment NN O
groups NNS O
. . O
null null null-Disease
Postoperatively RB O
, , O
a DT O
significantly RB O
higher JJR O
incidence NN O
of IN O
seizures NNS B-Disease
was VBD O
found VBN O
in IN O
Group NNP O
T NNP O
( SYM O
4 CD O
. . O
6 CD O
% NN O
vs IN O
1 CD O
. . O
2 CD O
% NN O
, , O
P NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
This DT O
difference NN O
was VBD O
also RB O
significant JJ O
in IN O
the DT O
primary JJ O
valve NN O
surgery NN O
and CC O
the DT O
high JJ O
risk NN O
surgery NN O
subgroups NNS O
( , O
7 CD O
. . O
9 CD O
% NN O
vs IN O
1 CD O
. . O
2 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
003 CD O
; : O
7 CD O
. . O
3 CD O
% NN O
vs IN O
2 CD O
. . O
4 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
035 CD O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
Persistent JJ O
atrial JJ O
fibrillation NN O
( : O
7 CD O
. . O
9 CD O
% NN O
vs IN O
2 CD O
. . O
3 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
020 CD O
) -RRB- O
and CC O
renal JJ B-Disease
failure NN I-Disease
( : O
9 CD O
. . O
7 CD O
% NN O
vs IN O
1 CD O
. . O
7 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
002 CD O
) -RRB- O
were VBD O
also RB O
more RBR O
common JJ O
in IN O
Group NNP O
T NNP O
, , O
in IN O
the DT O
primary JJ O
valve NN O
surgery NN O
subgroup NN O
. . O
null null null-Disease
On IN O
the DT O
contrary NN O
, , O
among IN O
primary JJ O
coronary JJ O
artery NN O
bypass NN O
surgery NN O
patients NNS O
, , O
there EX O
were VBD O
more RBR O
acute JJ O
myocardial JJ B-Disease
infarctions NNS I-Disease
and CC O
renal JJ B-Disease
dysfunction NN I-Disease
in IN O
Group NNP O
A NNP O
( SYM O
5 CD O
. . O
8 CD O
% NN O
vs IN O
2 CD O
. . O
0 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
027 CD O
; : O
22 CD O
. . O
5 CD O
% NN O
vs IN O
15 CD O
. . O
2 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
036 CD O
, , O
respectively RB O
) -RRB- O
. . O
null null null-Disease
The DT O
1 CD O
- HYPH O
yr NN O
mortality NN O
was VBD O
significantly RB O
higher JJR O
after IN O
aprotinin NN O
treatment NN O
in IN O
the DT O
high JJ O
risk NN O
surgery NN O
group NN O
( : O
17 CD O
. . O
7 CD O
% NN O
vs IN O
9 CD O
. . O
8 CD O
% NN O
, , O
P NN O
= SYM O
0 CD O
. . O
034 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Both DT O
antifibrinolytic JJ O
drugs NNS O
bear VBP O
the DT O
risk NN O
of IN O
adverse JJ O
outcome NN O
depending VBG O
on IN O
the DT O
type NN O
of IN O
cardiac JJ O
surgery NN O
. . O
null null null-Disease
Administration NN O
of IN O
aprotinin NN O
should MD O
be VB O
avoided VBN O
in IN O
coronary JJ O
artery NN O
bypass NN O
graft NN O
and CC O
high JJ O
risk NN O
patients NNS O
, , O
whereas IN O
administration NN O
of IN O
tranexamic JJ O
acid NN O
is VBZ O
not RB O
recommended VBN O
in IN O
valve NN O
surgery NN O
. . O
null null null-Disease
Delirium NN B-Disease
in IN O
an DT O
elderly JJ O
woman NN O
possibly RB O
associated VBN O
with IN O
administration NN O
of IN O
misoprostol NN O
. . O
null null null-Disease
Misoprostol NN O
has VBZ O
been VBN O
associated VBN O
with IN O
adverse JJ O
reactions NNS O
, , O
including VBG O
gastrointestinal JJ O
symptoms NNS O
, , O
gynecologic JJ O
problems NNS O
, , O
and CC O
headache NN B-Disease
. . O
null null null-Disease
Changes NNS O
in IN O
mental JJ O
status NN O
, , O
however RB O
, , O
have VBP O
not RB O
been VBN O
reported VBN O
. . O
null null null-Disease
We PRP O
present VBP O
a DT O
case NN O
in IN O
which WDT O
an DT O
89 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
in IN O
a DT O
long JJ O
- HYPH O
term NN O
care NN O
facility NN O
became VBD O
confused JJ O
after IN O
the DT O
initiation NN O
of IN O
misoprostol NN O
therapy NN O
. . O
null null null-Disease
The DT O
patient NN O
' POS O
s POS O
change NN O
in IN O
mental JJ O
status NN O
was VBD O
first RB O
reported VBN O
nine CD O
days NNS O
after IN O
the DT O
initiation NN O
of IN O
therapy NN O
. . O
null null null-Disease
Her PRP$ O
delirium NN B-Disease
significantly RB O
improved VBD O
after IN O
misoprostol NN O
was VBD O
discontinued VBN O
and CC O
her PRP$ O
mental JJ O
status NN O
returned VBD O
to IN O
normal JJ O
within IN O
a DT O
week NN O
. . O
null null null-Disease
Because IN O
no DT O
other JJ O
factors NNS O
related VBN O
to IN O
this DT O
patient NN O
changed VBD O
significantly RB O
, , O
the DT O
delirium NN B-Disease
experienced VBN O
by IN O
this DT O
patient NN O
possibly RB O
resulted VBD O
from IN O
misoprostol NN O
therapy NN O
. . O
null null null-Disease
The DT O
biological JJ O
properties NNS O
of IN O
the DT O
optical JJ O
isomers NNS O
of IN O
propranolol NN O
and CC O
their PRP$ O
effects NNS O
on IN O
cardiac JJ B-Disease
arrhythmias NNS I-Disease
. . O
null null null-Disease
1 LS O
. . O
null null null-Disease
The DT O
optical JJ O
isomers NNS O
of IN O
propranolol NN O
have VBP O
been VBN O
compared VBN O
for IN O
their PRP$ O
beta NN O
- HYPH O
blocking NN O
and CC O
antiarrhythmic JJ O
activities NNS O
. . O
2 LS O
. . O
null null null-Disease
In IN O
blocking VBG O
the DT O
positive JJ O
inotropic JJ O
and CC O
chronotropic JJ O
responses NNS O
to IN O
isoprenaline NN O
, , O
( , O
+ CC O
) -RRB- O
- HYPH O
propranolol NN O
had VBD O
less JJR O
than IN O
one CD O
hundredth NN O
the DT O
potency NN O
of IN O
( : O
- HYPH O
) NFP O
- HYPH O
propranolol NN O
. . O
null null null-Disease
At IN O
dose NN O
levels NNS O
of IN O
( : O
+ CC O
) -RRB- O
- HYPH O
propranolol NN O
which WDT O
attenuated VBD O
the DT O
responses NNS O
to IN O
isoprenaline NN O
, , O
there EX O
was VBD O
a DT O
significant JJ O
prolongation NN O
of IN O
the DT O
PR NN O
interval NN O
of IN O
the DT O
electrocardiogram NN O
. . O
3 CD O
. . O
null null null-Disease
The DT O
metabolic JJ O
responses NNS O
to IN O
isoprenaline NN O
in IN O
dogs NNS O
( , O
an DT O
increase NN O
in IN O
circulating VBG O
glucose NN O
, , O
lactate NN O
and CC O
free JJ O
fatty JJ O
acids NNS O
) -RRB- O
were VBD O
all DT O
blocked VBN O
by IN O
( : O
- HYPH O
) NFP O
- HYPH O
propranolol NN O
. . O
null null null-Disease
( NFP O
+ NFP O
) NFP O
- : O
Propranolol NN O
had VBD O
no DT O
effect NN O
on IN O
fatty NN O
acid NN O
mobilization NN O
but CC O
significantly RB O
reduced VBD O
the DT O
increments NNS O
in IN O
both CC O
lactate NN O
and CC O
glucose NN O
. . O
4 CD O
. . O
null null null-Disease
Both DT O
isomers NNS O
of IN O
propranolol NN O
possessed VBD O
similar JJ O
depressant JJ O
potency NN O
on IN O
isolated VBN O
atrial JJ O
muscle NN O
taken VBN O
from IN O
guinea NN O
- HYPH O
pigs NNS O
. . O
5 CD O
. . O
null null null-Disease
The DT O
isomers NNS O
of IN O
propranolol NN O
exhibited VBD O
similar JJ O
local JJ O
anaesthetic JJ O
potencies NNS O
on IN O
an DT O
isolated VBN O
frog NN O
nerve NN O
preparation NN O
at IN O
a DT O
level NN O
approximately RB O
three CD O
times NNS O
that DT O
of IN O
procaine NN O
. . O
null null null-Disease
The DT O
racemic JJ O
compound NN O
was VBD O
significantly RB O
less RBR O
potent JJ O
than IN O
either DT O
isomer NN O
. . O
6 LS O
. . O
null null null-Disease
Both DT O
isomers NNS O
of IN O
propranolol NN O
were VBD O
capable JJ O
of IN O
preventing VBG O
adrenaline NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
arrhythmias NNS I-Disease
in IN O
cats NNS O
anaesthetized VBN O
with IN O
halothane NN O
, , O
but CC O
the DT O
mean JJ O
dose NN O
of IN O
( : O
- HYPH O
) NFP O
- HYPH O
propranolol NN O
was VBD O
0 CD O
. . O
09 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
02 CD O
mg NN O
/ SYM O
kg NN O
whereas IN O
that DT O
of IN O
( , O
+ CC O
) NFP O
- HYPH O
propranolol NN O
was VBD O
4 CD O
. . O
2 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
2 CD O
mg NN O
/ SYM O
kg NN O
. . O
null null null-Disease
At IN O
the DT O
effective JJ O
dose NN O
level NN O
of IN O
( : O
+ CC O
) -RRB- O
- HYPH O
propranolol NN O
there EX O
was VBD O
a DT O
significant JJ O
prolongation NN O
of IN O
the DT O
PR NN O
interval NN O
of IN O
the DT O
electrocardiogram NN O
. . O
null null null-Disease
Blockade NN O
of IN O
arrhythmias NNS B-Disease
with IN O
both DT O
isomers NNS O
was VBD O
surmountable JJ O
by IN O
increasing VBG O
the DT O
dose NN O
of IN O
adrenaline NN O
. . O
7 LS O
. . O
null null null-Disease
Both DT O
isomers NNS O
of IN O
propranolol NN O
were VBD O
also RB O
capable JJ O
of IN O
reversing VBG O
ventricular JJ B-Disease
tachycardia NN I-Disease
caused VBN O
by IN O
ouabain NN O
in IN O
anaesthetized JJ O
cats NNS O
and CC O
dogs NNS O
. . O
null null null-Disease
The DT O
dose NN O
of IN O
( : O
- HYPH O
) NFP O
- HYPH O
propranolol NN O
was VBD O
significantly RB O
smaller JJR O
than IN O
that DT O
of IN O
( , O
+ CC O
) -RRB- O
- HYPH O
propranolol NN O
in IN O
both DT O
species NNS O
but CC O
much RB O
higher JJR O
than IN O
that DT O
required VBN O
to TO O
produce VB O
evidence NN O
of IN O
beta NN O
- HYPH O
blockade NN O
. . O
8 CD O
. . O
null null null-Disease
The DT O
implications NNS O
of IN O
these DT O
results NNS O
are VBP O
discussed VBN O
. . O
null null null-Disease
Topotecan NNP O
in IN O
combination NN O
with IN O
radiotherapy NN O
in IN O
unresectable JJ O
glioblastoma NN B-Disease
: : O
a DT O
phase NN O
2 CD O
study NN O
. . O
null null null-Disease
Improving VBG O
glioblastoma NN B-Disease
multiforme NN I-Disease
( , O
GBM NNP B-Disease
) -RRB- O
treatment NN O
with IN O
radio NN O
- HYPH O
chemotherapy NN O
remains VBZ O
a DT O
challenge NN O
. . O
null null null-Disease
Topotecan NNP O
is VBZ O
an DT O
attractive JJ O
option NN O
as IN O
it PRP O
exhibits VBZ O
growth NN O
inhibition NN O
of IN O
human JJ O
glioma NN B-Disease
as RB O
well RB O
as IN O
brain NN O
penetration NN O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
assessed VBD O
the DT O
combination NN O
of IN O
radiotherapy NN O
( , O
60 CD O
Gy NNP O
/ SYM O
30 CD O
fractions NNS O
/ SYM O
40 CD O
days NNS O
) -RRB- O
and CC O
topotecan NN O
( , O
0 CD O
. . O
9 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) CD O
/ SYM O
day NN O
on IN O
days NNS O
1 CD O
- SYM O
5 CD O
on IN O
weeks NNS O
1 CD O
, , O
3 CD O
and CC O
5 CD O
) CD O
in IN O
50 CD O
adults NNS O
with IN O
histologically RB O
proven VBN O
and CC O
untreated JJ O
GBM NNP B-Disease
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
non JJ O
- HYPH O
hematological JJ O
toxicities NNS B-Disease
was VBD O
low JJ O
and CC O
grade NN O
3 CD O
- SYM O
4 CD O
hematological JJ O
toxicities NNS B-Disease
were VBD O
reported VBN O
in IN O
20 CD O
patients NNS O
( , O
mainly RB O
lymphopenia NN B-Disease
and CC O
neutropenia NN B-Disease
) -RRB- O
. . O
null null null-Disease
Partial JJ O
response NN O
and CC O
stabilization NN O
rates NNS O
were VBD O
2 CD O
% NN O
and CC O
32 CD O
% NN O
, , O
respectively RB O
, , O
with IN O
an DT O
overall JJ O
time NN O
to IN O
progression NN O
of IN O
12 CD O
weeks NNS O
. . O
null null null-Disease
One CD O
- HYPH O
year NN O
overall JJ O
survival NN O
( : O
OS NNP O
) -RRB- O
rate NN O
was VBD O
42 CD O
% NN O
, , O
with IN O
a DT O
median JJ O
OS NN O
of IN O
40 CD O
weeks NNS O
. . O
null null null-Disease
Topotecan NNP O
in IN O
combination NN O
with IN O
radiotherapy NN O
was VBD O
well RB O
tolerated VBN O
. . O
null null null-Disease
However RB O
, , O
while IN O
response NN O
and CC O
stabilization NN O
concerned VBD O
one CD O
- HYPH O
third NN O
of IN O
the DT O
patients NNS O
, , O
the DT O
study NN O
did VBD O
not RB O
show VB O
increased JJ O
benefits NNS O
in IN O
terms NNS O
of IN O
survival NN O
in IN O
patients NNS O
with IN O
unresectable JJ O
GBM NNP B-Disease
. . O
null null null-Disease
Long JJ O
- HYPH O
term NN O
lithium NN O
therapy NN O
leading VBG O
to IN O
hyperparathyroidism NN B-Disease
: : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
This DT O
paper NN O
reviews VBZ O
the DT O
effect NN O
of IN O
chronic JJ O
lithium NN O
therapy NN O
on IN O
serum NN O
calcium NN O
level NN O
and CC O
parathyroid NN O
glands NNS O
, , O
its PRP$ O
pathogenesis NN O
, , O
and CC O
treatment NN O
options NNS O
. . O
null null null-Disease
We PRP O
examined VBD O
the DT O
case NN O
of IN O
a DT O
lithium NN O
- HYPH O
treated VBN O
patient NN O
who WP O
had VBD O
recurrent JJ O
hypercalcemia NN B-Disease
to TO O
better RBR O
understand VB O
the DT O
disease NN O
process NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Primary JJ B-Disease
hyperparathyroidism NN I-Disease
is VBZ O
a DT O
rare JJ O
but CC O
potentially RB O
life NN O
- HYPH O
threatening VBG O
side NN O
effect NN O
of IN O
long JJ O
- HYPH O
term NN O
lithium NN O
therapy NN O
. . O
null null null-Disease
Careful JJ O
patient JJ O
selection NN O
and CC O
long JJ O
- HYPH O
term NN O
follow NN O
- HYPH O
up NN O
can MD O
reduce VB O
morbidity NN O
. . O
null null null-Disease
PRACTICAL JJ O
IMPLICATIONS NNS O
: : O
As RB O
much JJ O
as IN O
15 CD O
% NN O
of IN O
lithium NN O
- HYPH O
treated VBN O
patients NNS O
become VBP O
hypercalcemic JJ B-Disease
. . O
null null null-Disease
By IN O
routinely RB O
monitoring VBG O
serum NN O
calcium NN O
levels NNS O
, , O
healthcare NN O
providers NNS O
can MD O
improve VB O
the DT O
quality NN O
of IN O
life NN O
of IN O
this DT O
patient NN O
group NN O
. . O
null null null-Disease
Comparison NN O
of IN O
laryngeal JJ O
mask NN O
with IN O
endotracheal JJ O
tube NN O
for IN O
anesthesia NN O
in IN O
endoscopic JJ O
sinus NN O
surgery NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
compare VB O
surgical JJ O
conditions NNS O
, , O
including VBG O
the DT O
amount NN O
of IN O
intraoperative JJ O
bleeding NN B-Disease
as RB O
well RB O
as IN O
intraoperative JJ O
blood NN O
pressure NN O
, , O
during IN O
functional JJ O
endoscopic JJ O
sinus NN O
surgery NN O
( , O
FESS NNP O
) -RRB- O
using VBG O
flexible JJ O
reinforced VBN O
laryngeal JJ O
mask NN O
airway NN O
( , O
FRLMA NNP O
) -RRB- O
versus IN O
endotracheal JJ O
tube NN O
( , O
ETT NNP O
) -RRB- O
in IN O
maintaining VBG O
controlled VBN O
hypotension NN B-Disease
anesthesia NN O
induced VBN O
by IN O
propofol NN O
- HYPH O
remifentanil NN O
total NN O
i PRP O
. . O
v NN O
. . O
anesthesia NN O
( : O
TIVA NNP O
) -RRB- O
. . O
null null null-Disease
METHODS NNS O
: : O
Sixty JJ O
normotensive JJ O
American NNP O
Society NNP O
of IN O
Anesthesiologists NNP O
I NNP O
- HYPH O
II NNP O
adult NN O
patients NNS O
undergoing VBG O
FESS NNP O
under IN O
controlled VBN O
hypotension NN B-Disease
anesthesia NN O
caused VBN O
by IN O
propofol NN O
- HYPH O
remifentanil NN O
- HYPH O
TIVA NNP O
were VBD O
randomly RB O
assigned VBN O
into IN O
two CD O
groups NNS O
: : O
group NN O
I NNP O
, , O
FRLMA NNP O
; : O
group NN O
II NNP O
, , O
ETT NNP O
. . O
null null null-Disease
Hemorrhage NN B-Disease
was VBD O
measured VBN O
and CC O
the DT O
visibility NN O
of IN O
the DT O
operative JJ O
field NN O
was VBD O
evaluated VBN O
according VBG O
to IN O
a DT O
six CD O
- HYPH O
point NN O
scale NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Controlled VBN O
hypotension NN B-Disease
was VBD O
achieved VBN O
within IN O
a DT O
shorter JJR O
period NN O
using VBG O
laryngeal JJ O
mask NN O
using VBG O
lower JJR O
rates NNS O
of IN O
remifentanil JJ O
infusion NN O
and CC O
lower JJR O
total JJ O
dose NN O
of IN O
remifentanil NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
In IN O
summary NN O
, , O
our PRP$ O
results NNS O
indicate VBP O
that IN O
airway NN O
management NN O
using VBG O
FRLMA NNP O
during IN O
controlled VBN O
hypotension NN B-Disease
anesthesia NN O
provided VBD O
better JJR O
surgical JJ O
conditions NNS O
in IN O
terms NNS O
of IN O
quality NN O
of IN O
operative JJ O
field NN O
and CC O
blood NN O
loss NN O
and CC O
allowed VBN O
for IN O
convenient JJ O
induced VBN O
hypotension NN B-Disease
with IN O
low JJ O
doses NNS O
of IN O
remifentanil NN O
during IN O
TIVA NNP O
in IN O
patients NNS O
undergoing VBG O
FESS NNP O
. . O
null null null-Disease
Nonalcoholic JJ B-Disease
fatty NN I-Disease
liver NN I-Disease
disease NN I-Disease
during IN O
valproate NN O
therapy NN O
. . O
null null null-Disease
Valproic NNP O
acid NN O
( : O
VPA NNP O
) -RRB- O
is VBZ O
effective JJ O
for IN O
the DT O
treatment NN O
of IN O
many JJ O
types NNS O
of IN O
epilepsy NN B-Disease
, , O
but CC O
its PRP$ O
use NN O
can MD O
be VB O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
body NN O
weight NN O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
nonalcoholic JJ B-Disease
fatty JJ I-Disease
liver NN I-Disease
disease NN I-Disease
( , O
NAFLD NNP B-Disease
) -RRB- O
arising VBG O
in IN O
a DT O
child NN O
who WP O
developed VBD O
obesity NN B-Disease
during IN O
VPA NNP O
treatment NN O
. . O
null null null-Disease
Laboratory NN O
data NNS O
revealed VBD O
hyperinsulinemia NN B-Disease
with IN O
insulin NN B-Disease
resistance NN I-Disease
. . O
null null null-Disease
After IN O
the DT O
withdrawal NN O
of IN O
VPA NNP O
therapy NN O
, , O
our PRP$ O
patient NN O
showed VBD O
a DT O
significant JJ O
weight NN B-Disease
loss NN I-Disease
, , O
a DT O
decrease NN O
of IN O
body NN O
mass NN O
index NN O
, , O
and CC O
normalization NN O
of IN O
metabolic JJ O
and CC O
endocrine JJ O
parameters NNS O
; : O
moreover RB O
, , O
ultrasound NN O
measurements NNS O
showed VBD O
a DT O
complete JJ O
normalization NN O
. . O
null null null-Disease
The DT O
present JJ O
case NN O
suggests VBZ O
that IN O
obesity NN B-Disease
, , O
hyperinsulinemia NN B-Disease
, , O
insulin NN B-Disease
resistance NN I-Disease
, , O
and CC O
long JJ O
- HYPH O
term NN O
treatment NN O
with IN O
VPA NNP O
may MD O
be VB O
all DT O
associated VBN O
with IN O
the DT O
development NN O
of IN O
NAFLD NNP B-Disease
; : O
this DT O
side NN O
effect NN O
is VBZ O
reversible JJ O
after IN O
VPA NNP O
withdrawal NN O
. . O
null null null-Disease
Carbimazole NNP O
induced VBD O
ANCA NNP B-Disease
positive JJ I-Disease
vasculitis NN I-Disease
. . O
null null null-Disease
Anti JJ O
- HYPH O
thyroid NN O
drugs NNS O
, , O
like IN O
carbimazole NN O
and CC O
propylthiouracil NN O
( , O
PTU NNP O
) -RRB- O
are VBP O
commonly RB O
prescribed VBN O
for IN O
the DT O
treatment NN O
of IN O
hyperthyroidism NN B-Disease
. . O
null null null-Disease
One PRP O
should MD O
be VB O
aware JJ O
of IN O
the DT O
side NN O
effects NNS O
of IN O
antithyroid JJ O
medications NNS O
. . O
null null null-Disease
Antineutrophil JJ B-Disease
cytoplasmic JJ I-Disease
antibody NN I-Disease
( , I-Disease
ANCA NNP I-Disease
) -RRB- I-Disease
- HYPH I-Disease
- HYPH I-Disease
associated VBN I-Disease
vasculitis NN I-Disease
is VBZ O
a DT O
potentially RB O
life NN O
- HYPH O
threatening VBG O
adverse JJ O
effect NN O
of IN O
antithyroidmedications NNS O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
patient NN O
with IN O
Graves NNP B-Disease
' POS I-Disease
disease NN I-Disease
who WP O
developed VBD O
ANCA NNP O
positive JJ O
carbimazole NN O
induced VBN O
vasculitis NN B-Disease
. . O
null null null-Disease
The DT O
episode NN O
was VBD O
characterized VBN O
by IN O
a DT O
vasculitic JJ B-Disease
skin NN B-Disease
rash NN I-Disease
associated VBN O
with IN O
large JJ O
joint NN O
arthritis NN B-Disease
, , O
pyrexia NN B-Disease
and CC O
parotiditis NN B-Disease
but CC O
no DT O
renal JJ O
or CC O
pulmonary JJ O
involvement NN O
. . O
null null null-Disease
He PRP O
was VBD O
referred VBN O
to IN O
us PRP O
for IN O
neurological JJ O
evaluation NN O
because IN O
he PRP O
had VBD O
difficulty NN O
in IN O
getting VBG O
up RP O
from IN O
squatting VBG O
position NN O
and CC O
was VBD O
suspected VBN O
to TO O
have VB O
myositis NN B-Disease
. . O
null null null-Disease
Carbimazole NNP O
and CC O
methimazole NN O
have VBP O
a DT O
lower JJR O
incidence NN O
of IN O
reported VBN O
ANCA NNP O
positive JJ O
side NN O
effects NNS O
than IN O
PUT VBN O
. . O
null null null-Disease
To IN O
the DT O
best JJS O
of IN O
our PRP$ O
knowledge NN O
this DT O
is VBZ O
the DT O
first JJ O
ANCA NNP O
positive JJ O
carbimazole NN O
induced VBN O
vasculitis NN B-Disease
case NN O
reported VBN O
from IN O
India NNP O
. . O
null null null-Disease
Aspirin NN O
for IN O
the DT O
primary JJ O
prevention NN O
of IN O
cardiovascular JJ O
events NNS O
: : O
an DT O
update NN O
of IN O
the DT O
evidence NN O
for IN O
the DT O
U NNP O
. . O
S NNP O
. . O
null null null-Disease
Preventive NNP O
Services NNPS O
Task NNP O
Force NNP O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Coronary JJ B-Disease
heart NN I-Disease
disease NN I-Disease
and CC O
cerebrovascular JJ B-Disease
disease NN I-Disease
are VBP O
leading VBG O
causes NNS O
of IN O
death NN O
in IN O
the DT O
United NNP O
States NNP O
. . O
null null null-Disease
In IN O
2002 CD O
, , O
the DT O
U NNP O
. . O
S NNP O
. . O
null null null-Disease
Preventive NNP O
Services NNPS O
Task NNP O
Force NNP O
( -LRB- O
USPSTF NNP O
) -RRB- O
strongly RB O
recommended VBD O
that IN O
clinicians NNS O
discuss VB O
aspirin NN O
with IN O
adults NNS O
who WP O
are VBP O
at IN O
increased VBN O
risk NN O
for IN O
coronary JJ B-Disease
heart NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
determine VB O
the DT O
benefits NNS O
and CC O
harms NNS O
of IN O
taking VBG O
aspirin NN O
for IN O
the DT O
primary JJ O
prevention NN O
of IN O
myocardial JJ B-Disease
infarctions NNS I-Disease
, , O
strokes NNS B-Disease
, , O
and CC O
death NN O
. . O
null null null-Disease
DATA NNP O
SOURCES NNS O
: : O
MEDLINE NNP O
and CC O
Cochrane NNP O
Library NNP O
( , O
search NN O
dates NNS O
, , O
1 CD O
January NNP O
2001 CD O
to IN O
28 CD O
August NNP O
2008 CD O
) -RRB- O
, , O
recent JJ O
systematic JJ O
reviews NNS O
, , O
reference NN O
lists NNS O
of IN O
retrieved VBN O
articles NNS O
, , O
and CC O
suggestions NNS O
from IN O
experts NNS O
. . O
null null null-Disease
STUDY NN O
SELECTION NN O
: : O
English NNP O
- HYPH O
language NN O
randomized VBN O
, , O
controlled VBN O
trials NNS O
( , O
RCTs NNP O
) -RRB- O
; , O
case NN O
- HYPH O
control NN O
studies NNS O
; , O
meta JJ O
- HYPH O
analyses NNS O
; , O
and CC O
systematic JJ O
reviews NNS O
of IN O
aspirin NN O
versus IN O
control NN O
for IN O
the DT O
primary JJ O
prevention NN O
of IN O
cardiovascular JJ B-Disease
disease NN I-Disease
( -LRB- O
CVD NN B-Disease
) -RRB- O
were VBD O
selected VBN O
to TO O
answer VB O
the DT O
following VBG O
questions NNS O
: : O
Does VBZ O
aspirin NN O
decrease VB O
coronary JJ O
heart NN O
events NNS O
, , O
strokes NNS B-Disease
, , O
death NN O
from IN O
coronary JJ O
heart NN O
events NNS O
or CC O
stroke NN B-Disease
, , O
or CC O
all RB O
- HYPH O
cause NN O
mortality NN O
in IN O
adults NNS O
without IN O
known VBN O
CVD NN B-Disease
? . O
null null null-Disease
Does VBZ O
aspirin NN O
increase VB O
gastrointestinal JJ B-Disease
bleeding NN I-Disease
or CC O
hemorrhagic JJ B-Disease
strokes NNS I-Disease
? . O
null null null-Disease
DATA NNP O
EXTRACTION NN O
: : O
All DT O
studies NNS O
were VBD O
reviewed VBN O
, , O
abstracted VBN O
, , O
and CC O
rated VBN O
for IN O
quality NN O
by IN O
using VBG O
predefined VBN O
USPSTF NNP O
criteria NNS O
. . O
null null null-Disease
DATA NNP O
SYNTHESIS NNP O
: : O
New JJ O
evidence NN O
from IN O
1 CD O
good JJ O
- HYPH O
quality NN O
RCT NNP O
, , O
1 CD O
good JJ O
- HYPH O
quality NN O
meta NN O
- HYPH O
analysis NN O
, , O
and CC O
2 CD O
fair JJ O
- HYPH O
quality NN O
subanalyses NNS O
of IN O
RCTs NNPS O
demonstrates VBZ O
that IN O
aspirin NN O
use NN O
reduces VBZ O
the DT O
number NN O
of IN O
CVD NN B-Disease
events NNS O
in IN O
patients NNS O
without IN O
known VBN O
CVD NN B-Disease
. . O
null null null-Disease
Men NNS O
in IN O
these DT O
studies NNS O
experienced VBD O
fewer JJR O
myocardial JJ B-Disease
infarctions NNS I-Disease
and CC O
women NNS O
experienced VBD O
fewer JJR O
ischemic JJ O
strokes NNS B-Disease
. . O
null null null-Disease
Aspirin NN O
does VBZ O
not RB O
seem VB O
to TO O
affect VB O
CVD NNP B-Disease
mortality NN O
or CC O
all RB O
- HYPH O
cause VB O
mortality NN O
in IN O
either CC O
men NNS O
or CC O
women NNS O
. . O
null null null-Disease
The DT O
use NN O
of IN O
aspirin NN O
for IN O
primary JJ O
prevention NN O
increases VBZ O
the DT O
risk NN O
for IN O
major JJ O
bleeding NN B-Disease
events NNS O
, , O
primarily RB O
gastrointestinal JJ B-Disease
bleeding NN I-Disease
events NNS O
, , O
in IN O
both DT O
men NNS O
and CC O
women NNS O
. . O
null null null-Disease
Men NNS O
have VBP O
an DT O
increased VBN O
risk NN O
for IN O
hemorrhagic JJ B-Disease
strokes NNS I-Disease
with IN O
aspirin NN O
use NN O
. . O
null null null-Disease
A DT O
new JJ O
RCT NNP O
and CC O
meta JJ O
- HYPH O
analysis NN O
suggest VBP O
that IN O
the DT O
risk NN O
for IN O
hemorrhagic JJ B-Disease
strokes NNS I-Disease
in IN O
women NNS O
is VBZ O
not RB O
statistically RB O
significantly RB O
increased VBN O
. . O
null null null-Disease
LIMITATIONS NNS O
: : O
New JJ O
evidence NN O
on IN O
aspirin NN O
for IN O
the DT O
primary JJ O
prevention NN O
of IN O
CVD NN B-Disease
is VBZ O
limited JJ O
. . O
null null null-Disease
The DT O
dose NN O
of IN O
aspirin NN O
used VBN O
in IN O
the DT O
RCTs NNS O
varied VBD O
, , O
which WDT O
prevented VBD O
the DT O
estimation NN O
of IN O
the DT O
most RBS O
appropriate JJ O
dose NN O
for IN O
primary JJ O
prevention NN O
. . O
null null null-Disease
Several JJ O
of IN O
the DT O
RCTs NNPS O
were VBD O
conducted VBN O
within IN O
populations NNS O
of IN O
health NN O
professionals NNS O
, , O
which WDT O
potentially RB O
limits VBZ O
generalizability NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Aspirin NN O
reduces VBZ O
the DT O
risk NN O
for IN O
myocardial JJ B-Disease
infarction NN I-Disease
in IN O
men NNS O
and CC O
strokes NNS B-Disease
in IN O
women NNS O
. . O
null null null-Disease
Aspirin NN O
use NN O
increases VBZ O
the DT O
risk NN O
for IN O
serious JJ O
bleeding NN B-Disease
events NNS O
. . O
null null null-Disease
Reducing VBG O
harm NN O
associated VBN O
with IN O
anticoagulation NN O
: : O
practical JJ O
considerations NNS O
of IN O
argatroban NN O
therapy NN O
in IN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
. . O
null null null-Disease
Argatroban NNP O
is VBZ O
a DT O
hepatically RB O
metabolized VBN O
, , O
direct JJ O
thrombin NN O
inhibitor NN O
used VBN O
for IN O
prophylaxis NN O
or CC O
treatment NN O
of IN O
thrombosis NN B-Disease
in IN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
( , O
HIT NNP B-Disease
) -RRB- O
and CC O
for IN O
patients NNS O
with IN O
or CC O
at IN O
risk NN O
of IN O
HIT NNP B-Disease
undergoing VBG O
percutaneous JJ O
coronary JJ O
intervention NN O
( -LRB- O
PCI NNP O
) -RRB- O
. . O
null null null-Disease
The DT O
objective NN O
of IN O
this DT O
review NN O
is VBZ O
to TO O
summarize VB O
practical JJ O
considerations NNS O
of IN O
argatroban JJ O
therapy NN O
in IN O
HIT NNP B-Disease
. . O
null null null-Disease
The DT O
US NNP O
FDA NNP O
- HYPH O
recommended VBN O
argatroban JJ O
dose NN O
in IN O
HIT NNP B-Disease
is VBZ O
2 CD O
microg NN O
/ SYM O
kg NN O
/ SYM O
min NN O
( , O
reduced VBN O
in IN O
patients NNS O
with IN O
hepatic JJ B-Disease
impairment NN I-Disease
and CC O
in IN O
paediatric JJ O
patients NNS O
) -RRB- O
, , O
adjusted VBN O
to TO O
achieve VB O
activated VBN O
partial JJ O
thromboplastin NN O
times NNS O
( : O
aPTTs NNS O
) SYM O
1 CD O
. . O
5 CD O
- SYM O
3 CD O
times NNS O
baseline NN O
( : O
not RB O
> SYM O
100 CD O
seconds NNS O
) -RRB- O
. . O
null null null-Disease
Contemporary JJ O
experiences NNS O
indicate VBP O
that IN O
reduced VBN O
doses NNS O
are VBP O
also RB O
needed VBN O
in IN O
patients NNS O
with IN O
conditions NNS O
associated VBN O
with IN O
hepatic JJ O
hypoperfusion NN O
, , O
e LS O
. . O
g LS O
. . O
heart NN B-Disease
failure NN I-Disease
, , O
yet CC O
are VBP O
unnecessary JJ O
for IN O
renal JJ B-Disease
dysfunction NN I-Disease
, , O
adult NN O
age NN O
, , O
sex NN O
, , O
race NN O
/ SYM O
ethnicity NN O
or CC O
obesity NN B-Disease
. . O
null null null-Disease
Argatroban NNP O
0 CD O
. . O
5 CD O
- SYM O
1 CD O
. . O
2 CD O
microg NN O
/ SYM O
kg NN O
/ SYM O
min NN O
typically RB O
supports VBZ O
therapeutic JJ O
aPTTs NNS O
. . O
null null null-Disease
The DT O
FDA NNP O
- HYPH O
recommended VBN O
dose NN O
during IN O
PCI NNP O
is VBZ O
25 CD O
microg NN O
/ SYM O
kg NNS O
/ SYM O
min NN O
( SYM O
350 CD O
microg NN O
/ SYM O
kg NN O
initial JJ O
bolus NN O
) -RRB- O
, , O
adjusted VBN O
to TO O
achieve VB O
activated VBN O
clotting NN O
times NNS O
( , O
ACTs NNS O
) -RRB- O
of IN O
300 CD O
- SYM O
450 CD O
sec NN O
. . O
null null null-Disease
For IN O
PCI NNP O
, , O
argatroban NN O
has VBZ O
not RB O
been VBN O
investigated VBN O
in IN O
hepatically RB O
impaired VBN O
patients NNS O
; : O
dose NN O
adjustment NN O
is VBZ O
unnecessary JJ O
for IN O
adult NN O
age NN O
, , O
sex NN O
, , O
race NN O
/ SYM O
ethnicity NN O
or CC O
obesity NN B-Disease
, , O
and CC O
lesser JJR O
doses NNS O
may MD O
be VB O
adequate JJ O
with IN O
concurrent JJ O
glycoprotein NN O
IIb NNP O
/ SYM O
IIIa NNP O
inhibition NN O
. . O
null null null-Disease
Argatroban NNP O
prolongs VBZ O
the DT O
International NNP O
Normalized NNP O
Ratio NNP O
, , O
and CC O
published VBN O
approaches NNS O
for IN O
monitoring VBG O
the DT O
argatroban NN O
- HYPH O
to IN O
- HYPH O
warfarin NN O
transition NN O
should MD O
be VB O
followed VBN O
. . O
null null null-Disease
Major JJ O
bleeding NN B-Disease
with IN O
argatroban NN O
is VBZ O
0 CD O
- SYM O
10 CD O
% NN O
in IN O
the DT O
non AFX O
- HYPH O
interventional JJ O
setting NN O
and CC O
0 CD O
- SYM O
5 CD O
. . O
8 CD O
% NN O
periprocedurally RB O
. . O
null null null-Disease
Argatroban NNP O
has VBZ O
no DT O
specific JJ O
antidote NN O
, , O
and CC O
if IN O
excessive JJ O
anticoagulation NN O
occurs VBZ O
, , O
argatroban JJ O
infusion NN O
should MD O
be VB O
stopped VBN O
or CC O
reduced VBN O
. . O
null null null-Disease
Improved JJ O
familiarity NN O
of IN O
healthcare NN O
professionals NNS O
with IN O
argatroban NN O
therapy NN O
in IN O
HIT NNP B-Disease
, , O
including VBG O
in IN O
special JJ O
populations NNS O
and CC O
during IN O
PCI NNP O
, , O
may MD O
facilitate VB O
reduction NN O
of IN O
harm NN O
associated VBN O
with IN O
HIT NNP B-Disease
( : O
e LS O
. . O
g LS O
. . O
fewer JJR O
thromboses NNS O
) -RRB- O
or CC O
its PRP$ O
treatment NN O
( : O
e LS O
. . O
g LS O
. . O
fewer JJR O
argatroban NN O
medication NN O
errors NNS O
) -RRB- O
. . O
null null null-Disease
Rhabdomyolysis NN B-Disease
and CC O
brain NN O
ischemic JJ B-Disease
stroke NN I-Disease
in IN O
a DT O
heroin NN O
- HYPH O
dependent JJ O
male NN O
under IN O
methadone NN O
maintenance NN O
therapy NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
There EX O
are VBP O
several JJ O
complications NNS O
associated VBN O
with IN O
heroin NN B-Disease
abuse NN I-Disease
, , O
some DT O
of IN O
which WDT O
are VBP O
life NN O
- HYPH O
threatening VBG O
. . O
null null null-Disease
Methadone NN O
may MD O
aggravate VB O
this DT O
problem NN O
. . O
null null null-Disease
METHOD NN O
: : O
A DT O
clinical JJ O
case NN O
description NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
A DT O
33 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
presented VBN O
with IN O
rhabdomyolysis NN B-Disease
and CC O
cerebral JJ O
ischemic JJ B-Disease
stroke NN I-Disease
after IN O
intravenous JJ O
heroin NN O
. . O
null null null-Disease
He PRP O
had VBD O
used VBN O
heroin NN O
since IN O
age NN O
20 CD O
, , O
and CC O
had VBD O
used VBN O
150 CD O
mg NN O
methadone NN O
daily RB O
for IN O
6 CD O
months NNS O
. . O
null null null-Disease
He PRP O
was VBD O
found VBN O
unconsciousness NN B-Disease
at IN O
home NN O
and CC O
was VBD O
sent VBN O
to IN O
our PRP$ O
hospital NN O
. . O
null null null-Disease
In IN O
the DT O
ER NNP O
, , O
his PRP$ O
opiate JJ O
level NN O
was VBD O
4497 CD O
ng CD O
/ SYM O
ml NN O
. . O
null null null-Disease
In IN O
the DT O
ICU NNP O
, , O
we PRP O
found VBD O
rhabdomyolysis NN B-Disease
, , O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
and CC O
acute JJ O
respiratory JJ B-Disease
failure NN I-Disease
. . O
null null null-Disease
After IN O
transfer NN O
to IN O
an DT O
internal JJ O
ward NN O
, , O
we PRP O
noted VBD O
aphasia NN B-Disease
and CC O
weakness NN B-Disease
of IN O
his PRP$ O
left JJ O
limbs NNS O
. . O
null null null-Disease
After IN O
MRI NNP O
, , O
we PRP O
found VBD O
cerebral JJ B-Disease
ischemic JJ I-Disease
infarction NN I-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
Those DT O
using VBG O
methadone NN O
and CC O
heroin NN O
simultaneously RB O
may MD O
increase VB O
risk NN O
of IN O
rhabdomyolysis NN B-Disease
and CC O
ischemic JJ B-Disease
stroke NN I-Disease
. . O
null null null-Disease
Patients NNS O
under IN O
methadone NN O
maintenance NN O
therapy NN O
should MD O
be VB O
warned VBN O
regarding VBG O
these DT O
serious JJ O
adverse JJ O
events NNS O
. . O
null null null-Disease
Hypotheses NNS O
of IN O
heroin NN O
- HYPH O
related VBN O
rhabdomyolysis NN B-Disease
and CC O
stroke NN B-Disease
in IN O
heroin NN O
abusers NNS O
are VBP O
discussed VBN O
. . O
null null null-Disease
Increased JJ O
vulnerability NN O
to IN O
6 CD O
- HYPH O
hydroxydopamine NN O
lesion NN O
and CC O
reduced VBN O
development NN O
of IN O
dyskinesias NNS B-Disease
in IN O
mice NNS O
lacking VBG O
CB1 NNP O
cannabinoid NN O
receptors NNS O
. . O
null null null-Disease
Motor NN O
impairment NN O
, , O
dopamine NN O
( , O
DA NN O
) , O
neuronal JJ O
activity NN O
and CC O
proenkephalin NN O
( -LRB- O
PENK NNP O
) -RRB- O
gene NN O
expression NN O
in IN O
the DT O
caudate NN O
- HYPH O
putamen NN O
( , O
CPu NNP O
) -RRB- O
were VBD O
measured VBN O
in IN O
6 CD O
- HYPH O
OHDA NN O
- HYPH O
lesioned VBN O
and CC O
treated VBN O
( , O
L NN O
- HYPH O
DOPA NNP O
+ SYM O
benserazide NN O
) -RRB- O
CB1 NNP O
KO NNP O
and CC O
WT NN O
mice NNS O
. . O
null null null-Disease
A DT O
lesion NN O
induced VBN O
by IN O
6 CD O
- HYPH O
OHDA NNP O
produced VBD O
more RBR O
severe JJ O
motor NN O
deterioration NN O
in IN O
CB1 NNP O
KO NNP O
mice NNS O
accompanied VBN O
by IN O
more JJR O
loss NN O
of IN O
DA NN O
neurons NNS O
and CC O
increased VBN O
PENK NNP O
gene NN O
expression NN O
in IN O
the DT O
CPu NNP O
. . O
null null null-Disease
Oxidative JJ O
/ SYM O
nitrosative JJ O
and CC O
neuroinflammatory JJ O
parameters NNS O
were VBD O
estimated VBN O
in IN O
the DT O
CPu NN O
and CC O
cingulate NN O
cortex NN O
( : O
Cg NNP O
) -RRB- O
. . O
null null null-Disease
CB1 NNP O
KO NNP O
mice NNS O
exhibited VBD O
higher JJR O
MDA NNP O
levels NNS O
and CC O
iNOS NN O
protein NN O
expression NN O
in IN O
the DT O
CPu NNP O
and CC O
Cg NNP O
compared VBN O
to IN O
WT NNP O
mice NNS O
. . O
null null null-Disease
Treatment NN O
with IN O
L NNP O
- HYPH O
DOPA NNP O
+ CC O
benserazide NN O
( : O
12 CD O
weeks NNS O
) -RRB- O
resulted VBD O
in IN O
less RBR O
severe JJ O
dyskinesias NNS B-Disease
in IN O
CB1 NNP O
KO NNP O
than IN O
in IN O
WT NNP O
mice NNS O
. . O
null null null-Disease
The DT O
results NNS O
revealed VBD O
that IN O
the DT O
lack NN O
of IN O
cannabinoid JJ O
CB1 NN O
receptors NNS O
increased VBD O
the DT O
severity NN O
of IN O
motor NN O
impairment NN O
and CC O
DA NN O
lesion NN O
, , O
and CC O
reduced VBD O
L NN O
- HYPH O
DOPA NNP O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
activation NN O
of IN O
CB1 NNP O
receptors NNS O
offers VBZ O
neuroprotection NN O
against IN O
dopaminergic JJ O
lesion NN O
and CC O
the DT O
development NN O
of IN O
L NNP O
- HYPH O
DOPA NNP O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
. . O
null null null-Disease
Hepatocellular JJ O
oxidant NN O
stress NN O
following VBG O
intestinal JJ O
ischemia NN B-Disease
- HYPH O
reperfusion NN B-Disease
injury NN I-Disease
. . O
null null null-Disease
Reperfusion NN O
of IN O
ischemic JJ B-Disease
intestine NN O
results VBZ O
in IN O
acute JJ O
liver NN B-Disease
dysfunction NN I-Disease
characterized VBN O
by IN O
hepatocellular JJ O
enzyme NN O
release NN O
into IN O
plasma NN O
, , O
reduction NN O
in IN O
bile NN O
flow NN O
rate NN O
, , O
and CC O
neutrophil NN O
sequestration NN O
within IN O
the DT O
liver NN O
. . O
null null null-Disease
The DT O
pathophysiology NN O
underlying VBG O
this DT O
acute JJ O
hepatic JJ B-Disease
injury NN I-Disease
is VBZ O
unknown JJ O
. . O
null null null-Disease
This DT O
study NN O
was VBD O
undertaken VBN O
to TO O
determine VB O
whether IN O
oxidants NNS O
are VBP O
associated VBN O
with IN O
the DT O
hepatic JJ B-Disease
injury NN I-Disease
and CC O
to TO O
determine VB O
the DT O
relative JJ O
value NN O
of IN O
several JJ O
indirect JJ O
methods NNS O
of IN O
assessing VBG O
oxidant JJ O
exposure NN O
in IN O
vivo NN O
. . O
null null null-Disease
Rats NNS O
were VBD O
subjected VBN O
to IN O
a DT O
standardized VBN O
intestinal JJ O
ischemia NN B-Disease
- HYPH O
reperfusion NN B-Disease
injury NN I-Disease
. . O
null null null-Disease
Hepatic JJ O
tissue NN O
was VBD O
assayed VBN O
for IN O
lipid NN O
peroxidation NN O
products NNS O
and CC O
oxidized VBD O
and CC O
reduced VBD O
glutathione NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
change NN O
in IN O
hepatic JJ O
tissue NN O
total JJ O
glutathione NN O
following VBG O
intestinal JJ O
ischemia NN B-Disease
- HYPH O
reperfusion NN B-Disease
injury NN I-Disease
. . O
null null null-Disease
Oxidized JJ O
glutathione NN O
( -LRB- O
GSSG NNP O
) -RRB- O
increased VBD O
significantly RB O
following VBG O
30 CD O
and CC O
60 CD O
min NN O
of IN O
reperfusion NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
increase NN O
in IN O
any DT O
of IN O
the DT O
products NNS O
of IN O
lipid NN O
peroxidation NN O
associated VBN O
with IN O
this DT O
injury NN O
. . O
null null null-Disease
An DT O
increase NN O
in IN O
GSSG NNP O
within IN O
hepatic JJ O
tissue NN O
during IN O
intestinal JJ O
reperfusion NN O
suggests VBZ O
exposure NN O
of IN O
hepatocytes NNS O
to IN O
an DT O
oxidant JJ O
stress NN O
. . O
null null null-Disease
The DT O
lack NN O
of IN O
a DT O
significant JJ O
increase NN O
in IN O
products NNS O
of IN O
lipid JJ O
peroxidation NN O
suggests VBZ O
that IN O
the DT O
oxidant JJ O
stress NN O
is VBZ O
of IN O
insufficient JJ O
magnitude NN O
to TO O
result VB O
in IN O
irreversible JJ O
injury NN O
to IN O
hepatocyte NN O
cell NN O
membranes NNS O
. . O
null null null-Disease
These DT O
data NNS O
also RB O
suggest VBP O
that IN O
the DT O
measurement NN O
of IN O
tissue NN O
GSSG NNP O
may MD O
be VB O
a DT O
more RBR O
sensitive JJ O
indicator NN O
of IN O
oxidant JJ O
stress NN O
than IN O
measurement NN O
of IN O
products NNS O
of IN O
lipid JJ O
peroxidation NN O
. . O
null null null-Disease
Animal NN O
model NN O
of IN O
mania NN B-Disease
induced VBN O
by IN O
ouabain NN O
: : O
Evidence NN O
of IN O
oxidative JJ O
stress NN O
in IN O
submitochondrial JJ O
particles NNS O
of IN O
the DT O
rat NN O
brain NN O
. . O
null null null-Disease
The DT O
intracerebroventricular JJ O
( -LRB- O
ICV NN O
) -RRB- O
administration NN O
of IN O
ouabain NN O
( , O
a DT O
Na NN O
( , O
+ CC O
) NFP O
/ SYM O
K NN O
( , O
+ CC O
) NFP O
- HYPH O
ATPase NN O
inhibitor NN O
) -RRB- O
in IN O
rats NNS O
has VBZ O
been VBN O
suggested VBN O
to TO O
mimic VB O
some DT O
symptoms NNS O
of IN O
human JJ O
bipolar JJ B-Disease
mania NN I-Disease
. . O
null null null-Disease
Clinical JJ O
studies NNS O
have VBP O
shown VBN O
that IN O
bipolar JJ B-Disease
disorder NN I-Disease
may MD O
be VB O
related VBN O
to IN O
mitochondrial JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
Herein RB O
, , O
we PRP O
investigated VBD O
the DT O
behavioral JJ O
and CC O
biochemical JJ O
effects NNS O
induced VBN O
by IN O
the DT O
ICV NNP O
administration NN O
of IN O
ouabain NN O
in IN O
rats NNS O
. . O
null null null-Disease
To TO O
achieve VB O
this DT O
aim NN O
, , O
the DT O
effects NNS O
of IN O
ouabain NN O
injection NN O
immediately RB O
after IN O
and CC O
7 CD O
days NNS O
following VBG O
a DT O
single JJ O
ICV NNP O
administration NN O
( : O
at IN O
concentrations NNS O
of IN O
10 CD O
( SYM O
- HYPH O
2 CD O
) SYM O
and CC O
10 CD O
( SYM O
- HYPH O
3 CD O
) SYM O
M NN O
) -RRB- O
on IN O
locomotion NN O
was VBD O
measured VBN O
using VBG O
the DT O
open JJ O
- HYPH O
field NN O
test NN O
. . O
null null null-Disease
Additionally RB O
, , O
thiobarbituric JJ O
acid NN O
reactive JJ O
substances NNS O
( , O
TBARSs NNP O
) -RRB- O
and CC O
superoxide NN O
production NN O
were VBD O
measured VBN O
in IN O
submitochondrial JJ O
particles NNS O
of IN O
the DT O
prefrontal JJ O
cortex NN O
, , O
hippocampus NN O
, , O
striatum NN O
and CC O
amygdala NN O
. . O
null null null-Disease
Our PRP$ O
findings NNS O
demonstrated VBD O
that IN O
ouabain NN O
at IN O
10 CD O
( SYM O
- HYPH O
2 CD O
) -RRB- O
and CC O
10 CD O
( SYM O
- HYPH O
3 CD O
) SYM O
M NN O
induced VBD O
hyperlocomotion NN B-Disease
in IN O
rats NNS O
, , O
and CC O
this DT O
response NN O
remained VBD O
up IN O
to TO O
7 CD O
days NNS O
following VBG O
a DT O
single JJ O
ICV NNP O
injection NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
we PRP O
observed VBD O
that IN O
the DT O
persistent JJ O
increase NN O
in IN O
the DT O
rat NN O
spontaneous JJ O
locomotion NN O
is VBZ O
associated VBN O
with IN O
increased VBN O
TBARS NNP O
levels NNS O
and CC O
superoxide NN O
generation NN O
in IN O
submitochondrial JJ O
particles NNS O
in IN O
the DT O
prefrontal JJ O
cortex NN O
, , O
striatum NN O
and CC O
amygdala NN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
ouabain NN O
- HYPH O
induced VBN O
mania NN B-Disease
- HYPH O
like JJ O
behavior NN O
may MD O
provide VB O
a DT O
useful JJ O
animal NN O
model NN O
to TO O
test VB O
the DT O
hypothesis NN O
of IN O
the DT O
involvement NN O
of IN O
oxidative JJ O
stress NN O
in IN O
bipolar JJ B-Disease
disorder NN I-Disease
. . O
null null null-Disease
Intraoperative JJ O
dialysis NN O
during IN O
liver NN O
transplantation NN O
with IN O
citrate NN O
dialysate NN O
. . O
null null null-Disease
Liver NN O
transplantation NN O
for IN O
acutely RB O
ill JJ O
patients NNS O
with IN O
fulminant JJ B-Disease
liver NN I-Disease
failure NN I-Disease
carries VBZ O
high JJ O
intraoperative JJ O
and CC O
immediate JJ O
postoperative JJ O
risks NNS O
. . O
null null null-Disease
These DT O
are VBP O
increased VBN O
with IN O
the DT O
presence NN O
of IN O
concomitant JJ O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
( , O
AKI NNP B-Disease
) -RRB- O
and CC O
intraoperative JJ O
dialysis NN O
is VBZ O
sometimes RB O
required VBN O
to TO O
allow VB O
the DT O
transplant NN O
to TO O
proceed VB O
. . O
null null null-Disease
The DT O
derangements NNS O
in IN O
the DT O
procoagulant JJ O
and CC O
anticoagulant JJ O
pathways NNS O
during IN O
fulminant JJ B-Disease
liver NN I-Disease
failure NN I-Disease
can MD O
lead VB O
to IN O
difficulties NNS O
with IN O
anticoagulation NN O
during IN O
dialysis NN O
, , O
especially RB O
when WRB O
continued VBN O
in IN O
the DT O
operating NN O
room NN O
. . O
null null null-Disease
Systemic JJ O
anticoagulation NN O
is VBZ O
unsafe JJ O
and CC O
regional JJ O
citrate NN O
anticoagulation NN O
in IN O
the DT O
absence NN O
of IN O
a DT O
functional JJ O
liver NN O
carries VBZ O
the DT O
risk NN O
of IN O
citrate NN O
toxicity NN B-Disease
. . O
null null null-Disease
Citrate NNP O
dialysate NN O
, , O
a DT O
new JJ O
dialysate NN O
with IN O
citric JJ O
acid NN O
can MD O
be VB O
used VBN O
for IN O
anticoagulation NN O
in IN O
patients NNS O
who WP O
cannot MD O
tolerate VB O
heparin NN O
or CC O
regional JJ O
citrate NN O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
a DT O
40 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
female NN O
with IN O
acetaminophen NN O
- HYPH O
induced VBN O
fulminant JJ B-Disease
liver NN I-Disease
failure NN I-Disease
with IN O
associated VBN O
AKI NNP B-Disease
who WP O
underwent VBD O
intraoperative JJ O
dialytic JJ O
support NN O
during IN O
liver NN O
transplantation NN O
anticoagulated VBN O
with IN O
citrate NN O
dialysate NN O
during IN O
the DT O
entire JJ O
procedure NN O
. . O
null null null-Disease
The DT O
patient NN O
tolerated VBD O
the DT O
procedure NN O
well RB O
without IN O
any DT O
signs NNS O
of IN O
citrate NN O
toxicity NN B-Disease
and CC O
maintained VBD O
adequate JJ O
anticoagulation NN O
for IN O
patency NN O
of IN O
the DT O
dialysis NN O
circuit NN O
. . O
null null null-Disease
Citrate NN O
dialysate NN O
is VBZ O
a DT O
safe JJ O
alternative NN O
for IN O
intradialytic JJ O
support NN O
of IN O
liver NN O
transplantation NN O
in IN O
fulminant JJ B-Disease
liver NN I-Disease
failure NN I-Disease
. . O
null null null-Disease
Delirium NN B-Disease
in IN O
a DT O
patient NN O
with IN O
toxic JJ O
flecainide NN O
plasma NN O
concentrations NNS O
: : O
the DT O
role NN O
of IN O
a DT O
pharmacokinetic JJ O
drug NN O
interaction NN O
with IN O
paroxetine NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
describe VB O
a DT O
case NN O
of IN O
flecainide NN O
- HYPH O
induced VBN O
delirium NN B-Disease
associated VBN O
with IN O
a DT O
pharmacokinetic JJ O
drug NN O
interaction NN O
with IN O
paroxetine NN O
. . O
null null null-Disease
CASE NNP O
SUMMARY NNP O
: : O
A DT O
69 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
white JJ O
female NN O
presented VBD O
to IN O
the DT O
emergency NN O
department NN O
with IN O
a DT O
history NN O
of IN O
confusion NN B-Disease
and CC O
paranoia NN B-Disease
over IN O
the DT O
past JJ O
several JJ O
days NNS O
. . O
null null null-Disease
On IN O
admission NN O
the DT O
patient NN O
was VBD O
taking VBG O
carvedilol NN O
12 CD O
mg NN O
twice RB O
daily RB O
, , O
warfarin NN O
2 CD O
mg NN O
/ SYM O
day NN O
, , O
folic JJ O
acid NN O
1 CD O
mg NN O
/ SYM O
day NN O
, , O
levothyroxine NN O
100 CD O
microg NN O
/ SYM O
day NN O
, , O
pantoprazole NN O
40 CD O
mg NN O
/ SYM O
day NN O
, , O
paroxetine NN O
40 CD O
mg NN O
/ SYM O
day NN O
, , O
and CC O
flecainide NN O
100 CD O
mg NN O
twice RB O
daily RB O
. . O
null null null-Disease
Flecainide NNP O
had VBD O
been VBN O
started VBN O
2 CD O
weeks NNS O
prior RB O
for IN O
atrial JJ B-Disease
fibrillation NN I-Disease
. . O
null null null-Disease
Laboratory NN O
test NN O
findings NNS O
on IN O
admission NN O
were VBD O
notable JJ O
only RB O
for IN O
a DT O
flecainide JJ O
plasma NN O
concentration NN O
of IN O
1360 CD O
microg NN O
/ SYM O
L NNP O
( HYPH O
reference NN O
range NN O
200 CD O
- SYM O
1000 CD O
) -RRB- O
. . O
null null null-Disease
A DT O
metabolic JJ O
drug NN O
interaction NN O
between IN O
flecainide NN O
and CC O
paroxetine NN O
, , O
which WDT O
the DT O
patient NN O
had VBD O
been VBN O
taking VBG O
for IN O
more JJR O
than IN O
5 CD O
years NNS O
, , O
was VBD O
considered VBN O
. . O
null null null-Disease
Paroxetine NN O
was VBD O
discontinued VBN O
and CC O
the DT O
dose NN O
of IN O
flecainide NN O
was VBD O
reduced VBN O
to IN O
50 CD O
mg NN O
twice RB O
daily RB O
. . O
null null null-Disease
Her PRP$ O
delirium NN B-Disease
resolved VBD O
3 CD O
days NNS O
later RB O
. . O
null null null-Disease
DISCUSSION NN O
: : O
Flecainide NN O
and CC O
pharmacologically RB O
similar JJ O
agents NNS O
that WDT O
interact VBP O
with IN O
sodium NN O
channels NNS O
may MD O
cause VB O
delirium NN B-Disease
in IN O
susceptible JJ O
patients NNS O
. . O
null null null-Disease
A DT O
MEDLINE NNP O
search NN O
( : O
1966 CD O
- HYPH O
January NNP O
2009 CD O
) , O
revealed VBD O
one CD O
in IN O
vivo NN O
pharmacokinetic JJ O
study NN O
on IN O
the DT O
interaction NN O
between IN O
flecainide NN O
, , O
a DT O
CYP2D6 NNP O
substrate NN O
, , O
and CC O
paroxetine NN O
, , O
a DT O
CYP2D6 NNP O
inhibitor NN O
, , O
as RB O
well RB O
as IN O
3 CD O
case NN O
reports NNS O
of IN O
flecainide NN O
- HYPH O
induced VBN O
delirium NN B-Disease
. . O
null null null-Disease
According VBG O
to IN O
the DT O
Naranjo NNP O
probability NN O
scale NN O
, , O
flecainide NN O
was VBD O
the DT O
probable JJ O
cause NN O
of IN O
the DT O
patient NN O
' POS O
s NN O
delirium NN B-Disease
; : O
the DT O
Horn NNP O
Drug NNP O
Interaction NNP O
Probability NNP O
Scale NNP O
indicates VBZ O
a DT O
possible JJ O
pharmacokinetic JJ O
drug NN O
interaction NN O
between IN O
flecainide NN O
and CC O
paroxetine NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Supratherapeutic JJ O
flecainide NN O
plasma NN O
concentrations NNS O
may MD O
cause VB O
delirium NN B-Disease
. . O
null null null-Disease
Because IN O
toxicity NN B-Disease
may MD O
occur VB O
when WRB O
flecainide NN O
is VBZ O
prescribed VBN O
with IN O
paroxetine NN O
and CC O
other JJ O
potent JJ O
CYP2D6 NN O
inhibitors NNS O
, , O
flecainide NN O
plasma NN O
concentrations NNS O
should MD O
be VB O
monitored VBN O
closely RB O
with IN O
commencement NN O
of IN O
CYP2D6 NNP O
inhibitors NNS O
. . O
null null null-Disease
Efficacy NN O
of IN O
everolimus NN O
( -LRB- O
RAD001 NN O
) -RRB- O
in IN O
patients NNS O
with IN O
advanced JJ O
NSCLC NNP B-Disease
previously RB O
treated VBN O
with IN O
chemotherapy NN O
alone RB O
or CC O
with IN O
chemotherapy NN O
and CC O
EGFR NNP O
inhibitors NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Treatment NN O
options NNS O
are VBP O
scarce JJ O
in IN O
pretreated VBN O
advanced JJ O
non JJ B-Disease
- HYPH I-Disease
small JJ I-Disease
- HYPH I-Disease
cell NN I-Disease
lung NN I-Disease
cancer NN I-Disease
( -LRB- O
NSCLC NNP B-Disease
) -RRB- O
patients NNS O
. . O
null null null-Disease
RAD001 NNP O
, , O
an DT O
oral JJ O
inhibitor NN O
of IN O
the DT O
mammalian JJ O
target NN O
of IN O
rapamycin NN O
( , O
mTOR NNP O
) -RRB- O
, , O
has VBZ O
shown VBN O
phase NN O
I NN O
efficacy NN O
in IN O
NSCLC NNP B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Stage NN O
IIIb NNP O
or CC O
IV NNP O
NSCLC NNP B-Disease
patients NNS O
, , O
with IN O
two CD O
or CC O
fewer JJR O
prior JJ O
chemotherapy NN O
regimens NNS O
, , O
one CD O
platinum NN O
based VBN O
( , O
stratum NN O
1 CD O
) -RRB- O
or CC O
both CC O
chemotherapy NN O
and CC O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
tyrosine NN O
kinase NN O
inhibitors NNS O
( , O
stratum NN O
2 CD O
) -RRB- O
, , O
received VBN O
RAD001 NN O
10 CD O
mg NN O
/ SYM O
day NN O
until IN O
progression NN O
or CC O
unacceptable JJ O
toxicity NN B-Disease
. . O
null null null-Disease
Primary JJ O
objective NN O
was VBD O
overall JJ O
response NN O
rate NN O
( , O
ORR NNP O
) -RRB- O
. . O
null null null-Disease
Analyses NNS O
of IN O
markers NNS O
associated VBN O
with IN O
the DT O
mTOR NNP O
pathway NN O
were VBD O
carried VBN O
out RP O
on IN O
archival JJ O
tumor NN B-Disease
from IN O
a DT O
subgroup NN O
using VBG O
immunohistochemistry NN O
( , O
IHC NNP O
) -RRB- O
and CC O
direct JJ O
mutation NN O
sequencing NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Eighty CD O
- HYPH O
five CD O
patients NNS O
were VBD O
enrolled VBN O
, , O
42 CD O
in IN O
stratum NN O
1 CD O
and CC O
43 CD O
in IN O
stratum NN O
. . O
null null null-Disease
ORR NNP O
was VBD O
4 CD O
. . O
7 CD O
% NN O
( SYM O
7 CD O
. . O
1 CD O
% NN O
stratum NN O
1 CD O
; : O
2 CD O
. . O
3 CD O
% NN O
stratum NN O
2 CD O
) -RRB- O
. . O
null null null-Disease
Overall JJ O
disease NN O
control NN O
rate NN O
was VBD O
47 CD O
. . O
1 CD O
% NN O
. . O
null null null-Disease
Median JJ O
progression NN O
- HYPH O
free JJ O
survivals NNS O
( -LRB- O
PFSs NNP O
) -RRB- O
were VBD O
2 CD O
. . O
6 CD O
( SYM O
stratum NN O
1 CD O
) -RRB- O
and CC O
2 CD O
. . O
7 CD O
months NNS O
( : O
stratum NN O
2 CD O
) -RRB- O
. . O
null null null-Disease
Common JJ O
> : O
or CC O
= SYM O
grade NN O
3 CD O
events NNS O
were VBD O
fatigue NN B-Disease
, , O
dyspnea NN B-Disease
, , O
stomatitis NN B-Disease
, , O
anemia NN B-Disease
, , O
and CC O
thrombocytopenia NN B-Disease
. . O
null null null-Disease
Pneumonitis NN B-Disease
, , O
probably RB O
or CC O
possibly RB O
related VBN O
, , O
mainly RB O
grade NN O
1 CD O
/ SYM O
2 CD O
, , O
occurred VBD O
in IN O
25 CD O
% NN O
. . O
null null null-Disease
Cox NN O
regression NN O
analysis NN O
of IN O
IHC NNP O
scores NNS O
found VBD O
that IN O
only RB O
phospho NN O
AKT NNP O
( , O
pAKT NNP O
) -RRB- O
was VBD O
a DT O
significant JJ O
independent JJ O
predictor NN O
of IN O
worse JJR O
PFS NNP O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
RAD001 NNP O
10 CD O
mg NN O
/ SYM O
day NN O
was VBD O
well RB O
tolerated VBN O
, , O
showing VBG O
modest JJ O
clinical JJ O
activity NN O
in IN O
pretreated VBN O
NSCLC NNP B-Disease
. . O
null null null-Disease
Evaluation NN O
of IN O
RAD001 NN O
plus CC O
standard JJ O
therapy NN O
for IN O
metastatic JJ O
NSCLC NNP B-Disease
continues VBZ O
. . O
null null null-Disease
Posttransplant NN O
anemia NN B-Disease
: : O
the DT O
role NN O
of IN O
sirolimus NN O
. . O
null null null-Disease
Posttransplant NN O
anemia NN B-Disease
is VBZ O
a DT O
common JJ O
problem NN O
that WDT O
may MD O
hinder VB O
patients NNS O
' POS O
quality NN O
of IN O
life NN O
. . O
null null null-Disease
It PRP O
occurs VBZ O
in IN O
12 CD O
to TO O
76 CD O
% NN O
of IN O
patients NNS O
, , O
and CC O
is VBZ O
most RBS O
common JJ O
in IN O
the DT O
immediate JJ O
posttransplant NN O
period NN O
. . O
null null null-Disease
A DT O
variety NN O
of IN O
factors NNS O
have VBP O
been VBN O
identified VBN O
that WDT O
increase VBP O
the DT O
risk NN O
of IN O
posttransplant NN O
anemia NN B-Disease
, , O
of IN O
which WDT O
the DT O
level NN O
of IN O
renal JJ O
function NN O
is VBZ O
most RBS O
important JJ O
. . O
null null null-Disease
Sirolimus NNP O
, , O
a DT O
mammalian JJ O
target NN O
of IN O
rapamycin NN O
inhibitor NN O
, , O
has VBZ O
been VBN O
implicated VBN O
as IN O
playing VBG O
a DT O
special JJ O
role NN O
in IN O
posttransplant NN O
anemia NN B-Disease
. . O
null null null-Disease
This DT O
review NN O
considers VBZ O
anemia NN B-Disease
associated VBN O
with IN O
sirolimus NN O
, , O
including VBG O
its PRP$ O
presentation NN O
, , O
mechanisms NNS O
, , O
and CC O
management NN O
. . O
null null null-Disease
Coronary JJ O
computerized VBN O
tomography NN O
angiography NN O
for IN O
rapid JJ O
discharge NN O
of IN O
low JJ O
- HYPH O
risk NN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Most JJS O
patients NNS O
presenting VBG O
to IN O
emergency NN O
departments NNS O
( : O
EDs NNS O
) , O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
are VBP O
admitted VBN O
for IN O
at RB O
least RBS O
12 CD O
hours NNS O
and CC O
receive VBP O
a DT O
"""" `` O
rule NN O
out RP O
acute JJ B-Disease
coronary JJ I-Disease
syndrome NN I-Disease
"""" '' O
protocol NN O
, , O
often RB O
with IN O
noninvasive JJ O
testing NN O
prior RB O
to IN O
discharge NN O
. . O
null null null-Disease
In IN O
patients NNS O
without IN O
cocaine NN O
use NN O
, , O
coronary JJ O
computerized JJ O
tomography NN O
angiography NN O
( , O
CTA NNP O
) -RRB- O
has VBZ O
been VBN O
shown VBN O
to TO O
be VB O
useful JJ O
for IN O
identifying VBG O
a DT O
group NN O
of IN O
patients NNS O
at IN O
low JJ O
risk NN O
for IN O
cardiac JJ O
events NNS O
who WP O
can MD O
be VB O
safely RB O
discharged VBN O
. . O
null null null-Disease
It PRP O
is VBZ O
unclear JJ O
whether IN O
a DT O
coronary JJ O
CTA NNP O
strategy NN O
would MD O
be VB O
efficacious JJ O
in IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
, , O
as IN O
coronary JJ B-Disease
vasospasm NN I-Disease
may MD O
account VB O
for IN O
some DT O
of IN O
the DT O
ischemia NN B-Disease
. . O
null null null-Disease
We PRP O
studied VBD O
whether IN O
a DT O
negative JJ O
coronary JJ O
CTA NN O
in IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
could MD O
identify VB O
a DT O
subset NN O
safe JJ O
for IN O
discharge NN O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
prospectively RB O
evaluated VBD O
the DT O
safety NN O
of IN O
coronary JJ O
CTA NN O
for IN O
low JJ O
- HYPH O
risk NN O
patients NNS O
who WP O
presented VBD O
to IN O
the DT O
ED NNP O
with IN O
cocaineassociated JJ O
chest NN B-Disease
pain NN I-Disease
( , O
self NN O
- HYPH O
reported VBN O
or CC O
positive JJ O
urine NN O
test NN O
) -RRB- O
. . O
null null null-Disease
Consecutive JJ O
patients NNS O
received VBD O
either CC O
immediate JJ O
coronary JJ O
CTA NN O
in IN O
the DT O
ED NNP O
( , O
without IN O
serial JJ O
markers NNS O
) -RRB- O
or CC O
underwent VBD O
coronary JJ O
CTA NN O
after IN O
a DT O
brief JJ O
observation NN O
period NN O
with IN O
serial JJ O
cardiac JJ O
marker NN O
measurements NNS O
. . O
null null null-Disease
Patients NNS O
with IN O
negative JJ O
coronary JJ O
CTA NNP O
( , O
maximal JJ O
stenosis NN B-Disease
less JJR O
than IN O
50 CD O
% NN O
) -RRB- O
were VBD O
discharged VBN O
. . O
null null null-Disease
The DT O
main JJ O
outcome NN O
was VBD O
30 CD O
- HYPH O
day NN O
cardiovascular JJ O
death NN O
or CC O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
A DT O
total NN O
of IN O
59 CD O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
chest NN B-Disease
pain NN I-Disease
were VBD O
evaluated VBN O
. . O
null null null-Disease
Patients NNS O
had VBD O
a DT O
mean JJ O
age NN O
of IN O
45 CD O
. . O
6 CD O
+ CD O
/ SYM O
- HYPH O
6 CD O
. . O
6 CD O
yrs NNS O
and CC O
were VBD O
86 CD O
% NN O
black NN O
, , O
66 CD O
% NN O
male JJ O
. . O
null null null-Disease
Seventy CD O
- HYPH O
nine CD O
percent NN O
had VBD O
a DT O
normal JJ O
or CC O
nonspecific JJ O
ECG NN O
and CC O
85 CD O
% NN O
had VBD O
a DT O
TIMI NNP O
score NN O
< SYM O
2 CD O
. . O
null null null-Disease
Twenty CD O
patients NNS O
received VBD O
coronary JJ O
CTA NNP O
immediately RB O
in IN O
the DT O
ED NNP O
, , O
18 CD O
of IN O
whom WP O
were VBD O
discharged VBN O
following VBG O
CTA NNP O
( : O
90 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Thirty CD O
- HYPH O
nine CD O
received VBD O
coronary JJ O
CTA NN O
after IN O
a DT O
brief JJ O
observation NN O
period NN O
, , O
with IN O
37 CD O
discharged VBN O
home NN O
following VBG O
CTA NNP O
( : O
95 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Six CD O
patients NNS O
had VBD O
coronary JJ B-Disease
stenosis NN I-Disease
> : O
or CC O
= SYM O
50 CD O
% NN O
. . O
null null null-Disease
During IN O
the DT O
30 CD O
- HYPH O
day NN O
follow NN O
- HYPH O
up NN O
period NN O
, , O
no DT O
patients NNS O
died VBD O
of IN O
a DT O
cardiovascular JJ O
event NN O
( : O
0 CD O
% NN O
; : O
95 CD O
% NN O
CI NN O
, , O
0 CD O
- SYM O
6 CD O
. . O
1 CD O
% NN O
) -RRB- O
and CC O
no DT O
patient NN O
sustained VBD O
a DT O
nonfatal JJ O
myocardial JJ B-Disease
infarction NN I-Disease
( : O
0 CD O
% NN O
; : O
95 CD O
% NN O
CI NN O
, , O
0 CD O
- SYM O
6 CD O
. . O
1 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Although IN O
cocaine NN O
- HYPH O
associated VBN O
myocardial JJ B-Disease
ischemia NN I-Disease
can MD O
result VB O
from IN O
coronary JJ O
vasoconstriction NN O
, , O
patients NNS O
with IN O
cocaine NN O
associated VBN O
chest NN B-Disease
pain NN I-Disease
, , O
a DT O
non JJ O
- HYPH O
ischemic JJ B-Disease
ECG NNP O
, , O
and CC O
a DT O
TIMI NNP O
risk NN O
score NN O
< IN O
2 CD O
may MD O
be VB O
safely RB O
discharged VBN O
from IN O
the DT O
ED NN O
after IN O
a DT O
negative JJ O
coronary JJ O
CTA NN O
with IN O
a DT O
low JJ O
risk NN O
of IN O
30 CD O
- HYPH O
day NN O
adverse JJ O
events NNS O
. . O
null null null-Disease
Bilateral JJ O
haemorrhagic JJ B-Disease
infarction NN I-Disease
of IN I-Disease
the DT I-Disease
globus NN I-Disease
pallidus NN I-Disease
after IN O
cocaine NN O
and CC O
alcohol NN O
intoxication NN O
. . O
null null null-Disease
Cocaine NN O
is VBZ O
a DT O
risk NN O
factor NN O
for IN O
both CC O
ischemic JJ B-Disease
and CC I-Disease
haemorrhagic JJ I-Disease
stroke NN I-Disease
. . O
null null null-Disease
We PRP O
present VBP O
the DT O
case NN O
of IN O
a DT O
31 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
with IN O
bilateral JJ O
ischemia NN B-Disease
of IN I-Disease
the DT I-Disease
globus NN I-Disease
pallidus NN I-Disease
after IN O
excessive JJ O
alcohol NN O
and CC O
intranasal JJ O
cocaine NN O
use NN O
. . O
null null null-Disease
Drug NN O
- HYPH O
related VBN O
globus NN B-Disease
pallidus NN I-Disease
infarctions NNS I-Disease
are VBP O
most RBS O
often RB O
associated VBN O
with IN O
heroin NN O
. . O
null null null-Disease
Bilateral JJ O
basal JJ B-Disease
ganglia NN I-Disease
infarcts NNS I-Disease
after IN O
the DT O
use NN O
of IN O
cocaine NN O
, , O
without IN O
concurrent JJ O
heroin NN O
use NN O
, , O
have VBP O
never RB O
been VBN O
reported VBN O
. . O
null null null-Disease
In IN O
our PRP$ O
patient NN O
, , O
transient JJ O
cardiac JJ B-Disease
arrhythmia NN I-Disease
or CC O
respiratory JJ B-Disease
dysfunction NN I-Disease
related VBN O
to IN O
cocaine NN O
and CC O
/ SYM O
or CC O
ethanol NN O
use NN O
were VBD O
the DT O
most RBS O
likely JJ O
causes NNS O
of IN O
cerebral JJ B-Disease
hypoperfusion NN I-Disease
. . O
null null null-Disease
Late JJ O
fulminant JJ O
posterior NN B-Disease
reversible JJ I-Disease
encephalopathy NN I-Disease
syndrome NN I-Disease
after IN O
liver NN O
transplant NN O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
Posterior JJ B-Disease
leukoencephalopathy NN I-Disease
due JJ O
to IN O
calcineurin NN O
- HYPH O
inhibitor NN O
- HYPH O
related VBN O
neurotoxicity NN B-Disease
is VBZ O
a DT O
rare JJ O
but CC O
severe JJ O
complication NN O
that WDT O
results VBZ O
from IN O
treatment NN O
with IN O
immunosuppressive JJ O
agents NNS O
( , O
primarily RB O
those DT O
administered VBN O
after IN O
a DT O
liver NN O
or CC O
kidney NN O
transplant NN O
) -RRB- O
. . O
null null null-Disease
The DT O
pathophysiologic JJ O
mechanisms NNS O
of IN O
that DT O
disorder NN O
remain VBP O
unknown JJ O
. . O
null null null-Disease
CASE NN O
: : O
We PRP O
report VBP O
the DT O
case NN O
of IN O
a DT O
46 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
who WP O
received VBD O
a DT O
liver NN O
transplant NN O
in IN O
our PRP$ O
center NN O
as IN O
treatment NN O
for IN O
alcoholic JJ B-Disease
cirrhosis NN I-Disease
and CC O
in IN O
whom WP O
either CC O
a DT O
fulminant JJ O
course NN O
of IN O
posterior NN B-Disease
leukoencephalopathy NN I-Disease
or CC O
posterior NN B-Disease
reversible JJ I-Disease
encephalopathy NN I-Disease
syndrome NN I-Disease
developed VBD O
110 CD O
days NNS O
after IN O
transplant NN O
. . O
null null null-Disease
After IN O
an DT O
initially RB O
uneventful JJ O
course NN O
after IN O
the DT O
transplant NN O
, , O
the DT O
patient NN O
rapidly RB O
fell VBD O
into IN O
deep JJ O
coma NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Cerebral JJ O
MRI NN O
scan NN O
showed VBD O
typical JJ O
signs NNS O
of IN O
enhancement NN O
in IN O
the DT O
pontine JJ O
and CC O
posterior JJ O
regions NNS O
. . O
null null null-Disease
Switching VBG O
the DT O
immunosuppressive JJ O
regimen NN O
from IN O
tacrolimus NN O
to IN O
cyclosporine NN O
did VBD O
not RB O
improve VB O
the DT O
clinical JJ O
situation NN O
. . O
null null null-Disease
The DT O
termination NN O
of IN O
treatment NN O
with IN O
any DT O
calcineurin NN O
inhibitor NN O
resulted VBD O
in IN O
a DT O
complete JJ O
resolution NN O
of IN O
that DT O
complication NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Posterior JJ B-Disease
reversible JJ I-Disease
encephalopathy NN I-Disease
syndrome NN I-Disease
after IN O
liver NN O
transplant NN O
is VBZ O
rare JJ O
. . O
null null null-Disease
We PRP O
recommend VBP O
a DT O
complete JJ O
cessation NN O
of IN O
any DT O
calcineurin NN O
inhibitor NN O
rather RB O
than IN O
a DT O
dose NN O
reduction NN O
. . O
null null null-Disease
Prolonged VBN O
hypothermia NN B-Disease
as IN O
a DT O
bridge NN O
to IN O
recovery NN O
for IN O
cerebral JJ B-Disease
edema NN I-Disease
and CC O
intracranial JJ B-Disease
hypertension NN I-Disease
associated VBN O
with IN O
fulminant JJ B-Disease
hepatic JJ I-Disease
failure NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
To TO O
review VB O
evidence NN O
- HYPH O
based VBN O
treatment NN O
options NNS O
in IN O
patients NNS O
with IN O
cerebral JJ B-Disease
edema NN I-Disease
complicating VBG O
fulminant JJ B-Disease
hepatic JJ I-Disease
failure NN I-Disease
( : O
FHF NNP B-Disease
) -RRB- O
and CC O
discuss VB O
the DT O
potential JJ O
applications NNS O
of IN O
hypothermia NN B-Disease
. . O
null null null-Disease
METHOD NN O
: : O
Case NN O
- HYPH O
based VBN O
observations NNS O
from IN O
a DT O
medical JJ O
intensive JJ O
care NN O
unit NN O
( : O
MICU NNP O
) -RRB- O
in IN O
a DT O
tertiary JJ O
care NN O
facility NN O
in IN O
a DT O
27 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
female NN O
with IN O
FHF NNP B-Disease
from IN O
acetaminophen NN O
and CC O
resultant JJ O
cerebral JJ B-Disease
edema NN I-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
Our PRP$ O
patient NN O
was VBD O
admitted VBN O
to IN O
the DT O
MICU NNP O
after IN O
being VBG O
found VBN O
unresponsive JJ O
with IN O
presumed VBN O
toxicity NN B-Disease
from IN O
acetaminophen NN O
which WDT O
was VBD O
ingested VBN O
over IN O
a DT O
2 CD O
- HYPH O
day NN O
period NN O
. . O
null null null-Disease
The DT O
patient NN O
had VBD O
depressed VBN O
of IN O
mental JJ O
status NN O
lasting VBG O
at IN O
least JJS O
24 CD O
h NN O
prior RB O
to IN O
admission NN O
. . O
null null null-Disease
Initial JJ O
evaluation NN O
confirmed VBD O
FHF NNP B-Disease
from IN O
acetaminophen NN O
and CC O
cerebral JJ B-Disease
edema NN I-Disease
. . O
null null null-Disease
The DT O
patient NN O
was VBD O
treated VBN O
with IN O
hyperosmolar JJ O
therapy NN O
, , O
hyperventilation NN B-Disease
, , O
sedation NN O
, , O
and CC O
chemical NN O
paralysis NN B-Disease
. . O
null null null-Disease
Her PRP$ O
intracranial JJ O
pressure NN O
remained VBD O
elevated VBN O
despite IN O
maximal JJ O
medical JJ O
therapy NN O
. . O
null null null-Disease
We PRP O
then RB O
initiated VBD O
therapeutic JJ O
hypothermia NN B-Disease
which WDT O
was VBD O
continued VBN O
for IN O
5 CD O
days NNS O
. . O
null null null-Disease
At IN O
re JJ O
- HYPH O
warming VBG O
, , O
patient NN O
had VBD O
resolution NN O
of IN O
her PRP$ O
cerebral JJ B-Disease
edema NN I-Disease
and CC O
intracranial JJ B-Disease
hypertension NN I-Disease
. . O
null null null-Disease
At IN O
discharge NN O
, , O
she PRP O
had VBD O
complete JJ O
recovery NN O
of IN O
neurological JJ O
and CC O
hepatic JJ O
functions NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
In IN O
patients NNS O
with IN O
FHF NNP B-Disease
and CC O
cerebral JJ B-Disease
edema NN I-Disease
from IN O
acetaminophen NN O
overdose NN B-Disease
, , O
prolonged VBN O
therapeutic JJ O
hypothermia NN B-Disease
could MD O
potentially RB O
be VB O
used VBN O
as IN O
a DT O
life NN O
saving VBG O
therapy NN O
and CC O
a DT O
bridge NN O
to IN O
hepatic JJ O
and CC O
neurological JJ O
recovery NN O
. . O
null null null-Disease
A DT O
clinical JJ O
trial NN O
of IN O
hypothermia NN B-Disease
in IN O
patients NNS O
with IN O
this DT O
condition NN O
is VBZ O
warranted VBN O
. . O
null null null-Disease
Binasal JJ B-Disease
visual JJ I-Disease
field NN I-Disease
defects NNS I-Disease
are VBP O
not RB O
specific JJ O
to IN O
vigabatrin NN O
. . O
null null null-Disease
This DT O
study NN O
investigated VBD O
the DT O
visual JJ B-Disease
defects NNS I-Disease
associated VBN O
with IN O
the DT O
antiepileptic JJ O
drug NN O
vigabatrin NN O
( , O
VGB NNP O
) -RRB- O
. . O
null null null-Disease
Two CD O
hundred CD O
four CD O
people NNS O
with IN O
epilepsy NN B-Disease
were VBD O
grouped VBN O
on IN O
the DT O
basis NN O
of IN O
antiepileptic JJ O
drug NN O
therapy NN O
( , O
current JJ O
, , O
previous JJ O
, , O
or CC O
no DT O
exposure NN O
to IN O
VGB NNP O
) -RRB- O
. . O
null null null-Disease
Groups NNS O
were VBD O
matched VBN O
with IN O
respect NN O
to IN O
age NN O
, , O
gender NN O
, , O
and CC O
seizure NN B-Disease
frequency NN O
. . O
null null null-Disease
All DT O
patients NNS O
underwent VBD O
objective JJ O
assessment NN O
of IN O
electrophysiological JJ O
function NN O
( , O
wide JJ O
- HYPH O
field NN O
multifocal JJ O
electroretinography NN O
) -RRB- O
and CC O
conventional JJ O
visual JJ O
field NN O
testing NN O
( , O
static JJ O
perimetry NN O
) -RRB- O
. . O
null null null-Disease
Bilateral JJ O
visual JJ O
field NN O
constriction NN O
was VBD O
observed VBN O
in IN O
59 CD O
% NN O
of IN O
patients NNS O
currently RB O
taking VBG O
VGB NNP O
, , O
43 CD O
% NN O
of IN O
patients NNS O
who WP O
previously RB O
took VBD O
VGB NNP O
, , O
and CC O
24 CD O
% NN O
of IN O
patients NNS O
with IN O
no DT O
exposure NN O
to IN O
VGB NNP O
. . O
null null null-Disease
Assessment NN O
of IN O
retinal JJ O
function NN O
revealed VBD O
abnormal JJ O
responses NNS O
in IN O
48 CD O
% NN O
of IN O
current JJ O
VGB NNP O
users NNS O
and CC O
22 CD O
% NN O
of IN O
prior JJ O
VGB NNP O
users NNS O
, , O
but CC O
in IN O
none NN O
of IN O
the DT O
patients NNS O
without IN O
previous JJ O
exposure NN O
to IN O
VGB NNP O
. . O
null null null-Disease
Bilateral JJ B-Disease
visual JJ I-Disease
field NN I-Disease
abnormalities NNS I-Disease
are VBP O
common JJ O
in IN O
the DT O
treated VBN O
epilepsy NN B-Disease
population NN O
, , O
irrespective JJ O
of IN O
drug NN O
history NN O
. . O
null null null-Disease
Assessment NN O
by IN O
conventional JJ O
static JJ O
perimetry NN O
may MD O
neither CC O
be VB O
sufficiently RB O
sensitive JJ O
nor CC O
specific JJ O
to TO O
reliably RB O
identify VB O
retinal JJ B-Disease
toxicity NN I-Disease
associated VBN O
with IN O
VGB NNP O
. . O
null null null-Disease
Smoking NN O
of IN O
crack NN O
cocaine NN O
as IN O
a DT O
risk NN O
factor NN O
for IN O
HIV NNP B-Disease
infection NN I-Disease
among IN O
people NNS O
who WP O
use VBP O
injection NN O
drugs NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Little JJ O
is VBZ O
known VBN O
about IN O
the DT O
possible JJ O
role NN O
that WDT O
smoking NN O
crack NN O
cocaine NN O
has VBZ O
on IN O
the DT O
incidence NN O
of IN O
HIV NNP B-Disease
infection NN I-Disease
. . O
null null null-Disease
Given VBN O
the DT O
increasing VBG O
use NN O
of IN O
crack NN O
cocaine NN O
, , O
we PRP O
sought VBD O
to TO O
examine VB O
whether IN O
use NN O
of IN O
this DT O
illicit JJ O
drug NN O
has VBZ O
become VBN O
a DT O
risk NN O
factor NN O
for IN O
HIV NNP B-Disease
infection NN I-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
included VBD O
data NNS O
from IN O
people NNS O
participating VBG O
in IN O
the DT O
Vancouver NNP O
Injection NNP O
Drug NNP O
Users NNPS O
Study NNP O
who WP O
reported VBD O
injecting VBG O
illicit JJ O
drugs NNS O
at IN O
least JJS O
once RB O
in IN O
the DT O
month NN O
before IN O
enrolment NN O
, , O
lived VBD O
in IN O
the DT O
greater JJR O
Vancouver NNP O
area NN O
, , O
were VBD O
HIV NNP O
- HYPH O
negative JJ O
at IN O
enrolment NN O
and CC O
completed VBD O
at RB O
least RBS O
1 CD O
follow NN O
- HYPH O
up NN O
study NN O
visit NN O
. . O
null null null-Disease
To TO O
determine VB O
whether IN O
the DT O
risk NN O
of IN O
HIV NNP B-Disease
seroconversion NN I-Disease
among IN O
daily JJ O
smokers NNS O
of IN O
crack NN O
cocaine NN O
changed VBD O
over IN O
time NN O
, , O
we PRP O
used VBD O
Cox NNP O
proportional JJ O
hazards NNS O
regression NN O
and CC O
divided VBD O
the DT O
study NN O
into IN O
3 CD O
periods NNS O
: : O
May NNP O
1 CD O
, , O
1996 CD O
- SYM O
Nov NNP O
. . O
null null null-Disease
30 CD O
, , O
1999 CD O
( , O
period NN O
1 CD O
) -RRB- O
, , O
Dec NNP O
. . O
null null null-Disease
1 CD O
, , O
1999 CD O
- SYM O
Nov NNP O
. . O
null null null-Disease
30 CD O
, , O
2002 CD O
( SYM O
period NN O
2 CD O
) -RRB- O
, , O
and CC O
Dec NNP O
. . O
null null null-Disease
1 CD O
, , O
2002 CD O
- : O
Dec NNP O
. . O
null null null-Disease
30 CD O
, , O
2005 CD O
( : O
period NN O
3 CD O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
Overall RB O
, , O
1048 CD O
eligible JJ O
injection NN O
drug NN O
users NNS O
were VBD O
included VBN O
in IN O
our PRP$ O
study NN O
. . O
null null null-Disease
Of IN O
these DT O
, , O
137 CD O
acquired VBN O
HIV NNP B-Disease
infection NN I-Disease
during IN O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
The DT O
mean JJ O
proportion NN O
of IN O
participants NNS O
who WP O
reported VBD O
daily JJ O
smoking NN O
of IN O
crack NN O
cocaine NN O
increased VBD O
from IN O
11 CD O
. . O
6 CD O
% NN O
in IN O
period NN O
1 CD O
to IN O
39 CD O
. . O
7 CD O
% NN O
in IN O
period NN O
3 CD O
. . O
null null null-Disease
After IN O
adjusting VBG O
for IN O
potential JJ O
confounders NNS O
, , O
we PRP O
found VBD O
that IN O
the DT O
risk NN O
of IN O
HIV NNP B-Disease
seroconversion NN I-Disease
among IN O
participants NNS O
who WP O
were VBD O
daily JJ O
smokers NNS O
of IN O
crack NN O
cocaine NN O
increased VBD O
over IN O
time NN O
( : O
period NN O
1 CD O
: : O
hazard NN O
ratio NN O
[ -LRB- O
HR NN O
] -RRB- O
1 CD O
. . O
03 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
[ -LRB- O
CI NN O
] -RRB- O
0 CD O
. . O
57 CD O
- SYM O
1 CD O
. . O
85 CD O
; : O
period NN O
2 CD O
: : O
HR NN O
1 CD O
. . O
68 CD O
, , O
95 CD O
% NN O
CI NN O
1 CD O
. . O
01 CD O
- SYM O
2 CD O
. . O
80 CD O
; : O
and CC O
period NN O
3 CD O
: : O
HR NN O
2 CD O
. . O
74 CD O
, , O
95 CD O
% NN O
CI NN O
1 CD O
. . O
06 CD O
- SYM O
7 CD O
. . O
11 CD O
) -RRB- O
. . O
null null null-Disease
INTERPRETATION NN O
: : O
Smoking NN O
of IN O
crack NN O
cocaine NN O
was VBD O
found VBN O
to TO O
be VB O
an DT O
independent JJ O
risk NN O
factor NN O
for IN O
HIV NNP B-Disease
seroconversion NN I-Disease
among IN O
people NNS O
who WP O
were VBD O
injection NN O
drug NN O
users NNS O
. . O
null null null-Disease
This DT O
finding NN O
points VBZ O
to IN O
the DT O
urgent JJ O
need NN O
for IN O
evidence NN O
- HYPH O
based VBN O
public JJ O
health NN O
initiatives NNS O
targeted VBN O
at IN O
people NNS O
who WP O
smoke VBP O
crack NN O
cocaine NN O
. . O
null null null-Disease
Fluoxetine NN O
improves VBZ O
the DT O
memory NN B-Disease
deficits NNS I-Disease
caused VBN O
by IN O
the DT O
chemotherapy NN O
agent NN O
5 CD O
- HYPH O
fluorouracil NN O
. . O
null null null-Disease
Cancer NN B-Disease
patients NNS O
who WP O
have VBP O
been VBN O
treated VBN O
with IN O
systemic JJ O
adjuvant NN O
chemotherapy NN O
have VBP O
described VBN O
experiencing VBG O
deteriorations NNS O
in IN O
cognition NN O
. . O
null null null-Disease
A DT O
widely RB O
used VBN O
chemotherapeutic JJ O
agent NN O
, , O
5 CD O
- HYPH O
fluorouracil NN O
( HYPH O
5 CD O
- HYPH O
FU NN O
) -RRB- O
, , O
readily RB O
crosses VBZ O
the DT O
blood NN O
- HYPH O
brain NN O
barrier NN O
and CC O
so RB O
could MD O
have VB O
a DT O
direct JJ O
effect NN O
on IN O
brain NN O
function NN O
. . O
null null null-Disease
In IN O
particular JJ O
this DT O
anti JJ O
mitotic JJ O
drug NN O
could MD O
reduce VB O
cell NN O
proliferation NN O
in IN O
the DT O
neurogenic JJ O
regions NNS O
of IN O
the DT O
adult NN O
brain NN O
. . O
null null null-Disease
In IN O
contrast NN O
reports NNS O
indicate VBP O
that IN O
hippocampal JJ O
dependent JJ O
neurogenesis NN O
and CC O
cognition NN O
are VBP O
enhanced VBN O
by IN O
the DT O
SSRI NNP O
antidepressant JJ O
Fluoxetine NNP O
. . O
null null null-Disease
In IN O
this DT O
investigation NN O
the DT O
behavioural JJ O
effects NNS O
of IN O
chronic JJ O
( , O
two CD O
week NN O
) , O
treatment NN O
with IN O
5 CD O
- HYPH O
FU NN O
and CC O
( : O
three CD O
weeks NNS O
) -RRB- O
with IN O
Fluoxetine NNP O
either CC O
separately RB O
or CC O
in IN O
combination NN O
with IN O
5 CD O
- HYPH O
FU NNP O
were VBD O
tested VBN O
on IN O
adult NN O
Lister NNP O
hooded JJ O
rats NNS O
. . O
null null null-Disease
Behavioural JJ O
effects NNS O
were VBD O
tested VBN O
using VBG O
a DT O
context NN O
dependent JJ O
conditioned VBN O
emotional JJ O
response NN O
test NN O
( -LRB- O
CER NNP O
) -RRB- O
which WDT O
showed VBD O
that IN O
animals NNS O
treated VBN O
with IN O
5 CD O
- HYPH O
FU NNP O
had VBD O
a DT O
significant JJ O
reduction NN O
in IN O
freezing JJ O
time NN O
compared VBN O
to IN O
controls NNS O
. . O
null null null-Disease
A DT O
separate JJ O
group NN O
of IN O
animals NNS O
was VBD O
tested VBN O
using VBG O
a DT O
hippocampal JJ O
dependent JJ O
spatial JJ O
working NN O
memory NN O
test NN O
, , O
the DT O
object NN O
location NN O
recognition NN O
test NN O
( -LRB- O
OLR NNP O
) -RRB- O
. . O
null null null-Disease
Animals NNS O
treated VBN O
only RB O
with IN O
5 CD O
- HYPH O
FU NNP O
showed VBD O
significant JJ O
deficits NNS O
in IN O
their PRP$ O
ability NN O
to TO O
carry VB O
out RP O
the DT O
OLR NNP O
task NN O
but CC O
co VB O
administration NN O
of IN O
Fluoxetine NNP O
improved VBD O
their PRP$ O
performance NN O
. . O
null null null-Disease
5 CD O
- HYPH O
FU NN O
chemotherapy NN O
caused VBD O
a DT O
significant JJ O
reduction NN O
in IN O
the DT O
number NN O
of IN O
proliferating VBG O
cells NNS O
in IN O
the DT O
sub NN O
granular JJ O
zone NN O
of IN O
the DT O
dentate NN O
gyrus NN O
compared VBN O
to IN O
controls NNS O
. . O
null null null-Disease
This DT O
reduction NN O
was VBD O
eliminated VBN O
when WRB O
Fluoxetine NNP O
was VBD O
co NN O
administered VBN O
with IN O
5 CD O
- HYPH O
FU NNP O
. . O
null null null-Disease
Fluoxetine NN O
on IN O
its PRP$ O
own JJ O
had VBD O
no DT O
effect NN O
on IN O
proliferating VBG O
cell NN O
number NN O
or CC O
behaviour NN O
. . O
null null null-Disease
These DT O
findings NNS O
suggest VBP O
that IN O
5 CD O
- HYPH O
FU NNP O
can MD O
negatively RB O
affect VB O
both CC O
cell NN O
proliferation NN O
and CC O
hippocampal JJ O
dependent JJ O
working VBG O
memory NN O
and CC O
that IN O
these DT O
deficits NNS O
can MD O
be VB O
reversed VBN O
by IN O
the DT O
simultaneous JJ O
administration NN O
of IN O
the DT O
antidepressant JJ O
Fluoxetine NNP O
. . O
null null null-Disease
Liver NN O
- HYPH O
specific JJ O
ablation NN O
of IN O
integrin NN O
- HYPH O
linked VBN O
kinase NN O
in IN O
mice NNS O
results VBZ O
in IN O
enhanced VBN O
and CC O
prolonged VBN O
cell NN O
proliferation NN O
and CC O
hepatomegaly NN B-Disease
after IN O
phenobarbital JJ O
administration NN O
. . O
null null null-Disease
We PRP O
have VBP O
recently RB O
demonstrated VBN O
that IN O
disruption NN O
of IN O
extracellular JJ O
matrix NN O
( , O
ECM NNP O
) -RRB- O
/ SYM O
integrin NN O
signaling NN O
via IN O
elimination NN O
of IN O
integrin NN O
- HYPH O
linked VBN O
kinase NN O
( , O
ILK NNP O
) -RRB- O
in IN O
hepatocytes NNS O
interferes VBZ O
with IN O
signals NNS O
leading VBG O
to IN O
termination NN O
of IN O
liver NN O
regeneration NN O
. . O
null null null-Disease
This DT O
study NN O
investigates VBZ O
the DT O
role NN O
of IN O
ILK NNP O
in IN O
liver NN O
enlargement NN O
induced VBN O
by IN O
phenobarbital NN O
( , O
PB NN O
) -RRB- O
. . O
null null null-Disease
Wild JJ O
- HYPH O
type NN O
( , O
WT NNP O
) -RRB- O
and CC O
ILK NN O
: : O
liver NN O
- HYPH O
/ SYM O
- HYPH O
mice NNS O
were VBD O
given VBN O
PB NN O
( : O
0 CD O
. . O
1 CD O
% NN O
in IN O
drinking NN O
water NN O
) -RRB- O
for IN O
10 CD O
days NNS O
. . O
null null null-Disease
Livers NNS O
were VBD O
harvested VBN O
on IN O
2 CD O
, , O
5 CD O
, , O
and CC O
10 CD O
days NNS O
during IN O
PB NNP O
administration NN O
. . O
null null null-Disease
In IN O
the DT O
hepatocyte NN O
- HYPH O
specific JJ O
ILK NN O
/ SYM O
liver NN O
- HYPH O
/ SYM O
- HYPH O
mice NNS O
, , O
the DT O
liver NN O
: : O
body NN O
weight NN O
ratio NN O
was VBD O
more JJR O
than IN O
double JJ O
as IN O
compared VBN O
to IN O
0 CD O
h NN O
at IN O
day NN O
2 CD O
( SYM O
2 CD O
. . O
5 CD O
times NNS O
) -RRB- O
, , O
while IN O
at IN O
days NNS O
5 CD O
and CC O
10 CD O
, , O
it PRP O
was VBD O
enlarged VBN O
three CD O
times NNS O
. . O
null null null-Disease
In IN O
the DT O
WT NNP O
mice NNS O
, , O
the DT O
increase NN O
was VBD O
as IN O
expected VBN O
from IN O
previous JJ O
literature NN O
( , O
1 CD O
. . O
8 CD O
times NNS O
) -RRB- O
and CC O
seems VBZ O
to TO O
have VB O
leveled VBN O
off RP O
after IN O
day NN O
2 CD O
. . O
null null null-Disease
There EX O
were VBD O
slightly RB O
increased VBN O
proliferating VBG O
cell NN O
nuclear JJ O
antigen NN O
- HYPH O
positive JJ O
cells NNS O
in IN O
the DT O
ILK NNP O
/ SYM O
liver NN O
- HYPH O
/ SYM O
- HYPH O
animals NNS O
at IN O
day NN O
2 CD O
as IN O
compared VBN O
to IN O
WT NNP O
after IN O
PB NN O
administration NN O
. . O
null null null-Disease
In IN O
the DT O
WT NNP O
animals NNS O
, , O
the DT O
proliferative JJ O
response NN O
had VBD O
come VBN O
back RB O
to IN O
normal JJ O
by IN O
days NNS O
5 CD O
and CC O
10 CD O
. . O
null null null-Disease
Hepatocytes NNS O
of IN O
the DT O
ILK NNP O
/ SYM O
liver NN O
- HYPH O
/ SYM O
- HYPH O
mice NNS O
continued VBD O
to TO O
proliferate VB O
up IN O
until IN O
day NN O
10 CD O
. . O
null null null-Disease
ILK NNP O
/ SYM O
liver NN O
- HYPH O
/ SYM O
- HYPH O
mice NNS O
also RB O
showed VBD O
increased VBN O
expression NN O
of IN O
key JJ O
genes NNS O
involved VBN O
in IN O
hepatocyte NN O
proliferation NN O
at IN O
different JJ O
time NN O
points NNS O
during IN O
PB NNP O
administration NN O
. . O
null null null-Disease
In IN O
summary NN O
, , O
ECM NNP O
proteins NNS O
communicate VBP O
with IN O
the DT O
signaling VBG O
machinery NN O
of IN O
dividing VBG O
cells NNS O
via IN O
ILK NNP O
to TO O
regulate VB O
hepatocyte NN O
proliferation NN O
and CC O
termination NN O
of IN O
the DT O
proliferative JJ O
response NN O
. . O
null null null-Disease
Lack NN O
of IN O
ILK NNP O
in IN O
the DT O
hepatocytes NNS O
imparts VBZ O
prolonged VBN O
proliferative JJ O
response NN O
not RB O
only RB O
to IN O
stimuli NN O
related VBN O
to IN O
liver NN O
regeneration NN O
but CC O
also RB O
to IN O
xenobiotic JJ O
chemical NN O
mitogens NNS O
, , O
such JJ O
as IN O
PB NN O
. . O
null null null-Disease
Decreased VBN O
Expression NNP O
of IN O
Na NNP O
/ SYM O
K NNP O
- HYPH O
ATPase NNP O
, , O
NHE3 NNP O
, , O
NBC1 NNP O
, , O
AQP1 NNP O
and CC O
OAT NN O
in IN O
Gentamicin NNP O
- HYPH O
induced VBN O
Nephropathy NNP B-Disease
. . O
null null null-Disease
The DT O
present JJ O
study NN O
was VBD O
aimed VBN O
to TO O
determine VB O
whether IN O
there EX O
is VBZ O
an DT O
altered VBN O
regulation NN O
of IN O
tubular JJ O
transporters NNS O
in IN O
gentamicin NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
. . O
null null null-Disease
Sprague NNP O
- HYPH O
Dawley NNP O
male NN O
rats NNS O
( : O
200 CD O
~ SYM O
250 CD O
g NNS O
) -RRB- O
were VBD O
subcutaneously RB O
injected VBN O
with IN O
gentamicin NN O
( , O
100 CD O
mg NNS O
/ SYM O
kg NNS O
per IN O
day NN O
) -RRB- O
for IN O
7 CD O
days NNS O
, , O
and CC O
the DT O
expression NN O
of IN O
tubular JJ O
transporters NNS O
was VBD O
determined VBN O
by IN O
immunoblotting NN O
and CC O
immunohistochemistry NN O
. . O
null null null-Disease
The DT O
mRNA NN O
and CC O
protein NN O
expression NN O
of IN O
OAT NNP O
was VBD O
also RB O
determined VBN O
. . O
null null null-Disease
Gentamicin NN O
- HYPH O
treated VBN O
rats NNS O
exhibited VBD O
significantly RB O
decreased VBN O
creatinine NN O
clearance NN O
along IN O
with IN O
increased VBN O
plasma NN O
creatinine NN O
levels NNS O
. . O
null null null-Disease
Accordingly RB O
, , O
the DT O
fractional JJ O
excretion NN O
of IN O
sodium NN O
increased VBD O
. . O
null null null-Disease
Urine NN O
volume NN O
was VBD O
increased VBN O
, , O
while IN O
urine NN O
osmolality NN O
and CC O
free JJ O
water NN O
reabsorption NN O
were VBD O
decreased VBN O
. . O
null null null-Disease
Immunoblotting NN O
and CC O
immunohistochemistry NN O
revealed VBD O
decreased VBN O
expression NN O
of IN O
Na NNP O
( , O
+ CC O
) NFP O
/ SYM O
K NNP O
( , O
+ CC O
) -RRB- O
- : O
ATPase NNP O
, , O
NHE3 NNP O
, , O
NBC1 NNP O
, , O
and CC O
AQP1 NN O
in IN O
the DT O
kidney NN O
of IN O
gentamicin NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
The DT O
expression NN O
of IN O
OAT1 NNP O
and CC O
OAT3 NNP O
was VBD O
also RB O
decreased VBN O
. . O
null null null-Disease
Gentamicin NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
may MD O
at IN O
least JJS O
in IN O
part NN O
be VB O
causally RB O
related VBN O
with IN O
a DT O
decreased VBN O
expression NN O
of IN O
Na NNP O
( , O
+ CC O
) NFP O
/ SYM O
K NN O
( , O
+ SYM O
) NFP O
- HYPH O
ATPase NN O
, , O
NHE3 NNP O
, , O
NBC1 NNP O
, , O
AQP1 NNP O
and CC O
OAT NN O
. . O
null null null-Disease
Acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
after IN O
high JJ O
- HYPH O
dose NN O
methotrexate NN O
therapy NN O
in IN O
a DT O
patient NN O
with IN O
ileostomy NN O
. . O
null null null-Disease
High JJ O
- HYPH O
dose NN O
methotrexate NN O
( -LRB- O
HD NN O
- HYPH O
MTX NNP O
) -RRB- O
is VBZ O
an DT O
important JJ O
treatment NN O
for IN O
Burkitt NNP B-Disease
lymphoma NN I-Disease
, , O
but CC O
can MD O
cause VB O
hepatic JJ B-Disease
and CC I-Disease
renal JJ I-Disease
toxicity NN I-Disease
when WRB O
its PRP$ O
clearance NN O
is VBZ O
delayed VBN O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
after IN O
HD NN O
- HYPH O
MTX NN O
therapy NN O
in IN O
a DT O
patient NN O
with IN O
ileostomy NN O
, , O
The DT O
patient NN O
was VBD O
a DT O
3 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
boy NN O
who WP O
had VBD O
received VBN O
a DT O
living NN O
- HYPH O
related VBN O
liver NN O
transplantation NN O
for IN O
congenital JJ O
biliary JJ B-Disease
atresia NN I-Disease
. . O
null null null-Disease
At IN O
day NN O
833 CD O
after IN O
the DT O
transplantation NN O
, , O
he PRP O
was VBD O
diagnosed VBN O
with IN O
PTLD NNP B-Disease
( HYPH O
post NN B-Disease
- HYPH I-Disease
transplantation NN I-Disease
lymphoproliferative JJ I-Disease
disorder NN I-Disease
, , O
Burkitt NNP B-Disease
- HYPH I-Disease
type NN I-Disease
malignant JJ I-Disease
lymphoma NN I-Disease
) -RRB- O
. . O
null null null-Disease
During IN O
induction NN O
therapy NN O
, , O
he PRP O
suffered VBD O
ileal JJ O
perforation NN O
and CC O
ileostomy NN O
was VBD O
performed VBN O
. . O
null null null-Disease
Subsequent JJ O
HD NNP O
- HYPH O
MTX NNP O
therapy NN O
caused VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
that WDT O
required VBD O
continuous JJ O
hemodialysis NN O
. . O
null null null-Disease
We PRP O
supposed VBD O
that IN O
intravascular JJ O
hypovolemia NN B-Disease
due JJ O
to IN O
substantial JJ O
drainage NN O
from IN O
the DT O
ileostoma NN O
caused VBD O
acute JJ B-Disease
prerenal JJ I-Disease
failure NN I-Disease
. . O
null null null-Disease
After IN O
recovery NN O
of IN O
his PRP$ O
renal JJ O
function NN O
, , O
we PRP O
could MD O
safely RB O
treat VB O
the DT O
patient NN O
with IN O
HD NNP O
- HYPH O
MTX NN O
therapy NN O
by IN O
controlling VBG O
drainage NN O
from IN O
ileostoma NN O
with IN O
total JJ O
parenteral JJ O
nutrition NN O
. . O
null null null-Disease
Longitudinal JJ O
association NN O
of IN O
alcohol NN O
use NN O
with IN O
HIV NNP B-Disease
disease NN I-Disease
progression NN O
and CC O
psychological JJ O
health NN O
of IN O
women NNS O
with IN O
HIV NNP O
. . O
null null null-Disease
We PRP O
evaluated VBD O
the DT O
association NN O
of IN O
alcohol NN O
consumption NN O
and CC O
depression NN B-Disease
, , O
and CC O
their PRP$ O
effects NNS O
on IN O
HIV NNP B-Disease
disease NN I-Disease
progression NN O
among IN O
women NNS O
with IN O
HIV NNP O
. . O
null null null-Disease
The DT O
study NN O
included VBD O
871 CD O
women NNS O
with IN O
HIV NNP O
who WP O
were VBD O
recruited VBN O
from IN O
1993 CD O
- SYM O
1995 CD O
in IN O
four CD O
US NNP O
cities NNS O
. . O
null null null-Disease
The DT O
participants NNS O
had VBD O
physical JJ O
examination NN O
, , O
medical JJ O
record NN O
extraction NN O
, , O
and CC O
venipuncture NN O
, , O
CD4 NN O
+ CC O
T NN O
- HYPH O
cell NN O
counts NNS O
determination NN O
, , O
measurement NN O
of IN O
depression NN B-Disease
symptoms NNS O
( , O
using VBG O
the DT O
self NN O
- HYPH O
report NN O
Center NNP O
for IN O
Epidemiological NNP O
Studies NNPS O
- HYPH O
Depression NNP B-Disease
Scale NNP O
) -RRB- O
, , O
and CC O
alcohol NN O
use NN O
assessment NN O
at IN O
enrollment NN O
, , O
and CC O
semiannually RB O
until IN O
March NNP O
2000 CD O
. . O
null null null-Disease
Multilevel JJ O
random JJ O
coefficient JJ O
ordinal JJ O
models NNS O
as RB O
well RB O
as IN O
multilevel JJ O
models NNS O
with IN O
joint JJ O
responses NNS O
were VBD O
used VBN O
in IN O
the DT O
analysis NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
significant JJ O
association NN O
between IN O
level NN O
of IN O
alcohol NN O
use NN O
and CC O
CD4 NN O
+ CC O
T NN O
- HYPH O
cell NN O
counts NNS O
. . O
null null null-Disease
When WRB O
participants NNS O
were VBD O
stratified VBN O
by IN O
antiretroviral JJ O
therapy NN O
( -LRB- O
ART NNP O
) -RRB- O
use NN O
, , O
the DT O
association NN O
between IN O
alcohol NN O
and CC O
CD4 NNP O
+ CC O
T NNP O
- HYPH O
cell NN O
did VBD O
not RB O
reach VB O
statistical JJ O
significance NN O
. . O
null null null-Disease
The DT O
association NN O
between IN O
alcohol NN O
consumption NN O
and CC O
depression NN B-Disease
was VBD O
significant JJ O
( : O
p NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Depression NN B-Disease
had VBD O
a DT O
significant JJ O
negative JJ O
effect NN O
on IN O
CD4 NNP O
+ CC O
T NN O
- HYPH O
cell NN O
counts NNS O
over IN O
time NN O
regardless RB O
of IN O
ART NN O
use NN O
. . O
null null null-Disease
Our PRP$ O
findings NNS O
suggest VBP O
that IN O
alcohol NN O
consumption NN O
has VBZ O
a DT O
direct JJ O
association NN O
with IN O
depression NN B-Disease
. . O
null null null-Disease
Moreover RB O
, , O
depression NN B-Disease
is VBZ O
associated VBN O
with IN O
HIV NNP B-Disease
disease NN I-Disease
progression NN O
. . O
null null null-Disease
Our PRP$ O
findings NNS O
have VBP O
implications NNS O
for IN O
the DT O
provision NN O
of IN O
alcohol NN O
use NN O
interventions NNS O
and CC O
psychological JJ O
resources NNS O
to TO O
improve VB O
the DT O
health NN O
of IN O
women NNS O
with IN O
HIV NNP O
. . O
null null null-Disease
Chemokine NN O
CCL2 NN O
and CC O
its PRP$ O
receptor NN O
CCR2 NN O
are VBP O
increased VBN O
in IN O
the DT O
hippocampus NN O
following VBG O
pilocarpine NN O
- HYPH O
induced VBN O
status NN B-Disease
epilepticus NN I-Disease
. . O
null null null-Disease
BACKGROUND NN O
: : O
Neuroinflammation NN B-Disease
occurs VBZ O
after IN O
seizures NNS B-Disease
and CC O
is VBZ O
implicated VBN O
in IN O
epileptogenesis NN O
. . O
null null null-Disease
CCR2 NNP O
is VBZ O
a DT O
chemokine NN O
receptor NN O
for IN O
CCL2 NNP O
and CC O
their PRP$ O
interaction NN O
mediates VBZ O
monocyte NN O
infiltration NN O
in IN O
the DT O
neuroinflammatory JJ B-Disease
cascade NN O
triggered VBN O
in IN O
different JJ O
brain NN O
pathologies NNS O
. . O
null null null-Disease
In IN O
this DT O
work NN O
CCR2 NNP O
and CC O
CCL2 NNP O
expression NN O
were VBD O
examined VBN O
following VBG O
status NN B-Disease
epilepticus NN I-Disease
( -LRB- O
SE NNP B-Disease
) -RRB- O
induced VBN O
by IN O
pilocarpine NN O
injection NN O
. . O
null null null-Disease
METHODS NNS O
: : O
SE NNP B-Disease
was VBD O
induced VBN O
by IN O
pilocarpine NN O
injection NN O
. . O
null null null-Disease
Control NN O
rats NNS O
were VBD O
injected VBN O
with IN O
saline NN O
instead RB O
of IN O
pilocarpine NN O
. . O
null null null-Disease
Five CD O
days NNS O
after IN O
SE NNP B-Disease
, , O
CCR2 NNP O
staining VBG O
in IN O
neurons NNS O
and CC O
glial NN O
cells NNS O
was VBD O
examined VBN O
using VBG O
imunohistochemical JJ O
analyses NNS O
. . O
null null null-Disease
The DT O
number NN O
of IN O
CCR2 NNP O
positive JJ O
cells NNS O
was VBD O
determined VBN O
using VBG O
stereology NN O
probes NNS O
in IN O
the DT O
hippocampus NN O
. . O
null null null-Disease
CCL2 NN O
expression NN O
in IN O
the DT O
hippocampus NN O
was VBD O
examined VBN O
by IN O
molecular JJ O
assay NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Increased VBN O
CCR2 NNP O
was VBD O
observed VBN O
in IN O
the DT O
hippocampus NN O
after IN O
SE NNP B-Disease
. . O
null null null-Disease
Seizures NNS B-Disease
also RB O
resulted VBD O
in IN O
alterations NNS O
to IN O
the DT O
cell NN O
types NNS O
expressing VBG O
CCR2 NNP O
. . O
null null null-Disease
Increased JJ O
numbers NNS O
of IN O
neurons NNS O
that WDT O
expressed VBD O
CCR2 NNP O
was VBD O
observed VBN O
following VBG O
SE NNP B-Disease
. . O
null null null-Disease
Microglial JJ O
cells NNS O
were VBD O
more RBR O
closely RB O
apposed VBN O
to IN O
the DT O
CCR2 NNP O
- HYPH O
labeled VBN O
cells NNS O
in IN O
SE NNP B-Disease
rats NNS O
. . O
null null null-Disease
In IN O
addition NN O
, , O
rats NNS O
that WDT O
experienced VBD O
SE NNP B-Disease
exhibited VBN O
CCR2 NNP O
- HYPH O
labeling VBG O
in IN O
populations NNS O
of IN O
hypertrophied JJ B-Disease
astrocytes NNS O
, , O
especially RB O
in IN O
CA1 NN O
and CC O
dentate NN O
gyrus NN O
. . O
null null null-Disease
These DT O
CCR2 NNP O
+ SYM O
astroctytes NNS O
were VBD O
not RB O
observed VBN O
in IN O
control NN O
rats NNS O
. . O
null null null-Disease
Examination NN O
of IN O
CCL2 NNP O
expression NN O
showed VBD O
that IN O
it PRP O
was VBD O
elevated VBN O
in IN O
the DT O
hippocampus NN O
following VBG O
SE NNP B-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
data NNS O
show VBP O
that IN O
CCR2 NNP O
and CC O
CCL2 NNP O
are VBP O
up RB O
- HYPH O
regulated VBN O
in IN O
the DT O
hippocampus NN O
after IN O
pilocarpine NN O
- HYPH O
induced VBN O
SE NNP B-Disease
. . O
null null null-Disease
Seizures NNS B-Disease
also RB O
result VBP O
in IN O
changes NNS O
to IN O
CCR2 NNP O
receptor NN O
expression NN O
in IN O
neurons NNS O
and CC O
astrocytes NNS O
. . O
null null null-Disease
These DT O
changes NNS O
might MD O
be VB O
involved VBN O
in IN O
detrimental JJ O
neuroplasticity NN O
and CC O
neuroinflammatory JJ B-Disease
changes NNS O
that WDT O
occur VBP O
following VBG O
seizures NNS B-Disease
. . O
null null null-Disease
Metallothionein NN O
induction NN O
reduces VBZ O
caspase NN O
- HYPH O
3 CD O
activity NN O
and CC O
TNFalpha NNP O
levels NNS O
with IN O
preservation NN O
of IN O
cognitive JJ O
function NN O
and CC O
intact JJ O
hippocampal NN O
neurons NNS O
in IN O
carmustine NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Hippocampal JJ O
integrity NN O
is VBZ O
essential JJ O
for IN O
cognitive JJ O
functions NNS O
. . O
null null null-Disease
On IN O
the DT O
other JJ O
hand NN O
, , O
induction NN O
of IN O
metallothionein NN O
( , O
MT NNP O
) -RRB- O
by IN O
ZnSO NNP O
( : O
4 CD O
) -RRB- O
and CC O
its PRP$ O
role NN O
in IN O
neuroprotection NN O
has VBZ O
been VBN O
documented VBN O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
aimed VBD O
to TO O
explore VB O
the DT O
effect NN O
of IN O
MT NNP O
induction NN O
on IN O
carmustine NN O
( , O
BCNU NNP O
) -RRB- O
- HYPH O
induced VBN O
hippocampal JJ O
cognitive JJ B-Disease
dysfunction NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
A DT O
total NN O
of IN O
60 CD O
male JJ O
Wistar NNP O
albino NN O
rats NNS O
were VBD O
randomly RB O
divided VBN O
into IN O
four CD O
groups NNS O
( , O
15 CD O
/ SYM O
group NN O
) -RRB- O
: : O
The DT O
control NN O
group NN O
injected VBN O
with IN O
single JJ O
doses NNS O
of IN O
normal JJ O
saline NN O
( : O
i LS O
. . O
c NN O
. . O
v NN O
) -RRB- O
followed VBD O
24 CD O
h NN O
later RB O
by IN O
BCNU NNP O
solvent NN O
( : O
i LS O
. . O
v NN O
) -RRB- O
. . O
null null null-Disease
The DT O
second JJ O
group NN O
administered VBN O
ZnSO NNP O
( : O
4 CD O
) CD O
( SYM O
0 CD O
. . O
1 CD O
micromol NN O
/ SYM O
10 CD O
microl NN O
normal JJ O
saline NN O
, , O
i LS O
. . O
c NN O
. . O
v NN O
, , O
once RB O
) , O
then RB O
BCNU NNP O
solvent JJ O
( : O
i PRP O
. . O
v NN O
) -RRB- O
after IN O
24 CD O
h NN O
. . O
null null null-Disease
Third JJ O
group NN O
received VBD O
BCNU NNP O
( SYM O
20 CD O
mg NN O
/ SYM O
kg NN O
, , O
i CD O
. , O
v NN O
, , O
once RB O
) SYM O
24 CD O
h NN O
after IN O
injection NN O
with IN O
normal JJ O
saline NN O
( : O
i PRP O
. . O
c NN O
. . O
v NN O
) -RRB- O
. . O
null null null-Disease
Fourth JJ O
group NN O
received VBD O
a DT O
single JJ O
dose NN O
of IN O
ZnSO NNP O
( SYM O
4 CD O
) CD O
( SYM O
0 CD O
. . O
1 CD O
micromol NN O
/ SYM O
10 CD O
microl NN O
normal JJ O
saline NN O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
) NFP O
then RB O
BCNU NNP O
( : O
20 CD O
mg NN O
/ SYM O
kg NN O
, , O
i PRP O
. . O
v NN O
, , O
once RB O
) -RRB- O
after IN O
24 CD O
h NN O
. . O
null null null-Disease
The DT O
obtained VBN O
data NNS O
revealed VBD O
that IN O
BCNU NNP O
administration NN O
resulted VBD O
in IN O
deterioration NN B-Disease
of IN I-Disease
learning NN I-Disease
and CC I-Disease
short JJ I-Disease
- HYPH I-Disease
term NN I-Disease
memory NN I-Disease
( -LRB- O
STM NNP O
) -RRB- O
, , O
as IN O
measured VBN O
by IN O
using VBG O
radial JJ O
arm NN O
water NN O
maze NN O
, , O
accompanied VBN O
with IN O
decreased VBN O
hippocampal JJ O
glutathione NN O
reductase NN O
( , O
GR NN O
) -RRB- O
activity NN O
and CC O
reduced VBN O
glutathione NN O
( -LRB- O
GSH NNP O
) -RRB- O
content NN O
. . O
null null null-Disease
Also RB O
, , O
BCNU NNP O
administration NN O
increased VBD O
serum JJ O
tumor NN B-Disease
necrosis NN B-Disease
factor NN O
- HYPH O
alpha NN O
( , O
TNFalpha NNP O
) -RRB- O
, , O
hippocampal JJ O
MT NN O
and CC O
malondialdehyde NN O
( , O
MDA NNP O
) -RRB- O
contents NNS O
as RB O
well RB O
as IN O
caspase NN O
- HYPH O
3 CD O
activity NN O
in IN O
addition NN O
to IN O
histological JJ O
alterations NNS O
. . O
null null null-Disease
ZnSO NNP O
( : O
4 CD O
) -RRB- O
pretreatment NN O
counteracted VBN O
BCNU NNP O
- HYPH O
induced VBN O
inhibition NN O
of IN O
GR NN O
and CC O
depletion NN O
of IN O
GSH NNP O
and CC O
resulted VBD O
in IN O
significant JJ O
reduction NN O
in IN O
the DT O
levels NNS O
of IN O
MDA NNP O
and CC O
TNFalpha NNP O
as RB O
well RB O
as IN O
the DT O
activity NN O
of IN O
caspase NN O
- HYPH O
3 CD O
. . O
null null null-Disease
The DT O
histological JJ O
features NNS O
were VBD O
improved VBN O
in IN O
hippocampus NN O
of IN O
rats NNS O
treated VBN O
with IN O
ZnSO NNP O
( , O
4 CD O
) SYM O
+ SYM O
BCNU NNP O
compared VBN O
to IN O
only RB O
BCNU NNP O
- HYPH O
treated VBN O
animals NNS O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
MT NNP O
induction NN O
halts VBZ O
BCNU NNP O
- HYPH O
induced VBN O
hippocampal JJ O
toxicity NN B-Disease
as IN O
it PRP O
prevented VBD O
GR NNP O
inhibition NN O
and CC O
GSH NNP O
depletion NN O
and CC O
counteracted VBD O
the DT O
increased VBN O
levels NNS O
of IN O
TNFalpha NNP O
, , O
MDA NNP O
and CC O
caspase NN O
- HYPH O
3 CD O
activity NN O
with IN O
subsequent JJ O
preservation NN O
of IN O
cognition NN O
. . O
null null null-Disease
Fatal JJ O
carbamazepine NN O
induced VBD O
fulminant JJ B-Disease
eosinophilic JJ I-Disease
( , O
hypersensitivity NN B-Disease
) , O
myocarditis NN B-Disease
: : O
emphasis NN O
on IN O
anatomical JJ O
and CC O
histological JJ O
characteristics NNS O
, , O
mechanisms NNS O
and CC O
genetics NNS O
of IN O
drug NN B-Disease
hypersensitivity NN I-Disease
and CC O
differential JJ O
diagnosis NN O
. . O
null null null-Disease
The DT O
most RBS O
severe JJ O
adverse JJ O
reactions NNS O
to IN O
carbamazepine NN O
have VBP O
been VBN O
observed VBN O
in IN O
the DT O
haemopoietic JJ O
system NN O
, , O
the DT O
liver NN O
and CC O
the DT O
cardiovascular JJ O
system NN O
. . O
null null null-Disease
A DT O
frequently RB O
fatal JJ O
, , O
although IN O
exceptionally RB O
rare JJ O
side NN O
effect NN O
of IN O
carbamazepine NN O
is VBZ O
necrotizing VBG O
eosinophilic JJ O
( , O
hypersensitivity NN B-Disease
) , O
myocarditis NN B-Disease
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
hypersensitivity NN B-Disease
myocarditis NN B-Disease
secondary JJ O
to IN O
administration NN O
of IN O
carbamazepine NN O
. . O
null null null-Disease
Acute JJ O
hypersensitivity NN B-Disease
myocarditis NN B-Disease
was VBD O
not RB O
suspected VBN O
clinically RB O
, , O
and CC O
the DT O
diagnosis NN O
was VBD O
made VBN O
post NN O
- HYPH O
mortem NN O
. . O
null null null-Disease
Histology NN O
revealed VBD O
diffuse JJ O
infiltration NN O
of IN O
the DT O
myocardium NN O
by IN O
eosinophils NNS O
and CC O
lymphocytes NNS O
with IN O
myocyte NN O
damage NN O
. . O
null null null-Disease
Clinically RB O
, , O
death NN O
was VBD O
due JJ O
to IN O
cardiogenic JJ B-Disease
shock NN I-Disease
. . O
null null null-Disease
To TO O
best RBS O
of IN O
our PRP$ O
knowledge NN O
this DT O
is VBZ O
the DT O
second JJ O
case NN O
of IN O
fatal JJ O
carbamazepine NN O
induced VBN O
myocarditis NN B-Disease
reported VBN O
in IN O
English NNP O
literature NN O
. . O
null null null-Disease
Neuropsychiatric JJ O
behaviors NNS O
in IN O
the DT O
MPTP NNP O
marmoset NN O
model NN O
of IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
Neuropsychiatric JJ O
symptoms NNS O
are VBP O
increasingly RB O
recognised VBN O
as IN O
a DT O
significant JJ O
problem NN O
in IN O
patients NNS O
with IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
( : O
PD NN B-Disease
) -RRB- O
. . O
null null null-Disease
These DT O
symptoms NNS O
may MD O
be VB O
due IN O
to IN O
' `` O
sensitisation NN O
' '' O
following VBG O
repeated VBN O
levodopa NN O
treatment NN O
or CC O
a DT O
direct JJ O
effect NN O
of IN O
dopamine NN O
on IN O
the DT O
disease NN O
state NN O
. . O
null null null-Disease
The DT O
levodopa NN O
- HYPH O
treated VBN O
MPTP NNP O
- HYPH O
lesioned VBN O
marmoset NN O
was VBD O
used VBN O
as IN O
a DT O
model NN O
of IN O
neuropsychiatric JJ B-Disease
symptoms NNS I-Disease
in IN O
PD NN B-Disease
patients NNS O
. . O
null null null-Disease
Here RB O
we PRP O
compare VBP O
the DT O
time NN O
course NN O
of IN O
levodopa NN O
- HYPH O
induced VBN O
motor NN O
fluctuations NNS O
and CC O
neuropsychiatric JJ B-Disease
- HYPH I-Disease
like JJ I-Disease
behaviors NNS I-Disease
to TO O
determine VB O
the DT O
relationship NN O
between IN O
duration NN O
of IN O
treatment NN O
and CC O
onset NN O
of IN O
symptoms NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
Marmosets NNS O
were VBD O
administered VBN O
1 CD O
- HYPH O
methyl NN O
- HYPH O
4 CD O
- HYPH O
phenyl NN O
- HYPH O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
6 CD O
- HYPH O
tetrahydropyridine NN O
( , O
2 CD O
. . O
0 CD O
mg NN O
/ SYM O
kg NN O
s NNS O
. . O
c NN O
. . O
) -RRB- O
for IN O
five CD O
days NNS O
, , O
resulting VBG O
in IN O
stable JJ O
parkinsonism NN B-Disease
. . O
null null null-Disease
Levodopa NNP O
( : O
15 CD O
mg NNS O
/ SYM O
kg NNS O
and CC O
benserazide NN O
, , O
3 CD O
. . O
75 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
p NN O
. . O
o NFP O
. . O
null null null-Disease
b LS O
. . O
i LS O
. . O
d LS O
, , O
was VBD O
administered VBN O
for IN O
30 CD O
days NNS O
. . O
null null null-Disease
Animals NNS O
were VBD O
evaluated VBN O
for IN O
parkinsonian NN B-Disease
disability NN I-Disease
, , O
dyskinesia NN B-Disease
and CC O
on IN O
- HYPH O
time NN O
( , O
motor NN O
fluctuations NNS O
) -RRB- O
and CC O
neuropsychiatric JJ B-Disease
- HYPH I-Disease
like JJ I-Disease
behaviors NNS I-Disease
on IN O
Day NNP O
0 CD O
( SYM O
prior RB O
to IN O
levodopa NN O
) -RRB- O
and CC O
on IN O
Days NNS O
1 CD O
, , O
7 CD O
, , O
13 CD O
, , O
27 CD O
and CC O
30 CD O
of IN O
treatment NN O
using VBG O
post NN O
hoc NN O
DVD NN O
analysis NN O
by IN O
a DT O
trained VBN O
rater NN O
, , O
blind JJ O
to IN O
the DT O
treatment NN O
day NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
neuropsychiatric JJ B-Disease
- HYPH I-Disease
like JJ I-Disease
behavior NN I-Disease
rating NN O
scale NN O
demonstrated VBD O
high JJ O
interrater NN O
reliability NN O
between IN O
three CD O
trained VBN O
raters NNS O
of IN O
differing VBG O
professional JJ O
backgrounds NNS O
. . O
null null null-Disease
As IN O
anticipated VBN O
, , O
animals NNS O
exhibited VBD O
a DT O
progressive JJ O
increase NN O
in IN O
levodopa NN O
- HYPH O
induced VBN O
motor NN O
fluctuations NNS O
, , O
dyskinesia NN B-Disease
and CC O
wearing VBG O
- HYPH O
off NN O
, , O
that WDT O
correlated VBD O
with IN O
the DT O
duration NN O
of IN O
levodopa NN O
therapy NN O
. . O
null null null-Disease
In IN O
contrast NN O
, , O
levodopa NN O
- HYPH O
induced VBN O
neuropsychiatric JJ B-Disease
- HYPH I-Disease
like JJ I-Disease
behaviors NNS I-Disease
were VBD O
present JJ O
on IN O
Day NNP O
1 CD O
of IN O
levodopa NN O
treatment NN O
and CC O
their PRP$ O
severity NN O
did VBD O
not RB O
correlate VB O
with IN O
duration NN O
of IN O
treatment NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
data NNS O
suggest VBP O
that IN O
neuropsychiatric JJ B-Disease
disorders NNS I-Disease
in IN O
PD NN B-Disease
are VBP O
more RBR O
likely JJ O
an DT O
interaction NN O
between IN O
levodopa NN O
and CC O
the DT O
disease NN O
state NN O
than IN O
a DT O
consequence NN O
of IN O
sensitisation NN O
to IN O
repeated VBN O
dopaminergic JJ O
therapy NN O
. . O
null null null-Disease
Contrast VB O
medium JJ O
nephrotoxicity NN B-Disease
after IN O
renal JJ O
artery NN O
and CC O
coronary JJ O
angioplasty NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Renal JJ B-Disease
dysfunction NN I-Disease
induced VBN O
by IN O
iodinated JJ O
contrast NN O
medium NN O
( , O
CM NN O
) -RRB- O
administration NN O
can MD O
minimize VB O
the DT O
benefit NN O
of IN O
the DT O
interventional JJ O
procedure NN O
in IN O
patients NNS O
undergoing VBG O
renal JJ O
angioplasty NN O
( -LRB- O
PTRA NNP O
) -RRB- O
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
compare VB O
the DT O
susceptibility NN O
to IN O
nephrotoxic JJ B-Disease
effect NN O
of IN O
CM NN O
in IN O
patients NNS O
undergoing VBG O
PTRA NNP O
with IN O
that DT O
of IN O
patients NNS O
submitted VBN O
to IN O
percutaneous JJ O
coronary JJ O
intervention NN O
( : O
PCI NNP O
) -RRB- O
. . O
null null null-Disease
MATERIAL NN O
AND CC O
METHODS NNS O
: : O
A DT O
total NN O
of IN O
33 CD O
patients NNS O
successfully RB O
treated VBN O
with IN O
PTRA NNP O
( , O
PTRA NNP O
group NN O
, , O
mean JJ O
age NN O
70 CD O
+ SYM O
/ SYM O
- HYPH O
12 CD O
years NNS O
, , O
23 CD O
female NN O
, , O
basal JJ O
creatinine NN O
1 CD O
. . O
46 CD O
+ CD O
/ SYM O
- HYPH O
0 CD O
. . O
79 CD O
, , O
range NN O
0 CD O
. . O
7 CD O
- SYM O
4 CD O
. . O
9 CD O
mg NN O
/ SYM O
dl NN O
) -RRB- O
were VBD O
compared VBN O
with IN O
33 CD O
patients NNS O
undergoing VBG O
successful JJ O
PCI NNP O
( -LRB- O
PCI NNP O
group NN O
) -RRB- O
, , O
matched VBN O
for IN O
basal JJ O
creatinine NN O
( , O
1 CD O
. . O
44 CD O
+ CD O
/ SYM O
- SYM O
0 CD O
. . O
6 CD O
, , O
range NN O
0 CD O
. . O
7 CD O
- SYM O
3 CD O
. . O
4 CD O
mg NN O
/ SYM O
dl NN O
) NFP O
, , O
gender NN O
, , O
and CC O
age NN O
. . O
null null null-Disease
In IN O
both DT O
groups NNS O
postprocedural JJ O
( : O
48 CD O
h NN O
) -RRB- O
serum NN O
creatinine NN O
was VBD O
measured VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Postprocedural JJ O
creatinine NN O
level NN O
decreased VBD O
nonsignificantly RB O
in IN O
the DT O
PTRA NNP O
group NN O
( : O
1 CD O
. . O
46 CD O
+ CD O
/ SYM O
- HYPH O
0 CD O
. . O
8 CD O
vs NN O
. . O
1 CD O
. . O
34 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
5 CD O
mg NN O
/ SYM O
dl NN O
, , O
P NN O
= SYM O
NS NN O
) -RRB- O
and CC O
increased VBN O
significantly RB O
in IN O
the DT O
PCI NNP O
group NN O
( : O
1 CD O
. . O
44 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
6 CD O
vs NN O
. . O
1 CD O
. . O
57 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
mg NN O
/ SYM O
dl NN O
, , O
P NN O
< NN O
0 CD O
. . O
02 CD O
) -RRB- O
. . O
null null null-Disease
Changes NNS O
in IN O
serum NN O
creatinine NN O
after IN O
intervention NN O
( , O
after IN O
- HYPH O
before RB O
) -RRB- O
were VBD O
significantly RB O
different JJ O
between IN O
the DT O
PTRA NNP O
and CC O
PCI NNP O
groups NNS O
( : O
- : O
0 CD O
. . O
12 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
5 CD O
vs NN O
. . O
0 CD O
. . O
13 CD O
+ CD O
/ SYM O
- HYPH O
0 CD O
. . O
3 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
014 CD O
) -RRB- O
. . O
null null null-Disease
This DT O
difference NN O
was VBD O
not RB O
related VBN O
to IN O
either CC O
a DT O
different JJ O
clinical JJ O
risk NN O
profile NN O
or CC O
to IN O
the DT O
volume NN O
of IN O
CM NNP O
administered VBN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
In IN O
this DT O
preliminary JJ O
study NN O
patients NNS O
submitted VBN O
to IN O
PTRA NNP O
showed VBD O
a DT O
lower JJR O
susceptibility NN O
to IN O
renal JJ B-Disease
damage NN I-Disease
induced VBN O
by IN O
CM NNP O
administration NN O
than IN O
PCI NNP O
patients NNS O
. . O
null null null-Disease
The DT O
effectiveness NN O
of IN O
PTRA NNP O
on IN O
renal JJ O
function NN O
seems VBZ O
to TO O
be VB O
barely RB O
influenced VBN O
by IN O
CM NNP O
toxicity NN B-Disease
. . O
null null null-Disease
Diphenhydramine NN O
prevents VBZ O
the DT O
haemodynamic JJ O
changes NNS O
of IN O
cimetidine NN O
in IN O
ICU NNP O
patients NNS O
. . O
null null null-Disease
Cimetidine NN O
, , O
a DT O
histamine NN O
2 CD O
( , O
H2 NN O
) -RRB- O
antagonist NN O
, , O
produces VBZ O
a DT O
decrease NN O
in IN O
arterial JJ O
pressure NN O
due IN O
to IN O
vasodilatation NN O
, , O
especially RB O
in IN O
critically RB O
ill JJ O
patients NNS O
. . O
null null null-Disease
This DT O
may MD O
be VB O
because IN O
cimetidine NN O
acts VBZ O
as IN O
a DT O
histamine NN O
agonist NN O
. . O
null null null-Disease
We PRP O
, , O
therefore RB O
, , O
investigated VBD O
the DT O
effects NNS O
of IN O
the DT O
histamine NN O
1 CD O
( , O
H1 NN O
) -RRB- O
receptor NN O
antagonist NN O
, , O
diphenhydramine NN O
, , O
on IN O
the DT O
haemodynamic JJ O
changes NNS O
observed VBN O
after IN O
cimetidine NN O
in IN O
ICU NNP O
patients NNS O
. . O
null null null-Disease
Each DT O
patient NN O
was VBD O
studied VBN O
on IN O
two CD O
separate JJ O
days NNS O
. . O
null null null-Disease
In IN O
a DT O
random JJ O
fashion NN O
, , O
they PRP O
received VBD O
cimetidine NN O
200 CD O
mg NN O
iv NN O
on IN O
one CD O
day NN O
, , O
and CC O
on IN O
the DT O
other JJ O
, , O
a DT O
pretreatment NN O
of IN O
diphenhydramine NN O
40 CD O
mg NN O
iv NN O
with IN O
cimetidine NN O
200 CD O
mg NN O
iv NN O
. . O
null null null-Disease
In IN O
the DT O
non JJ O
- HYPH O
pretreatment NN O
group NN O
, , O
mean JJ O
arterial JJ O
pressure NN O
( -LRB- O
MAP NNP O
) -RRB- O
decreased VBD O
from IN O
107 CD O
. . O
4 CD O
+ SYM O
/ SYM O
- HYPH O
8 CD O
. . O
4 CD O
mmHg NN O
to IN O
86 CD O
. . O
7 CD O
+ CD O
/ SYM O
- HYPH O
11 CD O
. . O
4 CD O
mmHg NN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
two CD O
minutes NNS O
after IN O
cimetidine NN O
. . O
null null null-Disease
Also RB O
, , O
systemic JJ O
vascular JJ O
resistance NN O
( , O
SVR NNP O
) -RRB- O
decreased VBD O
during IN O
the DT O
eight CD O
- HYPH O
minute NN O
observation NN O
period NN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
contrast NN O
, , O
in IN O
the DT O
pretreatment NN O
group NN O
, , O
little JJ O
haemodynamic JJ O
change NN O
was VBD O
seen VBN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
an DT O
H1 NNP O
antagonist NN O
may MD O
be VB O
useful JJ O
in IN O
preventing VBG O
hypotension NN B-Disease
caused VBN O
by IN O
iv FW O
cimetidine NN O
, , O
since IN O
the DT O
vasodilating VBG O
activity NN O
of IN O
cimetidine NN O
is VBZ O
mediated VBN O
, , O
in IN O
part NN O
, , O
through IN O
the DT O
H1 NNP O
receptor NN O
. . O
null null null-Disease
Medical JJ O
and CC O
psychiatric JJ O
outcomes NNS O
for IN O
patients NNS O
transplanted VBN O
for IN O
acetaminophen NN O
- HYPH O
induced VBN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
: : O
a DT O
case NN O
- HYPH O
control NN O
study NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Acetaminophen NN O
- HYPH O
induced VBN O
hepatotoxicity NN B-Disease
is VBZ O
the DT O
most RBS O
common JJ O
cause NN O
of IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
( -LRB- O
ALF NNP B-Disease
) -RRB- O
in IN O
the DT O
UK NNP O
. . O
null null null-Disease
Patients NNS O
often RB O
consume VBP O
the DT O
drug NN O
with IN O
suicidal JJ O
intent NN O
or CC O
with IN O
a DT O
background NN O
of IN O
substance NN O
dependence NN O
. . O
null null null-Disease
AIMS NNS O
AND CC O
METHODS NNS O
: : O
We PRP O
compared VBD O
the DT O
severity NN O
of IN O
pretransplant JJ O
illness NN O
, , O
psychiatric JJ O
co NN O
- HYPH O
morbidity NN O
, , O
medical JJ O
and CC O
psychosocial JJ O
outcomes NNS O
of IN O
all DT O
patients NNS O
who WP O
had VBD O
undergone VBN O
liver NN O
transplantation NN O
( -LRB- O
LT NNP O
) -RRB- O
emergently RB O
between IN O
1999 CD O
- SYM O
2004 CD O
for IN O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
( : O
n CD O
= SYM O
36 CD O
) -RRB- O
with IN O
age NN O
- HYPH O
and CC O
sex NN O
- HYPH O
matched VBN O
patients NNS O
undergoing VBG O
emergent JJ O
LT NNP O
for IN O
non JJ O
- HYPH O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
( : O
n NN O
= SYM O
35 CD O
) -RRB- O
and CC O
elective JJ O
LT NN O
for IN O
chronic JJ B-Disease
liver NN I-Disease
disease NN I-Disease
( : O
CLD NN B-Disease
, , O
n CD O
= SYM O
34 CD O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
Acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
patients NNS O
undergoing VBG O
LT NNP O
had VBD O
a DT O
greater JJR O
severity NN O
of IN O
pre JJ O
- HYPH O
LT NNP O
illness NN O
reflected VBN O
by IN O
higher JJR O
Acute NNP O
Physiology NNP O
and CC O
Chronic NNP O
Health NNP O
Evaluation NNP O
II NNP O
scores NNS O
and CC O
requirement NN O
for IN O
organ JJ O
support NN O
compared VBN O
with IN O
the DT O
other JJ O
two CD O
groups NNS O
. . O
null null null-Disease
Twenty CD O
( SYM O
56 CD O
% NN O
) , O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
patients NNS O
had VBD O
a DT O
formal JJ O
psychiatric JJ O
diagnosis NN O
before IN O
LT NNP O
( , O
non JJ O
- HYPH O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
= SYM O
0 CD O
/ SYM O
35 CD O
, , O
CLD NN B-Disease
= SYM O
2 CD O
/ SYM O
34 CD O
; : O
P NN O
< NN O
0 CD O
. . O
01 CD O
for IN O
all DT O
) -RRB- O
and CC O
nine CD O
( : O
25 CD O
% NN O
) -RRB- O
had VBD O
a DT O
previous JJ O
suicide NN O
attempt NN O
. . O
null null null-Disease
During IN O
follow NN O
- HYPH O
up NN O
( , O
median JJ O
5 CD O
years NNS O
) -RRB- O
, , O
there EX O
were VBD O
no DT O
significant JJ O
differences NNS O
in IN O
rejection NN O
( , O
acute JJ O
and CC O
chronic JJ O
) -RRB- O
, , O
graft NN O
failure NN O
or CC O
survival NN O
between IN O
the DT O
groups NNS O
( , O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
1 CD O
year NN O
87 CD O
% NN O
, , O
5 CD O
years NNS O
75 CD O
% NN O
; : O
non JJ O
- HYPH O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
88 CD O
% NN O
, , O
78 CD O
% NN O
; : O
CLD NN B-Disease
93 CD O
% NN O
, , O
82 CD O
% NN O
: : O
P NN O
> SYM O
0 CD O
. . O
6 CD O
log NN O
rank NN O
) -RRB- O
. . O
null null null-Disease
Two CD O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
patients NNS O
reattempted VBD O
suicide NN O
post NN O
- HYPH O
LT NNP O
( : O
one CD O
died VBD O
8 CD O
years NNS O
post NN O
- HYPH O
LT NNP O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Despite IN O
a DT O
high JJ O
prevalence NN O
of IN O
psychiatric JJ O
disturbance NN O
, , O
outcomes NNS O
for IN O
patients NNS O
transplanted VBN O
emergently RB O
for IN O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
were VBD O
comparable JJ O
to IN O
those DT O
transplanted VBN O
for IN O
non NN O
- HYPH O
acetaminophen NN O
- HYPH O
induced VBN O
ALF NNP B-Disease
and CC O
electively RB O
for IN O
CLD NNP B-Disease
. . O
null null null-Disease
Multidisciplinary JJ O
approaches NNS O
with IN O
long JJ O
- HYPH O
term NN O
psychiatric JJ O
follow NN O
- HYPH O
up NN O
may MD O
contribute VB O
to IN O
low JJ O
post NN O
- HYPH O
transplant NN O
suicide NN O
rates NNS O
seen VBN O
and CC O
low JJ O
rates NNS O
of IN O
graft NN O
loss NN O
because IN O
of IN O
non JJ O
- HYPH O
compliance NN O
. . O
null null null-Disease
Antithrombotic JJ O
drug NN O
use NN O
, , O
cerebral JJ B-Disease
microbleeds NNS I-Disease
, , O
and CC O
intracerebral JJ B-Disease
hemorrhage NN I-Disease
: : O
a DT O
systematic JJ O
review NN O
of IN O
published JJ O
and CC O
unpublished JJ O
studies NNS O
. . O
null null null-Disease
BACKGROUND NN O
AND CC O
PURPOSE NN O
: : O
Cerebral JJ B-Disease
microbleeds NNS I-Disease
( , O
MB NN B-Disease
) -RRB- O
are VBP O
potential JJ O
risk NN O
factors NNS O
for IN O
intracerebral JJ B-Disease
hemorrhage NN I-Disease
( -LRB- O
ICH NNP B-Disease
) -RRB- O
, , O
but CC O
it PRP O
is VBZ O
unclear JJ O
if IN O
they PRP O
are VBP O
a DT O
contraindication NN O
to IN O
using VBG O
antithrombotic JJ O
drugs NNS O
. . O
null null null-Disease
Insights NNS O
could MD O
be VB O
gained VBN O
by IN O
pooling VBG O
data NNS O
on IN O
MB NN B-Disease
frequency NN O
stratified VBN O
by IN O
antithrombotic JJ O
use NN O
in IN O
cohorts NNS O
with IN O
ICH NN B-Disease
and CC O
ischemic JJ B-Disease
stroke NN I-Disease
( , O
IS NN B-Disease
) NFP O
/ SYM O
transient JJ B-Disease
ischemic JJ I-Disease
attack NN I-Disease
( , O
TIA NNP B-Disease
) -RRB- O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
performed VBD O
a DT O
systematic JJ O
review NN O
of IN O
published VBN O
and CC O
unpublished JJ O
data NNS O
from IN O
cohorts NNS O
with IN O
stroke NN B-Disease
or CC O
TIA NNP B-Disease
to TO O
compare VB O
the DT O
presence NN O
of IN O
MB NN B-Disease
in IN O
: : O
( : O
1 CD O
) SYM O
antithrombotic JJ O
users NNS O
vs IN O
nonantithrombotic JJ O
users NNS O
with IN O
ICH NNP B-Disease
; : O
( : O
2 CD O
) SYM O
antithrombotic JJ O
users NNS O
vs IN O
nonusers NNS O
with IN O
IS NNP B-Disease
/ SYM O
TIA NNP B-Disease
; : O
and CC O
( : O
3 CD O
) -RRB- O
ICH NN B-Disease
vs IN O
ischemic JJ B-Disease
events NNS O
stratified VBN O
by IN O
antithrombotic JJ O
use NN O
. . O
null null null-Disease
We PRP O
also RB O
analyzed VBD O
published VBN O
and CC O
unpublished JJ O
follow NN O
- HYPH O
up NN O
data NNS O
to TO O
determine VB O
the DT O
risk NN O
of IN O
ICH NN B-Disease
in IN O
antithrombotic JJ O
users NNS O
with IN O
MB NNP B-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
In IN O
a DT O
pooled VBN O
analysis NN O
of IN O
1460 CD O
ICH NNP B-Disease
and CC O
3817 CD O
IS NNP B-Disease
/ SYM O
TIA NNP B-Disease
, , O
MB NNP B-Disease
were VBD O
more RBR O
frequent JJ O
in IN O
ICH NNP B-Disease
vs IN O
IS NNP B-Disease
/ SYM O
TIA NNP B-Disease
in IN O
all DT O
treatment NN O
groups NNS O
, , O
but CC O
the DT O
excess NN O
increased VBD O
from IN O
2 CD O
. . O
8 CD O
( HYPH O
odds NNS O
ratio NN O
; : O
range NN O
, , O
2 CD O
. . O
3 CD O
- HYPH O
3 CD O
. . O
5 CD O
) -RRB- O
in IN O
nonantithrombotic JJ O
users NNS O
to IN O
5 CD O
. . O
7 CD O
( HYPH O
range NN O
, , O
3 CD O
. . O
4 CD O
- SYM O
9 CD O
. . O
7 CD O
) -RRB- O
in IN O
antiplatelet JJ O
users NNS O
and CC O
8 CD O
. . O
0 CD O
( HYPH O
range NN O
, , O
3 CD O
. . O
5 CD O
- SYM O
17 CD O
. . O
8 CD O
) -RRB- O
in IN O
warfarin NN O
users NNS O
( : O
P NN O
difference NN O
= SYM O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
also RB O
an DT O
excess NN O
of IN O
MB NN B-Disease
in IN O
warfarin NN O
users NNS O
vs IN O
nonusers NNS O
with IN O
ICH NNP B-Disease
( : O
OR NNP O
, , O
2 CD O
. . O
7 CD O
; : O
95 CD O
% NN O
CI NN O
, , O
1 CD O
. . O
6 CD O
- SYM O
4 CD O
. . O
4 CD O
; : O
P NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
but CC O
none NN O
in IN O
warfarin NN O
users NNS O
with IN O
IS NN B-Disease
/ SYM O
TIA NNP B-Disease
( -LRB- O
OR CC O
, , O
1 CD O
. . O
3 CD O
; : O
95 CD O
% NN O
CI NN O
, , O
0 CD O
. . O
9 CD O
- SYM O
1 CD O
. . O
7 CD O
; : O
P NN O
= SYM O
0 CD O
. . O
33 CD O
; : O
P NN O
difference NN O
= SYM O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
smaller JJR O
excess NN O
of IN O
MB NN B-Disease
in IN O
antiplatelet JJ O
users NNS O
vs IN O
nonusers NNS O
with IN O
ICH NNP B-Disease
( -LRB- O
OR NNP O
, , O
1 CD O
. . O
7 CD O
; : O
95 CD O
% NN O
CI NN O
, , O
1 CD O
. . O
3 CD O
- SYM O
2 CD O
. . O
3 CD O
; : O
P NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
but CC O
findings NNS O
were VBD O
similar JJ O
for IN O
antiplatelet JJ O
users NNS O
with IN O
IS NN B-Disease
/ SYM O
TIA NNP B-Disease
( : O
OR NNP O
, , O
1 CD O
. . O
4 CD O
; : O
95 CD O
% NN O
CI NN O
, , O
1 CD O
. . O
2 CD O
- SYM O
1 CD O
. . O
7 CD O
; : O
P NN O
< NN O
0 CD O
. . O
001 CD O
; : O
P NN O
difference NN O
= SYM O
0 CD O
. . O
25 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
pooled VBN O
follow NN O
- HYPH O
up NN O
data NNS O
for IN O
768 CD O
antithrombotic JJ O
users NNS O
, , O
presence NN O
of IN O
MB NN B-Disease
at IN O
baseline NN O
was VBD O
associated VBN O
with IN O
a DT O
substantially RB O
increased VBN O
risk NN O
of IN O
subsequent JJ O
ICH NNP B-Disease
( , O
OR NNP O
, , O
12 CD O
. . O
1 CD O
; : O
95 CD O
% NN O
CI NN O
, , O
3 CD O
. . O
4 CD O
- SYM O
42 CD O
. . O
5 CD O
; : O
P NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
excess NN O
of IN O
MB NN B-Disease
in IN O
warfarin NN O
users NNS O
with IN O
ICH NNP B-Disease
compared VBN O
to IN O
other JJ O
groups NNS O
suggests VBZ O
that IN O
MB NN B-Disease
increase VBP O
the DT O
risk NN O
of IN O
warfarin NN O
- HYPH O
associated VBN O
ICH NNP B-Disease
. . O
null null null-Disease
Limited JJ O
prospective JJ O
data NNS O
corroborate VBP O
these DT O
findings NNS O
, , O
but CC O
larger JJR O
prospective JJ O
studies NNS O
are VBP O
urgently RB O
required VBN O
. . O
null null null-Disease
Studies NNS O
of IN O
synergy NN O
between IN O
morphine NN O
and CC O
a DT O
novel JJ O
sodium NN O
channel NN O
blocker NN O
, , O
CNSB002 NNP O
, , O
in IN O
rat NN O
models NNS O
of IN O
inflammatory JJ O
and CC O
neuropathic JJ B-Disease
pain NN I-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
This DT O
study NN O
determined VBD O
the DT O
antihyperalgesic JJ O
effect NN O
of IN O
CNSB002 NNP O
, , O
a DT O
sodium NN O
channel NN O
blocker NN O
with IN O
antioxidant JJ O
properties NNS O
given VBN O
alone RB O
and CC O
in IN O
combinations NNS O
with IN O
morphine NN O
in IN O
rat NN O
models NNS O
of IN O
inflammatory JJ O
and CC O
neuropathic JJ B-Disease
pain NN I-Disease
. . O
null null null-Disease
DESIGN NN O
: : O
Dose NN O
response NN O
curves NNS O
for IN O
nonsedating VBG O
doses NNS O
of IN O
morphine NN O
and CC O
CNSB002 NNP O
given VBN O
intraperitoneally RB O
alone RB O
and CC O
together RB O
in IN O
combinations NNS O
were VBD O
constructed VBN O
for IN O
antihyperalgesic JJ O
effect NN O
using VBG O
paw NN O
withdrawal NN O
from IN O
noxious JJ O
heat NN O
in IN O
two CD O
rat NN O
pain NN B-Disease
models NNS O
: : O
carrageenan NN O
- HYPH O
induced VBN O
paw NN O
inflammation NN B-Disease
and CC O
streptozotocin NN O
( , O
STZ NNP O
) -RRB- O
- HYPH O
induced VBN O
diabetic JJ B-Disease
neuropathy NN I-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
maximum JJ O
nonsedating JJ O
doses NNS O
were VBD O
: : O
morphine NN O
, , O
3 CD O
. . O
2 CD O
mg NN O
/ SYM O
kg NN O
; : O
CNSB002 NN O
10 CD O
. . O
0 CD O
mg NN O
/ SYM O
kg NN O
; : O
5 CD O
. . O
0 CD O
mg NN O
/ SYM O
kg NN O
CNSB002 NN O
with IN O
morphine NN O
3 CD O
. . O
2 CD O
mg NN O
/ SYM O
kg NN O
in IN O
combination NN O
. . O
null null null-Disease
The DT O
doses NNS O
calculated VBN O
to TO O
cause VB O
50 CD O
% NN O
reversal NN O
of IN O
hyperalgesia NN B-Disease
( -LRB- O
ED50 CD O
) -RRB- O
were VBD O
7 CD O
. . O
54 CD O
( SYM O
1 CD O
. . O
81 CD O
) -RRB- O
and CC O
4 CD O
. . O
83 CD O
( SYM O
1 CD O
. . O
54 CD O
) -RRB- O
in IN O
the DT O
carrageenan NN O
model NN O
and CC O
44 CD O
. . O
18 CD O
( SYM O
1 CD O
. . O
37 CD O
) -RRB- O
and CC O
9 CD O
. . O
14 CD O
( SYM O
1 CD O
. . O
24 CD O
) -RRB- O
in IN O
the DT O
STZ NNP O
- HYPH O
induced VBN O
neuropathy NN B-Disease
model NN O
for IN O
CNSB002 NNP O
and CC O
morphine NN O
, , O
respectively RB O
( : O
mg NN O
/ SYM O
kg NN O
; : O
mean JJ O
, , O
SEM NNP O
) -RRB- O
. . O
null null null-Disease
These DT O
values NNS O
were VBD O
greater JJR O
than IN O
the DT O
maximum JJ O
nonsedating JJ O
doses NNS O
. . O
null null null-Disease
The DT O
ED50 NNP O
values NNS O
for IN O
morphine NN O
when WRB O
given VBN O
in IN O
combination NN O
with IN O
CNSB002 NNP O
( SYM O
5 CD O
mg CD O
/ SYM O
kg NN O
) -RRB- O
were VBD O
less JJR O
than IN O
the DT O
maximum JJ O
nonsedating JJ O
dose NN O
: : O
0 CD O
. . O
56 CD O
( SYM O
1 CD O
. . O
55 CD O
) -RRB- O
in IN O
the DT O
carrageenan NN O
model NN O
and CC O
1 CD O
. . O
37 CD O
( SYM O
1 CD O
. . O
23 CD O
) -RRB- O
in IN O
the DT O
neuropathy NN B-Disease
model NN O
( : O
mg NN O
/ SYM O
kg NN O
; : O
mean JJ O
, , O
SEM NNP O
) -RRB- O
. . O
null null null-Disease
The DT O
antinociception NN O
after IN O
morphine NN O
( , O
3 CD O
. . O
2 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
was VBD O
increased VBN O
by IN O
co NN O
- HYPH O
administration NN O
with IN O
CNSB002 NNP O
from IN O
28 CD O
. . O
0 CD O
and CC O
31 CD O
. . O
7 CD O
% NN O
to IN O
114 CD O
. . O
6 CD O
and CC O
56 CD O
. . O
9 CD O
% NN O
reversal NN O
of IN O
hyperalgesia NN B-Disease
in IN O
the DT O
inflammatory JJ O
and CC O
neuropathic JJ B-Disease
models NNS O
, , O
respectively RB O
( , O
P NN O
< SYM O
0 CD O
. . O
01 CD O
; : O
one CD O
- HYPH O
way NN O
analysis NN O
of IN O
variance NN O
- : O
significantly RB O
greater JJR O
than IN O
either DT O
drug NN O
given VBN O
alone RB O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
maximum JJ O
antihyperalgesic JJ O
effect NN O
achievable JJ O
with IN O
nonsedating JJ O
doses NNS O
of IN O
morphine NN O
may MD O
be VB O
increased VBN O
significantly RB O
when WRB O
the DT O
drug NN O
is VBZ O
used VBN O
in IN O
combination NN O
with IN O
CNSB002 NNP O
. . O
null null null-Disease
Heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
: : O
a DT O
practical JJ O
review NN O
. . O
null null null-Disease
Heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
( -LRB- O
HIT NNP B-Disease
) -RRB- O
remains VBZ O
under IN O
- HYPH O
recognized VBN O
despite IN O
its PRP$ O
potentially RB O
devastating JJ O
outcomes NNS O
. . O
null null null-Disease
It PRP O
begins VBZ O
when WRB O
heparin NN O
exposure NN O
stimulates VBZ O
the DT O
formation NN O
of IN O
heparin NN O
- HYPH O
platelet NN O
factor NN O
4 CD O
antibodies NNS O
, , O
which WDT O
in IN O
turn NN O
triggers VBZ O
the DT O
release NN O
of IN O
procoagulant JJ O
platelet NN O
particles NNS O
. . O
null null null-Disease
Thrombosis NN B-Disease
and CC O
thrombocytopenia NN B-Disease
that WDT O
follow VBP O
comprise VBP O
the DT O
2 CD O
hallmark NN O
traits NNS O
of IN O
HIT NNP B-Disease
, , O
with IN O
the DT O
former JJ O
largely RB O
responsible JJ O
for IN O
significant JJ O
vascular JJ O
complications NNS O
. . O
null null null-Disease
The DT O
prevalence NN O
of IN O
HIT NNP B-Disease
varies VBZ O
among IN O
several JJ O
subgroups NNS O
, , O
with IN O
greater JJR O
incidence NN O
in IN O
surgical JJ O
as IN O
compared VBN O
with IN O
medical JJ O
populations NNS O
. . O
null null null-Disease
HIT NNP B-Disease
must MD O
be VB O
acknowledged VBN O
for IN O
its PRP$ O
intense JJ O
predilection NN O
for IN O
thrombosis NN B-Disease
and CC O
suspected VBN O
whenever WRB O
thrombosis NN B-Disease
occurs VBZ O
after IN O
heparin NN O
exposure NN O
. . O
null null null-Disease
Early JJ O
recognition NN O
that WDT O
incorporates VBZ O
the DT O
clinical JJ O
and CC O
serologic JJ O
clues NNS O
is VBZ O
paramount JJ O
to IN O
timely JJ O
institution NN O
of IN O
treatment NN O
, , O
as IN O
its PRP$ O
delay NN O
may MD O
result VB O
in IN O
catastrophic JJ O
outcomes NNS O
. . O
null null null-Disease
The DT O
treatment NN O
of IN O
HIT NNP B-Disease
mandates VBZ O
an DT O
immediate JJ O
cessation NN O
of IN O
all DT O
heparin NN O
exposure NN O
and CC O
the DT O
institution NN O
of IN O
an DT O
antithrombotic JJ O
therapy NN O
, , O
most RBS O
commonly RB O
using VBG O
a DT O
direct JJ O
thrombin NN O
inhibitor NN O
. . O
null null null-Disease
Current JJ O
"""" `` O
diagnostic JJ O
"""" '' O
tests NNS O
, , O
which WDT O
primarily RB O
include VBP O
functional JJ O
and CC O
antigenic JJ O
assays NNS O
, , O
have VBP O
more JJR O
of IN O
a DT O
confirmatory JJ O
than IN O
diagnostic JJ O
role NN O
in IN O
the DT O
management NN O
of IN O
HIT NN B-Disease
. . O
null null null-Disease
Special JJ O
attention NN O
must MD O
be VB O
paid VBN O
to IN O
cardiac JJ O
patients NNS O
who WP O
are VBP O
often RB O
exposed VBN O
to IN O
heparin NN O
multiple JJ O
times NNS O
during IN O
their PRP$ O
course NN O
of IN O
treatment NN O
. . O
null null null-Disease
Direct JJ O
thrombin NN O
inhibitors NNS O
are VBP O
appropriate JJ O
, , O
evidence NN O
- HYPH O
based VBN O
alternatives NNS O
to IN O
heparin NN O
in IN O
patients NNS O
with IN O
a DT O
history NN O
of IN O
HIT NNP B-Disease
, , O
who WP O
need VBP O
to TO O
undergo VB O
percutaneous JJ O
coronary JJ O
intervention NN O
. . O
null null null-Disease
As IN O
heparin NN O
remains VBZ O
one CD O
of IN O
the DT O
most RBS O
frequently RB O
used VBN O
medications NNS O
today NN O
with IN O
potential NN O
for IN O
HIT NNP B-Disease
with IN O
every DT O
heparin NN O
exposure NN O
, , O
a DT O
close JJ O
vigilance NN O
of IN O
platelet NN O
counts NNS O
must MD O
be VB O
practiced VBN O
whenever WRB O
heparin NN O
is VBZ O
initiated VBN O
. . O
null null null-Disease
Abductor NN O
paralysis NN B-Disease
after IN O
botox NN O
injection NN O
for IN O
adductor NN B-Disease
spasmodic JJ I-Disease
dysphonia NN I-Disease
. . O
null null null-Disease
OBJECTIVES NNS O
/ SYM O
HYPOTHESIS NN O
: : O
Botulinum JJ O
toxin NN O
( -LRB- O
Botox NNP O
) -RRB- O
injections NNS O
into IN O
the DT O
thyroarytenoid NN O
muscles NNS O
are VBP O
the DT O
current JJ O
standard NN O
of IN O
care NN O
for IN O
adductor NN B-Disease
spasmodic JJ I-Disease
dysphonia NN I-Disease
( : O
ADSD NN B-Disease
) -RRB- O
. . O
null null null-Disease
Reported VBN O
adverse JJ O
effects NNS O
include VBP O
a DT O
period NN O
of IN O
breathiness NN O
, , O
throat NN B-Disease
pain NN I-Disease
, , O
and CC O
difficulty NN O
with IN O
swallowing VBG O
liquids NNS O
. . O
null null null-Disease
Here RB O
we PRP O
report VBP O
multiple JJ O
cases NNS O
of IN O
bilateral JJ O
abductor NN O
paralysis NN B-Disease
following VBG O
Botox NNP O
injections NNS O
for IN O
ADSD NNP B-Disease
, , O
a DT O
complication NN O
previously RB O
unreported JJ O
. . O
null null null-Disease
STUDY NN O
DESIGN NN O
: : O
Retrospective JJ O
case NN O
series NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Patients NNS O
that WDT O
received VBD O
Botox NNP O
injections NNS O
for IN O
spasmodic JJ B-Disease
dysphonia NN I-Disease
between IN O
January NNP O
2000 CD O
and CC O
October NNP O
2009 CD O
were VBD O
evaluated VBN O
. . O
null null null-Disease
Patients NNS O
with IN O
ADSD NNP B-Disease
were VBD O
identified VBN O
. . O
null null null-Disease
The DT O
number NN O
of IN O
treatments NNS O
received VBN O
and CC O
adverse JJ O
effects NNS O
were VBD O
noted VBN O
. . O
null null null-Disease
For IN O
patients NNS O
with IN O
bilateral JJ O
abductor NN O
paralysis NN B-Disease
, , O
age NN O
, , O
sex NN O
, , O
paralytic JJ O
Botox NNP O
dose NN O
, , O
prior JJ O
Botox NNP O
dose NN O
, , O
and CC O
course NN O
following VBG O
paralysis NN B-Disease
were VBD O
noted VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
From IN O
a DT O
database NN O
of IN O
452 CD O
patients NNS O
receiving VBG O
Botox NNP O
, , O
352 CD O
patients NNS O
had VBD O
been VBN O
diagnosed VBN O
with IN O
ADSD NNP B-Disease
. . O
null null null-Disease
Of IN O
these DT O
352 CD O
patients NNS O
, , O
eight CD O
patients NNS O
suffered VBD O
bilateral JJ O
abductor NN O
paralysis NN B-Disease
, , O
and CC O
two CD O
suffered VBD O
this DT O
complication NN O
twice RB O
. . O
null null null-Disease
All DT O
affected JJ O
patients NNS O
were VBD O
females NNS O
over IN O
the DT O
age NN O
of IN O
50 CD O
years NNS O
. . O
null null null-Disease
Most JJS O
patients NNS O
had VBD O
received VBN O
treatments NNS O
prior RB O
to IN O
abductor NN O
paralysis NN B-Disease
and CC O
continued VBD O
receiving VBG O
after IN O
paralysis NN B-Disease
. . O
null null null-Disease
Seven CD O
patients NNS O
recovered VBD O
after IN O
a DT O
brief JJ O
period NN O
of IN O
activity NN O
restrictions NNS O
, , O
and CC O
one CD O
underwent VBD O
a DT O
tracheotomy NN O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
abductor NN O
paralysis NN B-Disease
after IN O
Botox NNP O
injection NN O
for IN O
ADSD NNP B-Disease
was VBD O
0 CD O
. . O
34 CD O
% NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Bilateral JJ O
abductor NN O
paralysis NN B-Disease
is VBZ O
a DT O
rare JJ O
complication NN O
of IN O
Botox NNP O
injections NNS O
for IN O
ADSD NNP B-Disease
, , O
causing VBG O
difficulty NN O
with IN O
breathing VBG O
upon IN O
exertion NN O
. . O
null null null-Disease
The DT O
likely JJ O
mechanism NN O
of IN O
paralysis NN B-Disease
is VBZ O
diffusion NN O
of IN O
Botox NNP O
around IN O
the DT O
muscular JJ O
process NN O
of IN O
the DT O
arytenoid NN O
to IN O
the DT O
posterior JJ O
cricoarytenoid NN O
muscles NNS O
. . O
null null null-Disease
The DT O
paralysis NN B-Disease
is VBZ O
temporary JJ O
, , O
and CC O
watchful JJ O
waiting VBG O
with IN O
restriction NN O
of IN O
activity NN O
is VBZ O
the DT O
recommended VBN O
management NN O
. . O
null null null-Disease
Mitochondrial JJ B-Disease
impairment NN I-Disease
contributes VBZ O
to IN O
cocaine NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
dysfunction NN I-Disease
: : O
Prevention NN O
by IN O
the DT O
targeted VBN O
antioxidant JJ O
MitoQ NNP O
. . O
null null null-Disease
The DT O
goal NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
assess VB O
mitochondrial JJ O
function NN O
and CC O
ROS NNP O
production NN O
in IN O
an DT O
experimental JJ O
model NN O
of IN O
cocaine NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
We PRP O
hypothesized VBD O
that IN O
cocaine NN B-Disease
abuse NN I-Disease
may MD O
lead VB O
to IN O
altered JJ O
mitochondrial JJ O
function NN O
that IN O
in IN O
turn NN O
may MD O
cause VB O
left VBN B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
Seven CD O
days NNS O
of IN O
cocaine NN O
administration NN O
to IN O
rats NNS O
led VBD O
to IN O
an DT O
increased VBN O
oxygen NN O
consumption NN O
detected VBN O
in IN O
cardiac JJ O
fibers NNS O
, , O
specifically RB O
through IN O
complex JJ O
I NN O
and CC O
complex NN O
III NNP O
. . O
null null null-Disease
ROS NNP O
levels NNS O
were VBD O
increased VBN O
, , O
specifically RB O
in IN O
interfibrillar JJ O
mitochondria NN O
. . O
null null null-Disease
In IN O
parallel NN O
there EX O
was VBD O
a DT O
decrease NN O
in IN O
ATP NNP O
synthesis NN O
, , O
whereas IN O
no DT O
difference NN O
was VBD O
observed VBN O
in IN O
subsarcolemmal JJ O
mitochondria NN O
. . O
null null null-Disease
This DT O
uncoupling JJ O
effect NN O
on IN O
oxidative JJ O
phosphorylation NN O
was VBD O
not RB O
detectable JJ O
after IN O
short JJ O
- HYPH O
term NN O
exposure NN O
to IN O
cocaine NN O
, , O
suggesting VBG O
that IN O
these DT O
mitochondrial JJ B-Disease
abnormalities NNS I-Disease
were VBD O
a DT O
late JJ O
rather RB O
than IN O
a DT O
primary JJ O
event NN O
in IN O
the DT O
pathological JJ O
response NN O
to IN O
cocaine NN O
. . O
null null null-Disease
MitoQ NNP O
, , O
a DT O
mitochondrial NN O
- HYPH O
targeted VBN O
antioxidant NN O
, , O
was VBD O
shown VBN O
to TO O
completely RB O
prevent VB O
these DT O
mitochondrial JJ B-Disease
abnormalities NNS I-Disease
as RB O
well RB O
as IN O
cardiac JJ B-Disease
dysfunction NN I-Disease
characterized VBN O
here RB O
by IN O
a DT O
diastolic JJ B-Disease
dysfunction NN I-Disease
studied VBN O
with IN O
a DT O
conductance NN O
catheter NN O
to TO O
obtain VB O
pressure NN O
- HYPH O
volume NN O
data NNS O
. . O
null null null-Disease
Taken VBN O
together RB O
, , O
these DT O
results NNS O
extend VBP O
previous JJ O
studies NNS O
and CC O
demonstrate VBP O
that IN O
cocaine NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
dysfunction NN I-Disease
may MD O
be VB O
due IN O
to IN O
a DT O
mitochondrial JJ B-Disease
defect NN I-Disease
. . O
null null null-Disease
Trimethoprim NN O
- HYPH O
induced VBN O
immune JJ O
hemolytic JJ B-Disease
anemia NN I-Disease
in IN O
a DT O
pediatric JJ O
oncology NN O
patient NN O
presenting VBG O
as IN O
an DT O
acute JJ O
hemolytic JJ O
transfusion NN O
reaction NN O
. . O
null null null-Disease
A DT O
10 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male NN O
with IN O
acute JJ B-Disease
leukemia NN I-Disease
presented VBN O
with IN O
post NN O
- HYPH O
chemotherapy NN O
anemia NN B-Disease
. . O
null null null-Disease
During IN O
red JJ O
cell NN O
transfusion NN O
, , O
he PRP O
developed VBD O
hemoglobinuria NN B-Disease
. . O
null null null-Disease
Transfusion NN O
reaction NN O
workup NN O
was VBD O
negative JJ O
. . O
null null null-Disease
Drug NN O
- HYPH O
induced VBN O
immune JJ O
hemolytic JJ B-Disease
anemia NN I-Disease
was VBD O
suspected VBN O
because IN O
of IN O
positive JJ O
direct JJ O
antiglobulin JJ O
test NN O
, , O
negative JJ O
eluate NN O
, , O
and CC O
microspherocytes NNS O
on IN O
smear NN O
pre NN O
- HYPH O
and CC O
post NN O
- HYPH O
transfusion NN O
. . O
null null null-Disease
Drug NN O
studies NNS O
using VBG O
the DT O
indirect JJ O
antiglobulin JJ O
test NN O
were VBD O
strongly RB O
positive JJ O
with IN O
trimethoprim NN O
and CC O
trimethoprim NN O
- HYPH O
sulfamethoxazole NN O
but CC O
negative JJ O
with IN O
sulfamethoxazole NN O
. . O
null null null-Disease
The DT O
patient NN O
recovered VBD O
after IN O
discontinuing VBG O
the DT O
drug NN O
, , O
with IN O
no DT O
recurrence NN O
in IN O
2 CD O
years NNS O
. . O
null null null-Disease
Other JJ O
causes NNS O
of IN O
anemia NN B-Disease
should MD O
be VB O
considered VBN O
in IN O
patients NNS O
with IN O
worse JJR O
- HYPH O
than IN O
- HYPH O
expected VBN O
anemia NN B-Disease
after IN O
chemotherapy NN O
. . O
null null null-Disease
Furthermore RB O
, , O
hemolysis NN B-Disease
during IN O
transfusion NN O
is VBZ O
not RB O
always RB O
a DT O
transfusion NN O
reaction NN O
. . O
null null null-Disease
Verapamil NNP O
stimulation NN O
test NN O
in IN O
hyperprolactinemia NN B-Disease
: : O
loss NN O
of IN O
prolactin JJ O
response NN O
in IN O
anatomic JJ O
or CC O
functional JJ O
stalk NN O
effect NN O
. . O
null null null-Disease
AIM NN O
: : O
Verapamil NNP O
stimulation NN O
test NN O
was VBD O
previously RB O
investigated VBN O
as IN O
a DT O
tool NN O
for IN O
differential JJ O
diagnosis NN O
of IN O
hyperprolactinemia NN B-Disease
, , O
but CC O
with IN O
conflicting JJ O
results NNS O
. . O
null null null-Disease
Macroprolactinemia NNP B-Disease
was VBD O
never RB O
considered VBN O
in IN O
those DT O
previous JJ O
studies NNS O
. . O
null null null-Disease
Here RB O
, , O
we PRP O
aimed VBD O
to TO O
re VB O
- HYPH O
investigate VB O
the DT O
diagnostic JJ O
value NN O
of IN O
verapamil NN O
in IN O
a DT O
population NN O
who WP O
were VBD O
all DT O
screened VBN O
for IN O
macroprolactinemia NN B-Disease
. . O
null null null-Disease
Prolactin JJ O
responses NNS O
to IN O
verapamil NN O
in IN O
65 CD O
female JJ O
patients NNS O
( , O
age NN O
: : O
29 CD O
. . O
9 CD O
+ SYM O
/ SYM O
- HYPH O
8 CD O
. . O
1 CD O
years NNS O
) -RRB- O
with IN O
hyperprolactinemia NN B-Disease
were VBD O
tested VBN O
in IN O
a DT O
descriptive JJ O
, , O
matched VBN O
case NN O
- HYPH O
control NN O
study NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Verapamil NNP O
80 CD O
mg NN O
, , O
p UH O
. . O
o NFP O
. . O
was VBD O
administered VBN O
, , O
and CC O
then RB O
PRL NNP O
levels NNS O
were VBD O
measured VBN O
at IN O
8th JJ O
and CC O
16th JJ O
hours NNS O
, , O
by IN O
immunometric JJ O
chemiluminescence NN O
. . O
null null null-Disease
Verapamil NNP O
responsiveness NN O
was VBD O
determined VBN O
by IN O
peak NN O
percent NN O
change NN O
in IN O
basal JJ O
prolactin NN O
levels NNS O
( -LRB- O
PRL NNP O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
Verapamil NNP O
significantly RB O
increased VBD O
PRL NNP O
levels NNS O
in IN O
healthy JJ O
controls NNS O
( , O
N NNP O
. . O
8 CD O
, , O
PRL NN O
: : O
183 CD O
% NN O
) -RRB- O
, , O
macroprolactinoma NN B-Disease
( , O
N NNP O
. . O
8 CD O
, , O
PRL NN O
: : O
7 CD O
% NN O
) -RRB- O
, , O
microprolactinoma NN B-Disease
( , O
N NNP O
. . O
19 CD O
, , O
PRL NN O
: : O
21 CD O
% NN O
) -RRB- O
, , O
macroprolactinemia NN B-Disease
( , O
N NNP O
. . O
23 CD O
, , O
PRL NN O
: : O
126 CD O
% NN O
) -RRB- O
, , O
but CC O
not RB O
in IN O
pseudoprolactinoma NN B-Disease
( , O
N NNP O
. . O
8 CD O
, , O
PRL NN O
: : O
0 CD O
. . O
8 CD O
% NN O
) -RRB- O
, , O
and CC O
risperidone NN O
- HYPH O
induced VBN O
hyperprolactinemia NN B-Disease
( , O
N NNP O
. . O
7 CD O
, , O
PRL NN O
: : O
3 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
ROC NNP O
curve NN O
analysis NN O
revealed VBD O
that IN O
unresponsiveness NN O
to IN O
verapamil NN O
defined VBN O
as IN O
PRL NNP O
< SYM O
7 CD O
% NN O
, , O
discriminated JJ O
anatomical JJ O
or CC O
functional JJ O
stalk NN O
effect NN O
( , O
sensitivity NN O
: : O
74 CD O
% NN O
, , O
specificity NN O
: : O
73 CD O
% NN O
, , O
AUC NN O
: : O
0 CD O
. . O
855 CD O
+ CD O
/ SYM O
- HYPH O
0 CD O
. . O
04 CD O
, , O
P NN O
< NN O
0 CD O
. . O
001 CD O
, , O
CI NN O
: : O
0 CD O
. . O
768 CD O
- HYPH O
0 CD O
. . O
942 CD O
) -RRB- O
associated VBN O
with IN O
pseudoprolactinoma NN B-Disease
or CC O
risperidone NN O
- HYPH O
induced VBN O
hyperprolactinemia NN B-Disease
, , O
respectively RB O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Verapamil NNP O
responsiveness NN O
is VBZ O
not RB O
a DT O
reliable JJ O
finding NN O
for IN O
the DT O
differential JJ O
diagnosis NN O
of IN O
hyperprolactinemia NN B-Disease
. . O
null null null-Disease
However RB O
, , O
verapamil JJ O
unresponsiveness NN O
discriminates VBZ O
stalk NN O
effect NN O
( , O
i PRP O
. . O
e LS O
. . O
, , O
anatomically RB O
or CC O
functionally RB O
inhibited VBN O
dopaminergic JJ O
tonus NN O
) -RRB- O
from IN O
other JJ O
causes NNS O
of IN O
hyperprolactinemia NN B-Disease
with IN O
varying VBG O
degrees NNS O
of IN O
responsiveness NN O
. . O
null null null-Disease
Blockade NN O
of IN O
endothelial JJ O
- HYPH O
mesenchymal NN O
transition NN O
by IN O
a DT O
Smad3 NNP O
inhibitor NN O
delays VBZ O
the DT O
early JJ O
development NN O
of IN O
streptozotocin NN O
- HYPH O
induced VBN O
diabetic JJ B-Disease
nephropathy NN I-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
A DT O
multicenter JJ O
, , O
controlled JJ O
trial NN O
showed VBD O
that IN O
early JJ O
blockade NN O
of IN O
the DT O
renin NN O
- HYPH O
angiotensin NN O
system NN O
in IN O
patients NNS O
with IN O
type NN B-Disease
1 NN I-Disease
diabetes NNS I-Disease
and CC O
normoalbuminuria NN O
did VBD O
not RB O
retard VB O
the DT O
progression NN O
of IN O
nephropathy NN B-Disease
, , O
suggesting VBG O
that IN O
other JJ O
mechanism NN O
( , O
s VBZ O
) -RRB- O
are VBP O
involved VBN O
in IN O
the DT O
pathogenesis NN O
of IN O
early JJ O
diabetic JJ B-Disease
nephropathy NN I-Disease
( , O
diabetic JJ B-Disease
nephropathy NN I-Disease
) -RRB- O
. . O
null null null-Disease
We PRP O
have VBP O
previously RB O
demonstrated VBN O
that IN O
endothelial JJ O
- HYPH O
mesenchymal NN O
- HYPH O
transition NN O
( -LRB- O
EndoMT NNP O
) -RRB- O
contributes VBZ O
to IN O
the DT O
early JJ O
development NN O
of IN O
renal JJ O
interstitial JJ O
fibrosis NN B-Disease
independently RB O
of IN O
microalbuminuria NN O
in IN O
mice NNS O
with IN O
streptozotocin NN O
( , O
STZ NNP O
) -RRB- O
- HYPH O
induced VBN O
diabetes NN B-Disease
. . O
null null null-Disease
In IN O
the DT O
present JJ O
study NN O
, , O
we PRP O
hypothesized VBD O
that IN O
blocking VBG O
EndoMT NNP O
reduces VBZ O
the DT O
early JJ O
development NN O
of IN O
diabetic JJ B-Disease
nephropathy NN I-Disease
. . O
null null null-Disease
RESEARCH NN O
DESIGN NN O
AND CC O
METHODS NNS O
: : O
EndoMT NNP O
was VBD O
induced VBN O
in IN O
a DT O
mouse NN O
pancreatic JJ O
microvascular JJ O
endothelial JJ O
cell NN O
line NN O
( , O
MMEC NNP O
) -RRB- O
in IN O
the DT O
presence NN O
of IN O
advanced JJ O
glycation NN O
end NN O
products NNS O
( , O
AGEs NNP O
) -RRB- O
and CC O
in IN O
the DT O
endothelial JJ O
lineage NN O
- HYPH O
traceble NN O
mouse NN O
line NN O
Tie2 NNP O
- HYPH O
Cre NNP O
; : O
Loxp NNP O
- HYPH O
EGFP NNP O
by IN O
administration NN O
of IN O
AGEs NNS O
, , O
with IN O
nonglycated JJ O
mouse NN O
albumin NN O
serving VBG O
as IN O
a DT O
control NN O
. . O
null null null-Disease
Phosphorylated VBN O
Smad3 NNP O
was VBD O
detected VBN O
by IN O
immunoprecipitation NN O
/ SYM O
Western JJ O
blotting NN O
and CC O
confocal JJ O
microscopy NN O
. . O
null null null-Disease
Blocking VBG O
studies NNS O
using VBG O
receptor NN O
for IN O
AGE NNP O
siRNA NNP O
and CC O
a DT O
specific JJ O
inhibitor NN O
of IN O
Smad3 NNP O
( -LRB- O
SIS3 NNP O
) -RRB- O
were VBD O
performed VBN O
in IN O
MMECs NNP O
and CC O
in IN O
STZ NNP O
- HYPH O
induced VBN O
diabetic JJ B-Disease
nephropathy NN I-Disease
in IN O
Tie2 NNP O
- HYPH O
Cre NNP O
; : O
Loxp NNP O
- HYPH O
EGFP NNP O
mice NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Confocal JJ O
microscopy NN O
and CC O
real JJ O
- HYPH O
time NN O
PCR NNP O
demonstrated VBD O
that IN O
AGEs NNS O
induced VBD O
EndoMT NNP O
in IN O
MMECs NNP O
and CC O
in IN O
Tie2 NNP O
- HYPH O
Cre NNP O
; : O
Loxp NNP O
- HYPH O
EGFP NNP O
mice NNS O
. . O
null null null-Disease
Immunoprecipitation NN O
/ SYM O
Western JJ O
blotting NN O
showed VBD O
that IN O
Smad3 NNP O
was VBD O
activated VBN O
by IN O
AGEs NNS O
but CC O
was VBD O
inhibited VBN O
by IN O
SIS3 NNP O
in IN O
MMECs NNP O
and CC O
in IN O
STZ NNP O
- HYPH O
induced VBN O
diabetic JJ B-Disease
nephropathy NN I-Disease
. . O
null null null-Disease
Confocal JJ O
microscopy NN O
and CC O
real JJ O
- HYPH O
time NN O
PCR NNP O
further RB O
demonstrated VBD O
that IN O
SIS3 NNP O
abrogated VBD O
EndoMT NNP O
, , O
reduced VBD O
renal JJ O
fibrosis NN B-Disease
, , O
and CC O
retarded VBD O
progression NN O
of IN O
nephropathy NN B-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
EndoMT NNP O
is VBZ O
a DT O
novel JJ O
pathway NN O
leading VBG O
to IN O
early JJ O
development NN O
of IN O
diabetic JJ B-Disease
nephropathy NN I-Disease
. . O
null null null-Disease
Blockade NN O
of IN O
EndoMT NNP O
by IN O
SIS3 NNP O
may MD O
provide VB O
a DT O
new JJ O
strategy NN O
to TO O
retard VB O
the DT O
progression NN O
of IN O
diabetic JJ B-Disease
nephropathy NN I-Disease
and CC O
other JJ O
diabetes NN B-Disease
complications NNS I-Disease
. . O
null null null-Disease
Cytostatic JJ O
and CC O
anti JJ O
- HYPH O
angiogenic JJ O
effects NNS O
of IN O
temsirolimus NN O
in IN O
refractory JJ O
mantle NN B-Disease
cell NN I-Disease
lymphoma NN I-Disease
. . O
null null null-Disease
Mantle NNP B-Disease
cell NN I-Disease
lymphoma NN I-Disease
( : O
MCL NNP B-Disease
) -RRB- O
is VBZ O
a DT O
rare JJ O
and CC O
aggressive JJ O
type NN O
of IN O
B NN B-Disease
- HYPH I-Disease
cell NN I-Disease
non NN I-Disease
- HYPH I-Disease
Hodgkin NNP I-Disease
' POS I-Disease
s NN I-Disease
lymphoma NN I-Disease
. . O
null null null-Disease
Patients NNS O
become VBP O
progressively RB O
refractory JJ O
to IN O
conventional JJ O
chemotherapy NN O
, , O
and CC O
their PRP$ O
prognosis NN O
is VBZ O
poor JJ O
. . O
null null null-Disease
However RB O
, , O
a DT O
38 CD O
% NN O
remission NN O
rate NN O
has VBZ O
been VBN O
recently RB O
reported VBN O
in IN O
refractory JJ O
MCL NNP B-Disease
treated VBN O
with IN O
temsirolimus NN O
, , O
a DT O
mTOR NNP O
inhibitor NN O
. , O
Here RB O
we PRP O
had VBD O
the DT O
opportunity NN O
to TO O
study VB O
a DT O
case NN O
of IN O
refractory JJ O
MCL NNP B-Disease
who WP O
had VBD O
tumor NN B-Disease
regression NN O
two CD O
months NNS O
after IN O
temsirolimus NN O
treatment NN O
, , O
and CC O
a DT O
progression NN O
- HYPH O
free JJ O
survival NN O
of IN O
10 CD O
months NNS O
. . O
null null null-Disease
In IN O
this DT O
case NN O
, , O
lymph NN O
node NN O
biopsies NNS O
were VBD O
performed VBN O
before RB O
and CC O
six CD O
months NNS O
after IN O
temsirolimus NN O
therapy NN O
. . O
null null null-Disease
Comparison NN O
of IN O
the DT O
two CD O
biopsies NNS O
showed VBD O
that IN O
temsirolimus NN O
inhibited VBD O
tumor NN B-Disease
cell NN O
proliferation NN O
through IN O
cell NN O
cycle NN O
arrest NN O
, , O
but CC O
did VBD O
not RB O
induce VB O
any DT O
change NN O
in IN O
the DT O
number NN O
of IN O
apoptotic JJ O
tumor NN B-Disease
cells NNS O
. . O
null null null-Disease
Apart RB O
from IN O
this DT O
cytostatic JJ O
effect NN O
, , O
temsirolimus NN O
had VBD O
an DT O
antiangiogenic JJ O
effect NN O
with IN O
decrease NN O
of IN O
tumor NN B-Disease
microvessel NN O
density NN O
and CC O
of IN O
VEGF NNP O
expression NN O
. . O
null null null-Disease
Moreover RB O
, , O
numerous JJ O
patchy JJ O
, , O
well RB O
- HYPH O
limited VBN O
fibrotic JJ O
areas NNS O
, , O
compatible JJ O
with IN O
post JJ O
- HYPH O
necrotic JJ B-Disease
tissue NN O
repair NN O
, , O
were VBD O
found VBN O
after IN O
6 CD O
- HYPH O
month NN O
temsirolimus NN O
therapy NN O
. . O
null null null-Disease
Thus RB O
, , O
temsirolimus NN O
reduced VBD O
tumor NN B-Disease
burden NN O
through IN O
associated JJ O
cytostatic JJ O
and CC O
anti JJ O
- HYPH O
angiogenic JJ O
effects NNS O
. , O
This DT O
dual JJ O
effect NN O
of IN O
temsirolimus NN O
on IN O
tumor NN B-Disease
tissue NN O
could MD O
contribute VB O
to IN O
its PRP$ O
recently RB O
reported VBN O
efficiency NN O
in IN O
refractory JJ O
MCL NNP B-Disease
resistant JJ O
to IN O
conventional JJ O
chemotherapy NN O
. . O
null null null-Disease
Acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
due IN O
to IN O
rifampicin NN O
. . O
null null null-Disease
A DT O
23 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male JJ O
patient NN O
with IN O
bacteriologically RB O
proven VBN O
pulmonary JJ B-Disease
tuberculosis NN I-Disease
was VBD O
treated VBN O
with IN O
the DT O
various JJ O
regimens NNS O
of IN O
antituberculosis JJ O
drugs NNS O
for IN O
nearly RB O
15 CD O
months NNS O
. . O
null null null-Disease
Rifampicin NNP O
was VBD O
administered VBN O
thrice RB O
as IN O
one CD O
of IN O
the DT O
3 CD O
- HYPH O
4 CD O
drug NN O
regimen NN O
and CC O
each DT O
time NN O
he PRP O
developed VBD O
untoward JJ O
side NN O
effects NNS O
like IN O
nausea NN B-Disease
, , O
vomiting NN B-Disease
and CC O
fever NN B-Disease
with IN O
chills NNS O
and CC O
rigors NNS O
. . O
null null null-Disease
The DT O
last JJ O
such JJ O
episode NN O
was VBD O
of IN O
acute JJ O
renal JJ O
failure NN O
at IN O
which WDT O
stage NN O
the DT O
patient NN O
was VBD O
seen VBN O
by IN O
the DT O
authors NNS O
of IN O
this DT O
report NN O
. . O
null null null-Disease
The DT O
patient NN O
, , O
however RB O
, , O
made VBD O
a DT O
full JJ O
recovery NN O
. . O
null null null-Disease
Syncope NNP B-Disease
caused VBN O
by IN O
hyperkalemia NN B-Disease
during IN O
use NN O
of IN O
a DT O
combined VBN O
therapy NN O
with IN O
the DT O
angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
inhibitor NN O
and CC O
spironolactone NN O
. . O
null null null-Disease
A DT O
76 CD O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
a DT O
history NN O
of IN O
coronary JJ O
artery NN O
bypass NN O
grafting NN O
and CC O
prior JJ O
myocardial JJ B-Disease
infarction NN I-Disease
was VBD O
transferred VBN O
to IN O
the DT O
emergency NN O
room NN O
with IN O
loss NN B-Disease
of IN I-Disease
consciousness NN I-Disease
due IN O
to IN O
marked JJ O
bradycardia NN B-Disease
caused VBN O
by IN O
hyperkalemia NN B-Disease
. . O
null null null-Disease
The DT O
concentration NN O
of IN O
serum NN O
potassium NN O
was VBD O
high JJ O
, , O
and CC O
normal JJ O
sinus NN O
rhythm NN O
was VBD O
restored VBN O
after IN O
correction NN O
of IN O
the DT O
serum NN O
potassium NN O
level NN O
. . O
null null null-Disease
The DT O
cause NN O
of IN O
hyperkalemia NN B-Disease
was VBD O
considered VBN O
to TO O
be VB O
several JJ O
doses NNS O
of IN O
spiranolactone NN O
, , O
an DT O
aldosterone NN O
antagonist NN O
, , O
in IN O
addition NN O
to IN O
the DT O
long JJ O
- HYPH O
term NN O
intake NN O
of IN O
ramipril NN O
, , O
an DT O
ACE NNP O
inhibitor NN O
. . O
null null null-Disease
This DT O
case NN O
is VBZ O
a DT O
good JJ O
example NN O
of IN O
electrolyte NN O
imbalance NN O
causing VBG O
acute JJ O
life NN O
- HYPH O
threatening VBG O
cardiac JJ O
events NNS O
. . O
null null null-Disease
Clinicians NNS O
should MD O
be VB O
alert JJ O
to IN O
the DT O
possibility NN O
of IN O
hyperkalemia NN B-Disease
, , O
especially RB O
in IN O
elderly JJ O
patients NNS O
using VBG O
ACE NN O
/ SYM O
ARB NN O
in IN O
combination NN O
with IN O
potassium NN O
sparing VBG O
agents NNS O
and CC O
who WP O
have VBP O
mild JJ O
renal JJ B-Disease
disturbance NN I-Disease
. . O
null null null-Disease
Diffuse JJ O
skeletal JJ O
pain NN B-Disease
after IN O
administration NN O
of IN O
alendronate NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Osteoporosis NN B-Disease
is VBZ O
caused VBN O
by IN O
bone NN O
resorption NN O
in IN O
excess NN O
of IN O
bone NN O
formation NN O
, , O
and CC O
bisphosphonates NNS O
, , O
are VBP O
used VBN O
to TO O
inhibit VB O
bone NN O
resorption NN O
. . O
null null null-Disease
Alendronate NNP O
, , O
a DT O
biphosphonate NN O
, , O
is VBZ O
effective JJ O
for IN O
both CC O
the DT O
treatment NN O
and CC O
prevention NN O
of IN O
osteoporosis NN B-Disease
in IN O
postmenopausal JJ O
women NNS O
. . O
null null null-Disease
Side JJ O
effects NNS O
are VBP O
relatively RB O
few JJ O
and CC O
prominently RB O
gastrointestinal JJ O
. . O
null null null-Disease
Musculoskeletal JJ B-Disease
pain NN I-Disease
may MD O
be VB O
an DT O
important JJ O
side NN O
effect NN O
in IN O
these DT O
patients NNS O
. . O
null null null-Disease
We PRP O
presented VBD O
a DT O
patient NN O
admitted VBN O
to IN O
our PRP$ O
out JJ O
- HYPH O
patient JJ O
clinic NN O
with IN O
diffuse JJ O
skeletal JJ O
pain NN B-Disease
after IN O
three CD O
consecutive JJ O
administration NN O
of IN O
alendronate NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
We PRP O
conclude VBP O
that IN O
patients NNS O
with IN O
osteoporosis NN B-Disease
can MD O
report VB O
pain NN B-Disease
, , O
and CC O
bisphosphonate NN O
- HYPH O
related VBN O
pain NN B-Disease
should MD O
also RB O
be VB O
considered VBN O
before IN O
ascribing VBG O
this DT O
complaint NN O
to IN O
osteoporosis NN B-Disease
. . O
null null null-Disease
Cerebrospinal JJ O
fluid NN O
penetration NN O
of IN O
high JJ O
- HYPH O
dose NN O
daptomycin NN O
in IN O
suspected VBN O
Staphylococcus NNP O
aureus NN O
meningitis NN B-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
report VB O
a DT O
case NN O
of IN O
methicillin NN O
- HYPH O
sensitive JJ O
Staphylococcus NNP O
aureus NN O
( : O
MSSA NNP O
) -RRB- O
bacteremia NN B-Disease
with IN O
suspected VBN O
MSSA NNP O
meningitis NN B-Disease
treated VBN O
with IN O
high JJ O
- HYPH O
dose NN O
daptomycin NN O
assessed VBN O
with IN O
concurrent JJ O
serum NN O
and CC O
cerebrospinal JJ O
fluid NN O
( -LRB- O
CSF NNP O
) -RRB- O
concentrations NNS O
. . O
null null null-Disease
CASE NNP O
SUMMARY NNP O
: : O
A DT O
54 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male NN O
presented VBD O
to IN O
the DT O
emergency NN O
department NN O
with IN O
generalized JJ O
weakness NN B-Disease
and CC O
presumed VBN O
health NN O
- HYPH O
care NN O
- HYPH O
associated VBN O
pneumonia NN B-Disease
shown VBN O
on IN O
chest NN O
radiograph NN O
. . O
null null null-Disease
Treatment NN O
was VBD O
empirically RB O
initiated VBN O
with IN O
vancomycin NN O
, , O
levofloxacin NN O
, , O
and CC O
piperacillin NN O
/ SYM O
tazobactam NN O
. . O
null null null-Disease
Blood NN O
cultures NNS O
revealed VBD O
S NNP O
. . O
aureus NN O
susceptible JJ O
to IN O
oxacillin NN O
. . O
null null null-Disease
Empiric JJ O
antibiotic JJ O
treatment NN O
was VBD O
narrowed VBN O
to IN O
nafcillin NN O
on IN O
day NN O
4 CD O
. . O
null null null-Disease
On IN O
day NN O
8 CD O
, , O
the DT O
patient NN O
developed VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
( , O
serum NN O
creatinine NN O
1 CD O
. . O
9 CD O
mg NN O
/ SYM O
dL NN O
, , O
increased VBD O
from IN O
1 CD O
. . O
2 CD O
mg NN O
/ SYM O
dL NN O
the DT O
previous JJ O
day NN O
and CC O
0 CD O
. . O
8 CD O
mg NN O
/ SYM O
dL NN O
on IN O
admission NN O
) -RRB- O
. . O
null null null-Disease
The DT O
patient NN O
' POS O
s POS O
Glasgow NNP O
Coma NNP O
Score NNP O
was VBD O
3 CD O
, , O
with IN O
normal JJ O
findings NNS O
shown VBN O
on IN O
computed VBN O
tomography NN O
scan NN O
of IN O
the DT O
head NN O
72 CD O
hours NNS O
following VBG O
an DT O
episode NN O
of IN O
cardiac JJ B-Disease
arrest NN I-Disease
on IN O
day NN O
10 CD O
. . O
null null null-Disease
The DT O
patient NN O
experienced VBD O
relapsing VBG O
MSSA NNP O
bacteremia NN B-Disease
on IN O
day NN O
9 CD O
, , O
increasing VBG O
the DT O
suspicion NN O
for IN O
a DT O
central JJ O
nervous JJ O
system NN O
( -LRB- O
CNS NNP O
) -RRB- O
infection NN B-Disease
. . O
null null null-Disease
Nafcillin NNP O
was VBD O
discontinued VBN O
and CC O
daptomycin NN O
9 CD O
mg NN O
/ SYM O
kg NN O
daily RB O
was VBD O
initiated VBN O
for IN O
suspected VBN O
meningitis NN B-Disease
and CC O
was VBD O
continued VBN O
until IN O
the DT O
patient NN O
' POS O
s NN O
death NN O
on IN O
day NN O
16 CD O
. . O
null null null-Disease
Daptomycin NNP O
serum NN O
and CC O
CSF NNP O
trough NN O
concentrations NNS O
were VBD O
11 CD O
. . O
21 CD O
ug NN O
/ SYM O
mL NN O
and CC O
0 CD O
. . O
52 CD O
ug NN O
/ SYM O
mL NN O
, , O
respectively RB O
, , O
prior RB O
to IN O
the DT O
third JJ O
dose NN O
. . O
null null null-Disease
Lumbar NNP O
puncture NN O
results NNS O
were VBD O
inconclusive JJ O
and CC O
no DT O
further JJ O
blood NN O
cultures NNS O
were VBD O
positive JJ O
for IN O
MSSA NNP O
. . O
null null null-Disease
Creatine JJ O
kinase NN O
levels NNS O
were VBD O
normal JJ O
prior RB O
to IN O
daptomycin NN O
therapy NN O
and CC O
were VBD O
not RB O
reassessed VBN O
. . O
null null null-Disease
DISCUSSION NN O
: : O
Daptomycin NNP O
was VBD O
initiated VBN O
in IN O
our PRP$ O
patient JJ O
secondary JJ O
to IN O
possible JJ O
nafcillin NN O
- HYPH O
induced VBN O
acute JJ O
interstitial JJ B-Disease
nephritis NN I-Disease
and CC O
relapsing VBG O
bacteremia NN B-Disease
. . O
null null null-Disease
At IN O
a DT O
dose NN O
of IN O
9 CD O
mg CD O
/ SYM O
kg NN O
, , O
resultant JJ O
penetration NN O
of IN O
5 CD O
% NN O
was VBD O
higher JJR O
than IN O
in IN O
previous JJ O
reports NNS O
, , O
more RBR O
consistent JJ O
with IN O
inflamed JJ O
meninges NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
High JJ O
- HYPH O
dose NN O
daptomycin NN O
may MD O
be VB O
an DT O
alternative JJ O
option NN O
for IN O
MSSA NNP O
bacteremia NN B-Disease
with IN O
or CC O
without IN O
a DT O
CNS NNP O
source NN O
in IN O
patients NNS O
who WP O
have VBP O
failed VBN O
or CC O
cannot MD O
tolerate VB O
standard JJ O
therapy NN O
. . O
null null null-Disease
Further JJ O
clinical JJ O
evaluation NN O
in IN O
patients NNS O
with IN O
confirmed VBN O
meningitis NNS B-Disease
is VBZ O
warranted VBN O
. . O
null null null-Disease
The DT O
role NN O
of IN O
nitric JJ O
oxide NN O
in IN O
convulsions NNS B-Disease
induced VBN O
by IN O
lindane NN O
in IN O
rats NNS O
. . O
null null null-Disease
Lindane NNP O
is VBZ O
an DT O
organochloride NN O
pesticide NN O
and CC O
scabicide NN O
. . O
null null null-Disease
It PRP O
evokes VBZ O
convulsions NNS B-Disease
mainly RB O
trough VB O
the DT O
blockage NN O
of IN O
GABA NNP O
( -LRB- O
A NN O
) , O
receptors NNS O
. . O
null null null-Disease
Nitric JJ O
oxide NN O
( , O
NO NNP O
) -RRB- O
, , O
gaseous JJ O
neurotransmitter NN O
, , O
has VBZ O
contradictor JJ O
role NN O
in IN O
epileptogenesis NN O
due IN O
to IN O
opposite JJ O
effects NNS O
of IN O
L NN O
- HYPH O
arginine NN O
, , O
precursor NN O
of IN O
NO NNP O
syntheses NNS O
( , O
NOS NNP O
) -RRB- O
, , O
and CC O
L NNP O
- HYPH O
NAME NNP O
( -LRB- O
NOS NNP O
inhibitor NN O
) , O
observed VBN O
in IN O
different JJ O
epilepsy NN B-Disease
models NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
current JJ O
study NN O
was VBD O
to TO O
determine VB O
the DT O
effects NNS O
of IN O
NO NNP O
on IN O
the DT O
behavioral JJ O
and CC O
EEG NNP O
characteristics NNS O
of IN O
lindane NN O
- HYPH O
induced VBN O
epilepsy NN B-Disease
in IN O
male JJ O
Wistar NNP O
albino JJ O
rats NNS O
. . O
null null null-Disease
The DT O
administration NN O
of IN O
L NNP O
- HYPH O
arginine NNP O
( , O
600 CD O
, , O
800 CD O
and CC O
1000 CD O
mg NN O
/ SYM O
kg NN O
, , O
i PRP O
. . O
p NN O
. . O
) -RRB- O
in IN O
dose NN O
- HYPH O
dependent JJ O
manner NN O
significantly RB O
increased VBD O
convulsion NN B-Disease
incidence NN O
and CC O
severity NN O
and CC O
shortened VBN O
latency NN O
time NN O
to IN O
first JJ O
convulsion NN B-Disease
elicited VBN O
by IN O
lower JJR O
lindane NN O
dose NN O
( : O
4 CD O
mg CD O
/ SYM O
kg CD O
, , O
i CD O
. . O
p NN O
. . O
) -RRB- O
. . O
null null null-Disease
On IN O
the DT O
contrary NN O
, , O
pretreatment NN O
with IN O
L NNP O
- HYPH O
NAME NNP O
( : O
500 CD O
, , O
700 CD O
and CC O
900 CD O
mg NN O
/ SYM O
kg NN O
, , O
i PRP O
. . O
p NN O
. . O
) -RRB- O
decreased VBN O
convulsion NN B-Disease
incidence NN O
and CC O
severity NN O
and CC O
prolonged VBN O
latency NN O
time NN O
to IN O
convulsion NN B-Disease
following VBG O
injection NN O
with IN O
a DT O
convulsive JJ B-Disease
dose NN O
of IN O
lindane NN O
( : O
8 CD O
mg CD O
/ SYM O
kg NN O
, , O
i CD O
. . O
p NN O
. . O
) -RRB- O
. . O
null null null-Disease
EEG NNP O
analyses NNS O
showed VBD O
increase NN O
of IN O
number NN O
and CC O
duration NN O
of IN O
ictal JJ O
periods NNS O
in IN O
EEG NNP O
of IN O
rats NNS O
receiving VBG O
l NN O
- HYPH O
arginine NN O
prior RB O
to IN O
lindane NN O
and CC O
decrease NN O
of IN O
this DT O
number NN O
in IN O
rats NNS O
pretreated VBN O
with IN O
L NNP O
- HYPH O
NAME NNP O
. . O
null null null-Disease
These DT O
results NNS O
support VBP O
the DT O
conclusion NN O
that IN O
NO NNP O
plays VBZ O
a DT O
role NN O
of IN O
endogenous JJ O
convulsant NN O
in IN O
rat NN O
model NN O
of IN O
lindane NN O
seizures NNS B-Disease
. . O
null null null-Disease
Severe JJ O
polyneuropathy NN B-Disease
and CC O
motor NN O
loss NN O
after IN O
intrathecal JJ O
thiotepa NN O
combination NN O
chemotherapy NN O
: : O
description NN O
of IN O
two CD O
cases NNS O
. . O
null null null-Disease
Two CD O
cases NNS O
of IN O
severe JJ O
delayed VBN O
neurologic JJ B-Disease
toxicity NN I-Disease
related VBN O
to IN O
the DT O
administration NN O
of IN O
intrathecal JJ O
( -LRB- O
IT NN O
) -RRB- O
combination NN O
chemotherapy NN O
including VBG O
thiotepa NN O
( -LRB- O
TSPA NNP O
) -RRB- O
are VBP O
presented VBN O
. . O
null null null-Disease
Both DT O
cases NNS O
developed VBD O
axonal JJ B-Disease
neuropathy NN I-Disease
with IN O
motor NN O
predominance NN O
in IN O
the DT O
lower JJ O
extremities NNS O
1 CD O
and CC O
6 CD O
months NNS O
after IN O
IT NN O
chemotherapy NN O
was VBD O
administered VBN O
. . O
null null null-Disease
Neurologic JJ B-Disease
toxicities NNS I-Disease
have VBP O
been VBN O
described VBN O
with IN O
IT NN O
- HYPH O
methotrexate NN O
, , O
IT NN O
- HYPH O
cytosine NN O
arabinoside NN O
and CC O
IT NN O
- HYPH O
TSPA NNP O
. . O
null null null-Disease
To IN O
our PRP$ O
knowledge NN O
, , O
however RB O
, , O
axonal JJ B-Disease
neuropathy NN I-Disease
following VBG O
administration NN O
of IN O
these DT O
three CD O
agents NNS O
has VBZ O
not RB O
been VBN O
previously RB O
described VBN O
. . O
null null null-Disease
In IN O
spite NN O
of IN O
the DT O
fact NN O
that IN O
TSPA NNP O
is VBZ O
a DT O
useful JJ O
IT NN O
agent NN O
, , O
its PRP$ O
combination NN O
with IN O
MTX NNP O
, , O
ara NN O
- HYPH O
C NN O
and CC O
radiotherapy NN O
could MD O
cause VB O
severe JJ O
neurotoxicity NN B-Disease
. . O
null null null-Disease
This DT O
unexpected JJ O
complication NN O
indicates VBZ O
the DT O
need NN O
for IN O
further JJ O
toxicology NN O
research NN O
on IN O
IT NNP O
- HYPH O
TSPA NNP O
. . O
null null null-Disease
Effects NNS O
of IN O
cromakalim NN O
and CC O
pinacidil NN O
on IN O
large JJ O
epicardial JJ O
and CC O
small JJ O
coronary JJ O
arteries NNS O
in IN O
conscious JJ O
dogs NNS O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
i DT O
. . O
v NN O
. . O
bolus NN O
administration NN O
of IN O
cromakalim NNP O
( , O
1 CD O
- HYPH O
10 CD O
micrograms NNS O
/ SYM O
kg NNS O
) -RRB- O
and CC O
pinacidil NN O
( SYM O
3 CD O
- SYM O
100 CD O
micrograms NNS O
/ SYM O
kg NNS O
) -RRB- O
on IN O
large JJ O
( HYPH O
circumflex JJ O
artery NN O
) , O
and CC O
small JJ O
coronary JJ O
arteries NNS O
and CC O
on IN O
systemic JJ O
hemodynamics NNS O
were VBD O
investigated VBN O
in IN O
chronically RB O
instrumented VBN O
conscious JJ O
dogs NNS O
and CC O
compared VBN O
to IN O
those DT O
of IN O
nitroglycerin NN O
( : O
0 CD O
. . O
03 CD O
- SYM O
10 CD O
micrograms NNS O
/ SYM O
kg NNS O
) -RRB- O
. . O
null null null-Disease
Nitroglycerin NN O
, , O
up IN O
to TO O
0 CD O
. . O
3 CD O
micrograms NNS O
/ SYM O
kg NN O
, , O
selectively RB O
increased VBN O
circumflex NN O
artery NN O
diameter NN O
( , O
CxAD NN O
) -RRB- O
without IN O
simultaneously RB O
affecting VBG O
any DT O
other JJ O
cardiac JJ O
or CC O
systemic JJ O
hemodynamic JJ O
parameter NN O
. . O
null null null-Disease
In IN O
contrast NN O
, , O
cromakalim NN O
and CC O
pinacidil NN O
at IN O
all DT O
doses NNS O
and CC O
nitroglycerin NN O
at IN O
doses NNS O
higher JJR O
than IN O
0 CD O
. . O
3 CD O
micrograms NNS O
/ SYM O
kg NN O
simultaneously RB O
and CC O
dose NN O
- HYPH O
dependently RB O
increased VBN O
CxAD NNP O
, , O
coronary JJ O
blood NN O
flow NN O
and CC O
heart NN O
rate NN O
and CC O
decreased VBN O
coronary JJ O
vascular JJ O
resistance NN O
and CC O
aortic JJ O
pressure NN O
. . O
null null null-Disease
Cromakalim NNP O
was VBD O
approximately RB O
8 CD O
- HYPH O
to IN O
9 CD O
. . O
5 CD O
- HYPH O
fold NN O
more RBR O
potent JJ O
than IN O
pinacidil NN O
in IN O
increasing VBG O
CxAD NNP O
. . O
null null null-Disease
Vasodilation NN O
of IN O
large JJ O
and CC O
small JJ O
coronary JJ O
vessels NNS O
and CC O
hypotension NN B-Disease
induced VBN O
by IN O
cromakalim NN O
and CC O
pinacidil NN O
were VBD O
not RB O
affected VBN O
by IN O
prior JJ O
combined VBN O
beta JJ O
adrenergic JJ O
and CC O
muscarinic JJ O
receptors NNS O
blockade NN O
but CC O
drug NN O
- HYPH O
induced VBN O
tachycardia NN B-Disease
was VBD O
abolished VBN O
. . O
null null null-Disease
When WRB O
circumflex JJ O
artery NN O
blood NN O
flow NN O
was VBD O
maintained VBN O
constant JJ O
, , O
the DT O
increases NNS O
in IN O
CxAD NNP O
induced VBN O
by IN O
cromakalim NN O
( , O
10 CD O
micrograms NNS O
/ SYM O
kg NNS O
) -RRB- O
, , O
pinacidil NN O
( , O
30 CD O
micrograms NNS O
/ SYM O
kg NNS O
) -RRB- O
and CC O
nitroglycerin NN O
( : O
10 CD O
micrograms NNS O
/ SYM O
kg NNS O
) -RRB- O
were VBD O
reduced VBN O
by IN O
68 CD O
+ SYM O
/ SYM O
- HYPH O
7 CD O
, , O
54 CD O
+ NN O
/ SYM O
- HYPH O
9 CD O
and CC O
1 CD O
+ NN O
/ SYM O
- SYM O
1 CD O
% NN O
, , O
respectively RB O
. . O
null null null-Disease
Thus RB O
, , O
whereas IN O
nitroglycerin NN O
preferentially RB O
and CC O
flow NN O
- HYPH O
independently RB O
dilates VBZ O
large JJ O
coronary JJ O
arteries NNS O
, , O
cromakalim NN O
and CC O
pinacidil NN O
dilate NN O
both CC O
large JJ O
and CC O
small JJ O
coronary JJ O
arteries NNS O
and CC O
this DT O
effect NN O
is VBZ O
not RB O
dependent JJ O
upon IN O
the DT O
simultaneous JJ O
beta NN O
adrenoceptors NNS O
- HYPH O
mediated VBN O
rise NN O
in IN O
myocardial JJ O
metabolic JJ O
demand NN O
. . O
null null null-Disease
Finally RB O
, , O
two CD O
mechanisms NNS O
at IN O
least JJS O
, , O
direct JJ O
vasodilation NN O
and CC O
flow NN O
dependency NN O
, , O
are VBP O
involved VBN O
in IN O
the DT O
cromakalim NN O
- HYPH O
and CC O
pinacidil NN O
- HYPH O
induced VBN O
increase NN O
in IN O
CxAD NNP O
. . O
null null null-Disease
Mefenamic JJ O
acid NN O
- HYPH O
induced VBN O
neutropenia NN B-Disease
and CC O
renal JJ B-Disease
failure NN I-Disease
in IN O
elderly JJ O
females NNS O
with IN O
hypothyroidism NN B-Disease
. . O
null null null-Disease
We PRP O
report VBP O
mefenamic JJ O
acid NN O
- HYPH O
induced VBN O
non JJ O
- HYPH O
oliguric JJ O
renal JJ B-Disease
failure NN I-Disease
and CC O
severe JJ O
neutropenia NN B-Disease
occurring VBG O
simultaneously RB O
in IN O
two CD O
elderly JJ O
females NNS O
. . O
null null null-Disease
The DT O
neutropenia NN B-Disease
was VBD O
due JJ O
to IN O
maturation NN O
arrest NN O
of IN O
the DT O
myeloid NN O
series NN O
in IN O
one CD O
patient NN O
. . O
null null null-Disease
Both DT O
patients NNS O
were VBD O
also RB O
hypothyroid JJ B-Disease
, , O
but CC O
it PRP O
is VBZ O
not RB O
clear JJ O
whether IN O
this DT O
was VBD O
a DT O
predisposing VBG O
factor NN O
to IN O
the DT O
development NN O
of IN O
these DT O
adverse JJ O
reactions NNS O
. . O
null null null-Disease
However RB O
, , O
it PRP O
would MD O
seem VB O
prudent JJ O
not RB O
to TO O
use VB O
mefenamic JJ O
acid NN O
in IN O
hypothyroid JJ B-Disease
patients NNS O
until IN O
the DT O
hypothyroidism NN B-Disease
has VBZ O
been VBN O
corrected VBN O
. . O
null null null-Disease
Etiology NN O
of IN O
hypercalcemia NN B-Disease
in IN O
hemodialysis NN O
patients NNS O
on IN O
calcium NN O
carbonate NN O
therapy NN O
. . O
null null null-Disease
Fourteen CD O
of IN O
39 CD O
dialysis NN O
patients NNS O
( : O
36 CD O
% NN O
) , O
became VBD O
hypercalcemic JJ B-Disease
after IN O
switching VBG O
to IN O
calcium NN O
carbonate NN O
as IN O
their PRP$ O
principal JJ O
phosphate NN O
binder NN O
. . O
null null null-Disease
In IN O
order NN O
to TO O
identify VB O
risk NN O
factors NNS O
associated VBN O
with IN O
the DT O
development NN O
of IN O
hypercalcemia NN B-Disease
, , O
indirect JJ O
parameters NNS O
of IN O
intestinal JJ O
calcium NN O
reabsorption NN O
and CC O
bone NN O
turnover NN O
rate NN O
in IN O
these DT O
14 CD O
patients NNS O
were VBD O
compared VBN O
with IN O
results NNS O
in IN O
14 CD O
eucalcemic JJ O
patients NNS O
matched VBN O
for IN O
age NN O
, , O
sex NN O
, , O
length NN O
of IN O
time NN O
on IN O
dialysis NN O
, , O
and CC O
etiology NN O
of IN O
renal JJ B-Disease
disease NN I-Disease
. . O
null null null-Disease
In IN O
addition NN O
to IN O
experiencing VBG O
hypercalcemic JJ B-Disease
episodes NNS O
with IN O
peak NN O
calcium NN O
values NNS O
of IN O
2 CD O
. . O
7 CD O
to TO O
3 CD O
. . O
8 CD O
mmol NN O
/ SYM O
L NN O
( SYM O
10 CD O
. . O
7 CD O
to TO O
15 CD O
. . O
0 CD O
mg NN O
/ SYM O
dL NN O
) -RRB- O
, , O
patients NNS O
in IN O
the DT O
hypercalcemic JJ B-Disease
group NN O
exhibited VBD O
a DT O
significant JJ O
increase NN O
in IN O
the DT O
mean JJ O
calcium NN O
concentration NN O
obtained VBN O
during IN O
6 CD O
months NNS O
before IN O
the DT O
switch NN O
, , O
compared VBN O
with IN O
the DT O
mean JJ O
value NN O
obtained VBN O
during IN O
the DT O
7 CD O
months NNS O
of IN O
observation NN O
after IN O
the DT O
switch NN O
( , O
2 CD O
. . O
4 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
03 CD O
to IN O
2 CD O
. . O
5 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
03 CD O
mmol NN O
/ SYM O
L NN O
[ -LRB- O
9 CD O
. . O
7 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
2 CD O
to IN O
10 CD O
. . O
2 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
1 CD O
mg NN O
/ SYM O
dL NN O
] -RRB- O
, , O
P NN O
= SYM O
0 CD O
. . O
006 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
contrast NN O
, , O
eucalcemic JJ O
patients NNS O
exhibited VBD O
no DT O
change NN O
in IN O
mean JJ O
calcium NN O
values NNS O
over IN O
the DT O
same JJ O
time NN O
period NN O
( : O
2 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
05 CD O
to IN O
2 CD O
. . O
3 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
05 CD O
mmol NN O
/ SYM O
L NN O
[ -LRB- O
9 CD O
. . O
2 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
2 CD O
to IN O
9 CD O
. . O
2 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
2 CD O
mg NN O
/ SYM O
dL NN O
] -RRB- O
) -RRB- O
. . O
null null null-Disease
CaCO3 NN O
dosage NN O
, , O
calculated VBN O
dietary JJ O
calcium NN O
intake NN O
, , O
and CC O
circulating VBG O
levels NNS O
of IN O
vitamin NN O
D NN O
metabolites NNS O
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O
null null null-Disease
Physical JJ O
activity NN O
index NN O
and CC O
predialysis NN O
serum NN O
bicarbonate NN O
levels NNS O
also RB O
were VBD O
similar JJ O
in IN O
both DT O
groups NNS O
. . O
null null null-Disease
However RB O
, , O
there EX O
was VBD O
a DT O
significant JJ O
difference NN O
in IN O
parameters NNS O
reflecting VBG O
bone NN O
turnover NN O
rates NNS O
between IN O
groups NNS O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) : O
null null null-Disease
Late JJ O
- HYPH O
onset NN O
scleroderma NN B-Disease
renal JJ I-Disease
crisis NN I-Disease
induced VBN O
by IN O
tacrolimus NN O
and CC O
prednisolone NN O
: : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
Scleroderma NNP B-Disease
renal JJ I-Disease
crisis NN I-Disease
( -LRB- O
SRC NNP B-Disease
) -RRB- O
is VBZ O
a DT O
rare JJ O
complication NN O
of IN O
systemic JJ B-Disease
sclerosis NN I-Disease
( : O
SSc NNP B-Disease
) -RRB- O
but CC O
can MD O
be VB O
severe JJ O
enough RB O
to TO O
require VB O
temporary JJ O
or CC O
permanent JJ O
renal JJ O
replacement NN O
therapy NN O
. . O
null null null-Disease
Moderate JJ O
to IN O
high JJ O
dose NN O
corticosteroid NN O
use NN O
is VBZ O
recognized VBN O
as IN O
a DT O
major JJ O
risk NN O
factor NN O
for IN O
SRC NNP B-Disease
. . O
null null null-Disease
Furthermore RB O
, , O
there EX O
have VBP O
been VBN O
reports NNS O
of IN O
thrombotic JJ B-Disease
microangiopathy NN I-Disease
precipitated VBN O
by IN O
cyclosporine NN O
in IN O
patients NNS O
with IN O
SSc NNP B-Disease
. . O
null null null-Disease
In IN O
this DT O
article NN O
, , O
we PRP O
report VBP O
a DT O
patient NN O
with IN O
SRC NNP B-Disease
induced VBN O
by IN O
tacrolimus NN O
and CC O
corticosteroids NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
work NN O
is VBZ O
to TO O
call VB O
attention NN O
to IN O
the DT O
risk NN O
of IN O
tacrolimus NN O
use NN O
in IN O
patients NNS O
with IN O
SSc NNP B-Disease
. . O
null null null-Disease
Methyldopa NNP O
- HYPH O
induced VBN O
hemolytic JJ B-Disease
anemia NN I-Disease
in IN O
a DT O
15 CD O
year NN O
old JJ O
presenting NN O
as IN O
near JJ O
- HYPH O
syncope NN B-Disease
. . O
null null null-Disease
Methyldopa NNP O
is VBZ O
an DT O
antihypertensive JJ O
medication NN O
which WDT O
is VBZ O
available JJ O
generically RB O
and CC O
under IN O
the DT O
trade NN O
name NN O
Aldomet NNP O
that WDT O
is VBZ O
widely RB O
prescribed VBN O
in IN O
the DT O
adult NN O
population NN O
and CC O
infrequently RB O
used VBN O
in IN O
children NNS O
. . O
null null null-Disease
Methyldopa NNP O
causes VBZ O
an DT O
autoimmune JJ B-Disease
hemolytic JJ I-Disease
anemia NN I-Disease
in IN O
a DT O
small JJ O
percentage NN O
of IN O
patients NNS O
who WP O
take VBP O
the DT O
drug NN O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
methyldopa NN O
- HYPH O
induced VBN O
hemolytic JJ B-Disease
anemia NN I-Disease
in IN O
a DT O
15 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
boy NN O
who WP O
presented VBD O
to IN O
the DT O
emergency NN B-Disease
department NN I-Disease
with IN O
near JJ O
- HYPH O
syncope NN B-Disease
. . O
null null null-Disease
The DT O
boy NN O
had VBD O
been VBN O
treated VBN O
with IN O
intravenous JJ O
methyldopa NN O
during IN O
a DT O
trauma NN B-Disease
admission NN O
seven CD O
weeks NNS O
prior RB O
to IN O
presentation NN O
. . O
null null null-Disease
Evaluation NN O
revealed VBD O
a DT O
hemoglobin NN O
of IN O
three CD O
grams NNS O
, , O
3 CD O
+ SYM O
Coombs NNS O
' POS O
test NN O
with IN O
polyspecific JJ O
anti JJ O
- HYPH O
human JJ O
globulin NN O
and CC O
monospecific JJ O
IgG NN O
reagents NNS O
, , O
and CC O
a DT O
warm JJ O
reacting VBG O
autoantibody NN O
. . O
null null null-Disease
Transfusion NN O
and CC O
corticosteroid NN O
therapy NN O
resulted VBD O
in IN O
a DT O
complete JJ O
recovery NN O
of IN O
the DT O
patient NN O
. . O
null null null-Disease
Emergency NN O
physicians NNS O
treating VBG O
children NNS O
must MD O
be VB O
aware JJ O
of IN O
this DT O
syndrome NN O
in IN O
order NN O
to TO O
diagnose VB O
and CC O
treat VB O
it PRP O
correctly RB O
. . O
null null null-Disease
A DT O
brief JJ O
review NN O
of IN O
autoimmune JJ O
and CC O
drug NN O
- HYPH O
induced VBN O
hemolytic JJ B-Disease
anemias NNS I-Disease
is VBZ O
provided VBN O
. . O
null null null-Disease
The DT O
risk NN O
and CC O
associated VBN O
factors NNS O
of IN O
methamphetamine NN O
psychosis NN B-Disease
in IN O
methamphetamine NN O
- HYPH O
dependent JJ O
patients NNS O
in IN O
Malaysia NNP O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
The DT O
objective NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
the DT O
risk NN O
of IN O
lifetime NN O
and CC O
current JJ O
methamphetamine NN O
- HYPH O
induced VBN O
psychosis NN B-Disease
in IN O
patients NNS O
with IN O
methamphetamine NN O
dependence NN O
. . O
null null null-Disease
The DT O
association NN O
between IN O
psychiatric JJ O
co NN O
- HYPH O
morbidity NN O
and CC O
methamphetamine NN O
- HYPH O
induced VBN O
psychosis NN B-Disease
was VBD O
also RB O
studied VBN O
. . O
null null null-Disease
METHODS NNS O
: : O
This DT O
was VBD O
a DT O
cross JJ O
- HYPH O
sectional JJ O
study NN O
conducted VBN O
concurrently RB O
at IN O
a DT O
teaching NN O
hospital NN O
and CC O
a DT O
drug NN O
rehabilitation NN O
center NN O
in IN O
Malaysia NNP O
. . O
null null null-Disease
Patients NNS O
with IN O
the DT O
diagnosis NN O
of IN O
methamphetamine NN O
based VBN O
on IN O
DSM NNP O
- HYPH O
IV NNP O
were VBD O
interviewed VBN O
using VBG O
the DT O
Mini NNP O
International NNP O
Neuropsychiatric NNP O
Interview NNP O
( , O
M NNP O
. . O
I NNP O
. . O
N NNP O
. . O
I PRP O
. . O
) -RRB- O
for IN O
methamphetamine NN O
- HYPH O
induced VBN O
psychosis NN B-Disease
and CC O
other JJ O
Axis NNP O
I NN O
psychiatric JJ B-Disease
disorders NNS I-Disease
. . O
null null null-Disease
The DT O
information NN O
on IN O
sociodemographic JJ O
background NN O
and CC O
drug NN O
use NN O
history NN O
was VBD O
obtained VBN O
from IN O
interview NN O
or CC O
medical JJ O
records NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Of IN O
292 CD O
subjects NNS O
, , O
47 CD O
. . O
9 CD O
% NN O
of IN O
the DT O
subjects NNS O
had VBD O
a DT O
past JJ O
history NN O
of IN O
psychotic JJ B-Disease
symptoms NNS I-Disease
and CC O
13 CD O
. . O
0 CD O
% NN O
of IN O
the DT O
patients NNS O
were VBD O
having VBG O
current JJ O
psychotic JJ B-Disease
symptoms NNS I-Disease
. . O
null null null-Disease
Co NN O
- HYPH O
morbid JJ O
major JJ O
depressive JJ B-Disease
disorder NN I-Disease
( : O
OR NN O
= SYM O
7 CD O
. . O
18 CD O
, , O
95 CD O
CI NN O
= SYM O
2 CD O
. . O
612 CD O
- HYPH O
19 CD O
. . O
708 CD O
) -RRB- O
, , O
bipolar JJ B-Disease
disorder NN I-Disease
( : O
OR CC O
= SYM O
13 CD O
. . O
807 CD O
, , O
95 CD O
CI NN O
= SYM O
5 CD O
. . O
194 CD O
- SYM O
36 CD O
. . O
706 CD O
) -RRB- O
, , O
antisocial JJ B-Disease
personality NN I-Disease
disorder NN I-Disease
( , O
OR CC O
= SYM O
12 CD O
. . O
619 CD O
, , O
95 CD O
CI NN O
= SYM O
6 CD O
. . O
702 CD O
- SYM O
23 CD O
. . O
759 CD O
) -RRB- O
and CC O
heavy JJ O
methamphetamine NN O
uses NNS O
were VBD O
significantly RB O
associated VBN O
with IN O
lifetime NN O
methamphetamine NN O
- HYPH O
induced VBN O
psychosis NN B-Disease
after IN O
adjusted VBN O
for IN O
other JJ O
factors NNS O
. . O
null null null-Disease
Major JJ B-Disease
depressive JJ I-Disease
disorder NN I-Disease
( : O
OR NN O
= SYM O
2 CD O
. . O
870 CD O
, , O
CI NN O
= SYM O
1 CD O
. . O
154 CD O
- HYPH O
7 CD O
. . O
142 CD O
) -RRB- O
and CC O
antisocial JJ B-Disease
personality NN I-Disease
disorder NN I-Disease
( : O
OR CC O
= SYM O
3 CD O
. . O
299 CD O
, , O
95 CD O
CI NN O
= SYM O
1 CD O
. . O
375 CD O
- SYM O
7 CD O
. . O
914 CD O
) -RRB- O
were VBD O
the DT O
only JJ O
factors NNS O
associated VBN O
with IN O
current JJ O
psychosis NN B-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
There EX O
was VBD O
a DT O
high JJ O
risk NN O
of IN O
psychosis NN B-Disease
in IN O
patients NNS O
with IN O
methamphetamine NN O
dependence NN O
. . O
null null null-Disease
It PRP O
was VBD O
associated VBN O
with IN O
co NN O
- HYPH O
morbid JJ O
affective JJ B-Disease
disorder NN I-Disease
, , O
antisocial JJ B-Disease
personality NN I-Disease
, , O
and CC O
heavy JJ O
methamphetamine NN O
use NN O
. . O
null null null-Disease
It PRP O
is VBZ O
recommended VBN O
that IN O
all DT O
cases NNS O
of IN O
methamphetamine NN O
dependence NN O
should MD O
be VB O
screened VBN O
for IN O
psychotic JJ B-Disease
symptoms NNS I-Disease
. . O
null null null-Disease
Cerebellar JJ O
sensory NN O
processing NN O
alterations NNS O
impact VBP O
motor NN O
cortical JJ O
plasticity NN O
in IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
: : O
clues NNS O
from IN O
dyskinetic JJ B-Disease
patients NNS O
. . O
null null null-Disease
The DT O
plasticity NN O
of IN O
primary JJ O
motor NN O
cortex NN O
( , O
M1 NNP O
) -RRB- O
in IN O
patients NNS O
with IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
( , O
PD NN B-Disease
) -RRB- O
and CC O
levodopa NN O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
( , O
LIDs NNP B-Disease
) -RRB- O
is VBZ O
severely RB O
impaired JJ O
. . O
null null null-Disease
We PRP O
recently RB O
reported VBD O
in IN O
young JJ O
healthy JJ O
subjects NNS O
that IN O
inhibitory JJ O
cerebellar NN O
stimulation NN O
enhanced VBD O
the DT O
sensorimotor NN O
plasticity NN O
of IN O
M1 NNP O
that WDT O
was VBD O
induced VBN O
by IN O
paired VBN O
associative JJ O
stimulation NN O
( , O
PAS NNP O
) -RRB- O
. . O
null null null-Disease
This DT O
study NN O
demonstrates VBZ O
that IN O
the DT O
deficient JJ O
sensorimotor NN O
M1 NN O
plasticity NN O
in IN O
16 CD O
patients NNS O
with IN O
LIDs NNS B-Disease
could MD O
be VB O
reinstated VBN O
by IN O
a DT O
single JJ O
session NN O
of IN O
real JJ O
inhibitory JJ O
cerebellar JJ O
stimulation NN O
but CC O
not RB O
sham NN O
stimulation NN O
. . O
null null null-Disease
This DT O
was VBD O
evident JJ O
only RB O
when WRB O
a DT O
sensory JJ O
component NN O
was VBD O
involved VBN O
in IN O
the DT O
induction NN O
of IN O
plasticity NN O
, , O
indicating VBG O
that IN O
cerebellar JJ O
sensory NN O
processing NN O
function NN O
is VBZ O
involved VBN O
in IN O
the DT O
resurgence NN O
of IN O
M1 NNP O
plasticity NN O
. . O
null null null-Disease
The DT O
benefit NN O
of IN O
inhibitory JJ O
cerebellar NN O
stimulation NN O
on IN O
LIDs NNP B-Disease
is VBZ O
known VBN O
. . O
null null null-Disease
To TO O
explore VB O
whether IN O
this DT O
benefit NN O
is VBZ O
linked VBN O
to IN O
the DT O
restoration NN O
of IN O
sensorimotor NN O
plasticity NN O
of IN O
M1 NNP O
, , O
we PRP O
conducted VBD O
an DT O
additional JJ O
study NN O
looking VBG O
at IN O
changes NNS O
in IN O
LIDs NNP B-Disease
and CC O
PAS NNP O
- HYPH O
induced VBN O
plasticity NN O
after IN O
10 CD O
sessions NNS O
of IN O
either CC O
bilateral JJ O
, , O
real JJ O
inhibitory JJ O
cerebellar NN O
stimulation NN O
or CC O
sham NN O
stimulation NN O
. . O
null null null-Disease
Only RB O
real JJ O
and CC O
not RB O
sham NN O
stimulation NN O
had VBD O
an DT O
antidyskinetic JJ O
effect NN O
and CC O
it PRP O
was VBD O
paralleled VBN O
by IN O
a DT O
resurgence NN O
in IN O
the DT O
sensorimotor NN O
plasticity NN O
of IN O
M1 NNP O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
alterations NNS O
in IN O
cerebellar JJ O
sensory NN O
processing NN O
function NN O
, , O
occurring VBG O
secondary JJ O
to IN O
abnormal JJ O
basal JJ O
ganglia NN O
signals NNS O
reaching VBG O
it PRP O
, , O
may MD O
be VB O
an DT O
important JJ O
element NN O
contributing VBG O
to IN O
the DT O
maladaptive JJ O
sensorimotor NN O
plasticity NN O
of IN O
M1 NNP O
and CC O
the DT O
emergence NN O
of IN O
abnormal JJ B-Disease
involuntary JJ I-Disease
movements NNS I-Disease
. . O
null null null-Disease
The DT O
long JJ O
- HYPH O
term NN O
safety NN O
of IN O
danazol NN O
in IN O
women NNS O
with IN O
hereditary JJ B-Disease
angioedema NN I-Disease
. . O
null null null-Disease
Although IN O
the DT O
short JJ O
- HYPH O
term NN O
safety NN O
( : O
less JJR O
than IN O
or CC O
equal JJ O
to IN O
6 CD O
months NNS O
) , O
of IN O
danazol NN O
has VBZ O
been VBN O
established VBN O
in IN O
a DT O
variety NN O
of IN O
settings NNS O
, , O
no DT O
information NN O
exists VBZ O
as IN O
to IN O
its PRP$ O
long JJ O
- HYPH O
term NN O
safety NN O
. . O
null null null-Disease
We PRP O
therefore RB O
investigated VBD O
the DT O
long JJ O
- HYPH O
term NN O
safety NN O
of IN O
danazol NN O
by IN O
performing VBG O
a DT O
retrospective JJ O
chart NN O
review NN O
of IN O
60 CD O
female JJ O
patients NNS O
with IN O
hereditary JJ B-Disease
angioedema NN I-Disease
treated VBN O
with IN O
danazol NN O
for IN O
a DT O
continuous JJ O
period NN O
of IN O
6 CD O
months NNS O
or CC O
longer RBR O
. . O
null null null-Disease
The DT O
mean JJ O
age NN O
of IN O
the DT O
patients NNS O
was VBD O
35 CD O
. . O
2 CD O
years NNS O
and CC O
the DT O
mean JJ O
duration NN O
of IN O
therapy NN O
was VBD O
59 CD O
. . O
7 CD O
months NNS O
. . O
null null null-Disease
Virtually RB O
all DT O
patients NNS O
experienced VBD O
one CD O
or CC O
more JJR O
adverse JJ O
reactions NNS O
. . O
null null null-Disease
Menstrual JJ B-Disease
abnormalities NNS I-Disease
( : O
79 CD O
% NN O
) -RRB- O
, , O
weight NN B-Disease
gain NN I-Disease
( , O
60 CD O
% NN O
) NN O
, , O
muscle NN B-Disease
cramps NNS I-Disease
/ SYM O
myalgias NNS B-Disease
( , O
40 CD O
% NN O
) -RRB- O
, , O
and CC O
transaminase NN O
elevations NNS O
( , O
40 CD O
% NN O
) -RRB- O
were VBD O
the DT O
most RBS O
common JJ O
adverse JJ O
reactions NNS O
. . O
null null null-Disease
The DT O
drug NN O
was VBD O
discontinued VBN O
due IN O
to IN O
adverse JJ O
reactions NNS O
in IN O
8 CD O
patients NNS O
. . O
null null null-Disease
No DT O
patient NN O
has VBZ O
died VBN O
or CC O
suffered VBN O
any DT O
apparent JJ O
long JJ O
- HYPH O
term NN O
sequelae NN O
that WDT O
were VBD O
directly RB O
attributable JJ O
to IN O
the DT O
drug NN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
, , O
despite IN O
a DT O
relatively RB O
high JJ O
incidence NN O
of IN O
adverse JJ O
reactions NNS O
, , O
danazol NN O
has VBZ O
proven VBN O
to TO O
be VB O
remarkably RB O
safe JJ O
over IN O
the DT O
long JJ O
- HYPH O
term NN O
in IN O
this DT O
group NN O
of IN O
patients NNS O
. . O
null null null-Disease
The DT O
function NN O
of IN O
P2X3 NN O
receptor NN O
and CC O
NK1 NNP O
receptor NN O
antagonists NNS O
on IN O
cyclophosphamide NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
PURPOSE NN O
: : O
The DT O
purpose NN O
of IN O
the DT O
study NN O
is VBZ O
to TO O
explore VB O
the DT O
function NN O
of IN O
P2X3 NN O
and CC O
NK1 NNP O
receptors NNS O
antagonists NNS O
on IN O
cyclophosphamide NN O
( -LRB- O
CYP NNP O
) -RRB- O
- HYPH O
induced VBN O
cystitis NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
Sixty JJ O
female JJ O
Sprague NNP O
- HYPH O
Dawley NNP O
( -LRB- O
SD NNP O
) -RRB- O
rats NNS O
were VBD O
randomly RB O
divided VBN O
into IN O
three CD O
groups NNS O
. . O
null null null-Disease
The DT O
rats NNS O
in IN O
the DT O
control NN O
group NN O
were VBD O
intraperitoneally RB O
( : O
i PRP O
. . O
p NN O
. . O
) -RRB- O
injected VBN O
with IN O
0 CD O
. . O
9 CD O
% NN O
saline NN O
( : O
4 CD O
ml NNS O
/ SYM O
kg NNS O
) -RRB- O
; : O
the DT O
rats NNS O
in IN O
the DT O
model NN O
group NN O
were VBD O
i XX O
. . O
p UH O
. . O
injected VBN O
with IN O
CYP NNP O
( : O
150 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
; : O
and CC O
the DT O
rats NNS O
in IN O
the DT O
intervention NN O
group NN O
were VBD O
i XX O
. . O
p UH O
. . O
injected VBN O
with IN O
CYP NNP O
with IN O
subsequently RB O
perfusion NN O
of IN O
bladder NN O
with IN O
P2X3 NN O
and CC O
NK1 NN O
receptors NNS O
' POS O
antagonists NNS O
, , O
Suramin NNP O
and CC O
GR NNP O
82334 CD O
. . O
null null null-Disease
Spontaneous JJ O
pain NN B-Disease
behaviors NNS O
following VBG O
the DT O
administration NN O
of IN O
CYP NNP O
were VBD O
observed VBN O
. . O
null null null-Disease
Urodynamic JJ O
parameters NNS O
, , O
bladder NN O
pressure NN O
- HYPH O
volume NN O
curve NN O
, , O
maximum JJ O
voiding NN O
pressure NN O
( , O
MVP NNP O
) -RRB- O
, , O
and CC O
maximum NN O
cystometric JJ O
capacity NN O
( -LRB- O
MCC NNP O
) -RRB- O
, , O
were VBD O
recorded VBN O
. . O
null null null-Disease
Pathological JJ O
changes NNS O
in IN O
bladder NN O
tissue NN O
were VBD O
observed VBN O
. . O
null null null-Disease
Immunofluorescence NN O
was VBD O
used VBN O
to TO O
detect VB O
the DT O
expression NN O
of IN O
P2X3 NN O
and CC O
NK1 NNP O
receptors NNS O
in IN O
bladder NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Cyclophosphamide NN O
treatment NN O
increased VBD O
the DT O
spontaneous JJ O
pain NN B-Disease
behaviors NNS O
scores NNS O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
bladder NN O
instability NN O
during IN O
urine NN O
storage NN O
period NN O
of IN O
model NN O
group NN O
was VBD O
significantly RB O
higher JJR O
than IN O
intervention NN O
group NN O
( : O
X NNP O
( : O
2 CD O
) SYM O
= SYM O
7 CD O
. . O
619 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
007 CD O
) -RRB- O
and CC O
control NN O
group NN O
( : O
X NN O
( : O
2 CD O
) SYM O
= SYM O
13 CD O
. . O
755 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
000 CD O
) -RRB- O
. . O
null null null-Disease
MCC NNP O
in IN O
the DT O
model NN O
group NN O
was VBD O
lower JJR O
than IN O
the DT O
control NN O
and CC O
intervention NN O
groups NNS O
( , O
P NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Histological JJ O
changes NNS O
evident JJ O
in IN O
model NN O
and CC O
intervention NN O
groups NNS O
rats VBZ O
' POS O
bladder NN O
included VBD O
edema NN B-Disease
, , O
vasodilation NN O
, , O
and CC O
infiltration NN O
of IN O
inflammatory JJ O
cells NNS O
. . O
null null null-Disease
In IN O
model NN O
group NN O
, , O
the DT O
expression NN O
of IN O
P2X3 NNP O
receptor NN O
increased VBD O
in IN O
urothelium NN O
and CC O
suburothelium NN O
, , O
and CC O
NK1 NNP O
receptor NN O
increased VBD O
in IN O
suburothelium NN O
, , O
while IN O
the DT O
expression NN O
of IN O
them PRP O
in IN O
intervention NN O
group NN O
was VBD O
lower JJR O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
In IN O
CYP NNP O
- HYPH O
induced VBN O
cystitis NN B-Disease
, , O
the DT O
expression NN O
of IN O
P2X3 NN O
and CC O
NK1 NNP O
receptors NNS O
increased VBD O
in IN O
urothelium NN O
and CC O
/ SYM O
or CC O
suburothelium NN O
. . O
null null null-Disease
Perfusion NN O
of IN O
bladder NN O
with IN O
P2X3 NN O
and CC O
NK1 NNP O
receptors NNS O
antagonists NNS O
ameliorated VBD O
the DT O
bladder NN O
function NN O
. . O
null null null-Disease
Patient JJ O
tolerance NN O
study NN O
of IN O
topical JJ O
chlorhexidine NN O
diphosphanilate NN O
: : O
a DT O
new JJ O
topical JJ O
agent NN O
for IN O
burns NNS B-Disease
. . O
null null null-Disease
Effective JJ O
topical JJ O
antimicrobial JJ O
agents NNS O
decrease VBP O
infection NN B-Disease
and CC O
mortality NN O
in IN O
burn NN B-Disease
patients NNS O
. . O
null null null-Disease
Chlorhexidine NN O
phosphanilate NN O
( -LRB- O
CHP NNP O
) -RRB- O
, , O
a DT O
new JJ O
broad JJ O
- HYPH O
spectrum NN O
antimicrobial JJ O
agent NN O
, , O
has VBZ O
been VBN O
evaluated VBN O
as IN O
a DT O
topical JJ O
burn NN B-Disease
wound NN O
dressing VBG O
in IN O
cream NN O
form NN O
, , O
but CC O
preliminary JJ O
clinical JJ O
trials NNS O
reported VBD O
that IN O
it PRP O
was VBD O
painful JJ O
upon IN O
application NN O
. . O
null null null-Disease
This DT O
study NN O
compared VBD O
various JJ O
concentrations NNS O
of IN O
CHP NNP O
to TO O
determine VB O
if IN O
a DT O
tolerable JJ O
concentration NN O
could MD O
be VB O
identified VBN O
with IN O
retention NN O
of IN O
antimicrobial JJ O
efficacy NN O
. . O
null null null-Disease
Twenty CD O
- HYPH O
nine CD O
burn NN B-Disease
patients NNS O
, , O
each DT O
with IN O
two CD O
similar JJ O
burns NNS B-Disease
which WDT O
could MD O
be VB O
separately RB O
treated VBN O
, , O
were VBD O
given VBN O
pairs NNS O
of IN O
treatments NNS O
at IN O
successive JJ O
12 CD O
- HYPH O
h NN O
intervals NNS O
over IN O
a DT O
3 CD O
- HYPH O
day NN O
period NN O
. . O
null null null-Disease
One CD O
burn NN B-Disease
site NN O
was VBD O
treated VBN O
with IN O
each DT O
of IN O
four CD O
different JJ O
CHP NNP O
concentrations NNS O
, , O
from IN O
0 CD O
. . O
25 CD O
per NN O
cent NN O
to IN O
2 CD O
per NN O
cent NN O
, , O
their PRP$ O
vehicle NN O
, , O
and CC O
1 CD O
per NN O
cent NN O
silver NN O
sulphadiazine NN O
( -LRB- O
AgSD NNP O
) -RRB- O
cream NN O
, , O
an DT O
antimicrobial JJ O
agent NN O
frequently RB O
used VBN O
for IN O
topical JJ O
treatment NN O
of IN O
burn NN B-Disease
wounds NNS O
. . O
null null null-Disease
The DT O
other JJ O
site NN O
was VBD O
always RB O
treated VBN O
with IN O
AgSD NNP O
cream NN O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
direct JJ O
relationship NN O
between IN O
CHP NNP O
concentration NN O
and CC O
patients NNS O
' POS O
ratings NNS O
of IN O
pain NN B-Disease
on IN O
an DT O
analogue NN O
scale NN O
. . O
null null null-Disease
The DT O
0 CD O
. . O
25 CD O
per NN O
cent NN O
CHP NN O
cream NN O
was VBD O
closest JJS O
to IN O
AgSD NNP O
in IN O
pain NN B-Disease
tolerance NN O
; : O
however RB O
, , O
none NN O
of IN O
the DT O
treatments NNS O
differed VBD O
statistically RB O
from IN O
AgSD NNP O
or CC O
from IN O
each DT O
other JJ O
. . O
null null null-Disease
In IN O
addition NN O
, , O
ease NN O
of IN O
application NN O
of IN O
CHP NNP O
creams NNS O
was VBD O
less RBR O
satisfactory JJ O
than IN O
that DT O
of IN O
AgSD NNP O
. . O
null null null-Disease
It PRP O
was VBD O
concluded VBN O
that IN O
formulations NNS O
at IN O
or CC O
below IN O
0 CD O
. . O
5 CD O
per NN O
cent NN O
CHP NNP O
may MD O
prove VB O
acceptable JJ O
for IN O
wound NN O
care NN O
, , O
but CC O
the DT O
vehicle NN O
system NN O
needs VBZ O
pharmaceutical JJ O
improvement NN O
to TO O
render VB O
it PRP O
more RBR O
tolerable JJ O
and CC O
easier JJR O
to TO O
use VB O
. . O
null null null-Disease
Acute JJ O
hepatitis NN B-Disease
associated VBN O
with IN O
clopidogrel NN O
: : O
a DT O
case NN O
report NN O
and CC O
review NN O
of IN O
the DT O
literature NN O
. . O
null null null-Disease
Drug NN O
- HYPH O
induced VBN O
hepatotoxicity NN B-Disease
is VBZ O
a DT O
common JJ O
cause NN O
of IN O
acute JJ O
hepatitis NN B-Disease
, , O
and CC O
the DT O
recognition NN O
of IN O
the DT O
responsible JJ O
drug NN O
may MD O
be VB O
difficult JJ O
. . O
null null null-Disease
We PRP O
describe VBP O
a DT O
case NN O
of IN O
clopidogrel NN O
- HYPH O
related VBN O
acute JJ O
hepatitis NN B-Disease
. . O
null null null-Disease
The DT O
diagnosis NN O
is VBZ O
strongly RB O
suggested VBN O
by IN O
an DT O
accurate JJ O
medical JJ O
history NN O
and CC O
liver NN O
biopsy NN O
. . O
null null null-Disease
Reports NNS O
about IN O
cases NNS O
of IN O
hepatotoxicity NN B-Disease
due IN O
to IN O
clopidogrel NN O
are VBP O
increasing VBG O
in IN O
the DT O
last JJ O
few JJ O
years NNS O
, , O
after IN O
the DT O
increased JJ O
use NN O
of IN O
this DT O
drug NN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
we PRP O
believe VBP O
that IN O
physicians NNS O
should MD O
carefully RB O
consider VB O
the DT O
risk NN O
of IN O
drug NN O
- HYPH O
induced VBN O
hepatic JJ B-Disease
injury NN I-Disease
when WRB O
clopidogrel NN O
is VBZ O
prescribed VBN O
. . O
null null null-Disease
Bortezomib NNP O
and CC O
dexamethasone NN O
as IN O
salvage NN O
therapy NN O
in IN O
patients NNS O
with IN O
relapsed VBN O
/ SYM O
refractory JJ O
multiple JJ B-Disease
myeloma NN I-Disease
: : O
analysis NN O
of IN O
long JJ O
- HYPH O
term NN O
clinical JJ O
outcomes NNS O
. . O
null null null-Disease
Bortezomib NNP O
( : O
bort NNP O
) -RRB- O
- HYPH O
dexamethasone NN O
( , O
dex NN O
) -RRB- O
is VBZ O
an DT O
effective JJ O
therapy NN O
for IN O
relapsed VBN O
/ SYM O
refractory JJ O
( , O
R NN O
/ , O
R NN O
) , O
multiple JJ B-Disease
myeloma NN I-Disease
( -LRB- O
MM NN B-Disease
) -RRB- O
. . O
null null null-Disease
This DT O
retrospective JJ O
study NN O
investigated VBD O
the DT O
combination NN O
of IN O
bort NN O
( , O
1 CD O
. . O
3 CD O
mg CD O
/ SYM O
m NN O
( SYM O
2 CD O
) NN O
on IN O
days NNS O
1 CD O
, , O
4 CD O
, , O
8 CD O
, , O
and CC O
11 CD O
every DT O
3 CD O
weeks NNS O
) -RRB- O
and CC O
dex NN O
( : O
20 CD O
mg NN O
on IN O
the DT O
day NN O
of IN O
and CC O
the DT O
day NN O
after IN O
bort NN O
) -RRB- O
as IN O
salvage NN O
treatment NN O
in IN O
85 CD O
patients NNS O
with IN O
R NNP O
/ SYM O
R NN O
MM NN B-Disease
after IN O
prior JJ O
autologous JJ O
stem NN O
cell NN O
transplantation NN O
or CC O
conventional JJ O
chemotherapy NN O
. . O
null null null-Disease
The DT O
median JJ O
number NN O
of IN O
prior JJ O
lines NNS O
of IN O
therapy NN O
was VBD O
2 CD O
. . O
null null null-Disease
Eighty CD O
- HYPH O
seven CD O
percent NN O
of IN O
the DT O
patients NNS O
had VBD O
received VBN O
immunomodulatory JJ O
drugs NNS O
included VBN O
in IN O
some DT O
line NN O
of IN O
therapy NN O
before IN O
bort NN O
- HYPH O
dex NN O
. . O
null null null-Disease
The DT O
median JJ O
number NN O
of IN O
bort NN O
- HYPH O
dex NN O
cycles NNS O
was VBD O
6 CD O
, , O
up IN O
to IN O
a DT O
maximum NN O
of IN O
12 CD O
cycles NNS O
. . O
null null null-Disease
On IN O
an DT O
intention NN O
- HYPH O
to IN O
- HYPH O
treat NN O
basis NN O
, , O
55 CD O
% NN O
of IN O
the DT O
patients NNS O
achieved VBD O
at IN O
least JJS O
partial JJ O
response NN O
, , O
including VBG O
19 CD O
% NN O
CR NN O
and CC O
35 CD O
% NN O
achieved VBD O
at RB O
least RBS O
very RB O
good JJ O
partial JJ O
response NN O
. . O
null null null-Disease
Median JJ O
durations NNS O
of IN O
response NN O
, , O
time NN O
to IN O
next JJ O
therapy NN O
and CC O
treatment NN O
- HYPH O
free JJ O
interval NN O
were VBD O
8 CD O
, , O
11 CD O
. . O
2 CD O
, , O
and CC O
5 CD O
. . O
1 CD O
months NNS O
, , O
respectively RB O
. . O
null null null-Disease
The DT O
most RBS O
relevant JJ O
adverse JJ O
event NN O
was VBD O
peripheral JJ B-Disease
neuropathy NN I-Disease
, , O
which WDT O
occurred VBD O
in IN O
78 CD O
% NN O
of IN O
the DT O
patients NNS O
( , O
grade NN O
II CD O
, , O
38 CD O
% NN O
; , O
grade NN O
III NNP O
, , O
21 CD O
% NN O
) -RRB- O
and CC O
led VBD O
to IN O
treatment NN O
discontinuation NN O
in IN O
6 CD O
% NN O
. . O
null null null-Disease
With IN O
a DT O
median JJ O
follow NN O
up RP O
of IN O
22 CD O
months NNS O
, , O
median JJ O
time NN O
to IN O
progression NN O
, , O
progression NN O
- HYPH O
free JJ O
survival NN O
( , O
PFS NNP O
) -RRB- O
and CC O
overall JJ O
survival NN O
( -LRB- O
OS NNP O
) -RRB- O
were VBD O
8 CD O
. . O
9 CD O
, , O
8 CD O
. . O
7 CD O
, , O
and CC O
22 CD O
months NNS O
, , O
respectively RB O
. . O
null null null-Disease
Prolonged VBN O
PFS NNP O
and CC O
OS NNP O
were VBD O
observed VBN O
in IN O
patients NNS O
achieving VBG O
CR NN O
and CC O
receiving VBG O
bort NN O
- HYPH O
dex NN O
a DT O
single JJ O
line NN O
of IN O
prior JJ O
therapy NN O
. . O
null null null-Disease
Bort NNP O
- HYPH O
dex NN O
was VBD O
an DT O
effective JJ O
salvage NN O
treatment NN O
for IN O
MM NNP B-Disease
patients NNS O
, , O
particularly RB O
for IN O
those DT O
in IN O
first JJ O
relapse NN O
. . O
null null null-Disease
Pubertal JJ O
exposure NN O
to IN O
Bisphenol NNP O
A NNP O
increases VBZ O
anxiety NN B-Disease
- HYPH O
like JJ O
behavior NN O
and CC O
decreases VBZ O
acetylcholinesterase NN O
activity NN O
of IN O
hippocampus NN O
in IN O
adult NN O
male JJ O
mice NN O
. . O
null null null-Disease
The DT O
negative JJ O
effects NNS O
of IN O
Bisphenol NNP O
A NNP O
( , O
BPA NNP O
) -RRB- O
on IN O
neurodevelopment NN O
and CC O
behaviors NNS O
have VBP O
been VBN O
well RB O
established VBN O
. . O
null null null-Disease
Acetylcholinesterase NNP O
( , O
AChE NNP O
) -RRB- O
is VBZ O
a DT O
regulatory JJ O
enzyme NN O
which WDT O
is VBZ O
involved VBN O
in IN O
anxiety NN B-Disease
- HYPH O
like JJ O
behavior NN O
. . O
null null null-Disease
This DT O
study NN O
investigated VBD O
behavioral JJ O
phenotypes NNS O
and CC O
AChE NN O
activity NN O
in IN O
male JJ O
mice NNS O
following VBG O
BPA NNP O
exposure NN O
during IN O
puberty NN O
. . O
null null null-Disease
On IN O
postnatal JJ O
day NN O
( , O
PND NN O
) SYM O
35 CD O
, , O
male JJ O
mice NNS O
were VBD O
exposed VBN O
to IN O
50mg CD O
BPA NN O
/ SYM O
kg NN O
diet NN O
per IN O
day NN O
for IN O
a DT O
period NN O
of IN O
35 CD O
days NNS O
. . O
null null null-Disease
On IN O
PND71 NNP O
, , O
a DT O
behavioral JJ O
assay NN O
was VBD O
performed VBN O
using VBG O
the DT O
elevated VBN O
plus JJ O
maze NN O
( , O
EPM NNP O
) -RRB- O
and CC O
the DT O
light JJ O
/ SYM O
dark JJ O
test NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
AChE NNP O
activity NN O
was VBD O
measured VBN O
in IN O
the DT O
prefrontal JJ O
cortex NN O
, , O
hypothalamus NN O
, , O
cerebellum NN O
and CC O
hippocampus NN O
. . O
null null null-Disease
Results NNS O
from IN O
our PRP$ O
behavioral JJ O
phenotyping NN O
indicated VBD O
that IN O
anxiety NN B-Disease
- HYPH O
like JJ O
behavior NN O
was VBD O
increased VBN O
in IN O
mice NNS O
exposed VBN O
to IN O
BPA NNP O
. . O
null null null-Disease
AChE NNP O
activity NN O
was VBD O
significantly RB O
decreased VBN O
in IN O
the DT O
hippocampus NN O
of IN O
mice NNS O
with IN O
BPA NNP O
compared VBN O
to IN O
control NN O
mice NNS O
, , O
whereas IN O
no DT O
difference NN O
was VBD O
found VBN O
in IN O
the DT O
prefrontal JJ O
cortex NN O
, , O
hypothalamus NN O
and CC O
cerebellum NN O
. . O
null null null-Disease
Our PRP$ O
findings NNS O
showed VBD O
that IN O
pubertal JJ O
BPA NNP O
exposure NN O
increased VBD O
anxiety NN B-Disease
- HYPH O
like JJ O
behavior NN O
, , O
which WDT O
may MD O
be VB O
associated VBN O
with IN O
decreased VBN O
AChE NNP O
activity NN O
of IN O
the DT O
hippocampus NN O
in IN O
adult NN O
male JJ O
mice NN O
. . O
null null null-Disease
Further JJ O
studies NNS O
are VBP O
necessary JJ O
to TO O
investigate VB O
the DT O
cholinergic JJ O
signaling NN O
of IN O
the DT O
hippocampus NN O
in IN O
PBE NNP O
induced VBN O
anxiety NN B-Disease
- HYPH O
like JJ O
behaviors NNS O
. . O
null null null-Disease
Biochemical JJ O
effects NNS O
of IN O
Solidago NNP O
virgaurea NN O
extract NN O
on IN O
experimental JJ O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
Cardiovascular JJ B-Disease
diseases NNS I-Disease
( , O
CVDs NNS B-Disease
) -RRB- O
are VBP O
the DT O
major JJ O
health NN O
problem NN O
of IN O
advanced JJ O
as RB O
well RB O
as IN O
developing VBG O
countries NNS O
of IN O
the DT O
world NN O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
investigate VB O
the DT O
protective JJ O
effect NN O
of IN O
the DT O
Solidago NNP O
virgaurea NN O
extract NN O
on IN O
isoproterenol NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
subcutaneous JJ O
injection NN O
of IN O
isoproterenol NN O
( : O
30 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
into IN O
rats NNS O
twice RB O
at IN O
an DT O
interval NN O
of IN O
24 CD O
h NNS O
, , O
for IN O
two CD O
consecutive JJ O
days NNS O
, , O
led VBD O
to IN O
a DT O
significant JJ O
increase NN O
in IN O
serum NN O
lactate NN O
dehydrogenase NN O
, , O
creatine JJ O
phosphokinase NN O
, , O
alanine NN O
transaminase NN O
, , O
aspartate NN O
transaminase NN O
, , O
and CC O
angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
activities NNS O
, , O
total JJ O
cholesterol NN O
, , O
triglycerides NNS O
, , O
free JJ O
serum NN O
fatty NN O
acid NN O
, , O
cardiac JJ O
tissue NN O
malondialdehyde NN O
( , O
MDA NN O
) -RRB- O
, , O
and CC O
nitric JJ O
oxide NN O
levels NNS O
and CC O
a DT O
significant JJ O
decrease NN O
in IN O
levels NNS O
of IN O
glutathione NN O
and CC O
superoxide NN O
dismutase NN O
in IN O
cardiac JJ O
tissue NN O
as IN O
compared VBN O
to IN O
the DT O
normal JJ O
control NN O
group NN O
( , O
P NN O
< SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Pretreatment NN O
with IN O
S NN O
. . O
virgaurea NN O
extract NN O
for IN O
5 CD O
weeks NNS O
at IN O
a DT O
dose NN O
of IN O
250 CD O
mg NNS O
/ SYM O
kg NN O
followed VBN O
by IN O
isoproterenol NN O
injection NN O
significantly RB O
prevented VBD O
the DT O
observed VBN O
alterations NNS O
. . O
null null null-Disease
Captopril NNP O
( : O
50 CD O
mg NN O
/ SYM O
kg NNS O
/ SYM O
day NN O
, , O
given VBN O
orally RB O
) -RRB- O
, , O
an DT O
inhibitor NN O
of IN O
angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
used VBN O
as IN O
a DT O
standard JJ O
cardioprotective JJ O
drug NN O
, , O
was VBD O
used VBN O
as IN O
a DT O
positive JJ O
control NN O
in IN O
this DT O
study NN O
. . O
null null null-Disease
The DT O
data NNS O
of IN O
the DT O
present JJ O
study NN O
suggest VBP O
that IN O
S NNP O
. . O
virgaurea NN O
extract NN O
exerts VBZ O
its PRP$ O
protective JJ O
effect NN O
by IN O
decreasing VBG O
MDA NNP O
level NN O
and CC O
increasing VBG O
the DT O
antioxidant JJ O
status NN O
in IN O
isoproterenol NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
The DT O
study NN O
emphasizes VBZ O
the DT O
beneficial JJ O
action NN O
of IN O
S NNP O
. . O
virgaurea NN O
extract NN O
as IN O
a DT O
cardioprotective JJ O
agent NN O
. . O
null null null-Disease
"""" `` O
Real JJ O
- HYPH O
world NN O
"""" '' O
data NNS O
on IN O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
lenalidomide NN O
and CC O
dexamethasone NN O
in IN O
patients NNS O
with IN O
relapsed VBN O
/ SYM O
refractory JJ O
multiple JJ B-Disease
myeloma NN I-Disease
who WP O
were VBD O
treated VBN O
according VBG O
to IN O
the DT O
standard JJ O
clinical JJ O
practice NN O
: : O
a DT O
study NN O
of IN O
the DT O
Greek NNP O
Myeloma NNP B-Disease
Study NNP O
Group NNP O
. . O
null null null-Disease
Lenalidomide NN O
and CC O
dexamethasone NN O
( , O
RD NN O
) -RRB- O
is VBZ O
a DT O
standard NN O
of IN O
care NN O
for IN O
relapsed VBN O
/ SYM O
refractory JJ O
multiple JJ B-Disease
myeloma NN I-Disease
( , O
RRMM NNP B-Disease
) -RRB- O
, , O
but CC O
there EX O
is VBZ O
limited JJ O
published VBN O
data NNS O
on IN O
its PRP$ O
efficacy NN O
and CC O
safety NN O
in IN O
the DT O
"""" `` O
real JJ O
world NN O
"""" '' O
( , O
RW NNP O
) -RRB- O
, , O
according VBG O
to IN O
the DT O
International NNP O
Society NNP O
of IN O
Pharmacoeconomics NNP O
and CC O
Outcomes NNPS O
Research NNP O
definition NN O
. . O
null null null-Disease
We PRP O
studied VBD O
212 CD O
RRMM NNP B-Disease
patients NNS O
who WP O
received VBD O
RD NN O
in IN O
RW NNP O
. . O
null null null-Disease
Objective JJ O
response NN O
( : O
> NFP O
PR NN O
( , O
partial JJ O
response NN O
) -RRB- O
) -RRB- O
rate NN O
was VBD O
77 CD O
. . O
4 CD O
% NN O
( , O
complete JJ O
response NN O
( -LRB- O
CR NN O
) -RRB- O
, , O
20 CD O
. . O
2 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Median JJ O
time NN O
to IN O
first JJ O
and CC O
best JJS O
response NN O
was VBD O
2 CD O
and CC O
5 CD O
months NNS O
, , O
respectively RB O
. . O
null null null-Disease
Median JJ O
time NN O
to IN O
CR NN O
when WRB O
RD NN O
was VBD O
given VBN O
as IN O
2nd JJ O
or CC O
> SYM O
2 CD O
( SYM O
nd CD O
) SYM O
- HYPH O
line NN O
treatment NN O
at IN O
4 CD O
and CC O
11 CD O
months NNS O
, , O
respectively RB O
. . O
null null null-Disease
Quality NN O
of IN O
response NN O
was VBD O
independent JJ O
of IN O
previous JJ O
lines NNS O
of IN O
therapies NNS O
or CC O
previous JJ O
exposure NN O
to IN O
thalidomide NN O
or CC O
bortezomib NN O
. . O
null null null-Disease
Median JJ O
duration NN O
of IN O
response NN O
was VBD O
34 CD O
. . O
4 CD O
months NNS O
, , O
and CC O
it PRP O
was VBD O
higher JJR O
in IN O
patients NNS O
who WP O
received VBD O
RD NN O
until IN O
progression NN O
( : O
not RB O
reached VBN O
versus IN O
19 CD O
months NNS O
, , O
p NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Improvement NN O
of IN O
humoral JJ O
immunity NN O
occurred VBD O
in IN O
60 CD O
% NN O
of IN O
responders NNS O
( , O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
and CC O
in IN O
the DT O
majority NN O
of IN O
patients NNS O
who WP O
achieved VBD O
stable JJ O
disease NN O
. . O
null null null-Disease
Adverse JJ O
events NNS O
were VBD O
reported VBN O
in IN O
68 CD O
. . O
9 CD O
% NN O
of IN O
patients NNS O
( , O
myelosuppression NN B-Disease
in IN O
49 CD O
. . O
4 CD O
% NN O
) -RRB- O
and CC O
12 CD O
. . O
7 CD O
% NN O
of IN O
patients NNS O
needed VBD O
hospitalization NN O
. . O
null null null-Disease
Peripheral JJ B-Disease
neuropathy NN I-Disease
was VBD O
observed VBN O
only RB O
in IN O
2 CD O
. . O
5 CD O
% NN O
of IN O
patients NNS O
and CC O
deep JJ B-Disease
vein NN I-Disease
thrombosis NN I-Disease
in IN O
5 CD O
. . O
7 CD O
% NN O
. . O
null null null-Disease
Dose NN O
reductions NNS O
were VBD O
needed VBN O
in IN O
31 CD O
% NN O
of IN O
patients NNS O
and CC O
permanent JJ O
discontinuation NN O
in IN O
38 CD O
. . O
9 CD O
% NN O
. . O
null null null-Disease
Median JJ O
time NN O
to IN O
treatment NN O
discontinuation NN O
was VBD O
16 CD O
. . O
8 CD O
months NNS O
. . O
null null null-Disease
Performance NN O
status NN O
( : O
PS NN O
) -RRB- O
and CC O
initial JJ O
lenalidomide NN O
dose NN O
predicted VBN O
for IN O
treatment NN O
discontinuation NN O
. . O
null null null-Disease
Extra JJ O
- HYPH O
medullary NN O
relapses NNS O
occurred VBD O
in IN O
3 CD O
. . O
8 CD O
% NN O
of IN O
patients NNS O
. . O
null null null-Disease
Our PRP$ O
study NN O
confirms VBZ O
that IN O
RD NN O
is VBZ O
effective JJ O
and CC O
safe JJ O
in IN O
RRMM NN B-Disease
in IN O
the DT O
RW NNP O
; : O
it PRP O
produces VBZ O
durable JJ O
responses NNS O
especially RB O
in IN O
patients NNS O
who WP O
continue VBP O
on IN O
treatment NN O
till IN O
progression NN O
and CC O
improves VBZ O
humoral JJ O
immunity NN O
even RB O
in IN O
patients NNS O
with IN O
stable JJ O
disease NN O
. . O
null null null-Disease
The DT O
cytogenetic JJ O
action NN O
of IN O
ifosfamide NN O
, , O
mesna NN O
, , O
and CC O
their PRP$ O
combination NN O
on IN O
peripheral JJ O
rabbit NN O
lymphocytes NNS O
: : O
an DT O
in FW O
vivo FW O
/ SYM O
in FW O
vitro FW O
cytogenetic JJ O
study NN O
. . O
null null null-Disease
Ifosfamide NNP O
( , O
IFO NNP O
) -RRB- O
is VBZ O
an DT O
alkylating VBG O
nitrogen NN O
mustard NN O
, , O
administrated VBN O
as IN O
an DT O
antineoplasmic JJ O
agent NN O
. . O
null null null-Disease
It PRP O
is VBZ O
characterized VBN O
by IN O
its PRP$ O
intense JJ O
urotoxic JJ O
action NN O
, , O
leading VBG O
to IN O
hemorrhagic JJ B-Disease
cystitis NN I-Disease
. . O
null null null-Disease
This DT O
side NN O
effect NN O
of IN O
IFO NNP O
raises VBZ O
the DT O
requirement NN O
for IN O
the DT O
co NN O
- HYPH O
administration NN O
with IN O
sodium NN O
2 CD O
- HYPH O
sulfanylethanesulfonate NN O
( -LRB- O
Mesna NNP O
) -RRB- O
aiming VBG O
to TO O
avoid VB O
or CC O
minimize VB O
this DT O
effect NN O
. . O
null null null-Disease
IFO NNP O
and CC O
Mesna NNP O
were VBD O
administrated VBN O
separately RB O
on IN O
rabbit NN O
' POS O
s NN O
lymphocytes NNS O
in IN O
vivo NN O
, , O
which WDT O
were VBD O
later RB O
developed VBN O
in IN O
vitro NN O
. . O
null null null-Disease
Cytogenetic JJ O
markers NNS O
for IN O
sister NN O
chromatid NN O
exchanges NNS O
( -LRB- O
SCEs NNP O
) -RRB- O
, , O
proliferation NN O
rate NN O
index NN O
( , O
PRI NNP O
) -RRB- O
and CC O
Mitotic NNP O
Index NNP O
were VBD O
recorded VBN O
. . O
null null null-Disease
Mesna NNP O
' POS O
s NNS O
action NN O
, , O
in IN O
conjunction NN O
with IN O
IFO NNP O
reduces VBZ O
the DT O
frequency NN O
of IN O
SCEs NNS O
, , O
in IN O
comparison NN O
with IN O
the DT O
SCEs NNS O
recordings NNS O
obtained VBN O
when WRB O
IFO NNP O
is VBZ O
administered VBN O
alone RB O
. . O
null null null-Disease
In IN O
addition NN O
to IN O
this DT O
, , O
when WRB O
high JJ O
concentrations NNS O
of IN O
Mesna NNP O
were VBD O
administered VBN O
alone RB O
significant JJ O
reductions NNS O
of IN O
the DT O
PRI NNP O
were VBD O
noted VBN O
, , O
than IN O
with IN O
IFO NNP O
acting VBG O
at IN O
the DT O
same JJ O
concentration NN O
on IN O
the DT O
lymphocytes NNS O
. . O
null null null-Disease
Mesna NNP O
significantly RB O
reduces VBZ O
IFO NNP O
' POS O
s NNS O
genotoxicity NN B-Disease
, , O
while IN O
when WRB O
administered VBN O
in IN O
high JJ O
concentrations NNS O
it PRP O
acts VBZ O
in IN O
an DT O
inhibitory JJ O
fashion NN O
on IN O
the DT O
cytostatic JJ O
action NN O
of IN O
the DT O
drug NN O
. . O
null null null-Disease
Risk NN O
factors NNS O
and CC O
predictors NNS O
of IN O
levodopa NN O
- HYPH O
induced VBN O
dyskinesia NN B-Disease
among IN O
multiethnic JJ O
Malaysians NNPS O
with IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
. . O
null null null-Disease
Chronic JJ O
pulsatile JJ O
levodopa NN O
therapy NN O
for IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
( -LRB- O
PD NN B-Disease
) -RRB- O
leads VBZ O
to IN O
the DT O
development NN O
of IN O
motor NN O
fluctuations NNS O
and CC O
dyskinesia NN B-Disease
. . O
null null null-Disease
We PRP O
studied VBD O
the DT O
prevalence NN O
and CC O
predictors NNS O
of IN O
levodopa NN O
- HYPH O
induced VBN O
dyskinesia NN B-Disease
among IN O
multiethnic JJ O
Malaysian JJ O
patients NNS O
with IN O
PD NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
This DT O
is VBZ O
a DT O
cross JJ O
- HYPH O
sectional JJ O
study NN O
involving VBG O
95 CD O
patients NNS O
with IN O
PD NN B-Disease
on IN O
uninterrupted JJ O
levodopa NN O
therapy NN O
for IN O
at RB O
least RBS O
6 CD O
months NNS O
. . O
null null null-Disease
The DT O
instrument NN O
used VBD O
was VBD O
the DT O
UPDRS NNP O
questionnaires NNS O
. . O
null null null-Disease
The DT O
predictors NNS O
of IN O
dyskinesia NN B-Disease
were VBD O
determined VBN O
using VBG O
multivariate JJ O
logistic JJ O
regression NN O
analysis NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
mean JJ O
age NN O
was VBD O
65 CD O
. . O
6 CD O
+ SYM O
8 CD O
. . O
5 CD O
years NNS O
. . O
null null null-Disease
The DT O
mean JJ O
onset NN O
age NN O
was VBD O
58 CD O
. . O
5 CD O
+ SYM O
9 CD O
. . O
8 CD O
years NNS O
. . O
null null null-Disease
The DT O
median JJ O
disease NN O
duration NN O
was VBD O
6 CD O
( SYM O
7 CD O
) SYM O
years NNS O
. . O
null null null-Disease
Dyskinesia NNP B-Disease
was VBD O
present JJ O
in IN O
44 CD O
% NN O
( , O
n CD O
= SYM O
42 CD O
) -RRB- O
with IN O
median JJ O
levodopa NN O
therapy NN O
of IN O
3 CD O
years NNS O
. . O
null null null-Disease
There EX O
were VBD O
64 CD O
. . O
3 CD O
% NN O
Chinese JJ O
, , O
31 CD O
% NN O
Malays NNPS O
, , O
and CC O
3 CD O
. . O
7 CD O
% NN O
Indians NNPS O
and CC O
other JJ O
ethnic JJ O
groups NNS O
. . O
null null null-Disease
Eighty CD O
- HYPH O
one CD O
percent NN O
of IN O
patients NNS O
with IN O
dyskinesia NN B-Disease
had VBD O
clinical JJ O
fluctuations NNS O
. . O
null null null-Disease
Patients NNS O
with IN O
dyskinesia NN B-Disease
had VBD O
lower JJR O
onset NN O
age NN O
( : O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
longer JJR O
duration NN O
of IN O
levodopa NN O
therapy NN O
( , O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
longer JJR O
disease NN O
duration NN O
( , O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
higher JJR O
total JJ O
daily JJ O
levodopa NN O
dose NN O
( , O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
and CC O
higher JJR O
total JJ O
UPDRS NNP O
scores NNS O
( : O
p NN O
= SYM O
0 CD O
. . O
005 CD O
) -RRB- O
than IN O
patients NNS O
without IN O
dyskinesia NN B-Disease
. . O
null null null-Disease
The DT O
three CD O
significant JJ O
predictors NNS O
of IN O
dyskinesia NN B-Disease
were VBD O
duration NN O
of IN O
levodopa NN O
therapy NN O
, , O
onset NN O
age NN O
, , O
and CC O
total JJ O
daily JJ O
levodopa NN O
dose NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
prevalence NN O
of IN O
levodopa NN O
- HYPH O
induced VBN O
dyskinesia NN B-Disease
in IN O
our PRP$ O
patients NNS O
was VBD O
44 CD O
% NN O
. . O
null null null-Disease
The DT O
most RBS O
significant JJ O
predictors NNS O
were VBD O
duration NN O
of IN O
levodopa NN O
therapy NN O
, , O
total JJ O
daily JJ O
levodopa NN O
dose NN O
, , O
and CC O
onset NN O
age NN O
. . O
null null null-Disease
Dose NN O
- HYPH O
dependent JJ O
neurotoxicity NN B-Disease
of IN O
high JJ O
- HYPH O
dose NN O
busulfan NN O
in IN O
children NNS O
: : O
a DT O
clinical JJ O
and CC O
pharmacological JJ O
study NN O
. . O
null null null-Disease
Busulfan NNP O
is VBZ O
known VBN O
to TO O
be VB O
neurotoxic JJ B-Disease
in IN O
animals NNS O
and CC O
humans NNS O
, , O
but CC O
its PRP$ O
acute JJ O
neurotoxicity NN B-Disease
remains VBZ O
poorly RB O
characterized VBN O
in IN O
children NNS O
. . O
null null null-Disease
We PRP O
report VBP O
here RB O
a DT O
retrospective JJ O
study NN O
of IN O
123 CD O
children NNS O
( , O
median JJ O
age NN O
, , O
6 CD O
. . O
5 CD O
years NNS O
) , O
receiving VBG O
high JJ O
- HYPH O
dose NN O
busulfan NN O
in IN O
combined VBN O
chemotherapy NN O
before IN O
bone NN O
marrow NN O
transplantation NN O
for IN O
malignant JJ O
solid JJ O
tumors NNS B-Disease
, , O
brain NN B-Disease
tumors NNS I-Disease
excluded VBN O
. . O
null null null-Disease
Busulfan NNP O
was VBD O
given VBN O
p NN O
. . O
o UH O
. . O
, , O
every DT O
6 CD O
hours NNS O
for IN O
16 CD O
doses NNS O
over IN O
4 CD O
days NNS O
. . O
null null null-Disease
Two CD O
total JJ O
doses NNS O
were VBD O
consecutively RB O
used VBN O
: : O
16 CD O
mg NN O
/ SYM O
kg NNS O
, , O
then RB O
600 CD O
mg NNS O
/ SYM O
m2 CD O
. . O
null null null-Disease
The DT O
dose NN O
calculation NN O
on IN O
the DT O
basis NN O
of IN O
body NN O
surface NN O
area NN O
results VBZ O
in IN O
higher JJR O
doses NNS O
in IN O
young JJ O
children NNS O
than IN O
in IN O
older JJR O
patients NNS O
( : O
16 CD O
to TO O
28 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
. . O
null null null-Disease
Ninety CD O
- HYPH O
six CD O
patients NNS O
were VBD O
not RB O
given VBN O
anticonvulsive JJ O
prophylaxis NN O
; : O
7 CD O
( SYM O
7 CD O
. . O
5 CD O
% NN O
) -RRB- O
developed VBD O
seizures NNS B-Disease
during IN O
the DT O
4 CD O
days NNS O
of IN O
the DT O
busulfan NN O
course NN O
or CC O
within IN O
24 CD O
h NN O
after IN O
the DT O
last JJ O
dosing NN O
. . O
null null null-Disease
When WRB O
the DT O
total JJ O
busulfan NN O
dose NN O
was VBD O
taken VBN O
into IN O
account NN O
, , O
there EX O
was VBD O
a DT O
significant JJ O
difference NN O
in IN O
terms NNS O
of IN O
neurotoxicity NN B-Disease
incidence NN O
among IN O
patients NNS O
under IN O
16 CD O
mg CD O
/ SYM O
kg CD O
( SYM O
1 CD O
of IN O
57 CD O
, , O
1 CD O
. . O
7 CD O
% NN O
) -RRB- O
and CC O
patients NNS O
under IN O
600 CD O
mg CD O
/ SYM O
m2 CD O
( SYM O
6 CD O
of IN O
39 CD O
, , O
15 CD O
. . O
4 CD O
% NN O
) -RRB- O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
02 CD O
) -RRB- O
. . O
null null null-Disease
Twenty CD O
- HYPH O
seven CD O
patients NNS O
were VBD O
given VBN O
a DT O
600 CD O
- HYPH O
mg NN O
/ SYM O
m2 NN O
busulfan NN O
total JJ O
dose NN O
with IN O
continuous JJ O
i NN O
. . O
v NN O
. . O
infusion NN O
of IN O
clonazepam NN O
; : O
none NN O
had VBD O
any DT O
neurological JJ B-Disease
symptoms NNS I-Disease
. . O
null null null-Disease
Busulfan NNP O
levels NNS O
were VBD O
measured VBN O
by IN O
a DT O
gas NN O
chromatographic JJ O
- HYPH O
mass NN O
spectrometry NN O
assay NN O
in IN O
the DT O
plasma NN O
and CC O
cerebrospinal JJ O
fluid NN O
of IN O
9 CD O
children NNS O
without IN O
central JJ B-Disease
nervous JJ I-Disease
system NN I-Disease
disease NN I-Disease
under IN O
600 CD O
mg NNS O
/ SYM O
m2 CD O
busulfan NN O
with IN O
clonazepam NN O
: : O
busulfan NN O
cerebrospinal JJ O
fluid NN O
: : O
plasma NN O
ratio NN O
was VBD O
1 CD O
. . O
39 CD O
. . O
null null null-Disease
This DT O
was VBD O
significantly RB O
different JJ O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
02 CD O
) -RRB- O
from IN O
the DT O
cerebrospinal JJ O
fluid NN O
: : O
plasma NN O
ratio NN O
previously RB O
defined VBN O
in IN O
children NNS O
receiving VBG O
a DT O
16 CD O
- HYPH O
mg NN O
/ SYM O
kg NN O
total JJ O
dose NN O
of IN O
busulfan NN O
. . O
null null null-Disease
This DT O
study NN O
shows VBZ O
that IN O
busulfan JJ O
neurotoxicity NN B-Disease
is VBZ O
dose NN O
- HYPH O
dependent JJ O
in IN O
children NNS O
and CC O
efficiently RB O
prevented VBN O
by IN O
clonazepam NN O
. . O
null null null-Disease
A DT O
busulfan JJ O
dose NN O
calculated VBN O
on IN O
the DT O
basis NN O
of IN O
body NN O
surface NN O
area NN O
, , O
resulting VBG O
in IN O
higher JJR O
doses NNS O
in IN O
young JJ O
children NNS O
, , O
was VBD O
followed VBN O
by IN O
increased VBN O
neurotoxicity NN B-Disease
, , O
close JJ O
to IN O
neurotoxicity NN B-Disease
incidence NN O
observed VBN O
in IN O
adults NNS O
. . O
null null null-Disease
Since IN O
plasma NN O
pharmacokinetic JJ O
studies NNS O
showed VBD O
a DT O
faster JJR O
busulfan NN O
clearance NN O
in IN O
children NNS O
than IN O
in IN O
adults NNS O
, , O
this DT O
new JJ O
dose NN O
may MD O
approximate VB O
more RBR O
closely RB O
the DT O
adult NN O
systemic JJ O
exposure NN O
obtained VBN O
after IN O
the DT O
usual JJ O
16 CD O
- HYPH O
mg NN O
/ SYM O
kg NN O
total JJ O
dose NN O
, , O
with IN O
potential JJ O
inferences NNS O
in IN O
terms NNS O
of IN O
anticancer NN O
or CC O
myeloablative JJ O
effects NNS O
. . O
null null null-Disease
The DT O
busulfan NN O
dose NN O
in IN O
children NNS O
and CC O
infants NNS O
undergoing VBG O
bone NN O
marrow NN O
transplantation NN O
should MD O
be VB O
reconsidered VBN O
on IN O
the DT O
basis NN O
of IN O
pharmacokinetic JJ O
studies NNS O
. . O
null null null-Disease
An DT O
unexpected JJ O
diagnosis NN O
in IN O
a DT O
renal JJ O
- HYPH O
transplant NN O
patient NN O
with IN O
proteinuria NN B-Disease
treated VBN O
with IN O
everolimus NN O
: : O
AL NNP B-Disease
amyloidosis NN B-Disease
. . O
null null null-Disease
Proteinuria NN B-Disease
is VBZ O
an DT O
expected VBN O
complication NN O
in IN O
transplant NN O
patients NNS O
treated VBN O
with IN O
mammalian JJ O
target NN O
of IN O
rapamycin NN O
inhibitors NNS O
( -LRB- O
mTOR NN O
- HYPH O
i CD O
) -RRB- O
. . O
null null null-Disease
However RB O
, , O
clinical JJ O
suspicion NN O
should MD O
always RB O
be VB O
supported VBN O
by IN O
histological JJ O
evidence NN O
in IN O
order NN O
to TO O
investigate VB O
potential JJ O
alternate JJ O
diagnoses NNS O
such JJ O
as IN O
acute JJ O
or CC O
chronic JJ O
rejection NN O
, , O
interstitial JJ O
fibrosis NN B-Disease
and CC O
tubular JJ O
atrophy NN B-Disease
, , O
or CC O
recurrent JJ O
or CC O
de FW O
novo FW O
glomerulopathy NN B-Disease
. . O
null null null-Disease
In IN O
this DT O
case NN O
we PRP O
report VBP O
the DT O
unexpected JJ O
diagnosis NN O
of IN O
amyloidosis NN B-Disease
in IN O
a DT O
renal JJ O
- HYPH O
transplant NN O
patient NN O
with IN O
pre JJ O
- HYPH O
transplant NN O
monoclonal JJ O
gammapathy NN O
of IN O
undetermined JJ O
significance NN O
who WP O
developed VBD O
proteinuria NN B-Disease
after IN O
conversion NN O
from IN O
tacrolimus NN O
to IN O
everolimus NN O
. . O
null null null-Disease
Long JJ O
- HYPH O
term NN O
oral JJ O
galactose NN O
treatment NN O
prevents VBZ O
cognitive JJ B-Disease
deficits NNS I-Disease
in IN O
male JJ O
Wistar NNP O
rats NNS O
treated VBN O
intracerebroventricularly RB O
with IN O
streptozotocin NN O
. . O
null null null-Disease
Basic JJ O
and CC O
clinical JJ O
research NN O
has VBZ O
demonstrated VBN O
that IN O
dementia NN B-Disease
of IN O
sporadic JJ O
Alzheimer NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
( -LRB- O
sAD NN O
) -RRB- O
type NN O
is VBZ O
associated VBN O
with IN O
dysfunction NN O
of IN O
the DT O
insulin NN O
- HYPH O
receptor NN O
( -LRB- O
IR NN O
) -RRB- O
system NN O
followed VBN O
by IN O
decreased VBN O
glucose NN O
transport NN O
via IN O
glucose NN O
transporter NN O
GLUT4 NN O
and CC O
decreased VBN O
glucose NN O
metabolism NN O
in IN O
brain NN O
cells NNS O
. . O
null null null-Disease
An DT O
alternative JJ O
source NN O
of IN O
energy NN O
is VBZ O
d NN O
- HYPH O
galactose NN O
( , O
the DT O
C NNP O
- HYPH O
4 CD O
- HYPH O
epimer NN O
of IN O
d NN O
- HYPH O
glucose NN O
) , O
which WDT O
is VBZ O
transported VBN O
into IN O
the DT O
brain NN O
by IN O
insulin NN O
- HYPH O
independent JJ O
GLUT3 NN O
transporter NN O
where WRB O
it PRP O
might MD O
be VB O
metabolized VBN O
to IN O
glucose NN O
via IN O
the DT O
Leloir NNP O
pathway NN O
. . O
null null null-Disease
Exclusively RB O
parenteral JJ O
daily JJ O
injections NNS O
of IN O
galactose NN O
induce VBP O
memory NN B-Disease
deterioration NN I-Disease
in IN O
rodents NNS O
and CC O
are VBP O
used VBN O
to TO O
generate VB O
animal NN O
aging NN O
model NN O
, , O
but CC O
the DT O
effects NNS O
of IN O
oral JJ O
galactose NN O
treatment NN O
on IN O
cognitive JJ O
functions NNS O
have VBP O
never RB O
been VBN O
tested VBN O
. . O
null null null-Disease
We PRP O
have VBP O
investigated VBN O
the DT O
effects NNS O
of IN O
continuous JJ O
daily JJ O
oral JJ O
galactose NN O
( , O
200 CD O
mg NN O
/ SYM O
kg NNS O
/ SYM O
day NN O
) , O
treatment NN O
on IN O
cognitive JJ B-Disease
deficits NNS I-Disease
in IN O
streptozotocin NN O
- HYPH O
induced VBN O
( , O
STZ NNP O
- HYPH O
icv NNP O
) -RRB- O
rat NN O
model NN O
of IN O
sAD NN O
, , O
tested VBN O
by IN O
Morris NNP O
Water NNP O
Maze NNP O
and CC O
Passive NNP O
Avoidance NNP O
test NN O
, , O
respectively RB O
. . O
null null null-Disease
One CD O
month NN O
of IN O
oral JJ O
galactose NN O
treatment NN O
initiated VBD O
immediately RB O
after IN O
the DT O
STZ NNP O
- HYPH O
icv NNP O
administration NN O
, , O
successfully RB O
prevented VBD O
development NN O
of IN O
the DT O
STZ NNP O
- HYPH O
icv NNP O
- HYPH O
induced VBN O
cognitive JJ B-Disease
deficits NNS I-Disease
. . O
null null null-Disease
Beneficial JJ O
effect NN O
of IN O
oral JJ O
galactose NN O
was VBD O
independent JJ O
of IN O
the DT O
rat NN O
age NN O
and CC O
of IN O
the DT O
galactose NN O
dose NN O
ranging VBG O
from IN O
100 CD O
to IN O
300 CD O
mg NNS O
/ SYM O
kg NNS O
/ SYM O
day NN O
. . O
null null null-Disease
Additionally RB O
, , O
oral JJ O
galactose NN O
administration NN O
led VBD O
to IN O
the DT O
appearance NN O
of IN O
galactose NN O
in IN O
the DT O
blood NN O
. . O
null null null-Disease
The DT O
increase NN O
of IN O
galactose NN O
concentration NN O
in IN O
the DT O
cerebrospinal JJ O
fluid NN O
was VBD O
several JJ O
times NNS O
lower JJR O
after IN O
oral JJ O
than IN O
after IN O
parenteral JJ O
administration NN O
of IN O
the DT O
same JJ O
galactose NN O
dose NN O
. . O
null null null-Disease
Oral JJ O
galactose NN O
exposure NN O
might MD O
have VB O
beneficial JJ O
effects NNS O
on IN O
learning NN O
and CC O
memory NN O
ability NN O
and CC O
could MD O
be VB O
worth JJ O
investigating VBG O
for IN O
improvement NN O
of IN O
cognitive JJ B-Disease
deficits NNS I-Disease
associated VBN O
with IN O
glucose NN B-Disease
hypometabolism NN I-Disease
in IN O
AD NN B-Disease
. . O
null null null-Disease
An DT O
investigation NN O
of IN O
the DT O
pattern NN O
of IN O
kidney NN B-Disease
injury NN I-Disease
in IN O
HIV NNP O
- HYPH O
positive JJ O
persons NNS O
exposed VBN O
to IN O
tenofovir NN O
disoproxil NN O
fumarate NN O
: : O
an DT O
examination NN O
of IN O
a DT O
large JJ O
population NN O
database NN O
( , O
MHRA NNP O
database NN O
) -RRB- O
. . O
null null null-Disease
The DT O
potential NN O
for IN O
tenofovir NN O
to TO O
cause VB O
a DT O
range NN O
of IN O
kidney NN O
syndromes NNS O
has VBZ O
been VBN O
established VBN O
from IN O
mechanistic JJ O
and CC O
randomised VBN O
clinical JJ O
trials NNS O
. . O
null null null-Disease
However RB O
, , O
the DT O
exact JJ O
pattern NN O
of IN O
kidney NN O
involvement NN O
is VBZ O
still RB O
uncertain JJ O
. . O
null null null-Disease
We PRP O
undertook VBD O
a DT O
descriptive JJ O
analysis NN O
of IN O
Yellow NNP O
Card NNP O
records NNS O
of IN O
407 CD O
HIV NNP O
- HYPH O
positive JJ O
persons NNS O
taking VBG O
tenofovir NN O
disoproxil NN O
fumarate NN O
( -LRB- O
TDF NNP O
) -RRB- O
as IN O
part NN O
of IN O
their PRP$ O
antiretroviral JJ O
therapy NN O
regimen NN O
and CC O
submitted VBN O
to IN O
the DT O
Medicines NNPS O
and CC O
Healthcare NNP O
Products NNPS O
Regulatory NNP O
Agency NNP O
( -LRB- O
MHRA NNP O
) -RRB- O
with IN O
suspected VBN O
kidney NN O
adverse JJ O
effects NNS O
. . O
null null null-Disease
Reports NNS O
that WDT O
satisfy VBP O
defined VBN O
criteria NNS O
were VBD O
classified VBN O
as IN O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
, , O
kidney NN B-Disease
tubular JJ I-Disease
dysfunction NN I-Disease
and CC O
Fanconi NNP B-Disease
syndrome NN I-Disease
. . O
null null null-Disease
Of IN O
the DT O
407 CD O
Yellow NNP O
Card NNP O
records NNS O
analysed VBN O
, , O
106 CD O
satisfied JJ O
criteria NNS O
for IN O
TDF NNP O
- HYPH O
related VBN O
kidney NN B-Disease
disease NN I-Disease
, , O
of IN O
which WDT O
53 CD O
( SYM O
50 CD O
% NN O
) , O
had VBD O
features NNS O
of IN O
kidney NN B-Disease
tubular JJ I-Disease
dysfunction NN I-Disease
, , O
35 CD O
( SYM O
33 CD O
% NN O
) CD O
were VBD O
found VBN O
to TO O
have VB O
features NNS O
of IN O
glomerular JJ B-Disease
dysfunction NN I-Disease
and CC O
18 CD O
( SYM O
17 CD O
% NN O
) -RRB- O
had VBD O
Fanconi NNP B-Disease
syndrome NN I-Disease
. . O
null null null-Disease
The DT O
median JJ O
TDF NNP O
exposure NN O
was VBD O
316 CD O
days NNS O
( : O
interquartile JJ O
range NN O
120 CD O
- HYPH O
740 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
hospitalisation NN O
for IN O
TDF NNP O
kidney NN O
adverse JJ O
effects NNS O
was VBD O
high JJ O
, , O
particularly RB O
amongst IN O
patients NNS O
with IN O
features NNS O
of IN O
Fanconi NNP B-Disease
syndrome NN I-Disease
. . O
null null null-Disease
The DT O
pattern NN O
of IN O
kidney NN O
syndromes NNS O
in IN O
this DT O
population NN O
series NN O
mirrors VBZ O
that IN O
reported VBN O
in IN O
randomised JJ O
clinical JJ O
trials NNS O
. . O
null null null-Disease
Cessation NN O
of IN O
TDF NNP O
was VBD O
associated VBN O
with IN O
complete JJ O
restoration NN O
of IN O
kidney NN O
function NN O
in IN O
up IN O
half NN O
of IN O
the DT O
patients NNS O
in IN O
this DT O
report NN O
. . O
null null null-Disease
Incidence NN O
of IN O
postoperative JJ B-Disease
delirium NN I-Disease
is VBZ O
high JJ O
even RB O
in IN O
a DT O
population NN O
without IN O
known JJ O
risk NN O
factors NNS O
. . O
null null null-Disease
PURPOSE NN O
: : O
Postoperative JJ B-Disease
delirium NN I-Disease
is VBZ O
a DT O
recognized VBN O
complication NN O
in IN O
populations NNS O
at IN O
risk NN O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
assess VB O
the DT O
prevalence NN O
of IN O
early JJ O
postoperative JJ B-Disease
delirium NN I-Disease
in IN O
a DT O
population NN O
without IN O
known JJ O
risk NN O
factors NNS O
admitted VBN O
to IN O
the DT O
ICU NNP O
for IN O
postoperative JJ O
monitoring NN O
after IN O
elective JJ O
major JJ O
surgery NN O
. . O
null null null-Disease
The DT O
secondary JJ O
outcome NN O
investigated VBN O
is VBZ O
to TO O
identify VB O
eventual JJ O
independent JJ O
risk NN O
factors NNS O
among IN O
demographic JJ O
data NNS O
and CC O
anesthetic JJ O
drugs NNS O
used VBN O
. . O
null null null-Disease
METHODS NNS O
: : O
An DT O
observational JJ O
, , O
prospective JJ O
study NN O
was VBD O
conducted VBN O
on IN O
a DT O
consecutive JJ O
cohort NN O
of IN O
patients NNS O
admitted VBN O
to IN O
our PRP$ O
ICU NNP O
within IN O
and CC O
for IN O
at IN O
least JJS O
24 CD O
h NN O
after IN O
major JJ O
surgical JJ O
procedures NNS O
. . O
null null null-Disease
Exclusion NN O
criteria NNS O
were VBD O
any DT O
preexisting VBG O
predisposing JJ O
factor NN O
for IN O
delirium NN B-Disease
or CC O
other JJ O
potentially RB O
confounding JJ O
neurological JJ B-Disease
dysfunctions NNS I-Disease
. . O
null null null-Disease
Patients NNS O
were VBD O
assessed VBN O
daily RB O
using VBG O
the DT O
confusion NN B-Disease
assessment NN O
method NN O
for IN O
the DT O
ICU NNP O
scale NN O
for IN O
3 CD O
days NNS O
after IN O
the DT O
surgical JJ O
procedure NN O
. . O
null null null-Disease
Early JJ O
postoperative JJ B-Disease
delirium NN I-Disease
incidence NN O
risk NN O
factors NNS O
were VBD O
then RB O
assessed VBN O
through IN O
three CD O
different JJ O
multiple JJ O
regression NN O
models NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
According VBG O
to IN O
the DT O
confusion NN O
assessment NN O
method NN O
for IN O
the DT O
ICU NNP O
scale NN O
, , O
28 CD O
% NN O
of IN O
patients NNS O
were VBD O
diagnosed VBN O
with IN O
early JJ O
postoperative JJ B-Disease
delirium NN I-Disease
. . O
null null null-Disease
The DT O
use NN O
of IN O
thiopentone NN O
was VBD O
significantly RB O
associated VBN O
with IN O
an DT O
eight CD O
- HYPH O
fold NN O
- HYPH O
higher JJR O
risk NN O
for IN O
delirium NN B-Disease
compared VBN O
to IN O
propofol NN O
( : O
57 CD O
. . O
1 CD O
% NN O
vs IN O
. . O
7 CD O
. . O
1 CD O
% NN O
, , O
RR NN O
= SYM O
8 CD O
. . O
0 CD O
, , O
X2 CD O
= SYM O
4 CD O
. . O
256 CD O
; : O
df IN O
= SYM O
1 CD O
; : O
0 CD O
. . O
05 CD O
< SYM O
p NN O
< NN O
0 CD O
. . O
02 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
In IN O
this DT O
study NN O
early JJ O
postoperative JJ B-Disease
delirium NN I-Disease
was VBD O
found VBN O
to TO O
be VB O
a DT O
very RB O
common JJ O
complication NN O
after IN O
major JJ O
surgery NN O
, , O
even RB O
in IN O
a DT O
population NN O
without IN O
known JJ O
risk NN O
factors NNS O
. . O
null null null-Disease
Thiopentone NNP O
was VBD O
independently RB O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
its PRP$ O
relative JJ O
risk NN O
. . O
null null null-Disease
A DT O
single JJ O
neurotoxic JJ B-Disease
dose NN O
of IN O
methamphetamine NN O
induces VBZ O
a DT O
long RB O
- HYPH O
lasting VBG O
depressive JJ B-Disease
- HYPH O
like JJ O
behaviour NN O
in IN O
mice NNS O
. . O
null null null-Disease
Methamphetamine NNP O
( , O
METH NNP O
) -RRB- O
triggers VBZ O
a DT O
disruption NN O
of IN O
the DT O
monoaminergic JJ O
system NN O
and CC O
METH NN O
abuse NN O
leads VBZ O
to IN O
negative JJ O
emotional JJ O
states NNS O
including VBG O
depressive JJ B-Disease
symptoms NNS I-Disease
during IN O
drug NN O
withdrawal NN O
. . O
null null null-Disease
However RB O
, , O
it PRP O
is VBZ O
currently RB O
unknown JJ O
if IN O
the DT O
acute JJ O
toxic JJ O
dosage NN O
of IN O
METH NNP O
also RB O
causes VBZ O
a DT O
long RB O
- HYPH O
lasting VBG O
depressive JJ B-Disease
phenotype NN O
and CC O
persistent JJ O
monoaminergic JJ O
deficits NNS O
. . O
null null null-Disease
Thus RB O
, , O
we PRP O
now RB O
assessed VBD O
the DT O
depressive JJ B-Disease
- HYPH O
like JJ O
behaviour NN O
in IN O
mice NNS O
at IN O
early JJ O
and CC O
long JJ O
- HYPH O
term NN O
periods NNS O
following VBG O
a DT O
single JJ O
high JJ O
METH NNP O
dose NN O
( : O
30 CD O
mg NN O
/ SYM O
kg CD O
, , O
i PRP O
. . O
p NN O
. . O
) -RRB- O
. . O
null null null-Disease
METH NNP O
did VBD O
not RB O
alter VB O
the DT O
motor NN O
function NN O
and CC O
procedural JJ O
memory NN O
of IN O
mice NNS O
as IN O
assessed VBN O
by IN O
swimming NN O
speed NN O
and CC O
escape VB O
latency NN O
to TO O
find VB O
the DT O
platform NN O
in IN O
a DT O
cued VBN O
version NN O
of IN O
the DT O
water NN O
maze NN O
task NN O
. . O
null null null-Disease
However RB O
, , O
METH NNP O
significantly RB O
increased VBD O
the DT O
immobility NN O
time NN O
in IN O
the DT O
tail NN O
suspension NN O
test NN O
at IN O
3 CD O
and CC O
49 CD O
days NNS O
post NN O
- HYPH O
administration NN O
. . O
null null null-Disease
This DT O
depressive JJ B-Disease
- HYPH O
like JJ O
profile NN O
induced VBN O
by IN O
METH NNP O
was VBD O
accompanied VBN O
by IN O
a DT O
marked JJ O
depletion NN O
of IN O
frontostriatal JJ O
dopaminergic JJ O
and CC O
serotonergic JJ O
neurotransmission NN O
, , O
indicated VBN O
by IN O
a DT O
reduction NN O
in IN O
the DT O
levels NNS O
of IN O
dopamine NN O
, , O
DOPAC NNP O
and CC O
HVA NNP O
, , O
tyrosine NN O
hydroxylase NN O
and CC O
serotonin NN O
, , O
observed VBN O
at IN O
both DT O
3 CD O
and CC O
49 CD O
days NNS O
post NN O
- HYPH O
administration NN O
. . O
null null null-Disease
In IN O
parallel NN O
, , O
another DT O
neurochemical JJ O
feature NN O
of IN O
depression NN B-Disease
- HYPH O
- HYPH O
astroglial NN O
dysfunction NN O
- : O
- : O
was VBD O
unaffected VBN O
in IN O
the DT O
cortex NN O
and CC O
the DT O
striatal JJ O
levels NNS O
of IN O
the DT O
astrocytic JJ O
protein NN O
marker NN O
, , O
glial NN O
fibrillary NN O
acidic JJ O
protein NN O
, , O
were VBD O
only RB O
transiently RB O
increased VBN O
at IN O
3 CD O
days NNS O
. . O
null null null-Disease
These DT O
findings NNS O
demonstrate VBP O
for IN O
the DT O
first JJ O
time NN O
that IN O
a DT O
single JJ O
high JJ O
dose NN O
of IN O
METH NNP O
induces VBZ O
long RB O
- HYPH O
lasting VBG O
depressive JJ B-Disease
- HYPH O
like JJ O
behaviour NN O
in IN O
mice NNS O
associated VBN O
with IN O
a DT O
persistent JJ O
disruption NN O
of IN O
frontostriatal JJ O
dopaminergic NN O
and CC O
serotonergic JJ O
homoeostasis NN O
. . O
null null null-Disease
Linezolid NNP O
- HYPH O
induced VBN O
optic JJ B-Disease
neuropathy NN I-Disease
. . O
null null null-Disease
Many JJ O
systemic JJ O
antimicrobials NNS O
have VBP O
been VBN O
implicated VBN O
to TO O
cause VB O
ocular JJ O
adverse JJ O
effects NNS O
. . O
null null null-Disease
This DT O
is VBZ O
especially RB O
relevant JJ O
in IN O
multidrug NN O
therapy NN O
where WRB O
more JJR O
than IN O
one CD O
drug NN O
can MD O
cause VB O
a DT O
similar JJ O
ocular JJ O
adverse JJ O
effect NN O
. . O
null null null-Disease
We PRP O
describe VBP O
a DT O
case NN O
of IN O
progressive JJ O
loss NN B-Disease
of IN I-Disease
vision NN I-Disease
associated VBN O
with IN O
linezolid NN O
therapy NN O
. . O
null null null-Disease
A DT O
45 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male JJ O
patient NN O
who WP O
was VBD O
on IN O
treatment NN O
with IN O
multiple JJ O
second JJ O
- HYPH O
line NN O
anti JJ O
- HYPH O
tuberculous JJ O
drugs NNS O
including VBG O
linezolid NN O
and CC O
ethambutol NN O
for IN O
extensively RB B-Disease
drug NN I-Disease
- HYPH I-Disease
resistant JJ I-Disease
tuberculosis NN I-Disease
( -LRB- O
XDR NNP B-Disease
- HYPH I-Disease
TB NNP I-Disease
) -RRB- O
presented VBD O
to IN O
us PRP O
with IN O
painless JJ O
progressive JJ O
loss NN B-Disease
of IN I-Disease
vision NN I-Disease
in IN O
both DT O
eyes NNS O
. . O
null null null-Disease
Color NN O
vision NN O
was VBD O
defective JJ O
and CC O
fundus NN O
examination NN O
revealed VBD O
optic JJ B-Disease
disc NN I-Disease
edema NN I-Disease
in IN O
both DT O
eyes NNS O
. . O
null null null-Disease
Ethambutol NNP O
- HYPH O
induced VBN O
toxic JJ B-Disease
optic JJ I-Disease
neuropathy NN I-Disease
was VBD O
suspected VBN O
and CC O
tablet NN O
ethambutol NN O
was VBD O
withdrawn VBN O
. . O
null null null-Disease
Deterioration NN B-Disease
of IN I-Disease
vision NN I-Disease
occurred VBD O
despite IN O
withdrawal NN O
of IN O
ethambutol NN O
. . O
null null null-Disease
Discontinuation NN O
of IN O
linezolid NN O
resulted VBD O
in IN O
marked JJ O
improvement NN O
of IN O
vision NN O
. . O
null null null-Disease
Our PRP$ O
report NN O
emphasizes VBZ O
the DT O
need NN O
for IN O
monitoring NN O
of IN O
visual JJ O
function NN O
in IN O
patients NNS O
on IN O
long JJ O
- HYPH O
term NN O
linezolid NN O
treatment NN O
. . O
null null null-Disease
Resuscitation NN O
with IN O
lipid NN O
, , O
epinephrine NN O
, , O
or CC O
both CC O
in IN O
levobupivacaine NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
toxicity NN I-Disease
in IN O
newborn JJ O
piglets NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
The DT O
optimal JJ O
dosing NN O
regimens NNS O
of IN O
lipid JJ O
emulsion NN O
, , O
epinephrine NN O
, , O
or CC O
both DT O
are VBP O
not RB O
yet RB O
determined VBN O
in IN O
neonates NNS O
in IN O
cases NNS O
of IN O
local JJ O
anaesthetic JJ O
systemic JJ O
toxicity NN B-Disease
( -LRB- O
LAST NNP O
) -RRB- O
. . O
null null null-Disease
METHODS NNS O
: : O
Newborn JJ O
piglets NNS O
received VBD O
levobupivacaine NN O
until IN O
cardiovascular JJ B-Disease
collapse NN I-Disease
occurred VBD O
. . O
null null null-Disease
Standard JJ O
cardiopulmonary JJ O
resuscitation NN O
was VBD O
started VBN O
and CC O
electrocardiogram NN O
( , O
ECG NNP O
) -RRB- O
was VBD O
monitored VBN O
for IN O
ventricular JJ B-Disease
tachycardia NN I-Disease
, , O
fibrillation NN B-Disease
, , O
or CC O
QRS NN O
prolongation NN O
. . O
null null null-Disease
Piglets NNS O
were VBD O
then RB O
randomly RB O
allocated VBN O
to IN O
four CD O
groups NNS O
: : O
control NN O
( , O
saline NN O
) -RRB- O
, , O
Intralipid NNP O
( , O
) -RRB- O
alone RB O
, , O
epinephrine NN O
alone RB O
, , O
or CC O
a DT O
combination NN O
of IN O
Intralipd NNP O
plus CC O
epinephrine NN O
. . O
null null null-Disease
Resuscitation NN O
continued VBD O
for IN O
30 CD O
min NN O
or CC O
until IN O
there EX O
was VBD O
a DT O
return NN O
of IN O
spontaneous JJ O
circulation NN O
( , O
ROSC NNP O
) , O
accompanied VBN O
by IN O
a DT O
mean JJ O
arterial JJ O
pressure NN O
at IN O
or CC O
superior JJ O
to IN O
the DT O
baseline NN O
pressure NN O
and CC O
normal JJ O
sinus NN O
rhythm NN O
for IN O
a DT O
period NN O
of IN O
30 CD O
min NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
ROSC NNP O
was VBD O
achieved VBN O
in IN O
only RB O
one CD O
of IN O
the DT O
control NN O
piglets NNS O
compared VBN O
with IN O
most JJS O
of IN O
the DT O
treated VBN O
piglets NNS O
. . O
null null null-Disease
Mortality NN O
was VBD O
not RB O
significantly RB O
different JJ O
between IN O
the DT O
three CD O
treatment NN O
groups NNS O
, , O
but CC O
was VBD O
significantly RB O
lower JJR O
in IN O
all PDT O
the DT O
treatment NN O
groups NNS O
compared VBN O
with IN O
control NN O
. . O
null null null-Disease
The DT O
number NN O
of IN O
ECG NNP O
abnormalities NNS O
was VBD O
zero CD O
in IN O
the DT O
Intralipid NNP O
only JJ O
group NN O
, , O
but CC O
14 CD O
and CC O
17 CD O
, , O
respectively RB O
, , O
in IN O
the DT O
epinephrine NN O
and CC O
epinephrine NN O
plus CC O
lipid JJ O
groups NNS O
( , O
P NN O
< SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Lipid JJ O
emulsion NN O
with IN O
or CC O
without IN O
epinephrine NN O
, , O
or CC O
epinephrine NN O
alone RB O
were VBD O
equally RB O
effective JJ O
in IN O
achieving VBG O
a DT O
return NN O
to IN O
spontaneous JJ O
circulation NN O
in IN O
this DT O
model NN O
of IN O
LAST JJ O
. . O
null null null-Disease
Epinephrine NN O
alone RB O
or CC O
in IN O
combination NN O
with IN O
lipid NN O
was VBD O
associated VBN O
with IN O
an DT O
increased VBN O
number NN O
of IN O
ECG NNP O
abnormalities NNS O
compared VBN O
with IN O
lipid JJ O
emulsion NN O
alone RB O
. . O
null null null-Disease
Incidence NN O
of IN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
type NN I-Disease
II NN I-Disease
and CC O
postoperative JJ O
recovery NN O
of IN O
platelet NN O
count NN O
in IN O
liver NN O
graft NN O
recipients NNS O
: : O
a DT O
retrospective JJ O
cohort NN O
analysis NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Thrombocytopenia NN B-Disease
in IN O
patients NNS O
with IN O
end NN B-Disease
- HYPH I-Disease
stage NN I-Disease
liver NN I-Disease
disease NN I-Disease
is VBZ O
a DT O
common JJ O
disorder NN O
caused VBN O
mainly RB O
by IN O
portal JJ B-Disease
hypertension NN I-Disease
, , O
low JJ O
levels NNS O
of IN O
thrombopoetin NN O
, , O
and CC O
endotoxemia NN B-Disease
. . O
null null null-Disease
The DT O
impact NN O
of IN O
immune NN O
- HYPH O
mediated VBN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
type NN I-Disease
II NN I-Disease
( -LRB- O
HIT NN B-Disease
type NN I-Disease
II NN I-Disease
) -RRB- O
as IN O
a DT O
cause NN O
of IN O
thrombocytopenia NN B-Disease
after IN O
liver NN O
transplantation NN O
is VBZ O
not RB O
yet RB O
understood VBN O
, , O
with IN O
few JJ O
literature NN O
citations NNS O
reporting VBG O
contradictory JJ O
results NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
our PRP$ O
study NN O
was VBD O
to TO O
demonstrate VB O
the DT O
perioperative JJ O
course NN O
of IN O
thrombocytopenia NN B-Disease
after IN O
liver NN O
transplantation NN O
and CC O
determine VB O
the DT O
occurrence NN O
of IN O
clinical JJ O
HIT NN B-Disease
type NN I-Disease
II CD I-Disease
. . O
null null null-Disease
METHOD NN O
: : O
We PRP O
retrospectively RB O
evaluated VBD O
the DT O
medical JJ O
records NNS O
of IN O
205 CD O
consecutive JJ O
adult NN O
patients NNS O
who WP O
underwent VBD O
full JJ O
- HYPH O
size NN O
liver NN O
transplantation NN O
between IN O
January NNP O
2006 CD O
and CC O
December NNP O
2010 CD O
due JJ O
to IN O
end JJ B-Disease
- HYPH I-Disease
stage NN I-Disease
or CC I-Disease
malignant JJ I-Disease
liver NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
Preoperative JJ O
platelet NN O
count NN O
, , O
postoperative JJ O
course NN O
of IN O
platelets NNS O
, , O
and CC O
clinical JJ O
signs NNS O
of IN O
HIT NNP B-Disease
type NN I-Disease
II CD I-Disease
were VBD O
analyzed VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
A DT O
total NN O
of IN O
155 CD O
( SYM O
75 CD O
. . O
6 CD O
% NN O
) , O
of IN O
205 CD O
patients NNS O
had VBD O
thrombocytopenia NN B-Disease
before IN O
transplantation NN O
, , O
significantly RB O
influenced VBN O
by IN O
Model NNP O
of IN O
End NNP B-Disease
- HYPH I-Disease
Stage NNP I-Disease
Liver NNP I-Disease
Disease NNP I-Disease
score NN O
and CC O
liver NN B-Disease
cirrhosis NN I-Disease
. . O
null null null-Disease
The DT O
platelet NN O
count NN O
exceeded VBD O
100 CD O
, , O
000 CD O
/ SYM O
uL CD O
in IN O
most JJS O
of IN O
the DT O
patients NNS O
( , O
n CD O
= SYM O
193 CD O
) -RRB- O
at IN O
a DT O
medium NN O
of IN O
7 CD O
d NN O
. . O
null null null-Disease
Regarding VBG O
HIT NNP B-Disease
II NNP I-Disease
, , O
there EX O
were VBD O
four CD O
( SYM O
1 CD O
. . O
95 CD O
% NN O
) SYM O
patients NNS O
with IN O
a DT O
background NN O
of IN O
HIT NN B-Disease
type NN I-Disease
II NNP I-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
incidence NN O
of IN O
HIT NNP B-Disease
in IN O
patients NNS O
with IN O
end JJ B-Disease
- HYPH I-Disease
stage NN I-Disease
hepatic JJ I-Disease
failure NN I-Disease
is VBZ O
, , O
with IN O
about RB O
1 CD O
. . O
95 CD O
% NN O
, , O
rare JJ O
. . O
null null null-Disease
For IN O
further JJ O
reduction NN O
of IN O
HIT NN B-Disease
type NN I-Disease
II NN I-Disease
, , O
the DT O
use NN O
of IN O
intravenous JJ O
heparin NN O
should MD O
be VB O
avoided VBN O
and CC O
the DT O
prophylactic JJ O
anticoagulation NN O
should MD O
be VB O
performed VBN O
with IN O
low JJ O
- HYPH O
molecular JJ O
- HYPH O
weight NN O
heparin NN O
after IN O
normalization NN O
of IN O
platelet NN O
count NN O
. . O
null null null-Disease
Takotsubo NNP B-Disease
syndrome NN I-Disease
( , O
or CC O
apical JJ B-Disease
ballooning NN I-Disease
syndrome NN I-Disease
) -RRB- O
secondary JJ O
to IN O
Zolmitriptan NNP O
. . O
null null null-Disease
Takotsubo NNP B-Disease
syndrome NN I-Disease
( , O
TS NNP B-Disease
) -RRB- O
, , O
also RB O
known VBN O
as IN O
broken VBN B-Disease
heart NN I-Disease
syndrome NN I-Disease
, , O
is VBZ O
characterized VBN O
by IN O
left JJ O
ventricle NN O
apical JJ O
ballooning NN O
with IN O
elevated VBN O
cardiac JJ O
biomarkers NNS O
and CC O
electrocardiographic JJ O
changes NNS O
suggestive JJ O
of IN O
an DT O
acute JJ B-Disease
coronary JJ I-Disease
syndrome NN I-Disease
( , O
ie IN O
, , O
ST NNP O
- HYPH O
segment NN O
elevation NN O
, , O
T NN O
wave NN O
inversions NNS O
, , O
and CC O
pathologic JJ O
Q NN O
waves NNS O
) -RRB- O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
54 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
medical JJ O
history NN O
of IN O
mitral JJ B-Disease
valve NN I-Disease
prolapse NN I-Disease
and CC O
migraines NNS B-Disease
, , O
who WP O
was VBD O
admitted VBN O
to IN O
the DT O
hospital NN O
for IN O
substernal JJ O
chest NN B-Disease
pain NN I-Disease
and CC O
electrocardiogram NN O
demonstrated VBN O
1 CD O
/ SYM O
2 CD O
mm NN O
ST NN O
- HYPH O
segment NN O
elevation NN O
in IN O
leads NNS O
II NNP O
, , O
III NNP O
, , O
aVF NNP O
, , O
V5 NN O
, , O
and CC O
V6 NN O
and CC O
positive JJ O
troponin NN O
I CD O
. . O
null null null-Disease
Emergent JJ O
coronary JJ O
angiogram NN O
revealed VBD O
normal JJ O
coronary JJ O
arteries NNS O
with IN O
moderately RB O
reduced VBN O
left VBN O
ventricular JJ O
ejection NN O
fraction NN O
with IN O
wall NN O
motion NN O
abnormalities NNS O
consistent JJ O
with IN O
TS NNP B-Disease
. . O
null null null-Disease
Detailed JJ O
history NN O
obtained VBN O
retrospectively RB O
revealed VBD O
that IN O
the DT O
patient NN O
took VBD O
zolmitriptan NN O
sparingly RB O
only RB O
when WRB O
she PRP O
had VBD O
migraines NNS B-Disease
. . O
null null null-Disease
But CC O
before IN O
this DT O
event NN O
, , O
she PRP O
was VBD O
taking VBG O
zolmitriptan NN O
2 CD O
- SYM O
3 CD O
times NNS O
daily RB O
for IN O
several JJ O
days NNS O
because IN O
of IN O
a DT O
persistent JJ O
migraine NN B-Disease
headache NN I-Disease
. . O
null null null-Disease
She PRP O
otherwise RB O
reported VBD O
that IN O
she PRP O
is VBZ O
quite RB O
active JJ O
, , O
rides VBZ O
horses NNS O
, , O
and CC O
does VBZ O
show VB O
jumping NN O
without IN O
any DT O
limitations NNS O
in IN O
her PRP$ O
physical JJ O
activity NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
evidence NN O
of IN O
any DT O
recent JJ O
stress NN O
or CC O
status NN B-Disease
migrainosus NN I-Disease
. . O
null null null-Disease
Extensive JJ O
literature NN O
search NN O
revealed VBD O
multiple JJ O
cases NNS O
of IN O
coronary JJ B-Disease
artery NN I-Disease
vasospasm NN I-Disease
secondary JJ O
to IN O
zolmitriptan NN O
, , O
but CC O
none NN O
of IN O
the DT O
cases NNS O
were VBD O
associated VBN O
with IN O
TS NNP B-Disease
. . O
null null null-Disease
Depression NN B-Disease
, , O
impulsiveness NN B-Disease
, , O
sleep NN O
, , O
and CC O
memory NN O
in IN O
past JJ O
and CC O
present JJ O
polydrug NN O
users NNS O
of IN O
3 CD O
, , O
4 CD O
- HYPH O
methylenedioxymethamphetamine NN O
( , O
MDMA NNP O
, , O
ecstasy NN O
) -RRB- O
. . O
null null null-Disease
RATIONALE NN O
: : O
Ecstasy NNP O
( : O
3 CD O
, , O
4 CD O
- HYPH O
methylenedioxymethamphetamine NN O
, , O
MDMA NNP O
) -RRB- O
is VBZ O
a DT O
worldwide JJ O
recreational JJ O
drug NN O
of IN O
abuse NN O
. . O
null null null-Disease
Unfortunately RB O
, , O
the DT O
results NNS O
from IN O
human JJ O
research NN O
investigating VBG O
its PRP$ O
psychological JJ O
effects NNS O
have VBP O
been VBN O
inconsistent JJ O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
The DT O
present JJ O
study NN O
aimed VBN O
to TO O
be VB O
the DT O
largest JJS O
to IN O
date NN O
in IN O
sample NN O
size NN O
and CC O
5HT NN O
- HYPH O
related VBN O
behaviors NNS O
; , O
the DT O
first JJ O
to TO O
compare VB O
present JJ O
ecstasy NN O
users NNS O
with IN O
past JJ O
users NNS O
after IN O
an DT O
abstinence NN O
of IN O
4 CD O
or CC O
more JJR O
years NNS O
, , O
and CC O
the DT O
first JJ O
to TO O
include VB O
robust JJ O
controls NNS O
for IN O
other JJ O
recreational JJ O
substances NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
sample NN O
of IN O
997 CD O
participants NNS O
( , O
52 CD O
% NN O
male NN O
) -RRB- O
was VBD O
recruited VBN O
to IN O
four CD O
control NN O
groups NNS O
( , O
non JJ O
- HYPH O
drug NN O
( -LRB- O
ND NNP O
) -RRB- O
, , O
alcohol NN O
/ SYM O
nicotine NN O
( , O
AN NNP O
) -RRB- O
, , O
cannabis NN O
/ SYM O
alcohol NN O
/ SYM O
nicotine NN O
( , O
CAN NNP O
) -RRB- O
, , O
non JJ O
- HYPH O
ecstasy NN O
polydrug NN O
( , O
PD NN O
) -RRB- O
) -RRB- O
, , O
and CC O
two CD O
ecstasy NN O
polydrug NN O
groups NNS O
( , O
present JJ O
( , O
MDMA NNP O
) -RRB- O
and CC O
past JJ O
users NNS O
( -LRB- O
EX NNP O
- HYPH O
MDMA NNP O
) -RRB- O
. . O
null null null-Disease
Participants NNS O
completed VBD O
a DT O
drug NN O
history NN O
questionnaire NN O
, , O
Beck NNP O
Depression NNP B-Disease
Inventory NNP O
, , O
Barratt NNP O
Impulsiveness NNP B-Disease
Scale NNP O
, , O
Pittsburgh NNP O
Sleep NNP O
Quality NNP O
Index NNP O
, , O
and CC O
Wechsler NNP O
Memory NNP O
Scale NNP O
- HYPH O
Revised VBN O
which WDT O
, , O
in IN O
total NN O
, , O
provided VBD O
13 CD O
psychometric JJ O
measures NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
While IN O
the DT O
CAN NNP O
and CC O
PD NN O
groups NNS O
tended VBD O
to TO O
record VB O
greater JJR O
deficits NNS O
than IN O
the DT O
non JJ O
- HYPH O
drug NN O
controls NNS O
, , O
the DT O
MDMA NNP O
and CC O
EX NNP O
- HYPH O
MDMA NNP O
groups NNS O
recorded VBD O
greater JJR O
deficits NNS O
than IN O
all PDT O
the DT O
control NN O
groups NNS O
on IN O
ten CD O
of IN O
the DT O
13 CD O
psychometric JJ O
measures NNS O
. . O
null null null-Disease
Strikingly RB O
, , O
despite IN O
prolonged VBN O
abstinence NN O
( , O
mean JJ O
, , O
4 CD O
. . O
98 CD O
; : O
range NN O
, , O
4 CD O
- SYM O
9 CD O
years NNS O
) -RRB- O
, , O
past JJ O
ecstasy NN O
users NNS O
showed VBD O
few JJ O
signs NNS O
of IN O
recovery NN O
. . O
null null null-Disease
Compared VBN O
with IN O
present JJ O
ecstasy NN O
users NNS O
, , O
the DT O
past JJ O
users NNS O
showed VBD O
no DT O
change NN O
for IN O
ten CD O
measures NNS O
, , O
increased VBN O
impairment NN O
for IN O
two CD O
measures NNS O
, , O
and CC O
improvement NN O
on IN O
just RB O
one CD O
measure NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Given VBN O
this DT O
record NN O
of IN O
impaired VBN B-Disease
memory NN I-Disease
and CC O
clinically RB O
significant JJ O
levels NNS O
of IN O
depression NN B-Disease
, , O
impulsiveness NN B-Disease
, , O
and CC O
sleep NN B-Disease
disturbance NN I-Disease
, , O
the DT O
prognosis NN O
for IN O
the DT O
current JJ O
generation NN O
of IN O
ecstasy NN O
users NNS O
is VBZ O
a DT O
major JJ O
cause NN O
for IN O
concern NN O
. . O
null null null-Disease
Association NNP O
of IN O
common JJ O
genetic JJ O
variants NNS O
of IN O
HOMER1 NNP O
gene NN O
with IN O
levodopa NN O
adverse JJ O
effects NNS O
in IN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
patients NNS O
. . O
null null null-Disease
Levodopa NNP O
is VBZ O
the DT O
most RBS O
effective JJ O
symptomatic JJ O
therapy NN O
for IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
, , O
but CC O
its PRP$ O
chronic JJ O
use NN O
could MD O
lead VB O
to IN O
chronic JJ O
adverse JJ O
outcomes NNS O
, , O
such JJ O
as IN O
motor NN O
fluctuations NNS O
, , O
dyskinesia NN B-Disease
and CC O
visual JJ B-Disease
hallucinations NNS I-Disease
. . O
null null null-Disease
HOMER1 NNP O
is VBZ O
a DT O
protein NN O
with IN O
pivotal JJ O
function NN O
in IN O
glutamate NN O
transmission NN O
, , O
which WDT O
has VBZ O
been VBN O
related VBN O
to IN O
the DT O
pathogenesis NN O
of IN O
these DT O
complications NNS O
. . O
null null null-Disease
This DT O
study NN O
investigates VBZ O
whether IN O
polymorphisms NNS O
in IN O
the DT O
HOMER1 NNP O
gene NN O
promoter NN O
region NN O
are VBP O
associated VBN O
with IN O
the DT O
occurrence NN O
of IN O
the DT O
chronic JJ O
complications NNS O
of IN O
levodopa NN O
therapy NN O
. . O
null null null-Disease
A DT O
total NN O
of IN O
205 CD O
patients NNS O
with IN O
idiopathic JJ B-Disease
Parkinson NNP I-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
were VBD O
investigated VBN O
. . O
null null null-Disease
Patients NNS O
were VBD O
genotyped VBN O
for IN O
rs4704559 CD O
, , O
rs10942891 CD O
and CC O
rs4704560 CD O
by IN O
allelic JJ O
discrimination NN O
with IN O
Taqman NNP O
assays NNS O
. . O
null null null-Disease
The DT O
rs4704559 CD O
G NN O
allele NN O
was VBD O
associated VBN O
with IN O
a DT O
lower JJR O
prevalence NN O
of IN O
dyskinesia NN B-Disease
( , O
prevalence NN O
ratio NN O
( , O
PR NN O
) -RRB- O
= SYM O
0 CD O
. . O
615 CD O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
( , O
CI NN O
) SYM O
0 CD O
. . O
426 CD O
- SYM O
0 CD O
. . O
887 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
009 CD O
) -RRB- O
and CC O
visual JJ B-Disease
hallucinations NNS I-Disease
( : O
PR NN O
= SYM O
0 CD O
. . O
515 CD O
, , O
95 CD O
% NN O
CI NN O
0 CD O
. . O
295 CD O
- SYM O
0 CD O
. . O
899 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
020 CD O
) -RRB- O
. . O
null null null-Disease
Our PRP$ O
data NNS O
suggest VBP O
that IN O
HOMER1 NNP O
rs4704559 CD O
G NN O
allele NN O
has VBZ O
a DT O
protective JJ O
role NN O
for IN O
the DT O
development NN O
of IN O
levodopa NN O
adverse JJ O
effects NNS O
. . O
null null null-Disease
Crocin NNP O
improves VBZ O
lipid JJ O
dysregulation NN O
in IN O
subacute JJ O
diazinon NN O
exposure NN O
through IN O
ERK1 NNP O
/ SYM O
2 CD O
pathway NN O
in IN O
rat NN O
liver NN O
. . O
null null null-Disease
INTRODUCTION NN O
: : O
Diazinon NNP O
Yis NNP O
one CD O
of IN O
the DT O
most RBS O
broadly RB O
used VBN O
organophosphorus NN O
insecticides NNS O
in IN O
agriculture NN O
. . O
null null null-Disease
It PRP O
has VBZ O
been VBN O
shown VBN O
that IN O
exposure NN O
to IN O
diazinon NN O
may MD O
interfere VB O
with IN O
lipid JJ O
metabolism NN O
. . O
null null null-Disease
Moreover RB O
, , O
the DT O
hypolipidemic JJ O
effect NN O
of IN O
crocin NN O
has VBZ O
been VBN O
established VBN O
. . O
null null null-Disease
Earlier JJR O
studies NNS O
revealed VBD O
the DT O
major JJ O
role NN O
of IN O
Extracellular JJ O
signal NN O
- HYPH O
regulated VBN O
kinase NN O
( , O
ERK NNP O
) -RRB- O
pathways NNS O
in IN O
low JJ O
- HYPH O
density NN O
lipoprotein NN O
receptor NN O
( -LRB- O
LDLr NNP O
) -RRB- O
expression NN O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
evaluate VB O
changes NNS O
in IN O
the DT O
regulation NN O
of IN O
lipid NN O
metabolism NN O
, , O
ERK NNP O
and CC O
LDLr NNP O
expression NN O
in IN O
the DT O
liver NN O
of IN O
rats NNS O
exposed VBN O
to IN O
subacute JJ O
diazinon NN O
. . O
null null null-Disease
Furthermore RB O
ameliorating VBG O
effect NN O
of IN O
crocin NN O
on IN O
diazinon NN O
induced VBN O
disturbed JJ O
cholesterol NN O
homeostasis NN O
was VBD O
studied VBN O
. . O
null null null-Disease
METHODS NNS O
: : O
24 CD O
Rats NNS O
were VBD O
divided VBN O
into IN O
4 CD O
groups NNS O
and CC O
received VBD O
following VBG O
treatments NNS O
for IN O
4 CD O
weeks NNS O
; : O
Corn NN O
oil NN O
( HYPH O
control NN O
) -RRB- O
, , O
diazinon NN O
( , O
15mg CD O
/ SYM O
kg NNS O
per IN O
day NN O
, , O
orally RB O
) , O
and CC O
crocin NN O
( , O
12 CD O
. . O
5 CD O
and CC O
25mg CD O
/ SYM O
kg NNS O
per IN O
day NN O
, , O
intraperitoneally RB O
) -RRB- O
in IN O
combination NN O
with IN O
diazinon NN O
( , O
15 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
. . O
null null null-Disease
The DT O
levels NNS O
of IN O
cholesterol NN O
, , O
triglyceride NN O
and CC O
LDL NN O
in IN O
blood NN O
of IN O
rats NNS O
were VBD O
analyzed VBN O
. . O
null null null-Disease
Moreover RB O
mRNA NNP O
levels NNS O
of IN O
LDLr NNP O
and CC O
ERK1 NNP O
/ SYM O
2 CD O
as RB O
well RB O
as IN O
protein NN O
levels NNS O
of IN O
total JJ O
and CC O
activated VBN O
forms NNS O
of IN O
ERK1 NNP O
/ SYM O
2 CD O
in IN O
rat NN O
liver NN O
were VBD O
evaluated VBN O
by IN O
Western JJ O
blotting NN O
and CC O
quantitative JJ O
real JJ O
time NN O
polymerase NN O
chain NN O
reaction NN O
analysis NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Our PRP$ O
data NNS O
showed VBD O
that IN O
subacute JJ O
exposure NN O
to IN O
diazinon NN O
significantly RB O
increased VBD O
concentrations NNS O
of IN O
cholesterol NN O
, , O
triglyceride NN O
and CC O
LDL NNP O
. . O
null null null-Disease
Moreover RB O
diazinon NN O
decreased VBD O
ERK1 NNP O
/ SYM O
2 CD O
protein NN O
phosphorylation NN O
and CC O
LDLr NNP O
transcript NN O
. . O
null null null-Disease
Crocin NNP O
reduced VBD O
inhibition NN O
of IN O
ERK NNP O
activation NN O
and CC O
diazinon NN O
- HYPH O
induced VBN O
hyperlipemia NN B-Disease
and CC O
increased VBN O
levels NNS O
of IN O
LDLr NNP O
transcript NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Crocin NNP O
may MD O
be VB O
considered VBN O
as IN O
a DT O
novel JJ O
protective JJ O
agent NN O
in IN O
diazinon NN O
- HYPH O
induced VBN O
hyperlipemia NN B-Disease
through IN O
modulating NN O
of IN O
ERK NNP O
pathway NN O
and CC O
increase NN O
of IN O
LDLr NNP O
expression NN O
. . O
null null null-Disease
GEM NNP O
- HYPH O
P NN O
chemotherapy NN O
is VBZ O
active JJ O
in IN O
the DT O
treatment NN O
of IN O
relapsed VBN O
Hodgkin NNP B-Disease
lymphoma NN I-Disease
. . O
null null null-Disease
Hodgkin NNP B-Disease
lymphoma NN I-Disease
( -LRB- O
HL NNP B-Disease
) -RRB- O
is VBZ O
a DT O
relatively RB O
chemosensitive JJ O
malignancy NN B-Disease
. . O
null null null-Disease
However RB O
, , O
for IN O
those DT O
who WP O
relapse VBP O
, , O
high JJ O
- HYPH O
dose NN O
chemotherapy NN O
with IN O
autologous JJ O
stem NN O
cell NN O
transplant NN O
is VBZ O
the DT O
treatment NN O
of IN O
choice NN O
which WDT O
relies VBZ O
on IN O
adequate JJ O
disease NN O
control NN O
with IN O
salvage NN O
chemotherapy NN O
. . O
null null null-Disease
Regimens NNS O
commonly RB O
used VBN O
often RB O
require VBP O
inpatient JJ O
administration NN O
and CC O
can MD O
be VB O
difficult JJ O
to TO O
deliver VB O
due IN O
to IN O
toxicity NN B-Disease
. . O
null null null-Disease
Gemcitabine NN O
and CC O
cisplatin NN O
have VBP O
activity NN O
in IN O
HL NNP B-Disease
, , O
non JJ O
- HYPH O
overlapping VBG O
toxicity NN B-Disease
with IN O
first JJ O
- HYPH O
line NN O
chemotherapeutics NNS O
, , O
and CC O
may MD O
be VB O
delivered VBN O
in IN O
an DT O
outpatient JJ O
setting NN O
. . O
null null null-Disease
In IN O
this DT O
retrospective JJ O
single JJ O
- HYPH O
centre NN O
analysis NN O
, , O
patients NNS O
with IN O
relapsed JJ O
or CC O
refractory JJ O
HL NN B-Disease
treated VBN O
with IN O
gemcitabine NN O
1 CD O
, , O
000 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) SYM O
day NN O
( -LRB- O
D NNP O
) , O
1 CD O
, , O
D8 CD O
and CC O
D15 CD O
; , O
methylprednisolone NN O
1 CD O
, , O
000 CD O
mg NN O
D1 NN O
- HYPH O
5 CD O
; : O
and CC O
cisplatin NN O
100 CD O
mg NNS O
/ SYM O
m CD O
( SYM O
2 CD O
) SYM O
D15 CD O
, , O
every DT O
28 CD O
days NNS O
( -LRB- O
GEM NNP O
- HYPH O
P NN O
) -RRB- O
were VBD O
included VBN O
. . O
null null null-Disease
Demographic JJ O
, , O
survival NN O
, , O
response NN O
and CC O
toxicity NN B-Disease
data NNS O
were VBD O
recorded VBN O
. . O
null null null-Disease
Forty CD O
- HYPH O
one CD O
eligible JJ O
patients NNS O
were VBD O
identified VBN O
: : O
median JJ O
age NN O
27 CD O
. . O
null null null-Disease
One CD O
hundred CD O
and CC O
twenty CD O
- HYPH O
two CD O
cycles NNS O
of IN O
GEM NNP O
- HYPH O
P NNP O
were VBD O
administered VBN O
in IN O
total NN O
( , O
median JJ O
3 CD O
cycles NNS O
; : O
range NN O
1 CD O
- SYM O
6 CD O
) -RRB- O
. . O
null null null-Disease
Twenty CD O
of IN O
41 CD O
( SYM O
48 CD O
% NN O
) SYM O
patients NNS O
received VBD O
GEM NNP O
- HYPH O
P NNP O
as IN O
second JJ O
- HYPH O
line NN O
treatment NN O
and CC O
11 CD O
/ SYM O
41 CD O
( SYM O
27 CD O
% NN O
) -RRB- O
as IN O
third JJ O
- HYPH O
line NN O
therapy NN O
. . O
null null null-Disease
Overall JJ O
response NN O
rate NN O
( , O
ORR NN O
) -RRB- O
to IN O
GEM NN O
- HYPH O
P NN O
in IN O
the DT O
entire JJ O
cohort NN O
was VBD O
80 CD O
% NN O
( , O
complete JJ O
response NN O
( -LRB- O
CR NN O
) -RRB- O
37 CD O
% NN O
, , O
partial JJ O
response NN O
44 CD O
% NN O
) , O
with IN O
14 CD O
/ SYM O
15 CD O
CR NN O
confirmed VBN O
as IN O
a DT O
metabolic JJ O
CR NN O
on IN O
PET NNP O
and CC O
ORR NN O
of IN O
85 CD O
% NN O
in IN O
the DT O
20 CD O
second JJ O
- HYPH O
line NN O
patients NNS O
. . O
null null null-Disease
The DT O
most RBS O
common JJ O
grade NN O
3 CD O
/ SYM O
4 CD O
toxicities NNS B-Disease
were VBD O
haematological JJ O
: : O
neutropenia NN B-Disease
54 CD O
% NN O
and CC O
thrombocytopenia NN B-Disease
51 CD O
% NN O
. . O
null null null-Disease
Median NNP O
follow NN O
- HYPH O
up NN O
from IN O
the DT O
start NN O
of IN O
GEM NNP O
- HYPH O
P NN O
was VBD O
4 CD O
. . O
5 CD O
years NNS O
. . O
null null null-Disease
Following VBG O
GEM NNP O
- HYPH O
P NNP O
, , O
5 CD O
- HYPH O
year NN O
progression NN O
- HYPH O
free JJ O
survival NN O
was VBD O
46 CD O
% NN O
( , O
95 CD O
% NN O
confidence NN O
interval NN O
( , O
CI NNP O
) -RRB- O
, , O
30 CD O
- SYM O
62 CD O
% NN O
) -RRB- O
and CC O
5 CD O
- HYPH O
year NN O
overall JJ O
survival NN O
was VBD O
59 CD O
% NN O
( , O
95 CD O
% NN O
CI NN O
, , O
43 CD O
- SYM O
74 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Fourteen CD O
of IN O
41 CD O
patients NNS O
proceeded VBD O
directly RB O
to IN O
autologous JJ O
transplant NN O
. . O
null null null-Disease
GEM NNP O
- HYPH O
P NNP O
is VBZ O
a DT O
salvage NN O
chemotherapy NN O
with IN O
relatively RB O
high JJ O
response NN O
rates NNS O
, , O
leading VBG O
to IN O
successful JJ O
transplantation NN O
in IN O
appropriate JJ O
patients NNS O
, , O
in IN O
the DT O
treatment NN O
of IN O
relapsed JJ O
or CC O
refractory JJ O
HL NNP B-Disease
. . O
null null null-Disease
Basal NNP O
functioning VBG O
of IN O
the DT O
hypothalamic JJ O
- HYPH O
pituitary NN O
- HYPH O
adrenal NN O
( , O
HPA NN O
) -RRB- O
axis NN O
and CC O
psychological JJ O
distress NN O
in IN O
recreational JJ O
ecstasy NN O
polydrug NN O
users NNS O
. . O
null null null-Disease
RATIONALE NN O
: : O
Ecstasy NNP O
( : O
MDMA NNP O
) -RRB- O
is VBZ O
a DT O
psychostimulant JJ O
drug NN O
which WDT O
is VBZ O
increasingly RB O
associated VBN O
with IN O
psychobiological JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
While IN O
some DT O
recent JJ O
studies NNS O
suggest VBP O
acute JJ O
changes NNS O
in IN O
neuroendocrine NN O
function NN O
, , O
less RBR O
is VBZ O
known VBN O
about IN O
long JJ O
- HYPH O
term NN O
changes NNS O
in IN O
HPA NN O
functionality NN O
in IN O
recreational JJ O
users NNS O
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
The DT O
current JJ O
study NN O
is VBZ O
the DT O
first JJ O
to TO O
explore VB O
the DT O
effects NNS O
of IN O
ecstasy NN O
- HYPH O
polydrug NN O
use NN O
on IN O
psychological JJ O
distress NN O
and CC O
basal JJ O
functioning NN O
of IN O
the DT O
HPA NNP O
axis NN O
through IN O
assessing VBG O
the DT O
secretion NN O
of IN O
cortisol NN O
across IN O
the DT O
diurnal JJ O
period NN O
. . O
null null null-Disease
METHOD NN O
: : O
Seventy CD O
- HYPH O
six CD O
participants NNS O
( , O
21 CD O
nonusers NNS O
, , O
29 CD O
light JJ O
ecstasy NN O
- HYPH O
polydrug NN O
users NNS O
, , O
26 CD O
heavy JJ O
ecstasy NN O
- HYPH O
polydrug NN O
users NNS O
) -RRB- O
completed VBD O
a DT O
substance NN O
use NN O
inventory NN O
and CC O
measures NNS O
of IN O
psychological JJ O
distress NN O
at IN O
baseline NN O
, , O
then RB O
two CD O
consecutive JJ O
days NNS O
of IN O
cortisol JJ O
sampling NN O
( , O
on IN O
awakening NN O
, , O
30 CD O
min NN O
post NN O
awakening NN O
, , O
between IN O
1400 CD O
and CC O
1600 CD O
hours NNS O
and CC O
pre NN O
bedtime NN O
) -RRB- O
. . O
null null null-Disease
On IN O
day NN O
2 CD O
, , O
participants NNS O
also RB O
attended VBD O
the DT O
laboratory NN O
to TO O
complete VB O
a DT O
20 CD O
- HYPH O
min NN O
multitasking NN O
stressor NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Both DT O
user NN O
groups NNS O
exhibited VBD O
significantly RB O
greater JJR O
levels NNS O
of IN O
anxiety NN B-Disease
and CC O
depression NN B-Disease
than IN O
nonusers NNS O
. . O
null null null-Disease
On IN O
day NN O
1 CD O
, , O
all DT O
participants NNS O
exhibited VBD O
a DT O
typical JJ O
cortisol NN O
profile NN O
, , O
though IN O
light JJ O
users NNS O
had VBD O
significantly RB O
elevated VBN O
levels NNS O
pre JJ O
- HYPH O
bed NN O
. . O
null null null-Disease
On IN O
day NN O
2 CD O
, , O
heavy JJ O
users NNS O
demonstrated VBD O
elevated VBN O
levels NNS O
upon IN O
awakening NN O
and CC O
all DT O
ecstasy NN O
- HYPH O
polydrug NN O
users NNS O
demonstrated VBD O
elevated JJ O
pre JJ O
- HYPH O
bed NN O
levels NNS O
compared VBN O
to IN O
non NN O
- HYPH O
users NNS O
. . O
null null null-Disease
Significant JJ O
between IN O
group NN O
differences NNS O
were VBD O
also RB O
observed VBN O
in IN O
afternoon NN O
cortisol NN O
levels NNS O
and CC O
in IN O
overall JJ O
cortisol NN O
secretion NN O
across IN O
the DT O
day NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
increases NNS O
in IN O
anxiety NN B-Disease
and CC O
depression NN B-Disease
are VBP O
in IN O
line NN O
with IN O
previous JJ O
observations NNS O
in IN O
recreational JJ O
ecstasy NN O
- HYPH O
polydrug NN O
users NNS O
. . O
null null null-Disease
Dysregulated VBN O
diurnal JJ O
cortisol NN O
may MD O
be VB O
indicative JJ O
of IN O
inappropriate JJ O
anticipation NN O
of IN O
forthcoming VBG O
demands NNS O
and CC O
hypersecretion NN O
may MD O
lead VB O
to IN O
the DT O
increased VBN O
psychological JJ O
and CC O
physical JJ O
morbidity NN O
associated VBN O
with IN O
heavy JJ O
recreational JJ O
use NN O
of IN O
ecstasy NN O
. . O
null null null-Disease
Ifosfamide NN O
related VBN O
encephalopathy NN B-Disease
: : O
the DT O
need NN O
for IN O
a DT O
timely JJ O
EEG NNP O
evaluation NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Ifosfamide NNP O
is VBZ O
an DT O
alkylating JJ O
agent NN O
useful JJ O
in IN O
the DT O
treatment NN O
of IN O
a DT O
wide JJ O
range NN O
of IN O
cancers NNS B-Disease
including VBG O
sarcomas NNS B-Disease
, , O
lymphoma NN B-Disease
, , O
gynecologic JJ B-Disease
and CC I-Disease
testicular JJ I-Disease
cancers NNS I-Disease
. . O
null null null-Disease
Encephalopathy NN B-Disease
has VBZ O
been VBN O
reported VBN O
in IN O
10 CD O
- SYM O
40 CD O
% NN O
of IN O
patients NNS O
receiving VBG O
high JJ O
- HYPH O
dose NN O
IV NN O
ifosfamide NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
highlight VB O
the DT O
role NN O
of IN O
electroencephalogram NN O
( , O
EEG NNP O
) -RRB- O
in IN O
the DT O
early JJ O
detection NN O
and CC O
management NN O
of IN O
ifosfamide NN O
related VBN O
encephalopathy NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Retrospective JJ O
chart NN O
review NN O
including VBG O
clinical JJ O
data NN O
and CC O
EEG NNP O
recordings NNS O
was VBD O
done VBN O
on IN O
five CD O
patients NNS O
, , O
admitted VBN O
to IN O
MD NNP O
Anderson NNP O
Cancer NNP B-Disease
Center NNP O
between IN O
years NNS O
2009 CD O
and CC O
2012 CD O
, , O
who WP O
developed VBD O
ifosfamide NN O
related VBN O
acute JJ O
encephalopathy NN B-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
All DT O
five CD O
patients NNS O
experienced VBD O
symptoms NNS O
of IN O
encephalopathy NN B-Disease
soon RB O
after IN O
( : O
within IN O
12 CD O
h CD O
- SYM O
2 CD O
days NNS O
) , O
receiving VBG O
ifosfamide NN O
. . O
null null null-Disease
Two CD O
patients NNS O
developed VBD O
generalized JJ O
convulsions NNS B-Disease
while IN O
one CD O
patient NN O
developed VBD O
continuous JJ O
non NN B-Disease
- HYPH I-Disease
convulsive JJ I-Disease
status NN I-Disease
epilepticus NN I-Disease
( -LRB- O
NCSE NNP B-Disease
) -RRB- O
that WDT O
required VBD O
ICU NNP O
admission NN O
and CC O
intubation NN O
. . O
null null null-Disease
Initial JJ O
EEG NNP O
showed VBD O
epileptiform NN O
discharges NNS O
in IN O
three CD O
patients NNS O
; : O
run VB O
of IN O
triphasic JJ O
waves NNS O
in IN O
one CD O
patient NN O
and CC O
moderate JJ O
degree NN O
diffuse NN O
generalized VBN O
slowing NN O
. . O
null null null-Disease
Mixed JJ O
pattern NN O
with IN O
the DT O
presence NN O
of IN O
both CC O
sharps NNS O
and CC O
triphasic JJ O
waves NNS O
were VBD O
also RB O
noted VBN O
. . O
null null null-Disease
Repeat NN O
EEGs NNS O
within IN O
24 CD O
_ SYM O
h NN O
of IN O
symptom NN O
onset NN O
showed VBD O
marked JJ O
improvement NN O
that WDT O
was VBD O
correlated VBN O
with IN O
clinical JJ O
improvement NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Severity NN O
of IN O
ifosfamide NN O
related VBN O
encephalopathy NN B-Disease
correlates VBZ O
with IN O
EEG NNP O
changes NNS O
. . O
null null null-Disease
We PRP O
suggest VBP O
a DT O
timely JJ O
EEG NNP O
evaluation NN O
for IN O
patients NNS O
receiving VBG O
ifosfamide NN O
who WP O
develop VBP O
features NNS O
of IN O
encephalopathy NN B-Disease
. . O
null null null-Disease
Incidence NN O
of IN O
contrast NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
in IN O
hospitalised VBN O
patients NNS O
with IN O
cancer NN B-Disease
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
To TO O
determine VB O
the DT O
frequency NN O
of IN O
and CC O
possible JJ O
factors NNS O
related VBN O
to IN O
contrast NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
( , O
CIN NNP O
) -RRB- O
in IN O
hospitalised VBN O
patients NNS O
with IN O
cancer NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Ninety CD O
adult NN O
patients NNS O
were VBD O
enrolled VBN O
. . O
null null null-Disease
Patients NNS O
with IN O
risk NN O
factors NNS O
for IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
were VBD O
excluded VBN O
. . O
null null null-Disease
Blood NN O
samples NNS O
were VBD O
examined VBN O
the DT O
day NN O
before IN O
contrast NN O
- HYPH O
enhanced VBN O
computed JJ O
tomography NN O
( , O
CT NNP O
) -RRB- O
and CC O
serially RB O
for IN O
3 CD O
days NNS O
thereafter RB O
. . O
null null null-Disease
CIN NNP O
was VBD O
defined VBN O
as IN O
an DT O
increase NN O
in IN O
serum NN O
creatinine NN O
( , O
Cr NN O
) -RRB- O
of IN O
0 CD O
. . O
5 CD O
mg NN O
/ SYM O
dl NNS O
or CC O
more JJR O
, , O
or CC O
elevation NN O
of IN O
Cr NN O
to IN O
25 CD O
% NN O
over IN O
baseline NN O
. . O
null null null-Disease
Relationships NNS O
between IN O
CIN NNP O
and CC O
possible JJ O
risk NN O
factors NNS O
were VBD O
investigated VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
CIN NNP O
was VBD O
detected VBN O
in IN O
18 CD O
/ SYM O
90 CD O
( SYM O
20 CD O
% NN O
) SYM O
patients NNS O
. . O
null null null-Disease
CIN NNP O
developed VBD O
in IN O
25 CD O
. . O
5 CD O
% NN O
patients NNS O
who WP O
underwent VBD O
chemotherapy NN O
and CC O
in IN O
11 CD O
% NN O
patients NNS O
who WP O
did VBD O
not RB O
( : O
P NN O
= SYM O
0 CD O
. . O
1 CD O
) -RRB- O
. . O
null null null-Disease
CIN NNP O
more RBR O
frequently RB O
developed VBN O
in IN O
patients NNS O
who WP O
had VBD O
undergone VBN O
CT NNP O
within IN O
45 CD O
days NNS O
after IN O
the DT O
last JJ O
chemotherapy NN O
( : O
P NN O
= SYM O
0 CD O
. . O
005 CD O
) -RRB- O
; : O
it PRP O
was VBD O
also RB O
an DT O
independent JJ O
risk NN O
factor NN O
( : O
P NN O
= SYM O
0 CD O
. . O
017 CD O
) -RRB- O
. . O
null null null-Disease
CIN NNP O
was VBD O
significantly RB O
more JJR O
after IN O
treatment NN O
with IN O
bevacizumab NN O
/ SYM O
irinotecan NN O
( , O
P NN O
= SYM O
0 CD O
. . O
021 CD O
) -RRB- O
and CC O
in IN O
patients NNS O
with IN O
hypertension NN B-Disease
( : O
P NN O
= SYM O
0 CD O
. . O
044 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
incidence NN O
of IN O
CIN NNP O
after IN O
CT NNP O
in IN O
hospitalised VBN O
oncological JJ O
patients NNS O
was VBD O
20 CD O
% NN O
. . O
null null null-Disease
CIN NNP O
developed VBD O
4 CD O
. . O
5 CD O
- HYPH O
times NNS O
more RBR O
frequently RB O
in IN O
patients NNS O
with IN O
cancer NN B-Disease
who WP O
had VBD O
undergone VBN O
recent JJ O
chemotherapy NN O
. . O
null null null-Disease
Hypertension NN B-Disease
and CC O
the DT O
combination NN O
of IN O
bevacizumab NN O
/ SYM O
irinotecan NN O
may MD O
be VB O
additional JJ O
risk NN O
factors NNS O
for IN O
CIN NNP O
development NN O
. . O
null null null-Disease
KEY JJ O
POINTS NNS O
: : O
. . O
null null null-Disease
Contrast NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
( , O
CIN NNP O
) -RRB- O
is VBZ O
a DT O
concern NN O
for IN O
oncological JJ O
patients NNS O
undergoing VBG O
CT NNP O
. . O
null null null-Disease
. . O
CIN NN O
occurs VBZ O
more RBR O
often RB O
when WRB O
CT NNP O
is VBZ O
performed VBN O
< SYM O
45 CD O
days NNS O
after IN O
chemotherapy NN O
. . O
null null null-Disease
. , O
Hypertension NN B-Disease
and CC O
treatment NN O
with IN O
bevacizumab NN O
appear VBP O
to TO O
be VB O
additional JJ O
risk NN O
factors NNS O
. . O
null null null-Disease
Syndrome NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
antidiuretic JJ I-Disease
hormone NN I-Disease
secretion NN O
associated VBN O
with IN O
desvenlafaxine NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
report VB O
a DT O
case NN O
of IN O
syndrome NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
anti JJ I-Disease
- HYPH I-Disease
diuretic JJ I-Disease
hormone NN I-Disease
( -LRB- O
SIADH NN B-Disease
) -RRB- O
secretion NN O
associated VBN O
with IN O
desvenlafaxine NN O
. . O
null null null-Disease
CASE NNP O
SUMMARY NNP O
: : O
A DT O
57 CD O
- HYPH O
year NN O
old JJ O
female NN O
with IN O
hyponatraemia NN B-Disease
. . O
null null null-Disease
Her PRP$ O
medications NNS O
included VBD O
desvenlafaxine NN O
, , O
and CC O
symptoms NNS O
included VBD O
nausea NN B-Disease
, , O
anxiety NN B-Disease
and CC O
confusion NN B-Disease
. . O
null null null-Disease
The DT O
serum NN O
sodium NN O
at IN O
this DT O
time NN O
was VBD O
120 CD O
mmol NN O
/ SYM O
L NN O
, , O
serum NN O
osmolality NN O
was VBD O
263 CD O
mosmol NN O
/ SYM O
kg NN O
, , O
urine NN O
osmolality NN O
410 CD O
mosmol NN O
/ SYM O
kg NN O
and CC O
urine NN O
sodium NN O
63 CD O
mmol NN O
/ SYM O
L NNP O
, , O
consistent JJ O
with IN O
a DT O
diagnosis NN O
of IN O
SIADH NNP B-Disease
. . O
null null null-Disease
Desvenlafaxine NNP O
was VBD O
ceased VBN O
and CC O
fluid JJ O
restriction NN O
implemented VBN O
. . O
null null null-Disease
After IN O
4 CD O
days NNS O
the DT O
sodium NN O
increased VBD O
to IN O
128 CD O
mmol NN O
/ SYM O
L NN O
and CC O
fluid JJ O
restriction NN O
was VBD O
relaxed VBN O
. . O
null null null-Disease
During IN O
her PRP$ O
further JJ O
3 CD O
weeks NNS O
inpatient JJ O
admission NN O
the DT O
serum NN O
sodium NN O
ranged VBD O
from IN O
134 CD O
to IN O
137 CD O
mmol NN O
/ SYM O
L NN O
during IN O
treatment NN O
with IN O
mirtazapine NN O
. . O
null null null-Disease
DISCUSSION NN O
: : O
SIADH NNP B-Disease
has VBZ O
been VBN O
widely RB O
reported VBN O
with IN O
a DT O
range NN O
of IN O
antidepressants NNS O
. . O
null null null-Disease
This DT O
case NN O
report NN O
suggests VBZ O
that IN O
desvenlafaxine NN O
might MD O
cause VB O
clinically RB O
significant JJ O
hyponatremia NN B-Disease
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Clinicians NNS O
should MD O
be VB O
aware JJ O
of IN O
the DT O
potential NN O
for IN O
antidepressants NNS O
to TO O
cause VB O
hyponatremia NN B-Disease
, , O
and CC O
take VB O
appropriate JJ O
corrective JJ O
action NN O
where WRB O
necessary JJ O
. . O
null null null-Disease
Oxidative JJ O
stress NN O
on IN O
cardiotoxicity NN B-Disease
after IN O
treatment NN O
with IN O
single JJ O
and CC O
multiple JJ O
doses NNS O
of IN O
doxorubicin NN O
. . O
null null null-Disease
The DT O
mechanism NN O
of IN O
doxorubicin NN O
( , O
DOX NNP O
) -RRB- O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
remains VBZ O
controversial JJ O
. . O
null null null-Disease
Wistar NNP O
rats NNS O
( , O
n CD O
= SYM O
66 CD O
) -RRB- O
received VBD O
DOX NNP O
injections NNS O
intraperitoneally RB O
and CC O
were VBD O
randomly RB O
assigned VBN O
to IN O
2 CD O
experimental JJ O
protocols NNS O
: : O
( : O
1 CD O
) -RRB- O
rats NNS O
were VBD O
killed VBN O
before RB O
( : O
- HYPH O
24 CD O
h NN O
, , O
n CD O
= SYM O
8 CD O
) -RRB- O
and CC O
24 CD O
h NN O
after IN O
( HYPH O
+ SYM O
24 CD O
h NN O
, , O
n CD O
= SYM O
8 CD O
) SYM O
a DT O
single JJ O
dose NN O
of IN O
DOX NNP O
( SYM O
4 CD O
mg NN O
/ SYM O
kg NN O
body NN O
weight NN O
) -RRB- O
to TO O
determine VB O
the DT O
DOX NNP O
acute JJ O
effect NN O
and CC O
( , O
2 CD O
) SYM O
rats NNS O
( , O
n CD O
= SYM O
58 CD O
) -RRB- O
received VBN O
4 CD O
injections NNS O
of IN O
DOX NNP O
( SYM O
4 CD O
mg NN O
/ SYM O
kg NN O
body NN O
weight NN O
/ SYM O
week NN O
) -RRB- O
and CC O
were VBD O
killed VBN O
before IN O
the DT O
first JJ O
injection NN O
( -LRB- O
M0 NNP O
) -RRB- O
and CC O
1 CD O
week NN O
after IN O
each DT O
injection NN O
( HYPH O
M1 NNP O
, , O
M2 NNP O
, , O
M3 NNP O
, , O
and CC O
M4 NNP O
) -RRB- O
to TO O
determine VB O
the DT O
chronological JJ O
effects NNS O
. . O
null null null-Disease
Animals NNS O
used VBN O
at IN O
M0 NNP O
( , O
n CD O
= SYM O
8 CD O
) -RRB- O
were VBD O
also RB O
used VBN O
at IN O
moment NN O
- HYPH O
24 CD O
h NN O
of IN O
acute JJ O
study NN O
. . O
null null null-Disease
Cardiac JJ O
total JJ O
antioxidant JJ O
performance NN O
( , O
TAP NNP O
) -RRB- O
, , O
DNA NN O
damage NN O
, , O
and CC O
morphology NN O
analyses NNS O
were VBD O
carried VBN O
out RP O
at IN O
each DT O
time NN O
point NN O
. . O
null null null-Disease
Single JJ O
dose NN O
of IN O
DOX NNP O
was VBD O
associated VBN O
with IN O
increased VBN O
cardiac JJ B-Disease
disarrangement NN I-Disease
, , O
necrosis NN B-Disease
, , O
and CC O
DNA NN O
damage NN O
( , O
strand NN O
breaks NNS O
( -LRB- O
SBs NNS O
) -RRB- O
and CC O
oxidized VBN O
pyrimidines NNS O
) -RRB- O
and CC O
decreased VBN O
TAP NN O
. . O
null null null-Disease
The DT O
chronological JJ O
study NN O
showed VBD O
an DT O
effect NN O
of IN O
a DT O
cumulative JJ O
dose NN O
on IN O
body NN O
weight NN O
( , O
R NN O
= SYM O
- HYPH O
0 CD O
. . O
99 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
011 CD O
) -RRB- O
, , O
necrosis NN B-Disease
( , O
R NN O
= SYM O
1 CD O
. . O
00 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
004 CD O
) -RRB- O
, , O
TAP NN O
( : O
R NN O
= SYM O
0 CD O
. . O
95 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
049 CD O
) -RRB- O
, , O
and CC O
DNA NN O
SBs NNS O
( : O
R NN O
= : O
- HYPH O
0 CD O
. . O
95 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
049 CD O
) -RRB- O
. . O
null null null-Disease
DNA NNP O
SBs NNP O
damage NN O
was VBD O
negatively RB O
associated VBN O
with IN O
TAP NNP O
( , O
R NNP O
= : O
- HYPH O
0 CD O
. . O
98 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
018 CD O
) -RRB- O
, , O
and CC O
necrosis NN B-Disease
( , O
R NN O
= : O
- HYPH O
0 CD O
. . O
97 CD O
, , O
p NN O
= SYM O
0 CD O
. . O
027 CD O
) -RRB- O
. . O
null null null-Disease
Our PRP$ O
results NNS O
suggest VBP O
that IN O
oxidative JJ O
damage NN O
is VBZ O
associated VBN O
with IN O
acute JJ O
cardiotoxicity NN B-Disease
induced VBN O
by IN O
a DT O
single JJ O
dose NN O
of IN O
DOX NNP O
only RB O
. . O
null null null-Disease
Increased VBN O
resistance NN O
to IN O
the DT O
oxidative JJ O
stress NN O
is VBZ O
plausible JJ O
for IN O
the DT O
multiple JJ O
dose NN O
of IN O
DOX NNP O
. . O
null null null-Disease
Thus RB O
, , O
different JJ O
mechanisms NNS O
may MD O
be VB O
involved VBN O
in IN O
acute JJ O
toxicity NN B-Disease
versus IN O
chronic JJ O
toxicity NN B-Disease
. . O
null null null-Disease
Tacrolimus NNP O
- HYPH O
related VBN O
seizure NN B-Disease
after IN O
pediatric JJ O
liver NN O
transplantation NN O
- , O
- : O
a DT O
single JJ O
- HYPH O
center NN O
experience NN O
. . O
null null null-Disease
To TO O
identify VB O
the DT O
risk NN O
factors NNS O
for IN O
new JJ O
- HYPH O
onset NN O
seizures NNS B-Disease
after IN O
pediatric JJ O
LT NNP O
and CC O
to TO O
assess VB O
their PRP$ O
clinical JJ O
implications NNS O
and CC O
long JJ O
- HYPH O
term NN O
prognosis NN O
. . O
null null null-Disease
The DT O
clinical JJ O
and CC O
laboratory NN O
data NNS O
of IN O
27 CD O
consecutive JJ O
children NNS O
who WP O
underwent VBD O
LT NNP O
from IN O
January NNP O
2007 CD O
to IN O
December NNP O
2010 CD O
in IN O
our PRP$ O
center NN O
were VBD O
analyzed VBN O
retrospectively RB O
. . O
null null null-Disease
Patients NNS O
were VBD O
divided VBN O
into IN O
seizures NNS B-Disease
group NN O
and CC O
a DT O
non AFX O
- HYPH O
seizures NNS B-Disease
group NN O
. . O
null null null-Disease
Pre NN O
- HYPH O
operative NN O
, , O
intra NN O
- HYPH O
operative NN O
, , O
and CC O
post NN O
- HYPH O
operative NN O
data NNS O
were VBD O
collected VBN O
. . O
null null null-Disease
Seizures NNS B-Disease
occurred VBD O
in IN O
four CD O
children NNS O
, , O
an DT O
incidence NN O
of IN O
14 CD O
. . O
8 CD O
% NN O
. . O
null null null-Disease
All DT O
exhibited VBD O
generalized VBN O
tonic JJ B-Disease
- HYPH I-Disease
clonic JJ I-Disease
seizures NNS I-Disease
within IN O
the DT O
first JJ O
two CD O
wk NN O
after IN O
LT NNP O
. . O
null null null-Disease
Univariate NN O
analysis NN O
showed VBD O
that IN O
the DT O
risk NN O
factors NNS O
associated VBN O
with IN O
seizures NNS B-Disease
after IN O
pediatric JJ O
LT NNP O
included VBD O
gender NN O
, , O
pediatric JJ O
end NN B-Disease
- HYPH I-Disease
stage NN I-Disease
liver NN I-Disease
disease NN I-Disease
score NN O
before IN O
surgery NN O
, , O
Child NNP O
- HYPH O
Pugh NNP O
score NN O
before IN O
surgery NN O
, , O
serum NN O
total JJ O
bilirubin NN O
after IN O
surgery NN O
, , O
and CC O
trough NN O
TAC NNP O
level NN O
. . O
null null null-Disease
Multivariate JJ O
analysis NN O
showed VBD O
that IN O
trough NN O
TAC NNP O
level NN O
was VBD O
the DT O
only JJ O
independent JJ O
risk NN O
factor NN O
associated VBN O
with IN O
the DT O
seizures NNS B-Disease
. . O
null null null-Disease
All DT O
children NNS O
who WP O
experienced VBD O
seizures NNS B-Disease
survived VBD O
with IN O
good JJ O
graft NN O
function NN O
and CC O
remained VBD O
seizure NN B-Disease
- HYPH O
free JJ O
without IN O
anti JJ O
- HYPH O
epileptic JJ B-Disease
drugs NNS O
over IN O
a DT O
mean JJ O
follow NN O
- HYPH O
up NN O
period NN O
of IN O
33 CD O
. . O
7 CD O
+ SYM O
14 CD O
. . O
6 CD O
months NNS O
. . O
null null null-Disease
High JJ O
trough NN O
TAC NNP O
level NN O
was VBD O
the DT O
predominant JJ O
factor NN O
that WDT O
contributed VBD O
to IN O
seizures NNS B-Disease
in IN O
the DT O
early JJ O
post NN O
- HYPH O
operative NN O
period NN O
after IN O
pediatric JJ O
LT NNP O
. . O
null null null-Disease
High JJ O
PELD NNP O
and CC O
Child NNP O
- HYPH O
Pugh NNP O
scores NNS O
before IN O
LT NNP O
and CC O
high JJ O
post NN O
- HYPH O
operative JJ O
serum NN O
Tbil NNP O
may MD O
be VB O
contributory JJ O
risk NN O
factors NNS O
for IN O
TAC NNP O
- HYPH O
related VBN O
seizures NNS B-Disease
. . O
null null null-Disease
The DT O
flavonoid NN O
apigenin NN O
delays VBZ O
forgetting NN O
of IN O
passive JJ O
avoidance NN O
conditioning NN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
present JJ O
experiments NNS O
were VBD O
performed VBN O
to TO O
study VB O
the DT O
effect NN O
of IN O
the DT O
flavonoid NN O
apigenin NN O
( SYM O
20 CD O
mg NN O
/ SYM O
kg NN O
intraperitoneally RB O
( : O
i CD O
. . O
p NN O
. . O
) -RRB- O
, , O
1 CD O
h NN O
before IN O
acquisition NN O
) -RRB- O
, , O
on IN O
24 CD O
h NN O
retention NN O
performance NN O
and CC O
forgetting NN O
of IN O
a DT O
step NN O
- HYPH O
through RP O
passive JJ O
avoidance NN O
task NN O
, , O
in IN O
young JJ O
male JJ O
Wistar NNP O
rats NNS O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
differences NNS O
between IN O
saline NN O
- HYPH O
and CC O
apigenin NN O
- HYPH O
treated VBN O
groups NNS O
in IN O
the DT O
24 CD O
h NN O
retention NN O
trial NN O
. . O
null null null-Disease
Furthermore RB O
, , O
apigenin NN O
did VBD O
not RB O
prevent VB O
the DT O
amnesia NN B-Disease
induced VBN O
by IN O
scopolamine NN O
( , O
1mg CD O
/ SYM O
kg NN O
, , O
i PRP O
. . O
p NN O
. . O
, , O
30 CD O
min NN O
before IN O
the DT O
acquisition NN O
) -RRB- O
. . O
null null null-Disease
The DT O
saline NN O
- HYPH O
and CC O
apigenin NN O
- HYPH O
treated VBN O
rats NNS O
that WDT O
did VBD O
not RB O
step VB O
through RP O
into IN O
the DT O
dark JJ O
compartment NN O
during IN O
the DT O
cut NN O
- HYPH O
off NN O
time NN O
( : O
540 CD O
s NNS O
) , O
were VBD O
retested VBN O
weekly RB O
for IN O
up IN O
to TO O
eight CD O
weeks NNS O
. . O
null null null-Disease
In IN O
the DT O
saline NN O
treated VBN O
group NN O
, , O
the DT O
first JJ O
significant JJ O
decline NN O
in IN O
passive JJ O
avoidance NN O
response NN O
was VBD O
observed VBN O
at IN O
four CD O
weeks NNS O
, , O
and CC O
complete JJ O
memory NN B-Disease
loss NN I-Disease
was VBD O
found VBN O
five CD O
weeks NNS O
after IN O
the DT O
acquisition NN O
of IN O
the DT O
passive JJ O
avoidance NN O
task NN O
. . O
null null null-Disease
At IN O
the DT O
end NN O
of IN O
the DT O
experimental JJ O
period NN O
, , O
60 CD O
% NN O
of IN O
the DT O
animals NNS O
treated VBN O
with IN O
apigenin NN O
still RB O
did VBD O
not RB O
step VB O
through RB O
. . O
null null null-Disease
These DT O
data NNS O
suggest VBP O
that IN O
1 CD O
) SYM O
apigenin NN O
delays VBZ O
the DT O
long JJ O
- HYPH O
term NN O
forgetting NN O
but CC O
did VBD O
not RB O
modulate VB O
the DT O
24 CD O
h NN O
retention NN O
of IN O
fear NN O
memory NN O
and CC O
2 CD O
) , O
the DT O
obtained VBN O
beneficial JJ O
effect NN O
of IN O
apigenin NN O
on IN O
the DT O
passive JJ O
avoidance NN O
conditioning NN O
is VBZ O
mediated VBN O
by IN O
mechanisms NNS O
that WDT O
do VBP O
not RB O
implicate VB O
its PRP$ O
action NN O
on IN O
the DT O
muscarinic JJ O
cholinergic JJ O
system NN O
. . O
null null null-Disease
Histamine NN O
antagonists NNS O
and CC O
d NN O
- HYPH O
tubocurarine NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
in IN O
cardiac JJ O
surgical JJ O
patients NNS O
. . O
null null null-Disease
Hemodynamic JJ O
effects NNS O
and CC O
histamine NN O
release NN O
by IN O
bolus NN O
injection NN O
of IN O
0 CD O
. . O
35 CD O
mg CD O
/ SYM O
kg NNS O
of IN O
d NN O
- HYPH O
tubocurarine NN O
were VBD O
studied VBN O
in IN O
24 CD O
patients NNS O
. . O
null null null-Disease
H1 NN O
- HYPH O
and CC O
H2 NNP O
- HYPH O
histamine NN O
antagonists NNS O
or CC O
placebo NN O
were VBD O
given VBN O
before IN O
dosing VBG O
with IN O
d NN O
- HYPH O
tubocurarine NN O
in IN O
a DT O
randomized VBN O
double JJ O
- HYPH O
blind JJ O
fashion NN O
to IN O
four CD O
groups NNS O
: : O
group NN O
1 CD O
- HYPH O
- HYPH O
placebo NN O
; : O
group NN O
2 CD O
- HYPH O
- HYPH O
cimetidine NN O
, , O
4 CD O
mg NN O
/ SYM O
kg NN O
, , O
plus CC O
placebo NN O
; : O
group NN O
3 CD O
- HYPH O
- HYPH O
chlorpheniramine NN O
, , O
0 CD O
. . O
1 CD O
mg NN O
/ SYM O
kg NN O
, , O
plus CC O
placebo NN O
; : O
and CC O
group NN O
4 CD O
- HYPH O
- HYPH O
cimetidine NN O
plus CC O
chlorpheniramine NN O
. . O
null null null-Disease
Histamine NN O
release NN O
occurred VBD O
in IN O
most JJS O
patients NNS O
, , O
the DT O
highest JJS O
level NN O
2 CD O
minutes NNS O
after IN O
d JJ O
- HYPH O
tubocurarine NN O
dosing NN O
. . O
null null null-Disease
Group NN O
1 CD O
had VBD O
a DT O
moderate JJ O
negative JJ O
correlation NN O
between IN O
plasma NN O
histamine NN O
change NN O
and CC O
systemic JJ O
vascular JJ O
resistance NN O
( : O
r NN O
= SYM O
0 CD O
. . O
58 CD O
; : O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
not RB O
present JJ O
in IN O
group NN O
4 CD O
. . O
null null null-Disease
Prior RB O
dosing VBG O
with IN O
antagonists NNS O
partially RB O
prevented VBD O
the DT O
fall NN O
in IN O
systemic JJ O
vascular JJ O
resistance NN O
. . O
null null null-Disease
These DT O
data NNS O
demonstrate VBP O
that IN O
the DT O
hemodynamic JJ O
changes NNS O
associated VBN O
with IN O
d NN O
- HYPH O
tubocurarine NN O
dosing NN O
are VBP O
only RB O
partially RB O
explained VBN O
by IN O
histamine NN O
release NN O
. . O
null null null-Disease
Thus RB O
prior JJ O
dosing NN O
with IN O
H1 NNP O
- HYPH O
and CC O
H2 NNP O
- HYPH O
antagonists NNS O
provides VBZ O
only RB O
partial JJ O
protection NN O
. . O
null null null-Disease
Cholecystokinin NN O
- HYPH O
octapeptide NN O
restored VBD O
morphine NN O
- HYPH O
induced VBN O
hippocampal JJ O
long JJ O
- HYPH O
term NN O
potentiation NN O
impairment NN O
in IN O
rats NNS O
. . O
null null null-Disease
Cholecystokinin NNP O
- HYPH O
octapeptide NNP O
( , O
CCK NNP O
- HYPH O
8 CD O
) -RRB- O
, , O
which WDT O
is VBZ O
a DT O
typical JJ O
brain NN O
- HYPH O
gut NN O
peptide NN O
, , O
exerts VBZ O
a DT O
wide JJ O
range NN O
of IN O
biological JJ O
activities NNS O
on IN O
the DT O
central JJ O
nervous JJ O
system NN O
. . O
null null null-Disease
We PRP O
have VBP O
previously RB O
reported VBN O
that IN O
CCK NNP O
- HYPH O
8 CD O
significantly RB O
alleviated VBD O
morphine NN O
- , O
induced VBD O
amnesia NN B-Disease
and CC O
reversed VBD O
spine NN O
density NN O
decreases NNS O
in IN O
the DT O
CA1 NNP O
region NN O
of IN O
the DT O
hippocampus NN O
in IN O
morphine NN O
- HYPH O
treated VBN O
animals NNS O
. . O
null null null-Disease
Here RB O
, , O
we PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
CCK NNP O
- HYPH O
8 CD O
on IN O
long JJ O
- HYPH O
term NN O
potentiation NN O
( -LRB- O
LTP NNP O
) -RRB- O
in IN O
the DT O
lateral JJ O
perforant JJ O
path NN O
( -LRB- O
LPP NNP O
) -RRB- O
- HYPH O
granule NN O
cell NN O
synapse NN O
of IN O
rat NN O
dentate NN O
gyrus NN O
( , O
DG NNP O
) -RRB- O
in IN O
acute JJ O
saline NN O
or CC O
morphine NN O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Population NN O
spikes NNS O
( , O
PS NNP O
) -RRB- O
, , O
which WDT O
were VBD O
evoked VBN O
by IN O
stimulation NN O
of IN O
the DT O
LPP NNP O
, , O
were VBD O
recorded VBN O
in IN O
the DT O
DG NNP O
region NN O
. . O
null null null-Disease
Acute JJ O
morphine NN O
( , O
30mg CD O
/ SYM O
kg NNS O
, , O
s VBZ O
. . O
c NN O
. . O
) -RRB- O
treatment NN O
significantly RB O
attenuated VBN O
hippocampal JJ O
LTP NNP O
and CC O
CCK NNP O
- HYPH O
8 CD O
( , O
1ug CD O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
. . O
) -RRB- O
restored VBD O
the DT O
amplitude NN O
of IN O
PS NN O
that WDT O
was VBD O
attenuated VBN O
by IN O
morphine NN O
injection NN O
. . O
null null null-Disease
Furthermore RB O
, , O
microinjection NN O
of IN O
CCK NNP O
- HYPH O
8 CD O
( SYM O
0 CD O
. . O
1 CD O
and CC O
1ug NN O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
. . O
) -RRB- O
also RB O
significantly RB O
augmented VBN O
hippocampal JJ O
LTP NNP O
in IN O
saline NN O
- HYPH O
treated VBN O
( : O
1ml NN O
/ SYM O
kg NNS O
, , O
s UH O
. . O
c NN O
. . O
) -RRB- O
rats NNS O
. . O
null null null-Disease
Pre NNP O
- HYPH O
treatment NN O
of IN O
the DT O
CCK2 NNP O
receptor NN O
antagonist NN O
L NNP O
- HYPH O
365 CD O
, , O
260 CD O
( , O
10ug CD O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
) -RRB- O
reversed VBD O
the DT O
effects NNS O
of IN O
CCK NNP O
- HYPH O
8 CD O
, , O
but CC O
the DT O
CCK1 NNP O
receptor NN O
antagonist NN O
L NNP O
- HYPH O
364 CD O
, , O
718 CD O
( , O
10ug CD O
, , O
i PRP O
. . O
c NN O
. . O
v NN O
) NFP O
did VBD O
not RB O
. . O
null null null-Disease
The DT O
present JJ O
results NNS O
demonstrate VBP O
that IN O
CCK NNP O
- HYPH O
8 CD O
attenuates VBZ O
the DT O
effect NN O
of IN O
morphine NN O
on IN O
hippocampal JJ O
LTP NNP O
through IN O
CCK2 NNP O
receptors NNS O
and CC O
suggest VBP O
an DT O
ameliorative JJ O
function NN O
of IN O
CCK NNP O
- HYPH O
8 CD O
on IN O
morphine NN O
- HYPH O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
. . O
null null null-Disease
Glial NN O
activation NN O
and CC O
post NN O
- HYPH O
synaptic JJ O
neurotoxicity NN B-Disease
: : O
the DT O
key JJ O
events NNS O
in IN O
Streptozotocin NNP O
( -LRB- O
ICV NNP O
) -RRB- O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
In IN O
the DT O
present JJ O
study NN O
the DT O
role NN O
of IN O
glial NN O
activation NN O
and CC O
post NN O
synaptic JJ O
toxicity NN B-Disease
in IN O
ICV NNP O
Streptozotocin NNP O
( -LRB- O
STZ NNP O
) -RRB- O
induced VBD O
memory NN B-Disease
impaired VBN I-Disease
rats NNS O
was VBD O
explored VBN O
. . O
null null null-Disease
In IN O
experiment NN O
set VBN O
up RP O
1 CD O
: : O
Memory NN B-Disease
deficit NN I-Disease
was VBD O
found VBN O
in IN O
Morris NNP O
water NN O
maze NN O
test NN O
on IN O
14 CD O
- SYM O
16 CD O
days NNS O
after IN O
STZ NNP O
( : O
ICV NNP O
; : O
3mg NNP O
/ SYM O
Kg NNP O
) -RRB- O
administration NN O
. . O
null null null-Disease
STZ NNP O
causes VBZ O
increased VBN O
expression NN O
of IN O
GFAP NNP O
, , O
CD11b NNP O
and CC O
TNF NNP O
- HYPH O
a DT O
indicating VBG O
glial NN O
activation NN O
and CC O
neuroinflammation NN B-Disease
. . O
null null null-Disease
STZ NNP O
also RB O
significantly RB O
increased VBD O
the DT O
level NN O
of IN O
ROS NNP O
, , O
nitrite NN O
, , O
Ca NNP O
( , O
2 CD O
+ CC O
) -RRB- O
and CC O
reduced VBD O
the DT O
mitochondrial JJ O
activity NN O
in IN O
synaptosomal JJ O
preparation NN O
illustrating VBG O
free JJ O
radical JJ O
generation NN O
and CC O
excitotoxicity NN B-Disease
. . O
null null null-Disease
Increased VBN O
expression NN O
and CC O
activity NN O
of IN O
Caspase NNP O
- HYPH O
3 CD O
was VBD O
also RB O
observed VBN O
in IN O
STZ NNP O
treated VBN O
rat NN O
which WDT O
specify VBP O
apoptotic JJ O
cell NN O
death NN O
in IN O
hippocampus NN O
and CC O
cortex NN O
. . O
null null null-Disease
STZ NNP O
treatment NN O
showed VBD O
decrease NN O
expression NN O
of IN O
post NN O
synaptic JJ O
markers NNS O
CaMKIIa NNP O
and CC O
PSD NNP O
- HYPH O
95 CD O
, , O
while IN O
, , O
expression NN O
of IN O
pre JJ O
synaptic JJ O
markers NNS O
( , O
synaptophysin NN O
and CC O
SNAP NNP O
- HYPH O
25 CD O
) -RRB- O
remains VBZ O
unaltered JJ O
indicating VBG O
selective JJ O
post NN O
synaptic JJ O
neurotoxicity NN B-Disease
. . O
null null null-Disease
Oral JJ O
treatment NN O
with IN O
Memantine NNP O
( , O
10mg CD O
/ SYM O
kg NNS O
) -RRB- O
and CC O
Ibuprofen NNP O
( SYM O
50 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
daily RB O
for IN O
13 CD O
days NNS O
attenuated VBN O
STZ NNP O
induced VBN O
glial NN O
activation NN O
, , O
apoptotic JJ O
cell NN O
death NN O
and CC O
post NN O
synaptic JJ O
neurotoxicity NN B-Disease
in IN O
rat NN O
brain NN O
. . O
null null null-Disease
Further RB O
, , O
in IN O
experiment NN O
set VBN O
up RP O
2 CD O
: : O
where WRB O
memory NN O
function NN O
was VBD O
not RB O
affected VBN O
i : O
. . O
e LS O
. . O
7 CD O
- SYM O
9 CD O
days NNS O
after IN O
STZ NNP O
treatment NN O
. . O
null null null-Disease
The DT O
level NN O
of IN O
GFAP NNP O
, , O
CD11b NNP O
, , O
TNF NNP O
- HYPH O
a DT O
, , O
ROS NNP O
and CC O
nitrite NN O
levels NNS O
were VBD O
increased VBN O
. . O
null null null-Disease
On IN O
the DT O
other JJ O
hand NN O
, , O
apoptotic JJ O
marker NN O
, , O
synaptic JJ O
markers NNS O
, , O
mitochondrial JJ O
activity NN O
and CC O
Ca NN O
( , O
2 CD O
+ CC O
) -RRB- O
levels NNS O
remained VBD O
unaffected JJ O
. . O
null null null-Disease
Collective JJ O
data NNS O
indicates VBZ O
that IN O
neuroinflammatory JJ B-Disease
process NN O
and CC O
oxidative JJ O
stress NN O
occurs VBZ O
earlier RBR O
to IN O
apoptosis NN O
and CC O
does VBZ O
not RB O
affect VB O
memory NN O
function NN O
. . O
null null null-Disease
Present JJ O
study NN O
clearly RB O
suggests VBZ O
that IN O
glial NN O
activation NN O
and CC O
post NN O
synaptic JJ O
neurotoxicity NN B-Disease
are VBP O
the DT O
key JJ O
factors NNS O
in IN O
STZ NNP O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
and CC O
neuronal JJ O
cell NN O
death NN O
. . O
null null null-Disease
Comparison NN O
of IN O
effects NNS O
of IN O
isotonic JJ O
sodium NN O
chloride NN O
with IN O
diltiazem NN O
in IN O
prevention NN O
of IN O
contrast NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
. . O
null null null-Disease
INTRODUCTION NN O
AND CC O
OBJECTIVE NN O
: : O
Contrast NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
( , O
CIN NNP O
) -RRB- O
significantly RB O
increases VBZ O
the DT O
morbidity NN O
and CC O
mortality NN O
of IN O
patients NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
investigate VB O
and CC O
compare VB O
the DT O
protective JJ O
effects NNS O
of IN O
isotonic JJ O
sodium NN O
chloride NN O
with IN O
sodium NN O
bicarbonate NN O
infusion NN O
and CC O
isotonic JJ O
sodium NN O
chloride NN O
infusion NN O
with IN O
diltiazem NN O
, , O
a DT O
calcium NN O
channel NN O
blocker NN O
, , O
in IN O
preventing VBG O
CIN NNP O
. . O
null null null-Disease
MATERIALS NNS O
AND CC O
METHODS NNS O
: : O
Our PRP$ O
study NN O
included VBD O
patients NNS O
who WP O
were VBD O
administered VBN O
30 CD O
- SYM O
60 CD O
mL NN O
of IN O
iodinated VBN O
contrast NN O
agent NN O
for IN O
percutaneous JJ O
coronary JJ O
angiography NN O
( : O
PCAG NNP O
) -RRB- O
, , O
all DT O
with IN O
creatinine NN O
values NNS O
between IN O
1 CD O
. . O
1 CD O
and CC O
3 CD O
. . O
1 CD O
mg NN O
/ SYM O
dL NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
divided VBN O
into IN O
three CD O
groups NNS O
and CC O
each DT O
group NN O
had VBD O
20 CD O
patients NNS O
. . O
null null null-Disease
The DT O
first JJ O
group NN O
of IN O
patients NNS O
was VBD O
administered VBN O
isotonic JJ O
sodium NN O
chloride NN O
; : O
the DT O
second JJ O
group NN O
was VBD O
administered VBN O
a DT O
solution NN O
that WDT O
of IN O
5 CD O
% NN O
dextrose NN O
and CC O
sodium NN O
bicarbonate NN O
, , O
while IN O
the DT O
third JJ O
group NN O
was VBD O
administered VBN O
isotonic JJ O
sodium NN O
chloride NN O
before IN O
and CC O
after IN O
the DT O
contrast NN O
injection NN O
. . O
null null null-Disease
The DT O
third JJ O
group NN O
received VBD O
an DT O
additional JJ O
injection NN O
of IN O
diltiazem NN O
the DT O
day NN O
before IN O
and CC O
first JJ O
2 CD O
days NNS O
after IN O
the DT O
contrast NN O
injection NN O
. . O
null null null-Disease
All DT O
of IN O
the DT O
patients NNS O
' POS O
plasma NN O
blood NN O
urea NN O
nitrogen NN O
( , O
BUN NNP O
) -RRB- O
and CC O
creatinine NN O
levels NNS O
were VBD O
measured VBN O
on IN O
the DT O
second JJ O
and CC O
seventh JJ O
day NN O
after IN O
the DT O
administration NN O
of IN O
intravenous JJ O
contrast NN O
material NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
basal JJ O
creatinine NN O
levels NNS O
were VBD O
similar JJ O
for IN O
all DT O
three CD O
groups NNS O
( : O
p NN O
> SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Among IN O
a DT O
total NN O
of IN O
60 CD O
patients NNS O
included VBN O
in IN O
the DT O
study NN O
, , O
16 CD O
patients NNS O
developed VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
( -LRB- O
ARF NN B-Disease
) -RRB- O
on IN O
the DT O
second JJ O
day NN O
after IN O
contrast NN O
material NN O
was VBD O
injected VBN O
( : O
26 CD O
. . O
6 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
The DT O
number NN O
of IN O
patients NNS O
who WP O
developed VBD O
ARF NNP B-Disease
on IN O
the DT O
second JJ O
day NN O
after IN O
the DT O
injection NN O
in IN O
the DT O
first JJ O
group NN O
was VBD O
five CD O
( SYM O
25 CD O
% NN O
) -RRB- O
, , O
in IN O
the DT O
second JJ O
group NN O
was VBD O
six CD O
( : O
30 CD O
% NN O
) -RRB- O
and CC O
the DT O
third JJ O
group NN O
was VBD O
five CD O
( : O
25 CD O
% NN O
) -RRB- O
( , O
p NN O
> SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
There EX O
was VBD O
no DT O
significant JJ O
difference NN O
between IN O
isotonic JJ O
sodium NN O
chloride NN O
, , O
sodium NN O
bicarbonate NN O
and CC O
isotonic JJ O
sodium NN O
chloride NN O
with IN O
diltiazem NN O
application NN O
in IN O
prevention NN O
of IN O
CIN NNP O
. . O
null null null-Disease
Neurocognitive JJ O
and CC O
neuroradiologic JJ O
central JJ O
nervous JJ O
system NN O
late JJ O
effects NNS O
in IN O
children NNS O
treated VBN O
on IN O
Pediatric NNP O
Oncology NNP O
Group NNP O
( -LRB- O
POG NNP O
) SYM O
P9605 CD O
( SYM O
standard JJ O
risk NN O
) -RRB- O
and CC O
P9201 CD O
( : O
lesser JJR O
risk NN O
) -RRB- O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
protocols NNS O
( : O
ACCL0131 CD O
) -RRB- O
: : O
a DT O
methotrexate NN O
consequence NN O
? . O
null null null-Disease
A DT O
report NN O
from IN O
the DT O
Children NNPS O
' POS O
s POS O
Oncology NNP O
Group NNP O
. . O
null null null-Disease
Concerns NNS O
about IN O
long JJ O
- HYPH O
term NN O
methotrexate NN O
( , O
MTX NNP O
) -RRB- O
neurotoxicity NN B-Disease
in IN O
the DT O
1990s CD O
led VBD O
to IN O
modifications NNS O
in IN O
intrathecal JJ O
( -LRB- O
IT NN O
) , O
therapy NN O
, , O
leucovorin NN O
rescue NN O
, , O
and CC O
frequency NN O
of IN O
systemic JJ O
MTX NNP O
administration NN O
in IN O
children NNS O
with IN O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
neurocognitive JJ O
outcomes NNS O
and CC O
neuroradiologic JJ O
evidence NN O
of IN O
leukoencephalopathy NN B-Disease
were VBD O
compared VBN O
in IN O
children NNS O
treated VBN O
with IN O
intense JJ O
central JJ O
nervous JJ O
system NN O
( -LRB- O
CNS NNP O
) -RRB- O
- HYPH O
directed VBN O
therapy NN O
( , O
P9605 CD O
) -RRB- O
versus IN O
those DT O
receiving VBG O
fewer JJR O
CNS NNP O
- HYPH O
directed VBN O
treatment NN O
days NNS O
during IN O
intensive JJ O
consolidation NN O
( SYM O
P9201 CD O
) -RRB- O
. . O
null null null-Disease
A DT O
total NN O
of IN O
66 CD O
children NNS O
from IN O
16 CD O
Pediatric NNP O
Oncology NNP O
Group NNP O
institutions NNS O
with IN O
"""" `` O
standard JJ O
- HYPH O
risk NN O
"""" '' O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
, , O
1 CD O
. . O
00 CD O
to TO O
9 CD O
. . O
99 CD O
years NNS O
at IN O
diagnosis NN O
, , O
without IN O
evidence NN O
of IN O
CNS NNP O
leukemia NN B-Disease
at IN O
diagnosis NN O
were VBD O
enrolled VBN O
on IN O
ACCL0131 NNP O
: : O
28 CD O
from IN O
P9201 CD O
and CC O
38 CD O
from IN O
P9605 CD O
. . O
null null null-Disease
Magnetic JJ O
resonance NN O
imaging NN O
scans NNS O
and CC O
standard JJ O
neuropsychological JJ O
tests NNS O
were VBD O
performed VBN O
> : O
2 CD O
. . O
6 CD O
years NNS O
after IN O
the DT O
end NN O
of IN O
treatment NN O
. . O
null null null-Disease
Significantly RB O
more JJR O
P9605 NNP O
patients NNS O
developed VBD O
leukoencephalopathy NN B-Disease
compared VBN O
with IN O
P9201 CD O
patients NNS O
( , O
68 CD O
% NN O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
49 CD O
% NN O
- SYM O
83 CD O
% NN O
vs NN O
. . O
22 CD O
% NN O
, , O
95 CD O
% NN O
confidence NN O
interval NN O
5 CD O
% NN O
- SYM O
44 CD O
% NN O
; : O
P NN O
= SYM O
0 CD O
. . O
001 CD O
) -RRB- O
identified VBN O
as RB O
late RB O
as IN O
7 CD O
. . O
7 CD O
years NNS O
after IN O
the DT O
end NN O
of IN O
treatment NN O
. . O
null null null-Disease
Overall RB O
, , O
40 CD O
% NN O
of IN O
patients NNS O
scored VBD O
< $ O
85 CD O
on IN O
either CC O
Verbal NNP O
or CC O
Performance NNP O
IQ NNP O
. . O
null null null-Disease
Children NNS O
on IN O
both DT O
studies NNS O
had VBD O
significant JJ O
attention NN B-Disease
problems NNS I-Disease
, , O
but CC O
P9605 NNP O
children NNS O
scored VBD O
below IN O
average JJ O
on IN O
more RBR O
neurocognitive JJ O
measures NNS O
than IN O
those DT O
treated VBN O
on IN O
P9201 CD O
( SYM O
82 CD O
% NN O
, , O
14 CD O
/ SYM O
17 CD O
measures NNS O
vs CC O
. . O
24 CD O
% NN O
, , O
4 CD O
/ SYM O
17 CD O
measures NNS O
) -RRB- O
. . O
null null null-Disease
This DT O
supports VBZ O
ongoing JJ O
concerns NNS O
about IN O
intensive JJ O
MTX NNP O
exposure NN O
as IN O
a DT O
major JJ O
contributor NN O
to IN O
CNS NNP O
late JJ O
effects NNS O
. . O
null null null-Disease
Tranexamic JJ O
acid NN O
overdosage NN O
- HYPH O
induced VBN O
generalized JJ O
seizure NN B-Disease
in IN O
renal JJ B-Disease
failure NN I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
45 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
lady NN O
with IN O
chronic JJ B-Disease
kidney NN I-Disease
disease NN I-Disease
stage NN O
4 CD O
due IN O
to IN O
chronic JJ O
tubulointerstial NN B-Disease
disease NN I-Disease
. . O
null null null-Disease
She PRP O
was VBD O
admitted VBN O
to IN O
our PRP$ O
center NN O
for IN O
severe JJ O
anemia NN B-Disease
due IN O
to IN O
menorrhagia NN B-Disease
and CC O
deterioration NN B-Disease
of IN I-Disease
renal JJ I-Disease
function NN I-Disease
. . O
null null null-Disease
She PRP O
was VBD O
infused VBN O
three CD O
units NNS O
of IN O
packed VBN O
cells NNS O
during IN O
a DT O
session NN O
of IN O
hemodialysis NN O
. . O
null null null-Disease
Tranexamic JJ O
acid NN O
( -LRB- O
TNA NNP O
) -RRB- O
1 CD O
g NN O
8 CD O
- HYPH O
hourly NN O
was VBD O
administered VBN O
to IN O
her PRP O
to TO O
control VB O
bleeding NN B-Disease
per IN O
vaginum NN O
. . O
null null null-Disease
Two CD O
hours NNS O
after IN O
the DT O
sixth JJ O
dose NN O
of IN O
TNA NNP O
, , O
she PRP O
had VBD O
an DT O
episode NN O
of IN O
generalized VBN O
tonic JJ B-Disease
clonic JJ I-Disease
convulsions NNS I-Disease
. . O
null null null-Disease
TNA NNP O
was VBD O
discontinued VBN O
. . O
null null null-Disease
Investigations NNS O
of IN O
the DT O
patient NN O
revealed VBD O
no DT O
biochemical JJ O
or CC O
structural JJ O
central JJ O
nervous JJ B-Disease
system NN I-Disease
abnormalities NNS I-Disease
that WDT O
could MD O
have VB O
provoked VBN O
the DT O
convulsions NNS B-Disease
. . O
null null null-Disease
She PRP O
did VBD O
not RB O
require VB O
any DT O
further JJ O
dialytic JJ O
support NN O
. . O
null null null-Disease
She PRP O
had VBD O
no DT O
further JJ O
episodes NNS O
of IN O
convulsion NN B-Disease
till IN O
dis VB O
- HYPH O
charge NN O
and CC O
during IN O
the DT O
two CD O
months NNS O
of IN O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
Thus RB O
, , O
the DT O
precipitating VBG O
cause NN O
of IN O
convulsions NNS B-Disease
was VBD O
believed VBN O
to TO O
be VB O
an DT O
overdose NN B-Disease
of IN O
TNA NNP O
. . O
null null null-Disease
Pre VB O
- HYPH O
treatment NN O
of IN O
bupivacaine NN O
- HYPH O
induced VBN O
cardiovascular JJ B-Disease
depression NN I-Disease
using VBG O
different JJ O
lipid JJ O
formulations NNS O
of IN O
propofol NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Pre NN O
- HYPH O
treatment NN O
with IN O
lipid NN O
emulsions NNS O
has VBZ O
been VBN O
shown VBN O
to TO O
increase VB O
lethal JJ O
doses NNS O
of IN O
bupivacaine NN O
, , O
and CC O
the DT O
lipid JJ O
content NN O
of IN O
propofol NN O
may MD O
alleviate VB O
bupivacaine NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
investigate VB O
the DT O
effects NNS O
of IN O
propofol NN O
in IN O
intralipid JJ O
or CC O
medialipid JJ O
emulsions NNS O
on IN O
bupivacaine NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Rats NNS O
were VBD O
anaesthetised VBN O
with IN O
ketamine NN O
and CC O
were VBD O
given VBN O
0 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
min NN O
propofol NN O
in IN O
intralipid NN O
( HYPH O
Group NNP O
P NNP O
) -RRB- O
, , O
propofol NN O
in IN O
medialipid NN O
( , O
Group NNP O
L NNP O
) -RRB- O
, , O
or CC O
saline NN O
( , O
Group NNP O
C NNP O
) -RRB- O
over IN O
20 CD O
min NN O
. . O
null null null-Disease
Thereafter RB O
, , O
2 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
min NN O
bupivacaine NN O
0 CD O
. . O
5 CD O
% NN O
was VBD O
infused VBN O
. . O
null null null-Disease
We PRP O
recorded VBD O
time NN O
to IN O
first JJ O
dysrhythmia NN B-Disease
occurrence NN O
, , O
respective JJ O
times NNS O
to IN O
25 CD O
% NN O
and CC O
50 CD O
% NN O
reduction NN O
of IN O
the DT O
heart NN O
rate NN O
( , O
HR NN O
) -RRB- O
and CC O
mean JJ O
arterial JJ O
pressure NN O
, , O
and CC O
time NN O
to IN O
asystole NN B-Disease
and CC O
total JJ O
amount NN O
of IN O
bupivacaine NN O
consumption NN O
. . O
null null null-Disease
Blood NN O
and CC O
tissue NN O
samples NNS O
were VBD O
collected VBN O
following VBG O
asystole NN B-Disease
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
time NN O
to IN O
first JJ O
dysrhythmia NN B-Disease
occurrence NN O
, , O
time NN O
to TO O
25 CD O
% NN O
and CC O
50 CD O
% NN O
reductions NNS O
in IN O
HR NN O
, , O
and CC O
time NN O
to IN O
asystole NN B-Disease
were VBD O
longer JJR O
in IN O
Group NNP O
P NNP O
than IN O
the DT O
other JJ O
groups NNS O
. . O
null null null-Disease
The DT O
cumulative JJ O
bupivacaine NN O
dose NN O
given VBN O
at IN O
those DT O
time NN O
points NNS O
was VBD O
higher JJR O
in IN O
Group NNP O
P NNP O
. , O
Plasma NN O
bupivacaine NN O
levels NNS O
were VBD O
significantly RB O
lower JJR O
in IN O
Group NNP O
P NNP O
than IN O
in IN O
Group NNP O
C NNP O
. , O
Bupivacaine NN O
levels NNS O
in IN O
the DT O
brain NN O
and CC O
heart NN O
were VBD O
significantly RB O
lower JJR O
in IN O
Group NNP O
P NNP O
and CC O
Group NNP O
L NNP O
than IN O
in IN O
Group NNP O
C NNP O
. . O
null null null-Disease
CONCLUSION NN O
: : O
We PRP O
conclude VBP O
that IN O
pre JJ O
- HYPH O
treatment NN O
with IN O
propofol NN O
in IN O
intralipid JJ O
, , O
compared VBN O
with IN O
propofol NN O
in IN O
medialipid NN O
or CC O
saline NN O
, , O
delayed VBD O
the DT O
onset NN O
of IN O
bupivacaine NN O
- HYPH O
induced VBN O
cardiotoxic JJ B-Disease
effects NNS O
as RB O
well RB O
as IN O
reduced VBN O
plasma NN O
bupivacaine NN O
levels NNS O
. . O
null null null-Disease
Further JJ O
studies NNS O
are VBP O
needed VBN O
to TO O
explore VB O
tissue NN O
bupivacaine NN O
levels NNS O
of IN O
propofol NN O
in IN O
medialipid NN O
and CC O
adapt VB O
these DT O
results NNS O
to IN O
clinical JJ O
practice NN O
. . O
null null null-Disease
Drug NN B-Disease
- HYPH I-Disease
Induced VBN I-Disease
Acute JJ I-Disease
Liver NN I-Disease
Injury NN I-Disease
Within IN O
12 CD O
Hours NNS O
After IN O
Fluvastatin NN O
Therapy NN O
. . O
null null null-Disease
Although IN O
statins NNS O
are VBP O
generally RB O
well RB O
- HYPH O
tolerated VBN O
drugs NNS O
, , O
recent JJ O
cases NNS O
of IN O
drug NN B-Disease
- HYPH I-Disease
induced VBN I-Disease
liver NN I-Disease
injury NN I-Disease
associated VBN O
with IN O
their PRP$ O
use NN O
have VBP O
been VBN O
reported VBN O
. . O
null null null-Disease
A DT O
52 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
Chinese JJ O
man NN O
reported VBN O
with IN O
liver NN B-Disease
damage NN I-Disease
, , O
which WDT O
appeared VBD O
12 CD O
hours NNS O
after IN O
beginning VBG O
treatment NN O
with IN O
fluvastatin NN O
. . O
null null null-Disease
Patient NN O
presented VBN O
with IN O
complaints NNS O
of IN O
increasing VBG O
nausea NN B-Disease
, , O
anorexia NN B-Disease
, , O
and CC O
upper JJ O
abdominal JJ B-Disease
pain NN I-Disease
. . O
null null null-Disease
His PRP$ O
laboratory NN O
values NNS O
showed VBD O
elevated JJ O
creatine JJ O
kinase NN O
and CC O
transaminases NNS O
. . O
null null null-Disease
Testing NN O
for IN O
autoantibodies NNS O
was VBD O
also RB O
negative JJ O
. . O
null null null-Disease
The DT O
liver NN O
biochemistries NNS O
eventually RB O
normalized VBD O
within IN O
3 CD O
weeks NNS O
of IN O
stopping VBG O
the DT O
fluvastatin NN O
. . O
null null null-Disease
Therefore RB O
, , O
when WRB O
prescribing VBG O
statins NNS O
, , O
the DT O
possibility NN O
of IN O
hepatic JJ B-Disease
damage NN I-Disease
should MD O
be VB O
taken VBN O
into IN O
account NN O
. . O
null null null-Disease
Fluconazole NNP O
associated VBD O
agranulocytosis NN B-Disease
and CC O
thrombocytopenia NN B-Disease
. . O
null null null-Disease
CASE NN O
: : O
We PRP O
describe VBP O
a DT O
second JJ O
case NN O
of IN O
fluconazole NN O
associated VBN O
agranulocytosis NN B-Disease
with IN O
thrombocytopenia NN B-Disease
and CC O
recovery NN O
upon IN O
discontinuation NN O
of IN O
therapy NN O
. . O
null null null-Disease
The DT O
patient NN O
began VBD O
to TO O
have VB O
changes NNS O
in IN O
white JJ O
blood NN O
cells NNS O
and CC O
platelets NNS O
within IN O
48 CD O
h NN O
of IN O
administration NN O
of IN O
fluconazole NN O
and CC O
began VBD O
to TO O
recover VB O
with IN O
48 CD O
h NN O
of IN O
discontinuation NN O
. . O
null null null-Disease
This DT O
case NN O
highlights VBZ O
that IN O
drug NN O
- HYPH O
induced VBN O
blood NN B-Disease
dyscrasias NNS I-Disease
can MD O
occur VB O
unexpectedly RB O
as IN O
a DT O
result NN O
of IN O
treatment NN O
with IN O
a DT O
commonly RB O
used VBN O
drug NN O
thought VBN O
to TO O
be VB O
"""" `` O
safe JJ O
"""" '' O
. . O
null null null-Disease
CONCLUSION NN O
: : O
According VBG O
to IN O
Naranjo NNP O
' POS O
s POS O
algorithm NN O
the DT O
likelihood NN O
that IN O
our PRP$ O
patient NN O
' '' O
s POS O
agranulocytosis NN B-Disease
and CC O
thrombocytopenia NN B-Disease
occurred VBD O
as IN O
a DT O
result NN O
of IN O
therapy NN O
with IN O
fluconazole NN O
is VBZ O
probable JJ O
, , O
with IN O
a DT O
total NN O
of IN O
six CD O
points NNS O
. . O
null null null-Disease
We PRP O
feel VBP O
that IN O
the DT O
weight NN O
of IN O
the DT O
overall JJ O
evidence NN O
of IN O
this DT O
evidence NN O
is VBZ O
strong JJ O
. . O
null null null-Disease
In IN O
particular JJ O
the DT O
temporal JJ O
relationship NN O
of IN O
bone NN B-Disease
marrow NN I-Disease
suppression NN I-Disease
to IN O
the DT O
initiation NN O
of IN O
fluconazole NN O
and CC O
the DT O
abatement NN O
of IN O
symptoms NNS O
that WDT O
rapidly RB O
reversed VBD O
immediately RB O
following VBG O
discontinuation NN O
. . O
null null null-Disease
Two CD O
- HYPH O
dimensional JJ O
speckle NN O
tracking NN O
echocardiography NN O
combined VBN O
with IN O
high JJ O
- HYPH O
sensitive JJ O
cardiac JJ O
troponin NN O
T NN O
in IN O
early JJ O
detection NN O
and CC O
prediction NN O
of IN O
cardiotoxicity NN B-Disease
during IN O
epirubicine NN O
- HYPH O
based VBN O
chemotherapy NN O
. . O
null null null-Disease
AIMS NNS O
: : O
To TO O
investigate VB O
whether IN O
alterations NNS O
of IN O
myocardial JJ B-Disease
strain NN I-Disease
and CC O
high JJ O
- HYPH O
sensitive JJ O
cardiac JJ O
troponin NN O
T NNP O
( , O
cTnT NNP O
) -RRB- O
could MD O
predict VB O
future JJ O
cardiac JJ B-Disease
dysfunction NN I-Disease
in IN O
patients NNS O
after IN O
epirubicin NN O
exposure NN O
. . O
null null null-Disease
METHODS NNS O
: : O
Seventy CD O
- HYPH O
five CD O
patients NNS O
with IN O
non JJ B-Disease
- HYPH I-Disease
Hodgkin NNP I-Disease
lymphoma NN I-Disease
treated VBN O
with IN O
epirubicin NN O
were VBD O
studied VBN O
. . O
null null null-Disease
Blood NN O
collection NN O
and CC O
echocardiography NN O
were VBD O
performed VBN O
at IN O
baseline NN O
, , O
1 CD O
day NN O
after IN O
the DT O
third JJ O
cycle NN O
, , O
and CC O
1 CD O
day NN O
after IN O
completion NN O
of IN O
chemotherapy NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
studied VBN O
using VBG O
echocardiography NN O
during IN O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
Global JJ O
longitudinal JJ O
( , O
GLS NNP O
) -RRB- O
, , O
circumferential JJ O
( , O
GCS NNP O
) -RRB- O
, , O
and CC O
radial JJ O
strain NN O
( , O
GRS NNP O
) -RRB- O
were VBD O
calculated VBN O
using VBG O
speckle NN O
tracking NN O
echocardiography NN O
. . O
null null null-Disease
Left VBN O
ventricular JJ O
ejection NN O
fraction NN O
was VBD O
analysed VBN O
by IN O
real JJ O
- HYPH O
time NN O
3D NN O
echocardiography NN O
. . O
null null null-Disease
Cardiotoxicity NN B-Disease
was VBD O
defined VBN O
as IN O
a DT O
reduction NN O
of IN O
the DT O
LVEF NNP O
of IN O
> SYM O
5 CD O
% NN O
to TO O
< $ O
55 CD O
% NN O
with IN O
symptoms NNS O
of IN O
heart NN B-Disease
failure NN I-Disease
or CC O
an DT O
asymptomatic JJ O
reduction NN O
of IN O
the DT O
LVEF NNP O
of IN O
> SYM O
10 CD O
% NN O
to TO O
< $ O
55 CD O
% NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Fourteen CD O
patients NNS O
( SYM O
18 CD O
. . O
67 CD O
% NN O
) -RRB- O
developed VBD O
cardiotoxicity NN B-Disease
after IN O
treatment NN O
. . O
null null null-Disease
GLS NNP O
( : O
- HYPH O
18 CD O
. . O
48 CD O
+ SYM O
1 CD O
. . O
72 CD O
% NN O
vs IN O
. . O
- : O
15 CD O
. . O
96 CD O
+ SYM O
1 CD O
. . O
6 CD O
% NN O
) -RRB- O
, , O
GCS NN O
( : O
- : O
20 CD O
. . O
93 CD O
+ SYM O
2 CD O
. . O
86 CD O
% NN O
vs IN O
. . O
- : O
19 CD O
. . O
20 CD O
+ SYM O
3 CD O
. . O
21 CD O
% NN O
) -RRB- O
, , O
and CC O
GRS NNP O
( : O
39 CD O
. . O
23 CD O
+ SYM O
6 CD O
. . O
44 CD O
% NN O
vs IN O
. . O
34 CD O
. . O
98 CD O
+ SYM O
6 CD O
. . O
2 CD O
% NN O
) -RRB- O
were VBD O
markedly RB O
reduced VBN O
and CC O
cTnT NN O
was VBD O
elevated VBN O
from IN O
0 CD O
. . O
0010 CD O
+ SYM O
0 CD O
. . O
0020 CD O
to IN O
0 CD O
. . O
0073 CD O
+ SYM O
0 CD O
. . O
0038 CD O
ng NN O
/ SYM O
mL NN O
( : O
P NN O
all DT O
< NN O
0 CD O
. . O
01 CD O
) -RRB- O
at IN O
the DT O
completion NN O
of IN O
chemotherapy NN O
compared VBN O
with IN O
baseline NN O
values NNS O
. . O
null null null-Disease
A DT O
> SYM O
15 CD O
. . O
9 CD O
% NN O
decrease NN O
in IN O
GLS NNP O
[ -LRB- O
sensitivity NN O
, , O
86 CD O
% NN O
; , O
specificity NN O
, , O
75 CD O
% NN O
; , O
area NN O
under IN O
the DT O
curve NN O
( : O
AUC NNP O
) -RRB- O
= SYM O
0 CD O
. . O
815 CD O
; : O
P NN O
= SYM O
0 CD O
. . O
001 CD O
] -RRB- O
and CC O
a DT O
> SYM O
0 CD O
. . O
004 CD O
ng NN O
/ SYM O
mL NN O
elevation NN O
in IN O
cTnT NN O
( : O
sensitivity NN O
, , O
79 CD O
% NN O
; : O
specificity NN O
, , O
64 CD O
% NN O
; : O
AUC NNP O
= SYM O
0 CD O
. . O
757 CD O
; : O
P NN O
= SYM O
0 CD O
. . O
005 CD O
) -RRB- O
from IN O
baseline NN O
to IN O
the DT O
third JJ O
cycle NN O
of IN O
chemotherapy NN O
predicted VBN O
later RB O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
The DT O
decrease NN O
in IN O
GLS NNP O
remained VBD O
the DT O
only JJ O
independent JJ O
predictor NN O
of IN O
cardiotoxicity NN B-Disease
( , O
P NN O
= SYM O
0 CD O
. . O
000 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
GLS NNP O
combined VBN O
with IN O
cTnT NN O
may MD O
provide VB O
a DT O
reliable JJ O
and CC O
non RB O
- HYPH O
invasive JJ O
method NN O
to TO O
predict VB O
cardiac JJ B-Disease
dysfunction NN I-Disease
in IN O
patients NNS O
receiving VBG O
anthracycline NN O
- HYPH O
based VBN O
chemotherapy NN O
. . O
null null null-Disease
Prevention NN O
of IN O
etomidate NN O
- HYPH O
induced VBN O
myoclonus NN B-Disease
: : O
which WDT O
is VBZ O
superior JJ O
: : O
Fentanyl NNP O
, , O
midazolam NN O
, , O
or CC O
a DT O
combination NN O
? . O
null null null-Disease
A DT O
Retrospective JJ O
comparative JJ O
study NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
In IN O
this DT O
retrospective JJ O
comparative JJ O
study NN O
, , O
we PRP O
aimed VBD O
to TO O
compare VB O
the DT O
effectiveness NN O
of IN O
fentanyl NN O
, , O
midazolam NN O
, , O
and CC O
a DT O
combination NN O
of IN O
fentanyl NN O
and CC O
midazolam NN O
to TO O
prevent VB O
etomidate NN O
- HYPH O
induced VBN O
myoclonus NN B-Disease
. . O
null null null-Disease
MATERIAL NN O
AND CC O
METHODS NNS O
: : O
This DT O
study NN O
was VBD O
performed VBN O
based VBN O
on IN O
anesthesia NN O
records NNS O
. . O
null null null-Disease
Depending VBG O
on IN O
the DT O
drugs NNS O
that WDT O
would MD O
be VB O
given VBN O
before IN O
the DT O
induction NN O
of IN O
anesthesia NN O
with IN O
etomidate NN O
, , O
the DT O
patients NNS O
were VBD O
separated VBN O
into IN O
4 CD O
groups NNS O
: : O
no DT O
pretreatment NN O
( , O
Group NNP O
NP NNP O
) -RRB- O
, , O
fentanyl NN O
1 CD O
ug NN O
. . O
kg NN O
- HYPH O
1 CD O
( HYPH O
Group NN O
F NN O
) -RRB- O
, , O
midazolam NN O
0 CD O
. . O
03 CD O
mg NN O
. . O
kg NN O
- HYPH O
1 CD O
( SYM O
Group NN O
M NN O
) -RRB- O
, , O
and CC O
midazolam NN O
0 CD O
. . O
015 CD O
mg NN O
. . O
kg NN O
- HYPH O
1 CD O
+ SYM O
fentanyl NN O
0 CD O
. . O
5 CD O
ug NN O
. . O
kg NN O
- HYPH O
1 CD O
( HYPH O
Group NN O
FM NN O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
who WP O
received VBD O
the DT O
same JJ O
anesthetic JJ O
procedure NN O
were VBD O
selected VBN O
: : O
2 CD O
minutes NNS O
after IN O
intravenous JJ O
injections NNS O
of IN O
the DT O
pretreatment NN O
drugs NNS O
, , O
anesthesia NN O
is VBZ O
induced VBN O
with IN O
0 CD O
. . O
3 CD O
mg NN O
. . O
kg NN O
- HYPH O
1 CD O
etomidate NN O
injected VBN O
intravenously RB O
over IN O
a DT O
period NN O
of IN O
20 CD O
- SYM O
30 CD O
seconds NNS O
. . O
null null null-Disease
Myoclonic JJ B-Disease
movements NNS I-Disease
are VBP O
evaluated VBN O
, , O
which WDT O
were VBD O
observed VBN O
and CC O
graded VBN O
according VBG O
to IN O
clinical JJ O
severity NN O
during IN O
the DT O
2 CD O
minutes NNS O
after IN O
etomidate JJ O
injection NN O
. . O
null null null-Disease
The DT O
severity NN O
of IN O
pain NN B-Disease
due JJ O
to IN O
etomidate JJ O
injection NN O
, , O
mean JJ O
arterial JJ O
pressure NN O
, , O
heart NN O
rate NN O
, , O
and CC O
adverse JJ O
effects NNS O
were VBD O
also RB O
evaluated VBN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Study NN O
results NNS O
showed VBD O
that IN O
myoclonus NN B-Disease
incidence NN O
was VBD O
85 CD O
% NN O
, , O
40 CD O
% NN O
, , O
70 CD O
% NN O
, , O
and CC O
25 CD O
% NN O
in IN O
Group NNP O
NP NNP O
, , O
Group NNP O
F NNP O
, , O
Group NNP O
M NNP O
, , O
and CC O
Group NNP O
FM NNP O
, , O
respectively RB O
, , O
and CC O
were VBD O
significantly RB O
lower JJR O
in IN O
Group NNP O
F NNP O
and CC O
Group NNP O
FM NNP O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
We PRP O
conclude VBP O
that IN O
pretreatment NN O
with IN O
fentanyl NN O
or CC O
combination NN O
of IN O
fentanyl NN O
and CC O
midazolam NN O
was VBD O
effective JJ O
in IN O
preventing VBG O
etomidate NN O
- HYPH O
induced VBN O
myoclonus NN B-Disease
. . O
null null null-Disease
Convulsant JJ O
effect NN O
of IN O
lindane NN O
and CC O
regional JJ O
brain NN O
concentration NN O
of IN O
GABA NNP O
and CC O
dopamine NN O
. . O
null null null-Disease
Lindane NNP O
( , O
gamma NN O
- HYPH O
hexachlorocyclohexane NN O
) -RRB- O
is VBZ O
an DT O
organochlorine NN O
insecticide NN O
with IN O
known VBN O
neurotoxic JJ B-Disease
effects NNS O
. . O
null null null-Disease
Its PRP$ O
mechanism NN O
of IN O
action NN O
is VBZ O
not RB O
well RB O
understood VBN O
although IN O
it PRP O
has VBZ O
been VBN O
proposed VBN O
that IN O
lindane NN O
acts VBZ O
as IN O
a DT O
non AFX O
- HYPH O
competitive JJ O
antagonist NN O
at IN O
the DT O
gamma NN O
- HYPH O
aminobutyric JJ O
acid NN O
( , O
GABA NNP O
) SYM O
- HYPH O
A NN O
receptor NN O
. . O
null null null-Disease
We PRP O
studied VBD O
the DT O
effect NN O
of IN O
lindane NN O
( , O
150 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
on IN O
the DT O
GABAergic JJ O
and CC O
dopaminergic JJ O
systems NNS O
by IN O
measuring VBG O
the DT O
concentration NN O
of IN O
GABA NNP O
, , O
dopamine NN O
and CC O
its PRP$ O
metabolites NNS O
in IN O
7 CD O
brain NN O
areas NNS O
at IN O
the DT O
onset NN O
of IN O
seizures NNS B-Disease
. . O
null null null-Disease
All DT O
animals NNS O
suffered VBD O
tonic JJ O
convulsions NNS B-Disease
at IN O
18 CD O
. . O
3 CD O
+ CD O
/ SYM O
- SYM O
1 CD O
. . O
4 CD O
min NN O
after IN O
lindane NN O
administration NN O
. . O
null null null-Disease
The DT O
concentration NN O
of IN O
GABA NNP O
was VBD O
only RB O
slightly RB O
but CC O
significantly RB O
decreased VBN O
in IN O
the DT O
colliculi NN O
without IN O
modifications NNS O
in IN O
the DT O
other JJ O
areas NNS O
. . O
null null null-Disease
The DT O
concentration NN O
of IN O
dopamine NN O
was VBD O
increased VBN O
in IN O
the DT O
mesencephalon NN O
and CC O
that DT O
of IN O
its PRP$ O
metabolite NN O
DOPAC NNP O
was VBD O
also RB O
increased VBN O
in IN O
the DT O
mesencephalon NN O
and CC O
the DT O
striatum NN O
. . O
null null null-Disease
Cholestatic JJ B-Disease
presentation NN O
of IN O
yellow JJ O
phosphorus NN O
poisoning NN B-Disease
. . O
null null null-Disease
Yellow JJ O
phosphorus NN O
, , O
a DT O
component NN O
of IN O
certain JJ O
pesticide NN O
pastes NNS O
and CC O
fireworks NNS O
, , O
is VBZ O
well RB O
known JJ O
to TO O
cause VB O
hepatotoxicity NN B-Disease
. . O
null null null-Disease
Poisoning VBG B-Disease
with IN O
yellow JJ O
phosphorus NN O
classically RB O
manifests VBZ O
with IN O
acute JJ B-Disease
hepatitis NN I-Disease
leading VBG O
to IN O
acute JJ B-Disease
liver NN I-Disease
failure NN I-Disease
which WDT O
may MD O
need VB O
liver NN O
transplantation NN O
. . O
null null null-Disease
We PRP O
present VBP O
a DT O
case NN O
of IN O
yellow JJ O
phosphorus NN O
poisoning NN B-Disease
in IN O
which WDT O
a DT O
patient NN O
presented VBD O
with IN O
florid JJ O
clinical JJ O
features NNS O
of IN O
cholestasis NN B-Disease
highlighting VBG O
the DT O
fact NN O
that IN O
cholestasis NN B-Disease
can MD O
rarely RB O
be VB O
a DT O
presenting VBG O
feature NN O
of IN O
yellow JJ O
phosphorus NN O
hepatotoxicity NN B-Disease
. . O
null null null-Disease
Vasovagal NNP B-Disease
syncope NN I-Disease
and CC O
severe JJ O
bradycardia NN B-Disease
following VBG O
intranasal JJ O
dexmedetomidine NN O
for IN O
pediatric JJ O
procedural JJ O
sedation NN O
. . O
null null null-Disease
We PRP O
report VBP O
syncope NN B-Disease
and CC O
bradycardia NN B-Disease
in IN O
an DT O
11 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
girl NN O
following VBG O
administration NN O
of IN O
intranasal JJ O
dexmedetomidine NN O
for IN O
sedation NN O
for IN O
a DT O
voiding VBG O
cystourethrogram NN O
. . O
null null null-Disease
Following VBG O
successful JJ O
completion NN O
of IN O
VCUG NNP O
and CC O
a DT O
60 CD O
- HYPH O
min NN O
recovery NN O
period NN O
, , O
the DT O
patient NN O
' POS O
s NN O
level NN O
of IN O
consciousness NN O
and CC O
vital JJ O
signs NNS O
returned VBD O
to IN O
presedation NN O
levels NNS O
. . O
null null null-Disease
Upon IN O
leaving VBG O
the DT O
sedation NN O
area NN O
, , O
the DT O
patient NN O
collapsed VBD O
, , O
with IN O
no DT O
apparent JJ O
inciting VBG O
event NN O
. . O
null null null-Disease
The DT O
patient NN O
quickly RB O
regained VBD O
consciousness NN O
and CC O
no DT O
injury NN O
occurred VBD O
. . O
null null null-Disease
The DT O
primary JJ O
abnormality NN O
found VBN O
was VBD O
persistent JJ O
bradycardia NN B-Disease
, , O
and CC O
she PRP O
was VBD O
admitted VBN O
to IN O
the DT O
hospital NN O
for IN O
telemetric JJ O
observation NN O
. . O
null null null-Disease
The DT O
bradycardia NN B-Disease
lasted VBD O
~ $ O
2 CD O
h NN O
, , O
and CC O
further JJ O
cardiac JJ O
workup NN O
revealed VBD O
no DT O
underlying VBG O
abnormality NN O
. . O
null null null-Disease
Unanticipated JJ O
and CC O
previously RB O
unreported JJ O
outcomes NNS O
may MD O
be VB O
witnessed VBN O
as IN O
we PRP O
expand VBP O
the DT O
use NN O
of IN O
certain JJ O
sedatives NNS O
to IN O
alternative JJ O
routes NNS O
of IN O
administration NN O
. . O
null null null-Disease
Paradoxical JJ O
severe JJ O
agitation NN B-Disease
induced VBN O
by IN O
add VB O
- HYPH O
on IN O
high JJ O
- HYPH O
doses NNS O
quetiapine NN O
in IN O
schizo NN B-Disease
- HYPH I-Disease
affective JJ I-Disease
disorder NN I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
the DT O
case NN O
of IN O
a DT O
35 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
patient NN O
suffering VBG O
from IN O
schizo NN B-Disease
- HYPH I-Disease
affective JJ I-Disease
disorder NN I-Disease
since IN O
the DT O
age NN O
of IN O
19 CD O
years NNS O
, , O
treated VBN O
by IN O
a DT O
combination NN O
of IN O
first JJ O
- HYPH O
generation NN O
antipsychotics NNS O
, , O
zuclopenthixol NN O
( , O
100 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
and CC O
lithium NN O
( , O
1200 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
( , O
serum NN O
lithium NN O
= SYM O
0 CD O
. . O
85 CD O
mEq NNS O
/ SYM O
l NN O
) -RRB- O
. . O
null null null-Disease
This DT O
patient NN O
had VBD O
no DT O
associated JJ O
personality NN B-Disease
disorder NN I-Disease
( : O
particularly RB O
no DT O
antisocial JJ B-Disease
disorder NN I-Disease
) -RRB- O
and CC O
no DT O
substance NN B-Disease
abuse NN I-Disease
disorder NN I-Disease
. . O
null null null-Disease
Within IN O
the DT O
48 CD O
h NN O
following VBG O
the DT O
gradual JJ O
introduction NN O
of IN O
quetiapine NN O
( , O
up IN O
to TO O
600 CD O
mg NNS O
/ SYM O
day NN O
) -RRB- O
, , O
the DT O
patient NN O
presented VBD O
severe JJ O
agitation NN B-Disease
without IN O
an DT O
environmental JJ O
explanation NN O
, , O
contrasting VBG O
with IN O
the DT O
absence NN O
of IN O
a DT O
history NN O
of IN O
aggressiveness NN B-Disease
or CC O
personality NN B-Disease
disorder NN I-Disease
. . O
null null null-Disease
The DT O
diagnoses NNS O
of IN O
manic JJ B-Disease
shift NN O
and CC O
akathisia NN B-Disease
were VBD O
dismissed VBN O
. . O
null null null-Disease
The DT O
withdrawal NN O
and CC O
the DT O
gradual JJ O
reintroduction NN O
of IN O
quetiapine NN O
2 CD O
weeks NNS O
later RB O
, , O
which WDT O
led VBD O
to IN O
another DT O
severe JJ O
agitation NN B-Disease
, , O
enabled VBD O
us PRP O
to TO O
attribute VB O
the DT O
agitation NN B-Disease
specifically RB O
to IN O
quetiapine NN O
. . O
null null null-Disease
Antioxidant JJ O
effects NNS O
of IN O
bovine JJ O
lactoferrin NN O
on IN O
dexamethasone NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
in IN O
rat NN O
. . O
null null null-Disease
Dexamethasone NNP O
- HYPH O
( : O
Dex NN O
- HYPH O
) , O
induced VBN O
hypertension NN B-Disease
is VBZ O
associated VBN O
with IN O
enhanced VBN O
oxidative JJ O
stress NN O
. . O
null null null-Disease
Lactoferrin NNP O
( -LRB- O
LF NNP O
) -RRB- O
is VBZ O
an DT O
iron NN O
- HYPH O
binding VBG O
glycoprotein NN O
with IN O
antihypertensive JJ O
properties NNS O
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
we PRP O
investigated VBD O
the DT O
effect NN O
of IN O
chronic JJ O
administration NN O
of IN O
LF NNP O
on IN O
oxidative JJ O
stress NN O
and CC O
hypertension NN B-Disease
upon IN O
Dex NNP O
administration NN O
. . O
null null null-Disease
Male JJ O
Wistar NNP O
rats NNS O
were VBD O
treated VBN O
by IN O
Dex NNP O
( : O
30 CD O
u NN O
g NN O
/ SYM O
kg NNS O
/ SYM O
day NN O
subcutaneously RB O
) , O
or CC O
saline NN O
for IN O
14 CD O
days NNS O
. . O
null null null-Disease
Oral JJ O
bovine NN O
LF NNP O
( : O
30 CD O
, , O
100 CD O
, , O
300 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
was VBD O
given VBN O
from IN O
day NN O
8 CD O
to IN O
14 CD O
in IN O
a DT O
reversal JJ O
study NN O
. . O
null null null-Disease
In IN O
a DT O
prevention NN O
study NN O
, , O
rats NNS O
received VBD O
4 CD O
days NNS O
of IN O
LF NNP O
treatment NN O
followed VBN O
by IN O
Dex NNP O
and CC O
continued VBD O
during IN O
the DT O
test NN O
period NN O
. . O
null null null-Disease
Systolic JJ O
blood NN O
pressure NN O
( -LRB- O
SBP NNP O
) -RRB- O
was VBD O
measured VBN O
using VBG O
tail JJ O
- HYPH O
cuff NN O
method NN O
. . O
null null null-Disease
Thymus NNP O
weight NN O
was VBD O
used VBN O
as IN O
a DT O
marker NN O
of IN O
glucocorticoid JJ O
activity NN O
. . O
null null null-Disease
Plasma NN O
hydrogen NN O
peroxide NN O
( -LRB- O
H2O2 NN O
) -RRB- O
concentration NN O
and CC O
ferric NN O
reducing VBG O
antioxidant JJ O
power NN O
( -LRB- O
FRAP NNP O
) -RRB- O
value NN O
were VBD O
determined VBN O
. . O
null null null-Disease
Dexamethasone NNP O
significantly RB O
increased VBD O
SBP NNP O
and CC O
plasma NN O
H2O2 NN O
level NN O
and CC O
decreased VBD O
thymus NN O
and CC O
body NN O
weights NNS O
. . O
null null null-Disease
LF NNP O
lowered VBD O
( : O
P NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
and CC O
dose NN O
dependently RB O
prevented VBN O
( , O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) SYM O
Dex NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
. . O
null null null-Disease
LF NNP O
prevented VBD O
body NN O
weight NN B-Disease
loss NN I-Disease
and CC O
significantly RB O
reduced VBD O
the DT O
elevated JJ O
plasma NN O
H2O2 NN O
and CC O
increased VBN O
FRAP NNP O
values NNS O
. . O
null null null-Disease
Chronic JJ O
administration NN O
of IN O
LF NNP O
strongly RB O
reduced VBD O
the DT O
blood NN O
pressure NN O
and CC O
production NN O
of IN O
ROS NNP O
and CC O
improved VBN O
antioxidant JJ O
capacity NN O
in IN O
Dex NNP O
- HYPH O
induced VBN O
hypertension NN B-Disease
, , O
suggesting VBG O
the DT O
role NN O
of IN O
inhibition NN O
of IN O
oxidative JJ O
stress NN O
as IN O
another DT O
mechanism NN O
of IN O
antihypertensive JJ O
action NN O
of IN O
LF NNP O
. . O
null null null-Disease
The DT O
association NN O
between IN O
tranexamic JJ O
acid NN O
and CC O
convulsive JJ B-Disease
seizures NNS B-Disease
after IN O
cardiac JJ O
surgery NN O
: : O
a DT O
multivariate JJ O
analysis NN O
in IN O
11 CD O
529 CD O
patients NNS O
. . O
null null null-Disease
Because IN O
of IN O
a DT O
lack NN O
of IN O
contemporary JJ O
data NNS O
regarding VBG O
seizures NNS B-Disease
after IN O
cardiac JJ O
surgery NN O
, , O
we PRP O
undertook VBD O
a DT O
retrospective JJ O
analysis NN O
of IN O
prospectively RB O
collected VBN O
data NNS O
from IN O
11 CD O
529 CD O
patients NNS O
in IN O
whom WP O
cardiopulmonary JJ O
bypass NN O
was VBD O
used VBN O
from IN O
January NNP O
2004 CD O
to IN O
December NNP O
2010 CD O
. . O
null null null-Disease
A DT O
convulsive JJ B-Disease
seizure NN B-Disease
was VBD O
defined VBN O
as IN O
a DT O
transient JJ O
episode NN O
of IN O
disturbed VBN O
brain NN O
function NN O
characterised VBN O
by IN O
abnormal JJ B-Disease
involuntary JJ I-Disease
motor NN I-Disease
movements NNS I-Disease
. . O
null null null-Disease
Multivariate JJ O
regression NN O
analysis NN O
was VBD O
performed VBN O
to TO O
identify VB O
independent JJ O
predictors NNS O
of IN O
postoperative JJ O
seizures NNS B-Disease
. . O
null null null-Disease
A DT O
total NN O
of IN O
100 CD O
( SYM O
0 CD O
. . O
9 CD O
% NN O
) -RRB- O
patients NNS O
developed VBD O
postoperative JJ O
convulsive JJ B-Disease
seizures NNS B-Disease
. . O
null null null-Disease
Generalised JJ B-Disease
and CC I-Disease
focal JJ I-Disease
seizures NNS I-Disease
were VBD O
identified VBN O
in IN O
68 CD O
and CC O
32 CD O
patients NNS O
, , O
respectively RB O
. . O
null null null-Disease
The DT O
median JJ O
( -LRB- O
IQR NN O
[ -LRB- O
range NN O
] -RRB- O
) -RRB- O
time NN O
after IN O
surgery NN O
when WRB O
the DT O
seizure NN B-Disease
occurred VBD O
was VBD O
7 CD O
( SYM O
6 CD O
- SYM O
12 CD O
[ CD O
1 CD O
- SYM O
216 CD O
] -RRB- O
) SYM O
h CD O
and CC O
8 CD O
( SYM O
6 CD O
- SYM O
11 CD O
[ -LRB- O
4 CD O
- SYM O
18 CD O
] -RRB- O
) -RRB- O
h CD O
, , O
respectively RB O
. . O
null null null-Disease
Epileptiform JJ O
findings NNS O
on IN O
electroencephalography NN O
were VBD O
seen VBN O
in IN O
19 CD O
patients NNS O
. . O
null null null-Disease
Independent JJ O
predictors NNS O
of IN O
postoperative JJ O
seizures NNS B-Disease
included VBD O
age NN O
, , O
female JJ O
sex NN O
, , O
redo JJ O
cardiac JJ O
surgery NN O
, , O
calcification NN O
of IN O
ascending VBG O
aorta NN O
, , O
congestive JJ B-Disease
heart NN I-Disease
failure NN I-Disease
, , O
deep JJ O
hypothermic JJ B-Disease
circulatory JJ O
arrest NN O
, , O
duration NN O
of IN O
aortic JJ O
cross NN O
- HYPH O
clamp NN O
and CC O
tranexamic NN O
acid NN O
. . O
null null null-Disease
When WRB O
tested VBN O
in IN O
a DT O
multivariate JJ O
regression NN O
analysis NN O
, , O
tranexamic JJ O
acid NN O
was VBD O
a DT O
strong JJ O
independent JJ O
predictor NN O
of IN O
seizures NNS B-Disease
( : O
OR CC O
14 CD O
. . O
3 CD O
, , O
95 CD O
% NN O
CI NN O
5 CD O
. . O
5 CD O
- SYM O
36 CD O
. . O
7 CD O
; : O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
with IN O
convulsive JJ B-Disease
seizures NNS B-Disease
had VBD O
2 CD O
. . O
5 CD O
times NNS O
higher JJR O
in IN O
- HYPH O
hospital NN O
mortality NN O
rates NNS O
and CC O
twice PDT O
the DT O
length NN O
of IN O
hospital NN O
stay NN O
compared VBN O
with IN O
patients NNS O
without IN O
convulsive JJ B-Disease
seizures NNS B-Disease
. . O
null null null-Disease
Mean NN O
( : O
IQR NNP O
[ -LRB- O
range NN O
] -RRB- O
) -RRB- O
length NN O
of IN O
stay NN O
in IN O
the DT O
intensive JJ O
care NN O
unit NN O
was VBD O
115 CD O
( SYM O
49 CD O
- HYPH O
228 CD O
[ SYM O
32 CD O
- HYPH O
481 CD O
] -RRB- O
) CD O
h NN O
in IN O
patients NNS O
with IN O
convulsive JJ B-Disease
seizures NNS B-Disease
compared VBN O
with IN O
26 CD O
( SYM O
22 CD O
- SYM O
69 CD O
[ -LRB- O
14 CD O
- SYM O
1080 CD O
] -RRB- O
) -RRB- O
h CD O
in IN O
patients NNS O
without IN O
seizures NNS B-Disease
( , O
p NN O
< NN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Convulsive JJ B-Disease
seizures NNS B-Disease
are VBP O
a DT O
serious JJ O
postoperative JJ B-Disease
complication NN I-Disease
after IN O
cardiac JJ O
surgery NN O
. . O
null null null-Disease
As IN O
tranexamic JJ O
acid NN O
is VBZ O
the DT O
only JJ O
modifiable JJ O
factor NN O
, , O
its PRP$ O
administration NN O
, , O
particularly RB O
in IN O
doses NNS O
exceeding VBG O
80 CD O
mg NN O
. . O
kg NNS O
( SYM O
- HYPH O
1 CD O
) -RRB- O
, , O
should MD O
be VB O
weighed VBN O
against IN O
the DT O
risk NN O
of IN O
postoperative JJ O
seizures NNS B-Disease
. . O
null null null-Disease
Dysfunctional JJ B-Disease
overnight JJ I-Disease
memory NN I-Disease
consolidation NN O
in IN O
ecstasy NN O
users NNS O
. . O
null null null-Disease
Sleep NN O
plays VBZ O
an DT O
important JJ O
role NN O
in IN O
the DT O
consolidation NN O
and CC O
integration NN O
of IN O
memory NN O
in IN O
a DT O
process NN O
called VBN O
overnight JJ O
memory NN O
consolidation NN O
. . O
null null null-Disease
Previous JJ O
studies NNS O
indicate VBP O
that IN O
ecstasy NN O
users NNS O
have VBP O
marked VBN O
and CC O
persistent JJ O
neurocognitive JJ O
and CC O
sleep NN B-Disease
- HYPH I-Disease
related VBN I-Disease
impairments NNS I-Disease
. . O
null null null-Disease
We PRP O
extend VBP O
past JJ O
research NN O
by IN O
examining VBG O
overnight JJ O
memory NN O
consolidation NN O
among IN O
regular JJ O
ecstasy NN O
users NNS O
( , O
n NNS O
= SYM O
12 CD O
) -RRB- O
and CC O
drug NN O
naive JJ O
healthy JJ O
controls NNS O
( : O
n CD O
= SYM O
26 CD O
) -RRB- O
. . O
null null null-Disease
Memory NN O
recall NN O
of IN O
word NN O
pairs NNS O
was VBD O
evaluated VBN O
before IN O
and CC O
after IN O
a DT O
period NN O
of IN O
sleep NN O
, , O
with IN O
and CC O
without IN O
interference NN O
prior RB O
to IN O
testing NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
we PRP O
assessed VBD O
neurocognitive JJ O
performances NNS O
across IN O
tasks NNS O
of IN O
learning NN O
, , O
memory NN O
and CC O
executive NN O
functioning NN O
. . O
null null null-Disease
Ecstasy NN O
users NNS O
demonstrated VBD O
impaired VBN B-Disease
overnight JJ I-Disease
memory NN I-Disease
consolidation NN O
, , O
a DT O
finding NN O
that WDT O
was VBD O
more RBR O
pronounced JJ O
following VBG O
associative JJ O
interference NN O
. . O
null null null-Disease
Additionally RB O
, , O
ecstasy NN O
users NNS O
demonstrated VBD O
impairments NNS O
on IN O
tasks NNS O
recruiting VBG O
frontostriatal JJ O
and CC O
hippocampal JJ O
neural JJ O
circuitry NN O
, , O
in IN O
the DT O
domains NNS O
of IN O
proactive JJ O
interference NN O
memory NN O
, , O
long JJ O
- HYPH O
term NN O
memory NN O
, , O
encoding NN O
, , O
working VBG O
memory NN O
and CC O
complex JJ O
planning NN O
. . O
null null null-Disease
We PRP O
suggest VBP O
that IN O
ecstasy NN O
- HYPH O
associated VBN O
dysfunction NN O
in IN O
fronto NN O
- HYPH O
temporal JJ O
circuitry NN O
may MD O
underlie VB O
overnight JJ O
consolidation NN O
memory NN B-Disease
impairments NNS I-Disease
in IN O
regular JJ O
ecstasy NN O
users NNS O
. . O
null null null-Disease
Normoammonemic JJ O
encephalopathy NN B-Disease
: : O
solely RB O
valproate JJ O
induced VBN O
or CC O
multiple JJ O
mechanisms NNS O
? . O
null null null-Disease
A DT O
77 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
presented VBN O
with IN O
subacute JJ O
onset NN O
progressive JJ O
confusion NN B-Disease
, , O
aggression NN B-Disease
, , O
auditory JJ B-Disease
hallucinations NNS I-Disease
and CC O
delusions NNS B-Disease
. . O
null null null-Disease
In IN O
the DT O
preceding VBG O
months NNS O
, , O
the DT O
patient NN O
had VBD O
a DT O
number NN O
of IN O
admissions NNS O
with IN O
transient JJ O
unilateral JJ O
hemiparesis NN B-Disease
with IN O
facial JJ O
droop NN O
, , O
and CC O
had VBD O
been VBN O
started VBN O
on IN O
valproate NN O
for IN O
presumed VBN O
hemiplegic JJ B-Disease
migraine NN I-Disease
. . O
null null null-Disease
Valproate NNP O
was VBD O
withdrawn VBN O
soon RB O
after IN O
admission NN O
and CC O
her PRP$ O
cognitive JJ O
abilities NNS O
have VBP O
gradually RB O
improved VBN O
over IN O
3 CD O
months NNS O
of IN O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
Valproate NN O
levels NNS O
taken VBN O
prior RB O
to IN O
withdrawal NN O
were VBD O
subtherapeutic JJ O
and CC O
the DT O
patient NN O
was VBD O
normoammonaemic JJ O
. . O
null null null-Disease
EEG NNP O
undertaken VBN O
during IN O
inpatient JJ O
stay NN O
showed VBD O
changes NNS O
consistent JJ O
with IN O
encephalopathy NN B-Disease
, , O
and CC O
low JJ O
titre NN O
N NN O
- HYPH O
methyl NN O
- HYPH O
D NNP O
- HYPH O
aspartate NN O
( -LRB- O
NMDA NNP O
) -RRB- O
receptor NN O
antibodies NNS O
were VBD O
present JJ O
in IN O
this DT O
patient NN O
. . O
null null null-Disease
The DT O
possible JJ O
aetiologies NNS O
of IN O
valproate NN O
- HYPH O
induced VBN O
encephalopathy NN B-Disease
and CC O
NMDA NNP O
receptor NN O
- HYPH O
associated VBN O
encephalitis NN B-Disease
present VBP O
a DT O
diagnostic JJ O
dilemma NN O
. . O
null null null-Disease
We PRP O
present VBP O
a DT O
putative JJ O
combinatorial JJ O
hypothesis NN O
to TO O
explain VB O
this DT O
patient NN O
' POS O
s POS O
symptoms NNS O
. . O
null null null-Disease
Cerebellar NN B-Disease
and CC I-Disease
oculomotor NN I-Disease
dysfunction NN I-Disease
induced VBN O
by IN O
rapid JJ O
infusion NN O
of IN O
pethidine NN O
. . O
null null null-Disease
Pethidine NN O
is VBZ O
an DT O
opioid NN O
that WDT O
gains VBZ O
its PRP$ O
popularity NN O
for IN O
the DT O
effective JJ O
pain NN B-Disease
control NN O
through IN O
acting VBG O
on IN O
the DT O
opioid NN O
- HYPH O
receptors NNS O
. . O
null null null-Disease
However RB O
, , O
rapid JJ O
pain NN B-Disease
relief NN O
sometimes RB O
brings VBZ O
about RP O
unfavourable JJ O
side NN O
effects NNS O
that WDT O
largely RB O
limit VBP O
its PRP$ O
clinical JJ O
utility NN O
. . O
null null null-Disease
Common JJ O
side NN O
effects NNS O
include VBP O
nausea NN B-Disease
, , O
vomiting NN B-Disease
and CC O
hypotension NN B-Disease
. . O
null null null-Disease
In IN O
patients NNS O
with IN O
impaired JJ B-Disease
renal JJ I-Disease
and CC I-Disease
liver NN I-Disease
function NN I-Disease
, , O
and CC O
those DT O
who WP O
need VBP O
long JJ O
- HYPH O
term NN O
pain NN B-Disease
control NN O
, , O
pethidine NN O
may MD O
cause VB O
excitatory JJ O
central JJ O
nervous JJ O
system NN O
( , O
CNS NNP O
) -RRB- O
effects NNS O
through IN O
its PRP$ O
neurotoxic JJ B-Disease
metabolite NN O
, , O
norpethidine NN O
, , O
resulting VBG O
in IN O
irritability NN B-Disease
and CC O
seizure NN B-Disease
attack NN O
. . O
null null null-Disease
On IN O
the DT O
contrary NN O
, , O
though IN O
not RB O
clinically RB O
apparent JJ O
, , O
pethidine NN O
potentially RB O
causes VBZ O
inhibitory JJ O
impacts NNS O
on IN O
the DT O
CNS NNP O
and CC O
impairs VBZ O
normal JJ O
cerebellar NN O
and CC O
oculomotor NN O
function NN O
in IN O
the DT O
short JJ O
term NN O
. . O
null null null-Disease
In IN O
this DT O
case NN O
report NN O
, , O
we PRP O
highlight VBP O
opioid NN O
' '' O
s NNS O
inhibitory JJ O
side NN O
effects NNS O
on IN O
the DT O
cerebellar JJ O
structure NN O
that WDT O
causes VBZ O
dysmetria NN B-Disease
, , O
dysarthria NN B-Disease
, , O
reduced VBN O
smooth JJ O
pursuit NN O
gain NN O
and CC O
decreased VBN O
saccadic JJ O
velocity NN O
. . O
null null null-Disease
Baboon NNP B-Disease
syndrome NN I-Disease
induced VBN O
by IN O
ketoconazole NN O
. . O
null null null-Disease
A DT O
27 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male JJ O
patient NN O
presented VBD O
with IN O
a DT O
maculopapular JJ B-Disease
eruption NN I-Disease
on IN O
the DT O
flexural JJ O
areas NNS O
and CC O
buttocks NNS O
after IN O
using VBG O
oral JJ O
ketoconazole NN O
. . O
null null null-Disease
The DT O
patient NN O
was VBD O
diagnosed VBN O
with IN O
drug NN O
- HYPH O
induced VBN O
baboon NN B-Disease
syndrome NN I-Disease
based VBN O
on IN O
his PRP$ O
history NN O
, , O
which WDT O
included VBD O
prior JJ O
sensitivity NN O
to IN O
topical JJ O
ketoconazole NN O
, , O
a DT O
physical JJ O
examination NN O
, , O
and CC O
histopathological JJ O
findings NNS O
. . O
null null null-Disease
Baboon NNP B-Disease
syndrome NN I-Disease
is VBZ O
a DT O
drug NN O
- HYPH O
or CC O
contact NN O
allergen NN O
- HYPH O
related VBN O
maculopapular JJ B-Disease
eruption NN I-Disease
that WDT O
typically RB O
involves VBZ O
the DT O
flexural JJ O
and CC O
gluteal JJ O
areas NNS O
. . O
null null null-Disease
To IN O
the DT O
best JJS O
of IN O
our PRP$ O
knowledge NN O
, , O
this DT O
is VBZ O
the DT O
first JJ O
reported VBN O
case NN O
of IN O
ketoconazole NN O
- HYPH O
induced VBN O
baboon NN B-Disease
syndrome NN I-Disease
in IN O
the DT O
English JJ O
literature NN O
. . O
null null null-Disease
A DT O
Case NN O
of IN O
Sudden JJ B-Disease
Cardiac JJ I-Disease
Death NN I-Disease
due JJ O
to IN O
Pilsicainide NNP O
- HYPH O
Induced VBN O
Torsades NNP B-Disease
de IN I-Disease
Pointes NNP I-Disease
. . O
null null null-Disease
An DT O
84 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male NN O
received VBD O
oral JJ O
pilsicainide NN O
, , O
a DT O
pure JJ O
sodium NN O
channel NN O
blocker NN O
with IN O
slow JJ O
recovery NN O
kinetics NNS O
, , O
to TO O
convert VB O
his PRP$ O
paroxysmal JJ O
atrial JJ B-Disease
fibrillation NN I-Disease
to IN O
a DT O
sinus NN O
rhythm NN O
; : O
the DT O
patient NN O
developed VBD O
sudden JJ B-Disease
cardiac JJ I-Disease
death NN I-Disease
two CD O
days NNS O
later RB O
. . O
null null null-Disease
The DT O
Holter NNP O
electrocardiogram NN O
, , O
which WDT O
was VBD O
worn VBN O
by IN O
chance NN O
, , O
revealed VBD O
torsade NN B-Disease
de FW I-Disease
pointes NNS I-Disease
with IN O
gradually RB O
prolonged VBN O
QT NNP O
intervals NNS O
. . O
null null null-Disease
This DT O
drug NN O
is VBZ O
rapidly RB O
absorbed VBN O
from IN O
the DT O
gastrointestinal JJ O
tract NN O
, , O
and CC O
most JJS O
of IN O
it PRP O
is VBZ O
excreted VBN O
from IN O
the DT O
kidney NN O
. . O
null null null-Disease
Although IN O
the DT O
patient NN O
' POS O
s NNS O
renal JJ O
function NN O
was VBD O
not RB O
highly RB O
impaired VBN O
and CC O
the DT O
dose NN O
of IN O
pilsicainide NN O
was VBD O
low JJ O
, , O
the DT O
plasma NN O
concentration NN O
of IN O
pilsicainide NN O
may MD O
have VB O
been VBN O
high JJ O
, , O
which WDT O
can MD O
produce VB O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
in IN O
the DT O
octogenarian NN O
. . O
null null null-Disease
Although IN O
the DT O
oral JJ O
administration NN O
of IN O
class NN O
IC NNP O
drugs NNS O
, , O
including VBG O
pilsicainide NN O
, , O
is VBZ O
effective JJ O
to TO O
terminate VB O
atrial JJ B-Disease
fibrillation NN I-Disease
, , O
careful JJ O
consideration NN O
must MD O
be VB O
taken VBN O
before IN O
giving VBG O
these DT O
drugs NNS O
to IN O
octogenarians NNS O
. . O
null null null-Disease
All RB O
- HYPH O
trans VBZ O
retinoic JJ O
acid NN O
- HYPH O
induced VBN O
inflammatory JJ O
myositis NN B-Disease
in IN O
a DT O
patient NN O
with IN O
acute JJ B-Disease
promyelocytic JJ I-Disease
leukemia NN I-Disease
. . O
null null null-Disease
All RB O
- HYPH O
trans NNS O
retinoic JJ O
acid NN O
( -LRB- O
ATRA NNP O
) -RRB- O
, , O
a DT O
component NN O
of IN O
standard JJ O
therapy NN O
for IN O
acute JJ B-Disease
promyelocytic JJ I-Disease
leukemia NN I-Disease
( , O
APL NNP B-Disease
) -RRB- O
, , O
is VBZ O
associated VBN O
with IN O
potentially RB O
serious JJ O
but CC O
treatable JJ O
adverse JJ O
effects NNS O
involving VBG O
numerous JJ O
organ NN O
systems NNS O
, , O
including VBG O
rare JJ O
skeletal JJ O
muscle NN O
involvement NN O
. . O
null null null-Disease
Only RB O
a DT O
handful NN O
of IN O
cases NNS O
of IN O
ATRA NNP O
- HYPH O
induced VBN O
myositis NN B-Disease
in IN O
children NNS O
have VBP O
been VBN O
reported VBN O
, , O
and CC O
none NN O
in IN O
the DT O
radiology NN O
literature NN O
. . O
null null null-Disease
We PRP O
present VBP O
such PDT O
a DT O
case NN O
in IN O
a DT O
15 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
boy NN O
with IN O
APL NNP B-Disease
, , O
where WRB O
recognition NN O
of IN O
imaging NN O
findings NNS O
played VBD O
a DT O
crucial JJ O
role NN O
in IN O
making VBG O
the DT O
diagnosis NN O
and CC O
facilitated VBD O
prompt JJ O
, , O
effective JJ O
treatment NN O
. . O
null null null-Disease
Tolerability NN O
of IN O
lomustine NN O
in IN O
combination NN O
with IN O
cyclophosphamide NN O
in IN O
dogs NNS O
with IN O
lymphoma NN B-Disease
. . O
null null null-Disease
This DT O
retrospective JJ O
study NN O
describes VBZ O
toxicity NN B-Disease
associated VBN O
with IN O
a DT O
protocol NN O
of IN O
lomustine NN O
( -LRB- O
CCNU NNP O
) -RRB- O
and CC O
cyclophosphamide NN O
( -LRB- O
CTX NNP O
) -RRB- O
in IN O
dogs NNS O
with IN O
lymphoma NN B-Disease
. . O
null null null-Disease
CCNU NNP O
was VBD O
administered VBN O
per IN O
os NN O
( -LRB- O
PO NN O
) -RRB- O
at IN O
a DT O
targeted VBN O
dosage NN O
of IN O
60 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) NN O
body NN O
surface NN O
area NN O
on IN O
day NN O
0 CD O
, , O
CTX NNP O
was VBD O
administered VBN O
PO NNP O
at IN O
a DT O
targeted VBN O
dosage NN O
of IN O
250 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) CD O
divided VBN O
over IN O
days NNS O
0 CD O
through IN O
4 CD O
, , O
and CC O
all DT O
dogs NNS O
received VBD O
prophylactic JJ O
antibiotics NNS O
. . O
null null null-Disease
Ninety CD O
treatments NNS O
were VBD O
given VBN O
to IN O
the DT O
57 CD O
dogs NNS O
included VBN O
in IN O
the DT O
study NN O
. . O
null null null-Disease
Neutropenia NN B-Disease
was VBD O
the DT O
principal JJ O
toxic JJ O
effect NN O
, , O
and CC O
the DT O
overall JJ O
frequency NN O
of IN O
grade NN O
4 CD O
neutropenia NN B-Disease
after IN O
the DT O
first JJ O
treatment NN O
of IN O
CCNU NNP O
/ SYM O
CTX NNP O
was VBD O
30 CD O
% NN O
( , O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
19 CD O
- SYM O
43 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
The DT O
mean JJ O
body NN O
weight NN O
of IN O
dogs NNS O
with IN O
grade NN O
4 CD O
neutropenia NN B-Disease
( SYM O
19 CD O
. . O
7 CD O
kg NNS O
+ SYM O
13 CD O
. . O
4 CD O
kg NNS O
) -RRB- O
was VBD O
significantly RB O
less JJR O
than IN O
the DT O
mean JJ O
body NN O
weight NN O
of IN O
dogs NNS O
that WDT O
did VBD O
not RB O
develop VB O
grade NN O
4 CD O
neutropenia NN B-Disease
( SYM O
31 CD O
. . O
7 CD O
kg NNS O
+ SYM O
12 CD O
. . O
4 CD O
kg NNS O
; : O
P NN O
= SYM O
. . O
005 CD O
) -RRB- O
. . O
null null null-Disease
One CD O
dog NN O
( : O
3 CD O
% NN O
) -RRB- O
developed VBD O
hematologic JJ O
changes NNS O
suggestive JJ O
of IN O
hepatotoxicity NN B-Disease
. . O
null null null-Disease
No DT O
dogs NNS O
had VBD O
evidence NN O
of IN O
either CC O
renal JJ B-Disease
toxicity NN I-Disease
or CC O
hemorrhagic JJ B-Disease
cystitis NN I-Disease
. . O
null null null-Disease
Adverse JJ O
gastrointestinal JJ O
effects NNS O
were VBD O
uncommon JJ O
. . O
null null null-Disease
On IN O
the DT O
basis NN O
of IN O
the DT O
findings NNS O
reported VBN O
herein RB O
, , O
a DT O
dose NN O
of IN O
60 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) CD O
of IN O
CCNU NNP O
combined VBN O
with IN O
250 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) CD O
of IN O
CTX NNP O
( , O
divided VBN O
over IN O
5 CD O
days NNS O
) -RRB- O
q NN O
4 CD O
wk NN O
is VBZ O
tolerable JJ O
in IN O
tumor NN B-Disease
- HYPH O
bearing VBG O
dogs NNS O
. . O
null null null-Disease
Nelarabine JJ O
neurotoxicity NN B-Disease
with IN O
concurrent JJ O
intrathecal JJ O
chemotherapy NN O
: : O
Case NN O
report NN O
and CC O
review NN O
of IN O
literature NN O
. . O
null null null-Disease
Severe JJ O
nelarabine NN O
neurotoxicity NN B-Disease
in IN O
a DT O
patient NN O
who WP O
received VBD O
concurrent JJ O
intrathecal JJ O
( -LRB- O
IT NN O
) -RRB- O
chemotherapy NN O
is VBZ O
reported VBN O
. . O
null null null-Disease
A DT O
37 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
Caucasian JJ O
woman NN O
with IN O
a DT O
history NN O
of IN O
T NNP B-Disease
- HYPH I-Disease
cell NN I-Disease
lymphoblastic JJ I-Disease
lymphoma NN I-Disease
was VBD O
admitted VBN O
for IN O
relapsed VBN O
disease NN O
. . O
null null null-Disease
She PRP O
was VBD O
originally RB O
treated VBN O
with IN O
induction NN O
chemotherapy NN O
followed VBN O
by IN O
an DT O
autologous JJ O
transplant NN O
. . O
null null null-Disease
She PRP O
developed VBD O
relapsed VBN O
disease NN O
10 CD O
months NNS O
later RB O
with IN O
leukemic JJ B-Disease
involvement NN O
. . O
null null null-Disease
She PRP O
was VBD O
re RB O
- HYPH O
induced VBN O
with IN O
nelarabine NN O
1500 CD O
mg NNS O
/ SYM O
m NN O
( SYM O
2 CD O
) NN O
on IN O
days NNS O
1 CD O
, , O
3 CD O
, , O
and CC O
5 CD O
with IN O
1 CD O
dose NN O
of IN O
IT NN O
cytarabine NN O
100 CD O
mg NN O
on IN O
day NN O
2 CD O
as IN O
central JJ O
nervous JJ O
system NN O
( : O
CNS NNP O
) -RRB- O
prophylaxis NN O
. . O
null null null-Disease
At IN O
the DT O
time NN O
of IN O
treatment NN O
, , O
she PRP O
was VBD O
on IN O
continuous JJ O
renal JJ O
replacement NN O
therapy NN O
due IN O
to IN O
sequelae NN O
of IN O
tumor NN B-Disease
lysis NN I-Disease
syndrome NN I-Disease
( -LRB- O
TLS NNP B-Disease
) -RRB- O
. . O
null null null-Disease
She PRP O
tolerated VBD O
therapy NN O
well RB O
, , O
entered VBD O
a DT O
complete JJ O
remission NN O
, , O
and CC O
recovered VBD O
her PRP$ O
renal JJ O
function NN O
. . O
null null null-Disease
She PRP O
received VBD O
a DT O
second JJ O
cycle NN O
of IN O
nelarabine NN O
without IN O
additional JJ O
IT NN O
prophylaxis NN O
one CD O
month NN O
later RB O
. . O
null null null-Disease
A DT O
week NN O
after IN O
this DT O
second JJ O
cycle NN O
, , O
she PRP O
noted VBD O
numbness NN O
in IN O
her PRP$ O
lower JJR O
extremities NNS O
. . O
null null null-Disease
Predominantly RB O
sensory JJ O
, , O
though IN O
also RB O
motor NN O
and CC O
autonomic JJ O
, , O
peripheral JJ B-Disease
neuropathy NN I-Disease
started VBD O
in IN O
her PRP$ O
feet NNS O
, , O
ascended VBD O
proximally RB O
to IN O
the DT O
mid JJ O
- HYPH O
thoracic JJ O
region NN O
, , O
and CC O
eventually RB O
included VBD O
her PRP$ O
distal JJ O
upper JJ O
extremities NNS O
. . O
null null null-Disease
A DT O
magnetic JJ O
resonance NN O
imaging NN O
( , O
MRI NNP O
) -RRB- O
of IN O
her PRP$ O
spine NN O
demonstrated VBD O
changes NNS O
from IN O
C2 NN O
to IN O
C6 NN O
consistent JJ O
with IN O
subacute NN O
combined VBN O
degeneration NN O
. . O
null null null-Disease
Nelarabine NNP O
was VBD O
felt VBN O
to TO O
be VB O
the DT O
cause NN O
of IN O
her PRP$ O
symptoms NNS O
. . O
null null null-Disease
Her PRP$ O
neuropathy NN B-Disease
stabilized VBD O
and CC O
showed VBD O
slight JJ O
improvement NN O
and CC O
ultimately RB O
received VBD O
an DT O
unrelated JJ O
, , O
reduced VBN O
- HYPH O
intensity NN O
allogeneic JJ O
transplant NN O
while IN O
in IN O
complete JJ O
remission NN O
, , O
but CC O
relapsed VBD O
disease NN O
10 CD O
weeks NNS O
later RB O
. . O
null null null-Disease
She PRP O
is VBZ O
currently RB O
being VBG O
treated VBN O
with IN O
best JJS O
supportive JJ O
care NN O
. . O
null null null-Disease
To IN O
our PRP$ O
knowledge NN O
, , O
this DT O
is VBZ O
the DT O
first JJ O
published VBN O
case NN O
report NN O
of IN O
severe JJ O
neurotoxicity NN B-Disease
caused VBN O
by IN O
nelarabine NN O
in IN O
a DT O
patient NN O
who WP O
received VBD O
concurrent JJ O
IT NN O
chemotherapy NN O
. . O
null null null-Disease
Valproate NN O
- HYPH O
induced VBN O
hyperammonemic JJ B-Disease
encephalopathy NN B-Disease
in IN O
a DT O
renal JJ O
transplanted VBN O
patient NN O
. . O
null null null-Disease
Neurological JJ B-Disease
complications NNS I-Disease
after IN O
renal JJ O
transplantation NN O
constitute VBP O
an DT O
important JJ O
cause NN O
of IN O
morbidity NN O
and CC O
mortality NN O
. . O
null null null-Disease
Their PRP$ O
differential JJ O
diagnosis NN O
is VBZ O
difficult JJ O
and CC O
essential JJ O
for IN O
subsequent JJ O
patient NN O
' '' O
s NN O
management NN O
. . O
null null null-Disease
Valproate NN O
- HYPH O
induced VBN O
hyperammonemic JJ B-Disease
encephalopathy NN B-Disease
is VBZ O
an DT O
uncommon JJ O
but CC O
serious JJ O
effect NN O
of IN O
valproate JJ O
treatment NN O
. . O
null null null-Disease
Here RB O
, , O
we PRP O
describe VBP O
the DT O
case NN O
of IN O
a DT O
15 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
girl NN O
who WP O
was VBD O
on IN O
a DT O
long JJ O
- HYPH O
term NN O
therapy NN O
with IN O
valproate NN O
due IN O
to IN O
epilepsy NN B-Disease
and CC O
revealed VBD O
impaired JJ B-Disease
consciousness NN I-Disease
with IN O
hyperammonemia NN B-Disease
12 CD O
days NNS O
after IN O
renal JJ O
transplantation NN O
. . O
null null null-Disease
After IN O
withdraw NN O
of IN O
valproate NN O
, , O
patients NNS O
' POS O
symptoms NNS O
resolved VBD O
within IN O
24 CD O
h NN O
. . O
null null null-Disease
Clinicians NNS O
should MD O
increase VB O
their PRP$ O
awareness NN O
for IN O
potential JJ O
complication NN O
of IN O
valproate NN O
, , O
especially RB O
in IN O
transplanted VBN O
patients NNS O
. . O
null null null-Disease
Necrotising VBG B-Disease
fasciitis NN I-Disease
after IN O
bortezomib NN O
and CC O
dexamethasone NN O
- HYPH O
containing VBG O
regimen NN O
in IN O
an DT O
elderly JJ O
patient NN O
of IN O
Waldenstrom NNP B-Disease
macroglobulinaemia NN I-Disease
. . O
null null null-Disease
Bortezomib NNP O
and CC O
high JJ O
- HYPH O
dose NN O
dexamethasone NN O
- HYPH O
containing VBG O
regimens NNS O
are VBP O
considered VBN O
to TO O
be VB O
generally RB O
tolerable JJ O
with IN O
few JJ O
severe JJ O
bacterial JJ B-Disease
infections NNS I-Disease
in IN O
patients NNS O
with IN O
B NN O
- HYPH O
cell NN O
malignancies NNS B-Disease
. . O
null null null-Disease
However RB O
, , O
information NN O
is VBZ O
limited JJ O
concerning VBG O
the DT O
safety NN O
of IN O
the DT O
regimen NN O
in IN O
elderly JJ O
patients NNS O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
a DT O
76 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
with IN O
Waldenstrom NNP B-Disease
macroglobulinaemia NN I-Disease
who WP O
suffered VBD O
necrotising VBG B-Disease
fasciitis NN I-Disease
without IN O
neutropenia NN B-Disease
after IN O
the DT O
combination NN O
treatment NN O
with IN O
bortezomib NN O
, , O
high JJ O
- HYPH O
dose NN O
dexamethasone NN O
and CC O
rituximab NN O
. . O
null null null-Disease
Despite IN O
immediate JJ O
intravenous JJ O
antimicrobial JJ O
therapy NN O
, , O
he PRP O
succumbed VBD O
23 CD O
h NN O
after IN O
the DT O
onset NN O
. . O
null null null-Disease
Physicians NNS O
should MD O
recognise VB O
the DT O
possibility NN O
of IN O
fatal JJ O
bacterial JJ B-Disease
infections NNS I-Disease
related VBN O
to IN O
bortezomib NN O
plus CC O
high JJ O
- HYPH O
dose NN O
dexamethasone NN O
in IN O
elderly JJ O
patients NNS O
, , O
and CC O
we PRP O
believe VBP O
this DT O
case NN O
warrants VBZ O
further JJ O
investigation NN O
. . O
null null null-Disease
An DT O
integrated JJ O
characterization NN O
of IN O
serological JJ O
, , O
pathological JJ O
, , O
and CC O
functional JJ O
events NNS O
in IN O
doxorubicin NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
Many JJ O
efficacious JJ O
cancer NN B-Disease
treatments NNS O
cause VBP O
significant JJ O
cardiac JJ O
morbidity NN O
, , O
yet CC O
biomarkers NNS O
or CC O
functional JJ O
indices NNS O
of IN O
early JJ O
damage NN O
, , O
which WDT O
would MD O
allow VB O
monitoring NN O
and CC O
intervention NN O
, , O
are VBP O
lacking VBG O
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
we PRP O
have VBP O
utilized VBN O
a DT O
rat NN O
model NN O
of IN O
progressive JJ O
doxorubicin NN O
( , O
DOX NNP O
) -RRB- O
- HYPH O
induced VBN O
cardiomyopathy NN B-Disease
, , O
applying VBG O
multiple JJ O
approaches NNS O
, , O
including VBG O
cardiac JJ O
magnetic JJ O
resonance NN O
imaging NN O
( , O
MRI NNP O
) -RRB- O
, , O
to TO O
provide VB O
the DT O
most RBS O
comprehensive JJ O
characterization NN O
to IN O
date NN O
of IN O
the DT O
timecourse NN O
of IN O
serological JJ O
, , O
pathological JJ O
, , O
and CC O
functional JJ O
events NNS O
underlying VBG O
this DT O
toxicity NN B-Disease
. . O
null null null-Disease
Hannover NNP O
Wistar NNP O
rats NNS O
were VBD O
dosed VBN O
with IN O
1 CD O
. . O
25 CD O
mg NN O
/ SYM O
kg NNP O
DOX NNP O
weekly RB O
for IN O
8 CD O
weeks NNS O
followed VBN O
by IN O
a DT O
4 CD O
week NN O
off RB O
- HYPH O
dosing VBG O
"""" `` O
recovery NN O
"""" '' O
period NN O
. . O
null null null-Disease
Electron NN O
microscopy NN O
of IN O
the DT O
myocardium NN O
revealed VBD O
subcellular JJ B-Disease
degeneration NN I-Disease
and CC O
marked VBD O
mitochondrial JJ O
changes NNS O
after IN O
a DT O
single JJ O
dose NN O
. . O
null null null-Disease
Histopathological JJ O
analysis NN O
revealed VBD O
progressive JJ O
cardiomyocyte NN B-Disease
degeneration NN I-Disease
, , O
hypertrophy NN B-Disease
/ SYM O
cytomegaly NN O
, , O
and CC O
extensive JJ O
vacuolation NN O
after IN O
two CD O
doses NNS O
. . O
null null null-Disease
Extensive JJ O
replacement NN O
fibrosis NN B-Disease
( , O
quantified VBN O
by IN O
Sirius NNP O
red JJ O
staining NN O
) , O
developed VBD O
during IN O
the DT O
off JJ O
- HYPH O
dosing VBG O
period NN O
. . O
null null null-Disease
Functional JJ O
indices NNS O
assessed VBN O
by IN O
cardiac JJ O
MRI NN O
( , O
including VBG O
left VBN O
ventricular JJ O
ejection NN O
fraction NN O
( , O
LVEF NNP O
) -RRB- O
, , O
cardiac JJ O
output NN O
, , O
and CC O
E NN O
/ SYM O
A NN O
ratio NN O
) , O
declined VBD O
progressively RB O
, , O
reaching VBG O
statistical JJ O
significance NN O
after IN O
two CD O
doses NNS O
and CC O
culminating VBG O
in IN O
"""" `` O
clinical JJ O
"""" '' O
LV NN B-Disease
dysfunction NN I-Disease
by IN O
12 CD O
weeks NNS O
. . O
null null null-Disease
Significant JJ O
increases NNS O
in IN O
peak NN O
myocardial JJ O
contrast NN O
enhancement NN O
and CC O
serological JJ O
cardiac JJ O
troponin NN O
I NNP O
( -LRB- O
cTnI NNP O
) -RRB- O
emerged VBD O
after IN O
eight CD O
doses NNS O
, , O
importantly RB O
preceding VBG O
the DT O
LVEF NNP O
decline NN O
to IN O
< $ O
50 CD O
% NN O
. . O
null null null-Disease
Troponin NN O
I NN O
levels VBZ O
positively RB O
correlated VBN O
with IN O
delayed JJ O
and CC O
peak NN O
gadolinium NN O
contrast NN O
enhancement NN O
, , O
histopathological JJ O
grading NN O
, , O
and CC O
diastolic JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
In IN O
summary NN O
, , O
subcellular JJ O
cardiomyocyte NN B-Disease
degeneration NN I-Disease
was VBD O
the DT O
earliest JJS O
marker NN O
, , O
followed VBN O
by IN O
progressive JJ O
functional JJ O
decline NN O
and CC O
histopathological JJ O
manifestations NNS O
. . O
null null null-Disease
Myocardial JJ O
contrast NN O
enhancement NN O
and CC O
elevations NNS O
in IN O
cTnI NNP O
occurred VBD O
later RBR O
. . O
null null null-Disease
However RB O
, , O
all DT O
indices NNS O
predated VBD O
"""" `` O
clinical JJ O
"""" '' O
LV NN B-Disease
dysfunction NN I-Disease
and CC O
thus RB O
warrant VBP O
further JJ O
evaluation NN O
as IN O
predictive JJ O
biomarkers NNS O
. . O
null null null-Disease
Intradermal JJ O
glutamate NN O
and CC O
capsaicin NN O
injections NNS O
: : O
intra NN O
- : O
and CC O
interindividual JJ O
variability NN O
of IN O
provoked VBN O
hyperalgesia NN B-Disease
and CC O
allodynia NN B-Disease
. . O
null null null-Disease
Intradermal JJ O
injections NNS O
of IN O
glutamate NN O
and CC O
capsaicin NN O
are VBP O
attractive JJ O
to IN O
use NN O
in IN O
human JJ O
experimental JJ O
pain NN B-Disease
models NNS O
because IN O
hyperalgesia NN B-Disease
and CC O
allodynia NN B-Disease
mimic VBP O
isolated VBN O
aspects NNS O
of IN O
clinical JJ O
pain NN B-Disease
disorders NNS I-Disease
. . O
null null null-Disease
The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
investigate VB O
the DT O
reproducibility NN O
of IN O
these DT O
models NNS O
. . O
null null null-Disease
Twenty CD O
healthy JJ O
male JJ O
volunteers NNS O
( , O
mean JJ O
age NN O
24 CD O
years NNS O
; : O
range NN O
18 CD O
- SYM O
38 CD O
years NNS O
) -RRB- O
received VBD O
intradermal JJ O
injections NNS O
of IN O
glutamate NN O
and CC O
capsaicin NN O
in IN O
the DT O
volar JJ O
forearm NN O
. . O
null null null-Disease
Magnitudes NNS O
of IN O
secondary JJ O
pinprick NN O
hyperalgesia NN B-Disease
and CC O
brush NN O
- HYPH O
evoked VBN O
allodynia NN B-Disease
were VBD O
investigated VBN O
using VBG O
von NNP O
Frey NNP O
filaments NNS O
( , O
gauges NNS O
10 CD O
, , O
15 CD O
, , O
60 CD O
and CC O
100 CD O
g NNS O
) , O
and CC O
brush NN O
strokes NNS O
. . O
null null null-Disease
Areas NNS O
of IN O
secondary JJ B-Disease
hyperalgesia NN I-Disease
and CC O
allodynia NN B-Disease
were VBD O
quantified VBN O
immediately RB O
after IN O
injection NN O
and CC O
after IN O
15 CD O
, , O
30 CD O
and CC O
60 CD O
min NN O
. . O
null null null-Disease
Two CD O
identical JJ O
experiments NNS O
separated VBN O
by IN O
at RB O
least RBS O
7 CD O
days NNS O
were VBD O
performed VBN O
. . O
null null null-Disease
Reproducibility NN O
across IN O
and CC O
within IN O
volunteers NNS O
( , O
inter JJ O
- HYPH O
and CC O
intra JJ O
- HYPH O
individual JJ O
variation NN O
, , O
respectively RB O
) -RRB- O
was VBD O
assessed VBN O
using VBG O
intraclass JJ O
correlation NN O
coefficient NN O
( -LRB- O
ICC NNP O
) -RRB- O
and CC O
coefficient JJ O
of IN O
variation NN O
( -LRB- O
CV NN O
) -RRB- O
. . O
null null null-Disease
Secondary JJ O
pinprick NN O
hyperalgesia NN B-Disease
was VBD O
observed VBN O
as IN O
a DT O
marked JJ O
increase NN O
in IN O
the DT O
visual JJ O
analogue NN O
scale NN O
( -LRB- O
VAS NNP O
) -RRB- O
response NN O
to IN O
von NNP O
Frey NNP O
gauges NNS O
60 CD O
and CC O
100 CD O
g NN O
( , O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
after IN O
glutamate NN O
injection NN O
. . O
null null null-Disease
For IN O
capsaicin NN O
, , O
secondary JJ O
pinprick NN O
hyperalgesia NN B-Disease
was VBD O
detected VBN O
with IN O
all DT O
von NNP O
Frey NNP O
gauges NNS O
( , O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Glutamate NNP O
evoked VBD O
reproducible JJ O
VAS NNP O
response NN O
to IN O
all DT O
von FW O
Frey NNP O
gauges NNS O
( , O
ICC NNP O
> SYM O
0 CD O
. . O
60 CD O
) -RRB- O
and CC O
brush NN O
strokes NNS O
( , O
ICC NNP O
> SYM O
0 CD O
. . O
83 CD O
) -RRB- O
. . O
null null null-Disease
Capsaicin NN O
injection NN O
was VBD O
reproducible JJ O
for IN O
secondary JJ B-Disease
hyperalgesia NN I-Disease
( , O
ICC NNP O
> SYM O
0 CD O
. . O
70 CD O
) -RRB- O
and CC O
allodynia NN B-Disease
( , O
ICC NNP O
> SYM O
0 CD O
. . O
71 CD O
) -RRB- O
. . O
null null null-Disease
Intra NNP O
- HYPH O
individual JJ O
variability NN O
was VBD O
generally RB O
lower JJR O
for IN O
the DT O
VAS NNP O
response NN O
to IN O
von NNP O
Frey NNP O
and CC O
brush NN O
compared VBN O
with IN O
areas NNS O
of IN O
secondary JJ B-Disease
hyperalgesia NN I-Disease
and CC O
allodynia NN B-Disease
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
glutamate NN O
and CC O
capsaicin NN O
yield VBP O
reproducible JJ O
hyperalgesic JJ B-Disease
and CC O
allodynic JJ B-Disease
responses NNS O
, , O
and CC O
the DT O
present JJ O
model NN O
is VBZ O
well RB O
suited JJ O
for IN O
basic JJ O
research NN O
, , O
as RB O
well RB O
as IN O
for IN O
assessing VBG O
the DT O
modulation NN O
of IN O
central JJ O
phenomena NNS O
. . O
null null null-Disease
Ocular JJ O
- HYPH O
specific JJ O
ER NN O
stress NN O
reduction NN O
rescues VBZ O
glaucoma NN B-Disease
in IN O
murine NN O
glucocorticoid NN O
- HYPH O
induced VBN O
glaucoma NN B-Disease
. . O
null null null-Disease
Administration NN O
of IN O
glucocorticoids NNS O
induces VBZ O
ocular JJ B-Disease
hypertension NN I-Disease
in IN O
some DT O
patients NNS O
. . O
null null null-Disease
If IN O
untreated JJ O
, , O
these DT O
patients NNS O
can MD O
develop VB O
a DT O
secondary JJ O
glaucoma NN B-Disease
that WDT O
resembles VBZ O
primary JJ B-Disease
open JJ I-Disease
- HYPH I-Disease
angle NN I-Disease
glaucoma NN I-Disease
( , O
POAG NNP B-Disease
) -RRB- O
. . O
null null null-Disease
The DT O
underlying VBG O
pathology NN O
of IN O
glucocorticoid NN O
- HYPH O
induced VBN O
glaucoma NN B-Disease
is VBZ O
not RB O
fully RB O
understood VBN O
, , O
due IN O
in IN O
part NN O
to IN O
lack NN O
of IN O
an DT O
appropriate JJ O
animal NN O
model NN O
. . O
null null null-Disease
Here RB O
, , O
we PRP O
developed VBD O
a DT O
murine NN O
model NN O
of IN O
glucocorticoid NN O
- HYPH O
induced VBN O
glaucoma NN B-Disease
that WDT O
exhibits VBZ O
glaucoma NN B-Disease
features NNS O
that WDT O
are VBP O
observed VBN O
in IN O
patients NNS O
. . O
null null null-Disease
Treatment NN O
of IN O
WT NN O
mice NNS O
with IN O
topical JJ O
ocular NN O
0 CD O
. . O
1 CD O
% NN O
dexamethasone NN O
led VBD O
to IN O
elevation NN O
of IN O
intraocular JJ O
pressure NN O
( , O
IOP NN O
) -RRB- O
, , O
functional JJ O
and CC O
structural JJ O
loss NN O
of IN O
retinal JJ B-Disease
ganglion NN I-Disease
cells NNS O
, , O
and CC O
axonal JJ B-Disease
degeneration NN I-Disease
, , O
resembling VBG O
glucocorticoid NN O
- HYPH O
induced VBN O
glaucoma NN B-Disease
in IN O
human JJ O
patients NNS O
. . O
null null null-Disease
Furthermore RB O
, , O
dexamethasone NN O
- HYPH O
induced VBN O
ocular JJ B-Disease
hypertension NN I-Disease
was VBD O
associated VBN O
with IN O
chronic JJ O
ER NN O
stress NN O
of IN O
the DT O
trabecular JJ O
meshwork NN O
( , O
TM NN O
) -RRB- O
. . O
null null null-Disease
Similar JJ O
to IN O
patients NNS O
, , O
withdrawal NN O
of IN O
dexamethasone NN O
treatment NN O
reduced VBD O
elevated JJ O
IOP NN O
and CC O
ER NN O
stress NN O
in IN O
this DT O
animal NN O
model NN O
. . O
null null null-Disease
Dexamethasone NNP O
induced VBD O
the DT O
transcriptional JJ O
factor NN O
CHOP NNP O
, , O
a DT O
marker NN O
for IN O
chronic JJ O
ER NN O
stress NN O
, , O
in IN O
the DT O
anterior JJ O
segment NN O
tissues NNS O
, , O
and CC O
Chop NN O
deletion NN O
reduced VBD O
ER NN O
stress NN O
in IN O
these DT O
tissues NNS O
and CC O
prevented VBD O
dexamethasone NN O
- HYPH O
induced VBN O
ocular JJ B-Disease
hypertension NN I-Disease
. . O
null null null-Disease
Furthermore RB O
, , O
reduction NN O
of IN O
ER NN O
stress NN O
in IN O
the DT O
TM NNP O
with IN O
sodium NN O
4 CD O
- HYPH O
phenylbutyrate NN O
prevented VBD O
dexamethasone NN O
- HYPH O
induced VBN O
ocular JJ B-Disease
hypertension NN I-Disease
in IN O
WT NNP O
mice NNS O
. . O
null null null-Disease
Our PRP$ O
data NNS O
indicate VBP O
that IN O
ER NNP O
stress NN O
contributes VBZ O
to IN O
glucocorticoid NN O
- HYPH O
induced VBN O
ocular JJ B-Disease
hypertension NN I-Disease
and CC O
suggest VB O
that IN O
reducing VBG O
ER NN O
stress NN O
has VBZ O
potential JJ O
as IN O
a DT O
therapeutic JJ O
strategy NN O
for IN O
treating VBG O
glucocorticoid NN O
- HYPH O
induced VBN O
glaucoma NN B-Disease
. . O
null null null-Disease
Effects NNS O
of IN O
ginsenosides NNS O
on IN O
opioid NN O
- HYPH O
induced VBN O
hyperalgesia NN B-Disease
in IN O
mice NNS O
. . O
null null null-Disease
Opioid NN O
- HYPH O
induced VBN O
hyperalgesia NN B-Disease
( , O
OIH NNP B-Disease
) -RRB- O
is VBZ O
characterized VBN O
by IN O
nociceptive JJ O
sensitization NN O
caused VBN O
by IN O
the DT O
cessation NN O
of IN O
chronic JJ O
opioid NN O
use NN O
. . O
null null null-Disease
OIH NNP B-Disease
can MD O
limit VB O
the DT O
clinical JJ O
use NN O
of IN O
opioid JJ O
analgesics NNS O
and CC O
complicate VB O
withdrawal NN O
from IN O
opioid JJ B-Disease
addiction NN I-Disease
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
we PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
Re NNP O
, , O
Rg1 NNP O
, , O
and CC O
Rb1 NNP O
ginsenosides NNS O
, , O
the DT O
bioactive JJ O
components NNS O
of IN O
ginseng NN O
, , O
on IN O
OIH NNP B-Disease
. . O
null null null-Disease
OIH NNP B-Disease
was VBD O
achieved VBN O
in IN O
mice NNS O
after IN O
subcutaneous JJ O
administration NN O
of IN O
morphine NN O
for IN O
7 CD O
consecutive JJ O
days NNS O
three CD O
times NNS O
per IN O
day NN O
. . O
null null null-Disease
During IN O
withdrawal NN O
( , O
days NNS O
8 CD O
and CC O
9 CD O
) -RRB- O
, , O
these DT O
mice NNS O
were VBD O
administered VBN O
Re NNP O
, , O
Rg1 NNP O
, , O
or CC O
Rb1 NNP O
intragastrically RB O
two CD O
times NNS O
per IN O
day NN O
. . O
null null null-Disease
On IN O
the DT O
test NN O
day NN O
( , O
day NN O
10 CD O
) -RRB- O
, , O
mice NNS O
were VBD O
subjected VBN O
to IN O
the DT O
thermal JJ O
sensitivity NN O
test NN O
and CC O
the DT O
acetic JJ O
acid NN O
- HYPH O
induced VBN O
writhing NN O
test NN O
. . O
null null null-Disease
Re IN O
( : O
300 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
inhibited VBN O
OIH NNP B-Disease
in IN O
both CC O
the DT O
thermal JJ O
sensitivity NN O
test NN O
and CC O
the DT O
acetic JJ O
acid NN O
- HYPH O
induced VBN O
writhing NN O
test NN O
. . O
null null null-Disease
However RB O
, , O
the DT O
Rg1 NNP O
and CC O
Rb1 NNP O
ginsenosides NNS O
failed VBD O
to TO O
prevent VB O
OIH NNP B-Disease
in IN O
either DT O
test NN O
. . O
null null null-Disease
Furthermore RB O
, , O
Rg1 NNP O
showed VBD O
a DT O
tendency NN O
to TO O
aggravate VB O
OIH NNP B-Disease
in IN O
the DT O
acetic JJ O
acid NN O
- HYPH O
induced VBN O
writhing NN O
test NN O
. . O
null null null-Disease
Our PRP$ O
data NNS O
suggested VBD O
that IN O
the DT O
ginsenoside NNP O
Re NNP O
, , O
but CC O
not RB O
Rg1 NNP O
or CC O
Rb1 NN O
, , O
may MD O
contribute VB O
toward IN O
reversal NN O
of IN O
OIH NNP B-Disease
. . O
null null null-Disease
A DT O
comparison NN O
of IN O
severe JJ O
hemodynamic JJ O
disturbances NNS O
between IN O
dexmedetomidine NN O
and CC O
propofol NN O
for IN O
sedation NN O
in IN O
neurocritical JJ O
care NN O
patients NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
Dexmedetomidine NN O
and CC O
propofol NN O
are VBP O
commonly RB O
used VBN O
sedatives NNS O
in IN O
neurocritical JJ O
care NN O
as IN O
they PRP O
allow VBP O
for IN O
frequent JJ O
neurologic JJ O
examinations NNS O
. . O
null null null-Disease
However RB O
, , O
both DT O
agents NNS O
are VBP O
associated VBN O
with IN O
significant JJ O
hemodynamic JJ O
side NN O
effects NNS O
. . O
null null null-Disease
The DT O
primary JJ O
objective NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
compare VB O
the DT O
prevalence NN O
of IN O
severe JJ O
hemodynamic JJ O
effects NNS O
in IN O
neurocritical JJ O
care NN O
patients NNS O
receiving VBG O
dexmedetomidine NN O
and CC O
propofol NN O
. . O
null null null-Disease
DESIGN NN O
: : O
Multicenter NNP O
, , O
retrospective JJ O
, , O
propensity NN O
- HYPH O
matched VBN O
cohort NN O
study NN O
. . O
null null null-Disease
SETTING NN O
: : O
Neurocritical JJ O
care NN O
units NNS O
at IN O
two CD O
academic JJ O
medical JJ O
centers NNS O
with IN O
dedicated JJ O
neurocritical JJ O
care NN O
teams NNS O
and CC O
board NN O
- HYPH O
certified VBN O
neurointensivists NNS O
. . O
null null null-Disease
PATIENTS NNS O
: : O
Neurocritical JJ O
care NN O
patients NNS O
admitted VBN O
between IN O
July NNP O
2009 CD O
and CC O
September NNP O
2012 CD O
were VBD O
evaluated VBN O
and CC O
then RB O
matched VBN O
1 CD O
: SYM O
1 CD O
based VBN O
on IN O
propensity NN O
scoring NN O
of IN O
baseline NN O
characteristics NNS O
. . O
null null null-Disease
INTERVENTIONS NNS O
: : O
Continuous JJ O
sedation NN O
with IN O
dexmedetomidine NN O
or CC O
propofol NN O
. . O
null null null-Disease
MEASUREMENTS NNS O
AND CC O
MAIN JJ O
RESULTS NNS O
: : O
A DT O
total NN O
of IN O
342 CD O
patients NNS O
( , O
105 CD O
dexmedetomidine NN O
and CC O
237 CD O
propofol NN O
) -RRB- O
were VBD O
included VBN O
in IN O
the DT O
analysis NN O
, , O
with IN O
190 CD O
matched VBN O
( SYM O
95 CD O
in IN O
each DT O
group NN O
) -RRB- O
by IN O
propensity NN O
score NN O
. . O
null null null-Disease
The DT O
primary JJ O
outcome NN O
of IN O
this DT O
study NN O
was VBD O
a DT O
composite NN O
of IN O
severe JJ O
hypotension NN B-Disease
( , O
mean JJ O
arterial JJ O
pressure NN O
< IN O
60 CD O
mm NN O
Hg NN O
) -RRB- O
and CC O
bradycardia NN B-Disease
( , O
heart NN O
rate NN O
< IN O
50 CD O
beats NNS O
/ SYM O
min NN O
) -RRB- O
during IN O
sedative JJ O
infusion NN O
. . O
null null null-Disease
No DT O
difference NN O
in IN O
the DT O
primary JJ O
composite JJ O
outcome NN O
in IN O
both CC O
the DT O
unmatched JJ O
( : O
30 CD O
% NN O
vs IN O
30 CD O
% NN O
, , O
p NN O
= SYM O
0 CD O
. . O
94 CD O
) -RRB- O
or CC O
matched VBN O
cohorts NNS O
( : O
28 CD O
% NN O
vs IN O
34 CD O
% NN O
, , O
p NN O
= SYM O
0 CD O
. . O
35 CD O
) -RRB- O
could MD O
be VB O
found VBN O
. . O
null null null-Disease
When WRB O
analyzed VBN O
separately RB O
, , O
no DT O
differences NNS O
could MD O
be VB O
found VBN O
in IN O
the DT O
prevalence NN O
of IN O
severe JJ O
hypotension NN B-Disease
or CC O
bradycardia NN B-Disease
in IN O
either CC O
the DT O
unmatched JJ O
or CC O
matched VBN O
cohorts NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Severe JJ O
hypotension NN B-Disease
and CC O
bradycardia NN B-Disease
occur VBP O
at IN O
similar JJ O
prevalence NN O
in IN O
neurocritical JJ O
care NN O
patients NNS O
who WP O
receive VBP O
dexmedetomidine NN O
or CC O
propofol NN O
. . O
null null null-Disease
Providers NNS O
should MD O
similarly RB O
consider VB O
the DT O
likelihood NN O
of IN O
hypotension NN B-Disease
or CC O
bradycardia NN B-Disease
before IN O
starting VBG O
either CC O
sedative JJ O
. . O
null null null-Disease
Hydroxytyrosol NN O
ameliorates VBZ O
oxidative JJ O
stress NN O
and CC O
mitochondrial JJ B-Disease
dysfunction NN I-Disease
in IN O
doxorubicin NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
in IN O
rats NNS O
with IN O
breast NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
Oxidative JJ O
stress NN O
is VBZ O
involved VBN O
in IN O
several JJ O
processes NNS O
including VBG O
cancer NN B-Disease
, , O
aging NN O
and CC O
cardiovascular JJ B-Disease
disease NN I-Disease
, , O
and CC O
has VBZ O
been VBN O
shown VBN O
to TO O
potentiate VB O
the DT O
therapeutic JJ O
effect NN O
of IN O
drugs NNS O
such JJ O
as IN O
doxorubicin NN O
. . O
null null null-Disease
Doxorubicin NNP O
causes VBZ O
significant JJ O
cardiotoxicity NN B-Disease
characterized VBN O
by IN O
marked JJ O
increases NNS O
in IN O
oxidative JJ O
stress NN O
and CC O
mitochondrial JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
Herein RB O
, , O
we PRP O
investigate VBP O
whether IN O
doxorubicin NN O
- HYPH O
associated VBN O
chronic JJ O
cardiac JJ B-Disease
toxicity NN I-Disease
can MD O
be VB O
ameliorated VBN O
with IN O
the DT O
antioxidant JJ O
hydroxytyrosol NN O
in IN O
rats NNS O
with IN O
breast NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
Thirty CD O
- HYPH O
six CD O
rats NNS O
bearing VBG O
breast NN B-Disease
tumors NNS I-Disease
induced VBN O
chemically RB O
were VBD O
divided VBN O
into IN O
4 CD O
groups NNS O
: : O
control NN O
, , O
hydroxytyrosol NN O
( , O
0 CD O
. . O
5mg CD O
/ SYM O
kg NN O
, , O
5days NNS O
/ SYM O
week NN O
) -RRB- O
, , O
doxorubicin NN O
( , O
1mg CD O
/ SYM O
kg NN O
/ SYM O
week NN O
) -RRB- O
, , O
and CC O
doxorubicin NN O
plus CC O
hydroxytyrosol NN O
. . O
null null null-Disease
Cardiac JJ B-Disease
disturbances NNS I-Disease
at IN O
the DT O
cellular JJ O
and CC O
mitochondrial JJ O
level NN O
, , O
mitochondrial JJ O
electron NN O
transport NN O
chain NN O
complexes NNS O
I NN O
- HYPH O
IV NN O
and CC O
apoptosis NN O
- HYPH O
inducing VBG O
factor NN O
, , O
and CC O
oxidative JJ O
stress NN O
markers NNS O
have VBP O
been VBN O
analyzed VBN O
. . O
null null null-Disease
Hydroxytyrosol NNP O
improved VBD O
the DT O
cardiac JJ B-Disease
disturbances NNS I-Disease
enhanced VBN O
by IN O
doxorubicin NN O
by IN O
significantly RB O
reducing VBG O
the DT O
percentage NN O
of IN O
altered JJ O
mitochondria NN O
and CC O
oxidative JJ O
damage NN O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
hydroxytyrosol NN O
improve VB O
the DT O
mitochondrial JJ O
electron NN O
transport NN O
chain NN O
. . O
null null null-Disease
This DT O
study NN O
demonstrates VBZ O
that IN O
hydroxytyrosol NN O
protect VBP O
rat JJ O
heart NN B-Disease
damage NN I-Disease
provoked VBN O
by IN O
doxorubicin NN O
decreasing VBG O
oxidative JJ O
damage NN O
and CC O
mitochondrial JJ O
alterations NNS O
. . O
null null null-Disease
Amiodarone NN O
- HYPH O
induced VBN O
myxoedema NN B-Disease
coma NN I-Disease
. . O
null null null-Disease
A DT O
62 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
was VBD O
found VBN O
to TO O
have VB O
bradycardia NN B-Disease
, , O
hypothermia NN B-Disease
and CC O
respiratory JJ B-Disease
failure NN I-Disease
3 CD O
weeks NNS O
after IN O
initiation NN O
of IN O
amiodarone NN O
therapy NN O
for IN O
atrial JJ B-Disease
fibrillation NN I-Disease
. . O
null null null-Disease
Thyroid NN O
- HYPH O
stimulating VBG O
hormone NN O
was VBD O
found VBN O
to TO O
be VB O
168 CD O
uIU NNP O
/ SYM O
mL NNP O
( : O
nl NN O
. . O
0 CD O
. . O
3 CD O
- SYM O
5 CD O
uIU NN O
/ SYM O
mL NN O
) -RRB- O
and CC O
free JJ O
thyroxine NN O
( : O
FT4 NNP O
) -RRB- O
was VBD O
< : O
0 CD O
. . O
2 CD O
ng CD O
/ SYM O
dL NN O
( : O
nl NN O
. . O
0 CD O
. . O
8 CD O
- SYM O
1 CD O
. . O
8 CD O
ng CD O
/ SYM O
dL NN O
) -RRB- O
. . O
null null null-Disease
He PRP O
received VBD O
intravenous JJ O
fluids NNS O
, , O
vasopressor NN O
therapy NN O
and CC O
stress NN O
dose NN O
steroids NNS O
; : O
he PRP O
was VBD O
intubated VBN O
and CC O
admitted VBN O
to IN O
the DT O
intensive JJ O
care NN O
unit NN O
. . O
null null null-Disease
He PRP O
received VBD O
500 CD O
ug NNS O
of IN O
intravenous JJ O
levothyroxine NN O
in IN O
the DT O
first JJ O
18 CD O
h NN O
of IN O
therapy NN O
, , O
and CC O
150 CD O
ug UH O
intravenous JJ O
daily RB O
thereafter RB O
. . O
null null null-Disease
Haemodynamic JJ O
improvement NN O
, , O
along IN O
with IN O
complete JJ O
recovery NN O
of IN O
mental JJ O
status NN O
, , O
occurred VBD O
after IN O
48 CD O
h NN O
. . O
null null null-Disease
Twelve CD O
hours NNS O
after IN O
the DT O
initiation NN O
of IN O
therapy NN O
, , O
FT4 NNP O
was VBD O
0 CD O
. . O
96 CD O
ng CD O
/ SYM O
dL NN O
. . O
null null null-Disease
The DT O
patient NN O
was VBD O
maintained VBN O
on IN O
levothyroxine NN O
175 CD O
( HYPH O
g NNP O
POorally NNP O
daily RB O
. . O
null null null-Disease
A DT O
thyroid JJ O
ultrasound NN O
showed VBD O
diffuse JJ O
heterogeneity NN O
. . O
null null null-Disease
The DT O
24 CD O
hour NN O
excretion NN O
of IN O
iodine NN O
was VBD O
3657 CD O
( HYPH O
mcg NN O
( HYPH O
25 CD O
- HYPH O
756 CD O
( HYPH O
mcg NN O
) -RRB- O
. . O
null null null-Disease
The DT O
only JJ O
two CD O
cases NNS O
of IN O
amiodarone NN O
- HYPH O
induced VBN O
myxoedema NN B-Disease
coma NN I-Disease
in IN O
the DT O
literature NN O
report VBP O
patient JJ O
death NN O
despite IN O
supportive JJ O
therapy NN O
and CC O
thyroid NN O
hormone NN O
replacement NN O
. . O
null null null-Disease
This DT O
case NN O
represents VBZ O
the DT O
most RBS O
thoroughly RB O
investigated VBN O
case NN O
of IN O
amiodarone NN O
- HYPH O
induced VBN O
myxoedema NN B-Disease
coma NN I-Disease
with IN O
a DT O
history NN O
significant JJ O
for IN O
subclinical JJ O
thyroid NN B-Disease
disease NN I-Disease
. . O
null null null-Disease
Use NN O
of IN O
argatroban NN O
and CC O
catheter NN O
- HYPH O
directed VBN O
thrombolysis NN B-Disease
with IN O
alteplase NN O
in IN O
an DT O
oncology NN O
patient NN O
with IN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
with IN O
thrombosis NN B-Disease
. . O
null null null-Disease
PURPOSE NN O
: : O
The DT O
case NN O
of IN O
an DT O
oncology NN O
patient NN O
who WP O
developed VBD O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
with IN O
thrombosis NN B-Disease
( , O
HITT NNP B-Disease
) -RRB- O
and CC O
was VBD O
treated VBN O
with IN O
argatroban NN O
plus CC O
catheter NN O
- HYPH O
directed VBN O
thrombolysis NN B-Disease
( -LRB- O
CDT NNP O
) -RRB- O
with IN O
alteplase NN O
is VBZ O
presented VBN O
. . O
null null null-Disease
SUMMARY NN O
: : O
A DT O
63 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
Caucasian JJ O
man NN O
with IN O
renal JJ O
amyloidosis NN B-Disease
undergoing VBG O
peripheral JJ O
blood NN O
stem NN O
cell NN O
collection NN O
for IN O
an DT O
autologous JJ O
stem NN O
cell NN O
transplant NN O
developed VBD O
extensive JJ O
bilateral JJ O
upper JJ B-Disease
- HYPH I-Disease
extremity NN I-Disease
deep JJ I-Disease
venous NN I-Disease
thrombosis NN I-Disease
( , O
DVT NNP B-Disease
) -RRB- O
and CC O
pulmonary JJ B-Disease
embolism NN I-Disease
secondary JJ O
to IN O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
. . O
null null null-Disease
A DT O
continuous JJ O
i NN O
. . O
v NN O
. . O
infusion NN O
of IN O
argatroban NN O
was VBD O
initiated VBN O
, , O
and CC O
the DT O
patient NN O
was VBD O
managed VBN O
on IN O
the DT O
general JJ O
medical JJ O
floor NN O
. . O
null null null-Disease
After IN O
one CD O
week NN O
of IN O
therapy NN O
, , O
he PRP O
was VBD O
transferred VBN O
to IN O
the DT O
intensive JJ O
care NN O
unit NN O
with IN O
cardiopulmonary JJ O
compromise NN O
related VBN O
to IN O
superior JJ B-Disease
vena NN I-Disease
cava NN I-Disease
( , I-Disease
SVC NNP I-Disease
) , I-Disease
syndrome NN I-Disease
. . O
null null null-Disease
A DT O
percutaneous JJ O
mechanical JJ O
thrombectomy NN O
and CC O
CDT NNP O
with IN O
alteplase NN O
were VBD O
attempted VBN O
, , O
but CC O
the DT O
procedure NN O
was VBD O
aborted VBN O
due IN O
to IN O
epistaxis NN B-Disease
. . O
null null null-Disease
The DT O
epistaxis NNS B-Disease
resolved VBD O
the DT O
next JJ O
day NN O
, , O
and CC O
the DT O
patient NN O
was VBD O
restarted VBN O
on IN O
argatroban NN O
. . O
null null null-Disease
A DT O
second JJ O
percutaneous JJ O
mechanical JJ O
thrombectomy NN O
was VBD O
performed VBN O
six CD O
days NNS O
later RB O
and CC O
resulted VBD O
in IN O
partial JJ O
revascularization NN O
of IN O
the DT O
SVC NNP O
and CC O
central JJ O
veins NNS O
. . O
null null null-Disease
Postthrombectomy NN O
continuous JJ O
CDT NNP O
with IN O
alteplase NN O
was VBD O
commenced VBN O
while IN O
argatroban NN O
was VBD O
withheld VBN O
, , O
and CC O
complete JJ O
patency NN O
of IN O
the DT O
SVC NNP O
and CC O
central JJ O
veins NNS O
was VBD O
achieved VBN O
after IN O
three CD O
days NNS O
of IN O
therapy NN O
. . O
null null null-Disease
Alteplase NNP O
was VBD O
discontinued VBN O
, , O
and CC O
the DT O
patient NN O
was VBD O
reinitiated VBN O
on IN O
argatroban NN O
; : O
ultimately RB O
, , O
he PRP O
was VBD O
transitioned VBN O
to IN O
warfarin NN O
for IN O
long JJ O
- HYPH O
term NN O
anticoagulation NN O
. . O
null null null-Disease
Although IN O
the DT O
patient NN O
recovered VBD O
, , O
he PRP O
experienced VBD O
permanent JJ O
vision NN B-Disease
and CC I-Disease
hearing NN I-Disease
loss NN I-Disease
, , O
as RB O
well RB O
as IN O
end JJ B-Disease
- HYPH I-Disease
stage NN I-Disease
renal JJ I-Disease
disease NN I-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
A DT O
63 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
with IN O
renal JJ O
amyloidosis NN B-Disease
and CC O
SVC NNP B-Disease
syndrome NN I-Disease
secondary JJ O
to IN O
HITT NNP B-Disease
was VBD O
successfully RB O
treated VBN O
with IN O
argatroban NN O
and CC O
CDT NNP O
with IN O
alteplase NN O
. . O
null null null-Disease
Effects NNS O
of IN O
dehydroepiandrosterone NN O
in IN O
amphetamine NN O
- HYPH O
induced VBN O
schizophrenia NN B-Disease
models NNS O
in IN O
mice NNS O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
examine VB O
the DT O
effects NNS O
of IN O
dehydroepiandrosterone NN O
( : O
DHEA NNP O
) -RRB- O
on IN O
animal NN O
models NNS O
of IN O
schizophrenia NN B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
Seventy CD O
Swiss JJ O
albino JJ O
female JJ O
mice NNS O
( , O
25 CD O
- SYM O
35 CD O
g CD O
) -RRB- O
were VBD O
divided VBN O
into IN O
4 CD O
groups NNS O
: : O
amphetamine NN O
- HYPH O
free JJ O
( HYPH O
control NN O
) -RRB- O
, , O
amphetamine NN O
, , O
50 CD O
, , O
and CC O
100 CD O
mg NN O
/ SYM O
kg NN O
DHEA NNP O
. . O
null null null-Disease
The DT O
DHEA NNP O
was VBD O
administered VBN O
intraperitoneally RB O
( , O
ip NN O
) -RRB- O
for IN O
5 CD O
days NNS O
. . O
null null null-Disease
Amphetamine NN O
( : O
3 CD O
mg NN O
/ SYM O
kg NN O
ip NN O
) -RRB- O
induced VBN O
hyper NN B-Disease
locomotion NN O
, , O
apomorphine NN O
( , O
1 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NN O
subcutaneously RB O
[ -LRB- O
sc NN O
] -RRB- O
) , O
induced VBN O
climbing NN O
, , O
and CC O
haloperidol NN O
( , O
1 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NN O
sc NN O
) -RRB- O
induced VBN O
catalepsy NN B-Disease
tests NNS O
were VBD O
used VBN O
as IN O
animal NN O
models NNS O
of IN O
schizophrenia NN B-Disease
. . O
null null null-Disease
The DT O
study NN O
was VBD O
conducted VBN O
at IN O
the DT O
Animal NNP O
Experiment NNP O
Laboratories NNPS O
, , O
Department NNP O
of IN O
Pharmacology NNP O
, , O
Medical NNP O
School NNP O
, , O
Eskisehir NNP O
Osmangazi NNP O
University NNP O
, , O
Eskisehir NNP O
, , O
Turkey NNP O
between IN O
March NNP O
and CC O
May NNP O
2012 CD O
. . O
null null null-Disease
Statistical JJ O
analysis NN O
was VBD O
carried VBN O
out RP O
using VBG O
Kruskal NNP O
- HYPH O
Wallis NNP O
test NN O
for IN O
hyper NN B-Disease
locomotion NN O
, , O
and CC O
one CD O
- HYPH O
way NN O
ANOVA NN O
for IN O
climbing NN O
and CC O
catalepsy NN B-Disease
tests NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
In IN O
the DT O
amphetamine NN O
- HYPH O
induced VBN O
locomotion NN O
test NN O
, , O
there EX O
were VBD O
significant JJ O
increases NNS O
in IN O
all DT O
movements NNS O
compared VBN O
with IN O
the DT O
amphetamine NN O
- HYPH O
free JJ O
group NN O
. . O
null null null-Disease
Both DT O
DHEA NNP O
50 CD O
mg NN O
/ SYM O
kg NNS O
( , O
p NN O
< SYM O
0 CD O
. SYM O
05 CD O
) -RRB- O
, , O
and CC O
100 CD O
mg NN O
/ SYM O
kg NN O
( , O
p NN O
< SYM O
0 CD O
. SYM O
01 CD O
) -RRB- O
significantly RB O
decreased VBD O
all DT O
movements NNS O
compared VBN O
with IN O
the DT O
amphetamine NN O
- HYPH O
induced VBN O
locomotion NN O
group NN O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
significant JJ O
difference NN O
between IN O
groups NNS O
in IN O
the DT O
haloperidol NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
test NN O
( , O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
significant JJ O
difference NN O
between IN O
groups NNS O
in IN O
terms NNS O
of IN O
total JJ O
climbing NN O
time NN O
in IN O
the DT O
apomorphine NN O
- HYPH O
induced VBN O
climbing NN O
test NN O
( , O
p NN O
> SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
We PRP O
observed VBD O
that IN O
DHEA NNP O
reduced VBD O
locomotor NN O
activity NN O
and CC O
increased VBD O
catalepsy NN B-Disease
at IN O
both DT O
doses NNS O
, , O
while IN O
it PRP O
had VBD O
no DT O
effect NN O
on IN O
climbing NN O
behavior NN O
. . O
null null null-Disease
We PRP O
suggest VBP O
that IN O
DHEA NNP O
displays VBZ O
typical JJ O
neuroleptic JJ O
- HYPH O
like JJ O
effects NNS O
, , O
and CC O
may MD O
be VB O
used VBN O
in IN O
the DT O
treatment NN O
of IN O
schizophrenia NN B-Disease
. . O
null null null-Disease
Availability NN O
of IN O
human JJ O
induced VBN O
pluripotent JJ O
stem NN O
cell NN O
- HYPH O
derived VBN O
cardiomyocytes NNS O
in IN O
assessment NN O
of IN O
drug NN O
potential NN O
for IN O
QT NNP B-Disease
prolongation NN I-Disease
. . O
null null null-Disease
Field NN O
potential JJ O
duration NN O
( -LRB- O
FPD NNP O
) -RRB- O
in IN O
human NN O
- HYPH O
induced VBN O
pluripotent JJ O
stem NN O
cell NN O
- HYPH O
derived VBN O
cardiomyocytes NNS O
( , O
hiPS NNP O
- HYPH O
CMs NNP O
) -RRB- O
, , O
which WDT O
can MD O
express VB O
QT NNP O
interval NN O
in IN O
an DT O
electrocardiogram NN O
, , O
is VBZ O
reported VBN O
to TO O
be VB O
a DT O
useful JJ O
tool NN O
to TO O
predict VB O
K NN O
( , O
+ CC O
) -RRB- O
channel NN O
and CC O
Ca NN O
( , O
2 CD O
+ CC O
) -RRB- O
channel NN O
blocker NN O
effects NNS O
on IN O
QT NNP O
interval NN O
. . O
null null null-Disease
However RB O
, , O
there EX O
is VBZ O
no DT O
report NN O
showing VBG O
that IN O
this DT O
technique NN O
can MD O
be VB O
used VBN O
to TO O
predict VB O
multichannel JJ O
blocker NN O
potential NN O
for IN O
QT NNP B-Disease
prolongation NN I-Disease
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
show VB O
that IN O
FPD NNP O
from IN O
MEA NNP O
( -LRB- O
Multielectrode NNP O
array NN O
) -RRB- O
of IN O
hiPS NNP O
- HYPH O
CMs NNS O
can MD O
detect VB O
QT NNP B-Disease
prolongation NN I-Disease
induced VBN O
by IN O
multichannel JJ O
blockers NNS O
. . O
null null null-Disease
hiPS NNP O
- HYPH O
CMs NNS O
were VBD O
seeded VBN O
onto IN O
MEA NNP O
and CC O
FPD NNP O
was VBD O
measured VBN O
for IN O
2min NN O
every DT O
10min NN O
for IN O
30min CD O
after IN O
drug NN O
exposure NN O
for IN O
the DT O
vehicle NN O
and CC O
each DT O
drug NN O
concentration NN O
. . O
null null null-Disease
IKr NNP O
and CC O
IKs NNP O
blockers NNS O
concentration NN O
- HYPH O
dependently RB O
prolonged VBN O
corrected VBN O
FPD NNP O
( , O
FPDc NNP O
) -RRB- O
, , O
whereas IN O
Ca NN O
( , O
2 CD O
+ SYM O
) -RRB- O
channel NN O
blockers NNS O
concentration NN O
- HYPH O
dependently RB O
shortened VBN O
FPDc NNP O
. . O
null null null-Disease
Also RB O
, , O
the DT O
multichannel JJ O
blockers NNS O
Amiodarone NNP O
, , O
Paroxetine NNP O
, , O
Terfenadine NNP O
and CC O
Citalopram NNP O
prolonged VBD O
FPDc NNP O
in IN O
a DT O
concentration NN O
dependent JJ O
manner NN O
. . O
null null null-Disease
Finally RB O
, , O
the DT O
IKr NNP O
blockers NNS O
, , O
Terfenadine NNP O
and CC O
Citalopram NNP O
, , O
which WDT O
are VBP O
reported VBN O
to TO O
cause VB O
Torsade NNP B-Disease
de NNP I-Disease
Pointes NNP I-Disease
( , O
TdP NNP B-Disease
) -RRB- O
in IN O
clinical JJ O
practice NN O
, , O
produced VBD O
early JJ O
afterdepolarization NN O
( , O
EAD NNP O
) -RRB- O
. . O
null null null-Disease
hiPS NNP O
- HYPH O
CMs NNS O
using VBG O
MEA NNP O
system NN O
and CC O
FPDc NNP O
can MD O
predict VB O
the DT O
effects NNS O
of IN O
drug NN O
candidates NNS O
on IN O
QT NNP O
interval NN O
. . O
null null null-Disease
This DT O
study NN O
also RB O
shows VBZ O
that IN O
this DT O
assay NN O
can MD O
help VB O
detect VB O
EAD NNP O
for IN O
drugs NNS O
with IN O
TdP NNP B-Disease
potential NN O
. . O
null null null-Disease
Dermal JJ O
developmental JJ O
toxicity NN B-Disease
of IN O
N NN O
- HYPH O
phenylimide NN O
herbicides NNS O
in IN O
rats NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
S NN O
- HYPH O
53482 CD O
and CC O
S NN O
- HYPH O
23121 CD O
are VBP O
N CD O
- HYPH O
phenylimide NN O
herbicides NNS O
and CC O
produced VBN O
embryolethality NN B-Disease
, , O
teratogenicity NN B-Disease
( , O
mainly RB O
ventricular JJ B-Disease
septal NN I-Disease
defects NNS I-Disease
and CC O
wavy NN O
ribs NNS O
) -RRB- O
, , O
and CC O
growth NN B-Disease
retardation NN I-Disease
in IN O
rats NNS O
in IN O
conventional JJ O
oral JJ O
developmental JJ O
toxicity NN B-Disease
studies NNS O
. . O
null null null-Disease
Our PRP$ O
objective NN O
in IN O
this DT O
study NN O
was VBD O
to TO O
investigate VB O
whether IN O
the DT O
compounds NNS O
induce VBP O
developmental JJ O
toxicity NN B-Disease
via IN O
the DT O
dermal JJ O
route NN O
, , O
which WDT O
is VBZ O
more RBR O
relevant JJ O
to IN O
occupational JJ O
exposure NN O
, , O
hence RB O
better RBR O
addressing VBG O
human JJ O
health NN O
risks NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
S NN O
- HYPH O
53482 CD O
was VBD O
administered VBN O
dermally RB O
to IN O
rats NNS O
at IN O
30 CD O
, , O
100 CD O
, , O
and CC O
300 CD O
mg NNS O
/ SYM O
kg NNS O
during IN O
organogenesis NN O
, , O
and CC O
S NNP O
- HYPH O
23121 CD O
was VBD O
administered VBN O
at IN O
200 CD O
, , O
400 CD O
, , O
and CC O
800 CD O
mg NN O
/ SYM O
kg NN O
( , O
the DT O
maximum JJ O
applicable JJ O
dose NN O
level NN O
) -RRB- O
. . O
null null null-Disease
Fetuses NNS O
were VBD O
obtained VBN O
by IN O
a DT O
Cesarean JJ O
section NN O
and CC O
examined VBN O
for IN O
external JJ O
, , O
visceral JJ O
, , O
and CC O
skeletal JJ O
alterations NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Dermal JJ O
exposure NN O
of IN O
rats NNS O
to IN O
S NN O
- HYPH O
53482 CD O
at IN O
300 CD O
mg NNS O
/ SYM O
kg NNS O
produced VBD O
patterns NNS O
of IN O
developmental JJ O
toxicity NN B-Disease
similar JJ O
to IN O
those DT O
resulting VBG O
from IN O
oral JJ O
exposure NN O
. . O
null null null-Disease
Toxicity NN B-Disease
included VBD O
embryolethality NN B-Disease
, , O
teratogenicity NN B-Disease
, , O
and CC O
growth NN B-Disease
retardation NN I-Disease
. . O
null null null-Disease
Dermal JJ O
administration NN O
of IN O
S NNP O
- HYPH O
23121 CD O
at IN O
800 CD O
mg NN O
/ SYM O
kg NNS O
resulted VBD O
in IN O
an DT O
increased JJ O
incidence NN O
of IN O
embryonic JJ B-Disease
death NN I-Disease
and CC O
ventricular JJ B-Disease
septal NN I-Disease
defect NN I-Disease
, , O
but CC O
retarded VBN O
fetal JJ O
growth NN O
was VBD O
not RB O
observed VBN O
as IN O
it PRP O
was VBD O
following VBG O
oral JJ O
exposure NN O
to IN O
S NN O
- HYPH O
23121 CD O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Based VBN O
on IN O
the DT O
results NNS O
, , O
S NNP O
- HYPH O
53482 CD O
and CC O
S NN O
- HYPH O
23121 CD O
were VBD O
teratogenic JJ B-Disease
when WRB O
administered VBN O
dermally RB O
to IN O
pregnant JJ O
rats NNS O
as IN O
were VBD O
the DT O
compounds NNS O
administered VBN O
orally RB O
. . O
null null null-Disease
Thus RB O
, , O
investigation NN O
of IN O
the DT O
mechanism NN O
and CC O
its PRP$ O
human JJ O
relevancy NN O
become VBP O
more RBR O
important JJ O
. . O
null null null-Disease
Rates NNS O
of IN O
Renal JJ B-Disease
Toxicity NN I-Disease
in IN O
Cancer NN B-Disease
Patients NNS O
Receiving VBG O
Cisplatin NN O
With IN O
and CC O
Without IN O
Mannitol NNP O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Cisplatin NN O
is VBZ O
a DT O
widely RB O
used VBN O
antineoplastic NN O
. . O
null null null-Disease
One CD O
of IN O
the DT O
major JJ O
complications NNS O
of IN O
cisplatin NN O
use NN O
is VBZ O
dose NN O
- HYPH O
limiting VBG O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
There EX O
are VBP O
many JJ O
strategies NNS O
to TO O
prevent VB O
this DT O
toxicity NN B-Disease
, , O
including VBG O
the DT O
use NN O
of IN O
mannitol NN O
as IN O
a DT O
nephroprotectant NN O
in IN O
combination NN O
with IN O
hydration NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
We PRP O
aimed VBD O
to TO O
evaluate VB O
the DT O
rates NNS O
of IN O
cisplatin NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
in IN O
cancer NN B-Disease
patients NNS O
receiving VBG O
single JJ O
- HYPH O
agent NN O
cisplatin NN O
with IN O
and CC O
without IN O
mannitol NN O
. . O
null null null-Disease
METHODS NNS O
: : O
This DT O
single JJ O
- HYPH O
center NN O
retrospective JJ O
analysis NN O
was VBD O
a DT O
quasi JJ O
experiment NN O
created VBN O
by IN O
the DT O
national JJ O
mannitol NN O
shortage NN O
. . O
null null null-Disease
Data NNS O
were VBD O
collected VBN O
on IN O
adult NN O
cancer NN B-Disease
patients NNS O
receiving VBG O
single JJ O
- HYPH O
agent NN O
cisplatin NN O
as IN O
an DT O
outpatient NN O
from IN O
January NNP O
2011 CD O
to IN O
September NNP O
2012 CD O
. . O
null null null-Disease
The DT O
primary JJ O
outcome NN O
was VBD O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
( : O
AKI NNP B-Disease
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
We PRP O
evaluated VBD O
143 CD O
patients NNS O
who WP O
received VBD O
single JJ O
- HYPH O
agent NN O
cisplatin NN O
; : O
97 CD O
. . O
2 CD O
% NN O
of IN O
patients NNS O
had VBD O
head NN B-Disease
and CC I-Disease
neck NN I-Disease
cancer NN I-Disease
as IN O
their PRP$ O
primary JJ O
malignancy NN B-Disease
. . O
null null null-Disease
Patients NNS O
who WP O
did VBD O
not RB O
receive VB O
mannitol NN O
were VBD O
more RBR O
likely JJ O
to TO O
develop VB O
nephrotoxicity NN B-Disease
: : O
odds NNS O
ratio NN O
[ -LRB- O
OR CC O
] -RRB- O
= SYM O
2 CD O
. . O
646 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
1 CD O
. . O
008 CD O
, , O
6 CD O
. . O
944 CD O
; : O
P NN O
= SYM O
0 CD O
. . O
048 CD O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
who WP O
received VBD O
the DT O
100 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) SYM O
dosing NN O
and CC O
patients NNS O
who WP O
had VBD O
a DT O
history NN O
of IN O
hypertension NN B-Disease
also RB O
had VBD O
a DT O
higher JJR O
likelihood NN O
of IN O
developing VBG O
nephrotoxicity NN B-Disease
: : O
OR CC O
= SYM O
11 CD O
. . O
494 CD O
( : O
95 CD O
% NN O
CI NN O
= SYM O
4 CD O
. . O
149 CD O
, , O
32 CD O
. . O
258 CD O
; : O
P NN O
< SYM O
0 CD O
. . O
0001 CD O
) -RRB- O
and CC O
OR NN O
= SYM O
3 CD O
. . O
219 CD O
( SYM O
95 CD O
% NN O
CI NN O
= SYM O
1 CD O
. . O
228 CD O
, , O
8 CD O
. . O
439 CD O
; : O
P NN O
= SYM O
0 CD O
. . O
017 CD O
) -RRB- O
, , O
respectively RB O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
When WRB O
limited JJ O
quantities NNS O
of IN O
mannitol NN O
are VBP O
available JJ O
, , O
it PRP O
should MD O
preferentially RB O
be VB O
given VBN O
to IN O
patients NNS O
at IN O
particularly RB O
high JJ O
risk NN O
of IN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
Our PRP$ O
analysis NN O
suggests VBZ O
that IN O
those DT O
patients NNS O
receiving VBG O
the DT O
dosing NN O
schedule NN O
of IN O
100 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) SYM O
cisplatin NN O
every DT O
3 CD O
weeks NNS O
and CC O
those DT O
with IN O
hypertension NN B-Disease
are VBP O
at IN O
the DT O
greatest JJS O
risk NN O
of IN O
nephrotoxicity NN B-Disease
and CC O
would MD O
benefit VB O
from IN O
the DT O
addition NN O
of IN O
mannitol NN O
. . O
null null null-Disease
Metformin NN O
protects VBZ O
against IN O
seizures NNS B-Disease
, , O
learning NN B-Disease
and CC I-Disease
memory NN I-Disease
impairments NNS I-Disease
and CC O
oxidative JJ O
damage NN O
induced VBN O
by IN O
pentylenetetrazole NN O
- HYPH O
induced VBN O
kindling NN O
in IN O
mice NNS O
. . O
null null null-Disease
Cognitive JJ B-Disease
impairment NN I-Disease
, , O
the DT O
most RBS O
common JJ O
and CC O
severe JJ O
comorbidity NN O
of IN O
epilepsy NN B-Disease
, , O
greatly RB O
diminishes VBZ O
the DT O
quality NN O
of IN O
life NN O
. . O
null null null-Disease
However RB O
, , O
current JJ O
therapeutic JJ O
interventions NNS O
for IN O
epilepsy NN B-Disease
can MD O
also RB O
cause VB O
untoward JJ O
cognitive JJ O
effects NNS O
. . O
null null null-Disease
Thus RB O
, , O
there EX O
is VBZ O
an DT O
urgent JJ O
need NN O
for IN O
new JJ O
kinds NNS O
of IN O
agents NNS O
targeting VBG O
both DT O
seizures NNS B-Disease
and CC O
cognition NN B-Disease
deficits NNS I-Disease
. . O
null null null-Disease
Oxidative JJ O
stress NN O
is VBZ O
considered VBN O
to TO O
play VB O
an DT O
important JJ O
role NN O
in IN O
epileptogenesis NN O
and CC O
cognitive JJ B-Disease
deficits NNS I-Disease
, , O
and CC O
antioxidants NNS O
have VBP O
a DT O
putative JJ O
antiepileptic JJ O
potential NN O
. . O
null null null-Disease
Metformin NNP O
, , O
the DT O
most RBS O
commonly RB O
prescribed VBN O
antidiabetic JJ O
oral JJ O
drug NN O
, , O
has VBZ O
antioxidant JJ O
properties NNS O
. . O
null null null-Disease
This DT O
study NN O
was VBD O
designed VBN O
to TO O
evaluate VB O
the DT O
ameliorative JJ O
effects NNS O
of IN O
metformin NN O
on IN O
seizures NNS B-Disease
, , O
cognitive JJ B-Disease
impairment NN I-Disease
and CC O
brain NN O
oxidative JJ O
stress NN O
markers NNS O
observed VBN O
in IN O
pentylenetetrazole NN O
- HYPH O
induced VBN O
kindling VBG O
animals NNS O
. . O
null null null-Disease
Male NNP O
C57BL NNP O
/ SYM O
6 CD O
mice NNS O
were VBD O
administered VBN O
with IN O
subconvulsive JJ O
dose NN O
of IN O
pentylenetetrazole NN O
( : O
37 CD O
mg NNS O
/ SYM O
kg NN O
, , O
i CD O
. . O
p NN O
. . O
) -RRB- O
every DT O
other JJ O
day NN O
for IN O
14 CD O
injections NNS O
. . O
null null null-Disease
Metformin NNP O
was VBD O
injected VBN O
intraperitoneally RB O
in IN O
dose NN O
of IN O
200mg CD O
/ SYM O
kg NN O
along IN O
with IN O
alternate JJ O
- HYPH O
day NN O
PTZ NN O
. . O
null null null-Disease
We PRP O
found VBD O
that IN O
metformin NN O
suppressed VBD O
the DT O
progression NN O
of IN O
kindling NN O
, , O
ameliorated VBD O
the DT O
cognitive JJ B-Disease
impairment NN I-Disease
and CC O
decreased VBN O
brain NN O
oxidative JJ O
stress NN O
. . O
null null null-Disease
Thus RB O
the DT O
present JJ O
study NN O
concluded VBD O
that IN O
metformin NN O
may MD O
be VB O
a DT O
potential JJ O
agent NN O
for IN O
the DT O
treatment NN O
of IN O
epilepsy NN B-Disease
as RB O
well RB O
as IN O
a DT O
protective JJ O
medicine NN O
against IN O
cognitive JJ B-Disease
impairment NN I-Disease
induced VBN O
by IN O
seizures NNS B-Disease
. . O
null null null-Disease
P53 NN O
inhibition NN O
exacerbates VBZ O
late JJ O
- HYPH O
stage NN O
anthracycline NN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
AIMS NNS O
: : O
Doxorubicin NNP O
( : O
DOX NNP O
) -RRB- O
is VBZ O
an DT O
effective JJ O
anti JJ O
- HYPH O
cancer NN B-Disease
therapeutic JJ O
, , O
but CC O
is VBZ O
associated VBN O
with IN O
both CC O
acute JJ O
and CC O
late JJ O
- HYPH O
stage NN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
Children NNS O
are VBP O
particularly RB O
sensitive JJ O
to IN O
DOX NNP O
- HYPH O
induced VBN O
heart NN B-Disease
failure NN I-Disease
. . O
null null null-Disease
Here RB O
, , O
the DT O
impact NN O
of IN O
p53 NN O
inhibition NN O
on IN O
acute JJ O
vs IN O
. . O
late JJ O
- HYPH O
stage NN O
DOX NNP O
cardiotoxicity NN B-Disease
was VBD O
examined VBN O
in IN O
a DT O
juvenile JJ O
model NN O
. . O
null null null-Disease
METHODS NNS O
AND CC O
RESULTS NNS O
: : O
Two CD O
- HYPH O
week NN O
- HYPH O
old JJ O
MHC NNP O
- HYPH O
CB7 NNP O
mice NNS O
( -LRB- O
which WDT O
express VBP O
dominant JJ O
- HYPH O
interfering VBG O
p53 NN O
in IN O
cardiomyocytes NNS O
) -RRB- O
and CC O
their PRP$ O
non NN O
- HYPH O
transgenic JJ O
( , O
NON NNP O
- HYPH O
TXG NNP O
) -RRB- O
littermates NNS O
received VBD O
weekly JJ O
DOX NNP O
injections NNS O
for IN O
5 CD O
weeks NNS O
( , O
25 CD O
mg NN O
/ SYM O
kg NN O
cumulative JJ O
dose NN O
) -RRB- O
. . O
null null null-Disease
One CD O
week NN O
after IN O
the DT O
last JJ O
DOX NNP O
treatment NN O
( , O
acute JJ O
stage NN O
) -RRB- O
, , O
MHC NNP O
- HYPH O
CB7 NN O
mice NNS O
exhibited VBD O
improved VBN O
cardiac JJ O
function NN O
and CC O
lower JJR O
levels NNS O
of IN O
cardiomyocyte NN O
apoptosis NN O
when WRB O
compared VBN O
with IN O
the DT O
NON NNP O
- HYPH O
TXG NNP O
mice NN O
. . O
null null null-Disease
Surprisingly RB O
, , O
by IN O
13 CD O
weeks NNS O
following VBG O
the DT O
last JJ O
DOX NNP O
treatment NN O
( , O
late JJ O
stage NN O
) -RRB- O
, , O
MHC NNP O
- HYPH O
CB7 NNP O
exhibited VBD O
a DT O
progressive JJ O
decrease NN O
in IN O
cardiac JJ O
function NN O
and CC O
higher JJR O
rates NNS O
of IN O
cardiomyocyte NN O
apoptosis NN O
when WRB O
compared VBN O
with IN O
NON NNP O
- HYPH O
TXG NNP O
mice NNS O
. . O
null null null-Disease
p53 NN O
inhibition NN O
blocked VBD O
transient JJ O
DOX NNP O
- HYPH O
induced VBN O
STAT3 NNP O
activation NN O
in IN O
MHC NNP O
- HYPH O
CB7 NNP O
mice NNS O
, , O
which WDT O
was VBD O
associated VBN O
with IN O
enhanced VBN O
induction NN O
of IN O
the DT O
DNA NNP O
repair NN O
proteins NNS O
Ku70 NNP O
and CC O
Ku80 NNP O
. . O
null null null-Disease
Mice NNS O
with IN O
cardiomyocyte NN O
- HYPH O
restricted VBN O
deletion NN O
of IN O
STAT3 NNP O
exhibited VBD O
worse JJR O
cardiac JJ O
function NN O
, , O
higher JJR O
levels NNS O
of IN O
cardiomyocyte NN O
apoptosis NN O
, , O
and CC O
a DT O
greater JJR O
induction NN O
of IN O
Ku70 NNP O
and CC O
Ku80 NNP O
in IN O
response NN O
to IN O
DOX NNP O
treatment NN O
during IN O
the DT O
acute JJ O
stage NN O
when WRB O
compared VBN O
with IN O
control NN O
animals NNS O
. . O
null null null-Disease
CONCLUSION NN O
: : O
These DT O
data NNS O
support VBP O
a DT O
model NN O
wherein WRB O
a DT O
p53 NN O
- HYPH O
dependent JJ O
cardioprotective JJ O
pathway NN O
, , O
mediated VBN O
via IN O
STAT3 NNP O
activation NN O
, , O
mitigates VBZ O
DOX NNP O
- HYPH O
induced VBN O
myocardial JJ O
stress NN O
during IN O
drug NN O
delivery NN O
. . O
null null null-Disease
Furthermore RB O
, , O
these DT O
data NNS O
suggest VBP O
an DT O
explanation NN O
as IN O
to IN O
how WRB O
p53 NN O
inhibition NN O
can MD O
result VB O
in IN O
cardioprotection NN O
during IN O
drug NN O
treatment NN O
and CC O
, , O
paradoxically RB O
, , O
enhanced VBN O
cardiotoxicity NN B-Disease
long RB O
after IN O
the DT O
cessation NN O
of IN O
drug NN O
treatment NN O
. . O
null null null-Disease
Metronidazole NNP O
- HYPH O
induced VBN O
encephalopathy NN B-Disease
: : O
an DT O
uncommon JJ O
scenario NN O
. . O
null null null-Disease
Metronidazole NNP O
can MD O
produce VB O
neurological JJ O
complications NNS O
although IN O
it PRP O
is VBZ O
not RB O
a DT O
common JJ O
scenario NN O
. . O
null null null-Disease
We PRP O
present VBP O
a DT O
case NN O
where WRB O
a DT O
patient NN O
developed VBD O
features NNS O
of IN O
encephalopathy NN B-Disease
following VBG O
prolonged VBN O
metronidazole NN O
intake NN O
. . O
null null null-Disease
Magnetic JJ O
resonance NN O
imaging NN O
( -LRB- O
MRI NNP O
) -RRB- O
brain NN O
showed VBD O
abnormal JJ O
signal NN O
intensity NN O
involving VBG O
both DT O
dentate NN O
nuclei NNS O
of IN O
cerebellum NN O
and CC O
splenium NN O
of IN O
corpus NN O
callosum NN O
. . O
null null null-Disease
The DT O
diagnosis NN O
of IN O
metronidazole NN O
toxicity NN B-Disease
was VBD O
made VBN O
by IN O
the DT O
MRI NNP O
findings NNS O
and CC O
supported VBN O
clinically RB O
. . O
null null null-Disease
Aconitine NN O
- HYPH O
induced VBN O
Ca2 NN O
+ SYM O
overload NN O
causes VBZ O
arrhythmia NN B-Disease
and CC O
triggers VBZ O
apoptosis NN O
through IN O
p38 NN O
MAPK NNP O
signaling NN O
pathway NN O
in IN O
rats NNS O
. . O
null null null-Disease
Aconitine NNP O
is VBZ O
a DT O
major JJ O
bioactive JJ O
diterpenoid NN O
alkaloid NN O
with IN O
high JJ O
content NN O
derived VBN O
from IN O
herbal JJ O
aconitum NN O
plants NNS O
. . O
null null null-Disease
Emerging VBG O
evidence NN O
indicates VBZ O
that IN O
voltage NN O
- HYPH O
dependent JJ O
Na NNP O
( , O
+ CC O
) -RRB- O
channels NNS O
have VBP O
pivotal JJ O
roles NNS O
in IN O
the DT O
cardiotoxicity NN B-Disease
of IN O
aconitine NN O
. . O
null null null-Disease
However RB O
, , O
no DT O
reports NNS O
are VBP O
available JJ O
on IN O
the DT O
role NN O
of IN O
Ca NN O
( SYM O
2 CD O
+ SYM O
) -RRB- O
in IN O
aconitine NN O
poisoning NN B-Disease
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
we PRP O
explored VBD O
the DT O
importance NN O
of IN O
pathological JJ O
Ca NN O
( , O
2 CD O
+ NFP O
) -RRB- O
signaling VBG O
in IN O
aconitine NN O
poisoning NN B-Disease
in IN O
vitro FW O
and CC O
in IN O
vivo NN O
. . O
null null null-Disease
We PRP O
found VBD O
that IN O
Ca NN O
( SYM O
2 CD O
+ SYM O
) -RRB- O
overload JJ O
lead NN O
to IN O
accelerated VBN O
beating VBG O
rhythm NN O
in IN O
adult NN O
rat NN O
ventricular JJ O
myocytes NNS O
and CC O
caused VBD O
arrhythmia NN B-Disease
in IN O
conscious JJ O
freely RB O
moving VBG O
rats NNS O
. . O
null null null-Disease
To TO O
investigate VB O
effects NNS O
of IN O
aconitine NN O
on IN O
myocardial JJ B-Disease
injury NN I-Disease
, , O
we PRP O
performed VBD O
cytotoxicity NN B-Disease
assay NN O
in IN O
neonatal JJ O
rat NN O
ventricular JJ O
myocytes NNS O
( , O
NRVMs NNP O
) -RRB- O
, , O
as RB O
well RB O
as IN O
measured VBN O
lactate NN O
dehydrogenase NN O
level NN O
in IN O
the DT O
culture NN O
medium NN O
of IN O
NRVMs NNS O
and CC O
activities NNS O
of IN O
serum NN O
cardiac JJ O
enzymes NNS O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
results NNS O
showed VBD O
that IN O
aconitine NN O
resulted VBD O
in IN O
myocardial JJ B-Disease
injury NN I-Disease
and CC O
reduced VBN O
NRVMs NNP O
viability NN O
dose NN O
- HYPH O
dependently RB O
. . O
null null null-Disease
To TO O
confirm VB O
the DT O
pro JJ O
- HYPH O
apoptotic JJ O
effects NNS O
, , O
we PRP O
performed VBD O
flow NN O
cytometric JJ O
detection NN O
, , O
cardiac JJ O
histology NN O
, , O
transmission NN O
electron NN O
microscopy NN O
and CC O
terminal JJ O
deoxynucleotidyl NN O
transferase NN O
- HYPH O
mediated VBN O
dUTP NN O
- HYPH O
biotin NN O
nick NN O
end NN O
labeling NN O
assay NN O
. . O
null null null-Disease
The DT O
results NNS O
showed VBD O
that IN O
aconitine NN O
stimulated VBD O
apoptosis NN O
time NN O
- : O
dependently RB O
. . O
null null null-Disease
The DT O
expression NN O
analysis NN O
of IN O
Ca NN O
( SYM O
2 CD O
+ SYM O
) -RRB- O
handling NN O
proteins NNS O
demonstrated VBD O
that IN O
aconitine NN O
promoted VBD O
Ca NN O
( , O
2 CD O
+ SYM O
) -RRB- O
overload RB O
through IN O
the DT O
expression NN O
regulation NN O
of IN O
Ca NN O
( , O
2 CD O
+ SYM O
) -RRB- O
handling NN O
proteins NNS O
. . O
null null null-Disease
The DT O
expression NN O
analysis NN O
of IN O
apoptosis NN O
- HYPH O
related VBN O
proteins NNS O
revealed VBD O
that IN O
pro JJ O
- HYPH O
apoptotic JJ O
protein NN O
expression NN O
was VBD O
upregulated VBN O
, , O
and CC O
anti JJ O
- HYPH O
apoptotic JJ O
protein NN O
BCL NNP O
- HYPH O
2 CD O
expression NN O
was VBD O
downregulated VBN O
. . O
null null null-Disease
Furthermore RB O
, , O
increased VBN O
phosphorylation NN O
of IN O
MAPK NNP O
family NN O
members NNS O
, , O
especially RB O
the DT O
P NNP O
- HYPH O
P38 NNP O
/ SYM O
P38 NN O
ratio NN O
was VBD O
found VBN O
in IN O
cardiac JJ O
tissues NNS O
. . O
null null null-Disease
Hence RB O
, , O
our PRP$ O
results NNS O
suggest VBP O
that IN O
aconitine NN O
significantly RB O
aggravates VBZ O
Ca NN O
( , O
2 CD O
+ CC O
) -RRB- O
overload NN O
and CC O
causes VBZ O
arrhythmia NN B-Disease
and CC O
finally RB O
promotes VBZ O
apoptotic JJ O
development NN O
via IN O
phosphorylation NN O
of IN O
P38 NN O
mitogen NN O
- HYPH O
activated VBN O
protein NN O
kinase NN O
. . O
null null null-Disease
Chronic JJ O
treatment NN O
with IN O
metformin NN O
suppresses VBZ O
toll NN O
- HYPH O
like JJ O
receptor NN O
4 CD O
signaling NN O
and CC O
attenuates VBZ O
left VBN B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
following VBG O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
Acute JJ O
treatment NN O
with IN O
metformin NN O
has VBZ O
a DT O
protective JJ O
effect NN O
in IN O
myocardial JJ B-Disease
infarction NN I-Disease
by IN O
suppression NN O
of IN O
inflammatory JJ O
responses NNS O
due IN O
to IN O
activation NN O
of IN O
AMP NN O
- HYPH O
activated VBN O
protein NN O
kinase NN O
( , O
AMPK NNP O
) -RRB- O
. . O
null null null-Disease
In IN O
the DT O
present JJ O
study NN O
, , O
the DT O
effect NN O
of IN O
chronic JJ O
pre NN O
- HYPH O
treatment NN O
with IN O
metformin NN O
on IN O
cardiac JJ B-Disease
dysfunction NN I-Disease
and CC O
toll NN O
- HYPH O
like JJ O
receptor NN O
4 CD O
( , O
TLR4 NNP O
) -RRB- O
activities NNS O
following VBG O
myocardial JJ B-Disease
infarction NN I-Disease
and CC O
their PRP$ O
relation NN O
with IN O
AMPK NNP O
were VBD O
assessed VBN O
. . O
null null null-Disease
Male JJ O
Wistar NNP O
rats NNS O
were VBD O
randomly RB O
assigned VBN O
to IN O
one CD O
of IN O
5 CD O
groups NNS O
( , O
n CD O
= SYM O
6 CD O
) -RRB- O
: : O
normal JJ O
control NN O
and CC O
groups NNS O
were VBD O
injected VBN O
isoproterenol NN O
after IN O
chronic JJ O
pre NN O
- HYPH O
treatment NN O
with IN O
0 CD O
, , O
25 CD O
, , O
50 CD O
, , O
or CC O
100mg CD O
/ SYM O
kg NNS O
of IN O
metformin NN O
twice RB O
daily RB O
for IN O
14 CD O
days NNS O
. . O
null null null-Disease
Isoproterenol NNP O
( -LRB- O
100mg CD O
/ SYM O
kg NN O
) -RRB- O
was VBD O
injected VBN O
subcutaneously RB O
on IN O
the DT O
13th JJ O
and CC O
14th JJ O
days NNS O
to TO O
induce VB O
acute JJ B-Disease
myocardial JJ I-Disease
infarction NN I-Disease
. . O
null null null-Disease
Isoproterenol NNP O
alone RB O
decreased VBD O
left VBN O
ventricular JJ O
systolic JJ O
pressure NN O
and CC O
myocardial JJ O
contractility NN O
indexed VBN O
as IN O
LVdp NNP O
/ SYM O
dtmax NN O
and CC O
LVdp NNP O
/ SYM O
dtmin NN O
. . O
null null null-Disease
The DT O
left JJ B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
was VBD O
significantly RB O
lower JJR O
in IN O
the DT O
groups NNS O
treated VBN O
with IN O
25 CD O
and CC O
50mg CD O
/ SYM O
kg NNS O
of IN O
metformin NN O
. . O
null null null-Disease
Metfromin NNP O
markedly RB O
lowered VBD O
isoproterenol NN O
- HYPH O
induced VBN O
elevation NN O
in IN O
the DT O
levels NNS O
of IN O
TLR4 NNP O
mRNA NNP O
, , O
myeloid NN O
differentiation NN O
protein NN O
88 CD O
( , O
MyD88 NNP O
) -RRB- O
, , O
tumor NN B-Disease
necrosis NN B-Disease
factor NN O
- HYPH O
alpha NN O
( , O
TNF NNP O
- HYPH O
a NN O
) -RRB- O
, , O
and CC O
interleukin NN O
6 CD O
( , O
IL NN O
- HYPH O
6 CD O
) -RRB- O
in IN O
the DT O
heart NN O
tissues NNS O
. . O
null null null-Disease
Similar JJ O
changes NNS O
were VBD O
also RB O
seen VBN O
in IN O
the DT O
serum NN O
levels NNS O
of IN O
TNF NNP O
- HYPH O
a DT O
and CC O
IL NN O
- HYPH O
6 CD O
. . O
null null null-Disease
However RB O
, , O
the DT O
lower JJR O
doses NNS O
of IN O
25 CD O
and CC O
50mg CD O
/ SYM O
kg NNS O
were VBD O
more RBR O
effective JJ O
than IN O
100mg CD O
/ SYM O
kg NN O
. . O
null null null-Disease
Phosphorylated JJ O
AMPKa NNP O
( , O
p NN O
- HYPH O
AMPK NNP O
) -RRB- O
in IN O
the DT O
myocardium NN O
was VBD O
significantly RB O
elevated VBN O
by IN O
25mg CD O
/ SYM O
kg NNS O
of IN O
metformin NN O
, , O
slightly RB O
by IN O
50mg CD O
/ SYM O
kg NN O
, , O
but CC O
not RB O
by IN O
100mg CD O
/ SYM O
kg NN O
. . O
null null null-Disease
Chronic JJ O
pre NN O
- HYPH O
treatment NN O
with IN O
metformin NN O
reduces VBZ O
post NN O
- HYPH O
myocardial JJ B-Disease
infarction NN I-Disease
cardiac JJ O
dysfunction NN O
and CC O
suppresses VBZ O
inflammatory JJ O
responses NNS O
, , O
possibly RB O
through IN O
inhibition NN O
of IN O
TLR4 NNP O
activities NNS O
. . O
null null null-Disease
This DT O
mechanism NN O
can MD O
be VB O
considered VBN O
as IN O
a DT O
target NN O
to TO O
protect VB O
infarcted JJ O
myocardium NN O
. . O
null null null-Disease
Unusual JJ O
complications NNS O
of IN O
antithyroid JJ O
drug NN O
therapy NN O
: : O
four CD O
case NN O
reports NNS O
and CC O
review NN O
of IN O
literature NN O
. . O
null null null-Disease
Two CD O
cases NNS O
of IN O
propylthiouracil NN O
- HYPH O
associated VBN O
acute JJ O
hepatitis NN B-Disease
, , O
one CD O
case NN O
of IN O
fatal JJ O
methimazole NN O
- HYPH O
associated VBN O
hepatocellular JJ B-Disease
necrosis NN I-Disease
and CC O
one CD O
case NN O
of IN O
propylthiouracil NN O
- HYPH O
associated VBN O
lupus NN B-Disease
- HYPH I-Disease
like JJ I-Disease
syndrome NN I-Disease
are VBP O
described VBN O
. . O
null null null-Disease
The DT O
literature NN O
related VBN O
to IN O
antithyroid JJ O
drug NN O
side NN O
effects NNS O
and CC O
the DT O
mechanisms NNS O
for IN O
their PRP$ O
occurrence NN O
are VBP O
reviewed VBN O
and CC O
the DT O
efficacy NN O
and CC O
complications NNS O
of IN O
thyroidectomy NN O
and CC O
radioiodine NN O
compared VBN O
to IN O
those DT O
of IN O
antithyroid JJ O
drugs NNS O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
in IN O
most JJS O
circumstances NNS O
131I NNP O
is VBZ O
the DT O
therapy NN O
of IN O
choice NN O
for IN O
hyperthyroidism NN B-Disease
. . O
null null null-Disease
Neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
induced VBN O
by IN O
combination NN O
therapy NN O
with IN O
tetrabenazine NN O
and CC O
tiapride NN O
in IN O
a DT O
Japanese JJ O
patient NN O
with IN O
Huntington NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
at IN O
the DT O
terminal JJ O
stage NN O
of IN O
recurrent JJ O
breast NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
We PRP O
herein RB O
describe VBP O
the DT O
case NN O
of IN O
an DT O
81 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
Japanese JJ O
woman NN O
with IN O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
that WDT O
occurred VBD O
36 CD O
days NNS O
after IN O
the DT O
initiation NN O
of IN O
combination NN O
therapy NN O
with IN O
tiapride NN O
( , O
75 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
and CC O
tetrabenazine NN O
( SYM O
12 CD O
. . O
5 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
for IN O
Huntington NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
The DT O
patient NN O
had VBD O
been VBN O
treated VBN O
with IN O
tiapride NN O
or CC O
tetrabenazine NN O
alone RB O
without IN O
any DT O
adverse JJ O
effects NNS O
before IN O
the DT O
administration NN O
of IN O
the DT O
combination NN O
therapy NN O
. . O
null null null-Disease
She PRP O
also RB O
had VBD O
advanced JJ O
breast NN B-Disease
cancer NN I-Disease
when WRB O
the DT O
combination NN O
therapy NN O
was VBD O
initiated VBN O
. . O
null null null-Disease
To IN O
the DT O
best JJS O
of IN O
our PRP$ O
knowledge NN O
, , O
the DT O
occurrence NN O
of IN O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
due IN O
to IN O
combination NN O
therapy NN O
with IN O
tetrabenazine NN O
and CC O
tiapride NN O
has VBZ O
not RB O
been VBN O
previously RB O
reported VBN O
. . O
null null null-Disease
Tetrabenazine NNP O
should MD O
be VB O
administered VBN O
very RB O
carefully RB O
in IN O
combination NN O
with IN O
other JJ O
neuroleptic JJ O
drugs NNS O
, , O
particularly RB O
in IN O
patients NNS O
with IN O
a DT O
worsening VBG O
general JJ O
condition NN O
. . O
null null null-Disease
A DT O
metoprolol NN O
- HYPH O
terbinafine NN O
combination NN O
induced VBD O
bradycardia NN B-Disease
. . O
null null null-Disease
To TO O
report VB O
a DT O
sinus NN B-Disease
bradycardia NN I-Disease
induced VBN O
by IN O
metoprolol NN O
and CC O
terbinafine NN O
drug NN O
- HYPH O
drug NN O
interaction NN O
and CC O
its PRP$ O
management NN O
. . O
null null null-Disease
A DT O
63 CD O
year NN O
- HYPH O
old JJ O
Caucasian JJ O
man NN O
on IN O
metoprolol NN O
200 CD O
mg NN O
/ SYM O
day NN O
for IN O
stable JJ O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
was VBD O
prescribed VBN O
a DT O
90 CD O
- HYPH O
day NN O
course NN O
of IN O
oral JJ O
terbinafine NN O
250 CD O
mg NN O
/ SYM O
day NN O
for IN O
onychomycosis NN B-Disease
. . O
null null null-Disease
On IN O
the DT O
49th JJ O
day NN O
of IN O
terbinafine NN O
therapy NN O
, , O
he PRP O
was VBD O
brought VBN O
to IN O
the DT O
emergency NN O
room NN O
for IN O
a DT O
decrease NN O
of IN O
his PRP$ O
global JJ O
health NN O
status NN O
, , O
confusion NN B-Disease
and CC O
falls NNS O
. . O
null null null-Disease
The DT O
electrocardiogram NN O
revealed VBD O
a DT O
37 CD O
beats NNS O
/ SYM O
min NN O
sinus NN B-Disease
bradycardia NN I-Disease
. . O
null null null-Disease
A DT O
score NN O
of IN O
7 CD O
on IN O
the DT O
Naranjo NNP O
adverse JJ B-Disease
drug NN I-Disease
reaction NN I-Disease
probability NN O
scale NN O
indicates VBZ O
a DT O
probable JJ O
relationship NN O
between IN O
the DT O
patient NN O
' POS O
s NNS O
sinus NN B-Disease
bradycardia NN I-Disease
and CC O
the DT O
drug NN O
interaction NN O
between IN O
metoprolol NN O
and CC O
terbinafine NN O
. . O
null null null-Disease
The DT O
heart NN O
rate NN O
ameliorated VBD O
first RB O
with IN O
a DT O
decrease NN O
in IN O
the DT O
dose NN O
of IN O
metoprolol NN O
. . O
null null null-Disease
It PRP O
was VBD O
subsequently RB O
changed VBN O
to IN O
bisoprolol NN O
and CC O
the DT O
heart NN O
rate NN O
remained VBD O
normal JJ O
. . O
null null null-Disease
By IN O
inhibiting VBG O
the DT O
cytochrome NN O
P450 NN O
2D6 CD O
, , O
terbinafine NN O
had VBD O
decreased VBN O
metoprolol NN O
' '' O
s NNS O
clearance NN O
, , O
leading VBG O
in IN O
metoprolol NN O
accumulation NN O
which WDT O
has VBZ O
resulted VBN O
in IN O
clinically RB O
significant JJ O
sinus NN B-Disease
bradycardia NN I-Disease
. . O
null null null-Disease
Optochiasmatic JJ O
and CC O
peripheral JJ B-Disease
neuropathy NN I-Disease
due IN O
to IN O
ethambutol NN O
overtreatment NN O
. . O
null null null-Disease
Ethambutol NNP O
is VBZ O
known VBN O
to TO O
cause VB O
optic JJ B-Disease
neuropathy NN I-Disease
and CC O
, , O
more RBR O
rarely RB O
, , O
axonal JJ O
polyneuropathy NN B-Disease
. . O
null null null-Disease
We PRP O
characterize VBP O
the DT O
clinical JJ O
, , O
neurophysiological JJ O
, , O
and CC O
neuroimaging NN O
findings NNS O
in IN O
a DT O
72 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
who WP O
developed VBD O
visual JJ B-Disease
loss NN I-Disease
and CC O
paresthesias NNS B-Disease
after IN O
11 CD O
weeks NNS O
of IN O
exposure NN O
to IN O
a DT O
supratherapeutic JJ O
dose NN O
of IN O
ethambutol NN O
. . O
null null null-Disease
This DT O
case NN O
demonstrates VBZ O
the DT O
selective JJ O
vulnerability NN O
of IN O
the DT O
anterior JJ O
visual JJ O
pathways NNS O
and CC O
peripheral JJ O
nerves NNS O
to IN O
ethambutol NN O
toxicity NN B-Disease
. . O
null null null-Disease
Testosterone NN O
ameliorates VBZ O
streptozotocin NN O
- HYPH O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
in IN O
male JJ O
rats NNS O
. . O
null null null-Disease
AIM NN O
: : O
To TO O
study VB O
the DT O
effects NNS O
of IN O
testosterone NN O
on IN O
streptozotocin NN O
( , O
STZ NNP O
) -RRB- O
- HYPH O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
in IN O
male JJ O
rats NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
Adult NN O
male JJ O
Wistar NNP O
rats NNS O
were VBD O
intracerebroventricularly RB O
( , O
icv NN O
) -RRB- O
infused VBN O
with IN O
STZ NNP O
( : O
750 CD O
ug NNS O
) -RRB- O
on IN O
d NN O
1 CD O
and CC O
d CD O
3 CD O
, , O
and CC O
a DT O
passive JJ O
avoidance NN O
task NN O
was VBD O
assessed VBN O
2 CD O
weeks NNS O
after IN O
the DT O
first JJ O
injection NN O
of IN O
STZ NNP O
. . O
null null null-Disease
Castration NN O
surgery NN O
was VBD O
performed VBN O
in IN O
another DT O
group NN O
of IN O
rats NNS O
, , O
and CC O
the DT O
passive JJ O
avoidance NN O
task NN O
was VBD O
assessed VBN O
4 CD O
weeks NNS O
after IN O
the DT O
operation NN O
. . O
null null null-Disease
Testosterone NN O
( : O
1 CD O
mg NN O
. . O
kg NN O
( HYPH O
- HYPH O
1 CD O
) NFP O
. . O
d CD O
( SYM O
- HYPH O
1 CD O
) -RRB- O
, , O
sc NN O
) -RRB- O
, , O
the DT O
androgen NN O
receptor NN O
antagonist NN O
flutamide NN O
( , O
10 CD O
mg NN O
. . O
kg NN O
( HYPH O
- HYPH O
1 CD O
) NFP O
. , O
d NN O
( SYM O
- HYPH O
1 CD O
) -RRB- O
, , O
ip NN O
) -RRB- O
, , O
the DT O
estrogen NN O
receptor NN O
antagonist NN O
tamoxifen NN O
( : O
1 CD O
mg NN O
. . O
kg NN O
( HYPH O
- HYPH O
1 CD O
) NFP O
. , O
d NN O
( SYM O
- HYPH O
1 CD O
) -RRB- O
, , O
ip NN O
) -RRB- O
or CC O
the DT O
aromatase NN O
inhibitor NN O
letrozole NN O
( : O
4 CD O
mg NN O
. . O
kg NN O
( HYPH O
- HYPH O
1 CD O
) -RRB- O
. , O
d CD O
( SYM O
- HYPH O
1 CD O
) -RRB- O
, , O
ip NN O
) -RRB- O
were VBD O
administered VBN O
for IN O
6 CD O
d NN O
after IN O
the DT O
first JJ O
injection NN O
of IN O
STZ NNP O
. . O
null null null-Disease
RESULTS NNS O
: : O
STZ NNP O
administration NN O
and CC O
castration NN O
markedly RB O
decreased VBD O
both DT O
STL1 NNP O
( , O
the DT O
short JJ O
memory NN O
) -RRB- O
and CC O
STL2 NNP O
( , O
the DT O
long JJ O
memory NN O
) -RRB- O
in IN O
passive JJ O
avoidance NN O
tests NNS O
. . O
null null null-Disease
Testosterone NN O
replacement NN O
almost RB O
restored VBD O
the DT O
STL1 NN O
and CC O
STL2 NN O
in IN O
castrated JJ O
rats NNS O
, , O
and CC O
significantly RB O
prolonged VBD O
the DT O
STL1 NNP O
and CC O
STL2 NN O
in IN O
STZ NNP O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
Administration NN O
of IN O
flutamide NN O
, , O
letrozole NN O
or CC O
tamoxifen NN O
significantly RB O
impaired VBD B-Disease
the DT I-Disease
memory NN I-Disease
in IN O
intact JJ O
rats NNS O
, , O
and CC O
significantly RB O
attenuated VBD O
the DT O
testosterone NN O
replacement NN O
in IN O
improving VBG O
STZ NN O
- HYPH O
and CC O
castration NN O
- HYPH O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
Testosterone NN O
administration NN O
ameliorates VBZ O
STZ NNP O
- HYPH O
and CC O
castration NN O
- HYPH O
induced VBN O
memory NN B-Disease
impairment NN I-Disease
in IN O
male JJ O
Wistar NNP O
rats NNS O
. . O
null null null-Disease
Behavioral JJ O
and CC O
neurochemical JJ O
studies NNS O
in IN O
mice NNS O
pretreated VBN O
with IN O
garcinielliptone NN O
FC NNP O
in IN O
pilocarpine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
. . O
null null null-Disease
Garcinielliptone NNP O
FC NNP O
( : O
GFC NNP O
) -RRB- O
isolated VBN O
from IN O
hexanic JJ O
fraction NN O
seed NN O
extract NN O
of IN O
species NNS O
Platonia NNP O
insignis NN O
Mart NNP O
. . O
null null null-Disease
It PRP O
is VBZ O
widely RB O
used VBN O
in IN O
folk NN O
medicine NN O
to TO O
treat VB O
skin NN B-Disease
diseases NNS I-Disease
in IN O
both CC O
humans NNS O
and CC O
animals NNS O
as RB O
well RB O
as IN O
the DT O
seed NN O
decoction NN O
has VBZ O
been VBN O
used VBN O
to TO O
treat VB O
diarrheas NNS B-Disease
and CC O
inflammatory JJ B-Disease
diseases NNS I-Disease
. . O
null null null-Disease
However RB O
, , O
there EX O
is VBZ O
no DT O
research NN O
on IN O
GFC NNP O
effects NNS O
in IN O
the DT O
central JJ O
nervous JJ O
system NN O
of IN O
rodents NNS O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
aimed VBD O
to TO O
evaluate VB O
the DT O
GFC NNP O
effects NNS O
at IN O
doses NNS O
of IN O
25 CD O
, , O
50 CD O
or CC O
75 CD O
mg NNS O
/ SYM O
kg NN O
on IN O
seizure NN B-Disease
parameters NNS O
to TO O
determine VB O
their PRP$ O
anticonvulsant JJ O
activity NN O
and CC O
its PRP$ O
effects NNS O
on IN O
amino NN O
acid NN O
( , O
r NN O
- HYPH O
aminobutyric JJ O
acid NN O
( -LRB- O
GABA NNP O
) -RRB- O
, , O
glutamine NN O
, , O
aspartate NN O
and CC O
glutathione NN O
) , O
levels NNS O
as RB O
well RB O
as IN O
on IN O
acetylcholinesterase NN O
( , O
AChE NN O
) -RRB- O
activity NN O
in IN O
mice NNS O
hippocampus NN O
after IN O
seizures NNS B-Disease
. . O
null null null-Disease
GFC NNP O
produced VBD O
an DT O
increased JJ O
latency NN O
to IN O
first JJ O
seizure NN B-Disease
, , O
at IN O
doses NNS O
25mg CD O
/ SYM O
kg CD O
( SYM O
20 CD O
. . O
12 CD O
+ SYM O
2 CD O
. . O
20 CD O
min NN O
) CD O
, , O
50mg CD O
/ SYM O
kg CD O
( SYM O
20 CD O
. . O
95 CD O
+ SYM O
2 CD O
. . O
21 CD O
min NN O
) CD O
or CC O
75 CD O
mg CD O
/ SYM O
kg CD O
( SYM O
23 CD O
. . O
43 CD O
+ SYM O
1 CD O
. . O
99 CD O
min NN O
) , O
when WRB O
compared VBN O
with IN O
seized VBN O
mice NNS O
. . O
null null null-Disease
In IN O
addition NN O
, , O
GABA NNP O
content NN O
of IN O
mice NN O
hippocampus NN O
treated VBN O
with IN O
GFC75 NNP O
plus CC O
P400 NNP O
showed VBD O
an DT O
increase NN O
of IN O
46 CD O
. . O
90 CD O
% NN O
when WRB O
compared VBN O
with IN O
seized VBN O
mice NNS O
. . O
null null null-Disease
In IN O
aspartate NN O
, , O
glutamine NN O
and CC O
glutamate NN O
levels NNS O
detected VBD O
a DT O
decrease NN O
of IN O
5 CD O
. . O
21 CD O
% NN O
, , O
13 CD O
. . O
55 CD O
% NN O
and CC O
21 CD O
. . O
80 CD O
% NN O
, , O
respectively RB O
in IN O
mice NN O
hippocampus NN O
treated VBN O
with IN O
GFC75 NNP O
plus CC O
P400 NNP O
when WRB O
compared VBN O
with IN O
seized VBN O
mice NNS O
. . O
null null null-Disease
Hippocampus NNP O
mice NNS O
treated VBN O
with IN O
GFC75 NNP O
plus CC O
P400 NNP O
showed VBD O
an DT O
increase NN O
in IN O
AChE NNP O
activity NN O
( : O
63 CD O
. . O
30 CD O
% NN O
) -RRB- O
when WRB O
compared VBN O
with IN O
seized VBN O
mice NNS O
. . O
null null null-Disease
The DT O
results NNS O
indicate VBP O
that IN O
GFC NNP O
can MD O
exert VB O
anticonvulsant JJ O
activity NN O
and CC O
reduce VB O
the DT O
frequency NN O
of IN O
installation NN O
of IN O
pilocarpine NN O
- HYPH O
induced VBN O
status NN B-Disease
epilepticus NN I-Disease
, , O
as IN O
demonstrated VBN O
by IN O
increase NN O
in IN O
latency NN O
to IN O
first JJ O
seizure NN B-Disease
and CC O
decrease NN O
in IN O
mortality NN O
rate NN O
of IN O
animals NNS O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
our PRP$ O
data NNS O
suggest VBP O
that IN O
GFC NNP O
may MD O
influence VB O
in IN O
epileptogenesis NN O
and CC O
promote VB O
anticonvulsant JJ O
actions NNS O
in IN O
pilocarpine NN O
model NN O
by IN O
modulating VBG O
the DT O
GABA NNP O
and CC O
glutamate NN O
contents NNS O
and CC O
of IN O
AChE NN O
activity NN O
in IN O
seized VBN O
mice NN O
hippocampus NN O
. . O
null null null-Disease
This DT O
compound NN O
may MD O
be VB O
useful JJ O
to TO O
produce VB O
neuronal JJ O
protection NN O
and CC O
it PRP O
can MD O
be VB O
considered VBN O
as IN O
an DT O
anticonvulsant JJ O
agent NN O
. . O
null null null-Disease
Standard JJ O
operating NN O
procedures NNS O
for IN O
antibiotic JJ O
therapy NN O
and CC O
the DT O
occurrence NN O
of IN O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
: : O
a DT O
prospective JJ O
, , O
clinical JJ O
, , O
non JJ O
- HYPH O
interventional JJ O
, , O
observational JJ O
study NN O
. . O
null null null-Disease
INTRODUCTION NN O
: : O
Acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
( : O
AKI NNP B-Disease
) -RRB- O
occurs VBZ O
in IN O
7 CD O
% NN O
of IN O
hospitalized VBN O
and CC O
66 CD O
% NN O
of IN O
Intensive NNP O
Care NNP O
Unit NNP O
( -LRB- O
ICU NNP O
) -RRB- O
patients NNS O
. . O
null null null-Disease
It PRP O
increases VBZ O
mortality NN O
, , O
hospital NN O
length NN O
of IN O
stay NN O
, , O
and CC O
costs NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
investigate VB O
, , O
whether IN O
there EX O
is VBZ O
an DT O
association NN O
between IN O
adherence NN O
to IN O
guidelines NNS O
( , O
standard JJ O
operating NN O
procedures NNS O
( , O
SOP NNP O
) -RRB- O
) , O
for IN O
potentially RB O
nephrotoxic JJ B-Disease
antibiotics NNS O
and CC O
the DT O
occurrence NN O
of IN O
AKI NNP B-Disease
. . O
null null null-Disease
METHODS NNS O
: : O
This DT O
study NN O
was VBD O
carried VBN O
out RP O
as IN O
a DT O
prospective JJ O
, , O
clinical JJ O
, , O
non RB O
- HYPH O
interventional JJ O
, , O
observational JJ O
study NN O
. . O
null null null-Disease
Data NN O
collection NN O
was VBD O
performed VBN O
over IN O
a DT O
total NN O
of IN O
170 CD O
days NNS O
in IN O
three CD O
ICUs NNS O
at IN O
Charite NNP O
- HYPH O
Universitaetsmedizin NNP O
Berlin NNP O
. . O
null null null-Disease
A DT O
total NN O
of IN O
675 CD O
patients NNS O
were VBD O
included VBN O
; : O
163 CD O
of IN O
these DT O
had VBD O
therapy NN O
with IN O
vancomycin NN O
, , O
gentamicin NN O
, , O
or CC O
tobramycin NN O
; : O
were VBD O
> SYM O
18 CD O
years NNS O
; : O
and CC O
treated VBN O
in IN O
the DT O
ICU NNP O
for IN O
> SYM O
24 CD O
hours NNS O
. . O
null null null-Disease
Patients NNS O
with IN O
an DT O
adherence NN O
to IN O
SOP NNP O
> SYM O
70 CD O
% NN O
were VBD O
classified VBN O
into IN O
the DT O
high JJ O
adherence NN O
group NN O
( -LRB- O
HAG NNP O
) -RRB- O
and CC O
patients NNS O
with IN O
an DT O
adherence NN O
of IN O
< $ O
70 CD O
% NN O
into IN O
the DT O
low JJ O
adherence NN O
group NN O
( -LRB- O
LAG NNP O
) -RRB- O
. . O
null null null-Disease
AKI NNP B-Disease
was VBD O
defined VBN O
according VBG O
to IN O
RIFLE NNP O
criteria NNS O
. . O
null null null-Disease
Adherence NN O
to IN O
SOPs NNPS O
was VBD O
evaluated VBN O
by IN O
retrospective JJ O
expert NN O
audit NN O
. . O
null null null-Disease
Development NN O
of IN O
AKI NNP B-Disease
was VBD O
compared VBN O
between IN O
groups NNS O
with IN O
exact JJ O
Chi2 NNP O
- HYPH O
test NN O
and CC O
multivariate NN O
logistic JJ O
regression NN O
analysis NN O
( , O
two CD O
- HYPH O
sided JJ O
P NN O
< SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
LAG NNP O
consisted VBD O
of IN O
75 CD O
patients NNS O
( : O
46 CD O
% NN O
) , O
versus IN O
88 CD O
HAG NNP O
patients NNS O
( : O
54 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
AKI NNP B-Disease
occurred VBD O
significantly RB O
more RBR O
often RB O
in IN O
LAG NNP O
with IN O
36 CD O
% NN O
versus IN O
21 CD O
% NN O
in IN O
HAG NNP O
( : O
P NN O
= SYM O
0 CD O
. . O
035 CD O
) -RRB- O
. . O
null null null-Disease
Basic JJ O
characteristics NNS O
were VBD O
comparable JJ O
, , O
except IN O
an DT O
increased JJ O
rate NN O
of IN O
soft JJ O
tissue NN O
infections NNS B-Disease
in IN O
LAG NNP O
. . O
null null null-Disease
Multivariate JJ O
analysis NN O
revealed VBD O
an DT O
odds NNS O
ratio NN O
of IN O
2 CD O
. . O
5 CD O
- HYPH O
fold NN O
for IN O
LAG NNP O
to TO O
develop VB O
AKI NNP B-Disease
compared VBN O
with IN O
HAG NNP O
( : O
95 CD O
% NN O
confidence NN O
interval NN O
1 CD O
. . O
195 CD O
to TO O
5 CD O
. . O
124 CD O
, , O
P NN O
= SYM O
0 CD O
. . O
039 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Low JJ O
adherence NN O
to IN O
SOPs NNS O
for IN O
potentially RB O
nephrotoxic JJ B-Disease
antibiotics NNS O
was VBD O
associated VBN O
with IN O
a DT O
higher JJR O
occurrence NN O
of IN O
AKI NNP B-Disease
. . O
null null null-Disease
TRIAL NN O
REGISTRATION NN O
: : O
Current JJ O
Controlled VBN O
Trials NNS O
ISRCTN54598675 NN O
. . O
null null null-Disease
Registered VBN O
17 CD O
August NNP O
2007 CD O
. . O
null null null-Disease
Rhabdomyolysis NNP B-Disease
in IN O
a DT O
hepatitis NN B-Disease
C NNP I-Disease
virus NN I-Disease
infected VBN I-Disease
patient NN O
treated VBN O
with IN O
telaprevir NN O
and CC O
simvastatin NN O
. . O
null null null-Disease
A DT O
46 CD O
- HYPH O
year NN O
old JJ O
man NN O
with IN O
a DT O
chronic JJ O
hepatitis NN B-Disease
C NNP I-Disease
virus NN I-Disease
infection NN I-Disease
received VBD O
triple JJ O
therapy NN O
with IN O
ribavirin NN O
, , O
pegylated VBN O
interferon NN O
and CC O
telaprevir NN O
. . O
null null null-Disease
The DT O
patient NN O
also RB O
received VBD O
simvastatin NN O
. . O
null null null-Disease
One CD O
month NN O
after IN O
starting VBG O
the DT O
antiviral JJ O
therapy NN O
, , O
the DT O
patient NN O
was VBD O
admitted VBN O
to IN O
the DT O
hospital NN O
because IN O
he PRP O
developed VBD O
rhabdomyolysis NN B-Disease
. . O
null null null-Disease
At IN O
admission NN O
simvastatin NN O
and CC O
all DT O
antiviral JJ O
drugs NNS O
were VBD O
discontinued VBN O
because IN O
toxicity NN B-Disease
due IN O
to IN O
a DT O
drug NN O
- HYPH O
drug NN O
interaction NN O
was VBD O
suspected VBN O
. . O
null null null-Disease
The DT O
creatine JJ O
kinase NN O
peaked VBD O
at IN O
62 CD O
, , O
246 CD O
IU NN O
/ SYM O
L NNP O
and CC O
the DT O
patient NN O
was VBD O
treated VBN O
with IN O
intravenous JJ O
normal JJ O
saline NN O
. . O
null null null-Disease
The DT O
patient NN O
' POS O
s NN O
renal JJ O
function NN O
remained VBD O
unaffected JJ O
. . O
null null null-Disease
Fourteen CD O
days NNS O
after IN O
hospitalization NN O
, , O
creatine JJ O
kinase NN O
level NN O
had VBD O
returned VBN O
to IN O
230 CD O
IU NNP O
/ SYM O
L NNP O
and CC O
the DT O
patient NN O
was VBD O
discharged VBN O
. . O
null null null-Disease
Telaprevir NNP O
was VBD O
considered VBN O
the DT O
probable JJ O
causative JJ O
agent NN O
of IN O
an DT O
interaction NN O
with IN O
simvastatin NN O
according VBG O
to IN O
the DT O
Drug NNP O
Interaction NNP O
Probability NNP O
Scale NNP O
. . O
null null null-Disease
The DT O
interaction NN O
is VBZ O
due JJ O
to IN O
inhibition NN O
of IN O
CYP3A4 NN O
- HYPH O
mediated VBN O
simvastatin NN O
clearance NN O
. . O
null null null-Disease
Simvastatin JJ O
plasma NN O
concentration NN O
increased VBD O
30 CD O
times NNS O
in IN O
this DT O
patient NN O
and CC O
statin NN O
induced VBN O
muscle NN B-Disease
toxicity NN I-Disease
is VBZ O
related VBN O
to IN O
the DT O
concentration NN O
of IN O
the DT O
statin NN O
in IN O
blood NN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
with IN O
this DT O
case NN O
we PRP O
illustrate VBP O
that IN O
telaprevir NN O
as RB O
well RB O
as IN O
statins NNS O
are VBP O
susceptible JJ O
to IN O
clinical JJ O
relevant JJ O
drug NN O
- HYPH O
drug NN O
interactions NNS O
. . O
null null null-Disease
Combination NN O
of IN O
bortezomib NN O
, , O
thalidomide NN O
, , O
and CC O
dexamethasone NN O
( , O
VTD NN O
) -RRB- O
as IN O
a DT O
consolidation NN O
therapy NN O
after IN O
autologous JJ O
stem NN O
cell NN O
transplantation NN O
for IN O
symptomatic JJ O
multiple JJ B-Disease
myeloma NN I-Disease
in IN O
Japanese JJ O
patients NNS O
. . O
null null null-Disease
Consolidation NN O
therapy NN O
for IN O
patients NNS O
with IN O
multiple JJ B-Disease
myeloma NN I-Disease
( -LRB- O
MM NN B-Disease
) -RRB- O
has VBZ O
been VBN O
widely RB O
adopted VBN O
to TO O
improve VB O
treatment NN O
response NN O
following VBG O
autologous JJ O
stem NN O
cell NN O
transplantation NN O
. . O
null null null-Disease
In IN O
this DT O
study NN O
, , O
we PRP O
retrospectively RB O
analyzed VBD O
the DT O
safety NN O
and CC O
efficacy NN O
of IN O
combination NN O
regimen NN O
of IN O
bortezomib NN O
, , O
thalidomide NN O
, , O
and CC O
dexamethasone NN O
( , O
VTD NN O
) -RRB- O
as IN O
consolidation NN O
therapy NN O
in IN O
24 CD O
Japanese JJ O
patients NNS O
with IN O
newly RB O
diagnosed VBN O
MM NNP B-Disease
. . O
null null null-Disease
VTD NNP O
consisted VBD O
of IN O
bortezomib NN O
at IN O
a DT O
dose NN O
of IN O
1 CD O
. . O
3 CD O
mg NN O
/ SYM O
m NN O
( SYM O
2 CD O
) -RRB- O
and CC O
dexamethasone NN O
at IN O
a DT O
dose NN O
of IN O
40 CD O
mg NNS O
/ SYM O
day NN O
on IN O
days NNS O
1 CD O
, , O
8 CD O
, , O
15 CD O
, , O
and CC O
22 CD O
of IN O
a DT O
35 CD O
- HYPH O
day NN O
cycle NN O
, , O
with IN O
daily JJ O
oral JJ O
thalidomide NN O
at IN O
a DT O
dose NN O
of IN O
100 CD O
mg NNS O
/ SYM O
day NN O
. . O
null null null-Disease
Grade NN O
3 CD O
- HYPH O
4 CD O
neutropenia NN B-Disease
and CC O
thrombocytopenia NN B-Disease
were VBD O
documented VBN O
in IN O
four CD O
and CC O
three CD O
patients NNS O
( : O
17 CD O
and CC O
13 CD O
% NN O
) -RRB- O
, , O
respectively RB O
, , O
but CC O
drug NN O
dose NN O
reduction NN O
due JJ O
to IN O
cytopenia NN B-Disease
was VBD O
not RB O
required VBN O
in IN O
any DT O
case NN O
. . O
null null null-Disease
Peripheral JJ B-Disease
neuropathy NN I-Disease
was VBD O
common JJ O
( : O
63 CD O
% NN O
) CD O
, , O
but CC O
severe JJ O
grade NN O
3 CD O
- SYM O
4 CD O
peripheral JJ B-Disease
neuropathy NN I-Disease
was VBD O
not RB O
observed VBN O
. . O
null null null-Disease
Very RB O
good JJ O
partial JJ O
response NN O
or CC O
better JJR O
response NN O
( : O
> NFP O
VGPR NNP O
) -RRB- O
rates NNS O
before IN O
and CC O
after IN O
consolidation NN O
therapy NN O
were VBD O
54 CD O
and CC O
79 CD O
% NN O
, , O
respectively RB O
. . O
null null null-Disease
Patients NNS O
had VBD O
a DT O
significant JJ O
probability NN O
of IN O
improving VBG O
from IN O
< IN O
VGPR NN O
before IN O
consolidation NN O
therapy NN O
to IN O
> XX O
VGPR NN O
after IN O
consolidation NN O
therapy NN O
( : O
p NN O
= SYM O
0 CD O
. . O
041 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
VTD NNP O
regimen NN O
may MD O
be VB O
safe JJ O
and CC O
effective JJ O
as IN O
a DT O
consolidation NN O
therapy NN O
in IN O
the DT O
treatment NN O
of IN O
MM NN O
in IN O
Japanese JJ O
population NN O
. . O
null null null-Disease
Conversion NN O
to IN O
sirolimus NN O
ameliorates VBZ O
cyclosporine NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
in IN O
the DT O
rat NN O
: : O
focus VB O
on IN O
serum NN O
, , O
urine NN O
, , O
gene NN O
, , O
and CC O
protein NN O
renal JJ O
expression NN O
biomarkers NNS O
. . O
null null null-Disease
Protocols NNS O
of IN O
conversion NN O
from IN O
cyclosporin NN O
A NNP O
( -LRB- O
CsA NNP O
) -RRB- O
to IN O
sirolimus NN O
( , O
SRL NNP O
) -RRB- O
have VBP O
been VBN O
widely RB O
used VBN O
in IN O
immunotherapy NN O
after IN O
transplantation NN O
to TO O
prevent VB O
CsA NNP O
- HYPH O
induced VBN O
nephropathy NN B-Disease
, , O
but CC O
the DT O
molecular JJ O
mechanisms NNS O
underlying VBG O
these DT O
protocols NNS O
remain VBP O
nuclear JJ O
. . O
null null null-Disease
This DT O
study NN O
aimed VBD O
to TO O
identify VB O
the DT O
molecular JJ O
pathways NNS O
and CC O
putative JJ O
biomarkers NNS O
of IN O
CsA NNP O
- HYPH O
to IN O
- HYPH O
SRL NN O
conversion NN O
in IN O
a DT O
rat NN O
model NN O
. . O
null null null-Disease
Four CD O
animal NN O
groups NNS O
( , O
n NN O
= SYM O
6 CD O
) -RRB- O
were VBD O
tested VBN O
during IN O
9 CD O
weeks NNS O
: : O
control NN O
, , O
CsA NNP O
, , O
SRL NNP O
, , O
and CC O
conversion NN O
( -LRB- O
CsA NNP O
for IN O
3 CD O
weeks NNS O
followed VBN O
by IN O
SRL NNP O
for IN O
6 CD O
weeks NNS O
) -RRB- O
. . O
null null null-Disease
Classical JJ O
and CC O
emergent JJ O
serum NN O
, , O
urinary JJ O
, , O
and CC O
kidney NN O
tissue NN O
( , O
gene NN O
and CC O
protein NN O
expression NN O
) -RRB- O
markers NNS O
were VBD O
assessed VBN O
. . O
null null null-Disease
Renal JJ B-Disease
lesions NNS I-Disease
were VBD O
analyzed VBN O
in IN O
hematoxylin NN O
and CC O
eosin NN O
, , O
periodic JJ O
acid NN O
- HYPH O
Schiff NNP O
, , O
and CC O
Masson NNP O
' POS O
s JJ O
trichrome NN O
stains NNS O
. . O
null null null-Disease
SRL NN O
- HYPH O
treated VBN O
rats NNS O
presented VBD O
proteinuria NN B-Disease
and CC O
NGAL NNP O
( , O
serum NN O
and CC O
urinary JJ O
) -RRB- O
as IN O
the DT O
best JJS O
markers NNS O
of IN O
renal JJ B-Disease
impairment NN I-Disease
. . O
null null null-Disease
Short JJ O
CsA NNP O
treatment NN O
presented VBD O
slight JJ O
or CC O
even RB O
absent JJ O
kidney NN B-Disease
lesions NNS I-Disease
and CC O
TGF NNP O
- HYPH O
b NN O
, , O
NF NNP O
- HYPH O
kb NNP O
, , O
mTOR NNP O
, , O
PCNA NNP O
, , O
TP53 NNP O
, , O
KIM NNP O
- HYPH O
1 CD O
, , O
and CC O
CTGF NNP O
as IN O
relevant JJ O
gene NN O
and CC O
protein NN O
changes NNS O
. . O
null null null-Disease
Prolonged VBN O
CsA NNP O
exposure NN O
aggravated VBD O
renal JJ B-Disease
damage NN I-Disease
, , O
without IN O
clear JJ O
changes NNS O
on IN O
the DT O
traditional JJ O
markers NNS O
, , O
but CC O
with IN O
changes NNS O
in IN O
serums NNS O
TGF NNP O
- HYPH O
b NN O
and CC O
IL NN O
- HYPH O
7 CD O
, , O
TBARs NNS O
clearance NN O
, , O
and CC O
kidney NN O
TGF NNP O
- HYPH O
b NN O
and CC O
mTOR NN O
. . O
null null null-Disease
Conversion NN O
to IN O
SRL NNP O
prevented VBD O
CsA NNP O
- HYPH O
induced VBN O
renal JJ B-Disease
damage NN I-Disease
evolution NN O
( , O
absent JJ O
/ SYM O
mild JJ O
grade NN O
lesions NNS O
) -RRB- O
, , O
while IN O
NGAL NNP O
( , O
serum NN O
versus IN O
urine NN O
) -RRB- O
seems VBZ O
to TO O
be VB O
a DT O
feasible JJ O
biomarker NN O
of IN O
CsA NNP O
replacement NN O
to IN O
SRL NNP O
. . O
null null null-Disease
Kinin NNP O
B2 NN O
receptor NN O
deletion NN O
and CC O
blockage NN O
ameliorates VBZ O
cisplatin NN O
- HYPH O
induced VBN O
acute JJ B-Disease
renal JJ I-Disease
injury NN I-Disease
. . O
null null null-Disease
Cisplatin NN O
treatment NN O
has VBZ O
been VBN O
adopted VBN O
in IN O
some DT O
chemotherapies NNS O
; : O
however RB O
, , O
this DT O
drug NN O
can MD O
induce VB O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
due IN O
its PRP$ O
ability NN O
to TO O
negatively RB O
affect VB O
renal JJ O
function NN O
, , O
augment VB O
serum NN O
levels NNS O
of IN O
creatinine NN O
and CC O
urea NN O
, , O
increase VB O
the DT O
acute JJ B-Disease
tubular JJ I-Disease
necrosis NN I-Disease
score NN O
and CC O
up IN O
- HYPH O
regulate VB O
cytokines NNS O
( : O
e LS O
. . O
g LS O
. . O
, , O
IL NN O
- HYPH O
1b NN O
and CC O
TNF NNP O
- HYPH O
a NN O
) -RRB- O
. . O
null null null-Disease
The DT O
kinin JJ O
B2 NN O
receptor NN O
has VBZ O
been VBN O
associated VBN O
with IN O
the DT O
inflammation NN B-Disease
process NN O
, , O
as RB O
well RB O
as IN O
the DT O
regulation NN O
of IN O
cytokine NN O
expression NN O
, , O
and CC O
its PRP$ O
deletion NN O
resulted VBD O
in IN O
an DT O
improvement NN O
in IN O
the DT O
diabetic JJ B-Disease
nephropathy NN I-Disease
status NN O
. . O
null null null-Disease
To TO O
examine VB O
the DT O
role NN O
of IN O
the DT O
kinin JJ O
B2 NN O
receptor NN O
in IN O
cisplatin NN O
- HYPH O
induced VBN O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
, , O
kinin JJ O
B2 NN O
receptor NN O
knockout NN O
mice NNS O
were VBD O
challenged VBN O
with IN O
cisplatin NN O
. . O
null null null-Disease
Additionally RB O
, , O
WT NNP O
mice NNS O
were VBD O
treated VBN O
with IN O
a DT O
B2 NNP O
receptor NN O
antagonist NN O
after IN O
cisplatin NN O
administration NN O
. . O
null null null-Disease
B2 NN O
receptor NN O
- HYPH O
deficient JJ O
mice NNS O
were VBD O
less RBR O
sensitive JJ O
to IN O
this DT O
drug NN O
than IN O
the DT O
WT NNP O
mice NN O
, , O
as IN O
shown VBN O
by IN O
reduced VBN O
weight NN B-Disease
loss NN I-Disease
, , O
better JJR O
preservation NN O
of IN O
kidney NN O
function NN O
, , O
down RB O
regulation NN O
of IN O
inflammatory JJ O
cytokines NNS O
and CC O
less RBR O
acute JJ B-Disease
tubular JJ I-Disease
necrosis NN I-Disease
. . O
null null null-Disease
Moreover RB O
, , O
treatment NN O
with IN O
the DT O
kinin JJ O
B2 NN O
receptor NN O
antagonist NN O
effectively RB O
reduced VBD O
the DT O
levels NNS O
of IN O
serum NN O
creatinine NN O
and CC O
blood NN O
urea NN O
after IN O
cisplatin NN O
administration NN O
. . O
null null null-Disease
Thus RB O
, , O
our PRP$ O
data NNS O
suggest VBP O
that IN O
the DT O
kinin NN O
B2 NN O
receptor NN O
is VBZ O
involved VBN O
in IN O
cisplatin NN O
- HYPH O
induced VBN O
acute JJ B-Disease
kidney NN I-Disease
injury NN I-Disease
by IN O
mediating VBG O
the DT O
necrotic JJ B-Disease
process NN O
and CC O
the DT O
expression NN O
of IN O
inflammatory JJ O
cytokines NNS O
, , O
thus RB O
resulting VBG O
in IN O
declined VBN O
renal JJ O
function NN O
. . O
null null null-Disease
These DT O
results NNS O
highlight VBP O
the DT O
kinin JJ O
B2 NN O
receptor NN O
antagonist NN O
treatment NN O
in IN O
amelioration NN O
of IN O
nephrotoxicity NN B-Disease
induced VBN O
by IN O
cisplatin NN O
therapy NN O
. . O
null null null-Disease
Safety NN O
and CC O
efficacy NN O
of IN O
fluocinolone NN O
acetonide NN O
intravitreal JJ O
implant NN O
( : O
0 CD O
. . O
59 CD O
mg NN O
) -RRB- O
in IN O
birdshot NN B-Disease
retinochoroidopathy NN I-Disease
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
report VB O
the DT O
treatment NN O
outcomes NNS O
of IN O
the DT O
fluocinolone NN O
acetonide NN O
intravitreal JJ O
implant NN O
( : O
0 CD O
. . O
59 CD O
mg NN O
) -RRB- O
in IN O
patients NNS O
with IN O
birdshot NN B-Disease
retinochoroidopathy NN I-Disease
whose WP$ O
disease NN O
is VBZ O
refractory JJ O
or CC O
intolerant JJ O
to IN O
conventional JJ O
immunomodulatory JJ O
therapy NN O
. . O
null null null-Disease
METHODS NNS O
: : O
A DT O
retrospective JJ O
case NN O
series NN O
involving VBG O
11 CD O
birdshot NN B-Disease
retinochoroidopathy JJ I-Disease
patients NNS O
( , O
11 CD O
eyes NNS O
) -RRB- O
. . O
null null null-Disease
Eleven CD O
patients NNS O
( , O
11 CD O
eyes NNS O
) , O
underwent VBD O
surgery NN O
for IN O
fluocinolone NN O
acetonide NN O
implant NN O
( , O
0 CD O
. . O
59 CD O
mg NN O
) -RRB- O
. . O
null null null-Disease
Treatment NN O
outcomes NNS O
of IN O
interest NN O
were VBD O
noted VBN O
at IN O
baseline NN O
, , O
before IN O
fluocinolone NN O
acetonide NN O
implant NN O
, , O
and CC O
then RB O
at IN O
6 CD O
months NNS O
, , O
1 CD O
year NN O
, , O
2 CD O
years NNS O
, , O
3 CD O
years NNS O
, , O
and CC O
beyond IN O
3 CD O
years NNS O
. . O
null null null-Disease
Disease NN O
activity NN O
markers NNS O
, , O
including VBG O
signs NNS O
of IN O
ocular JJ O
inflammation NN B-Disease
, , O
evidence NN O
of IN O
retinal JJ B-Disease
vasculitis NN I-Disease
, , O
Swedish JJ O
interactive JJ O
threshold NN O
algorithm NN O
- HYPH O
short JJ O
wavelength NN O
automated VBN O
perimetry NN O
Humphrey NNP O
visual JJ O
field NN O
analysis NN O
, , O
electroretinographic JJ O
parameters NNS O
, , O
and CC O
optical JJ O
coherence NN O
tomography NN O
were VBD O
recorded VBN O
. . O
null null null-Disease
Data NNS O
on IN O
occurrence NN O
of IN O
cataract NN B-Disease
and CC O
raised VBN B-Disease
intraocular JJ I-Disease
pressure NN I-Disease
were VBD O
collected VBN O
in IN O
all DT O
eyes NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
Intraocular JJ O
inflammation NN B-Disease
was VBD O
present JJ O
in IN O
54 CD O
. . O
5 CD O
, , O
9 CD O
. . O
9 CD O
, , O
11 CD O
. . O
1 CD O
, , O
and CC O
0 CD O
% NN O
of IN O
patients NNS O
at IN O
baseline NN O
, , O
6 CD O
months NNS O
, , O
1 CD O
year NN O
, , O
2 CD O
years NNS O
, , O
3 CD O
years NNS O
, , O
and CC O
beyond IN O
3 CD O
years NNS O
after IN O
receiving VBG O
the DT O
implant NN O
, , O
respectively RB O
. . O
null null null-Disease
Active JJ O
vasculitis NN B-Disease
was VBD O
noted VBN O
in IN O
36 CD O
. . O
3 CD O
% NN O
patients NNS O
at IN O
baseline NN O
and CC O
0 CD O
% NN O
at IN O
3 CD O
years NNS O
of IN O
follow NN O
- HYPH O
up NN O
. . O
null null null-Disease
More JJR O
than IN O
20 CD O
% NN O
( SYM O
47 CD O
. . O
61 CD O
- SYM O
67 CD O
. . O
2 CD O
% NN O
) , O
reduction NN O
in IN O
central JJ O
retinal JJ O
thickness NN O
was VBD O
noted VBN O
in IN O
all DT O
patients NNS O
with IN O
cystoid NN B-Disease
macular JJ I-Disease
edema NN I-Disease
at IN O
6 CD O
months NNS O
, , O
1 CD O
year NN O
, , O
2 CD O
years NNS O
, , O
and CC O
3 CD O
years NNS O
postimplant NN O
. . O
null null null-Disease
At IN O
baseline NN O
, , O
54 CD O
. . O
5 CD O
% NN O
patients NNS O
were VBD O
on IN O
immunomodulatory JJ O
agents NNS O
. . O
null null null-Disease
This DT O
percentage NN O
decreased VBD O
to IN O
45 CD O
. . O
45 CD O
, , O
44 CD O
. . O
4 CD O
, , O
and CC O
14 CD O
. . O
28 CD O
% NN O
at IN O
1 CD O
year NN O
, , O
2 CD O
years NNS O
, , O
and CC O
3 CD O
years NNS O
postimplant NN O
, , O
respectively RB O
. . O
null null null-Disease
Adverse JJ O
events NNS O
included VBD O
increased VBN B-Disease
intraocular JJ I-Disease
pressure NN I-Disease
( : O
54 CD O
. . O
5 CD O
% NN O
) -RRB- O
and CC O
cataract JJ B-Disease
formation NN O
( : O
100 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
data NNS O
suggest VBP O
that IN O
fluocinolone NN O
acetonide NN O
implant NN O
( : O
0 CD O
. . O
59 CD O
mg NN O
) -RRB- O
helps VBZ O
to TO O
control VB O
inflammation NN B-Disease
in IN O
otherwise RB O
treatment NN O
- HYPH O
refractory JJ O
cases NNS O
of IN O
birdshot NN B-Disease
retinochoroidopathy NN I-Disease
. . O
null null null-Disease
It PRP O
is VBZ O
associated VBN O
with IN O
significant JJ O
side NN O
effects NNS O
of IN O
cataract NN B-Disease
and CC O
ocular JJ B-Disease
hypertension NN I-Disease
requiring VBG O
treatment NN O
. . O
null null null-Disease
Optimal JJ O
precurarizing VBG O
dose NN O
of IN O
rocuronium NN O
to TO O
decrease VB O
fasciculation NN B-Disease
and CC O
myalgia NN B-Disease
following VBG O
succinylcholine NN O
administration NN O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Succinylcholine NN O
commonly RB O
produces VBZ O
frequent JJ O
adverse JJ O
effects NNS O
, , O
including VBG O
muscle NN B-Disease
fasciculation NN I-Disease
and CC O
myalgia NN B-Disease
. . O
null null null-Disease
The DT O
current JJ O
study NN O
identified VBD O
the DT O
optimal JJ O
dose NN O
of IN O
rocuronium NN O
to TO O
prevent VB O
succinylcholine NN O
- HYPH O
induced VBN O
fasciculation NN B-Disease
and CC O
myalgia NN B-Disease
and CC O
evaluated VBD O
the DT O
influence NN O
of IN O
rocuronium NN O
on IN O
the DT O
speed NN O
of IN O
onset NN O
produced VBN O
by IN O
succinylcholine NN O
. . O
null null null-Disease
METHODS NNS O
: : O
This DT O
randomized JJ O
, , O
double JJ O
- HYPH O
blinded JJ O
study NN O
was VBD O
conducted VBN O
in IN O
100 CD O
patients NNS O
randomly RB O
allocated VBN O
into IN O
five CD O
groups NNS O
of IN O
20 CD O
patients NNS O
each DT O
. . O
null null null-Disease
Patients NNS O
were VBD O
randomized VBN O
to TO O
receive VB O
0 CD O
. . O
02 CD O
, , O
0 CD O
. . O
03 CD O
, , O
0 CD O
. . O
04 CD O
, , O
0 CD O
. . O
05 CD O
and CC O
0 CD O
. . O
06 CD O
mg NN O
/ SYM O
kg NN O
rocuronium NN O
as IN O
a DT O
precurarizing VBG O
dose NN O
. . O
null null null-Disease
Neuromuscular JJ O
monitoring NN O
after IN O
each DT O
precurarizing VBG O
dose NN O
was VBD O
recorded VBN O
from IN O
the DT O
adductor NN O
pollicis NN O
muscle NN O
using VBG O
acceleromyography NN O
with IN O
train NN O
- HYPH O
of IN O
- HYPH O
four CD O
stimulation NN O
of IN O
the DT O
ulnar JJ O
nerve NN O
. . O
null null null-Disease
All DT O
patients NNS O
received VBD O
succinylcholine NN O
1 CD O
. . O
5 CD O
mg NN O
/ SYM O
kg NN O
at IN O
2 CD O
minutes NNS O
after IN O
the DT O
precurarization NN O
, , O
and CC O
were VBD O
assessed VBN O
the DT O
incidence NN O
and CC O
severity NN O
of IN O
fasciculations NNS B-Disease
, , O
while IN O
myalgia NN B-Disease
was VBD O
assessed VBN O
at IN O
24 CD O
hours NNS O
after IN O
surgery NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
incidence NN O
and CC O
severity NN O
of IN O
visible JJ O
muscle NN B-Disease
fasciculation NN I-Disease
was VBD O
significantly RB O
less JJR O
with IN O
increasing VBG O
the DT O
amount NN O
of IN O
precurarizing VBG O
dose NN O
of IN O
rocuronium NN O
( -LRB- O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Those DT O
of IN O
myalgia NN B-Disease
tend VBP O
to TO O
decrease VB O
according VBG O
to IN O
increasing VBG O
the DT O
amount NN O
of IN O
precurarizing VBG O
dose NN O
of IN O
rocuronium NN O
, , O
but CC O
there EX O
was VBD O
no DT O
significance NN O
( : O
P NN O
= SYM O
0 CD O
. . O
072 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
onset NN O
time NN O
of IN O
succinylcholine NN O
was VBD O
significantly RB O
longer JJR O
with IN O
increasing VBG O
the DT O
amount NN O
of IN O
precurarizing VBG O
dose NN O
of IN O
rocuronium NN O
( , O
P NN O
< SYM O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Precurarization NN O
with IN O
0 CD O
. . O
04 CD O
mg NN O
/ SYM O
kg NN O
rocuronium NN O
was VBD O
the DT O
optimal JJ O
dose NN O
considering VBG O
the DT O
reduction NN O
in IN O
the DT O
incidence NN O
and CC O
severity NN O
of IN O
fasciculation NN B-Disease
and CC O
myalgia NN B-Disease
with IN O
acceptable JJ O
onset NN O
time NN O
, , O
and CC O
the DT O
safe JJ O
and CC O
effective JJ O
precurarization NN O
. . O
null null null-Disease
Absence NN O
of IN O
PKC NNP O
- HYPH O
alpha NN O
attenuates VBZ O
lithium NN O
- HYPH O
induced VBN O
nephrogenic JJ B-Disease
diabetes NNS I-Disease
insipidus NN I-Disease
. . O
null null null-Disease
Lithium NNP O
, , O
an DT O
effective JJ O
antipsychotic JJ O
, , O
induces VBZ O
nephrogenic JJ B-Disease
diabetes NN I-Disease
insipidus NN I-Disease
( : O
NDI NNP B-Disease
) -RRB- O
in IN O
40 CD O
% NN O
of IN O
patients NNS O
. . O
null null null-Disease
The DT O
decreased VBN O
capacity NN O
to TO O
concentrate VB O
urine NN O
is VBZ O
likely JJ O
due IN O
to IN O
lithium NN O
acutely RB O
disrupting VBG O
the DT O
cAMP NNP O
pathway NN O
and CC O
chronically RB O
reducing VBG O
urea NN O
transporter NN O
( -LRB- O
UT NNP O
- HYPH O
A1 NNP O
) -RRB- O
and CC O
water NN O
channel NN O
( -LRB- O
AQP2 NN O
) -RRB- O
expression NN O
in IN O
the DT O
inner JJ O
medulla NN O
. . O
null null null-Disease
Targeting VBG O
an DT O
alternative JJ O
signaling NN O
pathway NN O
, , O
such JJ O
as IN O
PKC NNP O
- HYPH O
mediated VBN O
signaling NN O
, , O
may MD O
be VB O
an DT O
effective JJ O
method NN O
of IN O
treating VBG O
lithium NN O
- HYPH O
induced VBN O
polyuria NN B-Disease
. . O
null null null-Disease
PKC NNP O
- HYPH O
alpha NNP O
null NN O
mice NN O
( , O
PKCa NNP O
KO NNP O
) -RRB- O
and CC O
strain NN O
- HYPH O
matched VBN O
wild JJ O
type NN O
( , O
WT NNP O
) -RRB- O
controls NNS O
were VBD O
treated VBN O
with IN O
lithium NN O
for IN O
0 CD O
, , O
3 CD O
or CC O
5 CD O
days NNS O
. . O
null null null-Disease
WT NNP O
mice NNS O
had VBD O
increased VBN O
urine NN O
output NN O
and CC O
lowered VBN O
urine NN O
osmolality NN O
after IN O
3 CD O
and CC O
5 CD O
days NNS O
of IN O
treatment NN O
whereas IN O
PKCa NNP O
KO NNP O
mice NNS O
had VBD O
no DT O
change NN O
in IN O
urine NN O
output NN O
or CC O
concentration NN O
. . O
null null null-Disease
Western JJ O
blot NN O
analysis NN O
revealed VBD O
that IN O
AQP2 NNP O
expression NN O
in IN O
medullary JJ O
tissues NNS O
was VBD O
lowered VBN O
after IN O
3 CD O
and CC O
5 CD O
days NNS O
in IN O
WT NNP O
mice NNS O
; : O
however RB O
, , O
AQP2 NNP O
was VBD O
unchanged JJ O
in IN O
PKCa NNP O
KO NNP O
. . O
null null null-Disease
Similar JJ O
results NNS O
were VBD O
observed VBN O
with IN O
UT NNP O
- HYPH O
A1 NNP O
expression NN O
. . O
null null null-Disease
Animals NNS O
were VBD O
also RB O
treated VBN O
with IN O
lithium NN O
for IN O
6 CD O
weeks NNS O
. . O
null null null-Disease
Lithium NN O
- HYPH O
treated VBN O
WT NNP O
mice NNS O
had VBD O
19 CD O
- HYPH O
fold NN O
increased VBN O
urine NN O
output NN O
whereas IN O
treated VBN O
PKCa NNP O
KO NNP O
animals NNS O
had VBD O
a DT O
4 CD O
- HYPH O
fold NN O
increase NN O
in IN O
output NN O
. . O
null null null-Disease
AQP2 NNP O
and CC O
UT NNP O
- HYPH O
A1 NNP O
expression NN O
was VBD O
lowered VBN O
in IN O
6 CD O
week NN O
lithium NN O
- HYPH O
treated VBN O
WT NNP O
animals NNS O
whereas IN O
in IN O
treated VBN O
PKCa NNP O
KO NNP O
mice NNS O
, , O
AQP2 NNP O
was VBD O
only RB O
reduced VBN O
by IN O
2 CD O
- HYPH O
fold NN O
and CC O
UT NNP O
- HYPH O
A1 NNP O
expression NN O
was VBD O
unaffected JJ O
. . O
null null null-Disease
Urinary JJ O
sodium NN O
, , O
potassium NN O
and CC O
calcium NN O
were VBD O
elevated VBN O
in IN O
lithium NN O
- HYPH O
fed VBN O
WT NNP O
but CC O
not RB O
in IN O
lithium NN O
- HYPH O
fed VBN O
PKCa NNP O
KO NNP O
mice NNS O
. . O
null null null-Disease
Our PRP$ O
data NNS O
show VBP O
that IN O
ablation NN O
of IN O
PKCa NNP O
preserves VBZ O
AQP2 NN O
and CC O
UT NNP O
- HYPH O
A1 NN O
protein NN O
expression NN O
and CC O
localization NN O
in IN O
lithium NN O
- HYPH O
induced VBN O
NDI NNP B-Disease
, , O
and CC O
prevents VBZ O
the DT O
development NN O
of IN O
the DT O
severe JJ O
polyuria NN B-Disease
associated VBN O
with IN O
lithium NN O
therapy NN O
. . O
null null null-Disease
Is VBZ O
Dysguesia NNP B-Disease
Going VBG O
to TO O
be VB O
a DT O
Rare JJ O
or CC O
a DT O
Common JJ O
Side NN O
- HYPH O
effect NN O
of IN O
Amlodipine NN O
? . O
null null null-Disease
A DT O
very RB O
rare JJ O
side NN O
- HYPH O
effect NN O
of IN O
amlodipine NN O
is VBZ O
dysguesia NN B-Disease
. . O
null null null-Disease
A DT O
review NN O
of IN O
the DT O
literature NN O
produced VBD O
only RB O
one CD O
case NN O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
about IN O
a DT O
female NN O
with IN O
essential JJ O
hypertension NN B-Disease
on IN O
drug NN O
treatment NN O
with IN O
amlodipine NN O
developed VBN O
loss NN B-Disease
of IN I-Disease
taste NN I-Disease
sensation NN I-Disease
. . O
null null null-Disease
Condition NN O
moderately RB O
improved VBD O
on IN O
stoppage NN O
of IN O
the DT O
drug NN O
for IN O
25 CD O
days NNS O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
amlodipine NN O
can MD O
cause VB O
dysguesia NN B-Disease
. . O
null null null-Disease
Here RB O
, , O
we PRP O
describe VBP O
the DT O
clinical JJ O
presentation NN O
and CC O
review VBP O
the DT O
relevant JJ O
literature NN O
on IN O
amlodipine NN O
and CC O
dysguesia NN B-Disease
. . O
null null null-Disease
Rhabdomyolysis NN B-Disease
in IN O
association NN O
with IN O
simvastatin NN O
and CC O
dosage NN O
increment NN O
in IN O
clarithromycin NN O
. . O
null null null-Disease
Clarithromycin NNP O
is VBZ O
the DT O
most RBS O
documented JJ O
cytochrome NN O
P450 NN O
3A4 CD O
( , O
CYP3A4 NN O
) , O
inhibitor NN O
to TO O
cause VB O
an DT O
adverse JJ O
interaction NN O
with IN O
simvastatin NN O
. . O
null null null-Disease
This DT O
particular JJ O
case NN O
is VBZ O
of IN O
interest NN O
as IN O
rhabdomyolysis NN B-Disease
only RB O
occurred VBD O
after IN O
an DT O
increase NN O
in IN O
the DT O
dose NN O
of IN O
clarithromycin NN O
. . O
null null null-Disease
The DT O
patient NN O
developed VBD O
raised VBN O
cardiac JJ O
biomarkers NNS O
without IN O
any DT O
obvious JJ O
cardiac JJ O
issues NNS O
, , O
a DT O
phenomenon NN O
that WDT O
has VBZ O
been VBN O
linked VBN O
to IN O
rhabdomyolysis NN B-Disease
previously RB O
. . O
null null null-Disease
To IN O
date NN O
, , O
there EX O
has VBZ O
been VBN O
no DT O
reported VBN O
effect NN O
of IN O
rhabdomyolysis NN B-Disease
on IN O
the DT O
structure NN O
and CC O
function NN O
of IN O
cardiac JJ O
muscle NN O
. . O
null null null-Disease
Clinicians NNS O
need VBP O
to TO O
be VB O
aware JJ O
of IN O
prescribing VBG O
concomitant JJ O
medications NNS O
that WDT O
increase VBP O
the DT O
risk NN O
of IN O
myopathy NN B-Disease
or CC O
inhibit VBP O
the DT O
CYP3A4 NNP O
enzyme NN O
. . O
null null null-Disease
Our PRP$ O
case NN O
suggests VBZ O
that IN O
troponin NN O
elevation NN O
could MD O
be VB O
associated VBN O
with IN O
statin NN O
induced VBN O
rhabdomyolysis NN B-Disease
, , O
which WDT O
may MD O
warrant VB O
further JJ O
studies NNS O
. . O
null null null-Disease
Characterization NN O
of IN O
a DT O
novel NN O
BCHE NNP O
"""" `` O
silent JJ O
"""" '' O
allele NN O
: : O
point NN O
mutation NN O
( , O
p NN O
. . O
Val204Asp NNP O
) -RRB- O
causes VBZ O
loss NN O
of IN O
activity NN O
and CC O
prolonged JJ O
apnea NN B-Disease
with IN O
suxamethonium NN O
. . O
null null null-Disease
Butyrylcholinesterase JJ B-Disease
deficiency NN I-Disease
is VBZ O
characterized VBN O
by IN O
prolonged VBN O
apnea NN B-Disease
after IN O
the DT O
use NN O
of IN O
muscle NN O
relaxants NNS O
( , O
suxamethonium NN O
or CC O
mivacurium NN O
) -RRB- O
in IN O
patients NNS O
who WP O
have VBP O
mutations NNS O
in IN O
the DT O
BCHE NN O
gene NN O
. . O
null null null-Disease
Here RB O
, , O
we PRP O
report VBP O
a DT O
case NN O
of IN O
prolonged VBN O
neuromuscular JJ O
block NN O
after IN O
administration NN O
of IN O
suxamethonium NN O
leading VBG O
to IN O
the DT O
discovery NN O
of IN O
a DT O
novel JJ O
BCHE NNP O
variant NN O
( : O
c NN O
. . O
695T CD O
> SYM O
A NN O
, , O
p NN O
. . O
Val204Asp NN O
) -RRB- O
. . O
null null null-Disease
Inhibition NN O
studies NNS O
, , O
kinetic JJ O
analysis NN O
and CC O
molecular JJ O
dynamics NNS O
were VBD O
undertaken VBN O
to TO O
understand VB O
how WRB O
this DT O
mutation NN O
disrupts VBZ O
the DT O
catalytic JJ O
triad NN O
and CC O
determines VBZ O
a DT O
"""" `` O
silent JJ O
"""" '' O
phenotype NN O
. . O
null null null-Disease
Low JJ O
activity NN O
of IN O
patient JJ O
plasma NN O
butyrylcholinesterase NN O
with IN O
butyrylthiocholine NN O
( , O
BTC NNP O
) -RRB- O
and CC O
benzoylcholine NN O
, , O
and CC O
values NNS O
of IN O
dibucaine NN O
and CC O
fluoride NN O
numbers NNS O
fit JJ O
with IN O
heterozygous JJ O
atypical JJ O
silent JJ O
genotype NN O
. . O
null null null-Disease
Electrophoretic JJ O
analysis NN O
of IN O
plasma NN O
BChE NN O
of IN O
the DT O
proband NN O
and CC O
his PRP$ O
mother NN O
showed VBD O
that IN O
patient NN O
has VBZ O
a DT O
reduced VBN O
amount NN O
of IN O
tetrameric JJ O
enzyme NN O
in IN O
plasma NN O
and CC O
that DT O
minor JJ O
fast RB O
- HYPH O
moving VBG O
BChE NNP O
components NNS O
: : O
monomer NN O
, , O
dimer NN O
, , O
and CC O
monomer NN O
- HYPH O
albumin NN O
conjugate NN O
are VBP O
missing VBG O
. . O
null null null-Disease
Kinetic JJ O
analysis NN O
showed VBD O
that IN O
the DT O
p NN O
. . O
Val204Asp NN O
/ : O
p NN O
. . O
Asp70Gly NNP O
- HYPH O
p NN O
. . O
Ala539Thr NNP O
BChE NNP O
displays VBZ O
a DT O
pure JJ O
Michaelian JJ O
behavior NN O
with IN O
BTC NNP O
as IN O
the DT O
substrate NN O
. . O
null null null-Disease
Both DT O
catalytic JJ O
parameters NNS O
Km NNP O
= SYM O
265 CD O
uM UH O
for IN O
BTC NNP O
, , O
two CD O
times NNS O
higher JJR O
than IN O
that DT O
of IN O
the DT O
atypical JJ O
enzyme NN O
, , O
and CC O
a DT O
low JJ O
Vmax NNP O
are VBP O
consistent JJ O
with IN O
the DT O
absence NN O
of IN O
activity NN O
against IN O
suxamethonium NN O
. . O
null null null-Disease
Molecular JJ O
dynamic NN O
( , O
MD NNP O
) -RRB- O
simulations NNS O
showed VBD O
that IN O
the DT O
overall JJ O
effect NN O
of IN O
the DT O
mutation NN O
p NN O
. , O
Val204Asp NNP O
is VBZ O
disruption NN O
of IN O
hydrogen NN O
bonding NN O
between IN O
Gln223 NNP O
and CC O
Glu441 NNP O
, , O
leading VBG O
Ser198 NNP O
and CC O
His438 NNP O
to TO O
move VB O
away RB O
from IN O
each DT O
other JJ O
with IN O
subsequent JJ O
disruption NN O
of IN O
the DT O
catalytic JJ O
triad NN O
functionality NN O
regardless RB O
of IN O
the DT O
type NN O
of IN O
substrate NN O
. . O
null null null-Disease
MD NNP O
also RB O
showed VBD O
that IN O
the DT O
enzyme NN O
volume NN O
is VBZ O
increased VBN O
, , O
suggesting VBG O
a DT O
pre JJ O
- HYPH O
denaturation NN O
state NN O
. . O
null null null-Disease
This DT O
fits VBZ O
with IN O
the DT O
reduced VBN O
concentration NN O
of IN O
p NN O
. . O
Ala204Asp NNP O
/ : O
p NN O
. . O
Asp70Gly NNP O
- HYPH O
p NNP O
. . O
Ala539Thr NN O
tetrameric JJ O
enzyme NN O
in IN O
the DT O
plasma NN O
and CC O
non NN O
- HYPH O
detectable JJ O
fast JJ O
moving NN O
- HYPH O
bands NNS O
on IN O
electrophoresis NN O
gels NNS O
. . O
null null null-Disease
Delayed VBN O
anemia NN B-Disease
after IN O
treatment NN O
with IN O
injectable JJ O
artesunate NN O
in IN O
the DT O
Democratic NNP O
Republic NNP O
of IN O
the DT O
Congo NNP O
: : O
a DT O
manageable JJ O
issue NN O
. . O
null null null-Disease
Cases NNS O
of IN O
delayed VBN O
hemolytic JJ B-Disease
anemia NN I-Disease
have VBP O
been VBN O
described VBN O
after IN O
treatment NN O
with IN O
injectable JJ O
artesunate NN O
, , O
the DT O
current JJ O
World NNP O
Health NNP O
Organization NNP O
( , O
WHO NNP O
) -RRB- O
- HYPH O
recommended VBN O
first JJ O
- HYPH O
line NN O
drug NN O
for IN O
the DT O
treatment NN O
of IN O
severe JJ O
malaria NN B-Disease
. . O
null null null-Disease
A DT O
total NN O
of IN O
350 CD O
patients NNS O
( : O
215 CD O
[ SYM O
61 CD O
. , O
4 CD O
% NN O
] -RRB- O
< $ O
5 CD O
years NNS O
of IN O
age NN O
and CC O
135 CD O
[ -LRB- O
38 CD O
. . O
6 CD O
% NN O
] -RRB- O
> SYM O
5 CD O
years NNS O
of IN O
age NN O
) -RRB- O
were VBD O
followed VBN O
- HYPH O
up NN O
after IN O
treatment NN O
with IN O
injectable JJ O
artesunate NN O
for IN O
severe JJ O
malaria NN B-Disease
in IN O
hospitals NNS O
and CC O
health NN O
centers NNS O
of IN O
the DT O
Democratic NNP O
Republic NNP O
of IN O
the DT O
Congo NNP O
. . O
null null null-Disease
Complete JJ O
series NN O
of IN O
hemoglobin NN O
( , O
Hb NNP O
) -RRB- O
measurements NNS O
were VBD O
available JJ O
for IN O
201 CD O
patients NNS O
. . O
null null null-Disease
A DT O
decrease NN O
in IN O
Hb NNP O
levels NNS O
between IN O
2 CD O
and CC O
5 CD O
g NNS O
/ SYM O
dL NN O
was VBD O
detected VBN O
in IN O
23 CD O
( SYM O
11 CD O
. . O
4 CD O
% NN O
) SYM O
patients NNS O
during IN O
the DT O
follow NN O
- HYPH O
up NN O
period NN O
. . O
null null null-Disease
For IN O
five CD O
patients NNS O
, , O
Hb NNP O
levels NNS O
decreased VBD O
below IN O
5 CD O
g NNS O
/ SYM O
dL NN O
during IN O
at RB O
least RBS O
one CD O
follow NN O
- HYPH O
up NN O
visit NN O
. . O
null null null-Disease
All DT O
cases NNS O
of IN O
delayed VBN O
anemia NN B-Disease
were VBD O
clinically RB O
manageable JJ O
and CC O
resolved VBN O
within IN O
one CD O
month NN O
. . O
null null null-Disease
Regulation NN O
of IN O
signal NN O
transducer NN O
and CC O
activator NN O
of IN O
transcription NN O
3 CD O
and CC O
apoptotic JJ O
pathways NNS O
by IN O
betaine NN O
attenuates VBZ O
isoproterenol NN O
- HYPH O
induced VBN O
acute JJ O
myocardial JJ B-Disease
injury NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
was VBD O
designed VBN O
to TO O
investigate VB O
the DT O
cardioprotective JJ O
effects NNS O
of IN O
betaine NN O
on IN O
acute JJ O
myocardial JJ B-Disease
ischemia NN I-Disease
induced VBN O
experimentally RB O
in IN O
rats NNS O
focusing VBG O
on IN O
regulation NN O
of IN O
signal NN O
transducer NN O
and CC O
activator NN O
of IN O
transcription NN O
3 CD O
( , O
STAT3 NN O
) -RRB- O
and CC O
apoptotic JJ O
pathways NNS O
as IN O
the DT O
potential JJ O
mechanism NN O
underlying VBG O
the DT O
drug NN O
effect NN O
. . O
null null null-Disease
Male JJ O
Sprague NNP O
Dawley NNP O
rats NNS O
were VBD O
treated VBN O
with IN O
betaine NN O
( : O
100 CD O
, , O
200 CD O
, , O
and CC O
400 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
orally RB O
for IN O
40 CD O
days NNS O
. . O
null null null-Disease
Acute JJ O
myocardial JJ B-Disease
ischemic JJ I-Disease
injury NN I-Disease
was VBD O
induced VBN O
in IN O
rats NNS O
by IN O
subcutaneous JJ O
injection NN O
of IN O
isoproterenol NN O
( , O
85 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
, , O
for IN O
two CD O
consecutive JJ O
days NNS O
. . O
null null null-Disease
Serum NN O
cardiac JJ O
marker NN O
enzyme NN O
, , O
histopathological JJ O
variables NNS O
and CC O
expression NN O
of IN O
protein NN O
levels NNS O
were VBD O
analyzed VBN O
. . O
null null null-Disease
Oral JJ O
administration NN O
of IN O
betaine NN O
( : O
200 CD O
and CC O
400 CD O
mg NNS O
/ SYM O
kg NNS O
) , O
significantly RB O
reduced VBD O
the DT O
level NN O
of IN O
cardiac JJ O
marker NN O
enzyme NN O
in IN O
the DT O
serum NN O
and CC O
prevented VBD O
left VBN O
ventricular JJ B-Disease
remodeling NN I-Disease
. . O
null null null-Disease
Western JJ O
blot NN O
analysis NN O
showed VBD O
that IN O
isoproterenol NN O
- HYPH O
induced VBN O
phosphorylation NN O
of IN O
STAT3 NNP O
was VBD O
maintained VBN O
or CC O
further RBR O
enhanced VBN O
by IN O
betaine NN O
treatment NN O
in IN O
myocardium NN O
. . O
null null null-Disease
Furthermore RB O
, , O
betaine NN O
( , O
200 CD O
and CC O
400 CD O
mg NNS O
/ SYM O
kg NNS O
) , O
treatment NN O
increased VBD O
the DT O
ventricular JJ O
expression NN O
of IN O
Bcl NNP O
- HYPH O
2 CD O
and CC O
reduced VBD O
the DT O
level NN O
of IN O
Bax NNP O
, , O
therefore RB O
causing VBG O
a DT O
significant JJ O
increase NN O
in IN O
the DT O
ratio NN O
of IN O
Bcl NNP O
- HYPH O
2 CD O
/ SYM O
Bax NNP O
. . O
null null null-Disease
The DT O
protective JJ O
role NN O
of IN O
betaine NN O
on IN O
myocardial JJ B-Disease
damage NN I-Disease
was VBD O
further RB O
confirmed VBN O
by IN O
histopathological JJ O
examination NN O
. . O
null null null-Disease
In IN O
summary NN O
, , O
our PRP$ O
results NNS O
showed VBD O
that IN O
betaine NN O
pretreatment NN O
attenuated VBD O
isoproterenol NN O
- HYPH O
induced VBN O
acute JJ O
myocardial JJ B-Disease
ischemia NN I-Disease
via IN O
the DT O
regulation NN O
of IN O
STAT3 NNP O
and CC O
apoptotic JJ O
pathways NNS O
. . O
null null null-Disease
Quetiapine NN O
- HYPH O
induced VBN O
neutropenia NN B-Disease
in IN O
a DT O
bipolar JJ B-Disease
patient NN O
with IN O
hepatocellular JJ B-Disease
carcinoma NN I-Disease
. . O
null null null-Disease
OBJECTIVE NN O
: : O
Quetiapine NNP O
is VBZ O
a DT O
dibenzothiazepine NN O
derivative NN O
, , O
similar JJ O
to IN O
clozapine NN O
, , O
which WDT O
has VBZ O
the DT O
highest JJS O
risk NN O
of IN O
causing VBG O
blood NN B-Disease
dyscrasias NNS I-Disease
, , O
especially RB O
neutropenia NN B-Disease
. . O
null null null-Disease
There EX O
are VBP O
some DT O
case NN O
reports NNS O
about IN O
this DT O
side NN O
effect NN O
of IN O
quetiapine NN O
, , O
but CC O
possible JJ O
risk NN O
factors NNS O
are VBP O
seldom RB O
discussed VBN O
and CC O
identified VBN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
a DT O
patient NN O
with IN O
hepatocellular JJ B-Disease
carcinoma NN I-Disease
that WDT O
developed VBD O
neutropenia NN B-Disease
after IN O
treatment NN O
with IN O
quetiapine NN O
is VBZ O
described VBN O
here RB O
. . O
null null null-Disease
CASE NNP O
REPORT NNP O
: : O
A DT O
62 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
Taiwanese JJ O
widow NN O
with IN O
bipolar JJ B-Disease
disorder NN I-Disease
was VBD O
diagnosed VBN O
with IN O
hepatocellular JJ B-Disease
carcinoma NN I-Disease
at IN O
age NN O
60 CD O
. . O
null null null-Disease
She PRP O
developed VBD O
leucopenia NN B-Disease
after IN O
being VBG O
treated VBN O
with IN O
quetiapine NN O
. . O
null null null-Disease
After IN O
quetiapine NN O
was VBD O
discontinued VBN O
, , O
her PRP$ O
white JJ O
blood NN O
cell NN O
count NN O
returned VBD O
to IN O
normal JJ O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Although IN O
neutropenia NN B-Disease
is VBZ O
not RB O
a DT O
common JJ O
side NN O
effect NN O
of IN O
quetiapine NN O
, , O
physicians NNS O
should MD O
be VB O
cautious JJ O
about IN O
its PRP$ O
presentation NN O
and CC O
associated VBN O
risk NN O
factors NNS O
. . O
null null null-Disease
Hepatic JJ B-Disease
dysfunction NN I-Disease
may MD O
be VB O
one CD O
of IN O
the DT O
possible JJ O
risk NN O
factors NNS O
, , O
and CC O
concomitant JJ O
fever NN B-Disease
may MD O
be VB O
a DT O
diagnostic JJ O
marker NN O
for IN O
adverse JJ O
reaction NN O
to IN O
quetiapine NN O
. . O
null null null-Disease
Lateral JJ O
antebrachial JJ O
cutaneous JJ O
neuropathy NN B-Disease
after IN O
steroid NN O
injection NN O
at IN O
lateral JJ O
epicondyle NN O
. . O
null null null-Disease
BACKGROUND NN O
AND CC O
OBJECTIVES NNS O
: : O
This DT O
report NN O
aimed VBD O
to TO O
present VB O
a DT O
case NN O
of IN O
lateral JJ O
antebrachial JJ O
cutaneous JJ O
neuropathy NN B-Disease
( -LRB- O
LACNP NNP O
) -RRB- O
that WDT O
occurred VBD O
after IN O
a DT O
steroid NN O
injection NN O
in IN O
the DT O
lateral JJ O
epicondyle NN O
to TO O
treat VB O
lateral JJ B-Disease
epicondylitis NN I-Disease
in IN O
a DT O
40 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
. . O
null null null-Disease
MATERIAL NN O
AND CC O
METHOD NN O
: : O
A DT O
40 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
presented VBN O
with IN O
decreased VBN O
sensation NN O
and CC O
paresthesia NN B-Disease
over IN O
her PRP$ O
right JJ O
lateral JJ O
forearm NN O
; : O
the DT O
paresthesia NN B-Disease
had VBD O
occurred VBN O
after IN O
a DT O
steroid NN O
injection NN O
in IN O
the DT O
right JJ O
lateral JJ O
epicondyle NN O
3 CD O
months NNS O
before RB O
. . O
null null null-Disease
Her PRP$ O
sensation NN O
of IN O
light JJ O
touch NN O
and CC O
pain NN B-Disease
was VBD O
diminished VBN O
over IN O
the DT O
lateral JJ O
side NN O
of IN O
the DT O
right JJ O
forearm NN O
and CC O
wrist NN O
area NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
The DT O
sensory JJ O
action NN O
potential JJ O
amplitude NN O
of IN O
the DT O
right JJ O
lateral JJ O
antebrachial JJ O
cutaneous JJ O
nerve NN O
( : O
LACN NNP O
) -RRB- O
( , O
6 CD O
. . O
2 CD O
uV NN O
) -RRB- O
was VBD O
lower JJR O
than IN O
that DT O
of IN O
the DT O
left JJ O
( , O
13 CD O
. . O
1 CD O
uV NN O
) -RRB- O
. . O
null null null-Disease
The DT O
difference NN O
of IN O
amplitude NN O
between IN O
both DT O
sides NNS O
was VBD O
significant JJ O
because IN O
there EX O
was VBD O
more JJR O
than IN O
a DT O
50 CD O
% NN O
reduction NN O
. . O
null null null-Disease
She PRP O
was VBD O
diagnosed VBN O
with IN O
right JJ O
LACNP NNP O
( : O
mainly RB O
axonal JJ O
involvement NN O
) , O
on IN O
the DT O
basis NN O
of IN O
the DT O
clinical JJ O
manifestation NN O
and CC O
the DT O
electrodiagnostic JJ O
findings NNS O
. . O
null null null-Disease
Her PRP$ O
symptoms NNS O
improved VBD O
through IN O
physical NN O
therapy NN O
but CC O
persisted VBD O
to IN O
some DT O
degree NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
This DT O
report NN O
describes VBZ O
the DT O
case NN O
of IN O
a DT O
woman NN O
with IN O
LACNP NNP O
that WDT O
developed VBD O
after IN O
a DT O
steroid NN O
injection NN O
for IN O
the DT O
treatment NN O
of IN O
lateral JJ B-Disease
epicondylitis NN I-Disease
. . O
null null null-Disease
An DT O
electrodiagnostic JJ O
study NN O
, , O
including VBG O
a DT O
nerve JJ O
conduction NN O
study NN O
of IN O
the DT O
LACN NNP O
, , O
was VBD O
helpful JJ O
to TO O
diagnose VB O
right NN O
LACNP NNP O
and CC O
to TO O
find VB O
the DT O
passage NN O
of IN O
the DT O
LACN NNP O
on IN O
the DT O
lateral JJ O
epicondyle NN O
. . O
null null null-Disease
Curcumin NN O
prevents VBZ O
maleate NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
: : O
relation NN O
to IN O
hemodynamic JJ O
alterations NNS O
, , O
oxidative JJ O
stress NN O
, , O
mitochondrial JJ O
oxygen NN O
consumption NN O
and CC O
activity NN O
of IN O
respiratory JJ O
complex NN O
I CD O
. . O
null null null-Disease
The DT O
potential JJ O
protective JJ O
effect NN O
of IN O
the DT O
dietary JJ O
antioxidant JJ O
curcumin NN O
( : O
120 CD O
mg NN O
/ SYM O
Kg NNP O
/ SYM O
day NN O
for IN O
6 CD O
days NNS O
) -RRB- O
against IN O
the DT O
renal JJ B-Disease
injury NN I-Disease
induced VBN O
by IN O
maleate NN O
was VBD O
evaluated VBN O
. . O
null null null-Disease
Tubular JJ O
proteinuria NN B-Disease
and CC O
oxidative JJ O
stress NN O
were VBD O
induced VBN O
by IN O
a DT O
single JJ O
injection NN O
of IN O
maleate NN O
( , O
400 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
in IN O
rats NNS O
. . O
null null null-Disease
Maleate NN O
- HYPH O
induced VBN O
renal JJ B-Disease
injury NN I-Disease
included VBD O
increase NN O
in IN O
renal JJ O
vascular JJ O
resistance NN O
and CC O
in IN O
the DT O
urinary JJ O
excretion NN O
of IN O
total JJ O
protein NN O
, , O
glucose NN O
, , O
sodium NN O
, , O
neutrophil NN O
gelatinase NN O
- HYPH O
associated VBN O
lipocalin NN O
( , O
NGAL NNP O
) -RRB- O
and CC O
N NN O
- HYPH O
acetyl NN O
b NN O
- HYPH O
D NN O
- HYPH O
glucosaminidase NN O
( , O
NAG NNP O
) -RRB- O
, , O
upregulation NN O
of IN O
kidney NN B-Disease
injury NN I-Disease
molecule NN O
( , O
KIM NNP O
) -RRB- O
- HYPH O
1 CD O
, , O
decrease NN O
in IN O
renal JJ O
blood NN O
flow NN O
and CC O
claudin NN O
- HYPH O
2 CD O
expression NN O
besides IN O
of IN O
necrosis NN B-Disease
and CC O
apoptosis NN O
of IN O
tubular JJ O
cells NNS O
on IN O
24 CD O
h NN O
. . O
null null null-Disease
Oxidative JJ O
stress NN O
was VBD O
determined VBN O
by IN O
measuring VBG O
the DT O
oxidation NN O
of IN O
lipids NNS O
and CC O
proteins NNS O
and CC O
diminution NN O
in IN O
renal JJ O
Nrf2 NNP O
levels NNS O
. . O
null null null-Disease
Studies NNS O
were VBD O
also RB O
conducted VBN O
in IN O
renal JJ O
epithelial NN O
LLC NNP O
- HYPH O
PK1 NNP O
cells NNS O
and CC O
in IN O
mitochondria NN O
isolated VBN O
from IN O
kidneys NNS O
of IN O
all PDT O
the DT O
experimental JJ O
groups NNS O
. . O
null null null-Disease
Maleate NNP O
induced VBN O
cell NN O
damage NN O
and CC O
reactive JJ O
oxygen NN O
species NNS O
( , O
ROS NNP O
) -RRB- O
production NN O
in IN O
LLC NNP O
- HYPH O
PK1 NNP O
cells NNS O
in IN O
culture NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
maleate NN O
treatment NN O
reduced VBD O
oxygen NN O
consumption NN O
in IN O
ADP NNP O
- HYPH O
stimulated VBN O
mitochondria NN O
and CC O
diminished VBN O
respiratory JJ O
control NN O
index NN O
when WRB O
using VBG O
malate NN O
/ SYM O
glutamate NN O
as IN O
substrate NN O
. . O
null null null-Disease
The DT O
activities NNS O
of IN O
both DT O
complex NN O
I PRP O
and CC O
aconitase NN O
were VBD O
also RB O
diminished VBN O
. . O
null null null-Disease
All PDT O
the DT O
above RB O
- HYPH O
described VBN O
alterations NNS O
were VBD O
prevented VBN O
by IN O
curcumin NN O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
curcumin NN O
is VBZ O
able JJ O
to TO O
attenuate VB O
in IN O
vivo NN O
maleate NN O
- HYPH O
induced VBN O
nephropathy NN B-Disease
and CC O
in IN O
vitro FW O
cell NN O
damage NN O
. . O
null null null-Disease
The DT O
in IN O
vivo NN O
protection NN O
was VBD O
associated VBN O
to IN O
the DT O
prevention NN O
of IN O
oxidative JJ O
stress NN O
and CC O
preservation NN O
of IN O
mitochondrial JJ O
oxygen NN O
consumption NN O
and CC O
activity NN O
of IN O
respiratory JJ O
complex NN O
I NNP O
, , O
and CC O
the DT O
in FW O
vitro FW O
protection NN O
was VBD O
associated VBN O
to IN O
the DT O
prevention NN O
of IN O
ROS NNP O
production NN O
. . O
null null null-Disease
Anticonvulsant JJ O
actions NNS O
of IN O
MK NNP O
- HYPH O
801 CD O
on IN O
the DT O
lithium NN O
- HYPH O
pilocarpine NN O
model NN O
of IN O
status NN B-Disease
epilepticus NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
MK NNP O
- HYPH O
801 CD O
, , O
a DT O
noncompetitive JJ O
N NNP O
- HYPH O
methyl NN O
- HYPH O
D NNP O
- HYPH O
aspartate NN O
( , O
NMDA NNP O
) -RRB- O
receptor NN O
antagonist NN O
, , O
was VBD O
tested VBN O
for IN O
anticonvulsant JJ O
effects NNS O
in IN O
rats NNS O
using VBG O
two CD O
seizure NN B-Disease
models NNS O
, , O
coadministration NN O
of IN O
lithium NN O
and CC O
pilocarpine NN O
and CC O
administration NN O
of IN O
a DT O
high JJ O
dose NN O
of IN O
pilocarpine NN O
alone RB O
. . O
null null null-Disease
Three CD O
major JJ O
results NNS O
are VBP O
reported VBN O
. . O
null null null-Disease
First RB O
, , O
pretreatment NN O
with IN O
MK NNP O
- HYPH O
801 CD O
produced VBD O
an DT O
effective JJ O
and CC O
dose NN O
- HYPH O
dependent JJ O
anticonvulsant JJ O
action NN O
with IN O
the DT O
lithium NN O
- HYPH O
pilocarpine NN O
model NN O
but CC O
not RB O
with IN O
rats NNS O
treated VBN O
with IN O
pilocarpine NN O
alone RB O
, , O
suggesting VBG O
that IN O
different JJ O
biochemical JJ O
mechanisms NNS O
control VBP O
seizures NNS B-Disease
in IN O
these DT O
two CD O
models NNS O
. . O
null null null-Disease
Second RB O
, , O
the DT O
anticonvulsant JJ O
effect NN O
of IN O
MK NNP O
- HYPH O
801 CD O
in IN O
the DT O
lithium JJ O
- HYPH O
pilocarpine NN O
model NN O
only RB O
occurred VBD O
after IN O
initial JJ O
periods NNS O
of IN O
seizure NN B-Disease
activity NN O
. . O
null null null-Disease
This DT O
observation NN O
is VBZ O
suggested VBN O
to TO O
be VB O
an DT O
in IN O
vivo NN O
demonstration NN O
of IN O
the DT O
conclusion NN O
derived VBN O
from IN O
in FW O
vitro FW O
experiments NNS O
that IN O
MK NNP O
- HYPH O
801 CD O
binding NN O
requires VBZ O
agonist NN O
- HYPH O
induced VBN O
opening NN O
of IN O
the DT O
channel NN O
sites NNS O
of IN O
the DT O
NMDA NNP O
receptor NN O
. . O
null null null-Disease
Third RB O
, , O
although IN O
it PRP O
is VBZ O
relatively RB O
easy JJ O
to TO O
block VB O
seizures NNS B-Disease
induced VBN O
by IN O
lithium NN O
and CC O
pilocarpine NN O
by IN O
administration NN O
of IN O
anticonvulsants NNS O
prior RB O
to IN O
pilocarpine NN O
, , O
it PRP O
is VBZ O
more RBR O
difficult JJ O
to TO O
terminate VB O
ongoing JJ O
status NN B-Disease
epilepticus NN I-Disease
and CC O
block VB O
the DT O
lethality NN O
of IN O
the DT O
seizures NNS B-Disease
. . O
null null null-Disease
Administration NN O
of IN O
MK NNP O
- HYPH O
801 CD O
30 CD O
or CC O
60 CD O
min NN O
after IN O
pilocarpine NN O
, , O
i PRP O
. . O
e LS O
. . O
, , O
during IN O
status NN B-Disease
epilepticus NN I-Disease
, , O
gradually RB O
reduced VBD O
electrical JJ O
and CC O
behavioral JJ O
seizure NN B-Disease
activity NN O
and CC O
greatly RB O
enhanced VBD O
the DT O
survival NN O
rate NN O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
activation NN O
of IN O
NMDA NNP O
receptors NNS O
plays VBZ O
an DT O
important JJ O
role NN O
in IN O
status NN B-Disease
epilepticus NN I-Disease
and CC O
brain NN B-Disease
damage NN I-Disease
in IN O
the DT O
lithium NN O
- HYPH O
pilocarpine NN O
model NN O
. . O
null null null-Disease
This DT O
was VBD O
further RB O
supported VBN O
by IN O
results NNS O
showing VBG O
that IN O
nonconvulsive JJ O
doses NNS O
of IN O
NMDA NNP O
and CC O
pilocarpine NN O
were VBD O
synergistic JJ O
, , O
resulting VBG O
in IN O
status NN B-Disease
epilepticus NN I-Disease
and CC O
subsequent JJ O
mortality NN O
. . O
null null null-Disease
Continuous JJ O
infusion NN O
tobramycin NN O
combined VBN O
with IN O
carbenicillin NN O
for IN O
infections NNS B-Disease
in IN O
cancer NN B-Disease
patients NNS O
. . O
null null null-Disease
The DT O
cure NN O
rate NN O
of IN O
infections NNS B-Disease
in IN O
cancer NN B-Disease
patients NNS O
is VBZ O
adversely RB O
affected VBN O
by IN O
neutropenia NN B-Disease
( : O
less JJR O
than IN O
1 CD O
, , O
000 CD O
/ SYM O
mm3 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
particular JJ O
, , O
patients NNS O
with IN O
severe JJ O
neutropenia NN B-Disease
( , O
less JJR O
than IN O
100 CD O
/ SYM O
mm3 CD O
) , O
have VBP O
shown VBN O
a DT O
poor JJ O
response NN O
to IN O
antibiotics NNS O
. . O
null null null-Disease
To TO O
overcome VB O
the DT O
adverse JJ O
effects NNS O
of IN O
neutropenia NN B-Disease
, , O
tobramycin NN O
was VBD O
given VBN O
by IN O
continuous JJ O
infusion NN O
and CC O
combined VBN O
with IN O
intermittent JJ O
carbenicillin NN O
. . O
null null null-Disease
Tobramycin NNP O
was VBD O
given VBN O
to IN O
a DT O
total JJ O
daily JJ O
dose NN O
of IN O
300 CD O
mg NNS O
/ SYM O
m2 NN O
and CC O
carbenicillin NN O
was VBD O
given VBN O
at IN O
a DT O
dose NN O
of IN O
5 CD O
gm NN O
every DT O
four CD O
hours NNS O
. . O
null null null-Disease
There EX O
were VBD O
125 CD O
infectious JJ O
episodes NNS O
in IN O
116 CD O
cancer NN B-Disease
patients NNS O
receiving VBG O
myelosuppressive JJ O
chemotherapy NN O
. . O
null null null-Disease
The DT O
overall JJ O
cure NN O
rate NN O
was VBD O
70 CD O
% NN O
. . O
null null null-Disease
Pneumonia NN B-Disease
was VBD O
the DT O
most RBS O
common JJ O
infection NN B-Disease
and CC O
61 CD O
% NN O
of IN O
59 CD O
episodes NNS O
were VBD O
cured VBN O
. . O
null null null-Disease
Gram NNP O
- HYPH O
negative JJ O
bacilli NN O
were VBD O
the DT O
most RBS O
common JJ O
causative JJ O
organisms NNS O
and CC O
69 CD O
% NN O
of IN O
these DT O
infections NNS B-Disease
were VBD O
cured VBN O
. . O
null null null-Disease
The DT O
most RBS O
common JJ O
pathogen NN O
was VBD O
Klebsiella NNP O
pneumoniae NN B-Disease
and CC O
this DT O
, , O
together RB O
with IN O
Escherichia NNP O
coli NN O
and CC O
Pseudomonas NNP O
aeruginosa NN O
, , O
accounted VBD O
for IN O
74 CD O
% NN O
of IN O
all DT O
gram JJ B-Disease
- HYPH I-Disease
negative JJ I-Disease
bacillary NN I-Disease
infections NNS I-Disease
. . O
null null null-Disease
Response NN O
was VBD O
not RB O
influenced VBN O
by IN O
the DT O
initial JJ O
neutrophil NN O
count NN O
, , O
with IN O
a DT O
62 CD O
% NN O
cure NN O
rate NN O
for IN O
39 CD O
episodes NNS O
associated VBN O
with IN O
severe JJ O
neutropenia NN B-Disease
. . O
null null null-Disease
However RB O
, , O
failure NN O
of IN O
the DT O
neutrophil NN O
count NN O
to TO O
increase VB O
during IN O
therapy NN O
adversely RB O
affected VBD O
response NN O
. . O
null null null-Disease
Azotemia NNP B-Disease
was VBD O
the DT O
major JJ O
side NN O
effect NN O
recognized VBN O
, , O
and CC O
it PRP O
occurred VBD O
in IN O
11 CD O
% NN O
of IN O
episodes NNS O
. . O
null null null-Disease
Major JJ O
azotemia NN B-Disease
( , O
serum NN O
creatinine NN O
greater JJR O
than IN O
2 CD O
. . O
5 CD O
mg NN O
/ SYM O
dl NN O
or CC O
BUN NNP O
greater JJR O
than IN O
50 CD O
mg NNS O
/ SYM O
dl NN O
) -RRB- O
occurred VBD O
in IN O
only RB O
2 CD O
% NN O
. . O
null null null-Disease
Azotemia NNP B-Disease
was VBD O
not RB O
related VBN O
to IN O
duration NN O
of IN O
therapy NN O
or CC O
serum NN O
tobramycin NN O
concentration NN O
. . O
null null null-Disease
This DT O
antibiotic JJ O
regimen NN O
showed VBD O
both CC O
therapeutic JJ O
efficacy NN O
and CC O
acceptable JJ O
renal JJ B-Disease
toxicity NN I-Disease
for IN O
these DT O
patients NNS O
. . O
null null null-Disease
Incidence NN O
of IN O
solid JJ O
tumours NNS B-Disease
among IN O
pesticide NN O
applicators NNS O
exposed VBN O
to IN O
the DT O
organophosphate NN O
insecticide NN O
diazinon NN O
in IN O
the DT O
Agricultural NNP O
Health NNP O
Study NNP O
: : O
an DT O
updated JJ O
analysis NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
Diazinon NNP O
, , O
a DT O
common JJ O
organophosphate NN O
insecticide NN O
with IN O
genotoxic JJ O
properties NNS O
, , O
was VBD O
previously RB O
associated VBN O
with IN O
lung NN B-Disease
cancer NN I-Disease
in IN O
the DT O
Agricultural NNP O
Health NNP O
Study NNP O
( -LRB- O
AHS NNP O
) -RRB- O
cohort NN O
, , O
but CC O
few JJ O
other JJ O
epidemiological JJ O
studies NNS O
have VBP O
examined VBN O
diazinon NN O
- HYPH O
associated VBN O
cancer NN B-Disease
risk NN O
. . O
null null null-Disease
We PRP O
used VBD O
updated JJ O
diazinon NN O
exposure NN O
and CC O
cancer NN B-Disease
incidence NN O
information NN O
to TO O
evaluate VB O
solid JJ O
tumour NN B-Disease
risk NN O
in IN O
the DT O
AHS NNP O
. . O
null null null-Disease
METHODS NNS O
: : O
Male JJ O
pesticide NN O
applicators NNS O
in IN O
Iowa NNP O
and CC O
North NNP O
Carolina NNP O
reported VBD O
lifetime NN O
diazinon NN O
use NN O
at IN O
enrolment NN O
( , O
1993 CD O
- SYM O
1997 CD O
) -RRB- O
and CC O
follow NN O
- HYPH O
up NN O
( : O
1998 CD O
- SYM O
2005 CD O
) -RRB- O
; , O
cancer NN B-Disease
incidence NN O
was VBD O
assessed VBN O
through IN O
2010 CD O
( : O
North NNP O
Carolina NNP O
) , O
/ SYM O
2011 CD O
( , O
Iowa NNP O
) -RRB- O
. . O
null null null-Disease
Among IN O
applicators NNS O
with IN O
usage NN O
information NN O
sufficient JJ O
to TO O
evaluate VB O
exposure NN O
- HYPH O
response NN O
patterns NNS O
, , O
we PRP O
used VBD O
Poisson NNP O
regression NN O
to TO O
estimate VB O
adjusted VBN O
rate NN O
ratios NNS O
( , O
RRs NNS O
) -RRB- O
and CC O
95 CD O
% NN O
CI NN O
for IN O
cancer NN B-Disease
sites NNS O
with IN O
> SYM O
10 CD O
exposed VBN O
cases NNS O
for IN O
both DT O
lifetime NN O
( , O
LT NNP O
) -RRB- O
exposure NN O
days NNS O
and CC O
intensity NN O
- HYPH O
weighted VBN O
( -LRB- O
IW NN O
) -RRB- O
lifetime NN O
exposure NN O
days NNS O
( , O
accounting VBG O
for IN O
factors NNS O
impacting VBG O
exposure NN O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
We PRP O
observed VBD O
elevated VBN O
lung NN B-Disease
cancer NN I-Disease
risks NNS O
( , O
N CD O
= SYM O
283 CD O
) -RRB- O
among IN O
applicators NNS O
with IN O
the DT O
greatest JJS O
number NN O
of IN O
LT NNP O
( : O
RR NN O
= SYM O
1 CD O
. . O
60 CD O
; : O
95 CD O
% NN O
CI NN O
1 CD O
. . O
11 CD O
to TO O
2 CD O
. . O
31 CD O
; : O
Ptrend NN O
= SYM O
0 CD O
. . O
02 CD O
) -RRB- O
and CC O
IW NN O
days NNS O
of IN O
diazinon NN O
use NN O
( : O
RR NN O
= SYM O
1 CD O
. . O
41 CD O
; : O
95 CD O
% NN O
CI NN O
0 CD O
. . O
98 CD O
to TO O
2 CD O
. . O
04 CD O
; : O
Ptrend NN O
= SYM O
0 CD O
. . O
08 CD O
) -RRB- O
. . O
null null null-Disease
Kidney NN B-Disease
cancer NN I-Disease
( HYPH O
N NN O
= SYM O
94 CD O
) -RRB- O
risks NNS O
were VBD O
non RB O
- HYPH O
significantly RB O
elevated VBN O
( : O
RRLT NN O
days NNS O
= SYM O
1 CD O
. . O
77 CD O
; : O
95 CD O
% NN O
CI NN O
0 CD O
. . O
90 CD O
to TO O
3 CD O
. . O
51 CD O
; : O
Ptrend NN O
= SYM O
0 CD O
. . O
09 CD O
; : O
RRIW NN O
days NNS O
1 CD O
. . O
37 CD O
; : O
95 CD O
% NN O
CI NN O
0 CD O
. . O
64 CD O
to TO O
2 CD O
. . O
92 CD O
; : O
Ptrend NN O
= SYM O
0 CD O
. . O
50 CD O
) -RRB- O
, , O
as IN O
were VBD O
risks NNS O
for IN O
aggressive JJ O
prostate NN B-Disease
cancer NN I-Disease
( , O
N NNP O
= SYM O
656 CD O
) -RRB- O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Our PRP$ O
updated JJ O
evaluation NN O
of IN O
diazinon NN O
provides VBZ O
additional JJ O
evidence NN O
of IN O
an DT O
association NN O
with IN O
lung NN B-Disease
cancer NN I-Disease
risk NN O
. . O
null null null-Disease
Newly RB O
identified VBN O
links NNS O
to IN O
kidney NN B-Disease
cancer NN I-Disease
and CC O
associations NNS O
with IN O
aggressive JJ O
prostate NN B-Disease
cancer NN I-Disease
require VBP O
further JJ O
evaluation NN O
. . O
null null null-Disease
Associations NNS O
of IN O
Ozone NNP O
and CC O
PM2 NNP O
. . O
5 CD O
Concentrations NNS O
With IN O
Parkinson NNP B-Disease
' POS I-Disease
s NN I-Disease
Disease NNP I-Disease
Among IN O
Participants NNS O
in IN O
the DT O
Agricultural NNP O
Health NNP O
Study NNP O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
This DT O
study NN O
describes VBZ O
associations NNS O
of IN O
ozone NN O
and CC O
fine JJ O
particulate NN O
matter NN O
with IN O
Parkinson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
observed VBN O
among IN O
farmers NNS O
in IN O
North NNP O
Carolina NNP O
and CC O
Iowa NNP O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
used VBD O
logistic JJ O
regression NN O
to TO O
determine VB O
the DT O
associations NNS O
of IN O
these DT O
pollutants NNS O
with IN O
self NN O
- HYPH O
reported VBN O
, , O
doctor NN O
- HYPH O
diagnosed VBN O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
. . O
null null null-Disease
Daily NNP O
predicted VBD O
pollutant JJ O
concentrations NNS O
were VBD O
used VBN O
to TO O
derive VB O
surrogates NNS O
of IN O
long JJ O
- HYPH O
term NN O
exposure NN O
and CC O
link VB O
them PRP O
to TO O
study VB O
participants NNS O
' POS O
geocoded JJ O
addresses NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
We PRP O
observed VBD O
positive JJ O
associations NNS O
of IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
with IN O
ozone NN O
( , O
odds NNS O
ratio NN O
= SYM O
1 CD O
. . O
39 CD O
; : O
95 CD O
% NN O
CI NN O
: : O
0 CD O
. . O
98 CD O
to TO O
1 CD O
. . O
98 CD O
) -RRB- O
and CC O
fine JJ O
particulate NN O
matter NN O
( : O
odds NNS O
ratio NN O
= SYM O
1 CD O
. . O
34 CD O
; : O
95 CD O
% NN O
CI NN O
: : O
0 CD O
. . O
93 CD O
to TO O
1 CD O
. . O
93 CD O
) -RRB- O
in IN O
North NNP O
Carolina NNP O
but CC O
not RB O
in IN O
Iowa NNP O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
The DT O
plausibility NN O
of IN O
an DT O
effect NN O
of IN O
ambient JJ O
concentrations NNS O
of IN O
these DT O
pollutants NNS O
on IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
risk NN O
is VBZ O
supported VBN O
by IN O
experimental JJ O
data NNS O
demonstrating VBG O
damage NN O
to IN O
dopaminergic JJ O
neurons NNS O
at IN O
relevant JJ O
concentrations NNS O
. . O
null null null-Disease
Additional JJ O
studies NNS O
are VBP O
needed VBN O
to TO O
address VB O
uncertainties NNS O
related VBN O
to IN O
confounding VBG O
and CC O
to TO O
examine VB O
temporal JJ O
aspects NNS O
of IN O
the DT O
associations NNS O
we PRP O
observed VBD O
. . O
null null null-Disease
Low JJ O
functional JJ O
programming NN O
of IN O
renal JJ O
AT2R NNP O
mediates VBZ O
the DT O
developmental JJ O
origin NN O
of IN O
glomerulosclerosis NN B-Disease
in IN O
adult NN O
offspring NN O
induced VBN O
by IN O
prenatal JJ O
caffeine NN O
exposure NN O
. . O
null null null-Disease
UNASSIGNED JJ O
: : O
Our PRP$ O
previous JJ O
study NN O
has VBZ O
indicated VBN O
that IN O
prenatal JJ O
caffeine NN O
exposure NN O
( -LRB- O
PCE NNP O
) -RRB- O
could MD O
induce VB O
intrauterine JJ B-Disease
growth NN I-Disease
retardation NN I-Disease
( , O
IUGR NNP B-Disease
) -RRB- O
of IN O
offspring NN O
. . O
null null null-Disease
Recent JJ O
research NN O
suggested VBD O
that IN O
IUGR NNP B-Disease
is VBZ O
a DT O
risk NN O
factor NN O
for IN O
glomerulosclerosis NN B-Disease
. . O
null null null-Disease
However RB O
, , O
whether IN O
PCE NNP O
could MD O
induce VB O
glomerulosclerosis NN B-Disease
and CC O
its PRP$ O
underlying VBG O
mechanisms NNS O
remain VBP O
unknown JJ O
. . O
null null null-Disease
This DT O
study NN O
aimed VBD O
to TO O
demonstrate VB O
the DT O
induction NN O
to IN O
glomerulosclerosis NN B-Disease
in IN O
adult NN O
offspring NN O
by IN O
PCE NNP O
and CC O
its PRP$ O
intrauterine NN O
programming NN O
mechanisms NNS O
. . O
null null null-Disease
A DT O
rat NN O
model NN O
of IN O
IUGR NNP B-Disease
was VBD O
established VBN O
by IN O
PCE NNP O
, , O
male JJ O
fetuses NNS O
and CC O
adult NN O
offspring NN O
at IN O
the DT O
age NN O
of IN O
postnatal JJ O
week NN O
24 CD O
were VBD O
euthanized VBN O
. . O
null null null-Disease
The DT O
results NNS O
revealed VBD O
that IN O
the DT O
adult NN O
offspring NN O
kidneys NNS O
in IN O
the DT O
PCE NNP O
group NN O
exhibited VBD O
glomerulosclerosis NN B-Disease
as RB O
well RB O
as IN O
interstitial JJ B-Disease
fibrosis NN I-Disease
, , O
accompanied VBN O
by IN O
elevated VBN O
levels NNS O
of IN O
serum NN O
creatinine NN O
and CC O
urine NN O
protein NN O
. . O
null null null-Disease
Renal JJ O
angiotensin NN O
II NN O
receptor NN O
type NN O
2 CD O
( -LRB- O
AT2R NN O
) -RRB- O
gene NN O
expression NN O
in IN O
adult NN O
offspring NN O
was VBD O
reduced VBN O
by IN O
PCE NNP O
, , O
whereas IN O
the DT O
renal JJ O
angiotensin NN O
II NN O
receptor NN O
type NN O
1a CD O
( -LRB- O
AT1aR NN O
) -RRB- O
/ SYM O
AT2R NNP O
expression NN O
ratio NN O
was VBD O
increased VBN O
. . O
null null null-Disease
The DT O
fetal JJ O
kidneys NNS O
in IN O
the DT O
PCE NNP O
group NN O
displayed VBD O
an DT O
enlarged JJ O
Bowman NNP O
' POS O
s NN O
space NN O
and CC O
a DT O
shrunken VBN O
glomerular JJ O
tuft NN O
, , O
accompanied VBN O
by IN O
a DT O
reduced VBN O
cortex NN O
width NN O
and CC O
an DT O
increase NN O
in IN O
the DT O
nephrogenic JJ O
zone NN O
/ SYM O
cortical JJ O
zone NN O
ratio NN O
. . O
null null null-Disease
Observation NN O
by IN O
electronic JJ O
microscope NN O
revealed VBD O
structural JJ O
damage NN O
of IN O
podocytes NNS O
; , O
the DT O
reduced VBN O
expression NN O
level NN O
of IN O
podocyte NN O
marker NN O
genes NNS O
, , O
nephrin NN O
and CC O
podocin NN O
, , O
was VBD O
also RB O
detected VBN O
by IN O
q NN O
- HYPH O
PCR NN O
. . O
null null null-Disease
Moreover RB O
, , O
AT2R NNP O
gene NN O
and CC O
protein NN O
expressions NNS O
in IN O
fetal JJ O
kidneys NNS O
were VBD O
inhibited VBN O
by IN O
PCE NNP O
, , O
associated VBN O
with IN O
the DT O
repression NN O
of IN O
the DT O
gene NN O
expression NN O
of IN O
glial NN O
- HYPH O
cell NN O
- HYPH O
line NN O
- HYPH O
derived VBN O
neurotrophic JJ O
factor NN O
( , O
GDNF NNP O
) -RRB- O
/ SYM O
tyrosine NN O
kinase NN O
receptor NN O
( HYPH O
c NN O
- HYPH O
Ret NN O
) -RRB- O
signaling NN O
pathway NN O
. . O
null null null-Disease
These DT O
results NNS O
demonstrated VBD O
that IN O
PCE NNP O
could MD O
induce VB O
dysplasia NN B-Disease
of IN I-Disease
fetal JJ I-Disease
kidneys NNS I-Disease
as RB O
well RB O
as IN O
glomerulosclerosis NN B-Disease
of IN O
adult NN O
offspring NN O
, , O
and CC O
the DT O
low JJ O
functional JJ O
programming NN O
of IN O
renal JJ O
AT2R NN O
might MD O
mediate VB O
the DT O
developmental JJ O
origin NN O
of IN O
adult NN O
glomerulosclerosis NN B-Disease
. . O
null null null-Disease
1 CD O
, , O
3 CD O
- HYPH O
Butadiene NNP O
, , O
CML NNP B-Disease
and CC O
the DT O
t NN O
( , O
9 CD O
: SYM O
22 CD O
) , O
translocation NN O
: : O
A DT O
reality NN O
check NN O
. . O
null null null-Disease
UNASSIGNED JJ O
: : O
Epidemiological JJ O
studies NNS O
of IN O
1 CD O
, , O
3 CD O
- HYPH O
butadiene NN O
have VBP O
suggest VBP O
that IN O
exposures NNS O
to IN O
humans NNS O
are VBP O
associated VBN O
with IN O
chronic JJ B-Disease
myeloid NN I-Disease
leukemia NN I-Disease
( , O
CML NNP B-Disease
) -RRB- O
. . O
null null null-Disease
CML NNP B-Disease
has VBZ O
a DT O
well RB O
- HYPH O
documented VBN O
association NN O
with IN O
ionizing VBG O
radiation NN O
, , O
but CC O
reports NNS O
of IN O
associations NNS O
with IN O
chemical JJ O
exposures NNS O
have VBP O
been VBN O
questioned VBN O
. . O
null null null-Disease
Ionizing VBG O
radiation NN O
is VBZ O
capable JJ O
of IN O
inducing VBG O
the DT O
requisite JJ O
CML NN B-Disease
- HYPH O
associated VBN O
t NN O
( SYM O
9 CD O
: SYM O
22 CD O
) -RRB- O
translocation NN O
( , O
Philadelphia NNP B-Disease
chromosome NN I-Disease
) -RRB- O
in IN O
appropriate JJ O
cells NNS O
in IN O
vitro NN O
but CC O
, , O
thus RB O
far RB O
, , O
chemicals NNS O
have VBP O
not RB O
shown VBN O
this DT O
capacity NN O
. . O
null null null-Disease
We PRP O
have VBP O
proposed VBN O
that IN O
1 CD O
, , O
3 CD O
- HYPH O
butadiene NN O
metabolites NNS O
be VB O
so RB O
tested VBN O
as IN O
a DT O
reality NN O
check NN O
on IN O
the DT O
epidemiological JJ O
reports NNS O
. . O
null null null-Disease
In IN O
order NN O
to TO O
conduct VB O
reliable JJ O
testing NN O
in IN O
this DT O
regard NN O
, , O
it PRP O
is VBZ O
essential JJ O
that IN O
a DT O
positive JJ O
control NN O
for IN O
induction NN O
be VB O
available JJ O
. . O
null null null-Disease
We PRP O
have VBP O
used VBN O
ionizing VBG O
radiation NN O
to TO O
develop VB O
such PDT O
a DT O
control NN O
. . O
null null null-Disease
Results NNS O
described VBN O
here RB O
demonstrate VBP O
that IN O
this DT O
agent NN O
does VBZ O
in IN O
fact NN O
induce VB O
pathogenic JJ O
t NN O
( , O
9 CD O
: SYM O
22 CD O
) , O
translocations NNS O
in IN O
a DT O
human JJ O
myeloid NN O
cell NN O
line NN O
in IN O
vitro NN O
, , O
but CC O
does VBZ O
so RB O
at IN O
low JJ O
frequencies NNS O
. . O
null null null-Disease
Conditions NNS O
that WDT O
will MD O
be VB O
required VBN O
for IN O
studies NNS O
of IN O
1 CD O
, , O
3 CD O
- HYPH O
butadiene NN O
are VBP O
discussed VBN O
. . O
null null null-Disease
Cancer NN B-Disease
incidence NN O
and CC O
metolachlor NN O
use NN O
in IN O
the DT O
Agricultural NNP O
Health NNP O
Study NNP O
: : O
An DT O
update NN O
. . O
null null null-Disease
UNASSIGNED JJ O
: : O
Metolachlor NNP O
, , O
a DT O
widely RB O
used VBN O
herbicide NN O
, , O
is VBZ O
classified VBN O
as IN O
a DT O
Group NNP O
C NNP O
carcinogen NN O
by IN O
the DT O
U NNP O
. . O
S NNP O
. . O
null null null-Disease
Environmental NNP O
Protection NNP O
Agency NNP O
based VBN O
on IN O
increased JJ O
liver NN B-Disease
neoplasms NNS I-Disease
in IN O
female JJ O
rats NNS O
. . O
null null null-Disease
Epidemiologic JJ O
studies NNS O
of IN O
the DT O
health NN O
effects NNS O
of IN O
metolachlor NN O
have VBP O
been VBN O
limited VBN O
. . O
null null null-Disease
The DT O
Agricultural NNP O
Health NNP O
Study NNP O
( -LRB- O
AHS NNP O
) -RRB- O
is VBZ O
a DT O
prospective JJ O
cohort NN O
study NN O
including VBG O
licensed VBN O
private JJ O
and CC O
commercial JJ O
pesticide NN O
applicators NNS O
in IN O
Iowa NNP O
and CC O
North NNP O
Carolina NNP O
enrolled VBN O
1993 CD O
- SYM O
1997 CD O
. . O
null null null-Disease
We PRP O
evaluated VBD O
cancer NN B-Disease
incidence NN O
through IN O
2010 CD O
/ SYM O
2011 CD O
( , O
NC NNP O
/ SYM O
IA NNP O
) -RRB- O
for IN O
49 CD O
, , O
616 CD O
applicators NNS O
, , O
53 CD O
% NN O
of IN O
whom WP O
reported VBD O
ever RB O
using VBG O
metolachlor NN O
. . O
null null null-Disease
We PRP O
used VBD O
Poisson NNP O
regression NN O
to TO O
evaluate VB O
relations NNS O
between IN O
two CD O
metrics NNS O
of IN O
metolachlor NN O
use NN O
( , O
lifetime NN O
days NNS O
, , O
intensity NN O
- HYPH O
weighted JJ O
lifetime NN O
days NNS O
) -RRB- O
and CC O
cancer NN B-Disease
incidence NN O
. . O
null null null-Disease
We PRP O
saw VBD O
no DT O
association NN O
between IN O
metolachlor NN O
use NN O
and CC O
incidence NN O
of IN O
all DT O
cancers NNS B-Disease
combined VBN O
( : O
n CD O
= SYM O
5 CD O
, , O
701 CD O
with IN O
a DT O
5 CD O
- HYPH O
year NN O
lag NN O
) -RRB- O
or CC O
most JJS O
site NN O
- HYPH O
specific JJ O
cancers NNS B-Disease
. . O
null null null-Disease
For IN O
liver NN B-Disease
cancer NN I-Disease
, , O
in IN O
analyses NNS O
restricted VBN O
to IN O
exposed VBN O
workers NNS O
, , O
elevations NNS O
observed VBN O
at IN O
higher JJR O
categories NNS O
of IN O
use NN O
were VBD O
not RB O
statistically RB O
significant JJ O
. . O
null null null-Disease
However RB O
, , O
trends NNS O
for IN O
both CC O
lifetime NN O
and CC O
intensity NN O
- HYPH O
weighted JJ O
lifetime NN O
days NNS O
of IN O
metolachor NN O
use NN O
were VBD O
positive JJ O
and CC O
statistically RB O
significant JJ O
with IN O
an DT O
unexposed JJ O
reference NN O
group NN O
. . O
null null null-Disease
A DT O
similar JJ O
pattern NN O
was VBD O
observed VBN O
for IN O
follicular JJ B-Disease
cell NN I-Disease
lymphoma NN I-Disease
, , O
but CC O
no DT O
other JJ O
lymphoma NN B-Disease
subtypes NNS O
. . O
null null null-Disease
An DT O
earlier JJR O
suggestion NN O
of IN O
increased VBN O
lung NN B-Disease
cancer NN I-Disease
risk NN O
at IN O
high JJ O
levels NNS O
of IN O
metolachlor NN O
use NN O
in IN O
this DT O
cohort NN O
was VBD O
not RB O
confirmed VBN O
in IN O
this DT O
update NN O
. . O
null null null-Disease
This DT O
suggestion NN O
of IN O
an DT O
association NN O
between IN O
metolachlor NN O
and CC O
liver NN B-Disease
cancer NN I-Disease
among IN O
pesticide NN O
applicators NNS O
is VBZ O
a DT O
novel JJ O
finding NN O
and CC O
echoes VBZ O
observation NN O
of IN O
increased VBN O
liver NN B-Disease
neoplasms NNS I-Disease
in IN O
some DT O
animal NN O
studies NNS O
. . O
null null null-Disease
However RB O
, , O
our PRP$ O
findings NNS O
for IN O
both CC O
liver NN B-Disease
cancer NN I-Disease
and CC O
follicular JJ O
cell NN O
lymphoma NN B-Disease
warrant VBP O
follow NN O
- HYPH O
up NN O
to IN O
better JJR O
differentiate VBP O
effects NNS O
of IN O
metolachlor NN O
use NN O
from IN O
other JJ O
factors NNS O
. . O
null null null-Disease
Mechanisms NNS O
Underlying VBG O
Latent JJ O
Disease NN O
Risk NN O
Associated VBN O
with IN O
Early JJ O
- HYPH O
Life NN O
Arsenic JJ O
Exposure NN O
: : O
Current JJ O
Research NN O
Trends NNS O
and CC O
Scientific JJ O
Gaps NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Millions NNS O
of IN O
individuals NNS O
worldwide RB O
, , O
particularly RB O
those DT O
living VBG O
in IN O
rural JJ O
and CC O
developing VBG O
areas NNS O
, , O
are VBP O
exposed VBN O
to IN O
harmful JJ O
levels NNS O
of IN O
inorganic JJ O
arsenic NN O
( , O
iAs NNS O
) -RRB- O
in IN O
their PRP$ O
drinking NN O
water NN O
. . O
null null null-Disease
Inorganic JJ O
As IN O
exposure NN O
during IN O
key JJ O
developmental JJ O
periods NNS O
is VBZ O
associated VBN O
with IN O
a DT O
variety NN O
of IN O
adverse JJ O
health NN O
effects NNS O
including VBG O
those DT O
that WDT O
are VBP O
evident JJ O
in IN O
adulthood NN O
. . O
null null null-Disease
There EX O
is VBZ O
considerable JJ O
interest NN O
in IN O
identifying VBG O
the DT O
molecular JJ O
mechanisms NNS O
that WDT O
relate VBP O
early JJ O
- HYPH O
life NN O
iAs NNS O
exposure NN O
to IN O
the DT O
development NN O
of IN O
these DT O
latent NN O
diseases NNS O
, , O
particularly RB O
in IN O
relationship NN O
to IN O
cancer NN B-Disease
. . O
null null null-Disease
OBJECTIVES NNS O
: : O
This DT O
work NN O
summarizes VBZ O
research NN O
on IN O
the DT O
molecular JJ O
mechanisms NNS O
that WDT O
underlie VBP O
the DT O
increased VBN O
risk NN O
of IN O
cancer NN B-Disease
development NN O
in IN O
adulthood NN O
that WDT O
is VBZ O
associated VBN O
with IN O
early JJ O
- HYPH O
life NN O
iAs NNS O
exposure NN O
. . O
null null null-Disease
DISCUSSION NN O
: : O
Epigenetic JJ O
reprogramming NN O
that WDT O
imparts VBZ O
functional JJ O
changes NNS O
in IN O
gene NN O
expression NN O
, , O
the DT O
development NN O
of IN O
cancer NN B-Disease
stem NN O
cells NNS O
, , O
and CC O
immunomodulation NN O
are VBP O
plausible JJ O
underlying VBG O
mechanisms NNS O
by IN O
which WDT O
early JJ O
- HYPH O
life NN O
iAs NNS O
exposure NN O
elicits VBZ O
latent JJ O
carcinogenic JJ O
effects NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Evidence NN O
is VBZ O
mounting VBG O
that WDT O
relates VBZ O
early JJ O
- HYPH O
life NN O
iAs NNS O
exposure NN O
and CC O
cancer NN B-Disease
development NN O
later RB O
in IN O
life NN O
. . O
null null null-Disease
Future JJ O
research NN O
should MD O
include VB O
animal NN O
studies NNS O
that WDT O
address VBP O
mechanistic JJ O
hypotheses NNS O
and CC O
studies NNS O
of IN O
human JJ O
populations NNS O
that WDT O
integrate VBP O
early JJ O
- HYPH O
life NN O
exposure NN O
, , O
molecular JJ O
alterations NNS O
, , O
and CC O
latent JJ O
disease NN O
outcomes NNS O
. . O
null null null-Disease
Nifedipine NN O
induced VBD O
bradycardia NN B-Disease
in IN O
a DT O
patient NN O
with IN O
autonomic JJ B-Disease
neuropathy NN I-Disease
. . O
null null null-Disease
An DT O
80 CD O
year NN O
old JJ O
diabetic JJ B-Disease
male NN O
with IN O
evidence NN O
of IN O
peripheral JJ B-Disease
and CC I-Disease
autonomic JJ I-Disease
neuropathy NN I-Disease
was VBD O
admitted VBN O
with IN O
chest NN B-Disease
pain NN I-Disease
. . O
null null null-Disease
He PRP O
was VBD O
found VBN O
to TO O
have VB O
atrial JJ B-Disease
flutter NN I-Disease
at IN O
a DT O
ventricular JJ O
rate NN O
of IN O
70 CD O
/ SYM O
min NN O
which WDT O
slowed VBD O
down RP O
to IN O
30 CD O
- SYM O
40 CD O
/ SYM O
min NN O
when WRB O
nifedipine NN O
( , O
60 CD O
mg NN O
) -RRB- O
in IN O
3 CD O
divided VBN O
doses NNS O
, , O
during IN O
which WDT O
he PRP O
was VBD O
paced VBN O
at IN O
a DT O
rate NN O
of IN O
70 CD O
/ SYM O
min NN O
. . O
null null null-Disease
This DT O
is VBZ O
inconsistent JJ O
with IN O
the DT O
well RB O
- HYPH O
established VBN O
finding NN O
that IN O
nifedipine NN O
induces VBZ O
tachycardia NN B-Disease
in IN O
normally RB O
innervated VBN O
hearts NNS O
. . O
null null null-Disease
However RB O
, , O
in IN O
hearts NNS O
deprived VBN O
of IN O
compensatory JJ O
sympathetic JJ O
drive NN O
, , O
it PRP O
may MD O
lead VB O
to IN O
bradycardia NN B-Disease
. . O
null null null-Disease
The DT O
effect NN O
of IN O
haloperidol NN O
in IN O
cocaine NN O
and CC O
amphetamine NN O
intoxication NN O
. . O
null null null-Disease
The DT O
effectiveness NN O
of IN O
haloperidol NN O
pretreatment NN O
in IN O
preventing VBG O
the DT O
toxic JJ O
effects NNS O
of IN O
high JJ O
doses NNS O
of IN O
amphetamine NN O
and CC O
cocaine NN O
was VBD O
studied VBN O
in IN O
rats NNS O
. . O
null null null-Disease
In IN O
this DT O
model NN O
, , O
toxic JJ O
effects NNS O
were VBD O
induced VBN O
by IN O
intraperitoneal JJ O
( : O
i LS O
. . O
p NN O
. . O
) -RRB- O
injection NN O
of IN O
amphetamine NN O
75 CD O
mg NN O
/ SYM O
kg NN O
( SYM O
100 CD O
% NN O
death NN O
rate NN O
) , O
or CC O
cocaine NN O
70 CD O
mg NN O
/ SYM O
kg CD O
( SYM O
82 CD O
% NN O
death NN O
rate NN O
) -RRB- O
. . O
null null null-Disease
Haloperidol NNP O
failed VBD O
to TO O
prevent VB O
amphetamine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
, , O
but CC O
did VBD O
lower VB O
the DT O
mortality NN O
rate NN O
at IN O
most JJS O
doses NNS O
tested VBN O
. . O
null null null-Disease
Haloperidol NNP O
decreased VBD O
the DT O
incidence NN O
of IN O
cocaine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
at IN O
the DT O
two CD O
highest JJS O
doses NNS O
, , O
but CC O
the DT O
lowering NN O
of IN O
the DT O
mortality NN O
rate NN O
did VBD O
not RB O
reach VB O
statistical JJ O
significance NN O
at IN O
any DT O
dose NN O
. . O
null null null-Disease
These DT O
data NNS O
suggest VBP O
a DT O
protective JJ O
role NN O
for IN O
the DT O
central JJ O
dopamine NN O
blocker NN O
haloperidol NN O
against IN O
death NN O
from IN O
high JJ O
- HYPH O
dose NN O
amphetamine NN O
exposure NN O
without IN O
reducing VBG O
the DT O
incidence NN O
of IN O
seizures NNS B-Disease
. . O
null null null-Disease
In IN O
contrast NN O
, , O
haloperidol NN O
demonstrated VBD O
an DT O
ability NN O
to TO O
reduce VB O
cocaine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
without IN O
significantly RB O
reducing VBG O
mortality NN O
. . O
null null null-Disease
Autoradiographic JJ O
evidence NN O
of IN O
estrogen NN O
binding VBG O
sites NNS O
in IN O
nuclei NNS O
of IN O
diethylstilbesterol NN O
induced VBN O
hamster NN O
renal JJ B-Disease
carcinomas NNS I-Disease
. . O
null null null-Disease
Estrogen NN O
binding NN O
sites NNS O
were VBD O
demonstrated VBN O
by IN O
autoradiography NN O
in IN O
one CD O
transplantable JJ O
and CC O
five CD O
primary JJ O
diethylstilbesterol NN O
induced VBN O
renal JJ B-Disease
carcinomas NNS I-Disease
in IN O
three CD O
hamsters NNS O
. . O
null null null-Disease
Radiolabelling NN O
, , O
following VBG O
the DT O
in IN O
vivo NN O
injection NN O
of IN O
3H CD O
- HYPH O
17 CD O
beta NN O
estradiol NN O
, , O
was VBD O
increased VBN O
only RB O
over IN O
the DT O
nuclei NNS O
of IN O
tumor NN B-Disease
cells NNS O
; : O
stereologic JJ O
analysis NN O
revealed VBD O
a DT O
4 CD O
. . O
5 CD O
- HYPH O
to IN O
6 CD O
. . O
7 CD O
- HYPH O
times NNS O
higher JJR O
concentration NN O
of IN O
reduced VBN O
silver JJ O
grains NNS O
over IN O
nuclei NNS O
than IN O
cytoplasm NN O
of IN O
these DT O
cells NNS O
. . O
null null null-Disease
Despite IN O
rapid JJ O
tubular JJ O
excretion NN O
of IN O
estradiol NN O
which WDT O
peaked VBD O
in IN O
less JJR O
than IN O
1 CD O
h NN O
, , O
the DT O
normal JJ O
cells NNS O
did VBD O
not RB O
appear VB O
to TO O
bind VB O
the DT O
ligand NN O
. . O
null null null-Disease
This DT O
is VBZ O
the DT O
first JJ O
published JJ O
report NN O
documenting VBG O
the DT O
preferential JJ O
in IN O
vivo NN O
binding NN O
of IN O
estrogen NN O
to IN O
nuclei NNS O
of IN O
cells NNS O
in IN O
estrogen NN O
induced VBN O
hamster NN O
renal JJ B-Disease
carcinomas NNS I-Disease
. . O
null null null-Disease
Bradycardia NNP B-Disease
due JJ O
to TO O
biperiden VB O
. . O
null null null-Disease
In IN O
a DT O
38 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male JJ O
patient NN O
suffering VBG O
from IN O
a DT O
severe JJ O
postzosteric JJ B-Disease
trigeminal JJ B-Disease
neuralgia NN I-Disease
, , O
intravenous JJ O
application NN O
of IN O
10 CD O
mg NN O
biperiden NN O
lactate NN O
led VBD O
to IN O
a DT O
long RB O
- HYPH O
lasting VBG O
paradoxical JJ O
reaction NN O
characterized VBN O
by IN O
considerable JJ O
bradycardia NN B-Disease
, , O
dysarthria NN B-Disease
, , O
and CC O
dysphagia NN B-Disease
. . O
null null null-Disease
The DT O
heart NN O
rate NN O
was VBD O
back RB O
to IN O
normal JJ O
within IN O
12 CD O
hours NNS O
upon IN O
administration NN O
of IN O
orciprenaline NN O
under IN O
cardiac JJ O
monitoring NN O
in IN O
an DT O
intensive JJ O
care NN O
unit NN O
. . O
null null null-Disease
Bradycardia NNP B-Disease
induced VBN O
by IN O
biperiden NN O
is VBZ O
attributed VBN O
to IN O
the DT O
speed NN O
of IN O
injection NN O
and CC O
to IN O
a DT O
dose NN O
- HYPH O
related VBN O
dual JJ O
effect NN O
of IN O
atropine NN O
- HYPH O
like JJ O
drugs NNS O
on IN O
muscarine NN O
receptors NNS O
. . O
null null null-Disease
Deliberate JJ O
hypotension NN B-Disease
induced VBN O
by IN O
labetalol NN O
with IN O
halothane NN O
, , O
enflurane NN O
or CC O
isoflurane NN O
for IN O
middle JJ O
- HYPH O
ear NN O
surgery NN O
. . O
null null null-Disease
The DT O
feasibility NN O
of IN O
using VBG O
labetalol NN O
, , O
an DT O
alpha NN O
- HYPH O
and CC O
beta NN O
- HYPH O
adrenergic JJ O
blocking NN O
agent NN O
, , O
as IN O
a DT O
hypotensive JJ B-Disease
agent NN O
in IN O
combination NN O
with IN O
inhalation NN O
anaesthetics NNS O
( , O
halothane NN O
, , O
enflurane NN O
or CC O
isoflurane NN O
) , O
was VBD O
studied VBN O
in IN O
23 CD O
adult NN O
patients NNS O
undergoing VBG O
middle JJ O
- HYPH O
ear NN O
surgery NN O
. . O
null null null-Disease
The DT O
mean JJ O
arterial JJ O
pressure NN O
was VBD O
decreased VBN O
from IN O
86 CD O
+ SYM O
/ SYM O
- HYPH O
5 CD O
( , O
s NN O
. . O
e LS O
. . O
mean NN O
) : O
mmHg NN O
to IN O
52 CD O
+ CD O
/ SYM O
- HYPH O
1 CD O
mmHg NN O
( SYM O
11 CD O
. . O
5 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
to TO O
6 CD O
. . O
9 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
1 CD O
kPa NN O
) : O
for IN O
98 CD O
+ NN O
/ SYM O
- SYM O
10 CD O
min NN O
in IN O
the DT O
halothane NN O
( HYPH O
H NN O
) -RRB- O
group NN O
, , O
from IN O
79 CD O
+ CD O
/ SYM O
- HYPH O
5 CD O
to IN O
53 CD O
+ CD O
/ SYM O
- HYPH O
1 CD O
mmHg NN O
( SYM O
10 CD O
. . O
5 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
to TO O
7 CD O
. . O
1 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
1 CD O
kPa NN O
) : O
for IN O
129 CD O
+ SYM O
/ SYM O
- HYPH O
11 CD O
min NN O
in IN O
the DT O
enflurane NN O
( HYPH O
E NN O
) NFP O
group NN O
, , O
and CC O
from IN O
80 CD O
+ CD O
/ SYM O
- HYPH O
4 CD O
to TO O
49 CD O
+ CD O
/ SYM O
- HYPH O
1 CD O
mmHg NN O
( SYM O
10 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
5 CD O
to TO O
6 CD O
. . O
5 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
1 CD O
kPa NN O
) -RRB- O
for IN O
135 CD O
+ SYM O
/ SYM O
- HYPH O
15 CD O
min NN O
in IN O
the DT O
isoflurane NN O
( , O
I PRP O
) -RRB- O
group NN O
. . O
null null null-Disease
The DT O
mean JJ O
H NN O
concentration NN O
during IN O
hypotension NN B-Disease
in IN O
the DT O
inspiratory JJ O
gas NN O
was VBD O
0 CD O
. . O
7 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
1 CD O
vol NN O
% NN O
, , O
the DT O
mean JJ O
E NN O
concentration NN O
1 CD O
. . O
6 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
2 CD O
vol NN O
% NN O
, , O
and CC O
the DT O
mean JJ O
I NN O
concentration NN O
1 CD O
. . O
0 CD O
+ NFP O
/ SYM O
- SYM O
0 CD O
. . O
1 CD O
vol NN O
% NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
the DT O
patients NNS O
received VBD O
fentanyl NN O
and CC O
d NN O
- HYPH O
tubocurarine NN O
. . O
null null null-Disease
The DT O
initial JJ O
dose NN O
of IN O
labetalol NN O
for IN O
lowering VBG O
blood NN O
pressure NN O
was VBD O
similar JJ O
, , O
0 CD O
. . O
52 CD O
- SYM O
0 CD O
. . O
59 CD O
mg NN O
/ SYM O
kg NN O
, , O
in IN O
all PDT O
the DT O
groups NNS O
. . O
null null null-Disease
During IN O
hypotension NN B-Disease
, , O
the DT O
heart NN O
rate NN O
was VBD O
stable JJ O
without IN O
tachy JJ B-Disease
- HYPH I-Disease
or CC I-Disease
bradycardia NN I-Disease
. . O
null null null-Disease
The DT O
operating VBG O
conditions NNS O
regarding VBG O
bleeding NN B-Disease
were VBD O
estimated VBN O
in IN O
a DT O
double JJ O
- HYPH O
blind JJ O
manner NN O
, , O
and CC O
did VBD O
not RB O
differ VB O
significantly RB O
between IN O
the DT O
groups NNS O
. . O
null null null-Disease
During IN O
hypotension NN B-Disease
, , O
the DT O
serum NN O
creatinine NN O
concentration NN O
rose VBD O
significantly RB O
in IN O
all DT O
groups NNS O
from IN O
the DT O
values NNS O
before IN O
hypotension NN B-Disease
and CC O
returned VBD O
postoperatively RB O
to IN O
the DT O
initial JJ O
level NN O
in IN O
the DT O
other JJ O
groups NNS O
, , O
except IN O
the DT O
isoflurane NN O
group NN O
. . O
null null null-Disease
After IN O
hypotension NN B-Disease
there EX O
was VBD O
no DT O
rebound NN O
phenomenon NN O
in IN O
either CC O
blood NN O
pressure NN O
or CC O
heart NN O
rate NN O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
labetalol NN O
induces VBZ O
easily RB O
adjustable JJ O
hypotension NN B-Disease
without IN O
compensatory JJ O
tachycardia NN B-Disease
and CC O
rebound NN O
hypertension NN B-Disease
. . O
null null null-Disease
Convulsion NN B-Disease
following VBG O
intravenous JJ O
fluorescein NN O
angiography NN O
. . O
null null null-Disease
Tonic NN B-Disease
- HYPH I-Disease
clonic JJ I-Disease
seizures NNS I-Disease
followed VBD O
intravenous JJ O
fluorescein NN O
injection NN O
for IN O
fundus NN O
angiography NN O
in IN O
a DT O
47 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
male NN O
. . O
null null null-Disease
Despite IN O
precautions NNS O
this DT O
adverse JJ O
reaction NN O
recurred VBD O
on IN O
re IN O
- HYPH O
exposure NN O
to IN O
intravenous JJ O
fluorescein NN O
. . O
null null null-Disease
Pharmacology NN O
of IN O
ACC NNP O
- HYPH O
9653 CD O
( : O
phenytoin NN O
prodrug NN O
) -RRB- O
. . O
null null null-Disease
ACC NNP O
- HYPH O
9653 CD O
, , O
the DT O
disodium NN O
phosphate NN O
ester NN O
of IN O
3 CD O
- HYPH O
hydroxymethyl NN O
- HYPH O
5 CD O
, , O
5 CD O
- HYPH O
diphenylhydantoin NN O
, , O
is VBZ O
a DT O
prodrug NN O
of IN O
phenytoin NN O
with IN O
advantageous JJ O
physicochemical JJ O
properties NNS O
. . O
null null null-Disease
ACC NNP O
- HYPH O
9653 CD O
is VBZ O
rapidly RB O
converted VBN O
enzymatically RB O
to IN O
phenytoin NN O
in IN O
vivo NN O
. . O
null null null-Disease
ACC NNP O
- HYPH O
9653 CD O
and CC O
phenytoin NN O
sodium NN O
have VBP O
equivalent JJ O
anticonvulsant JJ O
activity NN O
against IN O
seizures NNS B-Disease
induced VBN O
by IN O
maximal JJ O
electroshock NN O
( : O
MES NNP O
) -RRB- O
in IN O
mice NNS O
following VBG O
i DT O
. . O
p NN O
. . O
, , O
oral JJ O
, , O
or CC O
i LS O
. . O
v NN O
. . O
administration NN O
. . O
null null null-Disease
The DT O
ED50 NNP O
doses NNS O
were VBD O
16 CD O
mg NNS O
/ SYM O
kg NN O
for IN O
i PRP O
. . O
v NN O
. . O
ACC NN O
- HYPH O
9653 CD O
and CC O
8 CD O
mg NN O
/ SYM O
kg NN O
for IN O
i CD O
. . O
v NN O
. . O
phenytoin NN O
sodium NN O
. . O
null null null-Disease
ACC NNP O
- HYPH O
9653 CD O
and CC O
phenytoin NN O
sodium NN O
have VBP O
similar JJ O
antiarrhythmic JJ O
activity NN O
against IN O
ouabain NN O
- HYPH O
induced VBN O
ventricular JJ B-Disease
tachycardia NN I-Disease
in IN O
anesthetized VBN O
dogs NNS O
. . O
null null null-Disease
The DT O
total JJ O
doses NNS O
of IN O
ACC NNP O
- HYPH O
9653 CD O
or CC O
phenytoin NN O
sodium NN O
necessary JJ O
to TO O
convert VB O
the DT O
arrhythmia NN B-Disease
to IN O
a DT O
normal JJ O
sinus NN O
rhythm NN O
were VBD O
24 CD O
+ SYM O
/ SYM O
- HYPH O
6 CD O
and CC O
14 CD O
+ CD O
/ SYM O
- SYM O
3 CD O
mg NN O
/ SYM O
kg NN O
, , O
respectively RB O
. . O
null null null-Disease
Only RB O
phenytoin NN O
sodium NN O
displayed VBD O
in IN O
vitro FW O
antiarrhythmic JJ O
activity NN O
against IN O
strophanthidin NN O
- HYPH O
induced VBN O
arrhythmias NNS B-Disease
in IN O
guinea NN O
pig NN O
right JJ O
atria NN O
. . O
null null null-Disease
In IN O
anesthetized JJ O
dogs NNS O
, , O
a DT O
high JJ O
dose NN O
of IN O
ACC NNP O
- HYPH O
9653 CD O
( SYM O
31 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
was VBD O
infused VBN O
over IN O
15 CD O
, , O
20 CD O
, , O
and CC O
30 CD O
min NN O
and CC O
the DT O
responses NNS O
were VBD O
compared VBN O
to IN O
an DT O
equimolar JJ O
dose NN O
of IN O
phenytoin NN O
sodium NN O
( : O
21 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
. . O
null null null-Disease
The DT O
ACC NNP O
- HYPH O
9653 CD O
and CC O
phenytoin NN O
sodium NN O
treatments NNS O
produced VBD O
similar JJ O
marked JJ O
reductions NNS O
in IN O
diastolic JJ O
blood NN O
pressure NN O
and CC O
contractile JJ O
force NN O
( -LRB- O
LVdP NN O
/ , O
dt FW O
) -RRB- O
. . O
null null null-Disease
The DT O
maximum JJ O
effects NNS O
of IN O
each DT O
treatment NN O
occurred VBD O
at IN O
the DT O
time NN O
of IN O
maximum JJ O
phenytoin NN O
sodium NN O
levels NNS O
. . O
null null null-Disease
Acute JJ O
toxicity NN B-Disease
studies NNS O
of IN O
ACC NNP O
- HYPH O
9653 CD O
and CC O
phenytoin NN O
sodium NN O
were VBD O
carried VBN O
out RP O
in IN O
mice NNS O
, , O
rats NNS O
, , O
rabbits NNS O
, , O
and CC O
dogs NNS O
by IN O
i PRP O
. . O
v NN O
. . O
, , O
i PRP O
. . O
m UH O
. . O
, , O
and CC O
i PRP O
. . O
p NN O
. . O
routes NNS O
of IN O
administration NN O
. . O
null null null-Disease
The DT O
systemic JJ O
toxic JJ O
signs NNS O
of IN O
both DT O
agents NNS O
were VBD O
similar JJ O
and CC O
occurred VBD O
at IN O
approximately RB O
equivalent JJ O
doses NNS O
. . O
null null null-Disease
Importantly RB O
, , O
the DT O
local JJ O
irritation NN O
of IN O
ACC NNP O
- HYPH O
9653 CD O
was VBD O
markedly RB O
less JJR O
than IN O
phenytoin NN O
sodium NN O
following VBG O
i : O
. . O
m UH O
. . O
administration NN O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) : O
null null null-Disease
Tachyphylaxis NNS O
to IN O
systemic JJ O
but CC O
not RB O
to IN O
airway NN O
responses NNS O
during IN O
prolonged VBN O
therapy NN O
with IN O
high JJ O
dose NN O
inhaled VBN O
salbutamol NN O
in IN O
asthmatics NNS B-Disease
. . O
null null null-Disease
High JJ O
doses NNS O
of IN O
inhaled VBN O
salbutamol NN O
produce VBP O
substantial JJ O
improvements NNS O
in IN O
airway NN O
response NN O
in IN O
patients NNS O
with IN O
asthma NN B-Disease
, , O
and CC O
are VBP O
associated VBN O
with IN O
dose NN O
- HYPH O
dependent JJ O
systemic JJ O
beta NN O
- HYPH O
adrenoceptor NN O
responses NNS O
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
investigate VB O
whether IN O
tachyphylaxis NN O
occurs VBZ O
during IN O
prolonged VBN O
treatment NN O
with IN O
high JJ O
dose NN O
inhaled VBN O
salbutamol NN O
. . O
null null null-Disease
Twelve CD O
asthmatic JJ B-Disease
patients NNS O
( , O
FEV1 CD O
, , O
81 CD O
+ NN O
/ SYM O
- HYPH O
4 CD O
% NN O
predicted VBN O
) -RRB- O
, , O
requiring VBG O
only RB O
occasional JJ O
inhaled VBN O
beta NN O
- HYPH O
agonists NNS O
as IN O
their PRP$ O
sole JJ O
therapy NN O
, , O
were VBD O
given VBN O
a DT O
14 CD O
- HYPH O
day NN O
treatment NN O
with IN O
high JJ O
dose NN O
inhaled VBN O
salbutamol NN O
( , O
HDS NNP O
) -RRB- O
, , O
4 CD O
, , O
000 CD O
micrograms NNS O
daily RB O
, , O
low JJ O
dose NN O
inhaled VBN O
salbutamol NN O
( , O
LDS NNP O
) -RRB- O
, , O
800 CD O
micrograms NNS O
daily RB O
, , O
or CC O
placebo NN O
( , O
PI NN O
) -RRB- O
by IN O
metered VBN O
- HYPH O
dose NN O
inhaler NN O
in IN O
a DT O
double JJ O
- HYPH O
blind JJ O
, , O
randomized JJ O
crossover NN O
design NN O
. . O
null null null-Disease
During IN O
the DT O
14 CD O
- HYPH O
day NN O
run NN O
- HYPH O
in NN O
and CC O
during IN O
washout NN O
periods NNS O
, , O
inhaled VBN O
beta NN O
- HYPH O
agonists NNS O
were VBD O
withheld VBN O
and CC O
ipratropium NN O
bromide NN O
was VBD O
substituted VBN O
for IN O
rescue NN O
purposes NNS O
. . O
null null null-Disease
At IN O
the DT O
end NN O
of IN O
each DT O
14 CD O
- HYPH O
day NN O
treatment NN O
, , O
a DT O
dose NN O
- HYPH O
response NN O
curve NN O
( -LRB- O
DRC NNP O
) -RRB- O
was VBD O
performed VBN O
, , O
and CC O
airway NN O
( , O
FEV1 NNP O
, , O
FEF25 CD O
- HYPH O
75 CD O
) -RRB- O
chronotropic NN O
( , O
HR NN O
) -RRB- O
, , O
tremor NN B-Disease
, , O
and CC O
metabolic NN O
( , O
K NNP O
, , O
Glu NNP O
) -RRB- O
responses NNS O
were VBD O
measured VBN O
at IN O
each DT O
step NN O
( : O
from IN O
100 CD O
to IN O
4 CD O
, , O
000 CD O
micrograms NNS O
) -RRB- O
. . O
null null null-Disease
Treatment NN O
had VBD O
no DT O
significant JJ O
effect NN O
on IN O
baseline NN O
values NNS O
. . O
null null null-Disease
There EX O
were VBD O
dose NN O
- HYPH O
dependent JJ O
increases NNS O
in IN O
FEV1 NNP O
and CC O
FEF25 CD O
- HYPH O
75 CD O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
and CC O
pretreatment NN O
with IN O
HDS NNP O
did VBD O
not RB O
displace VB O
the DT O
DRC NNP O
to IN O
the DT O
right NN O
. . O
null null null-Disease
DRC NNP O
for IN O
HR NNP O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
K NNP O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
and CC O
Glu NNP O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
005 CD O
) -RRB- O
were VBD O
attenuated VBN O
after IN O
treatment NN O
with IN O
HDS NNP O
compared VBN O
with IN O
PI NNP O
. . O
null null null-Disease
There EX O
were VBD O
also RB O
differences NNS O
between IN O
HDS NNP O
and CC O
LDS NNP O
for IN O
HR NNP O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
and CC O
Glu NNP O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
responses NNS O
. . O
null null null-Disease
Frequency NN O
and CC O
severity NN O
of IN O
subjective JJ O
adverse JJ O
effects NNS O
were VBD O
also RB O
reduced VBN O
after IN O
HDS NNP O
: : O
tremor NN B-Disease
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
palpitations NNS B-Disease
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) -RRB- O
null null null-Disease
Phenytoin NN O
induced VBD O
fatal JJ O
hepatic JJ B-Disease
injury NN I-Disease
. . O
null null null-Disease
A DT O
61 CD O
year NN O
old JJ O
female NN O
developed VBD O
fatal JJ O
hepatic JJ B-Disease
failure NN I-Disease
after IN O
phenytoin NN O
administration NN O
. . O
null null null-Disease
A DT O
typical JJ O
multisystem NN O
clinical JJ O
pattern NN O
precedes VBZ O
the DT O
manifestations NNS O
of IN O
hepatic JJ B-Disease
injury NN I-Disease
. . O
null null null-Disease
The DT O
hematologic JJ O
, , O
biochemical JJ O
and CC O
pathologic JJ O
features NNS O
indicate VBP O
a DT O
mixed JJ O
hepatocellular NN B-Disease
damage NN I-Disease
due IN O
to IN O
drug NN B-Disease
hypersensitivity NN I-Disease
. . O
null null null-Disease
In IN O
a DT O
patient NN O
receiving VBG O
phenytoin NN O
who WP O
presents VBZ O
a DT O
viral JJ O
- HYPH O
like JJ O
illness NN O
, , O
early JJ O
recognition NN O
and CC O
discontinuation NN O
of IN O
the DT O
drug NN O
are VBP O
mandatory JJ O
. . O
null null null-Disease
Treatment NN O
of IN O
lethal JJ O
pertussis NN O
vaccine NN O
reaction NN O
with IN O
histamine NN O
H1 NNP O
antagonists NNS O
. . O
null null null-Disease
We PRP O
studied VBD O
mortality NN O
after IN O
pertussis NN B-Disease
immunization NN O
in IN O
the DT O
mouse NN O
. . O
null null null-Disease
Without IN O
treatment NN O
, , O
73 CD O
of IN O
92 CD O
animals NNS O
( : O
80 CD O
% NN O
) -RRB- O
died VBD O
after IN O
injection NN O
of IN O
bovine JJ O
serum NN O
albumin NN O
( , O
BSA NNP O
) -RRB- O
on IN O
day NN O
+ SYM O
7 CD O
of IN O
pertussis NN B-Disease
immunization NN O
. . O
null null null-Disease
After IN O
pretreatment NN O
with IN O
3 CD O
mg NN O
of IN O
cyproheptadine NN O
, , O
2 CD O
mg NN O
mianserin NN O
, , O
or CC O
2 CD O
mg NN O
chlorpheniramine NN O
, , O
only RB O
5 CD O
of IN O
105 CD O
animals NNS O
( : O
5 CD O
% NN O
) -RRB- O
died VBD O
after IN O
receiving VBG O
BSA NNP O
on IN O
day NN O
+ NN O
7 CD O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Blockade NN O
of IN O
histamine NN O
H1 NN O
receptors NNS O
may MD O
reduce VB O
mortality NN O
in IN O
pertussis NN B-Disease
immunization NN O
- HYPH O
induced VBN O
encephalopathy NN B-Disease
in IN O
mice NNS O
. . O
null null null-Disease
Support NN O
for IN O
adrenaline NN O
- HYPH O
hypertension NN B-Disease
hypothesis NN O
: : O
18 CD O
hour NN O
pressor NN O
effect NN O
after IN O
6 CD O
hours NNS O
adrenaline NN O
infusion NN O
. . O
null null null-Disease
In IN O
a DT O
double JJ O
blind NN O
, , O
crossover NN O
study NN O
6 CD O
h NN O
infusions NNS O
of IN O
adrenaline NN O
( SYM O
15 CD O
ng CD O
/ SYM O
kg CD O
/ SYM O
min NN O
; : O
1 CD O
ng CD O
= SYM O
5 CD O
. . O
458 CD O
pmol NN O
) -RRB- O
, , O
noradrenaline NN O
( : O
30 CD O
ng CD O
/ SYM O
kg CD O
/ SYM O
min NN O
; : O
1 CD O
ng CD O
= SYM O
5 CD O
. . O
911 CD O
pmol NN O
) -RRB- O
, , O
and CC O
a DT O
5 CD O
% NN O
dextrose NN O
solution NN O
( , O
5 CD O
. . O
4 CD O
ml CD O
/ SYM O
h NN O
) -RRB- O
, , O
were VBD O
given VBN O
to IN O
ten CD O
healthy JJ O
volunteers NNS O
in IN O
random JJ O
order NN O
2 CD O
weeks NNS O
apart RB O
. . O
null null null-Disease
By IN O
means NNS O
of IN O
intra JJ O
- HYPH O
arterial JJ O
ambulatory NN O
monitoring NN O
the DT O
haemodynamic JJ O
effects NNS O
were VBD O
followed VBN O
for IN O
18 CD O
h NN O
after IN O
the DT O
infusions NNS O
were VBD O
stopped VBN O
. . O
null null null-Disease
Adrenaline NN O
, , O
but CC O
not RB O
noradrenaline JJ O
, , O
caused VBD O
a DT O
delayed JJ O
and CC O
protracted JJ O
pressor NN O
effect NN O
. . O
null null null-Disease
Over IN O
the DT O
total JJ O
postinfusion NN O
period NN O
systolic JJ O
and CC O
diastolic JJ O
arterial JJ O
pressure NN O
were VBD O
6 CD O
( SYM O
SEM NN O
2 CD O
) CD O
% NN O
and CC O
7 CD O
( SYM O
2 CD O
) CD O
% NN O
, , O
respectively RB O
, , O
higher JJR O
than IN O
after IN O
dextrose JJ O
infusion NN O
( , O
ANOVA NNP O
, , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
. . O
null null null-Disease
Thus RB O
, , O
"""" `` O
stress NN O
"""" '' O
levels NNS O
of IN O
adrenaline NN O
( : O
230 CD O
pg NNS O
/ SYM O
ml NNS O
) -RRB- O
for IN O
6 CD O
h NN O
cause VBP O
a DT O
delayed VBN O
and CC O
protracted JJ O
pressor NN O
effect NN O
. . O
null null null-Disease
These DT O
findings NNS O
are VBP O
strong JJ O
support NN O
for IN O
the DT O
adrenaline NN O
- HYPH O
hypertension NN B-Disease
hypothesis NN O
in IN O
man NN O
. . O
null null null-Disease
Effect NN O
of IN O
alkylxanthines NNS O
on IN O
gentamicin NN O
- HYPH O
induced VBN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
in IN O
the DT O
rat NN O
. . O
null null null-Disease
Adenosine NN O
antagonists NNS O
have VBP O
been VBN O
previously RB O
shown VBN O
to TO O
be VB O
of IN O
benefit NN O
in IN O
some DT O
ischaemic JJ B-Disease
and CC O
nephrotoxic JJ B-Disease
models NNS O
of IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
( : O
ARF NN B-Disease
) -RRB- O
. . O
null null null-Disease
In IN O
the DT O
present JJ O
study NN O
, , O
the DT O
effects NNS O
of IN O
three CD O
alkylxanthines NNS O
with IN O
different JJ O
potencies NNS O
as IN O
adenosine NN O
antagonists NNS O
8 CD O
- HYPH O
phenyltheophylline NN O
, , O
theophylline NN O
and CC O
enprofylline NN O
, , O
were VBD O
examined VBN O
in IN O
rats NNS O
developing VBG O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
after IN O
4 CD O
daily JJ O
injections NNS O
of IN O
gentamicin NN O
( : O
200 CD O
mg CD O
kg NNS O
- HYPH O
1 CD O
) -RRB- O
. . O
null null null-Disease
Renal JJ O
function NN O
was VBD O
assessed VBN O
by IN O
biochemical JJ O
( , O
plasma NN O
urea NN O
and CC O
creatinine NN O
) -RRB- O
, , O
functional JJ O
( , O
urine NN O
analysis NN O
and CC O
[ -LRB- O
3H NN O
] -RRB- O
inulin NN O
and CC O
[ -LRB- O
14C NN O
] -RRB- O
p NN O
- HYPH O
aminohippuric NN O
acid NN O
clearances NNS O
) -RRB- O
and CC O
morphological JJ O
( , O
degree NN O
of IN O
necrosis NN B-Disease
) -RRB- O
indices NNS O
. . O
null null null-Disease
The DT O
various JJ O
drug NN O
treatments NNS O
produced VBD O
improvements NNS O
in IN O
some DT O
, , O
but CC O
not RB O
all DT O
, , O
measurements NNS O
of IN O
renal JJ O
function NN O
. . O
null null null-Disease
However RB O
, , O
any DT O
improvement NN O
produced VBN O
by IN O
drug NN O
treatment NN O
was VBD O
largely RB O
a DT O
result NN O
of IN O
a DT O
beneficial JJ O
effect NN O
exerted VBN O
by IN O
its PRP$ O
vehicle NN O
( , O
polyethylene NN O
glycol NN O
and CC O
NaOH NNP O
) -RRB- O
. . O
null null null-Disease
The DT O
lack NN O
of IN O
any DT O
consistent JJ O
protective JJ O
effect NN O
noted VBN O
with IN O
the DT O
alkylxanthines NNS O
tested VBN O
in IN O
the DT O
present JJ O
study NN O
indicates VBZ O
that IN O
adenosine NN O
plays VBZ O
little JJ O
, , O
if IN O
any DT O
, , O
pathophysiological JJ O
role NN O
in IN O
gentamicin NN O
- HYPH O
induced VBN O
ARF NNP B-Disease
. . O
null null null-Disease
Adverse JJ O
ocular JJ O
reactions NNS O
possibly RB O
associated VBN O
with IN O
isotretinoin NN O
. . O
null null null-Disease
A DT O
total NN O
of IN O
261 CD O
adverse JJ O
ocular JJ O
reactions NNS O
occurred VBD O
in IN O
237 CD O
patients NNS O
who WP O
received VBD O
isotretinoin NN O
, , O
a DT O
commonly RB O
used VBN O
drug NN O
in IN O
the DT O
treatment NN O
of IN O
severe JJ O
cystic JJ O
acne NN B-Disease
. . O
null null null-Disease
Blepharoconjunctivitis NNP B-Disease
, , O
subjective JJ O
complaints NNS O
of IN O
dry JJ B-Disease
eyes NNS I-Disease
, , O
blurred VBN B-Disease
vision NN I-Disease
, , O
contact NN O
lens NN O
intolerance NN O
, , O
and CC O
photodermatitis NN B-Disease
are VBP O
reversible JJ O
side NN O
effects NNS O
. . O
null null null-Disease
More RBR O
serious JJ O
ocular JJ O
adverse JJ O
reactions NNS O
include VBP O
papilledema NN B-Disease
, , O
pseudotumor NN B-Disease
cerebri NN I-Disease
, , O
and CC O
white JJ O
or CC O
gray JJ O
subepithelial JJ O
corneal JJ B-Disease
opacities NNS I-Disease
; : O
all DT O
of IN O
these DT O
are VBP O
reversible JJ O
if IN O
the DT O
drug NN O
is VBZ O
discontinued VBN O
. . O
null null null-Disease
Reported VBN O
cases NNS O
of IN O
decreased VBN O
dark JJ O
adaptation NN O
are VBP O
under IN O
investigation NN O
. . O
null null null-Disease
Isotretinoin NN O
is VBZ O
contraindicated VBN O
in IN O
pregnancy NN O
because IN O
of IN O
the DT O
many JJ O
reported VBN O
congenital JJ B-Disease
abnormalities NNS I-Disease
after IN O
maternal JJ O
use NN O
( , O
including VBG O
microphthalmos NN B-Disease
, , O
orbital JJ O
hypertelorism NN B-Disease
, , O
and CC O
optic JJ B-Disease
nerve NN I-Disease
hypoplasia NN I-Disease
) -RRB- O
. . O
null null null-Disease
Procaterol NN O
and CC O
terbutaline NN O
in IN O
bronchial JJ B-Disease
asthma NN I-Disease
. . O
null null null-Disease
A DT O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
- HYPH O
controlled VBN O
, , O
cross NN O
- HYPH O
over IN O
study NN O
. . O
null null null-Disease
Procaterol NNP O
, , O
a DT O
new JJ O
beta NN O
- HYPH O
2 CD O
adrenoceptor NN O
stimulant NN O
, , O
was VBD O
studied VBN O
in IN O
a DT O
double JJ O
- HYPH O
blind JJ O
, , O
placebo NN O
- HYPH O
controlled VBN O
, , O
cross NN O
- HYPH O
over IN O
trial NN O
in IN O
patients NNS O
with IN O
bronchial JJ B-Disease
asthma NN I-Disease
. . O
null null null-Disease
Oral JJ O
procaterol NN O
50 CD O
micrograms NNS O
b NN O
. . O
d LS O
. . O
, , O
procaterol NN O
100 CD O
micrograms NNS O
b NN O
. . O
d NN O
. . O
, , O
and CC O
terbutaline NN O
5 CD O
mg NN O
t NN O
. . O
i LS O
. . O
d LS O
. . O
, , O
were VBD O
compared VBN O
when WRB O
given VBN O
randomly RB O
in IN O
1 CD O
- HYPH O
week NN O
treatment NN O
periods NNS O
. . O
null null null-Disease
The DT O
best JJS O
clinical JJ O
effect NN O
was VBD O
found VBN O
with IN O
terbutaline NN O
. . O
null null null-Disease
Both CC O
anti AFX O
- HYPH O
asthmatic JJ B-Disease
and CC O
tremorgenic JJ B-Disease
effects NNS O
of IN O
procaterol NN O
were VBD O
dose NN O
- HYPH O
related VBN O
. . O
null null null-Disease
Procaterol NN O
appeared VBD O
effective JJ O
in IN O
the DT O
doses NNS O
tested VBN O
, , O
and CC O
a DT O
twice RB O
daily JJ O
regimen NN O
would MD O
appear VB O
to TO O
be VB O
suitable JJ O
with IN O
this DT O
drug NN O
. . O
null null null-Disease
Subacute JJ O
effects NNS O
of IN O
propranolol NN O
and CC O
B NN O
24 CD O
/ SYM O
76 CD O
on IN O
isoproterenol NN O
- HYPH O
induced VBN O
rat NN O
heart NN B-Disease
hypertrophy NN I-Disease
in IN O
correlation NN O
with IN O
blood NN O
pressure NN O
. . O
null null null-Disease
We PRP O
compared VBD O
the DT O
potential JJ O
beta NN O
- HYPH O
receptor NN O
blocker NN O
, , O
B NN O
24 CD O
/ SYM O
76 CD O
i NN O
. . O
e ADD O
. . O
1 CD O
- HYPH O
( : O
2 CD O
, , O
4 CD O
- HYPH O
dichlorophenoxy NN O
) NFP O
- HYPH O
3 CD O
[ -LRB- O
2 CD O
- HYPH O
3 CD O
, , O
4 CD O
- HYPH O
dimethoxyphenyl NN O
) NFP O
ethanolamino NN O
] -RRB- O
- HYPH O
prop NN O
an DT O
- HYPH O
2 CD O
- HYPH O
ol NN O
, , O
which WDT O
is VBZ O
characterized VBN O
by IN O
beta NN O
1 CD O
- HYPH O
adrenoceptor NN O
blocking NN O
and CC O
beta NN O
2 CD O
- HYPH O
adrenoceptor NN O
stimulating VBG O
properties NNS O
with IN O
propranolol NN O
. . O
null null null-Disease
The DT O
studies NNS O
were VBD O
performed VBN O
using VBG O
an DT O
experimental JJ O
model NN O
of IN O
isoproterenol NN O
- HYPH O
induced VBN O
heart NN B-Disease
hypertrophy NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
A DT O
correlation NN O
of IN O
the DT O
blood NN O
pressure NN O
was VBD O
neither CC O
found VBN O
in IN O
the DT O
development NN O
nor CC O
in IN O
the DT O
attempt NN O
to TO O
suppress VB O
the DT O
development NN O
of IN O
heart NN B-Disease
hypertrophy NN I-Disease
with IN O
the DT O
two CD O
beta NN O
- HYPH O
receptor NN O
blockers NNS O
. . O
null null null-Disease
Both DT O
beta NN O
- HYPH O
blockers NNS O
influenced VBD O
the DT O
development NN O
of IN O
hypertrophy NN B-Disease
to IN O
a DT O
different JJ O
, , O
but CC O
not RB O
reproducible JJ O
extent NN O
. . O
null null null-Disease
It PRP O
was VBD O
possible JJ O
to TO O
suppress VB O
the DT O
increased JJ O
ornithine NN O
decarboxylase NN O
activity NN O
with IN O
both DT O
beta NN O
- HYPH O
blockers NNS O
in IN O
hypertrophied JJ B-Disease
hearts NNS I-Disease
, , O
but CC O
there EX O
was VBD O
no DT O
effect NN O
on IN O
the DT O
heart NN O
mass NN O
. . O
null null null-Disease
Neither CC O
propranolol NN O
nor CC O
B NN O
24 CD O
/ SYM O
76 CD O
could MD O
stop VB O
the DT O
changes NNS O
in IN O
the DT O
characteristic JJ O
myosin NN O
isoenzyme NN O
pattern NN O
of IN O
the DT O
hypertrophied JJ B-Disease
rat NN O
heart NN O
. . O
null null null-Disease
Thus RB O
, , O
the DT O
investigations NNS O
did VBD O
not RB O
provide VB O
any DT O
evidence NN O
that IN O
the DT O
beta NN O
- HYPH O
receptor NN O
blockers NNS O
propranolol NN O
and CC O
B NN O
24 CD O
/ SYM O
76 CD O
have VBP O
the DT O
potency NN O
to TO O
prevent VB O
isoproterenol NN O
from IN O
producing VBG O
heart NN B-Disease
hypertrophy NN I-Disease
. . O
null null null-Disease
Increased VBN O
anxiogenic JJ O
effects NNS O
of IN O
caffeine NN O
in IN O
panic NN B-Disease
disorders NNS I-Disease
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
oral JJ O
administration NN O
of IN O
caffeine NN O
( : O
10 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
on IN O
behavioral JJ O
ratings NNS O
, , O
somatic JJ O
symptoms NNS O
, , O
blood NN O
pressure NN O
and CC O
plasma NN O
levels NNS O
of IN O
3 CD O
- HYPH O
methoxy NN O
- HYPH O
4 CD O
- HYPH O
hydroxyphenethyleneglycol NN O
( -LRB- O
MHPG NNP O
) -RRB- O
and CC O
cortisol NN O
were VBD O
determined VBN O
in IN O
17 CD O
healthy JJ O
subjects NNS O
and CC O
21 CD O
patients NNS O
meeting VBG O
DSM NNP O
- HYPH O
III NNP O
criteria NNS O
for IN O
agoraphobia NN B-Disease
with IN O
panic NN B-Disease
attacks NNS I-Disease
or CC O
panic NN B-Disease
disorder NN I-Disease
. . O
null null null-Disease
Caffeine NN O
produced VBD O
significantly RB O
greater JJR O
increases NNS O
in IN O
subject NN O
- HYPH O
rated VBN O
anxiety NN B-Disease
, , O
nervousness NN O
, , O
fear NN O
, , O
nausea NN B-Disease
, , O
palpitations NNS B-Disease
, , O
restlessness NN B-Disease
, , O
and CC O
tremors NNS B-Disease
in IN O
the DT O
patients NNS O
compared VBN O
with IN O
healthy JJ O
subjects NNS O
. . O
null null null-Disease
In IN O
the DT O
patients NNS O
, , O
but CC O
not RB O
the DT O
healthy JJ O
subjects NNS O
, , O
these DT O
symptoms NNS O
were VBD O
significantly RB O
correlated VBN O
with IN O
plasma NN O
caffeine NN O
levels NNS O
. . O
null null null-Disease
Seventy CD O
- HYPH O
one CD O
percent NN O
of IN O
the DT O
patients NNS O
reported VBD O
that IN O
the DT O
behavioral JJ O
effects NNS O
of IN O
caffeine NN O
were VBD O
similar JJ O
to IN O
those DT O
experienced VBN O
during IN O
panic NN B-Disease
attacks NNS I-Disease
. . O
null null null-Disease
Caffeine NNP O
did VBD O
not RB O
alter VB O
plasma NN O
MHPG NNP O
levels NNS O
in IN O
either CC O
the DT O
healthy JJ O
subjects NNS O
or CC O
patients NNS O
. . O
null null null-Disease
Caffeine NN O
increased VBD O
plasma NN O
cortisol NN O
levels NNS O
equally RB O
in IN O
the DT O
patient JJ O
and CC O
healthy JJ O
groups NNS O
. . O
null null null-Disease
Because IN O
caffeine NN O
is VBZ O
an DT O
adenosine JJ O
receptor NN O
antagonist NN O
, , O
these DT O
results NNS O
suggest VBP O
that IN O
some DT O
panic NN B-Disease
disorder NN I-Disease
patients NNS O
may MD O
have VB O
abnormalities NNS B-Disease
in IN I-Disease
neuronal JJ I-Disease
systems NNS I-Disease
involving VBG O
adenosine NN O
. . O
null null null-Disease
Patients NNS O
with IN O
anxiety NN B-Disease
disorders NNS I-Disease
may MD O
benefit VB O
by IN O
avoiding VBG O
caffeine NN O
- HYPH O
containing VBG O
foods NNS O
and CC O
beverages NNS O
. . O
null null null-Disease
Comparison NN O
of IN O
the DT O
effect NN O
of IN O
oxitropium NN O
bromide NN O
and CC O
of IN O
slow JJ O
- HYPH O
release NN O
theophylline NN O
on IN O
nocturnal JJ O
asthma NN B-Disease
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
a DT O
new JJ O
inhaled VBN O
antimuscarinic JJ O
drug NN O
, , O
oxitropium NN O
bromide NN O
, , O
and CC O
of IN O
a DT O
slow JJ O
- HYPH O
release NN O
theophylline NN O
preparation NN O
upon IN O
nocturnal JJ O
asthma NN B-Disease
were VBD O
compared VBN O
in IN O
a DT O
placebo NN O
- HYPH O
controlled VBN O
double JJ O
- HYPH O
blind JJ O
study NN O
. . O
null null null-Disease
Two CD O
samples NNS O
were VBD O
studied VBN O
: : O
12 CD O
patients NNS O
received VBD O
oxitropium NN O
at IN O
600 CD O
micrograms NNS O
( SYM O
6 CD O
subjects NNS O
) -RRB- O
or CC O
at IN O
400 CD O
micrograms NNS O
t NN O
. . O
i PRP O
. . O
d LS O
. . O
null null null-Disease
( : O
6 CD O
subjects NNS O
) -RRB- O
whereas IN O
11 CD O
received VBD O
theophylline NN O
at IN O
300 CD O
mg NN O
b NN O
. . O
i LS O
. . O
d LS O
. . O
null null null-Disease
Morning NN O
dipping VBG O
, , O
assessed VBN O
by IN O
the DT O
fall NN O
in IN O
peak NN O
flow NN O
overnight RB O
, , O
was VBD O
significantly RB O
reduced VBN O
in IN O
the DT O
periods NNS O
when WRB O
either DT O
active JJ O
drug NN O
was VBD O
taken VBN O
, , O
whereas IN O
no DT O
difference NN O
was VBD O
noticed VBN O
during IN O
the DT O
placebo NN O
administration NN O
. . O
null null null-Disease
No DT O
significant JJ O
difference NN O
was VBD O
noticed VBN O
between IN O
results NNS O
obtained VBN O
with IN O
either CC O
active JJ O
drug NN O
, , O
as RB O
well RB O
as IN O
with IN O
either DT O
dosage NN O
of IN O
oxitropium NN O
. . O
null null null-Disease
No DT O
subject NN O
reported VBD O
side NN O
effects NNS O
of IN O
oxitropium NN O
, , O
as IN O
compared VBN O
to IN O
three CD O
subjects NNS O
reporting VBG O
nausea NN B-Disease
, , O
vomiting NN B-Disease
and CC O
tremors NNS B-Disease
after IN O
theophylline NN O
. . O
null null null-Disease
Oxitropium NN O
proves VBZ O
to TO O
be VB O
a DT O
valuable JJ O
alternative NN O
to IN O
theophylline NN O
in IN O
nocturnal JJ O
asthma NN B-Disease
, , O
since IN O
it PRP O
is VBZ O
equally RB O
potent JJ O
, , O
safer JJR O
and CC O
does VBZ O
not RB O
require VB O
the DT O
titration NN O
of IN O
dosage NN O
. . O
null null null-Disease
Penicillin NN O
anaphylaxis NN B-Disease
. . O
null null null-Disease
A DT O
case NN O
of IN O
oral JJ O
penicillin NN O
anaphylaxis NN B-Disease
is VBZ O
described VBN O
, , O
and CC O
the DT O
terminology NN O
, , O
occurrence NN O
, , O
clinical JJ O
manifestations NNS O
, , O
pathogenesis NN O
, , O
prevention NN O
, , O
and CC O
treatment NN O
of IN O
anaphylaxis NN B-Disease
are VBP O
reviewed VBN O
. . O
null null null-Disease
Emergency NN O
physicians NNS O
should MD O
be VB O
aware JJ O
of IN O
oral JJ O
penicillin NN O
anaphylaxis NN B-Disease
in IN O
order NN O
to TO O
prevent VB O
its PRP$ O
occurrence NN O
by IN O
prescribing VBG O
the DT O
antibiotic NN O
judiciously RB O
and CC O
knowledgeably RB O
and CC O
to TO O
offer VB O
optimal JJ O
medical JJ O
therapy NN O
once RB O
this DT O
life NN O
- HYPH O
threatening VBG O
reaction NN O
has VBZ O
begun VBN O
. . O
null null null-Disease
Reversible JJ O
valproic JJ O
acid NN O
- HYPH O
induced VBN O
dementia NN B-Disease
: : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
Reversible JJ O
valproic JJ O
acid NN O
- HYPH O
induced VBN O
dementia NN B-Disease
was VBD O
documented VBN O
in IN O
a DT O
21 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
with IN O
epilepsy NN B-Disease
who WP O
had VBD O
a DT O
3 CD O
- HYPH O
year NN O
history NN O
of IN O
insidious JJ O
progressive JJ O
decline NN O
in IN O
global JJ O
cognitive JJ O
abilities NNS O
documented VBN O
by IN O
serial JJ O
neuropsychological JJ O
studies NNS O
. . O
null null null-Disease
Repeat VB O
neuropsychological JJ O
testing NN O
7 CD O
weeks NNS O
after IN O
discontinuation NN O
of IN O
the DT O
drug NN O
revealed VBD O
dramatic JJ O
improvement NN O
in IN O
IQ NN O
, , O
memory NN O
, , O
naming NN O
, , O
and CC O
other JJ O
tasks NNS O
commensurate JJ O
with IN O
clinical JJ O
recovery NN O
in IN O
his PRP$ O
intellectual JJ O
capacity NN O
. . O
null null null-Disease
Possible JJ O
pathophysiological JJ O
mechanisms NNS O
which WDT O
may MD O
have VB O
been VBN O
operative JJ O
in IN O
this DT O
case NN O
include VBP O
: : O
a DT O
direct JJ O
central JJ O
nervous JJ O
system NN O
( -LRB- O
CNS NN O
) -RRB- O
toxic JJ O
effect NN O
of IN O
valproic JJ O
acid NN O
; , O
a DT O
paradoxical JJ O
epileptogenic JJ O
effect NN O
secondary JJ O
to IN O
the DT O
drug NN O
; : O
and CC O
an DT O
indirect JJ O
CNS NNP O
toxic JJ O
effect NN O
mediated VBN O
through IN O
valproic JJ O
acid NN O
- HYPH O
induced VBN O
hyperammonemia NN B-Disease
. . O
null null null-Disease
Reversal NN O
of IN O
scopolamine NN O
- HYPH O
induced VBN O
amnesia NN B-Disease
of IN O
passive JJ O
avoidance NN O
by IN O
pre NN O
- HYPH O
and CC O
post NN O
- HYPH O
training NN O
naloxone NN O
. . O
null null null-Disease
In IN O
a DT O
series NN O
of IN O
five CD O
experiments NNS O
, , O
the DT O
modulating VBG O
role NN O
of IN O
naloxone NN O
on IN O
a DT O
scopolamine NN O
- HYPH O
induced VBN O
retention NN B-Disease
deficit NN I-Disease
in IN O
a DT O
passive JJ O
avoidance NN O
paradigm NN O
was VBD O
investigated VBN O
in IN O
mice NNS O
. . O
null null null-Disease
Scopolamine NNP O
, , O
but CC O
not RB O
methyl NN O
scopolamine NN O
( , O
1 CD O
and CC O
3 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
, , O
induced VBD O
an DT O
amnesia NN B-Disease
as IN O
measured VBN O
by IN O
latency NN O
and CC O
duration NN O
parameters NNS O
. . O
null null null-Disease
Naloxone NNP O
( : O
0 CD O
. . O
3 CD O
, , O
1 CD O
, , O
3 CD O
, , O
and CC O
10 CD O
mg NN O
/ SYM O
kg NNS O
) -RRB- O
injected VBN O
prior RB O
to IN O
training NN O
attenuated VBD O
the DT O
retention NN B-Disease
deficit NN I-Disease
with IN O
a DT O
peak NN O
of IN O
activity NN O
at IN O
3 CD O
mg NN O
/ SYM O
kg NN O
. . O
null null null-Disease
The DT O
effect NN O
of IN O
naloxone NN O
could MD O
be VB O
antagonized VBN O
with IN O
morphine NN O
( , O
1 CD O
, , O
3 CD O
, , O
and CC O
10 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
, , O
demonstrating VBG O
the DT O
opioid JJ O
specificity NN O
of IN O
the DT O
naloxone NN O
effect NN O
. . O
null null null-Disease
Post NN O
- HYPH O
training NN O
administration NN O
of IN O
naloxone NN O
( , O
3 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
as IN O
a DT O
single JJ O
or CC O
as IN O
a DT O
split JJ O
dose NN O
also RB O
attenuated VBD O
the DT O
scopolamine NN O
- HYPH O
induced VBN O
amnesia NN B-Disease
. . O
null null null-Disease
Control NN O
experiments NNS O
indicated VBD O
that IN O
neither CC O
an DT O
increase NN O
in IN O
pain NN B-Disease
sensitivity NN O
( , O
pre IN O
- HYPH O
training VBG O
naloxone NN O
) -RRB- O
nor CC O
an DT O
induced VBN O
aversive JJ O
state NN O
( HYPH O
post NN O
- HYPH O
training VBG O
naloxone NN O
) -RRB- O
appear VBP O
to TO O
be VB O
responsible JJ O
for IN O
the DT O
influence NN O
of IN O
naloxone NN O
on IN O
the DT O
scopolamine NN O
- HYPH O
induced VBN O
retention NN B-Disease
deficit NN I-Disease
. . O
null null null-Disease
These DT O
results NNS O
extend VBP O
previous JJ O
findings NNS O
implicating VBG O
a DT O
cholinergic JJ O
- HYPH O
opioid JJ O
interaction NN O
in IN O
memory NN O
processes NNS O
. . O
null null null-Disease
A DT O
possible JJ O
mechanism NN O
for IN O
this DT O
interaction NN O
involving VBG O
the DT O
septo JJ O
- HYPH O
hippocampal JJ O
cholinergic JJ O
pathway NN O
is VBZ O
discussed VBN O
. . O
null null null-Disease
Electron NN O
microscopic JJ O
investigations NNS O
of IN O
the DT O
cyclophosphamide NN O
- HYPH O
induced VBN O
lesions NNS B-Disease
of IN I-Disease
the DT I-Disease
urinary JJ I-Disease
bladder NN I-Disease
of IN O
the DT O
rat NN O
and CC O
their PRP$ O
prevention NN O
by IN O
mesna NN O
. . O
null null null-Disease
Fully RB O
developed JJ O
cyclophosphamide NN O
- HYPH O
induced VBN O
cystitis NN B-Disease
is VBZ O
characterized VBN O
by IN O
nearly RB O
complete JJ O
detachment NN O
of IN O
the DT O
urothelium NN O
, , O
severe JJ O
submucosal JJ O
edema NN B-Disease
owing VBG O
to IN O
damage NN O
to IN O
the DT O
microvascular JJ O
bed NN O
and CC O
focal JJ O
muscle NN O
necroses NNS B-Disease
. . O
null null null-Disease
The DT O
initial JJ O
response NN O
to IN O
the DT O
primary JJ O
attack NN O
by IN O
the DT O
cyclophosphamide NN O
metabolites NNS O
seems VBZ O
to TO O
be VB O
fragmentation NN O
of IN O
the DT O
luminal JJ O
membrane NN O
. . O
null null null-Disease
This DT O
damages VBZ O
the DT O
cellular JJ O
barrier NN O
against IN O
the DT O
hypertonic JJ O
urine NN O
. . O
null null null-Disease
Subsequent JJ O
breaks NNS O
in IN O
the DT O
lateral JJ O
cell NN O
membranes NNS O
of IN O
the DT O
superficial JJ O
cells NNS O
and CC O
in IN O
all PDT O
the DT O
plasma NN O
membranes NNS O
of IN O
the DT O
intermediate JJ O
and CC O
basal JJ O
cells NNS O
, , O
intercellular JJ O
and CC O
intracellular JJ O
edema NN B-Disease
and CC O
disintegration NN O
of IN O
the DT O
desmosomes NNS O
and CC O
hemidesmosomes NNS O
lead VBP O
to IN O
progressive JJ O
degeneration NN O
and CC O
detachment NN O
of IN O
the DT O
epithelial JJ O
cells NNS O
with IN O
exposure NN O
and CC O
splitting NN O
of IN O
the DT O
basal JJ O
membrane NN O
. . O
null null null-Disease
The DT O
morphological JJ O
changes NNS O
of IN O
the DT O
endothelial JJ O
cells NNS O
, , O
which WDT O
become VBP O
more RBR O
pronounced VBN O
in IN O
the DT O
later JJ O
stages NNS O
of IN O
the DT O
experiment NN O
, , O
the DT O
involvement NN O
of IN O
blood NN O
vessels NNS O
regardless RB O
of IN O
their PRP$ O
diameter NN O
and CC O
the DT O
location NN O
- HYPH O
dependent JJ O
extent NN O
of IN O
the DT O
damage NN O
indicate VBP O
a DT O
direct JJ O
type NN O
of IN O
damage NN O
which WDT O
is VBZ O
preceded VBN O
by IN O
a DT O
mediator NN O
- HYPH O
induced VBN O
increase NN O
in IN O
permeability NN O
, , O
the DT O
morphological JJ O
correlate NN O
of IN O
which WDT O
is VBZ O
the DT O
formation NN O
of IN O
gaps NNS O
in IN O
the DT O
interendothelial JJ O
cell NN O
connections NNS O
on IN O
the DT O
venules NNS O
. . O
null null null-Disease
These DT O
changes NNS O
can MD O
be VB O
effectively RB O
prevented VBN O
by IN O
mesna NN O
. . O
null null null-Disease
The DT O
only JJ O
sign NN O
of IN O
a DT O
possible JJ O
involvement NN O
is VBZ O
the DT O
increase NN O
in IN O
the DT O
number NN O
of IN O
specific JJ O
granules NNS O
with IN O
a DT O
presumed VBN O
lysosomal JJ O
function NN O
in IN O
the DT O
superficial JJ O
cells NNS O
. . O
null null null-Disease
Increase VB O
in IN O
intragastric JJ O
pressure NN O
during IN O
suxamethonium NN O
- HYPH O
induced VBN O
muscle NN B-Disease
fasciculations NNS I-Disease
in IN O
children NNS O
: : O
inhibition NN O
by IN O
alfentanil NNP O
. . O
null null null-Disease
Changes NNS O
in IN O
intragastric JJ O
pressure NN O
after IN O
the DT O
administration NN O
of IN O
suxamethonium NN O
1 CD O
. . O
5 CD O
mg NN O
kg NN O
- HYPH O
1 CD O
i NN O
. . O
v NN O
. . O
were VBD O
studied VBN O
in IN O
32 CD O
children NNS O
( , O
mean JJ O
age NN O
6 CD O
. . O
9 CD O
yr CD O
) -RRB- O
pretreated VBN O
with IN O
either CC O
physiological JJ O
saline NN O
or CC O
alfentanil NN O
50 CD O
micrograms NNS O
kg CD O
- HYPH O
1 CD O
. . O
null null null-Disease
Anaesthesia NNP O
was VBD O
induced VBN O
with IN O
thiopentone NN O
5 CD O
mg CD O
kg NN O
- HYPH O
1 CD O
. . O
null null null-Disease
The DT O
incidence NN O
and CC O
intensity NN O
of IN O
muscle NN B-Disease
fasciculations NNS I-Disease
caused VBN O
by IN O
suxamethonium NN O
were VBD O
significantly RB O
greater JJR O
in IN O
the DT O
control NN O
than IN O
in IN O
the DT O
alfentanil JJ O
group NN O
. . O
null null null-Disease
The DT O
intragastric JJ O
pressure NN O
during IN O
muscle NN B-Disease
fasciculations NNS I-Disease
was VBD O
significantly RB O
higher JJR O
in IN O
the DT O
control NN O
group NN O
( : O
16 CD O
+ CD O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
( SYM O
SEM NN O
) -RRB- O
cm NN O
H2O NN O
) -RRB- O
than IN O
in IN O
the DT O
alfentanil JJ O
group NN O
( : O
7 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
5 CD O
( SYM O
SEM NN O
) : O
cm NN O
H2O NN O
) -RRB- O
. . O
null null null-Disease
The DT O
increase NN O
in IN O
intragastric JJ O
pressure NN O
was VBD O
directly RB O
related VBN O
to IN O
the DT O
intensity NN O
of IN O
muscle NN B-Disease
fasciculations NNS I-Disease
( , O
regression NN O
line NN O
: : O
y NFP O
= SYM O
0 CD O
. . O
5 CD O
+ SYM O
4 CD O
. . O
78x CD O
with IN O
r NN O
of IN O
0 CD O
. . O
78 CD O
) -RRB- O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
intragastric JJ O
pressure NN O
increases VBZ O
significantly RB O
during IN O
muscle NN B-Disease
fasciculations NNS I-Disease
caused VBN O
by IN O
suxamethonium NN O
in IN O
healthy JJ O
children NNS O
. . O
null null null-Disease
Alfentanil NNP O
50 CD O
micrograms NNS O
kg NN O
- HYPH O
1 CD O
effectively RB O
inhibits VBZ O
the DT O
incidence NN O
and CC O
intensity NN O
of IN O
suxamethonium NN O
- HYPH O
induced VBN O
muscle NN B-Disease
fasciculations NNS I-Disease
; : O
moreover RB O
, , O
intragastric JJ O
pressure NN O
remains VBZ O
at IN O
its PRP$ O
control NN O
value NN O
. . O
null null null-Disease
Acute JJ O
insulin NN O
treatment NN O
normalizes VBZ O
the DT O
resistance NN O
to IN O
the DT O
cardiotoxic JJ B-Disease
effect NN O
of IN O
isoproterenol NN O
in IN O
streptozotocin NN O
diabetic JJ B-Disease
rats NNS O
. . O
null null null-Disease
A DT O
morphometric JJ O
study NN O
of IN O
isoproterenol NN O
induced VBN O
myocardial JJ O
fibrosis NN B-Disease
. . O
null null null-Disease
The DT O
acute JJ O
effect NN O
of IN O
insulin NN O
treatment NN O
on IN O
the DT O
earlier JJR O
reported VBN O
protective JJ O
effect NN O
of IN O
streptozotocin NN O
diabetes NNS B-Disease
against IN O
the DT O
cardiotoxic JJ B-Disease
effect NN O
of IN O
high JJ O
doses NNS O
of IN O
isoproterenol NN O
( -LRB- O
ISO NNP O
) -RRB- O
was VBD O
investigated VBN O
in IN O
rats NNS O
. . O
null null null-Disease
Thirty CD O
to IN O
135 CD O
min NN O
after IN O
the DT O
injection NN O
of IN O
crystalline NN O
insulin NN O
, , O
ISO NNP O
was VBD O
given VBN O
subcutaneously RB O
and CC O
when WRB O
ISO NNP O
induced VBD O
fibrosis NN B-Disease
in IN O
the DT O
myocardium NN O
was VBD O
morphometrically RB O
analyzed VBN O
7 CD O
days NNS O
later RB O
, , O
a DT O
highly RB O
significant JJ O
correlation NN O
( : O
r NN O
= SYM O
0 CD O
. . O
83 CD O
, , O
2 CD O
p NN O
= SYM O
0 CD O
. . O
006 CD O
) -RRB- O
to IN O
the DT O
slope NN O
of IN O
the DT O
fall NN O
in IN O
blood NN O
glucose NN O
after IN O
insulin NN O
treatment NN O
appeared VBD O
. . O
null null null-Disease
The DT O
myocardial JJ O
content NN O
of IN O
catecholamines NNS O
was VBD O
estimated VBN O
in IN O
these DT O
8 CD O
day NN O
diabetic JJ B-Disease
rats NNS O
. . O
null null null-Disease
The DT O
norepinephrine JJ O
content NN O
was VBD O
significantly RB O
increased VBN O
while IN O
epinephrine NN O
remained VBD O
unchanged JJ O
. . O
null null null-Disease
An DT O
enhanced VBN O
sympathetic JJ O
nervous JJ O
system NN O
activity NN O
with IN O
a DT O
consequent JJ O
down JJ O
regulation NN O
of IN O
the DT O
myocardial JJ O
beta NN O
- HYPH O
adrenergic JJ O
receptors NNS O
could MD O
, , O
therefore RB O
, , O
explain VB O
this DT O
catecholamine NN O
resistance NN O
. . O
null null null-Disease
The DT O
rapid JJ O
reversion NN O
after IN O
insulin NN O
treatment NN O
excludes VBZ O
the DT O
possibility NN O
that IN O
streptozotocin NN O
in IN O
itself PRP O
causes VBZ O
the DT O
ISO NN O
resistance NN O
and CC O
points VBZ O
towards IN O
a DT O
direct JJ O
insulin NN O
effect NN O
on IN O
myocardial JJ O
catecholamine NN O
sensitivity NN O
in IN O
diabetic JJ B-Disease
rats NNS O
. . O
null null null-Disease
The DT O
phenomenon NN O
described VBN O
might MD O
elucidate VB O
pathogenetic JJ O
mechanisms NNS O
behind IN O
toxic JJ O
myocardial JJ O
cell NN O
degeneration NN O
and CC O
may MD O
possibly RB O
have VB O
relevance NN O
for IN O
acute JJ O
cardiovascular JJ O
complications NNS O
in IN O
diabetic JJ B-Disease
patients NNS O
. . O
null null null-Disease
Differential JJ O
effects NNS O
of IN O
non JJ O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
on IN O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
muscarinic JJ O
cholinergic JJ O
agonist NN O
pilocarpine NN O
induces VBZ O
in IN O
rats NNS O
seizures NNS B-Disease
and CC O
status NN B-Disease
epilepticus NN I-Disease
followed VBN O
by IN O
widespread JJ O
damage NN O
to IN O
the DT O
forebrain NN O
. . O
null null null-Disease
The DT O
present JJ O
study NN O
was VBD O
designed VBN O
to TO O
investigate VB O
the DT O
effect NN O
of IN O
5 CD O
non AFX O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
, , O
sodium NN O
salicylate NN O
, , O
phenylbutazone NN O
, , O
indomethacin NN O
, , O
ibuprofen NN O
and CC O
mefenamic JJ O
acid NN O
, , O
on IN O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
. . O
null null null-Disease
Pretreatment NN O
of IN O
rats NNS O
with IN O
sodium NN O
salicylate NN O
, , O
ED50 NNP O
103 CD O
mg NN O
/ SYM O
kg CD O
( SYM O
60 CD O
- SYM O
174 CD O
) -RRB- O
, , O
and CC O
phenylbutazone NN O
, , O
59 CD O
mg NNS O
/ SYM O
kg NNS O
( SYM O
50 CD O
- SYM O
70 CD O
) -RRB- O
converted VBD O
the DT O
non NN O
- HYPH O
convulsant JJ O
dose NN O
of IN O
pilocarpine NN O
, , O
200 CD O
mg NN O
/ SYM O
kg NN O
, , O
to IN O
a DT O
convulsant JJ O
one NN O
. . O
null null null-Disease
Indomethacin NNP O
, , O
1 CD O
- HYPH O
10 CD O
mg NN O
/ SYM O
kg NN O
, , O
and CC O
ibuprofen NN O
, , O
10 CD O
- SYM O
100 CD O
mg NN O
/ SYM O
kg NN O
, , O
failed VBD O
to TO O
modulate VB O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
. . O
null null null-Disease
Mefenamic JJ O
acid NN O
, , O
26 CD O
( SYM O
22 CD O
- SYM O
30 CD O
) NN O
mg NNS O
/ SYM O
kg NN O
, , O
prevented VBD O
seizures NNS B-Disease
and CC O
protected VBD O
rats NNS O
from IN O
seizure NN B-Disease
- HYPH O
related VBN O
brain NN B-Disease
damage NN I-Disease
induced VBN O
by IN O
pilocarpine NN O
, , O
380 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
non AFX O
- HYPH O
steroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drugs NNS O
differentially RB O
modulate VBP O
the DT O
threshold NN O
for IN O
pilocarpine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
. . O
null null null-Disease
Acute JJ B-Disease
neurologic JJ I-Disease
dysfunction NN I-Disease
after IN O
high JJ O
- HYPH O
dose NN O
etoposide NN O
therapy NN O
for IN O
malignant JJ B-Disease
glioma NN I-Disease
. . O
null null null-Disease
Etoposide NNP O
( , O
VP NNP O
- HYPH O
16 CD O
- HYPH O
213 CD O
) -RRB- O
has VBZ O
been VBN O
used VBN O
in IN O
the DT O
treatment NN O
of IN O
many JJ O
solid JJ O
tumors NNS B-Disease
and CC O
hematologic JJ B-Disease
malignancies NNS I-Disease
. . O
null null null-Disease
When WRB O
used VBN O
in IN O
high JJ O
doses NNS O
and CC O
in IN O
conjunction NN O
with IN O
autologous JJ O
bone NN O
marrow NN O
transplantation NN O
, , O
this DT O
agent NN O
has VBZ O
activity NN O
against IN O
several JJ O
treatment NN O
- HYPH O
resistant JJ O
cancers NNS B-Disease
including VBG O
malignant JJ B-Disease
glioma NN I-Disease
. . O
null null null-Disease
In IN O
six CD O
of IN O
eight CD O
patients NNS O
( : O
75 CD O
% NN O
) , O
who WP O
we PRP O
treated VBD O
for IN O
recurrent JJ O
or CC O
resistant JJ O
glioma NN B-Disease
, , O
sudden JJ O
severe JJ O
neurologic JJ B-Disease
deterioration NN I-Disease
occurred VBD O
. . O
null null null-Disease
This DT O
developed VBD O
a DT O
median NN O
of IN O
9 CD O
days NNS O
after IN O
initiation NN O
of IN O
high JJ O
- HYPH O
dose NN O
etoposide NN O
therapy NN O
. . O
null null null-Disease
Significant JJ O
clinical JJ O
manifestations NNS O
have VBP O
included VBN O
confusion NN B-Disease
, , O
papilledema NN B-Disease
, , O
somnolence NN B-Disease
, , O
exacerbation NN O
of IN O
motor NN B-Disease
deficits NNS I-Disease
, , O
and CC O
sharp JJ O
increase NN O
in IN O
seizure NN B-Disease
activity NN O
. . O
null null null-Disease
These DT O
abnormalities NNS O
resolved VBN O
rapidly RB O
after IN O
initiation NN O
of IN O
high JJ O
- HYPH O
dose NN O
intravenous JJ O
dexamethasone NN O
therapy NN O
. . O
null null null-Disease
In IN O
all DT O
patients NNS O
, , O
computerized VBN O
tomographic JJ O
( , O
CT NNP O
) -RRB- O
brain NN O
scans NNS O
demonstrated VBD O
stability NN O
in IN O
tumor NN B-Disease
size NN O
and CC O
peritumor NN O
edema NN B-Disease
when WRB O
compared VBN O
with IN O
pretransplant NN O
scans NNS O
. . O
null null null-Disease
This DT O
complication NN O
appears VBZ O
to TO O
represent VB O
a DT O
significant JJ O
new JJ O
toxicity NN B-Disease
of IN O
high JJ O
- HYPH O
dose NN O
etoposide NN O
therapy NN O
for IN O
malignant JJ B-Disease
glioma NN I-Disease
. . O
null null null-Disease
Progressive JJ O
bile NN B-Disease
duct NN I-Disease
injury NN I-Disease
after IN O
thiabendazole NN O
administration NN O
. . O
null null null-Disease
A DT O
27 CD O
- HYPH O
yr NN O
- HYPH O
old JJ O
man NN O
developed VBD O
jaundice NN B-Disease
2 CD O
wk NN O
after IN O
exposure NN O
to IN O
thiabendazole NN O
. . O
null null null-Disease
Cholestasis NNP B-Disease
persisted VBD O
for IN O
3 CD O
yr NN O
, , O
at IN O
which WDT O
time NN O
a DT O
liver NN O
transplant NN O
was VBD O
performed VBN O
. . O
null null null-Disease
Two CD O
liver NN O
biopsy NN O
specimens NNS O
and CC O
the DT O
hepatectomy NN O
specimen NNS O
were VBD O
remarkable JJ O
for IN O
almost RB O
complete JJ O
disappearance NN O
of IN O
interlobular JJ O
bile NN O
ducts NNS O
. . O
null null null-Disease
Prominent JJ O
fibrosis NN B-Disease
and CC O
hepatocellular JJ O
regeneration NN O
were VBD O
also RB O
present JJ O
; : O
however RB O
, , O
the DT O
lobular JJ O
architecture NN O
was VBD O
preserved VBN O
. . O
null null null-Disease
This DT O
case NN O
represents VBZ O
an DT O
example NN O
of IN O
"""" `` O
idiosyncratic JJ O
"""" '' O
drug NN B-Disease
- HYPH I-Disease
induced VBN I-Disease
liver NN I-Disease
damage NN I-Disease
in IN O
which WDT O
the DT O
primary JJ O
target NN O
of IN O
injury NN O
is VBZ O
the DT O
bile NN O
duct NN O
. . O
null null null-Disease
An DT O
autoimmune JJ O
pathogenesis NN O
of IN O
the DT O
bile NN B-Disease
duct NN I-Disease
destruction NN I-Disease
is VBZ O
suggested VBN O
. . O
null null null-Disease
Differential JJ O
effects NNS O
of IN O
1 CD O
, , O
4 CD O
- HYPH O
dihydropyridine NN O
calcium NN O
channel NN O
blockers NNS O
: : O
therapeutic JJ O
implications NNS O
. . O
null null null-Disease
Increasing VBG O
recognition NN O
of IN O
the DT O
importance NN O
of IN O
calcium NN O
in IN O
the DT O
pathogenesis NN O
of IN O
cardiovascular JJ B-Disease
disease NN I-Disease
has VBZ O
stimulated VBN O
research NN O
into IN O
the DT O
use NN O
of IN O
calcium NN O
channel NN O
blocking NN O
agents NNS O
for IN O
treatment NN O
of IN O
a DT O
variety NN O
of IN O
cardiovascular JJ B-Disease
diseases NNS I-Disease
. . O
null null null-Disease
The DT O
favorable JJ O
efficacy NN O
and CC O
tolerability NN O
profiles NNS O
of IN O
these DT O
agents NNS O
make VBP O
them PRP O
attractive JJ O
therapeutic JJ O
modalities NNS O
. . O
null null null-Disease
Clinical JJ O
applications NNS O
of IN O
calcium NN O
channel NN O
blockers NNS O
parallel VBP O
their PRP$ O
tissue NN O
selectivity NN O
. . O
null null null-Disease
In IN O
contrast NN O
to IN O
verapamil NN O
and CC O
diltiazem NN O
, , O
which WDT O
are VBP O
roughly RB O
equipotent JJ O
in IN O
their PRP$ O
actions NNS O
on IN O
the DT O
heart NN O
and CC O
vascular JJ O
smooth JJ O
muscle NN O
, , O
the DT O
dihydropyridine NN O
calcium NN O
channel NN O
blockers NNS O
are VBP O
a DT O
group NN O
of IN O
potent JJ O
peripheral JJ O
vasodilator NN O
agents NNS O
that WDT O
exert VBP O
minimal JJ O
electrophysiologic JJ O
effects NNS O
on IN O
cardiac JJ O
nodal NN O
or CC O
conduction NN O
tissue NN O
. . O
null null null-Disease
As IN O
the DT O
first JJ O
dihydropyridine NN O
available JJ O
for IN O
use NN O
in IN O
the DT O
United NNP O
States NNP O
, , O
nifedipine NN O
controls VBZ O
angina NN B-Disease
and CC O
hypertension NN B-Disease
with IN O
minimal JJ O
depression NN O
of IN O
cardiac JJ O
function NN O
. . O
null null null-Disease
Additional JJ O
members NNS O
of IN O
this DT O
group NN O
of IN O
calcium NN O
channel NN O
blockers NNS O
have VBP O
been VBN O
studied VBN O
for IN O
a DT O
variety NN O
of IN O
indications NNS O
for IN O
which WDT O
they PRP O
may MD O
offer VB O
advantages NNS O
over IN O
current JJ O
therapy NN O
. . O
null null null-Disease
Once RB O
or CC O
twice RB O
daily JJ O
dosage NN O
possible JJ O
with IN O
nitrendipine NN O
and CC O
nisoldipine NN O
offers VBZ O
a DT O
convenient JJ O
administration NN O
schedule NN O
, , O
which WDT O
encourages VBZ O
patient JJ O
compliance NN O
in IN O
long JJ O
- HYPH O
term NN O
therapy NN O
of IN O
hypertension NN B-Disease
. . O
null null null-Disease
The DT O
coronary JJ O
vasodilating VBG O
properties NNS O
of IN O
nisoldipine NN O
have VBP O
led VBN O
to IN O
the DT O
investigation NN O
of IN O
this DT O
agent NN O
for IN O
use NN O
in IN O
angina NN B-Disease
. . O
null null null-Disease
Selectivity NN O
for IN O
the DT O
cerebrovascular JJ O
bed NN O
makes VBZ O
nimodipine NN O
potentially RB O
useful JJ O
in IN O
the DT O
treatment NN O
of IN O
subarachnoid NN B-Disease
hemorrhage NN I-Disease
, , O
migraine NN B-Disease
headache NN I-Disease
, , O
dementia NN B-Disease
, , O
and CC O
stroke NN B-Disease
. . O
null null null-Disease
In IN O
general JJ O
, , O
the DT O
dihydropyridine NN O
calcium NN O
channel NN O
blockers NNS O
are VBP O
usually RB O
well RB O
tolerated VBN O
, , O
with IN O
headache NN B-Disease
, , O
facial JJ O
flushing NN B-Disease
, , O
palpitations NNS B-Disease
, , O
edema NN B-Disease
, , O
nausea NN B-Disease
, , O
anorexia NN B-Disease
, , O
and CC O
dizziness NN B-Disease
being VBG O
the DT O
more RBR O
common JJ O
adverse JJ O
effects NNS O
. . O
null null null-Disease
The DT O
enhancement NN O
of IN O
aminonucleoside NN O
nephrosis NN B-Disease
by IN O
the DT O
co NN O
- HYPH O
administration NN O
of IN O
protamine NN O
. . O
null null null-Disease
An DT O
experimental JJ O
model NN O
of IN O
focal JJ B-Disease
segmental JJ I-Disease
glomerular JJ I-Disease
sclerosis NN I-Disease
( -LRB- O
FSGS NNP B-Disease
) -RRB- O
was VBD O
developed VBN O
in IN O
rats NNS O
by IN O
the DT O
combined VBN O
administration NN O
of IN O
puromycin NN O
- HYPH O
aminonucleoside NN O
( , O
AMNS NNP O
) -RRB- O
and CC O
protamine NN O
sulfate NN O
( -LRB- O
PS NN O
) -RRB- O
. . O
null null null-Disease
Male NNP O
Sprague NNP O
- HYPH O
Dawley NNP O
rats NNS O
, , O
uninephrectomized JJ O
three CD O
weeks NNS O
before RB O
, , O
received VBD O
daily JJ O
injections NNS O
of IN O
subcutaneous JJ O
AMNS NNP O
( : O
1 CD O
mg CD O
/ SYM O
100 CD O
g NN O
body NN O
wt NN O
) -RRB- O
and CC O
intravenous JJ O
PS NN O
( , O
2 CD O
separated VBN O
doses NNS O
of IN O
2 CD O
. . O
5 CD O
mg NN O
/ SYM O
100 CD O
g NN O
body NN O
wt NN O
) -RRB- O
for IN O
four CD O
days NNS O
. . O
null null null-Disease
The DT O
series NN O
of IN O
injections NNS O
were VBD O
repeated VBN O
another DT O
three CD O
times NNS O
at IN O
10 CD O
day NN O
intervals NNS O
. . O
null null null-Disease
The DT O
animals NNS O
were VBD O
sacrificed VBN O
on IN O
days NNS O
24 CD O
, , O
52 CD O
, , O
and CC O
80 CD O
. . O
null null null-Disease
They PRP O
developed VBD O
nephrotic JJ B-Disease
syndrome NN I-Disease
and CC O
finally RB O
renal VBP B-Disease
failure NN I-Disease
. . O
null null null-Disease
The DT O
time NN O
- HYPH O
course NN O
curve NN O
of IN O
creatinine NN O
clearance NN O
dropped VBD O
and CC O
showed VBD O
significant JJ O
difference NN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
from IN O
that DT O
of IN O
each DT O
control NN O
group NN O
, , O
such JJ O
as IN O
, , O
AMNS NNP O
alone RB O
, , O
PS NN O
alone RB O
or CC O
saline NN O
injected VBN O
. . O
null null null-Disease
Their PRP$ O
glomeruli NN O
showed VBD O
changes NNS O
of IN O
progressive JJ O
FSGS NNP B-Disease
. . O
null null null-Disease
The DT O
ultrastructural JJ O
studies NNS O
in IN O
the DT O
initial JJ O
stage NN O
revealed VBD O
significant JJ O
lack NN O
of IN O
particles NNS O
of IN O
perfused VBN O
ruthenium NN O
red VBN O
on IN O
the DT O
lamina NN O
rara NN O
externa NN O
and CC O
marked VBN O
changes NNS O
in IN O
epithelial JJ O
cell NN O
cytoplasm NN O
. . O
null null null-Disease
Therefore RB O
, , O
it PRP O
is VBZ O
suggested VBN O
that IN O
the DT O
administration NN O
of IN O
PS NNP O
enhances VBZ O
the DT O
toxicity NN B-Disease
of IN O
AMNS NNP O
on IN O
the DT O
glomerulus NN O
and CC O
readily RB O
produces VBZ O
progressive JJ O
FSGS NNP B-Disease
in IN O
rats NNS O
resulting VBG O
in IN O
the DT O
end NN B-Disease
- HYPH I-Disease
stage NN I-Disease
renal JJ I-Disease
disease NN I-Disease
. . O
null null null-Disease
Theophylline NN O
neurotoxicity NN B-Disease
in IN O
pregnant JJ O
rats NNS O
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
this DT O
investigation NN O
was VBD O
to TO O
determine VB O
whether IN O
the DT O
neurotoxicity NN B-Disease
of IN O
theophylline NN O
is VBZ O
altered VBN O
in IN O
advanced JJ O
pregnancy NN O
. . O
null null null-Disease
Sprague NNP O
- HYPH O
Dawley NNP O
rats NNS O
that WDT O
were VBD O
20 CD O
days NNS O
pregnant JJ O
and CC O
nonpregnant JJ O
rats NNS O
of IN O
the DT O
same JJ O
age NN O
and CC O
strain NN O
received VBD O
infusions NNS O
of IN O
aminophylline NN O
until IN O
onset NN O
of IN O
maximal JJ O
seizures NNS B-Disease
which WDT O
occurred VBD O
after IN O
28 CD O
and CC O
30 CD O
minutes NNS O
respectively RB O
. . O
null null null-Disease
Theophylline NN O
concentrations NNS O
at IN O
this DT O
endpoint NN O
in IN O
serum NN O
( , O
total JJ O
) -RRB- O
and CC O
CSF NNP O
were VBD O
similar JJ O
but CC O
serum NN O
( HYPH O
free JJ O
) -RRB- O
and CC O
brain NN O
concentrations NNS O
were VBD O
slightly RB O
different JJ O
in IN O
pregnant JJ O
rats NNS O
. . O
null null null-Disease
Theophylline NN O
serum NN O
protein NN O
binding NN O
determined VBN O
by IN O
equilibrium NN O
dialysis NN O
was VBD O
lower JJR O
in IN O
pregnant JJ O
rats NNS O
. . O
null null null-Disease
Fetal JJ O
serum NN O
concentrations NNS O
at IN O
onset NN O
of IN O
seizures NNS B-Disease
in IN O
the DT O
mother NN O
were VBD O
similar JJ O
to IN O
maternal JJ O
brain NN O
and CC O
CSF NNP O
concentrations NNS O
and CC O
correlated VBD O
significantly RB O
with IN O
the DT O
former JJ O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
advanced JJ O
pregnancy NN O
has VBZ O
a DT O
negligible JJ O
effect NN O
on IN O
the DT O
neurotoxic JJ B-Disease
response NN O
to IN O
theophylline NN O
in IN O
rats NNS O
. . O
null null null-Disease
Hyperkalemia NNP B-Disease
induced VBN O
by IN O
indomethacin NN O
and CC O
naproxen NN O
and CC O
reversed VBN O
by IN O
fludrocortisone NN O
. . O
null null null-Disease
We PRP O
have VBP O
described VBN O
a DT O
patient NN O
with IN O
severe JJ O
rheumatoid NN B-Disease
arthritis NN I-Disease
and CC O
a DT O
history NN O
of IN O
mefenamic JJ O
acid NN O
nephropathy NN B-Disease
in IN O
whom WP O
hyperkalemia NN B-Disease
and CC O
inappropriate JJ O
hypoaldosteronism NN B-Disease
were VBD O
caused VBN O
by IN O
both CC O
indomethacin NN O
and CC O
naproxen NN O
, , O
without IN O
major JJ O
decline NN O
in IN O
renal JJ O
function NN O
. . O
null null null-Disease
It PRP O
is VBZ O
likely JJ O
that IN O
preexisting VBG O
renal JJ B-Disease
disease NN I-Disease
predisposed VBD O
this DT O
patient NN O
to IN O
type NN B-Disease
IV NN I-Disease
renal JJ I-Disease
tubular JJ I-Disease
acidosis NN I-Disease
with IN O
prostaglandin JJ O
synthetase NN O
inhibitors NNS O
. . O
null null null-Disease
Because IN O
he PRP O
was VBD O
unable JJ O
to TO O
discontinue VB O
nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
drug NN O
therapy NN O
, , O
fludrocortisone NN O
was VBD O
added VBN O
, , O
correcting VBG O
the DT O
hyperkalemia NN B-Disease
and CC O
allowing VBG O
indomethacin JJ O
therapy NN O
to TO O
be VB O
continued VBN O
safely RB O
. . O
null null null-Disease
Hypotension NN B-Disease
as IN O
a DT O
manifestation NN O
of IN O
cardiotoxicity NN B-Disease
in IN O
three CD O
patients NNS O
receiving VBG O
cisplatin NN O
and CC O
5 CD O
- HYPH O
fluorouracil NN O
. . O
null null null-Disease
Cardiac JJ O
symptoms NNS O
, , O
including VBG O
hypotension NN B-Disease
, , O
developed VBN O
in IN O
three CD O
patients NNS O
with IN O
advanced JJ O
colorectal JJ B-Disease
carcinoma NN I-Disease
while IN O
being VBG O
treated VBN O
with IN O
cisplatin NN O
( , O
CDDP NNP O
) -RRB- O
and CC O
5 CD O
- HYPH O
fluorouracil NN O
( HYPH O
5 CD O
- HYPH O
FU NN O
) -RRB- O
. . O
null null null-Disease
In IN O
two CD O
patients NNS O
, , O
hypotension NN B-Disease
was VBD O
associated VBN O
with IN O
severe JJ O
left VBN B-Disease
ventricular JJ I-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
All DT O
three CD O
patients NNS O
required VBD O
therapy NN O
discontinuation NN O
. . O
null null null-Disease
Cardiac JJ O
enzymes NNS O
remained VBD O
normal JJ O
despite IN O
transient JJ O
electrocardiographic JJ O
( -LRB- O
EKG NNP O
) -RRB- O
changes NNS O
. . O
null null null-Disease
The DT O
presentation NN O
and CC O
cardiac JJ O
evaluation NN O
( , O
hemodynamic JJ O
, , O
echocardiographic JJ O
, , O
and CC O
scintigraphic JJ O
) , O
of IN O
these DT O
patients NNS O
suggest VBP O
new JJ O
manifestations NNS O
of IN O
5 CD O
- HYPH O
FU NN O
cardiotoxicity NN B-Disease
that WDT O
may MD O
be VB O
influenced VBN O
by IN O
CDDP NNP O
. . O
null null null-Disease
The DT O
possible JJ O
pathophysiologic JJ O
mechanisms NNS O
are VBP O
discussed VBN O
. . O
null null null-Disease
Fatal JJ O
aplastic JJ B-Disease
anemia NN I-Disease
in IN O
a DT O
patient NN O
treated VBN O
with IN O
carbamazepine NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
fatal JJ O
aplastic JJ B-Disease
anemia NN I-Disease
due IN O
to IN O
carbamazepine NN O
treatment NN O
in IN O
an DT O
epileptic JJ B-Disease
woman NN O
is VBZ O
reported VBN O
. . O
null null null-Disease
Despite IN O
concerns NNS O
of IN O
fatal JJ O
bone NN B-Disease
marrow NN I-Disease
toxicity NN I-Disease
due IN O
to IN O
carbamazepine NN O
, , O
this DT O
is VBZ O
only RB O
the DT O
fourth JJ O
documented VBN O
and CC O
published VBN O
report NN O
. . O
null null null-Disease
Carbamazepine NNP O
is VBZ O
a DT O
safe JJ O
drug NN O
, , O
but CC O
physicians NNS O
and CC O
patients NNS O
should MD O
be VB O
aware JJ O
of IN O
the DT O
exceedingly RB O
rare JJ O
but CC O
potentially RB O
fatal JJ O
side NN O
effects NNS O
, , O
better RBR O
prevented VBN O
by IN O
clinical JJ O
than IN O
by IN O
laboratory NN O
monitoring NN O
. . O
null null null-Disease
Participation NN O
of IN O
a DT O
bulbospinal JJ O
serotonergic JJ O
pathway NN O
in IN O
the DT O
rat NN O
brain NN O
in IN O
clonidine NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
and CC O
bradycardia NN B-Disease
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
microinjection NN O
of IN O
clonidine NN O
( , O
1 CD O
- SYM O
10 CD O
micrograms NNS O
in IN O
1 CD O
microliter NN O
) -RRB- O
into IN O
a DT O
region NN O
adjacent JJ O
to IN O
the DT O
ventrolateral JJ O
surface NN O
of IN O
the DT O
medulla NN O
oblongata NN O
on IN O
cardiovascular JJ O
function NN O
were VBD O
assessed VBN O
in IN O
urethane NN O
- HYPH O
anesthetized VBN O
rats NNS O
. . O
null null null-Disease
Intramedullary JJ O
administration NN O
of IN O
clonidine NN O
, , O
but CC O
not RB O
saline JJ O
vehicle NN O
, , O
caused VBD O
a DT O
dose NN O
- HYPH O
dependent JJ O
decrease NN O
in IN O
both CC O
the DT O
mean JJ O
arterial JJ O
pressure NN O
and CC O
the DT O
heart NN O
rate NN O
. . O
null null null-Disease
The DT O
clonidine NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
was VBD O
antagonized VBN O
by IN O
prior JJ O
spinal JJ O
transection NN O
, , O
but CC O
not RB O
bilateral JJ O
vagotomy NN O
. . O
null null null-Disease
On IN O
the DT O
other JJ O
hand NN O
, , O
the DT O
clonidine NN O
- HYPH O
induced VBN O
bradycardia NN B-Disease
was VBD O
antagonized VBN O
by IN O
prior JJ O
bilateral JJ O
vagotomy NN O
, , O
but CC O
not RB O
spinal JJ O
transection NN O
. . O
null null null-Disease
Furthermore RB O
, , O
selective JJ O
destruction NN O
of IN O
the DT O
spinal JJ O
5 CD O
- HYPH O
HT NNP O
nerves NNS O
, , O
produced VBN O
by IN O
bilateral JJ O
spinal JJ O
injection NN O
of IN O
5 CD O
, , O
7 CD O
- HYPH O
dihydroxytryptamine NN O
, , O
reduced VBD O
the DT O
magnitude NN O
of IN O
the DT O
vasodepressor NN O
or CC O
the DT O
bradycardiac JJ B-Disease
responses NNS O
to IN O
clonidine NN O
microinjected VBN O
into IN O
the DT O
area NN O
near IN O
the DT O
ventrolateral JJ O
surface NN O
of IN O
the DT O
medulla NN O
oblongata NN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
data NNS O
indicate VBP O
that IN O
a DT O
bulbospinal JJ O
serotonergic JJ O
pathway NN O
is VBZ O
involved VBN O
in IN O
development NN O
of IN O
clonidine NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
and CC O
bradycardia NN B-Disease
. . O
null null null-Disease
The DT O
induced VBN O
hypotension NN B-Disease
is VBZ O
brought VBN O
about RP O
by IN O
a DT O
decrease NN O
in IN O
sympathetic JJ O
efferent JJ O
activity NN O
, , O
whereas IN O
the DT O
induced VBN O
bradycardia NN B-Disease
was VBD O
due JJ O
to IN O
an DT O
increase NN O
in IN O
vagal JJ O
efferent JJ O
activity NN O
. . O
null null null-Disease
Hypertension NN B-Disease
in IN O
neuroblastoma NN B-Disease
induced VBN O
by IN O
imipramine NN O
. . O
null null null-Disease
Hypertension NN B-Disease
is VBZ O
a DT O
well RB O
- HYPH O
known VBN O
finding NN O
in IN O
some DT O
patients NNS O
with IN O
neuroblastoma NN B-Disease
. . O
null null null-Disease
However RB O
, , O
it PRP O
has VBZ O
not RB O
previously RB O
been VBN O
described VBN O
in IN O
association NN O
with IN O
the DT O
use NN O
of IN O
Imipramine NNP O
. . O
null null null-Disease
We PRP O
report VBP O
the DT O
occurrence NN O
of IN O
severe JJ O
hypertension NN B-Disease
( , O
blood NN O
pressure NN O
190 CD O
/ SYM O
160 CD O
) -RRB- O
in IN O
a DT O
4 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
girl NN O
with IN O
neuroblastoma NN B-Disease
who WP O
was VBD O
given VBN O
Imipramine NNP O
to TO O
control VB O
a DT O
behavior NN B-Disease
disorder NN I-Disease
. . O
null null null-Disease
It PRP O
was VBD O
determined VBN O
later RB O
that IN O
this DT O
patient NN O
' POS O
s POS O
tumor NN B-Disease
was VBD O
recurring VBG O
at IN O
the DT O
time NN O
of IN O
her PRP$ O
hypertensive JJ B-Disease
episode NN O
. . O
null null null-Disease
Since IN O
she PRP O
had VBD O
no DT O
blood NN O
pressure NN O
elevation NN O
at IN O
initial JJ O
diagnosis NN O
and CC O
none NN O
following VBG O
discontinuation NN O
of IN O
the DT O
Imipramine NNP O
( , O
when WRB O
she PRP O
was VBD O
in IN O
florid JJ O
relapse NN O
) , O
, , O
we PRP O
believe VBP O
that IN O
this DT O
drug NN O
rather RB O
than IN O
her PRP$ O
underlying VBG O
disease NN O
alone RB O
caused VBD O
her PRP$ O
hypertension NN B-Disease
. . O
null null null-Disease
The DT O
mechanism NN O
for IN O
this DT O
reaction NN O
is VBZ O
believed VBN O
to TO O
be VB O
increased VBN O
levels NNS O
of IN O
vasoactive JJ O
catecholamines NNS O
due IN O
to IN O
interference NN O
of IN O
their PRP$ O
physiologic JJ O
inactivation NN O
by IN O
Imipramine NNP O
. . O
null null null-Disease
From IN O
this DT O
experience NN O
, , O
we PRP O
urge VBP O
extreme JJ O
caution NN O
in IN O
the DT O
use NN O
of IN O
tricyclic JJ O
antidepressants NNS O
in IN O
children NNS O
with IN O
active JJ O
neuroblastoma NN B-Disease
. . O
null null null-Disease
Rechallenge NN O
of IN O
patients NNS O
who WP O
developed VBD O
oral JJ B-Disease
candidiasis NN I-Disease
or CC O
hoarseness NN B-Disease
with IN O
beclomethasone NN O
dipropionate JJ O
. . O
null null null-Disease
Of IN O
158 CD O
asthmatic JJ B-Disease
patients NNS O
who WP O
were VBD O
placed VBN O
on IN O
inhaled VBN O
beclomethasone NN O
, , O
15 CD O
( SYM O
9 CD O
. . O
5 CD O
% NN O
) -RRB- O
developed VBD O
either CC O
hoarseness NN B-Disease
( , O
8 CD O
) -RRB- O
, , O
oral JJ O
thrush NN B-Disease
( , O
6 CD O
) -RRB- O
, , O
or CC O
both DT O
( SYM O
1 CD O
) -RRB- O
. . O
null null null-Disease
When WRB O
their PRP$ O
adverse JJ O
reactions NNS O
subsided VBD O
, , O
seven CD O
of IN O
these DT O
15 CD O
patients NNS O
were VBD O
rechallenged VBN O
with IN O
inhaled VBN O
beclomethasone NN O
. . O
null null null-Disease
These DT O
included VBD O
five CD O
cases NNS O
who WP O
developed VBD O
hoarseness NN B-Disease
and CC O
three CD O
who WP O
developed VBD O
Candidiasis NNP B-Disease
. . O
null null null-Disease
One CD O
patient NN O
had VBD O
both DT O
. . O
null null null-Disease
Oral JJ O
thrush NN B-Disease
did VBD O
not RB O
recur VB O
, , O
but CC O
60 CD O
% NN O
( SYM O
3 CD O
/ SYM O
5 CD O
) NN O
of IN O
patients NNS O
with IN O
hoarseness NN B-Disease
had VBD O
recurrence NN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
patients NNS O
may MD O
be VB O
restarted VBN O
on IN O
inhaled VBN O
beclomethasone NN O
when WRB O
clinically RB O
indicated VBN O
; : O
however RB O
, , O
because IN O
of IN O
the DT O
high JJ O
recurrence NN O
rate NN O
, , O
patients NNS O
who WP O
develop VBP O
hoarseness NN B-Disease
should MD O
not RB O
be VB O
re RB O
- HYPH O
challenged VBN O
. . O
null null null-Disease
Concomitant JJ O
use NN O
of IN O
oral JJ O
prednisone NN O
and CC O
topical JJ O
beclomethasone NN O
may MD O
increase VB O
the DT O
risk NN O
of IN O
developing VBG O
hoarseness NN B-Disease
or CC O
candidiasis NN B-Disease
. . O
null null null-Disease
Cyclophosphamide NN O
cardiotoxicity NN B-Disease
: : O
an DT O
analysis NN O
of IN O
dosing VBG O
as IN O
a DT O
risk NN O
factor NN O
. . O
null null null-Disease
Patients NNS O
who WP O
undergo VBP O
bone NN O
marrow NN O
transplantation NN O
are VBP O
generally RB O
immunosuppressed VBN O
with IN O
a DT O
dose NN O
of IN O
cyclophosphamide NN O
( -LRB- O
CYA NNP O
) -RRB- O
which WDT O
is VBZ O
usually RB O
calculated VBN O
based VBN O
on IN O
the DT O
patient NN O
' POS O
s NNS O
weight NN O
. . O
null null null-Disease
At IN O
these DT O
high JJ O
doses NNS O
of IN O
CYA NNP O
, , O
serious JJ O
cardiotoxicity NN B-Disease
may MD O
occur VB O
, , O
but CC O
definitive JJ O
risk NN O
factors NNS O
for IN O
the DT O
development NN O
of IN O
such JJ O
cardiotoxicity NN B-Disease
have VBP O
not RB O
been VBN O
described VBN O
. . O
null null null-Disease
Since IN O
chemotherapeutic JJ O
agent NN O
toxicity NN B-Disease
generally RB O
correlates VBZ O
with IN O
dose NN O
per IN O
body NN O
surface NN O
area NN O
, , O
we PRP O
retrospectively RB O
calculated VBD O
the DT O
dose NN O
of IN O
CYA NNP O
in IN O
patients NNS O
transplanted VBN O
at IN O
our PRP$ O
institution NN O
to TO O
determine VB O
whether IN O
the DT O
incidence NN O
of IN O
CYA NNP O
cardiotoxicity NN B-Disease
correlated VBD O
with IN O
the DT O
dose NN O
per IN O
body NN O
surface NN O
area NN O
. . O
null null null-Disease
Eighty CD O
patients NNS O
who WP O
were VBD O
to TO O
receive VB O
CYA NN O
50 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
d NN O
for IN O
four CD O
days NNS O
as IN O
preparation NN O
for IN O
marrow NN O
grafting NN O
underwent VBD O
a DT O
total NN O
of IN O
84 CD O
transplants NNS O
for IN O
aplastic JJ B-Disease
anemia NN I-Disease
, , O
Wiskott NNP B-Disease
- HYPH I-Disease
Aldrich NNP I-Disease
syndrome NN I-Disease
, , O
or CC O
severe JJ B-Disease
combined VBN I-Disease
immunodeficiency NN I-Disease
syndrome NN I-Disease
. . O
null null null-Disease
Fourteen CD O
of IN O
84 CD O
( SYM O
17 CD O
% NN O
) , O
patients NNS O
had VBD O
symptoms NNS O
and CC O
signs NNS O
consistent JJ O
with IN O
CYA NNP O
cardiotoxicity NN B-Disease
within IN O
ten CD O
days NNS O
of IN O
receiving VBG O
1 CD O
to TO O
4 CD O
doses NNS O
of IN O
CYA NNP O
. . O
null null null-Disease
Six CD O
of IN O
the DT O
14 CD O
patients NNS O
died VBD O
with IN O
congestive JJ B-Disease
heart NN I-Disease
failure NN I-Disease
. . O
null null null-Disease
The DT O
dose NN O
of IN O
CYA NNP O
per IN O
body NN O
surface NN O
area NN O
was VBD O
calculated VBN O
for IN O
all DT O
patients NNS O
and CC O
the DT O
patients NNS O
were VBD O
divided VBN O
into IN O
two CD O
groups NNS O
based VBN O
on IN O
daily JJ O
CYA NNP O
dose NN O
: : O
Group NN O
1 CD O
, , O
CYA NN O
less JJR O
than IN O
or CC O
equal JJ O
to IN O
1 CD O
. . O
55 CD O
g NN O
/ SYM O
m2 CD O
/ SYM O
d NN O
; : O
Group NN O
2 CD O
, , O
CYA NN O
greater JJR O
than IN O
1 CD O
. . O
55 CD O
g NN O
/ SYM O
m2 CD O
/ SYM O
d NN O
. . O
null null null-Disease
Cardiotoxicity NN B-Disease
that WDT O
was VBD O
thought VBN O
to TO O
be VB O
related VBN O
to IN O
CYA NNP O
occurred VBD O
in IN O
1 CD O
/ SYM O
32 CD O
( SYM O
3 CD O
% NN O
) -RRB- O
of IN O
patients NNS O
in IN O
Group NNP O
1 CD O
and CC O
in IN O
13 CD O
/ SYM O
52 CD O
( SYM O
25 CD O
% NN O
) SYM O
patients NNS O
in IN O
Group NNP O
2 CD O
( SYM O
P NN O
less JJR O
than IN O
0 CD O
. . O
025 CD O
) -RRB- O
. . O
null null null-Disease
Congestive JJ B-Disease
heart NN I-Disease
failure NN I-Disease
caused VBD O
or CC O
contributed VBN O
to IN O
death NN O
in IN O
0 CD O
/ SYM O
32 CD O
patients NNS O
in IN O
Group NNP O
1 CD O
v SYM O
6 CD O
/ SYM O
52 CD O
( SYM O
12 CD O
% NN O
) -RRB- O
of IN O
patients NNS O
in IN O
Group NNP O
2 CD O
( SYM O
P NN O
less JJR O
than IN O
0 CD O
. . O
25 CD O
) -RRB- O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
difference NN O
in IN O
the DT O
rate NN O
of IN O
engraftment NN O
of IN O
evaluable JJ O
patients NNS O
in IN O
the DT O
two CD O
groups NNS O
( -LRB- O
P NN O
greater JJR O
than IN O
0 CD O
. . O
5 CD O
) -RRB- O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
the DT O
CYA NNP O
cardiotoxicity NN B-Disease
correlates VBZ O
with IN O
CYA NNP O
dosage NN O
as IN O
calculated VBN O
by IN O
body NN O
surface NN O
area NN O
, , O
and CC O
that IN O
patients NNS O
with IN O
aplastic JJ B-Disease
anemia NN I-Disease
and CC O
immunodeficiencies NNS B-Disease
can MD O
be VB O
effectively RB O
prepared VBN O
for IN O
bone NN O
marrow NN O
grafting NN O
at IN O
a DT O
CYA NNP O
dose NN O
of IN O
1 CD O
. . O
55 CD O
g NN O
/ SYM O
m2 CD O
/ SYM O
d CD O
for IN O
four CD O
days NNS O
with IN O
a DT O
lower JJR O
incidence NN O
of IN O
cardiotoxicity NN B-Disease
than IN O
patients NNS O
whose WP$ O
CYA NNP O
dosage NN O
is VBZ O
calculated VBN O
based VBN O
on IN O
weight NN O
. . O
null null null-Disease
This DT O
study NN O
reaffirms VBZ O
the DT O
principle NN O
that IN O
drug NN O
toxicity NN B-Disease
correlates VBZ O
with IN O
dose NN O
per IN O
body NN O
surface NN O
area NN O
. . O
null null null-Disease
Studies NNS O
of IN O
risk NN O
factors NNS O
for IN O
aminoglycoside NN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
The DT O
epidemiology NN O
of IN O
aminoglycoside NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
is VBZ O
not RB O
fully RB O
understood VBN O
. . O
null null null-Disease
Experimental JJ O
studies NNS O
in IN O
healthy JJ O
human JJ O
volunteers NNS O
indicate VBP O
aminoglycosides NNS O
cause VBP O
proximal JJ O
tubular JJ O
damage NN O
in IN O
most JJS O
patients NNS O
, , O
but CC O
rarely RB O
, , O
if IN O
ever RB O
, , O
cause VBP O
glomerular JJ B-Disease
or CC I-Disease
tubular JJ I-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
Clinical JJ O
trials NNS O
of IN O
aminoglycosides NNS O
in IN O
seriously RB O
ill JJ O
patients NNS O
indicate VBP O
that IN O
the DT O
relative JJ O
risk NN O
for IN O
developing VBG O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
during IN O
therapy NN O
ranges VBZ O
from IN O
8 CD O
to IN O
10 CD O
and CC O
that IN O
the DT O
attributable JJ O
risk NN O
is VBZ O
70 CD O
% NN O
to TO O
80 CD O
% NN O
. . O
null null null-Disease
Further JJ O
analysis NN O
of IN O
these DT O
data NNS O
suggests VBZ O
that IN O
the DT O
duration NN O
of IN O
therapy NN O
, , O
plasma NN O
aminoglycoside NN O
levels NNS O
, , O
liver NN B-Disease
disease NN I-Disease
, , O
advanced JJ O
age NN O
, , O
high JJ O
initial JJ O
estimated VBN O
creatinine NN O
clearance NN O
and CC O
, , O
possibly RB O
, , O
female JJ O
gender NN O
all DT O
increase VBP O
the DT O
risk NN O
for IN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
Other JJ O
causes NNS O
of IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
, , O
such JJ O
as IN O
shock NN B-Disease
, , O
appear VBP O
to TO O
have VB O
an DT O
additive JJ O
effect NN O
. . O
null null null-Disease
Predictive JJ O
models NNS O
have VBP O
been VBN O
developed VBN O
from IN O
these DT O
analyses NNS O
that WDT O
should MD O
be VB O
useful JJ O
for IN O
identifying VBG O
patients NNS O
at IN O
high JJ O
risk NN O
. . O
null null null-Disease
These DT O
models NNS O
may MD O
also RB O
be VB O
useful JJ O
in IN O
developing VBG O
insights NNS O
into IN O
the DT O
pathophysiology NN O
of IN O
aminoglycoside NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
Central JJ O
action NN O
of IN O
narcotic JJ O
analgesics NNS O
. . O
null null null-Disease
Part NN O
IV NN O
. . O
null null null-Disease
Noradrenergic NNP O
influences VBZ O
on IN O
the DT O
activity NN O
of IN O
analgesics NNS O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
effect NN O
of IN O
clonidine NN O
, , O
naphazoline NN O
and CC O
xylometazoline NN O
on IN O
analgesia NN O
induced VBN O
by IN O
morphine NN O
, , O
codeine NN O
, , O
fentanyl NN O
and CC O
pentazocine NN O
, , O
and CC O
on IN O
cataleptic JJ B-Disease
effect NN O
of IN O
morphine NN O
, , O
codine NN O
and CC O
fentanyl NN O
was VBD O
studied VBN O
in IN O
rats NNS O
. . O
null null null-Disease
The DT O
biochemical JJ O
assays NNS O
on IN O
the DT O
influence NN O
of IN O
four CD O
analgesics NNS O
on IN O
the DT O
brain NN O
concentration NN O
and CC O
turnover NN O
of IN O
noradrenaline NN O
( -LRB- O
null NNP O
) -RRB- O
were VBD O
also RB O
performed VBN O
. . O
null null null-Disease
It PRP O
was VBD O
found VBN O
that IN O
three CD O
drugs NNS O
stimulating VBG O
central JJ O
null NNP O
receptors NNS O
failed VBD O
to TO O
affect VB O
the DT O
analgesic JJ O
ED50 NN O
of IN O
all DT O
antinociceptive JJ O
agents NNS O
and CC O
they PRP O
enhanced VBD O
catalepsy NN B-Disease
induced VBN O
by IN O
morphine NN O
and CC O
fentanyl NN O
. . O
null null null-Disease
Codeine NNP O
catalepsy NN B-Disease
was VBD O
increased VBN O
by IN O
clonidine NN O
and CC O
decreased VBN O
by IN O
naphazoline NN O
and CC O
xylometazoline NN O
. . O
null null null-Disease
The DT O
brain NN O
concentration NN O
of IN O
null NNP O
was VBD O
not RB O
changed VBN O
by IN O
morphine NN O
and CC O
fentanyl NN O
, , O
but CC O
one CD O
of IN O
the DT O
doses NNS O
of IN O
codeine NN O
( : O
45 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
slightly RB O
enhanced VBD O
it PRP O
. . O
null null null-Disease
Pentazocine NNP O
dose NN O
- HYPH O
dependently RB O
decreased VBD O
the DT O
brain NN O
level NN O
of IN O
null NNP O
. . O
null null null-Disease
The DT O
rate NN O
of IN O
null NNP O
turnover NN O
was VBD O
not RB O
altered VBN O
by IN O
analgesics NNS O
except IN O
for IN O
the DT O
higher JJR O
dose NN O
of IN O
fentanyl NN O
( SYM O
0 CD O
. . O
2 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
following VBG O
which WDT O
the DT O
disappearance NN O
of IN O
null NNP O
from IN O
the DT O
brain NN O
was VBD O
diminished VBN O
. . O
null null null-Disease
The DT O
results NNS O
are VBP O
discussed VBN O
in IN O
the DT O
light NN O
of IN O
various JJ O
and CC O
non AFX O
- HYPH O
uniform JJ O
data NNS O
from IN O
the DT O
literature NN O
. . O
null null null-Disease
It PRP O
is VBZ O
suggested VBN O
that IN O
in IN O
rats NNS O
the DT O
brain NN O
null NNP O
plays VBZ O
a DT O
less RBR O
important JJ O
function NN O
than IN O
the DT O
other JJ O
monoamines NNS O
in IN O
the DT O
behavioural JJ O
activity NN O
of IN O
potent JJ O
analgesics NNS O
. . O
null null null-Disease
Flurothyl NNP O
seizure NN B-Disease
thresholds NNS O
in IN O
mice NNS O
treated VBN O
neonatally RB O
with IN O
a DT O
single JJ O
injection NN O
of IN O
monosodium NN O
glutamate NN O
( , O
MSG NNP O
) -RRB- O
: : O
evaluation NN O
of IN O
experimental JJ O
parameters NNS O
in IN O
flurothyl NN O
seizure NN B-Disease
testing NN O
. . O
null null null-Disease
Monosodium NN O
glutamate NN O
( , O
MSG NNP O
) -RRB- O
administration NN O
to IN O
neonatal JJ O
rodents NNS O
produces VBZ O
convulsions NNS B-Disease
and CC O
results VBZ O
in IN O
numerous JJ O
biochemical JJ O
and CC O
behavioral JJ O
deficits NNS O
. . O
null null null-Disease
These DT O
studies NNS O
were VBD O
undertaken VBN O
to TO O
determine VB O
if IN O
neonatal JJ O
administration NN O
of IN O
MSG NNP O
produced VBD O
permanent JJ O
alterations NNS O
in IN O
seizure NN B-Disease
susceptibility NN O
, , O
since IN O
previous JJ O
investigations NNS O
were VBD O
inconclusive JJ O
. . O
null null null-Disease
A DT O
flurothyl JJ O
ether NN O
seizure NN B-Disease
screening NN O
technique NN O
was VBD O
used VBN O
to TO O
evaluate VB O
seizure NN B-Disease
susceptibility NN O
in IN O
adult NN O
mice NNS O
that WDT O
received VBD O
neonatal JJ O
injections NNS O
of IN O
MSG NNP O
( : O
4 CD O
mg NN O
/ SYM O
g NN O
and CC O
1 CD O
mg NN O
/ SYM O
g NN O
) -RRB- O
. . O
null null null-Disease
MSG NNP O
treatment NN O
resulted VBD O
in IN O
significant JJ O
reductions NNS O
in IN O
whole JJ O
brain NN O
weight NN O
but CC O
did VBD O
not RB O
alter VB O
seizure NN B-Disease
threshold NN O
. . O
null null null-Disease
A DT O
naloxone NN O
( : O
5 CD O
mg NN O
/ SYM O
kg NN O
) -RRB- O
challenge NN O
was VBD O
also RB O
ineffective JJ O
in IN O
altering VBG O
the DT O
seizure NN B-Disease
thresholds NNS O
of IN O
either CC O
control NN O
of IN O
MSG NNP O
- HYPH O
treated VBN O
mice NNS O
. . O
null null null-Disease
Flurothyl NNP O
ether RB O
produced VBD O
hypothermia NN B-Disease
which WDT O
was VBD O
correlated VBN O
with IN O
the DT O
duration NN O
of IN O
flurothyl NN O
exposure NN O
; : O
however RB O
, , O
the DT O
relationship NN O
of IN O
hypothermia NN B-Disease
to IN O
seizure NN B-Disease
induction NN O
was VBD O
unclear JJ O
. . O
null null null-Disease
Flurothyl NNP O
seizure NN B-Disease
testing NN O
proved VBD O
to TO O
be VB O
a DT O
rapid JJ O
and CC O
reliable JJ O
technique NN O
with IN O
which WDT O
to TO O
evaluate VB O
seizure NN B-Disease
susceptibility NN O
. . O
null null null-Disease
Susceptibility NN O
to IN O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
in IN O
rats NNS O
after IN O
microinjection NN O
of IN O
isoniazid NN O
or CC O
gamma NN O
- HYPH O
vinyl NN O
- HYPH O
GABA NNP O
into IN O
the DT O
substantia JJ O
nigra NN O
. . O
null null null-Disease
Pilocarpine NN O
, , O
given VBN O
intraperitoneally RB O
to IN O
rats NNS O
, , O
reproduces VBZ O
the DT O
neuropathological JJ O
sequelae NN O
of IN O
temporal JJ B-Disease
lobe NN I-Disease
epilepsy NN I-Disease
and CC O
provides VBZ O
a DT O
relevant JJ O
animal NN O
model NN O
for IN O
studying VBG O
mechanisms NNS O
of IN O
buildup NN O
of IN O
convulsive JJ B-Disease
activity NN O
and CC O
pathways NNS O
operative NN O
in IN O
the DT O
generalization NN O
and CC O
propagation NN O
of IN O
seizures NNS B-Disease
within IN O
the DT O
forebrain NN O
. . O
null null null-Disease
In IN O
the DT O
present JJ O
study NN O
, , O
the DT O
effects NNS O
of IN O
manipulating VBG O
the DT O
activity NN O
of IN O
the DT O
gamma NN O
- HYPH O
aminobutyric JJ O
acid NN O
( , O
GABA NNP O
) -RRB- O
- HYPH O
mediated VBN O
synaptic JJ O
inhibition NN O
within IN O
the DT O
substantia JJ O
nigra NN O
on IN O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
in IN O
rats NNS O
, , O
were VBD O
investigated VBN O
. . O
null null null-Disease
In IN O
animals NNS O
pretreated VBN O
with IN O
microinjections NNS O
of IN O
isoniazid NN O
, , O
150 CD O
micrograms NNS O
, , O
an DT O
inhibitor NN O
of IN O
activity NN O
of IN O
the DT O
GABA NNP O
- HYPH O
synthesizing VBG O
enzyme NN O
, , O
L NN O
- HYPH O
glutamic JJ O
acid NN O
decarboxylase NN O
, , O
into IN O
the DT O
substantia JJ O
nigra NN O
pars NNS O
reticulata NN O
( , O
SNR NNP O
) -RRB- O
, , O
bilaterally RB O
, , O
non JJ O
- HYPH O
convulsant JJ O
doses NNS O
of IN O
pilocarpine NN O
, , O
100 CD O
and CC O
200 CD O
mg NN O
/ SYM O
kg NN O
, , O
resulted VBD O
in IN O
severe JJ O
motor NN O
limbic JJ O
seizures NNS B-Disease
and CC O
status NN B-Disease
epilepticus NN I-Disease
. . O
null null null-Disease
Electroencephalographic JJ O
and CC O
behavioral JJ O
monitoring NN O
revealed VBD O
a DT O
profound JJ O
reduction NN O
of IN O
the DT O
threshold NN O
for IN O
pilocarpine NN O
- HYPH O
induced VBN O
convulsions NNS B-Disease
. . O
null null null-Disease
Morphological JJ O
analysis NN O
of IN O
frontal JJ O
forebrain NN O
sections NNS O
with IN O
light JJ O
microscopy NN O
revealed VBD O
seizure NN B-Disease
- HYPH O
related VBN O
damage NN O
to IN O
the DT O
hippocampal JJ O
formation NN O
, , O
thalamus NN O
, , O
amygdala NN O
, , O
olfactory JJ O
cortex NN O
, , O
substantia NN O
nigra NN O
and CC O
neocortex NN O
, , O
which WDT O
is VBZ O
typically RB O
observed VBN O
with IN O
pilocarpine NN O
in IN O
doses NNS O
exceeding VBG O
350 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
Bilateral JJ O
intrastriatal JJ O
injections NNS O
of IN O
isoniazid NN O
did VBD O
not RB O
augment VB O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
, , O
200 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
Application NN O
of IN O
an DT O
irreversible JJ O
inhibitor NN O
of IN O
GABA NNP O
transaminase NN O
, , O
gamma NN O
- HYPH O
vinyl NN O
- HYPH O
GABA NNP O
( : O
D NNP O
, , O
L NNP O
- HYPH O
4 CD O
- HYPH O
amino NN O
- HYPH O
hex NN O
- HYPH O
5 CD O
- HYPH O
enoic NN O
acid NN O
) -RRB- O
, , O
5 CD O
micrograms NNS O
, , O
into IN O
the DT O
SNR NNP O
, , O
bilaterally RB O
, , O
suppressed VBD O
the DT O
appearance NN O
of IN O
electrographic JJ O
and CC O
behavioral JJ O
seizures NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
, , O
380 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
This DT O
treatment NN O
was VBD O
also RB O
sufficient JJ O
to TO O
protect VB O
animals NNS O
from IN O
the DT O
occurrence NN O
of IN O
brain NN B-Disease
damage NN I-Disease
. . O
null null null-Disease
Microinjections NNS O
of IN O
gamma NN O
- HYPH O
vinyl NN O
- HYPH O
GABA NNP O
, , O
5 CD O
micrograms NNS O
, , O
into IN O
the DT O
dorsal JJ O
striatum NN O
, , O
bilaterally RB O
, , O
failed VBD O
to TO O
prevent VB O
the DT O
development NN O
of IN O
convulsions NNS B-Disease
produced VBN O
by IN O
pilocarpine NN O
, , O
380 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
The DT O
results NNS O
demonstrate VBP O
that IN O
the DT O
threshold NN O
for IN O
pilocarpine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
in IN O
rats NNS O
is VBZ O
subjected VBN O
to IN O
the DT O
regulation NN O
of IN O
the DT O
GABA NNP O
- HYPH O
mediated VBN O
synaptic JJ O
inhibition NN O
within IN O
the DT O
substantia JJ O
nigra NN O
. . O
null null null-Disease
Human JJ O
and CC O
canine NN O
ventricular JJ O
vasoactive JJ O
intestinal JJ O
polypeptide NN O
: : O
decrease VBP O
with IN O
heart NN B-Disease
failure NN I-Disease
. . O
null null null-Disease
Vasoactive JJ O
intestinal JJ O
polypeptide NN O
( , O
VIP NN O
) -RRB- O
is VBZ O
a DT O
systemic JJ O
and CC O
coronary JJ O
vasodilator NN O
that WDT O
may MD O
have VB O
positive JJ O
inotropic JJ O
properties NNS O
. . O
null null null-Disease
Myocardial JJ O
levels NNS O
of IN O
VIP NNP O
were VBD O
assayed VBN O
before IN O
and CC O
after IN O
the DT O
development NN O
of IN O
heart NN B-Disease
failure NN I-Disease
in IN O
two CD O
canine NN O
models NNS O
. . O
null null null-Disease
In IN O
the DT O
first JJ O
, , O
cobalt NN O
cardiomyopathy NN B-Disease
was VBD O
induced VBN O
in IN O
eight CD O
dogs NNS O
; : O
VIP NNP O
( , O
by IN O
radioimmunoassay NN O
) -RRB- O
decreased VBD O
from IN O
35 CD O
+ CD O
/ SYM O
- SYM O
11 CD O
pg NNS O
/ SYM O
mg NN O
protein NN O
( , O
mean JJ O
+ NN O
/ SYM O
- HYPH O
SD NN O
) -RRB- O
to IN O
5 CD O
+ SYM O
/ SYM O
- SYM O
4 CD O
pg NN O
/ SYM O
mg NN O
protein NN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
six CD O
dogs NNS O
with IN O
doxorubicin NN O
- HYPH O
induced VBN O
heart NN B-Disease
failure NN I-Disease
, , O
VIP NNP O
decreased VBD O
from IN O
31 CD O
+ CD O
/ SYM O
- SYM O
7 CD O
to IN O
11 CD O
+ NN O
/ SYM O
- SYM O
4 CD O
pg NN O
/ SYM O
mg NN O
protein NN O
( -LRB- O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
In IN O
addition NN O
, , O
VIP NNP O
content NN O
of IN O
left JJ O
ventricular JJ O
muscle NN O
of IN O
resected VBN O
failing VBG O
hearts NNS O
in IN O
10 CD O
patients NNS O
receiving VBG O
a DT O
heart NN O
transplant NN O
was VBD O
compared VBN O
with IN O
the DT O
papillary JJ O
muscles NNS O
in IN O
14 CD O
patients NNS O
( , O
five CD O
with IN O
rheumatic JJ B-Disease
disease NN I-Disease
, , O
nine CD O
with IN O
myxomatous JJ B-Disease
degeneration NN I-Disease
) , O
receiving VBG O
mitral JJ O
valve NN O
prostheses NNS O
. . O
null null null-Disease
The DT O
lowest JJS O
myocardial JJ O
VIP NNP O
concentration NN O
was VBD O
found VBN O
in IN O
the DT O
hearts NNS O
of IN O
patients NNS O
with IN O
coronary JJ B-Disease
disease NN I-Disease
( : O
one CD O
patient NN O
receiving VBG O
a DT O
transplant NN O
and CC O
three CD O
receiving VBG O
mitral JJ O
prostheses NNS O
) -RRB- O
( : O
6 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
9 CD O
pg NN O
/ SYM O
mg NN O
protein NN O
) -RRB- O
. . O
null null null-Disease
The DT O
other JJ O
patients NNS O
undergoing VBG O
transplantation NN O
had VBD O
an DT O
average JJ O
ejection NN O
fraction NN O
of IN O
17 CD O
% NN O
+ SYM O
/ SYM O
- SYM O
6 CD O
% NN O
and CC O
a DT O
VIP NN O
level NN O
of IN O
8 CD O
. . O
8 CD O
+ NN O
/ SYM O
- HYPH O
3 CD O
. . O
9 CD O
pg NN O
/ SYM O
mg NN O
protein NN O
. . O
null null null-Disease
The DT O
hearts NNS O
without IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
( , O
average JJ O
ejection NN O
fraction NN O
of IN O
this DT O
group NN O
62 CD O
% NN O
+ SYM O
/ SYM O
- SYM O
10 CD O
% NN O
) -RRB- O
had VBD O
a DT O
VIP NN O
concentration NN O
of IN O
14 CD O
. . O
1 CD O
+ NN O
/ SYM O
- HYPH O
7 CD O
. . O
9 CD O
pg NN O
/ SYM O
mg NN O
protein NN O
, , O
and CC O
this DT O
was VBD O
greater JJR O
than IN O
in IN O
hearts NNS O
of IN O
the DT O
patients NNS O
with IN O
coronary JJ B-Disease
disease NN I-Disease
and CC O
the DT O
hearts NNS O
of IN O
patients NNS O
receiving VBG O
a DT O
transplant NN O
( , O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Myocardial JJ O
catecholamines NNS O
were VBD O
also RB O
determined VBN O
in IN O
14 CD O
subjects NNS O
; : O
a DT O
weak JJ O
correlation NN O
( , O
r NN O
= SYM O
0 CD O
. . O
57 CD O
, , O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
between IN O
the DT O
tissue NN O
concentrations NNS O
of IN O
VIP NN O
and CC O
norepinephrine NN O
was VBD O
noted VBN O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) -RRB- O
null null null-Disease
Non NNP O
- HYPH O
invasive JJ O
detection NN O
of IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
by IN O
body NN O
surface NN O
electrocardiographic JJ O
mapping NN O
after IN O
dipyridamole NN O
infusion NN O
. . O
null null null-Disease
Electrocardiographic JJ O
changes NNS O
after IN O
dipyridamole NN O
infusion NN O
( , O
0 CD O
. . O
568 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
4 CD O
min NN O
) -RRB- O
were VBD O
studied VBN O
in IN O
41 CD O
patients NNS O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
and CC O
compared VBN O
with IN O
those DT O
after IN O
submaximal JJ O
treadmill NN O
exercise NN O
by IN O
use NN O
of IN O
the DT O
body NN O
surface NN O
mapping NN O
technique NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
divided VBN O
into IN O
three CD O
groups NNS O
; : O
19 CD O
patients NNS O
without IN O
myocardial JJ B-Disease
infarction NN I-Disease
( , O
non JJ O
- HYPH O
MI NN B-Disease
group NN O
) -RRB- O
, , O
14 CD O
with IN O
anterior JJ B-Disease
infarction NN I-Disease
( , O
ANT NNP B-Disease
- HYPH I-Disease
MI NNP I-Disease
) -RRB- O
and CC O
eight CD O
with IN O
inferior JJ B-Disease
infarction NN I-Disease
( , O
INF NNP B-Disease
- HYPH I-Disease
MI NNP I-Disease
) -RRB- O
. . O
null null null-Disease
Eighty CD O
- HYPH O
seven CD O
unipolar JJ O
electrocardiograms NNS O
( -LRB- O
ECGs NNPS O
) -RRB- O
distributed VBN O
over IN O
the DT O
entire JJ O
thoracic JJ O
surface NN O
were VBD O
simultaneously RB O
recorded VBN O
. . O
null null null-Disease
After IN O
dipyridamole NN O
, , O
ischemic JJ B-Disease
ST NN O
- HYPH O
segment NN O
depression NN B-Disease
( : O
0 CD O
. . O
05 CD O
mV NN O
or CC O
more JJR O
) -RRB- O
was VBD O
observed VBN O
in IN O
84 CD O
% NN O
of IN O
the DT O
non JJ O
- HYPH O
MI NNP B-Disease
group NN O
, , O
29 CD O
% NN O
of IN O
the DT O
ANT NNP B-Disease
- HYPH I-Disease
MI NNP I-Disease
group NN O
, , O
63 CD O
% NN O
of IN O
the DT O
INF NNP B-Disease
- HYPH I-Disease
MI NNP I-Disease
group NN O
and CC O
61 CD O
% NN O
of IN O
the DT O
total JJ O
population NN O
. . O
null null null-Disease
Exercise NN O
- HYPH O
induced VBN O
ST NNP O
depression NN B-Disease
was VBD O
observed VBN O
in IN O
84 CD O
% NN O
of IN O
the DT O
non AFX O
- HYPH O
MI NNP B-Disease
group NN O
, , O
43 CD O
% NN O
of IN O
the DT O
ANT NNP B-Disease
- HYPH I-Disease
MI NNP I-Disease
group NN O
, , O
38 CD O
% NN O
of IN O
the DT O
INF NNP B-Disease
- HYPH I-Disease
MI NNP I-Disease
group NN O
and CC O
61 CD O
% NN O
of IN O
the DT O
total NN O
. . O
null null null-Disease
For IN O
individual JJ O
patients NNS O
, , O
there EX O
were VBD O
no DT O
obvious JJ O
differences NNS O
between IN O
the DT O
body NN O
surface NN O
distribution NN O
of IN O
ST NNP O
depression NN B-Disease
in IN O
both DT O
tests NNS O
. . O
null null null-Disease
The DT O
increase NN O
in IN O
pressure NN O
rate NN O
product NN O
after IN O
dipyridamole NN O
was VBD O
significantly RB O
less JJR O
than IN O
that DT O
during IN O
the DT O
treadmill NN O
exercise NN O
. . O
null null null-Disease
The DT O
data NNS O
suggest VBP O
that IN O
the DT O
dipyridamole NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
ischemia NN I-Disease
is VBZ O
caused VBN O
by IN O
the DT O
inhomogenous JJ O
distribution NN O
of IN O
myocardial JJ O
blood NN O
flow NN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
the DT O
dipyridamole NN O
ECG NNP O
test NN O
is VBZ O
as RB O
useful JJ O
as IN O
the DT O
exercise NN O
ECG NNP O
test NN O
for IN O
the DT O
assessment NN O
of IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
. . O
null null null-Disease
Bradycardia NNP B-Disease
after IN O
high JJ O
- HYPH O
dose NN O
intravenous JJ O
methylprednisolone NN O
therapy NN O
. . O
null null null-Disease
In IN O
5 CD O
consecutive JJ O
patients NNS O
with IN O
rheumatoid NN B-Disease
arthritis NN I-Disease
who WP O
received VBD O
intravenous JJ O
high JJ O
- HYPH O
dose NN O
methylprednisolone NN O
( -LRB- O
MP NN O
) -RRB- O
therapy NN O
( : O
1 CD O
g NN O
daily RB O
for IN O
2 CD O
or CC O
3 CD O
consecutive JJ O
days NNS O
) -RRB- O
, , O
a DT O
decline NN O
in IN O
pulse NN O
rate NN O
was VBD O
observed VBN O
, , O
most RBS O
pronounced VBN O
on IN O
day NN O
4 CD O
. . O
null null null-Disease
In IN O
one CD O
of IN O
the DT O
5 CD O
patients NNS O
the DT O
bradycardia NN B-Disease
was VBD O
associated VBN O
with IN O
complaints NNS O
of IN O
substernal JJ O
pressure NN O
. . O
null null null-Disease
Reversal NN O
to IN O
normal JJ O
heart NN O
rate NN O
was VBD O
found VBN O
on IN O
day NN O
7 CD O
. . O
null null null-Disease
Electrocardiographic JJ O
registrations NNS O
showed VBD O
sinus NN B-Disease
bradycardia NN I-Disease
in IN O
all DT O
cases NNS O
. . O
null null null-Disease
No DT O
significant JJ O
changes NNS O
in IN O
plasma NN O
concentrations NNS O
of IN O
electrolytes NNS O
were VBD O
found VBN O
. . O
null null null-Disease
Careful JJ O
observation NN O
of IN O
patients NNS O
receiving VBG O
high JJ O
- HYPH O
dose NN O
MP NN O
is VBZ O
recommended VBN O
. . O
null null null-Disease
High JJ O
- HYPH O
dose NN O
MP NN O
may MD O
be VB O
contraindicated VBN O
in IN O
patients NNS O
with IN O
known VBN O
heart NN B-Disease
disease NN I-Disease
. . O
null null null-Disease
Two CD O
cases NNS O
of IN O
downbeat JJ B-Disease
nystagmus NN I-Disease
and CC O
oscillopsia NN B-Disease
associated VBN O
with IN O
carbamazepine NN O
. . O
null null null-Disease
Downbeat JJ B-Disease
nystagmus NN I-Disease
is VBZ O
often RB O
associated VBN O
with IN O
structural JJ O
lesions NNS O
at IN O
the DT O
craniocervical JJ O
junction NN O
, , O
but CC O
has VBZ O
occasionally RB O
been VBN O
reported VBN O
as IN O
a DT O
manifestation NN O
of IN O
metabolic JJ O
imbalance NN O
or CC O
drug NN O
intoxication NN O
. . O
null null null-Disease
We PRP O
recorded VBD O
the DT O
eye NN O
movements NNS O
of IN O
two CD O
patients NNS O
with IN O
reversible JJ O
downbeat JJ B-Disease
nystagmus NN I-Disease
related VBN O
to IN O
carbamazepine NN O
therapy NN O
. . O
null null null-Disease
The DT O
nystagmus NN B-Disease
of IN O
both DT O
patients NNS O
resolved VBN O
after IN O
reduction NN O
of IN O
the DT O
serum NN O
carbamazepine NN O
levels NNS O
. . O
null null null-Disease
Neuroradiologic JJ O
investigations NNS O
including VBG O
magnetic JJ O
resonance NN O
imaging NN O
scans NNS O
in IN O
both DT O
patients NNS O
showed VBD O
no DT O
evidence NN O
of IN O
intracranial JJ O
abnormality NN O
. . O
null null null-Disease
In IN O
patients NNS O
with IN O
downbeat JJ B-Disease
nystagmus NN I-Disease
who WP O
are VBP O
taking VBG O
anticonvulsant JJ O
medications NNS O
, , O
consideration NN O
should MD O
be VB O
given VBN O
to IN O
reduction NN O
in IN O
dose NN O
before IN O
further JJ O
investigation NN O
is VBZ O
undertaken VBN O
. . O
null null null-Disease
Improvement NN O
by IN O
denopamine NN O
( , O
TA NNP O
- HYPH O
064 CD O
) -RRB- O
of IN O
pentobarbital NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
failure NN I-Disease
in IN O
the DT O
dog NN O
heart NN O
- HYPH O
lung NN O
preparation NN O
. . O
null null null-Disease
The DT O
efficacy NN O
of IN O
denopamine NN O
, , O
an DT O
orally RB O
active JJ O
beta NN O
1 CD O
- HYPH O
adrenoceptor NN O
agonist NN O
, , O
in IN O
improving VBG O
cardiac JJ B-Disease
failure NN I-Disease
was VBD O
assessed VBN O
in IN O
dog NN O
heart NN O
- HYPH O
lung NN O
preparations NNS O
. . O
null null null-Disease
Cardiac JJ O
functions NNS O
depressed VBN O
by IN O
pentobarbital NN O
( , O
118 CD O
+ NN O
/ SYM O
- HYPH O
28 CD O
mg NN O
; : O
mean JJ O
value NN O
+ CC O
/ SYM O
- HYPH O
SD NN O
) -RRB- O
such JJ O
that IN O
cardiac JJ O
output NN O
and CC O
maximum NN O
rate NN O
of IN O
rise NN O
of IN O
left JJ O
ventricular JJ O
pressure NN O
( -LRB- O
LV NN O
dP NN O
/ SYM O
dt NN O
max NN O
) -RRB- O
had VBD O
been VBN O
reduced VBN O
by IN O
about RB O
35 CD O
% NN O
and CC O
26 CD O
% NN O
of IN O
the DT O
respective JJ O
controls NNS O
were VBD O
improved VBN O
by IN O
denopamine NN O
( : O
10 CD O
- SYM O
300 CD O
micrograms NNS O
) -RRB- O
in IN O
a DT O
dose NN O
- HYPH O
dependent JJ O
manner NN O
. . O
null null null-Disease
With IN O
100 CD O
micrograms NNS O
denopamine NN O
, , O
almost RB O
complete JJ O
restoration NN O
of IN O
cardiac JJ O
performance NN O
was VBD O
attained VBN O
, , O
associated VBN O
with IN O
a DT O
slight JJ O
increase NN O
in IN O
heart NN O
rate NN O
. . O
null null null-Disease
No DT O
arrhythmias NNS B-Disease
were VBD O
induced VBN O
by IN O
these DT O
doses NNS O
of IN O
denopamine NN O
. . O
null null null-Disease
The DT O
results NNS O
warrant VBP O
clinical JJ O
trials NNS O
of IN O
denopamine NN O
in IN O
the DT O
treatment NN O
of IN O
cardiac JJ B-Disease
failure NN I-Disease
. . O
null null null-Disease
Clonazepam NNP O
monotherapy NN O
for IN O
epilepsy NN B-Disease
in IN O
childhood NN O
. . O
null null null-Disease
Sixty CD O
patients NNS O
( , O
age NN O
- HYPH O
range VBP O
one CD O
month NN O
to IN O
14 CD O
years NNS O
) , O
with IN O
other JJ O
types NNS O
of IN O
epilepsy NN B-Disease
than IN O
infantile JJ B-Disease
spasms NNS I-Disease
were VBD O
treated VBN O
with IN O
clonazepam NN O
. . O
null null null-Disease
Disappearance NN O
of IN O
seizures NNS B-Disease
and CC O
normalization NN O
of IN O
abnormal JJ O
EEG NNP O
with IN O
disappearance NN O
of IN O
seizures NNS B-Disease
were VBD O
recognized VBN O
in IN O
77 CD O
% NN O
and CC O
50 CD O
% NN O
, , O
respectively RB O
. . O
null null null-Disease
Seizures NNS B-Disease
disappeared VBD O
in IN O
71 CD O
% NN O
of IN O
the DT O
patients NNS O
with IN O
generalized JJ O
seizures NNS B-Disease
and CC O
89 CD O
% NN O
of IN O
partial JJ O
seizures NNS B-Disease
. . O
null null null-Disease
Improvement NN O
of IN O
abnormal JJ O
EEG NNP O
was VBD O
noticed VBN O
in IN O
76 CD O
% NN O
of IN O
diffuse JJ O
paroxysms NNS O
and CC O
in IN O
67 CD O
% NN O
of IN O
focal JJ O
paroxysms NNS O
. . O
null null null-Disease
In IN O
excellent JJ O
cases NNS O
, , O
mean VB O
effective JJ O
dosages NNS O
were VBD O
0 CD O
. . O
086 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
021 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
day NN O
in IN O
infants NNS O
and CC O
0 CD O
. . O
057 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
022 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
day NN O
in IN O
schoolchildren NNS O
, , O
this DT O
difference NN O
was VBD O
statistically RB O
significant JJ O
( : O
p NN O
less JJR O
than IN O
0 CD O
. . O
005 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
side JJ O
effects NNS O
such JJ O
as IN O
drowsiness NN B-Disease
and CC O
ataxia NN B-Disease
was VBD O
only RB O
5 CD O
% NN O
. . O
null null null-Disease
Postmarketing NN O
study NN O
of IN O
timolol NN O
- HYPH O
hydrochlorothiazide NN O
antihypertensive JJ O
therapy NN O
. . O
null null null-Disease
A DT O
postmarketing NN O
surveillance NN O
study NN O
was VBD O
conducted VBN O
to TO O
determine VB O
the DT O
safety NN O
and CC O
efficacy NN O
of IN O
a DT O
fixed VBN O
- HYPH O
ratio NN O
combination NN O
containing VBG O
10 CD O
mg NN O
of IN O
timolol NN O
maleate NN O
and CC O
25 CD O
mg NN O
of IN O
hydrochlorothiazide NN O
, , O
administered VBN O
twice RB O
daily RB O
for IN O
one CD O
month NN O
to IN O
hypertensive JJ B-Disease
patients NNS O
. . O
null null null-Disease
Data NNS O
on IN O
9 CD O
, , O
037 CD O
patients NNS O
were VBD O
collected VBN O
by IN O
1 CD O
, , O
455 CD O
participating VBG O
physicians NNS O
. . O
null null null-Disease
Mean JJ O
systolic JJ O
blood NN O
pressure NN O
decreased VBD O
25 CD O
mmHg NN O
and CC O
mean VB O
diastolic JJ O
blood NN O
pressure NN O
declined VBD O
15 CD O
mmHg NN O
after IN O
one CD O
month NN O
of IN O
timolol NN O
- HYPH O
hydrochlorothiazide NN O
therapy NN O
( -LRB- O
P NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
, , O
both DT O
comparisons NNS O
) -RRB- O
. . O
null null null-Disease
Age NN O
, , O
race NN O
, , O
and CC O
sex NN O
appeared VBD O
to TO O
have VB O
no DT O
influence NN O
on IN O
the DT O
decrease NN O
in IN O
blood NN O
pressure NN O
. . O
null null null-Disease
The DT O
antihypertensive JJ O
effect NN O
of IN O
the DT O
drug NN O
was VBD O
greater JJR O
in IN O
patients NNS O
with IN O
more RBR O
severe JJ O
hypertension NN B-Disease
. . O
null null null-Disease
Overall RB O
, , O
1 CD O
, , O
453 CD O
patients NNS O
experienced VBD O
a DT O
total NN O
of IN O
2 CD O
, , O
658 CD O
adverse JJ O
events NNS O
, , O
the DT O
most RBS O
common JJ O
being VBG O
fatigue NN B-Disease
, , O
dizziness NN B-Disease
, , O
and CC O
weakness NN B-Disease
. . O
null null null-Disease
Treatment NN O
in IN O
590 CD O
patients NNS O
was VBD O
discontinued VBN O
because IN O
of IN O
adverse JJ O
events NNS O
. . O
null null null-Disease
Salicylate JJ O
nephropathy NN B-Disease
in IN O
the DT O
Gunn NNP O
rat NN O
: : O
potential JJ O
role NN O
of IN O
prostaglandins NNS O
. . O
null null null-Disease
We PRP O
examined VBD O
the DT O
potential JJ O
role NN O
of IN O
prostaglandins NNS O
in IN O
the DT O
development NN O
of IN O
analgesic JJ O
nephropathy NN B-Disease
in IN O
the DT O
Gunn NNP O
strain NN O
of IN O
rat NN O
. . O
null null null-Disease
The DT O
homozygous JJ O
Gunn NNP O
rats NNS O
have VBP O
unconjugated JJ O
hyperbilirubinemia NN B-Disease
due IN O
to IN O
the DT O
absence NN O
of IN O
glucuronyl NN O
transferase NN O
, , O
leading VBG O
to IN O
marked JJ O
bilirubin NN O
deposition NN O
in IN O
renal JJ O
medulla NN O
and CC O
papilla NN O
. . O
null null null-Disease
These DT O
rats NNS O
are VBP O
also RB O
highly RB O
susceptible JJ O
to TO O
develop VB O
papillary JJ B-Disease
necrosis NN I-Disease
with IN O
analgesic JJ O
administration NN O
. . O
null null null-Disease
We PRP O
used VBD O
homozygous NN O
( , O
jj NN O
) -RRB- O
and CC O
phenotypically RB O
normal JJ O
heterozygous JJ O
( , O
jJ NN O
) -RRB- O
animals NNS O
. . O
null null null-Disease
Four CD O
groups NNS O
of IN O
rats NNS O
( , O
n CD O
= SYM O
7 CD O
) -RRB- O
were VBD O
studied VBN O
: : O
jj NNP O
and CC O
jJ NNP O
rats NNS O
treated VBN O
either CC O
with IN O
aspirin NN O
300 CD O
mg NNS O
/ SYM O
kg NNS O
every DT O
other JJ O
day NN O
or CC O
sham NN O
- HYPH O
treated VBN O
. . O
null null null-Disease
After IN O
one CD O
week NN O
, , O
slices NNS O
of IN O
cortex NN O
, , O
outer JJ O
and CC O
inner JJ O
medulla NN O
from IN O
one CD O
kidney NN O
were VBD O
incubated VBN O
in IN O
buffer NN O
and CC O
prostaglandin NN O
synthesis NN O
was VBD O
determined VBN O
by IN O
radioimmunoassay NN O
. . O
null null null-Disease
The DT O
other JJ O
kidney NN O
was VBD O
examined VBN O
histologically RB O
. . O
null null null-Disease
A DT O
marked JJ O
corticomedullary JJ O
gradient NN O
of IN O
prostaglandin JJ O
synthesis NN O
was VBD O
observed VBN O
in IN O
all DT O
groups NNS O
. . O
null null null-Disease
PGE2 NNP O
synthesis NN O
was VBD O
significantly RB O
higher JJR O
in IN O
outer JJ O
medulla NN O
, , O
but CC O
not RB O
cortex NN O
or CC O
inner JJ O
medulla NN O
, , O
of IN O
jj NN O
( : O
38 CD O
+ SYM O
/ SYM O
- HYPH O
6 CD O
ng NN O
/ SYM O
mg NN O
prot NN O
) -RRB- O
than IN O
jJ NNP O
rats NNS O
( : O
15 CD O
+ SYM O
/ SYM O
- HYPH O
3 CD O
) -RRB- O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
Aspirin NN O
treatment NN O
reduced VBD O
PGE2 NNP O
synthesis NN O
in IN O
all DT O
regions NNS O
, , O
but CC O
outer JJ O
medullary NN O
PGE2 NNP O
remained VBD O
higher JJR O
in IN O
jj NN O
( : O
18 CD O
+ SYM O
/ SYM O
- HYPH O
3 CD O
) -RRB- O
than IN O
jJ NN O
rats NNS O
( , O
9 CD O
+ SYM O
/ SYM O
- HYPH O
2 CD O
) -RRB- O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
PGF2 NNP O
alpha NN O
was VBD O
also RB O
significantly RB O
higher JJR O
in IN O
the DT O
outer JJ O
medulla NN O
of IN O
jj NN O
rats NNS O
with IN O
and CC O
without IN O
aspirin NN O
administration NN O
( : O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
changes NNS O
in IN O
renal JJ O
prostaglandin NN O
synthesis NN O
were VBD O
accompanied VBN O
by IN O
evidence NN O
of IN O
renal JJ B-Disease
damage NN I-Disease
in IN O
aspirin NN O
- HYPH O
treated VBN O
jj NN O
but CC O
not RB O
jJ NN O
rats NNS O
as IN O
evidenced VBN O
by IN O
: : O
increased VBN O
incidence NN O
and CC O
severity NN O
of IN O
hematuria NN B-Disease
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
; , O
increased VBN O
serum JJ O
creatinine NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
; : O
and CC O
increase NN O
in IN O
outer JJ O
medullary JJ O
histopathologic JJ O
lesions NNS O
( , O
p NN O
less JJR O
than IN O
0 CD O
. , O
005 CD O
compared VBN O
to IN O
either CC O
sham NN O
- HYPH O
treated VBN O
jj NN O
or CC O
aspirin NN O
- HYPH O
treated VBN O
jJ NNP O
) -RRB- O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
enhanced VBN O
prostaglandin NN O
synthesis NN O
contributes VBZ O
to IN O
maintenance NN O
of IN O
renal JJ O
function NN O
and CC O
morphological JJ O
integrity NN O
, , O
and CC O
that IN O
inhibition NN O
of IN O
prostaglandin NN O
synthesis NN O
may MD O
lead VB O
to IN O
pathological JJ B-Disease
renal JJ I-Disease
medullary JJ I-Disease
lesions NNS I-Disease
and CC O
deterioration NN B-Disease
of IN I-Disease
renal JJ I-Disease
function NN I-Disease
. . O
null null null-Disease
Prophylactic JJ O
lidocaine NN O
in IN O
the DT O
early JJ O
phase NN O
of IN O
suspected VBN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
Four CD O
hundred CD O
two CD O
patients NNS O
with IN O
suspected VBN O
myocardial JJ B-Disease
infarction NN I-Disease
seen VBN O
within IN O
6 CD O
hours NNS O
of IN O
the DT O
onset NN O
of IN O
symptoms NNS O
entered VBD O
a DT O
double JJ O
- HYPH O
blind JJ O
randomized JJ O
trial NN O
of IN O
lidocaine NN O
vs IN O
placebo NN O
. . O
null null null-Disease
During IN O
the DT O
1 CD O
hour NN O
after IN O
administration NN O
of IN O
the DT O
drug NN O
the DT O
incidence NN O
of IN O
ventricular JJ B-Disease
fibrillation NN I-Disease
or CC O
sustained JJ O
ventricular JJ B-Disease
tachycardia NN I-Disease
among IN O
the DT O
204 CD O
patients NNS O
with IN O
acute JJ O
myocardial JJ B-Disease
infarction NN I-Disease
was VBD O
low JJ O
, , O
1 CD O
. . O
5 CD O
% NN O
. . O
null null null-Disease
Lidocaine NNP O
, , O
given VBN O
in IN O
a DT O
300 CD O
mg NN O
dose NN O
intramuscularly RB O
followed VBN O
by IN O
100 CD O
mg NN O
intravenously RB O
, , O
did VBD O
not RB O
prevent VB O
sustained JJ O
ventricular JJ B-Disease
tachycardia NN I-Disease
, , O
although IN O
there EX O
was VBD O
a DT O
significant JJ O
reduction NN O
in IN O
the DT O
number NN O
of IN O
patients NNS O
with IN O
warning VBG O
arrhythmias NNS B-Disease
between IN O
15 CD O
and CC O
45 CD O
minutes NNS O
after IN O
the DT O
administration NN O
of IN O
lidocaine NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
average JJ O
plasma NN O
lidocaine NN O
level NN O
10 CD O
minutes NNS O
after IN O
administration NN O
for IN O
patients NNS O
without IN O
a DT O
myocardial JJ B-Disease
infarction NN I-Disease
was VBD O
significantly RB O
higher JJR O
than IN O
that DT O
for IN O
patients NNS O
with IN O
an DT O
acute JJ O
infarction NN B-Disease
. . O
null null null-Disease
The DT O
mean JJ O
plasma NN O
lidocaine NN O
level NN O
of IN O
patients NNS O
on IN O
beta NN O
- HYPH O
blocking VBG O
agents NNS O
was VBD O
no RB O
different JJ O
from IN O
that DT O
in IN O
patients NNS O
not RB O
on IN O
beta JJ O
blocking NN O
agents NNS O
. . O
null null null-Disease
During IN O
the DT O
1 CD O
- HYPH O
hour NN O
study NN O
period NN O
, , O
the DT O
incidence NN O
of IN O
central JJ O
nervous JJ O
system NN O
side NN O
effects NNS O
was VBD O
significantly RB O
greater JJR O
in IN O
the DT O
lidocaine NN O
group NN O
, , O
hypotension NN B-Disease
occurred VBD O
in IN O
11 CD O
patients NNS O
, , O
nine CD O
of IN O
whom WP O
had VBD O
received VBN O
lidocaine NN O
, , O
and CC O
four CD O
patients NNS O
died VBD O
from IN O
asystole NN B-Disease
, , O
three CD O
of IN O
whom WP O
had VBD O
had VBN O
lidocaine NN O
. . O
null null null-Disease
We PRP O
cannot MD O
advocate VB O
the DT O
administration NN O
of IN O
lidocaine NN O
prophylactically RB O
in IN O
the DT O
early JJ O
hours NNS O
of IN O
suspected VBN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
Evidence NN O
for IN O
a DT O
cholinergic JJ O
role NN O
in IN O
haloperidol NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
. . O
null null null-Disease
Experiments NNS O
in IN O
mice NNS O
tested VBD O
previous JJ O
evidence NN O
that IN O
activation NN O
of IN O
cholinergic JJ O
systems NNS O
promotes VBZ O
catalepsy NN B-Disease
and CC O
that IN O
cholinergic JJ O
mechanisms NNS O
need VBP O
to TO O
be VB O
intact JJ O
for IN O
full JJ O
expression NN O
of IN O
neuroleptic NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
. . O
null null null-Disease
Large JJ O
doses NNS O
of IN O
the DT O
cholinomimetic JJ O
, , O
pilocarpine NN O
, , O
could MD O
induce VB O
catalepsy NN B-Disease
when WRB O
peripheral JJ O
cholinergic JJ O
receptors NNS O
were VBD O
blocked VBN O
. . O
null null null-Disease
Low JJ O
doses NNS O
of IN O
pilocarpine NN O
caused VBD O
a DT O
pronounced JJ O
enhancement NN O
of IN O
the DT O
catalepsy NN B-Disease
that WDT O
was VBD O
induced VBN O
by IN O
the DT O
dopaminergic JJ O
blocker NN O
, , O
haloperidol NN O
. . O
null null null-Disease
A DT O
muscarinic JJ O
receptor NN O
blocker NN O
, , O
atropine NN O
, , O
disrupted VBD O
haloperidol NN O
- HYPH O
induced VBN O
catalepsy NN B-Disease
. . O
null null null-Disease
Intracranial JJ O
injection NN O
of IN O
an DT O
acetylcholine NN O
- HYPH O
synthesis NN O
inhibitor NN O
, , O
hemicholinium NN O
, , O
prevented VBD O
the DT O
catalepsy NN B-Disease
that WDT O
is VBZ O
usually RB O
induced VBN O
by IN O
haloperidol NN O
. . O
null null null-Disease
These DT O
findings NNS O
suggest VBP O
the DT O
hypothesis NN O
that IN O
the DT O
catalepsy NN B-Disease
that WDT O
is VBZ O
produced VBN O
by IN O
neuroleptics NNS O
such JJ O
as IN O
haloperidol NN O
is VBZ O
actually RB O
mediated VBN O
by IN O
intrinsic JJ O
central JJ O
cholinergic JJ O
systems NNS O
. . O
null null null-Disease
Alternatively RB O
, , O
activation NN O
of IN O
central JJ O
cholinergic JJ O
systems NNS O
could MD O
promote VB O
catalepsy NN B-Disease
by IN O
suppression NN O
of IN O
dopaminergic JJ O
systems NNS O
. . O
null null null-Disease
Cardiovascular JJ B-Disease
dysfunction NN I-Disease
and CC O
hypersensitivity NN B-Disease
to IN O
sodium NN O
pentobarbital NN O
induced VBN O
by IN O
chronic JJ O
barium NN O
chloride NN O
ingestion NN O
. . O
null null null-Disease
Barium NNP O
- HYPH O
supplemented VBN O
Long NNP O
- HYPH O
Evans NNP O
hooded JJ O
rats NNS O
were VBD O
characterized VBN O
by IN O
a DT O
persistent JJ O
hypertension NN B-Disease
that WDT O
was VBD O
evident JJ O
after IN O
1 CD O
month NN O
of IN O
barium NN O
( , O
100 CD O
micrograms NNS O
/ SYM O
ml NN O
mineral NN O
fortified VBN O
water NN O
) , O
treatment NN O
. . O
null null null-Disease
Analysis NN O
of IN O
in IN O
vivo NN O
myocardial JJ O
excitability NN O
, , O
contractility NN O
, , O
and CC O
metabolic JJ O
characteristics NNS O
at IN O
16 CD O
months NNS O
revealed VBD O
other JJ O
significant JJ O
barium NN O
- HYPH O
induced VBN O
disturbances NNS B-Disease
within IN I-Disease
the DT I-Disease
cardiovascular JJ I-Disease
system NN I-Disease
. . O
null null null-Disease
The DT O
most RBS O
distinctive JJ O
aspect NN O
of IN O
the DT O
barium NN O
effect NN O
was VBD O
a DT O
demonstrated VBN O
hypersensitivity NN B-Disease
of IN O
the DT O
cardiovascular JJ O
system NN O
to IN O
sodium NN O
pentobarbital NN O
. . O
null null null-Disease
Under IN O
barbiturate NN O
anesthesia NN O
, , O
virtually RB O
all DT O
of IN O
the DT O
myocardial JJ O
contractile NN O
indices NNS O
were VBD O
depressed VBN O
significantly RB O
in IN O
barium NN O
- HYPH O
exposed VBN O
rats NNS O
relative JJ O
to IN O
the DT O
corresponding VBG O
control NN O
- HYPH O
fed VBN O
rats NNS O
. . O
null null null-Disease
The DT O
lack NN O
of IN O
a DT O
similar JJ O
response NN O
to IN O
ketamine NN O
and CC O
xylazine NN O
anesthesia NN O
revealed VBD O
that IN O
the DT O
cardiovascular JJ O
actions NNS O
of IN O
sodium NN O
pentobarbital NN O
in IN O
barium NN O
- HYPH O
treated VBN O
rats NNS O
were VBD O
linked VBN O
specifically RB O
to IN O
this DT O
anesthetic NN O
, , O
and CC O
were VBD O
not RB O
representative JJ O
of IN O
a DT O
generalized VBN O
anesthetic JJ O
response NN O
. . O
null null null-Disease
Other JJ O
myocardial JJ O
pathophysiologic JJ O
and CC O
metabolic JJ O
changes NNS O
induced VBN O
by IN O
barium NN O
were VBD O
manifest JJ O
, , O
irrespective RB O
of IN O
the DT O
anesthetic NN O
employed VBN O
. . O
null null null-Disease
The DT O
contractile JJ O
element NN O
shortening VBG O
velocity NN O
of IN O
the DT O
cardiac JJ O
muscle NN O
fibers NNS O
was VBD O
significantly RB O
slower JJR O
in IN O
both DT O
groups NNS O
of IN O
barium NN O
- HYPH O
treated VBN O
rats NNS O
relative JJ O
to IN O
the DT O
control NN O
groups NNS O
, , O
irrespective JJ O
of IN O
the DT O
anesthetic JJ O
regimen NN O
. . O
null null null-Disease
Similarly RB O
, , O
significant JJ O
disturbances NNS O
in IN O
myocardial JJ O
energy NN O
metabolism NN O
were VBD O
detected VBN O
in IN O
the DT O
barium NN O
- HYPH O
exposed VBN O
rats NNS O
which WDT O
were VBD O
consistent JJ O
with IN O
the DT O
reduced VBN O
contractile JJ O
element NN O
shortening VBG O
velocity NN O
. . O
null null null-Disease
In IN O
addition NN O
, , O
the DT O
excitability NN O
of IN O
the DT O
cardiac JJ O
conduction NN O
system NN O
was VBD O
depressed VBN O
preferentially RB O
in IN O
the DT O
atrioventricular JJ O
nodal JJ O
region NN O
of IN O
hearts NNS O
from IN O
barium NN O
- HYPH O
exposed VBN O
rats NNS O
. . O
null null null-Disease
Overall RB O
, , O
the DT O
altered JJ O
cardiac JJ O
contractility NN O
and CC O
excitability NN O
characteristics NNS O
, , O
the DT O
myocardial JJ O
metabolic JJ B-Disease
disturbances NNS I-Disease
, , O
and CC O
the DT O
hypersensitivity NN B-Disease
of IN O
the DT O
cardiovascular JJ O
system NN O
to IN O
sodium NN O
pentobarbital NN O
suggest VBP O
the DT O
existence NN O
of IN O
a DT O
heretofore JJ O
undescribed JJ O
cardiomyopathic JJ B-Disease
disorder NN I-Disease
induced VBN O
by IN O
chronic JJ O
barium NN O
exposure NN O
. . O
null null null-Disease
These DT O
experimental JJ O
findings NNS O
represent VBP O
the DT O
first JJ O
indication NN O
that IN O
life NN O
- HYPH O
long JJ O
barium NN O
ingestion NN O
may MD O
have VB O
significant JJ O
adverse JJ O
effects NNS O
on IN O
the DT O
mammalian JJ O
cardiovascular JJ O
system NN O
. . O
null null null-Disease
Propranolol NN O
antagonism NN O
of IN O
phenylpropanolamine NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
. . O
null null null-Disease
Phenylpropanolamine NN O
( -LRB- O
PPA NN O
) -RRB- O
overdose NN B-Disease
can MD O
cause VB O
severe JJ O
hypertension NN B-Disease
, , O
intracerebral JJ B-Disease
hemorrhage NN I-Disease
, , O
and CC O
death NN O
. . O
null null null-Disease
We PRP O
studied VBD O
the DT O
efficacy NN O
and CC O
safety NN O
of IN O
propranolol NN O
in IN O
the DT O
treatment NN O
of IN O
PPA NNP O
- HYPH O
induced VBN O
hypertension NN B-Disease
. . O
null null null-Disease
Subjects NNS O
received VBD O
propranolol NN O
either CC O
by IN O
mouth NN O
for IN O
48 CD O
hours NNS O
before IN O
PPA NNP O
or CC O
as IN O
a DT O
rapid JJ O
intravenous JJ O
infusion NN O
after IN O
PPA NNP O
. . O
null null null-Disease
PPA NNP O
, , O
75 CD O
mg NN O
alone RB O
, , O
increased VBN O
blood NN O
pressure NN O
( : O
31 CD O
+ NN O
/ SYM O
- SYM O
14 CD O
mm NN O
Hg NN O
systolic JJ O
, , O
20 CD O
+ NN O
/ SYM O
- SYM O
5 CD O
mm NN O
Hg NN O
diastolic JJ O
) -RRB- O
, , O
and CC O
propranolol NN O
pretreatment NN O
antagonized VBN O
this DT O
increase NN O
( : O
12 CD O
+ NN O
/ SYM O
- SYM O
10 CD O
mm NN O
Hg NN O
systolic JJ O
, , O
10 CD O
+ NN O
/ SYM O
- SYM O
7 CD O
mm NN O
Hg NN O
diastolic JJ O
) -RRB- O
. . O
null null null-Disease
Intravenous JJ O
propranolol NN O
after IN O
PPA NNP O
also RB O
decreased VBD O
blood NN O
pressure NN O
. . O
null null null-Disease
Left JJ O
ventricular JJ O
function NN O
( , O
assessed VBN O
by IN O
echocardiography NN O
) , O
showed VBD O
that IN O
PPA NNP O
increased VBD O
the DT O
stroke NN B-Disease
volume NN O
30 CD O
% NN O
( , O
from IN O
62 CD O
. . O
5 CD O
+ SYM O
/ SYM O
- SYM O
20 CD O
. . O
9 CD O
to TO O
80 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- SYM O
22 CD O
. . O
4 CD O
ml NN O
) -RRB- O
, , O
the DT O
ejection NN O
fraction NN O
9 CD O
% NN O
( , O
from IN O
64 CD O
% NN O
+ SYM O
/ SYM O
- SYM O
10 CD O
% NN O
to TO O
70 CD O
% NN O
+ SYM O
/ SYM O
- SYM O
7 CD O
% NN O
) -RRB- O
, , O
and CC O
cardiac JJ O
output NN O
14 CD O
% NN O
( : O
from IN O
3 CD O
. . O
6 CD O
+ CD O
/ SYM O
- SYM O
0 CD O
. . O
6 CD O
to IN O
4 CD O
. . O
1 CD O
+ NFP O
/ SYM O
- SYM O
1 CD O
. . O
0 CD O
L NN O
/ SYM O
min NN O
) -RRB- O
. . O
null null null-Disease
Intravenous JJ O
propranolol NN O
reversed VBD O
these DT O
effects NNS O
. . O
null null null-Disease
Systemic JJ O
vascular JJ O
resistance NN O
was VBD O
increased VBN O
by IN O
PPA NNP O
28 CD O
% NN O
( , O
from IN O
1710 CD O
+ SYM O
/ SYM O
- HYPH O
200 CD O
to IN O
2190 CD O
+ SYM O
/ SYM O
- HYPH O
700 CD O
dyne NN O
X NN O
sec NN O
/ SYM O
cm5 NN O
) -RRB- O
and CC O
was VBD O
further RB O
increased VBN O
by IN O
propranolol NN O
22 CD O
% NN O
( , O
to IN O
2660 CD O
+ SYM O
/ SYM O
- HYPH O
1200 CD O
dyne NN O
X NN O
sec NN O
/ SYM O
cm5 NN O
) -RRB- O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
PPA NNP O
increases VBZ O
blood NN O
pressure NN O
by IN O
increasing VBG O
systemic JJ O
vascular JJ O
resistance NN O
and CC O
cardiac JJ O
output NN O
, , O
and CC O
that IN O
propranolol NN O
antagonizes VBZ O
this DT O
increase NN O
by IN O
reversing VBG O
the DT O
effect NN O
of IN O
PPA NNP O
on IN O
cardiac JJ O
output NN O
. . O
null null null-Disease
That DT O
propranolol NN O
antagonizes VBZ O
the DT O
pressor NN O
effect NN O
of IN O
PPA NNP O
is VBZ O
in IN O
contrast NN O
to IN O
the DT O
interaction NN O
in IN O
which WDT O
propranolol NN O
enhances VBZ O
the DT O
pressor NN O
effect NN O
of IN O
norepinephrine NN O
. . O
null null null-Disease
This DT O
is VBZ O
probably RB O
because IN O
PPA NNP O
has VBZ O
less JJR O
beta NN O
2 CD O
activity NN O
than IN O
does VBZ O
norepinephrine NN O
. . O
null null null-Disease
Mesangial JJ O
function NN O
and CC O
glomerular JJ B-Disease
sclerosis NN I-Disease
in IN O
rats NNS O
with IN O
aminonucleoside NN O
nephrosis NN B-Disease
. . O
null null null-Disease
The DT O
possible JJ O
relationship NN O
between IN O
mesangial JJ B-Disease
dysfunction NN I-Disease
and CC O
development NN O
of IN O
glomerular JJ B-Disease
sclerosis NN I-Disease
was VBD O
studied VBN O
in IN O
the DT O
puromycin NN O
aminonucleoside NN O
( HYPH O
PAN NNP O
) -RRB- O
model NN O
. . O
null null null-Disease
Five CD O
male JJ O
Wistar NNP O
rats NNS O
received VBD O
repeated VBN O
subcutaneous JJ O
PAN NNP O
injections NNS O
; : O
five CD O
controls NNS O
received VBD O
saline NN O
only RB O
. . O
null null null-Disease
After IN O
4 CD O
weeks NNS O
the DT O
PAN NNP O
rats NNS O
were VBD O
severely RB O
proteinuric JJ B-Disease
( : O
190 CD O
+ CD O
/ SYM O
- SYM O
80 CD O
mg CD O
/ SYM O
24 CD O
hr NN O
) -RRB- O
, , O
and CC O
all DT O
rats NNS O
were VBD O
given VBN O
colloidal JJ O
carbon NN O
( -LRB- O
CC NN O
) -RRB- O
intravenously RB O
. . O
null null null-Disease
At IN O
5 CD O
months NNS O
glomerular JJ B-Disease
sclerosis NN I-Disease
was VBD O
found VBN O
in IN O
7 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- SYM O
3 CD O
. . O
4 CD O
% NN O
of IN O
the DT O
glomeruli NN O
of IN O
PAN NNP O
rats NNS O
; : O
glomeruli NN O
of IN O
the DT O
controls NNS O
were VBD O
normal JJ O
. . O
null null null-Disease
Glomeruli NNP O
of IN O
PAN NNP O
rats NNS O
contained VBD O
significantly RB O
more JJR O
CC NNP O
than IN O
glomeruli NN O
of IN O
controls NNS O
. . O
null null null-Disease
Glomeruli NNP O
with IN O
sclerosis NN B-Disease
contained VBD O
significantly RB O
more JJR O
CC NN O
than IN O
non JJ O
- HYPH O
sclerotic JJ O
glomeruli NN O
in IN O
the DT O
same JJ O
kidneys NNS O
. . O
null null null-Disease
CC NNP O
was VBD O
preferentially RB O
localized VBN O
within IN O
the DT O
sclerotic JJ O
areas NNS O
of IN O
the DT O
affected VBN O
glomeruli NN O
. . O
null null null-Disease
Since IN O
mesangial JJ O
CC NN O
clearance NN O
from IN O
the DT O
mesangium NN O
did VBD O
not RB O
change VB O
during IN O
chronic JJ O
PAN NNP O
treatment NN O
, , O
we PRP O
conclude VBP O
that IN O
this DT O
preferential JJ O
CC NNP O
localization NN O
within IN O
the DT O
lesions NNS O
is VBZ O
caused VBN O
by IN O
an DT O
increased VBN O
CC NN O
uptake NN O
shortly RB O
after IN O
injection NN O
in IN O
apparent JJ O
vulnerable JJ O
areas NNS O
where WRB O
sclerosis NN B-Disease
will MD O
develop VB O
subsequently RB O
. . O
null null null-Disease
Cluster NN O
analysis NN O
showed VBD O
a DT O
random JJ O
distribution NN O
of IN O
lesions NNS O
in IN O
the DT O
PAN NNP O
glomeruli NN O
in IN O
concordance NN O
with IN O
the DT O
random JJ O
localization NN O
of IN O
mesangial JJ O
areas NNS O
with IN O
dysfunction NN O
in IN O
this DT O
model NN O
. . O
null null null-Disease
Similar JJ O
to IN O
the DT O
remnant JJ O
kidney NN O
model NN O
in IN O
PAN NNP O
nephrosis NN B-Disease
the DT O
development NN O
of IN O
glomerular JJ B-Disease
sclerosis NN I-Disease
may MD O
be VB O
related VBN O
to IN O
"""" `` O
mesangial JJ O
overloading NN O
. . O
"""" '' O
null null null-Disease
Relationship NN O
between IN O
nicotine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
and CC O
hippocampal JJ O
nicotinic JJ O
receptors NNS O
. . O
null null null-Disease
A DT O
controversy NN O
has VBZ O
existed VBN O
for IN O
several JJ O
years NNS O
concerning VBG O
the DT O
physiological JJ O
relevance NN O
of IN O
the DT O
nicotinic JJ O
receptor NN O
measured VBN O
by IN O
alpha NN O
- HYPH O
bungarotoxin NN O
binding NN O
. . O
null null null-Disease
Using VBG O
mice NNS O
derived VBN O
from IN O
a DT O
classical JJ O
F2 NN O
and CC O
backcross JJ O
genetic JJ O
design NN O
, , O
a DT O
relationship NN O
between IN O
nicotine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
and CC O
alpha NN O
- HYPH O
bungarotoxin NN O
nicotinic JJ O
receptor NN O
concentration NN O
was VBD O
found VBN O
. . O
null null null-Disease
Mice NNS O
sensitive JJ O
to IN O
the DT O
convulsant JJ O
effects NNS O
of IN O
nicotine NN O
had VBD O
greater JJR O
alpha NN O
- HYPH O
bungarotoxin NN O
binding NN O
in IN O
the DT O
hippocampus NN O
than IN O
seizure NN B-Disease
insensitive JJ O
mice NNS O
. . O
null null null-Disease
The DT O
binding VBG O
sites NNS O
from IN O
seizure NN B-Disease
sensitive JJ O
and CC O
resistant JJ O
mice NN O
were VBD O
equally RB O
affected VBN O
by IN O
treatment NN O
with IN O
dithiothreitol NN O
, , O
trypsin NN O
or CC O
heat NN O
. . O
null null null-Disease
Thus RB O
it PRP O
appears VBZ O
that IN O
the DT O
difference NN O
between IN O
seizure NN B-Disease
sensitive JJ O
and CC O
insensitive JJ O
animals NNS O
may MD O
be VB O
due IN O
to IN O
a DT O
difference NN O
in IN O
hippocampal JJ O
nicotinic JJ O
receptor NN O
concentration NN O
as IN O
measured VBN O
with IN O
alpha NN O
- HYPH O
bungarotoxin NN O
binding NN O
. . O
null null null-Disease
The DT O
role NN O
of IN O
p NN O
- HYPH O
aminophenol NN O
in IN O
acetaminophen NN O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
: : O
effect NN O
of IN O
bis NN O
( HYPH O
p NN O
- HYPH O
nitrophenyl NN O
) -RRB- O
phosphate NN O
on IN O
acetaminophen NN O
and CC O
p NN O
- HYPH O
aminophenol NN O
nephrotoxicity NN B-Disease
and CC O
metabolism NN O
in IN O
Fischer NNP O
344 CD O
rats NNS O
. . O
null null null-Disease
Acetaminophen NNP O
( -LRB- O
APAP NNP O
) -RRB- O
produces VBZ O
proximal JJ O
tubular JJ B-Disease
necrosis NN I-Disease
in IN O
Fischer NNP O
344 CD O
( SYM O
F344 CD O
) -RRB- O
rats NNS O
. . O
null null null-Disease
Recently RB O
, , O
p NN O
- HYPH O
aminophenol NN O
( , O
PAP NNP O
) -RRB- O
, , O
a DT O
known VBN O
potent JJ O
nephrotoxicant NN O
, , O
was VBD O
identified VBN O
as IN O
a DT O
metabolite NN O
of IN O
APAP NN O
in IN O
F344 CD O
rats NNS O
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
if IN O
PAP NNP O
formation NN O
is VBZ O
a DT O
requisite JJ O
step NN O
in IN O
APAP NNP O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
Therefore RB O
, , O
the DT O
effect NN O
of IN O
bis NN O
( HYPH O
p NN O
- HYPH O
nitrophenyl NN O
) , O
phosphate NN O
( , O
BNPP NNP O
) -RRB- O
, , O
an DT O
acylamidase NN O
inhibitor NN O
, , O
on IN O
APAP NNP O
and CC O
PAP NNP O
nephrotoxicity NN B-Disease
and CC O
metabolism NN O
was VBD O
determined VBN O
. . O
null null null-Disease
BNPP NNP O
( : O
1 CD O
to TO O
8 CD O
mM NN O
) -RRB- O
reduced VBD O
APAP NNP O
deacetylation NN O
and CC O
covalent JJ O
binding NN O
in IN O
F344 CD O
renal JJ O
cortical JJ O
homogenates NNS O
in IN O
a DT O
concentration NN O
- HYPH O
dependent JJ O
manner NN O
. . O
null null null-Disease
Pretreatment NN O
of IN O
animals NNS O
with IN O
BNPP NNP O
prior RB O
to IN O
APAP NNP O
or CC O
PAP NNP O
administration NN O
resulted VBD O
in IN O
marked JJ O
reduction NN O
of IN O
APAP NNP O
( : O
900 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
nephrotoxicity NN B-Disease
but CC O
not RB O
PAP NN O
nephrotoxicity NN B-Disease
. . O
null null null-Disease
This DT O
result NN O
was VBD O
not RB O
due JJ O
to IN O
altered JJ O
disposition NN O
of IN O
either CC O
APAP NNP O
or CC O
acetylated VBN O
metabolites NNS O
in IN O
plasma NN O
or CC O
renal JJ O
cortical JJ O
and CC O
hepatic JJ O
tissue NN O
. . O
null null null-Disease
Rather RB O
, , O
BNPP NNP O
pretreatment NN O
reduced VBD O
the DT O
fraction NN O
of IN O
APAP NNP O
excreted VBN O
as IN O
PAP NNP O
by IN O
64 CD O
and CC O
75 CD O
% NN O
after IN O
APAP NNP O
doses NNS O
of IN O
750 CD O
and CC O
900 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
BNPP NNP O
did VBD O
not RB O
alter VB O
the DT O
excretion NN O
of IN O
APAP NNP O
or CC O
any DT O
of IN O
its PRP$ O
non AFX O
- HYPH O
deacetylated VBN O
metabolites NNS O
nor CC O
did VBD O
BNPP NNP O
alter VB O
excretion NN O
of IN O
PAP NNP O
or CC O
its PRP$ O
metabolites NNS O
after IN O
PAP NNP O
doses NNS O
of IN O
150 CD O
and CC O
300 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
Therefore RB O
, , O
the DT O
BNPP NNP O
- HYPH O
induced VBN O
reduction NN O
in IN O
APAP NNP O
- HYPH O
induced VBN O
nephrotoxicity NN B-Disease
appears VBZ O
to TO O
be VB O
due IN O
to IN O
inhibition NN O
of IN O
APAP NNP O
deacetylation NN O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
PAP NNP O
formation NN O
, , O
in IN O
vivo NN O
, , O
accounts VBZ O
, , O
at IN O
least JJS O
in IN O
part NN O
, , O
for IN O
APAP NNP O
- HYPH O
induced VBN O
renal JJ B-Disease
tubular JJ I-Disease
necrosis NN I-Disease
. . O
null null null-Disease
Morphine NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
in IN O
newborn JJ O
infants NNS O
. . O
null null null-Disease
Two CD O
neonates NNS O
suffered VBD O
from IN O
generalized JJ O
seizures NNS B-Disease
during IN O
the DT O
course NN O
of IN O
intravenous JJ O
morphine NN O
sulfate NN O
for IN O
post NN O
- HYPH O
operative JJ O
analgesia NN O
. . O
null null null-Disease
They PRP O
received VBD O
morphine NN O
in IN O
doses NNS O
of IN O
32 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
hr NN O
and CC O
40 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
hr NN O
larger JJR O
than IN O
a DT O
group NN O
of IN O
10 CD O
neonates NNS O
who WP O
received VBD O
6 CD O
- SYM O
24 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
hr NN O
and CC O
had VBD O
no DT O
seizures NNS B-Disease
. . O
null null null-Disease
Plasma NN O
concentrations NNS O
of IN O
morphine NN O
in IN O
these DT O
neonates NNS O
was VBD O
excessive JJ O
( : O
60 CD O
and CC O
90 CD O
mg NNS O
/ SYM O
ml NN O
) -RRB- O
. . O
null null null-Disease
Other JJ O
known VBN O
reasons NNS O
for IN O
seizures NNS B-Disease
were VBD O
ruled VBN O
out RP O
and CC O
the DT O
convulsions NNS B-Disease
stopped VBD O
a DT O
few JJ O
hours NNS O
after IN O
cessation NN O
of IN O
morphine NN O
and CC O
did VBD O
not RB O
reoccur VB O
in IN O
the DT O
subsequent JJ O
8 CD O
months NNS O
. . O
null null null-Disease
It PRP O
is VBZ O
suggested VBN O
that IN O
post NN O
- HYPH O
operative JJ O
intravenous JJ O
morphine NN O
should MD O
not RB O
exceed VB O
20 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
ml NNS O
in IN O
neonates NNS O
. . O
null null null-Disease
Indomethacin NN O
induced VBD O
hypotension NN B-Disease
in IN O
sodium NN O
and CC O
volume NN O
depleted VBN O
rats NNS O
. . O
null null null-Disease
After IN O
a DT O
single JJ O
oral JJ O
dose NN O
of IN O
4 CD O
mg NN O
/ SYM O
kg NN O
indomethacin NN O
( , O
IDM NNP O
) -RRB- O
to IN O
sodium NN O
and CC O
volume NN O
depleted VBN O
rats NNS O
plasma NN O
renin NN O
activity NN O
( -LRB- O
PRA NNP O
) -RRB- O
and CC O
systolic JJ O
blood NN O
pressure NN O
fell VBD O
significantly RB O
within IN O
four CD O
hours NNS O
. . O
null null null-Disease
In IN O
sodium NN O
repleted VBN O
animals NNS O
indomethacin NN O
did VBD O
not RB O
change VB O
systolic JJ O
blood NN O
pressure NN O
( : O
BP NNP O
) -RRB- O
although IN O
plasma NN O
renin NN O
activity NN O
was VBD O
decreased VBN O
. . O
null null null-Disease
Thus RB O
, , O
indomethacin NN O
by IN O
inhibition NN O
of IN O
prostaglandin JJ O
synthesis NN O
may MD O
diminish VB O
the DT O
blood NN O
pressure NN O
maintaining VBG O
effect NN O
of IN O
the DT O
stimulated JJ O
renin NN O
- HYPH O
angiotensin NN O
system NN O
in IN O
sodium NN O
and CC O
volume NN O
depletion NN O
. . O
null null null-Disease
On IN O
the DT O
antiarrhythmic JJ O
activity NN O
of IN O
one CD O
N NN O
- HYPH O
substituted VBN O
piperazine NN O
derivative NN O
of IN O
trans NNS O
- HYPH O
2 CD O
- HYPH O
amino NN O
- HYPH O
3 CD O
- HYPH O
hydroxy NN O
- HYPH O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
4 CD O
- HYPH O
tetrahydroanaphthalene NN O
. . O
null null null-Disease
The DT O
antiarrhythmic JJ O
activity NN O
of IN O
the DT O
compound NN O
N NNP O
- HYPH O
( HYPH O
trans NN O
- HYPH O
3 CD O
- HYPH O
hydroxy NN O
- HYPH O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
4 CD O
- HYPH O
tetrahydro NN O
- HYPH O
2 CD O
- HYPH O
naphthyl NN O
) : O
- HYPH O
N NN O
- HYPH O
( : O
3 CD O
- HYPH O
oxo NN O
- HYPH O
3 CD O
- HYPH O
phenyl NN O
- HYPH O
2 CD O
- HYPH O
methylpropyl NN O
) NFP O
- HYPH O
piperazine NN O
hydrochloride NN O
, , O
referred VBN O
to IN O
as IN O
P11 NNP O
, , O
is VBZ O
studied VBN O
on IN O
anaesthesized JJ O
cats NNS O
and CC O
Wistar JJ O
albino NN O
rats NNS O
, , O
as RB O
well RB O
as IN O
on IN O
non NN O
- HYPH O
anaesthesized JJ O
rabbits NNS O
. . O
null null null-Disease
Four CD O
types NNS O
of IN O
experimental JJ O
arrhythmia NN B-Disease
are VBP O
used VBN O
- HYPH O
- HYPH O
with IN O
BaCl2 NNP O
, , O
with IN O
chloroform NN O
- HYPH O
adrenaline NN O
, , O
with IN O
strophantine NN O
G NN O
and CC O
with IN O
aconitine NN O
. . O
null null null-Disease
The DT O
compound NN O
P11 NN O
is VBZ O
introduced VBN O
in IN O
doses NNS O
of IN O
0 CD O
. . O
25 CD O
and CC O
0 CD O
. . O
50 CD O
mg NN O
/ SYM O
kg NN O
intravenously RB O
and CC O
10 CD O
mg NN O
/ SYM O
kg NN O
orally RB O
. . O
null null null-Disease
The DT O
compound NN O
manifests VBZ O
antiarrhythmic JJ O
activity NN O
in IN O
all DT O
models NNS O
of IN O
experimental JJ O
arrhythmia NN B-Disease
used VBN O
, , O
causing VBG O
greatest JJS O
inhibition NN O
on IN O
the DT O
arrhythmia NN B-Disease
induced VBN O
by IN O
chloroform NN O
- HYPH O
adrenaline NN O
( , O
in IN O
90 CD O
per NN O
cent NN O
) , O
and CC O
with IN O
BaCl2 NNP O
( , O
in IN O
84 CD O
per NN O
cent NN O
) -RRB- O
. . O
null null null-Disease
The DT O
results NNS O
obtained VBN O
are VBP O
associated VBN O
with IN O
the DT O
beta NN O
- HYPH O
adrenoblocking NN O
and CC O
with IN O
the DT O
membrane NN O
- HYPH O
stabilizing VBG O
action NN O
of IN O
the DT O
compound NN O
. . O
null null null-Disease
Recurrent JJ O
subarachnoid NN B-Disease
hemorrhage NN I-Disease
associated VBN O
with IN O
aminocaproic JJ O
acid NN O
therapy NN O
and CC O
acute JJ B-Disease
renal JJ I-Disease
artery NN I-Disease
thrombosis NN I-Disease
. . O
null null null-Disease
Case NN O
report NN O
. . O
null null null-Disease
Epsilon NNP O
aminocaproic JJ O
acid NN O
( -LRB- O
EACA NNP O
) -RRB- O
has VBZ O
been VBN O
used VBN O
to TO O
prevent VB O
rebleeding NN O
in IN O
patients NNS O
with IN O
subarachnoid NN B-Disease
hemorrhage NN I-Disease
( , O
SAH NNP B-Disease
) -RRB- O
. . O
null null null-Disease
Although IN O
this DT O
agent NN O
does VBZ O
decrease VB O
the DT O
frequency NN O
of IN O
rebleeding NN O
, , O
several JJ O
reports NNS O
have VBP O
described VBN O
thrombotic JJ B-Disease
complications NNS O
of IN O
EACA NNP O
therapy NN O
. . O
null null null-Disease
These DT O
complications NNS O
have VBP O
included VBN O
clinical JJ O
deterioration NN O
and CC O
intracranial JJ B-Disease
vascular JJ I-Disease
thrombosis NN I-Disease
in IN O
patients NNS O
with IN O
SAH NNP B-Disease
, , O
arteriolar JJ O
and CC O
capillary JJ O
fibrin NN O
thrombi NN B-Disease
in IN O
patients NNS O
with IN O
fibrinolytic JJ O
syndromes NNS O
treated VBN O
with IN O
EACA NNP O
, , O
or CC O
other JJ O
thromboembolic JJ B-Disease
phenomena NNS I-Disease
. . O
null null null-Disease
Since IN O
intravascular JJ O
fibrin NN O
thrombi NN B-Disease
are VBP O
often RB O
observed VBN O
in IN O
patients NNS O
with IN O
fibrinolytic JJ O
disorders NNS O
, , O
EACA NNP O
should MD O
not RB O
be VB O
implicated VBN O
in IN O
the DT O
pathogenesis NN O
of IN O
fibrin NN O
thrombi NN B-Disease
in IN O
patients NNS O
with IN O
disseminated VBN B-Disease
intravascular JJ I-Disease
coagulation NN I-Disease
or CC O
other JJ O
"""" `` O
consumption NN B-Disease
coagulopathies NNS I-Disease
. , O
"""" '' O
This DT O
report NN O
describes VBZ O
subtotal JJ O
infarction NN B-Disease
of IN O
the DT O
kidney NN O
due IN O
to IN O
thrombosis NN B-Disease
of IN I-Disease
a DT I-Disease
normal JJ I-Disease
renal JJ I-Disease
artery NN I-Disease
. . O
null null null-Disease
This DT O
occlusion NN O
occurred VBD O
after IN O
EACA NNP O
therapy NN O
in IN O
a DT O
patient NN O
with IN O
SAH NNP B-Disease
and CC O
histopathological JJ O
documentation NN O
of IN O
recurrent JJ O
SAH NNP B-Disease
. . O
null null null-Disease
The DT O
corresponding VBG O
clinical JJ O
event NN O
was VBD O
characterized VBN O
by IN O
marked JJ O
hypertension NN B-Disease
and CC O
abrupt JJ O
neurological JJ O
deterioration NN O
. . O
null null null-Disease
Effect NN O
of IN O
vincristine NN O
sulfate NN O
on IN O
Pseudomonas NNP B-Disease
infections NNS I-Disease
in IN O
monkeys NNS O
. . O
null null null-Disease
In IN O
rhesus JJ O
monkeys NNS O
, , O
intravenous JJ O
challenge NN O
with IN O
0 CD O
. . O
6 CD O
x SYM O
10 CD O
( SYM O
10 CD O
) CD O
to TO O
2 CD O
. . O
2 CD O
x SYM O
10 CD O
( SYM O
10 CD O
) -RRB- O
Pseudomonas NNP O
aeruginosa NN O
organisms NNS O
caused VBD O
acute JJ O
illness NN O
of IN O
4 CD O
to TO O
5 CD O
days NNS O
' POS O
duration NN O
with IN O
spontaneous JJ O
recovery NN O
in IN O
13 CD O
of IN O
15 CD O
monkeys NNS O
; : O
blood NN O
cultures NNS O
became VBD O
negative JJ O
3 CD O
to TO O
17 CD O
days NNS O
after IN O
challenge NN O
. . O
null null null-Disease
Leukocytosis NNP B-Disease
was VBD O
observed VBN O
in IN O
all DT O
monkeys NNS O
. . O
null null null-Disease
Intravenous JJ O
or CC O
intratracheal JJ O
inoculation NN O
of IN O
2 CD O
. . O
0 CD O
to TO O
2 CD O
. . O
5 CD O
mg NN O
of IN O
vincristine NN O
sulfate NN O
was VBD O
followed VBN O
by IN O
leukopenia NN B-Disease
in IN O
4 CD O
to TO O
5 CD O
days NNS O
. . O
null null null-Disease
Intravenous JJ O
inoculation NN O
of IN O
4 CD O
. . O
2 CD O
x SYM O
10 CD O
( SYM O
10 CD O
) CD O
to TO O
7 CD O
. . O
8 CD O
x SYM O
10 CD O
( SYM O
10 CD O
) -RRB- O
pyocin NN O
type NN O
6 CD O
Pseudomonas NNP O
organisms NNS O
in IN O
monkeys NNS O
given VBN O
vincristine NN O
sulfate NN O
4 CD O
days NNS O
previously RB O
resulted VBD O
in IN O
fatal JJ O
infection NN B-Disease
in IN O
11 CD O
of IN O
14 CD O
monkeys NNS O
, , O
whereas IN O
none NN O
of IN O
four CD O
receiving VBG O
Pseudomonas NNP O
alone RB O
died VBD O
. . O
null null null-Disease
These DT O
studies NNS O
suggest VBP O
that IN O
an DT O
antimetabolite NN O
- HYPH O
induced VBN O
leukopenia NN B-Disease
predisposes VBZ O
to IN O
severe JJ O
Pseudomonas NNP O
sepsis NNS B-Disease
and CC O
that IN O
such JJ O
monkeys NNS O
may MD O
serve VB O
as IN O
a DT O
biological JJ O
model NN O
for IN O
study NN O
of IN O
comparative JJ O
efficacy NN O
of IN O
antimicrobial JJ O
agents NNS O
. . O
null null null-Disease
Modification NN O
by IN O
propranolol NN O
of IN O
cardiovascular JJ O
effects NNS O
of IN O
induced VBN O
hypoglycaemia NN B-Disease
. . O
null null null-Disease
The DT O
cardiovascular JJ O
effects NNS O
of IN O
hypoglycaemia NN B-Disease
, , O
with IN O
and CC O
without IN O
beta NN O
- HYPH O
blockade NN O
, , O
were VBD O
compared VBN O
in IN O
fourteen CD O
healthy JJ O
men NNS O
. . O
null null null-Disease
Eight CD O
received VBD O
insulin NN O
alone RB O
, , O
and CC O
eight CD O
, , O
including VBG O
two CD O
of IN O
the DT O
original JJ O
insulin NN O
- HYPH O
only RB O
group NN O
, , O
were VBD O
given VBN O
propranolol NN O
and CC O
insulin NN O
. . O
null null null-Disease
In IN O
the DT O
insulin NN O
- HYPH O
group NN O
the DT O
period NN O
of IN O
hypoglycaemia NN B-Disease
was VBD O
associated VBN O
with IN O
an DT O
increase NN O
in IN O
heart NN O
- HYPH O
rate NN O
and CC O
a DT O
fall NN O
in IN O
diastolic JJ O
blood NN O
- HYPH O
pressure NN O
. . O
null null null-Disease
In IN O
the DT O
propranolol NN O
- HYPH O
insulin NN O
group NN O
there EX O
was VBD O
a DT O
significant JJ O
fall NN O
in IN O
heart NN O
- HYPH O
rate NN O
in IN O
most JJS O
subjects NNS O
and CC O
an DT O
increase NN O
in IN O
diastolic JJ O
pressure NN O
. . O
null null null-Disease
Typical JJ O
S NNP O
- HYPH O
T NNP O
/ SYM O
T NNP O
changes NNS O
occurred VBD O
in IN O
the DT O
insulin NN O
- HYPH O
group NN O
but CC O
in IN O
none NN O
of IN O
the DT O
propranolol NN O
- HYPH O
insulin NN O
group NN O
. . O
null null null-Disease
Hypertension NN B-Disease
in IN O
diabetics NNS B-Disease
prone JJ O
to IN O
hypoglycaemia NN B-Disease
attacks NNS O
should MD O
not RB O
be VB O
treated VBN O
with IN O
beta NN O
- HYPH O
blockers NNS O
because IN O
these DT O
drugs NNS O
may MD O
cause VB O
a DT O
sharp JJ O
rise NN O
in IN O
blood NN O
- HYPH O
pressure NN O
in IN O
such JJ O
patients NNS O
. . O
null null null-Disease
Long JJ O
- HYPH O
term NN O
propranolol NN O
therapy NN O
in IN O
pregnancy NN O
: : O
maternal JJ O
and CC O
fetal JJ O
outcome NN O
. . O
null null null-Disease
Propranolol NN O
, , O
a DT O
beta NN O
- HYPH O
adrenergic JJ O
blocking NN O
agent NN O
, , O
has VBZ O
found VBN O
an DT O
important JJ O
position NN O
in IN O
the DT O
practice NN O
of IN O
medicine NN O
. . O
null null null-Disease
Its PRP$ O
use NN O
in IN O
pregnancy NN O
, , O
however RB O
, , O
is VBZ O
an DT O
open JJ O
question NN O
as IN O
a DT O
number NN O
of IN O
detrimental JJ O
side NN O
effects NNS O
have VBP O
been VBN O
reported VBN O
in IN O
the DT O
fetus NN O
and CC O
neonate NN O
. . O
null null null-Disease
Ten CD O
patients NNS O
and CC O
12 CD O
pregnancies NNS O
are VBP O
reported VBN O
where WRB O
chronic JJ O
propranolol NN O
has VBZ O
been VBN O
administered VBN O
. . O
null null null-Disease
Five CD O
patients NNS O
with IN O
serial JJ O
pregnancies NNS O
with IN O
and CC O
without IN O
propranolol NN O
therapy NN O
are VBP O
also RB O
examined VBN O
. . O
null null null-Disease
Maternal JJ O
, , O
fetal JJ O
, , O
and CC O
neonatal JJ O
complications NNS O
are VBP O
examined VBN O
. . O
null null null-Disease
An DT O
attempt NN O
is VBZ O
made VBN O
to TO O
differentiate VB O
drug NN O
- HYPH O
related VBN O
complications NNS O
from IN O
maternal JJ O
disease NN O
- HYPH O
- HYPH O
related VBN O
complications NNS O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
previously RB O
reported VBN O
hypoglycemia NN B-Disease
, , O
hyperbilirubinemia NN B-Disease
, , O
polycythemia NN B-Disease
, , O
neonatal JJ B-Disease
apnea NN I-Disease
, , O
and CC O
bradycardia NN B-Disease
are VBP O
not RB O
invariable JJ O
and CC O
cannot MD O
be VB O
statistically RB O
correlated VBN O
with IN O
chronic JJ O
propranolol NN O
therapy NN O
. . O
null null null-Disease
Growth NN B-Disease
retardation NN I-Disease
, , O
however RB O
, , O
appears VBZ O
to TO O
be VB O
significant JJ O
in IN O
both DT O
of IN O
our PRP$ O
series NN O
. . O
null null null-Disease
Central JJ O
excitatory JJ O
actions NNS O
of IN O
flurazepam NN O
. . O
null null null-Disease
Toxic JJ O
actions NNS O
of IN O
flurazepam NN O
( , O
FZP NNP O
) -RRB- O
were VBD O
studied VBN O
in IN O
cats NNS O
, , O
mice NNS O
and CC O
rats NNS O
. . O
null null null-Disease
High JJ O
doses NNS O
caused VBD O
an DT O
apparent JJ O
central JJ O
excitation NN O
, , O
most RBS O
clearly RB O
seen VBN O
as IN O
clonic JJ O
convulsions NNS B-Disease
, , O
superimposed VBN O
on IN O
general JJ O
depression NN B-Disease
. . O
null null null-Disease
Following VBG O
a DT O
lethal JJ O
dose NN O
, , O
death NN O
was VBD O
always RB O
associated VBN O
with IN O
convulsions NNS B-Disease
. . O
null null null-Disease
Comparing VBG O
the DT O
relative JJ O
sensitivity NN O
to IN O
central JJ O
depression NN B-Disease
and CC O
excitation NN O
revealed VBD O
that IN O
rats NNS O
were VBD O
least RBS O
likely JJ O
to TO O
have VB O
convulsions NNS B-Disease
at IN O
doses NNS O
that WDT O
did VBD O
not RB O
first RB O
cause VB O
loss NN B-Disease
of IN I-Disease
consciousness NN I-Disease
, , O
while IN O
cats NNS O
most RBS O
clearly RB O
showed VBD O
marked JJ O
central JJ O
excitatory JJ O
actions NNS O
. . O
null null null-Disease
Signs NNS O
of IN O
FZP NNP O
toxocity NN B-Disease
in IN O
cats NNS O
included VBD O
excessive JJ O
salivation NN B-Disease
, , O
extreme JJ O
apprehensive JJ O
behavior NN O
, , O
retching NN O
, , O
muscle NN B-Disease
tremors NNS I-Disease
and CC O
convulsions NNS B-Disease
. . O
null null null-Disease
An DT O
interaction NN O
between IN O
FZP NNP O
and CC O
pentylenetetrazol NN O
( , O
PTZ NNP O
) -RRB- O
was VBD O
shown VBN O
by IN O
pretreating VBG O
mice NNS O
with IN O
FZP NNP O
before IN O
PTZ NNP O
challenge NN O
. . O
null null null-Disease
As IN O
a DT O
function NN O
of IN O
dose NN O
, , O
FZP NNP O
first RB O
protected VBD O
against IN O
convulsions NNS B-Disease
and CC O
death NN O
. . O
null null null-Disease
At IN O
higher JJR O
doses NNS O
, , O
however RB O
, , O
convulsions NNS B-Disease
again RB O
emerged VBD O
. . O
null null null-Disease
These DT O
doses NNS O
of IN O
FZP NNP O
were VBD O
lower JJR O
than IN O
those DT O
that WDT O
would MD O
alone RB O
cause VB O
convulsions NNS B-Disease
. . O
null null null-Disease
These DT O
results NNS O
may MD O
be VB O
relevant JJ O
to IN O
the DT O
use NN O
of IN O
FZP NNP O
in IN O
clinical JJ O
situations NNS O
in IN O
which WDT O
there EX O
is VBZ O
increased VBN O
neural JJ O
excitability NN O
, , O
such JJ O
as IN O
epilepsy NN B-Disease
or CC O
sedative JJ O
- HYPH O
hypnotic JJ O
drug NN O
withdrawal NN O
. . O
null null null-Disease
Use NN O
of IN O
propranolol NN O
in IN O
the DT O
treatment NN O
of IN O
idiopathic JJ B-Disease
orthostatic JJ I-Disease
hypotension NN I-Disease
. . O
null null null-Disease
Five CD O
patients NNS O
with IN O
idiopathic JJ B-Disease
orthostatic JJ I-Disease
hypotension NN I-Disease
who WP O
had VBD O
physiologic JJ O
and CC O
biochemical JJ O
evidence NN O
of IN O
severe JJ O
autonomic JJ O
dysfunction NN O
were VBD O
included VBN O
in IN O
the DT O
study NN O
. . O
null null null-Disease
They PRP O
all DT O
exhibited VBD O
markedly RB O
reduced VBN O
plasma NN O
catecholamines NNS O
and CC O
plasma NN O
renin NN O
activity NN O
in IN O
both CC O
recumbent JJ O
and CC O
upright JJ O
positions NNS O
and CC O
had VBD O
marked VBN O
hypersensitivity NN B-Disease
to IN O
the DT O
pressor NN O
effects NNS O
of IN O
infused VBN O
norepinephrine NN O
. . O
null null null-Disease
Treatment NN O
with IN O
propanolol NN O
administered VBN O
intravenously RB O
( : O
1 CD O
- SYM O
5 CD O
mg NN O
) -RRB- O
produced VBD O
increases NNS O
in IN O
supine NN O
and CC O
upright JJ O
blood NN O
pressure NN O
in IN O
4 CD O
of IN O
the DT O
5 CD O
individuals NNS O
with IN O
rises NNS O
ranging VBG O
from IN O
11 CD O
/ SYM O
6 CD O
to IN O
22 CD O
/ SYM O
11 CD O
mmHg NN O
. . O
null null null-Disease
Chronic JJ O
oral JJ O
administration NN O
of IN O
propranolol NN O
( : O
40 CD O
- SYM O
160 CD O
mg NN O
/ SYM O
day NN O
) -RRB- O
also RB O
elevated VBD O
the DT O
blood NN O
pressures NNS O
of IN O
these DT O
individuals NNS O
with IN O
increases NNS O
in IN O
the DT O
order NN O
of IN O
20 CD O
- SYM O
35 CD O
/ SYM O
15 CD O
- SYM O
25 CD O
mmg NN O
being VBG O
observed VBN O
. . O
null null null-Disease
In IN O
1 CD O
patient NN O
, , O
marked VBN O
hypertension NN B-Disease
was VBD O
induced VBN O
by IN O
propranolol NN O
and CC O
the DT O
drug NN O
had VBD O
to TO O
be VB O
withdrawn VBN O
. . O
null null null-Disease
It PRP O
otherwise RB O
was VBD O
well RB O
tolerated JJ O
and CC O
no DT O
important JJ O
side NN O
effects NNS O
were VBD O
observed VBN O
. . O
null null null-Disease
Treatment NN O
has VBZ O
been VBN O
continued VBN O
in IN O
3 CD O
individuals NNS O
for IN O
6 CD O
- SYM O
13 CD O
months NNS O
with IN O
persistence NN O
of IN O
the DT O
pressor NN O
effect NN O
, , O
although IN O
there EX O
appears VBZ O
to TO O
have VB O
been VBN O
some DT O
decrease NN O
in IN O
the DT O
degree NN O
of IN O
response NN O
with IN O
time NN O
. . O
null null null-Disease
Hemodynamic JJ O
measurements NNS O
in IN O
1 CD O
of IN O
the DT O
patients NNS O
demonstrated VBD O
an DT O
increase NN O
in IN O
total JJ O
peripheral JJ O
resistance NN O
and CC O
essentially RB O
no DT O
change NN O
in IN O
cardiac JJ O
output NN O
following VBG O
propranolol NN O
therapy NN O
. . O
null null null-Disease
The DT O
studies NNS O
suggest VBP O
that IN O
propranolol NN O
is VBZ O
a DT O
useful JJ O
drug NN O
in IN O
selected VBN O
patients NNS O
with IN O
severe JJ O
idiopathic JJ B-Disease
orthostatic JJ I-Disease
hypotension NN I-Disease
. . O
null null null-Disease
Total JJ O
intravenous JJ O
anesthesia NN O
with IN O
etomidate NN O
. . O
null null null-Disease
III NNP O
. . O
null null null-Disease
Some DT O
observations NNS O
in IN O
adults NNS O
. . O
null null null-Disease
An DT O
investigation NN O
was VBD O
undertaken VBN O
to TO O
determine VB O
the DT O
dosage NN O
of IN O
etomidate NN O
required VBN O
to TO O
maintain VB O
sleep NN O
in IN O
adults NNS O
undergoing VBG O
surgery NN O
under IN O
regional JJ O
local JJ O
anesthesia NN O
. . O
null null null-Disease
Premedication NN O
of IN O
diazepam NN O
10 CD O
mg NN O
and CC O
atropine NN O
0 CD O
. . O
5 CD O
mg NN O
was VBD O
given VBN O
, , O
and CC O
sleep NN O
was VBD O
induced VBN O
and CC O
maintained VBN O
by IN O
intermittent JJ O
intravenous JJ O
injections NNS O
of IN O
etomidate NN O
0 CD O
. . O
1 CD O
/ SYM O
mg NN O
/ SYM O
kg NN O
, , O
given VBN O
whenever WRB O
the DT O
patient NN O
would MD O
open VB O
his PRP$ O
eyes NNS O
on IN O
request NN O
. . O
null null null-Disease
A DT O
mean JJ O
overall JJ O
dose NN O
of IN O
etomidate NN O
17 CD O
. . O
4 CD O
microgram NN O
/ SYM O
kg NN O
/ SYM O
min NN O
. . O
was VBD O
required VBN O
to TO O
maintain VB O
sleep NN O
, , O
but CC O
great JJ O
individual JJ O
variation NN O
occurred VBD O
, , O
with IN O
older JJR O
patients NNS O
requiring VBG O
less JJR O
drug NN O
. . O
null null null-Disease
The DT O
investigation NN O
was VBD O
discontinued VBN O
after IN O
18 CD O
patients NNS O
because IN O
of IN O
the DT O
frequency NN O
and CC O
intensity NN O
of IN O
side NN O
- HYPH O
effects NNS O
, , O
particularly RB O
pain NN B-Disease
and CC O
myoclonia NN B-Disease
, , O
which WDT O
caused VBD O
the DT O
technique NN O
to TO O
be VB O
abandoned VBN O
in IN O
two CD O
cases NNS O
. . O
null null null-Disease
It PRP O
is VBZ O
considered VBN O
unlikely JJ O
that IN O
etomidate NN O
will MD O
prove VB O
to TO O
be VB O
the DT O
hypnotic JJ O
of IN O
choice NN O
for IN O
a DT O
totally RB O
intravenous JJ O
anesthetic JJ O
technique NN O
in IN O
adults NNS O
because IN O
of IN O
the DT O
high JJ O
incidence NN O
of IN O
myoclonia NN B-Disease
after IN O
prolonged JJ O
administration NN O
. . O
null null null-Disease
In IN O
several JJ O
patients NNS O
uncontrollable JJ O
muscle NN O
movements NNS O
persisted VBD O
for IN O
many JJ O
minutes NNS O
after IN O
complete JJ O
recovery NN O
of IN O
consciousness NN O
. . O
null null null-Disease
Evidence NN O
for IN O
cardiac JJ O
beta NN O
2 CD O
- HYPH O
adrenoceptors NNS O
in IN O
man NN O
. . O
null null null-Disease
We PRP O
compared VBD O
the DT O
effects NNS O
of IN O
single JJ O
doses NNS O
of IN O
50 CD O
mg NN O
atenolol NN O
( , O
cardioselective JJ O
) -RRB- O
, , O
40 CD O
mg NN O
propranolol NN O
( , O
nonselective JJ O
) -RRB- O
, , O
and CC O
placebo NN O
on IN O
both CC O
exercise NN O
- HYPH O
and CC O
isoproterenol NN O
- HYPH O
induced VBN O
tachycardia NN B-Disease
in IN O
two CD O
experiments NNS O
involving VBG O
nine CD O
normal JJ O
subjects NNS O
. . O
null null null-Disease
Maximal JJ O
exercise NN O
heart NN O
rate NN O
was VBD O
reduced VBN O
from IN O
187 CD O
+ CD O
/ SYM O
- SYM O
4 CD O
( SYM O
SEM NN O
) -RRB- O
after IN O
placebo NN O
to IN O
146 CD O
+ SYM O
/ SYM O
- SYM O
7 CD O
bpm NN O
after IN O
atenolol NN O
and CC O
138 CD O
+ SYM O
/ SYM O
- SYM O
6 CD O
bpm NN O
after IN O
propranolol NN O
, , O
but CC O
there EX O
were VBD O
no DT O
differences NNS O
between IN O
the DT O
drugs NNS O
. . O
null null null-Disease
The DT O
effects NNS O
on IN O
isoproterenol NN O
tachycardia NN B-Disease
were VBD O
determined VBN O
before IN O
and CC O
after IN O
atropine NN O
( : O
0 CD O
. . O
04 CD O
mg NN O
/ SYM O
kg NN O
IV NN O
) -RRB- O
. . O
null null null-Disease
Isoproterenol NN O
sensitivity NN O
was VBD O
determined VBN O
as IN O
the DT O
intravenous JJ O
dose NN O
that WDT O
increased VBD O
heart NN O
rate NN O
by IN O
25 CD O
bpm NN O
( SYM O
CD25 CD O
) -RRB- O
and CC O
this DT O
was VBD O
increased VBN O
from IN O
1 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
3 CD O
micrograms NNS O
after IN O
placebo NN O
to IN O
38 CD O
. . O
9 CD O
+ NN O
/ SYM O
- HYPH O
8 CD O
. . O
3 CD O
micrograms NNS O
after IN O
propranolol NN O
and CC O
8 CD O
. . O
3 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
7 CD O
micrograms NNS O
after IN O
atenolol NN O
. . O
null null null-Disease
The DT O
difference NN O
in IN O
the DT O
effects NNS O
of IN O
the DT O
two CD O
was VBD O
significant JJ O
. . O
null null null-Disease
After IN O
atropine NN O
the DT O
CD25 NN O
was VBD O
unchanged JJ O
after IN O
placebo NN O
( : O
2 CD O
. . O
3 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
3 CD O
micrograms NNS O
) -RRB- O
and CC O
atenolol NN O
( : O
7 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
3 CD O
micrograms NNS O
) -RRB- O
; : O
it PRP O
was VBD O
reduced VBN O
after IN O
propranolol NN O
( SYM O
24 CD O
. . O
8 CD O
+ NN O
/ SYM O
- HYPH O
5 CD O
. . O
0 CD O
micrograms NNS O
) -RRB- O
, , O
but CC O
remained VBD O
different JJ O
from IN O
atenolol NN O
. . O
null null null-Disease
This DT O
change NN O
with IN O
propranolol NN O
sensitivity NN O
was VBD O
calculated VBN O
as IN O
the DT O
apparent JJ O
Ka NNP O
, , O
this DT O
was VBD O
unchanged JJ O
by IN O
atropine NN O
( : O
11 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- HYPH O
2 CD O
. . O
1 CD O
and CC O
10 CD O
. . O
1 CD O
+ NN O
/ SYM O
- HYPH O
2 CD O
. . O
5 CD O
ml NN O
/ SYM O
ng NN O
) -RRB- O
. . O
null null null-Disease
These DT O
data NNS O
are VBP O
consistent JJ O
with IN O
the DT O
hypothesis NN O
that IN O
exercise NN O
- HYPH O
induced VBN O
tachycardia NN B-Disease
results VBZ O
largely RB O
from IN O
beta NN O
1 CD O
- HYPH O
receptor NN O
activation NN O
that WDT O
is VBZ O
blocked VBN O
by IN O
both CC O
cardioselective JJ O
and CC O
nonselective JJ O
drugs NNS O
, , O
whereas IN O
isoproterenol NN O
activates VBZ O
both CC O
beta NN O
1 CD O
- HYPH O
and CC O
beta NN O
2 CD O
- HYPH O
receptors NNS O
so IN O
that IN O
after IN O
cardioselective JJ O
blockade NN O
there EX O
remains VBZ O
a DT O
beta JJ O
2 CD O
- HYPH O
component NN O
that WDT O
can MD O
be VB O
blocked VBN O
with IN O
a DT O
nonselective JJ O
drug NN O
. . O
null null null-Disease
While IN O
there EX O
appear VBP O
to TO O
be VB O
beta JJ O
2 CD O
- HYPH O
receptors NNS O
in IN O
the DT O
human JJ O
heart NN O
, , O
their PRP$ O
physiologic JJ O
or CC O
pathologic JJ O
roles NNS O
remain VBP O
to TO O
be VB O
defined VBN O
. . O
null null null-Disease
Hormones NNS O
and CC O
risk NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
This DT O
paper NN O
reports VBZ O
the DT O
results NNS O
of IN O
a DT O
study NN O
of IN O
50 CD O
menopausal JJ O
women NNS O
receiving VBG O
hormonal JJ O
replacement NN O
therapy NN O
. . O
null null null-Disease
The DT O
majority NN O
( SYM O
29 CD O
) -RRB- O
had VBD O
surgical JJ O
menopause NN O
; : O
their PRP$ O
mean JJ O
age NN O
was VBD O
45 CD O
. . O
7 CD O
years NNS O
. . O
null null null-Disease
It PRP O
was VBD O
hypothesized VBN O
that IN O
progestins NNS O
could MD O
equilibrate VB O
the DT O
effects NNS O
of IN O
the DT O
estrogenic JJ O
stimulation NN O
on IN O
the DT O
mammary JJ O
and CC O
endometrial JJ O
target NN O
tissues NNS O
of IN O
women NNS O
on IN O
hormonal JJ O
replacement NN O
therapy NN O
. . O
null null null-Disease
The DT O
treatment NN O
schedule NN O
consisted VBD O
of IN O
conjugated VBN O
estrogens NNS O
( -LRB- O
Premarin NNP O
) SYM O
1 CD O
. . O
25 CD O
mg NN O
/ SYM O
day NN O
for IN O
21 CD O
days NNS O
and CC O
Medroxyprogesterone NN O
acetate NN O
10 CD O
mg NN O
/ SYM O
day NN O
for IN O
10 CD O
days NNS O
in IN O
each DT O
month NN O
. . O
null null null-Disease
The DT O
mean JJ O
treatment NN O
period NN O
was VBD O
18 CD O
months NNS O
. . O
null null null-Disease
During IN O
the DT O
follow NN O
- HYPH O
up NN O
period NN O
, , O
attention NN O
was VBD O
paid VBN O
to IN O
breast NN O
modifications NNS O
as IN O
evidenced VBN O
by IN O
symptomatology NN O
, , O
physical JJ O
examination NN O
, , O
and CC O
plate NN O
thermography NN O
. . O
null null null-Disease
Mastodynia NNP B-Disease
was VBD O
reported VBN O
by IN O
21 CD O
patients NNS O
, , O
and CC O
physical JJ O
examination NN O
revealed VBD O
a DT O
light JJ O
increase NN O
in IN O
breast NN O
firmness NN O
in IN O
12 CD O
women NNS O
and CC O
a DT O
moderate JJ O
increase NN O
in IN O
breast NN O
nodularity NN O
in IN O
2 CD O
women NNS O
. . O
null null null-Disease
Themography NN O
confirmed VBD O
the DT O
existence NN O
of IN O
an DT O
excessive JJ O
breast NN O
stimulation NN O
in IN O
1 CD O
women NNS O
who WP O
complained VBD O
of IN O
moderate JJ O
mastodynia NN B-Disease
and CC O
in IN O
5 CD O
of IN O
the DT O
7 CD O
women NNS O
who WP O
complained VBD O
of IN O
severe JJ O
mastodynia NN B-Disease
. . O
null null null-Disease
Normalization NN O
was VBD O
obtained VBN O
by IN O
halving VBG O
the DT O
estrogen NN O
dose NN O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
hormonal JJ O
replacement NN O
therapy NN O
can MD O
be VB O
safely RB O
prescribed VBN O
if IN O
the DT O
following VBG O
criteria NNS O
are VBP O
satisfied VBN O
: : O
1 LS O
) -RRB- O
preliminary JJ O
evaluation NN O
of IN O
patients NNS O
from IN O
a DT O
clinical JJ O
, , O
metabolic JJ O
, , O
cytologic JJ O
, , O
and CC O
mammographic JJ O
perspective NN O
; : O
2 CD O
) SYM O
cyclic JJ O
treatment NN O
schedule NN O
, , O
with IN O
a DT O
progestative JJ O
phase NN O
of IN O
10 CD O
days NNS O
; : O
and CC O
3 CD O
) SYM O
periodic JJ O
complete JJ O
follow NN O
- HYPH O
up NN O
, , O
with IN O
accurate JJ O
thermographic JJ O
evaluation NN O
of IN O
the DT O
breast NN O
target NN O
tissues NNS O
. . O
null null null-Disease
Early JJ O
infections NNS B-Disease
in IN O
kidney NN O
, , O
heart NN O
, , O
and CC O
liver NN O
transplant NN O
recipients NNS O
on IN O
cyclosporine NN O
. . O
null null null-Disease
Eighty CD O
- HYPH O
one CD O
renal JJ O
, , O
seventeen CD O
heart NN O
, , O
and CC O
twenty CD O
- HYPH O
four CD O
liver NN O
transplant NN O
patients NNS O
were VBD O
followed VBN O
for IN O
infection NN B-Disease
. . O
null null null-Disease
Seventeen CD O
renal JJ O
patients NNS O
received VBD O
azathioprine NN O
( , O
Aza NNP O
) -RRB- O
and CC O
prednisone NN O
as IN O
part NN O
of IN O
a DT O
randomized VBN O
trial NN O
of IN O
immunosuppression NN O
with IN O
21 CD O
cyclosporine NN O
- HYPH O
and CC O
- HYPH O
prednisone NN O
- HYPH O
treated VBN O
renal JJ O
transplant NN O
patients NNS O
. . O
null null null-Disease
All DT O
others NNS O
received VBD O
cyclosporine NN O
and CC O
prednisone NN O
. . O
null null null-Disease
The DT O
randomized VBN O
Aza NNP O
patients NNS O
had VBD O
more JJR O
overall JJ O
infections NNS B-Disease
( -LRB- O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
and CC O
more JJR O
nonviral JJ O
infections NNS B-Disease
( -LRB- O
P NN O
less JJR O
than IN O
0 CD O
. . O
02 CD O
) -RRB- O
than IN O
the DT O
randomized VBN O
cyclosporine NN O
patients NNS O
. . O
null null null-Disease
Heart NN O
and CC O
liver NN O
patients NNS O
had VBD O
more JJR O
infections NNS B-Disease
than IN O
cyclosporine NN O
renal JJ O
patients NNS O
but CC O
fewer JJR O
infections NNS B-Disease
than IN O
the DT O
Aza NNP O
renal JJ O
patients NNS O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
infectious JJ O
deaths NNS O
in IN O
renal JJ O
transplant NN O
patients NNS O
on IN O
cyclosporine NN O
or CC O
Aza NNP O
, , O
but CC O
infection NN B-Disease
played VBD O
a DT O
major JJ O
role NN O
in IN O
3 CD O
out IN O
of IN O
6 CD O
cardiac JJ O
transplant NN O
deaths NNS O
and CC O
in IN O
8 CD O
out IN O
of IN O
9 CD O
liver NN O
transplant NN O
deaths NNS O
. . O
null null null-Disease
Renal JJ O
patients NNS O
on IN O
cyclosporine NN O
had VBD O
the DT O
fewest JJS O
bacteremias NNS B-Disease
. . O
null null null-Disease
Analysis NN O
of IN O
site NN O
of IN O
infection NN B-Disease
showed VBD O
a DT O
preponderance NN O
of IN O
abdominal JJ B-Disease
infections NNS I-Disease
in IN O
liver NN O
patients NNS O
, , O
intrathoracic JJ O
infections NNS B-Disease
in IN O
heart NN O
patients NNS O
, , O
and CC O
urinary JJ B-Disease
tract NN I-Disease
infections NNS I-Disease
in IN O
renal JJ O
patients NNS O
. . O
null null null-Disease
Pulmonary JJ O
infections NNS B-Disease
were VBD O
less RBR O
common JJ O
in IN O
cyclosporine NN O
- HYPH O
treated VBN O
renal JJ O
patients NNS O
than IN O
in IN O
Aza NNP O
- HYPH O
treated VBN O
patients NNS O
( -LRB- O
P NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
Aza NNP O
patients NNS O
had VBD O
significantly RB O
more JJR O
staphylococcal JJ B-Disease
infections NNS I-Disease
than IN O
all DT O
other JJ O
transplant NN O
groups NNS O
( -LRB- O
P NN O
less JJR O
than IN O
0 CD O
. . O
005 CD O
) -RRB- O
, , O
and CC O
systemic JJ O
fungal JJ B-Disease
infections NNS I-Disease
occurred VBD O
only RB O
in IN O
the DT O
liver NN O
transplant NN O
group NN O
. . O
null null null-Disease
Cytomegalovirus NNP O
( -LRB- O
CMV NNP O
) -RRB- O
shedding NN O
or CC O
serological JJ O
rises NNS O
in IN O
antibody NN O
titer NN O
, , O
or CC O
both DT O
occurred VBD O
in IN O
78 CD O
% NN O
of IN O
cyclosporine NN O
patients NNS O
and CC O
76 CD O
% NN O
of IN O
Aza NNP O
patients NNS O
. . O
null null null-Disease
Of IN O
the DT O
cyclosporine NN O
patients NNS O
, , O
15 CD O
% NN O
had VBD O
symptoms NNS O
related VBN O
to IN O
CMV NNP B-Disease
infection NN I-Disease
. . O
null null null-Disease
Serological JJ O
evidence NN O
for IN O
Epstein NNP B-Disease
Barr NNP I-Disease
Virus NNP I-Disease
infection NN I-Disease
was VBD O
found VBN O
in IN O
20 CD O
% NN O
of IN O
65 CD O
cyclosporine NN O
patients NNS O
studied VBN O
. . O
null null null-Disease
Three CD O
had VBD O
associated VBN O
symptoms NNS O
, , O
and CC O
one CD O
developed VBD O
a DT O
lymphoma NN B-Disease
. . O
null null null-Disease
Structure NN O
- HYPH O
activity NN O
and CC O
dose NN O
- HYPH O
effect NN O
relationships NNS O
of IN O
the DT O
antagonism NN O
of IN O
picrotoxin NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
by IN O
cholecystokinin NN O
, , O
fragments NNS O
and CC O
analogues NNS O
of IN O
cholecystokinin NN O
in IN O
mice NNS O
. . O
null null null-Disease
Intraperitoneal JJ O
administration NN O
of IN O
cholecystokinin NN O
octapeptide NN O
sulphate NN O
ester NN O
( , O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
SE NN O
) -RRB- O
and CC O
nonsulphated JJ O
cholecystokinin NN O
octapeptide NN O
( , O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
NS NN O
) -RRB- O
enhanced VBN O
the DT O
latency NN O
of IN O
seizures NNS B-Disease
induced VBN O
by IN O
picrotoxin NN O
in IN O
mice NNS O
. . O
null null null-Disease
Experiments NNS O
with IN O
N NN O
- HYPH O
and CC O
C NN O
- HYPH O
terminal JJ O
fragments NNS O
revealed VBD O
that IN O
the DT O
C NNP O
- HYPH O
terminal JJ O
tetrapeptide NN O
( -LRB- O
CCK NNP O
- HYPH O
5 CD O
- HYPH O
8 CD O
) -RRB- O
was VBD O
the DT O
active JJ O
centre NN O
of IN O
the DT O
CCK NNP O
octapeptide NN O
molecule NN O
. . O
null null null-Disease
The DT O
analogues NNS O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
SE NNP O
and CC O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
NS NN O
( HYPH O
dose NN O
range NN O
0 CD O
. . O
2 CD O
- HYPH O
6 CD O
. . O
4 CD O
mumol NN O
/ SYM O
kg NN O
) -RRB- O
and CC O
caerulein NN O
dose NN O
range NN O
0 CD O
. . O
1 CD O
- SYM O
0 CD O
. . O
8 CD O
mumol NN O
/ SYM O
kg NN O
) -RRB- O
showed VBN O
bell NN O
- HYPH O
shaped JJ O
dose NN O
- HYPH O
effect NN O
curves NNS O
, , O
with IN O
the DT O
greatest JJS O
maximum JJ O
inhibition NN O
for IN O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
NS NNP O
. . O
null null null-Disease
The DT O
peptide NN O
CCK NNP O
- HYPH O
5 CD O
- HYPH O
8 CD O
had VBD O
weak JJ O
anticonvulsant JJ O
activity NN O
in IN O
comparison NN O
to IN O
the DT O
octapeptides NNS O
, , O
3 CD O
. . O
2 CD O
mumol NN O
/ SYM O
kg NNS O
and CC O
larger JJR O
doses NNS O
of IN O
the DT O
reference NN O
drug NN O
, , O
diazepam NN O
, , O
totally RB O
prevented VBN O
picrotoxin NN O
- HYPH O
induced VBN O
seizures NNS B-Disease
and CC O
mortality NN O
. . O
null null null-Disease
The DT O
maximum JJ O
effect NN O
of IN O
the DT O
peptides NNS O
tested VBN O
was VBD O
less JJR O
than IN O
that DT O
of IN O
diazepam NN O
. . O
null null null-Disease
Experiments NNS O
with IN O
analogues NNS O
and CC O
derivatives NNS O
of IN O
CCK NNP O
- HYPH O
5 CD O
- HYPH O
8 CD O
demonstrated VBD O
that IN O
the DT O
effectiveness NN O
of IN O
the DT O
beta NN O
- HYPH O
alanyl NN O
derivatives NNS O
of IN O
CCK NNP O
- HYPH O
5 CD O
- HYPH O
8 CD O
were VBD O
enhanced VBN O
and CC O
that IN O
they PRP O
were VBD O
equipotent JJ O
with IN O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
SE NNP O
. . O
null null null-Disease
Of IN O
the DT O
CCK NNP O
- HYPH O
2 CD O
- SYM O
8 CD O
analogues NNS O
, , O
Ser NNP O
( -LRB- O
SO3H NNP O
) , O
7 CD O
- HYPH O
Ac NN O
- HYPH O
CCK NNP O
- HYPH O
2 CD O
- SYM O
8 CD O
- HYPH O
SE NN O
and CC O
Thr NNP O
( -LRB- O
SO3H NNP O
) SYM O
7 CD O
- HYPH O
Ac NN O
- HYPH O
CCK NNP O
- HYPH O
2 CD O
- HYPH O
8 CD O
- HYPH O
SE NN O
and CC O
Hyp NNP O
( , O
SO3H NNP O
) -RRB- O
- : O
Ac IN O
- HYPH O
CCK NNP O
- HYPH O
2 CD O
- HYPH O
8 CD O
- HYPH O
SE NN O
were VBD O
slightly RB O
more RBR O
active JJ O
than IN O
CCK NNP O
- HYPH O
8 CD O
- HYPH O
SE NN O
. . O
null null null-Disease
Vasopressin NNP O
as IN O
a DT O
possible JJ O
contributor NN O
to IN O
hypertension NN B-Disease
. . O
null null null-Disease
The DT O
role NN O
of IN O
vasopressin NN O
as IN O
a DT O
pressor NN O
agent NN O
to IN O
the DT O
hypertensive JJ B-Disease
process NN O
was VBD O
examined VBN O
. . O
null null null-Disease
Vasopressin NNP O
plays VBZ O
a DT O
major JJ O
role NN O
in IN O
the DT O
pathogenesis NN O
of IN O
DOCA NNP O
- HYPH O
salt NN O
hypertension NN B-Disease
, , O
since IN O
the DT O
elevation NN O
of IN O
blood NN O
pressure NN O
was VBD O
not RB O
substantial JJ O
in IN O
the DT O
rats NNS O
with IN O
lithium NN O
- HYPH O
treated VBN O
diabetes NNS B-Disease
insipidus NN I-Disease
after IN O
DOCA NNP O
- HYPH O
salt NN O
treatment NN O
. . O
null null null-Disease
Administration NN O
of IN O
DDAVP NNP O
which WDT O
has VBZ O
antidiuretic JJ O
action NN O
but CC O
minimal JJ O
vasopressor NN O
effect NN O
failed VBD O
to TO O
increase VB O
blood NN O
pressure NN O
to IN O
the DT O
levels NNS O
observed VBN O
after IN O
administration NN O
of IN O
AVP NNP O
. . O
null null null-Disease
Furthermore RB O
, , O
the DT O
pressor NN O
action NN O
of IN O
vasopressin NN O
appears VBZ O
to TO O
be VB O
important JJ O
in IN O
the DT O
development NN O
of IN O
this DT O
model NN O
of IN O
hypertension NN B-Disease
, , O
since IN O
the DT O
enhanced JJ O
pressor NN O
responsiveness NN O
to IN O
the DT O
hormone NN O
was VBD O
observed VBN O
in IN O
the DT O
initial JJ O
stage NN O
of IN O
hypertension NN B-Disease
. . O
null null null-Disease
Increased VBN O
secretion NN O
of IN O
vasopressin NN O
from IN O
neurohypophysis NN O
also RB O
promotes VBZ O
the DT O
function NN O
of IN O
the DT O
hormone NN O
as IN O
a DT O
pathogenetic JJ O
factor NN O
in IN O
hypertension NN B-Disease
. . O
null null null-Disease
An DT O
unproportional JJ O
release NN O
of IN O
vasopressin NN O
compared VBN O
to IN O
plasma NN O
osmolality NN O
may MD O
be VB O
induced VBN O
by IN O
the DT O
absence NN O
of IN O
an DT O
adjusting VBG O
control NN O
of IN O
angiotensin NN O
II NN O
forming NN O
and CC O
receptor NN O
binding NN O
capacity NN O
for IN O
sodium NN O
balance NN O
in IN O
the DT O
brain NN O
. . O
null null null-Disease
However RB O
, , O
the DT O
role NN O
of IN O
vasopressin NN O
remains VBZ O
to TO O
be VB O
determined VBN O
in IN O
human JJ O
essential JJ O
hypertension NN B-Disease
. . O
null null null-Disease
Toxic JJ B-Disease
hepatitis NN I-Disease
induced VBN O
by IN O
disulfiram NN O
in IN O
a DT O
non AFX O
- HYPH O
alcoholic NN O
. . O
null null null-Disease
A DT O
reversible JJ O
toxic JJ B-Disease
liver NN I-Disease
damage NN I-Disease
was VBD O
observed VBN O
in IN O
a DT O
non AFX O
- HYPH O
alcoholic JJ O
woman NN O
treated VBN O
with IN O
disulfiram NN O
. . O
null null null-Disease
The DT O
causative JJ O
relationship NN O
was VBD O
proven VBN O
by IN O
challenge NN O
. . O
null null null-Disease
Atrial JJ B-Disease
thrombosis NN I-Disease
involving VBG O
the DT O
heart NN O
of IN O
F NNP O
- HYPH O
344 CD O
rats NNS O
ingesting VBG O
quinacrine NN O
hydrochloride NN O
. . O
null null null-Disease
Quinacrine NN O
hydrochloride NN O
is VBZ O
toxic JJ O
for IN O
the DT O
heart NN O
of IN O
F NNP O
- HYPH O
344 CD O
rats NNS O
. . O
null null null-Disease
Rats NNS O
treated VBN O
with IN O
500 CD O
ppm NN O
quinacrine NN O
hydrochloride NN O
in IN O
the DT O
diet NN O
all DT O
developed VBD O
a DT O
high JJ O
incidence NN O
of IN O
left VBN O
atrial JJ B-Disease
thrombosis NN I-Disease
. . O
null null null-Disease
The DT O
lesion NN O
was VBD O
associated VBN O
with IN O
cardiac JJ B-Disease
hypertrophy NN I-Disease
and CC O
dilatation NN O
and CC O
focal JJ O
myocardial JJ B-Disease
degeneration NN I-Disease
. . O
null null null-Disease
Rats NNS O
died VBD O
from IN O
cardiac JJ B-Disease
hypertrophy NN I-Disease
with IN O
severe JJ O
acute JJ O
and CC O
chronic JJ O
congestion NN O
of IN O
the DT O
lungs NNS O
, , O
liver NN O
, , O
and CC O
other JJ O
organs NNS O
. . O
null null null-Disease
Seventy CD O
percent NN O
of IN O
rats NNS O
given VBN O
250 CD O
ppm NN O
quinacrine NN O
hydrochloride NN O
and CC O
1 CD O
, , O
000 CD O
ppm NN O
sodium NN O
nitrite NN O
simultaneously RB O
in IN O
the DT O
diet NN O
had VBD O
thrombosis NN B-Disease
of IN O
the DT O
atria NN O
of IN O
the DT O
heart NN O
, , O
while IN O
untreated JJ O
control NN O
rats NNS O
in IN O
this DT O
laboratory NN O
did VBD O
not RB O
have VB O
atrial JJ B-Disease
thrombosis NN I-Disease
. . O
null null null-Disease
Sodium NN O
nitrite NN O
in IN O
combination NN O
with IN O
quinacrine NN O
hydrochloride NN O
appeared VBD O
to TO O
have VB O
no DT O
additional JJ O
effect NN O
. . O
null null null-Disease
Alternating VBG B-Disease
sinus NN I-Disease
rhythm NN I-Disease
and CC O
intermittent JJ O
sinoatrial JJ B-Disease
block NN I-Disease
induced VBN O
by IN O
propranolol NN O
. . O
null null null-Disease
Alternating VBG B-Disease
sinus NN I-Disease
rhythm NN I-Disease
and CC O
intermittent JJ O
sinoatrial JJ B-Disease
( , I-Disease
S NNP I-Disease
- HYPH I-Disease
A NN I-Disease
) -RRB- I-Disease
block NN I-Disease
was VBD O
observed VBN O
in IN O
a DT O
57 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
, , O
under IN O
treatment NN O
for IN O
angina NN B-Disease
with IN O
80 CD O
mg NN O
propranolol NN O
daily RB O
. . O
null null null-Disease
The DT O
electrocardiogram NN O
showed VBD O
alternation NN O
of IN O
long JJ O
and CC O
short JJ O
P NN O
- HYPH O
P NN O
intervals NNS O
and CC O
occasional JJ O
pauses NNS O
. . O
null null null-Disease
These DT O
pauses NNS O
were VBD O
always RB O
preceded VBN O
by IN O
the DT O
short JJ O
P NN O
- HYPH O
P NN O
intervals NNS O
and CC O
were VBD O
usually RB O
followed VBN O
by IN O
one CD O
or CC O
two CD O
P NN O
- HYPH O
P NN O
intervals NNS O
of IN O
0 CD O
. . O
92 CD O
- HYPH O
0 CD O
. . O
95 CD O
s NNS O
representing VBG O
the DT O
basic JJ O
sinus NN O
cycle NN O
. . O
null null null-Disease
Following VBG O
these DT O
basic JJ O
sinus JJ O
cycles NNS O
, , O
alternating VBG B-Disease
rhythm NN I-Disease
started VBD O
with IN O
the DT O
longer JJR O
P NNP O
- HYPH O
P NN O
interval NN O
. . O
null null null-Disease
The DT O
long JJ O
P NN O
- HYPH O
P NN O
intervals NNS O
ranged VBD O
between IN O
1 CD O
. . O
04 CD O
- HYPH O
1 CD O
. . O
12 CD O
s NNS O
and CC O
the DT O
short JJ O
P NN O
- HYPH O
P NN O
intervals NNS O
between IN O
0 CD O
. . O
80 CD O
- SYM O
0 CD O
. . O
84 CD O
s NNS O
, , O
respectively RB O
. . O
null null null-Disease
The DT O
duration NN O
of IN O
the DT O
pauses NNS O
were VBD O
equal JJ O
or CC O
almost RB O
equal JJ O
to IN O
one CD O
short JJ O
plus CC O
one CD O
long JJ O
P NN O
- HYPH O
P NN O
interval NN O
or CC O
to IN O
twice PDT O
the DT O
basic JJ O
sinus NN O
cycle NN O
. . O
null null null-Disease
In IN O
one CD O
recording NN O
a DT O
short JJ O
period NN O
of IN O
regular JJ O
sinus NN O
rhythm NN O
with IN O
intermittent JJ O
2 CD O
/ SYM O
1 CD O
S NN B-Disease
- HYPH I-Disease
A NN I-Disease
block NN I-Disease
was VBD O
observed VBN O
. . O
null null null-Disease
This DT O
short JJ O
period NN O
of IN O
sinus JJ O
rhythm NN O
was VBD O
interrupted VBN O
by IN O
sudden JJ O
prolongation NN O
of IN O
the DT O
P NNP O
- HYPH O
P NN O
interval NN O
starting VBG O
the DT O
alternative JJ O
rhythm NN O
. . O
null null null-Disease
There EX O
were VBD O
small JJ O
changes NNS O
in IN O
the DT O
shape NN O
of IN O
the DT O
P NNP O
waves NNS O
and CC O
P NN O
- HYPH O
R NN O
intervals NNS O
. . O
null null null-Disease
S NNP O
- HYPH O
A DT O
conduction NN O
through IN O
two CD O
pathways NNS O
, , O
the DT O
first JJ O
with IN O
2 CD O
/ SYM O
1 CD O
block NN O
the DT O
second JJ O
having VBG O
0 CD O
. . O
12 CD O
- SYM O
0 CD O
. . O
14 CD O
s NNS O
longer JJR O
conduction NN O
time NN O
and CC O
with IN O
occasional JJ O
2 CD O
/ SYM O
1 CD O
block NN O
was VBD O
proposed VBN O
for IN O
the DT O
explanation NN O
of IN O
the DT O
alternating JJ O
P NN O
- HYPH O
P NN O
interval NN O
and CC O
other JJ O
electrocardiographic JJ O
features NNS O
seen VBN O
. . O
null null null-Disease
Atropine NN O
1 CD O
mg NN O
given VBN O
intravenously RB O
resulted VBD O
in IN O
shortening NN O
of IN O
all DT O
P NN O
- HYPH O
P NN O
intervals NNS O
without IN O
changing VBG O
the DT O
rhythm NN O
. . O
null null null-Disease
The DT O
abnormal JJ O
rhythm NN O
disappeared VBD O
with IN O
the DT O
withdrawal NN O
of IN O
propranolol NN O
and CC O
when WRB O
the DT O
drug NN O
was VBD O
restarted VBN O
a DT O
2 CD O
/ SYM O
1 CD O
S NN B-Disease
- HYPH I-Disease
A NN I-Disease
block NN I-Disease
was VBD O
seen VBN O
. . O
null null null-Disease
This DT O
was VBD O
accepted VBN O
as IN O
evidence NN O
for IN O
propranolol NN O
being VBG O
the DT O
cause NN O
of IN O
this DT O
conduction NN B-Disease
disorder NN I-Disease
. . O
null null null-Disease
Antitumor NN O
effect NN O
, , O
cardiotoxicity NN B-Disease
, , O
and CC O
nephrotoxicity NN B-Disease
of IN O
doxorubicin NN O
in IN O
the DT O
IgM NNP O
solid JJ O
immunocytoma NN B-Disease
- HYPH O
bearing VBG O
LOU NNP O
/ SYM O
M NNP O
/ SYM O
WSL NNP O
rat NN O
. . O
null null null-Disease
Antitumor NN O
activity NN O
, , O
cardiotoxicity NN B-Disease
, , O
and CC O
nephrotoxicity NN B-Disease
induced VBN O
by IN O
doxorubicin NN O
were VBD O
studied VBN O
in IN O
LOU NNP O
/ SYM O
M NNP O
/ SYM O
WSL NNP O
inbred NN O
rats NNS O
each DT O
bearing VBG O
a DT O
transplantable JJ O
solid JJ O
IgM NNP O
immunocytoma NN B-Disease
. . O
null null null-Disease
Animals NNS O
with IN O
a DT O
tumor NN B-Disease
( , O
diameter NN O
, , O
15 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
3 CD O
. . O
3 CD O
mm NN O
) -RRB- O
were VBD O
treated VBN O
with IN O
iv FW O
injections NNS O
of IN O
doxorubicin NN O
on IN O
5 CD O
consecutive JJ O
days NNS O
, , O
followed VBN O
by IN O
1 CD O
weekly JJ O
injection NN O
for IN O
7 CD O
weeks NNS O
( , O
dose NN O
range NN O
, , O
0 CD O
. . O
015 CD O
- HYPH O
4 CD O
. . O
0 CD O
mg NN O
/ SYM O
kg NN O
body NN O
wt NN O
) -RRB- O
. . O
null null null-Disease
Tumor NN B-Disease
regression NN O
was VBD O
observed VBN O
with IN O
0 CD O
. . O
5 CD O
mg NN O
doxorubicin NN O
/ SYM O
kg NN O
. . O
null null null-Disease
Complete JJ O
disappearance NN O
of IN O
the DT O
tumor NN B-Disease
was VBD O
induced VBN O
with IN O
1 CD O
. . O
0 CD O
mg NN O
doxorubicin NN O
/ SYM O
kg NN O
. . O
null null null-Disease
Histologic JJ O
evidence NN O
of IN O
cardiotoxicity NN B-Disease
scored VBD O
as IN O
grade NN O
III NNP O
was VBD O
only RB O
observed VBN O
at IN O
a DT O
dose NN O
of IN O
1 CD O
. . O
0 CD O
mg NN O
doxorubicin NN O
/ SYM O
kg NN O
. . O
null null null-Disease
Light JJ O
microscopic JJ O
evidence NN O
of IN O
renal JJ B-Disease
damage NN I-Disease
was VBD O
seen VBN O
above IN O
a DT O
dose NN O
of IN O
0 CD O
. . O
5 CD O
mg NN O
doxorubicin NN O
/ SYM O
kg NN O
, , O
which WDT O
resulted VBD O
in IN O
albuminuria NN B-Disease
and CC O
very RB O
low JJ O
serum NN O
albumin NN O
levels NNS O
. . O
null null null-Disease
In IN O
the DT O
group NN O
that WDT O
received VBD O
1 CD O
. . O
0 CD O
mg NN O
doxorubicin NN O
/ SYM O
kg NN O
, , O
the DT O
serum JJ O
albumin NN O
level NN O
decreased VBD O
from IN O
33 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- HYPH O
4 CD O
. . O
1 CD O
to IN O
1 CD O
. . O
5 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
5 CD O
g NN O
/ SYM O
liter NN O
. . O
null null null-Disease
Ascites NNS B-Disease
and CC O
hydrothorax NN B-Disease
were VBD O
observed VBN O
simultaneously RB O
. . O
null null null-Disease
The DT O
same JJ O
experiments NNS O
were VBD O
performed VBN O
with IN O
non JJ O
- HYPH O
tumor NN B-Disease
- HYPH O
bearing VBG O
rats NNS O
, , O
in IN O
which WDT O
no DT O
major JJ O
differences NNS O
were VBD O
observed VBN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
antitumor NN O
activity NN O
, , O
cardiotoxicity NN B-Disease
, , O
and CC O
nephrotoxicity NN B-Disease
were VBD O
studied VBN O
simultaneously RB O
in IN O
the DT O
same JJ O
LOU NNP O
/ SYM O
M NNP O
/ SYM O
WSL NNP O
rat NN O
. . O
null null null-Disease
Albuminuria NNP B-Disease
due IN O
to IN O
renal JJ B-Disease
damage NN I-Disease
led VBN O
to IN O
extremely RB O
low JJ O
serum NN O
albumin NN O
levels NNS O
, , O
so IN O
ascites NNS B-Disease
and CC O
hydrothorax NN B-Disease
were VBD O
not RB O
necessarily RB O
a DT O
consequence NN O
of IN O
the DT O
observed VBN O
cardiomyopathy NN B-Disease
. . O
null null null-Disease
Intraoperative JJ O
bradycardia NN B-Disease
and CC O
hypotension NN B-Disease
associated VBN O
with IN O
timolol NN O
and CC O
pilocarpine NN O
eye NN O
drops NNS O
. . O
null null null-Disease
A DT O
69 CD O
- HYPH O
yr NN O
- HYPH O
old JJ O
man NN O
, , O
who WP O
was VBD O
concurrently RB O
being VBG O
treated VBN O
with IN O
pilocarpine NN O
nitrate NN O
and CC O
timolol NN O
maleate NN O
eye NN O
drops NNS O
, , O
developed VBD O
a DT O
bradycardia NN B-Disease
and CC O
became VBD O
hypotensive JJ B-Disease
during IN O
halothane NN O
anaesthesia NN O
. . O
null null null-Disease
Both CC O
timolol NN O
and CC O
pilocarpine NN O
were VBD O
subsequently RB O
identified VBN O
in IN O
a DT O
24 CD O
- HYPH O
h NN O
collection NN O
of IN O
urine NN O
. . O
null null null-Disease
Timolol NNP O
( : O
but CC O
not RB O
pilocarpine NN O
) , O
was VBD O
detected VBN O
in IN O
a DT O
sample NN O
of IN O
plasma NN O
removed VBN O
during IN O
surgery NN O
; : O
the DT O
plasma NN O
concentration NN O
of IN O
timolol NN O
( , O
2 CD O
. . O
6 CD O
ng CD O
ml NN O
- HYPH O
1 CD O
) -RRB- O
was VBD O
consistent JJ O
with IN O
partial JJ O
beta NN O
- HYPH O
adrenoceptor NN O
blockade NN O
. . O
null null null-Disease
It PRP O
is VBZ O
postulated VBN O
that IN O
this DT O
action NN O
may MD O
have VB O
been VBN O
enhanced VBN O
during IN O
halothane NN O
anaesthesia NN O
with IN O
resultant JJ O
bradycardia NN B-Disease
and CC O
hypotension NN B-Disease
. . O
null null null-Disease
Pilocarpine NNP O
may MD O
have VB O
had VBN O
a DT O
contributory JJ O
effect NN O
. . O
null null null-Disease
Succinylcholine NN O
apnoea NN B-Disease
: : O
attempted VBN O
reversal NN O
with IN O
anticholinesterases NNS O
. . O
null null null-Disease
Anticholinesterases NNS O
were VBD O
administered VBN O
in IN O
an DT O
attempt NN O
to TO O
antagonize VB O
prolonged VBN O
neuromuscular JJ B-Disease
blockade NN I-Disease
following VBG O
the DT O
administration NN O
of IN O
succinylcholine NN O
in IN O
a DT O
patient NN O
later RB O
found VBN O
to TO O
be VB O
homozygous JJ O
for IN O
atypical JJ O
plasma NN O
cholinesterase NN O
. . O
null null null-Disease
Edrophonium NN O
10 CD O
mg NN O
, , O
given VBN O
74 CD O
min NN O
after IN O
succinylcholine NN O
, , O
when WRB O
train NN O
- HYPH O
of IN O
- HYPH O
four CD O
stimulation NN O
was VBD O
characteristic JJ O
of IN O
phase NN O
II NN O
block NN O
, , O
produced VBD O
partial JJ O
antagonism NN O
which WDT O
was VBD O
not RB O
sustained VBN O
. . O
null null null-Disease
Repeated VBN O
doses NNS O
of IN O
edrophonium NN O
to IN O
70 CD O
mg NN O
and CC O
neostigmine NN O
to IN O
2 CD O
. . O
5 CD O
mg NN O
did VBD O
not RB O
antagonize VB O
or CC O
augment VB O
the DT O
block NN O
. . O
null null null-Disease
Spontaneous JJ O
respiration NN O
recommenced VBD O
200 CD O
min NN O
after IN O
succinylcholine NN O
administration NN O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
anticholinesterases NNS O
are VBP O
only RB O
partially RB O
effective JJ O
in IN O
restoring VBG O
neuromuscular JJ O
function NN O
in IN O
succinylcholine NN O
apnoea NN B-Disease
despite IN O
muscle NN O
twitch NN O
activity NN O
typical JJ O
of IN O
phase NN O
II NN O
block NN O
. . O
null null null-Disease
Effect NN O
of IN O
doxorubicin NN O
on IN O
[ -LRB- O
omega NN O
- HYPH O
I CD O
- HYPH O
131 CD O
] -RRB- O
heptadecanoic NN O
acid NN O
myocardial JJ O
scintigraphy NN O
and CC O
echocardiography NN O
in IN O
dogs NNS O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
serial JJ O
treatment NN O
with IN O
doxorubicin NN O
on IN O
dynamic JJ O
myocardial JJ O
scintigraphy NN O
with IN O
[ -LRB- O
omega NN O
- HYPH O
I NNP O
- HYPH O
131 CD O
] -RRB- O
heptadecanoic NN O
acid NN O
( -LRB- O
I CD O
- HYPH O
131 CD O
HA NN O
) -RRB- O
, , O
and CC O
on IN O
global JJ O
left JJ O
- HYPH O
ventricular JJ O
function NN O
determined VBN O
echocardiographically RB O
, , O
were VBD O
studied VBN O
in IN O
a DT O
group NN O
of IN O
nine CD O
mongrel JJ O
dogs NNS O
. . O
null null null-Disease
Total JJ O
extractable JJ O
myocardial JJ O
lipid NN O
was VBD O
compared VBN O
postmortem NN O
between IN O
a DT O
group NN O
of IN O
control NN O
dogs NNS O
and CC O
doxorubicin NN O
- HYPH O
treated VBN O
dogs NNS O
. . O
null null null-Disease
A DT O
significant JJ O
and CC O
then RB O
progressive JJ O
fall NN O
in IN O
global JJ O
LV NN O
function NN O
was VBD O
observed VBN O
at IN O
a DT O
cumulative JJ O
doxorubicin NN O
dose NN O
of IN O
4 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
A DT O
significant JJ O
increase NN O
in IN O
the DT O
myocardial JJ O
t1 CD O
/ SYM O
2 CD O
of IN O
the DT O
I NNP O
- HYPH O
131 CD O
HA NN O
was VBD O
observed VBN O
only RB O
at IN O
a DT O
higher JJR O
cumulative JJ O
dose NN O
, , O
10 CD O
mg NN O
/ SYM O
kg NN O
. . O
null null null-Disease
No DT O
significant JJ O
alteration NN O
in IN O
total JJ O
extractable JJ O
myocardial JJ O
lipids NNS O
was VBD O
observed VBN O
between IN O
control NN O
dogs NNS O
and CC O
those DT O
treated VBN O
with IN O
doxorubicin NN O
. . O
null null null-Disease
Our PRP$ O
findings NNS O
suggest VBP O
that IN O
the DT O
changes NNS O
leading VBG O
to IN O
an DT O
alteration NN O
of IN O
myocardial JJ O
dynamic JJ O
imaging NN O
with IN O
I NNP O
- HYPH O
131 CD O
HA NN O
are VBP O
not RB O
the DT O
initiating VBG O
factor NN O
in IN O
doxorubicin NN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
Hemodynamics NN O
and CC O
myocardial JJ O
metabolism NN O
under IN O
deliberate JJ O
hypotension NN B-Disease
. . O
null null null-Disease
An DT O
experimental JJ O
study NN O
in IN O
dogs NNS O
. . O
null null null-Disease
Coronary JJ O
blood NN O
flow NN O
, , O
cardiac JJ O
work NN O
and CC O
metabolism NN O
were VBD O
studied VBN O
in IN O
dogs NNS O
under IN O
sodium NN O
nitroprusside NN O
( , O
SNP NNP O
) -RRB- O
and CC O
trimetaphan NN O
( -LRB- O
TMP NN O
) -RRB- O
deliberate JJ O
hypotension NN B-Disease
( : O
20 CD O
% NN O
and CC O
40 CD O
% NN O
mean JJ O
pressure NN O
decrease NN O
from IN O
baseline NN O
) -RRB- O
. . O
null null null-Disease
Regarding VBG O
the DT O
effects NNS O
of IN O
drug NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
on IN O
coronary JJ O
blood NN O
flow NN O
, , O
aortic JJ O
and CC O
coronary JJ O
sinus NN O
metabolic JJ O
data NNS O
( , O
pH NN O
, , O
pO2 NN O
, , O
pCO2 NN O
) -RRB- O
we PRP O
could MD O
confirm VB O
that IN O
nitroprusside NN O
hypotension NN B-Disease
could MD O
be VB O
safely RB O
used VBN O
to IN O
30 CD O
% NN O
mean JJ O
blood NN O
pressure NN O
decrease NN O
from IN O
control NN O
, , O
trimetaphan NN O
hypotension NN B-Disease
to IN O
20 CD O
% NN O
mean JJ O
blood NN O
pressure NN O
decrease NN O
. . O
null null null-Disease
Cardiac JJ O
work NN O
was VBD O
significantly RB O
reduced VBN O
during IN O
SNP NNP O
hypotension NN B-Disease
. . O
null null null-Disease
Myocardial JJ O
O2 NN O
consumption NN O
and CC O
O2 NN O
availability NN O
were VBD O
directly RB O
dependent JJ O
on IN O
the DT O
coronary JJ O
perfusion NN O
. . O
null null null-Disease
Careful JJ O
invasive JJ O
monitoring NN O
of IN O
the DT O
blood NN O
pressure NN O
, , O
blood NN O
gases NNS O
and CC O
of IN O
the DT O
ECG NNP O
ST NNP O
- HYPH O
T NNP O
segment NN O
is VBZ O
mandatory JJ O
. . O
null null null-Disease
Evidence NN O
for IN O
a DT O
selective JJ O
brain NN O
noradrenergic JJ O
involvement NN O
in IN O
the DT O
locomotor NN O
stimulant JJ O
effects NNS O
of IN O
amphetamine NN O
in IN O
the DT O
rat NN O
. . O
null null null-Disease
Male JJ O
rats NNS O
received VBD O
the DT O
noradrenaline JJ O
neurotoxin NN O
DSP4 NNP O
( : O
50 CD O
mg NNS O
/ SYM O
kg CD O
) SYM O
7 CD O
days NNS O
prior RB O
to IN O
injection NN O
of IN O
D NN O
- HYPH O
amphetamine NN O
( : O
10 CD O
or CC O
40 CD O
mumol NN O
/ SYM O
kg NN O
i CD O
. . O
p NN O
. . O
) -RRB- O
. . O
null null null-Disease
The DT O
hyperactivity NN B-Disease
induced VBN O
by IN O
D NNP O
- HYPH O
amphetamine NN O
( , O
10 CD O
mumol NN O
/ SYM O
kg NNS O
) -RRB- O
was VBD O
significantly RB O
reduced VBN O
by IN O
DSP4 NNP O
pretreatment NN O
. . O
null null null-Disease
However RB O
, , O
the DT O
increased JJ O
rearings NNS O
and CC O
the DT O
amphetamine NN O
- HYPH O
induced VBN O
stereotypies NNS B-Disease
were VBD O
not RB O
blocked VBN O
by IN O
pretreatment NN O
with IN O
DSP4 NNP O
. . O
null null null-Disease
The DT O
reduction NN O
of IN O
amphetamine NN O
hyperactivity NN B-Disease
induced VBN O
by IN O
DSP4 NNP O
was VBD O
blocked VBN O
by IN O
pretreatment NN O
with IN O
the DT O
noradrenaline NN O
- HYPH O
uptake NN O
blocking NN O
agent NN O
, , O
desipramine NN O
, , O
which WDT O
prevents VBZ O
the DT O
neurotoxic JJ B-Disease
action NN O
of IN O
DSP4 NNP O
. . O
null null null-Disease
The DT O
present JJ O
results NNS O
suggest VBP O
a DT O
selective JJ O
involvement NN O
of IN O
central JJ O
noradrenergic JJ O
neurones NNS O
in IN O
the DT O
locomotor NN O
stimulant JJ O
effect NN O
of IN O
amphetamine NN O
in IN O
the DT O
rat NN O
. . O
null null null-Disease
Accelerated JJ B-Disease
junctional JJ I-Disease
rhythms NNS I-Disease
during IN O
oral JJ O
verapamil NN O
therapy NN O
. . O
null null null-Disease
This DT O
study NN O
examined VBD O
the DT O
frequency NN O
of IN O
atrioventricular JJ O
( , O
AV NN O
) -RRB- O
dissociation NN O
and CC O
accelerated VBN B-Disease
junctional JJ I-Disease
rhythms NNS I-Disease
in IN O
59 CD O
patients NNS O
receiving VBG O
oral JJ O
verapamil NN O
. . O
null null null-Disease
Accelerated JJ B-Disease
junctional JJ I-Disease
rhythms NNS I-Disease
and CC O
AV NN O
dissociation NN O
were VBD O
frequent JJ O
in IN O
patients NNS O
with IN O
supraventricular JJ B-Disease
tachyarrhythmias NNS I-Disease
, , O
particularly RB O
AV NN O
nodal JJ O
reentry NN O
. . O
null null null-Disease
Verapamil NNP O
administration NN O
to IN O
these DT O
patients NNS O
led VBD O
to IN O
an DT O
asymptomatic JJ O
increase NN O
in IN O
activity NN O
of IN O
these DT O
junctional JJ O
pacemakers NNS O
. . O
null null null-Disease
In IN O
patients NNS O
with IN O
various JJ O
chest NN B-Disease
pain NN I-Disease
syndromes NNS O
, , O
verapamil NN O
neither CC O
increased VBD O
the DT O
frequency NN O
of IN O
junctional JJ O
rhythms NNS O
nor CC O
suppressed VBD O
their PRP$ O
role NN O
as IN O
escape NN O
rhythms NNS O
under IN O
physiologically RB O
appropriate JJ O
circumstances NNS O
. . O
null null null-Disease
Interstrain NN O
variation NN O
in IN O
acute JJ O
toxic JJ O
response NN O
to IN O
caffeine NN O
among IN O
inbred JJ O
mice NNS O
. . O
null null null-Disease
Acute JJ O
toxic JJ O
dosage NN O
- HYPH O
dependent JJ O
behavioral JJ O
effects NNS O
of IN O
caffeine NN O
were VBD O
compared VBN O
in IN O
adult NN O
males NNS O
from IN O
seven CD O
inbred JJ O
mouse NN O
strains NNS O
( , O
A NNP O
/ SYM O
J NNP O
, , O
BALB NNP O
/ SYM O
cJ NNP O
, , O
CBA NNP O
/ SYM O
J NNP O
, , O
C3H NNP O
/ SYM O
HeJ NNP O
, , O
C57BL NNP O
/ SYM O
6J NNP O
, , O
DBA NNP O
/ SYM O
2J NNP O
, , O
SWR NNP O
/ SYM O
J NNP O
) -RRB- O
. . O
null null null-Disease
C57BL NNP O
/ SYM O
6J NNP O
, , O
chosen VBN O
as IN O
a DT O
"""" `` O
prototypic JJ O
"""" '' O
mouse NN O
strain NN O
, , O
was VBD O
used VBN O
to TO O
determine VB O
behavioral JJ O
responses NNS O
to IN O
a DT O
broad JJ O
range NN O
( : O
5 CD O
- SYM O
500 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
of IN O
caffeine NN O
doses NNS O
. . O
null null null-Disease
Five CD O
phenotypic JJ O
characteristics NNS O
- HYPH O
- HYPH O
locomotor NN O
activity NN O
, , O
righting NN O
ability NN O
, , O
clonic JJ B-Disease
seizure NN I-Disease
induction NN O
, , O
stress NN O
- HYPH O
induced VBN O
lethality NN O
, , O
death NN O
without IN O
external JJ O
stress NN O
- , O
- : O
were VBD O
scored VBN O
at IN O
various JJ O
caffeine NN O
doses NNS O
in IN O
drug NN O
- HYPH O
naive JJ O
animals NNS O
under IN O
empirically RB O
optimized VBN O
, , O
rigidly RB O
constant JJ O
experimental JJ O
conditions NNS O
. . O
null null null-Disease
Mice NNS O
( : O
n CD O
= SYM O
12 CD O
for IN O
each DT O
point NN O
) -RRB- O
received VBD O
single JJ O
IP NN O
injections NNS O
of IN O
a DT O
fixed VBN O
volume NN O
/ SYM O
g JJ O
body NN O
weight NN O
of IN O
physiological JJ O
saline NN O
carrier NN O
with IN O
or CC O
without IN O
caffeine NN O
in IN O
doses NNS O
ranging VBG O
from IN O
125 CD O
- SYM O
500 CD O
mg NNS O
/ SYM O
kg NN O
. . O
null null null-Disease
Loss NN O
of IN O
righting NN O
ability NN O
was VBD O
scored VBN O
at IN O
1 CD O
, , O
3 CD O
, , O
5 CD O
min NN O
post NN O
dosing NN O
and CC O
at IN O
5 CD O
min NN O
intervals NNS O
thereafter RB O
for IN O
20 CD O
min NN O
. . O
null null null-Disease
In IN O
the DT O
same JJ O
animals NNS O
the DT O
occurrence NN O
of IN O
clonic JJ B-Disease
seizures NNS I-Disease
was VBD O
scored VBN O
as IN O
to IN O
time NN O
of IN O
onset NN O
and CC O
severity NN O
for IN O
20 CD O
min NN O
after IN O
drug NN O
administration NN O
. . O
null null null-Disease
When WRB O
these DT O
proceeded VBD O
to IN O
tonic JJ B-Disease
seizures NNS I-Disease
, , O
death NN O
occurred VBD O
in IN O
less JJR O
than IN O
20 CD O
min NN O
. . O
null null null-Disease
Animals NNS O
surviving VBG O
for IN O
20 CD O
min NN O
were VBD O
immediately RB O
stressed VBN O
by IN O
a DT O
swim NN O
test NN O
in IN O
25 CD O
degrees NNS O
C NN O
water NN O
, , O
and CC O
death NN O
- HYPH O
producing VBG O
tonic JJ B-Disease
seizures NNS I-Disease
were VBD O
scored VBN O
for IN O
2 CD O
min NN O
. . O
null null null-Disease
In IN O
other JJ O
animals NNS O
locomotor NN O
activity NN O
was VBD O
measured VBN O
15 CD O
or CC O
60 CD O
min NN O
after IN O
caffeine NN O
administration NN O
. . O
null null null-Disease
By IN O
any DT O
single JJ O
behavioral JJ O
criterion NN O
or CC O
a DT O
combination NN O
of IN O
these DT O
criteria NNS O
, , O
marked VBN O
differences NNS O
in IN O
response NN O
to IN O
toxic JJ O
caffeine NN O
doses NNS O
were VBD O
observed VBN O
between IN O
strains NNS O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
behavioral JJ O
toxicity NN B-Disease
testing NN O
of IN O
alkylxanthines NNS O
in IN O
a DT O
single JJ O
mouse NN O
strain NN O
may MD O
be VB O
misleading JJ O
and CC O
suggest VB O
that IN O
toxic JJ O
responses NNS O
of IN O
the DT O
central JJ O
nervous JJ O
system NN O
to IN O
this DT O
class NN O
of IN O
compounds NNS O
are VBP O
genetically RB O
influenced VBN O
in IN O
mammals NNS O
. . O
null null null-Disease
Treatment NN O
of IN O
ovarian JJ B-Disease
cancer NN I-Disease
with IN O
a DT O
combination NN O
of IN O
cis NN O
- HYPH O
platinum NN O
, , O
adriamycin NN O
, , O
cyclophosphamide NN O
and CC O
hexamethylmelamine NN O
. . O
null null null-Disease
During IN O
the DT O
last JJ O
2 CD O
1 CD O
/ SYM O
2 CD O
years NNS O
, , O
38 CD O
patients NNS O
with IN O
ovarian JJ B-Disease
cancer NN I-Disease
were VBD O
treated VBN O
with IN O
a DT O
combination NN O
of IN O
cisplatinum NN O
( , O
CPDD NNP O
) -RRB- O
, , O
50 CD O
mg NNS O
/ SYM O
m2 NN O
, , O
adriamycin NN O
, , O
30 CD O
mg NN O
/ SYM O
m2 NN O
, , O
cyclophosphamide NN O
, , O
300 CD O
mg NNS O
/ SYM O
m2 CD O
, , O
on IN O
day NN O
1 CD O
; , O
and CC O
hexamethylmelamine NN O
( , O
HMM NNP O
) -RRB- O
, , O
6 CD O
mg NN O
/ SYM O
kg NN O
daily RB O
, , O
for IN O
14 CD O
days NNS O
. . O
null null null-Disease
Each DT O
course NN O
was VBD O
repeated VBN O
monthly RB O
. . O
null null null-Disease
2 CD O
patients NNS O
had VBD O
stage NN O
II NN O
, , O
14 CD O
stage NN O
III NN O
and CC O
22 CD O
stage NN O
IV NN O
disease NN O
. . O
null null null-Disease
14 CD O
of IN O
the DT O
38 CD O
patients NNS O
were VBD O
previously RB O
treated VBN O
with IN O
chemotherapy NN O
, , O
1 CD O
with IN O
radiation NN O
, , O
6 CD O
with IN O
both CC O
chemotherapy NN O
and CC O
radiation NN O
, , O
and CC O
17 CD O
did VBD O
not RB O
have VB O
any DT O
treatment NN O
before IN O
CPDD NNP O
combination NN O
. . O
null null null-Disease
31 CD O
of IN O
the DT O
38 CD O
cases NNS O
( SYM O
81 CD O
. . O
5 CD O
% NN O
) -RRB- O
demonstrated VBD O
objective JJ O
responses NNS O
lasting VBG O
for IN O
2 CD O
months NNS O
or CC O
more JJR O
. . O
null null null-Disease
These DT O
responses NNS O
were VBD O
partial JJ O
in IN O
19 CD O
and CC O
complete JJ O
in IN O
12 CD O
cases NNS O
. . O
null null null-Disease
Hematologic JJ B-Disease
toxicity NN I-Disease
was VBD O
moderate JJ O
and CC O
with IN O
reversible JJ O
anemia NN B-Disease
developing VBG O
in IN O
71 CD O
% NN O
of IN O
patients NNS O
. . O
null null null-Disease
Gastrointestinal JJ O
side NN O
effects NNS O
from IN O
CPDD NNP O
were VBD O
universal JJ O
. . O
null null null-Disease
HMM NNP O
gastrointestinal JJ B-Disease
toxicity NN I-Disease
necessitated VBD O
discontinuation NN O
of IN O
the DT O
drug NN O
in IN O
5 CD O
patients NNS O
. . O
null null null-Disease
Severe JJ O
nephrotoxicity NN B-Disease
was VBD O
observed VBN O
in IN O
2 CD O
patients NNS O
but CC O
was VBD O
reversible JJ O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
drug NN O
- HYPH O
related VBN O
deaths NNS O
. . O
null null null-Disease
Nontraumatic JJ O
dissecting VBG B-Disease
aneurysm NN I-Disease
of IN O
the DT O
basilar JJ O
artery NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
nontraumatic JJ O
dissecting VBG B-Disease
aneurysm NN I-Disease
of IN O
the DT O
basilar JJ O
artery NN O
in IN O
association NN O
with IN O
hypertension NN B-Disease
, , O
smoke NN O
, , O
and CC O
oral JJ O
contraceptives NNS O
is VBZ O
reported VBN O
in IN O
a DT O
young JJ O
female JJ O
patient NN O
with IN O
a DT O
locked VBN B-Disease
- HYPH I-Disease
in RP I-Disease
syndrome NN I-Disease
. . O
null null null-Disease
A DT O
method NN O
for IN O
the DT O
measurement NN O
of IN O
tremor NN B-Disease
, , O
and CC O
a DT O
comparison NN O
of IN O
the DT O
effects NNS O
of IN O
tocolytic JJ O
beta NN O
- HYPH O
mimetics NNS O
. . O
null null null-Disease
A DT O
method NN O
permitting VBG O
measurement NN O
of IN O
finger NN O
tremor NN B-Disease
as IN O
a DT O
displacement NN O
- HYPH O
time NN O
curve NN O
is VBZ O
described VBN O
, , O
using VBG O
a DT O
test NN O
system NN O
with IN O
simple JJ O
amplitude NN O
calibration NN O
. . O
null null null-Disease
The DT O
coordinates NNS O
of IN O
the DT O
inversion NN O
points NNS O
of IN O
the DT O
displacement NN O
- HYPH O
time NN O
curves NNS O
were VBD O
transferred VBN O
through IN O
graphical JJ O
input NN O
equipment NN O
to IN O
punched VBN O
tape NN O
. . O
null null null-Disease
By IN O
means NNS O
of IN O
a DT O
computer NN O
program NN O
, , O
periods NNS O
and CC O
amplitudes NNS O
of IN O
tremor NN B-Disease
oscillations NNS O
were VBD O
calculated VBN O
and CC O
classified JJ O
. . O
null null null-Disease
The DT O
event NN O
frequency NN O
for IN O
each DT O
class NN O
of IN O
periods NNS O
and CC O
amplitudes NNS O
was VBD O
determined VBN O
. . O
null null null-Disease
The DT O
actions NNS O
of IN O
fenoterol NN O
- HYPH O
hydrobromide NN O
, , O
ritodrin NN O
- HYPH O
HCl NNP O
and CC O
placebo NN O
given VBN O
to IN O
10 CD O
healthy JJ O
subjects NNS O
by IN O
intravenous JJ O
infusion NN O
in IN O
a DT O
double JJ O
- HYPH O
blind JJ O
crossover NN O
study NN O
were VBD O
tested VBN O
by IN O
this DT O
method NN O
. . O
null null null-Disease
At IN O
therapeutic JJ O
doses NNS O
both DT O
substances NNS O
raised VBD O
the DT O
mean JJ O
tremor NN B-Disease
amplitude NN O
to IN O
about RB O
three CD O
times NNS O
the DT O
control NN O
level NN O
. . O
null null null-Disease
At IN O
the DT O
same JJ O
time NN O
, , O
the DT O
mean JJ O
period NN O
within IN O
each DT O
class NN O
of IN O
amplitudes NNS O
shortened VBN O
by IN O
10 CD O
- HYPH O
- HYPH O
20 CD O
ms NNS O
, , O
whereas IN O
the DT O
mean JJ O
periods NNS O
calculated VBN O
from IN O
all DT O
oscillations NNS O
together RB O
did VBD O
not RB O
change VB O
significantly RB O
. . O
null null null-Disease
After IN O
the DT O
end NN O
of IN O
fenoterol NN O
- HYPH O
hydrobromide NN O
infusion NN O
, , O
tremor NN B-Disease
amplitudes NNS O
decreased VBD O
significantly RB O
faster RBR O
than IN O
those DT O
following VBG O
ritodrin NN O
- HYPH O
HCl NNP O
infusion NN O
. . O
null null null-Disease
Propylthiouracil NN O
- HYPH O
induced VBN O
hepatic JJ B-Disease
damage NN I-Disease
. . O
null null null-Disease
Two CD O
cases NNS O
of IN O
propylthiouracil NN O
- HYPH O
induced VBN O
liver NN B-Disease
damage NN I-Disease
have VBP O
been VBN O
observed VBN O
. . O
null null null-Disease
The DT O
first JJ O
case NN O
is VBZ O
of IN O
an DT O
acute JJ O
type NN O
of IN O
damage NN O
, , O
proven VBN O
by IN O
rechallenge NN O
; : O
the DT O
second JJ O
presents VBZ O
a DT O
clinical JJ O
and CC O
histologic JJ O
picture NN O
resembling VBG O
chronic JJ B-Disease
active JJ I-Disease
hepatitis NN I-Disease
, , O
with IN O
spontaneous JJ O
remission NN O
. . O
null null null-Disease
Studies NNS O
on IN O
the DT O
bradycardia NN B-Disease
induced VBN O
by IN O
bepridil NNP O
. . O
null null null-Disease
Bepridil NNP O
, , O
a DT O
novel JJ O
active JJ O
compound NN O
for IN O
prophylactic JJ O
treatment NN O
of IN O
anginal JJ B-Disease
attacks NNS I-Disease
, , O
induced VBD O
persistent JJ O
bradycardia NN B-Disease
and CC O
a DT O
non AFX O
- HYPH O
specific JJ O
anti JJ O
- HYPH O
tachycardial JJ B-Disease
effect NN O
, , O
the DT O
mechanisms NNS O
of IN O
which WDT O
were VBD O
investigated VBN O
in IN O
vitro FW O
and CC O
in IN O
vivo NN O
. . O
null null null-Disease
In IN O
vitro FW O
perfusion NN O
of IN O
bepridil NN O
in IN O
the DT O
life NN O
- HYPH O
support NN O
medium NN O
for IN O
isolated VBN O
sino JJ O
- HYPH O
atrial JJ O
tissue NN O
from IN O
rabbit NN O
heart NN O
, , O
caused VBD O
a DT O
reduction NN O
in IN O
action NN O
potential NN O
( , O
AP NN O
) -RRB- O
spike NN O
frequency NN O
( , O
recorded VBN O
by IN O
KCl NNP O
microelectrodes NNS O
) -RRB- O
starting VBG O
at IN O
doses NNS O
of IN O
5 CD O
X SYM O
10 CD O
( SYM O
- HYPH O
6 CD O
) SYM O
M NN O
. . O
null null null-Disease
This DT O
effect NN O
was VBD O
dose NN O
- HYPH O
dependent JJ O
up IN O
to IN O
concentrations NNS O
of IN O
5 CD O
X SYM O
10 CD O
( SYM O
- HYPH O
5 CD O
) SYM O
M NN O
, , O
whereupon WRB O
blockade NN O
of IN O
sinus NN O
activity NN O
set VBD O
in RP O
. . O
null null null-Disease
Bepridil NNP O
at IN O
a DT O
dose NN O
of IN O
5 CD O
X NN O
10 CD O
( SYM O
- HYPH O
6 CD O
) SYM O
M NN O
, , O
induced VBD O
a DT O
concomitant JJ O
reduction NN O
in IN O
AP NNP O
amplitude NN O
( , O
falling VBG O
from IN O
71 CD O
+ CD O
/ SYM O
- SYM O
8 CD O
mV NN O
to IN O
47 CD O
+ SYM O
/ SYM O
- SYM O
6 CD O
mV NN O
) -RRB- O
, , O
maximum JJ O
systolic JJ O
depolarization NN O
velocity NN O
( , O
phase NN O
0 CD O
) -RRB- O
which WDT O
fell VBD O
from IN O
1 CD O
. . O
85 CD O
+ NN O
/ SYM O
- SYM O
0 CD O
. . O
35 CD O
V NN O
/ SYM O
s NNS O
to IN O
0 CD O
. . O
84 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
28 CD O
V NN O
/ SYM O
s NN O
, , O
together RB O
with IN O
maximum JJ O
diastolic JJ O
depolarization NN O
velocity NN O
( , O
phase NN O
4 CD O
) -RRB- O
which WDT O
fell VBD O
from IN O
38 CD O
+ CD O
/ SYM O
- SYM O
3 CD O
mV NN O
/ SYM O
s NNS O
to IN O
24 CD O
+ CD O
/ SYM O
- SYM O
5 CD O
mV NN O
/ SYM O
s NN O
. . O
null null null-Disease
In IN O
vivo NN O
injection NN O
of IN O
bepridil NN O
at IN O
a DT O
dose NN O
of IN O
5 CD O
mg NN O
/ SYM O
kg NN O
( : O
i PRP O
. . O
v NN O
. . O
) -RRB- O
into IN O
6 CD O
anaesthetized JJ O
dogs NNS O
which WDT O
had VBD O
undergone VBN O
ablation NN O
of IN O
all PDT O
the DT O
extrinsic JJ O
cardiac JJ O
afferent JJ O
nerve JJ O
supply NN O
, , O
together RB O
with IN O
a DT O
bilateral JJ O
medullo NN O
- HYPH O
adrenalectomy NN O
, , O
caused VBD O
a DT O
marked JJ O
reduction NN O
in IN O
heart NN O
rate NN O
which WDT O
fell VBD O
from IN O
98 CD O
. . O
7 CD O
+ NN O
/ SYM O
- HYPH O
4 CD O
. . O
2 CD O
beats NNS O
/ SYM O
min NN O
to IN O
76 CD O
+ CD O
/ SYM O
- SYM O
5 CD O
. . O
3 CD O
beats NNS O
/ SYM O
min NN O
sustained VBN O
for IN O
more JJR O
than IN O
45 CD O
min NN O
. . O
null null null-Disease
It PRP O
is VBZ O
concluded VBN O
that IN O
bepridil NN O
reduces VBZ O
heart NN O
rate NN O
by IN O
acting VBG O
directly RB O
on IN O
the DT O
sinus NN O
node NN O
. . O
null null null-Disease
This DT O
effect NN O
, , O
which WDT O
results VBZ O
in IN O
a DT O
flattening NN O
of IN O
the DT O
phase NN O
0 CD O
and CC O
phase NN O
4 CD O
slope NN O
, , O
together RB O
with IN O
a DT O
longer JJR O
AP NNP O
duration NN O
, , O
may MD O
be VB O
due IN O
to IN O
an DT O
increase NN O
in IN O
the DT O
time NN O
constants NNS O
of IN O
slow JJ O
inward JJ O
ionic JJ O
currents NNS O
( , O
already RB O
demonstrated VBN O
elsewhere RB O
) -RRB- O
, , O
but CC O
also RB O
to IN O
an DT O
increased JJ O
time NN O
constant NN O
for IN O
deactivation NN O
of IN O
the DT O
outward JJ O
potassium NN O
current NN O
( , O
Ip NNP O
) -RRB- O
. . O
null null null-Disease
Hepatitis NN B-Disease
and CC O
renal JJ B-Disease
tubular JJ I-Disease
acidosis NN I-Disease
after IN O
anesthesia NN O
with IN O
methoxyflurane NN O
. . O
null null null-Disease
A DT O
69 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
operated VBD O
for IN O
acute JJ B-Disease
cholecystitis NN I-Disease
under IN O
methoxyflurane NN O
anesthesia NN O
developed VBD O
postoperatively RB O
a DT O
hepatic JJ B-Disease
insufficiency NN I-Disease
syndrome NN I-Disease
and CC O
renal JJ B-Disease
tubular JJ I-Disease
acidosis NN I-Disease
. . O
null null null-Disease
Massive JJ O
bleeding NN B-Disease
appeared VBD O
during IN O
surgery NN O
which WDT O
lasted VBD O
for IN O
six CD O
hours NNS O
. . O
null null null-Disease
Postoperative JJ O
evolution NN O
under IN O
supportive JJ O
therapy NN O
was VBD O
favourable JJ O
. . O
null null null-Disease
Complete JJ O
recovery NN O
was VBD O
confirmed VBN O
by IN O
repeated VBN O
controls NNS O
performed VBN O
over IN O
a DT O
period NN O
of IN O
one CD O
year NN O
after IN O
surgery NN O
. . O
null null null-Disease
Pituitary JJ O
response NN O
to IN O
luteinizing VBG O
hormone NN O
- HYPH O
releasing VBG O
hormone NN O
during IN O
haloperidol NN O
- HYPH O
induced VBN O
hyperprolactinemia NN B-Disease
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
a DT O
6 CD O
- HYPH O
hour NN O
infusion NN O
with IN O
haloperidol NN O
on IN O
serum NN O
prolactin NN O
and CC O
luteinizing VBG O
hormone NN O
( , O
LH NNP O
) -RRB- O
levels NNS O
was VBD O
studied VBN O
in IN O
a DT O
group NN O
of IN O
male JJ O
subjects NNS O
. . O
null null null-Disease
Five CD O
hours NNS O
after IN O
starting VBG O
the DT O
infusions NNS O
, , O
a DT O
study NN O
of IN O
the DT O
pituitary JJ O
responses NNS O
to IN O
LH NNP O
- HYPH O
releasing VBG O
hormone NN O
( , O
LH NNP O
- HYPH O
RH NNP O
) -RRB- O
was VBD O
carried VBN O
out RP O
. . O
null null null-Disease
Control NN O
patients NNS O
received VBD O
infusions NNS O
of IN O
0 CD O
. . O
9 CD O
% NN O
NaCl NNP O
solution NN O
. . O
null null null-Disease
During IN O
the DT O
course NN O
of IN O
haloperidol NN O
infusions NNS O
, , O
significant JJ O
hyperprolactinemia NN B-Disease
was VBD O
found VBN O
, , O
together RB O
with IN O
an DT O
abolished VBN O
pituitary JJ O
response NN O
to IN O
LH NNP O
- HYPH O
RH NNP O
, , O
as IN O
compared VBN O
with IN O
responses NNS O
of IN O
control NN O
subjects NNS O
. . O
null null null-Disease
Antirifampicin NN O
antibodies NNS O
in IN O
acute JJ O
rifampicin NN O
- HYPH O
associated VBN O
renal JJ B-Disease
failure NN I-Disease
. . O
null null null-Disease
5 CD O
patients NNS O
with IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
( , O
3 CD O
with IN O
thrombopenia NN B-Disease
and CC O
hemolysis NN B-Disease
) , O
induced VBN O
by IN O
the DT O
reintroduction NN O
of IN O
rifampicin NN O
are VBP O
described VBN O
. . O
null null null-Disease
No DT O
correlation NN O
was VBD O
found VBN O
between IN O
the DT O
severity NN O
of IN O
clinical JJ O
manifestations NNS O
and CC O
the DT O
total JJ O
dose NN O
taken VBN O
by IN O
the DT O
patients NNS O
. . O
null null null-Disease
In IN O
all DT O
but IN O
1 CD O
patient NN O
, , O
antirifampicin NN O
antibodies NNS O
were VBD O
detected VBN O
. . O
null null null-Disease
Antibodies NNS O
suggested VBD O
to TO O
be VB O
of IN O
the DT O
IgM NNP O
class NN O
were VBD O
detected VBN O
in IN O
all DT O
3 CD O
patients NNS O
with IN O
hematological JJ B-Disease
disorders NNS I-Disease
. . O
null null null-Disease
The DT O
pattern NN O
of IN O
non AFX O
- HYPH O
specific JJ O
acute JJ B-Disease
tubular JJ I-Disease
necrosis NN I-Disease
found VBN O
in IN O
the DT O
2 CD O
biopsied VBN O
patients NNS O
, , O
indistinguishable JJ O
from IN O
that DT O
of IN O
ischemic JJ O
origin NN O
, , O
raised VBD O
the DT O
possibility NN O
of IN O
a DT O
vascular NN O
- HYPH O
mediated VBN O
damage NN O
. . O
null null null-Disease
In IN O
3 CD O
patients NNS O
, , O
the DT O
possibility NN O
of IN O
a DT O
triggering VBG O
immunoallergic JJ O
mechanism NN O
is VBZ O
discussed VBN O
. . O
null null null-Disease
Cardiovascular JJ O
effects NNS O
of IN O
hypotension NN B-Disease
induced VBN O
by IN O
adenosine NN O
triphosphate NN O
and CC O
sodium NN O
nitroprusside NN O
on IN O
dogs NNS O
with IN O
denervated JJ O
hearts NNS O
. . O
null null null-Disease
Adenosine NN O
triphosphate NN O
( , O
ATP NNP O
) -RRB- O
and CC O
sodium NN O
nitroprusside NN O
( -LRB- O
SNP NNP O
) -RRB- O
are VBP O
administered VBN O
to IN O
patients NNS O
to TO O
induce VB O
and CC O
control VB O
hypotension NN B-Disease
during IN O
anesthesia NN O
. . O
null null null-Disease
SNP NNP O
is VBZ O
authorized VBN O
for IN O
clinical JJ O
use NN O
in IN O
USA NNP O
and CC O
UK NNP O
, , O
and CC O
ATP NNP O
is VBZ O
clinically RB O
used VBN O
in IN O
other JJ O
countries NNS O
such JJ O
as IN O
Japan NNP O
. . O
null null null-Disease
We PRP O
investigated VBD O
how WRB O
these DT O
two CD O
drugs NNS O
act VBP O
on IN O
the DT O
cardiovascular JJ O
systems NNS O
of IN O
20 CD O
dogs NNS O
whose WP$ O
hearts NNS O
had VBD O
been VBN O
denervated VBN O
by IN O
a DT O
procedure NN O
we PRP O
had VBD O
devised VBN O
. . O
null null null-Disease
ATP NNP O
( : O
10 CD O
dogs NNS O
) -RRB- O
or CC O
SNP NNP O
( : O
10 CD O
dogs NNS O
) -RRB- O
was VBD O
administered VBN O
to TO O
reduce VB O
mean JJ O
arterial JJ O
pressure NN O
by IN O
30 CD O
% NN O
to IN O
70 CD O
% NN O
of IN O
control NN O
. . O
null null null-Disease
Before RB O
, , O
during IN O
and CC O
after IN O
induced VBN O
hypotension NN B-Disease
, , O
we PRP O
measured VBD O
major JJ O
cardiovascular JJ O
parameters NNS O
. . O
null null null-Disease
Hypotension NN B-Disease
induced VBN O
by IN O
ATP NNP O
was VBD O
accompanied VBN O
by IN O
significant JJ O
decreases NNS O
in IN O
mean JJ O
pulmonary JJ O
arterial JJ O
pressure NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
central JJ O
venous JJ O
pressure NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
left JJ O
ventricular JJ O
end NN O
- HYPH O
diastolic JJ O
pressure NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
total JJ O
peripheral JJ O
resistance NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
rate NN O
pressure NN O
product NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
total JJ O
body NN O
oxygen NN O
consumption NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
, , O
and CC O
heart NN O
rate NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
; : O
all PDT O
these DT O
variables NNS O
returned VBD O
normal JJ O
within IN O
30 CD O
min NN O
after IN O
ATP NNP O
was VBD O
stopped VBN O
. . O
null null null-Disease
Cardiac JJ O
output NN O
did VBD O
not RB O
change VB O
. . O
null null null-Disease
During IN O
hypotension NN B-Disease
produced VBN O
by IN O
SNP NNP O
similar JJ O
decreases NNS O
were VBD O
observed VBN O
in IN O
mean JJ O
pulmonary JJ O
arterial JJ O
pressure NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
central JJ O
venous JJ O
pressure NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
left JJ O
ventricular JJ O
end NN O
- HYPH O
diastolic JJ O
pressure NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
01 CD O
) -RRB- O
, , O
total JJ O
peripheral JJ O
resistance NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
rate NN O
pressure NN O
product NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
, , O
and CC O
oxygen NN O
content NN O
difference NN O
between IN O
arterial JJ O
and CC O
mixed JJ O
venous JJ O
blood NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
, , O
while IN O
heart NN O
rate NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
001 CD O
) -RRB- O
and CC O
cardiac JJ O
output NN O
( , O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
were VBD O
increased VBN O
. . O
null null null-Disease
Recoveries NNS O
of IN O
heart NN O
rate NN O
and CC O
left JJ O
ventricular JJ O
end NN O
- HYPH O
diastolic JJ O
pressure NN O
were VBD O
not RB O
shown VBN O
within IN O
60 CD O
min NN O
after IN O
SNP NNP O
had VBD O
been VBN O
stopped VBN O
. . O
null null null-Disease
Both CC O
ATP NNP O
and CC O
SNP NNP O
should MD O
act VB O
on IN O
the DT O
pacemaker NN O
tissue NN O
of IN O
the DT O
heart NN O
. . O
null null null-Disease
Comparative JJ O
study NN O
: : O
Endografine NN O
( , O
diatrizoate NN O
) -RRB- O
, , O
Vasurix NNP O
polyvidone NN O
( , O
acetrizoate NN O
) -RRB- O
, , O
Dimer NN O
- HYPH O
X NNP O
( , O
iocarmate NN O
) -RRB- O
and CC O
Hexabrix NN O
( : O
ioxaglate NN O
) -RRB- O
in IN O
hysterosalpingography NN O
. . O
null null null-Disease
Side JJ O
effects NNS O
of IN O
hysterosalpingography NN O
with IN O
Dimer NNP O
- HYPH O
X NNP O
, , O
Hexabrix NNP O
, , O
Vasurix NNP O
polyvidone NN O
and CC O
Endografine NNP O
in IN O
142 CD O
consecutive JJ O
patients NNS O
, , O
receiving VBG O
one CD O
of IN O
the DT O
four CD O
tested VBN O
media NNS O
were VBD O
evaluated VBN O
from IN O
replies NNS O
to IN O
postal JJ O
questionnaires NNS O
. . O
null null null-Disease
The DT O
Dimer NNP O
- HYPH O
X NNP O
group NN O
had VBD O
a DT O
higher JJR O
incidence NN O
of IN O
nausea NN B-Disease
and CC O
dizziness NN B-Disease
. . O
null null null-Disease
The DT O
Endografine NNP O
group NN O
had VBD O
a DT O
higher JJR O
incidence NN O
of IN O
abdominal JJ B-Disease
pain NN I-Disease
. . O
null null null-Disease
These DT O
differences NNS O
occur VBP O
especially RB O
in IN O
the DT O
age NN O
groups NNS O
under IN O
30 CD O
years NNS O
. . O
null null null-Disease
Hexabrix NNP O
and CC O
Vasurix NNP O
polyvidone NN O
are VBP O
considered VBN O
the DT O
best JJS O
contrast NN O
media NN O
for IN O
hysterosalpingography NN O
and CC O
perhaps RB O
because IN O
of IN O
its PRP$ O
low JJ O
toxicity NN B-Disease
Hexabrix NN O
should MD O
be VB O
preferred VBN O
. . O
null null null-Disease
Post NN O
- HYPH O
suxamethonium NN O
pains NNS B-Disease
in IN O
Nigerian JJ O
surgical JJ O
patients NNS O
. . O
null null null-Disease
Contrary JJ O
to IN O
an DT O
earlier JJR O
report NN O
by IN O
Coxon NNP O
, , O
scoline NN O
pain NN B-Disease
occurs VBZ O
in IN O
African JJ O
negroes NNS O
. . O
null null null-Disease
Its PRP$ O
incidence NN O
was VBD O
determined VBN O
in IN O
a DT O
prospective JJ O
study NN O
involving VBG O
a DT O
total NN O
of IN O
100 CD O
Nigerian JJ O
patients NNS O
( , O
50 CD O
out IN O
- HYPH O
patients NNS O
and CC O
50 CD O
in IN O
- HYPH O
patients NNS O
) -RRB- O
. . O
null null null-Disease
About RB O
62 CD O
% NN O
of IN O
the DT O
out RB O
- HYPH O
patients NNS O
developed VBD O
scoline NN O
pain NN B-Disease
as IN O
compared VBN O
with IN O
about RB O
26 CD O
% NN O
among IN O
the DT O
in IN O
- HYPH O
patients NNS O
. . O
null null null-Disease
The DT O
abolition NN O
of IN O
muscle NN O
fasciculations NNS B-Disease
( : O
by IN O
0 CD O
. . O
075mg CD O
/ SYM O
kg NN O
dose NN O
of IN O
Fazadinium NNP O
) -RRB- O
did VBD O
not RB O
influence VB O
the DT O
occurrence NN O
of IN O
scoline NN O
pain NN B-Disease
. . O
null null null-Disease
Neither CC O
the DT O
type NN O
of IN O
induction NN O
agent NN O
( , O
Althesin NNP O
or CC O
Thiopentone NNP O
) , O
nor CC O
the DT O
salt NN O
preparation NN O
of IN O
suxamethonium NN O
used VBN O
( , O
chloride NN O
or CC O
bromide NN O
) -RRB- O
, , O
affected VBD O
the DT O
incidence NN O
of IN O
scoline NN O
pain NN B-Disease
. . O
null null null-Disease
Invasive JJ O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
renal JJ I-Disease
pelvis NN I-Disease
following VBG O
cyclophosphamide NN O
therapy NN O
for IN O
nonmalignant JJ O
disease NN O
. . O
null null null-Disease
A DT O
47 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
right JJ O
hydroureteronephrosis NN B-Disease
due JJ O
to IN O
ureterovesical JJ O
junction NN O
obstruction NN O
had VBD O
gross JJ O
hematuria NN B-Disease
after IN O
being VBG O
treated VBN O
for IN O
five CD O
years NNS O
wtih JJ O
cyclophosphamide NN O
for IN O
cerebral JJ B-Disease
vasculitis NN I-Disease
. . O
null null null-Disease
A DT O
right JJ O
nephroureterectomy NN O
was VBD O
required VBN O
for IN O
control NN O
of IN O
bleeding NN B-Disease
. . O
null null null-Disease
The DT O
pathology NN O
specimen NN O
contained VBD O
clinically RB O
occult JJ O
invasive JJ O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
renal JJ I-Disease
pelvis NN I-Disease
. . O
null null null-Disease
Although IN O
the DT O
ability NN O
of IN O
cyclophosphamide NN O
to TO O
cause VB O
hemorrhagic JJ B-Disease
cystitis NN I-Disease
and CC O
urine JJ O
cytologic JJ O
abnormalities NNS O
indistinguishable JJ O
from IN O
high JJ O
grade NN O
carcinoma NN B-Disease
is VBZ O
well RB O
known JJ O
, , O
it PRP O
is VBZ O
less RBR O
widely RB O
appreciated VBN O
that IN O
it PRP O
is VBZ O
also RB O
associated VBN O
with IN O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
urinary JJ I-Disease
tract NN I-Disease
. . O
null null null-Disease
Twenty CD O
carcinomas NNS B-Disease
of IN I-Disease
the DT I-Disease
urinary JJ I-Disease
bladder NN I-Disease
and CC O
one CD O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
prostate NN I-Disease
have VBP O
been VBN O
reported VBN O
in IN O
association NN O
with IN O
its PRP$ O
use NN O
. . O
null null null-Disease
The DT O
present JJ O
case NN O
is VBZ O
the DT O
first JJ O
carcinoma NN B-Disease
of IN I-Disease
the DT I-Disease
renal JJ I-Disease
pelvis NN I-Disease
reported VBN O
in IN O
association NN O
with IN O
cyclophosphamide NN O
treatment NN O
. . O
null null null-Disease
It PRP O
is VBZ O
the DT O
third JJ O
urinary JJ B-Disease
tract NN I-Disease
cancer NN I-Disease
reported VBN O
in IN O
association NN O
with IN O
cyclophosphamide NN O
treatment NN O
for IN O
nonmalignant JJ O
disease NN O
. . O
null null null-Disease
The DT O
association NN O
of IN O
the DT O
tumor NN B-Disease
with IN O
preexisting JJ O
hydroureteronephrosis NN B-Disease
suggests VBZ O
that IN O
stasis NNS O
prolonged VBD O
and CC O
intensified VBN O
exposure NN O
of IN O
upper JJ O
urinary JJ O
tract NN O
epithelium NN O
to IN O
cyclophosphamide NN O
. . O
null null null-Disease
Patients NNS O
who WP O
are VBP O
candidates NNS O
for IN O
long JJ O
- HYPH O
term NN O
cyclophosphamide NN O
treatment NN O
should MD O
be VB O
routinely RB O
evaluated VBN O
for IN O
obstructive JJ B-Disease
uropathy NN I-Disease
. . O
null null null-Disease
Medial JJ O
changes NNS O
in IN O
arterial JJ O
spasm NN B-Disease
induced VBN O
by IN O
L NN O
- HYPH O
norepinephrine NN O
. . O
null null null-Disease
In IN O
normal JJ O
rats NNS O
, , O
the DT O
media NNS O
of IN O
small JJ O
arteries NNS O
( , O
0 CD O
. . O
4 CD O
- HYPH O
- HYPH O
0 CD O
. . O
2 CD O
mm NN O
in IN O
diameter NN O
) -RRB- O
previously RB O
was VBD O
shown VBN O
to TO O
contain VB O
intracellular JJ O
vacuoles NNS O
, , O
identified VBN O
ultrastructurally RB O
as IN O
herniations NNS O
of IN O
one CD O
smooth JJ O
muscle NN O
cell NN O
into IN O
another DT O
. . O
null null null-Disease
The DT O
hypothesis NN O
that IN O
intense JJ O
vasoconstriction NN O
would MD O
increase VB O
the DT O
number NN O
of IN O
such JJ O
vacuoles NNS O
has VBZ O
been VBN O
tested VBN O
. . O
null null null-Disease
In IN O
the DT O
media NNS O
of IN O
the DT O
saphenous JJ O
artery NN O
and CC O
its PRP$ O
distal JJ O
branch NN O
, , O
vasoconstriction NN O
induced VBN O
by IN O
L NNP O
- HYPH O
norepinephrine NN O
produced VBD O
many JJ O
cell NN O
- HYPH O
to IN O
- HYPH O
cell NN O
hernias NNS B-Disease
within IN O
15 CD O
minutes NNS O
. . O
null null null-Disease
At IN O
1 CD O
day NN O
their PRP$ O
number NN O
was VBD O
reduced VBN O
to IN O
about RB O
1 CD O
/ SYM O
10 CD O
of IN O
the DT O
original JJ O
number NN O
. . O
null null null-Disease
By IN O
7 CD O
days NNS O
the DT O
vessel NN O
was VBD O
almost RB O
restored VBN O
to IN O
normal JJ O
. . O
null null null-Disease
Triple JJ O
stimulation NN O
over IN O
1 CD O
day NN O
induced VBD O
more RBR O
severe JJ O
changes NNS O
in IN O
the DT O
media NNS O
. . O
null null null-Disease
These DT O
findings NNS O
suggest VBP O
that IN O
smooth JJ O
muscle NN O
cells NNS O
are VBP O
susceptible JJ O
to IN O
damage NN O
in IN O
the DT O
course NN O
of IN O
their PRP$ O
specific JJ O
function NN O
. . O
null null null-Disease
The DT O
experimental JJ O
data NNS O
are VBP O
discussed VBN O
in IN O
relation NN O
to IN O
medial JJ O
changes NNS O
observed VBN O
in IN O
other JJ O
instances NNS O
of IN O
arterial JJ O
spasm NN B-Disease
. . O
null null null-Disease
Endothelial JJ O
changes NNS O
that WDT O
developed VBD O
in IN O
the DT O
same JJ O
experimental JJ O
model NN O
were VBD O
described VBN O
in IN O
a DT O
previous JJ O
paper NN O
. . O
null null null-Disease
Bilateral JJ O
retinal JJ B-Disease
artery NN I-Disease
and CC I-Disease
choriocapillaris NN I-Disease
occlusion NN I-Disease
following VBG O
the DT O
injection NN O
of IN O
long RB O
- HYPH O
acting VBG O
corticosteroid NN O
suspensions NNS O
in IN O
combination NN O
with IN O
other JJ O
drugs NNS O
: : O
I PRP O
. . O
null null null-Disease
Clinical JJ O
studies NNS O
. . O
null null null-Disease
Two CD O
well RB O
- HYPH O
documented VBN O
cases NNS O
of IN O
bilateral JJ O
retinal JJ B-Disease
artery NN I-Disease
and CC I-Disease
choriocapillaris NN I-Disease
occlusions NNS I-Disease
with IN O
blindness NN B-Disease
following VBG O
head NN O
and CC O
neck NN O
soft JJ O
- HYPH O
tissue NN O
injection NN O
with IN O
methylprednisolone NN O
acetate NN O
in IN O
combination NN O
with IN O
lidocaine NN O
, , O
epinephrine NN O
, , O
or CC O
penicillin NN O
are VBP O
reported VBN O
. . O
null null null-Disease
One CD O
case NN O
had VBD O
only RB O
a DT O
unilateral JJ O
injection NN O
. . O
null null null-Disease
The DT O
acute JJ O
observations NNS O
included VBD O
hazy JJ O
sensorium NN O
, , O
superior JJ O
gaze NN O
palsy NN B-Disease
, , O
pupillary NN B-Disease
abnormalities NNS I-Disease
, , O
and CC O
conjunctival JJ O
hemorrhages NNS B-Disease
with IN O
edema NN B-Disease
. . O
null null null-Disease
Follow VB O
- HYPH O
up NN O
changes NNS O
showed VBD O
marked JJ O
visual JJ B-Disease
loss NN I-Disease
, , O
constricted VBN O
visual JJ O
fields NNS O
, , O
optic JJ O
nerve NN O
pallor NN O
, , O
vascular JJ O
attenuation NN O
, , O
and CC O
chorioretinal JJ B-Disease
atrophy NN I-Disease
. . O
null null null-Disease
The DT O
literature NN O
is VBZ O
reviewed VBN O
, , O
and CC O
possible JJ O
causes NNS O
are VBP O
discussed VBN O
. . O
null null null-Disease
Abnormalities NNS O
of IN O
the DT O
pupil NN O
and CC O
visual NN O
- HYPH O
evoked VBN O
potential NN O
in IN O
quinine NN O
amblyopia NN B-Disease
. . O
null null null-Disease
Total JJ O
blindness NN B-Disease
with IN O
a DT O
transient JJ O
tonic NN B-Disease
pupillary NN I-Disease
response NN O
, , O
denervation NN O
supersensitivity NN O
, , O
and CC O
abnormal JJ O
visual NN O
- HYPH O
evoked VBN O
potentials NNS O
developed VBN O
in IN O
a DT O
54 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
after IN O
the DT O
use NN O
of IN O
quinine NN O
sulfate NN O
for IN O
leg NN B-Disease
cramps NNS I-Disease
. . O
null null null-Disease
He PRP O
later RB O
recovered VBD O
normal JJ O
visual JJ O
acuity NN O
. . O
null null null-Disease
A DT O
transient JJ O
tonic NN B-Disease
pupillary NN I-Disease
response NN O
, , O
denervation NN O
supersensitivity NN O
, , O
and CC O
abnormal JJ O
visual NN O
- HYPH O
evoked VBN O
potentials NNS O
in IN O
quinine NN O
toxicity NN B-Disease
, , O
to IN O
our PRP$ O
knowledge NN O
, , O
have VBP O
not RB O
been VBN O
previously RB O
reported VBN O
. . O
null null null-Disease
Suxamethonium NN O
- HYPH O
induced VBN O
jaw NN B-Disease
stiffness NN I-Disease
and CC O
myalgia NN B-Disease
associated VBN O
with IN O
atypical JJ O
cholinesterase NN O
: : O
case NN O
report NN O
. . O
null null null-Disease
An DT O
11 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
boy NN O
was VBD O
given VBN O
halothane NN O
, , O
nitrous JJ O
oxide NN O
and CC O
oxygen NN O
, , O
pancuronium NN O
0 CD O
. . O
4 CD O
mg NN O
and CC O
suxamethonium NN O
100 CD O
mg NN O
for IN O
induction NN O
of IN O
anaesthesia NN O
. . O
null null null-Disease
In IN O
response NN O
to IN O
this DT O
a DT O
marked JJ O
jaw NN B-Disease
stiffness NN I-Disease
occurred VBD O
which WDT O
lasted VBD O
for IN O
two CD O
minutes NNS O
and CC O
the DT O
anaesthesia NN O
were VBD O
terminated VBN O
. . O
null null null-Disease
Four CD O
hours NNS O
of IN O
apnoea NN B-Disease
ensued VBD O
and CC O
he PRP O
suffered VBD O
generalized VBN O
severe JJ O
myalgia NN B-Disease
lasting VBG O
for IN O
one CD O
week NN O
. . O
null null null-Disease
He PRP O
was VBD O
found VBN O
to TO O
have VB O
atypical JJ O
plasma NN O
cholinesterase NN O
with IN O
a DT O
dibucaine NN O
number NN O
of IN O
12 CD O
, , O
indicating VBG O
homozygocity NN O
. . O
null null null-Disease
This DT O
was VBD O
verified VBN O
by IN O
study NN O
of IN O
the DT O
family NN O
. . O
null null null-Disease
The DT O
case NN O
shows VBZ O
that IN O
prolonged VBN B-Disease
jaw NN I-Disease
rigidity NN I-Disease
and CC O
myalgia NN B-Disease
may MD O
occur VB O
after IN O
suxamethonium NN O
in IN O
patients NNS O
with IN O
atypical JJ O
cholinesterase NN O
despite IN O
pretreatment NN O
with IN O
pancuronium NN O
. . O
null null null-Disease
Indomethacin NN O
- HYPH O
induced VBN O
hyperkalemia NN B-Disease
in IN O
three CD O
patients NNS O
with IN O
gouty JJ B-Disease
arthritis NN I-Disease
. . O
null null null-Disease
We PRP O
describe VBP O
three CD O
patients NNS O
in IN O
whom WP O
severe JJ O
, , O
life NN O
- HYPH O
threatening VBG O
hyperkalemia NN B-Disease
and CC O
renal JJ B-Disease
insufficiency NN I-Disease
developed VBN O
after IN O
treatment NN O
of IN O
acute JJ O
gouty JJ B-Disease
arthritis NN I-Disease
with IN O
indomethacin NN O
. . O
null null null-Disease
This DT O
complication NN O
may MD O
result VB O
from IN O
an DT O
inhibition NN O
of IN O
prostaglandin JJ O
synthesis NN O
and CC O
consequent JJ O
hyporeninemic JJ B-Disease
hypoaidosteronism NN I-Disease
. . O
null null null-Disease
Careful JJ O
attention NN O
to IN O
renal JJ O
function NN O
and CC O
potassium NN O
balance NN O
in IN O
patients NNS O
receiving VBG O
indomethacin NN O
or CC O
other JJ O
nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
agents NNS O
, , O
particularly RB O
in IN O
those DT O
patients NNS O
with IN O
diabetes NN B-Disease
mellitus NN I-Disease
or CC O
preexisting VBG O
renal JJ B-Disease
disease NN I-Disease
, , O
will MD O
help VB O
prevent VB O
this DT O
potentially RB O
serious JJ O
complication NN O
. . O
null null null-Disease
Etomidate NN O
: : O
a DT O
foreshortened JJ O
clinical JJ O
trial NN O
. . O
null null null-Disease
A DT O
clinical JJ O
evaluation NN O
of IN O
etomidate NN O
for IN O
outpatient JJ O
cystoscopy NN O
was VBD O
embarked VBN O
upon IN O
. . O
null null null-Disease
Unpremedicated JJ O
patients NNS O
were VBD O
given VBN O
fentanyl NN O
1 CD O
microgram NN O
/ SYM O
kg NN O
followed VBN O
by IN O
etomidate NN O
0 CD O
. . O
3 CD O
mg NN O
/ SYM O
kg NN O
. . O
null null null-Disease
Anaesthesia NN O
was VBD O
maintained VBN O
with IN O
intermittent JJ O
etomidate NN O
in IN O
2 CD O
- SYM O
4 CD O
mg NN O
doses NNS O
. . O
null null null-Disease
Patients NNS O
were VBD O
interviewed VBN O
personally RB O
later RB O
the DT O
same JJ O
day NN O
, , O
and CC O
by IN O
questionnaire NN O
three CD O
to IN O
four CD O
weeks NNS O
later RB O
. . O
null null null-Disease
The DT O
trial NN O
was VBD O
discontinued VBN O
after IN O
20 CD O
cases NNS O
because IN O
of IN O
an DT O
unacceptable JJ O
incidence NN O
of IN O
side NN O
effects NNS O
. . O
null null null-Disease
Venous JJ O
pain NN B-Disease
occurred VBD O
in IN O
68 CD O
% NN O
of IN O
patients NNS O
and CC O
50 CD O
% NN O
had VBD O
redness NN O
, , O
pain NN B-Disease
or CC O
swelling NN B-Disease
related VBN O
to IN O
the DT O
injection NN O
site NN O
, , O
in IN O
some DT O
cases NNS O
lasting VBG O
up IN O
to TO O
three CD O
weeks NNS O
after IN O
anaesthesia NN O
. . O
null null null-Disease
Skeletal JJ O
movements NNS O
occurred VBD O
in IN O
50 CD O
% NN O
of IN O
patients NNS O
; : O
30 CD O
% NN O
experienced VBD O
respiratory JJ B-Disease
upset NN I-Disease
, , O
one CD O
sufficiently RB O
severe JJ O
to TO O
necessitate VB O
abandoning VBG O
the DT O
technique NN O
. . O
null null null-Disease
Nausea NNP B-Disease
and CC O
vomiting NN B-Disease
occurred VBD O
in IN O
40 CD O
% NN O
and CC O
25 CD O
% NN O
had VBD O
disturbing JJ O
emergence NN O
psychoses NNS B-Disease
. . O
null null null-Disease
Levodopa NNP O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
are VBP O
improved VBN O
by IN O
fluoxetine NN O
. . O
null null null-Disease
We PRP O
evaluated VBD O
the DT O
severity NN O
of IN O
motor NN B-Disease
disability NN I-Disease
and CC O
dyskinesias NNS B-Disease
in IN O
seven CD O
levodopa NN O
- HYPH O
responsive JJ O
patients NNS O
with IN O
Parkinson NNP B-Disease
' POS I-Disease
s NN I-Disease
disease NN I-Disease
after IN O
an DT O
acute JJ O
challenge NN O
with IN O
the DT O
mixed JJ O
dopamine NN O
agonist NN O
, , O
apomorphine NN O
, , O
before IN O
and CC O
after IN O
the DT O
administration NN O
of IN O
fluoxetine NN O
( : O
20 CD O
mg NN O
twice RB O
per IN O
day NN O
) -RRB- O
for IN O
11 CD O
+ CD O
/ SYM O
- SYM O
1 CD O
days NNS O
. . O
null null null-Disease
After IN O
fluoxetine NN O
treatment NN O
, , O
there EX O
was VBD O
a DT O
significant JJ O
47 CD O
% NN O
improvement NN O
( , O
p NN O
< SYM O
0 CD O
. . O
05 CD O
) -RRB- O
of IN O
apomorphine NN O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
without IN O
modification NN O
of IN O
parkinsonian NN B-Disease
motor NN B-Disease
disability NN I-Disease
. . O
null null null-Disease
The DT O
dyskinesias NNS B-Disease
were VBD O
reduced VBN O
predominantly RB O
in IN O
the DT O
lower JJ O
limbs NNS O
during IN O
the DT O
onset NN O
and CC O
disappearance NN O
of IN O
dystonic JJ B-Disease
dyskinesias NNS I-Disease
( , O
onset JJ O
- HYPH O
and CC O
end NN O
- HYPH O
of IN O
- HYPH O
dose NN O
dyskinesias NN B-Disease
) -RRB- O
and CC O
in IN O
the DT O
upper JJ O
limbs NNS O
during IN O
choreic JJ B-Disease
mid JJ I-Disease
- HYPH I-Disease
dose NN I-Disease
dyskinesias NNS I-Disease
. . O
null null null-Disease
The DT O
results NNS O
suggest VBP O
that IN O
increased VBN O
brain NN O
serotoninergic JJ O
transmission NN O
with IN O
fluoxetine NN O
may MD O
reduce VB O
levodopa NN O
- HYPH O
or CC O
dopamine NN O
agonist NN O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
without IN O
aggravating VBG O
parkinsonian JJ B-Disease
motor NN B-Disease
disability NN I-Disease
. . O
null null null-Disease
A DT O
large JJ O
population NN O
- HYPH O
based VBN O
follow NN O
- HYPH O
up NN O
study NN O
of IN O
trimethoprim NN O
- HYPH O
sulfamethoxazole NN O
, , O
trimethoprim NN O
, , O
and CC O
cephalexin NN O
for IN O
uncommon JJ O
serious JJ O
drug NN B-Disease
toxicity NN I-Disease
. . O
null null null-Disease
We PRP O
conducted VBD O
a DT O
population NN O
- HYPH O
based VBN O
45 CD O
- HYPH O
day NN O
follow NN O
- HYPH O
up NN O
study NN O
of IN O
232 CD O
, , O
390 CD O
people NNS O
who WP O
were VBD O
prescribed VBN O
trimethoprim NN O
- HYPH O
sulfamethoxazole NNP O
( -LRB- O
TMP NNP O
- HYPH O
SMZ NNP O
) -RRB- O
, , O
266 CD O
, , O
951 CD O
prescribed VBN O
trimethoprim NN O
alone RB O
, , O
and CC O
196 CD O
, , O
397 CD O
prescribed VBN O
cephalexin NN O
, , O
to TO O
estimate VB O
the DT O
risk NN O
of IN O
serious JJ O
liver NN B-Disease
, , I-Disease
blood NN I-Disease
, , I-Disease
skin NN I-Disease
, , I-Disease
and CC I-Disease
renal JJ I-Disease
disorders NNS I-Disease
resulting VBG O
in IN O
referral NN O
or CC O
hospitalization NN O
associated VBN O
with IN O
these DT O
drugs NNS O
. . O
null null null-Disease
The DT O
results NNS O
were VBD O
based VBN O
on IN O
information NN O
recorded VBN O
on IN O
office NN O
computers NNS O
by IN O
selected VBN O
general JJ O
practitioners NNS O
in IN O
the DT O
United NNP O
Kingdom NNP O
, , O
together RB O
with IN O
a DT O
review NN O
of IN O
clinical JJ O
records NNS O
. . O
null null null-Disease
The DT O
risk NN O
of IN O
clinically RB O
important JJ O
idiopathic JJ O
liver NN B-Disease
disease NN I-Disease
was VBD O
similar JJ O
for IN O
persons NNS O
prescribed VBN O
TMP NNP O
- HYPH O
SMZ NNP O
( : O
5 CD O
. . O
2 CD O
/ SYM O
100 CD O
, , O
000 CD O
) -RRB- O
and CC O
those DT O
prescribed VBN O
trimethoprim NN O
alone RB O
( : O
3 CD O
. . O
8 CD O
/ SYM O
100 CD O
, , O
000 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
risk NN O
for IN O
those DT O
prescribed VBN O
cephalexin NN O
was VBD O
somewhat RB O
lower JJR O
( : O
2 CD O
. . O
0 CD O
/ SYM O
100 CD O
, , O
000 CD O
) -RRB- O
. . O
null null null-Disease
Only RB O
five CD O
patients NNS O
experienced VBD O
blood NN O
disorders NNS O
, , O
one CD O
of IN O
whom WP O
was VBD O
exposed VBN O
to IN O
TMP NNP O
- HYPH O
SMZ NNP O
; : O
of IN O
seven CD O
with IN O
erythema NN B-Disease
multiforme NN I-Disease
and CC O
Stevens NNP B-Disease
- HYPH I-Disease
Johnson NNP I-Disease
syndrome NN I-Disease
, , O
four CD O
were VBD O
exposed VBN O
to IN O
TMP NNP O
- HYPH O
SMZ NNP O
. . O
null null null-Disease
The DT O
one CD O
case NN O
of IN O
toxic JJ B-Disease
epidermal JJ I-Disease
necrolysis NN I-Disease
occurred VBD O
in IN O
a DT O
patient NN O
who WP O
took VBD O
cephalexin NN O
. . O
null null null-Disease
Finally RB O
, , O
only RB O
five CD O
cases NNS O
of IN O
acute JJ O
parenchymal NN O
renal JJ B-Disease
disease NN I-Disease
occurred VBD O
, , O
none NN O
likely JJ O
to TO O
be VB O
caused VBN O
by IN O
a DT O
study NN O
drug NN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
the DT O
risk NN O
of IN O
the DT O
serious JJ O
diseases NNS O
studied VBN O
is VBZ O
small JJ O
for IN O
the DT O
three CD O
agents NNS O
, , O
and CC O
compares VBZ O
reasonably RB O
with IN O
the DT O
risk NN O
for IN O
many JJ O
other JJ O
antibiotics NNS O
. . O
null null null-Disease
Clinical JJ O
safety NN O
of IN O
lidocaine NN O
in IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
STUDY NN O
OBJECTIVE NN O
: : O
To TO O
evaluate VB O
the DT O
safety NN O
of IN O
lidocaine NN O
in IN O
the DT O
setting NN O
of IN O
cocaine NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
infarction NN I-Disease
( , O
MI NNP B-Disease
) -RRB- O
. . O
null null null-Disease
DESIGN NN O
: : O
A DT O
retrospective JJ O
, , O
multicenter JJ O
study NN O
. . O
null null null-Disease
SETTING VBG O
: : O
Twenty CD O
- HYPH O
nine CD O
university NN O
, , O
university NN O
- HYPH O
affiliated VBN O
, , O
or CC O
community NN O
hospitals NNS O
during IN O
a DT O
6 CD O
- HYPH O
year NN O
period NN O
( , O
total NN O
of IN O
117 CD O
cumulative JJ O
hospital NN O
- HYPH O
years NNS O
) -RRB- O
. . O
null null null-Disease
PARTICIPANTS NNS O
: : O
Patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
MI NNP B-Disease
who WP O
received VBD O
lidocaine NN O
in IN O
the DT O
emergency NN O
department NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
Of IN O
29 CD O
patients NNS O
who WP O
received VBD O
lidocaine NN O
in IN O
the DT O
setting NN O
of IN O
cocaine NN O
- HYPH O
associated VBN O
MI NNP B-Disease
, , O
no DT O
patient NN O
died VBD O
; , O
exhibited VBD O
bradydysrhythmias NN B-Disease
, , O
ventricular JJ B-Disease
tachycardia NN I-Disease
, , O
or CC O
ventricular JJ B-Disease
fibrillation NN I-Disease
; , O
or CC O
experienced VBD O
seizures NNS B-Disease
after IN O
administration NN O
of IN O
lidocaine NN O
( : O
95 CD O
% NN O
confidence NN O
interval NN O
, , O
0 CD O
% NN O
to TO O
11 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Despite IN O
theoretical JJ O
concerns NNS O
that IN O
lidocaine NN O
may MD O
enhance VB O
cocaine NN O
toxicity NN B-Disease
, , O
the DT O
use NN O
of IN O
lidocaine NN O
in IN O
patients NNS O
with IN O
cocaine NN O
- HYPH O
associated VBN O
MI NNP B-Disease
was VBD O
not RB O
associated VBN O
with IN O
significant JJ O
cardiovascular JJ B-Disease
or CC I-Disease
central JJ I-Disease
nervous JJ I-Disease
system NN I-Disease
toxicity NN I-Disease
. . O
null null null-Disease
Experimental JJ O
progressive JJ O
muscular JJ B-Disease
dystrophy NN I-Disease
and CC O
its PRP$ O
treatment NN O
with IN O
high JJ O
doses NNS O
anabolizing VBG O
agents NNS O
. . O
null null null-Disease
We PRP O
are VBP O
still RB O
a DT O
long JJ O
way NN O
from IN O
discovering VBG O
an DT O
unequivocal JJ O
pathogenetic JJ O
interpretation NN O
of IN O
progressive JJ O
muscular JJ B-Disease
dystrophy NN I-Disease
in IN O
man NN O
. . O
null null null-Disease
Noteworthy JJ O
efforts NNS O
have VBP O
been VBN O
made VBN O
in IN O
the DT O
experimental JJ O
field NN O
; : O
a DT O
recessive JJ O
autosomic JJ O
form NN O
found VBN O
in IN O
the DT O
mouse NN O
seems VBZ O
to TO O
bear VB O
the DT O
closest JJS O
resemblance NN O
to IN O
the DT O
human JJ O
form NN O
from IN O
the DT O
genetic JJ O
point NN O
of IN O
view NN O
. . O
null null null-Disease
Myopathy NN B-Disease
due IN O
to IN O
lack NN O
of IN O
vitamin NN O
E NN O
and CC O
myopathy NN B-Disease
induced VBN O
by IN O
certain JJ O
viruses NNS O
have VBP O
much JJ O
in IN O
common JJ O
anatomically RB O
and CC O
pathologically RB O
with IN O
the DT O
human JJ O
form NN O
. . O
null null null-Disease
The DT O
authors NNS O
induced VBD O
myodystrophy NN B-Disease
in IN O
the DT O
rat NN O
by IN O
giving VBG O
it PRP O
a DT O
diet NN O
lacking VBG O
in IN O
vitamin NN O
E NN O
. . O
null null null-Disease
The DT O
pharmacological JJ O
characteristics NNS O
of IN O
vitamin NN O
E NN O
and CC O
the DT O
degenerative JJ O
changes NNS O
brought VBN O
about RP O
by IN O
its PRP$ O
deficiency NN O
, , O
especially RB O
in IN O
the DT O
muscles NNS O
, , O
are VBP O
illustrated VBN O
. . O
null null null-Disease
It PRP O
is VBZ O
thus RB O
confirmed VBN O
that IN O
the DT O
histological JJ O
characteristics NNS O
of IN O
myopathic JJ B-Disease
rat NN O
muscle NN O
induced VBN O
experimentally RB O
are VBP O
extraordinarily RB O
similar JJ O
to IN O
those DT O
of IN O
human JJ O
myopathy NN B-Disease
as IN O
confirmed VBN O
during IN O
biopsies NNS O
performed VBN O
at IN O
the DT O
Orthopaedic NNP O
Traumatological NNP O
Centre NNP O
, , O
Florence NNP O
. . O
null null null-Disease
The DT O
encouraging JJ O
results NNS O
obtained VBN O
in IN O
various JJ O
authoratative JJ O
departments NNS O
in IN O
myopathic JJ B-Disease
patients NNS O
by IN O
using VBG O
anabolizing NN O
steroids NNS O
have VBP O
encouraged VBN O
the DT O
authors NNS O
to TO O
investigate VB O
the DT O
beneficial JJ O
effects NNS O
of IN O
one CD O
anabolizing VBG O
agent NN O
( , O
Dianabol NNP O
, , O
CIBA NNP O
) -RRB- O
at IN O
high JJ O
doses NNS O
in IN O
rats NNS O
rendered VBN O
myopathic JJ B-Disease
by IN O
a DT O
diet NN O
deficient JJ O
in IN O
vitamin NN O
E NN O
. . O
null null null-Disease
In IN O
this DT O
way NN O
they PRP O
obtained VBD O
appreciable JJ O
changes NNS O
in IN O
body NN O
weight NN O
( , O
increased VBN O
from IN O
50 CD O
to IN O
70 CD O
g NN O
after IN O
forty CD O
days NNS O
at IN O
a DT O
dose NN O
of IN O
5 CD O
mg NNS O
per IN O
day NN O
of IN O
anabolizing NN O
agent NN O
) -RRB- O
, , O
but CC O
most JJS O
of IN O
all DT O
they PRP O
found VBD O
histological JJ O
changes NNS O
due IN O
to IN O
"""" `` O
regenerative JJ O
"""" '' O
changes NNS O
in IN O
the DT O
muscle NN O
tissue NN O
, , O
which WDT O
however RB O
maintained VBD O
its PRP$ O
myopathic JJ B-Disease
characteristics NNS O
in IN O
the DT O
control NN O
animals NNS O
that WDT O
were VBD O
not RB O
treated VBN O
with IN O
the DT O
anabolizing VBG O
agent NN O
. . O
null null null-Disease
The DT O
authors NNS O
conclude VBP O
by IN O
affirming VBG O
the DT O
undoubted JJ O
efficacy NN O
of IN O
the DT O
anabolizing VBG O
steroids NNS O
in IN O
experimental JJ O
myopathic JJ B-Disease
disease NN I-Disease
, , O
but CC O
they PRP O
have VBP O
reservations NNS O
as IN O
to IN O
the DT O
transfer NN O
of IN O
the DT O
results NNS O
into IN O
the DT O
human JJ O
field NN O
, , O
where WRB O
high JJ O
dosage NN O
cannot MD O
be VB O
carried VBN O
out RP O
continuously RB O
because IN O
of IN O
the DT O
effects NNS O
of IN O
the DT O
drug NN O
on IN O
virility NN O
; : O
because IN O
the DT O
tissue NN O
injury NN O
too RB O
often RB O
occurs VBZ O
at IN O
an DT O
irreversible JJ O
stage NN O
vis FW O
- HYPH O
a FW O
- HYPH O
vis FW O
the DT O
"""" `` O
regeneration NN O
"""" '' O
of IN O
the DT O
muscle NN O
tissue NN O
; : O
and CC O
finally RB O
because IN O
the DT O
dystrophic JJ O
injurious JJ O
agent NN O
is VBZ O
certainly RB O
not RB O
the DT O
lack NN O
of IN O
vitamin NN O
E NN O
but CC O
something NN O
as RB O
yet RB O
unknown JJ O
. . O
null null null-Disease
Paclitaxel NNP O
3 CD O
- HYPH O
hour NN O
infusion NN O
given VBN O
alone RB O
and CC O
combined VBN O
with IN O
carboplatin NN O
: : O
preliminary JJ O
results NNS O
of IN O
dose NN O
- HYPH O
escalation NN O
trials NNS O
. . O
null null null-Disease
Paclitaxel NNP O
( : O
Taxol NNP O
; : O
Bristol NNP O
- HYPH O
Myers NNP O
Squibb NNP O
Company NNP O
, , O
Princeton NNP O
, , O
NJ NNP O
) -RRB- O
by IN O
3 CD O
- HYPH O
hour NN O
infusion NN O
was VBD O
combined VBN O
with IN O
carboplatin NN O
in IN O
a DT O
phase NN O
I NNP O
/ SYM O
II NNP O
study NN O
directed VBN O
to IN O
patients NNS O
with IN O
non JJ B-Disease
- HYPH I-Disease
small JJ I-Disease
cell NN I-Disease
lung NN I-Disease
cancer NN I-Disease
. . O
null null null-Disease
Carboplatin NNP O
was VBD O
given VBN O
at IN O
a DT O
fixed VBN O
target NN O
area NN O
under IN O
the DT O
concentration NN O
- HYPH O
time NN O
curve NN O
of IN O
6 CD O
. . O
0 NFP O
by IN O
the DT O
Calvert NNP O
formula NN O
, , O
whereas IN O
paclitaxel NN O
was VBD O
escalated VBN O
in IN O
patient JJ O
cohorts NNS O
from IN O
150 CD O
mg NNS O
/ SYM O
m2 CD O
( HYPH O
dose NN O
level NN O
I NNP O
) -RRB- O
to IN O
175 CD O
, , O
200 CD O
, , O
225 CD O
, , O
and CC O
250 CD O
mg NNS O
/ SYM O
m2 CD O
. . O
null null null-Disease
The DT O
225 CD O
mg NN O
/ SYM O
m2 CD O
level NN O
was VBD O
expanded VBN O
for IN O
the DT O
phase NN O
II NNP O
study NN O
since IN O
the DT O
highest JJS O
level NN O
achieved VBD O
( , O
250 CD O
mg NNS O
/ SYM O
m2 CD O
) -RRB- O
required VBN O
modification NN O
because IN O
of IN O
nonhematologic JJ O
toxicities NNS B-Disease
( , O
arthralgia NN B-Disease
and CC O
sensory JJ B-Disease
neuropathy NN I-Disease
) -RRB- O
. . O
null null null-Disease
Therapeutic JJ O
effects NNS O
were VBD O
noted VBN O
at IN O
all DT O
dose NN O
levels NNS O
, , O
with IN O
objective JJ O
responses NNS O
in IN O
17 CD O
( , O
two CD O
complete JJ O
and CC O
15 CD O
partial JJ O
regressions NNS O
) , O
of IN O
41 CD O
previously RB O
untreated JJ O
patients NNS O
. . O
null null null-Disease
Toxicities NNS B-Disease
were VBD O
compared VBN O
with IN O
a DT O
cohort NN O
of IN O
patients NNS O
in IN O
a DT O
phase NN O
I NN O
trial NN O
of IN O
paclitaxel NN O
alone RB O
at IN O
identical JJ O
dose NN O
levels NNS O
. . O
null null null-Disease
Carboplatin NNP O
did VBD O
not RB O
appear VB O
to TO O
add VB O
to IN O
the DT O
hematologic JJ B-Disease
toxicities NNS I-Disease
observed VBN O
, , O
and CC O
the DT O
paclitaxel NN O
/ SYM O
carboplatin NN O
combination NN O
could MD O
be VB O
dosed VBN O
every DT O
3 CD O
weeks NNS O
. . O
null null null-Disease
The DT O
dose NN O
- HYPH O
dependent JJ O
effect NN O
of IN O
misoprostol NN O
on IN O
indomethacin NN O
- HYPH O
induced VBN O
renal JJ B-Disease
dysfunction NN I-Disease
in IN O
well RB O
compensated VBN O
cirrhosis NN B-Disease
. . O
null null null-Disease
Misoprostol NNP O
( : O
200 CD O
micrograms NNS O
) -RRB- O
has VBZ O
been VBN O
shown VBN O
to TO O
acutely RB O
counteract VB O
the DT O
indomethacin NN O
- HYPH O
induced VBN O
renal JJ B-Disease
dysfunction NN I-Disease
in IN O
well RB O
compensated VBN O
cirrhotic JJ B-Disease
patients NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
determine VB O
if IN O
the DT O
prophylactic JJ O
value NN O
of IN O
misoprostol NN O
was VBD O
dose NN O
- HYPH O
dependent JJ O
. . O
null null null-Disease
Parameters NNS O
of IN O
renal JJ O
hemodynamics NN O
and CC O
tubular JJ O
sodium NN O
and CC O
water NN O
handling NN O
were VBD O
assessed VBN O
by IN O
clearance NN O
techniques NNS O
in IN O
26 CD O
well RB O
compensated VBN O
cirrhotic JJ B-Disease
patients NNS O
before IN O
and CC O
after IN O
an DT O
oral JJ O
combination NN O
of IN O
50 CD O
mg NN O
of IN O
indomethacin NN O
and CC O
various JJ O
doses NNS O
of IN O
misoprostol NN O
. . O
null null null-Disease
The DT O
200 CD O
- HYPH O
micrograms NNS O
dose NN O
was VBD O
able JJ O
to TO O
totally RB O
abolish VB O
the DT O
deleterious JJ O
renal JJ O
effects NNS O
of IN O
indomethacin NN O
, , O
whereas IN O
the DT O
800 CD O
- HYPH O
micrograms NNS O
dose NN O
resulted VBD O
in IN O
significant JJ O
worsening NN O
of IN O
renal JJ O
hemodynamics NN O
and CC O
sodium NN O
retention NN O
. . O
null null null-Disease
These DT O
changes NNS O
were VBD O
maximal JJ O
in IN O
the DT O
hour NN O
immediately RB O
after IN O
medications NNS O
and CC O
slowly RB O
returned VBD O
toward IN O
base NN O
- HYPH O
line NN O
levels NNS O
thereafter RB O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
the DT O
renal JJ O
protective JJ O
effects NNS O
of IN O
misoprostol NN O
is VBZ O
dose NN O
- HYPH O
dependent JJ O
. . O
null null null-Disease
However RB O
, , O
until IN O
this DT O
apparent JJ O
ability NN O
of IN O
200 CD O
micrograms NNS O
of IN O
misoprostol NN O
to TO O
prevent VB O
the DT O
adverse JJ O
effects NNS O
of IN O
indomethacin NN O
on IN O
renal JJ O
function NN O
is VBZ O
confirmed VBN O
with IN O
chronic JJ O
frequent JJ O
dosing NN O
, , O
it PRP O
would MD O
be VB O
prudent JJ O
to TO O
avoid VB O
nonsteroidal JJ O
anti JJ O
- HYPH O
inflammatory JJ O
therapy NN O
in IN O
patients NNS O
with IN O
cirrhosis NN B-Disease
. . O
null null null-Disease
Increased JJ O
frequency NN O
and CC O
severity NN O
of IN O
angio NN B-Disease
- HYPH I-Disease
oedema NN I-Disease
related VBN O
to IN O
long JJ O
- HYPH O
term NN O
therapy NN O
with IN O
angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
inhibitor NN O
in IN O
two CD O
patients NNS O
. . O
null null null-Disease
Adverse JJ O
reactions NNS O
to IN O
drugs NNS O
are VBP O
well RB O
recognized VBN O
as IN O
a DT O
cause NN O
of IN O
acute JJ O
or CC O
chronic JJ O
urticaria NN B-Disease
, , O
and CC O
angio NN B-Disease
- HYPH I-Disease
oedema NN I-Disease
. . O
null null null-Disease
Angiotensin NN O
- HYPH O
converting VBG O
enzyme NN O
( -LRB- O
ACE NNP O
) -RRB- O
inhibitors NNS O
, , O
used VBN O
to TO O
treat VB O
hypertension NN B-Disease
and CC O
congestive JJ B-Disease
heart NN I-Disease
failure NN I-Disease
, , O
were VBD O
introduced VBN O
in IN O
Europe NNP O
in IN O
the DT O
middle NN O
of IN O
the DT O
eighties NNS O
, , O
and CC O
the DT O
use NN O
of IN O
these DT O
drugs NNS O
has VBZ O
increased VBN O
progressively RB O
. . O
null null null-Disease
Soon RB O
after IN O
the DT O
introduction NN O
of IN O
ACE NNP O
inhibitors NNS O
, , O
acute JJ O
bouts NNS O
of IN O
angio NN B-Disease
- HYPH I-Disease
oedema NN I-Disease
were VBD O
reported VBN O
in IN O
association NN O
with IN O
the DT O
use NN O
of IN O
these DT O
drugs NNS O
. . O
null null null-Disease
We PRP O
wish VBP O
to TO O
draw VB O
attention NN O
to IN O
the DT O
possibility NN O
of IN O
adverse JJ O
reactions NNS O
to IN O
ACE NNP O
inhibitors NNS O
after IN O
long JJ O
- HYPH O
term NN O
use NN O
and CC O
in IN O
patients NNS O
with IN O
pre NN O
- HYPH O
existing VBG O
angio NN B-Disease
- HYPH I-Disease
oedema NN I-Disease
. . O
null null null-Disease
Myoclonus NNP B-Disease
associated VBN O
with IN O
lorazepam NN O
therapy NN O
in IN O
very RB O
- HYPH O
low JJ O
- HYPH O
birth NN O
- HYPH O
weight NN O
infants NNS O
. . O
null null null-Disease
Lorazepam NNP O
is VBZ O
being VBG O
used VBN O
with IN O
increasing VBG O
frequency NN O
as IN O
a DT O
sedative NN O
in IN O
the DT O
newborn NN O
and CC O
the DT O
young JJ O
infant NN O
. . O
null null null-Disease
Concern NN O
has VBZ O
been VBN O
raised VBN O
with IN O
regard NN O
to IN O
the DT O
safety NN O
of IN O
lorazepam NN O
in IN O
this DT O
age NN O
group NN O
, , O
especially RB O
in IN O
very RB O
- HYPH O
low JJ O
- HYPH O
birth NN O
- HYPH O
weight NN O
( -LRB- O
VLBW NNP O
; : O
< $ O
1 CD O
, , O
500 CD O
g NNS O
) SYM O
infants NNS O
. . O
null null null-Disease
Three CD O
young JJ O
infants NNS O
, , O
all DT O
of IN O
birth NN O
weight NN O
< SYM O
1 CD O
, , O
500 CD O
g NN O
, , O
experienced VBD O
myoclonus NN B-Disease
following VBG O
the DT O
intravenous JJ O
administration NN O
of IN O
lorazepam NN O
. . O
null null null-Disease
The DT O
potential JJ O
neurotoxic JJ B-Disease
effects NNS O
of IN O
the DT O
drug NN O
( , O
and CC O
its PRP$ O
vehicle NN O
) -RRB- O
in IN O
this DT O
population NN O
are VBP O
discussed VBN O
. . O
null null null-Disease
Injectable JJ O
lorazepam NN O
should MD O
be VB O
used VBN O
with IN O
caution NN O
in IN O
VLBW NNP O
infants NNS O
. . O
null null null-Disease
Transvenous JJ O
right JJ O
ventricular JJ O
pacing NN O
during IN O
cardiopulmonary JJ O
resuscitation NN O
of IN O
pediatric JJ O
patients NNS O
with IN O
acute JJ O
cardiomyopathy NN B-Disease
. . O
null null null-Disease
We PRP O
describe VBP O
the DT O
cardiopulmonary JJ O
resuscitation NN O
efforts NNS O
on IN O
five CD O
patients NNS O
who WP O
presented VBD O
in IN O
acute JJ O
circulatory JJ B-Disease
failure NN I-Disease
from IN O
myocardial JJ B-Disease
dysfunction NN I-Disease
. . O
null null null-Disease
Three CD O
patients NNS O
had VBD O
acute JJ O
viral JJ O
myocarditis NN B-Disease
, , O
one CD O
had VBD O
a DT O
carbamazepine NN O
- HYPH O
induced VBN O
acute JJ O
eosinophilic JJ B-Disease
myocarditis NN I-Disease
, , O
and CC O
one CD O
had VBD O
cardiac JJ O
hemosiderosis NN O
resulting VBG O
in IN O
acute JJ O
cardiogenic JJ B-Disease
shock NN I-Disease
. . O
null null null-Disease
All DT O
patients NNS O
were VBD O
continuously RB O
monitored VBN O
with IN O
central JJ O
venous JJ O
and CC O
arterial JJ O
catheters NNS O
in IN O
addition NN O
to IN O
routine JJ O
noninvasive JJ O
monitoring NN O
. . O
null null null-Disease
An DT O
introducer NN O
sheath NN O
, , O
a DT O
pacemaker NN O
, , O
and CC O
sterile JJ O
pacing NN O
wires NNS O
were VBD O
made VBN O
readily RB O
available JJ O
for IN O
the DT O
patients NNS O
, , O
should MD O
the DT O
need NN O
arise VB O
to TO O
terminate VB O
resistant JJ O
cardiac JJ O
dysrhythmias NNS B-Disease
. . O
null null null-Disease
All DT O
patients NNS O
developed VBD O
cardiocirculatory JJ O
arrest NN O
associated VBN O
with IN O
extreme JJ O
hypotension NN B-Disease
and CC O
dysrhythmias NN B-Disease
within IN O
the DT O
first JJ O
48 CD O
hours NNS O
of IN O
their PRP$ O
admission NN O
to IN O
the DT O
pediatric JJ O
intensive JJ O
care NN O
unit NN O
( : O
PICU NNP O
) -RRB- O
. . O
null null null-Disease
Right JJ O
ventricular JJ O
pacemaker NN O
wires NNS O
were VBD O
inserted VBN O
in IN O
all DT O
of IN O
them PRP O
during IN O
cardiopulmonary JJ O
resuscitation NN O
( -LRB- O
CPR NN O
) -RRB- O
. . O
null null null-Disease
In IN O
four CD O
patients NNS O
, , O
cardiac JJ O
pacing NN O
was VBD O
used VBN O
, , O
resulting VBG O
in IN O
a DT O
temporary JJ O
captured VBN O
rhythm NN O
and CC O
restoration NN O
of IN O
their PRP$ O
cardiac JJ O
output NN O
. . O
null null null-Disease
These DT O
patients NNS O
had VBD O
a DT O
second JJ O
event NN O
of IN O
cardiac JJ B-Disease
arrest NN I-Disease
, , O
resulting VBG O
in IN O
death NN O
, , O
within IN O
10 CD O
to TO O
60 CD O
minutes NNS O
. . O
null null null-Disease
In IN O
one CD O
patient NN O
, , O
cardiac JJ O
pacing NN O
was VBD O
not RB O
used VBN O
, , O
because IN O
he PRP O
converted VBD O
to IN O
normal JJ O
sinus NN O
rhythm NN O
by IN O
electrical JJ O
defibrillation NN O
within IN O
three CD O
minutes NNS O
of IN O
initiating VBG O
CPR NN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
cardiac JJ O
pacing NN O
during IN O
resuscitative JJ O
efforts NNS O
in IN O
pediatric JJ O
patients NNS O
suffering VBG O
from IN O
acute JJ O
myocardial JJ B-Disease
dysfunction NN I-Disease
may MD O
not RB O
have VB O
long JJ O
- HYPH O
term NN O
value NN O
in IN O
and CC O
of IN O
itself PRP O
; : O
however RB O
, , O
if IN O
temporary JJ O
hemodynamic JJ O
stability NN O
is VBZ O
achieved VBN O
by IN O
this DT O
procedure NN O
, , O
it PRP O
may MD O
provide VB O
additional JJ O
time NN O
needed VBN O
to TO O
institute VB O
other JJ O
therapeutic JJ O
modalities NNS O
. . O
null null null-Disease
Efficacy NN O
and CC O
safety NN O
of IN O
granisetron NN O
, , O
a DT O
selective JJ O
5 CD O
- HYPH O
hydroxytryptamine NN O
- HYPH O
3 CD O
receptor NN O
antagonist NN O
, , O
in IN O
the DT O
prevention NN O
of IN O
nausea NN B-Disease
and CC O
vomiting NN B-Disease
induced VBN O
by IN O
high JJ O
- HYPH O
dose NN O
cisplatin NN O
. . O
null null null-Disease
PURPOSE NN O
: : O
To TO O
assess VB O
the DT O
antiemetic JJ O
effects NNS O
and CC O
safety NN O
profile NN O
of IN O
four CD O
different JJ O
doses NNS O
of IN O
granisetron NN O
( , O
Kytril NNP O
; : O
SmithKline NNP O
Beecham NNP O
Pharmaceuticals NNP O
, , O
Philadelphia NNP O
, , O
PA NNP O
) -RRB- O
when WRB O
administered VBN O
as IN O
a DT O
single JJ O
intravenous JJ O
( -LRB- O
IV NN O
) , O
dose NN O
for IN O
prophylaxis NN O
of IN O
cisplatin NN O
- HYPH O
induced VBN O
nausea NN B-Disease
and CC O
vomiting NN B-Disease
. . O
null null null-Disease
PATIENTS NNS O
AND CC O
METHODS NNS O
: : O
One CD O
hundred CD O
eighty CD O
- HYPH O
four CD O
chemotherapy NN O
- HYPH O
naive JJ O
patients NNS O
receiving VBG O
high JJ O
- HYPH O
dose NN O
cisplatin NN O
( : O
81 CD O
to TO O
120 CD O
mg NNS O
/ SYM O
m2 CD O
) -RRB- O
were VBD O
randomized VBN O
to TO O
receive VB O
one CD O
of IN O
four CD O
granisetron NN O
doses NNS O
( : O
5 CD O
, , O
10 CD O
, , O
20 CD O
, , O
or CC O
40 CD O
micrograms NNS O
/ SYM O
kg NNS O
) , O
administered VBN O
before IN O
chemotherapy NN O
. . O
null null null-Disease
Patients NNS O
were VBD O
observed VBN O
on IN O
an DT O
inpatient JJ O
basis NN O
for IN O
18 CD O
to TO O
24 CD O
hours NNS O
, , O
and CC O
vital JJ O
signs NNS O
, , O
nausea NN B-Disease
, , O
vomiting NN B-Disease
, , O
retching NN O
, , O
and CC O
appetite NN O
were VBD O
assessed VBN O
. . O
null null null-Disease
Safety NN O
analyses NNS O
included VBD O
incidence NN O
of IN O
adverse JJ O
experiences NNS O
and CC O
laboratory NN O
parameter NN O
changes NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
After IN O
granisetron NN O
doses NNS O
of IN O
5 CD O
, , O
10 CD O
, , O
20 CD O
, , O
and CC O
40 CD O
micrograms NNS O
/ SYM O
kg NNS O
, , O
a DT O
major JJ O
response NN O
( : O
< : O
or CC O
= SYM O
two CD O
vomiting NN B-Disease
or CC O
retching NN O
episodes NNS O
, , O
and CC O
no DT O
antiemetic JJ O
rescue NN O
) , O
was VBD O
recorded VBN O
in IN O
23 CD O
% NN O
, , O
57 CD O
% NN O
, , O
58 CD O
% NN O
, , O
and CC O
60 CD O
% NN O
of IN O
patients NNS O
, , O
respectively RB O
, , O
and CC O
a DT O
complete JJ O
response NN O
( , O
no DT O
vomiting NN B-Disease
or CC O
retching NN O
, , O
and CC O
no DT O
antiemetic JJ O
rescue NN O
) -RRB- O
in IN O
18 CD O
% NN O
, , O
41 CD O
% NN O
, , O
40 CD O
% NN O
, , O
and CC O
47 CD O
% NN O
of IN O
patients NNS O
, , O
respectively RB O
. . O
null null null-Disease
There EX O
was VBD O
a DT O
statistically RB O
longer JJR O
time NN O
to IN O
first JJ O
episode NN O
of IN O
nausea NN B-Disease
( , O
P NN O
= : O
. . O
0015 CD O
) -RRB- O
and CC O
vomiting NN B-Disease
( , O
P NN O
= SYM O
. . O
0001 CD O
) -RRB- O
, , O
and CC O
fewer JJR O
patients NNS O
were VBD O
administered VBN O
additional JJ O
antiemetic JJ O
medication NN O
in IN O
the DT O
10 CD O
- HYPH O
micrograms NNS O
/ SYM O
kg NNS O
dosing NN O
groups NNS O
than IN O
in IN O
the DT O
5 CD O
- HYPH O
micrograms NNS O
/ SYM O
kg NN O
dosing NN O
group NN O
. . O
null null null-Disease
As IN O
granisetron NN O
dose NN O
increased VBD O
, , O
appetite NN O
return NN O
increased VBD O
( : O
P NN O
= SYM O
. . O
040 CD O
) -RRB- O
. . O
null null null-Disease
Headache NN B-Disease
was VBD O
the DT O
most RBS O
frequently RB O
reported VBN O
adverse JJ O
event NN O
( : O
20 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
CONCLUSION NN O
: : O
A DT O
single JJ O
10 CD O
- HYPH O
, , O
20 CD O
- HYPH O
, , O
or CC O
40 CD O
- HYPH O
micrograms NNS O
/ SYM O
kg NN O
dose NN O
of IN O
granisetron NN O
was VBD O
effective JJ O
in IN O
controlling VBG O
vomiting NN B-Disease
in IN O
57 CD O
% NN O
to TO O
60 CD O
% NN O
of IN O
patients NNS O
who WP O
received VBD O
cisplatin NN O
at IN O
doses NNS O
greater JJR O
than IN O
81 CD O
mg NNS O
/ SYM O
m2 CD O
and CC O
totally RB O
prevented VBD O
vomiting VBG B-Disease
in IN O
40 CD O
% NN O
to TO O
47 CD O
% NN O
of IN O
patients NNS O
. . O
null null null-Disease
There EX O
were VBD O
no DT O
statistically RB O
significant JJ O
differences NNS O
in IN O
efficacy NN O
between IN O
the DT O
10 CD O
- HYPH O
micrograms NNS O
/ SYM O
kg NN O
dose NN O
and CC O
the DT O
20 CD O
- HYPH O
and CC O
40 CD O
- HYPH O
micrograms NNS O
/ SYM O
kg NN O
doses NNS O
. . O
null null null-Disease
Granisetron NNP O
was VBD O
well RB O
tolerated VBN O
at IN O
all DT O
doses NNS O
. . O
null null null-Disease
Adverse JJ O
interaction NN O
between IN O
clonidine NN O
and CC O
verapamil NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
report VB O
two CD O
cases NNS O
of IN O
a DT O
possible JJ O
adverse JJ O
interaction NN O
between IN O
clonidine NN O
and CC O
verapamil NN O
resulting VBG O
in IN O
atrioventricular JJ B-Disease
( -LRB- I-Disease
AV NN I-Disease
) -RRB- I-Disease
block NN I-Disease
in IN O
both DT O
patients NNS O
and CC O
severe JJ O
hypotension NN B-Disease
in IN O
one CD O
patient NN O
. . O
null null null-Disease
CASE NNP O
SUMMARIES NNPS O
: : O
A DT O
54 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
hyperaldosteronism NN B-Disease
was VBD O
treated VBN O
with IN O
verapamil NN O
480 CD O
mg NNS O
/ SYM O
d NN O
and CC O
spironolactone NN O
100 CD O
mg NN O
/ SYM O
d NN O
. . O
null null null-Disease
After IN O
the DT O
addition NN O
of IN O
a DT O
minimal JJ O
dose NN O
of IN O
clonidine NN O
( : O
0 CD O
. . O
15 CD O
mg NN O
bid NN O
) -RRB- O
, , O
she PRP O
developed VBD O
complete JJ O
AV NN B-Disease
block NN I-Disease
and CC O
severe JJ O
hypotension NN B-Disease
, , O
which WDT O
resolved VBD O
upon IN O
cessation NN O
of IN O
all DT O
medications NNS O
. . O
null null null-Disease
A DT O
65 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
was VBD O
treated VBN O
with IN O
extended VBN O
- HYPH O
release NN O
verapamil NN O
240 CD O
mg NN O
/ SYM O
d JJ O
. . O
null null null-Disease
After IN O
the DT O
addition NN O
of IN O
clonidine NN O
0 CD O
. . O
15 CD O
mg NN O
bid NN O
she PRP O
developed VBD O
complete JJ O
AV NN B-Disease
block NN I-Disease
, , O
which WDT O
resolved VBD O
after IN O
all DT O
therapy NN O
was VBD O
stopped VBN O
. . O
null null null-Disease
DISCUSSION NN O
: : O
An DT O
adverse JJ O
interaction NN O
between IN O
clonidine NN O
and CC O
verapamil NN O
has VBZ O
not RB O
been VBN O
reported VBN O
previously RB O
. . O
null null null-Disease
We PRP O
describe VBP O
two CD O
such JJ O
cases NNS O
and CC O
discuss VBP O
the DT O
various JJ O
mechanisms NNS O
that WDT O
might MD O
cause VB O
such PDT O
an DT O
interaction NN O
. . O
null null null-Disease
Clinicians NNS O
should MD O
be VB O
acquainted VBN O
with IN O
this DT O
possibly RB O
fatal JJ O
interaction NN O
between IN O
two CD O
commonly RB O
used VBN O
antihypertensive JJ O
drugs NNS O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
Caution NN O
is VBZ O
recommended VBN O
in IN O
combining VBG O
clonidine NN O
and CC O
verapamil NN O
therapy NN O
, , O
even RB O
in IN O
patients NNS O
who WP O
do VBP O
not RB O
have VB O
sinus NN O
or CC O
AV NN O
node NN O
dysfunction NN O
. . O
null null null-Disease
The DT O
two CD O
drugs NNS O
may MD O
act VB O
synergistically RB O
on IN O
both CC O
the DT O
AV NN O
node NN O
and CC O
the DT O
peripheral JJ O
circulation NN O
. . O
null null null-Disease
Pharmacological JJ O
studies NNS O
on IN O
a DT O
new JJ O
dihydrothienopyridine NN O
calcium NN O
antagonist NN O
, , O
S NNP O
- HYPH O
312 CD O
- HYPH O
d NN O
. . O
null null null-Disease
5th JJ O
communication NN O
: : O
anticonvulsant JJ O
effects NNS O
in IN O
mice NNS O
. . O
null null null-Disease
S NNP O
- HYPH O
312 CD O
, , O
S NNP O
- HYPH O
312 CD O
- HYPH O
d NN O
, , O
but CC O
not RB O
S NNP O
- HYPH O
312 CD O
- HYPH O
l NN O
, , O
L NN O
- HYPH O
type NN O
calcium NN O
channel NN O
antagonists NNS O
, , O
showed VBD O
anticonvulsant JJ O
effects NNS O
on IN O
the DT O
audiogenic JJ B-Disease
tonic NN I-Disease
convulsions NNS I-Disease
in IN O
DBA NNP O
/ SYM O
2 CD O
mice NNS O
; : O
and CC O
their PRP$ O
ED50 NN O
values NNS O
were VBD O
18 CD O
. . O
4 CD O
( SYM O
12 CD O
. . O
8 CD O
- HYPH O
27 CD O
. . O
1 CD O
) SYM O
mg CD O
/ SYM O
kg NN O
, , O
p UH O
. . O
o NFP O
. . O
and CC O
15 CD O
. . O
0 CD O
( SYM O
10 CD O
. . O
2 CD O
- HYPH O
23 CD O
. . O
7 CD O
) SYM O
mg NN O
/ SYM O
kg NN O
, , O
p UH O
. . O
o NFP O
. . O
, , O
respectively RB O
, , O
while IN O
that DT O
of IN O
flunarizine NN O
was VBD O
34 CD O
. . O
0 CD O
( SYM O
26 CD O
. . O
0 CD O
- HYPH O
44 CD O
. . O
8 CD O
) SYM O
mg CD O
/ SYM O
kg NN O
, , O
p UH O
. . O
o NFP O
. . O
null null null-Disease
Although IN O
moderate JJ O
anticonvulsant JJ O
effects NNS O
of IN O
S NNP O
- HYPH O
312 CD O
- HYPH O
d VBN O
in IN O
higher JJR O
doses NNS O
were VBD O
observed VBN O
against IN O
the DT O
clonic JJ O
convulsions NNS B-Disease
induced VBN O
by IN O
pentylenetetrazole NN O
( , O
85 CD O
mg NNS O
/ SYM O
kg NNS O
, , O
s NNS O
. . O
c NN O
. . O
) -RRB- O
or CC O
bemegride NN O
( , O
40 CD O
mg NNS O
/ SYM O
kg NNS O
, , O
s NNS O
. . O
c NN O
. . O
) -RRB- O
, , O
no DT O
effects NNS O
were VBD O
observed VBN O
in IN O
convulsions NNS B-Disease
induced VBN O
by IN O
N NNP O
- HYPH O
methyl NN O
- HYPH O
D NN O
- HYPH O
aspartate NN O
, , O
picrotoxin NN O
, , O
or CC O
electroshock NN O
in IN O
Slc NNP O
: : O
ddY NN O
mice NNS O
. . O
null null null-Disease
S NNP O
- HYPH O
312 CD O
- HYPH O
d NN O
may MD O
be VB O
useful JJ O
in IN O
the DT O
therapy NN O
of IN O
certain JJ O
types NNS O
of IN O
human JJ O
epilepsy NN B-Disease
. . O
null null null-Disease
Transmural JJ O
myocardial JJ B-Disease
infarction NN I-Disease
with IN O
sumatriptan NN O
. . O
null null null-Disease
For IN O
sumatriptan NN O
, , O
tightness NN O
in IN O
the DT O
chest NN O
caused VBN O
by IN O
an DT O
unknown JJ O
mechanism NN O
has VBZ O
been VBN O
reported VBN O
in IN O
3 CD O
- SYM O
5 CD O
% NN O
of IN O
users NNS O
. . O
null null null-Disease
We PRP O
describe VBP O
a DT O
47 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
an DT O
acute JJ O
myocardial JJ B-Disease
infarction NN I-Disease
after IN O
administration NN O
of IN O
sumatriptan NN O
6 CD O
mg NN O
subcutaneously RB O
for IN O
cluster NN B-Disease
headache NN I-Disease
. . O
null null null-Disease
The DT O
patient NN O
had VBD O
no DT O
history NN O
of IN O
underlying VBG O
ischaemic JJ B-Disease
heart NN I-Disease
disease NN I-Disease
or CC O
Prinzmetal NNP B-Disease
' POS I-Disease
s NN I-Disease
angina NN I-Disease
. . O
null null null-Disease
She PRP O
recovered VBD O
without IN O
complications NNS O
. . O
null null null-Disease
Flumazenil NNP O
induces VBZ O
seizures NNS B-Disease
and CC O
death NN O
in IN O
mixed JJ O
cocaine NN O
- HYPH O
diazepam NN O
intoxications NNS O
. . O
null null null-Disease
STUDY NN O
HYPOTHESIS NN O
: : O
Administration NN O
of IN O
the DT O
benzodiazepine NN O
antagonist NN O
flumazenil NN O
may MD O
unmask VB O
seizures NNS B-Disease
in IN O
mixed JJ O
cocaine NN O
- HYPH O
benzodiazepine NN O
intoxication NN O
. . O
null null null-Disease
DESIGN NN O
: : O
Male NNP O
Sprague NNP O
- HYPH O
Dawley NNP O
rats NNS O
received VBD O
100 CD O
mg CD O
/ SYM O
kg NN O
cocaine NN O
IP NN O
alone RB O
, , O
5 CD O
mg NN O
/ SYM O
kg NN O
diazepam NN O
alone RB O
, , O
or CC O
a DT O
combination NN O
of IN O
diazepam NN O
and CC O
cocaine NN O
. . O
null null null-Disease
Three CD O
minutes NNS O
later RB O
, , O
groups NNS O
were VBD O
challenged VBN O
with IN O
vehicle NN O
or CC O
flumazenil NN O
5 CD O
or CC O
10 CD O
mg NN O
/ SYM O
kg NN O
IP NN O
. . O
null null null-Disease
Animal NN O
behavior NN O
, , O
seizures NNS B-Disease
( , O
time NN O
to IN O
and CC O
incidence NN O
) -RRB- O
, , O
death NN O
( , O
time NN O
to IN O
and CC O
incidence NN O
) -RRB- O
, , O
and CC O
cortical JJ O
EEG NNP O
tracings NNS O
were VBD O
recorded VBN O
. . O
null null null-Disease
INTERVENTIONS NNS O
: : O
Administration NN O
of IN O
flumazenil NN O
to IN O
animals NNS O
after IN O
they PRP O
had VBD O
received VBN O
a DT O
combination NN O
dose NN O
of IN O
cocaine NN O
and CC O
diazepam NN O
. . O
null null null-Disease
RESULTS NNS O
: : O
In IN O
group NN O
1 CD O
, , O
animals NNS O
received VBD O
cocaine NN O
followed VBN O
by IN O
vehicle NN O
. . O
null null null-Disease
This DT O
resulted VBD O
in IN O
100 CD O
% NN O
developing VBG O
seizures NNS B-Disease
and CC O
death NN O
. . O
null null null-Disease
Group NNP O
2 CD O
received VBD O
diazepam NN O
alone RB O
followed VBN O
by IN O
vehicle NN O
. . O
null null null-Disease
Animals NNS O
became VBD O
somnolent JJ O
and CC O
none NN O
died VBD O
. . O
null null null-Disease
Group NN O
3 CD O
received VBD O
diazepam NN O
followed VBN O
by IN O
5 CD O
mg NNS O
/ SYM O
kg NN O
flumazenil NN O
. . O
null null null-Disease
Animals NNS O
became VBD O
somnolent JJ O
after IN O
diazepam NN O
and CC O
then RB O
active JJ O
after IN O
flumazenil NN O
administration NN O
. . O
null null null-Disease
In IN O
group NN O
4 CD O
, , O
a DT O
combination NN O
of IN O
cocaine NN O
and CC O
diazepam NN O
was VBD O
administered VBN O
simultaneously RB O
. . O
null null null-Disease
This DT O
resulted VBD O
in IN O
no DT O
overt JJ O
or CC O
EEG NNP O
- HYPH O
detectable JJ O
seizures NNS B-Disease
and CC O
a DT O
50 CD O
% NN O
incidence NN O
of IN O
death NN O
. . O
null null null-Disease
Group NNP O
5 CD O
received VBD O
a DT O
similar JJ O
combination NN O
of IN O
cocaine NN O
and CC O
diazepam NN O
, , O
followed VBN O
later RB O
by IN O
5 CD O
mg NN O
/ SYM O
kg NN O
flumazenil NN O
. . O
null null null-Disease
This DT O
resulted VBD O
in IN O
an DT O
increased VBN O
incidence NN O
of IN O
seizures NNS B-Disease
, , O
90 CD O
% NN O
( , O
P NN O
< NN O
. . O
01 CD O
) -RRB- O
, , O
and CC O
death NN O
, , O
100 CD O
% NN O
( , O
P NN O
< , O
or CC O
= SYM O
. . O
01 CD O
) -RRB- O
, , O
compared VBN O
with IN O
group NN O
4 CD O
. . O
null null null-Disease
Group NN O
6 CD O
received VBD O
cocaine NN O
and CC O
diazepam NN O
followed VBN O
by IN O
10 CD O
mg NNS O
/ SYM O
kg NN O
flumazenil NN O
. . O
null null null-Disease
This DT O
also RB O
resulted VBD O
in IN O
an DT O
increased VBN O
incidence NN O
of IN O
seizures NNS B-Disease
, , O
90 CD O
% NN O
( , O
P NN O
< , O
or CC O
= SYM O
. . O
01 CD O
) -RRB- O
, , O
and CC O
death NN O
, , O
90 CD O
% NN O
( , O
P NN O
< , O
or CC O
= SYM O
. . O
05 CD O
) -RRB- O
, , O
compared VBN O
with IN O
group NN O
4 CD O
. . O
null null null-Disease
CONCLUSION NN O
: : O
Flumazenil NNP O
can MD O
unmask VB O
seizures NNS B-Disease
and CC O
increase VB O
the DT O
incidence NN O
of IN O
death NN O
in IN O
a DT O
model NN O
of IN O
combined VBN O
cocaine NN O
- HYPH O
diazepam NN O
intoxications NNS O
. . O
null null null-Disease
Mechanisms NNS O
for IN O
protective JJ O
effects NNS O
of IN O
free JJ O
radical JJ O
scavengers NNS O
on IN O
gentamicin NN O
- HYPH O
mediated VBN O
nephropathy NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
Studies NNS O
were VBD O
performed VBN O
to TO O
examine VB O
the DT O
mechanisms NNS O
for IN O
the DT O
protective JJ O
effects NNS O
of IN O
free JJ O
radical JJ O
scavengers NNS O
on IN O
gentamicin NN O
( , O
GM NNP O
) -RRB- O
- HYPH O
mediated VBN O
nephropathy NN B-Disease
. . O
null null null-Disease
Administration NN O
of IN O
GM NNP O
at IN O
40 CD O
mg NN O
/ SYM O
kg NN O
sc NNS O
for IN O
13 CD O
days NNS O
to IN O
rats NNS O
induced VBD O
a DT O
significant JJ O
reduction NN O
in IN O
renal JJ O
blood NN O
flow NN O
( , O
RBF NN O
) -RRB- O
and CC O
inulin NN O
clearance NN O
( -LRB- O
CIn NNP O
) -RRB- O
as RB O
well RB O
as IN O
marked VBN O
tubular JJ B-Disease
damage NN I-Disease
. . O
null null null-Disease
A DT O
significant JJ O
reduction NN O
in IN O
urinary JJ O
guanosine NN O
3 CD O
' '' O
, , O
5 CD O
' '' O
- HYPH O
cyclic JJ O
monophosphate NN O
( -LRB- O
cGMP NN O
) -RRB- O
excretion NN O
and CC O
a DT O
significant JJ O
increase NN O
in IN O
renal JJ O
cortical JJ O
renin NN O
and CC O
endothelin NN O
- HYPH O
1 CD O
contents NNS O
were VBD O
also RB O
observed VBN O
in IN O
GM NNP O
- HYPH O
mediated VBN O
nephropathy NN B-Disease
. . O
null null null-Disease
Superoxide NN O
dismutase NN O
( -LRB- O
SOD NN O
) -RRB- O
or CC O
dimethylthiourea NN O
( , O
DMTU NNP O
) -RRB- O
significantly RB O
lessened VBD O
the DT O
GM NNP O
- HYPH O
induced VBN O
decrement NN O
in IN O
CIn NNP O
. . O
null null null-Disease
The DT O
SOD NN O
- HYPH O
induced VBN O
increase NN O
in IN O
glomerular JJ O
filtration NN O
rate NN O
was VBD O
associated VBN O
with IN O
a DT O
marked JJ O
improvement NN O
in IN O
RBF NNP O
, , O
an DT O
increase NN O
in IN O
urinary JJ O
cGMP NN O
excretion NN O
, , O
and CC O
a DT O
decrease NN O
in IN O
renal JJ O
renin NN O
and CC O
endothelin NN O
- HYPH O
1 CD O
content NN O
. . O
null null null-Disease
SOD NNP O
did VBD O
not RB O
attenuate VB O
the DT O
tubular JJ B-Disease
damage NN I-Disease
. . O
null null null-Disease
In IN O
contrast NN O
, , O
DMTU NNP O
significantly RB O
reduced VBD O
the DT O
tubular JJ B-Disease
damage NN I-Disease
and CC O
lipid NN O
peroxidation NN O
, , O
but CC O
it PRP O
did VBD O
not RB O
affect VB O
renal JJ O
hemodynamics NN O
and CC O
vasoactive JJ O
substances NNS O
. . O
null null null-Disease
Neither CC O
SOD NNP O
nor CC O
DMTU NNP O
affected VBD O
the DT O
renal JJ O
cortical JJ O
GM NNP O
content NN O
in IN O
GM NNP O
- HYPH O
treated VBN O
rats NNS O
. . O
null null null-Disease
These DT O
results NNS O
suggest VBP O
that IN O
1 CD O
) , O
both CC O
SOD NNP O
and CC O
DMTU NNP O
have VBP O
protective JJ O
effects NNS O
on IN O
GM NNP O
- HYPH O
mediated VBN O
nephropathy NN B-Disease
, , O
2 CD O
) , O
the DT O
mechanisms NNS O
for IN O
the DT O
protective JJ O
effects NNS O
differ VBP O
for IN O
SOD NNP O
and CC O
DMTU NNP O
, , O
and CC O
3 CD O
) SYM O
superoxide NN O
anions NNS O
play VBP O
a DT O
critical JJ O
role NN O
in IN O
GM NNP O
- HYPH O
induced VBN O
renal JJ O
vasoconstriction NN O
. . O
null null null-Disease
Cephalothin NNP O
- HYPH O
induced VBN O
immune JJ O
hemolytic JJ B-Disease
anemia NN I-Disease
. . O
null null null-Disease
A DT O
patient NN O
with IN O
renal JJ B-Disease
disease NN I-Disease
developed VBD O
Coombs NNP O
- HYPH O
positive JJ O
hemolytic JJ B-Disease
anemia NN I-Disease
while IN O
receiving VBG O
cephalothin NN O
therapy NN O
. . O
null null null-Disease
An DT O
anti AFX O
- HYPH O
cephalothin NN O
IgG NNP O
antibody NN O
was VBD O
detected VBN O
in IN O
the DT O
patient NN O
' POS O
s NNS O
serum NN O
and CC O
in IN O
the DT O
eluates NNS O
from IN O
her PRP$ O
erythrocytes NNS O
. . O
null null null-Disease
In IN O
addition NN O
, , O
nonimmunologic JJ O
binding NN O
of IN O
normal JJ O
and CC O
patient NN O
' '' O
s NNS O
serum NN O
proteins NNS O
to IN O
her PRP$ O
own JJ O
and CC O
cephalothin NN O
- HYPH O
coated VBN O
normal JJ O
red JJ O
cells NNS O
was VBD O
demonstrated VBN O
. . O
null null null-Disease
Skin NN O
tests NNS O
and CC O
in FW O
vitro FW O
lymphocyte NN O
stimulation NN O
revealed VBD O
that IN O
the DT O
patient NN O
was VBD O
sensitized VBN O
to IN O
cephalothin NN O
and CC O
also RB O
to IN O
ampicillin NN O
. . O
null null null-Disease
Careful JJ O
investigation NN O
of IN O
drug NN O
- HYPH O
induced VBN O
hemolytic JJ B-Disease
anemias NNS I-Disease
reveals VBZ O
the DT O
complexity NN O
of IN O
the DT O
immune JJ O
mechanisms NNS O
involved VBN O
. . O
null null null-Disease
Assessment NN O
of IN O
cardiomyocyte NN O
DNA NN O
synthesis NN O
during IN O
hypertrophy NN B-Disease
in IN O
adult NN O
mice NNS O
. . O
null null null-Disease
The DT O
ability NN O
of IN O
cardiomyocytes NNS O
to TO O
synthesize VB O
DNA NN O
in IN O
response NN O
to IN O
experimentally RB O
induced VBN O
cardiac JJ B-Disease
hypertrophy NN I-Disease
was VBD O
assessed VBN O
in IN O
adult NN O
mice NNS O
. . O
null null null-Disease
Isoproterenol NN O
delivered VBN O
by IN O
osmotic JJ O
minipump NN O
implantation NN O
in IN O
adult NN O
C3Heb NNP O
/ SYM O
FeJ NNP O
mice NNS O
resulted VBD O
in IN O
a DT O
46 CD O
% NN O
increase NN O
in IN O
heart NN O
weight NN O
and CC O
a DT O
19 CD O
. . O
3 CD O
% NN O
increase NN O
in IN O
cardiomyocyte NN O
area NN O
. . O
null null null-Disease
No DT O
DNA NN O
synthesis NN O
, , O
as IN O
assessed VBN O
by IN O
autoradiographic JJ O
analysis NN O
of IN O
isolated VBN O
cardiomyocytes NNS O
, , O
was VBD O
observed VBN O
in IN O
control NN O
or CC O
hypertrophic JJ B-Disease
hearts NNS I-Disease
. . O
null null null-Disease
A DT O
survey NN O
of IN O
15 CD O
independent JJ O
inbred NN O
strains NNS O
of IN O
mice NNS O
revealed VBD O
that IN O
ventricular JJ O
cardiomyocyte NN O
nuclear JJ O
number NN O
ranged VBD O
from IN O
3 CD O
to IN O
13 CD O
% NN O
mononucleate NN O
, , O
suggesting VBG O
that IN O
cardiomyocyte NN O
terminal JJ O
differentiation NN O
is VBZ O
influenced VBN O
directly RB O
or CC O
indirectly RB O
by IN O
genetic JJ O
background NN O
. . O
null null null-Disease
To TO O
determine VB O
whether IN O
the DT O
capacity NN O
for IN O
reactive JJ O
DNA NN O
synthesis NN O
was VBD O
also RB O
subject JJ O
to IN O
genetic JJ O
regulation NN O
, , O
cardiac JJ B-Disease
hypertrophy NN I-Disease
was VBD O
induced VBN O
in IN O
the DT O
strains NNS O
of IN O
mice NNS O
comprising VBG O
the DT O
extremes NNS O
of IN O
the DT O
nuclear JJ O
number NN O
survey NN O
. . O
null null null-Disease
These DT O
data NNS O
indicate VBP O
that IN O
adult NN O
mouse NN O
atrial JJ O
and CC O
ventricular JJ O
cardiomyocytes NNS O
do VBP O
not RB O
synthesize VB O
DNA NN O
in IN O
response NN O
to IN O
isoproterenol NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
hypertrophy NN I-Disease
. . O
null null null-Disease
Central JJ O
cardiovascular JJ O
effects NNS O
of IN O
AVP NNP O
and CC O
ANP NNP O
in IN O
normotensive JJ O
and CC O
spontaneously RB O
hypertensive JJ B-Disease
rats NNS O
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
compare VB O
influence NN O
of IN O
central JJ O
arginine NN O
vasopressin NN O
( , O
AVP NN O
) -RRB- O
and CC O
of IN O
atrial JJ O
natriuretic JJ O
peptide NN O
( , O
ANP NNP O
) -RRB- O
on IN O
control NN O
of IN O
arterial JJ O
blood NN O
pressure NN O
( , O
MAP NN O
) -RRB- O
and CC O
heart NN O
rate NN O
( -LRB- O
HR NN O
) -RRB- O
in IN O
normotensive JJ O
( , O
WKY NNP O
) -RRB- O
and CC O
spontaneously RB O
hypertensive JJ B-Disease
( -LRB- O
SHR NN O
) -RRB- O
rats NNS O
. . O
null null null-Disease
Three CD O
series NN O
of IN O
experiments NNS O
were VBD O
performed VBN O
on IN O
30 CD O
WKY NNP O
and CC O
30 CD O
SHR NN O
, , O
chronically RB O
instrumented VBN O
with IN O
guide NN O
tubes NNS O
in IN O
the DT O
lateral JJ O
ventricle NN O
( , O
LV NN O
) -RRB- O
and CC O
arterial JJ O
and CC O
venous JJ O
catheters NNS O
. . O
null null null-Disease
MAP NNP O
and CC O
HR NNP O
were VBD O
monitored VBN O
before IN O
and CC O
after IN O
i PRP O
. . O
v NN O
. . O
injections NNS O
of IN O
either DT O
vehicle NN O
or CC O
1 CD O
, , O
10 CD O
and CC O
50 CD O
ng NN O
of IN O
AVP NNP O
and CC O
25 CD O
, , O
125 CD O
and CC O
500 CD O
ng NNS O
of IN O
ANP NNP O
. . O
null null null-Disease
Sensitivity NN O
of IN O
cardiac JJ O
component NN O
of IN O
baroreflex NN O
( -LRB- O
CCB NNP O
) -RRB- O
, , O
expressed VBN O
as IN O
a DT O
slope NN O
of IN O
the DT O
regression NN O
line NN O
was VBD O
determined VBN O
from IN O
relationships NNS O
between IN O
systolic JJ O
arterial JJ O
pressure NN O
( , O
SAP NNP O
) -RRB- O
and CC O
HR NN O
period NN O
( , O
HRp NNP O
) -RRB- O
during IN O
phenylephrine NN O
( , O
Phe NNP O
) -RRB- O
- HYPH O
induced VBN O
hypertension NN B-Disease
and CC O
sodium NN O
nitroprusside NN O
( -LRB- O
SN NNP O
) -RRB- O
- HYPH O
induced VBN O
hypotension NN B-Disease
. . O
null null null-Disease
CCB NNP O
was VBD O
measured VBN O
before IN O
and CC O
after IN O
administration NN O
of IN O
either DT O
vehicle NN O
, , O
AVP NNP O
, , O
ANP NNP O
, , O
or CC O
both DT O
peptides NNS O
together RB O
. . O
null null null-Disease
Increases NNS O
of IN O
MAP NNP O
occurred VBD O
after IN O
LV NNP O
administration NN O
of IN O
1 CD O
, , O
10 CD O
and CC O
50 CD O
ng NNS O
of IN O
AVP NNP O
in IN O
WKY NNP O
and CC O
of IN O
10 CD O
and CC O
50 CD O
ng NN O
in IN O
SHR NNP O
. . O
null null null-Disease
ANP NNP O
did VBD O
not RB O
cause VB O
significant JJ O
changes NNS O
in IN O
MAP NNP O
in IN O
both DT O
strains NNS O
as IN O
compared VBN O
to IN O
vehicle NN O
, , O
but CC O
it PRP O
abolished VBD O
AVP NNP O
- HYPH O
induced VBN O
MAP NNP O
increase NN O
in IN O
WKY NNP O
and CC O
SHR NNP O
. . O
null null null-Disease
CCB NNP O
was VBD O
reduced VBN O
in IN O
WKY NNP O
and CC O
SHR NNP O
after IN O
LV NNP O
administration NN O
of IN O
AVP NNP O
during IN O
SN NNP O
- HYPH O
induced VBN O
hypotension NN B-Disease
. . O
null null null-Disease
In IN O
SHR NNP O
but CC O
not RB O
in IN O
WKY NNP O
administration NN O
of IN O
ANP NNP O
, , O
AVP NNP O
and CC O
ANP NNP O
+ CC O
AVP NNP O
decreased VBD O
CCB NNP O
during IN O
Phe NNP O
- HYPH O
induced VBN O
MAP NNP O
elevation NN O
. . O
null null null-Disease
The DT O
results NNS O
indicate VBP O
that IN O
centrally RB O
applied VBN O
AVP NNP O
and CC O
ANP NNP O
exert VBP O
differential JJ O
effects NNS O
on IN O
blood NN O
pressure NN O
and CC O
baroreflex NN O
control NN O
of IN O
heart NN O
rate NN O
in IN O
WKY NNP O
and CC O
SHR NN O
and CC O
suggest VBP O
interaction NN O
of IN O
these DT O
two CD O
peptides NNS O
in IN O
blood NN O
pressure NN O
regulation NN O
at IN O
the DT O
level NN O
of IN O
central JJ O
nervous JJ O
system NN O
. . O
null null null-Disease
Cutaneous JJ O
exposure NN O
to IN O
warfarin NN O
- HYPH O
like JJ O
anticoagulant NN O
causing VBG O
an DT O
intracerebral JJ B-Disease
hemorrhage NN I-Disease
: : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
intercerebral JJ O
hematoma NN B-Disease
due IN O
to IN O
warfarin NN O
- HYPH O
induced VBN O
coagulopathy NN B-Disease
is VBZ O
presented VBN O
. . O
null null null-Disease
The DT O
39 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
had VBD O
spread VBN O
a DT O
warfarin NN O
- HYPH O
type NN O
rat NN O
poison NN O
around IN O
her PRP$ O
house NN O
weekly RB O
using VBG O
her PRP$ O
bare JJ O
hands NNS O
, , O
with IN O
no DT O
washing NN O
post NN O
application NN O
. . O
null null null-Disease
Percutaneous JJ O
absorption NN O
of IN O
warfarin NN O
causing VBG O
coagulopathy NN B-Disease
, , O
reported VBN O
three CD O
times NNS O
in IN O
the DT O
past NN O
, , O
is VBZ O
a DT O
significant JJ O
risk NN O
if IN O
protective JJ O
measures NNS O
, , O
such JJ O
as IN O
gloves NNS O
, , O
are VBP O
not RB O
used VBN O
. . O
null null null-Disease
An DT O
adverse JJ O
drug NN O
interaction NN O
with IN O
piroxicam NN O
, , O
which WDT O
she PRP O
took VBD O
occasionally RB O
, , O
may MD O
have VB O
exacerbated VBN O
the DT O
coagulopathy NN B-Disease
. . O
null null null-Disease
Pediatric JJ O
heart NN O
transplantation NN O
without IN O
chronic JJ O
maintenance NN O
steroids NNS O
. . O
null null null-Disease
From IN O
1986 CD O
to IN O
February NNP O
1993 CD O
, , O
40 CD O
children NNS O
aged VBN O
2 CD O
months NNS O
to IN O
18 CD O
years NNS O
( , O
average JJ O
age NN O
10 CD O
. . O
4 CD O
+ CD O
/ SYM O
- HYPH O
5 CD O
. . O
8 CD O
years NNS O
) , O
underwent VBD O
heart NN O
transplantation NN O
. . O
null null null-Disease
Indications NNS O
for IN O
transplantation NN O
were VBD O
idiopathic JJ B-Disease
cardiomyopathy NN I-Disease
( , O
52 CD O
% NN O
) -RRB- O
, , O
congenital JJ B-Disease
heart NN I-Disease
disease NN I-Disease
( : O
35 CD O
% NN O
) -RRB- O
with IN O
and CC O
without IN O
prior JJ O
repair NN O
( , O
71 CD O
% NN O
and CC O
29 CD O
% NN O
, , O
respectively RB O
) CD O
, , O
hypertrophic JJ B-Disease
cardiomyopathy NN I-Disease
( , O
5 CD O
% NN O
) -RRB- O
, , O
valvular JJ B-Disease
heart NN I-Disease
disease NN I-Disease
( , O
3 CD O
% NN O
) -RRB- O
, , O
and CC O
doxorubicin NN O
cardiomyopathy NN B-Disease
( : O
5 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
were VBD O
managed VBN O
with IN O
cyclosporine NN O
and CC O
azathioprine NN O
. . O
null null null-Disease
No DT O
prophylaxis NN O
with IN O
antilymphocyte NN O
globulin NN O
was VBD O
used VBN O
. . O
null null null-Disease
Steroids NNS O
were VBD O
given VBN O
to IN O
39 CD O
% NN O
of IN O
patients NNS O
for IN O
refractory JJ O
rejection NN O
, , O
but CC O
weaning NN O
was VBD O
always RB O
attempted VBN O
and CC O
generally RB O
successful JJ O
( : O
64 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Five CD O
patients NNS O
( : O
14 CD O
% NN O
) -RRB- O
received VBD O
maintenance NN O
steroids NNS O
. . O
null null null-Disease
Four CD O
patients NNS O
died VBD O
in IN O
the DT O
perioperative JJ O
period NN O
and CC O
one CD O
died VBD O
4 CD O
months NNS O
later RB O
. . O
null null null-Disease
There EX O
have VBP O
been VBN O
no DT O
deaths NNS O
related VBN O
to IN O
rejection NN O
or CC O
infection NN B-Disease
. . O
null null null-Disease
Average JJ O
follow NN O
- HYPH O
up NN O
was VBD O
36 CD O
+ SYM O
/ SYM O
- HYPH O
19 CD O
months NNS O
( : O
range NN O
1 CD O
to TO O
65 CD O
months NNS O
) -RRB- O
. . O
null null null-Disease
Cumulative JJ O
survival NN O
is VBZ O
88 CD O
% NN O
at IN O
5 CD O
years NNS O
. . O
null null null-Disease
In IN O
patients NNS O
less JJR O
than IN O
7 CD O
years NNS O
of IN O
age NN O
, , O
rejection NN O
was VBD O
monitored VBN O
noninvasively RB O
. . O
null null null-Disease
In IN O
the DT O
first JJ O
postoperative JJ O
month NN O
, , O
89 CD O
% NN O
of IN O
patients NNS O
were VBD O
treated VBN O
for IN O
rejection NN O
. . O
null null null-Disease
Freedom NN O
from IN O
serious JJ O
infections NNS B-Disease
was VBD O
83 CD O
% NN O
at IN O
1 CD O
month NN O
and CC O
65 CD O
% NN O
at IN O
1 CD O
year NN O
. . O
null null null-Disease
Cytomegalovirus NNP B-Disease
infections NNS I-Disease
were VBD O
treated VBN O
successfully RB O
with IN O
ganciclovir NN O
in IN O
11 CD O
patients NNS O
. . O
null null null-Disease
No DT O
impairment NN O
of IN O
growth NN O
was VBD O
observed VBN O
in IN O
children NNS O
who WP O
underwent VBD O
transplantation NN O
compared VBN O
with IN O
a DT O
control NN O
population NN O
. . O
null null null-Disease
Twenty CD O
- HYPH O
one CD O
patients NNS O
( : O
60 CD O
% NN O
) , O
have VBP O
undergone VBN O
annual JJ O
catheterizations NNS O
and CC O
no DT O
sign NN O
of IN O
graft NN O
atherosclerosis NN B-Disease
has VBZ O
been VBN O
observed VBN O
. . O
null null null-Disease
Seizures NNS B-Disease
occurred VBD O
in IN O
five CD O
patients NNS O
( : O
14 CD O
% NN O
) , O
and CC O
hypertension NN B-Disease
was VBD O
treated VBN O
in IN O
10 CD O
patients NNS O
( : O
28 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
No DT O
patient NN O
was VBD O
disabled VBN O
and CC O
no DT O
lymphoproliferative JJ B-Disease
disorder NN I-Disease
was VBD O
observed VBN O
. . O
( : O
ABSTRACT NN O
TRUNCATED VBN O
AT IN O
250 CD O
WORDS NNS O
) : O
null null null-Disease
Delirium NN B-Disease
during IN O
fluoxetine NN O
treatment NN O
. . O
null null null-Disease
A DT O
case NN O
report NN O
. . O
null null null-Disease
The DT O
correlation NN O
between IN O
high JJ O
serum NN O
tricyclic JJ O
antidepressant JJ O
concentrations NNS O
and CC O
central JJ O
nervous JJ O
system NN O
side NN O
effects NNS O
has VBZ O
been VBN O
well RB O
established VBN O
. . O
null null null-Disease
Only RB O
a DT O
few JJ O
reports NNS O
exist VBP O
, , O
however RB O
, , O
on IN O
the DT O
relationship NN O
between IN O
the DT O
serum NN O
concentrations NNS O
of IN O
selective JJ O
serotonin NN O
reuptake NN O
inhibitors NNS O
( , O
SSRIs NNP O
) -RRB- O
and CC O
their PRP$ O
toxic JJ O
effects NNS O
. . O
null null null-Disease
In IN O
some DT O
cases NNS O
, , O
a DT O
high JJ O
serum JJ O
concentration NN O
of IN O
citalopram NN O
( -LRB- O
> SYM O
600 CD O
nmol NN O
/ SYM O
L NNP O
) -RRB- O
in IN O
elderly JJ O
patients NNS O
has VBZ O
been VBN O
associated VBN O
with IN O
increased VBN O
somnolence NN B-Disease
and CC O
movement NN B-Disease
difficulties NNS I-Disease
. . O
null null null-Disease
Widespread JJ O
cognitive JJ B-Disease
disorders NNS I-Disease
, , O
such JJ O
as IN O
delirium NN B-Disease
, , O
have VBP O
not RB O
been VBN O
previously RB O
linked VBN O
with IN O
high JJ O
blood NN O
levels NNS O
of IN O
SSRIs NNS O
. . O
null null null-Disease
In IN O
this DT O
report NN O
, , O
we PRP O
describe VBP O
a DT O
patient NN O
with IN O
acute JJ O
hyperkinetic JJ B-Disease
delirium NN B-Disease
connected VBN O
with IN O
a DT O
high JJ O
serum NN O
total JJ O
fluoxetine NN O
( , O
fluoxetine NN O
plus CC O
desmethylfluoxetine NN O
) -RRB- O
concentration NN O
. . O
null null null-Disease
Pulmonary JJ B-Disease
edema NN I-Disease
and CC O
shock NN B-Disease
after IN O
high JJ O
- HYPH O
dose NN O
aracytine NN O
- HYPH O
C NN O
for IN O
lymphoma NN B-Disease
; : O
possible JJ O
role NN O
of IN O
TNF NNP O
- HYPH O
alpha NN O
and CC O
PAF NN O
. . O
null null null-Disease
Four CD O
out IN O
of IN O
23 CD O
consecutive JJ O
patients NNS O
treated VBN O
with IN O
high JJ O
- HYPH O
dose NN O
Ara NNP O
- HYPH O
C NNP O
for IN O
lymphomas NNS B-Disease
in IN O
our PRP$ O
institution NN O
developed VBD O
a DT O
strikingly RB O
similar JJ O
syndrome NN O
during IN O
the DT O
perfusion NN O
. . O
null null null-Disease
It PRP O
was VBD O
characterized VBN O
by IN O
the DT O
onset NN O
of IN O
fever NN B-Disease
, , O
diarrhea NN B-Disease
, , O
shock NN B-Disease
, , O
pulmonary JJ B-Disease
edema NN I-Disease
, , O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
, , O
metabolic JJ B-Disease
acidosis NN I-Disease
, , O
weight NN B-Disease
gain NN I-Disease
and CC O
leukocytosis NN B-Disease
. . O
null null null-Disease
Thorough JJ O
bacteriological JJ O
screening NN O
failed VBD O
to TO O
provide VB O
evidence NN O
of IN O
infection NN B-Disease
. . O
null null null-Disease
Sequential JJ O
biological JJ O
assays NNS O
of IN O
IL NN O
- HYPH O
1 CD O
, , O
IL NN O
- HYPH O
2 CD O
, , O
TNF NNP O
and CC O
PAF NNP O
were VBD O
performed VBN O
during IN O
Ara NNP O
- HYPH O
C NN O
infusion NN O
to IN O
ten CD O
patients NNS O
, , O
including VBG O
the DT O
four CD O
who WP O
developed VBD O
the DT O
syndrome NN O
. . O
null null null-Disease
TNF NNP O
and CC O
PAF NNP O
activity NN O
was VBD O
found VBN O
in IN O
the DT O
serum NN O
of IN O
respectively RB O
two CD O
and CC O
four CD O
of IN O
the DT O
cases NNS O
, , O
but CC O
not RB O
in IN O
the DT O
six CD O
controls NNS O
. . O
null null null-Disease
As IN O
TNF NNP O
and CC O
PAF NNP O
are VBP O
thought VBN O
to TO O
be VB O
involved VBN O
in IN O
the DT O
development NN O
of IN O
septic NN O
shock NN B-Disease
and CC O
adult NN B-Disease
respiratory JJ I-Disease
distress NN I-Disease
syndrome NN I-Disease
, , O
we PRP O
hypothesize VBP O
that IN O
high JJ O
- HYPH O
dose NN O
Ara NNP O
- HYPH O
C NNP O
may MD O
be VB O
associated VBN O
with IN O
cytokine NN O
release NN O
. . O
null null null-Disease
Protective JJ O
effect NN O
of IN O
clentiazem NN O
against IN O
epinephrine NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
injury NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
We PRP O
investigated VBD O
the DT O
effects NNS O
of IN O
clentiazem NN O
, , O
a DT O
1 CD O
, , O
5 CD O
- HYPH O
benzothiazepine NN O
calcium NN O
antagonist NN O
, , O
on IN O
epinephrine NN O
- HYPH O
induced VBN O
cardiomyopathy NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
With IN O
2 CD O
- HYPH O
week NN O
chronic JJ O
epinephrine NN O
infusion NN O
, , O
16 CD O
of IN O
30 CD O
rats NNS O
died VBD O
within IN O
4 CD O
days NNS O
, , O
and CC O
severe JJ O
ischemic JJ B-Disease
lesions NNS I-Disease
and CC O
fibrosis NN B-Disease
of IN O
the DT O
left JJ O
ventricles NNS O
were VBD O
observed VBN O
. . O
null null null-Disease
In IN O
epinephrine NN O
- HYPH O
treated VBN O
rats NNS O
, , O
left VBN O
atrial JJ O
and CC O
left JJ O
ventricular JJ O
papillary NN O
muscle NN O
contractile NN O
responses NNS O
to IN O
isoproterenol NN O
were VBD O
reduced VBN O
, , O
but CC O
responses NNS O
to IN O
calcium NN O
were VBD O
normal JJ O
or CC O
enhanced VBN O
compared VBN O
to IN O
controls NNS O
. . O
null null null-Disease
Left VBN O
ventricular JJ O
alpha NN O
and CC O
beta JJ O
adrenoceptor NN O
densities NNS O
were VBD O
also RB O
reduced VBN O
compared VBN O
to IN O
controls NNS O
. . O
null null null-Disease
Treatment NN O
with IN O
clentiazem NN O
prevented VBD O
epinephrine NN O
- HYPH O
induced VBN O
death NN O
( , O
P NN O
< NN O
. . O
05 CD O
) -RRB- O
, , O
and CC O
attenuated VBD O
the DT O
ventricular JJ O
ischemic JJ B-Disease
lesions NNS I-Disease
and CC O
fibrosis NN B-Disease
, , O
in IN O
a DT O
dose NN O
- HYPH O
dependent JJ O
manner NN O
. . O
null null null-Disease
Left VBN O
atrial JJ O
and CC O
left JJ O
ventricular JJ O
papillary NN O
muscle NN O
contractile NN O
responses NNS O
to IN O
isoproterenol NN O
were VBD O
reduced VBN O
compared VBN O
to IN O
controls NNS O
in IN O
groups NNS O
treated VBN O
with IN O
clentiazem NN O
alone RB O
, , O
but CC O
combined VBN O
with IN O
epinephrine NN O
, , O
clentiazem NN O
restored VBN O
left VBN O
atrial JJ O
responses NNS O
and CC O
enhanced VBD O
left VBN O
ventricular JJ O
papillary NN O
responses NNS O
to IN O
isoproterenol NN O
. . O
null null null-Disease
On IN O
the DT O
other JJ O
hand NN O
clentiazem NN O
did VBD O
not RB O
prevent VB O
epinephrine NN O
- HYPH O
induced VBN O
down IN O
- HYPH O
regulation NN O
of IN O
alpha NN O
and CC O
beta NN O
adrenoceptors NNS O
. . O
null null null-Disease
Interestingly RB O
, , O
clentiazem NN O
, , O
infused VBN O
alone RB O
, , O
resulted VBD O
in IN O
decreased VBN O
adrenergic JJ O
receptor NN O
densities NNS O
in IN O
the DT O
left JJ O
ventricle NN O
. . O
null null null-Disease
Clentiazem NNP O
also RB O
did VBD O
not RB O
prevent VB O
the DT O
enhanced VBN O
responses NNS O
to IN O
calcium NN O
seen VBN O
in IN O
the DT O
epinephrine NN O
- HYPH O
treated VBN O
animals NNS O
, , O
although IN O
the DT O
high JJ O
dose NN O
of IN O
clentiazem NN O
partially RB O
attenuated VBD O
the DT O
maximal JJ O
response NN O
to IN O
calcium NN O
compared VBN O
to IN O
epinephrine NN O
- HYPH O
treated VBN O
animals NNS O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
clentiazem NN O
attenuated VBD O
epinephrine NN O
- HYPH O
induced VBN O
cardiac JJ B-Disease
injury NN I-Disease
, , O
possibly RB O
through IN O
its PRP$ O
effect NN O
on IN O
the DT O
adrenergic JJ O
pathway NN O
. . O
null null null-Disease
Kaliuretic NNP O
effect NN O
of IN O
L NNP O
- HYPH O
dopa NN O
treatment NN O
in IN O
parkinsonian NN B-Disease
patients NNS O
. . O
null null null-Disease
Hypokalemia NN B-Disease
, , O
sometimes RB O
severe JJ O
, , O
was VBD O
observed VBN O
in IN O
some DT O
L NNP O
- HYPH O
dopa NNP O
- HYPH O
treated VBN O
parkinsonian JJ B-Disease
patients NNS O
. . O
null null null-Disease
The DT O
influence NN O
of IN O
L NN O
- HYPH O
dopa NNP O
on IN O
the DT O
renal JJ O
excretion NN O
of IN O
potassium NN O
was VBD O
studied VBN O
in IN O
3 CD O
patients NNS O
with IN O
hypokalemia NN B-Disease
and CC O
in IN O
5 CD O
normokalemic JJ O
patients NNS O
by IN O
determination NN O
of IN O
renal JJ O
plasma NN O
flow NN O
, , O
glomerular JJ O
filtration NN O
rate NN O
, , O
plasma NN O
concentration NN O
of IN O
potassium NN O
and CC O
sodium NN O
as RB O
well RB O
as IN O
urinary JJ O
excretion NN O
of IN O
potassium NN O
, , O
sodium NN O
and CC O
aldosterone NN O
. . O
null null null-Disease
L NNP O
- HYPH O
Dopa NNP O
intake NN O
was VBD O
found VBN O
to TO O
cause VB O
an DT O
increased VBN O
excretion NN O
of IN O
potassium NN O
, , O
and CC O
sometimes RB O
also RB O
of IN O
sodium NN O
, , O
in IN O
the DT O
hypokalemic JJ O
but CC O
not RB O
in IN O
the DT O
normokalemic JJ O
patients NNS O
. . O
null null null-Disease
This DT O
effect NN O
on IN O
the DT O
renal JJ O
function NN O
could MD O
be VB O
prohibited VBN O
by IN O
the DT O
administration NN O
of IN O
a DT O
peripheral JJ O
dopa NN O
decarbodylase NN O
inhibitor NN O
. . O
null null null-Disease
It PRP O
is VBZ O
not RB O
known VBN O
why WRB O
this DT O
effect NN O
occurred VBD O
in IN O
some DT O
individuals NNS O
but CC O
not RB O
in IN O
others NNS O
, , O
but CC O
our PRP$ O
results NNS O
indicate VBP O
a DT O
correlation NN O
between IN O
aldosterone NN O
production NN O
and CC O
this DT O
renal JJ O
effect NN O
of IN O
L NN O
- HYPH O
dopa NNP O
. . O
null null null-Disease
Cocaine NN O
induced VBD O
myocardial JJ B-Disease
ischemia NN I-Disease
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
myocardial JJ B-Disease
ischemia NN I-Disease
induced VBN O
by IN O
cocaine NN O
. . O
null null null-Disease
The DT O
ischemia NN B-Disease
probably RB O
induced VBN O
by IN O
coronary JJ B-Disease
artery NN I-Disease
spasm NN I-Disease
was VBD O
reversed VBN O
by IN O
nitroglycerin NN O
and CC O
calcium NN O
blocking NN O
agents NNS O
. . O
null null null-Disease
Doxorubicin NNP O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
monitored VBN O
by IN O
ECG NNP O
in IN O
freely RB O
moving VBG O
mice NNS O
. . O
null null null-Disease
A DT O
new JJ O
model NN O
to TO O
test VB O
potential JJ O
protectors NNS O
. . O
null null null-Disease
In IN O
laboratory JJ O
animals NNS O
, , O
histology NN O
is VBZ O
most RBS O
commonly RB O
used VBN O
to TO O
study VB O
doxorubicin NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
. . O
null null null-Disease
However RB O
, , O
for IN O
monitoring NN O
during IN O
treatment NN O
, , O
large JJ O
numbers NNS O
of IN O
animals NNS O
are VBP O
needed VBN O
. . O
null null null-Disease
Recently RB O
we PRP O
developed VBD O
a DT O
new JJ O
method NN O
to TO O
measure VB O
ECG NNP O
values NNS O
in IN O
freely RB O
moving VBG O
mice NNS O
by IN O
telemetry NN O
. . O
null null null-Disease
With IN O
this DT O
model NN O
we PRP O
investigated VBD O
the DT O
effect NN O
of IN O
chronic JJ O
doxorubicin NN O
administration NN O
on IN O
the DT O
ECG NNP O
of IN O
freely RB O
moving VBG O
BALB NNP O
/ SYM O
c NN O
mice NNS O
and CC O
the DT O
efficacy NN O
of IN O
ICRF NNP O
- HYPH O
187 CD O
as IN O
a DT O
protective JJ O
agent NN O
. . O
null null null-Disease
The DT O
ST NNP O
interval NN O
significantly RB O
widened VBD O
from IN O
15 CD O
. . O
0 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
5 CD O
to TO O
56 CD O
. . O
8 CD O
+ NN O
/ SYM O
- HYPH O
11 CD O
. . O
8 CD O
ms NNS O
in IN O
week NN O
10 CD O
( SYM O
7 CD O
weekly JJ O
doses NNS O
of IN O
4 CD O
mg NN O
/ SYM O
kg NN O
doxorubicin NN O
given VBN O
i PRP O
. . O
v NN O
. . O
plus CC O
3 CD O
weeks NNS O
of IN O
observation NN O
) -RRB- O
. . O
null null null-Disease
The DT O
ECG NNP O
of IN O
the DT O
control NN O
animals NNS O
did VBD O
not RB O
change VB O
during IN O
the DT O
entire JJ O
study NN O
. . O
null null null-Disease
After IN O
sacrifice NN O
the DT O
hearts NNS O
of IN O
doxorubicin NN O
- HYPH O
treated VBN O
animals NNS O
were VBD O
enlarged VBN O
and CC O
the DT O
atria NN O
were VBD O
hypertrophic JJ B-Disease
. . O
null null null-Disease
As IN O
this DT O
schedule NN O
exerted VBD O
more JJR O
toxicity NN B-Disease
than IN O
needed VBN O
to TO O
investigate VB O
protective JJ O
agents NNS O
, , O
the DT O
protection NN O
of IN O
ICRF NNP O
- HYPH O
187 CD O
was VBD O
determined VBN O
using VBG O
a DT O
dose NN O
schedule NN O
with IN O
lower JJR O
general JJ O
toxicity NN B-Disease
( : O
6 CD O
weekly JJ O
doses NNS O
of IN O
4 CD O
mg NN O
/ SYM O
kg NN O
doxorubicin NN O
given VBN O
i PRP O
. . O
v NN O
. . O
plus CC O
2 CD O
weeks NNS O
of IN O
observation NN O
) -RRB- O
. . O
null null null-Disease
On IN O
this DT O
schedule NN O
, , O
the DT O
animals NNS O
' POS O
hearts NNS O
appeared VBD O
normal JJ O
after IN O
sacrifice NN O
and CC O
ICRF NNP O
- HYPH O
187 CD O
( SYM O
50 CD O
mg NNS O
/ SYM O
kg NNS O
given VBN O
i PRP O
. . O
p NN O
. . O
1 CD O
h NN O
before IN O
doxorubicin NN O
) -RRB- O
provided VBD O
almost RB O
full JJ O
protection NN O
. . O
null null null-Disease
These DT O
data NNS O
were VBD O
confirmed VBN O
by IN O
histology NN O
. . O
null null null-Disease
The DT O
results NNS O
indicate VBP O
that IN O
this DT O
new JJ O
model NN O
is VBZ O
very RB O
sensitive JJ O
and CC O
enables VBZ O
monitoring NN O
of IN O
the DT O
development NN O
of IN O
cardiotoxicity NN B-Disease
with IN O
time NN O
. . O
null null null-Disease
These DT O
findings NNS O
result VBP O
in IN O
a DT O
model NN O
that WDT O
allows VBZ O
the DT O
testing NN O
of IN O
protectors NNS O
against IN O
doxorubicin NN O
- HYPH O
induced VBN O
cardiotoxicity NN B-Disease
as IN O
demonstrated VBN O
by IN O
the DT O
protection NN O
provided VBN O
by IN O
ICRF NNP O
- HYPH O
187 CD O
. . O
null null null-Disease
Epinephrine NN O
dysrhythmogenicity NN O
is VBZ O
not RB O
enhanced VBN O
by IN O
subtoxic JJ O
bupivacaine NN O
in IN O
dogs NNS O
. . O
null null null-Disease
Since IN O
bupivacaine NN O
and CC O
epinephrine NN O
may MD O
both CC O
precipitate VB O
dysrhythmias NNS B-Disease
, , O
circulating VBG O
bupivacaine NN O
during IN O
regional JJ O
anesthesia NN O
could MD O
potentiate VB O
dysrhythmogenic JJ O
effects NNS O
of IN O
epinephrine NN O
. . O
null null null-Disease
We PRP O
therefore RB O
examined VBD O
whether IN O
bupivacaine NN O
alters VBZ O
the DT O
dysrhythmogenicity NN O
of IN O
subsequent JJ O
administration NN O
of IN O
epinephrine NN O
in IN O
conscious JJ O
, , O
healthy JJ O
dogs NNS O
and CC O
in IN O
anesthetized JJ O
dogs NNS O
with IN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
Forty CD O
- HYPH O
one CD O
conscious JJ O
dogs NNS O
received VBD O
10 CD O
micrograms NNS O
. . O
kg NN O
- HYPH O
1 CD O
. . O
min NN O
- HYPH O
1 CD O
epinephrine NN O
. . O
null null null-Disease
Seventeen CD O
animals NNS O
responded VBD O
with IN O
ventricular JJ B-Disease
tachycardia NN I-Disease
( , O
VT NNP B-Disease
) -RRB- O
within IN O
3 CD O
min NN O
. . O
null null null-Disease
After IN O
3 CD O
h NN O
, , O
these DT O
responders NNS O
randomly RB O
received VBD O
1 CD O
or CC O
2 CD O
mg NN O
/ SYM O
kg NN O
bupivacaine NN O
or CC O
saline NN O
over IN O
5 CD O
min NN O
, , O
followed VBN O
by IN O
10 CD O
micrograms NNS O
. . O
kg NN O
- HYPH O
1 CD O
. . O
min NN O
- HYPH O
1 CD O
epinephrine NN O
. . O
null null null-Disease
In IN O
the DT O
bupivacaine NN O
groups NNS O
, , O
epinephrine NN O
caused VBD O
fewer JJR O
prodysrhythmic JJ O
effects NNS O
than IN O
without IN O
bupivacaine NN O
. . O
null null null-Disease
VT NNP B-Disease
appeared VBD O
in IN O
fewer JJR O
dogs NNS O
and CC O
at IN O
a DT O
later JJ O
time NN O
, , O
and CC O
there EX O
were VBD O
more JJR O
sinoatrial JJ O
beats NNS O
and CC O
less JJR O
ectopies NNS O
. . O
null null null-Disease
Epinephrine NN O
shortened VBD O
QT NNP O
less JJR O
after IN O
bupivacaine NN O
than IN O
in IN O
control NN O
animals NNS O
. . O
null null null-Disease
One CD O
day NN O
after IN O
experimental JJ O
myocardial JJ B-Disease
infarction NN I-Disease
, , O
six CD O
additional JJ O
halothane NN O
- HYPH O
anesthetized VBN O
dogs NNS O
received VBD O
4 CD O
micrograms NNS O
. . O
kg CD O
- HYPH O
1 CD O
. . O
min NN O
- HYPH O
1 CD O
epinephrine NN O
until IN O
VT NNP B-Disease
appeared VBD O
. . O
null null null-Disease
After IN O
45 CD O
min NN O
, , O
1 CD O
mg NN O
/ SYM O
kg NN O
bupivacaine NN O
was VBD O
injected VBN O
over IN O
5 CD O
min NN O
, , O
again RB O
followed VBN O
by IN O
4 CD O
micrograms NNS O
. . O
kg NN O
- HYPH O
1 CD O
. . O
min NN O
- HYPH O
1 CD O
epinephrine NN O
. . O
null null null-Disease
In IN O
these DT O
dogs NNS O
, , O
the DT O
prodysrhythmic JJ O
response NN O
to IN O
epinephrine NN O
was VBD O
also RB O
mitigated VBN O
by IN O
preceding VBG O
bupivacaine NN O
. . O
null null null-Disease
Bupivacaine NN O
antagonizes VBZ O
epinephrine NN O
dysrhythmogenicity NN O
in IN O
conscious JJ O
dogs NNS O
susceptible JJ O
to IN O
VT NNP B-Disease
and CC O
in IN O
anesthetized VBN O
dogs NNS O
with IN O
spontaneous JJ O
postinfarct NN O
dysrhythmias NNS B-Disease
. . O
null null null-Disease
There EX O
is VBZ O
no DT O
evidence NN O
that IN O
systemic JJ O
subtoxic JJ O
bupivacaine NN O
administration NN O
enhances VBZ O
the DT O
dysrhythmogenicity NN O
of IN O
subsequent JJ O
epinephrine NN O
. . O
null null null-Disease
Milk NN B-Disease
- HYPH I-Disease
alkali NNP I-Disease
syndrome NN I-Disease
induced VBN O
by IN O
1 CD O
, , O
25 CD O
( , O
OH NN O
) , O
2D CD O
in IN O
a DT O
patient NN O
with IN O
hypoparathyroidism NN B-Disease
. . O
null null null-Disease
Milk NN B-Disease
- HYPH I-Disease
alkali NNP I-Disease
syndrome NN I-Disease
was VBD O
first RB O
described VBN O
70 CD O
years NNS O
ago RB O
in IN O
the DT O
context NN O
of IN O
the DT O
treatment NN O
of IN O
peptic JJ B-Disease
ulcer NN I-Disease
disease NN I-Disease
with IN O
large JJ O
amounts NNS O
of IN O
calcium NN O
and CC O
alkali NN O
. . O
null null null-Disease
Although IN O
with IN O
current JJ O
ulcer NN B-Disease
therapy NN O
( -LRB- O
H NN O
- HYPH O
2 CD O
blockers NNS O
, , O
omeprazole NN O
, , O
and CC O
sucralfate NN O
) -RRB- O
, , O
the DT O
frequency NN O
of IN O
milk NN B-Disease
- HYPH I-Disease
alkali NN I-Disease
syndrome NN I-Disease
has VBZ O
decreased VBN O
significantly RB O
, , O
the DT O
classic JJ O
triad NN O
of IN O
hypercalcemia NN B-Disease
, , O
alkalosis NN B-Disease
, , O
and CC O
renal JJ B-Disease
impairment NN I-Disease
remains VBZ O
the DT O
hallmark NN O
of IN O
the DT O
syndrome NN O
. . O
null null null-Disease
Milk NN B-Disease
- HYPH I-Disease
alkali NNP I-Disease
syndrome NN I-Disease
can MD O
present VB O
serious JJ O
and CC O
occasionally RB O
life NN O
- HYPH O
threatening VBG O
illness NN O
unless IN O
diagnosed VBN O
and CC O
treated VBN O
appropriately RB O
. . O
null null null-Disease
This DT O
article NN O
presents VBZ O
a DT O
patient NN O
with IN O
hypoparathyroidism NN B-Disease
who WP O
was VBD O
treated VBN O
with IN O
calcium NN O
carbonate NN O
and CC O
calcitriol NN O
resulting VBG O
in IN O
two CD O
admissions NNS O
to IN O
the DT O
hospital NN O
for IN O
milk NN B-Disease
- HYPH I-Disease
alkali NN I-Disease
syndrome NN I-Disease
. . O
null null null-Disease
The DT O
patient NN O
was VBD O
successfully RB O
treated VBN O
with IN O
intravenous JJ O
pamidronate NN O
on IN O
his PRP$ O
first JJ O
admission NN O
and CC O
with IN O
hydrocortisone NN O
on IN O
the DT O
second NN O
. . O
null null null-Disease
This DT O
illustrates VBZ O
intravenous JJ O
pamidronate NN O
as IN O
a DT O
valuable JJ O
therapeutic JJ O
tool NN O
when WRB O
milk NN B-Disease
- HYPH I-Disease
alkali NNP I-Disease
syndrome NN I-Disease
presents VBZ O
as IN O
hypercalcemic JJ B-Disease
emergency NN I-Disease
. . O
null null null-Disease
Famotidine NN O
- HYPH O
associated VBN O
delirium NN B-Disease
. . O
null null null-Disease
A DT O
series NN O
of IN O
six CD O
cases NNS O
. . O
null null null-Disease
Famotidine NN O
is VBZ O
a DT O
histamine NN O
H2 NN O
- HYPH O
receptor NN O
antagonist NN O
used VBN O
in IN O
inpatient NN O
settings NNS O
for IN O
prevention NN O
of IN O
stress NN O
ulcers NNS B-Disease
and CC O
is VBZ O
showing VBG O
increasing VBG O
popularity NN O
because IN O
of IN O
its PRP$ O
low JJ O
cost NN O
. . O
null null null-Disease
Although IN O
all DT O
of IN O
the DT O
currently RB O
available JJ O
H2 NN O
- HYPH O
receptor NN O
antagonists NNS O
have VBP O
shown VBN O
the DT O
propensity NN O
to TO O
cause VB O
delirium NN B-Disease
, , O
only RB O
two CD O
previously RB O
reported VBN O
cases NNS O
have VBP O
been VBN O
associated VBN O
with IN O
famotidine NN O
. . O
null null null-Disease
The DT O
authors NNS O
report VBP O
on IN O
six CD O
cases NNS O
of IN O
famotidine NN O
- HYPH O
associated VBN O
delirium NN B-Disease
in IN O
hospitalized VBN O
patients NNS O
who WP O
cleared VBD O
completely RB O
upon IN O
removal NN O
of IN O
famotidine NN O
. . O
null null null-Disease
The DT O
pharmacokinetics NNS O
of IN O
famotidine NN O
are VBP O
reviewed VBN O
, , O
with IN O
no DT O
change NN O
in IN O
its PRP$ O
metabolism NN O
in IN O
the DT O
elderly JJ O
population NN O
seen VBN O
. . O
null null null-Disease
The DT O
implications NNS O
of IN O
using VBG O
famotidine NN O
in IN O
elderly JJ O
persons NNS O
are VBP O
discussed VBN O
. . O
null null null-Disease
Encephalopathy NN B-Disease
during IN O
amitriptyline NN O
therapy NN O
: : O
are VBP O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
and CC O
serotonin NN B-Disease
syndrome NN I-Disease
spectrum NN O
disorders NNS O
? . O
null null null-Disease
This DT O
report NN O
describes VBZ O
a DT O
case NN O
of IN O
encephalopathy NN B-Disease
developed VBN O
in IN O
the DT O
course NN O
of IN O
amitriptyline NN O
therapy NN O
, , O
during IN O
a DT O
remission NN O
of IN O
unipolar JJ B-Disease
depression NN I-Disease
. . O
null null null-Disease
This DT O
patient NN O
could MD O
have VB O
been VBN O
diagnosed VBN O
as IN O
having VBG O
either CC O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
( , O
NMS NNP B-Disease
) -RRB- O
or CC O
serotonin NN B-Disease
syndrome NN I-Disease
( -LRB- O
SS NN B-Disease
) -RRB- O
. . O
null null null-Disease
The DT O
major JJ O
determinant NN O
of IN O
the DT O
symptoms NNS O
may MD O
have VB O
been VBN O
dopamine NN O
/ SYM O
serotonin NN O
imbalance NN O
in IN O
the DT O
central JJ O
nervous JJ O
system NN O
. . O
null null null-Disease
The DT O
NMS NNP B-Disease
- HYPH O
like JJ O
encephalopathy NN B-Disease
that WDT O
develops VBZ O
in IN O
association NN O
with IN O
the DT O
use NN O
of IN O
antidepressants NNS O
indicates VBZ O
that IN O
NMS NNP B-Disease
and CC O
SS NNP B-Disease
are VBP O
spectrum NN O
disorders NNS O
induced VBN O
by IN O
drugs NNS O
with IN O
both CC O
antidopaminergic JJ O
and CC O
serotonergic JJ O
effects NNS O
. . O
null null null-Disease
Genetic JJ O
separation NN O
of IN O
tumor NN B-Disease
growth NN O
and CC O
hemorrhagic JJ B-Disease
phenotypes NNS O
in IN O
an DT O
estrogen NN O
- HYPH O
induced VBN O
tumor NN B-Disease
. . O
null null null-Disease
Chronic JJ O
administration NN O
of IN O
estrogen NN O
to IN O
the DT O
Fischer NNP O
344 CD O
( SYM O
F344 CD O
) -RRB- O
rat NN O
induces VBZ O
growth NN O
of IN O
large JJ O
, , O
hemorrhagic JJ B-Disease
pituitary JJ B-Disease
tumors NNS I-Disease
. . O
null null null-Disease
Ten CD O
weeks NNS O
of IN O
diethylstilbestrol NN O
( , O
DES NNP O
) -RRB- O
treatment NN O
caused VBD O
female JJ O
F344 NN O
rat NN O
pituitaries NNS O
to TO O
grow VB O
to IN O
an DT O
average NN O
of IN O
109 CD O
. . O
2 CD O
+ NN O
/ SYM O
- HYPH O
6 CD O
. . O
3 CD O
mg NN O
( , O
mean VB O
+ NFP O
/ SYM O
- HYPH O
SE NN O
) -RRB- O
versus IN O
11 CD O
. . O
3 CD O
+ NN O
/ SYM O
- HYPH O
1 CD O
. . O
4 CD O
mg NN O
for IN O
untreated JJ O
rats NNS O
, , O
and CC O
to TO O
become VB O
highly RB O
hemorrhagic JJ B-Disease
. . O
null null null-Disease
The DT O
same JJ O
DES NNP O
treatment NN O
produced VBD O
no DT O
significant JJ O
growth NN O
( : O
8 CD O
. . O
9 CD O
+ SYM O
/ SYM O
- HYPH O
0 CD O
. . O
5 CD O
mg NN O
for IN O
treated VBN O
females NNS O
versus IN O
8 CD O
. . O
7 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
1 CD O
for IN O
untreated JJ O
females NNS O
) -RRB- O
or CC O
morphological JJ O
changes NNS O
in IN O
Brown NNP O
Norway NNP O
( : O
BN NNP O
) -RRB- O
rat NN O
pituitaries NNS O
. . O
null null null-Disease
An DT O
F1 NNP O
hybrid NN O
of IN O
F344 CD O
and CC O
BN NNP O
exhibited VBD O
significant JJ O
pituitary JJ O
growth NN O
after IN O
10 CD O
weeks NNS O
of IN O
DES NNP O
treatment NN O
with IN O
an DT O
average JJ O
mass NN O
of IN O
26 CD O
. . O
3 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
mg NN O
compared VBN O
with IN O
8 CD O
. . O
6 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
9 CD O
mg NN O
for IN O
untreated JJ O
rats NNS O
. . O
null null null-Disease
Surprisingly RB O
, , O
the DT O
F1 NNP O
hybrid NN O
tumors NNS B-Disease
were VBD O
not RB O
hemorrhagic JJ B-Disease
and CC O
had VBD O
hemoglobin NN O
content NN O
and CC O
outward JJ O
appearance NN O
identical JJ O
to IN O
that DT O
of IN O
BN NNP O
. . O
null null null-Disease
Expression NN O
of IN O
both CC O
growth NN O
and CC O
morphological JJ O
changes NNS O
is VBZ O
due JJ O
to IN O
multiple JJ O
genes NNS O
. . O
null null null-Disease
However RB O
, , O
while IN O
DES NNP O
- HYPH O
induced VBN O
pituitary JJ O
growth NN O
exhibited VBD O
quantitative JJ O
, , O
additive JJ O
inheritance NN O
, , O
the DT O
hemorrhagic JJ B-Disease
phenotype NN O
exhibited VBD O
recessive JJ O
, , O
epistatic JJ O
inheritance NN O
. . O
null null null-Disease
Only RB O
5 CD O
of IN O
the DT O
160 CD O
F2 NNP O
pituitaries NNS O
exhibited VBD O
the DT O
hemorrhagic JJ B-Disease
phenotype NN O
; : O
36 CD O
of IN O
the DT O
160 CD O
F2 NN O
pituitaries NNS O
were VBD O
in IN O
the DT O
F344 CD O
range NN O
of IN O
mass NN O
, , O
but CC O
31 CD O
of IN O
these DT O
were VBD O
not RB O
hemorrhagic JJ B-Disease
, , O
indicating VBG O
that IN O
the DT O
hemorrhagic JJ B-Disease
phenotype NN O
is VBZ O
not RB O
merely RB O
a DT O
consequence NN O
of IN O
extensive JJ O
growth NN O
. . O
null null null-Disease
The DT O
hemorrhagic JJ B-Disease
F2 NNP O
pituitaries NNS O
were VBD O
all DT O
among IN O
the DT O
most RBS O
massive JJ O
, , O
indicating VBG O
that IN O
some DT O
of IN O
the DT O
genes NNS O
regulate VBP O
both DT O
phenotypes NNS O
. . O
null null null-Disease
Increased VBN O
expression NN O
of IN O
neuronal JJ O
nitric JJ O
oxide NN O
synthase NN O
in IN O
bladder NN O
afferent JJ O
pathways NNS O
following VBG O
chronic JJ O
bladder NN B-Disease
irritation NN I-Disease
. . O
null null null-Disease
Immunocytochemical JJ O
techniques NNS O
were VBD O
used VBN O
to TO O
examine VB O
alterations NNS O
in IN O
the DT O
expression NN O
of IN O
neuronal JJ O
nitric JJ O
oxide NN O
synthase NN O
( , O
NOS NNP O
) -RRB- O
in IN O
bladder NN O
pathways NNS O
following VBG O
acute JJ O
and CC O
chronic JJ O
irritation NN B-Disease
of IN I-Disease
the DT I-Disease
urinary JJ I-Disease
tract NN I-Disease
of IN O
the DT O
rat NN O
. . O
null null null-Disease
Chemical JJ O
cystitis NN B-Disease
was VBD O
induced VBN O
by IN O
cyclophosphamide NN O
( -LRB- O
CYP NNP O
) -RRB- O
which WDT O
is VBZ O
metabolized VBN O
to IN O
acrolein NN O
, , O
an DT O
irritant NN O
eliminated VBN O
in IN O
the DT O
urine NN O
. . O
null null null-Disease
Injection NN O
of IN O
CYP NNP O
( : O
n NNP O
= SYM O
10 CD O
, , O
75 CD O
mg NNS O
/ SYM O
kg NN O
, , O
i PRP O
. . O
p NN O
. . O
) SYM O
2 CD O
hours NNS O
prior RB O
to IN O
perfusion NN O
( , O
acute JJ O
treatment NN O
) -RRB- O
of IN O
the DT O
animals NNS O
increased VBD O
Fos NNP O
- HYPH O
immunoreactivity NN O
( , O
IR NN O
) -RRB- O
in IN O
neurons NNS O
in IN O
the DT O
dorsal JJ O
commissure NN O
, , O
dorsal JJ O
horn NN O
, , O
and CC O
autonomic JJ O
regions NNS O
of IN O
spinal JJ O
segments NNS O
( -LRB- O
L1 NN O
- HYPH O
L2 CD O
and CC O
L6 NN O
- HYPH O
S1 NN O
) -RRB- O
which WDT O
receive VBP O
afferent JJ O
inputs NNS O
from IN O
the DT O
bladder NN O
, , O
urethra NN O
, , O
and CC O
ureter NN O
. . O
null null null-Disease
Fos NN O
- HYPH O
IR NN O
in IN O
the DT O
spinal JJ O
cord NN O
was VBD O
not RB O
changed VBN O
in IN O
rats NNS O
receiving VBG O
chronic JJ O
CYP NNP O
treatment NN O
( : O
n CD O
= SYM O
15 CD O
, , O
75 CD O
mg NN O
/ SYM O
kg CD O
, , O
i CD O
. . O
p NN O
. . O
, , O
every DT O
3rd JJ O
day NN O
for IN O
2 CD O
weeks NNS O
) -RRB- O
. . O
null null null-Disease
In IN O
control NN O
animals NNS O
and CC O
in IN O
animals NNS O
treated VBN O
acutely RB O
with IN O
CYP NNP O
, , O
only RB O
small JJ O
numbers NNS O
of IN O
NOS NNP O
- HYPH O
IR NN O
cells NNS O
( : O
0 CD O
. . O
5 CD O
- SYM O
0 CD O
. . O
7 CD O
cell NN O
profiles NNS O
/ SYM O
sections NNS O
) -RRB- O
were VBD O
detected VBN O
in IN O
the DT O
L6 NNP O
- HYPH O
S1 NNP O
dorsal JJ O
root NN O
ganglia NN O
( , O
DRG NNP O
) -RRB- O
. . O
null null null-Disease
Chronic JJ O
CYP NN O
administration NN O
significantly RB O
( : O
P NN O
< : O
or CC O
= SYM O
. . O
002 CD O
) -RRB- O
increased VBN O
bladder NN O
weight NN O
by IN O
60 CD O
% NN O
and CC O
increased VBN O
( SYM O
7 CD O
- HYPH O
to TO O
11 CD O
- HYPH O
fold NN O
) -RRB- O
the DT O
numbers NNS O
of IN O
NOS NNP O
- HYPH O
immunoreactive JJ O
( -LRB- O
IR NN O
) -RRB- O
afferent JJ O
neurons NNS O
in IN O
the DT O
L6 NNP O
- HYPH O
S1 NNP O
DRG NNP O
. . O
null null null-Disease
A DT O
small JJ O
increase NN O
( , O
1 CD O
. . O
5 CD O
- HYPH O
fold NN O
) -RRB- O
also RB O
occurred VBD O
in IN O
the DT O
L1 NNP O
DRG NNP O
, , O
but CC O
no DT O
change NN O
was VBD O
detected VBN O
in IN O
the DT O
L2 NNP O
and CC O
L5 NNP O
DRG NNP O
. . O
null null null-Disease
Bladder NN O
afferent JJ O
cells NNS O
in IN O
the DT O
L6 NNP O
- HYPH O
S1 NNP O
DRG NNP O
labeled VBN O
by IN O
Fluorogold NNP O
( : O
40 CD O
microliters NNS O
) -RRB- O
injected VBN O
into IN O
the DT O
bladder NN O
wall NN O
did VBD O
not RB O
exhibit VB O
NOS NNP O
- HYPH O
IR NN O
in IN O
control NN O
animals NNS O
; : O
however RB O
, , O
following VBG O
chronic JJ O
CYP NNP O
administration NN O
, , O
a DT O
significant JJ O
percentage NN O
of IN O
bladder NN O
afferent JJ O
neurons NNS O
were VBD O
NOS NNP O
- HYPH O
IR NN O
: : O
L6 NNP O
( : O
19 CD O
. . O
8 CD O
+ SYM O
/ SYM O
- HYPH O
4 CD O
. . O
6 CD O
% NN O
) NFP O
and CC O
S1 CD O
( SYM O
25 CD O
. . O
3 CD O
+ SYM O
/ SYM O
- HYPH O
2 CD O
. . O
9 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
neuronal JJ O
gene NN O
expression NN O
in IN O
visceral JJ O
sensory NN O
pathways NNS O
can MD O
be VB O
upregulated VBN O
by IN O
chemical JJ O
irritation NN O
of IN O
afferent JJ O
receptors NNS O
in IN O
the DT O
urinary JJ O
tract NN O
and CC O
/ SYM O
or CC O
that IN O
pathological JJ O
changes NNS O
in IN O
the DT O
urinary JJ O
tract NN O
can MD O
initiate VB O
chemical JJ O
signals NNS O
that WDT O
alter VBP O
the DT O
chemical JJ O
properties NNS O
of IN O
visceral JJ O
afferent JJ O
neurons NNS O
. . O
null null null-Disease
Effects NNS O
of IN O
a DT O
new JJ O
calcium NN O
antagonist NN O
, , O
CD NNP O
- HYPH O
832 CD O
, , O
on IN O
isoproterenol NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
ischemia NN I-Disease
in IN O
dogs NNS O
with IN O
partial JJ O
coronary JJ B-Disease
stenosis NN I-Disease
. . O
null null null-Disease
Effects NNS O
of IN O
CD NN O
- HYPH O
832 CD O
on IN O
isoproterenol NN O
( , O
ISO NNP O
) -RRB- O
- HYPH O
induced VBN O
myocardial JJ B-Disease
ischemia NN I-Disease
were VBD O
studied VBN O
in IN O
dogs NNS O
with IN O
partial JJ O
coronary JJ B-Disease
stenosis NN I-Disease
of IN O
the DT O
left JJ O
circumflex NN O
coronary JJ O
artery NN O
and CC O
findings NNS O
were VBD O
compared VBN O
with IN O
those DT O
for IN O
nifedipine NN O
or CC O
diltiazem NN O
. . O
null null null-Disease
In IN O
the DT O
presence NN O
of IN O
coronary JJ B-Disease
artery NN I-Disease
stenosis NN I-Disease
, , O
3 CD O
- HYPH O
min NN O
periods NNS O
of IN O
intracoronary JJ O
ISO NN O
infusion NN O
( SYM O
10 CD O
ng NNS O
/ SYM O
kg NNS O
/ SYM O
min NN O
) -RRB- O
increased VBD O
heart NN O
rate NN O
and CC O
maximal JJ O
rate NN O
of IN O
left JJ O
ventricular JJ O
pressure NN O
rise NN O
, , O
which WDT O
resulted VBD O
in IN O
a DT O
decrease NN O
in IN O
percentage NN O
segmental JJ O
shortening NN O
and CC O
ST NN O
- HYPH O
segment NN O
elevation NN O
of IN O
the DT O
epicardial JJ O
electrocardiogram NN O
. . O
null null null-Disease
After IN O
the DT O
control NN O
ISO NN O
infusion NN O
with IN O
stenosis NN B-Disease
was VBD O
performed VBN O
, , O
equihypotensive JJ O
doses NNS O
of IN O
CD NN O
- HYPH O
832 CD O
( SYM O
3 CD O
and CC O
10 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
min NN O
, , O
n CD O
= SYM O
7 CD O
) -RRB- O
, , O
nifedipine NN O
( , O
1 CD O
and CC O
3 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
min NN O
, , O
n CD O
= SYM O
9 CD O
) -RRB- O
or CC O
diltiazem NN O
( SYM O
10 CD O
and CC O
30 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
min NN O
, , O
n CD O
= SYM O
7 CD O
) -RRB- O
were VBD O
infused VBN O
5 CD O
min NN O
before IN O
and CC O
during IN O
the DT O
second JJ O
and CC O
third JJ O
ISO NN O
infusion NN O
. . O
null null null-Disease
Both DT O
CD NN O
- HYPH O
832 CD O
and CC O
diltiazem NN O
, , O
but CC O
not RB O
nifedipine NN O
, , O
significantly RB O
reduced VBD O
the DT O
increase NN O
in IN O
heart NN O
rate NN O
induced VBN O
by IN O
ISO NNP O
infusion NN O
. . O
null null null-Disease
In IN O
contrast NN O
to IN O
nifedipine NN O
, , O
CD NN O
- HYPH O
832 CD O
( SYM O
10 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
min NN O
) -RRB- O
prevented VBD O
the DT O
decrease NN O
in IN O
percentage NN O
segmental JJ O
shortening NN O
from IN O
32 CD O
+ CD O
/ SYM O
- SYM O
12 CD O
% NN O
to IN O
115 CD O
+ NN O
/ SYM O
- SYM O
26 CD O
% NN O
of IN O
the DT O
control NN O
value NN O
( , O
P NN O
< NN O
. . O
01 CD O
) -RRB- O
and CC O
ST NN O
- HYPH O
segment NN O
elevation NN O
from IN O
5 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
0 CD O
mV NN O
to IN O
1 CD O
. . O
6 CD O
+ SYM O
/ SYM O
- HYPH O
1 CD O
. . O
3 CD O
mV NN O
( , O
P NN O
< NN O
. . O
01 CD O
) -RRB- O
at IN O
3 CD O
min NN O
after IN O
ISO NNP O
infusion NN O
with IN O
stenosis NN B-Disease
. . O
null null null-Disease
Diltiazem NNP O
( : O
30 CD O
micrograms NNS O
/ SYM O
kg NNS O
/ SYM O
min NN O
) -RRB- O
also RB O
prevented VBD O
the DT O
decrease NN O
in IN O
percentage NN O
segmental JJ O
shortening NN O
from IN O
34 CD O
+ CD O
/ SYM O
- SYM O
14 CD O
% NN O
to IN O
63 CD O
+ NN O
/ SYM O
- SYM O
18 CD O
% NN O
of IN O
the DT O
control NN O
value NN O
( , O
P NN O
< NN O
. . O
05 CD O
) -RRB- O
and CC O
ST NN O
- HYPH O
segment NN O
elevation NN O
from IN O
4 CD O
. . O
7 CD O
+ CD O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
mV NN O
to IN O
2 CD O
. . O
1 CD O
+ NN O
/ SYM O
- HYPH O
0 CD O
. . O
7 CD O
mV NN O
( , O
P NN O
< NN O
. . O
01 CD O
) -RRB- O
at IN O
3 CD O
min NN O
after IN O
ISO NNP O
infusion NN O
with IN O
stenosis NN B-Disease
. . O
null null null-Disease
These DT O
data NNS O
show VBP O
that IN O
CD NN O
- HYPH O
832 CD O
improves VBZ O
myocardial JJ B-Disease
ischemia NN I-Disease
during IN O
ISO NNP O
infusion NN O
with IN O
stenosis NN B-Disease
and CC O
suggest VBP O
that IN O
the DT O
negative JJ O
chronotropic JJ O
property NN O
of IN O
CD NN O
- HYPH O
832 CD O
plays VBZ O
a DT O
major JJ O
role NN O
in IN O
the DT O
beneficial JJ O
effects NNS O
of IN O
CD NN O
- HYPH O
832 CD O
. . O
null null null-Disease
The DT O
effect NN O
of IN O
recombinant JJ O
human JJ O
insulin NN O
- HYPH O
like JJ O
growth NN O
factor NN O
- HYPH O
I NN O
on IN O
chronic JJ O
puromycin NN O
aminonucleoside NN O
nephropathy NN B-Disease
in IN O
rats NNS O
. . O
null null null-Disease
We PRP O
recently RB O
demonstrated VBD O
that IN O
recombinant JJ O
hGH NNP O
exacerbates VBZ O
renal JJ O
functional JJ O
and CC O
structural JJ O
injury NN O
in IN O
chronic JJ O
puromycin NN O
aminonucleoside NN O
( -LRB- O
PAN NNP O
) -RRB- O
nephropathy NN B-Disease
, , O
an DT O
experimental JJ O
model NN O
of IN O
glomerular JJ B-Disease
disease NN I-Disease
. . O
null null null-Disease
Therefore RB O
, , O
we PRP O
examined VBD O
whether IN O
recombinant JJ O
human JJ O
( , O
rh UH O
) , O
IGF NNP O
- HYPH O
I NNP O
is VBZ O
a DT O
safer JJR O
alternative NN O
for IN O
the DT O
treatment NN O
of IN O
growth NN B-Disease
failure NN I-Disease
in IN O
rats NNS O
with IN O
chronic JJ O
PAN NNP O
nephropathy NN B-Disease
. . O
null null null-Disease
The DT O
glomerulopathy NN B-Disease
was VBD O
induced VBN O
by IN O
seven CD O
serial JJ O
injections NNS O
of IN O
PAN NNP O
over IN O
12 CD O
wk NNS O
. . O
null null null-Disease
Experimental JJ O
animals NNS O
( : O
n -LRB- O
= SYM O
6 CD O
) -RRB- O
received VBD O
rhIGF NNP O
- HYPH O
I NNP O
, , O
400 CD O
micrograms NNS O
/ SYM O
d NN O
, , O
whereas IN O
control NN O
rats NNS O
( , O
n CD O
= SYM O
6 CD O
) -RRB- O
received VBD O
the DT O
vehicle NN O
. . O
null null null-Disease
rhIGF NNP O
- HYPH O
I PRP O
improved VBD O
weight NN O
gain NN O
by IN O
14 CD O
% NN O
( , O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
, , O
without IN O
altering VBG O
hematocrit NN O
or CC O
blood NN O
pressure NN O
in IN O
rats NNS O
with IN O
renal JJ B-Disease
disease NN I-Disease
. . O
null null null-Disease
Urinary JJ O
protein NN O
excretion NN O
was VBD O
unaltered JJ O
by IN O
rhIGF NNP O
- HYPH O
I NNP O
treatment NN O
in IN O
rats NNS O
with IN O
chronic JJ O
PAN NNP O
nephropathy NN B-Disease
. . O
null null null-Disease
After IN O
12 CD O
wk NN O
, , O
the DT O
inulin JJ O
clearance NN O
was VBD O
higher JJR O
in IN O
rhIGF NNP O
- HYPH O
I PRP O
- HYPH O
treated VBD O
rats NNS O
, , O
0 CD O
. . O
48 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
08 CD O
versus IN O
0 CD O
. . O
24 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
06 CD O
mL NN O
/ SYM O
min NN O
/ SYM O
100 CD O
g NN O
of IN O
body NN O
weight NN O
in IN O
untreated JJ O
PAN NNP O
nephropathy NN B-Disease
animals NNS O
, , O
p NN O
< NN O
0 CD O
. . O
05 CD O
. . O
null null null-Disease
The DT O
improvement NN O
in IN O
GFR NNP O
was VBD O
not RB O
associated VBN O
with IN O
enhanced VBN O
glomerular JJ B-Disease
hypertrophy NN I-Disease
or CC O
increased VBN O
segmental JJ O
glomerulosclerosis NN B-Disease
, , O
tubulointerstitial JJ B-Disease
injury NN I-Disease
, , O
or CC O
renal JJ O
cortical JJ O
malondialdehyde NN O
content NN O
. . O
null null null-Disease
In IN O
rats NNS O
with IN O
PAN NNP O
nephropathy NN B-Disease
, , O
administration NN O
of IN O
rhIGF NNP O
- HYPH O
I PRP O
increased VBD O
IGF NNP O
- HYPH O
I NNP O
and CC O
GH NNP O
receptor NN O
gene NN O
expression NN O
, , O
without IN O
altering VBG O
the DT O
steady JJ O
state NN O
level NN O
of IN O
IGF NNP O
- HYPH O
I NN O
receptor NN O
mRNA NNP O
. . O
null null null-Disease
In IN O
normal JJ O
rats NNS O
with IN O
intact JJ O
kidneys NNS O
, , O
rhIGF NNP O
- HYPH O
I NN O
administration NN O
( : O
n NN O
= SYM O
4 CD O
) -RRB- O
did VBD O
not RB O
alter VB O
weight NN O
gain NN O
, , O
blood NN O
pressure NN O
, , O
proteinuria NN B-Disease
, , O
GFR NN O
, , O
glomerular JJ O
planar NN O
area NN O
, , O
renal JJ O
cortical JJ O
malondialdehyde NN O
content NN O
, , O
or CC O
glomerular JJ O
or CC O
tubulointerstitial JJ B-Disease
damage NN I-Disease
, , O
compared VBN O
with IN O
untreated JJ O
animals NNS O
( : O
n NN O
= SYM O
4 CD O
) -RRB- O
. . O
null null null-Disease
rhIGF NNP O
- HYPH O
I NN O
treatment NN O
reduced VBD O
the DT O
steady JJ O
state NN O
renal JJ O
IGF NNP O
- HYPH O
I NNP O
mRNA NNP O
level NN O
but CC O
did VBD O
not RB O
modify VB O
gene NN O
expression NN O
of IN O
the DT O
IGF NNP O
- HYPH O
I NNP O
or CC O
GH NNP O
receptors NNS O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
: : O
1 LS O
) -RRB- O
administration NN O
of IN O
rhIGF NNP O
- HYPH O
I NNP O
improves VBZ O
growth NN O
and CC O
GFR NN O
in IN O
rats NNS O
with IN O
chronic JJ O
PAN NN O
nephropathy NN B-Disease
and CC O
2 CD O
) -RRB- O
unlike IN O
rhGH NNP O
, , O
long JJ O
- HYPH O
term NN O
use NN O
of IN O
rhIGF NNP O
- HYPH O
I PRP O
does VBZ O
not RB O
worsen VB O
renal JJ O
functional JJ O
and CC O
structural JJ O
injury NN O
in IN O
this DT O
disease NN O
model NN O
. . O
null null null-Disease
Nefiracetam NNP O
( -LRB- O
DM NNP O
- HYPH O
9384 CD O
) -RRB- O
reverses VBZ O
apomorphine NN O
- HYPH O
induced VBN O
amnesia NN B-Disease
of IN O
a DT O
passive JJ O
avoidance NN O
response NN O
: : O
delayed VBN O
emergence NN O
of IN O
the DT O
memory NN O
retention NN O
effects NNS O
. . O
null null null-Disease
Nefiracetam NNP O
is VBZ O
a DT O
novel JJ O
pyrrolidone NN O
derivative NN O
which WDT O
attenuates VBZ O
scopolamine NN O
- HYPH O
induced VBN O
learning NN B-Disease
and CC I-Disease
post NN I-Disease
- HYPH I-Disease
training NN I-Disease
consolidation NN I-Disease
deficits NNS I-Disease
. . O
null null null-Disease
Given VBN O
that IN O
apomorphine NN O
inhibits VBZ O
passive JJ O
avoidance NN O
retention NN O
when WRB O
given VBN O
during IN O
training NN O
or CC O
in IN O
a DT O
defined JJ O
10 CD O
- HYPH O
12h CD O
post NN O
- HYPH O
training NN O
period NN O
, , O
we PRP O
evaluated VBD O
the DT O
ability NN O
of IN O
nefiracetam NN O
to TO O
attenuate VB O
amnesia NN B-Disease
induced VBN O
by IN O
dopaminergic JJ O
agonism NN O
. . O
null null null-Disease
A DT O
step NN O
- HYPH O
down RP O
passive JJ O
avoidance NN O
paradigm NN O
was VBD O
employed VBN O
and CC O
nefiracetam NN O
( : O
3 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
and CC O
apomorphine NN O
( , O
0 CD O
. . O
5 CD O
mg CD O
/ SYM O
kg CD O
) -RRB- O
were VBD O
given VBN O
alone JJ O
or CC O
in IN O
combination NN O
during IN O
training NN O
and CC O
at IN O
the DT O
10 CD O
- HYPH O
12h CD O
post NN O
- HYPH O
training NN O
period NN O
of IN O
consolidation NN O
. . O
null null null-Disease
Co NN O
- HYPH O
administration NN O
of IN O
nefiracetam NN O
and CC O
apomorphine NN O
during IN O
training NN O
or CC O
10h CD O
thereafter RB O
produced VBD O
no DT O
significant JJ O
anti AFX O
- HYPH O
amnesic JJ O
effect NN O
. . O
null null null-Disease
However RB O
, , O
administration NN O
of IN O
nefiracetam NN O
during IN O
training NN O
completely RB O
reversed VBD O
the DT O
amnesia NN B-Disease
induced VBN O
by IN O
apomorphine NN O
at IN O
the DT O
10h CD O
post NN O
- HYPH O
training NN O
time NN O
and CC O
the DT O
converse NN O
was VBD O
also RB O
true JJ O
. . O
null null null-Disease
These DT O
effects NNS O
were VBD O
not RB O
mediated VBN O
by IN O
a DT O
dopaminergic JJ O
mechanism NN O
as IN O
nefiracetam NN O
, , O
at IN O
millimolar JJ O
concentrations NNS O
, , O
failed VBD O
to TO O
displace VB O
either CC O
[ -LRB- O
3H CD O
] -RRB- O
SCH NNP O
23390 CD O
or CC O
[ -LRB- O
3H CD O
] -RRB- O
spiperone NN O
binding NN O
from IN O
D1 NNP O
or CC O
D2 NN O
dopamine NN O
receptor NN O
subtypes NNS O
, , O
respectively RB O
. . O
null null null-Disease
It PRP O
is VBZ O
suggested VBN O
that IN O
nefiracetam NN O
augments VBZ O
molecular JJ O
processes NNS O
in IN O
the DT O
early JJ O
stages NNS O
of IN O
events NNS O
which WDT O
ultimately RB O
lead VBP O
to IN O
consolidation NN O
of IN O
memory NN O
. . O
null null null-Disease
Phenytoin NN O
encephalopathy NN B-Disease
as IN O
probable JJ O
idiosyncratic JJ O
reaction NN O
: : O
case NN O
report NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
phenytoin NN O
( , O
DPH NN O
) , O
encephalopathy NN B-Disease
with IN O
increasing VBG O
seizures NNS B-Disease
and CC O
EEG NN O
and CC O
mental JJ O
changes NNS O
is VBZ O
described VBN O
. . O
null null null-Disease
Despite IN O
adequate JJ O
oral JJ O
dosage NN O
of IN O
DPH NNP O
( SYM O
5 CD O
mg NN O
/ SYM O
kg NN O
/ SYM O
daily RB O
) , O
the DT O
plasma NN O
level NN O
was VBD O
very RB O
low JJ O
( : O
2 CD O
. . O
8 CD O
microgramg NN O
/ SYM O
ml NN O
) -RRB- O
. . O
null null null-Disease
The DT O
encephalopathy NN B-Disease
was VBD O
probably RB O
an DT O
idiosyncratic JJ O
and CC O
not RB O
toxic JJ O
or CC O
allergic JJ O
reaction NN O
. . O
null null null-Disease
In IN O
fact NN O
the DT O
concentration NN O
of IN O
free JJ O
DPH NNP O
was VBD O
normal JJ O
, , O
the DT O
patient NN O
presented VBD O
a DT O
retarded JJ O
morbilliform NN O
rash NN B-Disease
during IN O
DPH NNP O
treatment NN O
, , O
the DT O
protidogram NN O
was VBD O
normal JJ O
, , O
and CC O
an DT O
intradermic JJ O
DPH NN O
injection NN O
had VBD O
no DT O
local JJ O
effect NN O
. . O
null null null-Disease
The DT O
authors NNS O
conclude VBP O
that IN O
in IN O
a DT O
patient NN O
starting VBG O
DPH NNP O
treatment NN O
an DT O
unexpected JJ O
increase NN O
in IN O
seizures NNS B-Disease
, , O
with IN O
EEG NNP O
and CC O
mental JJ O
changes NNS O
occurring VBG O
simultaneously RB O
, , O
should MD O
alert VB O
the DT O
physician NN O
to IN O
the DT O
possible JJ O
need NN O
for IN O
eliminating VBG O
DPH NNP O
from IN O
the DT O
therapeutic JJ O
regimen NN O
, , O
even RB O
if IN O
plasma NN O
concentrations NNS O
are VBP O
low JJ O
. . O
null null null-Disease
Prevention NN O
and CC O
treatment NN O
of IN O
endometrial JJ B-Disease
disease NN I-Disease
in IN O
climacteric JJ O
women NNS O
receiving VBG O
oestrogen NN O
therapy NN O
. . O
null null null-Disease
The DT O
treatment NN O
regimens NNS O
are VBP O
described VBN O
in IN O
74 CD O
patients NNS O
with IN O
endometrial JJ B-Disease
disease NN I-Disease
among IN O
850 CD O
climacteric JJ O
women NNS O
receiving VBG O
oestrogen NN O
therapy NN O
. . O
null null null-Disease
Cystic JJ O
hyperplasia NN B-Disease
was VBD O
associated VBN O
with IN O
unopposed JJ O
oestrogen NN O
therapy NN O
without IN O
progestagen NN O
. . O
null null null-Disease
Two CD O
courses NNS O
of IN O
21 CD O
days NNS O
of IN O
5 CD O
mg JJ O
norethisterone NN O
daily RB O
caused VBD O
reversion NN O
to IN O
normal JJ O
in IN O
all DT O
57 CD O
cases NNS O
of IN O
cystic JJ O
hyperplasia NN B-Disease
and CC O
6 CD O
of IN O
the DT O
8 CD O
cases NNS O
of IN O
atypical JJ O
hyperplasia NN B-Disease
. . O
null null null-Disease
4 CD O
cases NNS O
of IN O
endometrial JJ B-Disease
carcinoma NN I-Disease
referred VBN O
from IN O
elsewhere RB O
demonstrated VBD O
the DT O
problems NNS O
of IN O
inappropriate JJ O
and CC O
unsupervised JJ O
unopposed JJ O
oestrogen NN O
therapy NN O
and CC O
the DT O
difficulty NN O
in IN O
distinguishing VBG O
severe JJ O
hyperplasia NN B-Disease
from IN O
malignancy NN B-Disease
. . O
null null null-Disease
Cyclical JJ O
low JJ O
- HYPH O
dose NN O
oestrogen NN O
therapy NN O
with IN O
7 CD O
- HYPH O
- HYPH O
13 CD O
days NNS O
of IN O
progestagen NN O
does VBZ O
not RB O
seem VB O
to TO O
increase VB O
the DT O
risk NN O
of IN O
endometrial JJ B-Disease
hyperplasia NN I-Disease
or CC O
carcinoma NN B-Disease
. . O
null null null-Disease
Effects NNS O
of IN O
exercise NN O
on IN O
the DT O
severity NN O
of IN O
isoproterenol NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
infarction NN I-Disease
. . O
null null null-Disease
The DT O
effect NN O
of IN O
exercise NN O
on IN O
the DT O
severity NN O
of IN O
isoproterenol NN O
- HYPH O
induced VBN O
myocardial JJ B-Disease
infarction NN I-Disease
was VBD O
studied VBN O
in IN O
male JJ O
rats NNS O
. . O
null null null-Disease
Ninety CD O
- HYPH O
three CD O
rats NNS O
were VBD O
randomly RB O
divided VBN O
into IN O
three CD O
groups NNS O
. . O
null null null-Disease
The DT O
exercise NN O
- HYPH O
isoproterenol NN O
( , O
E NNP O
- HYPH O
1 CD O
) -RRB- O
and CC O
exercise NN O
control NN O
( -LRB- O
EC NN O
) -RRB- O
groups NNS O
exercised VBD O
daily RB O
for IN O
thirty CD O
days NNS O
on IN O
a DT O
treadmill NN O
at IN O
1 CD O
mph NN O
, , O
2 CD O
% NN O
grade NN O
while IN O
animals NNS O
of IN O
the DT O
sedentary JJ O
- HYPH O
isoproterenol NN O
( , O
S NNP O
- HYPH O
I NNP O
) -RRB- O
group NN O
remained VBD O
sedentary JJ O
. . O
null null null-Disease
Eight CD O
animals NNS O
were VBD O
assigned VBN O
to IN O
the DT O
sedentary JJ O
control NN O
( HYPH O
SC NNP O
) -RRB- O
group NN O
which WDT O
remained VBD O
sedentary JJ O
throughout IN O
the DT O
experimental JJ O
period NN O
. . O
null null null-Disease
Forty CD O
- HYPH O
eight CD O
hours NNS O
after IN O
the DT O
final JJ O
exercise NN O
period NN O
, , O
S NNP O
- HYPH O
I PRP O
and CC O
E NN O
- HYPH O
I PRP O
animals NNS O
received VBD O
a DT O
single JJ O
subcutaneous JJ O
injection NN O
of IN O
isoproterenol NN O
( , O
250 CD O
mg NN O
/ SYM O
kg NN O
body NN O
weight NN O
) -RRB- O
. . O
null null null-Disease
Animals NNS O
of IN O
the DT O
S NNP O
- HYPH O
I NNP O
group NN O
exhibited VBD O
significantly RB O
( : O
Pp NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
greater JJR O
mortality NN O
from IN O
the DT O
effects NNS O
of IN O
isoproterenol NN O
than IN O
animals NNS O
of IN O
the DT O
E NN O
- HYPH O
I NNP O
group NN O
. . O
null null null-Disease
Serum NNP O
CPK NNP O
activity NN O
for IN O
E NNP O
- HYPH O
I NNP O
animals NNS O
was VBD O
significantly RB O
( : O
p NN O
less JJR O
than IN O
0 CD O
. . O
05 CD O
) -RRB- O
greater JJR O
than IN O
for IN O
animals NNS O
in IN O
the DT O
S NNP O
- HYPH O
I NNP O
and CC O
EC NNP O
groups NNS O
twenty CD O
hours NNS O
following VBG O
isoproterenol NN O
injection NN O
. . O
null null null-Disease
No DT O
statistically RB O
significant JJ O
differences NNS O
were VBD O
observed VBN O
between IN O
the DT O
two CD O
isoproterenol JJ O
treated VBN O
groups NNS O
for IN O
severity NN O
of IN O
the DT O
induced VBN O
lesions NNS O
, , O
changes NNS O
in IN O
heart NN O
weight NN O
, , O
or CC O
heart NN O
weight NN O
to IN O
body NN O
weight NN O
ratios NNS O
. . O
null null null-Disease
The DT O
results NNS O
indicated VBD O
that IN O
exercise NN O
reduced VBD O
the DT O
mortality NN O
associated VBN O
with IN O
the DT O
effects NNS O
of IN O
large JJ O
dosages NNS O
of IN O
isoproterenol NN O
but CC O
had VBD O
little JJ O
on IN O
the DT O
severity NN O
of IN O
the DT O
infarction NN B-Disease
. . O
null null null-Disease
Human JJ O
corticotropin NN O
- HYPH O
releasing VBG O
hormone NN O
and CC O
thyrotropin NN O
- HYPH O
releasing VBG O
hormone NN O
modulate VBP O
the DT O
hypercapnic JJ B-Disease
ventilatory JJ O
response NN O
in IN O
humans NNS O
. . O
null null null-Disease
Human JJ O
corticotropin NN O
- HYPH O
releasing VBG O
hormone NN O
( , O
hCRH NN O
) -RRB- O
and CC O
thyrotropin NN O
- HYPH O
releasing VBG O
hormone NN O
( -LRB- O
TRH NN O
) -RRB- O
are VBP O
known VBN O
to TO O
stimulate VB O
ventilation NN O
after IN O
i PRP O
. . O
v NN O
. . O
administration NN O
in IN O
humans NNS O
. . O
null null null-Disease
In IN O
a DT O
placebo NN O
- HYPH O
controlled VBN O
, , O
single JJ O
- HYPH O
blind JJ O
study NN O
we PRP O
aimed VBD O
to TO O
clarify VB O
if IN O
both DT O
peptides NNS O
act VBP O
by IN O
altering VBG O
central JJ O
chemosensitivity NN O
. . O
null null null-Disease
Two CD O
subsequent JJ O
CO2 NNP O
- HYPH O
rebreathing VBG O
tests NNS O
were VBD O
performed VBN O
in IN O
healthy JJ O
young JJ O
volunteers NNS O
. . O
null null null-Disease
During IN O
the DT O
first JJ O
test NN O
0 CD O
. . O
9 CD O
% NN O
NaCl NNP O
was VBD O
given VBN O
i PRP O
. . O
v NN O
. . O
; : O
during IN O
the DT O
second JJ O
test NN O
200 CD O
micrograms NNS O
of IN O
hCRH NNP O
( , O
n CD O
= SYM O
12 CD O
) -RRB- O
or CC O
400 CD O
micrograms NNS O
of IN O
TRH NN O
( : O
n NN O
= SYM O
6 CD O
) -RRB- O
was VBD O
administered VBN O
i : O
. . O
v NN O
. . O
Nine CD O
subjects NNS O
received VBD O
0 CD O
. . O
9 CD O
% NN O
NaCl NN O
i NN O
. . O
v NN O
. . O
during IN O
both DT O
rebreathing NN O
manoeuvres NNS O
. . O
null null null-Disease
The DT O
CO2 NNP O
- HYPH O
response NN O
curves NNS O
for IN O
the DT O
two CD O
tests NNS O
were VBD O
compared VBN O
within IN O
the DT O
same JJ O
subject NN O
. . O
null null null-Disease
In IN O
the DT O
hCRH NNP O
group NN O
a DT O
marked JJ O
parallel JJ O
shift NN O
of IN O
the DT O
CO2 NNP O
- HYPH O
response NN O
curve NN O
to IN O
the DT O
left NN O
was VBD O
observed VBN O
after IN O
hCRH NNP O
( : O
P NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
. . O
null null null-Disease
The DT O
same JJ O
effect NN O
occurred VBD O
following VBG O
TRH NNP O
but CC O
was VBD O
less RBR O
striking JJ O
( : O
P NN O
= SYM O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
hCRH NNP O
and CC O
TRH NNP O
caused VBD O
a DT O
reduction NN O
in IN O
the DT O
CO2 NNP O
threshold NN O
. . O
null null null-Disease
The DT O
CO2 NNP O
- HYPH O
response NN O
curves NNS O
in IN O
the DT O
control NN O
group NN O
were VBD O
nearly RB O
identical JJ O
. . O
null null null-Disease
The DT O
results NNS O
indicate VBP O
an DT O
additive JJ O
effect NN O
of IN O
both DT O
releasing VBG O
hormones NNS O
on IN O
the DT O
hypercapnic JJ B-Disease
ventilatory JJ O
response NN O
in IN O
humans NNS O
, , O
presumably RB O
independent JJ O
of IN O
central JJ O
chemosensitivity NN O
. . O
null null null-Disease
Lamivudine NNP O
is VBZ O
effective JJ O
in IN O
suppressing VBG O
hepatitis NNP B-Disease
B NNP I-Disease
virus NN O
DNA NN O
in IN O
Chinese JJ O
hepatitis NN O
B NNP O
surface NN O
antigen NN O
carriers NNS O
: : O
a DT O
placebo NN O
- HYPH O
controlled VBN O
trial NN O
. . O
null null null-Disease
Lamivudine NNP O
is VBZ O
a DT O
novel NN O
2 CD O
' '' O
, , O
3 CD O
' '' O
- HYPH O
dideoxy NN O
cytosine NN O
analogue NN O
that WDT O
has VBZ O
potent JJ O
inhibitory JJ O
effects NNS O
on IN O
hepatitis NNP B-Disease
B NNP I-Disease
virus NN O
replication NN O
in IN O
vitro FW O
and CC O
in IN O
vivo NN O
. . O
null null null-Disease
We PRP O
performed VBD O
a DT O
single JJ O
- HYPH O
blind NN O
, , O
placebo NN O
- HYPH O
controlled VBN O
study NN O
to TO O
assess VB O
its PRP$ O
effectiveness NN O
and CC O
safety NN O
in IN O
Chinese JJ O
hepatitis NN O
B NNP O
surface NN O
antigen NN O
( -LRB- O
HBsAg NNP O
) -RRB- O
carriers NNS O
. . O
null null null-Disease
Forty CD O
- HYPH O
two CD O
Chinese JJ O
HBsAg NNP O
carriers NNS O
were VBD O
randomized VBN O
to TO O
receive VB O
placebo NN O
( SYM O
6 CD O
patients NNS O
) -RRB- O
or CC O
lamivudine NN O
orally RB O
in IN O
dosages NNS O
of IN O
25 CD O
mg NNS O
, , O
100 CD O
mg NN O
, , O
or CC O
300 CD O
mg NN O
daily RB O
( : O
12 CD O
patients NNS O
for IN O
each DT O
dosage NN O
) -RRB- O
. . O
null null null-Disease
The DT O
drug NN O
was VBD O
given VBN O
for IN O
4 CD O
weeks NNS O
. . O
null null null-Disease
The DT O
patients NNS O
were VBD O
closely RB O
monitored VBN O
clinically RB O
, , O
biochemically RB O
, , O
and CC O
serologically RB O
up IN O
to TO O
4 CD O
weeks NNS O
after IN O
drug NN O
treatment NN O
. . O
null null null-Disease
All DT O
36 CD O
patients NNS O
receiving VBG O
lamivudine NN O
had VBD O
a DT O
decrease NN O
in IN O
hepatitis NNP B-Disease
B NNP I-Disease
virus NN O
( , O
HBV NNP O
) , O
DNA NN O
values NNS O
of IN O
> SYM O
90 CD O
% NN O
( , O
P NN O
< NN O
. . O
001 CD O
compared VBN O
with IN O
placebo NN O
) -RRB- O
. . O
null null null-Disease
Although IN O
25 CD O
mg NN O
of IN O
lamivudine NN O
was VBD O
slightly RB O
less RBR O
effective JJ O
than IN O
100 CD O
mg NNS O
( , O
P NN O
= SYM O
. . O
011 CD O
) -RRB- O
and CC O
300 CD O
mg NN O
( , O
P NN O
= SYM O
. SYM O
005 CD O
) -RRB- O
, , O
it PRP O
still RB O
induced VBD O
94 CD O
% NN O
suppression NN O
of IN O
HBV NN O
DNA NN O
after IN O
the DT O
fourth JJ O
week NN O
of IN O
therapy NN O
. . O
null null null-Disease
HBV NNP O
DNA NNP O
values NNS O
returned VBD O
to IN O
pretreatment NN O
levels NNS O
within IN O
4 CD O
weeks NNS O
of IN O
cessation NN O
of IN O
therapy NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
change NN O
in IN O
the DT O
hepatitis NN B-Disease
B NN I-Disease
e NN O
antigen NN O
status NN O
or CC O
in IN O
aminotransferase NN O
levels NNS O
. . O
null null null-Disease
No DT O
serious JJ O
adverse JJ O
events NNS O
were VBD O
observed VBN O
. . O
null null null-Disease
In IN O
conclusion NN O
, , O
a DT O
4 CD O
- HYPH O
week NN O
course NN O
of IN O
lamivudine NN O
was VBD O
safe JJ O
and CC O
effective JJ O
in IN O
suppression NN O
of IN O
HBV NNP O
DNA NNP O
in IN O
Chinese NNP O
HBsAg NNP O
carriers NNS O
. . O
null null null-Disease
The DT O
suppression NN O
was VBD O
> SYM O
90 CD O
% NN O
but CC O
reversible JJ O
. . O
null null null-Disease
Studies NNS O
with IN O
long JJ O
- HYPH O
term NN O
lamivudine NN O
administration NN O
should MD O
be VB O
performed VBN O
to TO O
determine VB O
if IN O
prolonged VBN O
suppression NN O
of IN O
HBV NNP O
DNA NNP O
can MD O
be VB O
achieved VBN O
. . O
null null null-Disease
Population NN O
- HYPH O
based VBN O
study NN O
of IN O
risk NN O
of IN O
venous JJ B-Disease
thromboembolism NN I-Disease
associated VBN O
with IN O
various JJ O
oral JJ O
contraceptives NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
Four CD O
studies NNS O
published VBN O
since IN O
December NNP O
, , O
1995 CD O
, , O
reported VBD O
that IN O
the DT O
incidence NN O
of IN O
venous JJ B-Disease
thromboembolism NN I-Disease
( , O
VTE NNP B-Disease
) -RRB- O
was VBD O
higher JJR O
in IN O
women NNS O
who WP O
used VBD O
oral JJ O
contraceptives NNS O
( -LRB- O
OCs NNS O
) -RRB- O
containing VBG O
the DT O
third JJ O
- HYPH O
generation NN O
progestagens NN O
gestodene NN O
or CC O
desogestrel NN O
than IN O
in IN O
users NNS O
of IN O
OCs NNS O
containing VBG O
second JJ O
- HYPH O
generation NN O
progestagens NNS O
. . O
null null null-Disease
However RB O
, , O
confounding JJ O
and CC O
bias NN O
in IN O
the DT O
design NN O
of IN O
these DT O
studies NNS O
may MD O
have VB O
affected VBN O
the DT O
findings NNS O
. . O
null null null-Disease
The DT O
aim NN O
of IN O
our PRP$ O
study NN O
was VBD O
to TO O
re VB O
- HYPH O
examine VB O
the DT O
association NN O
between IN O
risk NN O
of IN O
VTE NNP B-Disease
and CC O
OC NNP O
use NN O
with IN O
a DT O
different JJ O
study NN O
design NN O
and CC O
analysis NN O
to TO O
avoid VB O
some DT O
of IN O
the DT O
bias NN O
and CC O
confounding NN O
of IN O
the DT O
earlier JJR O
studies NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
We PRP O
used VBD O
computer NN O
records NNS O
of IN O
patients NNS O
from IN O
143 CD O
general JJ O
practices NNS O
in IN O
the DT O
UK NNP O
. . O
null null null-Disease
The DT O
study NN O
was VBD O
based VBN O
on IN O
the DT O
medical JJ O
records NNS O
of IN O
about RB O
540 CD O
, , O
000 CD O
women NNS O
born VBN O
between IN O
1941 CD O
and CC O
1981 CD O
. . O
null null null-Disease
All DT O
women NNS O
who WP O
had VBD O
a DT O
recorded VBN O
diagnosis NN O
of IN O
deep JJ B-Disease
- HYPH I-Disease
vein NN I-Disease
thrombosis NN I-Disease
, , O
venous JJ B-Disease
thrombosis NN I-Disease
not RB O
otherwise RB O
specified VBN O
, , O
or CC O
pulmonary JJ O
embolus NNS O
during IN O
the DT O
study NN O
period NN O
, , O
and CC O
who WP O
had VBD O
been VBN O
treated VBN O
with IN O
an DT O
anticoagulant NN O
were VBD O
identified VBN O
as IN O
potential JJ O
cases NNS O
of IN O
VTE NNP B-Disease
. . O
null null null-Disease
We PRP O
did VBD O
a DT O
cohort NN O
analysis NN O
to TO O
estimate VB O
and CC O
compare VB O
incidence NN O
of IN O
VTE NNP B-Disease
in IN O
users NNS O
of IN O
the DT O
main JJ O
OC NNP O
preparations NNS O
, , O
and CC O
a DT O
nested VBN O
case NN O
- HYPH O
control NN O
study NN O
to TO O
calculate VB O
the DT O
odds NNS O
ratios NNS O
of IN O
VTE NNP B-Disease
associated VBN O
with IN O
use NN O
of IN O
different JJ O
types NNS O
of IN O
OC NN O
, , O
after IN O
adjustment NN O
for IN O
potential JJ O
confounding JJ O
factors NNS O
. . O
null null null-Disease
In IN O
the DT O
case NN O
- HYPH O
control NN O
study NN O
, , O
we PRP O
matched VBD O
cases NNS O
to IN O
controls NNS O
by IN O
exact JJ O
year NN O
of IN O
birth NN O
, , O
practice NN O
, , O
and CC O
current JJ O
use NN O
of IN O
OCs NNS O
. . O
null null null-Disease
We PRP O
used VBD O
a DT O
multiple JJ O
logistic JJ O
regression NN O
model NN O
that WDT O
included VBD O
body NN O
- HYPH O
mass NN O
index NN O
, , O
number NN O
of IN O
cycles NNS O
, , O
change NN O
in IN O
type NN O
of IN O
OC NN O
prescribed VBN O
within IN O
3 CD O
months NNS O
of IN O
the DT O
event NN O
, , O
previous JJ O
pregnancy NN O
, , O
and CC O
concurrent JJ O
disease NN O
. . O
null null null-Disease
FINDINGS NNS O
: : O
85 CD O
women NNS O
met VBD O
the DT O
inclusion NN O
criteria NNS O
for IN O
VTE NNP B-Disease
, , O
two CD O
of IN O
whom WP O
were VBD O
users NNS O
of IN O
progestagen NN O
- HYPH O
only JJ O
OCs NNS O
. . O
null null null-Disease
Of IN O
the DT O
83 CD O
cases NNS O
of IN O
VTE NNP B-Disease
associated VBN O
with IN O
use NN O
of IN O
combined VBN O
OCs NNS O
, , O
43 CD O
were VBD O
recorded VBN O
as IN O
deep JJ B-Disease
- HYPH I-Disease
vein NN I-Disease
thrombosis NN I-Disease
, , O
35 CD O
as IN O
pulmonary JJ O
thrombosis NN B-Disease
, , O
and CC O
five CD O
as IN O
venous JJ B-Disease
thrombosis NN I-Disease
not RB O
otherwise RB O
specified VBN O
. . O
null null null-Disease
The DT O
crude JJ O
rate NN O
of IN O
VTE NNP B-Disease
per IN O
10 CD O
, , O
000 CD O
woman NN O
- HYPH O
years NNS O
was VBD O
4 CD O
. . O
10 CD O
in IN O
current JJ O
users NNS O
of IN O
any DT O
OC NNP O
, , O
3 CD O
. . O
10 CD O
in IN O
users NNS O
of IN O
second JJ O
- HYPH O
generation NN O
OCs NNS O
, , O
and CC O
4 CD O
. . O
96 CD O
in IN O
users NNS O
of IN O
third JJ O
- HYPH O
generation NN O
preparations NNS O
. . O
null null null-Disease
After IN O
adjustment NN O
for IN O
age NN O
, , O
the DT O
rate NN O
ratio NN O
of IN O
VTE NNP B-Disease
in IN O
users NNS O
of IN O
third JJ O
- HYPH O
generation NN O
relative JJ O
to IN O
second JJ O
- HYPH O
generation NN O
OCs NNS O
was VBD O
1 CD O
. . O
68 CD O
( SYM O
95 CD O
% NN O
CI NN O
1 CD O
. . O
04 CD O
- SYM O
2 CD O
. . O
75 CD O
) -RRB- O
. . O
null null null-Disease
Logistic JJ O
regression NN O
showed VBD O
no DT O
significant JJ O
difference NN O
in IN O
the DT O
risk NN O
of IN O
VTE NNP B-Disease
between IN O
users NNS O
of IN O
third JJ O
- HYPH O
generation NN O
and CC O
second JJ O
- HYPH O
generation NN O
OCs NNS O
. . O
null null null-Disease
Among IN O
users NNS O
of IN O
third JJ O
- HYPH O
generation NN O
progestagens NNS O
, , O
the DT O
risk NN O
of IN O
VTE NNP B-Disease
was VBD O
higher JJR O
in IN O
users NNS O
of IN O
desogestrel NN O
with IN O
20 CD O
g NN O
ethinyloestradiol NN O
than IN O
in IN O
users NNS O
of IN O
gestodene NN O
or CC O
desogestrel NN O
with IN O
30 CD O
g NN O
ethinyloestradiol NN O
. . O
null null null-Disease
With IN O
all DT O
second JJ O
- HYPH O
generation NN O
OCs NNS O
as IN O
the DT O
reference NN O
, , O
the DT O
odds NNS O
ratios NNS O
for IN O
VTE NNP B-Disease
were VBD O
3 CD O
. . O
49 CD O
( SYM O
1 CD O
. . O
21 CD O
- HYPH O
10 CD O
. . O
12 CD O
) -RRB- O
for IN O
desogestrel NN O
plus CC O
20 CD O
g NN O
ethinyloestradiol NN O
and CC O
1 CD O
. . O
18 CD O
( SYM O
0 CD O
. . O
66 CD O
- SYM O
2 CD O
. . O
17 CD O
) -RRB- O
for IN O
the DT O
other JJ O
third JJ O
- HYPH O
generation NN O
progestagens NNS O
. . O
null null null-Disease
INTERPRETATION NN O
: : O
The DT O
previously RB O
reported VBN O
increase NN O
in IN O
odds NNS O
ratio NN O
associated VBN O
with IN O
third JJ O
- HYPH O
generation NN O
OCs NNS O
when WRB O
compared VBN O
with IN O
second JJ O
- HYPH O
generation NN O
products NNS O
is VBZ O
likely JJ O
to TO O
have VB O
been VBN O
the DT O
result NN O
of IN O
residual JJ O
confounding NN O
by IN O
age NN O
. . O
null null null-Disease
The DT O
increased JJ O
odds NNS O
ratio NN O
associated VBN O
with IN O
products NNS O
containing VBG O
20 CD O
micrograms NNS O
ethinyloestradiol NN O
and CC O
desogestrel NN O
compared VBN O
with IN O
the DT O
30 CD O
micrograms NNS O
product NN O
is VBZ O
biologically RB O
implausible JJ O
, , O
and CC O
is VBZ O
likely JJ O
to TO O
be VB O
the DT O
result NN O
of IN O
preferential JJ O
prescribing NN O
and CC O
, , O
thus RB O
, , O
confounding VBG O
. . O
null null null-Disease
MK NNP O
- HYPH O
801 CD O
augments VBZ O
pilocarpine NN O
- HYPH O
induced VBN O
electrographic JJ O
seizure NN B-Disease
but CC O
protects VBZ O
against IN O
brain NN B-Disease
damage NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
1 LS O
. . O
null null null-Disease
The DT O
authors NNS O
examined VBD O
the DT O
anticonvulsant JJ O
effects NNS O
of IN O
MK NNP O
- HYPH O
801 CD O
on IN O
the DT O
pilocarpine NN O
- HYPH O
induced VBN O
seizure NN B-Disease
model NN O
. . O
null null null-Disease
Intraperitoneal JJ O
injection NN O
of IN O
pilocarpine NN O
( , O
400 CD O
mg NNS O
/ SYM O
kg NN O
) -RRB- O
induced VBD O
tonic NN B-Disease
and CC I-Disease
clonic JJ I-Disease
seizure NN I-Disease
. . O
null null null-Disease
Scopolamine NN O
( : O
10 CD O
mg NNS O
/ SYM O
kg NNS O
) -RRB- O
and CC O
pentobarbital NN O
( , O
5 CD O
mg NN O
/ SYM O
kg NNS O
) -RRB- O
prevented VBD O
development NN O
of IN O
pilocarpine NN O
- HYPH O
induced VBN O
behavioral JJ O
seizure NN B-Disease
but CC O
MK NNP O
- HYPH O
801 CD O
( SYM O
0 CD O
. . O
5 CD O
mg CD O
/ SYM O
kg CD O
) -RRB- O
did VBD O
not RB O
. . O
null null null-Disease
2 LS O
. . O
null null null-Disease
An DT O
electrical JJ O
seizure NN B-Disease
measured VBN O
with IN O
hippocampal JJ O
EEG NNP O
appeared VBD O
in IN O
the DT O
pilocarpine NN O
- HYPH O
treated VBN O
group NN O
. . O
null null null-Disease
Scopolamine NN O
and CC O
pentobarbital NN O
blocked VBD O
the DT O
pilocarpine NN O
- HYPH O
induced VBN O
electrographic JJ O
seizure NN B-Disease
, , O
MK NNP O
- HYPH O
801 CD O
treatment NN O
augmented VBD O
the DT O
electrographic JJ O
seizure NN B-Disease
induced VBN O
by IN O
pilocarpine NN O
. . O
null null null-Disease
3 LS O
. . O
null null null-Disease
Brain NN B-Disease
damage NN I-Disease
was VBD O
assessed VBN O
by IN O
examining VBG O
the DT O
hippocampus NN O
microscopically RB O
. . O
null null null-Disease
Pilocarpine NNP O
produced VBD O
neuronal JJ B-Disease
death NN I-Disease
in IN O
the DT O
hippocampus NN O
, , O
which WDT O
showed VBD O
pyknotic JJ O
changes NNS O
. . O
null null null-Disease
Pentobarbital NNP O
, , O
scopolamine NN O
and CC O
MK NNP O
- HYPH O
801 CD O
protected VBD O
the DT O
brain NN B-Disease
damage NN I-Disease
by IN O
pilocarpine NN O
, , O
though IN O
in IN O
the DT O
MK NNP O
- HYPH O
801 CD O
- HYPH O
treated VBN O
group NN O
, , O
the DT O
pyramidal JJ O
cells NNS O
of IN O
hippocampus NN O
appeared VBD O
darker JJR O
than IN O
normal JJ O
. . O
null null null-Disease
In IN O
all DT O
treatments NNS O
, , O
granule NN O
cells NNS O
of IN O
the DT O
dentate JJ O
gyrus NN O
were VBD O
not RB O
affected VBN O
. . O
null null null-Disease
4 LS O
. . O
null null null-Disease
These DT O
results NNS O
indicate VBP O
that IN O
status NN B-Disease
epilepticus NN I-Disease
induced VBN O
by IN O
pilocarpine NN O
is VBZ O
initiated VBN O
by IN O
cholinergic JJ O
overstimulation NN O
and CC O
propagated VBN O
by IN O
glutamatergic JJ O
transmission NN O
, , O
the DT O
elevation NN O
of IN O
which WDT O
may MD O
cause VB O
brain NN B-Disease
damage NN I-Disease
through IN O
an DT O
excitatory JJ O
NMDA NNP O
receptor NN O
- HYPH O
mediated VBN O
mechanism NN O
. . O
null null null-Disease
Paclitaxel NNP O
, , O
5 CD O
- HYPH O
fluorouracil NN O
, , O
and CC O
folinic JJ O
acid NN O
in IN O
metastatic JJ O
breast NN B-Disease
cancer NN I-Disease
: : O
BRE NNP O
- HYPH O
26 CD O
, , O
a DT O
phase NN O
II NN O
trial NN O
. . O
null null null-Disease
5 CD O
- HYPH O
Fluorouracil NN O
plus CC O
folinic JJ O
acid NN O
and CC O
paclitaxel NN O
( : O
Taxol NNP O
; : O
Bristol NNP O
- HYPH O
Myers NNP O
Squibb NNP O
Company NNP O
, , O
Princeton NNP O
, , O
NJ NNP O
) -RRB- O
are VBP O
effective JJ O
salvage NN O
therapies NNS O
for IN O
metastatic JJ O
breast NN B-Disease
cancer NN I-Disease
patients NNS O
. . O
null null null-Disease
Paclitaxel NNP O
and CC O
5 CD O
- HYPH O
fluorouracil NN O
have VBP O
additive JJ O
cytotoxicity NN B-Disease
in IN O
MCF NNP O
- HYPH O
7 CD O
cell NN O
lines NNS O
. . O
null null null-Disease
We PRP O
performed VBD O
a DT O
phase NN O
II NN O
trial NN O
of IN O
paclitaxel NN O
175 CD O
mg NN O
/ SYM O
m2 CD O
over IN O
3 CD O
hours NNS O
on IN O
day NN O
I PRP O
followed VBD O
by IN O
folinic JJ O
acid NN O
300 CD O
mg NN O
over IN O
1 CD O
hour NN O
before IN O
5 CD O
- HYPH O
fluorouracil NN O
350 CD O
mg NN O
/ SYM O
m2 CD O
on IN O
days NNS O
1 CD O
to IN O
3 CD O
every DT O
28 CD O
days NNS O
( , O
TFL NNP O
) -RRB- O
in IN O
women NNS O
with IN O
metastatic JJ O
breast NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
Analysis NN O
is VBZ O
reported VBN O
on IN O
37 CD O
patients NNS O
with IN O
a DT O
minimum NN O
of IN O
6 CD O
months NNS O
follow NN O
- HYPH O
up NN O
who WP O
received VBD O
a DT O
total NN O
of IN O
192 CD O
cycles NNS O
of IN O
TFL NNP O
: : O
nine CD O
cycles NNS O
( : O
5 CD O
% NN O
) -RRB- O
were VBD O
associated VBN O
with IN O
grade NN O
3 CD O
/ SYM O
4 CD O
neutropenia NN B-Disease
requiring VBG O
hospitalization NN O
; : O
seven CD O
( SYM O
4 CD O
% NN O
) , O
cycles NNS O
in IN O
two CD O
patients NNS O
required VBD O
granulocyte NN O
colony NN O
- HYPH O
stimulating VBG O
factor NN O
due IN O
to IN O
neutropenia NN B-Disease
; : O
no DT O
patient NN O
required VBN O
platelet NN O
transfusions NNS O
. . O
null null null-Disease
Grade NN O
3 CD O
/ SYM O
4 CD O
nonhematologic JJ O
toxicities NNS B-Disease
were VBD O
uncommon JJ O
. . O
null null null-Disease
Among IN O
the DT O
34 CD O
patients NNS O
evaluable JJ O
for IN O
response NN O
, , O
there EX O
were VBD O
three CD O
complete JJ O
responses NNS O
( : O
9 CD O
% NN O
) -RRB- O
and CC O
18 CD O
partial JJ O
responses NNS O
( : O
53 CD O
% NN O
) -RRB- O
for IN O
an DT O
overall JJ O
response NN O
rate NN O
of IN O
62 CD O
% NN O
. . O
null null null-Disease
Of IN O
the DT O
19 CD O
evaluable JJ O
patients NNS O
with IN O
prior JJ O
doxorubicin NN O
exposure NN O
, , O
11 CD O
( SYM O
58 CD O
% NN O
) -RRB- O
responded VBD O
compared VBN O
with IN O
nine CD O
of IN O
15 CD O
( : O
60 CD O
% NN O
) -RRB- O
without IN O
prior JJ O
doxorubicin NN O
. . O
null null null-Disease
Plasma NN O
paclitaxel NN O
concentrations NNS O
were VBD O
measured VBN O
at IN O
the DT O
completion NN O
of IN O
paclitaxel NN O
infusion NN O
and CC O
at IN O
24 CD O
hours NNS O
in IN O
19 CD O
patients NNS O
. . O
null null null-Disease
TFL NNP O
is VBZ O
an DT O
active JJ O
, , O
well RB O
- HYPH O
tolerated VBN O
regimen NN O
in IN O
metastatic JJ O
breast NN B-Disease
cancer NN I-Disease
. . O
null null null-Disease
Efficacy NN O
and CC O
proarrhythmia NN B-Disease
with IN O
the DT O
use NN O
of IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
for IN O
sustained JJ O
ventricular JJ B-Disease
tachyarrhythmias NNS I-Disease
. . O
null null null-Disease
This DT O
study NN O
prospectively RB O
evaluated VBD O
the DT O
clinical JJ O
efficacy NN O
, , O
the DT O
incidence NN O
of IN O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
, , O
and CC O
the DT O
presumable JJ O
risk NN O
factors NNS O
for IN O
torsades FW B-Disease
de FW I-Disease
pointes NNS I-Disease
in IN O
patients NNS O
treated VBN O
with IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
for IN O
sustained VBN O
ventricular JJ B-Disease
tachyarrhythmias NNS I-Disease
. . O
null null null-Disease
Eighty CD O
- HYPH O
one CD O
consecutive JJ O
patients NNS O
( : O
54 CD O
with IN O
coronary JJ B-Disease
artery NN I-Disease
disease NN I-Disease
, , O
and CC O
20 CD O
with IN O
dilated VBN B-Disease
cardiomyopathy NN I-Disease
) , O
with IN O
inducible JJ O
sustained JJ O
ventricular JJ B-Disease
tachycardia NN I-Disease
or CC O
ventricular JJ B-Disease
fibrillation NN I-Disease
received VBD O
oral JJ O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
to TO O
prevent VB O
induction NN O
of IN O
the DT O
ventricular JJ B-Disease
tachyarrhythmia NN I-Disease
. . O
null null null-Disease
During IN O
oral JJ O
loading NN O
with IN O
d NN O
, , O
l JJ O
- HYPH O
sotalol NN O
, , O
continuous JJ O
electrocardiographic JJ O
( , O
ECG NNP O
) -RRB- O
monitoring NN O
was VBD O
performed VBN O
. . O
null null null-Disease
Those DT O
patients NNS O
in IN O
whom WP O
d VBD O
, , O
l JJ O
- HYPH O
sotalol NN O
prevented VBD O
induction NN O
of IN O
ventricular JJ B-Disease
tachycardia NN I-Disease
or CC O
ventricular JJ B-Disease
fibrillation NN I-Disease
were VBD O
discharged VBN O
with IN O
the DT O
drug NN O
and CC O
followed VBD O
up RP O
on IN O
an DT O
outpatient JJ O
basis NN O
for IN O
21 CD O
+ SYM O
/ SYM O
- SYM O
18 CD O
months NNS O
. . O
null null null-Disease
Induction NN O
of IN O
the DT O
ventricular JJ B-Disease
tachyarrhythmia NN I-Disease
was VBD O
prevented VBN O
by IN O
oral JJ O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
in IN O
35 CD O
( SYM O
43 CD O
% NN O
) SYM O
patients NNS O
; : O
the DT O
ventricular JJ B-Disease
tachyarrhythmia NN I-Disease
remained VBD O
inducible JJ O
in IN O
40 CD O
( SYM O
49 CD O
% NN O
) SYM O
patients NNS O
; : O
and CC O
two CD O
( SYM O
2 CD O
. . O
5 CD O
% NN O
) -RRB- O
patients NNS O
did VBD O
not RB O
tolerate VB O
even RB O
40 CD O
mg NN O
of IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
once RB O
daily RB O
. . O
null null null-Disease
Four CD O
( SYM O
5 CD O
% NN O
) SYM O
patients NNS O
had VBD O
from IN O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
during IN O
the DT O
initial JJ O
oral JJ O
treatment NN O
with IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
. . O
null null null-Disease
Neither DT O
ECG NNP O
[ -LRB- O
sinus NN O
- HYPH O
cycle NN O
length NN O
( -LRB- O
SCL NNP O
) -RRB- O
, , O
QT NNP O
or CC O
QTc NNP O
interval NN O
, , O
or CC O
U NNP O
wave NN O
] -RRB- O
nor CC O
clinical JJ O
parameters NNS O
identified VBN O
patients NNS O
at IN O
risk NN O
for IN O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
. . O
null null null-Disease
However RB O
, , O
the DT O
oral JJ O
dose NN O
of IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
was VBD O
significantly RB O
lower JJR O
in IN O
patients NNS O
with IN O
torsades FW B-Disease
de FW I-Disease
pointes FW I-Disease
( , O
200 CD O
+ SYM O
/ SYM O
- HYPH O
46 CD O
vs IN O
. . O
328 CD O
+ SYM O
/ SYM O
- HYPH O
53 CD O
mg NN O
/ SYM O
day NN O
; : O
p NN O
= SYM O
0 CD O
. . O
0017 CD O
) -RRB- O
. . O
null null null-Disease
Risk NN O
factors NNS O
associated VBN O
with IN O
the DT O
development NN O
of IN O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
were VBD O
the DT O
appearance NN O
of IN O
an DT O
U NN O
wave NN O
( , O
p NN O
= SYM O
0 CD O
. . O
049 CD O
) -RRB- O
, , O
female JJ O
gender NN O
( , O
p NN O
= SYM O
0 CD O
. . O
015 CD O
) -RRB- O
, , O
and CC O
significant JJ O
dose NN O
- HYPH O
corrected VBN O
changes NNS O
of IN O
SCL NNP O
, , O
QT NNP O
interval NN O
, , O
and CC O
QTc NNP O
interval NN O
( : O
p NN O
< NN O
0 CD O
. . O
05 CD O
) -RRB- O
. . O
null null null-Disease
During IN O
follow NN O
- HYPH O
up NN O
, , O
seven CD O
( SYM O
20 CD O
% NN O
) , O
patients NNS O
had VBD O
a DT O
nonfatal JJ O
ventricular JJ B-Disease
tachycardia NN I-Disease
recurrence NN O
, , O
and CC O
two CD O
( SYM O
6 CD O
% NN O
) , O
patients NNS O
died VBD O
suddenly RB O
. . O
null null null-Disease
One CD O
female JJ O
patient NN O
with IN O
stable JJ O
cardiac JJ B-Disease
disease NN I-Disease
had VBD O
recurrent JJ O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
after IN O
2 CD O
years NNS O
of IN O
successful JJ O
treatment NN O
with IN O
d VBN O
, , O
l FW O
- HYPH O
sotalol NN O
. . O
null null null-Disease
Torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
occurred VBD O
early RB O
during IN O
treatment NN O
even RB O
with IN O
low JJ O
doses NNS O
of IN O
oral JJ O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
. . O
null null null-Disease
Pronounced VBN O
changes NNS O
in IN O
the DT O
surface NN O
ECG NNP O
( HYPH O
cycle NN O
length NN O
, , O
QT NNP O
, , O
and CC O
QTc NNP O
) -RRB- O
in IN O
relation NN O
to IN O
the DT O
dose NN O
of IN O
oral JJ O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
might MD O
identify VB O
a DT O
subgroup NN O
of IN O
patients NNS O
with IN O
an DT O
increased VBN O
risk NN O
for IN O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
. . O
null null null-Disease
Other JJ O
ECG NNP O
parameters NNS O
before IN O
the DT O
application NN O
of IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
did VBD O
not RB O
identify VB O
patients NNS O
at IN O
increased VBN O
risk NN O
for IN O
torsades NNS B-Disease
de FW I-Disease
pointes NNS I-Disease
. . O
null null null-Disease
Recurrence NN O
rates NNS O
of IN O
ventricular JJ B-Disease
tachyarrhythmias NNS I-Disease
are VBP O
high JJ O
despite IN O
complete JJ O
suppression NN O
of IN O
the DT O
arrhythmia NN B-Disease
during IN O
programmed VBN O
stimulation NN O
. . O
null null null-Disease
Therefore RB O
programmed VBN O
electrical JJ O
stimulation NN O
in IN O
the DT O
case NN O
of IN O
d NN O
, , O
l NN O
- HYPH O
sotalol NN O
seems VBZ O
to TO O
be VB O
of IN O
limited JJ O
prognostic JJ O
value NN O
. . O
null null null-Disease
Chronic JJ O
hyperprolactinemia NN B-Disease
and CC O
changes NNS O
in IN O
dopamine NN O
neurons NNS O
. . O
null null null-Disease
The DT O
tuberoinfundibular NN O
dopaminergic JJ O
( , O
TIDA NNP O
) -RRB- O
system NN O
is VBZ O
known VBN O
to TO O
inhibit VB O
prolactin NN O
( -LRB- O
PRL NN O
) -RRB- O
secretion NN O
. . O
null null null-Disease
In IN O
young JJ O
animals NNS O
this DT O
system NN O
responds VBZ O
to IN O
acute JJ O
elevations NNS O
in IN O
serum JJ O
PRL NN O
by IN O
increasing VBG O
its PRP$ O
activity NN O
. . O
null null null-Disease
However RB O
, , O
this DT O
responsiveness NN O
is VBZ O
lost VBN O
in IN O
aging VBG O
rats NNS O
with IN O
chronically RB O
high JJ O
serum JJ O
PRL NN O
levels NNS O
. . O
null null null-Disease
The DT O
purpose NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
induce VB O
hyperprolactinemia NN B-Disease
in IN O
rats NNS O
for IN O
extended VBN O
periods NNS O
of IN O
time NN O
and CC O
examine VB O
its PRP$ O
effects NNS O
on IN O
dopaminergic JJ O
systems NNS O
in IN O
the DT O
brain NN O
. . O
null null null-Disease
Hyperprolactinemia NN B-Disease
was VBD O
induced VBN O
by IN O
treatment NN O
with IN O
haloperidol NN O
, , O
a DT O
dopamine NN O
receptor NN O
antagonist NN O
, , O
and CC O
Palkovits NNP O
' POS O
microdissection NN O
technique NN O
in IN O
combination NN O
with IN O
high JJ O
- HYPH O
performance NN O
liquid NN O
chromatography NN O
was VBD O
used VBN O
to TO O
measure VB O
neurotransmitter NN O
concentrations NNS O
in IN O
several JJ O
areas NNS O
of IN O
the DT O
brain NN O
. . O
null null null-Disease
After IN O
6 CD O
months NNS O
of IN O
hyperprolactinemia NN B-Disease
, , O
dopamine NN O
( , O
DA NN O
) -RRB- O
concentrations NNS O
in IN O
the DT O
median JJ O
eminence NN O
( , O
ME NNP O
) -RRB- O
increased VBD O
by IN O
84 CD O
% NN O
over IN O
the DT O
control NN O
group NN O
. . O
null null null-Disease
Nine CD O
months NNS O
of IN O
hyperprolactinemia NN B-Disease
produced VBD O
a DT O
50 CD O
% NN O
increase NN O
in IN O
DA NN O
concentrations NNS O
in IN O
the DT O
ME NNP O
over IN O
the DT O
control NN O
group NN O
. . O
null null null-Disease
However RB O
, , O
DA NNP O
response NN O
was VBD O
lost VBN O
if IN O
a DT O
9 CD O
- HYPH O
month NN O
long JJ O
haloperidol NN O
- HYPH O
induced VBN O
hyperprolactinemia NN B-Disease
was VBD O
followed VBN O
by IN O
a DT O
1 CD O
1 CD O
/ SYM O
2 CD O
month NN O
- HYPH O
long JJ O
extremely RB O
high JJ O
increase NN O
in IN O
serum NN O
PRL NN O
levels NNS O
produced VBN O
by IN O
implantation NN O
of IN O
MMQ NNP O
cells NNS O
under IN O
the DT O
kidney NN O
capsule NN O
. . O
null null null-Disease
There EX O
was VBD O
no DT O
change NN O
in IN O
the DT O
levels NNS O
of IN O
DA NNP O
, , O
norepinephrine NN O
( , O
NE NNP O
) -RRB- O
, , O
serotonin NN O
( , O
5 CD O
- HYPH O
HT NN O
) -RRB- O
, , O
or CC O
their PRP$ O
metabolites NNS O
in IN O
the DT O
arcuate NN O
nucleus NN O
( , O
AN NNP O
) -RRB- O
, , O
medial JJ O
preoptic JJ O
area NN O
( , O
MPA NNP O
) -RRB- O
, , O
caudate NN O
putamen NN O
( , O
CP NNP O
) -RRB- O
, , O
substantia NN O
nigra NN O
( , O
SN NNP O
) -RRB- O
, , O
and CC O
zona NN O
incerta NN O
( , O
ZI NNP O
) -RRB- O
, , O
except IN O
for IN O
a DT O
decrease NN O
in IN O
5 CD O
- HYPH O
hydroxyindoleacetic NN O
acid NN O
( -LRB- O
5 CD O
- HYPH O
HIAA NNP O
) -RRB- O
in IN O
the DT O
AN NN O
after IN O
6 CD O
- HYPH O
months NNS O
of IN O
hyperprolactinemia NN B-Disease
and CC O
an DT O
increase NN O
in IN O
DA NN O
concentrations NNS O
in IN O
the DT O
AN NN O
after IN O
9 CD O
- HYPH O
months NNS O
of IN O
hyperprolactinemia NN B-Disease
. . O
null null null-Disease
These DT O
results NNS O
demonstrate VBP O
that IN O
hyperprolactinemia NN B-Disease
specifically RB O
affects VBZ O
TIDA NNP O
neurons NNS O
and CC O
these DT O
effects NNS O
vary VBP O
, , O
depending VBG O
on IN O
the DT O
duration NN O
and CC O
intensity NN O
of IN O
hyperprolactinemia NN B-Disease
. . O
null null null-Disease
The DT O
age NN O
- HYPH O
related VBN O
decrease NN O
in IN O
hypothalamic JJ O
dopamine NN O
function NN O
may MD O
be VB O
associated VBN O
with IN O
increases NNS O
in IN O
PRL NNP O
secretion NN O
. . O
null null null-Disease
Treatment NN O
- HYPH O
related VBN O
disseminated VBN O
necrotizing VBG O
leukoencephalopathy NN B-Disease
with IN O
characteristic JJ O
contrast NN O
enhancement NN O
of IN O
the DT O
white JJ O
matter NN O
. . O
null null null-Disease
This DT O
report NN O
describes VBZ O
unique JJ O
contrast NN O
enhancement NN O
of IN O
the DT O
white JJ O
matter NN O
on IN O
T1 NNP O
- HYPH O
weighted VBN O
magnetic JJ O
resonance NN O
images NNS O
of IN O
two CD O
patients NNS O
with IN O
disseminated VBN O
necrotizing JJ O
leukoencephalopathy NN B-Disease
, , O
which WDT O
developed VBD O
from IN O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
treated VBN O
with IN O
high JJ O
- HYPH O
dose NN O
methotrexate NN O
. . O
null null null-Disease
In IN O
both DT O
patients NNS O
, , O
the DT O
enhancement NN O
was VBD O
more RBR O
pronounced JJ O
near IN O
the DT O
base NN O
of IN O
the DT O
brain NN O
than IN O
at IN O
the DT O
vertex NN O
. . O
null null null-Disease
Necropsy NN O
of IN O
the DT O
first JJ O
case NN O
revealed VBD O
loss NN B-Disease
of IN I-Disease
myelination NN I-Disease
and CC O
necrosis NN B-Disease
of IN O
the DT O
white JJ O
matter NN O
. . O
null null null-Disease
Possible JJ O
mechanisms NNS O
causing VBG O
such PDT O
a DT O
leukoencephalopathy NN B-Disease
are VBP O
discussed VBN O
. . O
null null null-Disease
Thrombotic JJ B-Disease
complications NNS O
in IN O
acute JJ B-Disease
promyelocytic JJ I-Disease
leukemia NN I-Disease
during IN O
all RB O
- HYPH O
trans NN O
- HYPH O
retinoic NN O
acid NN O
therapy NN O
. . O
null null null-Disease
A DT O
case NN O
of IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
, , O
due IN O
to IN O
occlusion NN B-Disease
of IN I-Disease
renal JJ I-Disease
vessels NNS I-Disease
in IN O
a DT O
patient NN O
with IN O
acute JJ B-Disease
promyelocytic JJ I-Disease
leukemia NN I-Disease
( , O
APL NNP B-Disease
) , O
treated VBN O
with IN O
all DT O
- HYPH O
trans NNS O
- HYPH O
retinoic NN O
acid NN O
( , O
ATRA NNP O
) -RRB- O
and CC O
tranexamic JJ O
acid NN O
has VBZ O
been VBN O
described VBN O
recently RB O
. . O
null null null-Disease
We PRP O
report VBP O
a DT O
case NN O
of IN O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
in IN O
an DT O
APL NNP B-Disease
patient NN O
treated VBN O
with IN O
ATRA NNP O
alone RB O
. . O
null null null-Disease
This DT O
case NN O
further RB O
supports VBZ O
the DT O
concern NN O
about IN O
thromboembolic JJ B-Disease
complications NNS O
associated VBN O
with IN O
ATRA NNP O
therapy NN O
in IN O
APL NNP B-Disease
patients NNS O
. . O
null null null-Disease
The DT O
patients NNS O
, , O
a DT O
43 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
, , O
presented VBD O
all PDT O
the DT O
signs NNS O
and CC O
symptoms NNS O
of IN O
APL NNP B-Disease
and CC O
was VBD O
included VBN O
in IN O
a DT O
treatment NN O
protocol NN O
with IN O
ATRA NNP O
. . O
null null null-Disease
After IN O
10 CD O
days NNS O
of IN O
treatment NN O
, , O
he PRP O
developed VBD O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
that WDT O
was VBD O
completely RB O
reversible JJ O
after IN O
complete JJ O
remission NN O
of IN O
APL NNP B-Disease
was VBD O
achieved VBN O
and CC O
therapy NN O
discontinued VBN O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
ATRA NNP O
is VBZ O
a DT O
valid JJ O
therapeutic JJ O
choice NN O
for IN O
patients NNS O
with IN O
APL NNP B-Disease
, , O
although IN O
the DT O
procoagulant JJ O
tendency NN O
is VBZ O
not RB O
completely RB O
corrected VBN O
. . O
null null null-Disease
Thrombotic JJ B-Disease
events NNS O
, , O
however RB O
, , O
could MD O
be VB O
avoided VBN O
by IN O
using VBG O
low JJ O
- HYPH O
dose NN O
heparin NN O
. . O
null null null-Disease
Pupillary NN O
changes NNS O
associated VBN O
with IN O
the DT O
development NN O
of IN O
stimulant NN O
- HYPH O
induced VBN O
mania NN B-Disease
: : O
a DT O
case NN O
report NN O
. . O
null null null-Disease
A DT O
30 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
cocaine NN O
- HYPH O
dependent JJ O
man NN O
who WP O
was VBD O
a DT O
subject NN O
in IN O
a DT O
study NN O
evaluating VBG O
the DT O
anticraving VBG O
efficacy NN O
of IN O
the DT O
stimulant JJ O
medication NN O
diethylpropion NN O
( -LRB- O
DEP NNP O
) -RRB- O
became VBD O
manic JJ B-Disease
during IN O
his PRP$ O
second JJ O
week NN O
on IN O
the DT O
study NN O
drug NN O
. . O
null null null-Disease
Pupillometric JJ O
changes NNS O
while IN O
on IN O
DEP NNP O
, , O
especially RB O
changes NNS O
in IN O
the DT O
total JJ O
power NN O
of IN O
pupillary NN B-Disease
oscillation NN I-Disease
, , O
were VBD O
dramatically RB O
different JJ O
than IN O
those DT O
observed VBN O
in IN O
the DT O
eight CD O
other JJ O
study NN O
subjects NNS O
who WP O
did VBD O
not RB O
become VB O
manic JJ B-Disease
. . O
null null null-Disease
The DT O
large JJ O
changes NNS O
in IN O
total JJ O
power NN O
of IN O
pupillary JJ B-Disease
oscillation NN I-Disease
occurred VBD O
a DT O
few JJ O
days NNS O
before IN O
the DT O
patient NN O
became VBD O
fully RB O
manic JJ B-Disease
. . O
null null null-Disease
Such JJ O
medication NN O
- HYPH O
associated VBN O
changes NNS O
in IN O
the DT O
total JJ O
power NN O
of IN O
pupillary JJ B-Disease
oscillation NN I-Disease
might MD O
be VB O
of IN O
utility NN O
in IN O
identifying VBG O
persons NNS O
at IN O
risk NN O
for IN O
manic JJ B-Disease
- HYPH O
like JJ O
adverse JJ O
effects NNS O
during IN O
the DT O
medical JJ O
use NN O
of IN O
psychomotor NN O
stimulants NNS O
or CC O
sympathomimetic JJ O
agents NNS O
. . O
null null null-Disease
Fetal JJ O
risks NNS O
due JJ O
to IN O
warfarin NN O
therapy NN O
during IN O
pregnancy NN O
. . O
null null null-Disease
Two CD O
mothers NNS O
with IN O
heart NN O
valve NN O
prosthesis NN O
were VBD O
treated VBN O
with IN O
warfarin NN O
during IN O
pregnancy NN O
. . O
null null null-Disease
In IN O
the DT O
first JJ O
case NN O
a DT O
caesarean JJ O
section NN O
was VBD O
done VBN O
one CD O
week NN O
after IN O
replacement NN O
of IN O
warfarin NN O
with IN O
heparin NN O
. . O
null null null-Disease
The DT O
baby NN O
died VBD O
of IN O
cerebral JJ B-Disease
and CC I-Disease
pulmonary JJ I-Disease
hemorrhage NN I-Disease
. . O
null null null-Disease
The DT O
second JJ O
mother NN O
had VBD O
a DT O
male JJ O
infant NN O
by IN O
caesarean JJ O
section NN O
. . O
null null null-Disease
The DT O
baby NN O
showed VBD O
warfarin NN O
- HYPH O
induced VBN O
embryopathy NN B-Disease
with IN O
nasal JJ B-Disease
hypoplasia NN I-Disease
and CC O
stippled VBN B-Disease
epiphyses NNS I-Disease
( , O
chondrodysplasia NN B-Disease
punctata NN I-Disease
) -RRB- O
. . O
null null null-Disease
Nasal JJ B-Disease
hypoplasia NN I-Disease
with IN O
or CC O
without IN O
stippled VBN B-Disease
epiphyses NNS I-Disease
has VBZ O
now RB O
been VBN O
reported VBN O
in IN O
11 CD O
infants NNS O
born VBN O
to IN O
mothers NNS O
treated VBN O
with IN O
warfarin NN O
during IN O
the DT O
first JJ O
trimester NN O
, , O
and CC O
a DT O
causal JJ O
association NN O
is VBZ O
probable JJ O
. . O
null null null-Disease
In IN O
view NN O
of IN O
the DT O
risks NNS O
to IN O
both CC O
mother NN O
and CC O
fetus NN O
in IN O
women NNS O
with IN O
prosthetic JJ O
cardiac JJ O
valves NNS O
it PRP O
is VBZ O
recommended VBN O
that IN O
therapeutic JJ O
abortion NN O
be VB O
advised VBN O
as IN O
the DT O
first JJ O
alternative NN O
. . O
null null null-Disease
The DT O
negative JJ O
mucosal JJ O
potential NN O
: : O
separating VBG O
central JJ O
and CC O
peripheral JJ O
effects NNS O
of IN O
NSAIDs NNPS O
in IN O
man NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
We PRP O
wanted VBD O
to TO O
test VB O
whether IN O
assessment NN O
of IN O
both CC O
a DT O
central JJ O
pain NN B-Disease
- HYPH O
related VBN O
signal NN O
( , O
chemo NN O
- HYPH O
somatosensory NN O
evoked VBD O
potential JJ O
, , O
CSSEP NNP O
) -RRB- O
and CC O
a DT O
concomitantly RB O
recorded VBN O
peripheral JJ O
signal NN O
( , O
negative JJ O
mucosal JJ O
potential NN O
, , O
NMP NNP O
) -RRB- O
allows VBZ O
for IN O
separation NN O
of IN O
central JJ O
and CC O
peripheral JJ O
effects NNS O
of IN O
NSAIDs NNPS O
. . O
null null null-Disease
For IN O
this DT O
purpose NN O
, , O
experimental JJ O
conditions NNS O
were VBD O
created VBN O
in IN O
which WDT O
NSAIDs NNPS O
had VBD O
previously RB O
been VBN O
observed VBN O
to TO O
produce VB O
effects NNS O
on IN O
phasic JJ O
and CC O
tonic JJ O
pain NN B-Disease
by IN O
either CC O
central JJ O
or CC O
peripheral JJ O
mechanisms NNS O
. . O
null null null-Disease
METHODS NNS O
: : O
According VBG O
to IN O
a DT O
double JJ O
- HYPH O
blind JJ O
, , O
randomised JJ O
, , O
controlled VBN O
, , O
threefold JJ O
cross NN O
- HYPH O
over JJ O
design NN O
, , O
18 CD O
healthy JJ O
subjects NNS O
( , O
11 CD O
males NNS O
, , O
7 CD O
females NNS O
; : O
mean JJ O
age NN O
26 CD O
years NNS O
) -RRB- O
received VBD O
either CC O
placebo NN O
, , O
400 CD O
mg NN O
ibuprofen NN O
, , O
or CC O
800 CD O
mg NN O
ibuprofen NN O
. . O
null null null-Disease
Phasic JJ O
pain NN B-Disease
was VBD O
applied VBN O
by IN O
means NNS O
of IN O
short JJ O
pulses NNS O
of IN O
CO2 NNP O
to IN O
the DT O
nasal JJ O
mucosa NN O
( , O
stimulus NN O
duration NN O
500 CD O
ms NNS O
, , O
interval NN O
approximately RB O
60 CD O
s NNS O
) -RRB- O
, , O
and CC O
tonic NN O
pain NN B-Disease
was VBD O
induced VBN O
in IN O
the DT O
nasal JJ O
cavity NN O
by IN O
means NNS O
of IN O
dry JJ O
air NN O
of IN O
controlled VBN O
temperature NN O
, , O
humidity NN O
and CC O
flow NN O
rate NN O
( , O
22 CD O
degrees NNS O
C NN O
, , O
0 CD O
% NN O
relative JJ O
humidity NN O
, , O
145 CD O
ml NNS O
. . O
s NN O
- HYPH O
1 CD O
) -RRB- O
. . O
null null null-Disease
Both DT O
CSSEPs NNS O
as IN O
central JJ O
and CC O
NMPs NNPS O
as IN O
peripheral JJ O
correlates NNS O
of IN O
pain NN B-Disease
were VBD O
obtained VBN O
in IN O
response NN O
to IN O
the DT O
CO2 NNP O
stimuli NNS O
. . O
null null null-Disease
Additionally RB O
, , O
the DT O
subjects NNS O
rated VBD O
the DT O
intensity NN O
of IN O
both CC O
phasic JJ O
and CC O
tonic JJ O
pain NN B-Disease
by IN O
means NNS O
of IN O
visual JJ O
analogue NN O
scales NNS O
. . O
null null null-Disease
RESULTS NNS O
: : O
As IN O
described VBN O
earlier RBR O
, , O
administration NN O
of IN O
ibuprofen NN O
was VBD O
followed VBN O
by IN O
a DT O
decrease NN O
in IN O
tonic JJ O
pain NN B-Disease
but CC O
- HYPH O
relative JJ O
to IN O
placebo NN O
- : O
an DT O
increase NN O
in IN O
correlates NNS O
of IN O
phasic JJ O
pain NN B-Disease
, , O
indicating VBG O
a DT O
specific JJ O
effect NN O
of IN O
ibuprofen NN O
on IN O
the DT O
interaction NN O
between IN O
the DT O
pain NN B-Disease
stimuli NN O
under IN O
these DT O
special JJ O
experimental JJ O
conditions NNS O
. . O
null null null-Disease
Based VBN O
on IN O
the DT O
similar JJ O
behaviour NN O
of IN O
CSSEP NNP O
and CC O
NMP NNP O
, , O
it PRP O
was VBD O
concluded VBN O
that IN O
the DT O
pharmacological JJ O
process NN O
underlying VBG O
this DT O
phenomenon NN O
was VBD O
localised VBN O
in IN O
the DT O
periphery NN O
. . O
null null null-Disease
By IN O
means NNS O
of IN O
the DT O
simultaneous JJ O
recording NN O
of IN O
interrelated VBN O
peripheral JJ O
and CC O
central JJ O
electrophysiologic JJ O
correlates NNS O
of IN O
nociception NN O
, , O
it PRP O
was VBD O
possible JJ O
to TO O
separate VB O
central JJ O
and CC O
peripheral JJ O
effects NNS O
of IN O
an DT O
NSAID NNP O
. . O
null null null-Disease
The DT O
major JJ O
advantage NN O
of IN O
this DT O
pain NN B-Disease
model NN O
is VBZ O
the DT O
possibility NN O
of IN O
obtaining VBG O
peripheral JJ O
pain NN B-Disease
- HYPH O
related VBN O
activity NN O
directly RB O
using VBG O
a DT O
non AFX O
- HYPH O
invasive JJ O
technique NN O
in IN O
humans NNS O
. . O
null null null-Disease
Effect NN O
of IN O
D NN O
- HYPH O
Glucarates NNP O
on IN O
basic JJ O
antibiotic NN O
- HYPH O
induced VBN O
renal JJ B-Disease
damage NN I-Disease
in IN O
rats NNS O
. . O
null null null-Disease
Dehydrated JJ B-Disease
rats NNS O
regularly RB O
develop VBP O
acute JJ B-Disease
renal JJ I-Disease
failure NN I-Disease
following VBG O
single JJ O
injection NN O
of IN O
aminoglycoside NN O
antibiotics NNS O
combined VBN O
with IN O
dextran NN O
or CC O
of IN O
antibiotics NNS O
only RB O
. . O
null null null-Disease
Oral JJ O
administration NN O
of IN O
2 CD O
, , O
5 CD O
- HYPH O
di FW O
- HYPH O
O NNP O
- HYPH O
acetyl NNP O
- HYPH O
D NNP O
- HYPH O
glucaro NNP O
- HYPH O
1 CD O
, , O
4 CD O
- HYPH O
6 CD O
, , O
3 CD O
- HYPH O
dilactone NN O
protected VBN O
rats NNS O
against IN O
renal JJ B-Disease
failure NN I-Disease
induced VBN O
by IN O
kanamycin NNP O
- HYPH O
dextran NN O
. . O
null null null-Disease
The DT O
protective JJ O
effect NN O
was VBD O
prevalent JJ O
among IN O
D NN O
- HYPH O
glucarates NNS O
, , O
and CC O
also RB O
to IN O
other JJ O
saccharic JJ O
acid NN O
, , O
hexauronic JJ O
acids NNS O
and CC O
hexaaldonic JJ O
acids NNS O
, , O
although IN O
to IN O
a DT O
lesser JJR O
degree NN O
, , O
but CC O
not RB O
to IN O
a DT O
hexaaldose NN O
, , O
sugar NN O
alcohols NNS O
, , O
substances NNS O
inthe IN O
TCA NNP O
cycle NN O
and CC O
other JJ O
acidic JJ O
compounds NNS O
. . O
null null null-Disease
D NNP O
- HYPH O
Glucarates NNP O
were VBD O
effective JJ O
against IN O
renal JJ B-Disease
damage NN I-Disease
induced VBN O
by IN O
peptide NN O
antibiotics NNS O
as RB O
well RB O
as IN O
various JJ O
aminoglycoside NN O
antibitocis NNS O
. . O
null null null-Disease
Dose NN O
- HYPH O
responses NNS O
were VBD O
observed VBN O
in IN O
the DT O
protective JJ O
effect NN O
of IN O
D NNP O
- HYPH O
Glucarates NNP O
. . O
null null null-Disease
With IN O
a DT O
D NN O
- HYPH O
glucarate NN O
of IN O
a DT O
fixed VBN O
size NN O
of IN O
dose NN O
, , O
approximately RB O
the DT O
same JJ O
degree NN O
of IN O
protection NN O
was VBD O
obtained VBN O
against IN O
renal JJ B-Disease
damages NNS I-Disease
induced VBN O
by IN O
different JJ O
basic JJ O
antibiotics NNS O
despite IN O
large JJ O
disparities NNS O
in IN O
administration NN O
doses NNS O
of IN O
different JJ O
antibiotics NNS O
. . O
null null null-Disease
D NNP O
- HYPH O
Glucarates NNP O
had VBD O
the DT O
ability NN O
to TO O
prevent VB O
renal JJ B-Disease
damage NN I-Disease
but CC O
not RB O
to TO O
cure VB O
it PRP O
. . O
null null null-Disease
Rats NNS O
excreted VBD O
acidic JJ O
urine NN O
when WRB O
they PRP O
were VBD O
spared VBN O
from IN O
renal JJ B-Disease
lesions NNS I-Disease
by IN O
monosaccharides NNS O
. . O
null null null-Disease
The DT O
reduction NN O
effect NN O
of IN O
D NN O
- HYPH O
glucarates NNS O
against IN O
nephrotoxicity NN B-Disease
of IN O
basic JJ O
antibiotics NNS O
was VBD O
discussed VBN O
. . O
null null null-Disease
Acute JJ O
severe JJ O
depression NN B-Disease
following VBG O
peri NN O
- HYPH O
operative JJ O
ondansetron NN O
. . O
null null null-Disease
A DT O
41 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
woman NN O
with IN O
a DT O
strong JJ O
history NN O
of IN O
postoperative JJ B-Disease
nausea NN I-Disease
and CC I-Disease
vomiting NN I-Disease
presented VBN O
for IN O
abdominal JJ O
hysterectomy NN O
3 CD O
months NNS O
after IN O
a DT O
previous JJ O
anaesthetic NN O
where WRB O
ondansetron JJ O
prophylaxis NN O
had VBD O
been VBN O
used VBN O
. . O
null null null-Disease
She PRP O
had VBD O
developed VBN O
a DT O
severe JJ O
acute JJ O
major JJ B-Disease
depression NN I-Disease
disorder NN I-Disease
almost RB O
immediately RB O
thereafter RB O
, , O
possibly RB O
related VBN O
to IN O
the DT O
use NN O
of IN O
a DT O
serotonin NN O
antagonist NN O
. . O
null null null-Disease
Nine CD O
years NNS O
before IN O
she PRP O
had VBD O
experienced VBN O
a DT O
self NN O
- HYPH O
limited VBN O
puerperal JJ O
depressive JJ B-Disease
episode NN I-Disease
. . O
null null null-Disease
Anaesthesia NN O
with IN O
a DT O
propofol NN O
infusion NN O
and CC O
avoidance NN O
of IN O
serotonin NN O
antagonists NNS O
provided VBD O
a DT O
nausea NN B-Disease
- HYPH O
free JJ O
postoperative JJ O
course NN O
without IN O
exacerbation NN O
of IN O
the DT O
depression NN B-Disease
disorder NN I-Disease
. . O
null null null-Disease
Hypertensive JJ B-Disease
response NN O
during IN O
dobutamine NN O
stress NN O
echocardiography NN O
. . O
null null null-Disease
Among IN O
3 CD O
, , O
129 CD O
dobutamine JJ O
stress NN O
echocardiographic JJ O
studies NNS O
, , O
a DT O
hypertensive JJ B-Disease
response NN O
, , O
defined VBN O
as IN O
systolic JJ O
blood NN O
pressure NN O
( -LRB- O
BP NN O
) -RRB- O
> : O
or CC O
= SYM O
220 CD O
mm NN O
Hg NN O
and CC O
/ SYM O
or CC O
diastolic JJ O
BP NN O
> : O
or CC O
= SYM O
110 CD O
mm NN O
Hg NNP O
, , O
occurred VBD O
in IN O
30 CD O
patients NNS O
( , O
1 CD O
% NN O
) -RRB- O
. . O
null null null-Disease
Patients NNS O
with IN O
this DT O
response NN O
more RBR O
often RB O
had VBD O
a DT O
history NN O
of IN O
hypertension NN B-Disease
and CC O
had VBD O
higher JJR O
resting VBG O
systolic JJ O
and CC O
diastolic JJ O
BP NN O
before IN O
dobutamine NN O
infusion NN O
. . O
null null null-Disease
Continuously RB O
nebulized VBN O
albuterol NN O
in IN O
severe JJ O
exacerbations NNS O
of IN O
asthma NN B-Disease
in IN O
adults NNS O
: : O
a DT O
case NN O
- HYPH O
controlled VBN O
study NN O
. . O
null null null-Disease
A DT O
retrospective NN O
, , O
case NN O
- HYPH O
controlled VBN O
analysis NN O
comparing VBG O
patients NNS O
admitted VBN O
to IN O
a DT O
medical JJ O
intensive JJ O
care NN O
unit NN O
with IN O
severe JJ O
exacerbations NNS O
of IN O
asthma NN B-Disease
who WP O
received VBD O
continuously RB O
nebulized VBN O
albuterol NN O
( , O
CNA NNP O
) -RRB- O
versus IN O
intermittent JJ O
albuterol NN O
( -LRB- O
INA NNP O
) -RRB- O
treatments NNS O
is VBZ O
reported VBN O
. . O
null null null-Disease
Forty CD O
matched VBN O
pairs NNS O
of IN O
patients NNS O
with IN O
asthma NN B-Disease
are VBP O
compared VBN O
. . O
null null null-Disease
CNA NNP O
was VBD O
administered VBN O
for IN O
a DT O
mean NN O
of IN O
11 CD O
+ SYM O
/ SYM O
- HYPH O
10 CD O
hr NN O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
cardiac JJ B-Disease
dysrhythmias NNS I-Disease
was VBD O
similar JJ O
between IN O
groups NNS O
. . O
null null null-Disease
Symptomatic JJ O
hypokalemia NN B-Disease
did VBD O
not RB O
occur VB O
. . O
null null null-Disease
CNA NNP O
patients NNS O
had VBD O
higher JJR O
heart NN O
rates NNS O
during IN O
treatment NN O
, , O
which WDT O
may MD O
reflect VB O
severity NN O
of IN O
illness NN O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
intubation NN O
was VBD O
similar JJ O
. . O
null null null-Disease
We PRP O
conclude VBP O
that IN O
CNA NNP O
and CC O
INA NNP O
demonstrated VBD O
similar JJ O
profiles NNS O
with IN O
regard NN O
to IN O
safety NN O
, , O
morbidity NN O
, , O
and CC O
mortality NN O
. . O
null null null-Disease
Paraplegia NNP B-Disease
following VBG O
intrathecal JJ O
methotrexate NN O
: : O
report NN O
of IN O
a DT O
case NN O
and CC O
review NN O
of IN O
the DT O
literature NN O
. . O
null null null-Disease
A DT O
patient NN O
who WP O
developed VBD O
paraplegia NN B-Disease
following VBG O
the DT O
intrathecal JJ O
instillation NN O
of IN O
methotrexate NN O
is VBZ O
discribed VBN O
. . O
null null null-Disease
The DT O
ten CD O
previously RB O
reported VBN O
cases NNS O
of IN O
this DT O
unusual JJ O
complication NN O
are VBP O
reviewed VBN O
. . O
null null null-Disease
The DT O
following JJ O
factors NNS O
appear VBP O
to TO O
predispose VB O
to IN O
the DT O
development NN O
of IN O
this DT O
complication NN O
: : O
abnormal JJ O
cerebrospinal JJ O
dynamics NNS O
related VBN O
to IN O
the DT O
presence NN O
of IN O
central JJ B-Disease
nervous JJ I-Disease
system NN I-Disease
leukemia NN I-Disease
, , O
and CC O
epidural JJ O
cerebrospinal JJ O
leakage NN O
; , O
elevated VBN O
cerebrospinal JJ O
fluid NN O
methothexate NN O
concentration NN O
related VBN O
to IN O
abnormal JJ O
cerebrospinal JJ O
fluid NN O
dynamics NNS O
and CC O
to IN O
inappropriately RB O
high JJ O
methotrexate NN O
doses NNS O
based VBN O
on IN O
body NN O
surface NN O
area NN O
calculations NNS O
in IN O
older JJR O
children NNS O
and CC O
adults NNS O
; , O
the DT O
presence NN O
of IN O
neurotoxic JJ B-Disease
preservatives NNS O
in IN O
commercially RB O
available JJ O
methotrexate NN O
preparations NNS O
and CC O
diluents NNS O
; , O
and CC O
the DT O
use NN O
of IN O
methotrexate NN O
diluents NNS O
of IN O
unphysiologic JJ O
pH NN O
, , O
ionic JJ O
content NN O
and CC O
osmolarity NN O
. . O
null null null-Disease
The DT O
role NN O
of IN O
methotrexate NN O
contaminants NNS O
, , O
local JJ O
folate NN B-Disease
deficiency NN I-Disease
, , O
and CC O
cranial JJ O
irradiation NN O
in IN O
the DT O
pathogenesis NN O
of IN O
intrathecal JJ O
methotrexate NN O
toxicity NN B-Disease
is VBZ O
unclear JJ O
. . O
null null null-Disease
The DT O
incidence NN O
of IN O
neurotoxicity NN B-Disease
may MD O
be VB O
reduced VBN O
by IN O
employing VBG O
lower JJR O
doses NNS O
of IN O
methotrexate NN O
in IN O
the DT O
presence NN O
of IN O
central JJ B-Disease
nervous JJ I-Disease
system NN I-Disease
leukemia NN I-Disease
, , O
in IN O
older JJR O
children NNS O
and CC O
adults NNS O
, , O
and CC O
in IN O
the DT O
presence NN O
of IN O
epidural JJ O
leakage NN O
. . O
null null null-Disease
Only RB O
preservative NN O
- HYPH O
free JJ O
methotrexate NN O
in IN O
Elliott NNP O
' POS O
s NNS O
B NNP O
Solution NNP O
at IN O
a DT O
concentration NN O
of IN O
not RB O
more JJR O
than IN O
1 CD O
mg NNS O
/ SYM O
ml NNS O
should MD O
be VB O
used VBN O
for IN O
intrathecal JJ O
administration NN O
. . O
null null null-Disease
Periodic JJ O
monitoring NN O
of IN O
cerebruspinal JJ O
fluid NN O
methotrexate NN O
levels NNS O
may MD O
be VB O
predictive JJ O
of IN O
the DT O
development NN O
of IN O
serious JJ O
neurotoxicity NN B-Disease
. . O
null null null-Disease
Hyperosmolar JJ B-Disease
nonketotic JJ I-Disease
coma NN I-Disease
precipitated VBN O
by IN O
lithium NN O
- HYPH O
induced VBN O
nephrogenic JJ B-Disease
diabetes NNS I-Disease
insipidus NN I-Disease
. . O
null null null-Disease
A DT O
45 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
man NN O
, , O
with IN O
a DT O
10 CD O
- HYPH O
year NN O
history NN O
of IN O
manic JJ B-Disease
depression NN I-Disease
treated VBN O
with IN O
lithium NN O
, , O
was VBD O
admitted VBN O
with IN O
hyperosmolar JJ B-Disease
, , I-Disease
nonketotic JJ I-Disease
coma NN I-Disease
. . O
null null null-Disease
He PRP O
gave VBD O
a DT O
five CD O
- HYPH O
year NN O
history NN O
of IN O
polyuria NN B-Disease
and CC O
polydipsia NN B-Disease
, , O
during IN O
which WDT O
time NN O
urinalysis NN O
had VBD O
been VBN O
negative JJ O
for IN O
glucose NN O
. . O
null null null-Disease
After IN O
recovery NN O
from IN O
hyperglycaemia NN B-Disease
, , O
he PRP O
remained VBD O
polyuric JJ B-Disease
despite IN O
normal JJ O
blood NN O
glucose NN O
concentrations NNS O
; , O
water NN O
deprivation NN O
testing NN O
indicated VBD O
nephrogenic JJ B-Disease
diabetes NNS I-Disease
insipidus NN I-Disease
, , O
likely JJ O
to TO O
be VB O
lithium NN O
- HYPH O
induced VBN O
. . O
null null null-Disease
We PRP O
hypothesize VBP O
that IN O
when WRB O
this DT O
man NN O
developed VBD O
type NN B-Disease
2 CD I-Disease
diabetes NNS I-Disease
, , O
chronic JJ O
polyuria NN B-Disease
due JJ O
to IN O
nephrogenic JJ B-Disease
diabetes NN I-Disease
insipidus NN I-Disease
was VBD O
sufficient JJ O
to TO O
precipitate VB O
hyperosmolar JJ O
dehydration NN B-Disease
. . O
null null null-Disease
Effects NNS O
of IN O
the DT O
intracoronary JJ O
infusion NN O
of IN O
cocaine NN O
on IN O
left JJ O
ventricular JJ O
systolic JJ O
and CC O
diastolic JJ O
function NN O
in IN O
humans NNS O
. . O
null null null-Disease
BACKGROUND NN O
: : O
In IN O
dogs NNS O
, , O
a DT O
large JJ O
amount NN O
of IN O
intravenous JJ O
cocaine NN O
causes VBZ O
a DT O
profound JJ O
deterioration NN B-Disease
of IN I-Disease
left JJ I-Disease
ventricular JJ I-Disease
( , I-Disease
LV NN I-Disease
) -RRB- I-Disease
systolic JJ I-Disease
function NN I-Disease
and CC O
an DT O
increase NN O
in IN O
LV NN O
end NN O
- HYPH O
diastolic JJ O
pressure NN O
. . O
null null null-Disease
This DT O
study NN O
was VBD O
done VBN O
to TO O
assess VB O
the DT O
influence NN O
of IN O
a DT O
high JJ O
intracoronary JJ O
cocaine NN O
concentration NN O
on IN O
LV NN O
systolic JJ O
and CC O
diastolic JJ O
function NN O
in IN O
humans NNS O
. . O
null null null-Disease
METHODS NNS O
AND CC O
RESULTS NNS O
: : O
In IN O
20 CD O
patients NNS O
( , O
14 CD O
men NNS O
and CC O
6 CD O
women NNS O
aged VBN O
39 CD O
to TO O
72 CD O
years NNS O
) -RRB- O
referred VBD O
for IN O
cardiac JJ O
catheterization NN O
for IN O
the DT O
evaluation NN O
of IN O
chest NN B-Disease
pain NN I-Disease
, , O
we PRP O
measured VBD O
heart NN O
rate NN O
, , O
systemic JJ O
arterial JJ O
pressure NN O
, , O
LV NN O
pressure NN O
and CC O
its PRP$ O
first JJ O
derivative JJ O
( , O
dP NN O
/ SYM O
dt NN O
) -RRB- O
, , O
and CC O
LV NN O
volumes NNS O
and CC O
ejection NN O
fraction NN O
before IN O
and CC O
during IN O
the DT O
final JJ O
2 CD O
to TO O
3 CD O
minutes NNS O
of IN O
a DT O
15 CD O
- HYPH O
minute NN O
intracoronary JJ O
infusion NN O
of IN O
saline NN O
( , O
n NN O
= SYM O
10 CD O
, , O
control NN O
subjects NNS O
) -RRB- O
or CC O
cocaine NN O
hydrochloride NN O
1 CD O
mg NN O
/ SYM O
min NN O
( , O
n CD O
= SYM O
10 CD O
) -RRB- O
. . O
null null null-Disease
No DT O
variable NN O
changed VBN O
with IN O
saline NN O
. . O
null null null-Disease
With IN O
cocaine NN O
, , O
the DT O
drug NN O
concentration NN O
in IN O
blood NN O
obtained VBN O
from IN O
the DT O
coronary JJ O
sinus NN O
was VBD O
3 CD O
. . O
0 CD O
+ NFP O
/ SYM O
- HYPH O
0 CD O
. . O
4 CD O
( SYM O
mean NN O
+ SYM O
/ SYM O
- HYPH O
SD NN O
) SYM O
mg CD O
/ SYM O
L NNP O
, , O
similar JJ O
in IN O
magnitude NN O
to IN O
the DT O
blood NN O
cocaine NN O
concentration NN O
reported VBN O
in IN O
abusers NNS O
dying VBG O
of IN O
cocaine NN O
intoxication NN O
. . O
null null null-Disease
Cocaine NN O
induced VBD O
no DT O
significant JJ O
change NN O
in IN O
heart NN O
rate NN O
, , O
LV NN O
dP NN O
/ SYM O
dt NN O
( , O
positive JJ O
or CC O
negative JJ O
) -RRB- O
, , O
or CC O
LV NN O
end NN O
- HYPH O
diastolic JJ O
volume NN O
, , O
but CC O
it PRP O
caused VBD O
an DT O
increase NN O
in IN O
systolic JJ O
and CC O
mean JJ O
arterial JJ O
pressures NNS O
, , O
LV NN O
end NN O
- HYPH O
diastolic JJ O
pressure NN O
, , O
and CC O
LV NN O
end NN O
- HYPH O
systolic JJ O
volume NN O
, , O
as RB O
well RB O
as IN O
a DT O
decrease NN O
in IN O
LV NN O
ejection NN O
fraction NN O
. . O
null null null-Disease
CONCLUSIONS NNS O
: : O
In IN O
humans NNS O
, , O
the DT O
intracoronary JJ O
infusion NN O
of IN O
cocaine NN O
sufficient JJ O
in IN O
amount NN O
to TO O
achieve VB O
a DT O
high JJ O
drug NN O
concentration NN O
in IN O
coronary JJ O
sinus NN O
blood NN O
causes VBZ O
a DT O
deterioration NN B-Disease
of IN I-Disease
LV NN I-Disease
systolic JJ I-Disease
and CC I-Disease
diastolic JJ I-Disease
performance NN I-Disease
. . O
null null null-Disease
Ascending VBG O
dose NN O
tolerance NN O
study NN O
of IN O
intramuscular JJ O
carbetocin NN O
administered VBN O
after IN O
normal JJ O
vaginal JJ O
birth NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
To TO O
determine VB O
the DT O
maximum JJ O
tolerated VBN O
dose NN O
( , O
MTD NNP O
) -RRB- O
of IN O
carbetocin NN O
( , O
a DT O
long RB O
- HYPH O
acting VBG O
synthetic JJ O
analogue NN O
of IN O
oxytocin NN O
) -RRB- O
, , O
when WRB O
administered VBN O
immediately RB O
after IN O
vaginal JJ O
delivery NN O
at IN O
term NN O
. . O
null null null-Disease
MATERIALS NNS O
AND CC O
METHODS NNS O
: : O
Carbetocin NNP O
was VBD O
given VBN O
as IN O
an DT O
intramuscular JJ O
injection NN O
immediately RB O
after IN O
the DT O
birth NN O
of IN O
the DT O
infant NN O
in IN O
45 CD O
healthy JJ O
women NNS O
with IN O
normal JJ O
singleton NN O
pregnancies NNS O
who WP O
delivered VBD O
vaginally RB O
at IN O
term NN O
. . O
null null null-Disease
Dosage NN O
groups NNS O
of IN O
15 CD O
, , O
30 CD O
, , O
50 CD O
, , O
75 CD O
, , O
100 CD O
, , O
125 CD O
, , O
150 CD O
, , O
175 CD O
or CC O
200 CD O
microg NN O
carbetocin NN O
were VBD O
assigned VBN O
to IN O
blocks NNS O
of IN O
three CD O
women NNS O
according VBG O
to IN O
the DT O
continual JJ O
reassessment NN O
method NN O
( -LRB- O
CRM NNP O
) -RRB- O
. . O
null null null-Disease
RESULTS NNS O
: : O
All DT O
dosage NN O
groups NNS O
consisted VBD O
of IN O
three CD O
women NNS O
, , O
except IN O
those DT O
with IN O
100 CD O
microg NN O
( , O
n CD O
= SYM O
6 CD O
) -RRB- O
and CC O
200 CD O
microg NN O
( , O
n CD O
= SYM O
18 CD O
) -RRB- O
. . O
null null null-Disease
Recorded VBN O
were VBD O
dose NN O
- HYPH O
limiting VBG O
adverse JJ O
events NNS O
: : O
hyper NN B-Disease
- HYPH I-Disease
or CC I-Disease
hypotension NN I-Disease
( : O
three CD O
) -RRB- O
, , O
severe JJ O
abdominal JJ B-Disease
pain NN I-Disease
( , O
0 CD O
) -RRB- O
, , O
vomiting NN B-Disease
( , O
0 CD O
) -RRB- O
and CC O
retained VBN B-Disease
placenta NN I-Disease
( , O
four CD O
) -RRB- O
. . O
null null null-Disease
Serious JJ O
adverse JJ O
events NNS O
occurred VBD O
in IN O
seven CD O
women NNS O
: : O
six CD O
cases NNS O
with IN O
blood NN B-Disease
loss NN I-Disease
> SYM O
or CC O
= SYM O
1000 CD O
ml NNS O
, , O
four CD O
cases NNS O
of IN O
manual JJ O
placenta NN O
removal NN O
, , O
five CD O
cases NNS O
of IN O
additional JJ O
oxytocics NNS O
administration NN O
and CC O
five CD O
cases NNS O
of IN O
blood NN O
transfusion NN O
. . O
null null null-Disease
Maximum JJ O
blood NN B-Disease
loss NN I-Disease
was VBD O
greatest JJS O
at IN O
the DT O
upper JJ O
and CC O
lower JJR O
dose NN O
levels NNS O
, , O
and CC O
lowest JJS O
in IN O
the DT O
70 CD O
- SYM O
125 CD O
microg NN O
dose NN O
range NN O
. . O
null null null-Disease
Four CD O
out IN O
of IN O
six CD O
cases NNS O
with IN O
blood NN B-Disease
loss NN I-Disease
> : O
or CC O
= SYM O
1000 CD O
ml NNS O
occurred VBD O
in IN O
the DT O
200 CD O
microg NN O
group NN O
. . O
null null null-Disease
The DT O
majority NN O
of IN O
additional JJ O
administration NN O
of IN O
oxytocics NNS O
( , O
4 CD O
/ SYM O
5 CD O
) -RRB- O
and CC O
blood NN O
transfusion NN O
( , O
3 CD O
/ SYM O
5 CD O
) -RRB- O
occurred VBD O
in IN O
the DT O
dose NN O
groups NNS O
of IN O
200 CD O
microg NN O
. . O
null null null-Disease
All DT O
retained VBD O
placentae NN O
were VBD O
found VBN O
in IN O
the DT O
group NN O
of IN O
200 CD O
microg NN O
. . O
null null null-Disease
CONCLUSION NN O
: : O
The DT O
MTD NNP O
was VBD O
calculated VBN O
to TO O
be VB O
at IN O
200 CD O
microg NN O
carbetocin NN O
. . O
null null null-Disease
Heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
, , O
paradoxical JJ O
thromboembolism NN B-Disease
, , O
and CC O
other JJ O
side NN O
effects NNS O
of IN O
heparin NN O
therapy NN O
. . O
null null null-Disease
Although IN O
several JJ O
new JJ O
anticoagulant JJ O
drugs NNS O
are VBP O
in IN O
development NN O
, , O
heparin NN O
remains VBZ O
the DT O
drug NN O
of IN O
choice NN O
for IN O
most JJS O
anticoagulation NN O
needs NNS O
. . O
null null null-Disease
The DT O
clinical JJ O
effects NNS O
of IN O
heparin NN O
are VBP O
meritorious JJ O
, , O
but CC O
side NN O
effects NNS O
do VBP O
exist VB O
. . O
null null null-Disease
Important JJ O
untoward JJ O
effects NNS O
of IN O
heparin NN O
therapy NN O
including VBG O
heparin NN O
- HYPH O
induced VBN O
thrombocytopenia NN B-Disease
, , O
heparin NN O
- HYPH O
associated VBN O
osteoporosis NN B-Disease
, , O
eosinophilia NN B-Disease
, , O
skin NN B-Disease
reactions NNS I-Disease
, , O
allergic JJ B-Disease
reactions NNS I-Disease
other JJ O
than IN O
thrombocytopenia NN B-Disease
and CC O
alopecia NN B-Disease
will MD O
be VB O
discussed VBN O
in IN O
this DT O
article NN O
. . O
null null null-Disease
Nonopaque JJ O
crystal NN O
deposition NN O
causing VBG O
ureteric JJ B-Disease
obstruction NN I-Disease
in IN O
patients NNS O
with IN O
HIV NNP O
undergoing VBG O
indinavir NN O
therapy NN O
. . O
null null null-Disease
OBJECTIVE NN O
: : O
We PRP O
describe VBP O
the DT O
unique JJ O
CT NNP O
features NNS O
of IN O
ureteric JJ B-Disease
calculi NN I-Disease
in IN O
six CD O
HIV NNP B-Disease
- HYPH I-Disease
infected VBN I-Disease
patients NNS O
receiving VBG O
indinavir NN O
, , O
the DT O
most RBS O
commonly RB O
used VBN O
HIV NNP O
protease NN O
inhibitor NN O
, , O
which WDT O
is VBZ O
associated VBN O
with IN O
an DT O
increased JJ O
incidence NN O
of IN O
urolithiasis NN B-Disease
. . O
null null null-Disease
CONCLUSION NN O
: : O
Ureteric JJ B-Disease
obstruction NN I-Disease
caused VBN O
by IN O
precipitated VBN O
indinavir JJ O
crystals NNS O
may MD O
be VB O
difficult JJ O
to TO O
diagnose VB O
with IN O
unenhanced JJ O
CT NNP O
. . O
null null null-Disease
The DT O
calculi NN O
are VBP O
not RB O
opaque JJ O
, , O
and CC O
secondary JJ O
signs NNS O
of IN O
obstruction NN O
may MD O
be VB O
absent JJ O
or CC O
minimal JJ O
and CC O
should MD O
be VB O
sought VBN O
carefully RB O
. . O
null null null-Disease
Images NNS O
may MD O
need VB O
to TO O
be VB O
obtained VBN O
using VBG O
i PRP O
. . O
v NN O
. . O
contrast NN O
material NN O
to TO O
enable VB O
diagnosis NN O
of IN O
ureteric JJ B-Disease
stones NNS I-Disease
or CC I-Disease
obstruction NN I-Disease
in IN O
patients NNS O
with IN O
HIV NNP B-Disease
infection NN I-Disease
who WP O
receive VBP O
indinavir JJ O
therapy NN O
. . O
null null null-Disease
Ischemic JJ B-Disease
colitis NN I-Disease
and CC O
sumatriptan NN O
use NN O
. . O
null null null-Disease
Sumatriptan JJ O
succinate NN O
, , O
a DT O
serotonin NN O
- HYPH O
1 CD O
( SYM O
5 CD O
- HYPH O
hydroxytryptamine NN O
- HYPH O
1 CD O
) -RRB- O
receptor NN O
agonist NN O
, , O
is VBZ O
an DT O
antimigraine JJ O
drug NN O
that WDT O
is VBZ O
reported VBN O
to TO O
act VB O
by IN O
selectively RB O
constricting VBG O
intracranial JJ O
arteries NNS O
. . O
null null null-Disease
Recently RB O
, , O
vasopressor NN O
responses NNS O
that WDT O
are VBP O
distinct JJ O
from IN O
the DT O
cranial JJ O
circulation NN O
have VBP O
been VBN O
demonstrated VBN O
to TO O
occur VB O
in IN O
the DT O
systemic JJ O
, , O
pulmonary JJ O
, , O
and CC O
coronary JJ O
circulations NNS O
. . O
null null null-Disease
Cases NNS O
have VBP O
been VBN O
published VBN O
of IN O
coronary JJ B-Disease
vasospasm NN I-Disease
, , O
myocardial JJ B-Disease
ischemia NN I-Disease
, , O
and CC O
myocardial JJ B-Disease
infarction NN I-Disease
occurring VBG O
after IN O
sumatriptan JJ O
use NN O
. . O
null null null-Disease
We PRP O
report VBP O
on IN O
the DT O
development NN O
of IN O
8 CD O
serious JJ O
cases NNS O
of IN O
ischemic JJ B-Disease
colitis NN I-Disease
in IN O
patients NNS O
with IN O
migraine NN B-Disease
treated VBN O
with IN O
sumatriptan NN O
. . O
null null null-Disease
Pallidotomy NNP O
with IN O
the DT O
gamma NN O
knife NN O
: : O
a DT O
positive JJ O
experience NN O
. . O
null null null-Disease
51 CD O
patients NNS O
with IN O
medically RB O
refractory JJ O
Parkinson NNP B-Disease
' POS I-Disease
s NNS I-Disease
disease NN I-Disease
underwent VBD O
stereotactic JJ O
posteromedial JJ O
pallidotomy NN O
between IN O
August NNP O
1993 CD O
and CC O
February NNP O
1997 CD O
for IN O
treatment NN O
of IN O
bradykinesia NN B-Disease
, , O
rigidity NN B-Disease
, , O
and CC O
L NN O
- HYPH O
DOPA NNP O
- HYPH O
induced VBN O
dyskinesias NNS B-Disease
. . O
null null null-Disease
In IN O
29 CD O
patients NNS O
, , O
the DT O
pallidotomies NNS O
were VBD O
performed VBN O
with IN O
the DT O
Leksell NNP O
Gamma NNP O
Knife NNP O
and CC O
in IN O
22 CD O
they PRP O
were VBD O
performed VBN O
with IN O
the DT O
standard JJ O
radiofrequency NN O
( -LRB- O
RF NNP O
) -RRB- O
method NN O
. . O
null null null-Disease
Clinical JJ O
assessment NN O
as RB O
well RB O
as IN O
blinded VBN O
ratings NNS O
of IN O
Unified NNP O
Parkinson NNP B-Disease
' POS I-Disease
s NNP I-Disease
Disease NNP I-Disease
Rating NNP O
Scale NNP O
( -LRB- O
UPDRS NNP O
) -RRB- O
scores NNS O
were VBD O
carried VBN O
out RP O
pre RB O
- HYPH O
and CC O
postoperatively RB O
. . O
null null null-Disease
Mean VB O
follow NN O
- HYPH O
up NN O
time NN O
is VBZ O
20 CD O
. . O
6 CD O
months NNS O
( : O
range NN O
6 CD O
- HYPH O
48 CD O
) -RRB- O
and CC O
all DT O
except IN O
4 CD O
patients NNS O
have VBP O
been VBN O
followed VBN O
more JJR O
than IN O
one CD O
year NN O
. . O
null null null-Disease
85 CD O
percent NN O
of IN O
patients NNS O
with IN O
dyskinesias NNS B-Disease
were VBD O
relieved VBN O
of IN O
symptoms NNS O
, , O
regardless RB O
of IN O
whether IN O
the DT O
pallidotomies NNS O
were VBD O
performed VBN O
with IN O
the DT O
Gamma NNP O
Knife NNP O
or CC O
radiofrequency NN O
methods NNS O
. . O
null null null-Disease
About RB O
2 CD O
/ SYM O
3 CD O
of IN O
the DT O
patients NNS O
in IN O
both CC O
Gamma NNP O
Knife NNP O
and CC O
radiofrequency NN O
groups NNS O
showed VBD O
improvements NNS O
in IN O
bradykinesia NN B-Disease
and CC O
rigidity NN B-Disease
, , O
although IN O
when WRB O
considered VBN O
as IN O
a DT O
group NN O
neither CC O
the DT O
Gamma NNP O
Knife NNP O
nor CC O
the DT O
radiofrequency NN O
group NN O
showed VBD O
statistically RB O
significant JJ O
improvements NNS O
in IN O
UPDRS NNP O
scores NNS O
. . O
null null null-Disease
One CD O
patient NN O
in IN O
the DT O
Gamma NNP O
Knife NNP O
group NN O
( : O
3 CD O
. . O
4 CD O
% NN O
) -RRB- O
developed VBD O
a DT O
homonymous JJ B-Disease
hemianopsia NN I-Disease
9 CD O
months NNS O
following VBG O
treatment NN O
and CC O
5 CD O
patients NNS O
( SYM O
27 CD O
. . O
7 CD O
% NN O
) -RRB- O
in IN O
the DT O
radiofrequency NN O
group NN O
became VBD O
transiently RB O
confused JJ O
postoperatively RB O
. . O
null null null-Disease
No DT O
other JJ O
complications NNS O
were VBD O
seen VBN O
. . O
null null null-Disease
Gamma NNP O
Knife NNP O
pallidotomy NN O
is VBZ O
as RB O
effective JJ O
as IN O
radiofrequency NN O
pallidotomy NN O
in IN O
controlling VBG O
certain JJ O
of IN O
the DT O
symptoms NNS O
of IN O
Parkinson NNP B-Disease
' POS I-Disease
s POS I-Disease
disease NN I-Disease
. . O
null null null-Disease
It PRP O
may MD O
be VB O
the DT O
only JJ O
practical JJ O
technique NN O
available JJ O
in IN O
certain JJ O
patients NNS O
, , O
such JJ O
as IN O
those DT O
who WP O
take VBP O
anticoagulants NNS O
, , O
have VBP O
bleeding VBG B-Disease
diatheses NNS O
or CC O
serious JJ O
systemic JJ O
medical JJ O
illnesses NNS O
. . O
null null null-Disease
It PRP O
is VBZ O
a DT O
viable JJ O
option NN O
for IN O
other JJ O
patients NNS O
as RB O
well RB O
. . O
null null null-Disease
Centrally RB O
mediated VBN O
cardiovascular JJ O
effects NNS O
of IN O
intracisternal JJ O
application NN O
of IN O
carbachol NN O
in IN O
anesthetized VBN O
rats NNS O
. . O
null null null-Disease
The DT O
pressor NN O
response NN O
to IN O
the DT O
intracisternal JJ O
( : O
i LS O
. . O
c NN O
. . O
) -RRB- O
injection NN O
of IN O
carbachol NN O
( , O
1 CD O
mug NN O
) -RRB- O
in IN O
anesthetized JJ O
rats NNS O
was VBD O
analyzed VBN O
. . O
null null null-Disease
This DT O
response NN O
was VBD O
significantly RB O
reduced VBN O
by IN O
the DT O
intravenous JJ O
( : O
i LS O
. . O
v NN O
. . O
) -RRB- O
injection NN O
of IN O
guanethidine NN O
( , O
5 CD O
mg NN O
) -RRB- O
, , O
hexamethonium NN O
( , O
10 CD O
mg NN O
) , O
or CC O
phentolamine NN O
( , O
5 CD O
mg NN O
) -RRB- O
, , O
and CC O
conversely RB O
, , O
potentiated VBN O
by IN O
i DT O
. . O
v NN O
. . O
desmethylimipramine NN O
( : O
0 CD O
. . O
3 CD O
mg NN O
) -RRB- O
, , O
while IN O
propranolol NN O
( : O
0 CD O
. . O
5 CD O
mg NN O
) -RRB- O
i NN O
. . O
v NN O
. . O
selectively RB O
inhibited VBD O
the DT O
enlargement NN B-Disease
of IN I-Disease
pulse NN I-Disease
pressure NN I-Disease
and CC O
the DT O
tachycardia NN B-Disease
following VBG O
i NN O
. . O
c NN O
. . O
carbachol NN O
( : O
1 CD O
mug NN O
) -RRB- O
. . O
null null null-Disease
On IN O
the DT O
other JJ O
hand NN O
, , O
the DT O
pressor NN O
response NN O
to IN O
i PRP O
. . O
c NN O
. . O
carbachol NN O
( : O
1 CD O
mug NN O
) -RRB- O
was VBD O
almost RB O
completely RB O
blocked VBN O
by IN O
i PRP O
. . O
c NN O
. . O
atropine NN O
( , O
3 CD O
mug NN O
) -RRB- O
or CC O
hexamethonium NN O
( : O
500 CD O
mug NN O
) -RRB- O
, , O
and CC O
significantly RB O
reduced VBN O
by IN O
i DT O
. . O
c NN O
. . O
chlorpromazine NN O
( : O
50 CD O
mug NN O
) -RRB- O
but CC O
significantly RB O
potentiated VBN O
by IN O
i PRP O
. . O
c NN O
. . O
desmethylimipramine NN O
( : O
30 CD O
mug NN O
) -RRB- O
. . O
null null null-Disease
The DT O
pressor NN O
response NN O
to IN O
i PRP O
. . O
c NN O
. . O
carbachol NN O
( , O
1 CD O
mug NN O
) -RRB- O
remained VBD O
unchanged JJ O
after IN O
sectioning NN O
of IN O
the DT O
bilateral JJ O
cervical JJ O
vagal JJ O
nerves NNS O
but CC O
disappeared VBD O
after IN O
sectioning NN O
of IN O
the DT O
spinal JJ O
cord NN O
( : O
C7 NN O
- HYPH O
C8 NN O
) -RRB- O
. . O
null null null-Disease
From IN O
the DT O
above JJ O
result NN O
it PRP O
is VBZ O
suggested VBN O
that IN O
the DT O
pressor NN O
response NN O
to IN O
i PRP O
. . O
c NN O
. . O
carbachol NN O
ortral NN O
and CC O
peripheral JJ O
adrenergic JJ O
mechanisms NNS O
, , O
and CC O
that IN O
the DT O
sympathetic JJ O
trunk NN O
is VBZ O
the DT O
main JJ O
pathway NN O
. . O
null null null-Disease
Neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
and CC O
methylphenidate NN O
. . O
null null null-Disease
A DT O
1 CD O
- HYPH O
year NN O
- HYPH O
old JJ O
female NN O
presented VBN O
with IN O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
probably RB O
caused VBN O
by IN O
methylphenidate NN O
. . O
null null null-Disease
She PRP O
had VBD O
defects NNS O
in IN O
the DT O
supratentorial JJ O
brain NN O
including VBG O
the DT O
basal JJ O
ganglia NN O
and CC O
the DT O
striatum NN O
( , O
multicystic JJ B-Disease
encephalomalacia NN I-Disease
) , O
due IN O
to IN O
severe JJ O
perinatal JJ O
hypoxic JJ B-Disease
- HYPH I-Disease
ischemic JJ I-Disease
encephalopathy NN I-Disease
, , O
which WDT O
was VBD O
considered VBN O
to TO O
be VB O
a DT O
possible JJ O
predisposing JJ O
factor NN O
causing VBG O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
. . O
null null null-Disease
A DT O
dopaminergic JJ O
blockade NN O
mechanism NN O
generally RB O
is VBZ O
accepted VBN O
as IN O
the DT O
pathogenesis NN O
of IN O
this DT O
syndrome NN O
. . O
null null null-Disease
However RB O
, , O
methylphenidate NN O
is VBZ O
a DT O
dopamine NN O
agonist NN O
via IN O
the DT O
inhibition NN O
of IN O
uptake NN O
of IN O
dopamine NN O
, , O
and CC O
therefore RB O
dopaminergic JJ O
systems NNS O
in IN O
the DT O
brainstem NN O
( , O
mainly RB O
the DT O
midbrain NN O
) -RRB- O
and CC O
the DT O
spinal JJ O
cord NN O
were VBD O
unlikely JJ O
to TO O
participate VB O
in IN O
the DT O
onset NN O
of IN O
this DT O
syndrome NN O
. . O
null null null-Disease
A DT O
relative JJ O
gamma NN O
- HYPH O
aminobutyric JJ O
acid NN O
- HYPH O
ergic JJ O
deficiency NN O
might MD O
occur VB O
because IN O
diazepam NN O
, , O
a DT O
gamma NN O
- HYPH O
aminobutyric JJ O
acid NN O
- HYPH O
mimetic JJ O
agent NN O
, , O
was VBD O
strikingly RB O
effective JJ O
. . O
null null null-Disease
This DT O
is VBZ O
the DT O
first JJ O
reported VBN O
patient NN O
with IN O
neuroleptic JJ B-Disease
malignant JJ I-Disease
syndrome NN I-Disease
probably RB O
caused VBN O
by IN O
methylphenidate NN O
. . O
null null null-Disease
Differential JJ O
effects NNS O
of IN O
17alpha NN O
- HYPH O
ethinylestradiol NN O
on IN O
the DT O
neutral JJ O
and CC O
acidic JJ O
pathways NNS O
of IN O
bile NN O
salt NN O
synthesis NN O
in IN O
the DT O
rat NN O
. . O
null null null-Disease
Effects NNS O
of IN O
17alpha NN O
- HYPH O
ethinylestradiol NN O
( : O
EE NN O
) -RRB- O
on IN O
the DT O
neutral JJ O
and CC O
acidic JJ O
biosynthetic JJ O
pathways NNS O
of IN O
bile NN O
salt NN O
( -LRB- O
BS NN O
) -RRB- O
synthesis NN O
were VBD O
evaluated VBN O
in IN O
rats NNS O
with IN O
an DT O
intact JJ O
enterohepatic JJ O
circulation NN O
and CC O
in IN O
rats NNS O
with IN O
long JJ O
- HYPH O
term NN O
bile NN O
diversion NN O
to TO O
induce VB O
BS NNP O
synthesis NN O
. . O
null null null-Disease
For IN O
this DT O
purpose NN O
, , O
bile NN O
salt NN O
pool NN O
composition NN O
, , O
synthesis NN O
of IN O
individual JJ O
BS NN O
in IN O
vivo NN O
, , O
hepatic JJ O
activities NNS O
, , O
and CC O
expression NN O
levels NNS O
of IN O
cholesterol NN O
7alpha NN O
- HYPH O
hydroxylase NN O
( , O
CYP7A NNP O
) -RRB- O
, , O
and CC O
sterol NN O
27 CD O
- HYPH O
hydroxylase NN O
( -LRB- O
CYP27 NNP O
) -RRB- O
, , O
as RB O
well RB O
as IN O
of IN O
other JJ O
enzymes NNS O
involved VBN O
in IN O
BS NNP O
synthesis NN O
, , O
were VBD O
analyzed VBN O
in IN O
rats NNS O
treated VBN O
with IN O
EE NNP O
( , O
5 CD O
mg NN O
/ SYM O
kg NN O
, , O
3 CD O
days NNS O
) -RRB- O
or CC O
its PRP$ O
vehicle NN O
. . O
null null null-Disease
BS NNP O
pool NN O
size NN O
was VBD O
decreased VBN O
by IN O
27 CD O
% NN O
but CC O
total JJ O
BS NNP O
synthesis NN O
was VBD O
not RB O
affected VBN O
by IN O
EE NNP O
in IN O
intact JJ O
rats NNS O
. . O
null null null-Disease
Synthesis NN O
of IN O
cholate NN O
was VBD O
reduced VBN O
by IN O
68 CD O
% NN O
in IN O
EE NN O
- HYPH O
treated VBN O
rats NNS O
, , O
while IN O
that DT O
of IN O
chenodeoxycholate NN O
was VBD O
increased VBN O
by IN O
60 CD O
% NN O
. . O
null null null-Disease
The DT O
recently RB O
identified VBN O
Delta22 NNP O
- HYPH O
isomer NN O
of IN O
beta NN O
- HYPH O
muricholate NN O
contributed VBD O
for IN O
5 CD O
. . O
4 CD O
% NN O
and CC O
18 CD O
. . O
3 CD O
% NN O
( , O
P NN O
< SYM O
0 CD O
. . O
01 CD O
) -RRB- O
to IN O
the DT O
pool NN O
in IN O
control NN O
and CC O
EE NN O
- HYPH O
treated VBN O
rats NNS O
, , O
respectively RB O
, , O
but CC O
could MD O
not RB O
be VB O
detected VBN O
in IN O
bile NN O
after IN O
exhaustion NN O
of IN O
the DT O
pool NN O
. . O
null null null-Disease
A DT O
clear JJ O
reduction NN O
of IN O
BS NNP O
synthesis NN O
was VBD O
found VBN O
in IN O
bile NN O
- HYPH O
diverted VBN O
rats NNS O
treated VBN O
with IN O
EE NNP O
, , O
yet CC O
biliary JJ O
BS NN O
composition NN O
was VBD O
only RB O
minimally RB O
affected VBN O
. . O
null null null-Disease
Activity NN O
of IN O
CYP7A NN O
was VBD O
decreased VBN O
by IN O
EE NNP O
in IN O
both CC O
intact JJ O
and CC O
bile NN O
- HYPH O
diverted VBN O
rats NNS O
, , O
whereas IN O
the DT O
activity NN O
of IN O
the DT O
CYP27 NNP O
was VBD O
not RB O
affected VBN O
. . O
null null null-Disease
Hepatic JJ O
mRNA NN O
levels NNS O
of IN O
CYP7A NNP O
were VBD O
significantly RB O
reduced VBN O
by IN O
EE NNP O
in IN O
bile NN O
- HYPH O
diverted VBN O
rats NNS O
only RB O
; : O
CYP27 NNP O
mRNA NNP O
levels NNS O
were VBD O
not RB O
affected VBN O
by IN O
EE NNP O
. . O
null null null-Disease
In IN O
addition NN O
, , O
mRNA NNP O
levels NNS O
of IN O
sterol NN O
12alpha NN O
- HYPH O
hydroxylase NN O
and CC O
lithocholate NN O
6beta NN O
- HYPH O
hydroxylase NN O
were VBD O
increased VBN O
by IN O
bile NN O
diversion NN O
and CC O
suppressed VBN O
by IN O
EE NNP O
. . O
null null null-Disease
This DT O
study NN O
shows VBZ O
that IN O
17alpha NN O
- HYPH O
ethinylestradiol NN O
( -LRB- O
EE NN O
) -RRB- O
- HYPH O
induced VBN O
intrahepatic JJ B-Disease
cholestasis NN I-Disease
in IN O
rats NNS O
is VBZ O
associated VBN O
with IN O
selective JJ O
inhibition NN O
of IN O
the DT O
neutral JJ O
pathway NN O
of IN O
bile NN O
salt NN O
( , O
BS NN O
) -RRB- O
synthesis NN O
. . O
null null null-Disease
Simultaneous JJ O
impairment NN O
of IN O
other JJ O
enzymes NNS O
in IN O
the DT O
BS NNP O
biosynthetic JJ O
pathways NNS O
may MD O
contribute VB O
to IN O
overall JJ O
effects NNS O
of IN O
EE NN O
on IN O
BS NNP O
synthesis NN O
. . O
null null null-Disease
Glibenclamide NNP O
- HYPH O
sensitive JJ O
hypotension NN B-Disease
produced VBN O
by IN O
helodermin NN O
assessed VBN O
in IN O
the DT O
rat NN O
. . O
null null null-Disease
The DT O
effects NNS O
of IN O
helodermin NN O
, , O
a DT O
basic JJ O
35 CD O
- HYPH O
amino NN O
acid NN O
peptide NN O
isolated VBN O
from IN O
the DT O
venom NN O
of IN O
a DT O
lizard NN O
salivary JJ O
gland NN O
, , O
on IN O
arterial JJ O
blood NN O
pressure NN O
and CC O
heart NN O
rate NN O
were VBD O
examined VBN O
in IN O
the DT O
rat NN O
, , O
focusing VBG O
on IN O
the DT O
possibility NN O
that IN O
activation NN O
of IN O
ATP NNP O
sensitive JJ O
K NNP O
+ NNP O
( HYPH O
K NNP O
( , O
ATP NNP O
) -RRB- O
) -RRB- O
channels NNS O
is VBZ O
involved VBN O
in IN O
the DT O
responses NNS O
. . O
null null null-Disease
The DT O
results NNS O
were VBD O
also RB O
compared VBN O
with IN O
those DT O
of IN O
vasoactive JJ O
intestinal JJ O
polypeptide NN O
( , O
VIP NNP O
) -RRB- O
. . O
null null null-Disease
Helodermin NNP O
produced VBD O
hypotension NN B-Disease
in IN O
a DT O
dose NN O
- HYPH O
dependent JJ O
manner NN O
with IN O
approximately RB O
similar JJ O
potency NN O
and CC O
duration NN O
to IN O
VIP NN O
. . O
null null null-Disease
Hypotension NN B-Disease
induced VBN O
by IN O
both DT O
peptides NNS O
was VBD O
significantly RB O
attenuated VBN O
by IN O
glibenclamide NN O
, , O
which WDT O
abolished VBD O
a DT O
levcromakalim NN O
- HYPH O
produced VBN O
decrease NN O
in IN O
arterial JJ O
blood NN O
pressure NN O
. . O
null null null-Disease
Oxyhemoglobin NNP O
did VBD O
not RB O
affect VB O
helodermin NN O
- HYPH O
induced VBN O
hypotension NN B-Disease
, , O
whereas IN O
it PRP O
shortened VBD O
the DT O
duration NN O
of IN O
acetylcholine NN O
( , O
ACh NNP O
) -RRB- O
- HYPH O
produced VBN O
hypotension NN B-Disease
. . O
null null null-Disease
These DT O
findings NNS O
suggest VBP O
that IN O
helodermin NN O
- HYPH O
produced VBN O
hypotension NN B-Disease
is VBZ O
partly RB O
attributable JJ O
to IN O
the DT O
activation NN O
of IN O
glibenclamide NN O
- HYPH O
sensitive JJ O
K NN O
+ CC O
channels NNS O
( -LRB- O
K NNP O
( -LRB- O
ATP NNP O
) -RRB- O
channels NNS O
) -RRB- O
, , O
which WDT O
presumably RB O
exist VBP O
on IN O
arterial JJ O
smooth JJ O
muscle NN O
cells NNS O
. . O
null null null-Disease
EDRF NNP O
( , O
endothelium NN O
- HYPH O
derived VBN O
relaxing VBG O
factor NN O
) , O
/ SYM O
nitric JJ O
oxide NN O
does VBZ O
not RB O
seem VB O
to TO O
play VB O
an DT O
important JJ O
role NN O
in IN O
the DT O
peptide NN O
- HYPH O
produced VBN O
hypotension NN B-Disease
. . O
null null null-Disease
Long JJ O
- HYPH O
term NN O
efficacy NN O
and CC O
adverse JJ O
event NN O
of IN O
nifedipine NN O
sustained VBN O
- HYPH O
release NN O
tablets NNS O
for IN O
cyclosporin NN O
A NN O
- HYPH O
induced VBN O
hypertension NN B-Disease
in IN O
patients NNS O
with IN O
psoriasis NN B-Disease
. . O
null null null-Disease
Thirteen CD O
psoriatic JJ B-Disease
patients NNS O
with IN O
hypertension NN B-Disease
during IN O
the DT O
course NN O
of IN O
cyclosporin NN O
A NN O
therapy NN O
were VBD O
treated VBN O
for IN O
25 CD O
months NNS O
with IN O
a DT O
calcium NN O
channel NN O
blocker NN O
, , O
sustained VBN O
- HYPH O
release NN O
nifedipine NN O
, , O
to TO O
study VB O
the DT O
clinical JJ O
antihypertensive JJ O
effects NNS O
and CC O
adverse JJ O
events NNS O
during IN O
treatment NN O
with IN O
both DT O
drugs NNS O
. . O
null null null-Disease
Seven CD O
of IN O
the DT O
13 CD O
patients NNS O
had VBD O
exhibited VBN O
a DT O
subclinical JJ O
hypertensive JJ B-Disease
state NN O
before IN O
cyclosporin NN O
A NN O
therapy NN O
. . O
null null null-Disease
Both CC O
systolic JJ O
and CC O
diastolic JJ O
blood NN O
pressures NNS O
of IN O
these DT O
13 CD O
patients NNS O
were VBD O
decreased VBN O
significantly RB O
after IN O
4 CD O
weeks NNS O
of IN O
nifedipine NN O
therapy NN O
, , O
and CC O
blood NN O
pressure NN O
was VBD O
maintained VBN O
within IN O
the DT O
normal JJ O
range NN O
thereafter RB O
for IN O
25 CD O
months NNS O
. . O
null null null-Disease
The DT O
adverse JJ O
events NNS O
during IN O
combined JJ O
therapy NN O
with IN O
cyclosporin NN O
A NN O
and CC O
nifedipine NN O
included VBD O
an DT O
increase NN O
in IN O
blood NN O
urea NN O
nitrogen NN O
levels NNS O
in IN O
9 CD O
of IN O
the DT O
13 CD O
patients NNS O
and CC O
development NN O
of IN O
gingival JJ B-Disease
hyperplasia NN I-Disease
in IN O
2 CD O
of IN O
the DT O
13 CD O
patients NNS O
. . O
null null null-Disease
Our PRP$ O
findings NNS O
indicate VBP O
that IN O
sustained JJ O
- HYPH O
release NN O
nifedipine NN O
is VBZ O
useful JJ O
for IN O
hypertensive JJ B-Disease
psoriatic JJ B-Disease
patients NNS O
under IN O
long JJ O
- HYPH O
term NN O
treatment NN O
with IN O
cyclosporin NN O
A NNP O
, , O
but CC O
that IN O
these DT O
patients NNS O
should MD O
be VB O
monitored VBN O
for IN O
gingival JJ B-Disease
hyperplasia NN I-Disease
. . O
null null null-Disease
